PMID- 42905886 OWN - NLM STAT- Publisher LR - 20261022 IS - 1809-452X (Electronic) IS - 1516-4446 (Linking) DP - 2026 Oct 21 TI - Protective Effect of COVID-19 Vaccination on Post-Infection Visuospatial Deficits. LID - 10.47626/1516-4446-2026-4853 [doi] AB - OBJECTIVE: COVID-19 has been associated with persistent cognitive deficits months after SARS-CoV-2 infection. Vaccination reduces severe disease, but its effect on post-infection cognition remains uncertain. We evaluated whether COVID-19 vaccination attenuates cognitive deficits after SARS-CoV-2. METHODS: We assessed 237 adults with COVID-19 and 105 controls. Patients were grouped by vaccination status at infection (vaccinated n=87; unvaccinated n=150). The neuropsychological assessment covered language, visuospatial ability, visual memory, verbal memory, attention, executive functions, and working memory. Group differences were tested with Aligned Rank Transform ANOVA with Holm-corrected post hoc comparisons, adjusting for education. RESULTS: Significant group differences were observed in visuospatial ability and visual memory, assessed with the Rey-Osterrieth Complex Figure Test (Copy, Immediate and Delayed Recall) (all p < 0.001). The vaccinated group outperformed the unvaccinated group (p = 0.022) on visuospatial performance. The Rey-Osterrieth Complex Figure Test Copy did not differ significantly among participants vaccinated with CoronaVac, AstraZeneca, or Pfizer. CONCLUSIONS: The findings suggest that COVID-19 vaccination may mitigate post-infection visuospatial deficits, reinforcing the importance of immunization in preventing cognitive sequelae associated with the disease. FAU - da Silva, Lucas Gomes AU - da Silva LG AD - Graduate Program in Molecular Medicine, School of Medicine, Federal University of Minas Gerais (UFMG), Belo Horizonte, MG, Brazil. National Institute of Science and Technology for Responsible Neurotechnology (INCT-NeurotecR), School of Medicine, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil. FAU - Fini, Bruna Carmeni Di AU - Fini BCD AD - Graduate Program in Molecular Medicine, School of Medicine, Federal University of Minas Gerais (UFMG), Belo Horizonte, MG, Brazil. National Institute of Science and Technology for Responsible Neurotechnology (INCT-NeurotecR), School of Medicine, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil. FAU - Oliveira, Jordano Cesar Milagres AU - Oliveira JCM AD - Graduate Program in Molecular Medicine, School of Medicine, Federal University of Minas Gerais (UFMG), Belo Horizonte, MG, Brazil. National Institute of Science and Technology for Responsible Neurotechnology (INCT-NeurotecR), School of Medicine, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil. FAU - Rosa, Daniela Valadao AU - Rosa DV AD - National Institute of Science and Technology for Responsible Neurotechnology (INCT-NeurotecR), School of Medicine, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil. FAU - Costa, Danielle de Souza AU - Costa DS AD - National Institute of Science and Technology for Responsible Neurotechnology (INCT-NeurotecR), School of Medicine, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil. FAU - de Miranda, Debora Marques AU - de Miranda DM AD - Graduate Program in Molecular Medicine, School of Medicine, Federal University of Minas Gerais (UFMG), Belo Horizonte, MG, Brazil. National Institute of Science and Technology for Responsible Neurotechnology (INCT-NeurotecR), School of Medicine, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil. Department of Pediatrics, School of Medicine, Federal University of Minas Gerais (UFMG), Belo Horizonte, MG, Brazil. FAU - Romano-Silva, Marco Aurelio AU - Romano-Silva MA AD - Graduate Program in Molecular Medicine, School of Medicine, Federal University of Minas Gerais (UFMG), Belo Horizonte, MG, Brazil. National Institute of Science and Technology for Responsible Neurotechnology (INCT-NeurotecR), School of Medicine, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil. Department of Psychiatry, School of Medicine, Federal University of Minas Gerais (UFMG), Belo Horizonte, MG, Brazil. FAU - de Paula, Jonas Jardim AU - de Paula JJ AD - Graduate Program in Molecular Medicine, School of Medicine, Federal University of Minas Gerais (UFMG), Belo Horizonte, MG, Brazil. National Institute of Science and Technology for Responsible Neurotechnology (INCT-NeurotecR), School of Medicine, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil. Department of Psychiatry, School of Medicine, Federal University of Minas Gerais (UFMG), Belo Horizonte, MG, Brazil. LA - eng GR - CNPq/Conselho Nacional de Desenvolvimento Cientifico e Tecnologico/Brazil GR - FAPEMIG/Fundacao de Amparo a Pesquisa do Estado de Minas Gerais/Brazil GR - Decit/SECTICS/MS/Departamento de Ciencia e Tecnologia do Ministerio da Saude/Brazil GR - CAPES/Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior/Brazil PT - Journal Article DEP - 20261021 PL - Brazil TA - Braz J Psychiatry JT - Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999) JID - 100895975 SB - IM OTO - NOTNLM OT - SARS-CoV-2 OT - cognitive dysfunction OT - neuropsychological tests OT - post-acute COVID-19 Syndrome OT - spatial processing COIS- The authors declare no conflict of interest. EDAT- 2026/10/22 23:29 MHDA- 2026/10/22 23:29 CRDT- 2026/10/22 18:44 PHST- 2026/04/30 00:00 [received] PHST- 2026/10/05 00:00 [accepted] PHST- 2026/10/22 23:29 [medline] PHST- 2026/10/22 23:29 [pubmed] PHST- 2026/10/22 18:44 [entrez] AID - 10.47626/1516-4446-2026-4853 [doi] PST - aheadofprint SO - Braz J Psychiatry. 2026 Oct 21. doi: 10.47626/1516-4446-2026-4853. PMID- 42900956 OWN - NLM STAT- Publisher LR - 20261020 IS - 1809-452X (Electronic) IS - 1516-4446 (Linking) DP - 2026 Oct 20 TI - Protective Effect of COVID-19 Vaccination on Post-Infection Visuospatial Deficits. LID - 0.47626/1516-4446-2026-4853 [doi] AB - OBJECTIVE: COVID-19 has been associated with persistent cognitive deficits months after SARS-CoV-2 infection. Vaccination reduces severe disease, but its effect on post-infection cognition remains uncertain. We evaluated whether COVID-19 vaccination attenuates cognitive deficits after SARS-CoV-2. METHODS: We assessed 237 adults with COVID-19 and 105 controls. Patients were grouped by vaccination status at infection (vaccinated n=87; unvaccinated n=150). The neuropsychological assessment covered language, visuospatial ability, visual memory, verbal memory, attention, executive functions, and working memory. Group differences were tested with Aligned Rank Transform ANOVA with Holm-corrected post hoc comparisons, adjusting for education. RESULTS: Significant group differences were observed in visuospatial ability and visual memory, assessed with the Rey-Osterrieth Complex Figure Test (Copy, Immediate and Delayed Recall) (all p < 0.001). The vaccinated group outperformed the unvaccinated group (p = 0.022) on visuospatial performance. The Rey-Osterrieth Complex Figure Test Copy did not differ significantly among participants vaccinated with CoronaVac, AstraZeneca, or Pfizer. CONCLUSIONS: The findings suggest that COVID-19 vaccination may mitigate post-infection visuospatial deficits, reinforcing the importance of immunization in preventing cognitive sequelae associated with the disease. FAU - da Silva, Lucas Gomes AU - da Silva LG AD - Graduate Program in Molecular Medicine, School of Medicine, Federal University of Minas Gerais (UFMG), Belo Horizonte, MG, Brazil. National Institute of Science and Technology for Responsible Neurotechnology (INCT-NeurotecR), School of Medicine, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil. FAU - Fini, Bruna Carmeni Di AU - Fini BCD AD - Graduate Program in Molecular Medicine, School of Medicine, Federal University of Minas Gerais (UFMG), Belo Horizonte, MG, Brazil. National Institute of Science and Technology for Responsible Neurotechnology (INCT-NeurotecR), School of Medicine, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil. FAU - Oliveira, Jordano Cesar Milagres AU - Oliveira JCM AD - Graduate Program in Molecular Medicine, School of Medicine, Federal University of Minas Gerais (UFMG), Belo Horizonte, MG, Brazil. National Institute of Science and Technology for Responsible Neurotechnology (INCT-NeurotecR), School of Medicine, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil. FAU - Rosa, Daniela Valadao AU - Rosa DV AD - National Institute of Science and Technology for Responsible Neurotechnology (INCT-NeurotecR), School of Medicine, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil. FAU - Costa, Danielle de Souza AU - Costa DS AD - National Institute of Science and Technology for Responsible Neurotechnology (INCT-NeurotecR), School of Medicine, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil. FAU - de Miranda, Debora Marques AU - de Miranda DM AD - Graduate Program in Molecular Medicine, School of Medicine, Federal University of Minas Gerais (UFMG), Belo Horizonte, MG, Brazil. National Institute of Science and Technology for Responsible Neurotechnology (INCT-NeurotecR), School of Medicine, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil. Department of Pediatrics, School of Medicine, Federal University of Minas Gerais (UFMG), Belo Horizonte, MG, Brazil. FAU - Romano-Silva, Marco Aurelio AU - Romano-Silva MA AD - Graduate Program in Molecular Medicine, School of Medicine, Federal University of Minas Gerais (UFMG), Belo Horizonte, MG, Brazil. National Institute of Science and Technology for Responsible Neurotechnology (INCT-NeurotecR), School of Medicine, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil. Department of Psychiatry, School of Medicine, Federal University of Minas Gerais (UFMG), Belo Horizonte, MG, Brazil. FAU - de Paula, Jonas Jardim AU - de Paula JJ AD - Graduate Program in Molecular Medicine, School of Medicine, Federal University of Minas Gerais (UFMG), Belo Horizonte, MG, Brazil. National Institute of Science and Technology for Responsible Neurotechnology (INCT-NeurotecR), School of Medicine, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil. Department of Psychiatry, School of Medicine, Federal University of Minas Gerais (UFMG), Belo Horizonte, MG, Brazil. LA - eng GR - CNPq/Conselho Nacional de Desenvolvimento Cientifico e Tecnologico/Brazil GR - FAPEMIG/Fundacao de Amparo a Pesquisa do Estado de Minas Gerais/Brazil GR - Decit/SECTICS/MS/Departamento de Ciencia e Tecnologia do Ministerio da Saude/Brazil GR - CAPES/Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior/Brazil PT - Journal Article DEP - 20261020 PL - Brazil TA - Braz J Psychiatry JT - Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999) JID - 100895975 SB - IM OTO - NOTNLM OT - SARS-CoV-2 OT - cognitive dysfunction OT - neuropsychological tests OT - post-acute COVID-19 Syndrome OT - spatial processing COIS- The authors declare no conflict of interest. EDAT- 2026/10/20 23:29 MHDA- 2026/10/20 23:29 CRDT- 2026/10/20 17:14 PHST- 2026/04/30 00:00 [received] PHST- 2026/10/05 00:00 [accepted] PHST- 2026/10/20 23:29 [medline] PHST- 2026/10/20 23:29 [pubmed] PHST- 2026/10/20 17:14 [entrez] PST - aheadofprint SO - Braz J Psychiatry. 2026 Oct 20. PMID- 42841133 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20261007 LR - 20261008 IS - 1980-5764 (Print) IS - 2764-4863 (Electronic) IS - 1980-5764 (Linking) VI - 20 DP - 2026 TI - Prior COVID-19 vaccination and cognitive outcomes after SARS-CoV-2 infection: a mini-review. PG - e20260494 LID - 10.1590/1980-5764-DN-2026-0494 [doi] LID - e20260494 AB - COVID-19 infection has been frequently associated with cognitive deficits that persist for months after the acute phase, but the impact of vaccination on preventing these deficits remains uncertain. Evidence suggests that immunization reduces the incidence and severity of post-COVID symptoms, yet few studies have evaluated its influence on cognition using objective measures. To address this gap, a mini-review was conducted using a systematic search strategy, following PRISMA recommendations where applicable, with a protocol registered in PROSPERO (CRD42025636772). Searches were carried out in the PubMed/MEDLINE and Scopus databases, and eligible studies were those that assessed cognition using objective measures and compared vaccinated and unvaccinated individuals at the time of infection. A total of 1,796 records were identified, of which only five met the inclusion criteria. The included studies varied considerably in cognitive assessment tools, study designs, and sample sizes. Four of the five studies found no association between prior vaccination and cognitive deficits, whereas the only study that identified a subtle difference among individuals who had received at least two doses of the vaccine had a substantially larger sample than all the others combined. Methodological inconsistencies in cognitive assessment, variability in the definitions of vaccination status, and the lack of stratification by specific cognitive domains limit the interpretation of the current findings. Although vaccination may play a role in protecting against cognitive deficits following COVID-19 infection, the evidence remains limited and inconclusive. Further studies with standardized definitions of vaccination status and comprehensive objective assessments are needed to clarify this relationship. FAU - da Silva, Lucas Gomes AU - da Silva LG AUID- ORCID: 0000-0002-7314-1977 AD - Universidade Federal de Minas Gerais, Faculdade de Medicina, Programa de Pos-Graduacao em Medicina Molecular, Belo Horizonte MG, Brazil. AD - Universidade Federal de Minas Gerais, Faculdade de Medicina, Instituto Nacional de Ciencia e Tecnologia em Neurotecnologia Responsavel, Belo Horizonte MG, Brazil. FAU - Oliveira, Jordano Cesar Milagres AU - Oliveira JCM AUID- ORCID: 0000-0001-8723-7251 AD - Universidade Federal de Minas Gerais, Faculdade de Medicina, Programa de Pos-Graduacao em Medicina Molecular, Belo Horizonte MG, Brazil. AD - Universidade Federal de Minas Gerais, Faculdade de Medicina, Instituto Nacional de Ciencia e Tecnologia em Neurotecnologia Responsavel, Belo Horizonte MG, Brazil. FAU - Fini, Bruna Carmeni Di AU - Fini BCD AUID- ORCID: 0000-0002-3382-5186 AD - Universidade Federal de Minas Gerais, Faculdade de Medicina, Programa de Pos-Graduacao em Medicina Molecular, Belo Horizonte MG, Brazil. AD - Universidade Federal de Minas Gerais, Faculdade de Medicina, Instituto Nacional de Ciencia e Tecnologia em Neurotecnologia Responsavel, Belo Horizonte MG, Brazil. FAU - Porto, Aline Arantes AU - Porto AA AUID- ORCID: 0000-0002-8281-6729 AD - Universidade Federal de Minas Gerais, Faculdade de Medicina, Instituto Nacional de Ciencia e Tecnologia em Neurotecnologia Responsavel, Belo Horizonte MG, Brazil. FAU - Costa, Danielle de Souza AU - Costa DS AUID- ORCID: 0000-0001-6883-5133 AD - Universidade Federal de Minas Gerais, Faculdade de Medicina, Instituto Nacional de Ciencia e Tecnologia em Neurotecnologia Responsavel, Belo Horizonte MG, Brazil. FAU - de Miranda, Debora Marques AU - de Miranda DM AUID- ORCID: 0000-0002-7081-8401 AD - Universidade Federal de Minas Gerais, Faculdade de Medicina, Programa de Pos-Graduacao em Medicina Molecular, Belo Horizonte MG, Brazil. AD - Universidade Federal de Minas Gerais, Faculdade de Medicina, Instituto Nacional de Ciencia e Tecnologia em Neurotecnologia Responsavel, Belo Horizonte MG, Brazil. AD - Universidade Federal de Minas Gerais, Faculdade de Medicina, Departamento de Pediatria, Belo Horizonte MG, Brazil. FAU - Romano-Silva, Marco Aurelio AU - Romano-Silva MA AUID- ORCID: 0000-0002-6558-4639 AD - Universidade Federal de Minas Gerais, Faculdade de Medicina, Programa de Pos-Graduacao em Medicina Molecular, Belo Horizonte MG, Brazil. AD - Universidade Federal de Minas Gerais, Faculdade de Medicina, Instituto Nacional de Ciencia e Tecnologia em Neurotecnologia Responsavel, Belo Horizonte MG, Brazil. AD - Universidade Federal de Minas Gerais, Faculdade de Medicina, Departamento de Psiquiatria, Belo Horizonte MG, Brazil. FAU - de Paula, Jonas Jardim AU - de Paula JJ AUID- ORCID: 0000-0001-5530-2346 AD - Universidade Federal de Minas Gerais, Faculdade de Medicina, Programa de Pos-Graduacao em Medicina Molecular, Belo Horizonte MG, Brazil. AD - Universidade Federal de Minas Gerais, Faculdade de Medicina, Instituto Nacional de Ciencia e Tecnologia em Neurotecnologia Responsavel, Belo Horizonte MG, Brazil. AD - Universidade Federal de Minas Gerais, Faculdade de Medicina, Departamento de Psiquiatria, Belo Horizonte MG, Brazil. LA - eng PT - Journal Article PT - Review DEP - 20261002 PL - Brazil TA - Dement Neuropsychol JT - Dementia & neuropsychologia JID - 101506587 PMC - PMC13641761 OTO - NOTNLM OT - COVID-19 OT - Cognition OT - Memory Disorders OT - Post-Acute COVID-19 Syndrome OT - Vaccination. COIS- Disclosure: There is no conflict of interest to declare. EDAT- 2026/10/07 11:32 MHDA- 2026/10/07 11:33 PMCR- 2026/10/02 CRDT- 2026/10/07 11:00 PHST- 2026/02/25 00:00 [received] PHST- 2026/06/07 00:00 [revised] PHST- 2026/07/15 00:00 [accepted] PHST- 2026/10/07 11:33 [medline] PHST- 2026/10/07 11:32 [pubmed] PHST- 2026/10/07 11:00 [entrez] PHST- 2026/10/02 00:00 [pmc-release] AID - 10.1590/1980-5764-DN-2026-0494 [doi] PST - epublish SO - Dement Neuropsychol. 2026 Oct 2;20:e20260494. doi: 10.1590/1980-5764-DN-2026-0494. eCollection 2026. PMID- 42763758 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20261020 LR - 20261020 IS - 2067-0656 (Print) IS - 2069-4032 (Electronic) VI - 52 IP - 2 DP - 2026 Apr-Jun TI - Admission Acute Brain Dysfunction and In-ICU Mortality in a Single-Center Pre-Vaccination Romanian COVID-19 Cohort:A Retrospective Observational Analysis. PG - 185-205 LID - 10.12865/CHSJ.52.02.05 [doi] AB - BACKGROUND: Critically ill COVID-19 patients frequently develop organ dysfunction and acute brain dysfunction with features overlapping sepsis-associated encephalopathy (SAE). Real-world cohorts from Eastern European intensive care during the pre-vaccination period are scarce. METHODS: We retrospectively analysed 389 consecutive adults with RT-PCR-confirmed SARS-CoV-2 admitted to a single regional Romanian tertiary ICU during 2020-2021, entirely preceding population-level vaccination. Organ dysfunction was defined as admission SOFA>/=2, and acute brain dysfunction was op-erationalised from admission Glasgow Coma Scale and neurological SOFA (the acute brain dysfunction [ABD] proxy). Associations with in-ICU mortality were examined descriptively, with pre-specified sensitivity analyses restricted to non-ventilated pa-tients to address sedation confounding. RESULTS: In-ICU mortality was 65.8%. The ABD proxy was present in 49.6% of the cohort; mortality was 96.9% in ABD-proxy-positive patients versus 45.9% in those with preserved consciousness, an absolute difference of 51.0 percentage points, which was of similar magnitude (49.4 points) in non-ventilated patients, arguing against sedation as the sole explanation. Higher inflammatory markers accompanied the ABD proxy, and the association between admission acute brain dys-function and mortality was consistent across analyses. CONCLUSIONS: Admission acute brain dysfunction was strongly associated with in-ICU mortality, and this association persisted in non-ventilated patients. The findings are descriptive associations within an extreme, single-center pre-vaccination cohort under surge conditions; they are not causal, and should not be generalised to vaccinated or contemporary critical care. CI - Copyright (c) 2025, Medical University Publishing House Craiova. FAU - Neacsu, Alexandru Ionut AU - Neacsu AI AD - Doctoral School, University of Medicine and Pharmacy of Craiova, Romania. FAU - Rotaru-Zavaleanu, Alexandra-Daniela AU - Rotaru-Zavaleanu AD AD - Department of Epidemiology, University of Medicine and Pharmacy of Craiova, Romania. FAU - Novac, Marius-Bogdan AU - Novac MB AD - Department of Anesthesiology and Intensive Care, University of Medicine and Pharmacy of Craiova, Romania. FAU - Radu, Lucretiu AU - Radu L AD - Department of Hygiene, University of Medicine and Pharmacy of Craiova, Romania. FAU - Osiac, Eugen AU - Osiac E AD - Department of Biophysics, University of Medicine and Pharmacy of Craiova, Romania. LA - eng PT - Journal Article DEP - 20260630 PL - Romania TA - Curr Health Sci J JT - Current health sciences journal JID - 101597164 PMC - PMC13589594 OTO - NOTNLM OT - COVID-19 OT - acute brain dysfunction OT - critical care OT - intensive care epidemiology. OT - multiple organ dysfunction syndrome OT - sepsis-associated encephalopathy COIS- The authors declare that they have no competing of interests. EDAT- 2026/09/20 05:43 MHDA- 2026/09/20 05:44 PMCR- 2026/04/01 CRDT- 2026/09/20 04:01 PHST- 2025/12/18 00:00 [received] PHST- 2026/06/23 00:00 [accepted] PHST- 2026/09/20 05:43 [pubmed] PHST- 2026/09/20 05:44 [medline] PHST- 2026/09/20 04:01 [entrez] PHST- 2026/04/01 00:00 [pmc-release] AID - 2026.2.185 [pii] AID - 10.12865/CHSJ.52.02.05 [doi] PST - ppublish SO - Curr Health Sci J. 2026 Apr-Jun;52(2):185-205. doi: 10.12865/CHSJ.52.02.05. Epub 2026 Jun 30. PMID- 42675735 OWN - NLM STAT- MEDLINE DCOM- 20260901 LR - 20261014 IS - 1536-5964 (Electronic) IS - 0025-7974 (Print) IS - 0025-7974 (Linking) VI - 105 IP - 35 DP - 2026 Aug 28 TI - Long-term adverse effects following COVID-19 vaccination: A comparative analysis of Oxford AstraZeneca, Pfizer-BioNTech, and Moderna vaccines. PG - e50282 LID - 10.1097/MD.0000000000050282 [doi] LID - e50282 AB - During the COVID-19 pandemic, vaccinations were highly beneficial to public health, preventing disease and reducing mortality. This study aimed to investigate long-term adverse clinical symptoms following COVID-19 vaccination with the Oxford AstraZeneca (ChAdOx1 nCoV-19, Oxford), Pfizer-BioNTech (BNT162b2), and Moderna (mRNA-1273) vaccines. In this cross-sectional study, the total number of participants was 429; among them, 243 (56.6%) were male, and 186 (43.4%) were female. An online Google Form was prepared in both Arabic and English and distributed to participants who received the Oxford AstraZeneca, Pfizer-BioNTech, and Moderna vaccines. The most common long-term adverse effects reported after COVID-19 vaccination were chronic fatigue, impaired cognitive function, and menstrual irregularity. The Moderna vaccine had a higher self-reported symptom rate among male participants (50-61.5%) than among female participants (33.3-28%). Chronic fatigue was more frequent among Oxford AstraZeneca recipients (34.7%) than among Moderna (22.2%) and Pfizer-BioNTech (27.7%) recipients. The second dose was associated with slightly higher rates of chronic fatigue among Oxford AstraZeneca recipients (38.9%) than among Moderna (25%) and Pfizer-BioNTech recipients (27.3%). For cognitive problems, the prevalence was similar across all brands (25%). Menstrual irregularity was slightly higher among females who received Pfizer-BioNTech (14.8%) than among Oxford AstraZeneca recipients (18.9%). The highest proportion of recipients who were infected after vaccination was among those who received the Oxford AstraZeneca vaccine (46.3%). In conclusion, the most commonly reported long-term adverse effects after COVID-19 vaccination were chronic fatigue, cognitive impairment, and menstrual irregularity. Further large-scale studies are required to provide more conclusive evidence. CI - Copyright (c) 2026 the Author(s). Published by Wolters Kluwer Health, LLC. FAU - Aldali, Jehad A AU - Aldali JA AD - Department of Pathology, College of Medicine, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh, Saudi Arabia. FAU - Meo, Sultan Ayoub AU - Meo SA AUID- ORCID: 0000-0001-9820-1852 AD - Department of Physiology, College of Medicine, King Saud University, Riyadh, Saudi Arabia. LA - eng PT - Comparative Study PT - Journal Article PL - United States TA - Medicine (Baltimore) JT - Medicine JID - 2985248R RN - 0 (COVID-19 Vaccines) RN - B5S3K2V0G8 (ChAdOx1 nCoV-19) RN - 0 (BNT162 Vaccine) RN - EPK39PL4R4 (2019-nCoV Vaccine mRNA-1273) SB - IM MH - Humans MH - Female MH - Male MH - Cross-Sectional Studies MH - *COVID-19 Vaccines/adverse effects MH - ChAdOx1 nCoV-19/adverse effects MH - *COVID-19/prevention & control MH - BNT162 Vaccine/adverse effects MH - Adult MH - Middle Aged MH - 2019-nCoV Vaccine mRNA-1273/adverse effects MH - Vaccination/adverse effects MH - Fatigue/epidemiology PMC - PMC13529125 OTO - NOTNLM OT - COVID-19 vaccination OT - Moderna OT - Oxford AstraZeneca OT - Pfizer-BioNTech OT - adverse symptoms COIS- The authors have no funding and conflicts of interest to declare. EDAT- 2026/09/01 05:41 MHDA- 2026/09/01 05:42 PMCR- 2026/08/28 CRDT- 2026/09/01 01:01 PHST- 2026/06/03 00:00 [received] PHST- 2026/08/03 00:00 [accepted] PHST- 2026/09/01 05:42 [medline] PHST- 2026/09/01 05:41 [pubmed] PHST- 2026/09/01 01:01 [entrez] PHST- 2026/08/28 00:00 [pmc-release] AID - 00005792-202608280-00067 [pii] AID - MD-D-26-08262 [pii] AID - 10.1097/MD.0000000000050282 [doi] PST - ppublish SO - Medicine (Baltimore). 2026 Aug 28;105(35):e50282. doi: 10.1097/MD.0000000000050282. PMID- 42628376 OWN - NLM STAT- MEDLINE DCOM- 20260909 LR - 20260909 IS - 2352-3964 (Electronic) IS - 2352-3964 (Linking) VI - 131 DP - 2026 Sep TI - Role of plasmacytoid dendritic cells in humoural and CD8(+) T-cell memory responses following BNT162b2 mRNA vaccination: a preclinical mouse study. PG - 106432 LID - S2352-3964(26)00316-6 [pii] LID - 10.1016/j.ebiom.2026.106432 [doi] LID - 106432 AB - BACKGROUND: The Pfizer-BioNTech coronavirus vaccine (BNT162b2) was among the first nanoparticle-based vaccines approved by the World Health Organisation (WHO) and demonstrated 95% efficacy against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection. Despite its success, the precise immune mechanism behind its effectiveness remains poorly understood. This study investigated the early immune responses occurring in the draining lymph node (dLN) following vaccination. METHODS: A well-established murine vaccination model was used to investigate the distribution and immunological effects of BNT162b2 in vivo. Vaccine trafficking to the dLN, cellular uptake, and spike protein expression were assessed following immunisation. Single-cell transcriptomic analyses and functional in vivo experiments were performed to identify the immune cell populations involved in orchestrating vaccine-induced responses and to characterise their interactions with adaptive immune cells. FINDINGS: BNT162b2 was rapidly transported to the dLN, where it was predominantly captured by leukocytes that subsequently expressed the SARS-CoV-2 spike protein. Among these cells, plasmacytoid dendritic cells (pDCs) emerged as regulators involved in both inflammatory and humoural immune responses. Single-cell transcriptomic profiling revealed active interactions between pDCs and CD8(+) T cells. Functional in vivo studies further demonstrated that pDCs promoted CD8(+) T-cell activation and expansion, indicating an involvement in shaping adaptive immunity following vaccination. INTERPRETATION: These findings identify pDCs as antigen-presenting cells involved in coordinating the immune response to BNT162b2. By regulating both innate and adaptive immune pathways and facilitating CD8(+) T-cell activation, pDCs appear to play a functional role in the efficacy of this mRNA vaccine. This study provides additional insights into the immunological processes underlying mRNA vaccine-induced protection and may inform the future design and optimisation of mRNA-based immunotherapies and vaccines. FUNDING: Swiss National Science Foundation, Leonardo Foundation. CI - Copyright (c) 2026 The Author(s). Published by Elsevier B.V. All rights reserved. FAU - Pizzichetti, Chiara AU - Pizzichetti C AD - Faculty of Biomedical Sciences, Institute for Research in Biomedicine, Universita Della Svizzera Italiana, Bellinzona, Switzerland; Graduate School for Cellular and Biomedical Sciences, University of Bern, Bern, Switzerland. FAU - Latino, Irene AU - Latino I AD - Faculty of Biomedical Sciences, Institute for Research in Biomedicine, Universita Della Svizzera Italiana, Bellinzona, Switzerland. FAU - Virgilio, Tommaso AU - Virgilio T AD - Faculty of Biomedical Sciences, Institute for Research in Biomedicine, Universita Della Svizzera Italiana, Bellinzona, Switzerland. FAU - Capucetti, Arianna AU - Capucetti A AD - Faculty of Biomedical Sciences, Institute for Research in Biomedicine, Universita Della Svizzera Italiana, Bellinzona, Switzerland. FAU - Chahine, Kamil AU - Chahine K AD - Faculty of Biomedical Sciences, Institute for Research in Biomedicine, Universita Della Svizzera Italiana, Bellinzona, Switzerland; Graduate School for Cellular and Biomedical Sciences, University of Bern, Bern, Switzerland. FAU - Cascione, Luciano AU - Cascione L AD - Faculty of Biomedical Sciences, Institute of Oncology Research, Universita Della Svizzera Italiana, Bellinzona, Switzerland. FAU - Moro, Simone G AU - Moro SG AD - Faculty of Biomedical Sciences, Institute for Research in Biomedicine, Universita Della Svizzera Italiana, Bellinzona, Switzerland. FAU - Bilato, Giorgia AU - Bilato G AD - Immunology and General Pathology Laboratory, Department of Biotechnology and Life Sciences, University of Insubria, Varese, Italy; Unit of Molecular Pathology, Biochemistry and Immunology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) MultiMedica, Milan, Italy. FAU - Brugger, Melanie AU - Brugger M AD - Institute of Virology and Immunology, Bern and Mittelhausern, Bern, Switzerland; Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern, Bern, Switzerland. FAU - Kozarac, Nedim AU - Kozarac N AD - Graduate School for Cellular and Biomedical Sciences, University of Bern, Bern, Switzerland; Institute of Virology and Immunology, Bern and Mittelhausern, Bern, Switzerland; Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern, Bern, Switzerland. FAU - Pulfer, Alain AU - Pulfer A AD - Faculty of Biomedical Sciences, Institute for Research in Biomedicine, Universita Della Svizzera Italiana, Bellinzona, Switzerland. FAU - Renner, Louis AU - Renner L AD - Faculty of Biomedical Sciences, Institute for Research in Biomedicine, Universita Della Svizzera Italiana, Bellinzona, Switzerland. FAU - Thakur, Roshan S AU - Thakur RS AD - Faculty of Biomedical Sciences, Institute for Research in Biomedicine, Universita Della Svizzera Italiana, Bellinzona, Switzerland. FAU - Benarafa, Charaf AU - Benarafa C AD - Institute of Virology and Immunology, Bern and Mittelhausern, Bern, Switzerland; Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern, Bern, Switzerland; Multidisciplinary Center for Infectious Diseases, University of Bern, Bern, Switzerland. FAU - Legler, Daniel F AU - Legler DF AD - Institute of Cell Biology and Immunology Thurgau (BITG) at the University of Konstanz, Kreuzlingen, Switzerland; Theodor Kocher Institute, University of Bern, Bern, Switzerland; Department of Biology, University of Konstanz, Konstanz, Germany. FAU - Gonzalez, Santiago F AU - Gonzalez SF AD - Faculty of Biomedical Sciences, Institute for Research in Biomedicine, Universita Della Svizzera Italiana, Bellinzona, Switzerland. Electronic address: santiago.gonzalez@irb.usi.ch. LA - eng PT - Journal Article DEP - 20260821 PL - Netherlands TA - EBioMedicine JT - EBioMedicine JID - 101647039 RN - 0 (BNT162 Vaccine) RN - 0 (COVID-19 Vaccines) RN - 0 (Spike Glycoprotein, Coronavirus) RN - 0 (spike protein, SARS-CoV-2) SB - IM MH - Animals MH - *Dendritic Cells/immunology/metabolism MH - BNT162 Vaccine MH - Mice MH - *CD8-Positive T-Lymphocytes/immunology MH - *Immunologic Memory MH - Vaccination MH - *COVID-19/prevention & control/immunology/virology MH - Female MH - SARS-CoV-2/immunology MH - *COVID-19 Vaccines/immunology MH - Spike Glycoprotein, Coronavirus/immunology/genetics/metabolism MH - Lymph Nodes/immunology MH - Humans MH - Mice, Inbred C57BL PMC - PMC13524885 OTO - NOTNLM OT - BNT162b2 OT - CD8+ T cells OT - COVID-19 vaccines OT - Plasmacytoid dendritic cells OT - SARS-CoV2-immunity OT - mRNA vaccine COIS- Declaration of interests The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2026/08/21 23:37 MHDA- 2026/09/09 23:36 PMCR- 2026/08/21 CRDT- 2026/08/21 18:06 PHST- 2025/10/14 00:00 [received] PHST- 2026/07/29 00:00 [revised] PHST- 2026/07/29 00:00 [accepted] PHST- 2026/09/09 23:36 [medline] PHST- 2026/08/21 23:37 [pubmed] PHST- 2026/08/21 18:06 [entrez] PHST- 2026/08/21 00:00 [pmc-release] AID - S2352-3964(26)00316-6 [pii] AID - 106432 [pii] AID - 10.1016/j.ebiom.2026.106432 [doi] PST - ppublish SO - EBioMedicine. 2026 Sep;131:106432. doi: 10.1016/j.ebiom.2026.106432. Epub 2026 Aug 21. PMID- 42625910 OWN - NLM STAT- MEDLINE DCOM- 20260821 LR - 20260828 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 17 DP - 2026 TI - Differential functional immune recall across homologous and heterologous COVID-19 vaccination regimens. PG - 1921846 LID - 10.3389/fimmu.2026.1921846 [doi] LID - 1921846 AB - INTRODUCTION: Understanding how different COVID-19 vaccine combinations shape long-term immunity is essential for improving durability and guiding booster strategies. Despite extensive characterization of neutralizing antibodies, long-term memory B and T cell responses after homologous and heterologous vaccination regimens remain poorly understood. METHODS: In this study, peripheral blood mononuclear cells (PBMCs) from 50 individuals were analyzed 12 months after completion of a homologous two-dose primary COVID-19 vaccination series and had received a single booster dose (12-month follow-up). Participants initially received BNT162b2, ChAdOx1 nCoV-19, or CoronaVac as the primary vaccination series, followed by either a homologous booster or a heterologous BNT162b2 booster (ChAdOx1 nCoV-19/BNT162b2 and CoronaVac/BNT162b2). Unvaccinated individuals served as controls. B cell phenotypes were assessed using flow cytometry, while B and T cell recall responses were determined using ELISpot. IgG levels and cytokine/chemokine/growth factor profiles were evaluated using ELISA and Bio-Plex multiplex before and after in vitro stimulation. RESULTS: The homologous BNT162b2 vaccination regimen exhibited significantly higher frequencies of memory B cells recognizing the ancestral (Wuhan strain-derived) SARS-CoV-2 Spike protein compared to the ChAdOx1 nCoV-19, CoronaVac, and unvaccinated controls. The CoronaVac/BNT162b2 vaccination regimen demonstrated significantly elevated RBD-specific IgG+ memory B cells and higher stimulated IgG levels, together with the highest IFN-gamma-producing T cell responses. Homologous CoronaVac and CoronaVac/BNT162b2 vaccination regimens showed broader cytokine activation, including IL-6, IL-9, IL-15, TNF-alpha, and other cytokines. IL-6 levels were positively associated with memory B cell frequencies, suggesting a potential association with memory B cell differentiation and maintenance. DISCUSSION: Different vaccination regimens were associated with distinct long-term cellular immune profiles under real-world conditions, with both homologous BNT162b2 and heterologous CoronaVac/BNT162b2 vaccination regimens maintaining robust memory B cell signatures and functional recall responses. The results highlight how priming combinations shape the durability and quality of immune memory, supporting the potential utility of mixed-platform booster strategies for sustaining long-term immunity. CI - Copyright (c) 2026 Che-Kamaruddin, Johari, Yahaya, Zainal, Nguyen, Hontz, Letizia and AbuBakar. FAU - Che-Kamaruddin, Naim AU - Che-Kamaruddin N AD - Tropical Infectious Diseases Research and Education Centre (TIDREC), Higher Institution Centre of Excellence (HICoE), Universiti Malaya, Kuala Lumpur, Malaysia. AD - Institute for Advanced Studies, Universiti Malaya, Kuala Lumpur, Malaysia. FAU - Johari, Jefree AU - Johari J AD - Tropical Infectious Diseases Research and Education Centre (TIDREC), Higher Institution Centre of Excellence (HICoE), Universiti Malaya, Kuala Lumpur, Malaysia. FAU - Yahaya, Hasmawati AU - Yahaya H AD - Tropical Infectious Diseases Research and Education Centre (TIDREC), Higher Institution Centre of Excellence (HICoE), Universiti Malaya, Kuala Lumpur, Malaysia. FAU - Zainal, Nurhafiza AU - Zainal N AD - Department of Medical Microbiology, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia. FAU - Nguyen, Huy C AU - Nguyen HC AD - U.S. Naval Medical Research Unit INDO PACIFIC, Singapore, Singapore. FAU - Hontz, Robert D AU - Hontz RD AD - U.S. Naval Medical Research Unit INDO PACIFIC, Singapore, Singapore. FAU - Letizia, Andrew G AU - Letizia AG AD - U.S. Naval Medical Research Unit INDO PACIFIC, Singapore, Singapore. FAU - AbuBakar, Sazaly AU - AbuBakar S AD - Tropical Infectious Diseases Research and Education Centre (TIDREC), Higher Institution Centre of Excellence (HICoE), Universiti Malaya, Kuala Lumpur, Malaysia. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, Non-P.H.S. DEP - 20260806 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 RN - 0 (BNT162 Vaccine) RN - 0 (Antibodies, Viral) RN - 0 (Antibodies, Neutralizing) RN - 0 (COVID-19 Vaccines) RN - B5S3K2V0G8 (ChAdOx1 nCoV-19) RN - 0 (Immunoglobulin G) RN - 0 (Cytokines) SB - IM MH - Humans MH - Male MH - *COVID-19/immunology/prevention & control MH - Female MH - *SARS-CoV-2/immunology MH - BNT162 Vaccine/immunology MH - *Immunologic Memory MH - Antibodies, Viral/blood/immunology MH - Adult MH - Middle Aged MH - Immunization, Secondary MH - Vaccination MH - Antibodies, Neutralizing/immunology/blood MH - *Memory B Cells/immunology MH - *COVID-19 Vaccines/immunology MH - T-Lymphocytes/immunology MH - ChAdOx1 nCoV-19/immunology MH - Immunoglobulin G/blood/immunology MH - B-Lymphocytes/immunology MH - Cytokines PMC - PMC13490157 OTO - NOTNLM OT - COVID-19 booster vaccination OT - SARS-CoV-2 immunity OT - cellular immune responses OT - heterologous vaccination strategies OT - memory B cells COIS- The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2026/08/21 11:39 MHDA- 2026/08/21 11:40 PMCR- 2026/08/06 CRDT- 2026/08/21 05:35 PHST- 2026/06/28 00:00 [received] PHST- 2026/07/17 00:00 [revised] PHST- 2026/07/28 00:00 [accepted] PHST- 2026/08/21 11:40 [medline] PHST- 2026/08/21 11:39 [pubmed] PHST- 2026/08/21 05:35 [entrez] PHST- 2026/08/06 00:00 [pmc-release] AID - 10.3389/fimmu.2026.1921846 [doi] PST - epublish SO - Front Immunol. 2026 Aug 6;17:1921846. doi: 10.3389/fimmu.2026.1921846. eCollection 2026. PMID- 42568479 OWN - NLM STAT- MEDLINE DCOM- 20260808 LR - 20260826 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 17 DP - 2026 TI - Conserved CD4 T-cell responses correlate with antibody neutralization in solid organ transplant recipients after bivalent SARS-CoV-2 vaccination. PG - 1856861 LID - 10.3389/fimmu.2026.1856861 [doi] LID - 1856861 AB - INTRODUCTION: Vaccines against SARS-CoV-2 and influenza require reformulation due to viral evolution. It remains unclear how vaccination against evolving antigens influences T-cell responses and the impact of reformulation on T-cell responses to new variants in immunocompromised hosts. Solid organ transplant recipients (SOTRs) had significantly lower antibody levels following vaccination and required repeated boosting during the COVID-19 pandemic. METHODS: With the introduction of the Omicron spike (S) to the bivalent mRNA vaccines in 2022, the relative contribution of T-cell responses cross-reactive for Omicron mutated S sequences was assessed via intracellular cytokine staining using peptide pools containing conserved or mutated S sequences. RESULTS: S-specific CD4 T cells recognize both conserved and Omicron mutated S sequences pre- and post-bivalent vaccination, even in the absence of evidence of prior infection as detected by T-cell responses to a novel peptide pool. CD4 T-cell responses to both conserved and Omicron mutated sequences correlated with antibody pseudo-neutralization of BA.5 S. Importantly, pre-bivalent conserved S CD4 T-cell responses significantly correlated with antibody pseudo-neutralization of BA.5 S post-bivalent. DISCUSSION: These results emphasize the importance of conserved and cross-reactive responses in vaccine immunogenicity, providing a mechanism through which repeated boosting enhances vaccine immunogenicity in SOTRs and other immunocompromised populations. CI - Copyright (c) 2026 Stavrakis, Roznik, Stoddart, Johnston, Panda, Hage, Teles, Eby, Werbel, Tobian, Milstone, Sette, Grifoni, Karaba, Thompson and Cox. FAU - Stavrakis, Georgia AU - Stavrakis G AD - Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States. FAU - Roznik, Katerina AU - Roznik K AD - Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States. FAU - Stoddart, Laila AU - Stoddart L AD - Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States. FAU - Johnston, T Scott AU - Johnston TS AD - Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States. FAU - Panda, Snigdha AU - Panda S AD - Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, United States. FAU - Hage, Camille AU - Hage C AD - Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, United States. FAU - Teles, Aura T AU - Teles AT AD - Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, United States. FAU - Eby, Yolanda AU - Eby Y AD - Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, United States. FAU - Werbel, William A AU - Werbel WA AD - Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States. FAU - Tobian, Aaron A R AU - Tobian AAR AD - Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, United States. FAU - Milstone, Aaron M AU - Milstone AM AD - Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD, United States. FAU - Sette, Alessandro AU - Sette A AD - Center for Vaccine Innovation, La Jolla Institute for Immunology (LJI), La Jolla, CA, United States. AD - Department of Pathology, University of California, San Diego, San Diego, La Jolla, CA, United States. FAU - Grifoni, Alba AU - Grifoni A AD - Center for Vaccine Innovation, La Jolla Institute for Immunology (LJI), La Jolla, CA, United States. FAU - Karaba, Andrew H AU - Karaba AH AD - Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States. FAU - Thompson, Elizabeth A AU - Thompson EA AD - Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States. AD - Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States. FAU - Cox, Andrea L AU - Cox AL AD - Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States. AD - Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States. LA - eng GR - U54 CA260492/CA/NCI NIH HHS/United States GR - UM1 AI109565/AI/NIAID NIH HHS/United States GR - U01 AI138897/AI/NIAID NIH HHS/United States GR - K08 AI156021/AI/NIAID NIH HHS/United States GR - K23 AI157893/AI/NIAID NIH HHS/United States PT - Journal Article DEP - 20260724 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 RN - 0 (Spike Glycoprotein, Coronavirus) RN - 0 (Antibodies, Viral) RN - 0 (COVID-19 Vaccines) RN - 0 (Antibodies, Neutralizing) RN - 0 (spike protein, SARS-CoV-2) RN - 0 (BNT162 Vaccine) RN - 0 (BNT162b5) SB - IM MH - Humans MH - *SARS-CoV-2/immunology MH - *CD4-Positive T-Lymphocytes/immunology MH - Spike Glycoprotein, Coronavirus/immunology/genetics MH - *COVID-19/immunology/prevention & control MH - *Antibodies, Viral/immunology/blood MH - *COVID-19 Vaccines/immunology MH - *Antibodies, Neutralizing/immunology/blood MH - Vaccination MH - Organ Transplantation MH - Transplant Recipients MH - Immunocompromised Host MH - BNT162 Vaccine/immunology MH - Cross Reactions MH - BNT162b5 PMC - PMC13447162 OTO - NOTNLM OT - COVID-19 OT - T cells OT - immunocompromised OT - memory OT - vaccines COIS- AS reported shares of Sandoz Group, Alcon Inc., Sanofi, Eurofin, EuroApi, Merck, Amgen, Johnson and J.; has received honoraria in 2023 from Roche, Flowpharma, Gritstone Bio, Moderna and Rivervest. LJI has filed for patent protection for various aspects of T-cell epitope and vaccine design work. WW reported receiving consulting fees from and serving on the advisory boards of AstraZeneca and Novavax; consulting fees from US Centers for Disease Control and Prevention and Infectious Diseases Society of America. AHK reports consulting fees from Hologic and GSK. AC reported equity in AssayQuant Technologies, Inc., consulting fees from Eradivir, Inc. and XARNA Medicine, and patent: Use of Consensus Sequences as Vaccine Antigen to Enhance Recognition of Virulent Viral Variants US Patent Number: 8,168,771. The remaining author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2026/08/08 12:52 MHDA- 2026/08/08 12:53 PMCR- 2026/07/24 CRDT- 2026/08/08 05:05 PHST- 2026/04/15 00:00 [received] PHST- 2026/06/27 00:00 [revised] PHST- 2026/06/30 00:00 [accepted] PHST- 2026/08/08 12:53 [medline] PHST- 2026/08/08 12:52 [pubmed] PHST- 2026/08/08 05:05 [entrez] PHST- 2026/07/24 00:00 [pmc-release] AID - 10.3389/fimmu.2026.1856861 [doi] PST - epublish SO - Front Immunol. 2026 Jul 24;17:1856861. doi: 10.3389/fimmu.2026.1856861. eCollection 2026. PMID- 42543244 OWN - NLM STAT- Publisher LR - 20260802 IS - 1476-8321 (Electronic) IS - 0887-0446 (Linking) DP - 2026 Aug 2 TI - Predicting parents' COVID-19 vaccination intentions and behavior for their children: application of an integrated social cognition model. PG - 1-34 LID - 10.1080/08870446.2026.2707302 [doi] AB - OBJECTIVE: Identifying modifiable determinants of parent-for-child vaccination may inform interventions for ongoing management of infectious diseases including COVID-19. We tested an integrated theoretical model in which social cognition constructs (coping appraisals, anticipated regret, moral norms) mediated effects of dispositional constructs (political orientation, conspiracy beliefs, vaccine hesitancy) on parent-for-child COVID-19 vaccination intention and behaviour. METHODS AND MEASURES: In a prospective correlational study, US parents (N = 497) with an unvaccinated child completed political orientation, conspiracy beliefs, vaccine hesitancy, and social cognition construct measures referring to COVID-19 vaccination for their child. Parents reported their vaccination behaviour for their child five weeks later. RESULTS: Consistent with predictions, we observed indirect effects of political orientation and vaccination hesitancy on intentions mediated by coping efficacy, anticipated regret, and moral norms, and sums of indirect effects of political orientation, conspiracy beliefs, and vaccine hesitancy on intention mediated by social cognition constructs. We also observed a sum of indirect effects of vaccine hesitancy on behaviour. CONCLUSION: Findings contribute to an evidence base for the effects of dispositional and social cognition constructs of parent-for-child COVID-19 vaccination intentions and behaviour and signal a candidate mechanism. Findings may provide formative evidence for developing interventions to manage childhood COVID-19 infection rates. FAU - Griffith, Zoe M AU - Griffith ZM AD - Department of Psychological Sciences, University of California, Merced, California, USA. FAU - Royer, Zoe AU - Royer Z AD - Department of Psychology, Cal Poly Humboldt, Arcata, California, USA. FAU - Gaffney, Amber M AU - Gaffney AM AD - Department of Psychology, Cal Poly Humboldt, Arcata, California, USA. FAU - Hagger, Martin S AU - Hagger MS AD - Department of Psychological Sciences, University of California, Merced, California, USA. AD - Health Sciences Research Institute, University of California, Merced, California, USA. AD - Faculty of Sport and Health Sciences, University of Jyvaskyla, Jyvaskyla, Finland. AD - School of Applied Psychology, Griffith University. LA - eng PT - Journal Article DEP - 20260802 PL - England TA - Psychol Health JT - Psychology & health JID - 8807983 SB - IM OTO - NOTNLM OT - COVID-19 vaccination OT - Social cognition theory OT - dispositional-belief-motivation model OT - psychological determinants OT - theory integration EDAT- 2026/08/03 00:35 MHDA- 2026/08/03 00:35 CRDT- 2026/08/02 22:22 PHST- 2026/08/03 00:35 [medline] PHST- 2026/08/03 00:35 [pubmed] PHST- 2026/08/02 22:22 [entrez] AID - 10.1080/08870446.2026.2707302 [doi] PST - aheadofprint SO - Psychol Health. 2026 Aug 2:1-34. doi: 10.1080/08870446.2026.2707302. PMID- 42522246 OWN - NLM STAT- MEDLINE DCOM- 20260729 LR - 20260813 IS - 1600-065X (Electronic) IS - 0105-2896 (Print) IS - 0105-2896 (Linking) VI - 341 IP - 1 DP - 2026 Aug TI - The Role of CD4 T Cell Repertoire and Immune Memory Mechanisms in Vaccination and Infection Immunity. PG - e70148 LID - 10.1111/imr.70148 [doi] LID - e70148 AB - CD4(+) T cells orchestrate adaptive immunity against respiratory viruses through functionally distinct subsets, yet the qualitative differences between vaccine- and infection-induced responses remain incompletely understood. This review summarizes current evidence on how CD4(+) T cell subsets shape the magnitude, breadth, and durability of immunity to SARS-CoV-2 and influenza virus. mRNA vaccines elicit a potent Th1/Tfh1-biased response that generates high-affinity neutralizing antibodies and cytotoxic CD4(+) T cells (CD4-CTLs) with stem-cell memory properties. However, this strong type I bias may come at the cost of long-term maintenance of humoral memory. Natural infection additionally establishes tissue-resident memory CD4(+) T cells (CD4 TRMs) at respiratory mucosal surfaces, providing a frontline defense that current intramuscular vaccines fail to recapitulate efficiently. Crucially, this T cell immunity proves far more resilient than neutralizing antibodies against Variants of Concern, as many memory T cell epitopes from the ancestral strain are conserved across successive variants, a robustness further reinforced by pre-existing cross-reactive CD4(+) T cells primed through prior seasonal coronavirus exposure or influenza infection. These observations argue for a fundamental shift in vaccine design toward mucosal delivery and conserved-epitope antigens to achieve durable, broadly cross-reactive protection. CI - (c) 2026 The Author(s). Immunological Reviews published by John Wiley & Sons Ltd. FAU - Kubo, Masato AU - Kubo M AUID- ORCID: 0000-0001-7867-3086 AD - Immunomonitoring Center (KIC) Shogoin-Kawahara-cho, Kyoto University, Kyoto, Japan. AD - Division of Molecular Pathology, Research Institute for Biomedical Science, Tokyo University of Science, Noda-shi, Chiba, Japan. AD - Laboratory for Cytokine Regulation, Center for Integrative Medical Science (IMS), RIKEN Yokohama Institute, Yokohama, Kanagawa, Japan. LA - eng GR - 19gm1310002/Japan Agency for Medical Research and Development (AMED)/ GR - 25K10403/Japan Society for the Promotion of Science/ PT - Journal Article PT - Review PL - England TA - Immunol Rev JT - Immunological reviews JID - 7702118 RN - 0 (COVID-19 Vaccines) RN - 0 (Influenza Vaccines) RN - 0 (Antibodies, Neutralizing) SB - IM MH - Humans MH - *Immunologic Memory MH - Animals MH - *SARS-CoV-2/immunology MH - *CD4-Positive T-Lymphocytes/immunology MH - Vaccination MH - *Influenza, Human/immunology MH - *COVID-19/immunology/prevention & control MH - *COVID-19 Vaccines/immunology MH - *Influenza Vaccines/immunology MH - Antibodies, Neutralizing/immunology MH - Memory T Cells/immunology PMC - PMC13416234 OTO - NOTNLM OT - SARS-CoV-2 OT - T follicular helper (Tfh) OT - cytotoxic CD4+ T cells (CD4-CTL) OT - cytotoxic T lymphocyte (CTL) OT - helper T cells (Th) OT - influenza virus OT - memory CD4+ T cells (Tm) OT - variants of concern (VOC) COIS- The author declares no conflicts of interest. EDAT- 2026/07/29 06:35 MHDA- 2026/07/29 18:39 PMCR- 2026/07/29 CRDT- 2026/07/29 02:13 PHST- 2026/07/12 00:00 [revised] PHST- 2026/06/03 00:00 [received] PHST- 2026/07/17 00:00 [accepted] PHST- 2026/07/29 18:39 [medline] PHST- 2026/07/29 06:35 [pubmed] PHST- 2026/07/29 02:13 [entrez] PHST- 2026/07/29 00:00 [pmc-release] AID - IMR70148 [pii] AID - 10.1111/imr.70148 [doi] PST - ppublish SO - Immunol Rev. 2026 Aug;341(1):e70148. doi: 10.1111/imr.70148. PMID- 42498786 OWN - NLM STAT- MEDLINE DCOM- 20260724 LR - 20260813 IS - 2041-1723 (Electronic) IS - 2041-1723 (Linking) VI - 17 IP - 1 DP - 2026 Jul 24 TI - JN.1-adapted vaccination is associated with readjustment of ancestral memory B cells toward neutralization within the JN.1 antigenic space. LID - 10.1038/s41467-026-76035-z [doi] LID - 7266 AB - The antigenic drift of SARS-CoV-2 toward the JN.1 lineage has prompted the development of variant-adapted COVID-19 booster vaccines. However, these boosters are thought to primarily recall pre-existing memory B cells (MBC), raising concerns about their ability to realign the immune response in highly pre-exposed populations. Here we analyze antibody and B cell responses in pre-exposed individuals (n = 42; median 4.5 prior COVID-19 vaccinations; 90% with at least one prior SARS-CoV-2 infection) following vaccination with a JN.1-adapted mRNA vaccine. Vaccination is associated with increased IgG binding and enhanced neutralization of JN.1 and related descendant variants. Longitudinal profiling of antigen-specific MBC shows that Wu01-only and Wu01/JN.1 cross-reactive cells remain dominant, while JN.1-only cells modestly increase by day 21. Single-cell RNA-sequencing of antigen-specific MBC in a representative sub-cohort (n = 7), combined with functional monoclonal antibody analyses, demonstrates that somatic hypermutation (SHM) drives intra-clonotype specialization toward improved JN.1 binding and neutralization. These findings indicate maturation of pre-existing, class-switched MBC rather than substantial de novo recruitment of naive B cells. In conclusion, JN.1-adapted booster vaccination is associated with refinement of pre-existing MBC repertoires toward the JN.1 antigenic space and with enhanced neutralization of contemporary and antigenically proximate variants. CI - (c) 2026. The Author(s). FAU - Stankov, Metodi V AU - Stankov MV AUID- ORCID: 0000-0003-3001-2478 AD - Department of Rheumatology and Immunology, Hannover Medical School, Hannover, Germany. FAU - Bruhn, Matthias AU - Bruhn M AD - Institute for Experimental Infection Research, TWINCORE, Centre for Experimental and Clinical Infection Research, a joint venture between the Helmholtz Centre for Infection Research and the Hannover Medical School, Hannover, Germany. FAU - Hoffmann, Markus AU - Hoffmann M AUID- ORCID: 0000-0003-4603-7696 AD - Infection Biology Unit, German Primate Center - Leibniz Institute for Primate Research, Gottingen, Germany. FAU - Salam, Abdus AU - Salam A AD - Institute for Experimental Infection Research, TWINCORE, Centre for Experimental and Clinical Infection Research, a joint venture between the Helmholtz Centre for Infection Research and the Hannover Medical School, Hannover, Germany. FAU - Eichmann, Amy AU - Eichmann A AD - Infection Biology Unit, German Primate Center - Leibniz Institute for Primate Research, Gottingen, Germany. FAU - Nehlmeier, Inga AU - Nehlmeier I AUID- ORCID: 0000-0002-8752-7491 AD - Infection Biology Unit, German Primate Center - Leibniz Institute for Primate Research, Gottingen, Germany. FAU - Manthey, Luis A AU - Manthey LA AD - Department of Rheumatology and Immunology, Hannover Medical School, Hannover, Germany. FAU - Witte, Torsten AU - Witte T AD - Department of Rheumatology and Immunology, Hannover Medical School, Hannover, Germany. FAU - Pohlmann, Stefan AU - Pohlmann S AUID- ORCID: 0000-0001-6086-9136 AD - Infection Biology Unit, German Primate Center - Leibniz Institute for Primate Research, Gottingen, Germany. AD - Faculty of Biology and Psychology, Georg-August-University Gottingen, Gottingen, Germany. FAU - Ahrenstorf, Gerrit AU - Ahrenstorf G AD - Department of Rheumatology and Immunology, Hannover Medical School, Hannover, Germany. FAU - Happle, Christine AU - Happle C AD - Department of Rheumatology and Immunology, Hannover Medical School, Hannover, Germany. AD - Department of Pediatric Pulmonology, Allergology and Neonatology, Hannover Medical School, Hannover, Germany. AD - Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), German Center for Lung Research (DZL), Hannover, Germany. FAU - Dopfer-Jablonka, Alexandra AU - Dopfer-Jablonka A AUID- ORCID: 0000-0001-7129-100X AD - Department of Rheumatology and Immunology, Hannover Medical School, Hannover, Germany. FAU - Kalinke, Ulrich AU - Kalinke U AUID- ORCID: 0000-0003-0503-9564 AD - Institute for Experimental Infection Research, TWINCORE, Centre for Experimental and Clinical Infection Research, a joint venture between the Helmholtz Centre for Infection Research and the Hannover Medical School, Hannover, Germany. AD - Cluster of Excellence RESIST (EXC 2155), Hannover Medical School, Hannover, Germany. AD - German Center for Infection Research (DZIF), partner site Hannover-Braunschweig, Hannover, Germany. FAU - Behrens, Georg M N AU - Behrens GMN AUID- ORCID: 0000-0003-3111-621X AD - Department of Rheumatology and Immunology, Hannover Medical School, Hannover, Germany. Behrens.georg@mh-hannover.de. AD - Cluster of Excellence RESIST (EXC 2155), Hannover Medical School, Hannover, Germany. Behrens.georg@mh-hannover.de. AD - German Center for Infection Research (DZIF), partner site Hannover-Braunschweig, Hannover, Germany. Behrens.georg@mh-hannover.de. AD - Center for Individualized Infection Medicine (CiiM), Hannover, Germany. Behrens.georg@mh-hannover.de. LA - eng SI - Dataset DOI/PRJNA1431958 PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20260724 PL - England TA - Nat Commun JT - Nature communications JID - 101528555 RN - 0 (Antibodies, Viral) RN - 0 (COVID-19 Vaccines) RN - 0 (Antibodies, Neutralizing) RN - 0 (Antigens, Viral) RN - 0 (Immunoglobulin G) RN - SARS-CoV-2 variants SB - IM MH - Humans MH - *Memory B Cells/immunology MH - Antibodies, Viral/immunology MH - *SARS-CoV-2/immunology/genetics MH - *COVID-19 Vaccines/immunology/administration & dosage MH - *Antibodies, Neutralizing/immunology MH - *COVID-19/immunology/prevention & control/virology MH - Somatic Hypermutation, Immunoglobulin MH - Immunization, Secondary MH - Vaccination MH - Antigens, Viral/immunology MH - Immunoglobulin G/immunology MH - B-Lymphocytes/immunology MH - Immunologic Memory PMC - PMC13400639 COIS- Competing interests: M.V.S., M.B., M.H., U.K. and G.M.N.B. are listed as co-inventors on a patent application encompassing monoclonal antibodies generated in this study (European Patent Application No. 25 210 459.1). The remaining authors (A.S., A.E., I.N., L.A.M., T.W., S.P., G.A., C.H., A.D.-J.) declare no competing interests. EDAT- 2026/07/25 00:35 MHDA- 2026/07/25 00:36 PMCR- 2026/07/24 CRDT- 2026/07/24 23:16 PHST- 2025/08/18 00:00 [received] PHST- 2026/07/18 00:00 [accepted] PHST- 2026/07/25 00:36 [medline] PHST- 2026/07/25 00:35 [pubmed] PHST- 2026/07/24 23:16 [entrez] PHST- 2026/07/24 00:00 [pmc-release] AID - 10.1038/s41467-026-76035-z [pii] AID - 76035 [pii] AID - 10.1038/s41467-026-76035-z [doi] PST - epublish SO - Nat Commun. 2026 Jul 24;17(1):7266. doi: 10.1038/s41467-026-76035-z. PMID- 42478837 OWN - NLM STAT- MEDLINE DCOM- 20260812 LR - 20260815 IS - 2150-7511 (Electronic) VI - 17 IP - 8 DP - 2026 Aug 12 TI - Mucosal boosting of chimpanzee adenovirus-vectored vaccine encoding SARS-CoV-2 RBD-heterodimer provides robust protection in mice. PG - e0146426 LID - 10.1128/mbio.01464-26 [doi] LID - e01464-26 AB - The major route of COVID-19 vaccination currently is via intramuscular injection. Data from clinical trials and real-world studies have demonstrated its effectiveness in preventing severe illness and death caused by SARS-CoV-2 infection. However, its protective efficacy against SARS-CoV-2 infection and transmission in situ remains relatively low. Given that SARS-CoV-2, especially the Omicron variant and its sub-variants, primarily infects and replicates in the human upper respiratory tract, mucosal immune responses are crucial for preventing viral infection. Therefore, we constructed a chimpanzee adenovirus (AdC68)-vectored vaccine expressing the Delta-XBB receptor-binding domain (RBD)-dimer and comprehensively compared the immune responses induced by intramuscular injection, intranasal administration, or aerosol inhalation. Our results revealed that aerosol inhalation of the recombinant AdC68 vaccine induced robust systemic and mucosal immune responses and immune memory, particularly activating memory T cells in the lungs with a long duration in the mouse model. Additionally, we assessed long-term protection against a SARS-CoV-2 XBB.1 challenge after ~6 months following a booster vaccination with AdC68-Delta-XBB via different immunization routes. We found that, compared with the intramuscular route, aerosol inhalation provided significantly better protection, without detectable replicating virus in the nasal tissue. This study demonstrates that the AdC68-Delta-XBB vaccine induces robust mucosal immune responses via aerosol inhalation vaccination and prevents SARS-CoV-2 infection in mucosa.IMPORTANCEImmunity induced by first-generation COVID-19 vaccines administered by intramuscular injection is highly effective against severe disease and death but is limited in its ability to prevent viral infection and transmission. A more cost-effective and practical vaccine delivered by the respiratory route is needed to better understand mucosal immune responses and to assess protective efficacy. This study evaluated the immune responses and protective efficacy elicited by intramuscular injection, intranasal administration, or aerosol inhalation of AdC68-Delta-XBB in a mouse model and demonstrated that the aerosol inhalation approach is particularly advantageous for robustly stimulating both systemic and mucosal immune responses. These findings will help guide future clinical development and provide a basis for developing vaccines against other respiratory pathogens. FAU - Liu, Xueyuan AU - Liu X AUID- ORCID: 0009-0008-4319-0568 AD - School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan, Shandong Province, China. ROR: https://ror.org/0207yh398 FAU - An, Yaling AU - An Y AD - CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences (CAS), Beijing, China. ROR: https://ror.org/034t30j35 FAU - Duan, Huixin AU - Duan H AD - CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences (CAS), Beijing, China. ROR: https://ror.org/034t30j35 FAU - Shao, Fei AU - Shao F AD - CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences (CAS), Beijing, China. ROR: https://ror.org/034t30j35 FAU - Xu, Ke AU - Xu K AD - NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention (China CDC), Beijing, China. ROR: https://ror.org/04wktzw65 FAU - Yang, Chenxi AU - Yang C AD - CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences (CAS), Beijing, China. ROR: https://ror.org/034t30j35 FAU - Xu, Senyu AU - Xu S AD - Medical School, University of Chinese Academy of Sciences, Beijing, China. ROR: https://ror.org/05qbk4x57 FAU - Zhou, Xuemei AU - Zhou X AD - CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences (CAS), Beijing, China. ROR: https://ror.org/034t30j35 FAU - Duan, Minrun AU - Duan M AD - College of Animal Science and Veterinary Medicine, Guangxi University, Nanning, China. RINGGOLD: 12664. ROR: https://ror.org/02c9qn167 FAU - Zheng, Tianyi AU - Zheng T AD - Zhejiang University School of Medicine, Hangzhou, China. RINGGOLD: 26441. ROR: https://ror.org/00a2xv884 FAU - Sun, Shiyu AU - Sun S AD - College of Animal Science and Veterinary Medicine, Guangxi University, Nanning, China. RINGGOLD: 12664. ROR: https://ror.org/02c9qn167 FAU - Yang, Mengjie AU - Yang M AD - NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention (China CDC), Beijing, China. ROR: https://ror.org/04wktzw65 FAU - Cai, Kun AU - Cai K AD - NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention (China CDC), Beijing, China. ROR: https://ror.org/04wktzw65 FAU - Liu, William J AU - Liu WJ AD - Strategic Pandemic Preparedness Action and Research Center (SPARC), Guangzhou National Laboratory, Guangzhou, China. RINGGOLD: 612039. ROR: https://ror.org/03ybmxt82 FAU - Zhou, Dongming AU - Zhou D AUID- ORCID: 0000-0002-5989-7591 AD - Department of Pathogen Biology, School of Basic Medical Sciences, Medical University, Tianjin, China. FAU - Xu, Kun AU - Xu K AUID- ORCID: 0000-0002-9762-5001 AD - Institute of Zoology, Chinese Academy of Sciences, Beijing, China. RINGGOLD: 53024. ROR: https://ror.org/034t30j35 FAU - Dai, Lianpan AU - Dai L AD - CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences (CAS), Beijing, China. ROR: https://ror.org/034t30j35 FAU - Wang, Shuo AU - Wang S AUID- ORCID: 0000-0002-5383-3386 AD - CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences (CAS), Beijing, China. ROR: https://ror.org/034t30j35 FAU - Liu, Peipei AU - Liu P AUID- ORCID: 0000-0001-8374-9823 AD - NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention (China CDC), Beijing, China. ROR: https://ror.org/04wktzw65 FAU - Ma, Wei AU - Ma W AUID- ORCID: 0000-0002-8092-3280 AD - School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan, Shandong Province, China. ROR: https://ror.org/0207yh398 FAU - Gao, George F AU - Gao GF AUID- ORCID: 0000-0002-3869-615X AD - CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences (CAS), Beijing, China. ROR: https://ror.org/034t30j35 AD - NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention (China CDC), Beijing, China. ROR: https://ror.org/04wktzw65 AD - Strategic Pandemic Preparedness Action and Research Center (SPARC), Guangzhou National Laboratory, Guangzhou, China. RINGGOLD: 612039. ROR: https://ror.org/03ybmxt82 LA - eng GR - 2020YFA0907100/National Key R&D Program of China/ GR - 2018113/Chinese Academy of Sciences/ GR - 2023YFC2307604/National Key R&D Program of China/ GR - 2021YFC2302600/National Key R&D Program of China/ GR - YSBR-010/Chinese Academy of Sciences/ GR - 2023000CA0020/Beijing Life Science Academy/ GR - 2022QNRC001/Young Elite Scientists Sponsorship Program by CAST/ GR - 82202030/National Natural Science Foundation of China/ GR - INV-027420/Bill & Melinda Gates Foundation/United States GR - INV-027420/Bill & Melinda Gates Foundation/ GR - GZB20230818/Postdoctoral Fellowship Program of China Postdoctoral Science Foundation (CPSF)/ PT - Journal Article DEP - 20260721 PL - United States TA - mBio JT - mBio JID - 101519231 RN - 0 (COVID-19 Vaccines) RN - 0 (Antibodies, Viral) RN - 0 (Spike Glycoprotein, Coronavirus) RN - 0 (Vaccines, Synthetic) RN - 0 (spike protein, SARS-CoV-2) RN - 0 (Antibodies, Neutralizing) SB - IM MH - Animals MH - Mice MH - *SARS-CoV-2/immunology/genetics MH - *COVID-19/prevention & control/immunology MH - *Immunity, Mucosal MH - *COVID-19 Vaccines/immunology/administration & dosage/genetics MH - Female MH - Antibodies, Viral/immunology/blood MH - *Spike Glycoprotein, Coronavirus/immunology/genetics MH - Injections, Intramuscular MH - Administration, Intranasal MH - Genetic Vectors MH - Mice, Inbred BALB C MH - Vaccines, Synthetic/immunology/administration & dosage MH - Pan troglodytes MH - *Adenoviruses, Simian/genetics MH - Immunization, Secondary MH - Disease Models, Animal MH - Antibodies, Neutralizing/immunology MH - Immunologic Memory PMC - PMC13463698 OTO - NOTNLM OT - adenovirus-vectored vaccine OT - aerosol inhalation OT - memory T cells OT - mucosal immune responses COIS- T.Z., Kun Xu, L.D., and G.F.G. are listed in the patent as the inventors of the RBD heterodimer as a coronavirus vaccine. EDAT- 2026/07/21 12:35 MHDA- 2026/08/12 11:38 PMCR- 2026/07/21 CRDT- 2026/07/21 09:13 PHST- 2026/08/12 11:38 [medline] PHST- 2026/07/21 12:35 [pubmed] PHST- 2026/07/21 09:13 [entrez] PHST- 2026/07/21 00:00 [pmc-release] AID - mbio01464-26 [pii] AID - mbio.01464-26 [pii] AID - 10.1128/mbio.01464-26 [doi] PST - ppublish SO - mBio. 2026 Aug 12;17(8):e0146426. doi: 10.1128/mbio.01464-26. Epub 2026 Jul 21. PMID- 42472497 OWN - NLM STAT- MEDLINE DCOM- 20260811 LR - 20260811 IS - 1873-2518 (Electronic) IS - 0264-410X (Linking) VI - 88 DP - 2026 Aug 13 TI - ChAdOx1 nCoV-19 coronavirus vaccine: Long-term safety and immunological responses. PG - 128951 LID - S0264-410X(26)00760-7 [pii] LID - 10.1016/j.vaccine.2026.128951 [doi] AB - RATIONALE: Follow-up of pre-licensure trial participants potentially informs a vaccine's long-term safety profile. DESIGN: This prospective study enrolled participants from the first clinical trials of ChAdOx1 nCoV-19 vaccine, many of whom subsequently received COVID-19 vaccines in the UK vaccination programme. Serious adverse events (SAEs) and adverse events of special interest (AESIs) were captured. AESI selection was based on Brighton Collaboration definitions. RESULTS: Between September 2021 and April 2022, 4470 participants enrolled (58% female, median age 50 years); 3845/4470 (86.0%) completed the study. Median follow-up was 11.77 months; total follow-up was 48,116 person-months. There were 174 SAEs and 71 AESIs (33 events recorded as both) in 195 participants, including 5 deaths. Immunology data were available for a small subset of participants; total IgG against trimeric SARS-CoV-2 spike protein tended to increase during the study. CONCLUSIONS: Although no emergent safety signals were detected, continued post-marketing surveillance remains imperative, particularly for neurological disorders. EUDRACT NUMBER: 2021-003382-36. CI - Copyright (c) 2026 The Authors. Published by Elsevier Ltd.. All rights reserved. FAU - Ebrahimi, Narges AU - Ebrahimi N AD - Oxford Vaccine Group, Department of Paediatrics, Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Old Road, Headington, Oxford OX3 7LE, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK. FAU - de Whalley, Philip AU - de Whalley P AD - Oxford Vaccine Group, Department of Paediatrics, Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Old Road, Headington, Oxford OX3 7LE, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK. Electronic address: philip.dewhalley@paediatrics.ox.ac.uk. FAU - Kanji, Nasir AU - Kanji N AD - Oxford Vaccine Group, Department of Paediatrics, Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Old Road, Headington, Oxford OX3 7LE, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK. FAU - Ramasamy, Maheshi N AU - Ramasamy MN AD - Oxford Vaccine Group, Department of Paediatrics, Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Old Road, Headington, Oxford OX3 7LE, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK; Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Headley Way, Headington, Oxford OX3 9DU, UK. FAU - Aley, Parvinder K AU - Aley PK AD - Oxford Vaccine Group, Department of Paediatrics, Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Old Road, Headington, Oxford OX3 7LE, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK. FAU - Bibi, Sagida AU - Bibi S AD - Oxford Vaccine Group, Department of Paediatrics, Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Old Road, Headington, Oxford OX3 7LE, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK. FAU - Clutterbuck, Elizabeth A AU - Clutterbuck EA AD - Oxford Vaccine Group, Department of Paediatrics, Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Old Road, Headington, Oxford OX3 7LE, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK. FAU - Collins, Andrea M AU - Collins AM AD - University Hospital Liverpool Group and Liverpool School of Tropical Medicine (LSTM), Pembroke Place, Liverpool L3 5QA, UK. FAU - Darton, Thomas C AU - Darton TC AD - School of Medicine and Population Health, University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust, Royal Hallamshire Hospital, Glossop Road, Sheffield S10 2RX, UK. FAU - Duncan, Christopher J A AU - Duncan CJA AD - NIHR Newcastle Clinical Research Facility, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Royal Victoria Infirmary, Newcastle upon Tyne NE1 4LP, UK; Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne NE2 4HH, UK. FAU - Faust, Saul N AU - Faust SN AD - NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton SO16 6YD, UK; Faculty of Medicine and Institute of Life Sciences, University of Southampton, Southampton SO17 1BJ, UK. FAU - Feng, Elaine Shuo AU - Feng ES AD - Oxford Vaccine Group, Department of Paediatrics, Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Old Road, Headington, Oxford OX3 7LE, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK; School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. FAU - Goodman, Anna L AU - Goodman AL AD - Department of Infection at Guy's and St Thomas' NHS Foundation Trust, Department of Infection, St Thomas Hospital, Westminster Bridge Road, London SE1 7EH, UK; MRC Clinical trials unit at University College London, 90 High Holborn, London WC1V 6LJ, UK. FAU - Green, Christopher A AU - Green CA AD - NIHR/Wellcome Clinical Research Facility, University Hospitals Birmingham NHS Foundation Trust (UHB), Queen Elizabeth Hospital Birmingham, Mindelsohn Way, Birmingham B15 2TH, UK. FAU - Heath, Paul T AU - Heath PT AD - City St Georges, University of London, Tooting, London SW17 0QT, UK. FAU - Kwok, Jonathan AU - Kwok J AD - Oxford Vaccine Group, Department of Paediatrics, Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Old Road, Headington, Oxford OX3 7LE, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK. FAU - Lazarus, Rajeka AU - Lazarus R AD - University Hospitals Bristol and Weston NHS Foundation Trust, Marlborough Street, Avon, Bristol BS1 3NU, UK; Bristol Medical School, University of Bristol, Queens Road, Bristol BS8 1QU, UK. FAU - Libri, Vincenzo AU - Libri V AD - University College London Hospitals NHS Foundation Trust, 250 Euston Road, London NW1 2PG, UK. FAU - Lillie, Patrick J AU - Lillie PJ AD - Hull University Teaching Hospitals NHS Trust (HUTH), Hull Royal Infirmary, Anlaby Road, Hull HU3 2JZ, UK. FAU - McGregor, Alastair AU - McGregor A AD - Northwick Park Hospital, London North West University Healthcare Trust, Northwick Park Hospital, Watford Road, Harrow, HA1 3UJ, UK. FAU - Mujadidi, Yama F AU - Mujadidi YF AD - Oxford Vaccine Group, Department of Paediatrics, Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Old Road, Headington, Oxford OX3 7LE, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK. FAU - Owino, Nelly AU - Owino N AD - Oxford Vaccine Group, Department of Paediatrics, Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Old Road, Headington, Oxford OX3 7LE, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK. FAU - Plested, Emma AU - Plested E AD - Oxford Vaccine Group, Department of Paediatrics, Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Old Road, Headington, Oxford OX3 7LE, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK. FAU - Pollock, Katrina M AU - Pollock KM AD - Oxford Vaccine Group, Department of Paediatrics, Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Old Road, Headington, Oxford OX3 7LE, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK; NIHR Imperial Clinical Research Facility, Imperial College Healthcare NHS Trust, Hammersmith Hospital Campus, Du Cane Road, London W12 0HS, UK. FAU - Robinson, Hannah AU - Robinson H AD - Oxford Vaccine Group, Department of Paediatrics, Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Old Road, Headington, Oxford OX3 7LE, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK. FAU - Sutherland, Rebecca K AU - Sutherland RK AD - Clinical Infection Research Group, Regional Infectious Diseases Unit, Western General Hospital, Telford Road, Edinburgh EH4 2JP, UK. FAU - Thomson, Emma C AU - Thomson EC AD - MRC-University of Glasgow Centre for Virus Research (CVR), 464 Bearsden Road, Glasgow G61 1NH, UK; NHS Greater Glasgow and Clyde, Queen Elizabeth University Hospital (QEUH), 1345 Govan Road, Glasgow G51 4TF, UK. FAU - Toshner, Mark AU - Toshner M AD - Victor Phillip Dahdaleh Heart and Lung Research Institute, University of Cambridge, Biomedical Campus, Papworth Road, Trumpington, Cambridge CB2 0BB, UK. FAU - Turner, David P J AU - Turner DPJ AD - School of Life Sciences, University of Nottingham, University Park, Derby Road, Nottingham NG7 2RD, UK. FAU - Williams, Christopher J AU - Williams CJ AD - Public Health Wales, Aneurin Bevan University Health Board, St. Cadoc's Hospital, Lodge Road, Caerleon, Newport NP18 3XQ, UK. FAU - Hirsch, Ian AU - Hirsch I AD - Biometrics, Vaccines, & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK. FAU - Villafana, Tonya L AU - Villafana TL AD - AstraZeneca, One Medimmune Way, Gaithersburg, MD 20878, USA. FAU - Lambe, Teresa AU - Lambe T AD - Oxford Vaccine Group, Department of Paediatrics, Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Old Road, Headington, Oxford OX3 7LE, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK; Chinese Academy of Medical Science Oxford Institute, University of Oxford, Oxford, UK; Pandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK. FAU - Voysey, Merryn AU - Voysey M AD - Oxford Vaccine Group, Department of Paediatrics, Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Old Road, Headington, Oxford OX3 7LE, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK. FAU - Pollard, Andrew J AU - Pollard AJ AD - Oxford Vaccine Group, Department of Paediatrics, Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Old Road, Headington, Oxford OX3 7LE, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK. LA - eng PT - Journal Article DEP - 20260718 PL - Netherlands TA - Vaccine JT - Vaccine JID - 8406899 RN - B5S3K2V0G8 (ChAdOx1 nCoV-19) RN - 0 (COVID-19 Vaccines) RN - 0 (Antibodies, Viral) RN - 0 (Spike Glycoprotein, Coronavirus) RN - 0 (Immunoglobulin G) RN - 0 (spike protein, SARS-CoV-2) SB - IM MH - Humans MH - Female MH - ChAdOx1 nCoV-19 MH - *COVID-19 Vaccines/immunology/adverse effects/administration & dosage MH - Prospective Studies MH - Antibodies, Viral/blood/immunology MH - Middle Aged MH - Male MH - *COVID-19/prevention & control/immunology MH - *SARS-CoV-2/immunology MH - Spike Glycoprotein, Coronavirus/immunology MH - Immunoglobulin G/blood/immunology MH - Adult MH - United Kingdom MH - Follow-Up Studies OTO - NOTNLM OT - AZD1222 OT - Adenoviral vector vaccine OT - Booster vaccine OT - Covishield OT - Pandemic OT - Vaxzevria COIS- Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: AJP, TL, PKA, SB, EAC, SNF, YFM, NO, EP, HR and MV are inventors and/or contributors to the intellectual property licensed by Oxford University Innovation to AstraZeneca. AJP was the Chair of the UK Department of Health and Social Care's (DHSC) Joint Committee on Vaccines and Immunisation (JCVI) until October 2025 but did not participate in the JCVI COVID-19 committee while ChAdOx1-nCOV19 was in use in the UK, the views expressed in this article do not necessarily reflect the views of JCVI or DHSC. He is a member of WHOs Product Development Advisory Committee and technical advisory group on Salmonella Vaccines. AJP declares grant funding for research on vaccines from the Wellcome Trust, Innovate UK, Medical Research Council, National Institute for Health Research, European Commission, Gates Foundation, Ellison Institute of Technology, Serum Institute of India and AstraZeneca. AJP is a contributor to intellectual property licensed by Oxford University Innovation to AstraZeneca and has acted as a consultant for Ellison Institute of Technology. TL reports having provided SAB/consultancy or received honorarium/grants from - Infinitopes, Seqirus, Sanofi, AstraZeneca, Geovax Labs, Arabio, aVaxzipen. TL is a named inventor on ChAdOx1-Zoster, ChAdOx1-SARSCoV2 and Gene insertion into MVA. IH and TLV are employees of AstraZeneca and may hold stock or stock options. CJAD reports grant funding and a Clinician Scientist Fellowship from the UK Medical Research Council (MR/X001598/1); acting on behalf of Newcastle upon Tyne Hospitals NHS Foundation Trust as an investigator on clinical trials funded or sponsored by manufacturers of vaccines and antimicrobials, including Moderna, AstraZeneca, Synairgen, Janssen, and Valneva, with no remuneration; remuneration to Newcastle University for provision of consultative advice to Synairgen; and serving on data safety and monitoring boards for non-commercial clinical trials sponsored by Oxford University, with no remuneration. SNF acts on behalf of University Hospital Southampton NHS Foundation Trust as an Investigator and/or providing consultative advice on clinical trials and studies of COVID-19 and other vaccines funded or sponsored by vaccine manufacturers including Janssen, Pfizer, AstraZeneca, GlaxoSmithKline, Novavax, Seqirus, Sanofi, Medimmune, Merck and Valneva vaccines and antimicrobials. He receives no personal financial payment for this work. ALG is named on a patent for technology used in ChAdOx1 nCoV19 vaccine (AZD1222) which has led to financial benefit. Guy's and St Thomas' has received income from a range of vaccine commercial sponsors to deliver vaccine trials. RL has received investigator-initiated funding from GSK, an honorarium from Sanofi for attending an advisory board and conference registration and travel expenses from Astra Zeneca. KMP has served as a data safety monitoring board member for Moderna (NCT05575492, NCT05249829), is a member of the British HIV Association vaccination guidelines writing committee and has received grant funding from MRC/UKRI, Horizon 2020, The Sir Joseph Hotung Charitable Settlement, the Chan Zuckerberg Initiative, and the NIHR Oxford Biomedical Research Centre outside the submitted work. MNR is CI/PI for vaccine research funded by CEPI, NIHR, Wellcome and Horizon 2020. JK is CEO of Infinitopes. All other authors report no conflict of interest. EDAT- 2026/07/19 18:34 MHDA- 2026/08/11 06:36 CRDT- 2026/07/19 17:59 PHST- 2026/03/19 00:00 [received] PHST- 2026/05/30 00:00 [revised] PHST- 2026/07/14 00:00 [accepted] PHST- 2026/08/11 06:36 [medline] PHST- 2026/07/19 18:34 [pubmed] PHST- 2026/07/19 17:59 [entrez] AID - S0264-410X(26)00760-7 [pii] AID - 10.1016/j.vaccine.2026.128951 [doi] PST - ppublish SO - Vaccine. 2026 Aug 13;88:128951. doi: 10.1016/j.vaccine.2026.128951. Epub 2026 Jul 18. PMID- 42436688 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260712 LR - 20260813 IS - 1179-5735 (Print) IS - 1179-5735 (Electronic) IS - 1179-5735 (Linking) VI - 18 DP - 2026 TI - The Impact of COVID-19 Infection and Vaccination on Neuromyelitis Optica Spectrum Disorder and Myelin Oligodendrocyte Glycoprotein Antibody Disease: A Narrative Review. PG - 11795735261467600 LID - 10.1177/11795735261467600 [doi] LID - 11795735261467600 AB - Despite the estimated 776 million coronavirus disease 2019 (COVID-19) cases globally, little is known about its impact on immune-mediated neurological disorders such as neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody disorder (MOGAD). Scattered case reports, and reviews address this association, but none have collectively examined the impact of COVID-19 infection or vaccination on established and new-onset NMOSD and MOGAD. Reviewing all published reports of COVID-19 infection and vaccination in NMOSD and MOGAD from December 2019 to October 2024, this report examined the effects of infection and vaccination on patients with established disease and the occurrence of new-onset NMOSD and MOGAD. Outcomes associated with COVID-19 infection in NMOSD and MOGAD patients revealed similar hospitalization rates but a notable difference in deaths in NMOSD patients treated with rituximab. Following COVID-19 infection, twice as many patients developed new-onset MOGAD compared to NMOSD, with a similar larger number of patients who developed MOGAD than NMOSD post-COVID-19 vaccination. While the heavy female predominance in NMOSD is well-established, a greater ratio of male to female patients developed MOGAD post-infection and post-vaccination. Clinicians should closely monitor NMOSD patients with COVID-19 infection, particularly those receiving B-cell depleting therapies, among whom mortality was more frequently reported. The rise in NMOSD and MOGAD following COVID-19 infection and vaccination cases warrants further investigation of the underlying immunological mechanisms. Molecular mimicry and a bystander immune-mediated injury likely play a greater role in central nervous system damage than does direct viral injury. CI - (c) The Author(s) 2026. FAU - Hernandez, Jeffrey AU - Hernandez J AUID- ORCID: 0000-0001-6139-7396 AD - Department of Neurology, University of Miami, Miami, FL, USA. RINGGOLD: 166788 AD - School of Nursing and Health Studies (SONHS), University of Miami, Coral Gables, FL, USA. FAU - Delgado, Silvia AU - Delgado S AD - Department of Neurology, University of Miami, Miami, FL, USA. RINGGOLD: 166788 FAU - McCarthy, Micheline AU - McCarthy M AD - Department of Neurology, University of Miami, Miami, FL, USA. RINGGOLD: 166788 FAU - Nelson, Flavia AU - Nelson F AD - Department of Neurology, University of Miami, Miami, FL, USA. RINGGOLD: 166788 FAU - Rammohan, Kottil AU - Rammohan K AD - Department of Neurology, University of Miami, Miami, FL, USA. RINGGOLD: 166788 LA - eng PT - Journal Article PT - Review DEP - 20260710 PL - United States TA - J Cent Nerv Syst Dis JT - Journal of central nervous system disease JID - 101595026 PMC - PMC13354917 OTO - NOTNLM OT - COVID-19 infection OT - COVID-19 vaccination OT - MOGAD OT - NMOSD OT - myelin oligodendrocyte glycoprotein antibody disease OT - neuromyelitis optica spectrum disorder COIS- The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: JH reports a relationship with UHealth, Sanofi, EMD Serono, TG Therapeutics, Novartis Pharmaceuticals, Amgen, Banner Life Sciences, Genentech, Can Do MS, and the Consortium of Multiple Sclerosis Centers that includes: consulting or advisory and/or speaking and lecture fees. SD has received research grants from Novartis and EMD-Serono. MM reports no conflicts of interest. FN reports a relationship with Novartis, Genentech, Sanofi, and EMD-Serono that includes: consulting or advisory and/or speaking and lecture fees. KR reports a relationship with EMD-Serono and Novartis that includes: consulting or advisory and/or speaking and lecture fees; and he has received research grants from Alexion, Novartis, Genentech, and Sanofi. EDAT- 2026/07/12 06:38 MHDA- 2026/07/12 06:39 PMCR- 2026/07/10 CRDT- 2026/07/12 04:04 PHST- 2026/01/29 00:00 [received] PHST- 2026/05/01 00:00 [revised] PHST- 2026/06/15 00:00 [accepted] PHST- 2026/07/12 06:39 [medline] PHST- 2026/07/12 06:38 [pubmed] PHST- 2026/07/12 04:04 [entrez] PHST- 2026/07/10 00:00 [pmc-release] AID - 10.1177_11795735261467600 [pii] AID - 10.1177/11795735261467600 [doi] PST - epublish SO - J Cent Nerv Syst Dis. 2026 Jul 10;18:11795735261467600. doi: 10.1177/11795735261467600. eCollection 2026. PMID- 42426643 OWN - NLM STAT- MEDLINE DCOM- 20261006 LR - 20261008 IS - 1471-2318 (Electronic) IS - 1471-2318 (Linking) VI - 26 IP - 1 DP - 2026 Jul 9 TI - Strict long COVID, symptom persistence, and functional decline among community-dwelling older adults in Quito, Ecuador: a cross-sectional study. LID - 10.1186/s12877-026-07976-9 [doi] LID - 1256 AB - BACKGROUND: Long COVID is an increasingly recognized health concern in older adults, yet data from Latin America remain limited. Older adults may be particularly vulnerable to post-COVID sequelae because of frailty, multimorbidity, and reduced physiological reserve. This study aimed to estimate the prevalence of strict long COVID among older Ecuadorian adults and to characterize persistent post-COVID symptoms, clinical correlates, and functional/cognitive worsening. METHODS: We conducted a cross-sectional study of 1,050 community-dwelling adults aged 65 years or older with PCR-confirmed SARS-CoV-2 infection in Quito, Ecuador. Data were collected through structured face-to-face interviews and cognitive screening. Strict long COVID was defined as symptoms persisting for more than 12 weeks after SARS-CoV-2 infection. Symptoms lasting 4-12 weeks were classified as persistent post-COVID symptoms but were not considered strict long COVID. Multivariable logistic regression was used to evaluate factors associated with strict long COVID. RESULTS: The mean age was 74.2 +/- 7.5 years, and 565 participants (53.8%) were women. Overall, 191 participants met criteria for strict long COVID, corresponding to a prevalence of 18.2% (95% CI, 16.0-20.6). Persistent post-COVID symptoms lasting 4-6 weeks and 7-12 weeks were reported by 401 (38.2%) and 458 (43.6%) participants, respectively. Participants with strict long COVID had higher frequencies of dyspnea, cognitive impairment, sleep disturbance, myalgia, depression, anxiety, and difficulty sleeping. Functional/cognitive worsening was more frequent among participants with strict long COVID than among those without strict long COVID (53.4% vs. 36.6%; p < 0.001), particularly for walking or climbing stairs. In multivariable analysis, severe or critical acute COVID-19 was independently associated with strict long COVID (adjusted OR, 2.36; 95% CI, 1.62-3.41; p < 0.001). Female sex, age >/= 81 years, incomplete vaccination, diabetes with organ involvement, hospitalization, and care dependence were not independently associated with strict long COVID. CONCLUSION: Strict long COVID affected nearly one in five older adults with PCR-confirmed SARS-CoV-2 infection in Quito, Ecuador. Severe or critical acute COVID-19 was the main factor independently associated with strict long COVID, and affected participants had greater functional/cognitive worsening. These findings support integrating post-COVID screening, functional assessment, and geriatric rehabilitation into primary care for older adults in Latin America. CI - (c) 2026. The Author(s). FAU - Gonzalez-Andrade, Fabricio AU - Gonzalez-Andrade F AUID- ORCID: 0000-0002-2091-9095 AD - Faculty of Health Sciences, Dean's Office of Postgraduate Studies in Health, Indoamerica Technological University, Machala and Sabanilla Street, Quito, 170301, Ecuador. fabriciogonzaleza@gmail.com. LA - eng PT - Journal Article DEP - 20260709 PL - England TA - BMC Geriatr JT - BMC geriatrics JID - 100968548 SB - IM MH - Humans MH - Ecuador/epidemiology MH - Cross-Sectional Studies MH - Female MH - Aged MH - Post-Acute COVID-19 Syndrome MH - Male MH - *Independent Living MH - *COVID-19/epidemiology/diagnosis/psychology/complications MH - Aged, 80 and over MH - *Cognitive Dysfunction/epidemiology PMC - PMC13640318 OTO - NOTNLM OT - Cognitive impairment OT - Ecuador OT - Functional decline OT - Long COVID OT - Older adults OT - Persistent post-COVID symptoms OT - Post-COVID condition OT - Strict long COVID OT - Sustainable development goal 3 OT - Vaccination COIS- Declarations. Ethics approval and consent to participate: The study received approval from the Committee on Ethics in Human Research (CEISH) from Carlos Andrade Marin Specialty Hospital (HCAM) on July 6, 2020, under protocol code IESS-HCAM-CEISH-2020-200-DF, in compliance with national and international research regulations. Consent for publication: Not applicable. This manuscript does not contain identifying images or personal clinical details that could compromise participant anonymity. Competing interests: The authors declare no competing interests. EDAT- 2026/07/10 06:35 MHDA- 2026/10/06 05:29 PMCR- 2026/07/09 CRDT- 2026/07/10 00:06 PHST- 2026/04/13 00:00 [received] PHST- 2026/07/07 00:00 [accepted] PHST- 2026/10/06 05:29 [medline] PHST- 2026/07/10 06:35 [pubmed] PHST- 2026/07/10 00:06 [entrez] PHST- 2026/07/09 00:00 [pmc-release] AID - 10.1186/s12877-026-07976-9 [pii] AID - 7976 [pii] AID - 10.1186/s12877-026-07976-9 [doi] PST - epublish SO - BMC Geriatr. 2026 Jul 9;26(1):1256. doi: 10.1186/s12877-026-07976-9. PMID- 42415697 OWN - NLM STAT- MEDLINE DCOM- 20260708 LR - 20260813 IS - 2314-7156 (Electronic) IS - 2314-8861 (Print) IS - 2314-7156 (Linking) VI - 2026 IP - 1 DP - 2026 TI - Dynamics of Circulating Follicular Helper and Regulatory T-Cell Memory Induced by mRNA, Inactivated, and Live-Attenuated Vaccines. PG - e2293380 LID - 10.1155/jimr/2293380 [doi] LID - 2293380 AB - OX40 signaling promotes the differentiation of memory CD4(+) T cells into T follicular helper (Tfh) cells that support germinal center (GC) B-cell responses. Using an extended activation-induced marker (AIM) assay based on OX40 (CD134) and CD25 coexpression, we quantified antigen-specific circulating memory Tfh and T follicular regulatory (Tfr) cells following in vitro stimulation with influenza, SARS-CoV-2, or measles antigens. Responses were assessed longitudinally in recipients of inactivated influenza (n = 20) and mRNA COVID-19 (n = 13) vaccines and cross-sectionally in individuals vaccinated with the live-attenuated measles vaccine (n = 8). All three vaccines elicited humoral responses. Functional assays, performed when sufficient cell numbers were available, showed that sorted influenza-specific Tfh cells (OX40(+)CD25(+)CXCR5(+)), cocultured with autologous CD27(+)CD19(+) memory B cells, promoted B-cell expansion and antibody secretion. This was accompanied by increased CXCL13, IL-21, soluble CD40L, and APRIL, consistent with effective T-cell help and B-cell activation. Comparative analyses revealed distinct patterns of follicular immune responses: influenza vaccination induced coordinated Tfh and Tfr responses, whereas mRNA COVID-19 vaccination generated increased Tfh but minimal Tfr cells. At peak response, measles and influenza vaccinees exhibited comparable Tfh and Tfr frequencies, while COVID-19 vaccinees showed similar Tfh but reduced Tfr proportions. Overall, the extended AIM assay represents a practical and minimally invasive approach for simultaneous monitoring of Tfh and Tfr populations in humans, providing a scalable framework to investigate follicular immune balance across vaccination settings. Beyond enabling sensitive detection of antigen-specific memory responses, this approach highlights the importance of assessing both helper and regulatory follicular compartments to better understand vaccine-induced immunity. CI - Copyright (c) 2026 A. China et al. Journal of Immunology Research published by John Wiley & Sons Ltd. FAU - China, A AU - China A AUID- ORCID: 0009-0002-6790-4496 AD - U955 -Team 16, Faculty of Medicine, INSERM, Creteil, 94000, France, inserm.fr. AD - Paris-Est Creteil University, Creteil, 94000, France. AD - Vaccine Research Institute (VRI), Creteil, 94000, France, vaccine-research-institute.fr. FAU - Rahman, A AU - Rahman A AD - U955 -Team 16, Faculty of Medicine, INSERM, Creteil, 94000, France, inserm.fr. AD - Paris-Est Creteil University, Creteil, 94000, France. AD - Vaccine Research Institute (VRI), Creteil, 94000, France, vaccine-research-institute.fr. FAU - Hani, L AU - Hani L AD - U955 -Team 16, Faculty of Medicine, INSERM, Creteil, 94000, France, inserm.fr. AD - Paris-Est Creteil University, Creteil, 94000, France. AD - Vaccine Research Institute (VRI), Creteil, 94000, France, vaccine-research-institute.fr. FAU - Kumamoto, M AU - Kumamoto M AD - Laboratory of Precision Immunology, Center for Intractable Disease and ImmunoGenomics, National Institutes of Biomedical Innovation Health and Nutrition, Ibaraki, Osaka, 567-0085, Japan. AD - Laboratory of Aging and Immune Regulation, Graduate School of Pharmaceutical Sciences, The University of Osaka, Suita, Osaka, 565-0871, Japan, osaka-u.ac.jp. FAU - Surenaud, Mathieu AU - Surenaud M AD - U955 -Team 16, Faculty of Medicine, INSERM, Creteil, 94000, France, inserm.fr. AD - Paris-Est Creteil University, Creteil, 94000, France. AD - Vaccine Research Institute (VRI), Creteil, 94000, France, vaccine-research-institute.fr. FAU - Tcherakian, C AU - Tcherakian C AD - Pneumology Department, Foch Hospital, Suresnes, France. AD - Simone Veil Research Unit, Versailles Saint-Quentin-en-Yvelines University, Montigny-Le-Bretonneux, France, uvsq.fr. FAU - Godot, V AU - Godot V AD - U955 -Team 16, Faculty of Medicine, INSERM, Creteil, 94000, France, inserm.fr. AD - Paris-Est Creteil University, Creteil, 94000, France. AD - Vaccine Research Institute (VRI), Creteil, 94000, France, vaccine-research-institute.fr. FAU - Nogimori, T AU - Nogimori T AD - Laboratory of Precision Immunology, Center for Intractable Disease and ImmunoGenomics, National Institutes of Biomedical Innovation Health and Nutrition, Ibaraki, Osaka, 567-0085, Japan. FAU - Lelievre, J D AU - Lelievre JD AD - U955 -Team 16, Faculty of Medicine, INSERM, Creteil, 94000, France, inserm.fr. AD - Paris-Est Creteil University, Creteil, 94000, France. AD - Vaccine Research Institute (VRI), Creteil, 94000, France, vaccine-research-institute.fr. AD - Henri Mondor Hospital- A. Chenevier, Service Clinical Immunology and Infectious Diseases Department, Creteil, 94000, France. FAU - Levy, Y AU - Levy Y AUID- ORCID: 0000-0002-5549-6256 AD - U955 -Team 16, Faculty of Medicine, INSERM, Creteil, 94000, France, inserm.fr. AD - Paris-Est Creteil University, Creteil, 94000, France. AD - Vaccine Research Institute (VRI), Creteil, 94000, France, vaccine-research-institute.fr. AD - Henri Mondor Hospital- A. Chenevier, Service Clinical Immunology and Infectious Diseases Department, Creteil, 94000, France. FAU - Tangy, F AU - Tangy F AD - Institut Pasteur - Oncovita Joint Laboratory, Universite de Paris Cite, Paris, France. FAU - Yamamoto, T AU - Yamamoto T AD - Laboratory of Precision Immunology, Center for Intractable Disease and ImmunoGenomics, National Institutes of Biomedical Innovation Health and Nutrition, Ibaraki, Osaka, 567-0085, Japan. AD - Laboratory of Aging and Immune Regulation, Graduate School of Pharmaceutical Sciences, The University of Osaka, Suita, Osaka, 565-0871, Japan, osaka-u.ac.jp. AD - Department of Virology and Immunology, Graduate School of Medicine, The University of Osaka, Suita, Osaka, 565-0871, Japan, osaka-u.ac.jp. FAU - Seddiki, N AU - Seddiki N AUID- ORCID: 0000-0002-0379-8527 AD - U955 -Team 16, Faculty of Medicine, INSERM, Creteil, 94000, France, inserm.fr. AD - Paris-Est Creteil University, Creteil, 94000, France. AD - Vaccine Research Institute (VRI), Creteil, 94000, France, vaccine-research-institute.fr. AD - Immune Diseases, Microbiology and Innovative Therapies (IDMIT/UMRS1184), Inserm, Paris-Saclay University, CEA, Fontenay-aux-Roses, Le Kremlin-Bicetre, France, universite-paris-saclay.fr. AD - Institut Hospitalo-Universitaire Comprehensive SEPSIS Center, Paris-Saclay University, Saclay, France, universite-paris-saclay.fr. AD - Immunology and Pathogenesis Program, Kirby Institute, UNSW, Sydney, New South Wales, Australia, unsw.edu.au. LA - eng GR - INSERM/University of Paris-Est-Creteil/ GR - 24K02498/Japan Society for the Promotion of Science/ PT - Journal Article PL - Egypt TA - J Immunol Res JT - Journal of immunology research JID - 101627166 RN - 0 (Influenza Vaccines) RN - 0 (COVID-19 Vaccines) RN - 0 (Vaccines, Attenuated) RN - 0 (Vaccines, Inactivated) RN - 0 (Measles Vaccine) RN - 0 (mRNA Vaccines) RN - 0 (Antibodies, Viral) SB - IM MH - Humans MH - *Influenza Vaccines/immunology MH - *Immunologic Memory MH - *COVID-19 Vaccines/immunology MH - *T-Lymphocytes, Regulatory/immunology MH - *SARS-CoV-2/immunology MH - Female MH - *T Follicular Helper Cells/immunology MH - Vaccines, Attenuated/immunology MH - Vaccines, Inactivated/immunology MH - *T-Lymphocytes, Helper-Inducer/immunology MH - Measles Vaccine/immunology MH - mRNA Vaccines/immunology MH - Lymphocyte Activation MH - *COVID-19/immunology/prevention & control MH - B-Lymphocytes/immunology MH - Adult MH - Male MH - Antibodies, Viral PMC - PMC13342843 COIS- The authors declare no conflicts of interest. EDAT- 2026/07/08 10:10 MHDA- 2026/07/08 18:50 PMCR- 2026/07/08 CRDT- 2026/07/08 04:22 PHST- 2026/05/26 00:00 [revised] PHST- 2026/04/29 00:00 [received] PHST- 2026/06/06 00:00 [accepted] PHST- 2026/07/08 18:50 [medline] PHST- 2026/07/08 10:10 [pubmed] PHST- 2026/07/08 04:22 [entrez] PHST- 2026/07/08 00:00 [pmc-release] AID - JIMR2293380 [pii] AID - 10.1155/jimr/2293380 [doi] PST - ppublish SO - J Immunol Res. 2026;2026(1):e2293380. doi: 10.1155/jimr/2293380. PMID- 42404887 OWN - NLM STAT- MEDLINE DCOM- 20260706 LR - 20260813 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 17 DP - 2026 TI - Mechanisms and impact of long COVID: pathophysiology, neuropsychiatric effects and vaccination. PG - 1710777 LID - 10.3389/fimmu.2026.1710777 [doi] LID - 1710777 AB - Long COVID or post-acute sequelae of COVID-19 is defined as an after-effect of acute COVID-19 infection. Its broad clinical symptoms include brain fog, shortness of breath, fatigue, joint, chest, or muscle pain, dysautonomia and neuropsychiatric symptoms such as anxiety, depression and post-traumatic stress disorder. It is estimated that 1 in every 5 COVID-19 survivors exhibit symptoms within the Long COVID bracket. An array of risk factors such as smoking habit, age, obesity, female sex, and prior hospitalization may increase the probability of a person developing Long COVID. While the underlying mechanisms of Long COVID remain elusive, we examine the various possible pathophysiologies involved in Long COVID. We take up impactful neuropsychiatric issues as another spectrum of Long COVID symptoms and the likely effect of various forms of COVID-19 vaccines. In this review, the focus will be on the main mechanisms associated with the development of long COVID, which include latent Epstein-Barr virus reactivation, molecular mimicry, virus persistence, autoantibodies, and mitochondrial dysfunction. Understanding these mechanisms shed light on the continued persistence of COVID-19 related symptoms long after the resolution of acute infection. For instance, the reactivation of Epstein-Barr virus in the immunocompromised context seen post-acute SARS-CoV-2 infection could lead to the symptoms commonly observed in Long COVID such as fatigue and brain fog. The Epstein-Barr virus could possibly disrupt mitochondrial function, explaining the fatigue commonly observed in Long COVID patients. Other factors such as continued presence of viral particles in specific areas such as the gut may result in continued inflammation, leading to manifestations such as fatigue, cognitive impairment and gastrointestinal dysfunction. Additionally, heightened and persistent presence of autoantibodies post-acute infection results in persistent symptoms and could potentially trigger the onset of autoimmune disorders. We also aim to revisit the diverse and prolonged effects of the COVID-19 pandemic that continue to affect the well-being and quality of human life. CI - Copyright (c) 2026 Ponnachan, Dhawlarker, Yasmin, Shah, Malhotra, Shastri, Al-Ramadi and Kishore. FAU - Ponnachan, Pretty AU - Ponnachan P AD - Department of Veterinary Medicine (CAVM), United Arab Emirates University, Al Ain, United Arab Emirates. AD - Department of Medical Microbiology and Immunology, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates. FAU - Dhawlarker, Anam AU - Dhawlarker A AD - National Institute of Virology (NIV), Indian Council of Medical Research (ICMR), Pune, India. FAU - Yasmin, Hadida AU - Yasmin H AD - Institute of Health Sciences, Presidency University, Kolkata, West Bengal, India. FAU - Shah, Akash AU - Shah A AD - Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom. AD - Ashford and St Peter's NHS Foundation Trust, Ashford, United Kingdom. FAU - Malhotra, Aastha AU - Malhotra A AD - Department of Zoology, Hans Raj College, University of Delhi, Delhi, India. FAU - Shastri, Abhishek AU - Shastri A AD - Central and North West London National Health Service (NHS) Foundation Trust, London, United Kingdom. FAU - Al-Ramadi, Basel K AU - Al-Ramadi BK AD - Department of Medical Microbiology and Immunology, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates. AD - Zayed Centre for Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates. AD - ASPIRE Precision Medicine Research Institute Abu Dhabi, United Arab Emirates University, Al Ain, United Arab Emirates. FAU - Kishore, Uday AU - Kishore U AD - Department of Veterinary Medicine (CAVM), United Arab Emirates University, Al Ain, United Arab Emirates. AD - Zayed Centre for Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates. LA - eng PT - Journal Article PT - Review DEP - 20260619 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - *COVID-19/immunology/physiopathology/psychology/complications/prevention & control MH - Post-Acute COVID-19 Syndrome MH - *SARS-CoV-2/immunology MH - *COVID-19 Vaccines/immunology MH - Vaccination MH - Mental Disorders/etiology PMC - PMC13328189 OTO - NOTNLM OT - Epstein-Barr virus OT - SARS-CoV-2 OT - autoimmunity OT - complement system OT - immune dysregulation OT - long COVID OT - neuropsychiatric effects COIS- The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2026/07/06 10:10 MHDA- 2026/07/06 12:42 PMCR- 2026/06/19 CRDT- 2026/07/06 05:40 PHST- 2025/09/22 00:00 [received] PHST- 2026/04/23 00:00 [revised] PHST- 2026/05/12 00:00 [accepted] PHST- 2026/07/06 12:42 [medline] PHST- 2026/07/06 10:10 [pubmed] PHST- 2026/07/06 05:40 [entrez] PHST- 2026/06/19 00:00 [pmc-release] AID - 10.3389/fimmu.2026.1710777 [doi] PST - epublish SO - Front Immunol. 2026 Jun 19;17:1710777. doi: 10.3389/fimmu.2026.1710777. eCollection 2026. PMID- 42299732 OWN - NLM STAT- In-Process LR - 20260624 IS - 1096-9071 (Electronic) IS - 0146-6615 (Linking) VI - 98 IP - 6 DP - 2026 Jun TI - Correction to "Preconception COVID-19 Vaccination Reprograms Fetal Metabolism to Accelerate Intrauterine Recovery and Suppress Persistent Metabolic Memory". PG - e71017 LID - 10.1002/jmv.71017 [doi] LA - eng PT - Published Erratum PL - United States TA - J Med Virol JT - Journal of medical virology JID - 7705876 SB - IM EFR - J Med Virol. 2025 Dec;97(12):e70740. doi: 10.1002/jmv.70740. PMID: 41347654 EDAT- 2026/06/16 06:35 MHDA- 2026/06/16 06:35 CRDT- 2026/06/16 05:53 PHST- 2026/06/16 06:35 [medline] PHST- 2026/06/16 06:35 [pubmed] PHST- 2026/06/16 05:53 [entrez] AID - 10.1002/jmv.71017 [doi] PST - ppublish SO - J Med Virol. 2026 Jun;98(6):e71017. doi: 10.1002/jmv.71017. PMID- 42297775 OWN - NLM STAT- MEDLINE DCOM- 20260823 LR - 20260826 IS - 2158-3188 (Electronic) IS - 2158-3188 (Linking) VI - 16 IP - 1 DP - 2026 Jun 15 TI - Exploring offspring behaviour after prenatal COVID-19 vaccination in mice. LID - 10.1038/s41398-026-04147-7 [doi] LID - 428 AB - Maternal immunisation allows the transfer of protective antibodies to the offspring, reducing the risk of severe infection during early life. While vaccination during pregnancy is clinically recommended, its long-term impact on neurodevelopment remains under investigation. Autism spectrum disorder (ASD) is a neurodevelopmental condition characterised by social and behavioural alterations. Here, we evaluated whether prenatal exposure to the COVID-19 mRNA BNT162b2 vaccine or influenza vaccine affects general and autism-related behavioural outcomes in juvenile (4 weeks) and adult (8 weeks) mouse offspring. We also assessed maternal and fetal immune responses by measuring cytokines, soluble P2X7 receptor, BDNF, CRP, and lipid peroxidation in maternal plasma and fetal brain tissue. Prenatal COVID-19 vaccination elicited a moderate maternal cytokine response (increased IL-6 and KC) without overt fetal brain inflammation. Mild, age- and sex-dependent behavioural changes were observed, including anxiety-related parameters in the elevated plus maze and altered locomotion in the open field at 4-8 weeks, however, no consistent or robust ASD-like behavioural phenotype emerged across ages. Fetal P2X7 receptor levels were elevated, while fetal CRP, BDNF, and TBARS remained unchanged. In adult offspring, BDNF was selectively reduced in the prefrontal cortex, whereas hippocampal BDNF and P2X7 receptor levels in both regions were unaffected. Although embryonic P2X7 receptor levels were transiently elevated following COVID-19 vaccination, these changes were not accompanied by fetal inflammation or persistent adult purinergic alterations. Prenatal influenza vaccination induced mild, age-dependent behavioural alterations, such as increased circling in juveniles and reduced sociability in females, without detectable maternal or fetal inflammatory responses or changes in fetal neurotrophic markers. In contrast, maternal poly(I:C) administration provoked robust systemic inflammation and pronounced fetal brain effects, including elevated cytokines, CRP, P2X7 receptor, and region-specific microglial density, accompanied by persistent reductions in adult BDNF expression. Overall, within the limits of this experimental design, prenatal COVID-19 vaccination did not produce long-lasting ASD-like phenotypes or widespread neurodevelopmental alterations, while influenza vaccination had limited and transient effects. These findings are consistent with the absence of widespread or persistent neurodevelopmental disruption in this experimental model, although further studies-including multiple doses, gestational timepoints, and cellular-level analyses-are warranted to fully elucidate mechanisms and long-term outcomes. CI - (c) 2026. The Author(s). FAU - Otrokocsi, Lilla AU - Otrokocsi L AD - Laboratory of Molecular Pharmacology, HUN-REN Institute of Experimental Medicine, Budapest, 1083, Hungary. FAU - Maacz, Fruzsina AU - Maacz F AD - Laboratory of Molecular Pharmacology, HUN-REN Institute of Experimental Medicine, Budapest, 1083, Hungary. AD - Janos Szentagothai School of Neurosciences, Semmelweis University School of PhD Studies, Budapest, 1085, Hungary. FAU - Tod, Pal AU - Tod P AD - Laboratory of Molecular Pharmacology, HUN-REN Institute of Experimental Medicine, Budapest, 1083, Hungary. FAU - Goloncser, Flora AU - Goloncser F AUID- ORCID: 0009-0008-2965-3044 AD - Laboratory of Molecular Pharmacology, HUN-REN Institute of Experimental Medicine, Budapest, 1083, Hungary. goloncser.flora@koki.hu. FAU - Sperlagh, Beata AU - Sperlagh B AD - Laboratory of Molecular Pharmacology, HUN-REN Institute of Experimental Medicine, Budapest, 1083, Hungary. sperlagh@koki.hu. AD - Janos Szentagothai School of Neurosciences, Semmelweis University School of PhD Studies, Budapest, 1085, Hungary. sperlagh@koki.hu. LA - eng PT - Journal Article DEP - 20260615 PL - United States TA - Transl Psychiatry JT - Translational psychiatry JID - 101562664 RN - 0 (Brain-Derived Neurotrophic Factor) RN - 0 (COVID-19 Vaccines) RN - 0 (Influenza Vaccines) RN - 0 (Cytokines) SB - IM MH - Animals MH - Female MH - Pregnancy MH - Mice MH - *Prenatal Exposure Delayed Effects/immunology MH - *Behavior, Animal MH - *COVID-19/prevention & control MH - Male MH - Brain-Derived Neurotrophic Factor/metabolism MH - *COVID-19 Vaccines/immunology/adverse effects MH - Vaccination MH - *Autism Spectrum Disorder/immunology MH - Influenza Vaccines MH - Cytokines MH - Brain/metabolism PMC - PMC13500820 COIS- Competing interests: The authors declare no competing interests. Ethics approval and consent to participate: All methods were performed in accordance with the relevant guidelines and regulations, including the ARRIVE guidelines. Experimental protocols were approved by the local Animal Care Committee of the Institute of Experimental Medicine (IEM) (Permission No: PE/EA/00149-4/2024). EDAT- 2026/06/16 00:33 MHDA- 2026/08/24 05:34 PMCR- 2026/06/15 CRDT- 2026/06/15 23:23 PHST- 2025/06/11 00:00 [received] PHST- 2026/05/27 00:00 [accepted] PHST- 2026/04/22 00:00 [revised] PHST- 2026/08/24 05:34 [medline] PHST- 2026/06/16 00:33 [pubmed] PHST- 2026/06/15 23:23 [entrez] PHST- 2026/06/15 00:00 [pmc-release] AID - 10.1038/s41398-026-04147-7 [pii] AID - 4147 [pii] AID - 10.1038/s41398-026-04147-7 [doi] PST - epublish SO - Transl Psychiatry. 2026 Jun 15;16(1):428. doi: 10.1038/s41398-026-04147-7. PMID- 42292488 OWN - NLM STAT- MEDLINE DCOM- 20260615 LR - 20260813 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 17 DP - 2026 TI - Preliminary evaluation of a DDA cationic liposome-based pulmonary mucosal immunization platform carrying a SARS-CoV-2 spike-derived branched peptide. PG - 1824741 LID - 10.3389/fimmu.2026.1824741 [doi] LID - 1824741 AB - INTRODUCTION: Current injectable vaccines targeting respiratory viruses are highly effective in inducing systemic immunity, yet they fall short in establishing effective defenses at mucosal sites, ultimately failing to completely block viral infection and transmission. Developing novel immune strategies that can simultaneously activate mucosal and systemic immunity is vitally important. METHODS: In this study, we created a pulmonary mucosal immune nanovaccine platform based on dimethyldioctadecyl ammonium (DDA) cationic liposomes. The immune effect was systematically evaluated using in vitro dendritic cell activation tests and a mouse pulmonary mucosal immune model. RESULTS: The results showed that the prepared formulation had a uniform particle size (approximately 101 nm), positive zeta potential (+42.67 mV), and high encapsulation efficiency (over 80%). The formulation effectively stimulated the maturation of dendritic cells, induced high levels of antigen-specific IgG antibodies in serum and IgA antibodies in bronchoalveolar lavage fluid. It also significantly promoted the proliferation of activated T/B cells and the formation of tissue-resident memory T cells in lung tissues. Mechanistic studies revealed that the vaccine was retained in the lung for a long time and was subsequently detected in mediastinal lymph nodes, accompanied by increased activation-associated dendritic-cell phenotypes, thereby synergistically activating mucosal and systemic immune responses. DISCUSSION: Overall, this study provides preliminary proof-of-concept evidence that the DDA liposome-based formulation has immunogenic potential following pulmonary mucosal administration. However, additional in vivo control groups and more rigorous validation of antigen-specific immune responses will be required in future studies. CI - Copyright (c) 2026 Xia, Yang, Shi, Huang and Xu. FAU - Xia, Zhifa AU - Xia Z AD - Medical School of Chinese People's Liberation Army General Hospital, Beijing, China. AD - Pharmaceutical Sciences Research Division, Department of Pharmacy, Medical Supplies Center, Chinese People's Liberation Army General Hospital, Beijing, China. FAU - Yang, Zhenyong AU - Yang Z AD - Medical School of Chinese People's Liberation Army General Hospital, Beijing, China. AD - Pharmaceutical Sciences Research Division, Department of Pharmacy, Medical Supplies Center, Chinese People's Liberation Army General Hospital, Beijing, China. FAU - Shi, Zhenwei AU - Shi Z AD - Medical School of Chinese People's Liberation Army General Hospital, Beijing, China. AD - Pharmaceutical Sciences Research Division, Department of Pharmacy, Medical Supplies Center, Chinese People's Liberation Army General Hospital, Beijing, China. FAU - Huang, Songtao AU - Huang S AD - Medical School of Chinese People's Liberation Army General Hospital, Beijing, China. AD - Pharmaceutical Sciences Research Division, Department of Pharmacy, Medical Supplies Center, Chinese People's Liberation Army General Hospital, Beijing, China. FAU - Xu, Fenghua AU - Xu F AD - Pharmaceutical Sciences Research Division, Department of Pharmacy, Medical Supplies Center, Chinese People's Liberation Army General Hospital, Beijing, China. LA - eng PT - Journal Article DEP - 20260529 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 RN - 0 (Liposomes) RN - 0 (Nanovaccines) RN - 0 (Quaternary Ammonium Compounds) RN - 251IW5I21C (dimethyldioctadecylammonium) RN - 0 (spike protein, SARS-CoV-2) RN - 0 (COVID-19 Vaccines) RN - 0 (Antibodies, Viral) RN - 0 (Cations) RN - 0 (Immunoglobulin A) RN - 0 (Immunoglobulin G) RN - 0 (Spike Glycoprotein, Coronavirus) SB - IM MH - Animals MH - *Liposomes/chemistry MH - Mice MH - Immunity, Mucosal MH - *Lung/immunology MH - Nanovaccines MH - Female MH - *Quaternary Ammonium Compounds/chemistry MH - Dendritic Cells/immunology MH - *SARS-CoV-2/immunology MH - *COVID-19 Vaccines/immunology/administration & dosage MH - Antibodies, Viral/immunology/blood MH - *COVID-19/immunology/prevention & control MH - Immunization MH - Cations MH - Immunoglobulin A MH - Immunoglobulin G/blood MH - Mice, Inbred BALB C MH - Spike Glycoprotein, Coronavirus PMC - PMC13260544 OTO - NOTNLM OT - DDA cationic liposomes OT - cellular immunity OT - humoral immunity OT - mucosal vaccine OT - pulmonary immunization OT - tissue-resident memory T cells (TRM cells) COIS- The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2026/06/15 12:49 MHDA- 2026/06/15 12:50 PMCR- 2026/05/29 CRDT- 2026/06/15 07:28 PHST- 2026/03/06 00:00 [received] PHST- 2026/05/12 00:00 [revised] PHST- 2026/05/12 00:00 [accepted] PHST- 2026/06/15 12:50 [medline] PHST- 2026/06/15 12:49 [pubmed] PHST- 2026/06/15 07:28 [entrez] PHST- 2026/05/29 00:00 [pmc-release] AID - 10.3389/fimmu.2026.1824741 [doi] PST - epublish SO - Front Immunol. 2026 May 29;17:1824741. doi: 10.3389/fimmu.2026.1824741. eCollection 2026. PMID- 42277158 OWN - NLM STAT- MEDLINE DCOM- 20260613 LR - 20260813 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 16 IP - 1 DP - 2026 Jun 11 TI - Does mRNA-based COVID-19 vaccination in the subacute phase lead to microstructural brain changes? A prospective pilot MRI study using T1 relaxometry. LID - 10.1038/s41598-026-56181-6 [doi] LID - 18188 AB - Messenger ribonucleic acid (mRNA)-based vaccines delivered via lipid nanoparticles (LNP) were pivotal in managing the severe acute respiratory syndrome coronavirus (SARS-CoV-2) pandemic. While mild systemic reactions are common after vaccination, rare neurological complications have raised concerns about potential structural cerebral changes. This prospective pilot study tested the hypothesis that LNP-mRNA-based SARS-CoV-2 vaccination does not induce significant microstructural cerebral changes in healthy adults. Dedicated 3 Tesla brain MRI was performed at three time points: up to one month before the first vaccination (t1), and 1-2 weeks (t2) and 2-3 months (t3) after the second dose of either BNT162b2 or mRNA-1273. Across 85 MRI scans from 29 initially SARS-CoV-2-seronegative adults, 2D T2-weighted fluid-attenuated inversion recovery, synthetic 3D T1 magnetization prepared rapid acquisition of gradient echoes and 3D quantitative T1 mapping were analyzed. Changes in w matter hyperintensities (WMH) were evaluated visually (Prins scale) and semiquantitatively (Longitudinal Brain Imaging). Microstructural changes of deep and cortical gray matter and white matter were analyzed using qT1 values via paired t-tests or Wilcoxon signed-rank tests. No new or progressive WMH nor significant intraindividual qT1 changes were observed. QT1% deviations were small (mean 0.1%, SD 0.9%; maximum 2.08%) and remained within established scan-rescan variability limits at 3 T. Apart from a 1 mm decrease of a preexisting WMH in one participant, no visually detectable structural brain alterations were observed. Our findings provide no evidence for WMH progression or microstructural cerebral changes after LNP-mRNA-based SARS-CoV-2 vaccination in healthy adults in the subacute phase. CI - (c) 2026. The Author(s). FAU - Willems, Rafael AU - Willems R AUID- ORCID: 0009-0007-4976-6890 AD - Institute of Neuroradiology, Goethe University Frankfurt, University Hospital, Theodor-Stern-Kai 7, 60596, Frankfurt, Germany. rwillems@med.uni-frankfurt.de. FAU - Cappelletti, Marta AU - Cappelletti M AUID- ORCID: 0000-0002-6161-2380 AD - Institute of Neuroradiology, Goethe University Frankfurt, University Hospital, Theodor-Stern-Kai 7, 60596, Frankfurt, Germany. FAU - Schure, Jan R AU - Schure JR AUID- ORCID: 0000-0002-1472-9471 AD - Institute of Neuroradiology, Goethe University Frankfurt, University Hospital, Theodor-Stern-Kai 7, 60596, Frankfurt, Germany. FAU - Deichmann, Ralf AU - Deichmann R AUID- ORCID: 0000-0002-4110-1225 AD - Cooperative Brain Imaging Center - CoBIC, Goethe University Frankfurt, Frankfurt, Germany. FAU - Hattingen, Elke AU - Hattingen E AUID- ORCID: 0000-0002-8392-9004 AD - Institute of Neuroradiology, Goethe University Frankfurt, University Hospital, Theodor-Stern-Kai 7, 60596, Frankfurt, Germany. FAU - Arendt, Christophe T AU - Arendt CT AUID- ORCID: 0000-0003-3300-3729 AD - Institute of Neuroradiology, Goethe University Frankfurt, University Hospital, Theodor-Stern-Kai 7, 60596, Frankfurt, Germany. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20260611 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 RN - 0 (BNT162 Vaccine) RN - 0 (COVID-19 Vaccines) RN - EPK39PL4R4 (2019-nCoV Vaccine mRNA-1273) RN - 0 (RNA, Messenger) SB - IM MH - Humans MH - Pilot Projects MH - Magnetic Resonance Imaging/methods MH - Male MH - Female MH - Prospective Studies MH - *COVID-19/prevention & control/virology MH - *Brain/diagnostic imaging/pathology MH - BNT162 Vaccine/adverse effects MH - Adult MH - SARS-CoV-2/immunology MH - Middle Aged MH - Vaccination/adverse effects MH - *COVID-19 Vaccines/adverse effects/administration & dosage MH - 2019-nCoV Vaccine mRNA-1273/adverse effects/administration & dosage MH - RNA, Messenger MH - Nanoparticles PMC - PMC13260724 OTO - NOTNLM OT - Brain inflammation OT - Magnetic resonance imaging OT - Quantitative MRI OT - Severe acute respiratory syndrome coronavirus 2 OT - mRNA vaccines COIS- Declarations. Competing interests: The authors declare no competing interests. Ethics approval and consent to participate: This study was approved by the ethics committee of the University Hospital Frankfurt (ethics reference: 20-838; date of approval: October 1, 2020). All participants provided written informed consent prior to participation. The study was conducted in accordance with the ethical guidelines for research involving human subjects, according to the Declaration of Helsinki. EDAT- 2026/06/12 00:39 MHDA- 2026/06/13 07:33 PMCR- 2026/06/11 CRDT- 2026/06/11 23:35 PHST- 2025/11/26 00:00 [received] PHST- 2026/05/29 00:00 [accepted] PHST- 2026/06/13 07:33 [medline] PHST- 2026/06/12 00:39 [pubmed] PHST- 2026/06/11 23:35 [entrez] PHST- 2026/06/11 00:00 [pmc-release] AID - 10.1038/s41598-026-56181-6 [pii] AID - 56181 [pii] AID - 10.1038/s41598-026-56181-6 [doi] PST - epublish SO - Sci Rep. 2026 Jun 11;16(1):18188. doi: 10.1038/s41598-026-56181-6. PMID- 42272704 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260611 LR - 20260813 IS - 2055-2076 (Print) IS - 2055-2076 (Electronic) IS - 2055-2076 (Linking) VI - 12 DP - 2026 Jan-Dec TI - Specialist care at a distance: Patient-reported experience with telemedicine video consultations for neurological symptoms associated with post-COVID-19 condition or in temporal association with COVID-19 vaccination in a single-center retrospective cross-sectional study. PG - 20552076261451372 LID - 10.1177/20552076261451372 [doi] LID - 20552076261451372 AB - OBJECTIVES: To describe patient-reported experience with a structured telemedicine video consultation (TVC) pathway in routine neurological care among adults with persistent neurological symptoms with onset after SARS-CoV-2 infection or in temporal association with COVID-19 vaccination. METHODS: This single-center retrospective cross-sectional study examined TVC delivered in routine clinical care at the Department of Neurology, Charite-Universitatsmedizin Berlin (11/2022-12/2023). Patients with neurological symptoms persisting >/=3 months after SARS-CoV-2 infection or occurring in temporal association with COVID-19 vaccination were included. Data included demographics, symptom assessments, validated questionnaires on mood, fatigue, and subjective memory, audiovisual cognitive screening, and a post-consultation survey of patient-reported telemedicine experience. RESULTS: Forty-one patients (mean age 41.3+/-12.8 years; 61% female) were included. The median home-to-clinic distance was 356 km; and 39% reported mobility limitations affecting in-person attendance. Patients reported positive immediate experiences: most found scheduling easy, reported good audio/video quality, and considered the consultation relevant and time-saving. A minority reported technical difficulties or required assistance. Patients reported high fatigue levels (Fatigue Severity Scale 5.3+/-1.8), frequent subjective cognitive symptoms, moderate subjective memory satisfaction (Multifactorial Memory Questionnaire-Satisfaction Domain, 47.7+/-17.3), and mean Montreal Cognitive Assessment score of 27.3+/-2.3. DISCUSSION: These exploratory findings indicate positive patient-reported experience with a structured TVC pathway in routine neurological care. Fatigue and subjective cognitive difficulties were common across the selected cohort. This study describes a tele-neurology workflow integrating document pre-review, digital symptom assessment, remote history taking, and cognitive screening. Further controlled longitudinal studies are needed to determine the clinical role, safety, and equitable implementation of such approaches. CI - (c) The Author(s) 2026. FAU - Raeder, Vanessa AU - Raeder V AUID- ORCID: 0000-0002-5969-7581 AD - Charite - Universitatsmedizin Berlin, corporate member of Freie Universitat Berlin and Humboldt Universitat zu Berlin, Department of Neurology and Experimental Neurology, Hindenburgdamm, Berlin, Germany. FAU - Boesl, Fabian AU - Boesl F AD - Charite - Universitatsmedizin Berlin, corporate member of Freie Universitat Berlin and Humboldt Universitat zu Berlin, Department of Neurology and Experimental Neurology, Hindenburgdamm, Berlin, Germany. FAU - Bremer, Benno AU - Bremer B AD - Charite - Universitatsmedizin Berlin, corporate member of Freie Universitat Berlin and Humboldt Universitat zu Berlin, Department of Neurology and Experimental Neurology, Hindenburgdamm, Berlin, Germany. FAU - Breuer, Ameli AU - Breuer A AD - Charite - Universitatsmedizin Berlin, corporate member of Freie Universitat Berlin and Humboldt Universitat zu Berlin, Department of Neurology and Experimental Neurology, Hindenburgdamm, Berlin, Germany. FAU - Audebert, Heinrich J AU - Audebert HJ AD - Charite - Universitatsmedizin Berlin, corporate member of Freie Universitat Berlin and Humboldt Universitat zu Berlin, Department of Neurology and Experimental Neurology, Hindenburgdamm, Berlin, Germany. FAU - Franke, Christiana AU - Franke C AD - Charite - Universitatsmedizin Berlin, corporate member of Freie Universitat Berlin and Humboldt Universitat zu Berlin, Department of Neurology and Experimental Neurology, Hindenburgdamm, Berlin, Germany. LA - eng PT - Journal Article DEP - 20260608 PL - United States TA - Digit Health JT - Digital health JID - 101690863 PMC - PMC13247382 OTO - NOTNLM OT - cognitive dysfunction OT - fatigue OT - patient satisfaction OT - post-COVID-19 condition OT - telemedicine OT - vaccination OT - video conferencing COIS- The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2026/06/11 06:36 MHDA- 2026/06/11 06:37 PMCR- 2026/06/08 CRDT- 2026/06/11 04:46 PHST- 2025/11/05 00:00 [received] PHST- 2026/04/14 00:00 [revised] PHST- 2026/04/25 00:00 [accepted] PHST- 2026/06/11 06:37 [medline] PHST- 2026/06/11 06:36 [pubmed] PHST- 2026/06/11 04:46 [entrez] PHST- 2026/06/08 00:00 [pmc-release] AID - 10.1177_20552076261451372 [pii] AID - 10.1177/20552076261451372 [doi] PST - epublish SO - Digit Health. 2026 Jun 8;12:20552076261451372. doi: 10.1177/20552076261451372. eCollection 2026 Jan-Dec. PMID- 42268936 OWN - NLM STAT- MEDLINE DCOM- 20260612 LR - 20261009 IS - 1946-6242 (Electronic) IS - 1946-6234 (Linking) VI - 18 IP - 853 DP - 2026 Jun 10 TI - SARS-CoV-2 variant booster vaccination and infection alter the breadth of the memory B cell repertoire. PG - eaeb9847 LID - 10.1126/scitranslmed.aeb9847 [doi] AB - Evolving endemic viruses such as influenza and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remain major health threats. Although variant updated vaccines aim to enhance protection, preexisting immunity shapes memory B cell (MBC) responses. To assess how SARS-CoV-2 spike protein variant-based vaccine boosters and infections alter the MBC repertoire, we analyzed MBC responses in the COVAIL vaccine trial, where participants previously vaccinated with SARS-CoV-2 Wuhan-1 spike immunogen were boosted with Wuhan-1, variant, or bivalent spike immunogens. Some participants also experienced a subsequent infection with an Omicron variant. We determined that variant vaccine boosters and SARS-CoV-2 infections led to transiently greater recall of cross-reactive MBCs compared with a Wuhan-1 vaccine booster. Long term, we detected little change in the MBC repertoire after an Omicron vaccine booster, but MBCs evaluated several months after Omicron variant infection had higher neutralization capacity to both Wuhan-1 and BA.1 compared with those from individuals who had not experienced an infection. However, these Wuhan-1/BA.1 cross-reactive MBCs from infected individuals displayed less breadth toward the more distant BA.2.86 lineage than MBCs from uninfected individuals. Thus, SARS-CoV-2 variant boosters and infections differentially shape the long-term MBC repertoire. FAU - Malek, Rory AU - Malek R AUID- ORCID: 0000-0003-4433-6430 AD - Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. FAU - Matassoli, Flavio AU - Matassoli F AUID- ORCID: 0009-0000-5559-8781 AD - Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. FAU - Gordon, Kyle AU - Gordon K AD - Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. FAU - Shimberg, Geoffrey D AU - Shimberg GD AUID- ORCID: 0000-0001-7986-0895 AD - Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. FAU - Mantus, Grace E AU - Mantus GE AUID- ORCID: 0009-0003-1925-0851 AD - Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. FAU - Spangler, Abby AU - Spangler A AUID- ORCID: 0000-0002-0028-9348 AD - Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. FAU - Chopde, Ankita J AU - Chopde AJ AUID- ORCID: 0009-0007-6998-0245 AD - Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. FAU - Teng, I-Ting AU - Teng IT AUID- ORCID: 0000-0002-4704-7100 AD - Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. FAU - Zhou, Tongqing AU - Zhou T AUID- ORCID: 0000-0002-3935-4637 AD - Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. FAU - Lin, Bob C AU - Lin BC AUID- ORCID: 0000-0002-1373-1406 AD - Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. FAU - Carroll, Robin AU - Carroll R AD - Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. FAU - Kazmierski, Rachel AU - Kazmierski R AUID- ORCID: 0009-0007-0870-3666 AD - Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. FAU - Wang, Lingshu AU - Wang L AUID- ORCID: 0000-0002-8404-4910 AD - Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. FAU - Posavad, Christine M AU - Posavad CM AUID- ORCID: 0000-0002-5641-3934 AD - IDCRC Laboratory Operations Unit, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA98109, USA. AD - Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA 98109, USA. FAU - Rouphael, Nadine G AU - Rouphael NG AUID- ORCID: 0000-0002-2512-7919 AD - Hope Clinic of Emory Vaccine Center, Division of Infectious Diseases, Department of Medicine, Emory University, Decatur, GA 30030, USA. FAU - Branche, Angela R AU - Branche AR AUID- ORCID: 0000-0002-7742-5352 AD - Department of Medicine, Division of Infectious Diseases, University of Rochester, Rochester, NY 14642, USA. FAU - Roberts, Paul C AU - Roberts PC AUID- ORCID: 0000-0002-4452-141X AD - Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. FAU - Serebryannyy, Leonid AU - Serebryannyy L AD - Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. FAU - Andrews, Sarah F AU - Andrews SF AUID- ORCID: 0000-0002-2583-1949 AD - Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. LA - eng GR - UM1 AI148450/AI/NIAID NIH HHS/United States PT - Journal Article DEP - 20260610 PL - United States TA - Sci Transl Med JT - Science translational medicine JID - 101505086 RN - 0 (COVID-19 Vaccines) RN - 0 (Spike Glycoprotein, Coronavirus) RN - 0 (spike protein, SARS-CoV-2) RN - 0 (Antibodies, Viral) RN - 0 (Antibodies, Neutralizing) RN - SARS-CoV-2 variants SB - IM MH - Humans MH - *COVID-19 Vaccines/immunology MH - *SARS-CoV-2/immunology MH - *COVID-19/immunology/prevention & control/virology MH - *Memory B Cells/immunology MH - *Immunization, Secondary MH - Spike Glycoprotein, Coronavirus/immunology MH - Antibodies, Viral/immunology MH - Antibodies, Neutralizing/immunology MH - Cross Reactions MH - Immunologic Memory MH - Female MH - Breakthrough Infections MH - Adult EDAT- 2026/06/11 05:38 MHDA- 2026/06/12 13:03 CRDT- 2026/06/10 14:03 PHST- 2026/06/12 13:03 [medline] PHST- 2026/06/11 05:38 [pubmed] PHST- 2026/06/10 14:03 [entrez] AID - 10.1126/scitranslmed.aeb9847 [doi] PST - ppublish SO - Sci Transl Med. 2026 Jun 10;18(853):eaeb9847. doi: 10.1126/scitranslmed.aeb9847. Epub 2026 Jun 10. PMID- 42190640 OWN - NLM STAT- MEDLINE DCOM- 20260613 LR - 20260813 IS - 2352-3964 (Electronic) IS - 2352-3964 (Linking) VI - 128 DP - 2026 Jun TI - Comprehensive longitudinal profiling identifies differential frequency, epitope specificity, and effector function of CD8(+) T-cells across COVID-19 disease severities. PG - 106310 LID - S2352-3964(26)00192-1 [pii] LID - 10.1016/j.ebiom.2026.106310 [doi] LID - 106310 AB - BACKGROUND: CD8(+) T-cells are crucial for controlling and resolving SARS-CoV-2 infection, yet their epitope specificity and relationship to COVID-19 disease severity remain incompletely understood. METHODS: We performed comprehensive longitudinal profiling of antigen-specific CD8(+) T-cell populations using DNA-barcoded peptide-HLA multimers, analysing 553 SARS-CoV-2 epitopes across globally prevalent HLA alleles in patients with mild and severe COVID-19. Functional and phenotypic characterisation was performed using multidimensional single-cell analysis and detailed cytokine profiling. The impact of post-infection COVID-19 vaccination on T-cell memory was also assessed. FINDINGS: Severe and mild COVID-19 were associated with robust yet distinct patterns of CD8(+) T-cell activation. In the acute phase, severe disease was characterised by a broader T-cell repertoire (139 unique epitopes) with a median frequency of 1.4% (IQR 0.2-5.0) and a high-frequency of immunodominant epitope-specific T-cells that exhibited reduced cytotoxic profile. In contrast, patients with mild COVID-19 mounted responses against a more limited set of epitopes (98 unique epitopes), partially overlapping with those observed in severe disease, with a median T-cell frequency of 0.7% (IQR 0-1.9) and displayed a stronger cytotoxic phenotype and functional state. Over time, the memory T-cell compartment contracted to a restricted subset of immunodominant epitopes in the two patient groups and COVID-19 vaccination further enhanced frequencies of spike-specific T-cells independent of prior disease severity. INTERPRETATION: These findings delineate the epitope-specific frequency, function, and persistence of antigen-specific T-cell populations during SARS-CoV-2 infection, highlighting how differential activation, rather than magnitude alone, shapes immune outcomes across disease severities and other viral infections. FUNDING: This work was supported by the Independent Research Fund Denmark (DFF-Sapere Aude, 2066-00044B), the EU Horizon Europe REACT project (101057129), the European Research Council (ERC) Starting Grant MIMIC (101045517), and the Danish National Research Foundation (DNRF170). CI - Copyright (c) 2026 The Authors. Published by Elsevier B.V. All rights reserved. FAU - Amaya Hernandez, Susana Patricia AU - Amaya Hernandez SP AD - Department of Health Technology, Section of Experimental and Translational Immunology, Technical University of Denmark, Kongens Lyngby, 2800, Denmark. FAU - Munk, Kamilla Kjaergaard AU - Munk KK AD - Department of Health Technology, Section of Experimental and Translational Immunology, Technical University of Denmark, Kongens Lyngby, 2800, Denmark. FAU - Danilov, Konstantin AU - Danilov K AD - Department of Health Technology, Section of Experimental and Translational Immunology, Technical University of Denmark, Kongens Lyngby, 2800, Denmark. FAU - Kadivar, Mohammad AU - Kadivar M AD - Department of Health Technology, Section of Experimental and Translational Immunology, Technical University of Denmark, Kongens Lyngby, 2800, Denmark. FAU - Hersby, Ditte Stampe AU - Hersby DS AD - Department of Hematology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, 2100, Denmark. FAU - Tamhane, Tripti AU - Tamhane T AD - Department of Health Technology, Section of Experimental and Translational Immunology, Technical University of Denmark, Kongens Lyngby, 2800, Denmark. FAU - Stegenborg-Grathwohl, Simone Majken AU - Stegenborg-Grathwohl SM AD - Department of Health Technology, Section of Experimental and Translational Immunology, Technical University of Denmark, Kongens Lyngby, 2800, Denmark. FAU - Pedersen, Anders Gorm AU - Pedersen AG AD - Department of Health Technology, Section for Bioinformatics, Technical University of Denmark, Kongens Lyngby, 2800, Denmark. FAU - Gang, Anne Ortved AU - Gang AO AD - Department of Hematology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, 2100, Denmark; Department of Clinical Medicine, University of Copenhagen, Copenhagen, 2200, Denmark. FAU - Hadrup, Sine Reker AU - Hadrup SR AD - Department of Health Technology, Section of Experimental and Translational Immunology, Technical University of Denmark, Kongens Lyngby, 2800, Denmark. FAU - Saini, Sunil Kumar AU - Saini SK AD - Department of Health Technology, Section of Experimental and Translational Immunology, Technical University of Denmark, Kongens Lyngby, 2800, Denmark. Electronic address: sukusa@dtu.dk. LA - eng PT - Journal Article DEP - 20260526 PL - Netherlands TA - EBioMedicine JT - EBioMedicine JID - 101647039 RN - 0 (Epitopes, T-Lymphocyte) RN - 0 (Cytokines) RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - *COVID-19/immunology/pathology MH - *CD8-Positive T-Lymphocytes/immunology MH - *Epitopes, T-Lymphocyte/immunology MH - *SARS-CoV-2/immunology MH - Male MH - Female MH - Middle Aged MH - Immunologic Memory MH - Severity of Illness Index MH - Cytokines/metabolism MH - Longitudinal Studies MH - COVID-19 Vaccines/immunology MH - Lymphocyte Activation MH - Aged MH - Adult MH - Vaccination PMC - PMC13234737 OTO - NOTNLM OT - CD8(+) T-cells OT - COVID-19 OT - COVID-19 vaccination OT - SARS-CoV-2 OT - T-cell epitopes OT - T-cell memory OT - Viral infections COIS- Declaration of interests Otto Monsteds Fond Travel grant was paid to S.P.A.H., and subsequently transferred to the author's institution, in accordance with institutional policy. All other authors declare no competing interest. EDAT- 2026/05/27 00:30 MHDA- 2026/06/15 11:36 PMCR- 2026/05/26 CRDT- 2026/05/26 18:19 PHST- 2025/11/10 00:00 [received] PHST- 2026/04/21 00:00 [revised] PHST- 2026/05/08 00:00 [accepted] PHST- 2026/06/15 11:36 [medline] PHST- 2026/05/27 00:30 [pubmed] PHST- 2026/05/26 18:19 [entrez] PHST- 2026/05/26 00:00 [pmc-release] AID - S2352-3964(26)00192-1 [pii] AID - 106310 [pii] AID - 10.1016/j.ebiom.2026.106310 [doi] PST - ppublish SO - EBioMedicine. 2026 Jun;128:106310. doi: 10.1016/j.ebiom.2026.106310. Epub 2026 May 26. PMID- 42151278 OWN - NLM STAT- MEDLINE DCOM- 20260719 LR - 20260813 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 16 IP - 1 DP - 2026 May 19 TI - A novel lexicon dictionary and CNN-LSTM employed hybrid approach for sentiment detection of COVID-19 vaccines. LID - 10.1038/s41598-026-51418-w [doi] LID - 22615 AB - With the rapid advancement of the internet, social media has become an integral part of human life. It provides a soothing platform for people to share their opinions. Twitter became the most popular social platform during the COVID-19 pandemic to connect people internationally and support the fight against the infectious epidemic. Nevertheless, the increasing use of social media generates a massive amount of meaningless information, which researchers need to refine to interpret the material. Recently, investigators have proposed various approaches to gain insights from unstructured data on social platforms. Still, researchers face innumerable challenges in dealing with vague content. Meticulous polarity detection of people's opinions is an exhilarating and ongoing problem. Therefore, a hybrid lexicon-based dictionary and a CNN-LSTM-based approach have been proposed to analyze tweets related to COVID-19 vaccines. This model is enriched with enhanced feature transformations via the attention mechanism and an extensive lexicon. However, the lexicon approach is very domain-specific; on the other hand, neural networks are less interpretable and dependent on content quality. Consequently, the proposed hybrid model combines the strengths of lexicon-based dictionaries and neural networks while mitigating their limitations. The experimental results demonstrated the outperformance of the proposed hybrid model, achieving 83.44% accuracy, 88% F1-score, 91% recall, and 86% precision on COVID-19 tweets. It indicates that the proposed hybrid solution is robust and practical for addressing similar problems and other epidemic situations. CI - (c) 2026. The Author(s). FAU - Tiwari, Dimple AU - Tiwari D AD - School of Engineering & Technology, Vivekananda Institute of Professional Studies - Technical Campus, Delhi, India. FAU - Bhati, Bhoopesh Singh AU - Bhati BS AD - Indian Institute of Information Technology, Sonepat, India. FAU - Garg, Puneet AU - Garg P AD - Krishna Institute of Engineering & Technology (KIET), Delhi-NCR, Ghaziabad, Uttar Pradesh, India. FAU - Babbar, Nandini AU - Babbar N AD - Manipal University Jaipur, Rajasthan, India. nandini.babbar@jaipur.manipal.edu. LA - eng PT - Journal Article DEP - 20260519 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - *COVID-19/prevention & control MH - Convolutional Neural Networks MH - *COVID-19 Vaccines MH - *Social Media MH - *Sentiment Analysis MH - SARS-CoV-2 MH - Long Short Term Memory MH - Pandemics/prevention & control MH - Neural Networks, Computer PMC - PMC13381905 OTO - NOTNLM OT - COVID-19 Vaccines OT - Convolutional Neural Network OT - Feature Engineering OT - Long Short-Term Memory OT - Sentiment Analysis OT - VADER Lexicon COIS- Declarations. Competing interests: The authors declare no competing interests. EDAT- 2026/05/19 00:28 MHDA- 2026/07/20 00:37 PMCR- 2026/05/19 CRDT- 2026/05/18 23:25 PHST- 2025/09/24 00:00 [received] PHST- 2026/04/28 00:00 [accepted] PHST- 2026/07/20 00:37 [medline] PHST- 2026/05/19 00:28 [pubmed] PHST- 2026/05/18 23:25 [entrez] PHST- 2026/05/19 00:00 [pmc-release] AID - 10.1038/s41598-026-51418-w [pii] AID - 51418 [pii] AID - 10.1038/s41598-026-51418-w [doi] PST - epublish SO - Sci Rep. 2026 May 19;16(1):22615. doi: 10.1038/s41598-026-51418-w. PMID- 42094979 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260507 LR - 20260813 IS - 2296-858X (Print) IS - 2296-858X (Electronic) IS - 2296-858X (Linking) VI - 13 DP - 2026 TI - Hybrid immunity strategies: heterologous vaccination combined with natural SARS-CoV-2 infection. PG - 1828887 LID - 10.3389/fmed.2026.1828887 [doi] LID - 1828887 AB - The continuous evolution of SARS-CoV-2 poses a significant challenge to existing immune barriers, highlighting the limitations of single-modality immunization. Hybrid immunity, shaped by the combination of natural infection and vaccination, induces more potent, broad-spectrum, and durable protective immunity. This review proposes that heterologous vaccination - the sequential use of vaccines based on different technological platforms - can serve as an active public health strategy to simulate and optimize hybrid immunity. We systematically elaborate on the synergistic advantages of hybrid immunity at both the humoral and cellular levels, citing evidence from multiple clinical trials that for both convalescent individuals and infection-naive populations, heterologous vaccination regimens outperform homologous regimens in enhancing the breadth of neutralizing antibodies, strengthening cross-protection, and establishing robust immune memory. By mimicking the antigenic distance effect, heterologous vaccination safely replicates the immunological benefits of natural infection without the associated risks, positioning it as a key strategic tool to counter persistent viral evolution and build a resilient population-wide immune barrier. CI - Copyright (c) 2026 Huang, Zhang, Miao, Wang, Xi, Pan, Lu and Li. FAU - Huang, Yuan AU - Huang Y AD - Department of Public Health, Gansu University of Chinese Medicine, Lanzhou, China. FAU - Zhang, Xiaolu AU - Zhang X AD - Department of Public Health, Gansu University of Chinese Medicine, Lanzhou, China. FAU - Miao, Ruixia AU - Miao R AD - Department of Public Health, Gansu University of Chinese Medicine, Lanzhou, China. FAU - Wang, Jing AU - Wang J AD - Department of Public Health, Gansu University of Chinese Medicine, Lanzhou, China. FAU - Xi, Xuan AU - Xi X AD - Department of Public Health, Gansu University of Chinese Medicine, Lanzhou, China. FAU - Pan, Heng AU - Pan H AD - Department of Public Health, Gansu University of Chinese Medicine, Lanzhou, China. FAU - Lu, Yan AU - Lu Y AD - Department of Clinical Laboratory, Gansu Provincial Hospital, Lanzhou, China. FAU - Li, Dehong AU - Li D AD - Department of Blood Transfusion, Gansu Provincial Hospital, Lanzhou, China. LA - eng PT - Journal Article PT - Review DEP - 20260421 PL - Switzerland TA - Front Med (Lausanne) JT - Frontiers in medicine JID - 101648047 PMC - PMC13138905 OTO - NOTNLM OT - SARS-CoV-2 variants OT - antigenic distance OT - heterologous strategies OT - hybrid immunity OT - immune memory COIS- The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2026/05/07 06:36 MHDA- 2026/05/07 06:37 PMCR- 2026/04/21 CRDT- 2026/05/07 05:19 PHST- 2026/03/12 00:00 [received] PHST- 2026/03/30 00:00 [revised] PHST- 2026/04/08 00:00 [accepted] PHST- 2026/05/07 06:37 [medline] PHST- 2026/05/07 06:36 [pubmed] PHST- 2026/05/07 05:19 [entrez] PHST- 2026/04/21 00:00 [pmc-release] AID - 10.3389/fmed.2026.1828887 [doi] PST - epublish SO - Front Med (Lausanne). 2026 Apr 21;13:1828887. doi: 10.3389/fmed.2026.1828887. eCollection 2026. PMID- 42072463 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260504 LR - 20260813 IS - 2227-9059 (Print) IS - 2227-9059 (Electronic) IS - 2227-9059 (Linking) VI - 14 IP - 4 DP - 2026 Apr 17 TI - The Effects of Past COVID-19 and Vaccination on Antibody Levels, Cellular Immunity, and Cytokine Production by Peripheral Blood Mononuclear Cells. LID - 10.3390/biomedicines14040923 [doi] LID - 923 AB - Background/Objective: This study is a cross-sectional investigation of long-term immune responses measured at different time intervals after COVID-19 infections, vaccinations, or combined exposure. The focus is on immune reactivity against recombinant spike (S) and nucleocapsid (N) protein antigens. Materials and Methods: Serum antibody levels were assessed up to four to four and a half years after infection or immunization, including virus-specific immunoglobulin G (IgG), IgA and IgM antibodies, as well as neutralizing antibodies against the S-protein. Cellular immunity was assessed by analyzing peripheral blood mononuclear cells (PBMC; n = 43 in first cohort, n = 32 in second cohort), including T-helper memory and cytotoxic subsets, and cytokine production after in vitro stimulation with recombinant SARS-CoV-2 proteins. A multiplex cytokine assay was used to analyze effector and regulatory immune responses. Results: Virus-specific IgG antibodies persisted for years after exposure to SARS-CoV-2, with IgG against the receptor-binding domain (RBD) correlating most strongly with neutralizing activity. Vaccinated individuals demonstrated higher IgA responses, whereas antibodies to the N-protein were associated with previous infection. No IgM antibodies were detected in any subjects, suggesting an immune response based on memory rather than ongoing infection. PBMCs from individuals with a history of both COVID-19 exposure and vaccination exhibited enhanced responsiveness, characterized by increased frequencies of memory T cells compared to vaccination alone. Stimulating with the S-protein induces higher cytokine production, including IFN-gamma, TNF-alfa, and IL-12(p70), compared with stimulation by the N-protein. Cytokines such as IL-10 and TGF-beta are also elevated, suggesting immune regulation rather than persistent inflammation. Conclusions: SARS-CoV-2 infection and vaccination are associated with persistent humoral and cellular immune responses detectable several years after exposure. Individuals with hybrid immunity exhibit broader and functionally enhanced immune reactivity, indicating more robust long-term immune memory. Future studies should focus on the long-term consequences of hybrid immunity and optimize other vaccine strategies, including recombinant antigen vaccines. FAU - Desheva, Yulia A AU - Desheva YA AUID- ORCID: 0000-0001-9794-3520 AD - Federal State Budgetary Scientific Institution "Institute of Experimental Medicine", Academician Pavlova St., 12D, St. Petersburg 197022, Russia. FAU - Gupalova, Tatiana V AU - Gupalova TV AUID- ORCID: 0000-0002-4824-3621 AD - Federal State Budgetary Scientific Institution "Institute of Experimental Medicine", Academician Pavlova St., 12D, St. Petersburg 197022, Russia. FAU - Kudar, Polina A AU - Kudar PA AUID- ORCID: 0000-0002-3342-5828 AD - Federal State Budgetary Scientific Institution "Institute of Experimental Medicine", Academician Pavlova St., 12D, St. Petersburg 197022, Russia. FAU - Leontieva, Galina F AU - Leontieva GF AUID- ORCID: 0000-0002-9876-6594 AD - Federal State Budgetary Scientific Institution "Institute of Experimental Medicine", Academician Pavlova St., 12D, St. Petersburg 197022, Russia. FAU - Kudryavtsev, Igor V AU - Kudryavtsev IV AD - Federal State Budgetary Scientific Institution "Institute of Experimental Medicine", Academician Pavlova St., 12D, St. Petersburg 197022, Russia. FAU - Trulioff, Andrey S AU - Trulioff AS AD - Federal State Budgetary Scientific Institution "Institute of Experimental Medicine", Academician Pavlova St., 12D, St. Petersburg 197022, Russia. FAU - Guzenkov, Danila S AU - Guzenkov DS AUID- ORCID: 0009-0000-1680-399X AD - Federal State Budgetary Scientific Institution "Institute of Experimental Medicine", Academician Pavlova St., 12D, St. Petersburg 197022, Russia. FAU - Matyushenko, Victoria A AU - Matyushenko VA AD - Federal State Budgetary Scientific Institution "Institute of Experimental Medicine", Academician Pavlova St., 12D, St. Petersburg 197022, Russia. FAU - Bormotova, Elena A AU - Bormotova EA AD - Federal State Budgetary Scientific Institution "Institute of Experimental Medicine", Academician Pavlova St., 12D, St. Petersburg 197022, Russia. FAU - Sokolovsky, Daniil D AU - Sokolovsky DD AUID- ORCID: 0009-0005-8530-8059 AD - Federal State Budgetary Scientific Institution "Institute of Experimental Medicine", Academician Pavlova St., 12D, St. Petersburg 197022, Russia. FAU - Matveev, Georgy A AU - Matveev GA AUID- ORCID: 0000-0002-2695-4924 AD - Federal State Budgetary Scientific Institution "Institute of Experimental Medicine", Academician Pavlova St., 12D, St. Petersburg 197022, Russia. FAU - Nikolaev, Boris P AU - Nikolaev BP AUID- ORCID: 0000-0001-7574-5996 AD - Technopark of St. Petersburg, Prospekt Medikov, 3, lit. A, St. Petersburg 197022, Russia. AD - Institute of Cytology of the Russian Academy of Sciences (RAS), St. Petersburg 194064, Russia. FAU - Suvorov, Alexander N AU - Suvorov AN AD - Federal State Budgetary Scientific Institution "Institute of Experimental Medicine", Academician Pavlova St., 12D, St. Petersburg 197022, Russia. LA - eng GR - FGWG-2026-0007/Ministry of Science and Higher Education of the Russian Federation/ PT - Journal Article DEP - 20260417 PL - Switzerland TA - Biomedicines JT - Biomedicines JID - 101691304 PMC - PMC13113839 OTO - NOTNLM OT - IFN-gamma OT - IL-10 OT - IL-12p70 OT - PBMC stimulation OT - SARS-CoV-2 OT - TNF-alpha OT - antigen-specific cellular immunity OT - cytokine profile OT - immune memory OT - long-term immune response OT - nucleocapsid protein OT - recombinant viral antigens OT - spike protein COIS- The authors declare no conflicts of interest. EDAT- 2026/05/04 06:32 MHDA- 2026/05/04 06:33 PMCR- 2026/04/17 CRDT- 2026/05/04 01:07 PHST- 2026/02/22 00:00 [received] PHST- 2026/04/03 00:00 [revised] PHST- 2026/04/10 00:00 [accepted] PHST- 2026/05/04 06:33 [medline] PHST- 2026/05/04 06:32 [pubmed] PHST- 2026/05/04 01:07 [entrez] PHST- 2026/04/17 00:00 [pmc-release] AID - biomedicines14040923 [pii] AID - biomedicines-14-00923 [pii] AID - 10.3390/biomedicines14040923 [doi] PST - epublish SO - Biomedicines. 2026 Apr 17;14(4):923. doi: 10.3390/biomedicines14040923. PMID- 42034835 OWN - NLM STAT- MEDLINE DCOM- 20260627 LR - 20260813 IS - 1573-2592 (Electronic) IS - 0271-9142 (Print) IS - 0271-9142 (Linking) VI - 46 IP - 1 DP - 2026 Apr 25 TI - Three Doses and Six Months Later: Real-World SARS-CoV-2 Specific Humoral and Cell-Mediated Immunity in Children With Inborn Errors of Immunity. LID - 10.1007/s10875-026-02021-1 [doi] LID - 68 AB - PURPOSE: To assess the durability of SARS-CoV-2-specific immunity following three doses of COVID-19 vaccine in children with inborn errors of immunity (IEI). METHODS: In this multi-center observational study, we compared SARS-CoV-2 specific humoral and T-cell immunity 24 weeks after the third dose of monovalent mRNA COVID-19 vaccine in children (5-18 years) with IEI and healthy controls (HC). Participants with IEI were categorized into predominant antibody deficiency (PAD) or non-PAD subgroups. RESULTS: Forty-three children with IEI (26 with PAD and 17 with non-PAD; 16 females, mean age 10.5 +/- 4 years) and 12 HC (7 females, mean age 14.1 +/- 3 years) were included. Anti-RBD IgG and anti-S IgG seropositivity was 100% in both groups. However, geometric mean concentrations (95% confidence interval) were significantly lower in IEI versus HC: 1,349.0 (905.4-2,009.9) vs. 3,324.2 (1,762.8-6,268.6) BAU/mL, p = 0.03 for anti-RBD IgG, and 1,336.4 (938.2 - 1,903.5) vs. 3,320.9 (2,158.4 - 5109.7), BAU/mL, p = 0.012 for anti-S IgG. Neutralizing antibody titers against ancestral and Omicron BA.1, BA.4/BA.5, and XBB.1.5 were also significantly lower in IEI, especially among PAD participants (p = 0.001). In contrast, S-specific T-cell responses did not differ significantly between IEI and HC. CONCLUSION: Six months after the third COVID-19 vaccine dose, children with IEI retained SARS-CoV-2-specific humoral and cellular immunity, though antibody responses were attenuated, particularly among PAD cases. Importantly, spike-specific T-cell responses were preserved and comparable to HC. These findings underscore that, in real-world settings, children with IEI maintain durable SARS-CoV-2-specific cellular immunity-including memory T-cell responses-highlighting the benefit of vaccination and the potential for continued immune protection despite impaired humoral responses. CI - (c) 2026. The Author(s). FAU - Porto, Luana L T N AU - Porto LLTN AD - The Ottawa Hospital Research Institute, Ottawa, ON, Canada. FAU - Yazji, Dina AU - Yazji D AD - Department of Biochemistry, Microbiology, and Immunology, University of Ottawa, Ottawa, ON, Canada. FAU - Unninayar, Dana AU - Unninayar D AD - Department of Medicine, University of Ottawa, Ottawa, ON, Canada. FAU - Decaluwe, Helene AU - Decaluwe H AD - Pediatric Immunology and Rheumatology Division, Department of Pediatrics, Sainte-Justine University Hospital Center, University of Montreal, Montreal, QC, Canada. FAU - Derfalvi, Beata AU - Derfalvi B AD - Department of Pediatrics, IWK Health, Dalhousie University, Halifax, NS, Canada. FAU - Palma, Alejandro AU - Palma A AD - Department of Pediatrics, IWK Health, Dalhousie University, Halifax, NS, Canada. FAU - Issekutz, Thomas AU - Issekutz T AD - Department of Pediatrics, IWK Health, Dalhousie University, Halifax, NS, Canada. FAU - Kalashnikova, Tatiana AU - Kalashnikova T AD - Section of Hematology and Immunology, Alberta Children's Hospital, University of Calgary, Calgary, AB, Canada. FAU - Murguia-Favela, Luis AU - Murguia-Favela L AD - Section of Hematology and Immunology, Alberta Children's Hospital, University of Calgary, Calgary, AB, Canada. FAU - Pham-Huy, Anne AU - Pham-Huy A AD - Department of Pediatrics, University of Ottawa, Children's Hospital of Eastern Ontario, Ottawa, ON, Canada. FAU - Rubin, Tamar AU - Rubin T AD - Department of Pediatrics and Child Health, Children's Hospital Winnipeg, University of Manitoba, Winnipeg, MB, Canada. FAU - Suresh, Sneha AU - Suresh S AD - Department of Pediatrics, University of Alberta, Edmonton, AB, Canada. FAU - Upton, Julia AU - Upton J AD - The Hospital for Sick Children, Department of Pediatrics, University of Toronto, Toronto, ON, Canada. FAU - Wright, Nicola A M AU - Wright NAM AD - Section of Hematology and Immunology, Alberta Children's Hospital, University of Calgary, Calgary, AB, Canada. FAU - Chapdelaine, Hugo AU - Chapdelaine H AD - Center for Immunity, Inflammation and Infectious Diseases, Montreal Clinical Research Institute (IRCM) and Department of Medicine, Universite de Montreal, Montreal, QC, Canada. FAU - Falcone, Emilia Liana AU - Falcone EL AD - Center for Immunity, Inflammation and Infectious Diseases, Montreal Clinical Research Institute (IRCM) and Department of Medicine, Universite de Montreal, Montreal, QC, Canada. FAU - Top, Karina A AU - Top KA AD - Department of Pediatrics, IWK Health, Dalhousie University, Halifax, NS, Canada. AD - Department of Pediatrics, University of Alberta, Edmonton, AB, Canada. FAU - Sadarangani, Manish AU - Sadarangani M AD - Department of Pediatrics, and Vaccine Evaluation Center, University of British Columbia, BC Children's Hospital Research Institute, Vancouver, BC, Canada, Canada. FAU - Vinh, Donald C AU - Vinh DC AD - McGill University Health Centre, Montreal, QC, Canada. FAU - Barrett, Lisa AU - Barrett L AD - Department of Medicine, Dalhousie University, Halifax, NS, Canada. FAU - Oldford, Sharon AU - Oldford S AD - Department of Medicine, Dalhousie University, Halifax, NS, Canada. FAU - Langlois, Marc-Andre AU - Langlois MA AD - Department of Biochemistry, Microbiology, and Immunology, University of Ottawa, Ottawa, ON, Canada. FAU - Arnold, Corey AU - Arnold C AD - Department of Biochemistry, Microbiology, and Immunology, University of Ottawa, Ottawa, ON, Canada. FAU - Zhang, Tinghua AU - Zhang T AD - The Ottawa Hospital Research Institute, Ottawa, ON, Canada. FAU - Ramsay, Tim AU - Ramsay T AD - The Ottawa Hospital Research Institute, Ottawa, ON, Canada. FAU - Cowan, Juthaporn AU - Cowan J AD - The Ottawa Hospital Research Institute, Ottawa, ON, Canada. jcowan@toh.ca. AD - Department of Biochemistry, Microbiology, and Immunology, University of Ottawa, Ottawa, ON, Canada. jcowan@toh.ca. AD - Department of Medicine, University of Ottawa, Ottawa, ON, Canada. jcowan@toh.ca. CN - VISID study investigators LA - eng GR - 2122-HQ-000073/The Canada COVID-19 Immunity Task Force, Public Health Agency of Canada/ PT - Journal Article PT - Multicenter Study PT - Observational Study DEP - 20260425 PL - Netherlands TA - J Clin Immunol JT - Journal of clinical immunology JID - 8102137 RN - 0 (Antibodies, Viral) RN - 0 (COVID-19 Vaccines) RN - 0 (Immunoglobulin G) RN - 0 (Antibodies, Neutralizing) SB - IM MH - Humans MH - Female MH - Child MH - *SARS-CoV-2/immunology MH - Male MH - *Immunity, Cellular MH - *COVID-19/immunology/prevention & control MH - *Immunity, Humoral MH - Antibodies, Viral/blood/immunology MH - Child, Preschool MH - Adolescent MH - *COVID-19 Vaccines/immunology/administration & dosage MH - T-Lymphocytes/immunology MH - Immunoglobulin G/blood/immunology MH - Antibodies, Neutralizing/blood/immunology PMC - PMC13284020 OTO - NOTNLM OT - COVID-19 vaccine OT - Children OT - Durability OT - Inborn errors of immunity OT - Memory responses COIS- Declarations. Conflict of interest: KAT and HD received grants from the Coalition for Epidemic Preparedness Innovations outside the submitted work. MS has been an investigator on projects funded by GlaxoSmithKline, Merck, Moderna, Pfizer and Sanofi-Pasteur. All funds have been paid to his institute, and he has not received any personal payments. JC has received consultation, speaker fees, and educational funding not related to this study from Takeda, CSL Behring, Grifols, and Octapharma, GSK, Pfizer, Astrazeneca, EMD Serono, and Avir Pharma. LMF is a member of the Data Safety Monitoring Committee for Encoded Therapeutics and has participated as an Advisory Board Member for Takeda, both unrelated to the submitted work. BD is a member of a Data Safety Monitoring Committee and has participated as an Advisory Board Member for Takeda, not related to this study. APH has received educational funding not related to this study from CSL Behring. The authors whose names are listed immediately below certify that they have NO affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers' bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript: LLTNP, DY, DU, ELF, HC, DV, TI, JU, BS, TR, SS, NW, TK, LB, SO, MAL, CA, TZ, TR. FIR - Ritchie, Bruce IR - Ritchie B FIR - Buchan, Arianne C IR - Buchan AC FIR - Kalincinsky, Chrystyna IR - Kalincinsky C FIR - Haddad, Elie IR - Haddad E FIR - Touzot, Fabien IR - Touzot F FIR - Lacuesta, Gina IR - Lacuesta G FIR - Hildebrand, Kyla IR - Hildebrand K FIR - Kim, Vy IR - Kim V FIR - Betschel, Stephen D IR - Betschel SD EDAT- 2026/04/26 05:13 MHDA- 2026/06/22 13:42 PMCR- 2026/04/25 CRDT- 2026/04/25 23:57 PHST- 2025/07/29 00:00 [received] PHST- 2026/04/11 00:00 [accepted] PHST- 2026/06/22 13:42 [medline] PHST- 2026/04/26 05:13 [pubmed] PHST- 2026/04/25 23:57 [entrez] PHST- 2026/04/25 00:00 [pmc-release] AID - 10.1007/s10875-026-02021-1 [pii] AID - 2021 [pii] AID - 10.1007/s10875-026-02021-1 [doi] PST - epublish SO - J Clin Immunol. 2026 Apr 25;46(1):68. doi: 10.1007/s10875-026-02021-1. PMID- 42027105 OWN - NLM STAT- MEDLINE DCOM- 20260715 LR - 20260813 IS - 2164-554X (Electronic) IS - 2164-5515 (Print) IS - 2164-5515 (Linking) VI - 22 IP - 1 DP - 2026 Dec TI - Pre-vaccination immune signatures of children with inborn errors of immunity associate with COVID-19 vaccine response. PG - 2661495 LID - 10.1080/21645515.2026.2661495 [doi] LID - 2661495 AB - Individuals with inborn errors of immunity often mount suboptimal responses to vaccination, yet the molecular determinants underlying their variable responses to mRNA vaccines remain poorly defined. The present study aimed to identify baseline immune transcriptional signatures predictive of humoral responses to the BNT162b2 (Comirnaty) mRNA vaccine in individuals with inborn errors of immunity. Twenty-one SARS-CoV-2-naive participants with diverse inborn errors of immunity were stratified as high or low responders to the BNT162b2 vaccine based on anti-SARS-CoV-2 spike IgG titers at day 28 post-vaccination. Although vaccine-induced T cell responses were broadly comparable, low responders had significantly lower frequencies of switched memory B cells (p = .014). Transcriptional profiling revealed 41 differentially expressed genes between groups at baseline. Activated memory B cells and peripheral T follicular helper cells from high responders exhibited greater induction of activation and memory-related genes, including NFKB1, CD69, TIGIT, CD40L, and BATF, indicating greater intrinsic readiness to support coordinated antibody production. These findings demonstrate that distinct pre-vaccination gene expression patterns within specific immune subsets are associated with differential humoral responses to mRNA vaccination in individuals with inborn errors of immunity. More broadly, the study highlights that baseline molecular immune features substantially influence vaccine efficacy and suggests that pre-vaccination transcriptional profiling may enable more personalized vaccination strategies for individuals with impaired immunity. FAU - Palma, Paolo AU - Palma P AUID- ORCID: 0000-0002-3066-4719 AD - Department of Systems Medicine, University of Rome "Tor Vergata", Rome, Italy. AD - Vaccinopolis, Centre for the Evaluation of Vaccination and Vaccine & Infectious Disease Institute, University of Antwerp, Antwerp, Belgium. FAU - Emili, Elena AU - Emili E AUID- ORCID: 0000-0001-6779-1378 AD - Department of Systems Medicine, University of Rome "Tor Vergata", Rome, Italy. FAU - Pighi, Chiara AU - Pighi C AUID- ORCID: 0000-0001-6163-0135 AD - Clinical Immunology and Vaccinology Unit, IRCCS Bambino Gesu Children's Hospital, Rome, Italy. FAU - Colantoni, Nicole AU - Colantoni N AUID- ORCID: 0009-0007-7122-1766 AD - Clinical Immunology and Vaccinology Unit, IRCCS Bambino Gesu Children's Hospital, Rome, Italy. FAU - Morrocchi, Elena AU - Morrocchi E AUID- ORCID: 0000-0002-3243-9291 AD - Clinical Immunology and Vaccinology Unit, IRCCS Bambino Gesu Children's Hospital, Rome, Italy. FAU - Pascucci, Giuseppe Rubens AU - Pascucci GR AUID- ORCID: 0000-0002-5978-1193 AD - Clinical Immunology and Vaccinology Unit, IRCCS Bambino Gesu Children's Hospital, Rome, Italy. FAU - Rivalta, Beatrice AU - Rivalta B AUID- ORCID: 0000-0003-2199-289X AD - Clinical Immunology and Vaccinology Unit, IRCCS Bambino Gesu Children's Hospital, Rome, Italy. FAU - Rotulo, Gioacchino Andrea AU - Rotulo GA AUID- ORCID: 0000-0002-6926-0877 AD - Clinical Immunology and Vaccinology Unit, IRCCS Bambino Gesu Children's Hospital, Rome, Italy. FAU - Rossetti, Chiara AU - Rossetti C AUID- ORCID: 0000-0001-8200-8724 AD - Clinical Immunology and Vaccinology Unit, IRCCS Bambino Gesu Children's Hospital, Rome, Italy. FAU - Santilli, Veronica AU - Santilli V AUID- ORCID: 0000-0003-1329-6827 AD - Clinical Immunology and Vaccinology Unit, IRCCS Bambino Gesu Children's Hospital, Rome, Italy. FAU - Zangari, Paola AU - Zangari P AUID- ORCID: 0000-0003-0892-6222 AD - Clinical Immunology and Vaccinology Unit, IRCCS Bambino Gesu Children's Hospital, Rome, Italy. FAU - Manno, Emma Concetta AU - Manno EC AUID- ORCID: 0009-0009-0095-8167 AD - Clinical Immunology and Vaccinology Unit, IRCCS Bambino Gesu Children's Hospital, Rome, Italy. FAU - Sanna, Marco AU - Sanna M AUID- ORCID: 0000-0001-5709-5782 AD - Clinical Immunology and Vaccinology Unit, IRCCS Bambino Gesu Children's Hospital, Rome, Italy. FAU - Finocchi, Andrea AU - Finocchi A AUID- ORCID: 0000-0003-0958-8536 AD - Department of Systems Medicine, University of Rome "Tor Vergata", Rome, Italy. AD - Clinical Immunology and Vaccinology Unit, IRCCS Bambino Gesu Children's Hospital, Rome, Italy. FAU - Cancrini, Caterina AU - Cancrini C AUID- ORCID: 0000-0001-8410-9617 AD - Department of Systems Medicine, University of Rome "Tor Vergata", Rome, Italy. AD - Clinical Immunology and Vaccinology Unit, IRCCS Bambino Gesu Children's Hospital, Rome, Italy. FAU - Cicalese, Maria Pia AU - Cicalese MP AUID- ORCID: 0000-0003-0371-3279 AD - Pediatric Immunohematology Unit and BMT Program and San Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy. FAU - Cenciarelli, Sabina AU - Cenciarelli S AUID- ORCID: 0000-0002-1413-4371 AD - Pediatric Immunohematology Unit and BMT Program and San Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy. AD - Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy. FAU - Cirillo, Emilia AU - Cirillo E AUID- ORCID: 0000-0002-0605-649X AD - Department of Translational Medical Sciences, Section of Pediatrics, Federico II University, Naples, Italy. FAU - Giardino, Giuliana AU - Giardino G AUID- ORCID: 0000-0002-0621-9527 AD - Department of Translational Medical Sciences, Section of Pediatrics, Federico II University, Naples, Italy. FAU - Moschese, Viviana AU - Moschese V AUID- ORCID: 0000-0001-7650-0632 AD - Department of Systems Medicine, University of Rome "Tor Vergata", Rome, Italy. FAU - Amodio, Donato AU - Amodio D AUID- ORCID: 0000-0003-4550-3018 AD - Department of Systems Medicine, University of Rome "Tor Vergata", Rome, Italy. AD - Clinical Immunology and Vaccinology Unit, IRCCS Bambino Gesu Children's Hospital, Rome, Italy. FAU - Cotugno, Nicola AU - Cotugno N AUID- ORCID: 0000-0002-7748-1581 AD - Department of Systems Medicine, University of Rome "Tor Vergata", Rome, Italy. AD - Clinical Immunology and Vaccinology Unit, IRCCS Bambino Gesu Children's Hospital, Rome, Italy. LA - eng PT - Journal Article DEP - 20260424 PL - United States TA - Hum Vaccin Immunother JT - Human vaccines & immunotherapeutics JID - 101572652 RN - 0 (Antibodies, Viral) RN - 0 (BNT162 Vaccine) RN - 0 (Immunoglobulin G) RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - Antibodies, Viral/blood/immunology MH - *COVID-19/prevention & control/immunology MH - *BNT162 Vaccine/immunology MH - Male MH - Child MH - Female MH - *SARS-CoV-2/immunology MH - Immunoglobulin G/blood MH - Child, Preschool MH - Immunologic Memory MH - Memory B Cells/immunology MH - Immunity, Humoral MH - Vaccination MH - Gene Expression Profiling MH - *COVID-19 Vaccines/immunology PMC - PMC13114128 OAB - People with inborn errors of immunity do not gain the same level of protection from vaccines as others but the reasons underlying such phenomena are not fully understood. In this study, 21 participants with this condition, who had never had COVID-19, received the BNT162b2 (Comirnaty) mRNA vaccine. Participants were classified as "high responders" or "low responders" based on the amount of antibodies they produced 28 d after vaccination. While both groups showed similar T cell responses, which help fight infections, low responders had fewer switched memory B cells, a type of immune cell important for producing strong and long-lasting antibodies. To investigate why these differences occurred, researchers examined several immune cell types before vaccination. After stimulating these cells in the laboratory, 41 genes were identified as being different between high and low responders. High responders showed stronger activity in genes that help immune cells respond and remember infections. These results show that differences already present in the immune system before vaccination can influence how well people with inborn errors of immunity respond to an mRNA vaccine. Understanding these differences may help researchers find better ways to protect people with immune deficiencies and improve vaccine effectiveness for everyone. OABL- eng OTO - NOTNLM OT - BNT162b2 OT - COVID-19 OT - Inborn errors of immunity OT - T follicular helper cells OT - antibody response OT - mRNA vaccine OT - memory B cells OT - transcriptional profiling OT - vaccine response biomarkers COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. NC, DA and GRP are respectively co-founders and CEO of Probiomics SRL, which is unrelated to the present work. EDAT- 2026/04/24 06:33 MHDA- 2026/04/24 06:34 PMCR- 2026/04/24 CRDT- 2026/04/24 04:03 PHST- 2026/04/24 06:34 [medline] PHST- 2026/04/24 06:33 [pubmed] PHST- 2026/04/24 04:03 [entrez] PHST- 2026/04/24 00:00 [pmc-release] AID - 2661495 [pii] AID - 10.1080/21645515.2026.2661495 [doi] PST - ppublish SO - Hum Vaccin Immunother. 2026 Dec;22(1):2661495. doi: 10.1080/21645515.2026.2661495. Epub 2026 Apr 24. PMID- 41973883 OWN - NLM STAT- In-Process LR - 20260605 IS - 1097-6825 (Electronic) IS - 0091-6749 (Linking) VI - 157 IP - 6 DP - 2026 Jun TI - Three-dose COVID-19 vaccination elicits immune memory in patients with inborn errors of immunity even in the absence of neutralizing antibodies. PG - 1450-1453 LID - S0091-6749(26)00181-8 [pii] LID - 10.1016/j.jaci.2026.02.040 [doi] FAU - Edwards, Emily S J AU - Edwards ESJ AD - Allergy and Clinical Immunology Laboratory, Department of Immunology, School of Translational Medicine, Monash University, Melbourne, Australia; Jeffrey Modell Diagnostic and Research Centre for Primary Immunodeficiencies in Melbourne, Australia; Allergy, Asthma and Clinical Immunology, Alfred Hospital, Melbourne, Australia. Electronic address: emily.edwards@monash.edu. FAU - Gugasyan, Raffi AU - Gugasyan R AD - Allergy and Clinical Immunology Laboratory, Department of Immunology, School of Translational Medicine, Monash University, Melbourne, Australia; Jeffrey Modell Diagnostic and Research Centre for Primary Immunodeficiencies in Melbourne, Australia; Immunohaematology Research Group, Centre for Cancer Research, Hudson Institute of Medical Research, Clayton, Australia; Diagnostic Markers and Chronic Immune Disorders Group, Burnet Institute, Melbourne, Australia. FAU - Varese, Nirupama AU - Varese N AD - Allergy and Clinical Immunology Laboratory, Department of Immunology, School of Translational Medicine, Monash University, Melbourne, Australia; Immune Therapies Group, Burnet Institute, Melbourne, Australia. FAU - Sun, Shir AU - Sun S AD - Allergy and Clinical Immunology Laboratory, Department of Immunology, School of Translational Medicine, Monash University, Melbourne, Australia; Jeffrey Modell Diagnostic and Research Centre for Primary Immunodeficiencies in Melbourne, Australia; Immunohaematology Research Group, Centre for Cancer Research, Hudson Institute of Medical Research, Clayton, Australia; Diagnostic Markers and Chronic Immune Disorders Group, Burnet Institute, Melbourne, Australia. FAU - Canning, Jessica E AU - Canning JE AD - Allergy and Clinical Immunology Laboratory, Department of Immunology, School of Translational Medicine, Monash University, Melbourne, Australia; Jeffrey Modell Diagnostic and Research Centre for Primary Immunodeficiencies in Melbourne, Australia. FAU - Blight, Ebony G AU - Blight EG AD - Allergy and Clinical Immunology Laboratory, Department of Immunology, School of Translational Medicine, Monash University, Melbourne, Australia; Jeffrey Modell Diagnostic and Research Centre for Primary Immunodeficiencies in Melbourne, Australia. FAU - Aui, Pei M AU - Aui PM AD - Allergy and Clinical Immunology Laboratory, Department of Immunology, School of Translational Medicine, Monash University, Melbourne, Australia; Jeffrey Modell Diagnostic and Research Centre for Primary Immunodeficiencies in Melbourne, Australia. FAU - Boo, Irene AU - Boo I AD - Viral Entry and Vaccines Group, Burnet Institute, Melbourne, Australia. FAU - Turville, Stuart AU - Turville S AD - The Kirby Institute, University of New South Wales, Australia. FAU - Aggarwal, Anupriya AU - Aggarwal A AD - The Kirby Institute, University of New South Wales, Australia. FAU - Ojaimi, Samar AU - Ojaimi S AD - Jeffrey Modell Diagnostic and Research Centre for Primary Immunodeficiencies in Melbourne, Australia; Monash Pathology, Monash Infectious Diseases, and Monash Lung, Sleep, Allergy and Immunology, Monash Health, Melbourne, Australia; Department of Medicine, Southern Clinical School, Monash Health and Monash University, Melbourne, Australia. FAU - Bosco, Julian J AU - Bosco JJ AD - Jeffrey Modell Diagnostic and Research Centre for Primary Immunodeficiencies in Melbourne, Australia; Allergy, Asthma and Clinical Immunology, Alfred Hospital, Melbourne, Australia. FAU - Stojanovic, Stephanie AU - Stojanovic S AD - Jeffrey Modell Diagnostic and Research Centre for Primary Immunodeficiencies in Melbourne, Australia; Allergy, Asthma and Clinical Immunology, Alfred Hospital, Melbourne, Australia. FAU - Hogarth, P Mark AU - Hogarth PM AD - Immune Therapies Group, Burnet Institute, Melbourne, Australia; Department of Pathology, The University of Melbourne, Parkville, Australia. FAU - Drummer, Heidi E AU - Drummer HE AD - Viral Entry and Vaccines Group, Burnet Institute, Melbourne, Australia; Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, Australia; Department of Microbiology, Monash University, Clayton, Australia. FAU - Bornheimer, Scott J AU - Bornheimer SJ AD - BD Biosciences, San Jose, Calif. FAU - O'Hehir, Robyn E AU - O'Hehir RE AD - Allergy and Clinical Immunology Laboratory, Department of Immunology, School of Translational Medicine, Monash University, Melbourne, Australia; Jeffrey Modell Diagnostic and Research Centre for Primary Immunodeficiencies in Melbourne, Australia; Allergy, Asthma and Clinical Immunology, Alfred Hospital, Melbourne, Australia. FAU - van Zelm, Menno C AU - van Zelm MC AD - Allergy and Clinical Immunology Laboratory, Department of Immunology, School of Translational Medicine, Monash University, Melbourne, Australia; Jeffrey Modell Diagnostic and Research Centre for Primary Immunodeficiencies in Melbourne, Australia; Allergy, Asthma and Clinical Immunology, Alfred Hospital, Melbourne, Australia; Department of Immunology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands. Electronic address: m.vanzelm@erasmusmc.nl. LA - eng PT - Letter DEP - 20260413 PL - United States TA - J Allergy Clin Immunol JT - The Journal of allergy and clinical immunology JID - 1275002 SB - IM OTO - NOTNLM OT - COVID-19 vaccination OT - Inborn errors of immunity OT - immune memory OT - neutralizing antibodies COIS- Disclosure statement Supported by the Australian Medical Research Future Fund (project no. 2016108), the Jeffrey Modell Foundation, and the Allergy and Immunology Foundation of Australasia (a Primary Immunodeficiency Clinical Research Grant [supported by CSL Behring, Australia]). Disclosure of potential conflict of interest: M. C. van Zelm, R. E. O'Hehir, and P. M. Hogarth are inventers on a patent application related to this work. S. J. Bornheimer is an employee of and owns stock in BD. The rest of the authors declare that they have no relevant conflicts of interest. EDAT- 2026/04/13 18:31 MHDA- 2026/04/13 18:31 CRDT- 2026/04/13 14:57 PHST- 2025/10/21 00:00 [received] PHST- 2026/01/27 00:00 [revised] PHST- 2026/02/03 00:00 [accepted] PHST- 2026/04/13 18:31 [pubmed] PHST- 2026/04/13 18:31 [medline] PHST- 2026/04/13 14:57 [entrez] AID - S0091-6749(26)00181-8 [pii] AID - 10.1016/j.jaci.2026.02.040 [doi] PST - ppublish SO - J Allergy Clin Immunol. 2026 Jun;157(6):1450-1453. doi: 10.1016/j.jaci.2026.02.040. Epub 2026 Apr 13. PMID- 41939860 OWN - NLM STAT- MEDLINE DCOM- 20260714 LR - 20260813 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 17 DP - 2026 TI - Immune correlates underlying small fiber neuropathy presenting as vaccine-associated post-acute SARS- coronavirus syndrome. PG - 1752120 LID - 10.3389/fimmu.2026.1752120 [doi] LID - 1752120 AB - BACKGROUND: A spectrum of adverse events overlapping with Post-acute Sequelae of SARS-CoV-2 infection (PASC) occurs in some patients following SARS-CoV-2 vaccination including small fiber neuropathy (SFN) and cognitive symptoms. AIMS: Accruing information regarding disease course and immune response imbalances in these patients. METHODS: We studied 71 previously healthy patients with neurological symptoms following SARS-CoV-vaccination. All had negative neurological workup for central/peripheral involvement (MR, EMG/EN). Cutaneous biopsy (21pts.) and peripheral blood sampling (20pts) were performed for anti-idiotype Ab analysis (ACE-2,NRP-1) (ELISA, IF) and for Flowcytometric analysis. RESULTS: Paresthesia, cognitive impairment and autonomic symptoms agreed with SFN international definition. Comparative differences included abrupt onset, presence of simultaneous diverse paresthesia across multiple body regions frequently affecting the facial and cervical regions (44%) and the trunk (26%), associated to dysautonomia. Median time from vaccination to symptom manifestation was 3 days (mean +/- SD: 8.76 +/- 17.4 days). Symptom severity was still high (5.9 +/- 1.9 mean+SD) at the time of evaluation and sampling, (382 +/- 133 days from onset. Reduced small fiber density was observed in 19/21 biopsies. Anti-ACE-2 antibodies in 9/71pts. (12%) and 4/19 (21%) vaccinated HD sera and NRP-1 reactivity in 14/71 (20%) patient and 1/19 (5%) HD sera were not significantly increased. Peripheral NKG2D+CD8+ and NKG2D+DNAM-1+CD4+ T-cells were increased. Circulating inflammatory CD34+ cells were increased and generated in vitro a prevalence of NKG2D+DNAM-1+ T-cells. CONCLUSION: PASC-vac SFN is associated with persistent immune imbalances common to other immune-mediated diseases. Additional effort to identify immune mechanisms unleashing PASC-vac SFN will contribute to modulate future early interventions for these patients and refine vaccine design. CI - Copyright (c) 2026 Limongelli, Bozzano, Hajabbas Farshchi, Bellucci, Bavastro, Castellano, Pesce, Antonini, Incensi, Giannoccaro, Uccelli, Del Zotto, Moretta, Donadio, Benedetti and De Maria. FAU - Limongelli, Alessandro AU - Limongelli A AD - Universita degli Studi di Genova, Department of Health Sciences, Genoa, Italy. FAU - Bozzano, Federica AU - Bozzano F AD - Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS), Ospedale Policlinico San Martino, Genova, Italy. FAU - Hajabbas Farshchi, Alireza AU - Hajabbas Farshchi A AD - Universita degli Studi di Genova, Department of Health Sciences, Genoa, Italy. FAU - Bellucci, Margherita AU - Bellucci M AD - Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genova, Genoa, Italy. FAU - Bavastro, Martina AU - Bavastro M AD - Universita degli Studi di Genova, Department of Health Sciences, Genoa, Italy. FAU - Castellano, Chiara AU - Castellano C AD - Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS), Ospedale Policlinico San Martino, Genova, Italy. FAU - Pesce, Giampaola AU - Pesce G AD - Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS), Ospedale Policlinico San Martino, Genova, Italy. FAU - Antonini, Francesca AU - Antonini F AD - Integrated Department of Services and Laboratories, IRCCS Istituto Giannina Gaslini, Genova, Italy. FAU - Incensi, Alex AU - Incensi A AD - IRCCS Istituto delle Scienze Neurologiche di Bologna, UOC Clinica Neurologica, Bologna, Italy. FAU - Giannoccaro, Maria Pia AU - Giannoccaro MP AD - IRCCS Istituto delle Scienze Neurologiche di Bologna, UOC Clinica Neurologica, Bologna, Italy. FAU - Uccelli, Antonio AU - Uccelli A AD - Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS), Ospedale Policlinico San Martino, Genova, Italy. AD - Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genova, Genoa, Italy. FAU - Del Zotto, Genny AU - Del Zotto G AD - Integrated Department of Services and Laboratories, IRCCS Istituto Giannina Gaslini, Genova, Italy. FAU - Moretta, Lorenzo AU - Moretta L AD - Tumor Immunology Unit, Bambino Gesu Children's Hospital, IRCCS, Rome, Italy. FAU - Donadio, Vincenzo AU - Donadio V AD - IRCCS Istituto delle Scienze Neurologiche di Bologna, UOC Clinica Neurologica, Bologna, Italy. FAU - Benedetti, Luana AU - Benedetti L AD - Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genova, Genoa, Italy. FAU - De Maria, Andrea AU - De Maria A AD - Universita degli Studi di Genova, Department of Health Sciences, Genoa, Italy. AD - S.C. Malattie Infettive, Azienda Sociosanitaria Ligure n.5, La Spezia, Italy. LA - eng PT - Journal Article DEP - 20260319 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - Female MH - *Small Fiber Neuropathy/immunology/etiology/pathology MH - Male MH - *COVID-19/immunology/prevention & control MH - *SARS-CoV-2/immunology MH - Middle Aged MH - Post-Acute COVID-19 Syndrome MH - Adult MH - *COVID-19 Vaccines/adverse effects/immunology MH - Vaccination/adverse effects MH - Aged PMC - PMC13043346 OTO - NOTNLM OT - Long-COVID OT - NKG2D OT - PASC OT - SARS-CoV-2 OT - innate-like T cells OT - post-acute sequelae of SARS-CoV-2 infection OT - small fiber neuropathy OT - vaccine COIS- The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2026/04/06 12:36 MHDA- 2026/04/06 12:37 PMCR- 2026/03/19 CRDT- 2026/04/06 06:21 PHST- 2025/11/22 00:00 [received] PHST- 2026/01/25 00:00 [revised] PHST- 2026/02/03 00:00 [accepted] PHST- 2026/04/06 12:37 [medline] PHST- 2026/04/06 12:36 [pubmed] PHST- 2026/04/06 06:21 [entrez] PHST- 2026/03/19 00:00 [pmc-release] AID - 10.3389/fimmu.2026.1752120 [doi] PST - epublish SO - Front Immunol. 2026 Mar 19;17:1752120. doi: 10.3389/fimmu.2026.1752120. eCollection 2026. PMID- 41906364 OWN - NLM STAT- MEDLINE DCOM- 20260714 LR - 20260813 IS - 1529-8027 (Electronic) IS - 1085-9489 (Print) IS - 1085-9489 (Linking) VI - 31 IP - 2 DP - 2026 Jun TI - A Next-Generation ELISA for the Detection of Anti-(Para)Nodal Antibodies in Autoimmune Nodopathy and COVID-19 Vaccinated Individuals. PG - e70117 LID - 10.1111/jns.70117 [doi] LID - e70117 AB - BACKGROUND AND AIMS: Autoimmune nodopathy (AN) is a subtype of antibody-mediated inflammatory neuropathy targeting the node of Ranvier (NoR). Diagnosis requires detection of anti-(para)nodal autoantibodies like contactin-1 and neurofascin-155 via ELISA or cell-based assays, but protocols are inconsistent. Causes of node autoimmunity are unknown, and respiratory infections, including SARS-CoV-2 infection or COVID-19 vaccination as triggers, have not been thoroughly investigated. We aim to establish and validate a next-generation automated ELISA for anti-(para)nodal antibodies and investigate whether low-titer antibodies occur in recently COVID-19-vaccinated healthy individuals. METHODS: We used the Ella platform to customize an automated ELISA for anti-contactin-1, -neurofascin-155, and -Caspr-1 serum IgG. Patients with known AN (23 anti-neurofascin, 13 anti-contactin-1, and 8 anti-Caspr-1), 64 patients with seronegative (sub) acute inflammatory neuropathies, and 30 healthy controls served for validation, including quality analysis versus standard ELISA. Thirty-seven diagnostic samples of patients with suspected AN and 280 sera of healthcare workers included in the CoVacSer study, collected 3 weeks after COVID-19 vaccination or infection, were tested for anti-contactin-1 and anti-neurofascin-155. RESULTS: The automated ELISA showed high sensitivity (87.5%-100%) and specificity (98.4%-100%) for identifying AN, with reduced hands-on time, high automation, and similar quality and titer characteristics as standard ELISA. Low-titer anti-neurofascin-155, but no anti-contactin-1 autoantibodies, were detected in 1/280 post-SARS-CoV-2-vaccination or infection sera (0.36%). Longitudinal testing and clinical assessment did not indicate SARS-CoV-2-related neurological symptoms. INTERPRETATION: We provide a highly automated, rapid, universally applicable test platform for anti-(para)nodal antibodies. The low frequency of anti-(para)nodal antibodies and absence of clinical AN manifestations in COVID-19-vaccinated individuals support vaccination safety regarding AN development. CI - (c) 2026 The Author(s). Journal of the Peripheral Nervous System published by Wiley Periodicals LLC on behalf of Peripheral Nerve Society. FAU - Appeltshauser, Luise AU - Appeltshauser L AUID- ORCID: 0000-0001-5248-4009 AD - Department of Neurology, University Hospital Wurzburg, Wurzburg, Germany. AD - German Center for Neurodegenerative Diseases (DZNE) Berlin, Berlin, Germany. FAU - Ruprecht, Chiara AU - Ruprecht C AD - Department of Neurology, University Hospital Wurzburg, Wurzburg, Germany. FAU - Reusch, Julia AU - Reusch J AD - Department of General, Visceral, Transplantation, Vascular and Pediatric Surgery, University Hospital Wurzburg, Wurzburg, Germany. FAU - Mees, Juliane AU - Mees J AUID- ORCID: 0009-0000-4383-3107 AD - Central Laboratory Unit, University Hospital Wurzburg, Wurzburg, Germany. FAU - Glenewinkel, Helena AU - Glenewinkel H AD - Department of Neurology, University Hospital Wurzburg, Wurzburg, Germany. FAU - Sommer, Claudia AU - Sommer C AD - Department of Anesthesiology, Intensive Care, Emergency Medicine and Pain Medicine, Centre for Interdisciplinary Pain Medicine, University Hospital Wurzburg, Wurzburg, Germany. FAU - Krone, Manuel AU - Krone M AD - Central Laboratory Unit, University Hospital Wurzburg, Wurzburg, Germany. FAU - Wagenhauser, Isabell AU - Wagenhauser I AD - Department of Pediatrics, University Hospital Wurzburg, Wurzburg, Germany. FAU - Doppler, Kathrin AU - Doppler K AD - Department of Neurology, University Hospital Wurzburg, Wurzburg, Germany. FAU - Petri, Nils AU - Petri N AD - Department of Internal Medicine I, University Hospital Wurzburg, Wurzburg, Germany. LA - eng GR - AP1/1/Deutsche Gesellschaft fur Muskelkranke/ GR - 01KX2021/German Federal Ministry of Education and Research (Bundesministerium fur Bildung und Forschung, BMBF)/ GR - 01KX2121/German Federal Ministry of Education and Research (Bundesministerium fur Bildung und Forschung, BMBF)/ GR - Julius-Maximilians-Universitat Wurzburg/ PT - Journal Article PL - United States TA - J Peripher Nerv Syst JT - Journal of the peripheral nervous system : JPNS JID - 9704532 RN - 0 (Autoantibodies) RN - 0 (COVID-19 Vaccines) RN - 0 (Contactin 1) RN - 0 (Nerve Growth Factors) RN - 0 (Cell Adhesion Molecules) RN - 0 (NFASC protein, human) SB - IM MH - Humans MH - Enzyme-Linked Immunosorbent Assay/methods MH - Female MH - *Autoantibodies/blood MH - Adult MH - Middle Aged MH - *COVID-19/prevention & control/immunology MH - *COVID-19 Vaccines MH - Male MH - Contactin 1/immunology MH - Nerve Growth Factors/immunology MH - Aged MH - Cell Adhesion Molecules/immunology MH - SARS-CoV-2 PMC - PMC13033911 OTO - NOTNLM OT - COVID-19 OT - ELISA OT - SARS-CoV-2 OT - autoimmune nodopathy OT - contactin-1 OT - neurofascin EDAT- 2026/03/30 06:29 MHDA- 2026/03/30 06:30 PMCR- 2026/03/30 CRDT- 2026/03/30 01:23 PHST- 2026/01/30 00:00 [revised] PHST- 2025/09/10 00:00 [received] PHST- 2026/02/24 00:00 [accepted] PHST- 2026/03/30 06:30 [medline] PHST- 2026/03/30 06:29 [pubmed] PHST- 2026/03/30 01:23 [entrez] PHST- 2026/03/30 00:00 [pmc-release] AID - JNS70117 [pii] AID - 10.1111/jns.70117 [doi] PST - ppublish SO - J Peripher Nerv Syst. 2026 Jun;31(2):e70117. doi: 10.1111/jns.70117. PMID- 41901323 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260328 LR - 20260813 IS - 1424-8247 (Print) IS - 1424-8247 (Electronic) IS - 1424-8247 (Linking) VI - 19 IP - 3 DP - 2026 Mar 14 TI - Incidence of Guillain-Barre Syndrome Following COVID-19 Vaccination and SARS-CoV-2 Infection: A Population-Based Cohort Study Using the Valencia Health System Integrated Database (Spain). LID - 10.3390/ph19030477 [doi] LID - 477 AB - Background/Objectives: Guillain-Barre syndrome (GBS) is a rare but serious immune-mediated neurological disorder monitored as an adverse event of special interest during the COVID-19 pandemic. This study aimed to estimate the incidence of GBS following COVID-19 vaccination and SARS-CoV-2 infection and to compare the risk by vaccine platform. Methods: We conducted a population-based retrospective cohort study using data from the Valencia Health System Integrated Database (Spain) between January 2018 and March 2022. Two cohorts were defined: individuals receiving COVID-19 vaccines (mRNA-based vaccines (BNT162b2 [Pfizer-BioNTech] and mRNA-1273 [Moderna]) or non-virus-vectored (NVV) adenoviral vector-based vaccines (ChAdOx1-S [AstraZeneca] and Ad26.COV2.S [Janssen])) and individuals with laboratory-confirmed SARS-CoV-2 infection. Incident GBS cases were identified within a predefined 42-day risk window following vaccination or infection. Incidence rates were calculated per 100,000 vaccine doses administered or SARS-CoV-2 infections. Results: Among 5,109,919 individuals, 4,270,610 received at least one COVID-19 vaccine dose and 920,643 experienced at least one SARS-CoV-2 infection. A total of 69 GBS cases occurred within 42 days following vaccination (incidence: 0.67 per 100,000 doses), whereas 21 cases occurred after infection (incidence: 2.20 per 100,000 infections). Incidence was lower after mRNA-based vaccines (0.55 per 100,000 doses) than after NVV vaccines (1.57 per 100,000 doses). Conclusions: This study confirms that GBS occurrence following vaccination is rare. The incidence is lower among individuals who received mRNA vaccines compared to those who received NVV vaccines. Moreover, GBS appears to be more frequent after a COVID-19 infection than after vaccination. These findings highlight the importance of integrating pharmacoepidemiological analyses with pharmacovigilance data to contextualize rare but serious adverse events. FAU - Correcher-Martinez, Elisa AU - Correcher-Martinez E AUID- ORCID: 0009-0005-0069-5652 AD - Vaccine Research Department, Foundation for the Promotion of Health and Biomedical Research in the Valencian Region (FISABIO-Public Health), 46020 Valencia, Spain. FAU - Viciedo-Mata, Sergio Pascual AU - Viciedo-Mata SP AUID- ORCID: 0000-0003-1766-480X AD - Subdirectorate of Epidemiology and Public Health Surveillance, Autonomous Community of Valencia, 46020 Valencia, Spain. FAU - Urchueguia-Fornes, Arantxa AU - Urchueguia-Fornes A AUID- ORCID: 0000-0003-4689-9077 AD - Vaccine Research Department, Foundation for the Promotion of Health and Biomedical Research in the Valencian Region (FISABIO-Public Health), 46020 Valencia, Spain. AD - Biomedical Research Consortium of Epidemiology and Public Health (CIBER-ESP), Instituto de Salud Carlos III, 28029 Madrid, Spain. FAU - Carreras, Juan Jose AU - Carreras JJ AUID- ORCID: 0000-0002-5725-8972 AD - Vaccine Research Department, Foundation for the Promotion of Health and Biomedical Research in the Valencian Region (FISABIO-Public Health), 46020 Valencia, Spain. AD - Biomedical Research Consortium of Epidemiology and Public Health (CIBER-ESP), Instituto de Salud Carlos III, 28029 Madrid, Spain. LA - eng PT - Journal Article DEP - 20260314 PL - Switzerland TA - Pharmaceuticals (Basel) JT - Pharmaceuticals (Basel, Switzerland) JID - 101238453 PMC - PMC13029112 OTO - NOTNLM OT - COVID-19 vaccines OT - Guillain-Barre Syndrome OT - SARS-CoV-2 infection OT - pharmacoepidemiology OT - pharmacovigilance OT - real-world data OT - vaccine safety COIS- The authors declare no conflicts of interest related to the content of this study. Additional disclosure, E.C.-M., A.U.-F. and J.J.C. are employees of the Vaccine Research Department at FISABIO. The research group performs financially supported studies for government, other related healthcare authorities, and several pharmaceutical companies. A.U.-F. and E.C.-M. are working on other projects, not related to this study, funded by pharmaceutical companies. E.C.-M., S.P.V.-M. and A.U.-F. have attended congresses for which inscription has been covered by pharmaceutical companies. EDAT- 2026/03/28 06:40 MHDA- 2026/03/28 06:41 PMCR- 2026/03/14 CRDT- 2026/03/28 01:32 PHST- 2026/01/24 00:00 [received] PHST- 2026/03/02 00:00 [revised] PHST- 2026/03/10 00:00 [accepted] PHST- 2026/03/28 06:41 [medline] PHST- 2026/03/28 06:40 [pubmed] PHST- 2026/03/28 01:32 [entrez] PHST- 2026/03/14 00:00 [pmc-release] AID - ph19030477 [pii] AID - pharmaceuticals-19-00477 [pii] AID - 10.3390/ph19030477 [doi] PST - epublish SO - Pharmaceuticals (Basel). 2026 Mar 14;19(3):477. doi: 10.3390/ph19030477. PMID- 41884846 OWN - NLM STAT- MEDLINE DCOM- 20260713 LR - 20260813 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 17 DP - 2026 TI - Immunization with MVA-based vaccines protects K18-hACE2 mice from SARS-CoV-2 infection-associated inflammatory lesions in brains. PG - 1788665 LID - 10.3389/fimmu.2026.1788665 [doi] LID - 1788665 AB - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is known as the etiological agent of coronavirus disease 2019 (COVID-19). Extrapulmonary manifestations of COVID-19 have gained increasing recognition as significant contributors to disease severity and long-term complications. The aim of this study is to investigate the neuroprotective properties of vaccines based on modified Vaccinia Virus Ankara (MVA) against SARS-CoV-2 infection in K18-hACE2 mice using different immunization protocols. Animals received PBS, vector, recombinant MVA expressing native (S) or stabilized (ST) SARS-CoV-2 spike protein, nucleocapsid protein (N) or both ST and N protein twice, followed by infection with SARS-CoV-2 four weeks later. In further experiments, mice were immunized only once and infected two days (Emergency experiment) or four weeks (Prime experiment) later. Both the control groups and the animals immunized with vaccines expressing only N-protein showed mild to moderate, lymphohistiocytic meningoencephalitis, microgliosis and numerous virus antigen-positive neurons in the brains and to a lesser extent in the retinas. Groups immunized four weeks prior to infection with vaccines containing viral spike protein showed no or minimal inflammatory changes and no neuroinvasion. Animals infected two days after immunization showed milder lesions than unvaccinated control groups. CI - Copyright (c) 2026 Rosiak, Clever, Leitzen, Beythien, Michaely, Lockow, Allnoch, Ciurkiewicz, Meyer zu Natrup, Tuchel, Tscherne, Limpinsel, Sutter, Volz, Baumgartner, Hulskotter and Gregor. FAU - Rosiak, Malgorzata AU - Rosiak M AD - Department of Pathology, University of Veterinary Medicine Hannover, Hannover, Germany. AD - Center for Systems Neuroscience, Hannover, Germany. FAU - Clever, Sabrina AU - Clever S AD - Institute of Virology and Research Center for Emerging Infections and Zoonoses, University of Veterinary Medicine Hannover, Hannover, Germany. FAU - Leitzen, Eva AU - Leitzen E AD - Department of Pathology, University of Veterinary Medicine Hannover, Hannover, Germany. FAU - Beythien, Georg AU - Beythien G AD - Department of Pathology, University of Veterinary Medicine Hannover, Hannover, Germany. AD - Center for Systems Neuroscience, Hannover, Germany. FAU - Michaely, Lukas Mathias AU - Michaely LM AD - Department of Pathology, University of Veterinary Medicine Hannover, Hannover, Germany. FAU - Lockow, Sandra AU - Lockow S AD - Department of Pathology, University of Veterinary Medicine Hannover, Hannover, Germany. FAU - Allnoch, Lisa AU - Allnoch L AD - Department of Pathology, University of Veterinary Medicine Hannover, Hannover, Germany. FAU - Ciurkiewicz, Malgorzata AU - Ciurkiewicz M AD - Department of Pathology, University of Veterinary Medicine Hannover, Hannover, Germany. FAU - Meyer Zu Natrup, Christian AU - Meyer Zu Natrup C AD - Institute of Virology and Research Center for Emerging Infections and Zoonoses, University of Veterinary Medicine Hannover, Hannover, Germany. FAU - Tuchel, Tamara AU - Tuchel T AD - Department of Pathology, University of Veterinary Medicine Hannover, Hannover, Germany. FAU - Tscherne, Alina AU - Tscherne A AD - Division of Virology, Department of Veterinary Sciences, LMU Munich, Munich, Germany. FAU - Limpinsel, Leonard AU - Limpinsel L AD - Division of Virology, Department of Veterinary Sciences, LMU Munich, Munich, Germany. FAU - Sutter, Gerd AU - Sutter G AD - Division of Virology, Department of Veterinary Sciences, LMU Munich, Munich, Germany. FAU - Volz, Asisa AU - Volz A AD - Center for Systems Neuroscience, Hannover, Germany. AD - Institute of Virology and Research Center for Emerging Infections and Zoonoses, University of Veterinary Medicine Hannover, Hannover, Germany. FAU - Baumgartner, Wolfgang AU - Baumgartner W AD - Department of Pathology, University of Veterinary Medicine Hannover, Hannover, Germany. AD - Center for Systems Neuroscience, Hannover, Germany. FAU - Hulskotter, Kirsten AU - Hulskotter K AD - Department of Pathology, University of Veterinary Medicine Hannover, Hannover, Germany. FAU - Gregor, Katharina Manuela AU - Gregor KM AD - Department of Pathology, University of Veterinary Medicine Hannover, Hannover, Germany. AD - Center for Systems Neuroscience, Hannover, Germany. LA - eng PT - Journal Article DEP - 20260310 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 RN - 0 (COVID-19 Vaccines) RN - 0 (Spike Glycoprotein, Coronavirus) RN - EC 3.4.17.23 (Angiotensin-Converting Enzyme 2) RN - 0 (spike protein, SARS-CoV-2) RN - 0 (Coronavirus Nucleocapsid Proteins) RN - 0 (MVA vaccine) RN - 0 (Antibodies, Viral) RN - 0 (Viral Vaccines) RN - 0 (Vaccines, DNA) SB - IM MH - Animals MH - Mice MH - *Brain/pathology/immunology/virology MH - *COVID-19/prevention & control/immunology/pathology MH - *COVID-19 Vaccines/immunology MH - *SARS-CoV-2/immunology MH - Spike Glycoprotein, Coronavirus/immunology/genetics MH - *Vaccinia virus/genetics/immunology MH - *Angiotensin-Converting Enzyme 2/genetics MH - Immunization MH - Coronavirus Nucleocapsid Proteins/immunology/genetics MH - Female MH - Humans MH - Antibodies, Viral/blood MH - Disease Models, Animal MH - Viral Vaccines MH - Vaccines, DNA PMC - PMC13008624 OTO - NOTNLM OT - COVID-19 OT - K18-hACE2 mice OT - SARS-CoV-2 OT - modified vaccinia ankara-based vaccines OT - vaccines COIS- The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2026/03/26 07:09 MHDA- 2026/03/26 07:10 PMCR- 2026/03/10 CRDT- 2026/03/26 05:08 PHST- 2026/01/15 00:00 [received] PHST- 2026/02/17 00:00 [revised] PHST- 2026/02/23 00:00 [accepted] PHST- 2026/03/26 07:10 [medline] PHST- 2026/03/26 07:09 [pubmed] PHST- 2026/03/26 05:08 [entrez] PHST- 2026/03/10 00:00 [pmc-release] AID - 10.3389/fimmu.2026.1788665 [doi] PST - epublish SO - Front Immunol. 2026 Mar 10;17:1788665. doi: 10.3389/fimmu.2026.1788665. eCollection 2026. PMID- 41824149 OWN - NLM STAT- MEDLINE DCOM- 20260627 LR - 20261009 IS - 1534-6293 (Electronic) IS - 1528-4042 (Linking) VI - 26 IP - 1 DP - 2026 Mar 13 TI - Cognition and Long COVID: a Review. LID - 15 [pii] LID - 10.1007/s11910-026-01485-3 [doi] AB - PURPOSE OF REVIEW: Provide an overview of current knowledge regarding cognitive issues in patients with long COVID, also termed brain fog or cognitive COVID. RECENT FINDINGS: Subjective cognitive symptoms in long COVID patients are common but often go undetected by traditional standardised cognitive test batteries. This discrepancy poses a major clinical and societal problem, given the prevalence, protracted course and impact of cognitive COVID on work functioning. New, online assessment methods for cognitive function are feasible and corroborate subjective self-report symptoms, finding executive function impairments in cognitive COVID. As vaccination protects against brain fog and not against anxiety and depression in long COVID, brain fog can be seen as a core symptom of long COVID, concerning executive functioning, and a direct effect of neurotropic viral brain infiltration. Depression and anxiety are comorbid conditions due to indirect factors associated with the pandemic, such as increased social isolation and loss of work. Ongoing vaccination programs should not only target the elderly, but also working-age people. Online cognitive assessment batteries are recommended for assessment and treatment monitoring in long COVID. Integrated care is recommended given the high rate of multimorbidity. Future research might explore the effects of antiviral medication, modulation of the immune response, and GLP-1 agonists in long COVID. FAU - van der Feltz-Cornelis, Christina M AU - van der Feltz-Cornelis CM AUID- ORCID: 0000-0001-6925-8956 AD - Department of Health Sciences, University of York, ARRC Building, MHARG, Heslington York, York, YO10 5DD, UK. christina.vanderfeltz-cornelis@york.ac.uk. LA - eng PT - Journal Article PT - Review DEP - 20260313 PL - United States TA - Curr Neurol Neurosci Rep JT - Current neurology and neuroscience reports JID - 100931790 SB - IM MH - Humans MH - *COVID-19/complications/psychology MH - Post-Acute COVID-19 Syndrome MH - SARS-CoV-2 MH - Pandemics MH - *Cognition Disorders/etiology MH - *Cognition/physiology MH - *Cognitive Dysfunction/etiology MH - Neuropsychological Tests OTO - NOTNLM OT - Brain fog OT - Cognitive function OT - Diagnostic assessment OT - Integrated care OT - Long COVID OT - Review OT - Vaccination COIS- Declarations. Human and Animal Rights and Informed Consent: This article does not contain any studies with human or animal subjects performed by any of the authors. Competing interests: The authors declare no competing interests. EDAT- 2026/03/13 19:31 MHDA- 2026/06/27 12:36 CRDT- 2026/03/13 12:18 PHST- 2026/02/12 00:00 [received] PHST- 2026/02/16 00:00 [accepted] PHST- 2026/06/27 12:36 [medline] PHST- 2026/03/13 19:31 [pubmed] PHST- 2026/03/13 12:18 [entrez] AID - 10.1007/s11910-026-01485-3 [pii] AID - 10.1007/s11910-026-01485-3 [doi] PST - epublish SO - Curr Neurol Neurosci Rep. 2026 Mar 13;26(1):15. doi: 10.1007/s11910-026-01485-3. PMID- 41817302 OWN - NLM STAT- MEDLINE DCOM- 20260710 LR - 20260926 IS - 1521-4141 (Electronic) IS - 0014-2980 (Print) IS - 0014-2980 (Linking) VI - 56 IP - 3 DP - 2026 Mar TI - Heterogeneous Activated B Cell Compartments Arising Early and Transiently After SARS-CoV-2 Vaccination. PG - e70165 LID - 10.1002/eji.70165 [doi] LID - e70165 AB - In humans, the stages and dynamics of B cell development after antigen encounter remain unclear. Identifying early B cell differentiation stages could reveal biomarkers for humoral immunity and potential targets to prevent unwanted antibody responses. We characterized antigen-specific B cell responses longitudinally after SARS-CoV-2 mRNA vaccination using multiparameter spectral flow cytometry. Spike-specific IgG(+) CD27(+) CD71(+) activated B cells (ActBCs), presumed to be germinal center-derived and IgG(+) DN2 extrafollicular B cells, dominated the early antigen-specific B cell response, while memory B cells were the main population 6 months after vaccination. Within the IgG(+) ActBC compartment, we delineated six novel clusters with specific contraction dynamics. Following the second vaccination, certain ActBC clusters displayed sustained expansion over time, being phenotypically similar to memory B cells, while others strongly expanded and subsequently contracted. Several of the rapidly contracting ActBC clusters expressed CD11c, a defining marker for atypical B cells, suggesting a possible extrafollicular origin of these clusters. The transient presence of heterogeneous ActBC clusters was also observed for total B cells when gated in an antigen-independent manner. Characterization of novel ActBC clusters early after antigen encounter helps delineate and dissect the complexity of B cell differentiation, which is vital for understanding unwanted B cell responses. CI - (c) 2026 The Author(s). European Journal of Immunology published by Wiley-VCH GmbH. FAU - Fernandez Blanco, Laura AU - Fernandez Blanco L AUID- ORCID: 0000-0002-3485-1378 AD - Sanquin Research and Landsteiner Laboratory of the Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands. AD - Department of Neurology and Neurophysiology, Amsterdam UMC, Amsterdam, the Netherlands. FAU - Kuijper, Lisan H AU - Kuijper LH AUID- ORCID: 0000-0003-3009-0943 AD - Sanquin Research and Landsteiner Laboratory of the Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands. FAU - Kummer, Laura Y L AU - Kummer LYL AD - Sanquin Research and Landsteiner Laboratory of the Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands. AD - Department of Neurology and Neurophysiology, Amsterdam UMC, Amsterdam, the Netherlands. FAU - Verstegen, Niels J M AU - Verstegen NJM AD - Sanquin Research and Landsteiner Laboratory of the Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands. FAU - Bos, Amelie AU - Bos A AD - Sanquin Research and Landsteiner Laboratory of the Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands. FAU - Claireaux, Mathieu AU - Claireaux M AD - Department of Medical Microbiology and Infection Prevention, Amsterdam UMC, AMC, Amsterdam, the Netherlands. FAU - Duurland, Mariel C AU - Duurland MC AD - Sanquin Research and Landsteiner Laboratory of the Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands. FAU - Jorritsma, Tineke AU - Jorritsma T AD - Sanquin Research and Landsteiner Laboratory of the Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands. FAU - Steenhuis, Maurice AU - Steenhuis M AD - Sanquin Research and Landsteiner Laboratory of the Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands. FAU - Kerster, Gius AU - Kerster G AD - Department of Medical Microbiology and Infection Prevention, Amsterdam UMC, AMC, Amsterdam, the Netherlands. FAU - Vallejo, Juan J Garcia AU - Vallejo JJG AD - Department of Molecular Cell Biology and Immunology, Amsterdam UMC, VUmc, Amsterdam, the Netherlands. FAU - van Gils, Marit J AU - van Gils MJ AD - Department of Medical Microbiology and Infection Prevention, Amsterdam UMC, AMC, Amsterdam, the Netherlands. FAU - van Dam, Koos P J AU - van Dam KPJ AD - Department of Neurology and Neurophysiology, Amsterdam UMC, Amsterdam, the Netherlands. FAU - Stalman, Eileen W AU - Stalman EW AD - Department of Neurology and Neurophysiology, Amsterdam UMC, Amsterdam, the Netherlands. FAU - Wieske, Luuk AU - Wieske L AD - Department of Clinical Neurophysiology, St. Antonius Hospital, Nieuwegein, the Netherlands. FAU - Boekel, Laura AU - Boekel L AD - Amsterdam Rheumatology and Immunology Center, Reade, Amsterdam, the Netherlands. FAU - Wolbink, Gertjan J AU - Wolbink GJ AD - Amsterdam Rheumatology and Immunology Center, Reade, Amsterdam, the Netherlands. FAU - Tas, Sander W AU - Tas SW AD - Amsterdam Rheumatology and Immunology Center, Amsterdam UMC, Amsterdam, the Netherlands. FAU - Rispens, Theo AU - Rispens T AUID- ORCID: 0000-0001-9600-1312 AD - Sanquin Research and Landsteiner Laboratory of the Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands. FAU - Kuijpers, Taco W AU - Kuijpers TW AD - Department of Pediatric Immunology, Rheumatology and Infectious Disease, Amsterdam UMC, Amsterdam, the Netherlands. FAU - Eftimov, Filip AU - Eftimov F AD - Department of Neurology and Neurophysiology, Amsterdam UMC, Amsterdam, the Netherlands. FAU - Brinke, Anja Ten AU - Brinke AT AD - Sanquin Research and Landsteiner Laboratory of the Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands. FAU - van Ham, S Marieke AU - van Ham SM AD - Sanquin Research and Landsteiner Laboratory of the Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands. AD - Swammerdam Institute for Life Sciences, University of Amsterdam, Amsterdam, the Netherlands. CN - of T2B! Immunity Against SARS-CoV-2 Study Group LA - eng GR - 10430072010007/ZONMW_/ZonMw/Netherlands GR - L2506/Sanquin Blood Supply PPOC OPTIMAL/ PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - Germany TA - Eur J Immunol JT - European journal of immunology JID - 1273201 RN - 0 (COVID-19 Vaccines) RN - 0 (Immunoglobulin G) RN - 0 (Antibodies, Viral) SB - IM MH - Humans MH - Lymphocyte Activation/immunology MH - *B-Lymphocytes/immunology MH - *SARS-CoV-2/immunology MH - *Memory B Cells/immunology MH - *COVID-19/immunology/prevention & control MH - *COVID-19 Vaccines/immunology MH - Immunologic Memory MH - Vaccination MH - Germinal Center/immunology MH - Immunoglobulin G/immunology MH - Cell Differentiation/immunology MH - Antibodies, Viral/immunology PMC - PMC12981206 OTO - NOTNLM OT - B-cell differentiation OT - CD11c+ activated B cells OT - extrafollicular responses OT - germinal center OT - immunological memory OT - mRNA vaccination COIS- Filip Eftimov, Gertjan J. Wolbink, S. Marieke van Ham, and Taco W. Kuijpers report (governmental) grants from ZonMw to study immune response after SARS-CoV-2 vaccination in autoimmune diseases. Filip Eftimov also reports grants from Prinses Beatrix Spierfonds, CSL Behring, Kedrion, Terumo BCT, Grifols, Takeda Pharmaceutical Company, and GBS-CIDP Foundation; consulting fees from UCB Pharma and CSl Behring; honoraria from Grifols. The remaining authors declare no conflicts of interest. EDAT- 2026/03/12 13:55 MHDA- 2026/03/12 13:56 PMCR- 2026/03/12 CRDT- 2026/03/12 09:53 PHST- 2026/02/19 00:00 [revised] PHST- 2025/07/04 00:00 [received] PHST- 2026/02/23 00:00 [accepted] PHST- 2026/03/12 13:56 [medline] PHST- 2026/03/12 13:55 [pubmed] PHST- 2026/03/12 09:53 [entrez] PHST- 2026/03/12 00:00 [pmc-release] AID - EJI70165 [pii] AID - 10.1002/eji.70165 [doi] PST - ppublish SO - Eur J Immunol. 2026 Mar;56(3):e70165. doi: 10.1002/eji.70165. PMID- 41800618 OWN - NLM STAT- MEDLINE DCOM- 20260710 LR - 20260928 IS - 2211-1247 (Electronic) VI - 45 IP - 3 DP - 2026 Mar 24 TI - Repeated COVID-19 vaccine boosters elicit variant-specific memory B cells in humans. PG - 117052 LID - S2211-1247(26)00130-0 [pii] LID - 10.1016/j.celrep.2026.117052 [doi] AB - The first exposure to a pathogen impacts subsequent immune responses toward related pathogens. This immune imprinting explains that infection or vaccination with circulating SARS-CoV-2 variants primarily recalls cross-reactive memory B cells induced by prior Wuhan-Hu-1 (Wu) spike (S) exposure. The magnitude and persistence of immune imprinting in mRNA vaccinees are not understood. We investigate serum antibody and memory B cell responses after administration of multiple XBB.1.5 and JN.1/KP.2 COVID-19 vaccine boosters. We find that the JN.1/KP.2 booster elicits broadly neutralizing antibody responses against recent SARS-CoV-2 variants by recalling Wu S-induced immunity in all but one individual. We detect an increased fraction of serum antibodies, and particularly memory B cells, recognizing XBB.1.5 and KP.2, but not Wu, relative to individuals who received a single XBB.1.5 booster. Repeated exposures to antigenically divergent S thus contribute to overcoming immune imprinting and support vaccine updates for continued protection. CI - Copyright (c) 2026 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Tortorici, M Alejandra AU - Tortorici MA AD - Department of Biochemistry, University of Washington, Seattle, WA 98195, USA. FAU - Sprouse, Kaitlin R AU - Sprouse KR AD - Department of Biochemistry, University of Washington, Seattle, WA 98195, USA; Howard Hughes Medical Institute, University of Washington, Seattle, WA 98195, USA. FAU - Addetia, Amin AU - Addetia A AD - Department of Biochemistry, University of Washington, Seattle, WA 98195, USA. FAU - Brown, Jack T AU - Brown JT AD - Department of Biochemistry, University of Washington, Seattle, WA 98195, USA. FAU - Lee, Jimin AU - Lee J AD - Department of Biochemistry, University of Washington, Seattle, WA 98195, USA. FAU - Stewart, Cameron AU - Stewart C AD - Department of Biochemistry, University of Washington, Seattle, WA 98195, USA. FAU - Merz, Benjamin AU - Merz B AD - Department of Biochemistry, University of Washington, Seattle, WA 98195, USA. FAU - Harteloo, Alex AU - Harteloo A AD - Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA 98195, USA. FAU - Elias-Warren, Anna AU - Elias-Warren A AD - Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA 98195, USA. FAU - Chu, Helen Y AU - Chu HY AD - Howard Hughes Medical Institute, University of Washington, Seattle, WA 98195, USA. FAU - Veesler, David AU - Veesler D AD - Department of Biochemistry, University of Washington, Seattle, WA 98195, USA; Howard Hughes Medical Institute, University of Washington, Seattle, WA 98195, USA. Electronic address: dveesler@uw.edu. LA - eng GR - HHMI/Howard Hughes Medical Institute/United States GR - 75N93022C00036/OD/NIH HHS/United States GR - DP1 AI158186/AI/NIAID NIH HHS/United States GR - P01 AI167966/AI/NIAID NIH HHS/United States PT - Journal Article DEP - 20260307 PL - United States TA - Cell Rep JT - Cell reports JID - 101573691 RN - 0 (COVID-19 Vaccines) RN - 0 (Antibodies, Neutralizing) RN - 0 (Antibodies, Viral) RN - 0 (Spike Glycoprotein, Coronavirus) RN - 0 (spike protein, SARS-CoV-2) RN - SARS-CoV-2 variants SB - IM UOF - bioRxiv. 2025 Oct 20:2025.10.16.682893. doi: 10.1101/2025.10.16.682893. PMID: 41279737 MH - Humans MH - *COVID-19 Vaccines/immunology/administration & dosage MH - *Memory B Cells/immunology MH - *SARS-CoV-2/immunology MH - *Immunization, Secondary/methods MH - *COVID-19/immunology/prevention & control/virology MH - Antibodies, Neutralizing/immunology/blood MH - Antibodies, Viral/immunology/blood MH - Spike Glycoprotein, Coronavirus/immunology MH - Immunologic Memory PMC - PMC13607844 MID - NIHMS2210869 OTO - NOTNLM OT - COVID-19 vaccines OT - CP: immunology OT - SARS-CoV-2 spike glycoprotein OT - antigenic sin OT - coronaviruses OT - immune imprinting OT - immunology OT - memory B cells OT - neutralizing antibodies OT - serum antibodies OT - virology COIS- Declaration of interests H.Y.C. has served on advisory boards for Vir and AbbVie. D.V. is named as an inventor on patents for coronavirus vaccines filed by the University of Washington. EDAT- 2026/03/09 13:42 MHDA- 2026/03/27 07:14 PMCR- 2026/09/24 CRDT- 2026/03/09 07:12 PHST- 2025/09/01 00:00 [received] PHST- 2026/01/09 00:00 [revised] PHST- 2026/02/06 00:00 [accepted] PHST- 2026/03/27 07:14 [medline] PHST- 2026/03/09 13:42 [pubmed] PHST- 2026/03/09 07:12 [entrez] PHST- 2026/09/24 00:00 [pmc-release] AID - S2211-1247(26)00130-0 [pii] AID - 10.1016/j.celrep.2026.117052 [doi] PST - ppublish SO - Cell Rep. 2026 Mar 24;45(3):117052. doi: 10.1016/j.celrep.2026.117052. Epub 2026 Mar 7. PMID- 41762950 OWN - NLM STAT- MEDLINE DCOM- 20260709 LR - 20260804 IS - 2211-0356 (Electronic) IS - 2211-0348 (Linking) VI - 109 DP - 2026 May TI - Machine learning model predicts prognosis in SARS-CoV-2-infected autoimmune encephalitis patients. PG - 107028 LID - S2211-0348(26)00064-7 [pii] LID - 10.1016/j.msard.2026.107028 [doi] AB - OBJECTIVE: To assess the neurological prognosis of patients with autoimmune encephalitis (AE) after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and construct risk prediction models for a worse prognosis. METHODS: This was a prospective, multicenter, observational cohort study. Patients with AE, with or without SARS-CoV-2, were followed up every 3 months. Multivariate logistic regression was used to identify factors influencing neurological prognosis. Prediction models were created using nine machine-learning strategies. RESULTS: SARS-CoV-2 infection was noted in 241 of 308 patients. Multivariate logistic regression showed inactivated immunizations plus recombinant or adenovirus vector vaccines protected against SARS-CoV-2 infection (odds ratio [OR] 0.05, 95% confidence interval [CI] 0.01-0.52, p = 0.01). Three months after infection, 12.4% of patients with stable AE had a worse neurological prognosis, 6.2% failed to recover their working conditions. Pre-infection modified Rankin Scale (mRS) = 1 (OR 4.06, 95% CI 1.11-14.91, p = 0.04) and mRS > 1 (OR 13.4, 95% CI 3.31-54.02, p < 0.01), immunotherapy during infection (OR 5.1, 95% CI 1.65-15.79, p = 0.01), and SARS-CoV-2-related drowsiness (OR 19.5, 95% CI 5.42-70.34, p < 0.01) and gastrointestinal symptoms (OR 4.4, 95% CI 1.58-11.96, p < 0.01) were identified as risk factors for worse prognosis. The ranger model(https://xingjieli1999.shinyapps.io/clinical_prediction_app/) using these four parameters showed a discrimination accuracy of 0.96 (95% CI 0.94-0.99). CONCLUSIONS: Patients with AE could experience exacerbated neurological symptoms following SARS-CoV-2 infection. Machine-learning algorithms showed feasibility of predicting prognoses based on clinical information in patients with AE. CI - Copyright (c) 2026 Elsevier B.V. All rights reserved. FAU - Li, Xingjie AU - Li X AD - Department of Neurology, West China Hospital of Sichuan University, Chengdu, Sichuan, China; Institute of Brain science and Brain-inspired technology of West China Hospital, of Sichuan University, Chengdu, Sichuan, China. FAU - Kong, Xueying AU - Kong X AD - Department of Neurology, West China Hospital of Sichuan University, Chengdu, Sichuan, China; Institute of Brain science and Brain-inspired technology of West China Hospital, of Sichuan University, Chengdu, Sichuan, China. FAU - Li, Aiqing AU - Li A AD - Department of Neurology, West China Hospital of Sichuan University, Chengdu, Sichuan, China; Institute of Brain science and Brain-inspired technology of West China Hospital, of Sichuan University, Chengdu, Sichuan, China. FAU - Gong, Xue AU - Gong X AD - Department of Neurology, West China Hospital of Sichuan University, Chengdu, Sichuan, China; Institute of Brain science and Brain-inspired technology of West China Hospital, of Sichuan University, Chengdu, Sichuan, China. FAU - Guo, Kundian AU - Guo K AD - Department of Neurology, West China Hospital of Sichuan University, Chengdu, Sichuan, China; Institute of Brain science and Brain-inspired technology of West China Hospital, of Sichuan University, Chengdu, Sichuan, China. FAU - Liu, Xu AU - Liu X AD - Department of Neurology, West China Hospital of Sichuan University, Chengdu, Sichuan, China; Institute of Brain science and Brain-inspired technology of West China Hospital, of Sichuan University, Chengdu, Sichuan, China. FAU - Liu, Yue AU - Liu Y AD - Department of Neurology, West China Hospital of Sichuan University, Chengdu, Sichuan, China; Institute of Brain science and Brain-inspired technology of West China Hospital, of Sichuan University, Chengdu, Sichuan, China. FAU - Zhang, Tianyu AU - Zhang T AD - Department of Neurology, West China Hospital of Sichuan University, Chengdu, Sichuan, China; Institute of Brain science and Brain-inspired technology of West China Hospital, of Sichuan University, Chengdu, Sichuan, China. FAU - Deng, Xiaolin AU - Deng X AD - Department of Neurology, West China Hospital of Sichuan University, Chengdu, Sichuan, China; Institute of Brain science and Brain-inspired technology of West China Hospital, of Sichuan University, Chengdu, Sichuan, China. FAU - Li, Jinmei AU - Li J AD - Department of Neurology, West China Hospital of Sichuan University, Chengdu, Sichuan, China; Institute of Brain science and Brain-inspired technology of West China Hospital, of Sichuan University, Chengdu, Sichuan, China; Department of Neurology, Chengdu Shangjin Nanfu Hospital, Chengdu, Sichuan 611730, China. FAU - Zhou, Dong AU - Zhou D AD - Department of Neurology, West China Hospital of Sichuan University, Chengdu, Sichuan, China; Institute of Brain science and Brain-inspired technology of West China Hospital, of Sichuan University, Chengdu, Sichuan, China; Department of Neurology, Chengdu Shangjin Nanfu Hospital, Chengdu, Sichuan 611730, China. FAU - Hong, Zhen AU - Hong Z AD - Department of Neurology, West China Hospital of Sichuan University, Chengdu, Sichuan, China; Institute of Brain science and Brain-inspired technology of West China Hospital, of Sichuan University, Chengdu, Sichuan, China; Department of Neurology, Chengdu Shangjin Nanfu Hospital, Chengdu, Sichuan 611730, China. Electronic address: hongzhengoog@aliyun.com. LA - eng PT - Journal Article PT - Multicenter Study PT - Observational Study DEP - 20260206 PL - Netherlands TA - Mult Scler Relat Disord JT - Multiple sclerosis and related disorders JID - 101580247 RN - Hashimoto's encephalitis SB - IM MH - Humans MH - Female MH - Prognosis MH - Predictive Learning Models MH - *COVID-19/complications/diagnosis MH - *Hashimoto Disease/diagnosis/complications MH - Male MH - *Machine Learning MH - Adult MH - Middle Aged MH - Prospective Studies MH - *Encephalitis/diagnosis MH - SARS-CoV-2 OTO - NOTNLM OT - Autoimmune encephalitis OT - Machine learning prediction model OT - Prognosis OT - SARS-CoV-2 infection and vaccination COIS- Declaration of competing interest None of the authors have any conflicts of interest to disclose. Funding sources were not involved in the study design, data collection, analysis, interpretation, writing of the report, or decision to submit the article for publication. EDAT- 2026/03/01 00:35 MHDA- 2026/04/11 00:32 CRDT- 2026/02/28 18:07 PHST- 2024/08/15 00:00 [received] PHST- 2025/06/06 00:00 [revised] PHST- 2026/01/24 00:00 [accepted] PHST- 2026/04/11 00:32 [medline] PHST- 2026/03/01 00:35 [pubmed] PHST- 2026/02/28 18:07 [entrez] AID - S2211-0348(26)00064-7 [pii] AID - 10.1016/j.msard.2026.107028 [doi] PST - ppublish SO - Mult Scler Relat Disord. 2026 May;109:107028. doi: 10.1016/j.msard.2026.107028. Epub 2026 Feb 6. PMID- 41737426 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260225 LR - 20260813 IS - 2398-8835 (Electronic) IS - 2398-8835 (Linking) VI - 9 IP - 2 DP - 2026 Feb TI - The Impact of COVID-19 on Obstructive Pulmonary Diseases: A Narrative Review of Long-Term Consequences and Vaccination Strategies. PG - e71882 LID - 10.1002/hsr2.71882 [doi] LID - e71882 AB - BACKGROUND AND AIMS: The COVID-19 pandemic has posed significant challenges for individuals with obstructive pulmonary diseases (OPDs), such as asthma and chronic obstructive pulmonary disease (COPD). Emerging evidence highlights the complex interplay between SARS-CoV-2 infection and OPDs, including increased risks of severe disease, long-term sequelae, and potential new-onset respiratory conditions. This narrative review synthesizes current knowledge on the pathophysiological mechanisms, clinical outcomes, and management strategies for COVID-19 in OPD patients, with a focus on long-term consequences and vaccination efficacy. METHODS: A comprehensive literature search was conducted using PubMed, Embase, and Scopus (January 2020-June 2025). Inclusion criteria encompassed original studies, reviews, and meta-analyses examining COVID-19's impact on asthma or COPD, while non-English publications, animal studies, and case reports were excluded. Data were extracted and thematically synthesized to address acute outcomes, long COVID, vaccination, and therapeutic considerations. RESULTS: Risk and Severity: COPD patients faced higher risks of severe COVID-19 (hospitalization, ICU admission, and mortality), while asthma phenotypes influenced outcomes (eosinophilic asthma conferred milder disease).Long COVID: Persistent respiratory symptoms (dyspnea and cough), fatigue, and cognitive dysfunction were prevalent in OPD patients, with new-onset asthma reported post-infection.Vaccination: mRNA vaccines significantly reduced severe outcomes in OPDs, though biologic therapies in asthma may attenuate immune responses.Treatment: Antivirals (e.g., nirmatrelvir-ritonavir) and corticosteroids were effective, but drug interactions (e.g., CYP3A4 inhibitors) required careful management. CONCLUSION: COVID-19 exacerbates OPD-related morbidity, underscoring the need for tailored prevention (vaccination and early diagnosis) and multidisciplinary management. Future research should prioritize phenotype-specific therapeutic strategies and long-term surveillance to mitigate post-COVID sequelae in this vulnerable population. CI - (c) 2026 The Author(s). Health Science Reports published by Wiley Periodicals LLC. FAU - Dalfardi, Behnam AU - Dalfardi B AD - Clinical Research Development Unit, Afzalipour Hospital Kerman University of Medical Sciences Kerman Iran. FAU - Abtahi, Hamidreza AU - Abtahi H AD - Thoracic Research Center, Imam Khomeini Hospital Complex Tehran University of Medical Sciences Tehran Iran. FAU - Edalatifard, Maryam AU - Edalatifard M AD - Thoracic Research Center, Imam Khomeini Hospital Complex Tehran University of Medical Sciences Tehran Iran. FAU - Mozaffari, Sedigheh AU - Mozaffari S AD - Thoracic Research Center, Imam Khomeini Hospital Complex Tehran University of Medical Sciences Tehran Iran. FAU - Rahimi, Besharat AU - Rahimi B AD - Thoracic Research Center, Imam Khomeini Hospital Complex Tehran University of Medical Sciences Tehran Iran. FAU - Roostaei, Ghazal AU - Roostaei G AD - Rasool Akram Hospital Clinical Research Development Center, School of Medicine, Rasool Akram Medical Complex Iran University of Medical Sciences Tehran Iran. FAU - Khoshnam Rad, Niloofar AU - Khoshnam Rad N AUID- ORCID: 0000-0001-6700-3570 AD - Thoracic Research Center, Imam Khomeini Hospital Complex Tehran University of Medical Sciences Tehran Iran. LA - eng PT - Journal Article DEP - 20260220 PL - United States TA - Health Sci Rep JT - Health science reports JID - 101728855 PMC - PMC12927929 OTO - NOTNLM OT - COPD OT - COVID-19 OT - asthma OT - long COVID OT - obstructive pulmonary diseases OT - vaccination COIS- The authors declare no conflicts of interest. EDAT- 2026/02/25 10:21 MHDA- 2026/02/25 10:22 PMCR- 2026/02/20 CRDT- 2026/02/25 04:50 PHST- 2025/03/30 00:00 [received] PHST- 2025/08/04 00:00 [revised] PHST- 2026/02/12 00:00 [accepted] PHST- 2026/02/25 10:22 [medline] PHST- 2026/02/25 10:21 [pubmed] PHST- 2026/02/25 04:50 [entrez] PHST- 2026/02/20 00:00 [pmc-release] AID - HSR271882 [pii] AID - 10.1002/hsr2.71882 [doi] PST - epublish SO - Health Sci Rep. 2026 Feb 20;9(2):e71882. doi: 10.1002/hsr2.71882. eCollection 2026 Feb. PMID- 41709791 OWN - NLM STAT- MEDLINE DCOM- 20260708 LR - 20260813 IS - 2164-554X (Electronic) IS - 2164-5515 (Print) IS - 2164-5515 (Linking) VI - 22 IP - 1 DP - 2026 Dec TI - Understanding the practices and perceptions of Chinese older adults towards vaccination in the context of COVID-19: A qualitative study in Anhui Province. PG - 2622184 LID - 10.1080/21645515.2026.2622184 [doi] LID - 2622184 AB - This study examines vaccination perceptions and practices among rural older adults in China during the COVID-19 pandemic to inform strategies for promoting vaccination among older adults. Qualitative research was employed, involving 13 rural older adults aged 60 and above in Anhui Province. Two rounds of in-depth interviews were conducted in May 2022 (during the severe pandemic period) and May 2024 (post-pandemic era), with data analyzed using grounded theory. Rural older adults exhibited dual perceptions of COVID-19 characterized by "seriousness" and "relative reassurance," maintaining trust, understanding, and acknowledgment of government prevention policies. They generally recognized the necessity of COVID-19 vaccination as a key means to alleviate infection fears and reduce risk exposure. However, they exhibited self-marginalization, believing vaccine resources should be prioritized for younger individuals and those deemed more deserving. And, collectivist values motivated active compliance with epidemic control policies but also led to attention bias, causing them to overlook routine vaccines such as influenza and pneumonia vaccines that received less government promotion. As the pandemic progressed, individual awareness gradually awakened. Professional authority and family opinions emerged as new drivers for vaccination, though health belief biases also surfaced, with some seniors refusing shots citing "good physical constitution." The government should intensify vaccination outreach, optimize community services, guide seniors toward accurate self-perception, and leverage the roles of family members and medical professionals in vaccination efforts. These measures will enhance vaccination rates among rural seniors and safeguard the health of the population. FAU - He, Aiping AU - He A AD - Department of Health Services Management, School of Health Services Management, Anhui Medical University, Hefei, China. FAU - Wang, Zixin AU - Wang Z AD - Department of Health Services Management, School of Health Services Management, Anhui Medical University, Hefei, China. FAU - Yang, Yang AU - Yang Y AD - Department of Health Services Management, School of Health Services Management, Anhui Medical University, Hefei, China. FAU - Zhang, Xinyi AU - Zhang X AD - Department of Health Services Management, School of Health Services Management, Anhui Medical University, Hefei, China. FAU - Yao, Lili AU - Yao L AD - Department of Health Services Management, School of Health Services Management, Anhui Medical University, Hefei, China. FAU - Wang, Li AU - Wang L AD - Department of Health Services Management, School of Health Services Management, Anhui Medical University, Hefei, China. AD - Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada. FAU - Chen, Ren AU - Chen R AD - Department of Health Services Management, School of Health Services Management, Anhui Medical University, Hefei, China. FAU - Wang, Peizhong Peter AU - Wang PP AD - Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada. AD - Division of Population Health and Applied Health Sciences, Faculty of Medicine, Memorial University, St. John's, NL, Canada. AD - Centre for New Immigrant Well-Being (CNIW), Toronto, ON, Canada. FAU - Wei, Xiaolin AU - Wei X AD - Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada. LA - eng PT - Journal Article DEP - 20260219 PL - United States TA - Hum Vaccin Immunother JT - Human vaccines & immunotherapeutics JID - 101572652 RN - 0 (COVID-19 Vaccines) RN - Chinese people SB - IM MH - Humans MH - Aged MH - China/epidemiology MH - *COVID-19/prevention & control/psychology/epidemiology MH - Male MH - Female MH - *Vaccination/psychology MH - *COVID-19 Vaccines/administration & dosage MH - Qualitative Research MH - *Health Knowledge, Attitudes, Practice MH - Middle Aged MH - Rural Population MH - Aged, 80 and over MH - SARS-CoV-2/immunology MH - East Asian People PMC - PMC12928655 OTO - NOTNLM OT - COVID-19 OT - cognition OT - older adults OT - qualitative research OT - rural OT - vaccination COIS- No potential conflict of interest was reported by the author(s). EDAT- 2026/02/19 07:03 MHDA- 2026/02/19 07:04 PMCR- 2026/02/19 CRDT- 2026/02/19 03:53 PHST- 2026/02/19 07:04 [medline] PHST- 2026/02/19 07:03 [pubmed] PHST- 2026/02/19 03:53 [entrez] PHST- 2026/02/19 00:00 [pmc-release] AID - 2622184 [pii] AID - 10.1080/21645515.2026.2622184 [doi] PST - ppublish SO - Hum Vaccin Immunother. 2026 Dec;22(1):2622184. doi: 10.1080/21645515.2026.2622184. Epub 2026 Feb 19. PMID- 41691247 OWN - NLM STAT- MEDLINE DCOM- 20260627 LR - 20260904 IS - 1479-5876 (Electronic) IS - 1479-5876 (Linking) VI - 24 IP - 1 DP - 2026 Feb 14 TI - HLA-E-restricted SARS-CoV-2 epitopes drive CD8(+) T cell memory in convalescent and vaccinated individuals: implications for the design of next-generation vaccines and immunotherapeutics. PG - 280 LID - 10.1186/s12967-026-07825-8 [doi] LID - 280 AB - BACKGROUND: Human leukocyte antigen-E (HLA-E) is a non-polymorphic, non-classical HLA class Ib molecule that presents signal peptides from classical HLA class Ia molecules to natural killer (NK) cell receptors. Emerging evidence suggests that HLA-E also presents viral peptides to CD8+ T cells, potentially influencing the control of viral infections. However, CD8+ T cell responses to viral epitopes presented by HLA-E remain largely unexplored. OBJECTIVE: This study investigates the potential of SARS-CoV-2-derived peptides presented by HLA-E to elicit CD8+ T cell responses and to identify T cell-mediated immunity in SARS-CoV-2 infection. METHODS: We describe seven peptides from SARS-CoV-2 that display substantial conservation among the predominant strains from December 2021 to February 2025. These peptides fit within the HLA-E pocket and elicit HLA-E-restricted CD8+ T cell responses by producing cytokines. RESULTS: HLA-E/SARS-CoV-2-restricted CD8+ T cells were identified in the blood of convalescent patients, predominantly expressing TNF-alpha, with lower levels of IFN-gamma and IL-2, in response to predicted immunogenic epitopes. These cytokines were detected at higher frequencies in convalescent patients but were nearly absent in hospitalized patients with severe COVID-19. HLA-E/SARS-CoV-2-restricted CD8+ T cells were induced after BNT162b2 mRNA vaccination, with their frequencies increasing with more vaccine doses. Furthermore, they were significantly elicited in vaccinated individuals after SARS-CoV-2 infection. CONCLUSION: These findings underscore the translational potential of targeting HLA-E-restricted CD8+ T cell responses in next-generation vaccine design. The high conservation of HLA-E-presented epitopes across SARS-CoV-2 variants suggests that these peptides may offer a potentially valuable basis for expanding studies on vaccineinduced cellular immunity, independent of viral sequence drift. This strategy could be extended beyond SARS-CoV-2 to other rapidly evolving pathogens, providing a framework for broad-spectrum, T cell-focused vaccine platforms in precision vaccinology. FAU - Rafieiyan, Mahsa AU - Rafieiyan M AD - Central Laboratory of Advanced Diagnosis and Biomedical Research (CLADIBIOR), Azienda Ospedaliera Universitaria Policlinico (AOUP) Paolo Giaccone, University of Palermo, via del Vespro 129, 90127, Palermo, Italy. FAU - Badami, Giusto Davide AU - Badami GD AD - Central Laboratory of Advanced Diagnosis and Biomedical Research (CLADIBIOR), Azienda Ospedaliera Universitaria Policlinico (AOUP) Paolo Giaccone, University of Palermo, via del Vespro 129, 90127, Palermo, Italy. FAU - Scichilone, Nicola AU - Scichilone N AD - Department of Health Promotion Sciences, Maternal and Infant Care, Internal Medicine and Medical Specialities (PROMISE), University of Palermo, Palermo, Italy. FAU - Corrao, Salvatore AU - Corrao S AD - Department of Health Promotion Sciences, Maternal and Infant Care, Internal Medicine and Medical Specialities (PROMISE), University of Palermo, Palermo, Italy. AD - Department of Internal Medicine, ARNAS Civico, Di Cristina, Benfratelli Hospital, Palermo, Italy. FAU - Restivo, Vincenzo AU - Restivo V AD - Department of Health Promotion Sciences, Maternal and Infant Care, Internal Medicine and Medical Specialities (PROMISE), University of Palermo, Palermo, Italy. AD - Department of Medicine and Surgery, University of Enna Kore, 94100, Enna, Italy. FAU - Farinella, Enzo Massimo AU - Farinella EM AD - Infectious Diseases Unit, Villa Sofia- Cervello Hospitals, Palermo, Italy. FAU - Bottone, Martina AU - Bottone M AD - Department of Biomedicine, Neurosciences and Advanced Diagnostic (Bi.N.D.), University of Palermo, via del Vespro 129, 90127, Palermo, Italy. AD - Clinical Oncology Unit - St. Anna University-Hospital, Ferrara, Italy. FAU - Pietra, Gabriella AU - Pietra G AD - Department of Experimental Medicine (DIMES), University of Genoa, Genoa, Italy. AD - UO Pathology and Experimental Immunology, IRCCS Ospedale Policlinico, San Martino, Genova, Italy. FAU - Fallo, Miriana AU - Fallo M AD - Central Laboratory of Advanced Diagnosis and Biomedical Research (CLADIBIOR), Azienda Ospedaliera Universitaria Policlinico (AOUP) Paolo Giaccone, University of Palermo, via del Vespro 129, 90127, Palermo, Italy. AD - Department of Biomedicine, Neurosciences and Advanced Diagnostic (Bi.N.D.), University of Palermo, via del Vespro 129, 90127, Palermo, Italy. FAU - Aglio, Andrea Maria AU - Aglio AM AD - Central Laboratory of Advanced Diagnosis and Biomedical Research (CLADIBIOR), Azienda Ospedaliera Universitaria Policlinico (AOUP) Paolo Giaccone, University of Palermo, via del Vespro 129, 90127, Palermo, Italy. AD - Department of Biomedicine, Neurosciences and Advanced Diagnostic (Bi.N.D.), University of Palermo, via del Vespro 129, 90127, Palermo, Italy. FAU - La Manna, Marco Pio AU - La Manna MP AUID- ORCID: 0000-0002-3327-9541 AD - Central Laboratory of Advanced Diagnosis and Biomedical Research (CLADIBIOR), Azienda Ospedaliera Universitaria Policlinico (AOUP) Paolo Giaccone, University of Palermo, via del Vespro 129, 90127, Palermo, Italy. marcopio.lamanna@unipa.it. FAU - Dieli, Francesco AU - Dieli F AD - Central Laboratory of Advanced Diagnosis and Biomedical Research (CLADIBIOR), Azienda Ospedaliera Universitaria Policlinico (AOUP) Paolo Giaccone, University of Palermo, via del Vespro 129, 90127, Palermo, Italy. FAU - Azgomi, Mojtaba Shekarkar AU - Azgomi MS AD - Central Laboratory of Advanced Diagnosis and Biomedical Research (CLADIBIOR), Azienda Ospedaliera Universitaria Policlinico (AOUP) Paolo Giaccone, University of Palermo, via del Vespro 129, 90127, Palermo, Italy. AD - CANTHER - Cancer, Heterogeneity, Plasticity and Resistance to Therapies- Research Center, Lille, France. FAU - Caccamo, Nadia AU - Caccamo N AD - Central Laboratory of Advanced Diagnosis and Biomedical Research (CLADIBIOR), Azienda Ospedaliera Universitaria Policlinico (AOUP) Paolo Giaccone, University of Palermo, via del Vespro 129, 90127, Palermo, Italy. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20260214 PL - England TA - J Transl Med JT - Journal of translational medicine JID - 101190741 RN - 0 (HLA-E Antigens) RN - 0 (COVID-19 Vaccines) RN - 0 (Epitopes, T-Lymphocyte) RN - 0 (Histocompatibility Antigens Class I) RN - 0 (Cytokines) SB - IM MH - Humans MH - *CD8-Positive T-Lymphocytes/immunology MH - HLA-E Antigens MH - *SARS-CoV-2/immunology MH - *COVID-19/immunology/prevention & control MH - *COVID-19 Vaccines/immunology MH - *Epitopes, T-Lymphocyte/immunology MH - *Histocompatibility Antigens Class I/immunology MH - *Immunologic Memory MH - Female MH - Immunotherapy MH - Vaccination MH - Convalescence MH - Cytokines MH - Male MH - Adult PMC - PMC12922205 OTO - NOTNLM OT - CD8+ T cells OT - COVID-19 disease OT - Cytokines OT - HLA-E OT - SARS CoV-2 COIS- Declarations. Ethics approval and consent to participate: The study adhered to the Declaration of Helsinki and was approved by the Ethical Committee of the A.O.U.P. "Paolo Giaccone" Hospital (protocol code 09/2021). Written informed consent was obtained from all participants. Consent for publication:: All the authors have approved this manuscript for publication. Conflict of interest: Mojtaba Shekarkar Azgomi, Marco Pio La Manna, Nadia Caccamo, and Francesco Dieli are inventors on patent application WO/2023/180966 submitted by the University of Palermo entitled "Peptides for the preparation of vaccines against SARS-CoV-2". EDAT- 2026/02/15 00:31 MHDA- 2026/06/27 18:36 PMCR- 2026/02/14 CRDT- 2026/02/14 23:25 PHST- 2025/11/06 00:00 [received] PHST- 2026/02/02 00:00 [accepted] PHST- 2026/06/27 18:36 [medline] PHST- 2026/02/15 00:31 [pubmed] PHST- 2026/02/14 23:25 [entrez] PHST- 2026/02/14 00:00 [pmc-release] AID - 10.1186/s12967-026-07825-8 [pii] AID - 7825 [pii] AID - 10.1186/s12967-026-07825-8 [doi] PST - epublish SO - J Transl Med. 2026 Feb 14;24(1):280. doi: 10.1186/s12967-026-07825-8. PMID- 41681966 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260213 LR - 20260216 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 18 IP - 3 DP - 2026 Feb 2 TI - COVID-19 and Influenza Booster Vaccination Elicits Robust Antibody Responses in Patients with Primary Brain Tumors Comparable to Healthy Adults. LID - 10.3390/cancers18030494 [doi] LID - 494 AB - Background: Patients with primary brain tumors face profound disease- and treatment-related immunosuppression, placing them at high risk for severe infections. Their capacity to mount protective immune responses to vaccination, particularly to repeated antigen exposures such as COVID-19 boosters, remains critically under-defined, leading to uncertainty in clinical practice. Methods: In this prospective cohort study, we analyzed humoral responses to seasonal COVID-19 (mRNA-based) and influenza vaccination in 17 patients with primary brain tumors (recruited from an initial cohort of 37) who received a booster shot, and 19 healthy controls. Serum samples were collected before (T1) and 30 +/- 2 days after (T2) vaccination to quantify SARS-CoV-2 anti-Spike (S) IgG and anti-Influenza IgG titers. Results: Despite ongoing chemotherapy in 47% of patients, baseline anti-S antibody titers were comparable between groups. Following the booster, median anti-S titers increased significantly and to a similar magnitude in both patients (from 5030 to 18,500 BAU/mL; IQR: 13,885-24,420) and controls (from 4429 to 20,200 BAU/mL; IQR: 11,075-26,680; p = 0.6137, Mann-Whitney U test). Only two heavily pre-treated patients showed no booster response. All participants showed sero-positivity to Anti-Influenza IgG at baseline. For the primary brain tumor cohort, a significant increase for anti-Influenza IgG at T2 was observed (p = 0.0002). Mean antibody titers did not differ between both cohorts. Conclusions: Our findings provide evidence that patients with primary brain tumors can mount robust recall immunity to mRNA vaccines, addressing clinical uncertainty about booster efficacy in this population. These data provide a strong rationale for prioritizing booster vaccinations in this vulnerable population and argue for the inclusion of these patients in future pivotal vaccine trials. FAU - Schmidt, Teresa AU - Schmidt T AD - Division of Clinical Neuro-Oncology, Department of Neurology and Center for Translational Neuro- and Behavioral Sciences (C-TNBS), University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany. FAU - Trilling, Mirko AU - Trilling M AUID- ORCID: 0000-0003-3659-3541 AD - Institute for Virology, University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany. AD - Institute for the Research on HIV and AIDS-Associated Diseases, University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany. FAU - Le-Trilling, Vu Thuy Khanh AU - Le-Trilling VTK AUID- ORCID: 0000-0002-2733-3732 AD - Institute for Virology, University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany. AD - Institute for the Research on HIV and AIDS-Associated Diseases, University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany. FAU - Asar, Lucia AU - Asar L AD - Institute for Virology, University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany. FAU - Fiedler, Melanie AU - Fiedler M AD - Institute for Virology, University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany. FAU - Oster, Christoph AU - Oster C AUID- ORCID: 0000-0002-0683-0430 AD - Division of Clinical Neuro-Oncology, Department of Neurology and Center for Translational Neuro- and Behavioral Sciences (C-TNBS), University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany. AD - DKFZ-Division of Translational Neurooncology at the West German Cancer Center (WTZ), University Medicine Essen, University of Duisburg-Essen, 45147 Essen, Germany. AD - German Cancer Consortium (DKTK), Partner Site Essen-Dusseldorf, Partnership Between DKFZ and University Hospital Essen, 45147 Essen, Germany. FAU - Grieger, Jana AU - Grieger J AD - Division of Clinical Neuro-Oncology, Department of Neurology and Center for Translational Neuro- and Behavioral Sciences (C-TNBS), University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany. FAU - Cappello, Giorgio AU - Cappello G AD - Division of Clinical Neuro-Oncology, Department of Neurology and Center for Translational Neuro- and Behavioral Sciences (C-TNBS), University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany. FAU - Kizina, Kathrin AU - Kizina K AD - Division of Clinical Neuro-Oncology, Department of Neurology and Center for Translational Neuro- and Behavioral Sciences (C-TNBS), University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany. FAU - Grzib, Leandra AU - Grzib L AD - Division of Clinical Neuro-Oncology, Department of Neurology and Center for Translational Neuro- and Behavioral Sciences (C-TNBS), University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany. FAU - Jekel, Leon AU - Jekel L AD - Division of Clinical Neuro-Oncology, Department of Neurology and Center for Translational Neuro- and Behavioral Sciences (C-TNBS), University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany. FAU - Scheffler, Bjorn AU - Scheffler B AD - DKFZ-Division of Translational Neurooncology at the West German Cancer Center (WTZ), University Medicine Essen, University of Duisburg-Essen, 45147 Essen, Germany. AD - German Cancer Consortium (DKTK), Partner Site Essen-Dusseldorf, Partnership Between DKFZ and University Hospital Essen, 45147 Essen, Germany. AD - German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany. FAU - Sure, Ulrich AU - Sure U AUID- ORCID: 0000-0002-9073-1821 AD - Department of Neurosurgery and Spine Surgery, University Hospital Essen, 45147 Essen, Germany. FAU - Ahmadipour, Yahya AU - Ahmadipour Y AUID- ORCID: 0000-0003-3759-8301 AD - Department of Neurosurgery and Spine Surgery, University Hospital Essen, 45147 Essen, Germany. FAU - Rauschenbach, Laurel AU - Rauschenbach L AUID- ORCID: 0000-0001-8348-4298 AD - DKFZ-Division of Translational Neurooncology at the West German Cancer Center (WTZ), University Medicine Essen, University of Duisburg-Essen, 45147 Essen, Germany. AD - German Cancer Consortium (DKTK), Partner Site Essen-Dusseldorf, Partnership Between DKFZ and University Hospital Essen, 45147 Essen, Germany. AD - Department of Neurosurgery and Spine Surgery, University Hospital Essen, 45147 Essen, Germany. FAU - Kleinschnitz, Christoph AU - Kleinschnitz C AUID- ORCID: 0000-0002-1650-8875 AD - Department of Neurology and Center for Translational Neuro- and Behavioral Sciences (C-TNBS), University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany. FAU - Dittmer, Ulf AU - Dittmer U AD - Institute for Virology, University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany. FAU - Glas, Martin AU - Glas M AD - Department of Neurology and Neurooncology, St. Marien Hospital, 44534 Lunen, Germany. AD - Department of Neurooncology, Center for Neurology, University Hospital Bonn, University of Bonn, 53127 Bonn, Germany. FAU - Kebir, Sied AU - Kebir S AD - Division of Clinical Neuro-Oncology, Department of Neurology and Center for Translational Neuro- and Behavioral Sciences (C-TNBS), University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany. AD - DKFZ-Division of Translational Neurooncology at the West German Cancer Center (WTZ), University Medicine Essen, University of Duisburg-Essen, 45147 Essen, Germany. AD - German Cancer Consortium (DKTK), Partner Site Essen-Dusseldorf, Partnership Between DKFZ and University Hospital Essen, 45147 Essen, Germany. LA - eng PT - Journal Article DEP - 20260202 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC12896601 OTO - NOTNLM OT - COVID-19 booster OT - glioma OT - healthy control OT - humoral antibody response OT - immunogenicity OT - influenza booster OT - primary brain tumor patients COIS- Christoph Oster received travel support from Novocure and honoraria by Horizon and Novocure. He received a Clinician Scientist Stipendium of the University Medicine Essen Clinician Scientist Academy (UMEA) sponsored by the faculty of medicine and Deutsche Forschungsgemeinschaft (DFG) and a research grant by Servier. Martin Glas reports honoraria from Roche, Novartis, UCB, AbbVie, Daiichi Sankyo, Novocure, Bayer, Janssen-Cilag, Medac, Merck, and Kyowa Kirin; travel support from Novocure and Medac; and a research grant from Novocure. Sied Kebir is a fellow of the Else Kroner-Fresenius Foundation and the Advanced Clinician Scientist Program (UMEA(2)), funded by the Federal Ministry for Education and Research (BMBF). He received research grants from Novocure and Servier, as well as honoraria and consulting fees from Novocure (institutional). All remaining authors have declared no conflicts of interest. EDAT- 2026/02/13 06:32 MHDA- 2026/02/13 06:33 PMCR- 2026/02/02 CRDT- 2026/02/13 01:04 PHST- 2025/10/26 00:00 [received] PHST- 2026/01/20 00:00 [revised] PHST- 2026/01/29 00:00 [accepted] PHST- 2026/02/13 06:33 [medline] PHST- 2026/02/13 06:32 [pubmed] PHST- 2026/02/13 01:04 [entrez] PHST- 2026/02/02 00:00 [pmc-release] AID - cancers18030494 [pii] AID - cancers-18-00494 [pii] AID - 10.3390/cancers18030494 [doi] PST - epublish SO - Cancers (Basel). 2026 Feb 2;18(3):494. doi: 10.3390/cancers18030494. PMID- 41644979 OWN - NLM STAT- MEDLINE DCOM- 20260628 LR - 20260813 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 16 IP - 1 DP - 2026 Feb 5 TI - Mesoporous silicon microparticles enhance antiviral immunity and memory responses against SARS-CoV-2. LID - 10.1038/s41598-026-38583-8 [doi] LID - 7355 AB - Silica-based materials have attracted considerable interest as vaccine adjuvants due to their ability to potentiate immune responses. In this study, we evaluated the immunogenicity and protective efficacy of heteromorphous mesoporous silicon microparticles (MSMPs) as an adjuvant in the context of SARS-CoV-2 vaccination. MSMPs conjugated with the S1 subunit of the spike protein (MSMPs-S1) elicited a robust and sustained humoral immune response in BALB/c mice, comparable to that induced by aluminum-based adjuvants. Following a booster dose, MSMPs-S1 significantly increased IgG2a titers and neutralizing antibody levels, surpassing those observed with Al(OH)(3)-based formulations. In addition, MSMPs-S1 enhanced cellular immunity, as reflected by higher IFN-gamma production in T cells relative to the aluminum-adjuvanted group. In k18-hACE2 transgenic mice, vaccination with MSMPs-S1 conferred protection against a lethal SARS-CoV-2 challenge, resulting in marked reductions in viral loads in both lung and brain tissues. In vitro, stimulation of human peripheral blood mononuclear cells (PBMCs) with MSMPs-S1 increased IFN-gamma production in T cells, particularly in the presence of dendritic cells. Collectively, these findings support the potential of MSMPs as an effective adjuvant capable of promoting both humoral and cellular immunity, with relevance for the development of vaccines targeting emerging viral pathogens. FAU - Lopez-Gomez, Ana AU - Lopez-Gomez A AD - Department of Cellular Biology and Histology, School of Medicine, Universidad Complutense of Madrid (UCM), Madrid, 28040, Spain. AD - Department of Immunology, Ophthalmology and ORL, School of Medicine, Universidad Complutense of Madrid (UCM), Madrid, 28040, Spain. FAU - Real-Arevalo, Irene AU - Real-Arevalo I AD - Department of Immunology, Ophthalmology and ORL, School of Medicine, Universidad Complutense of Madrid (UCM), Madrid, 28040, Spain. AD - Inmunotek S.L., Alcala de Henares, 28805, Spain. FAU - Mayol-Hornero, Elsa AU - Mayol-Hornero E AD - Department of Cellular Biology and Histology, School of Medicine, Universidad Complutense of Madrid (UCM), Madrid, 28040, Spain. AD - Department of Immunology, Ophthalmology and ORL, School of Medicine, Universidad Complutense of Madrid (UCM), Madrid, 28040, Spain. FAU - Cendra, Jana Ausio AU - Cendra JA AD - Department of Cellular Biology and Histology, School of Medicine, Universidad Complutense of Madrid (UCM), Madrid, 28040, Spain. FAU - Laxalde-Fernandez, Diego AU - Laxalde-Fernandez D AD - Department of Biochemistry and Molecular Biology, School of Chemistry, Universidad Complutense of Madrid, Madrid, 28040, Spain. FAU - Nogales-Altozano, Pablo AU - Nogales-Altozano P AD - Centro de Investigacion en Sanidad Animal, Instituto Nacional de Investigacion y Tecnologia Agraria y Alimentaria, Consejo Superior de Investigaciones Cientificas (CISA-INIA-CSIC), Valdeolmos, Madrid, Spain. FAU - Rivas-Pardo, Benigno AU - Rivas-Pardo B AD - Department of Immunology, Ophthalmology and ORL, School of Medicine, Universidad Complutense of Madrid (UCM), Madrid, 28040, Spain. FAU - Amoros-Perez, Beatriz AU - Amoros-Perez B AD - Department of Immunology, Ophthalmology and ORL, School of Medicine, Universidad Complutense of Madrid (UCM), Madrid, 28040, Spain. AD - Inmunotek S.L., Alcala de Henares, 28805, Spain. FAU - Martin-Adrados, Beatriz AU - Martin-Adrados B AD - Department of Immunology, Ophthalmology and ORL, School of Medicine, Universidad Complutense of Madrid (UCM), Madrid, 28040, Spain. FAU - Juarez, Ignacio AU - Juarez I AD - Department of Immunology, Ophthalmology and ORL, School of Medicine, Universidad Complutense of Madrid (UCM), Madrid, 28040, Spain. FAU - Martinez-Del-Pozo, Alvaro AU - Martinez-Del-Pozo A AD - Department of Biochemistry and Molecular Biology, School of Chemistry, Universidad Complutense of Madrid, Madrid, 28040, Spain. FAU - Martin-Palma, Raul J AU - Martin-Palma RJ AD - Department of applied physics, Universidad Autonoma de Madrid, Madrid, Espana. FAU - Sevilla, Noemi AU - Sevilla N AD - Centro de Investigacion en Sanidad Animal, Instituto Nacional de Investigacion y Tecnologia Agraria y Alimentaria, Consejo Superior de Investigaciones Cientificas (CISA-INIA-CSIC), Valdeolmos, Madrid, Spain. FAU - Martinez-Naves, Eduardo AU - Martinez-Naves E AD - Department of Immunology, Ophthalmology and ORL, School of Medicine, Universidad Complutense of Madrid (UCM), Madrid, 28040, Spain. emnaves@ucm.es. AD - Instituto de Investigacion Sanitaria Hospital 12 Octubre (imas12), Madrid, 28041, Spain. emnaves@ucm.es. FAU - Del Moral, Manuel Gomez AU - Del Moral MG AD - Department of Cellular Biology and Histology, School of Medicine, Universidad Complutense of Madrid (UCM), Madrid, 28040, Spain. mgomezm@ucm.es. AD - Instituto de Investigacion Sanitaria Hospital 12 Octubre (imas12), Madrid, 28041, Spain. mgomezm@ucm.es. LA - eng PT - Journal Article DEP - 20260205 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 RN - Z4152N8IUI (Silicon) RN - 0 (Spike Glycoprotein, Coronavirus) RN - 0 (Antibodies, Viral) RN - 0 (COVID-19 Vaccines) RN - 0 (spike protein, SARS-CoV-2) RN - 0 (Antibodies, Neutralizing) RN - 82115-62-6 (Interferon-gamma) RN - 0 (Adjuvants, Immunologic) RN - 0 (Protein Subunit Vaccines) SB - IM MH - Animals MH - *Silicon/chemistry MH - Mice MH - *SARS-CoV-2/immunology MH - *COVID-19/prevention & control/immunology/virology MH - Mice, Inbred BALB C MH - Humans MH - Spike Glycoprotein, Coronavirus/immunology MH - *Immunologic Memory MH - Antibodies, Viral/immunology/blood MH - Female MH - *COVID-19 Vaccines/immunology/administration & dosage MH - Immunity, Humoral MH - Antibodies, Neutralizing/immunology MH - Interferon-gamma/metabolism MH - Adjuvants, Immunologic MH - Immunity, Cellular MH - Mice, Transgenic MH - T-Lymphocytes/immunology MH - Porosity MH - Protein Subunit Vaccines PMC - PMC12923835 OTO - NOTNLM OT - Cytotoxic OT - Mesoporous silicon microparticles OT - Vaccine OT - Virus COIS- Declarations. Competing interests: The authors declare no competing interests. Ethics approval: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Universidad Complutense of Madrid and Comunidad of Madrid (Dec 14/2022/PROEX 272.5/22). Consent to participate: Informed consent was obtained from all individual participants included in the study. EDAT- 2026/02/06 00:30 MHDA- 2026/06/28 16:09 PMCR- 2026/02/05 CRDT- 2026/02/05 23:36 PHST- 2025/09/03 00:00 [received] PHST- 2026/01/30 00:00 [accepted] PHST- 2026/06/28 16:09 [medline] PHST- 2026/02/06 00:30 [pubmed] PHST- 2026/02/05 23:36 [entrez] PHST- 2026/02/05 00:00 [pmc-release] AID - 10.1038/s41598-026-38583-8 [pii] AID - 38583 [pii] AID - 10.1038/s41598-026-38583-8 [doi] PST - epublish SO - Sci Rep. 2026 Feb 5;16(1):7355. doi: 10.1038/s41598-026-38583-8. PMID- 41638327 OWN - NLM STAT- MEDLINE DCOM- 20260706 LR - 20260706 IS - 1521-7035 (Electronic) IS - 1521-6616 (Linking) VI - 284 DP - 2026 Apr TI - HIV patients with poor immune recovery show exhausted CD4(+) stem cell memory cells and impaired COVID-19 vaccine response. PG - 110676 LID - S1521-6616(26)00014-8 [pii] LID - 10.1016/j.clim.2026.110676 [doi] AB - Vaccination triggers both humoral and cellular immune responses, generating memory T cells that ensure long-term protection. Among these, stem cell-like memory T cells (T(SCM)) are crucial for durable immunity due to their self-renewal and multipotency. In people with HIV (PWHIV), vaccine-induced responses can be weakened by persistent immune dysfunction. In this study, we longitudinally analyzed T cell memory responses following mRNA-1273 vaccination in PWHIV. Individuals with incomplete immune reconstitution (CD4(+) < 500 cells/muL, CD4/CD8 < 0.4) showed reduced frequencies of Spike-specific CD4(+) T(SCM), lower levels of TCF-1 and higher expression of immune checkpoint molecules. We identified a subset of PD-1(+)TIGIT(+) CD4(+) T(SCM) and T(CM) cells that phenotypically resemble CD8(+) exhausted-like progenitors (T(PEX)) and are enriched in PWHIV with poor immune recovery. Modulation of the Wnt/mTORs pathway via GSK3beta inhibition restored TCF-1 expression and partially rescued antigen responsiveness, highlighting a potential strategy to improve vaccine efficacy in PWHIV. CI - Copyright (c) 2026 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Scaglioni, Susanna AU - Scaglioni S AD - INGM, Istituto Nazionale Genetica Molecolare "Romeo ed Enrica Invernizzi", Milan, Italy; Department of Pharmacological and Biomolecular Sciences (DISFEB), University of Milan, Milan, Italy. FAU - Lombardi, Andrea AU - Lombardi A AD - Infectious Diseases Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy; Centre for Multidisciplinary Research in Health Science (MACH), University of Milano, Milan 20122, Italy. FAU - Butta, Giacomo M AU - Butta GM AD - INGM, Istituto Nazionale Genetica Molecolare "Romeo ed Enrica Invernizzi", Milan, Italy; Department of Pharmacological and Biomolecular Sciences (DISFEB), University of Milan, Milan, Italy. FAU - Bozzi, Giorgio AU - Bozzi G AD - Infectious Diseases Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. FAU - Centazzo, Matteo AU - Centazzo M AD - INGM, Istituto Nazionale Genetica Molecolare "Romeo ed Enrica Invernizzi", Milan, Italy; Department of Pharmacological and Biomolecular Sciences (DISFEB), University of Milan, Milan, Italy. FAU - Mariani, Bianca AU - Mariani B AD - Infectious Diseases Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. FAU - Muscatello, Antonio AU - Muscatello A AD - Infectious Diseases Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. FAU - Bono, Patrizia AU - Bono P AD - Microbiology and Virology Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. FAU - Donnici, Lorena AU - Donnici L AD - INGM, Istituto Nazionale Genetica Molecolare "Romeo ed Enrica Invernizzi", Milan, Italy. FAU - Conti, Matteo AU - Conti M AD - INGM, Istituto Nazionale Genetica Molecolare "Romeo ed Enrica Invernizzi", Milan, Italy. FAU - Nodari, Riccardo AU - Nodari R AD - INGM, Istituto Nazionale Genetica Molecolare "Romeo ed Enrica Invernizzi", Milan, Italy; Department of Pharmacological and Biomolecular Sciences (DISFEB), University of Milan, Milan, Italy. FAU - Callegaro, Annapaola AU - Callegaro A AD - Microbiology and Virology Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. FAU - Scarpa, Edoardo AU - Scarpa E AD - INGM, Istituto Nazionale Genetica Molecolare "Romeo ed Enrica Invernizzi", Milan, Italy; Department of Pharmacological Sciences, University of Milan, Milan, Italy. FAU - Grifantini, Renata AU - Grifantini R AD - INGM, Istituto Nazionale Genetica Molecolare "Romeo ed Enrica Invernizzi", Milan, Italy; CheckmAb Srl, Milan, Italy. FAU - Abrignani, Sergio AU - Abrignani S AD - INGM, Istituto Nazionale Genetica Molecolare "Romeo ed Enrica Invernizzi", Milan, Italy; Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy. FAU - De Francesco, Raffaele AU - De Francesco R AD - INGM, Istituto Nazionale Genetica Molecolare "Romeo ed Enrica Invernizzi", Milan, Italy; Department of Pharmacological and Biomolecular Sciences (DISFEB), University of Milan, Milan, Italy. FAU - Gori, Andrea AU - Gori A AD - Division of Infectious Diseases, Luigi Sacco Hospital, University of Milan, Milan, Italy; Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy. FAU - Bandera, Alessandra AU - Bandera A AD - Infectious Diseases Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy; Centre for Multidisciplinary Research in Health Science (MACH), University of Milano, Milan 20122, Italy. FAU - Manganaro, Lara AU - Manganaro L AD - INGM, Istituto Nazionale Genetica Molecolare "Romeo ed Enrica Invernizzi", Milan, Italy; Department of Pharmacological and Biomolecular Sciences (DISFEB), University of Milan, Milan, Italy; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. Electronic address: lara.manganaro@unimi.it. LA - eng PT - Journal Article DEP - 20260202 PL - United States TA - Clin Immunol JT - Clinical immunology (Orlando, Fla.) JID - 100883537 RN - 0 (COVID-19 Vaccines) RN - 0 (T Cell Transcription Factor 1) RN - 0 (TCF7 protein, human) RN - 0 (Hepatocyte Nuclear Factor 1-alpha) SB - IM MH - Humans MH - *CD4-Positive T-Lymphocytes/immunology MH - *Memory T Cells/immunology MH - *HIV Infections/immunology MH - T-Cell Exhaustion/immunology MH - *Immunologic Memory/immunology MH - *COVID-19 Vaccines/immunology MH - *COVID-19/immunology/prevention & control MH - *SARS-CoV-2/immunology MH - Female MH - Male MH - T Cell Transcription Factor 1 MH - Hepatocyte Nuclear Factor 1-alpha/immunology OTO - NOTNLM OT - Incomplete immune reconstitution OT - People with HIV (PWHIV) OT - Stem cell-like memory T cells OT - Vaccine-induced immune response EDAT- 2026/02/05 00:30 MHDA- 2026/03/08 01:37 CRDT- 2026/02/04 19:11 PHST- 2025/10/17 00:00 [received] PHST- 2026/01/11 00:00 [revised] PHST- 2026/01/29 00:00 [accepted] PHST- 2026/03/08 01:37 [medline] PHST- 2026/02/05 00:30 [pubmed] PHST- 2026/02/04 19:11 [entrez] AID - S1521-6616(26)00014-8 [pii] AID - 10.1016/j.clim.2026.110676 [doi] PST - ppublish SO - Clin Immunol. 2026 Apr;284:110676. doi: 10.1016/j.clim.2026.110676. Epub 2026 Feb 2. PMID- 41635700 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260204 LR - 20260206 IS - 1662-4548 (Print) IS - 1662-453X (Electronic) IS - 1662-453X (Linking) VI - 19 DP - 2025 TI - Neural mechanisms of cognitive conflict: processing COVID-19 vaccine misinformation. PG - 1661523 LID - 10.3389/fnins.2025.1661523 [doi] LID - 1661523 AB - INTRODUCTION: The rapid spread of misinformation during the COVID-19 pandemic has raised important questions about how individuals evaluate false information, particularly when it conflicts with strongly held prior attitudes. Understanding the neural mechanisms underlying the processing of vaccine-related misinformation may clarify why such beliefs persist despite corrective information. METHODS: Using functional magnetic resonance imaging (fMRI), we examined neural responses to COVID-19 vaccine misinformation and factual information in vaccine-receptive participants (N = 29). During scanning, participants were presented with a series of vaccine-related statements-both accurate and false-and indicated their level of agreement. Analyses focused on the influence of prior beliefs and attitude congruence on neural activation. RESULTS: Contrary to our hypotheses, exposure to attitude-incongruent misinformation did not elicit significant activation in emotional processing regions such as the amygdala or precuneus. However, when participants made attitude-incongruent responses-endorsing misinformation or rejecting accurate information-we observed increased activation in the left dorsolateral prefrontal cortex (DLPFC), dorsomedial prefrontal cortex (DMPFC), intraparietal sulcus (IPS), and middle frontal gyrus (MFG), regions associated with decision-making, moral reasoning, memory integration, and cognitive control. DISCUSSION: These findings suggest that conflicts between incoming information and prior attitudes engage effortful, higher-order cognitive systems rather than affective processing. Resolving such conflicts appears to rely on decision-making and control mechanisms that manage uncertainty and cognitive dissonance. Due to recruitment limitations, the present study focused exclusively on vaccine-receptive individuals. Future research should investigate whether vaccine-resistant individuals exhibit similar or distinct neural patterns, which may provide further insight into the persistence of misinformation in the context of negative prior attitudes. CI - Copyright (c) 2026 McClellan, Kirwan and Ashby. FAU - McClellan, Morgan Chase AU - McClellan MC AD - Center for Neuroscience, Brigham Young University, Provo, UT, United States. FAU - Kirwan, C Brock AU - Kirwan CB AD - MindCORE, University of Pennsylvania, Philadelphia, PA, United States. FAU - Ashby, Stefania R AU - Ashby SR AD - Center for Neuroscience, Brigham Young University, Provo, UT, United States. AD - Department of Psychology, Brigham Young University, Provo, UT, United States. LA - eng PT - Journal Article DEP - 20260119 PL - Switzerland TA - Front Neurosci JT - Frontiers in neuroscience JID - 101478481 PMC - PMC12862833 OTO - NOTNLM OT - decision-making OT - functional MRI (fMRI) OT - misinformation OT - prior attitudes OT - semantic memory OT - vaccine hesitancy COIS- The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2026/02/04 11:32 MHDA- 2026/02/04 11:33 PMCR- 2026/01/19 CRDT- 2026/02/04 04:09 PHST- 2025/07/07 00:00 [received] PHST- 2025/12/18 00:00 [revised] PHST- 2025/12/22 00:00 [accepted] PHST- 2026/02/04 11:33 [medline] PHST- 2026/02/04 11:32 [pubmed] PHST- 2026/02/04 04:09 [entrez] PHST- 2026/01/19 00:00 [pmc-release] AID - 10.3389/fnins.2025.1661523 [doi] PST - epublish SO - Front Neurosci. 2026 Jan 19;19:1661523. doi: 10.3389/fnins.2025.1661523. eCollection 2025. PMID- 41605700 OWN - NLM STAT- MEDLINE DCOM- 20260701 LR - 20260701 IS - 2164-554X (Electronic) IS - 2164-5515 (Print) IS - 2164-5515 (Linking) VI - 22 IP - 1 DP - 2026 Dec TI - Unexpectedly competent immune response to SARS-CoV-2 vaccination in Rett syndrome. PG - 2612817 LID - 10.1080/21645515.2026.2612817 [doi] LID - 2612817 AB - Rett syndrome (RTT) is a rare neurodevelopmental disorder of genetic origin characterized by chronic low-grade inflammation, immune imbalance, and frequently associated with compromised respiratory function. During the COVID-19 pandemic, individuals with RTT were classified as high-risk and invited to follow stringent vaccination protocols that included multiple booster doses. However, the immune response elicited by vaccination in this population has never been systematically investigated. Here, we provide the first characterization of spike-specific antibody and memory B cell responses in 23 RTT patients following two or three doses of SARS-CoV-2 mRNA vaccines. RTT patients developed spike-specific IgG levels comparable to those observed in healthy female controls (GMT 8476 [range 5120-20480] and 9213 [640-81920] after the first two vaccine doses, respectively). The frequencies and phenotype of spike-specific memory B cells were also similar between RTT and controls (mean frequency of 1.3 +/- 0.6 and 1.6 +/- 1.1, respectively) and these cells displayed functional reactivity upon antigenic stimulation in vitro. The assessment of vaccine-induced immunity in RTT addresses a critical knowledge gap by demonstrating the ability of these patients to develop an immune response to mRNA vaccination, thereby providing insights that may inform tailored vaccination strategies and improve understanding of immune competence in this rare disorder. FAU - Soldateschi, Ludovica AU - Soldateschi L AD - Laboratory of Molecular Microbiology and Biotechnology, Department of Medical Biotechnologies, University of Siena, Siena, Italy. FAU - Leoncini, Silvia AU - Leoncini S AD - Rett Syndrome Trial Center, Azienda Ospedaliera Universitaria Senese, Siena, Italy. AD - Neonatal Intensive Care Unit, Azienda Ospedaliera Universitaria Senese, Siena, Italy. AD - U.O.S.A. Programmazione e Ricerca Clinica, Azienda Ospedaliera Universitaria Senese, Siena, Italy. FAU - Fiorino, Fabio AU - Fiorino F AD - Laboratory of Molecular Microbiology and Biotechnology, Department of Medical Biotechnologies, University of Siena, Siena, Italy. AD - Department of Medicine and Surgery, LUM University, Bari, Italy. FAU - Lucchesi, Simone AU - Lucchesi S AD - Laboratory of Molecular Microbiology and Biotechnology, Department of Medical Biotechnologies, University of Siena, Siena, Italy. FAU - Polvere, Jacopo AU - Polvere J AD - Laboratory of Molecular Microbiology and Biotechnology, Department of Medical Biotechnologies, University of Siena, Siena, Italy. FAU - Boasiako, Lidia AU - Boasiako L AD - Rett Syndrome Trial Center, Azienda Ospedaliera Universitaria Senese, Siena, Italy. AD - Neonatal Intensive Care Unit, Azienda Ospedaliera Universitaria Senese, Siena, Italy. FAU - Pastore, Gabiria AU - Pastore G AD - Laboratory of Molecular Microbiology and Biotechnology, Department of Medical Biotechnologies, University of Siena, Siena, Italy. FAU - Fazzi, Caterina AU - Fazzi C AD - Rett Syndrome Trial Center, Azienda Ospedaliera Universitaria Senese, Siena, Italy. FAU - Altamura, Maria AU - Altamura M AD - Rett Syndrome Trial Center, Azienda Ospedaliera Universitaria Senese, Siena, Italy. FAU - Scandurra, Valeria AU - Scandurra V AD - Child Neuropsychiatry Unit, Azienda Ospedaliera Universitaria Senese, Siena, Italy. FAU - Grosso, Salvatore AU - Grosso S AD - U.O.C. Pediatria, Azienda Ospedaliera Universitaria Senese, Siena, Italy. FAU - Montagnani, Francesca AU - Montagnani F AD - Department of Medical Sciences, Infectious and Tropical Diseases Unit, Azienda Ospedaliera Universitaria Senese, Siena, Italy. FAU - De Felice, Claudio AU - De Felice C AD - Rett Syndrome Trial Center, Azienda Ospedaliera Universitaria Senese, Siena, Italy. AD - Neonatal Intensive Care Unit, Azienda Ospedaliera Universitaria Senese, Siena, Italy. AD - U.O.S.A. Programmazione e Ricerca Clinica, Azienda Ospedaliera Universitaria Senese, Siena, Italy. AD - U.O.C. Pediatria, Azienda Ospedaliera Universitaria Senese, Siena, Italy. FAU - Ciabattini, Annalisa AU - Ciabattini A AUID- ORCID: 0000-0002-4585-7783 AD - Laboratory of Molecular Microbiology and Biotechnology, Department of Medical Biotechnologies, University of Siena, Siena, Italy. FAU - Medaglini, Donata AU - Medaglini D AD - Laboratory of Molecular Microbiology and Biotechnology, Department of Medical Biotechnologies, University of Siena, Siena, Italy. LA - eng PT - Journal Article DEP - 20260128 PL - United States TA - Hum Vaccin Immunother JT - Human vaccines & immunotherapeutics JID - 101572652 RN - 0 (Antibodies, Viral) RN - 0 (COVID-19 Vaccines) RN - 0 (Spike Glycoprotein, Coronavirus) RN - 0 (Immunoglobulin G) RN - 0 (spike protein, SARS-CoV-2) SB - IM MH - Humans MH - Female MH - *Rett Syndrome/immunology MH - Antibodies, Viral/blood/immunology MH - *COVID-19/prevention & control/immunology MH - *SARS-CoV-2/immunology MH - Child MH - Adolescent MH - *COVID-19 Vaccines/immunology/administration & dosage MH - Spike Glycoprotein, Coronavirus/immunology MH - Memory B Cells/immunology MH - Immunoglobulin G/blood/immunology MH - Adult MH - Vaccination MH - Young Adult MH - Immunologic Memory MH - Child, Preschool PMC - PMC12854380 OTO - NOTNLM OT - COVID-19 OT - Rett syndrome OT - SARS-CoV-2 OT - memory B cells OT - vaccination COIS- No potential conflict of interest was reported by the author(s). EDAT- 2026/01/29 01:47 MHDA- 2026/01/29 01:48 PMCR- 2026/01/28 CRDT- 2026/01/28 21:53 PHST- 2026/01/29 01:48 [medline] PHST- 2026/01/29 01:47 [pubmed] PHST- 2026/01/28 21:53 [entrez] PHST- 2026/01/28 00:00 [pmc-release] AID - 2612817 [pii] AID - 10.1080/21645515.2026.2612817 [doi] PST - ppublish SO - Hum Vaccin Immunother. 2026 Dec;22(1):2612817. doi: 10.1080/21645515.2026.2612817. Epub 2026 Jan 28. PMID- 41534070 OWN - NLM STAT- MEDLINE DCOM- 20260626 LR - 20260922 IS - 1537-7385 (Electronic) IS - 0894-9115 (Linking) VI - 105 IP - 4 DP - 2026 Apr 1 TI - COVID-19 Vaccination Among Persons With Complicated Mild to Severe Traumatic Brain Injury: A TBI Model Systems Study. PG - 291-296 LID - 10.1097/PHM.0000000000002884 [doi] AB - OBJECTIVE: The aim of the study was to investigate demographic differences in COVID-19 vaccination uptake and to assess whether vaccination status is associated with societal participation, mental health, and quality of life among individuals with complicated mild to severe traumatic brain injury. DESIGN: This is a secondary analysis of a prospective, longitudinal cohort study using the Traumatic Brain Injury Model Systems (TBIMS) National Database from 1961 individuals aged 16-years-old and older who completed interviews between October 1, 2021, and January 15, 2023, and responded to questions regarding COVID-19 vaccination status. Demographic, injury severity, societal participation, mental health, and quality of life metrics were compared between those with and without COVID-19 vaccination. RESULTS: Vaccinated individuals (68%) were more likely to be older, female, nonsmokers, White, and of Asian American or Hispanic ethnicity. Traumatic brain injury severity did not significantly differ between vaccinated and unvaccinated groups. In multivariate analysis, vaccination status was not independently associated with social participation (Participation Assessment with Recombined Tools-Objective), anxiety (General Anxiety Disorder 7), depression (Patient Health Questionnaire 9), or quality of life (Satisfaction with Life Scale). CONCLUSIONS: Demographic disparities in vaccination uptake exist among individuals with traumatic brain injury, but vaccination status was not independently linked to mental health, participation, or quality of life outcomes. These findings underscore the need for targeted outreach to address vaccination gaps and promote health equity in this vulnerable population. CI - Copyright (c) 2025 Wolters Kluwer Health, Inc. All rights reserved. FAU - Chen, Ziyi AU - Chen Z AUID- ORCID: 0000-0001-6450-6957 AD - From the Department of Physical Medicine and Rehabilitation, University of Texas Southwestern Medical Center, Dallas, Texas. FAU - Kiernan, Sophia AU - Kiernan S AUID- ORCID: 0009-0005-5403-9503 AD - Departments of Physical Medicine and Rehabilitation and Family and Community Medicine, Peter O'Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dallas, Texas. FAU - Thakur, Bhaskar AU - Thakur B AUID- ORCID: 0000-0001-6869-8968 AD - From the Department of Physical Medicine and Rehabilitation, University of Texas Southwestern Medical Center, Dallas, Texas. FAU - Hicks, Amelia J AU - Hicks AJ AUID- ORCID: 0000-0002-1152-0576 AD - Department of Rehabilitation and Human Performance, Icahn School of Medicine at Mount Sinai, New York, New York. FAU - Hammond, Flora M AU - Hammond FM AUID- ORCID: 0000-0002-9840-0744 AD - Department of Physical Medicine & Rehabilitation, Indiana University School of Medicine, Rehabilitation Hospital of Indiana, Indianapolis, Indiana. FAU - Pinto, Shanti M AU - Pinto SM AUID- ORCID: 0000-0002-8882-7533 LA - eng GR - 90DPTB0022/ACL/ACL HHS/United States GR - 90DPTB0028/ACL/ACL HHS/United States GR - 90DPTB0023/ACL/ACL HHS/United States PT - Journal Article PT - Research Support, U.S. Gov't, P.H.S. DEP - 20251016 PL - United States TA - Am J Phys Med Rehabil JT - American journal of physical medicine & rehabilitation JID - 8803677 RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - Female MH - *Brain Injuries, Traumatic/psychology MH - Male MH - Quality of Life MH - Adult MH - Middle Aged MH - Adolescent MH - *Vaccination/statistics & numerical data MH - *COVID-19/prevention & control MH - Young Adult MH - Longitudinal Studies MH - Prospective Studies MH - *COVID-19 Vaccines/administration & dosage MH - Social Participation MH - Mental Health MH - Aged OTO - NOTNLM OT - COVID Vaccination OT - Quality of Life OT - Societal Participation OT - Traumatic Brain Injury (TBI) EDAT- 2026/01/15 16:13 MHDA- 2026/03/30 06:29 CRDT- 2026/01/14 16:52 PHST- 2025/05/14 00:00 [received] PHST- 2025/10/11 00:00 [accepted] PHST- 2026/03/30 06:29 [medline] PHST- 2026/01/15 16:13 [pubmed] PHST- 2026/01/14 16:52 [entrez] AID - 00002060-990000000-00833 [pii] AID - 10.1097/PHM.0000000000002884 [doi] PST - ppublish SO - Am J Phys Med Rehabil. 2026 Apr 1;105(4):291-296. doi: 10.1097/PHM.0000000000002884. Epub 2025 Oct 16. PMID- 41527553 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260113 LR - 20260115 IS - 2050-0068 (Print) IS - 2050-0068 (Electronic) IS - 2050-0068 (Linking) VI - 15 IP - 1 DP - 2026 TI - Prolonged persistence of tissue-resident memory cells in the upper airway following SARS-CoV-2 infection and vaccination. PG - e70075 LID - 10.1002/cti2.70075 [doi] LID - e70075 AB - OBJECTIVES: Here, we characterised the diversity and persistence of immunological memory cells-particularly tissue-resident memory T (T(RM)) and B (B(RM)) cells-in the nasopharyngeal lymphoid tissues of healthy vaccinated (HV) individuals and those who experienced SARS-CoV-2 breakthrough infection (BR). METHODS: Nasopharynx (NP) samples were obtained using brushing from HV and BR subjects. Immune cell populations were analysed using transcriptomic profiling and flow cytometry. RESULTS: Transcriptomic profiling revealed that the NP of SARS-CoV-2-infected individuals exhibited distinctive signatures of lymphocyte-mediated immunity, underscoring its role as a key site for viral invasion and immune activation. Effector memory CD4+ and CD8+ T (T(EM)) cells, along with non-germinal center (GC) B cells, predominated in the NP. Although overall frequencies of memory T cells were comparable between HV and BR groups, CD4+ T(EM) and GC B cells were significantly enriched in the NP of BR individuals at least 1 year post infection. Notably, over 80% of CD4+ T(EM) and 40% of CD8+ T(EM) cells were T(RM), and more than 30% of memory B cells exhibited a B(RM) phenotype. These populations of CD4+, CD8+ T(RM) and B(RM) persisted in the NP for over 2 years following SARS-CoV-2 infection or vaccination. In particular, CD4+ T(RM) cells were significantly more abundant and durably maintained in the NP mucosa of BR individuals. CONCLUSION: Our findings identify the nasopharynx as a key site of long-lived immunological memory, marked by persistent T(RM) and B(RM) cells after SARS-CoV-2 exposure. CI - (c) 2026 The Author(s). Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of Australian and New Zealand Society for Immunology, Inc. FAU - Cha, Hyunkyung AU - Cha H AUID- ORCID: 0000-0002-3462-3789 AD - Department of Otorhinolaryngology-Head and Neck Surgery Soonchunhyang University Cheonan Hospital Cheonan Korea. FAU - Won, Jina AU - Won J AD - Department of Otorhinolaryngology Seoul National University College of Medicine Seoul Korea. FAU - Kim, Soo Min AU - Kim SM AD - Department of Otorhinolaryngology Seoul National University College of Medicine Seoul Korea. FAU - Lim, Suhyun AU - Lim S AD - Department of Otorhinolaryngology Seoul National University College of Medicine Seoul Korea. FAU - Kim, Sujin AU - Kim S AD - Department of Otorhinolaryngology Seoul National University College of Medicine Seoul Korea. FAU - Jin, Siyeon AU - Jin S AUID- ORCID: 0000-0002-6358-8900 AD - Department of Otorhinolaryngology Seoul National University Hospital Seoul Korea. FAU - Cho, Sung Dong AU - Cho SD AUID- ORCID: 0000-0002-7140-6863 AD - Department of Otorhinolaryngology Seoul National University Hospital Seoul Korea. FAU - Kim, Hyun Jik AU - Kim HJ AD - Department of Otorhinolaryngology Seoul National University College of Medicine Seoul Korea. AD - Department of Otorhinolaryngology Seoul National University Hospital Seoul Korea. AD - Sensory Organ Research Institute Seoul National University Medical Research Center Seoul Korea. LA - eng PT - Journal Article DEP - 20260111 PL - Australia TA - Clin Transl Immunology JT - Clinical & translational immunology JID - 101638268 PMC - PMC12790937 OTO - NOTNLM OT - SARS-CoV-2 OT - localised immune memory OT - nasopharyngeal lymphoid tissues OT - tissue-resident memory T and B cells COIS- The authors declare no conflict of interest. EDAT- 2026/01/13 07:43 MHDA- 2026/01/13 07:44 PMCR- 2026/01/11 CRDT- 2026/01/13 03:44 PHST- 2025/06/12 00:00 [received] PHST- 2025/12/23 00:00 [revised] PHST- 2025/12/28 00:00 [accepted] PHST- 2026/01/13 07:44 [medline] PHST- 2026/01/13 07:43 [pubmed] PHST- 2026/01/13 03:44 [entrez] PHST- 2026/01/11 00:00 [pmc-release] AID - CTI270075 [pii] AID - 10.1002/cti2.70075 [doi] PST - epublish SO - Clin Transl Immunology. 2026 Jan 11;15(1):e70075. doi: 10.1002/cti2.70075. eCollection 2026. PMID- 41502006 OWN - NLM STAT- MEDLINE DCOM- 20260625 LR - 20260918 IS - 1521-4141 (Electronic) IS - 0014-2980 (Print) IS - 0014-2980 (Linking) VI - 56 IP - 1 DP - 2026 Jan TI - SARS-CoV-2 mRNA Vaccination Leads to Transient Humoral and B Cell Bystander Responses in Adults. PG - e70127 LID - 10.1002/eji.70127 [doi] LID - e70127 AB - After antigen encounter, long-lived antibody-secreting cells (ASC) secrete high-affinity circulating antibodies. In addition, memory B cells (MBC) are quickly reactivated upon antigen re-exposure and predominantly generate shorter-lived ASCs. Studies have suggested that MBC can differentiate into ASCs without recognizing their cognate antigen, a process known as "bystander activation". This antigen-independent reactivation of MBC could help maintain circulating antibody levels, thereby protecting against future infections. To elucidate whether SARS-CoV-2 mRNA vaccination leads to bystander activation of B cells, the dynamics of antibody concentrations against six pathogen-specific antigens not encountered during the sampling period were analyzed over time. Deep profiling of antigen-specific B cell responses was simultaneously performed using multiparameter high-dimensional spectral flow cytometry. Antibody concentrations against tetanus toxoid (TT), respiratory syncytial virus (RSV), and influenza hemagglutinin (HA) unexpectedly increased 6 weeks after the first SARS-CoV-2 vaccination. Deep profiling of B cell differentiation stages demonstrated a short-term increase in influenza-specific IgG+ DN3 B cells, RSV-specific IgG+ CD11c+ activated B cells, and TT-specific IgG+ MBC following vaccination. In this study, we demonstrated at both the antibody and cellular levels that SARS-CoV-2 mRNA vaccination transiently activates distinct early activated B cell compartments directed against influenza HA, RSV, and TT. CI - (c) 2026 The Author(s). European Journal of Immunology published by Wiley-VCH GmbH. FAU - Kuijper, Lisan H AU - Kuijper LH AUID- ORCID: 0000-0003-3009-0943 AD - Sanquin Research and Landsteiner Laboratory of the Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands. AD - Amsterdam Institute for Immunology and Infectious Diseases, Amsterdam, the Netherlands. FAU - Kummer, Laura Y L AU - Kummer LYL AD - Sanquin Research and Landsteiner Laboratory of the Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands. AD - Amsterdam Institute for Immunology and Infectious Diseases, Amsterdam, the Netherlands. AD - Department of Neurology and Neurophysiology, Amsterdam UMC, Amsterdam, the Netherlands. FAU - Blanco, Laura Fernandez AU - Blanco LF AD - Sanquin Research and Landsteiner Laboratory of the Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands. AD - Amsterdam Institute for Immunology and Infectious Diseases, Amsterdam, the Netherlands. AD - Department of Neurology and Neurophysiology, Amsterdam UMC, Amsterdam, the Netherlands. FAU - van der Straten, Karlijn AU - van der Straten K AD - Amsterdam Institute for Immunology and Infectious Diseases, Amsterdam, the Netherlands. AD - Department of Medical Microbiology and Infection Prevention, Amsterdam UMC, Amsterdam, the Netherlands. FAU - Claireaux, Mathieu A F AU - Claireaux MAF AD - Amsterdam Institute for Immunology and Infectious Diseases, Amsterdam, the Netherlands. AD - Department of Medical Microbiology and Infection Prevention, Amsterdam UMC, Amsterdam, the Netherlands. FAU - Bos, Amelie V AU - Bos AV AD - Sanquin Research and Landsteiner Laboratory of the Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands. AD - Amsterdam Institute for Immunology and Infectious Diseases, Amsterdam, the Netherlands. FAU - Dieker-Meijer, Miranda C AU - Dieker-Meijer MC AD - Sanquin Research and Landsteiner Laboratory of the Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands. AD - Amsterdam Institute for Immunology and Infectious Diseases, Amsterdam, the Netherlands. FAU - Jorritsma, Tineke AU - Jorritsma T AD - Sanquin Research and Landsteiner Laboratory of the Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands. AD - Amsterdam Institute for Immunology and Infectious Diseases, Amsterdam, the Netherlands. FAU - Duurland, Mariel C AU - Duurland MC AD - Sanquin Research and Landsteiner Laboratory of the Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands. AD - Amsterdam Institute for Immunology and Infectious Diseases, Amsterdam, the Netherlands. FAU - Steenhuis, Maurice AU - Steenhuis M AD - Sanquin Research and Landsteiner Laboratory of the Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands. AD - Amsterdam Institute for Immunology and Infectious Diseases, Amsterdam, the Netherlands. FAU - Vallejo, Juan J Garcia AU - Vallejo JJG AD - Amsterdam Institute for Immunology and Infectious Diseases, Amsterdam, the Netherlands. AD - Department of Molecular Cell Biology and Immunology, Amsterdam UMC, Amsterdam, the Netherlands. FAU - van Dam, Koos P J AU - van Dam KPJ AD - Department of Neurology and Neurophysiology, Amsterdam UMC, Amsterdam, the Netherlands. FAU - Stalman, Eileen W AU - Stalman EW AD - Department of Neurology and Neurophysiology, Amsterdam UMC, Amsterdam, the Netherlands. FAU - Wieske, Luuk AU - Wieske L AD - Department of Neurology and Neurophysiology, Amsterdam UMC, Amsterdam, the Netherlands. AD - Department of Clinical Neurophysiology, St. Antonius Hospital, Nieuwegein, the Netherlands. FAU - Tas, Sander W AU - Tas SW AD - Amsterdam Institute for Immunology and Infectious Diseases, Amsterdam, the Netherlands. AD - Amsterdam Rheumatology and Immunology Center, Amsterdam UMC, Amsterdam, the Netherlands. FAU - Boekel, Laura AU - Boekel L AD - Amsterdam Institute for Immunology and Infectious Diseases, Amsterdam, the Netherlands. AD - Amsterdam Rheumatology and Immunology Center, Reade, Amsterdam, the Netherlands. FAU - Wolbink, Gert-Jan AU - Wolbink GJ AD - Amsterdam Institute for Immunology and Infectious Diseases, Amsterdam, the Netherlands. AD - Amsterdam Rheumatology and Immunology Center, Reade, Amsterdam, the Netherlands. FAU - Rispens, Theo AU - Rispens T AUID- ORCID: 0000-0001-9600-1312 AD - Sanquin Research and Landsteiner Laboratory of the Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands. AD - Amsterdam Institute for Immunology and Infectious Diseases, Amsterdam, the Netherlands. FAU - Kuijpers, Taco W AU - Kuijpers TW AD - Amsterdam Institute for Immunology and Infectious Diseases, Amsterdam, the Netherlands. AD - Department of Pediatric Immunology, Rheumatology and Infectious Disease, Amsterdam UMC, Amsterdam, the Netherlands. FAU - Eftimov, Filip AU - Eftimov F AD - Department of Neurology and Neurophysiology, Amsterdam UMC, Amsterdam, the Netherlands. FAU - van Gils, Marit J AU - van Gils MJ AD - Amsterdam Institute for Immunology and Infectious Diseases, Amsterdam, the Netherlands. AD - Department of Medical Microbiology and Infection Prevention, Amsterdam UMC, Amsterdam, the Netherlands. FAU - Ten Brinke, Anja AU - Ten Brinke A AD - Sanquin Research and Landsteiner Laboratory of the Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands. AD - Amsterdam Institute for Immunology and Infectious Diseases, Amsterdam, the Netherlands. FAU - van Ham, S Marieke AU - van Ham SM AD - Sanquin Research and Landsteiner Laboratory of the Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands. AD - Amsterdam Institute for Immunology and Infectious Diseases, Amsterdam, the Netherlands. AD - Swammerdam Institute for Life Sciences, University of Amsterdam, Amsterdam, the Netherlands. CN - T2B! immunity against SARS-CoV-2 study group LA - eng GR - 10430072010007/ZONMW_/ZonMw/Netherlands GR - L2506/Sanquin Blood Supply program grant PPOC OPTIMAL/ PT - Journal Article PL - Germany TA - Eur J Immunol JT - European journal of immunology JID - 1273201 RN - 0 (Antibodies, Viral) RN - 0 (COVID-19 Vaccines) RN - 0 (Tetanus Toxoid) SB - IM MH - Humans MH - *SARS-CoV-2/immunology MH - Antibodies, Viral/immunology/blood MH - *Memory B Cells/immunology MH - *COVID-19/immunology/prevention & control MH - Adult MH - *B-Lymphocytes/immunology MH - *Immunity, Humoral MH - *COVID-19 Vaccines/immunology MH - Lymphocyte Activation/immunology MH - Vaccination MH - Bystander Effect/immunology MH - Tetanus Toxoid/immunology MH - Female MH - Immunologic Memory MH - Cell Differentiation PMC - PMC12779779 OTO - NOTNLM OT - DN3 OT - IgG+ activated B cells OT - antibodies OT - antibody-secreting cells OT - memory B cells OT - noncognate antigen OT - serological memory COIS- Filip Eftimov, Gert-Jan Wolbink, S. Marieke van Ham, and Taco W. Kuijpers report (governmental) grants from ZonMw to study immune response after SARS-CoV-2 vaccination in autoimmune diseases. Filip Eftimov also reports grants from Prinses Beatrix Spierfonds, CSL Behring, Kedrion, Terumo BCT, Grifols, Takeda Pharmaceutical, and GBS-CIDP Foundation; consulting fees from UCB Pharma and CSl Behring; and honoraria from Grifols. All other authors report no conflicts of interest. EDAT- 2026/01/08 07:13 MHDA- 2026/01/08 07:14 PMCR- 2026/01/08 CRDT- 2026/01/08 00:22 PHST- 2025/12/19 00:00 [revised] PHST- 2025/03/11 00:00 [received] PHST- 2025/12/19 00:00 [accepted] PHST- 2026/01/08 07:14 [medline] PHST- 2026/01/08 07:13 [pubmed] PHST- 2026/01/08 00:22 [entrez] PHST- 2026/01/08 00:00 [pmc-release] AID - EJI70127 [pii] AID - 10.1002/eji.70127 [doi] PST - ppublish SO - Eur J Immunol. 2026 Jan;56(1):e70127. doi: 10.1002/eji.70127. PMID- 41481458 OWN - NLM STAT- MEDLINE DCOM- 20260102 LR - 20260919 IS - 1091-6490 (Electronic) IS - 0027-8424 (Print) IS - 0027-8424 (Linking) VI - 123 IP - 1 DP - 2026 Jan 6 TI - Memory B cell development in response to mRNA SARS-CoV-2 and nanoparticle immunization in mice. PG - e2527869123 LID - 10.1073/pnas.2527869123 [doi] LID - e2527869123 AB - Nanoparticle immunogens excel at rapidly inducing high levels of circulating antibodies and are being deployed as part of several novel vaccines. However, their ability to elicit memory B cell responses is less well understood. Here, we compared serologic and memory B cell responses after prime boost vaccination with either SARS-CoV-2 Wuhan-Hu-1 mRNA vaccine, or protein nanoparticles: SARS-CoV-2 B.1.351 homotypic containing a single receptor binding domain (RBD); (homotypic beta) or a combination of different Sarbecovirus RBDs (mosaic 8b), respectively. The memory B cells elicited by the 3 vaccine regimens showed closely related antibody sequences, similar levels of somatic mutation, and clonal diversity. The breadth of serologic responses elicited by the mosaic nanoparticles was comparable to the homotypic nanoparticle and superior to the mRNA vaccine for some mismatched strains. However, serum neutralizing titers to SARS-CoV-2 were highest after mRNA vaccination. The three vaccines elicited memory B cells that produced antibodies specific to a broad range of epitopes on the RBD that differed in a way that may reflect epitope masking. Monoclonal antibodies derived from memory B cells elicited by the mosaic 8b nanoparticle showed greater breadth against a panel of SARS-CoV-2 variants and SARS-CoV. FAU - Wiatr, Marie AU - Wiatr M AD - Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065. FAU - Wang, Zijun AU - Wang Z AD - Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065. FAU - Canis, Marie AU - Canis M AUID- ORCID: 0000-0002-9243-867X AD - Laboratory of Retrovirology, The Rockefeller University, New York, NY 10065. FAU - Hernandez, Brianna AU - Hernandez B AD - Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065. FAU - Gazumyan, Anna AU - Gazumyan A AD - Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065. FAU - Santos, Gabriela S Silva AU - Santos GSS AD - Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065. FAU - Shawraz, Sadman AU - Shawraz S AD - Laboratory of Retrovirology, The Rockefeller University, New York, NY 10065. FAU - Lee, Songhee AU - Lee S AD - Laboratory of Retrovirology, The Rockefeller University, New York, NY 10065. FAU - Bieniasz, Paul D AU - Bieniasz PD AUID- ORCID: 0000-0002-2368-3719 AD - Laboratory of Retrovirology, The Rockefeller University, New York, NY 10065. AD - HHMI, The Rockefeller University, New York, NY 10065. FAU - Hatziioannou, Theodora AU - Hatziioannou T AUID- ORCID: 0000-0002-7889-0766 AD - Laboratory of Retrovirology, The Rockefeller University, New York, NY 10065. FAU - Muecksch, Frauke AU - Muecksch F AD - Laboratory of Retrovirology, The Rockefeller University, New York, NY 10065. AD - Department of Infectious Diseases, Virology, Medical Faculty Heidelberg, Heidelberg University, Heidelberg 69120, Germany. FAU - Nussenzweig, Michel C AU - Nussenzweig MC AD - Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065. AD - HHMI, The Rockefeller University, New York, NY 10065. LA - eng GR - R37 AI037526/AI/NIAID NIH HHS/United States GR - UM1 AI144462/AI/NIAID NIH HHS/United States GR - 1UM1AI144462-01/HHS | National Institutes of Health (NIH)/ GR - 5R37 AI037526/HHS | National Institutes of Health (NIH)/ PT - Journal Article DEP - 20260102 PL - United States TA - Proc Natl Acad Sci U S A JT - Proceedings of the National Academy of Sciences of the United States of America JID - 7505876 RN - 0 (COVID-19 Vaccines) RN - 0 (Antibodies, Viral) RN - 0 (Antibodies, Neutralizing) RN - 0 (Spike Glycoprotein, Coronavirus) RN - 0 (RNA, Messenger) RN - 0 (mRNA Vaccines) RN - 0 (spike protein, SARS-CoV-2) SB - IM UOF - bioRxiv. 2025 Oct 02:2025.10.01.679787. doi: 10.1101/2025.10.01.679787. PMID: 41256446 MH - Animals MH - *SARS-CoV-2/immunology/genetics MH - *Nanoparticles/administration & dosage MH - Mice MH - *Memory B Cells/immunology MH - *COVID-19 Vaccines/immunology/administration & dosage MH - Antibodies, Viral/immunology/blood MH - *COVID-19/immunology/prevention & control MH - Antibodies, Neutralizing/immunology/blood MH - Spike Glycoprotein, Coronavirus/immunology MH - Female MH - RNA, Messenger/immunology MH - mRNA Vaccines/immunology MH - Immunologic Memory MH - Humans MH - Immunization MH - Mice, Inbred BALB C MH - B-Lymphocytes/immunology PMC - PMC12773752 OTO - NOTNLM OT - SARS-CoV-2 OT - mRNA vaccine OT - memory B cell OT - nanoparticle vaccine OT - neutralizing antibodies COIS- Competing interests statement:The authors declare no competing interest. EDAT- 2026/01/02 19:38 MHDA- 2026/01/02 19:39 PMCR- 2026/01/02 CRDT- 2026/01/02 12:43 PHST- 2026/01/02 19:39 [medline] PHST- 2026/01/02 19:38 [pubmed] PHST- 2026/01/02 12:43 [entrez] PHST- 2026/01/02 00:00 [pmc-release] AID - 202527869 [pii] AID - 10.1073/pnas.2527869123 [doi] PST - ppublish SO - Proc Natl Acad Sci U S A. 2026 Jan 6;123(1):e2527869123. doi: 10.1073/pnas.2527869123. Epub 2026 Jan 2. PMID- 41416941 OWN - NLM STAT- MEDLINE DCOM- 20251219 LR - 20260925 IS - 1521-4141 (Electronic) IS - 0014-2980 (Print) IS - 0014-2980 (Linking) VI - 55 IP - 12 DP - 2025 Dec TI - Characterization of the SARS-CoV-2-Specific T Cell Responses in Rheumatoid Arthritis Subjects Vaccinated for COVID-19 Protection. PG - e70105 LID - 10.1002/eji.70105 [doi] LID - e70105 AB - The efficacy of mRNA-based vaccines to prevent COVID-19 in autoimmune patients is controversial due to immunosuppressive therapies. Here, we characterized the T cell responses to SARS-CoV-2 in rheumatoid arthritis (RA) subjects, who received as few as one or up to seven vaccine injections. The study population had different disease severities and an association with other autoimmune comorbidities. All the subjects studied showed SARS-CoV-2 spike-specific CD4+ T helper (Th) cells in circulation, and in most of the subjects, CD8(+) cytotoxic T cells. CD4(+) and CD8(+) T cells were CCR6+, suggesting trafficking to tissues. T cell memory did not correlate with the number of vaccine boosts received. Nonspike-specific T cells were enumerated in subjects who had symptomatic or asymptomatic COVID-19. Spike- and nonspike-specific regulatory T cells (Treg) were detectable in most subjects. CD4(-) CD8(-) double-negative (DN) T cells expanded in response to SARS-CoV-2 peptides. DN T cells co-cultured with autologous myeloid dendritic cells (DC) differentiated into CD8(+) T cells, depending upon the strength of the stimuli. RA subjects responded to mRNA-based vaccination for COVID-19 protection, with no correlation with the number of injections. DN T cells differentiated into CD8(+) T cells after stimulation, potentially exacerbating inflammation in RA vaccine recipients. CI - (c) 2025 The Author(s). European Journal of Immunology published by Wiley-VCH GmbH. FAU - Song, Jaeyoon AU - Song J AD - School of Medicine, Department of Pediatrics, University of California San Diego, La Jolla, California, USA. FAU - da Silva Antunes, Ricardo AU - da Silva Antunes R AD - Center For Vaccine Innovation, La Jolla Institute for Immunology (LJI); Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California San Diego (UCSD), La Jolla, California, USA. FAU - Seyede, Mehrnaz Agili AU - Seyede MA AD - Department of Medicine, School of Medicine, University of California San Diego, La Jolla, California, USA. FAU - Guma, Monica AU - Guma M AD - Department of Medicine, School of Medicine, University of California San Diego, La Jolla, California, USA. FAU - Sette, Alessandro AU - Sette A AD - Center For Vaccine Innovation, La Jolla Institute for Immunology (LJI); Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California San Diego (UCSD), La Jolla, California, USA. FAU - Franco, Alessandra AU - Franco A AD - School of Medicine, Department of Pediatrics, University of California San Diego, La Jolla, California, USA. LA - eng GR - Praespero, an Autoimmune Research Fund/ GR - Gordon and Marylin Macklin Foundation/ GR - 75N9301900065/NIH NIAID/ PT - Journal Article PL - Germany TA - Eur J Immunol JT - European journal of immunology JID - 1273201 RN - 0 (COVID-19 Vaccines) RN - 0 (Spike Glycoprotein, Coronavirus) RN - 0 (spike protein, SARS-CoV-2) SB - IM MH - Humans MH - *Arthritis, Rheumatoid/immunology MH - *COVID-19/immunology/prevention & control MH - *SARS-CoV-2/immunology MH - Middle Aged MH - Female MH - Male MH - *COVID-19 Vaccines/immunology/administration & dosage MH - Aged MH - Adult MH - CD8-Positive T-Lymphocytes/immunology MH - Spike Glycoprotein, Coronavirus/immunology MH - T-Lymphocytes, Regulatory/immunology MH - Immunologic Memory MH - Vaccination PMC - PMC12716210 OTO - NOTNLM OT - CD4-CD8- double negative (DN) T cells OT - SARS-CoV-2 vaccination in rheumatoid arthritis OT - T cell memory OT - regulatory T cells COIS- The authors declare no conflicts of interest. EDAT- 2025/12/19 15:03 MHDA- 2025/12/19 15:04 PMCR- 2025/12/19 CRDT- 2025/12/19 10:13 PHST- 2025/11/14 00:00 [revised] PHST- 2025/06/12 00:00 [received] PHST- 2025/11/14 00:00 [accepted] PHST- 2025/12/19 15:04 [medline] PHST- 2025/12/19 15:03 [pubmed] PHST- 2025/12/19 10:13 [entrez] PHST- 2025/12/19 00:00 [pmc-release] AID - EJI70105 [pii] AID - 10.1002/eji.70105 [doi] PST - ppublish SO - Eur J Immunol. 2025 Dec;55(12):e70105. doi: 10.1002/eji.70105. PMID- 41367201 OWN - NLM STAT- MEDLINE DCOM- 20251210 LR - 20260702 IS - 1521-4141 (Electronic) IS - 0014-2980 (Print) IS - 0014-2980 (Linking) VI - 55 IP - 12 DP - 2025 Dec TI - IL-10- and IL-13-Biased T Cell Responses to SARS-CoV-2 Vaccination in Diabetes. PG - e70112 LID - 10.1002/eji.70112 [doi] LID - e70112 AB - Type 1 and type 2 diabetes are associated with increased severity and mortality from respiratory virus infections. Vaccination in the general population significantly reduces the risk of severe respiratory viral infection and triggers a strong, polyfunctional, and lasting T cell response in healthy individuals. However, vaccine effectiveness in people with type 1 diabetes is unclear. Here, we studied the magnitude and functional characteristics of vaccine-specific CD4(+) and CD8(+) T cell responses to vaccination in people with type 1 and type 2 diabetes and compared them to those of people living without diabetes, using the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine as a model. We found defects in both CD4(+) and CD8(+) T cell memory maintenance and the functionality of the vaccine-specific T cells in people with diabetes compared with people without. In those individuals with type 1 and type 2 diabetes who harbored detectable vaccine-specific T cells, they displayed an unfocused, tolerogenic phenotype characterized by increased expression of IL-10 and IL-13 compared with people without diabetes. These results have implications for vaccination strategies for people with diabetes. CI - (c) 2025 The Author(s). European Journal of Immunology published by Wiley-VCH GmbH. FAU - Jones, Emma M AU - Jones EM AD - Department of Infectious Disease, Faculty of Medicine, Imperial College London, London, UK. FAU - Sourij, Caren AU - Sourij C AD - Division of Cardiology, Medical University of Graz, Austria. FAU - Stradner, Martin AU - Stradner M AD - Division of Rheumatology and Immunology, Medical University of Graz, Austria. FAU - Schlenke, Peter AU - Schlenke P AD - Department of Blood Group Serology and Transfusion Medicine, Medical University of Graz, Austria. FAU - Sereban, Nazanin AU - Sereban N AD - Department of Blood Group Serology and Transfusion Medicine, Medical University of Graz, Austria. FAU - Moser, Othmar AU - Moser O AD - University of Bayreuth, Bayreuth, Germany. AD - Interdisciplinary Metabolic Medicine Trials Unit, Division of Endocrinology and Diabetology, Medical University of Graz, Austria. FAU - Quinlan, Rachael AU - Quinlan R AD - Department of Infectious Disease, Faculty of Medicine, Imperial College London, London, UK. AD - Imperial College NHS Trust, London, UK. FAU - Short, Charlotte-Eve AU - Short CE AD - Department of Infectious Disease, Faculty of Medicine, Imperial College London, London, UK. AD - Imperial College NHS Trust, London, UK. FAU - Harris, Benjamin H L AU - Harris BHL AD - Department of Bioengineering, Faculty of Engineering, Imperial College London, London, UK. FAU - Fertleman, Michael AU - Fertleman M AD - Department of Bioengineering, Faculty of Engineering, Imperial College London, London, UK. FAU - Taylor, Graham P AU - Taylor GP AD - Department of Infectious Disease, Faculty of Medicine, Imperial College London, London, UK. AD - Imperial College NHS Trust, London, UK. FAU - Oliver, Nick AU - Oliver N AD - Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, London, UK. FAU - Sourij, Harald AU - Sourij H AD - Interdisciplinary Metabolic Medicine Trials Unit, Division of Endocrinology and Diabetology, Medical University of Graz, Austria. FAU - Dominguez-Villar, Margarita AU - Dominguez-Villar M AD - Department of Infectious Disease, Faculty of Medicine, Imperial College London, London, UK. LA - eng GR - DUK_/Diabetes UK/United Kingdom GR - Austrian Science Fund/ PT - Journal Article PL - Germany TA - Eur J Immunol JT - European journal of immunology JID - 1273201 RN - 130068-27-8 (Interleukin-10) RN - 0 (Interleukin-13) RN - 0 (COVID-19 Vaccines) RN - 0 (IL10 protein, human) RN - 0 (IL13 protein, human) SB - IM MH - Humans MH - *Diabetes Mellitus, Type 2/immunology MH - *Diabetes Mellitus, Type 1/immunology MH - *Interleukin-10/immunology/metabolism MH - *SARS-CoV-2/immunology MH - Female MH - Male MH - Middle Aged MH - *CD8-Positive T-Lymphocytes/immunology MH - *COVID-19/prevention & control/immunology MH - *Interleukin-13/immunology/metabolism MH - *COVID-19 Vaccines/immunology MH - Adult MH - *CD4-Positive T-Lymphocytes/immunology MH - Vaccination MH - Aged MH - Immunologic Memory PMC - PMC12690275 OTO - NOTNLM OT - SARS-CoV-2 OT - T cells OT - diabetes OT - memory OT - type 1 diabetes OT - vaccination COIS- The authors declare no conflicts of interest. EDAT- 2025/12/10 06:28 MHDA- 2025/12/10 06:29 PMCR- 2025/12/10 CRDT- 2025/12/10 03:03 PHST- 2025/11/20 00:00 [revised] PHST- 2025/05/08 00:00 [received] PHST- 2025/11/25 00:00 [accepted] PHST- 2025/12/10 06:29 [medline] PHST- 2025/12/10 06:28 [pubmed] PHST- 2025/12/10 03:03 [entrez] PHST- 2025/12/10 00:00 [pmc-release] AID - EJI70112 [pii] AID - 10.1002/eji.70112 [doi] PST - ppublish SO - Eur J Immunol. 2025 Dec;55(12):e70112. doi: 10.1002/eji.70112. PMID- 41347654 OWN - NLM STAT- MEDLINE DCOM- 20251205 LR - 20260616 IS - 1096-9071 (Electronic) IS - 0146-6615 (Linking) VI - 97 IP - 12 DP - 2025 Dec TI - Preconception COVID-19 Vaccination Reprograms Fetal Metabolism to Accelerate Intrauterine Recovery and Suppress Persistent Metabolic Memory. PG - e70740 LID - 10.1002/jmv.70740 [doi] AB - This study aimed to investigate the impact of preconception maternal inactivated COVID-19 vaccination on fetal metabolic recovery following maternal SARS-CoV-2 infection during pregnancy. Umbilical cord blood samples were collected from neonates born to mothers with SARS-CoV-2 infection during pregnancy. Mothers were stratified into two groups: those fully vaccinated (inactivated COVID-19 vaccines) before conception (n = 81) and unvaccinated (n = 56). Ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) was employed for metabolomic profiling. The vaccinated group exhibited markedly reduced amino acid/purine metabolism dysregulation and oxidative stress compared to unvaccinated counterparts. Crucially, within the critical IRT window of 5-6 months, vaccination effectively suppressed mTOR signaling-driven pathological metabolic remodeling. In contrast, the unvaccinated group demonstrated sustained metabolic disturbances (> 6 months from infection). In conclusion, preconception maternal inactivated COVID-19 vaccination reprograms fetal metabolism and accelerates intrauterine recovery from maternal SARS-CoV-2 infection, which may confer a beneficial impact on early-life growth. It prevents the establishment of a detrimental "metabolic memory" effect posing potential developmental risks. These findings reveal a novel non-immune, metabolome-mediated protective mechanism of maternal vaccination, which thus supports COVID-19 vaccination for women of childbearing age. CI - (c) 2025 Wiley Periodicals LLC. FAU - Huang, Roujie AU - Huang R AD - National Clinical Research Center for Obstetric & Gynecologic Diseases, Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. FAU - Xu, Jiyu AU - Xu J AD - State Key Laboratory of Common Mechanism Research for Major Diseases, Department of Biochemistry and Molecular Biology, Institute of Basic Medical Sciences Chinese Academy of Medical Sciences, School of Basic Medicine Peking Union Medical College, Beijing, China. FAU - Liu, Zimo AU - Liu Z AD - National Clinical Research Center for Obstetric & Gynecologic Diseases, Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. FAU - Sun, Tianshu AU - Sun T AD - Clinical Biobank, Medical Research Center, National Science and Technology Key Infrastructure on Translational Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. AD - The State Key Laboratory for Complex, Severe, and Rare Diseases, Peking Union Medical College Hospital, Beijing, China. FAU - Liu, Xudong AU - Liu X AD - The State Key Laboratory for Complex, Severe, and Rare Diseases, Peking Union Medical College Hospital, Beijing, China. AD - Laboratory Animal Research Facility, National Infrastructures for Translational Medicine, Institute of Clinical Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China. FAU - Guo, Jianbin AU - Guo J AD - Department of Gynaecology and Obstetrics, Shandong Key Laboratory of Reproductive Research and Birth Defect Prevention, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China. FAU - Zhang, Zhibo AU - Zhang Z AD - National Clinical Research Center for Obstetric & Gynecologic Diseases, Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. FAU - Yang, Hua AU - Yang H AD - National Clinical Research Center for Obstetric & Gynecologic Diseases, Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. FAU - Song, Yingna AU - Song Y AD - National Clinical Research Center for Obstetric & Gynecologic Diseases, Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. FAU - Liu, Jiangfeng AU - Liu J AD - State Key Laboratory of Common Mechanism Research for Major Diseases, Department of Biochemistry and Molecular Biology, Institute of Basic Medical Sciences Chinese Academy of Medical Sciences, School of Basic Medicine Peking Union Medical College, Beijing, China. FAU - Yang, Juntao AU - Yang J AUID- ORCID: 0000-0003-1180-391X AD - State Key Laboratory of Common Mechanism Research for Major Diseases, Department of Biochemistry and Molecular Biology, Institute of Basic Medical Sciences Chinese Academy of Medical Sciences, School of Basic Medicine Peking Union Medical College, Beijing, China. FAU - Zhu, Lan AU - Zhu L AD - National Clinical Research Center for Obstetric & Gynecologic Diseases, Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. AD - The State Key Laboratory for Complex, Severe, and Rare Diseases, Peking Union Medical College Hospital, Beijing, China. LA - eng GR - This study was supported by grants from the National Key Clinical Specialty Construction Project (U114000), the National Key R&D Program of China (2023YFC2507102), the Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences, China (CIFMS2021-I2M-1-044), the National High Level Hospital Clinical Research Funding (2022-PUMCH-C-060), the Beijing Natural Science Foundation (L232074), and the Special Foundation for Taishan Scholars Program of Shandong Province (tsqnz20240855)./ PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - J Med Virol JT - Journal of medical virology JID - 7705876 RN - 0 (COVID-19 Vaccines) SB - IM EIN - J Med Virol. 2026 Jun;98(6):e71017. doi: 10.1002/jmv.71017. PMID: 42299732 MH - Humans MH - Female MH - Pregnancy MH - *COVID-19/prevention & control/immunology/metabolism MH - *COVID-19 Vaccines/immunology/administration & dosage MH - Adult MH - Infant, Newborn MH - *Pregnancy Complications, Infectious/prevention & control/immunology/virology/metabolism MH - Fetal Blood/metabolism MH - *Fetus/metabolism MH - Vaccination MH - SARS-CoV-2/immunology MH - Metabolomics MH - Oxidative Stress MH - Metabolome OTO - NOTNLM OT - COVID-19 OT - cord blood OT - maternal vaccination OT - metabolomics OT - vaccine EDAT- 2025/12/05 13:08 MHDA- 2025/12/05 13:09 CRDT- 2025/12/05 07:03 PHST- 2025/10/18 00:00 [revised] PHST- 2025/08/11 00:00 [received] PHST- 2025/11/10 00:00 [accepted] PHST- 2025/12/05 13:09 [medline] PHST- 2025/12/05 13:08 [pubmed] PHST- 2025/12/05 07:03 [entrez] AID - 10.1002/jmv.70740 [doi] PST - ppublish SO - J Med Virol. 2025 Dec;97(12):e70740. doi: 10.1002/jmv.70740. PMID- 41319437 OWN - NLM STAT- MEDLINE DCOM- 20251211 LR - 20251211 IS - 1873-2518 (Electronic) IS - 0264-410X (Linking) VI - 70 DP - 2026 Jan 5 TI - Examining the independent and interactive roles of intolerance of uncertainty in vaccination intent. PG - 128008 LID - S0264-410X(25)01306-4 [pii] LID - 10.1016/j.vaccine.2025.128008 [doi] AB - Vaccine hesitancy remains common and sociopolitical anti-vaccine movements continue to gain ground in the United States and beyond. To inform more effective public health campaigns and increase vaccination intent, research is needed on how cognitive and emotional variables interact to influence vaccination intent. Intolerance of uncertainty (IU), defined as experiencing distress or discomfort in response to uncertain situations, is known to influence both approach and avoidance behaviors. IU may interact with other decision-making factors that impact vaccination intent, including people's actual knowledge about disease, perception of disease risk, and worry about vaccine safety. We recruited a community sample of Florida residents (N = 2152) for a longitudinal study spanning the first eight months of the COVID-19 pandemic and tested how COVID-specific IU (i.e., IU pertaining specifically to the disease) independently and interactively influenced vaccination intent. We found that higher COVID-IU early in the pandemic (May/June 2020) significantly predicted greater vaccination intent measured months later (December 2020/January 2021), even after controlling for relevant demographic variables, depression and anxiety symptoms, subjective risk, perceived vaccine safety, and disease knowledge. There was also a significant interaction between IU and knowledge, such that the effect of COVID-IU on vaccination intent was stronger for those with less disease knowledge. These findings suggest that disease specific IU can shape vaccination intent, independently and in interaction with disease knowledge. Our findings suggest that public health messaging seeking to increase vaccine uptake could benefit from emphasizing the distressing nature of the uncertainty inherent in contracting major diseases. CI - Copyright (c) 2025 Elsevier Ltd. All rights reserved. FAU - Dev, Amelia S AU - Dev AS AD - Department of Psychology, University of Miami, United States. Electronic address: ameliadev@miami.edu. FAU - Broos, Hannah C AU - Broos HC AD - Department of Psychology, University of Miami, United States. FAU - Llabre, Maria M AU - Llabre MM AD - Department of Psychology, University of Miami, United States. FAU - Saab, Patrice G AU - Saab PG AD - Department of Psychology, University of Miami, United States. FAU - Timpano, Kiara R AU - Timpano KR AD - Department of Psychology, University of Miami, United States. LA - eng PT - Journal Article DEP - 20251129 PL - Netherlands TA - Vaccine JT - Vaccine JID - 8406899 RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - Uncertainty MH - Female MH - Male MH - *COVID-19/prevention & control/psychology/epidemiology MH - Adult MH - Middle Aged MH - *Vaccination/psychology MH - *Vaccination Hesitancy/psychology MH - Longitudinal Studies MH - Florida/epidemiology MH - Health Knowledge, Attitudes, Practice MH - *COVID-19 Vaccines/administration & dosage MH - SARS-CoV-2/immunology MH - Young Adult MH - Aged MH - Intention MH - Decision Making MH - Adolescent OTO - NOTNLM OT - Cognition OT - Disease knowledge OT - Intolerance of uncertainty OT - Vaccine hesitancy OT - Vaccine intent COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2025/12/01 00:29 MHDA- 2025/12/12 01:38 CRDT- 2025/11/30 18:03 PHST- 2025/08/27 00:00 [received] PHST- 2025/11/17 00:00 [revised] PHST- 2025/11/17 00:00 [accepted] PHST- 2025/12/12 01:38 [medline] PHST- 2025/12/01 00:29 [pubmed] PHST- 2025/11/30 18:03 [entrez] AID - S0264-410X(25)01306-4 [pii] AID - 10.1016/j.vaccine.2025.128008 [doi] PST - ppublish SO - Vaccine. 2026 Jan 5;70:128008. doi: 10.1016/j.vaccine.2025.128008. Epub 2025 Nov 29. PMID- 41316388 OWN - NLM STAT- MEDLINE DCOM- 20251129 LR - 20260725 IS - 1479-5876 (Electronic) IS - 1479-5876 (Linking) VI - 23 IP - 1 DP - 2025 Nov 28 TI - Booster dose reshapes SARS-CoV-2 RBD-specific B cell immunity in people living with HIV. PG - 1364 LID - 10.1186/s12967-025-07414-1 [doi] LID - 1364 AB - BACKGROUND: Long-term persistence of spike-specific memory B cells (MBC) upon mRNA SARS-CoV-2 vaccination remains poorly explored in people living with HIV (PLWH). We previously observed that the primary two-dose immunization elicited a B cell response quantitatively similar but phenotypically different compared to healthy participants (HC), with higher prevalence of CD27(-)IgD(-) double-negative cells and lower proportion of CD27(+) Ig-switched MBC. METHODS: The PatoVac_COV longitudinal prospective single-centre study included 74 PLWH vaccinated with mRNA SARS-CoV-2 vaccines. Building upon our previous findings, blood samples were collected before and after the third and fourth doses, and two years after the first dose. PBMC were analysed for the RBD-specific MBC response by multidimensional flow cytometry, while spike-specific IgG were tested in plasma samples by ELISA and by surrogate virus neutralization assay. A supervised decision tree model was used to identify clinical and demographic predictors of RBD-specific MBC persistence. RESULTS: The third vaccine dose robustly recalled RBD-specific MBC, driving their differentiation into Ig-switched resting MBC, a subset undetectable before boosting and dominant also in HC. The fourth vaccine dose minimally impacted on the MBC response. IgG(+) resting MBC, recognizing both wild type and Omicron BA.2 strains, were still present two years after vaccination. Clinical and demographic factors associated to the persistence of IgG(+) resting RBD-specific MBC were time since initiation of current ART, BMI, CD8(+) cells count, granulocytes count and blood creatinine levels. CONCLUSIONS: These findings highlight the impact of boosting, particularly the third dose, in enhancing and shaping the RBD-specific MBC in PLWH. Clinical and demographic variables associated with long-term MBC persistence may serve as potential biomarkers for predicting durable vaccine responses in PLWH. CI - (c) 2025. The Author(s). FAU - Polvere, Jacopo AU - Polvere J AUID- ORCID: 0000-0002-8345-0546 AD - Laboratory of Molecular Microbiology and Biotechnology, Department of Medical Biotechnologies, University of Siena, Siena, Italy. FAU - Lucchesi, Simone AU - Lucchesi S AUID- ORCID: 0000-0003-3545-7433 AD - Laboratory of Molecular Microbiology and Biotechnology, Department of Medical Biotechnologies, University of Siena, Siena, Italy. FAU - Montesi, Giorgio AU - Montesi G AUID- ORCID: 0000-0002-9054-2756 AD - Laboratory of Molecular Microbiology and Biotechnology, Department of Medical Biotechnologies, University of Siena, Siena, Italy. FAU - Fiorino, Fabio AU - Fiorino F AUID- ORCID: 0000-0002-1440-8061 AD - Laboratory of Molecular Microbiology and Biotechnology, Department of Medical Biotechnologies, University of Siena, Siena, Italy. AD - Department of Medicine and Surgery, LUM University "Giuseppe Degennaro", Bari, Italy. FAU - Pastore, Gabiria AU - Pastore G AUID- ORCID: 0000-0002-3219-6170 AD - Laboratory of Molecular Microbiology and Biotechnology, Department of Medical Biotechnologies, University of Siena, Siena, Italy. FAU - Fabbiani, Massimiliano AU - Fabbiani M AUID- ORCID: 0000-0002-1343-812X AD - Department of Medical Sciences, Infectious and Tropical Diseases Unit, University Hospital of Siena, Siena, Italy. AD - Department of Medical Biotechnologies, University of Siena, Siena, Italy. FAU - Tumbarello, Mario AU - Tumbarello M AUID- ORCID: 0000-0002-9519-8552 AD - Department of Medical Sciences, Infectious and Tropical Diseases Unit, University Hospital of Siena, Siena, Italy. AD - Department of Medical Biotechnologies, University of Siena, Siena, Italy. FAU - Montagnani, Francesca AU - Montagnani F AUID- ORCID: 0000-0002-2267-1337 AD - Department of Medical Sciences, Infectious and Tropical Diseases Unit, University Hospital of Siena, Siena, Italy. francesca.montagnani@unisi.it. AD - Department of Medical Biotechnologies, University of Siena, Siena, Italy. francesca.montagnani@unisi.it. FAU - Medaglini, Donata AU - Medaglini D AUID- ORCID: 0000-0003-1729-7325 AD - Laboratory of Molecular Microbiology and Biotechnology, Department of Medical Biotechnologies, University of Siena, Siena, Italy. AD - Mycobacteriology and Cell Response to Infection Programme, Department of Cell Therapies, Hematology and Laboratory Medicine, University Hospital of Siena, Siena, Italy. FAU - Ciabattini, Annalisa AU - Ciabattini A AUID- ORCID: 0000-0002-4585-7783 AD - Laboratory of Molecular Microbiology and Biotechnology, Department of Medical Biotechnologies, University of Siena, Siena, Italy. annalisa.ciabattini@unisi.it. LA - eng GR - ECS00000017-THE/Ministero dell'Universita e della Ricerca/ PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20251128 PL - England TA - J Transl Med JT - Journal of translational medicine JID - 101190741 RN - 0 (COVID-19 Vaccines) RN - 0 (Spike Glycoprotein, Coronavirus) RN - 0 (Antibodies, Viral) RN - 0 (spike protein, SARS-CoV-2) RN - 0 (Immunoglobulin G) SB - IM MH - Humans MH - *HIV Infections/immunology/virology MH - *SARS-CoV-2/immunology MH - Male MH - Female MH - *COVID-19/immunology/prevention & control MH - Middle Aged MH - Adult MH - *Immunization, Secondary MH - *COVID-19 Vaccines/immunology/administration & dosage MH - *Spike Glycoprotein, Coronavirus/immunology MH - *B-Lymphocytes/immunology MH - Antibodies, Viral/immunology/blood MH - Longitudinal Studies MH - Prospective Studies MH - Memory B Cells/immunology MH - Immunoglobulin G/immunology/blood PMC - PMC12661889 OTO - NOTNLM OT - COVID-19 OT - DN OT - HIV OT - Memory B cells OT - Omicron-adapted vaccines OT - SARS-CoV-2 OT - mRNA vaccine COIS- Declarations. Ethics approval and consent to participate: The study was approved by the local Ethical Committee for Clinical experimentation (Comitato Etico Regione Toscana - Area Vasta Sud Est, CEAVSE) and written informed consent was obtained from each participant. Consent for publication: All authors have read and agreed to the submitted version of the manuscript. Competing interests: All the authors declare no conflict of interest regarding this study. EDAT- 2025/11/29 06:29 MHDA- 2025/11/29 06:30 PMCR- 2025/11/28 CRDT- 2025/11/29 00:57 PHST- 2025/08/30 00:00 [received] PHST- 2025/10/29 00:00 [accepted] PHST- 2025/11/29 06:30 [medline] PHST- 2025/11/29 06:29 [pubmed] PHST- 2025/11/29 00:57 [entrez] PHST- 2025/11/28 00:00 [pmc-release] AID - 10.1186/s12967-025-07414-1 [pii] AID - 7414 [pii] AID - 10.1186/s12967-025-07414-1 [doi] PST - epublish SO - J Transl Med. 2025 Nov 28;23(1):1364. doi: 10.1186/s12967-025-07414-1. PMID- 41306864 OWN - NLM STAT- MEDLINE DCOM- 20251127 LR - 20251129 IS - 2296-2565 (Electronic) IS - 2296-2565 (Linking) VI - 13 DP - 2025 TI - A systematic review on the psychological factors behind vaccine hesitancy in the COVID-19 era. PG - 1711428 LID - 10.3389/fpubh.2025.1711428 [doi] LID - 1711428 AB - BACKGROUND: Vaccine hesitancy may represent a global threat because of its inherent consequences for health, social and economic systems. Understanding the factors associated with vaccine hesitancy is fundamental to developing effective healthcare policies. While previous studies have mainly focused on sociological and cultural variables and transient illness-specific fears and beliefs, the present systematic review focuses on the psychological factors (such as emotional dispositions, cognitive functioning and expectations, and stable personality traits) associated with vaccine hesitancy during the COVID-19 era. METHODS: A systematic review using a systematic search of PubMed, PsychINFO and Web of Science databases was performed with a time frame ranging between 1 January 2020 to 31 January 2025 focusing on psychological factors and vaccine hesitancy. Studies targeting the general population and employing validated instruments to assess emotional, cognitive and personality factors and vaccine hesitancy were selected, while investigations on context-specific, psycho-social, cultural and political factors were excluded. Quality and risk of bias in the selected studies was assessed using an adapted version of the Newcastle-Ottawa Scale, and main studies' characteristics, variables and outcomes were synthesised using a narrative approach and table. RESULTS: Fourteen studies were finally included in the qualitative synthesis. The results showed that some variables such as depressive and anxiety levels, as well as emotion regulation strategies may affect vaccination behaviour, although some cultural and generational differences were also observed. Differences in cognitive flexibility, decision-making, and personal expectations may influence vaccine hesitancy. Notably, some personality factors, like extraversion, openness, conscientiousness and dark personality traits, may influence hesitancy to vaccinate. CONCLUSION: This review highlights emotional, cognitive, and personality factors associated with vaccine hesitancy, providing evidence for personalised, evidence-based interventions aimed at promoting adherence to national vaccination policies. CI - Copyright (c) 2025 Panico, De Biase, Catalano, Zappullo, D'Olimpio, Trojano and Sagliano. FAU - Panico, Francesco AU - Panico F AD - Department of Psychology, University of Campania "Luigi Vanvitelli", Caserta, Italy. FAU - De Biase, Rosalia AU - De Biase R AD - Department of Psychology, University of Campania "Luigi Vanvitelli", Caserta, Italy. FAU - Catalano, Laura AU - Catalano L AD - Department of Psychology, University of Campania "Luigi Vanvitelli", Caserta, Italy. FAU - Zappullo, Isa AU - Zappullo I AD - Department of Psychology, University of Campania "Luigi Vanvitelli", Caserta, Italy. FAU - D'Olimpio, Francesca AU - D'Olimpio F AD - Department of Psychology, University of Campania "Luigi Vanvitelli", Caserta, Italy. FAU - Trojano, Luigi AU - Trojano L AD - Department of Psychology, University of Campania "Luigi Vanvitelli", Caserta, Italy. FAU - Sagliano, Laura AU - Sagliano L AD - Department of Psychology, University of Campania "Luigi Vanvitelli", Caserta, Italy. LA - eng PT - Journal Article PT - Systematic Review DEP - 20251111 PL - Switzerland TA - Front Public Health JT - Frontiers in public health JID - 101616579 RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - *COVID-19/prevention & control/psychology MH - *Vaccination Hesitancy/psychology MH - *COVID-19 Vaccines/administration & dosage MH - SARS-CoV-2 MH - *Vaccination/psychology MH - Personality PMC - PMC12644076 OTO - NOTNLM OT - COVID-19 OT - cognition OT - emotion OT - health OT - intervention OT - personality OT - vaccine hesitancy COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision. EDAT- 2025/11/27 06:28 MHDA- 2025/11/27 12:28 PMCR- 2025/11/11 CRDT- 2025/11/27 04:34 PHST- 2025/09/23 00:00 [received] PHST- 2025/10/24 00:00 [accepted] PHST- 2025/11/27 12:28 [medline] PHST- 2025/11/27 06:28 [pubmed] PHST- 2025/11/27 04:34 [entrez] PHST- 2025/11/11 00:00 [pmc-release] AID - 10.3389/fpubh.2025.1711428 [doi] PST - epublish SO - Front Public Health. 2025 Nov 11;13:1711428. doi: 10.3389/fpubh.2025.1711428. eCollection 2025. PMID- 41258118 OWN - NLM STAT- MEDLINE DCOM- 20260213 LR - 20260216 IS - 1433-8491 (Electronic) IS - 0940-1334 (Print) IS - 0940-1334 (Linking) VI - 276 IP - 1 DP - 2026 Feb TI - Cognitive impairment, depression, and fatigue in post-COVID and post-vaccination syndrome: a large-scale cross-sectional study. PG - 221-234 LID - 10.1007/s00406-025-02144-3 [doi] AB - BACKGROUND: Persistent cognitive difficulties are among the most prevalent symptoms observed after COVID-19. This study examined the neuropsychological characteristics, mental health and risk factors associated with cognitive impairment in patients with Post-Acute Sequelae of COVID-19 (PASC). In addition, differences regarding the cognitive dysfunctions between individuals with PASC and Post-Vaccination Syndrome (PVS) were explored. METHODS: Participants were consecutively recruited at the Post-COVID Center of the University Hospital Erlangen in Germany (12/2022-02/2025). Assessments included a broad neuropsychological assessment: d2 Test of Attention, digit span backwards from the Wechsler Memory Scale-Revised (WMS-R) and module 1 (formal lexical fluency) of the Regensburger Verbal Fluency Test (RWT), along with assessments of depression, fatigue, and inflammatory markers (C-reactive protein). RESULTS: The sample (N = 793, mean age: 46.1 +/- 12.4 years; 66.8% women) included n = 723 PASC patients and n = 70 PVS patients. In the total sample, deficits were most frequent in working speed (61.7%), attention (54.7%) and verbal fluency (48.8%); 30.3% showed multidomain impairment. Clinically significant depressive symptoms (64.5%) and fatigue (92.4%) were common. Cognitive patterns, depressive symptoms and fatigue in the PVS group closely resembled those observed in PASC. In PASC, lower education, older age, depressive symptoms, and elevated CRP were associated with cognitive impairment. CONCLUSION: Cognitive impairment is highly prevalent in PASC and PVS and appears to be influenced by both psychological and biological factors. Similar patterns identified in PVS suggest possible shared mechanisms. Further research is needed to clarify trajectories and optimize treatment strategies. CI - (c) 2025. The Author(s). FAU - Hanc, Evelyne AU - Hanc E AUID- ORCID: 0009-0009-6008-9573 AD - Department of Psychosomatic Medicine and Psychotherapy, University Hospital of Erlangen, Friedrich-Alexander University Erlangen-Nurnberg (FAU), Schwabachanlage 6, 91054, Erlangen, Germany. evelyne.hanc@uk-erlangen.de. FAU - Koller, Katharina AU - Koller K AD - Department of Psychosomatic Medicine and Psychotherapy, University Hospital of Erlangen, Friedrich-Alexander University Erlangen-Nurnberg (FAU), Schwabachanlage 6, 91054, Erlangen, Germany. FAU - Herold, Regina AU - Herold R AD - Department of Psychosomatic Medicine and Psychotherapy, University Hospital of Erlangen, Friedrich-Alexander University Erlangen-Nurnberg (FAU), Schwabachanlage 6, 91054, Erlangen, Germany. FAU - Erim, Yesim AU - Erim Y AD - Department of Psychosomatic Medicine and Psychotherapy, University Hospital of Erlangen, Friedrich-Alexander University Erlangen-Nurnberg (FAU), Schwabachanlage 6, 91054, Erlangen, Germany. AD - Post-COVID Center of the University Hospital of Erlangen, Erlangen, Germany. FAU - Morawa, Eva AU - Morawa E AD - Department of Psychosomatic Medicine and Psychotherapy, University Hospital of Erlangen, Friedrich-Alexander University Erlangen-Nurnberg (FAU), Schwabachanlage 6, 91054, Erlangen, Germany. LA - eng PT - Journal Article DEP - 20251119 PL - Germany TA - Eur Arch Psychiatry Clin Neurosci JT - European archives of psychiatry and clinical neuroscience JID - 9103030 RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - Female MH - Male MH - Middle Aged MH - Adult MH - Cross-Sectional Studies MH - *Fatigue/epidemiology/etiology/physiopathology MH - *COVID-19/complications/epidemiology MH - *Cognitive Dysfunction/epidemiology/etiology/physiopathology MH - *Depression/epidemiology/etiology MH - Germany/epidemiology MH - Post-Acute COVID-19 Syndrome MH - Neuropsychological Tests MH - *COVID-19 Vaccines/adverse effects MH - *Vaccination/adverse effects PMC - PMC12904920 OTO - NOTNLM OT - Cognitive impairments OT - Depression OT - Fatigue OT - Neuropsychological assessment OT - Post-COVID syndrome OT - Post-Vaccination syndrome COIS- Declarations. Conflict of interest: The authors declare that they have no conflict of interest. Avaliability of data and materials: The datasets analyzed during the current study contain sensitive patient information and are therefore not publicly avaliable due to ethical and legal restrictions. Aggregate statistical results relevant to the study are provided within the article. EDAT- 2025/11/19 12:28 MHDA- 2026/02/13 12:50 PMCR- 2025/11/19 CRDT- 2025/11/19 09:12 PHST- 2025/07/14 00:00 [received] PHST- 2025/10/27 00:00 [accepted] PHST- 2026/02/13 12:50 [medline] PHST- 2025/11/19 12:28 [pubmed] PHST- 2025/11/19 09:12 [entrez] PHST- 2025/11/19 00:00 [pmc-release] AID - 10.1007/s00406-025-02144-3 [pii] AID - 2144 [pii] AID - 10.1007/s00406-025-02144-3 [doi] PST - ppublish SO - Eur Arch Psychiatry Clin Neurosci. 2026 Feb;276(1):221-234. doi: 10.1007/s00406-025-02144-3. Epub 2025 Nov 19. PMID- 41251472 OWN - NLM STAT- MEDLINE DCOM- 20251223 LR - 20260127 IS - 2379-5042 (Electronic) IS - 2379-5042 (Linking) VI - 10 IP - 12 DP - 2025 Dec 23 TI - T and B cell responses following primary COVID-19 vaccination with CoronaVac and two heterologous BNT162b2 booster doses. PG - e0072225 LID - 10.1128/msphere.00722-25 [doi] LID - e00722-25 AB - The present study investigated T and B cell responses following a second heterologous booster dose of BNT162b2 administered after a two-dose CoronaVac regimen for coronavirus disease 2019 (COVID-19) vaccination in 15 healthcare workers. Blood samples were collected 4 weeks after the first booster and at both 4 and 24 weeks after the second BNT162b2 booster. Interferon-gamma-secreting CD4+ and CD8+ T cells were detectable 4 weeks after the first booster, whereas only CD4+ T cells remained detectable at both 4 and 24 weeks after the second booster. Seven of the 15 participants (46.7%) were diagnosed with COVID-19 approximately 16 weeks after receiving the second booster. These individuals exhibited significantly higher frequencies of CD4+ T cells at 24 weeks post-booster than at 4 weeks post-booster. In contrast, the non-COVID-19 group exhibited significantly higher CD4+ T cell responses 4 weeks after the second booster. Memory B cells were detected at low frequencies at all three time points. IgG antibodies against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein were detectable at all three time points, with a significant decline observed 24 weeks after the second booster. Overall, CD4+ T and B cell responses induced by a heterologous second booster dose of BNT162b2 following a primary two-dose CoronaVac regimen were rapidly elicited and sustained for at least 6 months.IMPORTANCEThere is limited evidence regarding T and B cell responses following a primary COVID-19 vaccination series with CoronaVac and two heterologous BNT162b2 booster doses. This study investigated the longitudinal T and B cell responses induced by a second heterologous BNT162b2 booster following a primary two-dose CoronaVac COVID-19 vaccination regimen. These results demonstrate that CD4+ T cells induced by the second heterologous BNT162b2 booster play a key role in protection against SARS-CoV-2 infection and progression to severe disease. This study suggests the need for the future consideration of repeated emergency vaccine-boosting strategies in response to emerging viral infections. FAU - Wangteeraprasert, Apirath AU - Wangteeraprasert A AD - Division of Immunology, Department of Internal Medicine, Faculty of Medicine, Naresuan University, Phitsanulok, Thailand. RINGGOLD: 59212. ROR: https://ror.org/03e2qe334 FAU - Pongcharoen, Sutatip AU - Pongcharoen S AD - Division of Immunology, Department of Internal Medicine, Faculty of Medicine, Naresuan University, Phitsanulok, Thailand. RINGGOLD: 59212. ROR: https://ror.org/03e2qe334 FAU - Ngoenkam, Jatuporn AU - Ngoenkam J AD - Department of Microbiology and Parasitology, Faculty of Medical Science, Naresuan University, Phitsanulok, Thailand. RINGGOLD: 59212. ROR: https://ror.org/03e2qe334 FAU - Makanut, Supawadee AU - Makanut S AUID- ORCID: 0000-0002-2708-5863 AD - Division of Pulmonology, Department of Internal Medicine, Faculty of Medicine, Naresuan University, Phitsanulok, Thailand. RINGGOLD: 59212. ROR: https://ror.org/03e2qe334 LA - eng GR - L60 MD002565/MD/NIMHD NIH HHS/United States GR - MD2565C004/Naresuan University/ GR - R2565B001, R2566B001/Thailand Science Research and Innovation/ PT - Journal Article DEP - 20251118 PL - United States TA - mSphere JT - mSphere JID - 101674533 RN - 0 (BNT162 Vaccine) RN - 0 (COVID-19 Vaccines) RN - 0 (Antibodies, Viral) RN - 0 (Immunoglobulin G) RN - 82115-62-6 (Interferon-gamma) RN - 0 (sinovac COVID-19 vaccine) RN - 0 (Vaccines, Inactivated) SB - IM MH - Humans MH - BNT162 Vaccine/immunology MH - *Immunization, Secondary MH - *COVID-19/prevention & control/immunology MH - Male MH - Female MH - Adult MH - *SARS-CoV-2/immunology MH - *COVID-19 Vaccines/immunology/administration & dosage MH - CD4-Positive T-Lymphocytes/immunology MH - *B-Lymphocytes/immunology MH - Antibodies, Viral/blood/immunology MH - Middle Aged MH - CD8-Positive T-Lymphocytes/immunology MH - Vaccination MH - Immunoglobulin G/blood MH - Health Personnel MH - Interferon-gamma MH - Vaccines, Inactivated PMC - PMC12724281 OTO - NOTNLM OT - CD4+ T cell OT - CD8+ T cell OT - COVID-19 vaccines OT - memory B cell OT - memory T cell COIS- The authors declare no conflict of interest. EDAT- 2025/11/18 12:28 MHDA- 2025/12/23 12:47 PMCR- 2025/11/18 CRDT- 2025/11/18 09:04 PHST- 2025/12/23 12:47 [medline] PHST- 2025/11/18 12:28 [pubmed] PHST- 2025/11/18 09:04 [entrez] PHST- 2025/11/18 00:00 [pmc-release] AID - msphere00722-25 [pii] AID - msphere.00722-25 [pii] AID - 10.1128/msphere.00722-25 [doi] PST - ppublish SO - mSphere. 2025 Dec 23;10(12):e0072225. doi: 10.1128/msphere.00722-25. Epub 2025 Nov 18. PMID- 41180683 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251230 LR - 20260917 IS - 2049-0801 (Print) IS - 2049-0801 (Electronic) IS - 2049-0801 (Linking) VI - 87 IP - 11 DP - 2025 Nov TI - Neurological manifestations of COVID-19 and its vaccines: an updated comprehensive review with an insight into pathophysiology. PG - 7390-7399 LID - 10.1097/MS9.0000000000003931 [doi] AB - The COVID-19 pandemic caused by SARS-CoV-2 has had a significant global impact on the respiratory system and multiple organ systems, including the nervous system. Neurological manifestations associated with COVID-19 infection and its vaccines have been increasingly recognized, ranging from problems with smell and taste to more severe conditions such as encephalitis, stroke, and Guillain-Barre syndrome. This narrative review critically evaluates the neurological manifestations of COVID-19 infection and its vaccines, providing insights into potential pathophysiological mechanisms. A comprehensive literature search was conducted, and data were retrieved from various databases. The prevalence, types, and severity of neurological symptoms in COVID-19 patients were discussed. The possible mechanisms of neurological injury in COVID-19 were explored, including direct viral invasion, hypoxic brain injury, immune-mediated damage, and cerebrovascular injury. Furthermore, the review addressed the neurological complications associated with COVID-19 vaccination. While severe vaccine-related adverse effects remain rare, understanding their occurrence is essential for risk assessment and public health interventions. In conclusion, COVID-19 can affect the nervous system in various ways, leading to various neurological symptoms. Further research is necessary to enhance our understanding of these manifestations and develop effective preventive and treatment strategies to manage this global health crisis. CI - Copyright (c) 2025 The Author(s). Published by Wolters Kluwer Health, Inc. FAU - Abbasher Hussien Mohamed Ahmed, Khabab AU - Abbasher Hussien Mohamed Ahmed K AUID- ORCID: 0000-0003-4608-5321 AD - Faculty of Medicine, University of Khartoum, Khartoum, Sudan. FAU - Kalool Fadlalla Ahmad, Tagwa AU - Kalool Fadlalla Ahmad T AD - Faculty of Medicine, Ahfad University for Women, Omdurman, Sudan. FAU - Ismail Abdu Ismail, Mohamed AU - Ismail Abdu Ismail M AD - Faculty of Medicine, Sudan International University, Khartoum, Sudan. FAU - Elgadi, Ammar T AU - Elgadi AT AUID- ORCID: 0000-0003-1730-9023 AD - Faculty of Medicine, University of Khartoum, Khartoum, Sudan. FAU - Hassan Salih Elhaj, Esraa AU - Hassan Salih Elhaj E AUID- ORCID: 0000-0001-9363-9230 AD - Faculty of Medicine, University of Khartoum, Khartoum, Sudan. FAU - Mustafa Ahmed, Ghassan E AU - Mustafa Ahmed GE AUID- ORCID: 0000-0002-0258-6282 AD - Faculty of Medicine, University of Khartoum, Khartoum, Sudan. FAU - Khan, Faheemullah AU - Khan F AD - Cardiovascular Imaging Fellow, Diagnostic Institute, Cleveland Clinic, Main Campus, Ohio, USA. FAU - Mohammed, Mohammed Babiker Habbiballah AU - Mohammed MBH AD - Faculty of Medicine, University of Khartoum, Khartoum, Sudan. FAU - Manhal, Gaffar Alemam A AU - Manhal GAA AUID- ORCID: 0000-0001-7939-0117 AD - Faculty of Medicine, University of Khartoum, Khartoum, Sudan. FAU - Daffalla Mussaad Mohammed, Ahmed AU - Daffalla Mussaad Mohammed A AD - Faculty of Medicine, University of Khartoum, Khartoum, Sudan. FAU - Ali, Mustafa Mohamed Ibrahim AU - Ali MMI AUID- ORCID: 0009-0001-3870-2791 AD - Faculty of Medicine, University of Khartoum, Khartoum, Sudan. FAU - Abdullah Mohammed, Mohammed Elmustafa Adil AU - Abdullah Mohammed MEA AD - Faculty of Medicine, University of Khartoum, Khartoum, Sudan. FAU - Meshref, Mostafa AU - Meshref M AD - Department of Neurology, Faculty of Medicine, Al-Azhar University, Cairo, Egypt. FAU - Hussien, Abbasher AU - Hussien A AD - Faculty of Medicine, University of Khartoum, Khartoum, Sudan. LA - eng PT - Journal Article PT - Review DEP - 20250918 PL - England TA - Ann Med Surg (Lond) JT - Annals of medicine and surgery (2012) JID - 101616869 PMC - PMC12577873 OTO - NOTNLM OT - COVID-19 OT - COVID-19 pathophysiology OT - SARS-coV-2 OT - neurological manifestations OT - vaccination COIS- Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article. The authors have no conflict of interest to declare. EDAT- 2025/11/03 13:42 MHDA- 2025/11/03 13:43 PMCR- 2025/09/18 CRDT- 2025/11/03 07:12 PHST- 2024/12/24 00:00 [received] PHST- 2025/09/09 00:00 [accepted] PHST- 2025/11/03 13:42 [pubmed] PHST- 2025/11/03 13:43 [medline] PHST- 2025/11/03 07:12 [entrez] PHST- 2025/09/18 00:00 [pmc-release] AID - AMSU-D-24-02716 [pii] AID - 10.1097/MS9.0000000000003931 [doi] PST - epublish SO - Ann Med Surg (Lond). 2025 Sep 18;87(11):7390-7399. doi: 10.1097/MS9.0000000000003931. eCollection 2025 Nov. PMID- 41179613 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251103 LR - 20260925 IS - 2050-0904 (Print) IS - 2050-0904 (Electronic) IS - 2050-0904 (Linking) VI - 13 IP - 11 DP - 2025 Nov TI - Parsonage-Turner Syndrome and Vocal Fold Paresis Following Soberana 2 FINLAY-FR-2 COVID-19 Vaccination: A Case Report. PG - e71348 LID - 10.1002/ccr3.71348 [doi] LID - e71348 AB - This case report presents a 58-year-old male who developed Parsonage-Turner syndrome (PTS) and vocal cord paresis after receiving the Soberana 2 FINLAY-FR-2 COVID-19 vaccine. The patient experienced escalating pain and weakness in both shoulders and upper limbs after each vaccine dose, with subsequent neurological symptoms including headaches, dysphagia, hoarseness, numbness, dyspnea, and chest discomfort. Neurological examinations and electrodiagnostic studies confirmed upper trunk brachial plexopathy along with vocal fold paresis. This patient was treated with intravenous methylprednisolone. Despite therapeutic intervention, the patient exhibited persistent neurological deficits during follow-up. CI - (c) 2025 The Author(s). Clinical Case Reports published by John Wiley & Sons Ltd. FAU - Bordbari, Amir-Hassan AU - Bordbari AH AD - Student Research Committee, School of Medicine Mazandaran University of Medical Sciences Sari Iran. FAU - Heidari, Negar AU - Heidari N AD - Department of Neurology, Clinical Research Development Unit of Bou Ali Sina Hospital Mazandaran University of Medical Sciences Sari Iran. FAU - Karimi, Narges AU - Karimi N AUID- ORCID: 0000-0001-5912-3732 AD - Department of Neurology, School of Medicine, Immunogenetics Research Center, Clinical Research Development Unit of Bou Ali Sina Hospital Mazandaran University of Medical Sciences Sari Iran. LA - eng PT - Journal Article DEP - 20251031 PL - England TA - Clin Case Rep JT - Clinical case reports JID - 101620385 PMC - PMC12578595 OTO - NOTNLM OT - COVID-19 vaccines OT - Parsonage-Turner syndrome OT - brachial plexus neuritis OT - vocal fold paralysis COIS- The authors declare no conflicts of interest. EDAT- 2025/11/03 13:42 MHDA- 2025/11/03 13:43 PMCR- 2025/10/31 CRDT- 2025/11/03 06:59 PHST- 2024/09/23 00:00 [received] PHST- 2025/10/03 00:00 [revised] PHST- 2025/10/14 00:00 [accepted] PHST- 2025/11/03 13:43 [medline] PHST- 2025/11/03 13:42 [pubmed] PHST- 2025/11/03 06:59 [entrez] PHST- 2025/10/31 00:00 [pmc-release] AID - CCR371348 [pii] AID - 10.1002/ccr3.71348 [doi] PST - epublish SO - Clin Case Rep. 2025 Oct 31;13(11):e71348. doi: 10.1002/ccr3.71348. eCollection 2025 Nov. PMID- 41173090 OWN - NLM STAT- Publisher LR - 20260208 IS - 1527-5418 (Electronic) IS - 0890-8567 (Print) IS - 0890-8567 (Linking) DP - 2025 Oct 30 TI - Systematic Review and Meta-Analysis: The Associations of Prenatal Exposure to SARS-CoV-2 Infection and COVID-19 Vaccination With Child Neurodevelopment. LID - S0890-8567(25)02151-3 [pii] LID - 10.1016/j.jaac.2025.10.018 [doi] AB - OBJECTIVE: To systematically review and meta-analyze evidence on the associations between prenatal exposure to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection or COVID-19 vaccination and child neurodevelopmental outcomes. METHOD: MEDLINE, EMBASE, PsycINFO, Web of Science, Scopus, and Cochrane CENTRAL databases were searched for original research on neurodevelopmental outcomes in children prenatally exposed to SARS-CoV-2 infection and COVID-19 vaccination published in any language before November 8, 2024. Meta-analyses were performed on any outcome reported in >/=3 controlled studies. RESULTS: A total of 70 studies were identified on neurological (7), neuroimaging (12), motor (3), audiological (29), and neurodevelopmental (35) assessments and neurodevelopmental disorders (2) with median sample sizes of 117 (interquartile range: 44-340) and follow-up /= 60 years (p = 0.02744) and comorbidities (p = 0.000002). CONCLUSION: Neurological adverse events after COVID-19 immunisation were frequent and benign among spontaneous notifications. Headache was the most common neurological adverse effect of COVID-19 vaccines. Serious side effects were more frequent in the elderly and people with comorbidities. CI - (c) 2025. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Dabilgou, Alfred Anselme AU - Dabilgou AA AD - Department of Neurology, Yalgado Ouedraogo University Hospital, Ouagadougou, Burkina Faso. dabilgouanselm@yahoo.fr. FAU - Ouedraogo, Emile Wendni AU - Ouedraogo EW AD - Laboratory for Medical Development, University Joseph KI-ZERBO, Ouagadougou, Burkina Faso. FAU - Kyelem, Julie Marie Adeline Wendlamita AU - Kyelem JMAW AD - Department of Neurology, Yalgado Ouedraogo University Hospital, Ouagadougou, Burkina Faso. FAU - Drave, Alassane AU - Drave A AD - Department of Neurology, Regional University Hospital of Ouahigouya, Ouahigouya, Burkina Faso. FAU - Wanre, Ousmane AU - Wanre O AD - Department of Neurology, Yalgado Ouedraogo University Hospital, Ouagadougou, Burkina Faso. FAU - Napon, Christain AU - Napon C AD - Department of Neurology, University Hospital of Bogodogo, Ouagadougou, Burkina Faso. FAU - Millogo, Athanase AU - Millogo A AD - Department of Neurology, University Hospital Sourou Sanou, Bobo-Dioulasso, Burkina Faso. LA - eng PT - Journal Article DEP - 20251013 PL - United States TA - J Neuroimmune Pharmacol JT - Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology JID - 101256586 RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - Male MH - Female MH - Cross-Sectional Studies MH - Adult MH - Middle Aged MH - *Pharmacovigilance MH - *COVID-19 Vaccines/adverse effects MH - Burkina Faso/epidemiology MH - Young Adult MH - *Nervous System Diseases/epidemiology/chemically induced MH - *COVID-19/prevention & control/epidemiology MH - Aged MH - Databases, Factual/trends MH - Adolescent MH - *Vaccination/adverse effects MH - Child OTO - NOTNLM OT - Burkina Faso OT - Covid-19 vaccines OT - Headaches OT - Neurological manifestations OT - Pharmacovigilance COIS- Declarations. Ethical Approval: We had the permission of the Ethics Board of the School of the University Joseph KI-ZERBO and of the Director of the National Department of Pharmacovigilance in Burkina Faso. The study was conducted in accordance with the Declaration of Helsinki. Human Ethics and Consent to Participate: Not applicable. Consent to Participate: Not applicable. Publication Consent of the Participants: Not applicable. Consent for Publication: All authors of the manuscript have read and agreed on its content and are responsible for all aspects of the accuracy and integrity of the manuscript in accordance with the ICMJE criteria. Conflict of interest: The authors declare no competing interests. Conflicts of interest/Competing interests: All authors certify that they have no affiliations with or involvement in any organisation or entity with any financial interest or non-financial interest in the subject matter or materials discussed in this manuscript. EDAT- 2025/10/13 12:30 MHDA- 2025/10/13 12:31 CRDT- 2025/10/13 11:22 PHST- 2024/07/24 00:00 [received] PHST- 2025/09/03 00:00 [accepted] PHST- 2025/10/13 12:31 [medline] PHST- 2025/10/13 12:30 [pubmed] PHST- 2025/10/13 11:22 [entrez] AID - 10.1007/s11481-025-10249-8 [pii] AID - 10.1007/s11481-025-10249-8 [doi] PST - epublish SO - J Neuroimmune Pharmacol. 2025 Oct 13;20(1):89. doi: 10.1007/s11481-025-10249-8. PMID- 41080595 OWN - NLM STAT- MEDLINE DCOM- 20251013 LR - 20251015 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 16 DP - 2025 TI - Impact of chemotherapy on humoral and cellular immune responses to COVID-19 vaccination in patients with solid tumors. PG - 1664072 LID - 10.3389/fimmu.2025.1664072 [doi] LID - 1664072 AB - INTRODUCTION: Despite SARS-CoV-2 pandemic has subsided, vaccine response profiling in patients with cancer remains critical. METHODS: We longitudinally assessed humoral and cellular immunity in adults with solid tumours treated with chemotherapy (ChT) or non-ChT regimens after two mRNA vaccine doses plus booster, compared with vaccinated cancer-free controls, naturally infected (convalescent) subjects including both patients with cancer and cancer-free individuals, and unvaccinated/uninfected individuals with or without cancer as a baseline reference. RESULTS: Anti-Spike IgG titres matched cancer-free controls, but anti-RBD titres and neutralising activity were consistently lower in cancer post-vaccination, most markedly with ChT, and declined faster over 4-6 months. Boosters restored IgG, yet gains were smaller in ChT recipients. Cellular analyses revealed sustained and booster-enhanced Spike-specific B cells in all groups; however, ChT exposure was associated with reduced CD27 expression on these cells, suggesting impaired activation and memory maturation. DISCUSSION: These findings support tailored immune monitoring and vaccination strategies in oncology and identify CD27 downregulation as a novel B-cell dysfunction detected by high-dimensional immunophenotyping. CI - Copyright (c) 2025 Favalli, Patelli, Gruarin, Gobbini, Pesce, Mariano, Bombaci, Vincenti, Donnici, Marchese, Piscazzi, Amatu, Tosi, Ghezzi, Pani, Principato, Lombardi, Bandera, Abrignani, Siena, Sartore-Bianchi and Grifantini. FAU - Favalli, Andrea AU - Favalli A AD - INGM, Istituto Nazionale Genetica Molecolare "Romeo ed Enrica Invernizzi", Milan, Italy. FAU - Patelli, Giorgio AU - Patelli G AD - Department of Oncology and Hemato-Oncology, Universita degli Studi di Milano, Milan, Italy. AD - ⁠Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy. FAU - Gruarin, Paola AU - Gruarin P AD - INGM, Istituto Nazionale Genetica Molecolare "Romeo ed Enrica Invernizzi", Milan, Italy. FAU - Gobbini, Andrea AU - Gobbini A AD - INGM, Istituto Nazionale Genetica Molecolare "Romeo ed Enrica Invernizzi", Milan, Italy. FAU - Pesce, Elisa AU - Pesce E AD - INGM, Istituto Nazionale Genetica Molecolare "Romeo ed Enrica Invernizzi", Milan, Italy. AD - Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy. FAU - Mariano, Sara AU - Mariano S AD - ⁠Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy. FAU - Bombaci, Mauro AU - Bombaci M AD - INGM, Istituto Nazionale Genetica Molecolare "Romeo ed Enrica Invernizzi", Milan, Italy. FAU - Vincenti, Francesca AU - Vincenti F AD - INGM, Istituto Nazionale Genetica Molecolare "Romeo ed Enrica Invernizzi", Milan, Italy. FAU - Donnici, Lorena AU - Donnici L AD - INGM, Istituto Nazionale Genetica Molecolare "Romeo ed Enrica Invernizzi", Milan, Italy. FAU - Marchese, Silvia AU - Marchese S AD - INGM, Istituto Nazionale Genetica Molecolare "Romeo ed Enrica Invernizzi", Milan, Italy. AD - DiSFeB Dipartimento di scienze farmacologiche e biomolecolari, Universita degli studi di Milano, Milan, Italy. FAU - Piscazzi, Daniele AU - Piscazzi D AD - Department of Oncology and Hemato-Oncology, Universita degli Studi di Milano, Milan, Italy. AD - ⁠Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy. FAU - Amatu, Alessio AU - Amatu A AD - ⁠Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy. FAU - Tosi, Federica AU - Tosi F AD - ⁠Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy. FAU - Ghezzi, Silvia AU - Ghezzi S AD - ⁠Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy. FAU - Pani, Arianna AU - Pani A AD - Department of Oncology and Hemato-Oncology, Universita degli Studi di Milano, Milan, Italy. FAU - Principato, Silvia AU - Principato S AD - INGM, Istituto Nazionale Genetica Molecolare "Romeo ed Enrica Invernizzi", Milan, Italy. FAU - Lombardi, Andrea AU - Lombardi A AD - Infectious Diseases Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. AD - Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy. FAU - Bandera, Alessandra AU - Bandera A AD - Infectious Diseases Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. AD - Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy. FAU - Abrignani, Sergio AU - Abrignani S AD - INGM, Istituto Nazionale Genetica Molecolare "Romeo ed Enrica Invernizzi", Milan, Italy. AD - Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy. FAU - Siena, Salvatore AU - Siena S AD - Department of Oncology and Hemato-Oncology, Universita degli Studi di Milano, Milan, Italy. AD - ⁠Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy. FAU - Sartore-Bianchi, Andrea AU - Sartore-Bianchi A AD - Department of Oncology and Hemato-Oncology, Universita degli Studi di Milano, Milan, Italy. AD - ⁠Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy. FAU - Grifantini, Renata AU - Grifantini R AD - INGM, Istituto Nazionale Genetica Molecolare "Romeo ed Enrica Invernizzi", Milan, Italy. AD - CheckmAb Srl, Milan, Italy. LA - eng PT - Journal Article DEP - 20250925 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 RN - 0 (COVID-19 Vaccines) RN - 0 (Antibodies, Viral) RN - 0 (Spike Glycoprotein, Coronavirus) RN - 0 (Tumor Necrosis Factor Receptor Superfamily, Member 7) RN - 0 (Immunoglobulin G) RN - 0 (Antineoplastic Agents) RN - 0 (spike protein, SARS-CoV-2) RN - 0 (Antibodies, Neutralizing) SB - IM MH - Humans MH - *Neoplasms/drug therapy/immunology MH - *COVID-19/prevention & control/immunology MH - Middle Aged MH - *SARS-CoV-2/immunology MH - Female MH - Male MH - *COVID-19 Vaccines/immunology/administration & dosage MH - *Immunity, Humoral/drug effects MH - *Immunity, Cellular/drug effects MH - Aged MH - Antibodies, Viral/blood/immunology MH - Adult MH - Vaccination MH - Spike Glycoprotein, Coronavirus/immunology MH - B-Lymphocytes/immunology MH - Tumor Necrosis Factor Receptor Superfamily, Member 7/metabolism MH - Immunoglobulin G/blood/immunology MH - *Antineoplastic Agents/therapeutic use MH - Immunization, Secondary MH - Antibodies, Neutralizing/blood/immunology PMC - PMC12507793 OTO - NOTNLM OT - SARS-CoV-2 OT - high-dimensional OT - memory B cells OT - seroconversion OT - solid tumors OT - unbiased immunophenotyping OT - vaccinations COIS- RG is currently employed by CheckmAb Srl. AS-B participates to advisory boards for Amgen, Bayer, Pierre-Fabre, Servier, Takeda. SS is an advisory board member for Agenus, AstraZeneca, Bayer, Bristol Myers Squibb, CheckmAb, Daiichi-Sankyo, GlaxoSmithKline, MSD, Merck, Novartis, Pierre-Fabre, Pfizer, Seagen, and T-One Therapeutics. SA is a cofounder of the startup CheckMab s.r.l. and T-One Therapeutics s.r.l. AA has an advisory role for Amgen, Italfarmaco, Merck Serono. SP is currently employed by GlaxoSmithKline. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. RG declares that she was an Review Editor for Translational Medicine in Frontiers at the time of submission. This had no impact on the peer review process and final decision. EDAT- 2025/10/13 12:31 MHDA- 2025/10/13 12:32 PMCR- 2025/09/25 CRDT- 2025/10/13 07:36 PHST- 2025/07/11 00:00 [received] PHST- 2025/08/26 00:00 [accepted] PHST- 2025/10/13 12:32 [medline] PHST- 2025/10/13 12:31 [pubmed] PHST- 2025/10/13 07:36 [entrez] PHST- 2025/09/25 00:00 [pmc-release] AID - 10.3389/fimmu.2025.1664072 [doi] PST - epublish SO - Front Immunol. 2025 Sep 25;16:1664072. doi: 10.3389/fimmu.2025.1664072. eCollection 2025. PMID- 41076807 OWN - NLM STAT- MEDLINE DCOM- 20251101 LR - 20251101 IS - 1873-2518 (Electronic) IS - 0264-410X (Linking) VI - 66 DP - 2025 Nov 14 TI - Differentiating COVID-19 vaccine-related adverse events from long COVID: A comprehensive review of clinical manifestations, pathophysiology, and diagnostic approaches. PG - 127842 LID - S0264-410X(25)01139-9 [pii] LID - 10.1016/j.vaccine.2025.127842 [doi] AB - The global deployment of COVID-19 vaccines has introduced diagnostic challenges due to overlapping symptoms with long COVID, or post-acute sequelae of SARS-CoV-2 infection (PASC), prompting a comprehensive review of vaccine safety profiles, long COVID manifestations, and evidence-based differentiation strategies. Through a literature search (PubMed, Scopus, Web of Science) from December 2020 to June 2025, including peer-reviewed studies, clinical trials, and cohort studies, the present review reports that COVID-19 vaccines maintain robust safety, with rare adverse events like myocarditis and thrombosis with thrombocytopenia syndrome, while long COVID affects 10-40 % of SARS-CoV-2 survivors, presenting symptoms such as fatigue, cognitive dysfunction, and dyspnea. Differentiation between these conditions relies on careful analysis of the timing of symptom onset, detailed symptom characterization, and the use of advanced diagnostic tools. Systematic clinical assessment is essential for accurate diagnosis, which is critical for appropriate patient management, maintaining public confidence in vaccination, and guiding future research. Further studies are needed to validate diagnostic biomarkers, develop targeted therapies, and monitor long-term outcomes, with standardized global registries and interdisciplinary collaboration identified as key priorities for improving care and advancing the field. CI - Copyright (c) 2025 The Author(s). Published by Elsevier Ltd.. All rights reserved. FAU - Domingo, Jose L AU - Domingo JL AD - Universitat Rovira i Virgili, School of Medicine, Laboratory of Toxicology and Environmental Health, San Llorens 21, 43201 Reus, Catalonia, Spain.. Electronic address: joseluis.domingo@urv.cat. LA - eng PT - Journal Article PT - Review DEP - 20251011 PL - Netherlands TA - Vaccine JT - Vaccine JID - 8406899 RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - *COVID-19 Vaccines/adverse effects/administration & dosage MH - *COVID-19/prevention & control/diagnosis/immunology MH - SARS-CoV-2/immunology MH - Post-Acute COVID-19 Syndrome MH - Vaccination/adverse effects OTO - NOTNLM OT - COVID-19 vaccines OT - adverse events OT - differential diagnosis OT - long COVID OT - vaccine safety COIS- Declaration of competing interest The author declares that he has no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2025/10/13 00:27 MHDA- 2025/11/02 00:33 CRDT- 2025/10/12 18:04 PHST- 2025/07/02 00:00 [received] PHST- 2025/08/10 00:00 [revised] PHST- 2025/10/04 00:00 [accepted] PHST- 2025/11/02 00:33 [medline] PHST- 2025/10/13 00:27 [pubmed] PHST- 2025/10/12 18:04 [entrez] AID - S0264-410X(25)01139-9 [pii] AID - 10.1016/j.vaccine.2025.127842 [doi] PST - ppublish SO - Vaccine. 2025 Nov 14;66:127842. doi: 10.1016/j.vaccine.2025.127842. Epub 2025 Oct 11. PMID- 41013180 OWN - NLM STAT- MEDLINE DCOM- 20250927 LR - 20260904 IS - 1528-3658 (Electronic) IS - 1076-1551 (Print) IS - 1076-1551 (Linking) VI - 31 IP - 1 DP - 2025 Sep 26 TI - Immunogenicity and memory B-cell potency induced by an inactivated COVID-19 vaccine in pregnant women. PG - 297 LID - 10.1186/s10020-025-01357-5 [doi] LID - 297 AB - During pregnancy, profound immunological, hormonal, and metabolic adaptations occur to support fetal development. The impact of pregnancy on vaccine-induced immunity remains incompletely characterized, as previous studies have primarily focused on serological antibody levels but not immune memory. Immune memory is critical for vaccine effectiveness, but effect of pregnancy on immune memory remain unknown. In addition, the memory B cell response profile induced by inactivated coronavirus disease 2019 (COVID-19) vaccines in pregnant women remains unclear. This study comprehensively investigated the serological responses and memory B cell response induced by an inactivated COVID-19 vaccine in pregnant women. The results demonstrated that while pregnant women and non-pregnant women of childbearing age showed comparable serological antibody levels, vaccine-induced monoclonal antibodies (mAbs) from pregnant women exhibited significantly lower binding potency to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein and its segments and weaker neutralizing potency and breadth than those from non-pregnant women. Vaccine-induced mAbs from pregnant women were derived predominantly from IGHV3-30, whereas those from non-pregnant women were derived diverse germline genes. Most of mAbs from pregnant women targeted the receptor-binding domain (RBD) (40.9%) and S2 domain (31.8%), whereas most of mAbs from non-pregnant women targeted the RBD (51.3%) and N-terminal domain (30.8%). These findings suggested that pregnancy may impair the potency of vaccine-induced memory B cells. These insights may be valuable for the development of vaccination strategies for pregnant women. CI - (c) 2025. The Author(s). FAU - Wen, Gui-Ping AU - Wen GP AD - Department of Central Laboratory, Fujian Key Clinical Specialty of Laboratory Medicine, Department of Obstetrics and Gynecology, Women and Children's Hospital, School of Medicine, Xiamen University, Xiamen, Fujian, 361102, China. wenguiping@xmu.edu.cn. AD - United Diagnostic and Research Center for Clinical Genetics, Women and Children's Hospital, School of Medicine, School of Public Health, Xiamen University, Xiamen, Fujian, 361102, China. wenguiping@xmu.edu.cn. FAU - Wang, Yi-Zhen AU - Wang YZ AD - State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen, Fujian, 361102, China. AD - Xiang An Biomedicine Laboratory, Xiamen, Fujian, 361102, China. FAU - Wang, Min-Ming AU - Wang MM AD - United Diagnostic and Research Center for Clinical Genetics, Women and Children's Hospital, School of Medicine, School of Public Health, Xiamen University, Xiamen, Fujian, 361102, China. FAU - Wang, Wen-Rong AU - Wang WR AD - Department of Aristogenesis, Department of Obstetrics and Gynecology, Women and Children's Hospital, School of Medicine, Xiamen University, Xiamen, Fujian, 361102, China. FAU - Wang, Si-Ling AU - Wang SL AD - State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen, Fujian, 361102, China. AD - Xiang An Biomedicine Laboratory, Xiamen, Fujian, 361102, China. FAU - Wang, Zheng AU - Wang Z AD - United Diagnostic and Research Center for Clinical Genetics, Women and Children's Hospital, School of Medicine, School of Public Health, Xiamen University, Xiamen, Fujian, 361102, China. AD - School of Pharmacy, Xiamen University, Xiamen, Fujian, 361102, China. FAU - Tang, Zi-Min AU - Tang ZM AD - State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen, Fujian, 361102, China. AD - Xiang An Biomedicine Laboratory, Xiamen, Fujian, 361102, China. AD - NMPA Key Laboratory for Research and Evaluation of Infectious Disease Diagnostic Technology, School of Public Health, Xiamen University, Xiamen, Fujian, 361102, China. FAU - Luo, Zhen-Yu AU - Luo ZY AD - Department of Aristogenesis, Department of Obstetrics and Gynecology, Women and Children's Hospital, School of Medicine, Xiamen University, Xiamen, Fujian, 361102, China. FAU - Chen, Zi-Hao AU - Chen ZH AD - State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen, Fujian, 361102, China. AD - Xiang An Biomedicine Laboratory, Xiamen, Fujian, 361102, China. FAU - Chen, Jia-Yan AU - Chen JY AD - Department of Central Laboratory, Fujian Key Clinical Specialty of Laboratory Medicine, Department of Obstetrics and Gynecology, Women and Children's Hospital, School of Medicine, Xiamen University, Xiamen, Fujian, 361102, China. FAU - Cai, Mei-Jiao AU - Cai MJ AD - Department of Central Laboratory, Fujian Key Clinical Specialty of Laboratory Medicine, Department of Obstetrics and Gynecology, Women and Children's Hospital, School of Medicine, Xiamen University, Xiamen, Fujian, 361102, China. FAU - Ge, Yun-Sheng AU - Ge YS AD - Department of Central Laboratory, Fujian Key Clinical Specialty of Laboratory Medicine, Department of Obstetrics and Gynecology, Women and Children's Hospital, School of Medicine, Xiamen University, Xiamen, Fujian, 361102, China. FAU - Zheng, Zi-Zheng AU - Zheng ZZ AD - State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen, Fujian, 361102, China. zhengzizheng@xmu.edu.cn. AD - Xiang An Biomedicine Laboratory, Xiamen, Fujian, 361102, China. zhengzizheng@xmu.edu.cn. FAU - Zhou, Yu-Lin AU - Zhou YL AD - Department of Central Laboratory, Fujian Key Clinical Specialty of Laboratory Medicine, Department of Obstetrics and Gynecology, Women and Children's Hospital, School of Medicine, Xiamen University, Xiamen, Fujian, 361102, China. zhou_yulin@126.com. AD - United Diagnostic and Research Center for Clinical Genetics, Women and Children's Hospital, School of Medicine, School of Public Health, Xiamen University, Xiamen, Fujian, 361102, China. zhou_yulin@126.com. LA - eng GR - 82101757/National Natural Science Foundation of China/ GR - 2023J05263/Fujian Provincial Natural Science Foundation of China/ GR - 2022J02005/Fujian Provincial Natural Science Foundation of China/ GR - 2023J011607/Fujian Provincial Natural Science Foundation of China/ GR - 2024GZL-GG39/the Xiamen Health High Quality Development Science and Technology Project/ GR - 2024YFC2310602/National Key Research and Development Program of China/ GR - 3502Z20224014/Science and Technology Project of Xiamen/ PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20250926 PL - England TA - Mol Med JT - Molecular medicine (Cambridge, Mass.) JID - 9501023 RN - 0 (COVID-19 Vaccines) RN - 0 (Antibodies, Viral) RN - 0 (Spike Glycoprotein, Coronavirus) RN - 0 (Antibodies, Neutralizing) RN - 0 (Vaccines, Inactivated) RN - 0 (spike protein, SARS-CoV-2) RN - 0 (Antibodies, Monoclonal) SB - IM MH - Humans MH - Female MH - Pregnancy MH - *SARS-CoV-2/immunology MH - *COVID-19/immunology/prevention & control MH - *COVID-19 Vaccines/immunology MH - *Memory B Cells/immunology MH - Antibodies, Viral/immunology/blood MH - Adult MH - Spike Glycoprotein, Coronavirus/immunology MH - Antibodies, Neutralizing/immunology/blood MH - Vaccines, Inactivated/immunology MH - Immunologic Memory MH - Antibodies, Monoclonal/immunology MH - *Immunogenicity, Vaccine MH - Young Adult MH - *B-Lymphocytes/immunology PMC - PMC12465604 OTO - NOTNLM OT - Humoral immune response OT - Inactivated COVID-19 vaccine OT - Memory B cell OT - Pregnancy OT - SARS-CoV-2. COIS- Declarations. Ethical approval and consent to participate: This study was carried out according to the principles of the Declaration of Helsinki and approved by the Ethics Committee of the Women and Children's Hospital, School of Medicine, Xiamen University. Written informed consent was obtained from all participants. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests. EDAT- 2025/09/27 06:33 MHDA- 2025/09/27 06:34 PMCR- 2025/09/26 CRDT- 2025/09/27 01:30 PHST- 2025/06/13 00:00 [received] PHST- 2025/08/22 00:00 [accepted] PHST- 2025/09/27 06:34 [medline] PHST- 2025/09/27 06:33 [pubmed] PHST- 2025/09/27 01:30 [entrez] PHST- 2025/09/26 00:00 [pmc-release] AID - 10.1186/s10020-025-01357-5 [pii] AID - 1357 [pii] AID - 10.1186/s10020-025-01357-5 [doi] PST - epublish SO - Mol Med. 2025 Sep 26;31(1):297. doi: 10.1186/s10020-025-01357-5. PMID- 41012146 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20250927 LR - 20260925 IS - 2076-393X (Print) IS - 2076-393X (Electronic) IS - 2076-393X (Linking) VI - 13 IP - 9 DP - 2025 Sep 3 TI - SARS-CoV-2 Infection or COVID-19 mRNA Vaccination Elicits Partially Different Spike-Reactive Memory B Cell Responses in Naive Individuals. LID - 10.3390/vaccines13090944 [doi] LID - 944 AB - Background: The COVID-19 pandemic provided a unique opportunity to evaluate how the human immune system responded to a novel pathogen and to determine whether immune responses initiated through natural infection differ from those elicited by vaccination against the same antigen. Here, we provide a comprehensive analysis of SARS-CoV-2 Spike (S-antigen)-reactive memory B cells (B(mem)) elicited in previously immunologically naive subjects following their first infection with the original Wuhan-Hu-1 (WH1)-like strain or their initial COVID-19 mRNA prime-boost regimen encoding the same WH1-S-antigen. In particular, we tested the hypothesis that the primary encounter of SARS-CoV-2 S-antigen in lung mucosal tissues during infection vs. intramuscular COVID-19 mRNA injection would elicit different B(mem) responses. Methods: Cryopreserved peripheral blood mononuclear cell (PBMC) samples collected following primary infection with the WH1 strain or completion of the initial prime-boost vaccination regimen were tested in ImmunoSpot((R)) assays to assess the frequency, Ig class/subclass usage, and cross-reactivity of the S-antigen-reactive B(mem) compartment; pre-pandemic blood draws served as naive controls. Results: The B(mem) repertoires generated post-infection vs. post-vaccination were found to be quite similar but with some subtle differences. In both cases, the prevalent induction of IgG1-expressing B(mem) in similar frequencies was seen, ~30% of which targeted the receptor binding domain (RBD) of the WH1-S-antigen. Also, the extent of cross-reactivity with the future Omicron (BA.1) RBD was found to be similar for both cohorts. However, IgA(+) B(mem) were preferentially induced after infection, while IgG4(+) B(mem) were detected only after vaccination. Conclusions: B(mem) elicited in naive human subjects following SARS-CoV-2 infection or after WH1-S encoding mRNA vaccination were only subtly different, although the relevance of these differences as it relates to immune protection warrants further investigation. Our findings serve to illustrate the usefulness and feasibility of performing comprehensive monitoring of antigen-specific B cell memory in larger cohorts using the ImmunoSpot((R)) technique. FAU - Yao, Lingling AU - Yao L AUID- ORCID: 0009-0000-3134-8630 AD - Research and Development, Cellular Technology Ltd. (CTL), Shaker Heights, OH 44122, USA. FAU - Becza, Noemi AU - Becza N AD - Research and Development, Cellular Technology Ltd. (CTL), Shaker Heights, OH 44122, USA. FAU - Stylianou, Georgia AU - Stylianou G AUID- ORCID: 0009-0000-9062-8157 AD - Faculty of Health & Life Sciences, Northumbria University, Newcastle upon Tyne NE1 8ST, UK. FAU - Tary-Lehmann, Magdalena AU - Tary-Lehmann M AD - Contract Laboratory, Cellular Technology Ltd. (CTL), Shaker Heights, OH 44122, USA. FAU - Todryk, Stephen M AU - Todryk SM AUID- ORCID: 0000-0003-4566-0793 AD - Faculty of Health & Life Sciences, Northumbria University, Newcastle upon Tyne NE1 8ST, UK. FAU - Kirchenbaum, Greg A AU - Kirchenbaum GA AUID- ORCID: 0000-0001-6463-7623 AD - Research and Development, Cellular Technology Ltd. (CTL), Shaker Heights, OH 44122, USA. AD - Faculty of Health & Life Sciences, Northumbria University, Newcastle upon Tyne NE1 8ST, UK. FAU - Lehmann, Paul V AU - Lehmann PV AD - Research and Development, Cellular Technology Ltd. (CTL), Shaker Heights, OH 44122, USA. LA - eng GR - the R&D budget of Cellular Technology Limited (CTL)/ PT - Journal Article DEP - 20250903 PL - Switzerland TA - Vaccines (Basel) JT - Vaccines JID - 101629355 PMC - PMC12474496 OTO - NOTNLM OT - ELISPOT OT - FluoroSpot OT - Ig class OT - IgG subclass OT - humoral OT - immune monitoring OT - immunological memory OT - plasma cell COIS- P.V.L. is Founder, President, and CEO of Cellular Technology Limited (CTL), a company that specializes in immune monitoring by ImmunoSpot((R)). M.T.-L. is a cofounder and CSO of CTL. L.Y., N.B. and G.A.K. are employees of CTL. G.S. and S.M.T. received funding, reagents, and instrumentation from CTL to support their research. This study was funded by CTL, and the funder directed the study design, collection, analysis, interpretation of data, the writing of this article, and made the decision to submit it for publication. EDAT- 2025/09/27 06:33 MHDA- 2025/09/27 06:34 PMCR- 2025/09/03 CRDT- 2025/09/27 01:26 PHST- 2025/07/23 00:00 [received] PHST- 2025/08/29 00:00 [revised] PHST- 2025/08/29 00:00 [accepted] PHST- 2025/09/27 06:34 [medline] PHST- 2025/09/27 06:33 [pubmed] PHST- 2025/09/27 01:26 [entrez] PHST- 2025/09/03 00:00 [pmc-release] AID - vaccines13090944 [pii] AID - vaccines-13-00944 [pii] AID - 10.3390/vaccines13090944 [doi] PST - epublish SO - Vaccines (Basel). 2025 Sep 3;13(9):944. doi: 10.3390/vaccines13090944. PMID- 40977400 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20250922 LR - 20250926 IS - 2056-4724 (Print) IS - 2056-4724 (Electronic) IS - 2056-4724 (Linking) VI - 11 IP - 5 DP - 2025 Sep 22 TI - Short-term risk of psychiatric adverse events following COVID-19 vaccination: nationwide self-controlled case series study. PG - e218 LID - 10.1192/bjo.2025.10803 [doi] LID - e218 AB - BACKGROUND: To date, little is known about the evidence of a potential risk of psychiatric adverse events following COVID-19 vaccination in large populations with adequate study design. AIMS: To investigate whether COVID-19 vaccination is associated with increased risk of psychiatric adverse events. METHOD: We used South Korea's linkage database to obtain registry data and claims data from 2019 to 2021, and conducted a population-based self-controlled case series study including 11 751 806 individuals. Primary outcomes included anxiety/nervousness, mood disorders, perceptual disturbances/psychoses, aggression/behavioural disturbances, cognitive impairments and sleep disorders within 21 days of COVID-19 vaccination. Secondary outcomes were the stratified primary outcomes according to each individual's psychiatric history. Conditional Poisson regression was used to estimate incidence rate ratios (IRR) and 95% confidence intervals. RESULTS: COVID-19 vaccination did not increase the rate of anxiety and nervousness (adjusted IRR 0.95, 95% CI 0.95-0.96), mood disorders (adjusted IRR 0.75, 95% CI 0.75-0.76), perceptual disturbances and psychoses (adjusted IRR 0.72, 95% CI 0.70-0.74), aggression and behavioural disturbances (adjusted IRR 0.93, 95% CI 0.89-0.97), cognitive impairment (adjusted IRR 0.68, 95% CI 0.67-0.69) or sleep disorders (adjusted IRR 0.90, 95% CI 0.89-0.91). Secondary outcomes were consistent with the primary outcome, although the adjusted IRRs for anxiety and nervousness (adjusted IRR 1.17, 95% CI 1.15-1.18) and sleep disorders (adjusted IRR 1.07, 95% CI 1.06-1.09) were statistically significant in individuals with no history of psychiatric disorders. Sensitivity analyses showed consistent results with our main findings. CONCLUSIONS: Our findings provide short-term safety profiles for COVID-19 vaccines regarding psychiatric adverse events. Continuous monitoring of anxiety/nervousness or sleep disorders after COVID-19 vaccination is required regardless of history of psychiatric comorbidities. FAU - Lee, Hyesung AU - Lee H AD - Department of Medical Informatics, Kangwon National University College of Medicine, Chuncheon, Republic of Korea. AD - School of Pharmacy, Sungkyunkwan University, Suwon, Republic of Korea. FAU - Hong, Bin AU - Hong B AD - School of Pharmacy, Sungkyunkwan University, Suwon, Republic of Korea. FAU - Lee, Eun AU - Lee E AD - Department of Psychiatry, Institute of Behavioral Science in Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea. AD - Department of Psychiatry, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea. FAU - Park, Jin Young AU - Park JY AD - Department of Psychiatry, Institute of Behavioral Science in Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea. AD - Department of Psychiatry, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin, Republic of Korea. AD - Center for Digital Health, Yongin Severance Hospital, Yonsei University Health System, Yongin, Republic of Korea. FAU - Jung, Jaehun AU - Jung J AD - Department of Preventive Medicine, Korea University College of Medicine, Seoul, Republic of Korea. AD - Institute on Aging, Korea University, Seoul, Republic of Korea. FAU - Kim, Woo Jung AU - Kim WJ AUID- ORCID: 0000-0002-4963-4819 AD - Department of Psychiatry, Institute of Behavioral Science in Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea. AD - Department of Psychiatry, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin, Republic of Korea. AD - Institute for Innovation in Digital Healthcare, Yonsei University, Seoul, Republic of Korea. FAU - Shin, Ju-Young AU - Shin JY AUID- ORCID: 0000-0003-1010-7525 AD - Department of Medical Informatics, Kangwon National University College of Medicine, Chuncheon, Republic of Korea. AD - Department of Biohealth Regulatory Science, Sungkyunkwan University, Suwon, Republic of Korea. AD - Samsung Advanced Institute for Health Sciences & Technology, Sungkyunkwan University, Seoul, Republic of Korea. LA - eng PT - Journal Article DEP - 20250922 PL - England TA - BJPsych Open JT - BJPsych open JID - 101667931 PMC - PMC12458088 OTO - NOTNLM OT - COVID-19 vaccine OT - psychiatric adverse events OT - self-controlled case series COIS- J.-Y.S. received grants from the Ministry of Food and Drug Safety, the National Research Foundation of Korea and pharmaceutical companies, including Pfizer, Yuhan Corporation and the UCB Korea. No other relationships or activities have influenced the submitted work. EDAT- 2025/09/22 06:31 MHDA- 2025/09/22 06:32 PMCR- 2025/09/22 CRDT- 2025/09/22 05:05 PHST- 2025/09/22 06:32 [medline] PHST- 2025/09/22 06:31 [pubmed] PHST- 2025/09/22 05:05 [entrez] PHST- 2025/09/22 00:00 [pmc-release] AID - S205647242510803X [pii] AID - 10.1192/bjo.2025.10803 [doi] PST - epublish SO - BJPsych Open. 2025 Sep 22;11(5):e218. doi: 10.1192/bjo.2025.10803. PMID- 40969767 OWN - NLM STAT- MEDLINE DCOM- 20250919 LR - 20250921 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 16 DP - 2025 TI - The impact of mycobacteria-induced trained immunity on SARS-CoV-2 vaccine responses. PG - 1633977 LID - 10.3389/fimmu.2025.1633977 [doi] LID - 1633977 AB - INTRODUCTION: Beyond the role of Bacillus Calmette-Guerin (BCG) for tuberculosis prevention, BCG has demonstrated heterologous protective effects. The global health crisis caused by the SARS-CoV-2 virus led to research on whether BCG-induced trained immunity could strengthen antiviral defenses. However, studies reported quite different results on its effect against COVID-19. METHODS AND RESULTS: In this study, we evaluated the impact of pre-existing trained immunity induced by a BCG-derived Mycobacterium bovis strain (dpB), in both live and inactivated forms, in combination with SARS-CoV-2 vaccination prior to challenge in a mouse model. While the SARS-CoV-2 vaccine was enough for protection in morbidity and mortality terms, its combination with live dpB significantly enhanced immune responses reflected in higher levels of pro-inflammatory cytokines, reduced pulmonary viral loads, and improved histopathological outcomes. Additionally, the formation of inducible bronchus-associated lymphoid tissue (iBALT) in lungs in vaccinated animals pre-exposed to live dpB points to a potential mechanism for long-term immune surveillance in the respiratory tract. CONCLUSIONS: These immunological findings highlight the potential benefits of integrating trained immunity inducers with pathogen-specific vaccines to enhance immune responses and protection. Further research is needed to optimize immunomodulation strategies, dosing regimens and administration routes to maximize these synergistic effects and prevent potential negative effects. CI - Copyright (c) 2025 Sanchez-Morales, Porras, Perez-Domingo, Perez-Sancho, Garcia-Seco, Diaz-Frutos, Buendia, Moreno, Zamora, Balseiro, Risalde, Rodriguez-Bertos, Gortazar, Dominguez and Dominguez. FAU - Sanchez-Morales, Lidia AU - Sanchez-Morales L AD - VISAVET Health Surveillance Centre, Complutense University of Madrid, Madrid, Spain. AD - Department of Animal Health, Faculty of Veterinary Medicine, Complutense University of Madrid, Madrid, Spain. FAU - Porras, Nestor AU - Porras N AD - VISAVET Health Surveillance Centre, Complutense University of Madrid, Madrid, Spain. FAU - Perez-Domingo, Andrea AU - Perez-Domingo A AD - VISAVET Health Surveillance Centre, Complutense University of Madrid, Madrid, Spain. FAU - Perez-Sancho, Marta AU - Perez-Sancho M AD - VISAVET Health Surveillance Centre, Complutense University of Madrid, Madrid, Spain. AD - Department of Animal Health, Faculty of Veterinary Medicine, Complutense University of Madrid, Madrid, Spain. FAU - Garcia-Seco, Teresa AU - Garcia-Seco T AD - VISAVET Health Surveillance Centre, Complutense University of Madrid, Madrid, Spain. FAU - Diaz-Frutos, Marta AU - Diaz-Frutos M AD - VISAVET Health Surveillance Centre, Complutense University of Madrid, Madrid, Spain. AD - Department of Animal Health, Faculty of Veterinary Medicine, Complutense University of Madrid, Madrid, Spain. FAU - Buendia, Aranzazu AU - Buendia A AD - VISAVET Health Surveillance Centre, Complutense University of Madrid, Madrid, Spain. FAU - Moreno, Inmaculada AU - Moreno I AD - Immunology Unit, National Microbiology Centre, Carlos III Health Institute, Majadahonda, Madrid, Spain. FAU - Zamora, Leydis AU - Zamora L AD - VISAVET Health Surveillance Centre, Complutense University of Madrid, Madrid, Spain. FAU - Balseiro, Ana AU - Balseiro A AD - Department of Animal Health, Faculty of Veterinary Medicine, University of Leon, Leon, Spain. AD - Instituto de Ganaderia de Montana (IGM, CSIC-ULE), Leon, Spain. FAU - Risalde, M A AU - Risalde MA AD - Department of Comparative Anatomy and Pathology and Toxicology, Animal Health and Zoonosis Research Group (GISAZ), UIC Zoonosis and Emerging Diseases (ENZOEM), University of Cordoba, Cordoba, Spain. FAU - Rodriguez-Bertos, Antonio AU - Rodriguez-Bertos A AD - VISAVET Health Surveillance Centre, Complutense University of Madrid, Madrid, Spain. AD - Department of Internal Medicine and Animal Surgery, Faculty of Veterinary Medicine, Complutense University of Madrid, Madrid, Spain. FAU - Gortazar, Christian AU - Gortazar C AD - SaBio Instituto de Investigacion en Recursos Cinegeticos IREC (CSIC-UCLM-JCCM), Ciudad Real, Spain. FAU - Dominguez, Mercedes AU - Dominguez M AD - Immunology Unit, National Microbiology Centre, Carlos III Health Institute, Majadahonda, Madrid, Spain. FAU - Dominguez, Lucas AU - Dominguez L AD - VISAVET Health Surveillance Centre, Complutense University of Madrid, Madrid, Spain. AD - Department of Animal Health, Faculty of Veterinary Medicine, Complutense University of Madrid, Madrid, Spain. LA - eng PT - Journal Article DEP - 20250903 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 RN - 0 (COVID-19 Vaccines) RN - 0 (BCG Vaccine) RN - 0 (Cytokines) SB - IM MH - Animals MH - *SARS-CoV-2/immunology MH - Mice MH - *COVID-19/immunology/prevention & control MH - *COVID-19 Vaccines/immunology MH - *BCG Vaccine/immunology MH - *Mycobacterium bovis/immunology MH - Female MH - Cytokines/immunology MH - Lung/immunology/virology/pathology MH - Humans MH - Disease Models, Animal MH - Viral Load MH - Trained Immunity PMC - PMC12441830 OTO - NOTNLM OT - SARS-CoV-2 vaccine OT - adaptative immunity OT - innate memory OT - mycobacteria OT - trained immunity COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2025/09/19 06:33 MHDA- 2025/09/19 06:34 PMCR- 2025/09/03 CRDT- 2025/09/19 05:06 PHST- 2025/05/23 00:00 [received] PHST- 2025/08/18 00:00 [accepted] PHST- 2025/09/19 06:34 [medline] PHST- 2025/09/19 06:33 [pubmed] PHST- 2025/09/19 05:06 [entrez] PHST- 2025/09/03 00:00 [pmc-release] AID - 10.3389/fimmu.2025.1633977 [doi] PST - epublish SO - Front Immunol. 2025 Sep 3;16:1633977. doi: 10.3389/fimmu.2025.1633977. eCollection 2025. PMID- 40910738 OWN - NLM STAT- MEDLINE DCOM- 20250905 LR - 20260904 IS - 2164-554X (Electronic) IS - 2164-5515 (Print) IS - 2164-5515 (Linking) VI - 21 IP - 1 DP - 2025 Dec TI - Correlation between the immune response to COVID-19 vaccines and the constitutions of traditional Chinese medicine. PG - 2553371 LID - 10.1080/21645515.2025.2553371 [doi] LID - 2553371 AB - Traditional Chinese Medicine (TCM) classifies individuals into constitution types that may influence physiological responses. SARS-CoV-2 vaccines induce spike-specific antibodies and activate B and T cells, including memory subsets. This study investigates whether TCM constitution types are associated with immune responses and adverse events following COVID-19 vaccination. From March 2021 to December 2023, 78 adults received two doses of the COVID-19 vaccine, including AstraZeneca, Moderna, MVC-COV1901, and Pfizer-BioNTech. PBMCs were collected before and after vaccination. Immune parameters-cytokines, antibody titers, dendritic cells (DCs), T cells, B cells, and memory T cell subsets-were measured. TCM constitution scores were determined using the Constitution in Chinese Medicine Questionnaire (CCMQ) before vaccination. Adverse reactions were recorded through structured surveys, and correlations between constitution scores and adverse events were analyzed using the Pearson correlation. Pre-vaccination TNF-alpha was negatively correlated with the gentleness constitution and positively with the qi-deficiency. DCs increased post-vaccination in individuals with qi-deficiency, phlegm-dampness, qi-depression, yin-deficiency, dampness-heat, and special diathesis constitutions. T cell proportions increased in yin-deficiency, dampness-heat, and special diathesis groups. Dampness-heat scores were negatively correlated with central memory T cell (Tcm) induction. No significant correlations were found between constitution types and antibody levels or neutralization. Adverse reactions were more frequent in individuals with phlegm-dampness, qi-depression, and blood-stasis constitutions, and less frequent in those with a gentleness constitution. TCM constitutions correlate with cellular immune responses and adverse reaction profiles, but not antibody production, after COVID-19 vaccination. This supports integrating TCM constitution frameworks into personalized vaccine prediction. FAU - Chen, Ping AU - Chen P AD - School of Chinese Medicine, College of Chinese Medicine, China Medical University, Taichung, Taiwan. FAU - Yen, Hung-Rong AU - Yen HR AD - School of Chinese Medicine, College of Chinese Medicine, China Medical University, Taichung, Taiwan. AD - Chinese Medicine Research Center, China Medical University, Taichung, Taiwan. AD - Research Center of Traditional Chinese Medicine, Department of Medical Research, China Medical University Hospital, Taichung, Taiwan. AD - Department of Chinese Medicine, China Medical University Hospital, Taichung, Taiwan. FAU - Lee, Hui-Ju AU - Lee HJ AD - Chinese Medicine Research Center, China Medical University, Taichung, Taiwan. AD - Research Center of Traditional Chinese Medicine, Department of Medical Research, China Medical University Hospital, Taichung, Taiwan. AD - Graduate Institute of Integrated Medicine, College of Chinese Medicine, China Medical University, Taichung, Taiwan. FAU - Wu, Mei-Yao AU - Wu MY AD - Research Center of Traditional Chinese Medicine, Department of Medical Research, China Medical University Hospital, Taichung, Taiwan. AD - Department of Chinese Medicine, China Medical University Hospital, Taichung, Taiwan. AD - School of Post-Baccalaureate Chinese Medicine, College of Chinese Medicine, China Medical University, Taichung, Taiwan. FAU - Park, Kyungmo AU - Park K AD - Department of Biomedical Engineering, Kyung Hee University, Yongin, Republic of Korea. FAU - Song, Ying-Chyi AU - Song YC AUID- ORCID: 0000-0003-0279-4652 AD - Chinese Medicine Research Center, China Medical University, Taichung, Taiwan. AD - Research Center of Traditional Chinese Medicine, Department of Medical Research, China Medical University Hospital, Taichung, Taiwan. AD - Graduate Institute of Integrated Medicine, College of Chinese Medicine, China Medical University, Taichung, Taiwan. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20250905 PL - United States TA - Hum Vaccin Immunother JT - Human vaccines & immunotherapeutics JID - 101572652 RN - 0 (COVID-19 Vaccines) RN - 0 (Antibodies, Viral) RN - 0 (Cytokines) SB - IM MH - Humans MH - *COVID-19 Vaccines/immunology/adverse effects/administration & dosage MH - Female MH - Middle Aged MH - Male MH - Adult MH - *COVID-19/prevention & control/immunology MH - *Medicine, Chinese Traditional/methods MH - Antibodies, Viral/blood/immunology MH - SARS-CoV-2/immunology MH - Aged MH - Young Adult MH - Cytokines/immunology MH - Dendritic Cells/immunology PMC - PMC12416171 OTO - NOTNLM OT - COVID-19 vaccine OT - adverse reaction OT - memory T-cell OT - spike antibody OT - traditional Chinese medicine (TCM) constitutions COIS- No potential conflict of interest was reported by the author(s). EDAT- 2025/09/05 12:40 MHDA- 2025/09/05 12:41 PMCR- 2025/09/05 CRDT- 2025/09/05 08:42 PHST- 2025/09/05 12:41 [medline] PHST- 2025/09/05 12:40 [pubmed] PHST- 2025/09/05 08:42 [entrez] PHST- 2025/09/05 00:00 [pmc-release] AID - 2553371 [pii] AID - 10.1080/21645515.2025.2553371 [doi] PST - ppublish SO - Hum Vaccin Immunother. 2025 Dec;21(1):2553371. doi: 10.1080/21645515.2025.2553371. Epub 2025 Sep 5. PMID- 40883541 OWN - NLM STAT- MEDLINE DCOM- 20250829 LR - 20250901 IS - 2399-3642 (Electronic) IS - 2399-3642 (Linking) VI - 8 IP - 1 DP - 2025 Aug 29 TI - SARS-CoV-2 vaccination during pregnancy enhances offspring hippocampal neurogenesis and working memory via IFN-gamma-responsive microglia. PG - 1307 LID - 10.1038/s42003-025-08691-8 [doi] LID - 1307 AB - In the face of severe outcomes from COVID-19, vaccines have proven immunogenic and safe and are strongly recommended during pregnancy. This study examines the effects of maternal COVID-19 vaccination on physical development, behavior, and neurogenesis in mouse offspring. After inoculation with inactivated SARS-CoV-2 vaccine (Vero Cell) at gestational day 14.5, antibodies were detected in the serum of dams and pups. At one month of age, offspring of vaccinated dams-but not controls-showed enhanced working memory, increased neural proliferation, neuroblast formation, stem cell activity, and more mature neurons in the dentate gyrus (DG). Luminex assay showed elevated hippocampal IFN-gamma and CX3CL1, both linked to neurogenesis and memory. Conditional knockout experiments identified microglial IFNgammaR1 and CX3CR1 as key mediators of neuronal development through regulating microglial activation and chemotaxis. These findings suggest maternal SARS-CoV-2 vaccination transiently enhances hippocampal neurogenesis and working memory in offspring, without causing neurodevelopmental risk. CI - (c) 2025. The Author(s). FAU - Tang, Jiaoling AU - Tang J AD - Department of Anatomy and Physiology, Guangdong Province Key Laboratory of Brain Function and Disease, Advanced Medical Technology Center, The First Affiliated Hospital, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China. FAU - Qi, Fangfang AU - Qi F AD - Department of Anatomy and Physiology, Guangdong Province Key Laboratory of Brain Function and Disease, Advanced Medical Technology Center, The First Affiliated Hospital, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China. qi.fangfang@mayo.edu. AD - Department of Neurology, Mayo Clinic, Rochester, MN, USA. qi.fangfang@mayo.edu. FAU - Zou, Juntao AU - Zou J AD - Department of Anatomy and Physiology, Guangdong Province Key Laboratory of Brain Function and Disease, Advanced Medical Technology Center, The First Affiliated Hospital, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China. FAU - Liu, Hao AU - Liu H AD - Department of Anatomy and Physiology, Guangdong Province Key Laboratory of Brain Function and Disease, Advanced Medical Technology Center, The First Affiliated Hospital, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China. FAU - Zuo, Zejie AU - Zuo Z AD - Department of Rehabilitation Medicine, the Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China. FAU - Wang, Lingxiao AU - Wang L AD - Department of Neurology, Mayo Clinic, Rochester, MN, USA. AD - Mayo Clinic Graduate School of Biomedical Sciences, Rochester, MN, USA. FAU - Wang, Na AU - Wang N AD - Department of Neurology, Mayo Clinic, Rochester, MN, USA. FAU - Li, Zhihui AU - Li Z AD - Department of Anatomy and Physiology, Guangdong Province Key Laboratory of Brain Function and Disease, Advanced Medical Technology Center, The First Affiliated Hospital, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China. FAU - Kumar, Ashutosh AU - Kumar A AD - Department of Anatomy, All India Institute of Medical Sciences (AIIMS), Patna, India. AD - Etiologically Elusive Disorders Research Network (EEDRN), New Delhi, India. FAU - Guo, Kaihua AU - Guo K AD - Department of Anatomy and Physiology, Guangdong Province Key Laboratory of Brain Function and Disease, Advanced Medical Technology Center, The First Affiliated Hospital, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China. guokh@mail.sysu.edu.cn. FAU - Hu, Dandan AU - Hu D AD - Children's Health Section, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China. guohdd@126.com. FAU - Yao, Zhibin AU - Yao Z AUID- ORCID: 0000-0003-1613-9157 AD - Department of Anatomy and Physiology, Guangdong Province Key Laboratory of Brain Function and Disease, Advanced Medical Technology Center, The First Affiliated Hospital, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China. yao.zb@163.com. LA - eng GR - 82271473;81971021/National Natural Science Foundation of China (National Science Foundation of China)/ PT - Journal Article DEP - 20250829 PL - England TA - Commun Biol JT - Communications biology JID - 101719179 RN - 82115-62-6 (Interferon-gamma) RN - 0 (COVID-19 Vaccines) RN - 0 (Interferon gamma Receptor) RN - 0 (Receptors, Interferon) RN - 0 (CX3C Chemokine Receptor 1) RN - 0 (Cx3cr1 protein, mouse) SB - IM MH - Animals MH - *Neurogenesis/drug effects MH - Female MH - *Microglia/immunology/metabolism MH - Pregnancy MH - *Hippocampus/immunology MH - Mice MH - *Memory, Short-Term/drug effects MH - *COVID-19/prevention & control/immunology MH - *Interferon-gamma/metabolism MH - *SARS-CoV-2/immunology MH - *COVID-19 Vaccines/immunology/administration & dosage MH - Vaccination MH - Interferon gamma Receptor MH - Receptors, Interferon/genetics/metabolism MH - CX3C Chemokine Receptor 1/genetics/metabolism MH - Mice, Inbred C57BL MH - Male MH - Mice, Knockout PMC - PMC12397237 COIS- Competing interests: The authors declare no competing interests. EDAT- 2025/08/31 04:45 MHDA- 2025/08/31 04:46 PMCR- 2025/08/29 CRDT- 2025/08/29 23:34 PHST- 2024/12/21 00:00 [received] PHST- 2025/08/07 00:00 [accepted] PHST- 2025/08/31 04:46 [medline] PHST- 2025/08/31 04:45 [pubmed] PHST- 2025/08/29 23:34 [entrez] PHST- 2025/08/29 00:00 [pmc-release] AID - 10.1038/s42003-025-08691-8 [pii] AID - 8691 [pii] AID - 10.1038/s42003-025-08691-8 [doi] PST - epublish SO - Commun Biol. 2025 Aug 29;8(1):1307. doi: 10.1038/s42003-025-08691-8. PMID- 40884220 OWN - NLM STAT- MEDLINE DCOM- 20260114 LR - 20260622 IS - 1460-2377 (Electronic) IS - 0953-8178 (Linking) VI - 38 IP - 1 DP - 2026 Jan 14 TI - The role of IL-4+ memory T cells in SARS-CoV-2 booster vaccination. PG - 41-55 LID - 10.1093/intimm/dxaf051 [doi] AB - Vaccines effectively stimulate protective immune responses in healthy individuals, but the precise roles of germinal center (GC) and follicular helper T (TFH) cells in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine responses are not fully understood. This study used a conditional loss-of-function mouse model to investigate antibody responses to the Wuhan spike protein, specifically eliminating newly developed TFH cells during either the primary or memory phase. Our findings demonstrated that TFH-mediated GC responses are essential for primary vaccination. However, after booster immunization, memory B-cell responses were effectively regulated through extrafollicular mechanisms, independent of TFH cells. Ablating IL-4 receptor signaling in B cells attenuated antibody production in both the primary and memory phases, highlighting the critical role of IL-4 for optimal humoral immunity. We identified a unique population of IL-4-expressing memory T (IL-4+Tm) cells, characterized by CD27, GATA3, and IRF4 expression, that is strongly associated with these extrafollicular memory B-cell responses, capable of neutralizing SARS-CoV-2 variants. Furthermore, Omicron-based booster immunization recovered the immunity against emerging variants under TFH-deficient conditions. These results suggest that IL-4+Tm cells are an alternative pathway to sustain memory responses when GC function is impaired, particularly in immunocompromised states. Our study advances the understanding of memory T-cell-mediated humoral responses to SARS-CoV-2, offering insights for future vaccine strategies. CI - (c) The Author(s) 2025. Published by Oxford University Press on behalf of The Japanese Society for Immunology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site-for further information please contact journals.permissions@oup.com. FAU - Khalil, Jumana AU - Khalil J AD - Division of Molecular Pathology, Research Institute for Biomedical Science, Tokyo University of Science, Chiba, Japan. AD - Department of Immunology, Graduate School of Medicine, Kyoto University, Yoshida-Konoe-cho, Sakyo-ku, Kyoto 606-8501, Japan. FAU - Miyauchi, Kosuke AU - Miyauchi K AD - Laboratory for Infectious Diseases and Immunology, Center for Integrative Medical Sciences, RIKEN, Yokohama, Japan. AD - Laboratory for Cytokine Regulation, Center for Integrative Medical Sciences, RIKEN, Yokohama, Japan. FAU - Suzuki, Yoshie AU - Suzuki Y AD - Laboratory for Cytokine Regulation, Center for Integrative Medical Sciences, RIKEN, Yokohama, Japan. FAU - Ki, Sewon AU - Ki S AD - Laboratory for Cytokine Regulation, Center for Integrative Medical Sciences, RIKEN, Yokohama, Japan. FAU - Harada, Yasuyo AU - Harada Y AD - Division of Molecular Pathology, Research Institute for Biomedical Science, Tokyo University of Science, Chiba, Japan. FAU - Sasaki, Takanori AU - Sasaki T AD - Division of Molecular Pathology, Research Institute for Biomedical Science, Tokyo University of Science, Chiba, Japan. AD - Division of Rheumatology, Inflammation, Immunity, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. FAU - Yamamoto, Yuichiro AU - Yamamoto Y AD - Department of Pharmaceutical Sciences, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Chiba, Japan. FAU - Hashimoto, Rina AU - Hashimoto R AUID- ORCID: 0000-0002-7174-4563 AD - Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan. FAU - Yamamoto, Takako AU - Yamamoto T AD - Laboratory for Developmental Genetics, Center for Integrative Medical Sciences, RIKEN, Yokohama, Japan. FAU - Matsuda, Masashi AU - Matsuda M AD - Laboratory for Developmental Genetics, Center for Integrative Medical Sciences, RIKEN, Yokohama, Japan. FAU - Koseki, Haruhiko AU - Koseki H AD - Laboratory for Developmental Genetics, Center for Integrative Medical Sciences, RIKEN, Yokohama, Japan. FAU - Nakayama, Manabu AU - Nakayama M AD - Laboratory of Medical Omics Research, Department of Frontier Research and Development, Kazusa DNA Research Institute, Kisarazu, Japan. FAU - Fukasawa, Masayoshi AU - Fukasawa M AD - National Institute of Infectious Diseases, 1-23-1, Toyama, Shinjuku-ku, Tokyo 162-8640, Japan. FAU - Wakita, Takaji AU - Wakita T AD - National Institute of Infectious Diseases, 1-23-1, Toyama, Shinjuku-ku, Tokyo 162-8640, Japan. FAU - Ueno, Hideki AU - Ueno H AD - Department of Immunology, Graduate School of Medicine, Kyoto University, Yoshida-Konoe-cho, Sakyo-ku, Kyoto 606-8501, Japan. AD - Kyoto University Immunomonitoring Center (KIC) Shogoin-Kawahara-cho, Sakyou-ku, Kyoto 606-8397, Japan. FAU - Noguchi, Kohji AU - Noguchi K AD - Department of Pharmaceutical Sciences, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Chiba, Japan. FAU - Takayama, Kazuo AU - Takayama K AUID- ORCID: 0000-0002-1132-2457 AD - Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan. AD - Department of Synthetic Human Body System, Medical Research Institute, Institute of Science Tokyo, Tokyo, Japan. FAU - Kubo, Masato AU - Kubo M AUID- ORCID: 0000-0001-7867-3086 AD - Division of Molecular Pathology, Research Institute for Biomedical Science, Tokyo University of Science, Chiba, Japan. AD - Laboratory for Cytokine Regulation, Center for Integrative Medical Sciences, RIKEN, Yokohama, Japan. AD - Kyoto University Immunomonitoring Center (KIC) Shogoin-Kawahara-cho, Sakyou-ku, Kyoto 606-8397, Japan. LA - eng GR - 19gm1310002/AMED-CREST/ PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - England TA - Int Immunol JT - International immunology JID - 8916182 RN - 207137-56-2 (Interleukin-4) RN - 0 (COVID-19 Vaccines) RN - 0 (Antibodies, Viral) RN - 0 (Spike Glycoprotein, Coronavirus) RN - 0 (Il4 protein, mouse) RN - 0 (spike protein, SARS-CoV-2) SB - IM MH - Animals MH - Immunization, Secondary MH - *Interleukin-4/immunology/metabolism MH - *SARS-CoV-2/immunology MH - Mice MH - *COVID-19/immunology/prevention & control MH - *COVID-19 Vaccines/immunology MH - Germinal Center/immunology MH - *Memory T Cells/immunology MH - Antibodies, Viral/immunology MH - Spike Glycoprotein, Coronavirus/immunology MH - Humans MH - Immunologic Memory MH - Memory B Cells/immunology MH - Mice, Inbred C57BL MH - Vaccination MH - B-Lymphocytes/immunology OTO - NOTNLM OT - IL-4 signal OT - germinal center OT - mRNA vaccine OT - virus immunity EDAT- 2025/08/30 08:45 MHDA- 2026/01/18 20:59 CRDT- 2025/08/30 05:12 PHST- 2025/06/23 00:00 [received] PHST- 2025/08/17 00:00 [accepted] PHST- 2026/01/18 20:59 [medline] PHST- 2025/08/30 08:45 [pubmed] PHST- 2025/08/30 05:12 [entrez] AID - 8244489 [pii] AID - 10.1093/intimm/dxaf051 [doi] PST - ppublish SO - Int Immunol. 2026 Jan 14;38(1):41-55. doi: 10.1093/intimm/dxaf051. PMID- 40872886 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20250915 LR - 20250915 IS - 2076-393X (Print) IS - 2076-393X (Electronic) IS - 2076-393X (Linking) VI - 13 IP - 8 DP - 2025 Jul 28 TI - Humoral and Memory B Cell Responses Following SARS-CoV-2 Infection and mRNA Vaccination. LID - 10.3390/vaccines13080799 [doi] LID - 799 AB - BACKGROUND: Understanding the duration and quality of immune memory following SARS-CoV-2 infection and vaccination is critical for informing public health strategies and vaccine development. While waning antibody levels have raised concerns about long-term protection, the persistence of memory B cells (MBCs) and T cells plays a vital role in sustaining immunity. MATERIALS AND METHODS: We conducted a longitudinal prospective study over 12 months, enrolling 285 participants in total, either after natural infection or vaccination with BNT162b2 or mRNA-1273. Peripheral blood samples were collected at four defined time points (baseline, 1-2 months, 6-7 months, and 12-13 months after vaccination or disease onset). Immune responses were assessed through serological assays quantifying anti-RBD IgG and neutralizing antibodies, B-ELISPOT, and multiparameter flow cytometry for S1-specific memory B cells. RESULTS: Both mRNA vaccines induced robust B cell and antibody responses, exceeding those observed after natural infection. Memory B cell frequencies peaked at 6 months and declined by 12 months, but remained above the baseline. The mRNA-1273 vaccine elicited stronger and more durable humoral and memory B-cell-mediated immunity compared to BNT162b2, likely influenced by its higher mRNA dose and longer prime-boost interval. Class-switched memory B cells and S1-specific B cells were significantly expanded in vaccine recipients. Natural infection induced more heterogeneous immune memory. CONCLUSIONS: Both mRNA vaccination and natural SARS-CoV-2 infection induce a comparable expansion of memory B cell subsets, reflecting a consistent pattern of humoral immune responses across all studied groups. These findings highlight the importance of vaccination in generating sustained immunological memory and suggest that the vaccine platform and dosage influence the magnitude and durability of immune responses against SARS-CoV-2. FAU - Bozhkova, Martina AU - Bozhkova M AUID- ORCID: 0000-0003-4230-3299 AD - Department of Medical Microbiology and Immunology-"Prof. Dr. Elissay Yanev", Medical University of Plovdiv, 4002 Plovdiv, Bulgaria. AD - Research Institute, Medical University of Plovdiv, 4002 Plovdiv, Bulgaria. FAU - Raycheva, Ralitsa AU - Raycheva R AD - Department of Social Medicine and Public Health, Medical University of Plovdiv, 4002 Plovdiv, Bulgaria. FAU - Petrov, Steliyan AU - Petrov S AUID- ORCID: 0000-0003-0522-5682 AD - Department of Medical Microbiology and Immunology-"Prof. Dr. Elissay Yanev", Medical University of Plovdiv, 4002 Plovdiv, Bulgaria. AD - Research Institute, Medical University of Plovdiv, 4002 Plovdiv, Bulgaria. FAU - Dudova, Dobrina AU - Dudova D AD - Department of Medical Microbiology and Immunology-"Prof. Dr. Elissay Yanev", Medical University of Plovdiv, 4002 Plovdiv, Bulgaria. AD - Research Institute, Medical University of Plovdiv, 4002 Plovdiv, Bulgaria. FAU - Kalfova, Teodora AU - Kalfova T AUID- ORCID: 0000-0001-6395-4109 AD - Department of Medical Microbiology and Immunology-"Prof. Dr. Elissay Yanev", Medical University of Plovdiv, 4002 Plovdiv, Bulgaria. AD - Research Institute, Medical University of Plovdiv, 4002 Plovdiv, Bulgaria. FAU - Murdjeva, Marianna AU - Murdjeva M AD - Department of Medical Microbiology and Immunology-"Prof. Dr. Elissay Yanev", Medical University of Plovdiv, 4002 Plovdiv, Bulgaria. AD - Research Institute, Medical University of Plovdiv, 4002 Plovdiv, Bulgaria. FAU - Taskov, Hristo AU - Taskov H AD - Research Institute, Medical University of Plovdiv, 4002 Plovdiv, Bulgaria. FAU - Shivarov, Velizar AU - Shivarov V AUID- ORCID: 0000-0001-5362-7999 AD - Department of Experimental Research, Medical University-Pleven, 5800 Pleven, Bulgaria. LA - eng GR - capital KA, Cyrilliccapital PE, Cyrillic-06-capital EN, Cyrillic53/1/Duration of immunological memory after vaccination against COVID-19 - cellular and humoral immunity defined by memory T and B cell subsets/ GR - SRIPD-MUP/Strategic Research and Innovation Program for the Development of MU - PLOVDIV-(SRIPD-MUP) ", Creation of a network of research higher schools, National plan for recovery and sustainability, financed by the European Union - NextGenerationEU./ PT - Journal Article DEP - 20250728 PL - Switzerland TA - Vaccines (Basel) JT - Vaccines JID - 101629355 PMC - PMC12390443 OTO - NOTNLM OT - B cell memory OT - BNT162b2 OT - COVID-19 OT - SARS-CoV-2 OT - antigen-specific B cells OT - humoral immune response OT - mRNA-1273 COIS- The authors declare no conflicts of interest. EDAT- 2025/08/30 04:50 MHDA- 2025/08/30 04:51 PMCR- 2025/07/28 CRDT- 2025/08/28 01:26 PHST- 2025/06/11 00:00 [received] PHST- 2025/07/21 00:00 [revised] PHST- 2025/07/25 00:00 [accepted] PHST- 2025/08/30 04:51 [medline] PHST- 2025/08/30 04:50 [pubmed] PHST- 2025/08/28 01:26 [entrez] PHST- 2025/07/28 00:00 [pmc-release] AID - vaccines13080799 [pii] AID - vaccines-13-00799 [pii] AID - 10.3390/vaccines13080799 [doi] PST - epublish SO - Vaccines (Basel). 2025 Jul 28;13(8):799. doi: 10.3390/vaccines13080799. PMID- 40803144 OWN - NLM STAT- MEDLINE DCOM- 20250915 LR - 20250915 IS - 1873-2518 (Electronic) IS - 0264-410X (Linking) VI - 62 DP - 2025 Aug 30 TI - Type 2 diabetes compromises SARS-CoV-2-specific immunological memory following ChAdOx1 nCoV-19 vaccination. PG - 127604 LID - S0264-410X(25)00901-6 [pii] LID - 10.1016/j.vaccine.2025.127604 [doi] AB - INTRODUCTION: Despite the success of vaccination, isolated cases of COVID-19 infection are being reported in the vulnerable subjects worldwide. Given that individuals with type-2 diabetes (T2D) often exhibit immune dysregulation, this study aimed to characterize SARS-CoV-2-specific immunity following ChAdOx1 nCoV-19 vaccination in subjects with T2D. METHODS: We recruited 55 T2D and 60 healthy control (HC) subjects and monitored their immunological parameters at baseline, 3rd, 6th, and 12th month post-ChAdOx1 nCoV-19 vaccination. The frequency of SARS-CoV-2 epitope-specific CD8+ T cells were determined using MHC-I dextramers. The SARS-CoV-2 specific recall responses were assessed by lymphocyte proliferation, intracellular (TNF-alpha, IFN-gamma) and extracellular (IL-2, IL-4, IL-6, IL-10, IFN-gamma, TGF-beta) cytokine estimation following in-vitro stimulation with SARS-CoV-2 S-protein peptide pool (SP). The anti-S antibody titers and the frequency of memory B cells (CD19+ CD27+), plasmablasts (CD19+ CD27hiCD38hi), and plasma cells (CD38hi CD138+) were also determined. RESULTS: Following vaccination, the incidence of COVID-19 disease was significantly higher in T2D individuals, suggesting an increased rate of breakthrough infections. The T2D cohort also exhibited lower frequency of SARS-CoV-2-specific peripheral CD8+ T cells and demonstrated diminished recall responses, as evidenced by reduced in-vitro lymphocyte proliferation. During breakthrough COVID-19 disease, systemic levels of IFN-gamma were elevated in T2D subjects, whereas higher IL-10 levels were observed only in HC. Upon SP stimulation, a greater proportion of CD8+ and CD4+ T cells from HC expressed IFN-gamma and TNF-alpha, indicating a more robust antiviral cell-mediated immune response. Additionally, B cell immunophenotyping revealed a reduced frequency of memory B cells in T2D. CONCLUSION: The data indicate that individuals with T2D exhibit impaired vaccine-induced SARS-CoV-2-specific immunological memory, in contrast to HC, who demonstrate a well-regulated balance between pro- and anti-inflammatory responses. CI - Copyright (c) 2025 Elsevier Ltd. All rights reserved. FAU - Bhat, Swati AU - Bhat S AD - Department of Endocrinology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India. FAU - Basak, Preetam AU - Basak P AD - Department of Endocrinology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India. FAU - Verma, Shivani AU - Verma S AD - Department of Endocrinology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India. FAU - Siddiqui, Kasmeen AU - Siddiqui K AD - Department of Endocrinology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India. FAU - Dutta, Pinaki AU - Dutta P AD - Department of Endocrinology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India. FAU - Das, Liza AU - Das L AD - Department of Endocrinology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India. FAU - Singh, Harvinder AU - Singh H AD - Department of Translational and Regenerative Medicine, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India. FAU - Bhadada, Sanjay AU - Bhadada S AD - Department of Endocrinology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India. FAU - Sachdeva, Naresh AU - Sachdeva N AD - Department of Endocrinology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India. Electronic address: sachdeva.naresh@pgimer.edu.in. LA - eng PT - Journal Article DEP - 20250812 PL - Netherlands TA - Vaccine JT - Vaccine JID - 8406899 RN - B5S3K2V0G8 (ChAdOx1 nCoV-19) RN - 0 (COVID-19 Vaccines) RN - 0 (Cytokines) RN - 0 (Antibodies, Viral) RN - 0 (Spike Glycoprotein, Coronavirus) SB - IM MH - Humans MH - Female MH - Middle Aged MH - Male MH - *Immunologic Memory MH - *COVID-19/prevention & control/immunology MH - *Diabetes Mellitus, Type 2/immunology MH - ChAdOx1 nCoV-19/immunology MH - CD8-Positive T-Lymphocytes/immunology MH - *SARS-CoV-2/immunology MH - *COVID-19 Vaccines/immunology/administration & dosage MH - Adult MH - Aged MH - Cytokines/metabolism MH - Antibodies, Viral/blood/immunology MH - Vaccination MH - Spike Glycoprotein, Coronavirus/immunology OTO - NOTNLM OT - B cell memory OT - ChAdOx1 nCoV-19 vaccine OT - Hybrid immunity OT - Lymphocyte proliferation OT - Type 2 diabetes COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2025/08/14 00:28 MHDA- 2025/09/16 00:33 CRDT- 2025/08/13 18:08 PHST- 2025/06/06 00:00 [received] PHST- 2025/08/03 00:00 [revised] PHST- 2025/08/06 00:00 [accepted] PHST- 2025/09/16 00:33 [medline] PHST- 2025/08/14 00:28 [pubmed] PHST- 2025/08/13 18:08 [entrez] AID - S0264-410X(25)00901-6 [pii] AID - 10.1016/j.vaccine.2025.127604 [doi] PST - ppublish SO - Vaccine. 2025 Aug 30;62:127604. doi: 10.1016/j.vaccine.2025.127604. Epub 2025 Aug 12. PMID- 40802507 OWN - NLM STAT- MEDLINE DCOM- 20250829 LR - 20260307 IS - 2211-1247 (Electronic) VI - 44 IP - 8 DP - 2025 Aug 26 TI - Clonal expansion and diversification of germinal center and memory B cell responses to booster immunization in primates. PG - 116142 LID - S2211-1247(25)00913-1 [pii] LID - 10.1016/j.celrep.2025.116142 [doi] AB - Effective vaccines elicit B cell clonal expansion in germinal centers (GCs) that produce memory B cells and antibody-secreting plasma cells. In mice, memory B cells rarely re-enter GCs upon boosting and instead differentiate into plasma cells. However, mouse circulating memory constitutes only 1%-2% of B cells, compared to 30%-50% in primates. We examine memory and GC B cell responses in rhesus macaques immunized and boosted ipsilaterally or contralaterally with an mRNA vaccine encoding the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein. The neutralizing activity of antibodies cloned from the memory compartment, as well as the size of the compartment, was independent of the site of boosting. We show that memory B cells enter and undergo iterative expansion in newly developing GCs when boosting is at a site distal to the site of priming. Thus, in primates, high-affinity memory B cells constitute a reservoir that actively participates in further development of immunity irrespective of the anatomical site of vaccine boosting. CI - Copyright (c) 2025 The Author(s). Published by Elsevier Inc. All rights reserved. FAU - Deimel, Lachlan P AU - Deimel LP AD - Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA. Electronic address: ldeimel@rockefeller.edu. FAU - Nishimura, Yoshiaki AU - Nishimura Y AD - Laboratory of Molecular Microbiology, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD, USA. FAU - Silva Santos, Gabriela S AU - Silva Santos GS AD - Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA. FAU - Baharani, Viren A AU - Baharani VA AD - Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA; Laboratory of Retrovirology, The Rockefeller University, New York, NY, USA. FAU - Hernandez, Brianna AU - Hernandez B AD - Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA. FAU - Oliveira, Thiago Y AU - Oliveira TY AD - Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA. FAU - MacLean, Andrew J AU - MacLean AJ AD - Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA. FAU - Canis, Marie AU - Canis M AD - Laboratory of Retrovirology, The Rockefeller University, New York, NY, USA. FAU - Shawraz, Sadman AU - Shawraz S AD - Laboratory of Retrovirology, The Rockefeller University, New York, NY, USA. FAU - Gazumyan, Anna AU - Gazumyan A AD - Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA. FAU - Hartweger, Harald AU - Hartweger H AD - Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA. FAU - Bieniasz, Paul D AU - Bieniasz PD AD - Laboratory of Retrovirology, The Rockefeller University, New York, NY, USA; Howard Hughes Medical Institute, New York, NY, USA. FAU - Hatziioannou, Theodora AU - Hatziioannou T AD - Laboratory of Retrovirology, The Rockefeller University, New York, NY, USA. FAU - Martin, Malcolm A AU - Martin MA AD - Laboratory of Molecular Microbiology, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD, USA. FAU - Nussenzweig, Michel C AU - Nussenzweig MC AD - Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA; Howard Hughes Medical Institute, New York, NY, USA. Electronic address: nussen@rockefeller.edu. LA - eng GR - P01 AI100148/AI/NIAID NIH HHS/United States GR - R37 AI037526/AI/NIAID NIH HHS/United States GR - UM1 AI144462/AI/NIAID NIH HHS/United States PT - Journal Article DEP - 20250812 PL - United States TA - Cell Rep JT - Cell reports JID - 101573691 RN - 0 (Spike Glycoprotein, Coronavirus) RN - 0 (Antibodies, Neutralizing) RN - 0 (spike protein, SARS-CoV-2) RN - 0 (COVID-19 Vaccines) RN - 0 (Antibodies, Viral) SB - IM UOF - bioRxiv. 2025 Jun 30:2025.06.27.661994. doi: 10.1101/2025.06.27.661994. PMID: 40747431 MH - Animals MH - *Germinal Center/immunology/cytology MH - *Memory B Cells/immunology MH - Macaca mulatta/immunology MH - *Immunization, Secondary MH - *Immunologic Memory MH - Spike Glycoprotein, Coronavirus/immunology MH - SARS-CoV-2/immunology MH - Antibodies, Neutralizing/immunology MH - *COVID-19/immunology/prevention & control MH - *B-Lymphocytes/immunology MH - *COVID-19 Vaccines/immunology MH - Antibodies, Viral/immunology PMC - PMC12617206 MID - NIHMS2107294 OTO - NOTNLM OT - B cells OT - CP: Immunology OT - SARS-CoV-2 OT - antibodies OT - germinal center OT - mRNA vaccines OT - memory B cells OT - neutralization OT - non-human primates OT - vaccine boosters COIS- Declaration of interests M.C.N. is a member of the Celldex Scientific Advisory Board. EDAT- 2025/08/13 18:27 MHDA- 2025/08/31 20:07 PMCR- 2025/11/14 CRDT- 2025/08/13 12:35 PHST- 2025/04/08 00:00 [received] PHST- 2025/06/26 00:00 [revised] PHST- 2025/07/22 00:00 [accepted] PHST- 2025/08/31 20:07 [medline] PHST- 2025/08/13 18:27 [pubmed] PHST- 2025/08/13 12:35 [entrez] PHST- 2025/11/14 00:00 [pmc-release] AID - S2211-1247(25)00913-1 [pii] AID - 10.1016/j.celrep.2025.116142 [doi] PST - ppublish SO - Cell Rep. 2025 Aug 26;44(8):116142. doi: 10.1016/j.celrep.2025.116142. Epub 2025 Aug 12. PMID- 40796844 OWN - NLM STAT- MEDLINE DCOM- 20250827 LR - 20250827 IS - 1743-422X (Electronic) IS - 1743-422X (Linking) VI - 22 IP - 1 DP - 2025 Aug 12 TI - Acute transverse myelitis and associate vaccine complication in SARS-CoV-2 patients: a retrospective cohort analysis in real-world database. PG - 277 LID - 10.1186/s12985-025-02905-5 [doi] LID - 277 AB - INTRODUCTION: Acute transverse myelitis (ATM) is a rare neurological disorder often associated with infections, autoimmunity, and vaccination. During the COVID-19 pandemic, the incidence of ATM appeared to increase; however, the causal relationship remains uncertain due to limited follow-up and variability in case reporting. This study aims to evaluate the incidence of ATM in SARS-CoV-2 patients, identify associated risk factors, and explore potential links to vaccination using real-world data. METHODS: A retrospective cohort analysis was conducted using electronic health records from the USA collaborative network within the TriNetX database. The study included SARS-CoV-2-infected patients and a matched non-COVID-19 cohort from 2020 to 2023. Propensity score matching (1:1) was applied to minimize baseline differences between the groups. Kaplan-Meier survival curves and Cox proportional hazards models were used to assess the risk of developing ATM within a one-year follow-up period. RESULTS: Patients with SARS-CoV-2 infection had a significantly higher risk of developing ATM compared to non-infected individuals (HR = 1.46, 95% CI = 1.21-1.74). Stratified analyses confirmed this increased risk across various subgroups, including patients younger and older than 65 years, both males and females, and those infected during the Alpha strain-dominant period. No statistical significance between patients with and without SARS-CoV-2 infection after received different SARS-CoV-2 Vaccines. CONCLUSION: SARS-CoV-2 infection appears to be more strongly associated with ATM than COVID-19 vaccination. Given the potential for lifelong disability and the need for long-term care in affected individuals, further studies are warranted to explore the underlying mechanisms and preventive strategies. CI - (c) 2025. The Author(s). FAU - Lu, Jack Yu-Shuo AU - Lu JY AD - Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan. AD - Department of Emergency Medicine, School of Medicine, Chung Shan Medical University, 110, Section 1, Jianguo N. Road, Taichung, Taiwan. AD - Department of Emergency Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan. FAU - Yang, Shun-Fa AU - Yang SF AD - Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan. AD - Department of Medical Research, Chung Shan Medical University Hospital, Taichung, Taiwan. FAU - Tzeng, Shu-Ling AU - Tzeng SL AD - Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan. AD - Department of Medical Research, Chung Shan Medical University Hospital, Taichung, Taiwan. FAU - Lee, Yuan-Ti AU - Lee YT AD - Department of Emergency Medicine, School of Medicine, Chung Shan Medical University, 110, Section 1, Jianguo N. Road, Taichung, Taiwan. AD - Division of Infectious Diseases, Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan. FAU - Wang, Yu-Hsun AU - Wang YH AD - Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan. AD - Department of Medical Research, Chung Shan Medical University Hospital, Taichung, Taiwan. FAU - Yeh, Chao-Bin AU - Yeh CB AD - Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan. sky5ff@gmail.com. AD - Department of Emergency Medicine, School of Medicine, Chung Shan Medical University, 110, Section 1, Jianguo N. Road, Taichung, Taiwan. sky5ff@gmail.com. AD - Department of Emergency Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan. sky5ff@gmail.com. LA - eng PT - Journal Article DEP - 20250812 PL - England TA - Virol J JT - Virology journal JID - 101231645 RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - Retrospective Studies MH - Male MH - *Myelitis, Transverse/epidemiology/etiology MH - Female MH - *COVID-19/prevention & control/complications/epidemiology MH - Middle Aged MH - Adult MH - Aged MH - SARS-CoV-2/immunology MH - Risk Factors MH - Incidence MH - *COVID-19 Vaccines/adverse effects MH - Databases, Factual MH - Vaccination/adverse effects PMC - PMC12344938 OTO - NOTNLM OT - Acute transverse myelitis OT - COVID-19 vaccine OT - Incidence OT - Risk factors OT - SARS-CoV-2 COIS- Declarations. Ethical approval and consent to participate: This study was approved by the Institutional Review Board for Ethics of Chung Shan Medical University Hospital (IRB number: CS2-23180) and performed in accordance with the Declaration of Helsinki. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests. EDAT- 2025/08/13 00:28 MHDA- 2025/08/31 20:07 PMCR- 2025/08/12 CRDT- 2025/08/12 23:35 PHST- 2025/03/22 00:00 [received] PHST- 2025/07/30 00:00 [accepted] PHST- 2025/08/31 20:07 [medline] PHST- 2025/08/13 00:28 [pubmed] PHST- 2025/08/12 23:35 [entrez] PHST- 2025/08/12 00:00 [pmc-release] AID - 10.1186/s12985-025-02905-5 [pii] AID - 2905 [pii] AID - 10.1186/s12985-025-02905-5 [doi] PST - epublish SO - Virol J. 2025 Aug 12;22(1):277. doi: 10.1186/s12985-025-02905-5. PMID- 40791594 OWN - NLM STAT- MEDLINE DCOM- 20250812 LR - 20250814 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 16 DP - 2025 TI - Mixed lipopeptide-based mucosal vaccine elicits a long-term bone marrow memory response that is potentially cross-reactive against a broad-spectrum of coronaviruses in mice. PG - 1619882 LID - 10.3389/fimmu.2025.1619882 [doi] LID - 1619882 AB - INTRODUCTION: SARS-CoV-2 is continuing to prevail as an endemic virus, and therefore, we need a next-generation vaccine that prevents SARS-CoV-2 infections, broadly protects against multiple CoVs, and induces long-term local and systemic immunity. To address that need, we have designed a mixed lipopeptide-based pan-coronavirus (LP(Mix)) vaccine based on T and B cell epitopes derived from highly conserved and functional regions of the SARS-CoV-2 spike (S), nucleocapsid (N), and membrane (M) proteins. METHODS: Male C57BL/6 mice (n=5 per group) were immunized intranasally twice, 14 days apart, with the LP(Mix) vaccine candidates, which consisted of seven lipopeptides (LP1-LP7), with or without HKCC (heat-killed Caulobacter crescentus), a novel mucosal adjuvant. At 2.5 weeks, 2 months, and 7 months post-immunization, lung, spleen, bone marrow, and bronchoalveolar lavage (BAL) samples were collected for immunological analyses. Additionally, blood samples were collected monthly to monitor antibody titers. RESULTS: We demonstrate that intranasal immunizations of mice with LP(Mix) induced a long-lasting systemic IgM/IgG, and mucosal IgA response against a broad-spectrum of CoVs, showing clinically significant levels of neutralizing antibody titers. Splenocytes and bone marrow cells, derived from LP(Mix) immunized mice, demonstrated a robust proliferation response against vaccine antigens (P(1-7)), which were maintained up to 2 months and 7 months, after LP(Mix) immunizations, respectively. Moreover, antigen-specific B cells and memory CD4(+)/CD8(+) T cells were long-lived and maintained up to 7 months after LP(Mix) immunizations, in the lungs, spleen and bone marrow. The addition of HKCC (heat-killed Caulobacter crescentus), a novel mucosal adjuvant, promoted the longevity of memory CD4(+)/CD8(+) T cell and B cell responses. DISCUSSION: Overall, our study demonstrates that a mucosal lipopeptide-based vaccine targeting conserved SARS-CoV-2 epitopes elicits durable, long-lasting immune responses against a broad range of coronaviruses. CI - Copyright (c) 2025 Patel and Agrawal. FAU - Patel, Raj S AU - Patel RS AD - Department of Surgery, Faculty of Medicine and Dentistry, College of Health Sciences, University Alberta, Edmonton, AB, Canada. FAU - Agrawal, Babita AU - Agrawal B AD - Department of Surgery, Faculty of Medicine and Dentistry, College of Health Sciences, University Alberta, Edmonton, AB, Canada. LA - eng PT - Journal Article DEP - 20250728 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 RN - 0 (Lipopeptides) RN - 0 (COVID-19 Vaccines) RN - 0 (Antibodies, Viral) RN - 0 (Spike Glycoprotein, Coronavirus) RN - 0 (Epitopes, B-Lymphocyte) RN - 0 (Epitopes, T-Lymphocyte) RN - 0 (spike protein, SARS-CoV-2) SB - IM MH - Animals MH - *Lipopeptides/immunology MH - Mice MH - Male MH - *Immunologic Memory MH - Mice, Inbred C57BL MH - *COVID-19 Vaccines/immunology/administration & dosage MH - *COVID-19/immunology/prevention & control MH - Antibodies, Viral/immunology/blood MH - Spike Glycoprotein, Coronavirus/immunology MH - *SARS-CoV-2/immunology MH - Cross Reactions/immunology MH - *Bone Marrow/immunology MH - Epitopes, B-Lymphocyte/immunology MH - Epitopes, T-Lymphocyte/immunology MH - Administration, Intranasal MH - Immunity, Mucosal PMC - PMC12336212 OTO - NOTNLM OT - SARS-CoV-2 OT - broad-spectrum OT - immunological memory OT - lipopeptide-based vaccine OT - mucosal immunity OT - pan-coronavirus COIS- BA is a co-inventor on a number of patents issued worldwide on HKCC adjuvant. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision. EDAT- 2025/08/12 11:15 MHDA- 2025/08/12 11:16 PMCR- 2025/07/28 CRDT- 2025/08/12 05:14 PHST- 2025/04/28 00:00 [received] PHST- 2025/06/27 00:00 [accepted] PHST- 2025/08/12 11:16 [medline] PHST- 2025/08/12 11:15 [pubmed] PHST- 2025/08/12 05:14 [entrez] PHST- 2025/07/28 00:00 [pmc-release] AID - 10.3389/fimmu.2025.1619882 [doi] PST - epublish SO - Front Immunol. 2025 Jul 28;16:1619882. doi: 10.3389/fimmu.2025.1619882. eCollection 2025. PMID- 40746539 OWN - NLM STAT- MEDLINE DCOM- 20250801 LR - 20260127 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 16 DP - 2025 TI - Immune memory reactivation and T cell dynamics following 12-month homologous CoronaVac booster: a longitudinal cohort study. PG - 1636629 LID - 10.3389/fimmu.2025.1636629 [doi] LID - 1636629 AB - BACKGROUND: Inactivated COVID-19 vaccines exhibit more rapid declines in antibody levels than other vaccine platforms, likely owing to transient antigen exposure and limited germinal center persistence. Moreover, although homologous boosting effectively restores humoral immunity, concerns persist regarding potential T cell exhaustion with repeated antigen exposure. We evaluated the effectiveness of delayed homologous CoronaVac booster immunization in reactivating immune memory. METHODS: A prospective longitudinal cohort study was conducted with 83 healthy adults who received two CoronaVac vaccine doses (14-day interval) and a homologous booster shot after 12 months. Peripheral blood samples were collected 0, 3, 7, 10, and 14 days after booster vaccination. Neutralizing antibodies were analysed using live-virus microneutralization assays. Anti-receptor-binding domain immunoglobulin subclasses (IgG1, IgG2, IgG3, IgG4) were detected using enzyme-linked immunosorbent assay. Cytokine secretion (interferon [IFN]-gamma/interleukin [IL]-2/IL-4/IL-5) was assessed using enzyme-linked immunospot assay. T cell polarization and exhaustion markers (T-bet/GATA3 and CD69/CTLA-4/PD-1) were evaluated using flow cytometry. RESULTS: The geometric mean titer of neutralizing antibodies reached 254.5 on day 14. The initial immune response was dominated by IgG3, which subsequently shifted to IgG1. A significant Th1-type cellular immune response was characterized by increased IFN-gamma and IL-2 secretion, and upregulated T-bet expression. Transient CD69+ T cell activation occurred between days 3 and 10 without sustained PD-1 and CTLA-4 elevation. CONCLUSIONS: Delayed homologous CoronaVac booster immunization effectively reactivates immune memory, facilitated by Th1 polarization and transient T cell activation, which do not result in T cell exhaustion. These findings suggest the potential application of long-interval immunization strategies against COVID-19. CI - Copyright (c) 2025 Song, Chen, Bai, Lv, Wang, Zhang, Wu and Zhao. FAU - Song, Xinran AU - Song X AD - Beijing Key Laboratory of Surveillance, Early Warning and Pathogen Research on Emerging Infectious Diseases, Beijing Center for Disease Prevention and Control, Beijing, China. AD - Beijing Research Center for Respiratory Infectious Diseases, Beijing, China. FAU - Chen, Weixin AU - Chen W AD - Beijing Key Laboratory of Surveillance, Early Warning and Pathogen Research on Emerging Infectious Diseases, Beijing Center for Disease Prevention and Control, Beijing, China. AD - Beijing Research Center for Respiratory Infectious Diseases, Beijing, China. FAU - Bai, Shuang AU - Bai S AD - Beijing Key Laboratory of Surveillance, Early Warning and Pathogen Research on Emerging Infectious Diseases, Beijing Center for Disease Prevention and Control, Beijing, China. AD - Beijing Research Center for Respiratory Infectious Diseases, Beijing, China. FAU - Lv, Min AU - Lv M AD - Beijing Key Laboratory of Surveillance, Early Warning and Pathogen Research on Emerging Infectious Diseases, Beijing Center for Disease Prevention and Control, Beijing, China. AD - Beijing Research Center for Respiratory Infectious Diseases, Beijing, China. FAU - Wang, Jian AU - Wang J AD - Beijing Key Laboratory of Surveillance, Early Warning and Pathogen Research on Emerging Infectious Diseases, Beijing Center for Disease Prevention and Control, Beijing, China. AD - Beijing Research Center for Respiratory Infectious Diseases, Beijing, China. FAU - Zhang, Ao AU - Zhang A AD - Beijing Key Laboratory of Surveillance, Early Warning and Pathogen Research on Emerging Infectious Diseases, Beijing Center for Disease Prevention and Control, Beijing, China. AD - Beijing Research Center for Respiratory Infectious Diseases, Beijing, China. FAU - Wu, Jiang AU - Wu J AD - Beijing Key Laboratory of Surveillance, Early Warning and Pathogen Research on Emerging Infectious Diseases, Beijing Center for Disease Prevention and Control, Beijing, China. AD - Beijing Research Center for Respiratory Infectious Diseases, Beijing, China. FAU - Zhao, Wei AU - Zhao W AD - Beijing Key Laboratory of Surveillance, Early Warning and Pathogen Research on Emerging Infectious Diseases, Beijing Center for Disease Prevention and Control, Beijing, China. AD - Beijing Research Center for Respiratory Infectious Diseases, Beijing, China. AD - School of Public Health, Capital Medical University, Beijing, China. LA - eng PT - Journal Article DEP - 20250717 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 RN - 0 (COVID-19 Vaccines) RN - 0 (Antibodies, Viral) RN - 0 (Antibodies, Neutralizing) RN - 0 (Cytokines) RN - 0 (Immunoglobulin G) RN - 0 (sinovac COVID-19 vaccine) RN - 0 (Vaccines, Inactivated) SB - IM MH - Humans MH - *Immunologic Memory MH - *Immunization, Secondary MH - Longitudinal Studies MH - Male MH - Female MH - Adult MH - *SARS-CoV-2/immunology MH - *COVID-19/immunology/prevention & control MH - *COVID-19 Vaccines/immunology/administration & dosage MH - Middle Aged MH - Antibodies, Viral/blood/immunology MH - Antibodies, Neutralizing/blood/immunology MH - *T-Lymphocytes/immunology MH - Prospective Studies MH - Cytokines MH - Young Adult MH - Lymphocyte Activation MH - Immunoglobulin G/blood MH - Vaccines, Inactivated PMC - PMC12310696 OTO - NOTNLM OT - SARS-CoV-2 inactivated vaccine OT - T cell exhaustion OT - Th1 polarization OT - homologous boosting OT - neutralizing antibodies COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2025/08/01 11:33 MHDA- 2025/08/01 11:34 PMCR- 2025/07/17 CRDT- 2025/08/01 05:00 PHST- 2025/05/28 00:00 [received] PHST- 2025/06/28 00:00 [accepted] PHST- 2025/08/01 11:34 [medline] PHST- 2025/08/01 11:33 [pubmed] PHST- 2025/08/01 05:00 [entrez] PHST- 2025/07/17 00:00 [pmc-release] AID - 10.3389/fimmu.2025.1636629 [doi] PST - epublish SO - Front Immunol. 2025 Jul 17;16:1636629. doi: 10.3389/fimmu.2025.1636629. eCollection 2025. PMID- 40717731 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250731 IS - 2373-7972 (Electronic) IS - 2373-8006 (Print) IS - 2373-8006 (Linking) VI - 12 IP - 2 DP - 2025 TI - COVID-19 vaccines and neurological disorders: A narrative review of immune responses and adverse reactions. PG - 222-249 LID - 10.3934/Neuroscience.2025013 [doi] AB - COVID-19 vaccines have been effective in providing strong immunity within a relatively short time frame, significantly reducing both the severity of the disease and associated mortality. However, post-vaccination complications, particularly neurological disorders, have been reported. Among the more frequently documented neurological complications are acute disseminated encephalomyelitis (ADEM), multiple sclerosis (MS), transverse myelitis (TM), optic neuritis (ON), Bell's palsy (BP), and Guillain-Barre syndrome (GBS). The precise role of COVID-19 vaccines in triggering the onset or relapse of these conditions remains uncertain. Immunological processes involving cytokines, chemokines, antibodies, and immune cells are believed to contribute to the pathogenesis of these neurological side effects. This review examines the immune responses triggered by COVID-19 vaccines and their potential role in the development of such complications. Despite reports of neurological side effects, these cases remain rare, and the overall benefits of vaccination in curbing the pandemic and preventing severe illness far exceed the risks. It is vital to sustain the progress of global vaccination efforts while continuously evaluating the risk-benefit ratio, particularly for individuals with underlying conditions. Ongoing research and surveillance are crucial for creating safer vaccines and identifying individuals who may be more susceptible to adverse reactions, ensuring broader protection against COVID-19. CI - (c) 2025 the Author(s), licensee AIMS Press. FAU - Joodaki, Mehran AU - Joodaki M AD - Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran. FAU - Seif, Farhad AU - Seif F AD - Department of Photodynamic, Medical Laser Research Center, Yara Institute, Academic Center for Education, Culture, and Research (ACECR), Tehran, Iran. FAU - Afzalnia, Azadeh AU - Afzalnia A AD - Rajaei Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran. FAU - Emtiazi, Nikoo AU - Emtiazi N AD - Department of Pathology Medicine, Rasool Akram Hospital, School of Medicine, Iran University of Medical Sciences, Tehran, Iran. FAU - Shirazi, Mona Merati AU - Shirazi MM AD - Biomedical Engineering Faculty, Biomechanics Department, Islamic Azad University, Science and Research Branch, Tehran, Iran. FAU - Ashtari, Behnaz AU - Ashtari B AD - Radiation Biology Research Center, Iran University of Medical Sciences, Tehran, Iran. AD - Department of Medical Nanotechnology, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran, Iran. FAU - Hosseinian, Seyed Mohamad AU - Hosseinian SM AD - Rheumatology Department, Shafa Hospital, Kerman University of Medical Sciences, Kerman, Iran. FAU - Hosseini, Nasrin AU - Hosseini N AD - Neuroscience Research Center, Iran University of Medical Sciences, Tehran, Iran. LA - eng PT - Journal Article PT - Review DEP - 20250618 PL - United States TA - AIMS Neurosci JT - AIMS neuroscience JID - 101665668 PMC - PMC12287643 OTO - NOTNLM OT - COVID-19 OT - immunogenicity OT - neurodegeneration OT - neurological complication OT - vaccine COIS- Conflict of interest: The authors declare no conflict of interest. EDAT- 2025/07/28 18:51 MHDA- 2025/07/28 18:52 PMCR- 2025/06/18 CRDT- 2025/07/28 04:53 PHST- 2025/01/17 00:00 [received] PHST- 2025/05/27 00:00 [revised] PHST- 2025/05/30 00:00 [accepted] PHST- 2025/07/28 18:52 [medline] PHST- 2025/07/28 18:51 [pubmed] PHST- 2025/07/28 04:53 [entrez] PHST- 2025/06/18 00:00 [pmc-release] AID - neurosci-12-02-013 [pii] AID - 10.3934/Neuroscience.2025013 [doi] PST - epublish SO - AIMS Neurosci. 2025 Jun 18;12(2):222-249. doi: 10.3934/Neuroscience.2025013. eCollection 2025. PMID- 40706509 OWN - NLM STAT- MEDLINE DCOM- 20260205 LR - 20260205 IS - 1873-2518 (Electronic) IS - 0264-410X (Linking) VI - 62 DP - 2025 Aug 30 TI - Evaluation of T cell immune memory response after BBIBP-CorV, gam-COVID-Vac, and heterologous gam-COVID-Vac /mRNA-1273 COVID-19 vaccination schemes against different SARS-CoV-2 variants. PG - 127526 LID - S0264-410X(25)00823-0 [pii] LID - 10.1016/j.vaccine.2025.127526 [doi] AB - INTRODUCTION: The adaptive immune response plays a crucial role in resolution of viral infections; however, there is limited data on the T cell response to SARS-CoV-2 vaccines such as BBIBP-CorV, Gam-COVID-Vac, and especially for the heterologous combination Gam-COVID-Vac/mRNA-1273 scheme. Furthermore, emerging variants may compromise the adaptive immune response established in the population. OBJECTIVE: To evaluate the T cell immune response induced by the BBIBP-CorV, Gam-COVID-Vac and Gam-COVID-Vac/mRNA-1273, against the ancestral wild type (WT) virus and the Gamma and Omicron variants. METHODS: Serum levels of IgG antibodies were assessed by CMIA (Abbott Diagnostics, Abbott Park, Illinois). T cell responses against WT virus, Gamma and Omicron were evaluated through an activation-induced marker assay. Sixty individuals, evenly distributed across the BBIBP-CorV, Gam-COVID-Vac, and Gam-COVID-Vac/mRNA-1273 groups, were included. RESULTS: The median age of participants was 48 years (IQR: 34-56), with 58.3 % (n = 35) being female. Seventeen (28.3 %) individuals had a prior confirmed COVID-19 infection. Gam-COVID-Vac/mRNA-1273 scheme elicited significantly higher humoral responses (p < 0.001). However, the three vaccination platforms showed consistent T cell responses across the three stimuli tested. Particularly, all three schemes induced stronger CD8(+) responses against the WT virus. In addition, more responders to WT were observed in the BBIBP-CorV and Gam-COVID-Vac groups, while the Gam-COVID-Vac/mRNA-1273 group showed a greater proportion of responders to Omicron. CONCLUSION: This study provides new data on effective humoral and cellular immune responses against the ancestral WT virus as well as the Gamma and Omicron variants. Moreover, memory CD4(+) and CD8(+) T cell responses remain protective, and the heterologous scheme may elicit stronger T cell responses against emerging variants. CI - Copyright (c) 2025 Elsevier Ltd. All rights reserved. FAU - Pereson, Matias J AU - Pereson MJ AD - Instituto de Medicina Experimental (IMEX), Academia Nacional de Medicina. Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET), Ciudad Autonoma de Buenos Aires, Argentina. FAU - Badano, Maria Noel AU - Badano MN AD - Instituto de Medicina Experimental (IMEX), Academia Nacional de Medicina. Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET), Ciudad Autonoma de Buenos Aires, Argentina. FAU - Sabbione, Florencia AU - Sabbione F AD - Instituto de Medicina Experimental (IMEX), Academia Nacional de Medicina. Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET), Ciudad Autonoma de Buenos Aires, Argentina. FAU - Keitelman, Irene AU - Keitelman I AD - Instituto de Medicina Experimental (IMEX), Academia Nacional de Medicina. Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET), Ciudad Autonoma de Buenos Aires, Argentina. FAU - Aloisi, Natalia AU - Aloisi N AD - Instituto de Investigaciones Hematologicas Mariano R. Castex (IIHEMA), Academia Nacional de Medicina, Buenos Aires, Argentina. FAU - Fink, Susana AU - Fink S AD - Instituto de Medicina Experimental (IMEX), Academia Nacional de Medicina. Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET), Ciudad Autonoma de Buenos Aires, Argentina. FAU - Amaya, Lucas AU - Amaya L AD - Universidad de Buenos Aires. Facultad de Farmacia y Bioquimica. Buenos Aires, Argentina. FAU - Garcia, Gabriel H AU - Garcia GH AD - Universidad de Buenos Aires. Facultad de Farmacia y Bioquimica. Buenos Aires, Argentina. FAU - Martinez, Alfredo P AU - Martinez AP AD - Virology Section, Centro de Educacion Medica e Investigaciones Clinicas Norberto Quirno (CEMIC). Buenos Aires, Argentina. FAU - Di Lello, Federico A AU - Di Lello FA AD - Instituto de Medicina Experimental (IMEX), Academia Nacional de Medicina. Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET), Ciudad Autonoma de Buenos Aires, Argentina. FAU - Bare, Patricia AU - Bare P AD - Instituto de Medicina Experimental (IMEX), Academia Nacional de Medicina. Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET), Ciudad Autonoma de Buenos Aires, Argentina; Instituto de Investigaciones Hematologicas Mariano R. Castex (IIHEMA), Academia Nacional de Medicina, Buenos Aires, Argentina. Electronic address: pbare@hematologia.anm.edu.ar. LA - eng PT - Evaluation Study PT - Journal Article DEP - 20250723 PL - Netherlands TA - Vaccine JT - Vaccine JID - 8406899 RN - 0 (COVID-19 Vaccines) RN - 0 (Vaccines, Inactivated) RN - 0 (spike protein, SARS-CoV-2) RN - 0 (Spike Glycoprotein, Coronavirus) RN - 0 (Immunoglobulin G) RN - 0 (Antibodies, Viral) RN - SARS-CoV-2 variants SB - IM MH - Humans MH - Male MH - Female MH - Adult MH - Middle Aged MH - *Immunologic Memory MH - *T-Lymphocytes/immunology MH - *COVID-19 Vaccines/immunology MH - *SARS-CoV-2/genetics/immunology MH - Mutation MH - Vaccination/methods MH - Vaccines, Inactivated/immunology MH - Spike Glycoprotein, Coronavirus/immunology MH - Immunoglobulin G/blood/immunology MH - Antibodies, Viral/blood/immunology OTO - NOTNLM OT - Argentina OT - SARS-CoV-2 OT - T cell immune response OT - Vaccines OT - Variants of concern COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2025/07/25 00:29 MHDA- 2025/09/16 00:34 CRDT- 2025/07/24 18:12 PHST- 2024/12/17 00:00 [received] PHST- 2025/07/11 00:00 [revised] PHST- 2025/07/14 00:00 [accepted] PHST- 2025/09/16 00:34 [medline] PHST- 2025/07/25 00:29 [pubmed] PHST- 2025/07/24 18:12 [entrez] AID - S0264-410X(25)00823-0 [pii] AID - 10.1016/j.vaccine.2025.127526 [doi] PST - ppublish SO - Vaccine. 2025 Aug 30;62:127526. doi: 10.1016/j.vaccine.2025.127526. Epub 2025 Jul 23. PMID- 40655221 OWN - NLM STAT- MEDLINE DCOM- 20250714 LR - 20260925 IS - 2296-2565 (Electronic) IS - 2296-2565 (Linking) VI - 13 DP - 2025 TI - Understanding the social and cognitive influences on the adoption of COVID-19 non-pharmaceutical interventions: a survey of a Saudi Arabian sample. PG - 1588931 LID - 10.3389/fpubh.2025.1588931 [doi] LID - 1588931 AB - INTRODUCTION: COVID-19 vaccines prevent death and severe illness, but not infection. Public health leaders continue to stress the importance of non-pharmaceutical intervention behaviors (NPIs). However, little is known about how social, environmental, and cognitive factors influence the adoption of NPIs. METHODS: A theory-informed survey was distributed to adults living in Al-Ahsa, Saudi Arabia. The primary focus is self-reported adherence with NPIs. Socio-environmental factors included observational learning, social norms, and media. Personal cognitive factors included self-efficacy, outcome expectancies, and knowledge. RESULTS: The mean age was 31 years (n = 368), most participants were males (62%), and the study sample were significantly more vaccinated (40%) than the Saudi public (5.3%). NPIs were strongly correlated with social norms (r = 0.73, p < 0.001), and positively correlated with self-efficacy (r = 0.25, p < 0.001). Females reported higher NPIs adherence rates (M = 17.04, SD = 3.86) than males (M = 16.29, SD = 4.12). The hierarchical multiple regression model revealed that socio-environmental factors explained a significant proportion of variance in NPIs (R (2) = 0.52, p < 0.001). DISCUSSION: The findings highlight the usefulness of a social cognitive model in predicting NPIs. The study shows that social factors, especially social norms, significantly influence the adoption of NPIs. Hence, health organizations should consider social factors when developing campaigns against current and future infectious diseases. CI - Copyright (c) 2025 Alobaydullah, LaJoie, Thomas, Fumey and Alsaleem. FAU - Alobaydullah, Ahmed AU - Alobaydullah A AD - Emergency Medical Services Program, College of Applied Medical Sciences, King Saud bin Abdulaziz University for Health Sciences, Al Ahsa, Saudi Arabia. AD - King Abdullah International Medical Research Center, Al Ahsa, Saudi Arabia. FAU - LaJoie, Andrew Scott AU - LaJoie AS AD - Department of Health Promotion and Behavioral Sciences, University of Louisville, Louisville, KY, United States. FAU - Thomas, Susann Denise AU - Thomas SD AD - Department of Health Promotion and Behavioral Sciences, University of Louisville, Louisville, KY, United States. FAU - Fumey, Raphael AU - Fumey R AD - Department of Health Promotion and Behavioral Sciences, University of Louisville, Louisville, KY, United States. FAU - Alsaleem, Abdulrahman AU - Alsaleem A AD - Emergency Medical Services Program, College of Applied Medical Sciences, King Saud bin Abdulaziz University for Health Sciences, Al Ahsa, Saudi Arabia. AD - King Abdullah International Medical Research Center, Al Ahsa, Saudi Arabia. LA - eng PT - Journal Article DEP - 20250627 PL - Switzerland TA - Front Public Health JT - Frontiers in public health JID - 101616579 RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - Saudi Arabia MH - Male MH - Female MH - Adult MH - *COVID-19/prevention & control MH - Self Efficacy MH - Middle Aged MH - Surveys and Questionnaires MH - SARS-CoV-2 MH - *COVID-19 Vaccines/administration & dosage MH - Young Adult MH - *Health Knowledge, Attitudes, Practice MH - *Cognition MH - Adolescent MH - Social Norms PMC - PMC12245856 OTO - NOTNLM OT - COVID-19 OT - Saudi Arabia OT - non-pharmaceutical interventions OT - preventive behaviors OT - social cognitive theory OT - social norms COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2025/07/14 12:29 MHDA- 2025/07/14 12:30 PMCR- 2025/06/27 CRDT- 2025/07/14 07:36 PHST- 2025/03/06 00:00 [received] PHST- 2025/05/31 00:00 [accepted] PHST- 2025/07/14 12:30 [medline] PHST- 2025/07/14 12:29 [pubmed] PHST- 2025/07/14 07:36 [entrez] PHST- 2025/06/27 00:00 [pmc-release] AID - 10.3389/fpubh.2025.1588931 [doi] PST - epublish SO - Front Public Health. 2025 Jun 27;13:1588931. doi: 10.3389/fpubh.2025.1588931. eCollection 2025. PMID- 40642065 OWN - NLM STAT- MEDLINE DCOM- 20250711 LR - 20250712 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 16 DP - 2025 TI - A consensus mathematical model of vaccine-induced antibody dynamics for multiple vaccine platforms and pathogens. PG - 1596518 LID - 10.3389/fimmu.2025.1596518 [doi] LID - 1596518 AB - INTRODUCTION: Vaccine platforms used in successful, licensed vaccines have varied among pathogens. However, antibody level is still the main clinical correlate of protection in most approved vaccines. Decisions as to the best vaccine platform to pursue for a given pathogen may be informed through improved understanding of the process of antibody generation and its temporal dynamics, as well as the relationship between these processes and the type of vaccine. METHODS: We have analyzed the dynamics of antibody generation for different vaccine platforms against diverse pathogens, and developed a consensus mathematical model that captures antibody dynamics across these diverse systems. Initially, the model was fitted to a rich dataset of antibody and immune cell concentrations in a SARS-CoV-2 vaccine experiment. We then used concepts from machine learning, such as transfer learning, to apply the same model to a variety of systems, involving different pathogens, vaccine platforms, and booster dose use/timing, fixing most parameter values relating to the dynamics of the immune system. RESULTS: The model includes B cell proliferation and differentiation, as well as the generation of plasma cells, which secrete large amounts of antibody, and memory B cells. Overall, the model describes antibody generation in all systems tested well and shows that the main differences across platforms are related to the dynamics of antigen presentation. DISCUSSION: This model can be used to predict antibody generation in pairs of vaccine platform/pathogen, allowing for the use of in silico results to narrow down experimental burden in vaccine development. CI - Copyright (c) 2025 Wilding, Molina-Paris, Kubicek-Sutherland, McMahon, Perelson and Ribeiro. FAU - Wilding, Kristen M AU - Wilding KM AD - Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM, United States. FAU - Molina-Paris, Carmen AU - Molina-Paris C AD - Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM, United States. FAU - Kubicek-Sutherland, Jessica Z AU - Kubicek-Sutherland JZ AD - Physical Chemistry and Applied Spectroscopy Group, Los Alamos National Laboratory, Los Alamos, NM, United States. FAU - McMahon, Benjamin AU - McMahon B AD - Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM, United States. FAU - Perelson, Alan S AU - Perelson AS AD - Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM, United States. FAU - Ribeiro, Ruy M AU - Ribeiro RM AD - Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM, United States. LA - eng PT - Journal Article DEP - 20250626 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 RN - 0 (Antibodies, Viral) RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - *Antibodies, Viral/immunology MH - *SARS-CoV-2/immunology MH - *COVID-19 Vaccines/immunology MH - *COVID-19/immunology/prevention & control MH - B-Lymphocytes/immunology MH - *Models, Immunological MH - *Models, Theoretical MH - Animals PMC - PMC12241011 OTO - NOTNLM OT - B cell OT - SARS-CoV-2 OT - antibody dynamics OT - ebola OT - mathematical model OT - memory OT - vaccine OT - vaccine platform COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2025/07/11 06:27 MHDA- 2025/07/11 06:28 PMCR- 2025/06/26 CRDT- 2025/07/11 05:12 PHST- 2025/03/19 00:00 [received] PHST- 2025/06/02 00:00 [accepted] PHST- 2025/07/11 06:28 [medline] PHST- 2025/07/11 06:27 [pubmed] PHST- 2025/07/11 05:12 [entrez] PHST- 2025/06/26 00:00 [pmc-release] AID - 10.3389/fimmu.2025.1596518 [doi] PST - epublish SO - Front Immunol. 2025 Jun 26;16:1596518. doi: 10.3389/fimmu.2025.1596518. eCollection 2025. PMID- 40573882 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250630 IS - 2076-393X (Print) IS - 2076-393X (Electronic) IS - 2076-393X (Linking) VI - 13 IP - 6 DP - 2025 May 22 TI - Longitudinal Immunoprofiling of the CD8(+) T-Cell Response in SARS-CoV-2 mRNA Vaccinees and COVID-19 Patients. LID - 10.3390/vaccines13060551 [doi] LID - 551 AB - Background: SARS-CoV-2 was the causing agent of the COVID-19 pandemic, which resulted in millions of deaths worldwide and massive economic losses. Although there are already several vaccines licensed, as novel variants develop, understanding the immune response induced by vaccination and natural infection is key for the development of future vaccines. Methods: In this study, we have used flow cytometry and next-generation sequencing to assess the longitudinal CD8(+) T-cell response against natural infection and vaccination in convalescent and vaccinated individuals, from early activation to immune memory establishment. Moreover, we have characterized the T-cell receptor clonality and diversity at different stages post-infection and post-vaccination. Results: We have found no significant differences in CD8(+) T-cell activation during the first three weeks post-infection compared to the first three weeks after first vaccination. Conversely, natural infection resulted in sustained high levels of T-cell activation at four weeks post-infection, a point in which we observed a decline in T-cell activation post-vaccination despite boosting with a second vaccination shot. Moreover, additional vaccination did not result in enhanced T-cell activation. Of note, we have observed variations in the memory subset structure at every stage of disease and vaccination. Overall, both infection and immunization induced a highly diverse T-cell receptor repertoire, which was observed both between study groups and between patients inside a given group. Conclusions: These data contribute to expand our knowledge about the immune response to SARS-CoV-2 infection and vaccination and call for additional strategies to enhance T-cell responses by booster immunization. FAU - Brunetti, Jesus Emanuel AU - Brunetti JE AUID- ORCID: 0000-0001-9276-3408 AD - Bernhard Nocht Institute for Tropical Medicine, 20359 Hamburg, Germany. AD - Centre de Recherche de Saint Antoine (CRSA), Institut National de la Sante et de la Recherche Medicale (INSERM), Sorbonne Universite, 75012 Paris, France. FAU - Escudero-Perez, Beatriz AU - Escudero-Perez B AD - Bernhard Nocht Institute for Tropical Medicine, 20359 Hamburg, Germany. AD - German Center for Infection Research (DZIF), Partner Site Hamburg-Borstel-Lubeck-Riems, 38124 Braunschweig, Germany. AD - Department of Clinical Microbiology, Hospital Clinic de Barcelona, 08036 Barcelona, Spain. AD - Barcelona Institute for Global Health (ISGlobal), Hospital Clinic de Barcelona, Universitat de Barcelona, 08036 Barcelona, Spain. FAU - Lasala, Fatima AU - Lasala F AUID- ORCID: 0000-0001-8183-1866 AD - Instituto de Investigacion, Hospital Universitario 12 de Octubre (Imas12), 28041 Madrid, Spain. FAU - Rivas, Gonzalo AU - Rivas G AD - Instituto de Investigacion, Hospital Universitario 12 de Octubre (Imas12), 28041 Madrid, Spain. FAU - Mancheno-Losa, Mikel AU - Mancheno-Losa M AD - Department of Internal Medicine, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain. FAU - Rial-Crestelo, David AU - Rial-Crestelo D AUID- ORCID: 0000-0001-9951-712X AD - Department of Internal Medicine, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain. AD - CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, 28029 Madrid, Spain. FAU - Lora-Tamayo, Jaime AU - Lora-Tamayo J AD - Department of Internal Medicine, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain. AD - CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, 28029 Madrid, Spain. FAU - Cadar, Daniel AU - Cadar D AD - Bernhard Nocht Institute for Tropical Medicine, 20359 Hamburg, Germany. FAU - Carroll, Miles AU - Carroll M AD - Nuffield Department of Medicine, University of Oxford, Oxford OX3 7BN, UK. FAU - Delgado, Rafael AU - Delgado R AUID- ORCID: 0000-0002-6912-4736 AD - Instituto de Investigacion, Hospital Universitario 12 de Octubre (Imas12), 28041 Madrid, Spain. AD - School of Medicine, Universidad Complutense de Madrid, 28040 Madrid, Spain. FAU - Munoz-Fontela, Cesar AU - Munoz-Fontela C AUID- ORCID: 0000-0002-7725-2586 AD - Bernhard Nocht Institute for Tropical Medicine, 20359 Hamburg, Germany. AD - German Center for Infection Research (DZIF), Partner Site Hamburg-Borstel-Lubeck-Riems, 38124 Braunschweig, Germany. FAU - Rodriguez, Estefania AU - Rodriguez E AUID- ORCID: 0000-0003-3367-2754 AD - Bernhard Nocht Institute for Tropical Medicine, 20359 Hamburg, Germany. AD - German Center for Infection Research (DZIF), Partner Site Hamburg-Borstel-Lubeck-Riems, 38124 Braunschweig, Germany. AD - National Centre for Microbiology, Instituto de Salud Carlos III, 28220 Madrid, Spain. LA - eng GR - GR4261/4-1 | RO 5956/2-1/Deutsche Forschungsgemeinschaft/ GR - 101046084; 848166/European Union/ PT - Journal Article DEP - 20250522 PL - Switzerland TA - Vaccines (Basel) JT - Vaccines JID - 101629355 PMC - PMC12197383 OTO - NOTNLM OT - CD8+ T cells OT - COVID-19 OT - SARS-CoV-2 OT - T-cell activation OT - T-cell memory OT - TCR OT - natural infection OT - vaccination COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2025/06/27 06:27 MHDA- 2025/06/27 06:28 PMCR- 2025/05/22 CRDT- 2025/06/27 01:11 PHST- 2025/04/10 00:00 [received] PHST- 2025/05/18 00:00 [revised] PHST- 2025/05/20 00:00 [accepted] PHST- 2025/06/27 06:28 [medline] PHST- 2025/06/27 06:27 [pubmed] PHST- 2025/06/27 01:11 [entrez] PHST- 2025/05/22 00:00 [pmc-release] AID - vaccines13060551 [pii] AID - vaccines-13-00551 [pii] AID - 10.3390/vaccines13060551 [doi] PST - epublish SO - Vaccines (Basel). 2025 May 22;13(6):551. doi: 10.3390/vaccines13060551. PMID- 40554922 OWN - NLM STAT- MEDLINE DCOM- 20250810 LR - 20250810 IS - 1973-8102 (Electronic) IS - 0010-9452 (Linking) VI - 189 DP - 2025 Aug TI - Changes in memory function in adults following SARS-CoV-2 infection: Findings from the Covid and Cognition online study. PG - 205-225 LID - S0010-9452(25)00158-3 [pii] LID - 10.1016/j.cortex.2025.05.019 [doi] AB - SARS-CoV-2, the virus responsible for the Covid-19 pandemic, has been shown to have an impact on cognitive function, but the specific aspects of cognition that are affected remain unclear. In this Registered Report, we analysed cognitive data collected online from 296 participants (209 who had experienced Covid-19 infection and 87 who did not). We have found previously reported effect of Covid status on accuracy in 2 long-term memory tasks (verbal item memory task and nonverbal associative memory task), but did not replicate previously reported effect on reaction times. Further, across 4 long-term memory tasks, we found consistent effect of Covid status on memory accuracy but not reaction times. Contrary to our predictions, we did not find an interaction with memory type (associative versus item) or stimulus type (verbal versus nonverbal). Moreover, we compared cognitive functioning amongst vaccinated and unvaccinated individuals to explore the role of vaccination status in cognitive symptoms associated with Covid-19. Using Bayesian analysis, we did not find conclusive evidence for either the null or alternative hypothesis. Overall, the study replicates and extends previously reported findings, thereby providing valuable insights into the effects of SARS-CoV-2 infection on cognitive functions. CI - Copyright (c) 2025 The Author(s). Published by Elsevier Ltd.. All rights reserved. FAU - Weinerova, Josefina AU - Weinerova J AD - School of Psychology, University of Nottingham, Nottingham, United Kingdom. FAU - Yeung, Sabine AU - Yeung S AD - Department of Psychology, University of Cambridge, Cambridge, United Kingdom. FAU - Guo, Panyuan AU - Guo P AD - Department of Psychology, University of Cambridge, Cambridge, United Kingdom. FAU - Yau, Alice AU - Yau A AD - Department of Psychology, University of Cambridge, Cambridge, United Kingdom. FAU - Horne, Connor AU - Horne C AD - Department of Psychology, University of Cambridge, Cambridge, United Kingdom. FAU - Ghinn, Molly AU - Ghinn M AD - Department of Psychology, University of Cambridge, Cambridge, United Kingdom. FAU - Curtis, Lyn AU - Curtis L AD - School of Psychology, College of Life and Environmental Sciences, University of Exeter, Exeter, United Kingdom. FAU - Adlard, Francess AU - Adlard F AD - Department of Psychology, University of Cambridge, Cambridge, United Kingdom. FAU - Bhagat, Vidita AU - Bhagat V AD - Department of Psychology, University of Cambridge, Cambridge, United Kingdom. FAU - Zhang, Seraphina AU - Zhang S AD - Department of Psychology, University of Cambridge, Cambridge, United Kingdom. FAU - Kaser, Muzaffer AU - Kaser M AD - Department of Psychiatry, University of Cambridge, Cambridge, United Kingdom; Cambridgeshire and Peterborough NHS Trust, Cambridge, United Kingdom. FAU - Bozic, Mirjana AU - Bozic M AD - Department of Psychology, University of Cambridge, Cambridge, United Kingdom. FAU - Schluppeck, Denis AU - Schluppeck D AD - School of Psychology, University of Nottingham, Nottingham, United Kingdom. FAU - Reid, Andrew AU - Reid A AD - School of Social and Behavioural Sciences, Tilburg University, Tilburg, Netherlands. FAU - Tibon, Roni AU - Tibon R AD - School of Psychology, University of Nottingham, Nottingham, United Kingdom. Electronic address: roni.tibon@nottingham.ac.uk. FAU - Cheke, Lucy AU - Cheke L AD - Department of Psychology, University of Cambridge, Cambridge, United Kingdom. LA - eng PT - Journal Article DEP - 20250611 PL - Italy TA - Cortex JT - Cortex; a journal devoted to the study of the nervous system and behavior JID - 0100725 SB - IM MH - Humans MH - *COVID-19/psychology/complications MH - Male MH - Female MH - Adult MH - *Cognition/physiology MH - Middle Aged MH - Reaction Time/physiology MH - SARS-CoV-2 MH - Neuropsychological Tests MH - Aged MH - Young Adult MH - *Memory/physiology MH - *Memory, Long-Term/physiology OTO - NOTNLM OT - Associative memory OT - Cognition OT - Covid-19 OT - Item memory OT - Long Covid OT - Long-term memory OT - SARS-CoV-2 OT - Vaccination COIS- Declaration of competing interest No conflict of interest is declared. EDAT- 2025/06/25 00:28 MHDA- 2025/08/11 00:26 CRDT- 2025/06/24 18:04 PHST- 2025/05/20 00:00 [received] PHST- 2025/05/29 00:00 [revised] PHST- 2025/05/29 00:00 [accepted] PHST- 2025/08/11 00:26 [medline] PHST- 2025/06/25 00:28 [pubmed] PHST- 2025/06/24 18:04 [entrez] AID - S0010-9452(25)00158-3 [pii] AID - 10.1016/j.cortex.2025.05.019 [doi] PST - ppublish SO - Cortex. 2025 Aug;189:205-225. doi: 10.1016/j.cortex.2025.05.019. Epub 2025 Jun 11. PMID- 40482741 OWN - NLM STAT- MEDLINE DCOM- 20250719 LR - 20250719 IS - 1879-0003 (Electronic) IS - 0141-8130 (Linking) VI - 318 IP - Pt 1 DP - 2025 Jul TI - [Illuminating the shadows - perspectives on mRNA vaccine adverse events - mechanisms, risks and management]: A review. PG - 145010 LID - S0141-8130(25)05563-1 [pii] LID - 10.1016/j.ijbiomac.2025.145010 [doi] AB - Apparently, mRNA vaccines have played a pivotal role in curbing the further spread of COVID-19. However, their deployment has been accompanied by reports of adverse events (AEs), including cardiovascular and neurological symptoms. The comprehensive review proposes a conceptual framework to better characterize AEs, elucidate the underlying mechanisms, and outline therapeutic strategies. It also profiles AEs into a three-axe mechanism classification: host susceptibility, delivery system interactions, and mRNA component immunogenicity, thereby advancing current understanding of their etiology. Finally, the analysis integrates these axes with critical perspectives - mRNA molecular design, platform-specific toxicity, and human nature - to provide a comprehensive roadmap for addressing above issues. CI - Copyright (c) 2025 Elsevier B.V. All rights reserved. FAU - Kang, Haobo AU - Kang H AD - Department of Immunology, Basic Medicine School, Air Force Medical University (the Fourth Military Medical University), Xi'an 710032, Shaanxi, China. FAU - Sun, Yubo AU - Sun Y AD - Department of Immunology, Basic Medicine School, Air Force Medical University (the Fourth Military Medical University), Xi'an 710032, Shaanxi, China; The Key Laboratory of Bio-Hazard Damage and Prevention Medicine, Basic Medicine School, Air-Force Medical University (The Fourth Military Medical University), Xi'an 710032, China. FAU - Fang, Zhenchi AU - Fang Z AD - Department of Immunology, Basic Medicine School, Air Force Medical University (the Fourth Military Medical University), Xi'an 710032, Shaanxi, China. FAU - Ding, Weijie AU - Ding W AD - Department of Immunology, Basic Medicine School, Air Force Medical University (the Fourth Military Medical University), Xi'an 710032, Shaanxi, China. FAU - Bai, Tianyuan AU - Bai T AD - Department of Immunology, Basic Medicine School, Air Force Medical University (the Fourth Military Medical University), Xi'an 710032, Shaanxi, China. FAU - Yang, Kun AU - Yang K AD - Department of Immunology, Basic Medicine School, Air Force Medical University (the Fourth Military Medical University), Xi'an 710032, Shaanxi, China; The Key Laboratory of Bio-Hazard Damage and Prevention Medicine, Basic Medicine School, Air-Force Medical University (The Fourth Military Medical University), Xi'an 710032, China. Electronic address: yangkunkun@fmmu.edu.cn. FAU - Jiang, Dongbo AU - Jiang D AD - Department of Immunology, Basic Medicine School, Air Force Medical University (the Fourth Military Medical University), Xi'an 710032, Shaanxi, China; The Key Laboratory of Bio-Hazard Damage and Prevention Medicine, Basic Medicine School, Air-Force Medical University (The Fourth Military Medical University), Xi'an 710032, China; Department of Rehabilitation, Tangdu Hospital, Air-Force Medical University (The Fourth Military Medical University), Xi'an 710038, Shaanxi, China; Department of Microbiology, Basic Medicine School, Air-Force Medical University (the Fourth Military Medical University), Xi'an 710032, Shaanxi, China. Electronic address: superjames1991@fmmu.edu.cn. LA - eng PT - Journal Article PT - Review DEP - 20250605 PL - Netherlands TA - Int J Biol Macromol JT - International journal of biological macromolecules JID - 7909578 RN - 0 (COVID-19 Vaccines) RN - 0 (mRNA Vaccines) RN - 0 (RNA, Messenger) RN - 0 (Vaccines, Synthetic) SB - IM MH - Humans MH - *COVID-19 Vaccines/adverse effects/immunology MH - *COVID-19/prevention & control/immunology MH - SARS-CoV-2/immunology MH - *mRNA Vaccines/adverse effects MH - *RNA, Messenger/immunology MH - *Vaccines, Synthetic/adverse effects/immunology MH - *Drug-Related Side Effects and Adverse Reactions OTO - NOTNLM OT - Adverse event OT - Mechanism OT - mRNA vaccine COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2025/06/08 03:37 MHDA- 2025/07/19 16:45 CRDT- 2025/06/07 19:36 PHST- 2025/03/11 00:00 [received] PHST- 2025/06/03 00:00 [revised] PHST- 2025/06/04 00:00 [accepted] PHST- 2025/07/19 16:45 [medline] PHST- 2025/06/08 03:37 [pubmed] PHST- 2025/06/07 19:36 [entrez] AID - S0141-8130(25)05563-1 [pii] AID - 10.1016/j.ijbiomac.2025.145010 [doi] PST - ppublish SO - Int J Biol Macromol. 2025 Jul;318(Pt 1):145010. doi: 10.1016/j.ijbiomac.2025.145010. Epub 2025 Jun 5. PMID- 40432716 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250528 IS - 2666-3546 (Electronic) IS - 2666-3546 (Linking) VI - 45 DP - 2025 May TI - Corrigendum to "COVID-19 vaccination and the behavioral immune system: The newcomer and the old friend get along in preventing infection" [Brain Behav. Immun. Health. 2023]. PG - 100971 LID - 10.1016/j.bbih.2025.100971 [doi] LID - 100971 AB - [This corrects the article DOI: 10.1016/j.bbih.2023.100621.]. CI - (c) 2025 The Author(s). FAU - Troisi, Alfonso AU - Troisi A AD - International Medical School, University of Rome Tor Vergata, Rome, Italy. FAU - Croce Nanni, Roberta AU - Croce Nanni R AD - Policlinico Tor Vergata, Viale Oxford 81, 00133, Rome, Italy. FAU - De Sanctis, Simone Antonio AU - De Sanctis SA AD - International Medical School, University of Rome Tor Vergata, Rome, Italy. FAU - Dieguez, Giulia AU - Dieguez G AD - International Medical School, University of Rome Tor Vergata, Rome, Italy. FAU - Carola, Valeria AU - Carola V AD - Department of Dynamic and Clinical Psychology, University of Rome La Sapienza, Rome, Italy. LA - eng PT - Published Erratum DEP - 20250312 PL - United States TA - Brain Behav Immun Health JT - Brain, behavior, & immunity - health JID - 101759062 EFR - Brain Behav Immun Health. 2023 Jul;30:100621. doi: 10.1016/j.bbih.2023.100621. PMID: 37063495 PMC - PMC12107251 EDAT- 2025/05/28 06:28 MHDA- 2025/05/28 06:29 PMCR- 2025/03/12 CRDT- 2025/05/28 04:45 PHST- 2025/05/28 06:29 [medline] PHST- 2025/05/28 06:28 [pubmed] PHST- 2025/05/28 04:45 [entrez] PHST- 2025/03/12 00:00 [pmc-release] AID - S2666-3546(25)00029-8 [pii] AID - 100971 [pii] AID - 10.1016/j.bbih.2025.100971 [doi] PST - epublish SO - Brain Behav Immun Health. 2025 Mar 12;45:100971. doi: 10.1016/j.bbih.2025.100971. eCollection 2025 May. PMID- 40411153 OWN - NLM STAT- MEDLINE DCOM- 20251104 LR - 20260814 IS - 1708-8267 (Electronic) IS - 1081-5589 (Linking) VI - 73 IP - 8 DP - 2025 Dec TI - Protective effects of booster dose of SARS-COV-2 vaccination against post-acute COVID-19 syndrome: A systematic review. PG - 606-613 LID - 10.1177/10815589251346963 [doi] AB - The global impact of COVID-19, caused by SARS-CoV-2, has extended beyond acute infection, with post-acute COVID-19 syndrome (PACS) affecting an estimated 10% of recovered individuals. PACS manifests a range of debilitating symptoms, including fatigue, cognitive impairment, and gastrointestinal issues. While vaccination has proven effective in mitigating severe COVID-19 outcomes, the role of booster doses in preventing PACS remains unclear. This study aimed to evaluate whether COVID-19 booster vaccinations reduce the incidence and severity of PACS in individuals with prior SARS-CoV-2 infection. A systematic review and meta-analysis were conducted, adhering to Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. Databases PubMed, Embase, and Cochrane were searched for peer-reviewed studies published in English from January 2020 to August 2023. Inclusion criteria encompassed randomized controlled trials, prospective cohort studies, and case-control studies comparing PACS prevalence between booster recipients and non-recipients. The risk of bias was assessed using the Joanna Briggs Institute appraisal tool. Data synthesis included pooled prevalence estimates and narrative analyses. Of 849 identified studies, 22 met inclusion criteria, with 12 providing complete data for meta-analysis. Among 38,718 participants, a trend toward lower PACS prevalence was observed in booster recipients (RR: 0.66; 95% CI: 0.41-1.09), though heterogeneity (I(2) = 98%) limited statistical significance. Risk of bias analysis classified most studies as low or moderate risk, with two high-risk studies reporting higher PACS rates in boosted individuals. This study suggests a potential protective effect of booster vaccinations against PACS, though findings were not statistically significant. Further research with larger, standardized cohorts is essential to validate these observations and guide vaccination strategies.Prospero Record Number: CRD42023461326. FAU - Patel, Ved AU - Patel V AUID- ORCID: 0009-0008-7764-3844 AD - Donald and Barbara Zucker School of Medicine at Hofstra, Northwell, Hempstead, NY, USA. FAU - Korsun, Maximilian AU - Korsun M AUID- ORCID: 0000-0001-7289-7564 AD - Hospital for Special Surgery, New York, NY, USA. FAU - Cervia, Joseph AU - Cervia J AUID- ORCID: 0000-0002-8286-0009 AD - Donald and Barbara Zucker School of Medicine at Hofstra, Northwell, Hempstead, NY, USA. AD - HealthCare Partners, IPA, & MSO, Manhasset, NY, USA. LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20250523 PL - England TA - J Investig Med JT - Journal of investigative medicine : the official publication of the American Federation for Clinical Research JID - 9501229 RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - *COVID-19/prevention & control/immunology/epidemiology/complications MH - *COVID-19 Vaccines/administration & dosage/immunology MH - *Immunization, Secondary MH - *Post-Acute COVID-19 Syndrome/epidemiology/immunology/prevention & control/virology MH - *SARS-CoV-2/immunology MH - Vaccination OTO - NOTNLM OT - COVID-19 OT - Vaccination OT - booster vaccination OT - post-acute COVID-19 syndrome COIS- Declaration of conflicting interestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2025/05/25 00:45 MHDA- 2025/11/04 06:29 CRDT- 2025/05/24 01:43 PHST- 2025/11/04 06:29 [medline] PHST- 2025/05/25 00:45 [pubmed] PHST- 2025/05/24 01:43 [entrez] AID - 10.1177/10815589251346963 [doi] PST - ppublish SO - J Investig Med. 2025 Dec;73(8):606-613. doi: 10.1177/10815589251346963. Epub 2025 May 23. PMID- 40347503 OWN - NLM STAT- MEDLINE DCOM- 20250510 LR - 20260502 IS - 0971-5916 (Print) IS - 0971-5916 (Linking) VI - 161 IP - 3 DP - 2025 Mar TI - Immunological memory in infected & exposure naive individuals one year post SARS-CoV-2 vaccination. PG - 287-297 LID - 10.25259/IJMR_923_2024 [pii] AB - Background & objectives COVID-19 has affected millions and wreaked havoc on global healthcare systems as well as a devastating impact on the economies of various nations. Vaccines are highly pivotal in promoting an appropriate immune response. Understanding the effectiveness and stability of the vaccines is essential as these may differ across populations. Hence, this study explored the durability and efficacy of the COVISHIELD (ChAdOx1 nCoV-A) vaccine among healthcare workers (HCWs). Methods In this study, 84 HCWs who received two doses of COVISHIELD and had no breakthrough infections or precautionary doses were assessed. Participants were categorised into four groups (A, B, C, and D) based on pre-immunisation antibody status and SARS-CoV-2 RT-PCR results. Group A had prior infection and IgG antibodies, group B had RT-PCR positivity without detectable antibodies, group C had IgG antibodies without RT-PCR testing, and group D was exposure-naive. Humoral immunity was assessed by measuring IgG antibodies to the spike protein, while cell-mediated immunity was evaluated through SARS-CoV-2-specific T-cell markers and immunophenotyping. Results Over one year, a significant decrease in anti-spike IgG levels was observed in all groups (P<0.0001). It was observed that memory B cells declined significantly among all the groups over a period of one year [group A (P<0.0001), group B (P=0.0080), group C (P=0.0158), and group D (P=0.0004)]; no significant decrease inactivated T-cells was observed over a year. The mean of anti-spike IgG levels in samples from exposed participants (group A, B, C) versus non-exposed (group D) was significantly higher (P<0.0001). Interpretation & conclusions These findings indicate the need for regular booster doses of vaccination due to the waning of immunity by the vaccine. We also demonstrate that hybrid immunity (a combination of immune response post-natural infection and vaccination) provides better protection than vaccination alone. FAU - Das, Priti AU - Das P AD - Department of Neurovirology, National Institute of Mental Health and Neurosciences (NIMHANS), Bengaluru, India. FAU - Varun, Chakrakodi N AU - Varun CN AD - Department of Neurovirology, National Institute of Mental Health and Neurosciences (NIMHANS), Bengaluru, India. FAU - Ashwini, M A AU - Ashwini MA AD - Department of Neurovirology, National Institute of Mental Health and Neurosciences (NIMHANS), Bengaluru, India. FAU - Kesavan, Muralidharan AU - Kesavan M AD - Department of Psychiatry, National Institute of Mental Health and Neurosciences (NIMHANS), Bengaluru, India. FAU - Ravi, Vasanthapuram AU - Ravi V AD - Department of Neurovirology, National Institute of Mental Health and Neurosciences (NIMHANS), Bengaluru, India. FAU - Desai, Anita AU - Desai A AD - Department of Neurovirology, National Institute of Mental Health and Neurosciences (NIMHANS), Bengaluru, India. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Indian J Med Res JT - The Indian journal of medical research JID - 0374701 RN - 0 (Antibodies, Viral) RN - 0 (Immunoglobulin G) RN - 0 (COVID-19 Vaccines) RN - B5S3K2V0G8 (ChAdOx1 nCoV-19) RN - 0 (Spike Glycoprotein, Coronavirus) SB - IM MH - Humans MH - *COVID-19/immunology/prevention & control/virology MH - *SARS-CoV-2/immunology MH - *Immunologic Memory/immunology MH - Male MH - Adult MH - Female MH - Antibodies, Viral/immunology/blood MH - Immunoglobulin G/immunology/blood MH - *COVID-19 Vaccines/immunology MH - Health Personnel MH - Middle Aged MH - Vaccination MH - ChAdOx1 nCoV-19/immunology MH - Immunity, Humoral MH - Spike Glycoprotein, Coronavirus/immunology MH - Immunity, Cellular PMC - PMC12066133 OTO - NOTNLM OT - COVID-19 OT - COVISHIELD vaccine OT - Cell-mediated immunity OT - humoral immunity COIS- None. EDAT- 2025/05/11 18:54 MHDA- 2025/05/11 18:55 PMCR- 2025/03/01 CRDT- 2025/05/10 14:20 PHST- 2024/07/06 00:00 [received] PHST- 2025/03/11 00:00 [accepted] PHST- 2025/05/11 18:55 [medline] PHST- 2025/05/11 18:54 [pubmed] PHST- 2025/05/10 14:20 [entrez] PHST- 2025/03/01 00:00 [pmc-release] AID - 10.25259/IJMR_923_2024 [pii] AID - 10.25259/IJMR_923_2024 [doi] PST - ppublish SO - Indian J Med Res. 2025 Mar;161(3):287-297. doi: 10.25259/IJMR_923_2024. PMID- 40332719 OWN - NLM STAT- MEDLINE DCOM- 20250924 LR - 20261010 IS - 1439-0973 (Electronic) IS - 0300-8126 (Linking) VI - 53 IP - 5 DP - 2025 Oct TI - Delayed but successful development of immune memory against SARS-COV-2 after B cell-depleting monotherapy. PG - 2045-2052 LID - 10.1007/s15010-025-02544-6 [doi] AB - PURPOSE: Patients receiving CD20-directed therapies are known to insufficiently develop neutralizing antibody titers against SARS-COV-2 after two vaccinations. We investigated the impact of a third and fourth vaccination, possibly deriving predictive factors. METHODS: In a monocentric, prospective, non-interventional observational study patients who had received at least one administration of a monoclonal CD20 antibody (mCD20Ab) within 9 months prior to vaccination were included to receive mRNA-based third vaccination. SARS-COV-2 IgG titer was determined before and four weeks after immunisation. Patients without adequate humoral immune response proceeded to a fourth vaccination. Furthermore, tolerability and prespecified potentially influencing factors such as age, baseline lymphocyte counts and others were analysed. RESULTS: Twenty-four patients were included and vaccination was well tolerated. Quantitative analysis of humoral response four weeks after third vaccination revealed a significant increase which, however, did not translate into a clinically relevant seroconversion rate. In the subgroup analysis, patients older than 65 years and mCD20Ab therapy longer than 6 months ago benefited. All evaluable patients on mCD20Ab monotherapy (n = 7) showed an immediate or delayed immune response after third vaccination, while all non-responders (n = 7) were on combination therapy. Clinical parameters such as lymphocyte count, immunoglobulin status and others did not appear to have any influence. CONCLUSION: An interval of at least 6 months after the last mCD20Ab administration and mCD20Ab monotherapy appears to be favorable for humoral immune response to third vaccination. Furthermore, patients can be reassured that delayed immune responses are possible. Future studies should therefore also investigate seroconversion at later time points. CI - (c) 2025. Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Graf, Nicolas AU - Graf N AD - Medical Department II, Section Oncology, Donau-Isar-Klinikum Deggendorf, Deggendorf, Germany. nicolasgraf@gmx.de. AD - Ambulantes Therapiezentrum fur Hamatologie und Onkologie Arztehaus, 4. Stock Ebertplatz 12, 77654, Offenburg, Germany. nicolasgraf@gmx.de. FAU - Bayerl, Joseph AU - Bayerl J AD - Institute for Laboratory Diagnostics, Immunohaematology and Microbiology, Donau-Isar-Klinikum Deggendorf, Deggendorf, Germany. FAU - Schmidt, Barbara AU - Schmidt B AD - Institute of Microbiology and Hygiene, Clinical Virology and Infection Immunology, University Hospital Regensburg, Regensburg, Germany. LA - eng PT - Journal Article PT - Observational Study DEP - 20250507 PL - Germany TA - Infection JT - Infection JID - 0365307 RN - 0 (Antibodies, Viral) RN - 0 (Antibodies, Neutralizing) RN - 0 (COVID-19 Vaccines) RN - 0 (Immunoglobulin G) RN - 0 (BNT162 Vaccine) SB - IM MH - Humans MH - Male MH - Female MH - Aged MH - Middle Aged MH - *SARS-CoV-2/immunology MH - Prospective Studies MH - *COVID-19/immunology/prevention & control MH - Antibodies, Viral/blood/immunology MH - *B-Lymphocytes/immunology/drug effects MH - *Immunologic Memory MH - Antibodies, Neutralizing/blood/immunology MH - *COVID-19 Vaccines/immunology/administration & dosage MH - Adult MH - Immunoglobulin G/blood MH - Aged, 80 and over MH - BNT162 Vaccine OTO - NOTNLM OT - Antibodies OT - B-cell depletion OT - Immune memory OT - SARS-CoV-2 OT - Vaccination COIS- Declarations. Ethical approval: This study protocol was reviewed and approved by the Ethics commitee of the Technical University of Munich (685/21 S). This work was performed in accordance with the ethical standards of the Declaration of Helsinki. Informed Consent: Written informed consent to participate in the study was obtained from all patients. Consent to publish from individual participants was not required. Competing interests: The authors declare no competing interests. EDAT- 2025/05/07 12:32 MHDA- 2025/09/24 13:01 CRDT- 2025/05/07 11:24 PHST- 2024/12/13 00:00 [received] PHST- 2025/04/23 00:00 [accepted] PHST- 2025/09/24 13:01 [medline] PHST- 2025/05/07 12:32 [pubmed] PHST- 2025/05/07 11:24 [entrez] AID - 10.1007/s15010-025-02544-6 [pii] AID - 10.1007/s15010-025-02544-6 [doi] PST - ppublish SO - Infection. 2025 Oct;53(5):2045-2052. doi: 10.1007/s15010-025-02544-6. Epub 2025 May 7. PMID- 40331973 OWN - NLM STAT- MEDLINE DCOM- 20250507 LR - 20250509 IS - 1422-0067 (Electronic) IS - 1422-0067 (Linking) VI - 26 IP - 8 DP - 2025 Apr 8 TI - Single-Cell RNA Sequencing of Baseline Immune Profiles After Third Vaccination Associated with Subsequent SARS-CoV-2 Infection in Naive Individuals. LID - 10.3390/ijms26083494 [doi] LID - 3494 AB - Even though vaccines protected many from infection, not all were protected, and vaccinated individuals displayed a wide range of clinical outcomes, from complete protection against infection to multiple breakthrough infections. This study aimed to identify baseline differences following identical ChAdOx1/ChAdOx1/BNT162b2 in infection-free and breakthrough-infected individuals to find molecular signatures linked to enhanced SARS-CoV-2 protection. Samples from a previous longitudinal study were analyzed, classifying subjects as 'Protected' or 'Infected' based on infection status over two years. SARS-CoV-2-specific immunological assays and single-cell RNA sequencing evaluated baseline differences. Although humoral response measurements showed no significant difference, enhanced cellular responses via enzyme-linked immunospot assays were observed in the Protected group. Differentially expressed genes and pathway analysis of T/NK subsets showed the Infected group had reduced inflammation and interferon responses. The Infected group also displayed downregulated interaction with CD4+ T cells. B subset analysis revealed more memory B cells in the Infected group, accompanied by downregulation of immune regulatory genes and upregulation of the small ubiquitin-related modifier pathway. Our findings revealed differential molecular signatures in the baseline immune subsets of vaccinated individuals with prolonged protection and breakthrough infection. Reduced immune regulation and altered cell interactions may contribute to breakthrough infection, providing insights for future vaccine development and targeted protective strategies. FAU - Kang, Hyunhye AU - Kang H AUID- ORCID: 0000-0003-1338-6451 AD - Department of Laboratory Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea. AD - Department of Laboratory Medicine, Shinwon Medical Foundation, Gwangmyeong-si 14316, Republic of Korea. FAU - Park, Junseong AU - Park J AUID- ORCID: 0000-0003-0436-8614 AD - Cancer Evolution Research Center, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea. AD - Precision Medicine Research Center, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea. FAU - Bae, Hyunjoo AU - Bae H AUID- ORCID: 0000-0001-5143-6806 AD - Department of Medical Sciences, Graduate School, The Catholic University of Korea, Seoul 06591, Republic of Korea. FAU - Chung, Yeun-Jun AU - Chung YJ AUID- ORCID: 0000-0002-6943-5948 AD - Precision Medicine Research Center, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea. AD - Department of Microbiology, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea. FAU - Oh, Eun-Jee AU - Oh EJ AUID- ORCID: 0000-0001-5870-915X AD - Department of Laboratory Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea. AD - Research and Development Institute for In Vitro Diagnostic Medical Devices, The Catholic University of Korea, Seoul 06591, Republic of Korea. LA - eng GR - NRF-2020R1A2B5B01001859/National Research Foundation of Korea/ PT - Journal Article DEP - 20250408 PL - Switzerland TA - Int J Mol Sci JT - International journal of molecular sciences JID - 101092791 RN - 0 (BNT162 Vaccine) RN - 0 (COVID-19 Vaccines) RN - 0 (Antibodies, Viral) SB - IM MH - Humans MH - *COVID-19/immunology/prevention & control/genetics/virology MH - *SARS-CoV-2/immunology MH - Single-Cell Analysis/methods MH - Vaccination MH - Female MH - Male MH - Adult MH - Sequence Analysis, RNA MH - Middle Aged MH - BNT162 Vaccine/immunology MH - *COVID-19 Vaccines/immunology MH - CD4-Positive T-Lymphocytes/immunology MH - Antibodies, Viral/immunology PMC - PMC12027237 OTO - NOTNLM OT - NK OT - SARS-CoV-2 OT - innate immunity OT - interferon OT - memory B cell OT - single-cell RNA sequencing OT - vaccine COIS- The authors declare no conflicts of interest. EDAT- 2025/05/07 12:31 MHDA- 2025/05/07 12:32 PMCR- 2025/04/08 CRDT- 2025/05/07 10:14 PHST- 2025/03/10 00:00 [received] PHST- 2025/04/01 00:00 [revised] PHST- 2025/04/07 00:00 [accepted] PHST- 2025/05/07 12:32 [medline] PHST- 2025/05/07 12:31 [pubmed] PHST- 2025/05/07 10:14 [entrez] PHST- 2025/04/08 00:00 [pmc-release] AID - ijms26083494 [pii] AID - ijms-26-03494 [pii] AID - 10.3390/ijms26083494 [doi] PST - epublish SO - Int J Mol Sci. 2025 Apr 8;26(8):3494. doi: 10.3390/ijms26083494. PMID- 40326950 OWN - NLM STAT- MEDLINE DCOM- 20250506 LR - 20260912 IS - 1096-9071 (Electronic) IS - 0146-6615 (Linking) VI - 97 IP - 5 DP - 2025 May TI - Dynamics of SARS-CoV-2 Spike Receptor-Binding Domain-Targeted Specific Peripheral Memory B Cells in Patients With End-Stage Chronic Kidney Disease Undergoing Replacement Therapy Following COVID-19 Vaccination. PG - e70382 LID - 10.1002/jmv.70382 [doi] AB - Memory B cells (MBCs) are responsible for maintaining long-lasting functional B-cell immune responses. Little is known about the kinetics of peripheral blood (PB) SARS-CoV-2 vaccine-induced MBCs in end-stage chronic kidney disease (CKD) patients undergoing replacement therapies. We investigated this issue in this prospective, observational cohort study including 27 patients (9 females and 18 males; median age, 68.4 years, range 48-82) comprising 20 hemodialysis patients and 7 Kidney transplant recipients. SARS-CoV-2-Receptor-Binding Domain (RBD)-targeted PB-MBCs were enumerated by flow cytometry using a tetramer-binding assay after the second COVID-19 mRNA vaccine dose (Post-2D), before (Pre-3D), and after the first mRNA vaccine booster dose (Post-3D). Commercially available electrochemiluminescent immunoassays were used to measure total anti-RBD antibodies targeting an IgG against the S trimeric protein. Overall, 18/27 patients (66.6%) exhibited detectable RBD-MBC responses at Post-2D, 12/27 (44.4%) at Pre-3D, and 16/27 (59.2%) at Post-3D. RBD-MBC levels dropped non-significantly between post-2D and Pre-3D (p = 0.38). A nonsignificant increase in RBD-MBCs was noticed post-3D (p = 0.65). Overall, both antibody specificities displayed the same dynamics but the drop in anti-trimeric spike antibody levels between Post-2D and Pre-3D and increases post-3D were statistically significant (p < 0.001). No correlation (rho = 0.05; p = 0.64) was observed between total antibodies against RBD and RBD-MBC counts. The correlation between IgG antibodies against the trimeric S protein and SARS-CoV-2 RBD-MBC counts was very weak (rho, 0.18; p = 0.11). In summary, waning RBD-MBC counts Pre-3D and increases post-3D are less marked than that of anti-RBD and anti-S trimeric antibodies. CI - (c) 2025 Wiley Periodicals LLC. FAU - Sanchez-Simarro, Angela AU - Sanchez-Simarro A AD - Microbiology Service, Hospital Clinico Universitario de Valencia, INCLIVA Health Research Institute, Valencia, Spain. FAU - Panizo, Nayara AU - Panizo N AD - Nephrology Service, Hospital Clinico Universitario de Valencia, INCLIVA Health Research Institute, Valencia, Spain. FAU - Gimenez, Estela AU - Gimenez E AD - Microbiology Service, Hospital Clinico Universitario de Valencia, INCLIVA Health Research Institute, Valencia, Spain. AD - Nephrology Service, Transplant Unit, Hospital Universitario Dr. Peset, Valencia, Spain. AD - CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain. FAU - Albert, Eliseo AU - Albert E AD - Microbiology Service, Hospital Clinico Universitario de Valencia, INCLIVA Health Research Institute, Valencia, Spain. FAU - Montomoli, Marco AU - Montomoli M AD - Nephrology Service, Hospital Clinico Universitario de Valencia, INCLIVA Health Research Institute, Valencia, Spain. FAU - Sanchis, Irina AU - Sanchis I AD - Nephrology Service, Hospital Clinico Universitario de Valencia, INCLIVA Health Research Institute, Valencia, Spain. FAU - Kanter, Julia AU - Kanter J AD - Nephrology Service, Transplant Unit, Hospital Universitario Dr. Peset, Valencia, Spain. FAU - Gorriz, Jose Luis AU - Gorriz JL AD - Nephrology Service, Hospital Clinico Universitario de Valencia, INCLIVA Health Research Institute, Valencia, Spain. AD - Department of Medicine, School of Medicine, University of Valencia, Valencia, Spain. FAU - Navarro, David AU - Navarro D AUID- ORCID: 0000-0003-3010-4110 AD - Microbiology Service, Hospital Clinico Universitario de Valencia, INCLIVA Health Research Institute, Valencia, Spain. AD - CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain. AD - Department of Microbiology, School of Medicine, University of Valencia, Valencia, Spain. LA - eng GR - This study was supported by Eliseo Albert holds a contract (Juan Rodes JR20/00011) funded by the Carlos III Health Institute (co-financed by the European Regional Development Fund, ERDF/FEDER. This study was supported by the Instituto de Salud Carlos III, Madrid, Spain (FIS, PI21/00563) granted to David Navarro./ PT - Journal Article PT - Observational Study PT - Research Support, Non-U.S. Gov't PL - United States TA - J Med Virol JT - Journal of medical virology JID - 7705876 RN - 0 (Spike Glycoprotein, Coronavirus) RN - 0 (COVID-19 Vaccines) RN - 0 (spike protein, SARS-CoV-2) RN - 0 (Antibodies, Viral) RN - 0 (Immunoglobulin G) SB - IM MH - Humans MH - Male MH - Female MH - Aged MH - Middle Aged MH - *Spike Glycoprotein, Coronavirus/immunology MH - *COVID-19 Vaccines/immunology/administration & dosage MH - Aged, 80 and over MH - *COVID-19/prevention & control/immunology MH - *SARS-CoV-2/immunology MH - Antibodies, Viral/blood/immunology MH - Prospective Studies MH - *Kidney Failure, Chronic/immunology/therapy MH - *Memory B Cells/immunology MH - Immunoglobulin G/blood/immunology MH - Renal Dialysis MH - Vaccination OTO - NOTNLM OT - COVID-19 vaccine OT - SARS-CoV-2 OT - booster vaccine dose OT - hemodialysis OT - kidney transplant recipients OT - memory B cells OT - spike-specific antibodies EDAT- 2025/05/06 12:42 MHDA- 2025/05/06 12:43 CRDT- 2025/05/06 10:12 PHST- 2025/04/04 00:00 [revised] PHST- 2024/11/15 00:00 [received] PHST- 2025/04/23 00:00 [accepted] PHST- 2025/05/06 12:43 [medline] PHST- 2025/05/06 12:42 [pubmed] PHST- 2025/05/06 10:12 [entrez] AID - 10.1002/jmv.70382 [doi] PST - ppublish SO - J Med Virol. 2025 May;97(5):e70382. doi: 10.1002/jmv.70382. PMID- 40300604 OWN - NLM STAT- MEDLINE DCOM- 20250627 LR - 20260706 IS - 1097-4172 (Electronic) IS - 0092-8674 (Linking) VI - 188 IP - 13 DP - 2025 Jun 26 TI - Macrophages direct location-dependent recall of B cell memory to vaccination. PG - 3477-3496.e22 LID - S0092-8674(25)00407-6 [pii] LID - 10.1016/j.cell.2025.04.005 [doi] AB - Vaccines generate long-lived plasma cells and memory B cells (Bmems) that may re-enter secondary germinal centers (GCs) to further mutate their B cell receptor upon boosting and re-exposure to antigen. We show in mouse models that lymph nodes draining the site of primary vaccination harbor a subset of Bmems that reside in the subcapsular niche, generate larger recall responses, and are more likely to re-enter GCs compared with circulating Bmems in non-draining lymph nodes. This location-dependent recall of Bmems into the GC in the draining lymph node was dependent on CD169(+) subcapsular sinus macrophages (SSMs) in the subcapsular niche. In human participants, boosting of the BNT162b2 vaccine in the same arm generated more rapid secretion of broadly neutralizing antibodies, GC participation, and clonal expansion of SARS-CoV-2-specific B cells than boosting of the opposite arm. These data reveal an unappreciated role for primed draining lymph node SSMs in Bmem cell fate determination. CI - Copyright (c) 2025 The Author(s). Published by Elsevier Inc. All rights reserved. FAU - Dhenni, Rama AU - Dhenni R AD - Precision Immunology Program, Garvan Institute of Medical Research, Sydney, NSW, Australia; St. Vincent's Healthcare Clinical Campus, School of Clinical Medicine, Faculty of Medicine and Health, UNSW Sydney, Kensington, Sydney, NSW, Australia. FAU - Carey Hoppe, Alexandra AU - Carey Hoppe A AD - Immunovirology and Pathogenesis Program, Kirby Institute, UNSW Sydney, Sydney, NSW, Australia. FAU - Reynaldi, Arnold AU - Reynaldi A AD - Infection Analytics Program, Kirby Institute, UNSW Sydney, Sydney, NSW, Australia. FAU - Kyaw, Wunna AU - Kyaw W AD - Precision Immunology Program, Garvan Institute of Medical Research, Sydney, NSW, Australia; St. Vincent's Healthcare Clinical Campus, School of Clinical Medicine, Faculty of Medicine and Health, UNSW Sydney, Kensington, Sydney, NSW, Australia. FAU - Handoko, Nathalie Tricia AU - Handoko NT AD - Precision Immunology Program, Garvan Institute of Medical Research, Sydney, NSW, Australia; St. Vincent's Healthcare Clinical Campus, School of Clinical Medicine, Faculty of Medicine and Health, UNSW Sydney, Kensington, Sydney, NSW, Australia. FAU - Grootveld, Abigail K AU - Grootveld AK AD - Precision Immunology Program, Garvan Institute of Medical Research, Sydney, NSW, Australia; St. Vincent's Healthcare Clinical Campus, School of Clinical Medicine, Faculty of Medicine and Health, UNSW Sydney, Kensington, Sydney, NSW, Australia. FAU - Keith, Yuki Honda AU - Keith YH AD - Precision Immunology Program, Garvan Institute of Medical Research, Sydney, NSW, Australia; St. Vincent's Healthcare Clinical Campus, School of Clinical Medicine, Faculty of Medicine and Health, UNSW Sydney, Kensington, Sydney, NSW, Australia. FAU - Bhattacharyya, Nayan Deger AU - Bhattacharyya ND AD - Precision Immunology Program, Garvan Institute of Medical Research, Sydney, NSW, Australia; St. Vincent's Healthcare Clinical Campus, School of Clinical Medicine, Faculty of Medicine and Health, UNSW Sydney, Kensington, Sydney, NSW, Australia. FAU - Ahel, Holly I AU - Ahel HI AD - Precision Immunology Program, Garvan Institute of Medical Research, Sydney, NSW, Australia; St. Vincent's Healthcare Clinical Campus, School of Clinical Medicine, Faculty of Medicine and Health, UNSW Sydney, Kensington, Sydney, NSW, Australia. FAU - Telfser, Aiden Josiah AU - Telfser AJ AD - Precision Immunology Program, Garvan Institute of Medical Research, Sydney, NSW, Australia. FAU - McCorkindale, Andrew N AU - McCorkindale AN AD - Data Science Platform, Garvan Institute of Medical Research, Sydney, NSW 2010, Australia. FAU - Yazar, Seyhan AU - Yazar S AD - Precision Immunology Program, Garvan Institute of Medical Research, Sydney, NSW, Australia; St. Vincent's Healthcare Clinical Campus, School of Clinical Medicine, Faculty of Medicine and Health, UNSW Sydney, Kensington, Sydney, NSW, Australia. FAU - Bui, Christina H T AU - Bui CHT AD - St. Vincent's Healthcare Clinical Campus, School of Clinical Medicine, Faculty of Medicine and Health, UNSW Sydney, Kensington, Sydney, NSW, Australia; Cancer Plasticity and Dormancy Program, The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Sydney, NSW 2010, Australia. FAU - Smith, James T AU - Smith JT AD - St. Vincent's Healthcare Clinical Campus, School of Clinical Medicine, Faculty of Medicine and Health, UNSW Sydney, Kensington, Sydney, NSW, Australia; Cancer Plasticity and Dormancy Program, The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Sydney, NSW 2010, Australia. FAU - Khoo, Weng Hua AU - Khoo WH AD - Cancer Plasticity and Dormancy Program, The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Sydney, NSW 2010, Australia. FAU - Boyd, Mollie AU - Boyd M AD - Immunovirology and Pathogenesis Program, Kirby Institute, UNSW Sydney, Sydney, NSW, Australia. FAU - Obeid, Solange AU - Obeid S AD - St. Vincent's Hospital Sydney, Sydney, NSW, Australia. FAU - Milner, Brad AU - Milner B AD - St. Vincent's Hospital Sydney, Sydney, NSW, Australia. FAU - Starr, Mitchell AU - Starr M AD - St. Vincent's Centre for Applied Medical Research, Sydney, NSW, Australia. FAU - Brilot, Fabienne AU - Brilot F AD - Brain Autoimmunity Group, Kids Neuroscience Centre, The Children's Hospital at Westmead, Faculty of Medicine and Health, School of Medical Sciences, Sydney, NSW, Australia; School of Medical Science, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia. FAU - Milogiannakis, Vanessa AU - Milogiannakis V AD - Immunovirology and Pathogenesis Program, Kirby Institute, UNSW Sydney, Sydney, NSW, Australia. FAU - Akerman, Anouschka AU - Akerman A AD - Immunovirology and Pathogenesis Program, Kirby Institute, UNSW Sydney, Sydney, NSW, Australia. FAU - Aggarwal, Anupriya AU - Aggarwal A AD - Immunovirology and Pathogenesis Program, Kirby Institute, UNSW Sydney, Sydney, NSW, Australia. FAU - Davenport, Miles P AU - Davenport MP AD - Infection Analytics Program, Kirby Institute, UNSW Sydney, Sydney, NSW, Australia. FAU - Deenick, Elissa K AU - Deenick EK AD - Precision Immunology Program, Garvan Institute of Medical Research, Sydney, NSW, Australia; Immunovirology and Pathogenesis Program, Kirby Institute, UNSW Sydney, Sydney, NSW, Australia. FAU - Chaffer, Christine L AU - Chaffer CL AD - St. Vincent's Healthcare Clinical Campus, School of Clinical Medicine, Faculty of Medicine and Health, UNSW Sydney, Kensington, Sydney, NSW, Australia; Cancer Plasticity and Dormancy Program, The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Sydney, NSW 2010, Australia. FAU - Croucher, Peter I AU - Croucher PI AD - St. Vincent's Healthcare Clinical Campus, School of Clinical Medicine, Faculty of Medicine and Health, UNSW Sydney, Kensington, Sydney, NSW, Australia; Cancer Plasticity and Dormancy Program, The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Sydney, NSW 2010, Australia. FAU - Brink, Robert AU - Brink R AD - Precision Immunology Program, Garvan Institute of Medical Research, Sydney, NSW, Australia; Immune Biotherapies Program, Garvan Institute of Medical Research, Sydney, NSW 2010, Australia. FAU - Goldstein, Leonard D AU - Goldstein LD AD - St. Vincent's Healthcare Clinical Campus, School of Clinical Medicine, Faculty of Medicine and Health, UNSW Sydney, Kensington, Sydney, NSW, Australia; Data Science Platform, Garvan Institute of Medical Research, Sydney, NSW 2010, Australia. FAU - Cromer, Deborah AU - Cromer D AD - Infection Analytics Program, Kirby Institute, UNSW Sydney, Sydney, NSW, Australia. FAU - Turville, Stuart G AU - Turville SG AD - Immunovirology and Pathogenesis Program, Kirby Institute, UNSW Sydney, Sydney, NSW, Australia. FAU - Kelleher, Anthony D AU - Kelleher AD AD - Immunovirology and Pathogenesis Program, Kirby Institute, UNSW Sydney, Sydney, NSW, Australia; St. Vincent's Hospital Sydney, Sydney, NSW, Australia. Electronic address: akelleher@kirby.unsw.edu.au. FAU - Venturi, Vanessa AU - Venturi V AD - Immunovirology and Pathogenesis Program, Kirby Institute, UNSW Sydney, Sydney, NSW, Australia. Electronic address: vventuri@kirby.unsw.edu.au. FAU - Munier, C Mee Ling AU - Munier CML AD - Immunovirology and Pathogenesis Program, Kirby Institute, UNSW Sydney, Sydney, NSW, Australia. Electronic address: cmunier@kirby.unsw.edu.au. FAU - Phan, Tri Giang AU - Phan TG AD - Precision Immunology Program, Garvan Institute of Medical Research, Sydney, NSW, Australia; St. Vincent's Healthcare Clinical Campus, School of Clinical Medicine, Faculty of Medicine and Health, UNSW Sydney, Kensington, Sydney, NSW, Australia. Electronic address: t.phan@garvan.org.au. LA - eng PT - Journal Article DEP - 20250429 PL - United States TA - Cell JT - Cell JID - 0413066 RN - 0 (Antibodies, Neutralizing) RN - 0 (Sialic Acid Binding Ig-like Lectin 1) RN - 0 (BNT162 Vaccine) RN - 0 (Antibodies, Viral) RN - 0 (Siglec1 protein, mouse) SB - IM MH - Animals MH - *Memory B Cells/immunology MH - Mice MH - Lymph Nodes/immunology MH - Germinal Center/immunology MH - *Immunologic Memory/immunology MH - Humans MH - *Macrophages/immunology MH - Vaccination MH - Mice, Inbred C57BL MH - Antibodies, Neutralizing/immunology MH - SARS-CoV-2/immunology MH - Plasma Cells/immunology MH - Sialic Acid Binding Ig-like Lectin 1/metabolism MH - *B-Lymphocytes/immunology MH - BNT162 Vaccine/immunology MH - Female MH - *COVID-19/immunology/prevention & control MH - Antibodies, Viral/immunology MH - Male OTO - NOTNLM OT - SARS-CoV-2 OT - affinity maturation OT - broadly neutralizing antibodies OT - germinal center OT - immune imprinting OT - memory OT - original antigenic sin OT - plasma cells OT - subcapsular sinus macrophage OT - vaccine COIS- Declaration of interests The authors declare no competing interests. EDAT- 2025/04/30 00:31 MHDA- 2025/06/28 00:39 CRDT- 2025/04/29 18:41 PHST- 2023/09/19 00:00 [received] PHST- 2024/08/31 00:00 [revised] PHST- 2025/04/02 00:00 [accepted] PHST- 2025/06/28 00:39 [medline] PHST- 2025/04/30 00:31 [pubmed] PHST- 2025/04/29 18:41 [entrez] AID - S0092-8674(25)00407-6 [pii] AID - 10.1016/j.cell.2025.04.005 [doi] PST - ppublish SO - Cell. 2025 Jun 26;188(13):3477-3496.e22. doi: 10.1016/j.cell.2025.04.005. Epub 2025 Apr 29. PMID- 40294012 OWN - NLM STAT- MEDLINE DCOM- 20250428 LR - 20260930 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 20 IP - 4 DP - 2025 TI - Impact of memory T cells on SARS-CoV-2 vaccine response in hematopoietic stem cell transplant. PG - e0320744 LID - 10.1371/journal.pone.0320744 [doi] LID - e0320744 AB - During the COVID-19 pandemic, hematopoietic stem cell transplant (HSCT) recipients had elevated mortality rates from SARS-CoV-2 infection, ranging between 10-40%. SARS-CoV-2 mRNA vaccines are important tools in preventing severe disease, yet their efficacy post-transplant remains unclear, especially in patients subjected to myeloablative chemotherapy and immunosuppression. We evaluated humoral and adaptive immune responses to the SARS-CoV-2 mRNA vaccination series in 42 HSCT recipients and 5 healthy controls. Post-vaccination responses were assessed by anti-spike IgG and nucleocapsid levels, and antigen specific T cell activity. Immune profiling was performed using clinical flow and mass cytometry. Patients were selected based on humoral and cellular responses for single-cell RNA with TCR and BCR sequencing. Our studies revealed defects in memory T cells that correlated with an absence of cellular response despite nearly universal humoral response. Several patients with a robust antibody response developed COVID-19 infection, but none developed severe disease or died from the infection. CI - Copyright: (c) 2025 VanOudenhove et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. FAU - VanOudenhove, Jennifer AU - VanOudenhove J AUID- ORCID: 0000-0001-8206-5542 AD - Section of Hematology, Department of Internal Medicine and Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut, United States of America. FAU - Liu, Yuxin AU - Liu Y AD - Section of Hematology, Department of Internal Medicine and Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut, United States of America. FAU - Nelakanti, Raman AU - Nelakanti R AD - Section of Hematology, Department of Internal Medicine and Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut, United States of America. FAU - Kim, Dongjoo AU - Kim D AD - Department of Biomedical Engineering, Yale University, New Haven, Connecticut, United States of America. FAU - Busarello, Emma AU - Busarello E AD - Department of Cellular, Computational and Integrative Biology (CIBIO), University of Trento, Trento, Italy. FAU - Ovalle, Natalia Tijaro AU - Ovalle NT AD - Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, United States of America. FAU - Qi, Zhihong AU - Qi Z AD - Section of Hematology, Department of Internal Medicine and Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut, United States of America. FAU - Mamillapalli, Padmavathi AU - Mamillapalli P AD - Section of Hematology, Department of Internal Medicine and Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut, United States of America. FAU - Siddon, Alexa AU - Siddon A AD - Department of Laboratory Medicine, Yale University School of Medicine, New Haven, Connecticut, United States of America. FAU - Bai, Zhiliang AU - Bai Z AD - Department of Biomedical Engineering, Yale University, New Haven, Connecticut, United States of America. FAU - Axtmayer, Alfredo AU - Axtmayer A AD - Bone Marrow Transplant and Cellular Therapy Program, Yale New Haven Hospital and Yale Cancer Center, New Haven, Connecticut, United States of America. FAU - Corso, Cheryl AU - Corso C AD - Bone Marrow Transplant and Cellular Therapy Program, Yale New Haven Hospital and Yale Cancer Center, New Haven, Connecticut, United States of America. FAU - Kothari, Shalin AU - Kothari S AD - Section of Hematology, Department of Internal Medicine and Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut, United States of America. FAU - Foss, Francine AU - Foss F AUID- ORCID: 0000-0001-7843-3162 AD - Section of Hematology, Department of Internal Medicine and Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut, United States of America. FAU - Isufi, Iris AU - Isufi I AD - Section of Hematology, Department of Internal Medicine and Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut, United States of America. AD - Bone Marrow Transplant and Cellular Therapy Program, Yale New Haven Hospital and Yale Cancer Center, New Haven, Connecticut, United States of America. FAU - Tebaldi, Toma AU - Tebaldi T AD - Department of Cellular, Computational and Integrative Biology (CIBIO), University of Trento, Trento, Italy. FAU - Gowda, Lohith AU - Gowda L AD - Section of Hematology, Department of Internal Medicine and Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut, United States of America. FAU - Fan, Rong AU - Fan R AD - Department of Biomedical Engineering, Yale University, New Haven, Connecticut, United States of America. FAU - Seropian, Stuart AU - Seropian S AD - Section of Hematology, Department of Internal Medicine and Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut, United States of America. FAU - Halene, Stephanie AU - Halene S AD - Section of Hematology, Department of Internal Medicine and Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut, United States of America. AD - Department of Pathology, Yale University School of Medicine, New Haven, Connecticut, United States of America. LA - eng GR - S10 OD026996/OD/NIH HHS/United States GR - U54 DK106857/DK/NIDDK NIH HHS/United States GR - P30 CA016359/CA/NCI NIH HHS/United States GR - U01 CA260507/CA/NCI NIH HHS/United States GR - S10 OD030363/OD/NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, U.S. Gov't, P.H.S. DEP - 20250428 PL - United States TA - PLoS One JT - PloS one JID - 101285081 RN - 0 (COVID-19 Vaccines) RN - 0 (Antibodies, Viral) RN - 0 (Immunoglobulin G) RN - 0 (Spike Glycoprotein, Coronavirus) SB - IM UOF - bioRxiv. 2023 Oct 27:2023.10.26.564259. doi: 10.1101/2023.10.26.564259. PMID: 37961434 MH - Humans MH - *Hematopoietic Stem Cell Transplantation MH - *COVID-19/prevention & control/immunology MH - Female MH - Male MH - Middle Aged MH - *SARS-CoV-2/immunology MH - *COVID-19 Vaccines/immunology MH - Adult MH - *Memory T Cells/immunology MH - Antibodies, Viral/immunology/blood MH - Aged MH - Immunoglobulin G/immunology MH - Immunity, Humoral MH - Spike Glycoprotein, Coronavirus/immunology PMC - PMC12036906 COIS- The authors have declared that no competing interests exist. EDAT- 2025/04/28 18:32 MHDA- 2025/04/28 18:33 PMCR- 2025/04/28 CRDT- 2025/04/28 13:34 PHST- 2024/10/29 00:00 [received] PHST- 2025/02/24 00:00 [accepted] PHST- 2025/04/28 18:33 [medline] PHST- 2025/04/28 18:32 [pubmed] PHST- 2025/04/28 13:34 [entrez] PHST- 2025/04/28 00:00 [pmc-release] AID - PONE-D-24-45083 [pii] AID - 10.1371/journal.pone.0320744 [doi] PST - epublish SO - PLoS One. 2025 Apr 28;20(4):e0320744. doi: 10.1371/journal.pone.0320744. eCollection 2025. PMID- 40281501 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250605 IS - 1348-8945 (Print) IS - 1349-4147 (Electronic) IS - 1348-8945 (Linking) VI - 53 IP - 1 DP - 2025 Apr 25 TI - Attention to COVID 19 pandemic resulted in increased measles cases and deaths in Zambia. PG - 59 LID - 10.1186/s41182-025-00736-2 [doi] LID - 59 AB - BACKGROUND: The COVID-19 pandemic had a devastating impact on childhood routine immunization programs, resulting in increased measles mortalities and complications. In Zambia, the likelihood of measles-related deaths and complications in children was possibly increased because of high rates of unvaccinated children, late diagnosis, and poor case management, which could have been a consequence of exclusive focus on COVID-19 interventions. This study aimed at examining the effect of the COVID-19 pandemic on measles mortality and its predictors among patients seen at health facilities in Zambia. METHODS: We used longitudinal data (January 2020 to August 2023) from outbreak investigations and time series data from 2017 to 2023 to understand the impact of COVID-19 on measles immunization and know the predictors of measles mortalities. The period running from January 2017 to February 2020, just before the first reported COVID-19 case, was defined as pre-COVID-19, and March 2020 to December 2023 as post-COVID-19. Multivariable logistic regression analysis was used to determine predictors of mortality. A segmented Poisson regression model was used to determine the correlation between the underlying patterns of measles mortality and the commencement of the COVID-19 pandemic. RESULTS: A total of 3429 measles cases were reported during the study period. Of these, 1261 had complete metadata and were included in the analysis. The median age was 3 years (IQR, 1-7). Out of the 1261 enrolled, 54 (4.3%) were reported died. A total of 205 (21.0%) were IgM positive, and 207 (16.9%) were vaccinated. Monthly measles mortality increased by 220%, from 0.06 per 100,000 before COVID-19 to 0.23 during the pandemic. Predictors of mortality were younger age category (0-4) (AOR = 2.78; 95% CI 1.16-7.14), testing positive for measles IgM (AOR = 2.17; 95% CI 1.07-4.39), rush (AOR = 3.66; 95% CI 1.31, 6.21), and female sex (AOR = 1.90; 95% CI 1.04-3.50), which increased the odds of dying. However, being vaccinated (AOR = 0.06; 95% CI 0.01-0.42) reduced the odds of dying. Evidence for the COVID-19 effect was strongly associated with increased measles mortality (RR, 1.02; 95% CI 1.00, 1.04; 0.017) with a trend step change of 81% (RR, 1.81; 95% CI 1.14-2.87). There was also an increased trend of measles cases (RR, 1.04; 95% CI 1.01-1.06) during the pandemic. Measles dose 2 vaccination trends increased by about 0.3% during the COVID-19 pandemic due to the Supplementary Immunization Activity (SIA) (RR, 1.003; 95% CI 1.000-1.010). However, there was a dramatic drop of about 42% (RR = 0.58, 95% CI 0.46-0.72). CONCLUSIONS: Measles caused a significant increase in child mortality during the pandemic period. A mix of systemic, clinical, and individual factors affected measles mortality. Prioritizing vaccine coverage, especially for younger children and marginalized populations; enhancing diagnostic and treatment capacities; and addressing gender and healthcare access disparities are all essential components of interventions aimed at lowering mortality. The findings suggest that public health interventions focusing on measles vaccination, rapid detection, and appropriate case management are crucial to reducing mortality and preventing further transmission. To achieve population immunity, sustained efforts are required to maintain high coverage rates. CI - (c) 2025. The Author(s). FAU - Mwangilwa, Kelvin AU - Mwangilwa K AD - Zambia National Public Health Institute, Stand Number 1186 Corner of Chaholi Road and Addis Ababa, Rhodes Park, Lusaka, Zambia. kelvinpetersj@gmail.com. FAU - Sialubanje, Cephas AU - Sialubanje C AD - Zambia National Public Health Institute, Stand Number 1186 Corner of Chaholi Road and Addis Ababa, Rhodes Park, Lusaka, Zambia. FAU - Chipoya, Musole AU - Chipoya M AD - Zambia National Public Health Institute, Stand Number 1186 Corner of Chaholi Road and Addis Ababa, Rhodes Park, Lusaka, Zambia. FAU - Mulenga, Chilufya AU - Mulenga C AD - Zambia National Public Health Institute, Stand Number 1186 Corner of Chaholi Road and Addis Ababa, Rhodes Park, Lusaka, Zambia. FAU - Mwale, Moses AU - Mwale M AD - WHO Country Office, PO Box 32346, 10101, Lusaka, Zambia. FAU - Chileshe, Charles AU - Chileshe C AD - Zambia National Public Health Institute, Stand Number 1186 Corner of Chaholi Road and Addis Ababa, Rhodes Park, Lusaka, Zambia. FAU - Sinyange, Danny AU - Sinyange D AD - Zambia National Public Health Institute, Stand Number 1186 Corner of Chaholi Road and Addis Ababa, Rhodes Park, Lusaka, Zambia. FAU - Banda, Moses AU - Banda M AD - Zambia National Public Health Institute, Stand Number 1186 Corner of Chaholi Road and Addis Ababa, Rhodes Park, Lusaka, Zambia. FAU - Gardner, Priscilla Nkonde AU - Gardner PN AD - Zambia National Public Health Institute, Stand Number 1186 Corner of Chaholi Road and Addis Ababa, Rhodes Park, Lusaka, Zambia. FAU - Lamba, Lilian AU - Lamba L AD - Zambia National Public Health Institute, Stand Number 1186 Corner of Chaholi Road and Addis Ababa, Rhodes Park, Lusaka, Zambia. FAU - Kalubula, Precious AU - Kalubula P AD - WHO Country Office, PO Box 32346, 10101, Lusaka, Zambia. FAU - Simwanza, John AU - Simwanza J AD - Zambia National Public Health Institute, Stand Number 1186 Corner of Chaholi Road and Addis Ababa, Rhodes Park, Lusaka, Zambia. FAU - Simwaba, Davie AU - Simwaba D AD - Zambia National Public Health Institute, Stand Number 1186 Corner of Chaholi Road and Addis Ababa, Rhodes Park, Lusaka, Zambia. FAU - Kapata, Nathan AU - Kapata N AD - Zambia National Public Health Institute, Stand Number 1186 Corner of Chaholi Road and Addis Ababa, Rhodes Park, Lusaka, Zambia. FAU - Mwanza, Jonathan AU - Mwanza J AD - Zambia National Public Health Institute, Stand Number 1186 Corner of Chaholi Road and Addis Ababa, Rhodes Park, Lusaka, Zambia. FAU - Chipimo, Peter J AU - Chipimo PJ AD - WHO Country Office, PO Box 32346, 10101, Lusaka, Zambia. FAU - Mbewe, Nyuma AU - Mbewe N AD - Zambia National Public Health Institute, Stand Number 1186 Corner of Chaholi Road and Addis Ababa, Rhodes Park, Lusaka, Zambia. FAU - Sinyange, Nyambe AU - Sinyange N AD - Zambia National Public Health Institute, Stand Number 1186 Corner of Chaholi Road and Addis Ababa, Rhodes Park, Lusaka, Zambia. FAU - Fwemba, Isaac AU - Fwemba I AD - Department of Health Policy, Systems and Management, School of Public Health, University of Zambia, Ridgeway Campus, P.O. Box 50110, Lusaka, Zambia. FAU - Kapin'a, Muzala AU - Kapin'a M AD - Zambia National Public Health Institute, Stand Number 1186 Corner of Chaholi Road and Addis Ababa, Rhodes Park, Lusaka, Zambia. FAU - Chilengi, Roma AU - Chilengi R AD - Zambia National Public Health Institute, Stand Number 1186 Corner of Chaholi Road and Addis Ababa, Rhodes Park, Lusaka, Zambia. LA - eng GR - 001/WHO_/World Health Organization/International PT - Journal Article DEP - 20250425 PL - Japan TA - Trop Med Health JT - Tropical medicine and health JID - 101215093 PMC - PMC12023654 OTO - NOTNLM OT - COVID-19 pandemic OT - Childhood OT - Measles mortality OT - Measles vaccination OT - Routine immunization COIS- Declarations. Ethics approval and consent to participate: This study did not involve any patients and worked entirely with no personal identifiers. We used secondary aggregated data from web sources for routine health information. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests. EDAT- 2025/04/26 16:16 MHDA- 2025/04/26 16:17 PMCR- 2025/04/25 CRDT- 2025/04/25 23:41 PHST- 2024/10/30 00:00 [received] PHST- 2025/04/01 00:00 [accepted] PHST- 2025/04/26 16:17 [medline] PHST- 2025/04/26 16:16 [pubmed] PHST- 2025/04/25 23:41 [entrez] PHST- 2025/04/25 00:00 [pmc-release] AID - 10.1186/s41182-025-00736-2 [pii] AID - 736 [pii] AID - 10.1186/s41182-025-00736-2 [doi] PST - epublish SO - Trop Med Health. 2025 Apr 25;53(1):59. doi: 10.1186/s41182-025-00736-2. PMID- 40274002 OWN - NLM STAT- MEDLINE DCOM- 20250723 LR - 20250723 IS - 1090-2139 (Electronic) IS - 0889-1591 (Linking) VI - 128 DP - 2025 Aug TI - SARS-CoV2 vaccination during pregnancy - Vetting the impact on maternal health and long-term consequences for offspring brain function. PG - 549-557 LID - S0889-1591(25)00166-7 [pii] LID - 10.1016/j.bbi.2025.04.029 [doi] AB - The COVID-19 pandemic has shown the critical importance of vaccination strategies to protect vulnerable populations, including pregnant women, from severe disease and its lingering consequences. Although growing evidence demonstrates that COVID-19 vaccines are both safe and highly beneficial during pregnancy, vaccine hesitancy among pregnant women persists, partly fueled by the persistent, decade-old "urban myth" linking vaccination during pregnancy to neuropsychiatric disorders in children. Here we used a mouse model of passive immunization with severe acute respiratory syndrome coronavirus 2 spike neutralizing monoclonal antibodies (SaCoV-AB) to determine the effects of gestational COVID-19 vaccination on key pregnancy outcomes, maternal and offspring health, and behavior. We show that at a higher SaCoV-AB dosage, maternal immune response is reflected in elevated TNF-alpha levels in maternal serum, but not in the placenta or the fetal brain, with no effect on pregnancy outcomes. We report no consequences for postpartum maternal care behavior and neonatal communication signatures. Behavioral assessment of adult female and male offspring after maternal SaCoV-AB treatment revealed no differences in phenotypes relevant to neurodevelopmental disorders. Our findings indicate that in a preclinical model, passive immunization with SaCoV-AB during pregnancy is well-tolerated, with no discernable impact on maternal or offspring health and behavior. CI - Copyright (c) 2025 The Author(s). Published by Elsevier Inc. All rights reserved. FAU - Gundacker, Anna AU - Gundacker A AD - Department of Neurophysiology and Neuropharmacology, Center for Physiology and Pharmacology, Medical University of Vienna, Vienna, Austria. FAU - Schaer, Ron AU - Schaer R AD - Institute of Pharmacology and Toxicology, University of Zurich-Vetsuisse, Zurich, Switzerland. FAU - Pollak, Arnold AU - Pollak A AD - Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria. FAU - Weber-Stadlbauer, Ulrike AU - Weber-Stadlbauer U AD - Institute of Pharmacology and Toxicology, University of Zurich-Vetsuisse, Zurich, Switzerland. FAU - Pollak, Daniela D AU - Pollak DD AD - Department of Neurophysiology and Neuropharmacology, Center for Physiology and Pharmacology, Medical University of Vienna, Vienna, Austria. Electronic address: daniela.pollak@meduniwien.ac.at. LA - eng PT - Journal Article DEP - 20250422 PL - Netherlands TA - Brain Behav Immun JT - Brain, behavior, and immunity JID - 8800478 RN - 0 (COVID-19 Vaccines) RN - 0 (Antibodies, Neutralizing) RN - 0 (Tumor Necrosis Factor-alpha) SB - IM MH - Female MH - Pregnancy MH - Animals MH - *COVID-19/prevention & control/immunology MH - *COVID-19 Vaccines/adverse effects/immunology/administration & dosage MH - Mice MH - SARS-CoV-2/immunology MH - *Brain/immunology MH - Male MH - Maternal Health MH - Vaccination MH - Pregnancy Complications, Infectious/prevention & control/immunology MH - Antibodies, Neutralizing/immunology MH - Immunization, Passive MH - Tumor Necrosis Factor-alpha/blood MH - Prenatal Exposure Delayed Effects/immunology MH - Pregnancy Outcome MH - Maternal Behavior OTO - NOTNLM OT - Cytokines OT - Gestational vaccination OT - Maternal behavior OT - Passive immunization OT - Severe acute respiratory syndrome coronavirus 2 OT - Ultrasonic vocalization COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2025/04/25 01:20 MHDA- 2025/07/24 00:25 CRDT- 2025/04/24 19:35 PHST- 2024/12/03 00:00 [received] PHST- 2025/04/12 00:00 [revised] PHST- 2025/04/21 00:00 [accepted] PHST- 2025/07/24 00:25 [medline] PHST- 2025/04/25 01:20 [pubmed] PHST- 2025/04/24 19:35 [entrez] AID - S0889-1591(25)00166-7 [pii] AID - 10.1016/j.bbi.2025.04.029 [doi] PST - ppublish SO - Brain Behav Immun. 2025 Aug;128:549-557. doi: 10.1016/j.bbi.2025.04.029. Epub 2025 Apr 22. PMID- 40222009 OWN - NLM STAT- MEDLINE DCOM- 20250425 LR - 20250530 IS - 2211-1247 (Electronic) VI - 44 IP - 4 DP - 2025 Apr 22 TI - Phenotypic heterogeneity defines B cell responses to repeated SARS-CoV-2 exposures through vaccination and infection. PG - 115557 LID - S2211-1247(25)00328-6 [pii] LID - 10.1016/j.celrep.2025.115557 [doi] AB - Long-lived humoral memory is key to durable immunity against pathogens yet remains challenging to define due to heterogeneity among antigen-reactive B cells. We addressed this gap through longitudinal sampling over the course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccinations with or without breakthrough infection. High-dimensional phenotypic profiling performed on approximately 72 million B cells showed that receptor-binding domain (RBD) reactivity was associated with five distinct immunoglobulin G (IgG) B cell populations. Two expressed the activation marker CD71, both correlated with neutralizing antibodies, yet the one lacking the memory marker CD27 was induced by vaccination and blunted by infection. Two were resting memory populations; one lacking CD73 arose early and contributed to cross-reactivity; the other, expressing CD73, arose later and correlated with neutralizing antibodies. The fifth, a rare germinal center-like population, contributed to recall responses and was highly cross reactive. Overall, robust and distinct responses to booster vaccination overcame the superiority of hybrid immunity provided by breakthrough infection. CI - Published by Elsevier Inc. FAU - Kardava, Lela AU - Kardava L AD - Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD 20892, USA. FAU - Lim, James AU - Lim J AD - Monoceros Biosystems, San Diego, CA 29130, USA. FAU - Buckner, Clarisa M AU - Buckner CM AD - Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD 20892, USA. FAU - Lopes de Assis, Felipe AU - Lopes de Assis F AD - Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD 20892, USA. FAU - Zhang, Xiaozhen AU - Zhang X AD - Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD 20892, USA. FAU - Wang, Wei AU - Wang W AD - Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD 20892, USA. FAU - Melnyk, Mattie L AU - Melnyk ML AD - Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD 20892, USA. FAU - El Merhebi, Omar AU - El Merhebi O AD - Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD 20892, USA. FAU - Trihemasava, Krittin AU - Trihemasava K AD - Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD 20892, USA. FAU - Teng, I-Ting AU - Teng IT AD - Vaccine Research Center, NIAID, NIH, Bethesda, MD 20892, USA. FAU - Carroll, Robin AU - Carroll R AD - Vaccine Research Center, NIAID, NIH, Bethesda, MD 20892, USA. FAU - Jethmalani, Yogita AU - Jethmalani Y AD - Vaccine Research Center, NIAID, NIH, Bethesda, MD 20892, USA. FAU - Castro, Mike AU - Castro M AD - Vaccine Research Center, NIAID, NIH, Bethesda, MD 20892, USA. FAU - Lin, Bob C AU - Lin BC AD - Vaccine Research Center, NIAID, NIH, Bethesda, MD 20892, USA. FAU - Praiss, Lauren H AU - Praiss LH AD - Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD 20892, USA. FAU - Seamon, Catherine A AU - Seamon CA AD - Critical Care Medicine Department, Clinical Center, NIH, Bethesda, MD 20892, USA. FAU - Kwong, Peter D AU - Kwong PD AD - Vaccine Research Center, NIAID, NIH, Bethesda, MD 20892, USA; Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032, USA. FAU - Koup, Richard A AU - Koup RA AD - Vaccine Research Center, NIAID, NIH, Bethesda, MD 20892, USA. FAU - Serebryannyy, Leonid AU - Serebryannyy L AD - Vaccine Research Center, NIAID, NIH, Bethesda, MD 20892, USA. FAU - Nickle, David C AU - Nickle DC AD - Monoceros Biosystems, San Diego, CA 29130, USA; Department of Global Health, University of Washington, Seattle, WA 98105, USA. FAU - Chun, Tae-Wook AU - Chun TW AD - Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD 20892, USA. FAU - Moir, Susan AU - Moir S AD - Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD 20892, USA. Electronic address: smoir@niaid.nih.gov. LA - eng GR - ZIA AI001325/ImNIH/Intramural NIH HHS/United States PT - Journal Article DEP - 20250412 PL - United States TA - Cell Rep JT - Cell reports JID - 101573691 RN - 0 (Antibodies, Neutralizing) RN - 0 (COVID-19 Vaccines) RN - 0 (Antibodies, Viral) RN - 0 (Immunoglobulin G) RN - 0 (Spike Glycoprotein, Coronavirus) SB - IM MH - Humans MH - *COVID-19/immunology/prevention & control/virology MH - *SARS-CoV-2/immunology MH - *B-Lymphocytes/immunology MH - Antibodies, Neutralizing/immunology MH - Vaccination MH - *COVID-19 Vaccines/immunology MH - Antibodies, Viral/immunology MH - Immunoglobulin G/immunology MH - Immunologic Memory MH - Phenotype MH - Female MH - Male MH - Adult MH - Immunization, Secondary MH - Memory B Cells/immunology MH - Spike Glycoprotein, Coronavirus/immunology PMC - PMC12080740 MID - NIHMS2076671 OTO - NOTNLM OT - B cells OT - COVID-19 mRNA vaccines OT - CP: Immunology OT - SARS-CoV-2 OT - adaptive immune memory OT - antibodies OT - booster vaccination OT - breakthrough infection OT - hybrid immunity COIS- Declaration of interests The authors declare no competing interests. EDAT- 2025/04/13 23:18 MHDA- 2025/04/25 13:47 PMCR- 2025/05/15 CRDT- 2025/04/13 12:36 PHST- 2024/09/23 00:00 [received] PHST- 2025/01/29 00:00 [revised] PHST- 2025/03/21 00:00 [accepted] PHST- 2025/04/25 13:47 [medline] PHST- 2025/04/13 23:18 [pubmed] PHST- 2025/04/13 12:36 [entrez] PHST- 2025/05/15 00:00 [pmc-release] AID - S2211-1247(25)00328-6 [pii] AID - 10.1016/j.celrep.2025.115557 [doi] PST - ppublish SO - Cell Rep. 2025 Apr 22;44(4):115557. doi: 10.1016/j.celrep.2025.115557. Epub 2025 Apr 12. PMID- 40213554 OWN - NLM STAT- MEDLINE DCOM- 20250411 LR - 20250412 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 16 DP - 2025 TI - Longitudinal cellular and humoral immune responses following COVID-19 BNT162b2-mRNA-based booster vaccination of craft and manual workers in Qatar. PG - 1557426 LID - 10.3389/fimmu.2025.1557426 [doi] LID - 1557426 AB - BACKGROUND: In March 2020, the rapid spread of SARS-CoV-2 prompted global vaccination campaigns to mitigate COVID-19 disease severity and mortality. The 2-dose BNT162b2-mRNA vaccine effectively reduced infection and mortality rates, however, waning vaccine effectiveness necessitated the introduction of a third vaccine dose or booster. AIM: To assess the magnitude and longevity of booster-induced immunity, we conducted a longitudinal study of SARS-CoV-2 specific cellular and humoral immune responses among Qatar's vulnerable craft and manual worker community. We also investigated the impact of prior naturally acquired immunity on booster vaccination efficacy. METHODS: Seventy healthy participants were enrolled in the study, of whom half had prior SARS-CoV-2 infection. Blood samples were collected before and after booster vaccination to evaluate immune responses through SARS-CoV-2 specific ELISpots, IgG ELISA, neutralization assays, and flow cytometric immunophenotyping. RESULTS: T cell analysis revealed increased Th1 cytokine responses, marked by enhanced IFN-gamma release, in recently infected participants, which was further enhanced by booster vaccination for up to 6-months. Furthermore, booster vaccination stimulated cytotoxic responses in infection-naive participants, characterized by granzyme B production. Both natural SARS-CoV-2 infection and booster vaccination induced robust and durable SARS-CoV-2 specific humoral immune responses, with high neutralizing antibody levels. Prior natural infection was also linked to an increased number of class-switched B cells prior to booster vaccination. CONCLUSIONS: These findings underscore the importance of booster vaccination in enhancing anti-viral immunity across both infection-naive and previously infected individuals, enhancing distinct arms of the anti-viral immune response and prolonging naturally acquired immunity. CI - Copyright (c) 2025 Thomas, Zaqout, Meqbel, Jafar, Vaikath, Aldushain, Naik, Shaath, Al-Akl, Adam, Moussa, Shin, Taha, Abukhattab, Almaslamani, Alajez, Arredouani, Park, Abdulla, El-Agnaf, Omrani and Decock. FAU - Thomas, Remy AU - Thomas R AD - Translational Oncology Research Center, Qatar Biomedical Research Institute (QBRI), Hamad Bin Khalifa University (HBKU), Qatar Foundation (QF), Doha, Qatar. FAU - Zaqout, Ahmed AU - Zaqout A AD - Communicable Disease Center, Hamad Medical Corporation (HMC), Doha, Qatar. FAU - Meqbel, Bakhita AU - Meqbel B AD - Translational Oncology Research Center, Qatar Biomedical Research Institute (QBRI), Hamad Bin Khalifa University (HBKU), Qatar Foundation (QF), Doha, Qatar. FAU - Jafar, Umar AU - Jafar U AD - Translational Oncology Research Center, Qatar Biomedical Research Institute (QBRI), Hamad Bin Khalifa University (HBKU), Qatar Foundation (QF), Doha, Qatar. AD - College of Health and Life Sciences (CHLS), Hamad Bin Khalifa University (HBKU), Qatar Foundation (QF), Doha, Qatar. FAU - Vaikath, Nishant N AU - Vaikath NN AD - Neurological Disorders Research Center, Qatar Biomedical Research Institute (QBRI), Hamad Bin Khalifa University (HBKU), Qatar Foundation (QF), Doha, Qatar. FAU - Aldushain, Abdullah AU - Aldushain A AD - Communicable Disease Center, Hamad Medical Corporation (HMC), Doha, Qatar. FAU - Naik, Adviti AU - Naik A AD - Translational Oncology Research Center, Qatar Biomedical Research Institute (QBRI), Hamad Bin Khalifa University (HBKU), Qatar Foundation (QF), Doha, Qatar. FAU - Shaath, Hibah AU - Shaath H AD - Translational Oncology Research Center, Qatar Biomedical Research Institute (QBRI), Hamad Bin Khalifa University (HBKU), Qatar Foundation (QF), Doha, Qatar. FAU - Al-Akl, Neyla S AU - Al-Akl NS AD - Diabetes Research Center, Qatar Biomedical Research Institute (QBRI), Hamad Bin Khalifa University (HBKU), Qatar Foundation (QF), Doha, Qatar. FAU - Adam, Abdi AU - Adam A AD - Clinical Core, Qatar Biomedical Research Institute (QBRI), Hamad Bin Khalifa University (HBKU), Qatar Foundation (QF), Doha, Qatar. FAU - Moussa, Houda Y A AU - Moussa HYA AD - Neurological Disorders Research Center, Qatar Biomedical Research Institute (QBRI), Hamad Bin Khalifa University (HBKU), Qatar Foundation (QF), Doha, Qatar. FAU - Shin, Kyung C AU - Shin KC AD - Neurological Disorders Research Center, Qatar Biomedical Research Institute (QBRI), Hamad Bin Khalifa University (HBKU), Qatar Foundation (QF), Doha, Qatar. FAU - Taha, Rowaida Z AU - Taha RZ AD - Neurological Disorders Research Center, Qatar Biomedical Research Institute (QBRI), Hamad Bin Khalifa University (HBKU), Qatar Foundation (QF), Doha, Qatar. FAU - Abukhattab, Mohammed AU - Abukhattab M AD - Communicable Disease Center, Hamad Medical Corporation (HMC), Doha, Qatar. FAU - Almaslamani, Muna A AU - Almaslamani MA AD - Communicable Disease Center, Hamad Medical Corporation (HMC), Doha, Qatar. FAU - Alajez, Nehad M AU - Alajez NM AD - Translational Oncology Research Center, Qatar Biomedical Research Institute (QBRI), Hamad Bin Khalifa University (HBKU), Qatar Foundation (QF), Doha, Qatar. AD - College of Health and Life Sciences (CHLS), Hamad Bin Khalifa University (HBKU), Qatar Foundation (QF), Doha, Qatar. FAU - Arredouani, Abdelilah AU - Arredouani A AD - College of Health and Life Sciences (CHLS), Hamad Bin Khalifa University (HBKU), Qatar Foundation (QF), Doha, Qatar. AD - Diabetes Research Center, Qatar Biomedical Research Institute (QBRI), Hamad Bin Khalifa University (HBKU), Qatar Foundation (QF), Doha, Qatar. FAU - Park, Yongsoo AU - Park Y AD - College of Health and Life Sciences (CHLS), Hamad Bin Khalifa University (HBKU), Qatar Foundation (QF), Doha, Qatar. AD - Neurological Disorders Research Center, Qatar Biomedical Research Institute (QBRI), Hamad Bin Khalifa University (HBKU), Qatar Foundation (QF), Doha, Qatar. FAU - Abdulla, Sara A AU - Abdulla SA AD - College of Health and Life Sciences (CHLS), Hamad Bin Khalifa University (HBKU), Qatar Foundation (QF), Doha, Qatar. AD - Neurological Disorders Research Center, Qatar Biomedical Research Institute (QBRI), Hamad Bin Khalifa University (HBKU), Qatar Foundation (QF), Doha, Qatar. FAU - El-Agnaf, Omar M A AU - El-Agnaf OMA AD - College of Health and Life Sciences (CHLS), Hamad Bin Khalifa University (HBKU), Qatar Foundation (QF), Doha, Qatar. AD - Neurological Disorders Research Center, Qatar Biomedical Research Institute (QBRI), Hamad Bin Khalifa University (HBKU), Qatar Foundation (QF), Doha, Qatar. FAU - Omrani, Ali S AU - Omrani AS AD - Communicable Disease Center, Hamad Medical Corporation (HMC), Doha, Qatar. AD - College of Medicine, Qatar University, Doha, Qatar. FAU - Decock, Julie AU - Decock J AD - Translational Oncology Research Center, Qatar Biomedical Research Institute (QBRI), Hamad Bin Khalifa University (HBKU), Qatar Foundation (QF), Doha, Qatar. AD - College of Health and Life Sciences (CHLS), Hamad Bin Khalifa University (HBKU), Qatar Foundation (QF), Doha, Qatar. LA - eng PT - Journal Article DEP - 20250327 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 RN - 0 (BNT162 Vaccine) RN - 0 (Antibodies, Viral) RN - 0 (Antibodies, Neutralizing) RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - *COVID-19/immunology/prevention & control MH - *BNT162 Vaccine/immunology MH - *Immunization, Secondary MH - *SARS-CoV-2/immunology MH - Male MH - Adult MH - Female MH - Qatar MH - *Immunity, Humoral MH - Antibodies, Viral/blood/immunology MH - Longitudinal Studies MH - *Immunity, Cellular MH - Middle Aged MH - Antibodies, Neutralizing/blood/immunology MH - Young Adult MH - *COVID-19 Vaccines/immunology/administration & dosage PMC - PMC11983602 OTO - NOTNLM OT - BNT162b2 OT - SARS-CoV-2 OT - booster OT - immune response OT - immunological memory COIS- All authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.​ The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision. EDAT- 2025/04/11 06:25 MHDA- 2025/04/11 12:28 PMCR- 2025/01/01 CRDT- 2025/04/11 05:51 PHST- 2025/01/08 00:00 [received] PHST- 2025/03/11 00:00 [accepted] PHST- 2025/04/11 12:28 [medline] PHST- 2025/04/11 06:25 [pubmed] PHST- 2025/04/11 05:51 [entrez] PHST- 2025/01/01 00:00 [pmc-release] AID - 10.3389/fimmu.2025.1557426 [doi] PST - epublish SO - Front Immunol. 2025 Mar 27;16:1557426. doi: 10.3389/fimmu.2025.1557426. eCollection 2025. PMID- 40196126 OWN - NLM STAT- MEDLINE DCOM- 20250409 LR - 20261017 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 16 DP - 2025 TI - Memory B cell proliferation drives differences in neutralising responses between ChAdOx1 and BNT162b2 SARS-CoV-2 vaccines. PG - 1487066 LID - 10.3389/fimmu.2025.1487066 [doi] LID - 1487066 AB - INTRODUCTION: Vaccination against COVID-19 has been pivotal in reducing the global burden of the disease. However, Phase III trial results and observational studies underscore differences in efficacy across vaccine technologies and dosing regimens. Notably, mRNA vaccines have exhibited superior effectiveness compared to Adenovirus (AdV) vaccines, especially with extended dosing intervals. METHODS: Using in-host mechanistic modelling, this study elucidates these variations and unravels the biological mechanisms shaping the immune responses at the cellular level. We used data on the change in memory B cells, plasmablasts, and antibody titres after the second dose of a COVID-19 vaccine for Australian healthcare workers. Alongside this dataset, we constructed a kinetic model of humoral immunity which jointly captured the dynamics of multiple immune markers, and integrated hierarchical effects into this kinetics model, including age, dosing schedule, and vaccine type. RESULTS: Our analysis estimated that mRNA vaccines induced 2.1 times higher memory B cell proliferation than AdV vaccines after adjusting for age, interval between doses and priming dose. Additionally, extending the duration between the second vaccine dose and priming dose beyond 28 days boosted neutralising antibody production per plasmablast concentration by 30%. We also found that antibody responses after the second dose were more persistent when mRNA vaccines were used over AdV vaccines and for longer dosing regimens. DISCUSSION: Reconstructing in-host kinetics in response to vaccination could help optimise vaccine dosing regimens, improve vaccine efficacy in different population groups, and inform the design of future vaccines for enhanced protection against emerging pathogens. CI - Copyright (c) 2025 Hodgson, Liu, Carolan, Mahanty, Subbarao, Sullivan, Fox and Kucharski. FAU - Hodgson, David AU - Hodgson D AD - Centre of Mathematical Modelling of Infectious Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom. FAU - Liu, Yi AU - Liu Y AD - WHO Collaborating Centre for Reference and Research on Influenza, Royal Melbourne Hospital, at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia. AD - Department of Infectious Diseases, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia. FAU - Carolan, Louise AU - Carolan L AD - WHO Collaborating Centre for Reference and Research on Influenza, Royal Melbourne Hospital, at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia. FAU - Mahanty, Siddhartha AU - Mahanty S AD - Department of Infectious Diseases, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia. FAU - Subbarao, Kanta AU - Subbarao K AD - WHO Collaborating Centre for Reference and Research on Influenza, Royal Melbourne Hospital, at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia. AD - Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia. FAU - Sullivan, Sheena G AU - Sullivan SG AD - WHO Collaborating Centre for Reference and Research on Influenza, Royal Melbourne Hospital, at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia. AD - Department of Infectious Diseases, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia. AD - School of Clinical Sciences, Monash University, Melbourne, VIC, Australia. FAU - Fox, Annette AU - Fox A AD - WHO Collaborating Centre for Reference and Research on Influenza, Royal Melbourne Hospital, at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia. AD - Department of Infectious Diseases, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia. FAU - Kucharski, Adam AU - Kucharski A AD - Centre of Mathematical Modelling of Infectious Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom. LA - eng GR - HHSN272201400005C/OD/NIH HHS/United States GR - R01 AI141534/AI/NIAID NIH HHS/United States PT - Journal Article DEP - 20250324 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 RN - 0 (BNT162 Vaccine) RN - 0 (Antibodies, Neutralizing) RN - 0 (Antibodies, Viral) RN - B5S3K2V0G8 (ChAdOx1 nCoV-19) RN - 0 (COVID-19 Vaccines) SB - IM UOF - medRxiv. 2024 Jul 11:2024.07.11.24310221. doi: 10.1101/2024.07.11.24310221. PMID: 39040163 MH - Humans MH - BNT162 Vaccine/immunology MH - *SARS-CoV-2/immunology MH - *COVID-19/immunology/prevention & control MH - *Antibodies, Neutralizing/immunology/blood MH - *Memory B Cells/immunology MH - Antibodies, Viral/immunology/blood MH - *ChAdOx1 nCoV-19/immunology MH - *COVID-19 Vaccines/immunology/administration & dosage MH - Cell Proliferation MH - Adult MH - Vaccination MH - Middle Aged MH - Australia MH - Immunologic Memory MH - Male MH - Female MH - Immunity, Humoral PMC - PMC11974255 OTO - NOTNLM OT - B cell OT - SARS-CoV-2 OT - immunology OT - mathematical modelling OT - vaccination COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2025/04/08 06:24 MHDA- 2025/04/08 06:25 PMCR- 2025/01/01 CRDT- 2025/04/08 04:27 PHST- 2024/08/27 00:00 [received] PHST- 2025/03/03 00:00 [accepted] PHST- 2025/04/08 06:25 [medline] PHST- 2025/04/08 06:24 [pubmed] PHST- 2025/04/08 04:27 [entrez] PHST- 2025/01/01 00:00 [pmc-release] AID - 10.3389/fimmu.2025.1487066 [doi] PST - epublish SO - Front Immunol. 2025 Mar 24;16:1487066. doi: 10.3389/fimmu.2025.1487066. eCollection 2025. PMID- 40191213 OWN - NLM STAT- MEDLINE DCOM- 20250515 LR - 20250515 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 16 DP - 2025 TI - Enhanced and long-lasting SARS-CoV-2 immune memory in individuals with common cold coronavirus cross-reactive T cell immunity. PG - 1501704 LID - 10.3389/fimmu.2025.1501704 [doi] LID - 1501704 AB - With the continuous emergence of novel SARS-CoV-2 variants, long-lasting and broadly reactive cellular and humoral immunity is critical for durable protection from COVID-19. We investigated SARS-CoV-2-specific T cell immunity in relation to antibodies, infection outcome and disease severity and assessed its durability in a longitudinal cohort over a three-year time course. We identified pre-existing T cells reactive to the seasonal coronavirus (CoV) OC43 that cross-react with the conserved SARS-CoV-2 spike S(813-829) peptide. These cross-reactive T cells increased in frequency following SARS-CoV-2 infection or vaccination and correlated with enhanced spike-specific T cell responses and significantly reduced viral loads. Furthermore, our data revealed that CoV-cross-reactive T cells were maintained as part of the long-lasting memory response, contributing to increased T cell frequencies against omicron variants. These findings suggest a functional role of CoV-cross-reactive T cells that extends beyond the initial SARS-CoV-2 exposure, contributing to enhanced immunity against highly mutated SARS-CoV-2 variants. CI - Copyright (c) 2025 Florian, Bauer, Popovitsch, Fae, Springer, Graninger, Traugott, Weseslindtner, Aberle, Fischer, Kundi, Stiasny, Zoufaly, Landry and Aberle. FAU - Florian, David M AU - Florian DM AD - Center for Virology, Medical University of Vienna, Vienna, Austria. FAU - Bauer, Michael AU - Bauer M AD - Center for Virology, Medical University of Vienna, Vienna, Austria. FAU - Popovitsch, Amelie AU - Popovitsch A AD - Center for Virology, Medical University of Vienna, Vienna, Austria. FAU - Fae, Ingrid AU - Fae I AD - Department of Transfusion Medicine and Cell Therapy, Medical University of Vienna, Vienna, Austria. FAU - Springer, David N AU - Springer DN AD - Center for Virology, Medical University of Vienna, Vienna, Austria. FAU - Graninger, Marianne AU - Graninger M AD - Center for Virology, Medical University of Vienna, Vienna, Austria. FAU - Traugott, Marianna AU - Traugott M AD - Department of Medicine IV, Klinik Favoriten, Vienna, Austria. FAU - Weseslindtner, Lukas AU - Weseslindtner L AD - Center for Virology, Medical University of Vienna, Vienna, Austria. FAU - Aberle, Stephan W AU - Aberle SW AD - Center for Virology, Medical University of Vienna, Vienna, Austria. FAU - Fischer, Gottfried AU - Fischer G AD - Department of Transfusion Medicine and Cell Therapy, Medical University of Vienna, Vienna, Austria. FAU - Kundi, Michael AU - Kundi M AD - Center for Public Health, Department for Environmental Health, Medical University of Vienna, Vienna, Austria. FAU - Stiasny, Karin AU - Stiasny K AD - Center for Virology, Medical University of Vienna, Vienna, Austria. FAU - Zoufaly, Alexander AU - Zoufaly A AD - Department of Medicine IV, Klinik Favoriten, Vienna, Austria. AD - Faculty of Medicine, Sigmund Freud University, Vienna, Austria. FAU - Landry, Samuel J AU - Landry SJ AD - Department of Biochemistry and Molecular Biology, Tulane University School of Medicine, New Orleans, LA, United States. FAU - Aberle, Judith H AU - Aberle JH AD - Center for Virology, Medical University of Vienna, Vienna, Austria. LA - eng PT - Journal Article DEP - 20250321 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 RN - 0 (Spike Glycoprotein, Coronavirus) RN - 0 (Antibodies, Viral) RN - 0 (spike protein, SARS-CoV-2) SB - IM MH - Humans MH - *SARS-CoV-2/immunology MH - Cross Reactions/immunology MH - *Immunologic Memory MH - *COVID-19/immunology/virology MH - Spike Glycoprotein, Coronavirus/immunology MH - Male MH - Middle Aged MH - Female MH - Antibodies, Viral/immunology/blood MH - *T-Lymphocytes/immunology MH - Adult MH - *Common Cold/immunology MH - Longitudinal Studies MH - Viral Load MH - Aged MH - Coronavirus OC43, Human/immunology PMC - PMC11968687 OTO - NOTNLM OT - CD4 T cell response OT - SARS-CoV-2 OT - cell-mediated immunity OT - long term immunity OT - mRNA vaccination COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2025/04/07 06:25 MHDA- 2025/04/07 06:26 PMCR- 2025/01/01 CRDT- 2025/04/07 05:15 PHST- 2024/09/25 00:00 [received] PHST- 2025/03/03 00:00 [accepted] PHST- 2025/04/07 06:26 [medline] PHST- 2025/04/07 06:25 [pubmed] PHST- 2025/04/07 05:15 [entrez] PHST- 2025/01/01 00:00 [pmc-release] AID - 10.3389/fimmu.2025.1501704 [doi] PST - epublish SO - Front Immunol. 2025 Mar 21;16:1501704. doi: 10.3389/fimmu.2025.1501704. eCollection 2025. PMID- 40144475 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250328 IS - 0253-8253 (Print) IS - 2227-0426 (Electronic) IS - 0253-8253 (Linking) VI - 2025 IP - 1 DP - 2025 TI - A comparison of Gam-COVID-Vac vaccination and non-vaccination on neurological symptoms and immune response in post-COVID-19 syndrome. PG - 6 LID - 10.5339/qmj.2025.6 [doi] LID - 6 AB - The post-COVID-19 syndrome may present with a range of neurological symptoms such as headaches, sleep disorders, and dizziness. The objective of this study was to examine the effectiveness of the Gam-COVID-Vac vaccine in mitigating the neurological symptoms of post-COVID-19 syndrome. The study involved 95 patients diagnosed with the neurological form of long COVID-19, who were divided into two groups according to their vaccination status. The immunological parameters of humoral immunity were evaluated by enzyme-linked immunosorbent assay (ELISA), while the parameters of cellular immunity were evaluated using flow cytometry. Administration of the vaccination resulted in a reduction in clinical symptoms of the neurological form of long COVID-19. Statistically significant differences (p = 0.035) were found in symptoms such as headaches, sleep disturbances, and dizziness, especially in central nervous system (CNS) disorders, between the groups that received the vaccination and those that did not. More than 90% of patients had elevated levels of Receptor Binding Domain (RBD) immunoglobulin G against the viral S-protein (>2,500 BAU/ml), indicating strong humoral immunity regardless of vaccination status. An increase in B-lymphocyte (CD3(-)CD19(+)) counts was noted in both groups, with levels significantly higher in the group that received the vaccination (p < 0.03). Analysis of T-cell profiles and NK (natural killer) cell levels showed no changes. The study suggests that administration of Gam-COVID-Vac vaccination could reduce the occurrence of CNS symptoms in individuals with post-COVID-19 syndrome. Although certain neurological symptoms may continue, immunization has a beneficial influence on their progression. The results emphasize the crucial role of an increased humoral immune response in individuals with post-COVID-19 syndrome, but do not show significant changes in T-cell immune parameters. CI - (c) 2025 Kurmangaliyeva, Madenbayeva, Urazayeva, Baktikulova, Kurmangaliyev, licensee HBKU Press. FAU - Kurmangaliyeva, Saulesh AU - Kurmangaliyeva S AD - Department of Microbiology, Virology and Immunology, West Kazakhstan Marat Ospanov Medical University, Aktobe, Republic of Kazakhstan. FAU - Madenbayeva, Akzhan AU - Madenbayeva A AD - Department of Microbiology, Virology and Immunology, West Kazakhstan Marat Ospanov Medical University, Aktobe, Republic of Kazakhstan. FAU - Urazayeva, Saltanat AU - Urazayeva S AD - Department of Epidemiology, West Kazakhstan Marat Ospanov Medical University, Aktobe, Republic of Kazakhstan. FAU - Baktikulova, Kristina AU - Baktikulova K AD - Department of Transfusiology, West Kazakhstan Marat Ospanov Medical University, Aktobe, Republic of Kazakhstan*Correspondence: Saltanat Urazayeva. Email: sal.urazayeva@gmail.com. FAU - Kurmangaliyev, Kairat AU - Kurmangaliyev K AD - Department of Microbiology, Virology and Immunology, West Kazakhstan Marat Ospanov Medical University, Aktobe, Republic of Kazakhstan. LA - eng PT - Journal Article DEP - 20250223 PL - Qatar TA - Qatar Med J JT - Qatar medical journal JID - 8101648 PMC - PMC11938678 OTO - NOTNLM OT - Post-COVID-19 OT - cellular and humoral immunity OT - coronavirus OT - damage to the nervous system OT - hybrid immunity OT - long COVID-19 COIS- The authors have no conflicts of interest to declare. EDAT- 2025/03/27 06:29 MHDA- 2025/03/27 06:30 PMCR- 2025/02/23 CRDT- 2025/03/27 05:11 PHST- 2024/05/16 00:00 [received] PHST- 2024/10/13 00:00 [accepted] PHST- 2025/03/27 06:30 [medline] PHST- 2025/03/27 06:29 [pubmed] PHST- 2025/03/27 05:11 [entrez] PHST- 2025/02/23 00:00 [pmc-release] AID - qmj.2025.6 [pii] AID - 10.5339/qmj.2025.6 [doi] PST - epublish SO - Qatar Med J. 2025 Feb 23;2025(1):6. doi: 10.5339/qmj.2025.6. eCollection 2025. PMID- 40135763 OWN - NLM STAT- MEDLINE DCOM- 20250326 LR - 20260910 IS - 1365-2060 (Electronic) IS - 0785-3890 (Print) IS - 0785-3890 (Linking) VI - 57 IP - 1 DP - 2025 Dec TI - Growing attention of immunogenicity among patients with autoimmune diseases post-SARS-CoV-2 vaccination: meta-analysis and systematic reviews of the current studies. PG - 2478319 LID - 10.1080/07853890.2025.2478319 [doi] LID - 2478319 AB - OBJECTIVE: This study aimed to identify the optimal strategy for patients with autoimmune diseases by comparing the immunoreaction and effectiveness of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines between healthy individuals and patients. METHODS: The PubMed, Embase, and Cochrane Library were searched for eligible studies on effectiveness and immunoreaction to SARS-CoV-2 vaccines in patients with autoimmune diseases published until October 07, 2022. The quality of each included study was evaluated by independent reviewers using National Institutes of Health study quality assessment tool, and the STATA 15.0 software was used for all statistical analyses. RESULTS: A total of 84 publications were included and analyzed in this meta-analysis, favoring healthy controls regarding serological response (risk ratio, RR=0.88, 95% CI (confidence interval): 0.86-0.91), antibody response (RR=0.90, 95%CI: 0.87-0.94), and incidence of seropositive immunoglobulin G (IgG) (RR=0.74, 95%CI: 0.69-0.80) than patients post-vaccination. Patients with autoimmune diseases developed lower IgG (standard mean difference, SMD=-0.64 95%CI: -0.84 to -0.43) and antibody titer level (SMD=-1.39, 95%CI: -2.30 to -0.49) than healthy individuals in AU/ml. Stratified analyses were conducted further according to various potential factors in full-text studies. CONCLUSION: Patients who are immunocompromised and received more vaccines demonstrated poorer humoral responses and seropositive incidence after SARS-CoV-2 vaccination than healthy individuals. Despite the lack of observable favor for patients with autoimmune diseases, the trend of effectiveness of SARS-CoV-2 vaccines is close to that for healthy populations. Patients who are immunocompromised should be provided a better SARS-CoV-2 vaccination schedule, considering various vaccine subtypes, dose(s), variants of concern, and immunoassays. FAU - Zhang, Chao AU - Zhang C AD - Center for Evidence-Based Medicine and Clinical Research, Hubei Provincial Clinical Research Center of Central Nervous System Repair and Functional Reconstruction, Taihe Hospital, Hubei University of Medicine, Shiyan, China. FAU - Zhang, Yu-Qiang AU - Zhang YQ AD - Department of Neurosurgery, Hubei Provincial Clinical Research Center of Central Nervous System Repair and Functional Reconstruction, Taihe Hospital, Hubei University of Medicine, Shiyan, China. FAU - Liu, Run-Ben AU - Liu RB AD - Center for Evidence-Based Medicine and Clinical Research, Hubei Provincial Clinical Research Center of Central Nervous System Repair and Functional Reconstruction, Taihe Hospital, Hubei University of Medicine, Shiyan, China. FAU - Ma, Yu-Tong AU - Ma YT AD - Center for Evidence-Based Medicine and Clinical Research, Hubei Provincial Clinical Research Center of Central Nervous System Repair and Functional Reconstruction, Taihe Hospital, Hubei University of Medicine, Shiyan, China. FAU - Zhao, Lin-Kang AU - Zhao LK AD - Center for Evidence-Based Medicine and Clinical Research, Hubei Provincial Clinical Research Center of Central Nervous System Repair and Functional Reconstruction, Taihe Hospital, Hubei University of Medicine, Shiyan, China. FAU - Yin, Fu-Qiang AU - Yin FQ AD - Center for Evidence-Based Medicine and Clinical Research, Hubei Provincial Clinical Research Center of Central Nervous System Repair and Functional Reconstruction, Taihe Hospital, Hubei University of Medicine, Shiyan, China. FAU - Tu, Jing AU - Tu J AD - Center for Evidence-Based Medicine and Clinical Research, Hubei Provincial Clinical Research Center of Central Nervous System Repair and Functional Reconstruction, Taihe Hospital, Hubei University of Medicine, Shiyan, China. FAU - Yao, Yang-Yang AU - Yao YY AD - Department of Anesthesiology and Perioperative Medicine, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China. LA - eng PT - Journal Article PT - Meta-Analysis PT - Research Support, Non-U.S. Gov't PT - Systematic Review DEP - 20250326 PL - England TA - Ann Med JT - Annals of medicine JID - 8906388 RN - 0 (COVID-19 Vaccines) RN - 0 (Antibodies, Viral) RN - 0 (Immunoglobulin G) SB - IM MH - Humans MH - *Autoimmune Diseases/immunology MH - *COVID-19 Vaccines/immunology/administration & dosage MH - *COVID-19/prevention & control/immunology MH - SARS-CoV-2/immunology MH - *Immunogenicity, Vaccine/immunology MH - Antibodies, Viral/blood/immunology MH - Immunoglobulin G/blood/immunology MH - Vaccination PMC - PMC11948354 OTO - NOTNLM OT - Autoimmune disease OT - SARS-CoV-2 vaccines OT - immunogenicity OT - meta-analysis COIS- No potential conflict of interest was reported by the author(s). EDAT- 2025/03/26 12:31 MHDA- 2025/03/26 12:32 PMCR- 2025/03/26 CRDT- 2025/03/26 08:23 PHST- 2025/03/26 12:32 [medline] PHST- 2025/03/26 12:31 [pubmed] PHST- 2025/03/26 08:23 [entrez] PHST- 2025/03/26 00:00 [pmc-release] AID - 2478319 [pii] AID - 10.1080/07853890.2025.2478319 [doi] PST - ppublish SO - Ann Med. 2025 Dec;57(1):2478319. doi: 10.1080/07853890.2025.2478319. Epub 2025 Mar 26. PMID- 40133533 OWN - NLM STAT- MEDLINE DCOM- 20250514 LR - 20260804 IS - 1744-4292 (Electronic) IS - 1744-4292 (Linking) VI - 21 IP - 4 DP - 2025 Apr TI - Persistent epigenetic memory of SARS-CoV-2 mRNA vaccination in monocyte-derived macrophages. PG - 341-360 LID - 10.1038/s44320-025-00093-6 [doi] LID - 2 AB - Immune memory plays a critical role in the development of durable antimicrobial immune responses. How precisely mRNA vaccines train innate immune cells to shape protective host defense mechanisms remains unknown. Here we show that SARS-CoV-2 mRNA vaccination significantly establishes histone H3 lysine 27 acetylation (H3K27ac) at promoters of human monocyte-derived macrophages, suggesting epigenetic memory. However, we found that two consecutive vaccinations were required for the persistence of H3K27ac, which matched with pro-inflammatory innate immune-associated transcriptional changes and antigen-mediated cytokine secretion. H3K27ac at promoter regions were preserved for six months and a single mRNA booster vaccine potently restored their levels and release of macrophage-derived cytokines. Interestingly, we found that H3K27ac at promoters is enriched for G-quadruplex DNA secondary structure-forming sequences in macrophage-derived nucleosome-depleted regions, linking epigenetic memory to nucleic acid structure. Collectively, these findings reveal that mRNA vaccines induce a highly dynamic and persistent training of innate immune cells enabling a sustained pro-inflammatory immune response. CI - (c) 2025. The Author(s). FAU - Simonis, Alexander AU - Simonis A AUID- ORCID: 0000-0003-2945-9897 AD - Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, 50937, Germany. AD - Center for Molecular Medicine Cologne (CMMC), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, 50931, Germany. AD - German Center for Infection Research (DZIF), Partner Site Bonn-Cologne, Cologne, Germany. FAU - Theobald, Sebastian J AU - Theobald SJ AD - Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, 50937, Germany. AD - Center for Molecular Medicine Cologne (CMMC), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, 50931, Germany. AD - German Center for Infection Research (DZIF), Partner Site Bonn-Cologne, Cologne, Germany. FAU - Koch, Anna E AU - Koch AE AUID- ORCID: 0009-0003-1593-9715 AD - Center for Molecular Medicine Cologne (CMMC), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, 50931, Germany. FAU - Mummadavarapu, Ram AU - Mummadavarapu R AUID- ORCID: 0009-0009-4244-8982 AD - Max Planck Research Group "Chromatin and Ageing", Max Planck Institute for Biology of Ageing, Joseph-Stelzmann-Str. 9b, Cologne, 50931, Germany. FAU - Mudler, Julie M AU - Mudler JM AUID- ORCID: 0000-0003-1378-9648 AD - Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, 50937, Germany. AD - Center for Molecular Medicine Cologne (CMMC), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, 50931, Germany. FAU - Pouikli, Andromachi AU - Pouikli A AD - Max Planck Research Group "Chromatin and Ageing", Max Planck Institute for Biology of Ageing, Joseph-Stelzmann-Str. 9b, Cologne, 50931, Germany. FAU - Gobel, Ulrike AU - Gobel U AD - Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany. FAU - Acton, Richard AU - Acton R AUID- ORCID: 0000-0002-2574-9611 AD - Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany. AD - Babraham Institute, Cambridge, UK. FAU - Winter, Sandra AU - Winter S AD - Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, 50937, Germany. AD - Center for Molecular Medicine Cologne (CMMC), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, 50931, Germany. FAU - Albus, Alexandra AU - Albus A AD - Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, 50937, Germany. AD - Center for Molecular Medicine Cologne (CMMC), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, 50931, Germany. FAU - Holzmann, Dmitriy AU - Holzmann D AD - Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, 50937, Germany. AD - Center for Molecular Medicine Cologne (CMMC), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, 50931, Germany. FAU - Albert, Marie-Christine AU - Albert MC AD - Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany. AD - Institute of Biochemistry I, Faculty of Medicine, University Hospital Cologne, University of Cologne, Cologne, Germany. FAU - Hallek, Michael AU - Hallek M AD - Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, 50937, Germany. AD - Center for Molecular Medicine Cologne (CMMC), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, 50931, Germany. FAU - Walczak, Henning AU - Walczak H AUID- ORCID: 0000-0002-6312-4591 AD - Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany. AD - Institute of Biochemistry I, Faculty of Medicine, University Hospital Cologne, University of Cologne, Cologne, Germany. AD - Center for Cell Death, Cancer and Inflammation, UCL Cancer Institute, University College London, London, United Kingdom. FAU - Ulas, Thomas AU - Ulas T AD - Systems Medicine, German Center for Neurodegenerative Diseases (DZNE), University of Bonn, Bonn, Germany. AD - PRECISE Plattform for Single Cell Genomics and Epigenomics, DZNE, University of Bonn, Bonn and West German Genome Center, Bonn, Germany. AD - Genomics and Immunoregulation, Life & Medical Sciences (LIMES) Institute, University of Bonn, Bonn, Germany. FAU - Koch, Manuel AU - Koch M AUID- ORCID: 0000-0002-2962-7814 AD - Institute of Biochemistry I, Faculty of Medicine, University Hospital Cologne, University of Cologne, Cologne, Germany. AD - Institute for Dental Research and Oral Musculoskeletal Biology, Center for Dental, Oral and Maxillofacial Medicine (central facilities), Medical Faculty and University of Cologne, Cologne, Germany. FAU - Tessarz, Peter AU - Tessarz P AUID- ORCID: 0000-0002-6953-9835 AD - Max Planck Research Group "Chromatin and Ageing", Max Planck Institute for Biology of Ageing, Joseph-Stelzmann-Str. 9b, Cologne, 50931, Germany. AD - Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany. AD - Department of Human Biology, Radboud Institute for Molecular Life Sciences, Faculty of Science, Radboud University, Nijmegen, The Netherlands. FAU - Hansel-Hertsch, Robert AU - Hansel-Hertsch R AUID- ORCID: 0000-0002-2835-4471 AD - Center for Molecular Medicine Cologne (CMMC), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, 50931, Germany. robert.haensel-hertsch@uni-koeln.de. AD - Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany. robert.haensel-hertsch@uni-koeln.de. AD - Department of Translational Genomics, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany. robert.haensel-hertsch@uni-koeln.de. AD - Institute of Human Genetics, University Hospital Cologne, Cologne, Germany. robert.haensel-hertsch@uni-koeln.de. FAU - Rybniker, Jan AU - Rybniker J AUID- ORCID: 0000-0001-8351-2690 AD - Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, 50937, Germany. jan.rybniker@uk-koeln.de. AD - Center for Molecular Medicine Cologne (CMMC), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, 50931, Germany. jan.rybniker@uk-koeln.de. AD - German Center for Infection Research (DZIF), Partner Site Bonn-Cologne, Cologne, Germany. jan.rybniker@uk-koeln.de. LA - eng GR - 01KI2108/Bundesministerium fur Bildung und Forschung (BMBF)/ GR - IdEpiCo/Bundesministerium fur Bildung und Forschung (BMBF)/ GR - NaFoUniMedCovid19 grant COVIM 01KX2021/Bundesministerium fur Bildung und Forschung (BMBF)/ GR - FI 773/15-1/Deutsche Forschungsgemeinschaft (DFG)/ GR - SFB1403/Deutsche Forschungsgemeinschaft (DFG)/ GR - INST 216/1057-2/Deutsche Forschungsgemeinschaft (DFG)/ GR - HA 8562/4-1/Deutsche Forschungsgemeinschaft (DFG)/ GR - HA 8562/5-1/Deutsche Forschungsgemeinschaft (DFG)/ GR - INST 216/1317-1/Deutsche Forschungsgemeinschaft (DFG)/ GR - TTU-TB grant 02.913/Deutsches Zentrum fur Infektionsforschung (DZIF)/ GR - TTU-TB grant 02.814/Deutsches Zentrum fur Infektionsforschung (DZIF)/ GR - ERA4TB/European Union Horizon 2020 program/ GR - 01KX2121/Federal Ministry of Education and Research/ GR - EXC 2030-390661388/German Excellence Strategy/ GR - 10.22.1.010MN/Fritz Thyssen Foundation/ PT - Journal Article DEP - 20250325 PL - Germany TA - Mol Syst Biol JT - Molecular systems biology JID - 101235389 RN - 0 (Histones) RN - 0 (COVID-19 Vaccines) RN - 0 (Cytokines) RN - 0 (RNA, Messenger) RN - 0 (mRNA Vaccines) SB - IM MH - Humans MH - *Macrophages/immunology/metabolism MH - *Epigenesis, Genetic MH - *SARS-CoV-2/immunology/genetics MH - *COVID-19/immunology/prevention & control MH - Histones/metabolism/immunology/genetics MH - *Immunologic Memory MH - Promoter Regions, Genetic MH - Acetylation MH - *COVID-19 Vaccines/immunology MH - Immunity, Innate MH - Cytokines/metabolism MH - Vaccination MH - RNA, Messenger/immunology MH - mRNA Vaccines/immunology MH - Epigenetic Memory PMC - PMC11965535 OTO - NOTNLM OT - Epigenetic Memory OT - G-quadruplex OT - H3K27ac OT - SARS-Cov-2 mRNA Vaccination OT - Trained Innate Immunity COIS- Disclosure and competing interests statement. The authors declare no competing interests. EDAT- 2025/03/26 13:06 MHDA- 2025/04/03 18:25 PMCR- 2025/03/25 CRDT- 2025/03/26 00:27 PHST- 2023/06/15 00:00 [received] PHST- 2025/02/24 00:00 [accepted] PHST- 2025/02/10 00:00 [revised] PHST- 2025/04/03 18:25 [medline] PHST- 2025/03/26 13:06 [pubmed] PHST- 2025/03/26 00:27 [entrez] PHST- 2025/03/25 00:00 [pmc-release] AID - 10.1038/s44320-025-00093-6 [pii] AID - 93 [pii] AID - 10.1038/s44320-025-00093-6 [doi] PST - ppublish SO - Mol Syst Biol. 2025 Apr;21(4):341-360. doi: 10.1038/s44320-025-00093-6. Epub 2025 Mar 25. PMID- 40115993 OWN - NLM STAT- MEDLINE DCOM- 20250514 LR - 20260703 IS - 1468-1331 (Electronic) IS - 1351-5101 (Print) IS - 1351-5101 (Linking) VI - 32 IP - 3 DP - 2025 Mar TI - Neurological long COVID in the outpatient clinic: Is it so long? PG - e16510 LID - 10.1111/ene.16510 [doi] LID - e16510 AB - BACKGROUND AND PURPOSE: Neurological involvement in long COVID (coronavirus disease 2019) is well known. In a previous study we identified two subtypes of neurological long COVID, one characterized by memory disturbances, psychological impairment, headache, anosmia and ageusia, and the other characterized by peripheral nervous system involvement, each of which present a different risk factor profile. In this study, we aimed to clarify the persistence of neurological long COVID symptoms with a significantly longer term follow-up. METHODS: We prospectively collected data from patients with prior COVID-19 infection who showed symptoms of neurological long COVID. We conducted a descriptive analysis to investigate the progression of neurological symptoms over time at 3-, 6-, 12-, and 18-month follow-ups. We performed a k-means clustering analysis on the temporal evolution of the symptoms at 6, 12, and 18 months. Finally, we assessed the difference between the recovery course of vaccinated and non-vaccinated patients by computing the cumulative recovery rate of symptoms in the two groups. RESULTS: The study confirmed the presence of two subtypes of neurological long COVID. Further, 50% of patients presented a complete resolution of symptoms at 18 months of follow-up, regardless of which subtype of neurological long COVID they had. Vaccination against SARS-Cov-2 appeared to imply a higher overall recovery rate for all neurological symptoms, although the statistical reliability of this finding is hampered by the limited sample size of the unvaccinated patients included in this study. CONCLUSIONS: Neurological long COVID can undergo complete resolution after 18 months of follow-up in 50% of patients and vaccination can accelerate the recovery. CI - (c) 2025 The Author(s). European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology. FAU - Grisanti, Stefano Giuseppe AU - Grisanti SG AUID- ORCID: 0000-0002-6293-9756 AD - Struttura Complessa Neurologia P.O. Ponente, Dipartimento Testa-Collo, Ospedale Santa Corona, Pietra Ligure, Italy. FAU - Garbarino, Sara AU - Garbarino S AD - Life Science Computational Laboratory, IRCCS Ospedale Policlinico San Martino, Genoa, Italy. FAU - Bellucci, Margherita AU - Bellucci M AD - Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica E Scienze Materno-Infantili, Universita di Genova, Genoa, Italy. FAU - Schenone, Cristina AU - Schenone C AD - Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica E Scienze Materno-Infantili, Universita di Genova, Genoa, Italy. FAU - Candiani, Valentina AU - Candiani V AD - MIDA group, Dipartimento di Matematica, Universita di Genova, Genoa, Italy. FAU - Di Lillo, Simmaco AU - Di Lillo S AD - Dipartimento di Matematica, Universita di Roma Tor Vergata, Rome, Italy. FAU - Campi, Cristina AU - Campi C AD - Life Science Computational Laboratory, IRCCS Ospedale Policlinico San Martino, Genoa, Italy. AD - MIDA group, Dipartimento di Matematica, Universita di Genova, Genoa, Italy. FAU - Barisione, Emanuela AU - Barisione E AD - IRCCS, Ospedale Policlinico San Martino, Genoa, Italy. FAU - Aloe, Teresita AU - Aloe T AD - IRCCS, Ospedale Policlinico San Martino, Genoa, Italy. FAU - Tagliabue, Elena AU - Tagliabue E AD - IRCCS, Ospedale Policlinico San Martino, Genoa, Italy. FAU - Serventi, Alberto AU - Serventi A AD - Chirurgia presidio ospedaliero Mons. Giovanni Galliano, Acqui Terme, Italy. FAU - Pesce, Giampaola AU - Pesce G AD - IRCCS, Ospedale Policlinico San Martino, Genoa, Italy. FAU - Massucco, Sara AU - Massucco S AD - Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica E Scienze Materno-Infantili, Universita di Genova, Genoa, Italy. FAU - Cabona, Corrado AU - Cabona C AUID- ORCID: 0000-0002-4282-8805 AD - IRCCS, Ospedale Policlinico San Martino, Genoa, Italy. FAU - Lechiara, Anastasia AU - Lechiara A AD - IRCCS, Ospedale Policlinico San Martino, Genoa, Italy. FAU - Uccelli, Antonio AU - Uccelli A AD - Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica E Scienze Materno-Infantili, Universita di Genova, Genoa, Italy. AD - IRCCS, Ospedale Policlinico San Martino, Genoa, Italy. FAU - Schenone, Angelo AU - Schenone A AD - Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica E Scienze Materno-Infantili, Universita di Genova, Genoa, Italy. AD - IRCCS, Ospedale Policlinico San Martino, Genoa, Italy. FAU - Piana, Michele AU - Piana M AD - Life Science Computational Laboratory, IRCCS Ospedale Policlinico San Martino, Genoa, Italy. AD - MIDA group, Dipartimento di Matematica, Universita di Genova, Genoa, Italy. FAU - Benedetti, Luana AU - Benedetti L AUID- ORCID: 0000-0002-9540-9727 AD - IRCCS, Ospedale Policlinico San Martino, Genoa, Italy. LA - eng GR - NET-2018-12366666/Ministero della Salute/ GR - PE0000006/NEXTGENERATIONEU (NGEU)/ GR - ECS00000035/NEXTGENERATIONEU (NGEU)/ PT - Journal Article PL - England TA - Eur J Neurol JT - European journal of neurology JID - 9506311 SB - IM MH - Humans MH - *COVID-19/complications/epidemiology MH - Male MH - Female MH - Middle Aged MH - Adult MH - *Nervous System Diseases/epidemiology MH - Aged MH - Ambulatory Care Facilities MH - Prospective Studies MH - Follow-Up Studies MH - Post-Acute COVID-19 Syndrome MH - SARS-CoV-2 MH - Disease Progression MH - Anosmia/etiology PMC - PMC11926444 OTO - NOTNLM OT - COVID-19 OT - clustering OT - neurological long COVID OT - recovery rate OT - vaccination COIS- The authors declare no conflicts of interest. EDAT- 2025/03/21 11:17 MHDA- 2025/03/21 11:18 PMCR- 2025/03/21 CRDT- 2025/03/21 05:11 PHST- 2024/09/20 00:00 [revised] PHST- 2024/03/07 00:00 [received] PHST- 2024/09/21 00:00 [accepted] PHST- 2025/03/21 11:18 [medline] PHST- 2025/03/21 11:17 [pubmed] PHST- 2025/03/21 05:11 [entrez] PHST- 2025/03/21 00:00 [pmc-release] AID - ENE16510 [pii] AID - 10.1111/ene.16510 [doi] PST - ppublish SO - Eur J Neurol. 2025 Mar;32(3):e16510. doi: 10.1111/ene.16510. PMID- 40034392 OWN - NLM STAT- MEDLINE DCOM- 20250510 LR - 20250510 IS - 2235-2988 (Electronic) IS - 2235-2988 (Linking) VI - 15 DP - 2025 TI - Immunological memory to COVID-19 vaccines in immunocompromised and immunocompetent children. PG - 1527573 LID - 10.3389/fcimb.2025.1527573 [doi] LID - 1527573 AB - BACKGROUND: Most children in Argentina received only the initial COVID-19 vaccine series, with presumed hybrid immunity after multiple Omicron waves. However, the durability of immune memory, particularly in immunocompromised (IC) children, remains poorly studied. METHODS: A cohort of IC (n=45) and healthy children (HC, n=79) was assessed between 13 to 17 months after receiving two or three doses of BBIBP-CorV and/or BNT162b2. Plasma anti-spike IgG, neutralizing activity and antigen-specific CD4+ and CD8+ T cells against Wuhan and Omicron BA.5 variants were assessed. RESULTS: Most children remained seropositive after two vaccine doses, but compared with HC, IC exhibited lower neutralizing titers against both Wuhan and Omicron BA.5, particularly those vaccinated with BBIBP-CorV. Even after three vaccine doses, IC showed weaker neutralizing antibody response, CD8+ T cell responses and lower IFN-gamma production compared with HC. Integrated analysis of neutralizing antibodies, memory CD4(+), and CD8(+) T cells revealed a weak immune memory among IC with an important compromise in memory CD8(+) T cell responses. CONCLUSIONS: Immunity can last up to 17 months, but reduced effectiveness against new variants highlights the need for updated COVID-19 vaccines, especially for IC children. Additional efforts are essential to enhance vaccination coverage and protect this vulnerable population. CI - Copyright (c) 2025 Russo, Otero, Uranga, Seery, Raiden, Algieri, De Carli, Borda, Albistur, Heinitz, Marco del Pont, Pardini, Budano, Alvarez, Simaz, Merhar, Quintana, Garbini, Portela, Pereira, Ferrero, Geffner and Arruvito. FAU - Russo, Constanza AU - Russo C AD - Instituto de Investigaciones Biomedicas en Retrovirus y SIDA (INBIRS), Facultad de Medicina, UBA-CONICET, Buenos Aires, Argentina. FAU - Otero, Adrian AU - Otero A AD - Instituto de Investigaciones Biomedicas en Retrovirus y SIDA (INBIRS), Facultad de Medicina, UBA-CONICET, Buenos Aires, Argentina. FAU - Uranga, Macarena AU - Uranga M AD - Departamento de Medicina, Hospital Universitario Austral, Buenos Aires, Argentina. FAU - Seery, Vanesa AU - Seery V AD - Instituto de Investigaciones Biomedicas en Retrovirus y SIDA (INBIRS), Facultad de Medicina, UBA-CONICET, Buenos Aires, Argentina. FAU - Raiden, Silvina AU - Raiden S AD - Departamento de Medicina, Hospital General de Ninos Pedro de Elizalde, Buenos Aires, Argentina. FAU - Algieri, Silvia AU - Algieri S AD - Servicio de Pediatria, Hospital Nacional Profesor Alejandro Posadas, Buenos Aires, Argentina. FAU - De Carli, Norberto AU - De Carli N AD - Servicio de Pediatria, Clinica del Nino de Quilmes, Buenos Aires, Argentina. FAU - Borda, Mauricio AU - Borda M AD - Servicio de Pediatria, Hospital Pediatrico Juan Pablo II, Corrientes, Argentina. FAU - Albistur, Maria F AU - Albistur MF AD - Departamento de Medicina, Hospital Universitario Austral, Buenos Aires, Argentina. FAU - Heinitz, Lourdes AU - Heinitz L AD - Departamento de Medicina, Hospital Universitario Austral, Buenos Aires, Argentina. FAU - Marco Del Pont, Maria AU - Marco Del Pont M AD - Departamento de Medicina, Hospital Universitario Austral, Buenos Aires, Argentina. FAU - Pardini, Martina AU - Pardini M AD - Departamento de Medicina, Hospital Universitario Austral, Buenos Aires, Argentina. FAU - Budano, Guillermina AU - Budano G AD - Departamento de Medicina, Hospital Universitario Austral, Buenos Aires, Argentina. FAU - Alvarez, Laura AU - Alvarez L AD - Departamento de Medicina, Hospital Universitario Austral, Buenos Aires, Argentina. FAU - Simaz, Nancy AU - Simaz N AD - Servicio de Pediatria, Hospital Nacional Profesor Alejandro Posadas, Buenos Aires, Argentina. FAU - Merhar, Claudia AU - Merhar C AD - Servicio de Pediatria, Hospital Nacional Profesor Alejandro Posadas, Buenos Aires, Argentina. FAU - Quintana, Maria C AU - Quintana MC AD - Servicio de Pediatria, Hospital Nacional Profesor Alejandro Posadas, Buenos Aires, Argentina. FAU - Garbini, Cecilia AU - Garbini C AD - Servicio de Pediatria, Hospital Nacional Profesor Alejandro Posadas, Buenos Aires, Argentina. FAU - Portela, Luisa Aedo AU - Portela LA AD - Servicio de Pediatria, Clinica del Nino de Quilmes, Buenos Aires, Argentina. FAU - Pereira, Misael Salcedo AU - Pereira MS AD - Servicio de Pediatria, Clinica del Nino de Quilmes, Buenos Aires, Argentina. FAU - Ferrero, Fernando AU - Ferrero F AD - Departamento de Medicina, Hospital General de Ninos Pedro de Elizalde, Buenos Aires, Argentina. FAU - Geffner, Jorge AU - Geffner J AD - Instituto de Investigaciones Biomedicas en Retrovirus y SIDA (INBIRS), Facultad de Medicina, UBA-CONICET, Buenos Aires, Argentina. FAU - Arruvito, Lourdes AU - Arruvito L AD - Instituto de Investigaciones Biomedicas en Retrovirus y SIDA (INBIRS), Facultad de Medicina, UBA-CONICET, Buenos Aires, Argentina. LA - eng PT - Journal Article DEP - 20250217 PL - Switzerland TA - Front Cell Infect Microbiol JT - Frontiers in cellular and infection microbiology JID - 101585359 RN - 0 (Antibodies, Neutralizing) RN - 0 (Antibodies, Viral) RN - 0 (COVID-19 Vaccines) RN - 0 (BNT162 Vaccine) RN - 0 (Spike Glycoprotein, Coronavirus) RN - 0 (Immunoglobulin G) RN - 0 (spike protein, SARS-CoV-2) SB - IM MH - Humans MH - *Immunocompromised Host/immunology MH - *Immunologic Memory MH - Antibodies, Neutralizing/blood/immunology MH - Antibodies, Viral/blood/immunology MH - *COVID-19/prevention & control/immunology MH - *SARS-CoV-2/immunology MH - *COVID-19 Vaccines/immunology/administration & dosage MH - CD8-Positive T-Lymphocytes/immunology MH - Child MH - Male MH - Female MH - BNT162 Vaccine/immunology MH - CD4-Positive T-Lymphocytes/immunology MH - Child, Preschool MH - Infant MH - Spike Glycoprotein, Coronavirus/immunology MH - Immunoglobulin G/blood MH - Immunocompetence MH - Argentina MH - Vaccination PMC - PMC11873107 OTO - NOTNLM OT - SARS-CoV-2 OT - T cells OT - antibodies OT - children OT - vaccines OT - variants COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be constructed as a potential conflict of interest. EDAT- 2025/03/04 06:22 MHDA- 2025/03/04 06:23 PMCR- 2025/01/01 CRDT- 2025/03/04 04:48 PHST- 2024/11/13 00:00 [received] PHST- 2025/01/21 00:00 [accepted] PHST- 2025/03/04 06:23 [medline] PHST- 2025/03/04 06:22 [pubmed] PHST- 2025/03/04 04:48 [entrez] PHST- 2025/01/01 00:00 [pmc-release] AID - 10.3389/fcimb.2025.1527573 [doi] PST - epublish SO - Front Cell Infect Microbiol. 2025 Feb 17;15:1527573. doi: 10.3389/fcimb.2025.1527573. eCollection 2025. PMID- 40026299 OWN - NLM STAT- MEDLINE DCOM- 20250511 LR - 20250511 IS - 1735-3688 (Electronic) IS - 0253-0716 (Print) IS - 0253-0716 (Linking) VI - 50 IP - 2 DP - 2025 Feb TI - The Role of Memory T-Cell Mediated Immunity in Long-term COVID-19: Effects of Vaccination Status. PG - 61-68 LID - 10.30476/ijms.2024.104003.3744 [doi] AB - T-cell-mediated immunity is essential for controlling severe acute respiratory syndrome coronavirus 2 (SARSCoV2) infection, preventing severe disease, and potentially reducing the risk of long-term coronavirus disease (COVID). This study investigated the impact of natural infection, vaccination, and hybrid immunity on T-cell responses, with a particular emphasis on the role of memory T-cells in long-term COVID-19. The present study reviewed current literature on T-cell responses, including memory T-cell development, in individuals with natural SARS-CoV-2 infection, those vaccinated with messenger RNA (mRNA) vaccines, and those with hybrid immunity. It examined studies that compared T-cell activity, immune regulation, and the prevalence of long-term COVID-19 across these groups. Natural infection induces variable T-cell responses, with severe cases showing stronger but sometimes dysregulated immunological activity, which may contribute to prolonged COVID-19. Vaccination, particularly with mRNA vaccines, elicits targeted and consistent T-cell responses, including memory T-cells, reducing disease severity, and the incidence of long-term COVID-19. Hybrid immunity combines natural infection and vaccination, provides the most robust protection, enhanceds memory T-cell responses, and reduces the risk of long-term COVID-19 through balanced immune regulation. Memory T-cells play a critical role in mitigating long-term COVID-19. Vaccination significantly enhances T-cell-mediated immunity, minimizing the risk of chronic symptoms compared to natural infection alone. Hybrid immunity provides the most effective defense, emphasizing the importance of vaccination, even after natural infection, to prevent long-term COVID-19. CI - Copyright: (c) Iranian Journal of Medical Sciences. FAU - Kurmangaliyeva, Saulesh S AU - Kurmangaliyeva SS AD - Department of Microbiology, Virology, and Immunology, West Kazakhstan Marat Ospanov Medical University, Aktobe, Kazakhstan. FAU - Madenbayeva, Akzhan M AU - Madenbayeva AM AD - Department of Internal Diseases 1, West Kazakhstan Marat Ospanov Medical University, Aktobe, Kazakhstan. FAU - Urazayeva, Saltanat T AU - Urazayeva ST AD - Department of Epidemiology, West Kazakhstan Marat Ospanov Medical University, Aktobe, Kazakhstan. FAU - Bazargaliyev, Yerlan Sh AU - Bazargaliyev YS AD - Department of Internal Diseases 1, West Kazakhstan Marat Ospanov Medical University, Aktobe, Kazakhstan. FAU - Kudabayeva, Khatimya I AU - Kudabayeva KI AD - Department of Internal Diseases 1, West Kazakhstan Marat Ospanov Medical University, Aktobe, Kazakhstan. FAU - Kurmangaliyev, Kairat B AU - Kurmangaliyev KB AD - Department of Microbiology, Virology, and Immunology, West Kazakhstan Marat Ospanov Medical University, Aktobe, Kazakhstan. LA - eng PT - Journal Article PT - Review DEP - 20250201 PL - Iran TA - Iran J Med Sci JT - Iranian journal of medical sciences JID - 8104374 RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - *COVID-19/immunology/prevention & control MH - *Memory T Cells/immunology MH - *COVID-19 Vaccines/immunology MH - SARS-CoV-2/immunology MH - Vaccination MH - *Immunologic Memory MH - *Immunity, Cellular/immunology PMC - PMC11870859 OTO - NOTNLM OT - Adaptive immunity OT - COVID-19 Vaccines OT - Post-acute COVID-19 syndrome OT - SARS-CoV-2 OT - T-lymphocytes COIS- None declared. EDAT- 2025/03/03 17:12 MHDA- 2025/03/03 17:13 PMCR- 2025/02/01 CRDT- 2025/03/03 06:05 PHST- 2024/09/08 00:00 [received] PHST- 2024/11/05 00:00 [revised] PHST- 2024/11/26 00:00 [accepted] PHST- 2025/03/03 17:13 [medline] PHST- 2025/03/03 17:12 [pubmed] PHST- 2025/03/03 06:05 [entrez] PHST- 2025/02/01 00:00 [pmc-release] AID - IJMS-50-2 [pii] AID - 10.30476/ijms.2024.104003.3744 [doi] PST - epublish SO - Iran J Med Sci. 2025 Feb 1;50(2):61-68. doi: 10.30476/ijms.2024.104003.3744. eCollection 2025 Feb. PMID- 40006661 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250228 IS - 2076-393X (Print) IS - 2076-393X (Electronic) IS - 2076-393X (Linking) VI - 13 IP - 2 DP - 2025 Jan 23 TI - Comparison of Phenotypes of Headaches After COVID-19 Vaccinations Differentiated According to the Vaccine Used. LID - 10.3390/vaccines13020113 [doi] LID - 113 AB - Background/Objectives: In this ongoing, multicenter, global cohort observational study, phenotypes of headaches after COVID-19 vaccination were directly compared between different vaccines. Methods: Phenotypes of postvaccinal headache were recorded in 18,544 participants. The study was launched immediately after the start of the global COVID-19 vaccination campaign on 12 January 2021 and continued until 1 August 2023. Specific aspects of headaches and related variables were collected via an online questionnaire. The clinical headache characteristics of patients vaccinated with the Comirnaty (BioNTech), Jcovden (Johnson & Johnson), Sputnik V (Gamelaya), Covilo (Sinopharm), Spikevax (Moderna), Vaxzevria (AstraZeneca), and Convidecia (CanSino Biologics) vaccines were investigated. Results: Across all vaccines, the median and mean latency of headache onset after vaccine administration were 12 h and 23.3 h, respectively. The median and mean headache duration were 12 h and 23.3 h, respectively. When the nonreplicating viral vector vaccine Sputnik V was used, headaches occurred the fastest, with a latency of 17 h. The latencies for the Vaxzevria and Convidecia nonreplicating viral vector vaccines were 14.9 h and 19.1 h, respectively. The Covilo inactivated whole-virus vaccine had a latency of 20.5 h. The latencies of the mRNA-based Comirnaty and Spikevax vaccines were 26.0 h and 22.02 h, respectively. Analysis of variance revealed no significant differences in the mean duration of postvaccinal headache for the vaccines tested. Compared with the Comirnaty, Covilo, and Vaxzevria vaccines, the Spikevax vaccine induced significantly greater headache intensities. Vaxzevria was associated with a significantly higher frequency of concomitant symptoms than the other vaccines. Conclusions: The phenotype of postvaccinal headache can vary significantly between vaccines. These results have clinical implications for differentiating between postvaccinal headache and other primary and secondary headaches. This knowledge is clinically relevant in differentiating life-threatening vaccination complications, such as thrombotic syndromes, which are also associated with headaches. Based on these results, new diagnostic criteria for postvaccinal headaches can be developed. FAU - Gobel, Carl Hartmut AU - Gobel CH AD - Kiel Migraine and Headache Centre, 24149 Kiel, Germany. AD - Department of Neurology, University Hospital Schleswig-Holstein, Campus Kiel, 24105 Kiel, Germany. FAU - Heinze, Axel AU - Heinze A AD - Kiel Migraine and Headache Centre, 24149 Kiel, Germany. FAU - Heinze-Kuhn, Katja AU - Heinze-Kuhn K AD - Kiel Migraine and Headache Centre, 24149 Kiel, Germany. FAU - Karstedt, Sarah AU - Karstedt S AD - Kiel Migraine and Headache Centre, 24149 Kiel, Germany. FAU - Morscheck, Mascha AU - Morscheck M AD - Kiel Migraine and Headache Centre, 24149 Kiel, Germany. FAU - Tashiro, Lilian AU - Tashiro L AUID- ORCID: 0000-0002-3612-1811 AD - Kiel Migraine and Headache Centre, 24149 Kiel, Germany. FAU - Cirkel, Anna AU - Cirkel A AD - Kiel Migraine and Headache Centre, 24149 Kiel, Germany. AD - Department of Neurology, University Hospital Schleswig-Holstein, Campus Lubeck, 23562 Lubeck, Germany. FAU - Hamid, Qutyaba AU - Hamid Q AUID- ORCID: 0000-0002-1107-190X AD - Sharjah Institute of Medical Research, University of Sharjah, Sharjah 26666, United Arab Emirates. AD - Department of Clinical Sciences, College of Medicine, University of Sharjah, Sharjah 26666, United Arab Emirates. FAU - Halwani, Rabih AU - Halwani R AD - Sharjah Institute of Medical Research, University of Sharjah, Sharjah 26666, United Arab Emirates. AD - Department of Clinical Sciences, College of Medicine, University of Sharjah, Sharjah 26666, United Arab Emirates. FAU - Temsah, Mohamad-Hani AU - Temsah MH AUID- ORCID: 0000-0002-4389-9322 AD - College of Medicine, King Saud University, Riyadh 12373, Saudi Arabia. FAU - Ziemann, Malte AU - Ziemann M AUID- ORCID: 0000-0003-0919-0237 AD - Institute of Transfusion Medicine, University Hospital Schleswig-Holstein, Campus Lubeck, 23562 Lubeck, Germany. FAU - Gorg, Siegfried AU - Gorg S AD - Institute of Transfusion Medicine, University Hospital Schleswig-Holstein, Campus Lubeck, 23562 Lubeck, Germany. FAU - Munte, Thomas AU - Munte T AD - Department of Neurology, University Hospital Schleswig-Holstein, Campus Lubeck, 23562 Lubeck, Germany. FAU - Gobel, Hartmut AU - Gobel H AUID- ORCID: 0000-0003-2163-112X AD - Kiel Migraine and Headache Centre, 24149 Kiel, Germany. LA - eng PT - Journal Article DEP - 20250123 PL - Switzerland TA - Vaccines (Basel) JT - Vaccines JID - 101629355 PMC - PMC11861871 OTO - NOTNLM OT - COVID-19 OT - Comirnaty (BioNTech) OT - Covilo (Sinopharm) OT - ICHD-3 OT - Jcovden (Johnson & Johnson) OT - SARS-CoV-2 virus OT - Spikevax (Moderna) OT - Sputnik V (Gamelaya) OT - Vaxzevria (AstraZeneca) and Convidecia (CanSino Biologics) OT - brain OT - complications OT - coronavirus disease 2019 OT - head-to-head comparison OT - headache OT - mRNA vaccine OT - phenotype OT - postvaccinal headaches OT - spike protein OT - vaccination COIS- The authors declare that they have no financial conflicts of interest or competing interests. EDAT- 2025/02/26 06:28 MHDA- 2025/02/26 06:29 PMCR- 2025/01/23 CRDT- 2025/02/26 01:29 PHST- 2024/12/27 00:00 [received] PHST- 2025/01/15 00:00 [revised] PHST- 2025/01/20 00:00 [accepted] PHST- 2025/02/26 06:29 [medline] PHST- 2025/02/26 06:28 [pubmed] PHST- 2025/02/26 01:29 [entrez] PHST- 2025/01/23 00:00 [pmc-release] AID - vaccines13020113 [pii] AID - vaccines-13-00113 [pii] AID - 10.3390/vaccines13020113 [doi] PST - epublish SO - Vaccines (Basel). 2025 Jan 23;13(2):113. doi: 10.3390/vaccines13020113. PMID- 39998800 OWN - NLM STAT- MEDLINE DCOM- 20250509 LR - 20261010 IS - 1538-2443 (Electronic) IS - 1355-0284 (Linking) VI - 31 IP - 1 DP - 2025 Feb TI - SARS-CoV-2: A synergy to the Alzheimer's disease. PG - 16-23 LID - 10.1007/s13365-025-01247-w [doi] AB - COVID-19 was a nightmare in humankind's history that challenged our advanced medical technology. All credit goes to the researchers who played a crucial role in curbing COVID-19 and proved our medical technology supremacy. However, COVID-19 has left some mysterious scars on human well-being. It is believed that COVID-19 has a significant negative impact on various cardiovascular (CVS) and central nervous system (CNS) diseases, especially in the case of CNS diseases like Alzheimer's. Surprisingly, COVID-19 affects the respiratory system, whereas Alzheimer's disease (AD) alters brain function. To explain this phenomenon, several hypotheses were proposed, but the mechanism needs to be clearly understood. Another critical thing to be concerned about is that COVID-19 will worsen pre-existing conditions and lead to the onset of AD. In the race to curb COVID-19, the invention of vaccines was speeded up, and it is necessary to fight against COVID-19. However, postvaccination follow-up is mandatory when an individual is a victim of AD. In this review article, we compiled the various dreadful effects of the COVID-19 virus on AD, the Post effects of the virus on AD, and the effect of the COVID-19 vaccination on AD. This article provides a new direction for research concerning COVID-19 and AD. CI - (c) 2025. The Author(s) under exclusive licence to The Journal of NeuroVirology, Inc. FAU - Shaik, Khaja Moinuddin AU - Shaik KM AD - Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research (NIPER), Sector 67, S.A.S. Nagar, 160 062, Punjab, India. FAU - Kumar, Deepak AU - Kumar D AD - Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research (NIPER), Sector 67, S.A.S. Nagar, 160 062, Punjab, India. FAU - Srikanth, Pirangi AU - Srikanth P AD - Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research (NIPER), Sector 67, S.A.S. Nagar, 160 062, Punjab, India. FAU - Nandi, Sukhendu AU - Nandi S AD - Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research (NIPER), Sector 67, S.A.S. Nagar, 160 062, Punjab, India. sukhendu@niper.ac.in. LA - eng PT - Journal Article PT - Review DEP - 20250225 PL - United States TA - J Neurovirol JT - Journal of neurovirology JID - 9508123 RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - *Alzheimer Disease/virology/immunology/pathology MH - *COVID-19/complications/virology/immunology/prevention & control MH - *SARS-CoV-2/pathogenicity/immunology MH - COVID-19 Vaccines/immunology MH - Brain/virology/pathology/immunology OTO - NOTNLM OT - Alzheimer's disease OT - COVID 19 OT - Dreadful effect of SARS CoV 2 virus on Alzheimer's disease OT - Impact of COVID 19 vaccination on AD OT - Post COVID 19 effect on AD COIS- Declarations. Competing interests: The authors declare no competing interests. EDAT- 2025/02/25 12:24 MHDA- 2025/04/04 12:30 CRDT- 2025/02/25 11:23 PHST- 2025/01/13 00:00 [received] PHST- 2025/02/14 00:00 [accepted] PHST- 2025/02/10 00:00 [revised] PHST- 2025/04/04 12:30 [medline] PHST- 2025/02/25 12:24 [pubmed] PHST- 2025/02/25 11:23 [entrez] AID - 10.1007/s13365-025-01247-w [pii] AID - 10.1007/s13365-025-01247-w [doi] PST - ppublish SO - J Neurovirol. 2025 Feb;31(1):16-23. doi: 10.1007/s13365-025-01247-w. Epub 2025 Feb 25. PMID- 39908650 OWN - NLM STAT- MEDLINE DCOM- 20250505 LR - 20250526 IS - 2352-3964 (Electronic) IS - 2352-3964 (Linking) VI - 113 DP - 2025 Mar TI - Longitudinal immunogenicity cohort study of SARS-CoV-2 mRNA vaccines across individuals with different immunocompromising conditions: heterogeneity in the immune response and crucial role of Omicron-adapted booster doses. PG - 105577 LID - S2352-3964(25)00021-0 [pii] LID - 10.1016/j.ebiom.2025.105577 [doi] LID - 105577 AB - BACKGROUND: Individuals with primary and secondary immunodeficiencies, being more susceptible to infections, are a priority for vaccination. Here, we determined and compared in a longitudinal study the immune response elicited by SARS-CoV-2 vaccination across different groups of individuals who are immunocompromised. METHODS: In the PatoVac_COV longitudinal prospective single-centre study, the spike-specific B cell and antibody responses to SARS-CoV-2 mRNA vaccination were compared across 5 different groups of individuals with haematological malignancies, hematopoietic stem cell (HCT) or solid organ transplantation (SOT), undergoing haemodialysis, and people living with HIV (PLWH), for a total of 585 participants. Data from participants who were immunocompromised were compared to a group of 123 participants who were immunocompetent. Blood samples were collected before and after each vaccine administration, up to 2 years. FINDINGS: A different immune responsiveness was observed after the first two vaccine doses, with haematological, haemodialysis, and SOT participants showing reduced responsiveness compared to HCT and PLWH, and relative to the comparison group. Spike-specific B cell response was both slower and lower in all groups except in PLWH when compared to participants who were immunocompetent. However, the first booster dose enhanced both the B and the antibody responses in all groups, that persisted up to 2 years after the first vaccine administration. The administration of Omicron-adapted booster vaccines promoted a primary BA.2 RBD-specific B cell response, especially in participants who were immunocompromised. Despite repeated vaccinations, a subset of persistent low-responders, especially among SOT, was identified. INTERPRETATION: Our study highlights the heterogeneous immune response across individuals with different pathologies, the pivotal role of the first booster dose, the primary activation of Omicron-specific B cells elicited by updated variant-adapted vaccines and the persistence of low-responders despite multiple vaccine administrations. These aspects have a clinical relevance for planning vaccination schedules tailored for individuals with different immunocompromising conditions. FUNDING: This work was supported by funds from the Department of Medical Biotechnologies of the University of Siena, and from EU within the NextGenerationEU-MUR PNRR Tuscany Health Ecosystem (Project no ECS00000017-THE). CI - Copyright (c) 2025 The Authors. Published by Elsevier B.V. All rights reserved. FAU - Ciabattini, Annalisa AU - Ciabattini A AD - Laboratory of Molecular Microbiology and Biotechnology, Department of Medical Biotechnologies, University of Siena, Siena, Italy. Electronic address: annalisa.ciabattini@unisi.it. FAU - Pettini, Elena AU - Pettini E AD - Laboratory of Molecular Microbiology and Biotechnology, Department of Medical Biotechnologies, University of Siena, Siena, Italy. FAU - Fiorino, Fabio AU - Fiorino F AD - Laboratory of Molecular Microbiology and Biotechnology, Department of Medical Biotechnologies, University of Siena, Siena, Italy; Department of Medicine and Surgery, LUM University "Giuseppe Degennaro", Bari, Italy. FAU - Polvere, Jacopo AU - Polvere J AD - Laboratory of Molecular Microbiology and Biotechnology, Department of Medical Biotechnologies, University of Siena, Siena, Italy. FAU - Lucchesi, Simone AU - Lucchesi S AD - Laboratory of Molecular Microbiology and Biotechnology, Department of Medical Biotechnologies, University of Siena, Siena, Italy. FAU - Coppola, Chiara AU - Coppola C AD - Laboratory of Molecular Microbiology and Biotechnology, Department of Medical Biotechnologies, University of Siena, Siena, Italy. FAU - Costagli, Simone AU - Costagli S AD - Laboratory of Molecular Microbiology and Biotechnology, Department of Medical Biotechnologies, University of Siena, Siena, Italy. FAU - Pastore, Gabiria AU - Pastore G AD - Laboratory of Molecular Microbiology and Biotechnology, Department of Medical Biotechnologies, University of Siena, Siena, Italy. FAU - Sicuranza, Anna AU - Sicuranza A AD - Haematology Unit, Department of Medical Science, Surgery and Neuroscience, University Hospital of Siena, Siena, Italy. FAU - Tozzi, Monica AU - Tozzi M AD - Cellular Therapy Unit, Department of Innovation, Experimentation, Clinical and Translational Research, University Hospital of Siena, Siena, Italy. FAU - Lippi, Arianna AU - Lippi A AD - Department of Medical Sciences, Infectious and Tropical Diseases Unit, University Hospital of Siena, Siena, Italy; Department of Medical Biotechnologies, University of Siena, Siena, Italy. FAU - Panza, Francesca AU - Panza F AD - Department of Medical Sciences, Infectious and Tropical Diseases Unit, University Hospital of Siena, Siena, Italy; Department of Medical Biotechnologies, University of Siena, Siena, Italy. FAU - Bocchia, Monica AU - Bocchia M AD - Haematology Unit, Department of Medical Science, Surgery and Neuroscience, University Hospital of Siena, Siena, Italy. FAU - Bucalossi, Alessandro AU - Bucalossi A AD - Cellular Therapy Unit, Department of Innovation, Experimentation, Clinical and Translational Research, University Hospital of Siena, Siena, Italy. FAU - Garosi, Guido AU - Garosi G AD - Department of Medical Science, Nephrology, Dialysis and Transplantation Unit, University Hospital of Siena, Italy. FAU - Bennett, David AU - Bennett D AD - Respiratory Disease and Lung Transplant Unit, University of Siena, University Hospital of Siena, Italy. FAU - Bernazzali, Sonia AU - Bernazzali S AD - Department of Cardiac Surgery, University of Siena, Siena, Italy. FAU - Fabbiani, Massimiliano AU - Fabbiani M AD - Department of Medical Sciences, Infectious and Tropical Diseases Unit, University Hospital of Siena, Siena, Italy; Department of Medical Biotechnologies, University of Siena, Siena, Italy. FAU - Montagnani, Francesca AU - Montagnani F AD - Department of Medical Sciences, Infectious and Tropical Diseases Unit, University Hospital of Siena, Siena, Italy; Department of Medical Biotechnologies, University of Siena, Siena, Italy. FAU - Medaglini, Donata AU - Medaglini D AD - Laboratory of Molecular Microbiology and Biotechnology, Department of Medical Biotechnologies, University of Siena, Siena, Italy. LA - eng PT - Journal Article DEP - 20250204 PL - Netherlands TA - EBioMedicine JT - EBioMedicine JID - 101647039 RN - 0 (Antibodies, Viral) RN - 0 (COVID-19 Vaccines) RN - 0 (Spike Glycoprotein, Coronavirus) RN - 0 (spike protein, SARS-CoV-2) RN - 0 (mRNA Vaccines) SB - IM MH - Humans MH - *Immunocompromised Host/immunology MH - *SARS-CoV-2/immunology MH - *COVID-19/prevention & control/immunology/virology MH - Female MH - Male MH - Longitudinal Studies MH - Middle Aged MH - Adult MH - Antibodies, Viral/immunology/blood MH - *COVID-19 Vaccines/immunology/administration & dosage MH - Immunization, Secondary MH - B-Lymphocytes/immunology MH - Spike Glycoprotein, Coronavirus/immunology MH - *Immunogenicity, Vaccine MH - Aged MH - Prospective Studies MH - Vaccination MH - mRNA Vaccines/immunology PMC - PMC11847306 OTO - NOTNLM OT - Immunocompromised OT - Memory B cells OT - SARS-CoV-2 OT - Vaccine immunogenicity OT - mRNA vaccines COIS- Declaration of interests MB has received honoraria and support for attending meetings from NOVARTIS, ABVVIE, INCYTE. EDAT- 2025/02/06 00:21 MHDA- 2025/03/15 00:37 PMCR- 2025/02/04 CRDT- 2025/02/05 18:02 PHST- 2024/05/14 00:00 [received] PHST- 2025/01/15 00:00 [revised] PHST- 2025/01/16 00:00 [accepted] PHST- 2025/03/15 00:37 [medline] PHST- 2025/02/06 00:21 [pubmed] PHST- 2025/02/05 18:02 [entrez] PHST- 2025/02/04 00:00 [pmc-release] AID - S2352-3964(25)00021-0 [pii] AID - 105577 [pii] AID - 10.1016/j.ebiom.2025.105577 [doi] PST - ppublish SO - EBioMedicine. 2025 Mar;113:105577. doi: 10.1016/j.ebiom.2025.105577. Epub 2025 Feb 4. PMID- 39905221 OWN - NLM STAT- MEDLINE DCOM- 20250205 LR - 20260514 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 15 IP - 1 DP - 2025 Feb 4 TI - Multicentre case-control study on the association between COVID-19 vaccines and neurological disorders (COVIVAX). PG - 4179 LID - 10.1038/s41598-025-88837-0 [doi] LID - 4179 AB - The COVIVAX study assessed the association between COVID-19 vaccination and the risk of common neurological disorders in a multicenter case-control design. Vaccination exposure was compared between individuals with a first diagnosis of a neurological disorder (cases) and age- and sex-matched controls. A total of 624 participants were enrolled, and after random 1:1 matching 265 cases and 265 matched controls (total 530 participants) were included in the analyses. The most frequent neurological diagnosis in cases were stroke (60.4%), multiple sclerosis (11.3%) and seizures (6.4%). The proportion of vaccinated participants was 72.1% among cases and 79.6% among controls. A protective role of vaccination on the risk of developing a new neurological disorder was detected in the unadjusted analysis (OR 0.50; 95% CI 0.29-0.86; p = 0.0114). After adjustment for confounders, the number of vaccination doses received was associated with a reduced risk of developing new neurological disorders for participants aged over 60 years ( p = 0.0472; OR 0.14, 95% CI 0.03-0.68), with pre-existing comorbidities (p = 0.0122; OR 0.04, 95% CI 0.01-0.99) and for stroke (p = 0.0232; OR 0.04, 95% CI 0.02-0.97). The COVIVAX study provided no warning sign regarding an increase in the risk of developing new neurological disorders following COVID-19 vaccination of any type or doses. A potentially protective effect of multiple doses of COVID-19 vaccines against the risk of stroke in people aged over 60 needs to be confirmed by further studies. CI - (c) 2025. The Author(s). FAU - Pupillo, Elisabetta AU - Pupillo E AD - Dipartimento di Neuroscienze, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy. FAU - Bianchi, Elisa AU - Bianchi E AD - Dipartimento di Neuroscienze, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy. FAU - Beghi, Ettore AU - Beghi E AD - Dipartimento di Neuroscienze, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy. FAU - Pedrazzini, Francesco Andrea AU - Pedrazzini FA AD - Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy. FAU - Giglio, Angela AU - Giglio A AD - Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy. FAU - Schilke, Edoardo Dalmato AU - Schilke ED AD - Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy. FAU - Percetti, Marco AU - Percetti M AD - Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy. FAU - Morotti Colleoni, Carlo AU - Morotti Colleoni C AD - Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy. FAU - Mainini, Gabriele AU - Mainini G AD - Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy. FAU - Calabresi, Paolo AU - Calabresi P AD - Dipartimento di Neuroscienze, Organi di Senso e Torace, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy. AD - Dipartimento di Neuroscienze, Universita Cattolica del Sacro Cuore, Rome, Italy. FAU - Primiano, Guido AU - Primiano G AD - Dipartimento di Neuroscienze, Organi di Senso e Torace, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy. AD - Dipartimento di Neuroscienze, Universita Cattolica del Sacro Cuore, Rome, Italy. FAU - Frisullo, Giovanni AU - Frisullo G AD - Dipartimento di Neuroscienze, Organi di Senso e Torace, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy. AD - Dipartimento di Neuroscienze, Universita Cattolica del Sacro Cuore, Rome, Italy. FAU - Padovani, Alessandro AU - Padovani A AD - Spedali civili di Brescia, Brescia, Italy. FAU - Cristillo, Viviana AU - Cristillo V AD - Spedali civili di Brescia, Brescia, Italy. FAU - Pilotto, Andrea AU - Pilotto A AD - Spedali civili di Brescia, Brescia, Italy. FAU - Arici, Davide AU - Arici D AD - Spedali civili di Brescia, Brescia, Italy. FAU - Gipponi, Stefano AU - Gipponi S AD - Spedali civili di Brescia, Brescia, Italy. FAU - Tedeschi, Gioacchino AU - Tedeschi G AD - Division of Neurology, Department of Advanced Medical and Surgical Sciences (DAMSS), University of Campania "Luigi Vanvitelli", Naples, Italy. FAU - d'Ambrosio, Alessandro AU - d'Ambrosio A AD - Division of Neurology, Department of Advanced Medical and Surgical Sciences (DAMSS), University of Campania "Luigi Vanvitelli", Naples, Italy. FAU - Melisi, Rosario Domenico AU - Melisi RD AD - Division of Neurology, Department of Advanced Medical and Surgical Sciences (DAMSS), University of Campania "Luigi Vanvitelli", Naples, Italy. FAU - Gallo, Antonio AU - Gallo A AD - Division of Neurology, Department of Advanced Medical and Surgical Sciences (DAMSS), University of Campania "Luigi Vanvitelli", Naples, Italy. FAU - Bisecco, Alvino AU - Bisecco A AD - Division of Neurology, Department of Advanced Medical and Surgical Sciences (DAMSS), University of Campania "Luigi Vanvitelli", Naples, Italy. FAU - Salmaggi, Andrea AU - Salmaggi A AD - Neurosciences Department, ASST Lecco, Lecco, Italy. FAU - Basilico, Paola AU - Basilico P AD - Neurosciences Department, ASST Lecco, Lecco, Italy. FAU - Scaccabarozzi, Chiara AU - Scaccabarozzi C AD - Neurosciences Department, ASST Lecco, Lecco, Italy. FAU - Kiferle, Lorenzo AU - Kiferle L AD - SOC Neurologia Ospedale S. Stefano Prato Azienda USL Toscana Centro, Prato, Italy. FAU - Valenti, Raffaella AU - Valenti R AD - SOC Neurologia Ospedale S. Stefano Prato Azienda USL Toscana Centro, Prato, Italy. FAU - Avino, Gianluca AU - Avino G AD - SOC Neurologia Ospedale S. Stefano Prato Azienda USL Toscana Centro, Prato, Italy. FAU - Borghi, Annamaria AU - Borghi A AD - Department of Neurology and Stroke Center, IRCCS Istituto delle Scienze Neurologiche di Bologna, Maggiore Hospital, Bologna, Italy. FAU - Contardi, Sara AU - Contardi S AD - Department of Neurology and Stroke Center, IRCCS Istituto delle Scienze Neurologiche di Bologna, Maggiore Hospital, Bologna, Italy. FAU - Zini, Andrea AU - Zini A AD - Department of Neurology and Stroke Center, IRCCS Istituto delle Scienze Neurologiche di Bologna, Maggiore Hospital, Bologna, Italy. FAU - Ferrarese, Carlo AU - Ferrarese C AD - Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy. AD - Department of Neurology, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy. FAU - Beretta, Simone AU - Beretta S AUID- ORCID: 0000-0002-9417-2748 AD - Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy. simone.beretta@unimib.it. AD - Department of Neurology, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy. simone.beretta@unimib.it. AD - Department of Neurology, Fondazione IRCCS San Gerardo dei Tintori Monza University of Milano Bicocca, Via Pergolesi, 33, Monza, 20900, MI, Italy. simone.beretta@unimib.it. LA - eng PT - Journal Article PT - Multicenter Study PT - Research Support, Non-U.S. Gov't DEP - 20250204 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - Female MH - Male MH - Case-Control Studies MH - Middle Aged MH - *COVID-19/prevention & control/epidemiology MH - Aged MH - *Nervous System Diseases/epidemiology/etiology MH - *COVID-19 Vaccines/adverse effects/administration & dosage MH - Adult MH - SARS-CoV-2/immunology MH - Vaccination MH - Risk Factors PMC - PMC11794632 OTO - NOTNLM OT - Attributable risk OT - COVID-19 OT - Case-control study OT - Epidemiology OT - Neurological disorders OT - Vaccines COIS- Declarations. Competing interests: The authors declare no competing interests. EDAT- 2025/02/05 06:20 MHDA- 2025/02/05 06:21 PMCR- 2025/02/04 CRDT- 2025/02/05 00:18 PHST- 2024/04/02 00:00 [received] PHST- 2025/01/31 00:00 [accepted] PHST- 2025/02/05 06:21 [medline] PHST- 2025/02/05 06:20 [pubmed] PHST- 2025/02/05 00:18 [entrez] PHST- 2025/02/04 00:00 [pmc-release] AID - 10.1038/s41598-025-88837-0 [pii] AID - 88837 [pii] AID - 10.1038/s41598-025-88837-0 [doi] PST - epublish SO - Sci Rep. 2025 Feb 4;15(1):4179. doi: 10.1038/s41598-025-88837-0. PMID- 39903350 OWN - NLM STAT- MEDLINE DCOM- 20250505 LR - 20250525 IS - 1590-3478 (Electronic) IS - 1590-1874 (Print) IS - 1590-1874 (Linking) VI - 46 IP - 4 DP - 2025 Apr TI - Is there still hesitancy towards SARS-CoV-2 vaccination among people with neurological disease- a survey of the NeuroCOVID-19 task force of the European Academy of Neurology. PG - 1467-1476 LID - 10.1007/s10072-025-08017-w [doi] AB - BACKGROUND: An online 3-item survey was sent to the European Academy of Neurology (EAN) community and inquired about the persistence of SARS-CoV-2 vaccination skepticism and the underlying thoughts and factors restricting vaccine use among patients with neurological conditions. RESULTS: We obtained 616 responses from 84 countries, predominantly from Europe. In the view of the treating neurologist, patients with multiple sclerosis (MS), neuroimmunological disorders (ND), and chronic neurological infections continued to have high levels of skepticism toward SARS-CoV-2 vaccination. Patients with MS/ND were quoted as the most hesitant group, with 60% of the respondents sharing this impression. The patient group perceived as most confident towards immunization against COVID-19 and with the lowest level of distrust towards the vaccine were those with sleep disorders. For all other conditions, perceived distrust ranged between 42 and 52%. Fear of adverse events of vaccination or disease reactivation was perceived by 87% of patients with MS/ND and more than 70% of patients with stroke/vascular neurology, neuromuscular disorders, chronic neurological infections, and peripheral neuropathy. Patients with sleep disorders (54%), autonomic disorders (46%), movement disorders (43%), and dementia (43%) were sensed as less fearful of vaccine-related adverse events. CONCLUSION: Despite the large body of evidence proving the efficacy and safety of SARS-CoV-2 vaccination, patients with certain neurological disorders still have a surprisingly high percentage of distrust and fear of adverse events. Our observations emphasize the importance of continuous evidence-based information delivery and patient education by treating neurologists. CI - (c) 2025. The Author(s). FAU - Hochmeister, Sonja AU - Hochmeister S AD - Department of Neurology, Medical University of Graz, Graz, Austria. FAU - Rakusa, Martin AU - Rakusa M AD - Division of Neurology, University Medical Centre Maribor, Maribor, Slovenia. FAU - Moro, Elena AU - Moro E AD - Division of Neurology, Grenoble Alpes University, CHU of Grenoble, Grenoble Institute of Neurosciences, INSERM U1216, Grenoble, France. FAU - Bereczki, Daniel AU - Bereczki D AD - Department of Neurology, Semmelweis University, Budapest, Hungary. FAU - Cavallieri, Francesco AU - Cavallieri F AD - Neurology Unit, Neuromotor & Rehabilitation Department, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy. FAU - Fanciulli, Alessandra AU - Fanciulli A AD - Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria. FAU - Filipovic, Sasa R AU - Filipovic SR AD - Institute for Medical Research, University of Belgrade, Belgrade, Serbia. FAU - Guekht, Alla AU - Guekht A AD - Research and Clinical Center for Neuropsychiatry, Moscow, Russian Federation. AD - Pirogov Russian National Research Medical University, Moscow, Russian Federation. FAU - Helbok, Raimund AU - Helbok R AD - Department of Neurology, Kepler University Hospital, Johannes Kepler University, Linz, Austria. FAU - Boneschi, Filippo Martinelli AU - Boneschi FM AD - Neurology Unit, ASST Santi Paolo e Carlo, Milan, Italy. AD - Department of Health Sciences, University of Milan, Milan, Italy. FAU - Ozturk, Serefnur AU - Ozturk S AD - Department of Neurology, Faculty of Medicine, Selcuk University, Konya, Turkey. FAU - Priori, Alberto AU - Priori A AD - ''Aldo Ravelli'' Center for Neurotechnology and Experimental Brain Therapeutics, Department of Health Sciences, University of Milan, Milan, Italy. AD - Clinical Neurology Unit, Department of Health Sciences, "Azienda Socio-Sanitaria Territoriale Santi Paolo E Carlo", University of Milan, Milan, Italy. FAU - Willekens, Barbara AU - Willekens B AD - Department of Neurology, Antwerp University Hospital, Edegem, Belgium. AD - Translational Neurosciences Research Group, University of Antwerp, Wilrijk, Belgium. FAU - Ramankulov, Dauren AU - Ramankulov D AD - European Academy of Neurology, Vienna, Austria. FAU - Sellner, Johann AU - Sellner J AUID- ORCID: 0000-0001-8749-5533 AD - Department of Neurology, Landesklinikum Mistelbach-Ganserndorf, Liechtensteinstrasse 67, Mistelbach, 2130, Austria. johann.sellner@mistelbach.lknoe.at. AD - Karl Landsteiner University of Health Sciences, Krems, Austria. johann.sellner@mistelbach.lknoe.at. AD - Department of Neurology, Christian Doppler Medical Center, Paracelsus Medical University, Salzburg, Austria. johann.sellner@mistelbach.lknoe.at. AD - Department of Neurology, Klinikum rechts der Isar, School of Medicine, Technische Universitat Munchen, Munchen, Germany. johann.sellner@mistelbach.lknoe.at. LA - eng PT - Journal Article DEP - 20250204 PL - Italy TA - Neurol Sci JT - Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology JID - 100959175 RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - *COVID-19/prevention & control MH - *Nervous System Diseases/psychology MH - *Vaccination Hesitancy/psychology/statistics & numerical data MH - Europe MH - *COVID-19 Vaccines/adverse effects MH - Female MH - Male MH - Middle Aged MH - Adult MH - Neurology MH - Surveys and Questionnaires MH - Aged MH - Advisory Committees MH - *Vaccination/psychology PMC - PMC11920348 OTO - NOTNLM OT - Autoimmune OT - COVID-19 OT - Disease prevention OT - Multiple sclerosis OT - Neurological disease OT - Public health OT - SARS-CoV-2 OT - Vaccination hesitancy COIS- Declarations. Ethical approval: No ethics approval was required for this anonymized online survey study according to Austrian regulations. Conflict of interest: All authors are members of the NeuroCOVID-19 Task Force of the European Academy of Neurology. No further competing interests. EDAT- 2025/02/04 17:02 MHDA- 2025/03/18 18:22 PMCR- 2025/02/04 CRDT- 2025/02/04 11:19 PHST- 2024/10/27 00:00 [received] PHST- 2025/01/16 00:00 [accepted] PHST- 2025/03/18 18:22 [medline] PHST- 2025/02/04 17:02 [pubmed] PHST- 2025/02/04 11:19 [entrez] PHST- 2025/02/04 00:00 [pmc-release] AID - 10.1007/s10072-025-08017-w [pii] AID - 8017 [pii] AID - 10.1007/s10072-025-08017-w [doi] PST - ppublish SO - Neurol Sci. 2025 Apr;46(4):1467-1476. doi: 10.1007/s10072-025-08017-w. Epub 2025 Feb 4. PMID- 39857653 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20260923 IS - 2227-9059 (Print) IS - 2227-9059 (Electronic) IS - 2227-9059 (Linking) VI - 13 IP - 1 DP - 2024 Dec 30 TI - Persistent Health and Cognitive Impairments up to Four Years Post-COVID-19 in Young Students: The Impact of Virus Variants and Vaccination Timing. LID - 10.3390/biomedicines13010069 [doi] LID - 69 AB - Background: The long-term consequences of COVID-19 infection are becoming increasingly evident in recent studies. This repeated cross-sectional study aimed to explore the long-term health and cognitive effects of COVID-19, focusing on how virus variants, vaccination, illness severity, and time since infection impact post-COVID-19 outcomes. Methods: We examined three cohorts of university students (N = 584) and used non-parametric methods to assess correlations of various health and cognitive variables with SARS-CoV-2 infection, COVID-19 severity, vaccination status, time since infection, time since vaccination, and virus variants. Results: Our results suggest that some health and cognitive impairments may persist, with some even appearing to progressively worsen-particularly fatigue in women and memory in men-up to four years post-infection. The data further indicate that the ancestral SARS-CoV-2 variant may have the most significant long-term impact, while the Omicron variant appears to have the least. Interestingly, the severity of the acute illness was not correlated with the variant of SARS-CoV-2. The analysis also revealed that individuals who contracted COVID-19 after vaccination had better health and cognitive outcomes compared to those infected before vaccination. Conclusions: Overall, our results indicate that even in young individuals who predominantly experienced only mild forms of the infection, a gradual decline in health and fitness can occur over a span of four years post-infection. Notably, some negative trends-at least in men-only began to stabilize or even reverse during the fourth year, whereas in women, these trends showed no such improvement. These findings suggest that the long-term public health impacts of COVID-19 may be more severe and affect a much broader population than is commonly assumed. FAU - Latifi, Ashkan AU - Latifi A AUID- ORCID: 0000-0001-8725-2910 AD - Laboratory of Evolutionary Biology, Department of Philosophy and History of Sciences, Faculty of Science, Charles University, Vinicna 7, 128 00 Prague, Czech Republic. FAU - Flegr, Jaroslav AU - Flegr J AUID- ORCID: 0000-0002-0822-0126 AD - Laboratory of Evolutionary Biology, Department of Philosophy and History of Sciences, Faculty of Science, Charles University, Vinicna 7, 128 00 Prague, Czech Republic. LA - eng GR - 22-20785S/Czech Science Foundation/ PT - Journal Article DEP - 20241230 PL - Switzerland TA - Biomedicines JT - Biomedicines JID - 101691304 PMC - PMC11760454 OTO - NOTNLM OT - SARS-CoV-2 OT - cognition OT - long COVID OT - long-term effects OT - mental health COIS- The authors declare no conflicts of interest. EDAT- 2025/01/25 13:52 MHDA- 2025/01/25 13:53 PMCR- 2024/12/30 CRDT- 2025/01/25 01:06 PHST- 2024/11/09 00:00 [received] PHST- 2024/12/27 00:00 [revised] PHST- 2024/12/28 00:00 [accepted] PHST- 2025/01/25 13:53 [medline] PHST- 2025/01/25 13:52 [pubmed] PHST- 2025/01/25 01:06 [entrez] PHST- 2024/12/30 00:00 [pmc-release] AID - biomedicines13010069 [pii] AID - biomedicines-13-00069 [pii] AID - 10.3390/biomedicines13010069 [doi] PST - epublish SO - Biomedicines. 2024 Dec 30;13(1):69. doi: 10.3390/biomedicines13010069. PMID- 39827600 OWN - NLM STAT- MEDLINE DCOM- 20250502 LR - 20250905 IS - 1873-2518 (Electronic) IS - 0264-410X (Linking) VI - 48 DP - 2025 Feb 27 TI - Impairment of the T cell memory response in chronic lymphocytic leukemia patients after SARS-CoV-2 vaccination. PG - 126723 LID - S0264-410X(25)00020-9 [pii] LID - 10.1016/j.vaccine.2025.126723 [doi] AB - CLL patients face increased vulnerability to COVID-19 because of weakened immune systems from comorbidities and treatments. Therefore, the need for these patients of vaccination is of outermost importance. In our study we have evaluated T cell-mediated responses to COVID19 vaccines by performing the activation-induced markers (AIM) assay which allows to determine spike-specific CD4+ and CD8+ T cell responses. A CD4+ T cell memory response was registered in all healthy control (HC) (responders), while 28.60 % of CLL patients did not respond to the stimulation (non-responders). CD8+ T cell memory response was impaired in 61.90 % of CLL patients and in 33.33 % of HC. In addition, CLL responders showed a significant impairment of the magnitude of memory response in CD8 subset. Interestingly, impairment of the CD4+ AIM+ memory was associated to a more severe COVID-19 infection. Ibrutinib therapy had negative impact on IL-2 production by CD8+ cells, while the duration of the treatment positively affected the memory response. The majority of CLL patients don't respond well to vaccination, leaving clinicians in need of a reliable way to identify non-responders and assess the protection levels of those who do. Our findings suggest the AIM test as a promising method for screening and categorizing patients, potentially addressing this need. CI - Copyright (c) 2025 The Authors. Published by Elsevier Ltd.. All rights reserved. FAU - Raineri, Davide AU - Raineri D AD - Department of Health Sciences, Interdisciplinary Research Center of Autoimmune Diseases-IRCAD, Universita del Piemonte Orientale, Novara, Italy; Center for Translational Research on Autoimmune and Allergic Diseases, University of Piemonte Orientale, 28100 Novara, Italy. Electronic address: davide.raineri@med.uniupo.it. FAU - Mazzucca, Camilla Barbero AU - Mazzucca CB AD - Department of Health Sciences, Interdisciplinary Research Center of Autoimmune Diseases-IRCAD, Universita del Piemonte Orientale, Novara, Italy; Center for Translational Research on Autoimmune and Allergic Diseases, University of Piemonte Orientale, 28100 Novara, Italy. Electronic address: camilla.barbero@uniupo.it. FAU - Moia, Riccardo AU - Moia R AD - Division of Hematology, Department of Translational Medicine, Universita del Piemonte Orientale and Azienda Ospedaliero-Universitaria Maggiore della Carita, 28100 Novara, Italy. FAU - Bruna, Riccardo AU - Bruna R AD - Division of Hematology, Department of Translational Medicine, Universita del Piemonte Orientale and Azienda Ospedaliero-Universitaria Maggiore della Carita, 28100 Novara, Italy. FAU - Kustrimovic, Natasa AU - Kustrimovic N AD - Department of Health Sciences, Interdisciplinary Research Center of Autoimmune Diseases-IRCAD, Universita del Piemonte Orientale, Novara, Italy; Center for Translational Research on Autoimmune and Allergic Diseases, University of Piemonte Orientale, 28100 Novara, Italy. Electronic address: natasa.kustrimovic@uniupo.it. FAU - Cappellano, Giuseppe AU - Cappellano G AD - Department of Health Sciences, Interdisciplinary Research Center of Autoimmune Diseases-IRCAD, Universita del Piemonte Orientale, Novara, Italy; Center for Translational Research on Autoimmune and Allergic Diseases, University of Piemonte Orientale, 28100 Novara, Italy. Electronic address: giuseppe.cappellano@med.uniupo.it. FAU - Bellan, Mattia AU - Bellan M AD - Center for Translational Research on Autoimmune and Allergic Diseases, University of Piemonte Orientale, 28100 Novara, Italy; Department of Translational Medicine (DIMET), Universita del Piemonte Orientale, Novara, Italy; Department of Internal Medicine, Rheumatology Unit, "AOU Maggiore della Carita", Novara, Italy. FAU - Perazzi, Mattia AU - Perazzi M AD - Department of Translational Medicine (DIMET), Universita del Piemonte Orientale, Novara, Italy; Department of Internal Medicine, Rheumatology Unit, "AOU Maggiore della Carita", Novara, Italy. FAU - Gaidano, Gianluca AU - Gaidano G AD - Division of Hematology, Department of Translational Medicine, Universita del Piemonte Orientale and Azienda Ospedaliero-Universitaria Maggiore della Carita, 28100 Novara, Italy. FAU - Chiocchetti, Annalisa AU - Chiocchetti A AD - Department of Health Sciences, Interdisciplinary Research Center of Autoimmune Diseases-IRCAD, Universita del Piemonte Orientale, Novara, Italy; Center for Translational Research on Autoimmune and Allergic Diseases, University of Piemonte Orientale, 28100 Novara, Italy. Electronic address: annalisa.chiocchetti@med.uniupo.it. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20250118 PL - Netherlands TA - Vaccine JT - Vaccine JID - 8406899 RN - 0 (COVID-19 Vaccines) RN - 0 (Piperidines) RN - 0 (Interleukin-2) RN - 1X70OSD4VX (ibrutinib) RN - JAC85A2161 (Adenine) SB - IM MH - Humans MH - *Leukemia, Lymphocytic, Chronic, B-Cell/immunology/drug therapy MH - *COVID-19 Vaccines/immunology/administration & dosage MH - Female MH - Male MH - CD8-Positive T-Lymphocytes/immunology MH - Middle Aged MH - Aged MH - *COVID-19/prevention & control/immunology MH - CD4-Positive T-Lymphocytes/immunology MH - *Immunologic Memory MH - SARS-CoV-2/immunology MH - *Memory T Cells/immunology MH - Vaccination MH - Piperidines MH - Interleukin-2 MH - Aged, 80 and over MH - Adenine/analogs & derivatives MH - Adult OTO - NOTNLM OT - Activation-induced markers assay OT - COVID-19 OT - Chronic lymphocytic leukemia OT - Vaccine COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2025/01/20 22:52 MHDA- 2025/02/20 00:21 CRDT- 2025/01/19 18:05 PHST- 2024/09/02 00:00 [received] PHST- 2024/12/19 00:00 [revised] PHST- 2024/12/27 00:00 [accepted] PHST- 2025/02/20 00:21 [medline] PHST- 2025/01/20 22:52 [pubmed] PHST- 2025/01/19 18:05 [entrez] AID - S0264-410X(25)00020-9 [pii] AID - 10.1016/j.vaccine.2025.126723 [doi] PST - ppublish SO - Vaccine. 2025 Feb 27;48:126723. doi: 10.1016/j.vaccine.2025.126723. Epub 2025 Jan 18. PMID- 39792199 OWN - NLM STAT- MEDLINE DCOM- 20250530 LR - 20261010 IS - 1434-4726 (Electronic) IS - 0937-4477 (Linking) VI - 282 IP - 6 DP - 2025 Jun TI - Analytical review of facial nerve palsy following SARS-CoV-2 vaccination: comprehensive assessment. PG - 2787-2797 LID - 10.1007/s00405-024-09173-z [doi] AB - PURPOSE: The SARS-CoV-2 vaccination has reduced COVID-19 infection, though facial nerve palsy (FNP) has emerged as a notable side effect of the vaccine. We evaluated the current literature on the clinical presentation and outcomes of FNP related to COVID-19 vaccination. METHODS: A comprehensive search of seven databases was conducted for studies up to January 2023. We included individually reported patients on FNP following COVID-19 vaccination, while cases with co-existing neurological disorders or secondary causes of FNP were excluded. Pooled descriptive and inferential analyses were conducted, with prognostic factors evaluated through regression and Kaplan-Meier survival analysis. RESULTS: A total of 33 studies were included, with data from 52 patients who developed post-COVID-19 vaccination FNP (PV-FNP). Most cases (71%) followed mRNA vaccines, primarily occurring after the first dose and within the first week post-vaccination. Nearly all cases (98%) were unilateral, with Grade III palsy being most common. Complete recovery was achieved in 55% of patients, significantly lower than pre-pandemic rate (83%). A longer latency period was associated with a reduced likelihood of full recovery, and females experienced faster recovery compared to males. CONCLUSION: FNP following SARS-CoV-2 vaccination tends to present as mild and unilateral, with a lower full recovery rate compared to pre-pandemic cases. Symptoms often develop within the first week after vaccination, and earlier symptom onset is associated with a higher likelihood of full recovery. Recognizing these patterns provides valuable guidance for clinicians in counseling patients about prognosis and managing follow-up care effectively. CI - (c) 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Mirza, Ahmad A AU - Mirza AA AUID- ORCID: 0000-0001-6035-9566 AD - Department of Otolaryngology-Head and Neck Surgery, Faculty of Medicine in Rabigh, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia. aamirza1@kau.edu.sa. AD - Department of Otolaryngology-Head and Neck Surgery, Temerty Faculty of Medicine, University of Toronto, 6 Queen's Park Crescent West, Suite 120, Toronto, ON, M5S 3H2, Canada. aamirza1@kau.edu.sa. FAU - Almalki, Abdulaziz H AU - Almalki AH AD - Division of Otolaryngology - Head and Neck Surgery, Department of Surgery, King Abdulaziz Medical City, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia. FAU - AlMubarak, Zaid AU - AlMubarak Z AD - Department of Otolaryngology-Head and Neck Surgery, Schulich School of Medicine and Dentistry, Western University, 1151 Richmond St, London, ON, N6A 5C1, Canada. AD - Department of Otolaryngology Head and Neck Surgery, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia. FAU - Spiegel, Jennifer L AU - Spiegel JL AUID- ORCID: 0000-0002-6187-0195 AD - Department of Otolaryngology-Head & Neck Surgery, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada. AD - Department of Otorhinolaryngology, University Hospital, LMU Munich, Munich, Germany. FAU - Dahm, Valerie AU - Dahm V AD - Department of Otolaryngology-Head & Neck Surgery, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada. AD - Department of Otolaryngology-Head & Neck Surgery, Medical University of Vienna, Vienna, Austria. FAU - Lin, Vincent Y AU - Lin VY AUID- ORCID: 0000-0003-0505-158X AD - Department of Otolaryngology-Head and Neck Surgery, Temerty Faculty of Medicine, University of Toronto, 6 Queen's Park Crescent West, Suite 120, Toronto, ON, M5S 3H2, Canada. AD - Department of Otolaryngology-Head & Neck Surgery, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada. AD - Biological Sciences Platform, Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, ON, Canada. LA - eng PT - Journal Article PT - Review DEP - 20250110 PL - Germany TA - Eur Arch Otorhinolaryngol JT - European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery JID - 9002937 RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - *Facial Paralysis/etiology/epidemiology MH - *COVID-19 Vaccines/adverse effects MH - *COVID-19/prevention & control MH - SARS-CoV-2 MH - Male MH - Female MH - *Vaccination/adverse effects OTO - NOTNLM OT - Bell Palsy OT - COVID-19 OT - Facial nerve diseases OT - SARS-CoV-2 OT - Vaccination COIS- Declarations. Conflict of interest: The authors declare that they have no competing interests. Ethics approval and consent to participate: Not applicable. Consent for publication: Not applicable. EDAT- 2025/01/10 12:24 MHDA- 2025/05/30 01:49 CRDT- 2025/01/10 11:04 PHST- 2024/10/30 00:00 [received] PHST- 2024/12/14 00:00 [accepted] PHST- 2025/05/30 01:49 [medline] PHST- 2025/01/10 12:24 [pubmed] PHST- 2025/01/10 11:04 [entrez] AID - 10.1007/s00405-024-09173-z [pii] AID - 10.1007/s00405-024-09173-z [doi] PST - ppublish SO - Eur Arch Otorhinolaryngol. 2025 Jun;282(6):2787-2797. doi: 10.1007/s00405-024-09173-z. Epub 2025 Jan 10. PMID- 39787799 OWN - NLM STAT- MEDLINE DCOM- 20250430 LR - 20250905 IS - 1873-2518 (Electronic) IS - 0264-410X (Linking) VI - 47 DP - 2025 Feb 15 TI - Post-COVID symptoms after SARS-CoV-2 omicron infection and the effect of booster vaccination: A population-based cohort study. PG - 126664 LID - S0264-410X(24)01346-X [pii] LID - 10.1016/j.vaccine.2024.126664 [doi] AB - BACKGROUND: The impact of vaccination on the type and risk of specific post-COVID symptoms after Omicron infection is not clear. We aimed to investigate the excess risk and patterns of 22 symptoms 3-5 months after Omicron infection, comparing uninfected and infected subjects with and without recent booster vaccination. METHODS: We conducted a population-based prospective study based on four questionnaire-based cohorts linked to national health registries. Our study includes female and male participants aged 11-80 years from The Norwegian Mother, Father, and Child Cohort Study, The Norwegian Influenza Pregnancy Cohort, The Senior Cohort, and The Young Adult Cohort. All participants registered presence of 22 COVID-related symptoms irrespective of infection and vaccination status. RESULTS: The study sample includes more than 31,000 uninfected and 26,000 Omicron infected subjects. Among infected subjects, 12 % were vaccinated with two doses >130 days before the primary infection (median 154 days) but had not received a third dose, while 76 % had received a third (booster) dose (median 40 days before infection). Among those with two doses only, the excess risk for new symptoms after infection (vs. no infection) were up to 15 % for women and 9 % for men. Among infected subjects with recent booster dose, the corresponding excess risks were 7 % among women and up to 5 % among men. The largest risk differences after recent booster vaccination were seen for poor memory, brain fog, and fatigue. Post-COVID symptoms were more often detected among young and middle-aged adults than among adolescents and older age groups. CONCLUSION: Recent booster vaccination before infection substantially reduced both neurocognitive and cardiorespiratory symptoms occurring at least 3 months after Omicron infection. CI - Copyright (c) 2025 The Authors. Published by Elsevier Ltd.. All rights reserved. FAU - Caspersen, Ida Henriette AU - Caspersen IH AD - Centre for Fertility and Health, Norwegian Institute of Public Health, Oslo, Norway. Electronic address: ida.henriette.caspersen@fhi.no. FAU - Skodvin, Siri N AU - Skodvin SN AD - Centre for Fertility and Health, Norwegian Institute of Public Health, Oslo, Norway. FAU - Blix, Kristine AU - Blix K AD - Department of Method Development and Analysis, Norwegian Institute of Public Health, Oslo, Norway. FAU - Robertson, Anna Hayman AU - Robertson AH AD - Department of Method Development and Analysis, Norwegian Institute of Public Health, Oslo, Norway. FAU - Laake, Ida AU - Laake I AD - Department of Method Development and Analysis, Norwegian Institute of Public Health, Oslo, Norway. FAU - Feiring, Berit AU - Feiring B AD - Department of Method Development and Analysis, Norwegian Institute of Public Health, Oslo, Norway. FAU - Magnus, Per AU - Magnus P AD - Centre for Fertility and Health, Norwegian Institute of Public Health, Oslo, Norway. FAU - Mjaaland, Siri AU - Mjaaland S AD - Department of Method Development and Analysis, Norwegian Institute of Public Health, Oslo, Norway. FAU - Trogstad, Lill AU - Trogstad L AD - Department of Method Development and Analysis, Norwegian Institute of Public Health, Oslo, Norway. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20250108 PL - Netherlands TA - Vaccine JT - Vaccine JID - 8406899 RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - Female MH - Male MH - Middle Aged MH - Adult MH - *Immunization, Secondary MH - Adolescent MH - Aged MH - *COVID-19/prevention & control/epidemiology/immunology/complications MH - Child MH - Young Adult MH - Aged, 80 and over MH - Prospective Studies MH - *COVID-19 Vaccines/administration & dosage/immunology MH - *SARS-CoV-2/immunology MH - Norway/epidemiology MH - Vaccination OTO - NOTNLM OT - COVID-19 OT - MoBa OT - Post-acute sequelae OT - SARS-CoV-2 OT - The Norwegian Mother, Father and Child Cohort Study COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2025/01/10 00:21 MHDA- 2025/01/31 00:21 CRDT- 2025/01/09 18:06 PHST- 2024/09/06 00:00 [received] PHST- 2024/12/19 00:00 [revised] PHST- 2024/12/19 00:00 [accepted] PHST- 2025/01/31 00:21 [medline] PHST- 2025/01/10 00:21 [pubmed] PHST- 2025/01/09 18:06 [entrez] AID - S0264-410X(24)01346-X [pii] AID - 10.1016/j.vaccine.2024.126664 [doi] PST - ppublish SO - Vaccine. 2025 Feb 15;47:126664. doi: 10.1016/j.vaccine.2024.126664. Epub 2025 Jan 8. PMID- 39777257 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20260925 IS - 2632-1297 (Electronic) IS - 2632-1297 (Linking) VI - 7 IP - 1 DP - 2025 TI - Vaccination prior to SARS-CoV-2 infection does not affect the neurologic manifestations of long COVID. PG - fcae448 LID - 10.1093/braincomms/fcae448 [doi] LID - fcae448 AB - Persistent symptoms after COVID-19 constitute the long COVID syndrome, also called post-acute sequelae of SARS-CoV-2 infection (PASC). COVID-19 vaccines reduce the gravity of ensuing SARS-CoV-2 infections. However, whether vaccines also have an impact on PASC remain unknown. We investigated whether vaccination prior to infection alters the subsequent neurologic post-acute sequelae of SARS-CoV-2 infection (Neuro-PASC). We studied prospectively the first consecutive 200 post-hospitalization Neuro-PASC (PNP) and 1100 non-hospitalized Neuro-PASC (NNP) patients evaluated at our neuro-COVID-19 clinic between May 2020 and January 2023. Among PNP patients, 87% had a pre-vaccination infection and 13% had a breakthrough infection post-vaccination. Among the NNP patients, 70.7% had a pre-vaccination infection and 29.3% had a breakthrough infection. Both PNP and NNP breakthrough infection patients had more frequent pre-existing depression/anxiety than their respective pre-vaccination infection groups, and NNP breakthrough infection patients also had more frequent comorbidities of headache, lung and gastrointestinal diseases than the NNP pre-vaccination infection group. An average of 10 months after symptom onset, the three most common neurological symptoms for PNP patients were brain fog (86.5%), numbness/tingling (56.5%) and headache (56.5%). Of all Neuro-PASC symptoms, PNP breakthrough infection more frequently reported anosmia compared to PNP pre-vaccination infection patients (69.2 versus 37.9%; P = 0.005). For NNP patients, the three most common neurological symptoms were brain fog (83.9%), headache (70.9%) and dizziness (53.8%). NNP pre-vaccination infection reported anosmia (56.6 versus 39.1%; P < 0.0001) and dysgeusia (53.3 versus 37.3%; P < 0.0001) more frequently than breakthrough infection patients. NNP breakthrough infection more frequently reported dizziness compared to NNP pre-vaccination infection patients (61.5 versus 50.6%; P = 0.001). Both PNP and NNP patients had impaired quality-of-life in cognitive, fatigue, sleep, anxiety and depression domains with no differences between pre-vaccination infection and breakthrough infection groups. PNP patients performed worse on National Institutes of Health Toolbox tests of processing speed, attention, executive function and working memory than a US normative population whereas NNP patients had lower results in processing, speed, attention and working memory, without differences between pre-vaccination infection and breakthrough infection groups. These results indicate that vaccination prior to SARS-CoV-2 infection does not affect the neurologic manifestations of long COVID in either PNP or NNP patients. Minor differences in neurologic symptoms between pre-vaccination infection and breakthrough infection groups may be caused by SARS-CoV-2 strains evolution. Patients developing Neuro-PASC after breakthrough infection have a higher burden of comorbidities, highlighting different risk factors warranting targeted management. CI - (c) The Author(s) 2025. Published by Oxford University Press on behalf of the Guarantors of Brain. FAU - Mukherjee, Shreya AU - Mukherjee S AD - Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA. FAU - Singer, Tracey AU - Singer T AD - Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA. FAU - Venkatesh, Aditi AU - Venkatesh A AD - Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA. FAU - Choudhury, Natasha A AU - Choudhury NA AD - Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA. FAU - Perez Giraldo, Gina S AU - Perez Giraldo GS AD - Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA. FAU - Jimenez, Millenia AU - Jimenez M AD - Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA. FAU - Miller, Janet AU - Miller J AD - Northwestern Medicine, Chicago, IL 60611, USA. FAU - Lopez, Melissa AU - Lopez M AD - Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA. FAU - Hanson, Barbara A AU - Hanson BA AD - Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA. FAU - Bawa, Aasheeta P AU - Bawa AP AD - Northwestern Medicine, Chicago, IL 60611, USA. FAU - Batra, Ayush AU - Batra A AUID- ORCID: 0000-0002-4783-5801 AD - Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA. FAU - Liotta, Eric M AU - Liotta EM AUID- ORCID: 0000-0003-3182-585X AD - Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA. FAU - Koralnik, Igor J AU - Koralnik IJ AUID- ORCID: 0000-0001-6836-1468 AD - Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA. LA - eng GR - K23 AG078705/AG/NIA NIH HHS/United States GR - R21 AG086751/AG/NIA NIH HHS/United States PT - Journal Article DEP - 20250107 PL - England TA - Brain Commun JT - Brain communications JID - 101755125 PMC - PMC11703551 OTO - NOTNLM OT - COVID-19 OT - SARS-CoV-2 infection OT - long COVID OT - neurology OT - post-acute sequelae of SARS-CoV-2 infection COIS- The authors report no competing interests. EDAT- 2025/01/09 00:23 MHDA- 2025/01/09 00:24 PMCR- 2025/01/07 CRDT- 2025/01/08 18:04 PHST- 2024/07/29 00:00 [received] PHST- 2024/11/18 00:00 [revised] PHST- 2024/12/09 00:00 [accepted] PHST- 2025/01/09 00:24 [medline] PHST- 2025/01/09 00:23 [pubmed] PHST- 2025/01/08 18:04 [entrez] PHST- 2025/01/07 00:00 [pmc-release] AID - fcae448 [pii] AID - 10.1093/braincomms/fcae448 [doi] PST - epublish SO - Brain Commun. 2025 Jan 7;7(1):fcae448. doi: 10.1093/braincomms/fcae448. eCollection 2025. PMID- 39767429 OWN - NLM STAT- MEDLINE DCOM- 20250129 LR - 20260728 IS - 1660-4601 (Electronic) IS - 1661-7827 (Print) IS - 1660-4601 (Linking) VI - 21 IP - 12 DP - 2024 Nov 28 TI - Barriers and Facilitators to Vaccine Equity Amidst the COVID-19 Vaccine Rollout in the United States. LID - 10.3390/ijerph21121588 [doi] LID - 1588 AB - State and local health departments were responsible for ensuring equitable distribution of the COVID-19 vaccine. This qualitative study aimed to identify the challenges, strategies, disappointments, and successes in achieving equity for hard-to-reach and at-risk populations. Using a purposive sampling strategy, 16 individuals affiliated with health departments across nine states, each holding leadership roles in vaccine distribution, were interviewed between late 2021 and mid-2022. The key factors promoting vaccine equity included (1) inviting community members to serve on vaccine advisory groups to participate in decision-making; (2) utilizing pre-existing community relationships and spaces to facilitate the planning and distribution of the vaccine; and (3) establishing and building upon community outreach to support accessibility and uptake of the vaccine. The barriers included (1) a lack of clarity on vaccine prioritization criteria; (2) language/communication access; and (3) the initial focus on mass vaccination sites for vaccine delivery. The stakeholders also highlighted potential facilitators for increasing equity in future vaccine rollouts. Overall, community engagement emerged as a critical factor in ensuring equity during disaster response efforts. FAU - Piltch-Loeb, Rachael AU - Piltch-Loeb R AD - Institute for Implementation Science in Population Health (ISPH), City University of New York (CUNY), New York City, NY 10027, USA. AD - Department of Environmental, Occupational, Geospatial Health Sciences, City University of New York (CUNY), New York City, NY 10027, USA. FAU - Nunez Sahr, Josefina AU - Nunez Sahr J AUID- ORCID: 0009-0005-1459-836X AD - Institute for Implementation Science in Population Health (ISPH), City University of New York (CUNY), New York City, NY 10027, USA. FAU - Nelson, LaRon E AU - Nelson LE AD - Yale School of Nursing, New Haven, CT 06477, USA. AD - Justice, Community Capacity & Equity (JuCCE) Core, Center for Interdisciplinary Research on AIDS, Yale School of Public Health, New Haven, CT 06510, USA. FAU - Vlahov, David AU - Vlahov D AD - Yale School of Nursing, New Haven, CT 06477, USA. FAU - Gershon, Robyn R AU - Gershon RR AD - Department of Epidemiology, New York University School of Global Public Health, New York City, NY 10003, USA. LA - eng GR - UL1 TR001863/TR/NCATS NIH HHS/United States GR - NA/Science Applications International Corporation (SAIC)/ PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20241128 PL - Switzerland TA - Int J Environ Res Public Health JT - International journal of environmental research and public health JID - 101238455 RN - 0 (COVID-19 Vaccines) SB - IM MH - *COVID-19/epidemiology/prevention & control MH - *COVID-19 Vaccines/administration & dosage/supply & distribution MH - United States/epidemiology MH - Qualitative Research MH - *Health Equity/organization & administration/standards MH - Decision Making, Shared MH - *Community Participation MH - Health Planning/organization & administration/standards MH - Community-Institutional Relations MH - *Healthcare Disparities/organization & administration/standards MH - Centers for Disease Control and Prevention, U.S./organization & administration/standards MH - Health Services Accessibility/organization & administration/standards MH - Humans MH - *Mass Vaccination/organization & administration/standards PMC - PMC11675886 OTO - NOTNLM OT - COVID-19 OT - community engagement OT - healthcare access OT - public health OT - qualitative study OT - vaccine equity COIS- The authors declare no conflicts of interest. EDAT- 2025/01/08 06:21 MHDA- 2025/01/08 06:22 PMCR- 2024/11/28 CRDT- 2025/01/08 01:12 PHST- 2024/09/13 00:00 [received] PHST- 2024/11/14 00:00 [revised] PHST- 2024/11/25 00:00 [accepted] PHST- 2025/01/08 06:22 [medline] PHST- 2025/01/08 06:21 [pubmed] PHST- 2025/01/08 01:12 [entrez] PHST- 2024/11/28 00:00 [pmc-release] AID - ijerph21121588 [pii] AID - ijerph-21-01588 [pii] AID - 10.3390/ijerph21121588 [doi] PST - epublish SO - Int J Environ Res Public Health. 2024 Nov 28;21(12):1588. doi: 10.3390/ijerph21121588. PMID- 39765453 OWN - NLM STAT- MEDLINE DCOM- 20250516 LR - 20250516 IS - 1995-9133 (Electronic) IS - 1684-1182 (Linking) VI - 58 IP - 3 DP - 2025 Jun TI - BNT162b2 mRNA vaccine elicits robust virus-specific antibodies but poor cross-protective CD8(+) memory T cell responses in adolescents with type 1 diabetes. PG - 294-303 LID - S1684-1182(25)00001-5 [pii] LID - 10.1016/j.jmii.2024.12.009 [doi] AB - BACKGROUND: COVID-19 mRNA vaccines have demonstrated 95 % efficacy in the general population. However, their immunogenicity in adolescents with Type 1 Diabetes (T1D), who exhibit weaken immune responses, remains insufficiently explored. METHODS: Longitudinal analysis of innate immune responses following PRR-agonists and BNT162b2 vaccine stimulations, along with S-specific antibody responses, memory T cell recall responses, and RNA-sequencing were assessed in eight T1D adolescents and 16 healthy controls at six different timepoints. RESULTS: After BNT162b2 vaccination, T1D adolescents produced SARS-CoV-2-specific binding and neutralizing antibodies (Nabs) comparable to healthy controls. Lower pre-vaccination blood HbA1c level correlated with higher antibody responses among T1D adolescents. However, they exhibited impaired TLR9-induced B cells and the first vaccine-induced monocyte activation. These differences were supported by transcriptomic analysis, which revealed the impairment in innate immune-related signatures both before and after vaccination. One year post-second vaccination, T1D adolescents demonstrated compromised cross-protection of T cell against BA.1 compared to healthy controls, which correlated with impaired innate immune responses identified in this study. CONCLUSION: This study reveals that while T1D adolescents vaccinated with the BNT162b2 vaccine develop robust S-specific antibodies, their cross-protective T cell responses are suboptimal. CI - Copyright (c) 2025. Published by Elsevier B.V. FAU - Shen, Ching-Fen AU - Shen CF AD - Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, 70101, Taiwan; Department of Pediatrics, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, 70101, Taiwan. FAU - Chang, Pei-De AU - Chang PD AD - Department of Microbiology and Immunology, College of Medicine, National Cheng Kung University, Tainan, 70101, Taiwan. FAU - Chou, Yen-Yin AU - Chou YY AD - Department of Pediatrics, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, 70101, Taiwan. FAU - Wang, Shih-Wei AU - Wang SW AD - Department of Pediatrics, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, 70101, Taiwan. FAU - Pan, Yu-Wen AU - Pan YW AD - Department of Pediatrics, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, 70101, Taiwan. FAU - Chen, Chih-An AU - Chen CA AD - Department of Pediatrics, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, 70101, Taiwan. FAU - Lin, Ching-Wei AU - Lin CW AD - Department of Pediatrics, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, 70101, Taiwan. FAU - Tsai, Bo-Yang AU - Tsai BY AD - Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, 70101, Taiwan. FAU - Tsai, Pei-Jane AU - Tsai PJ AD - Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan, 70101, Taiwan; Department of Medical Laboratory Science and Biotechnology, College of Medicine, National Cheng Kung University, Tainan, 70101, Taiwan. FAU - Liu, Ching-Chuan AU - Liu CC AD - Department of Pediatrics, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, 70101, Taiwan; Center of Infectious Disease and Signaling Research, National Cheng Kung University, Tainan, 70101, Taiwan. FAU - Cheng, Chao-Min AU - Cheng CM AD - Institute of Biomedical Engineering, National Tsing Hua University, Hsinchu, 30013, Taiwan. FAU - Ko, Wen-Chien AU - Ko WC AD - Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, 70101, Taiwan. FAU - Shieh, Chi-Chang AU - Shieh CC AD - Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, 70101, Taiwan; Department of Pediatrics, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, 70101, Taiwan. Electronic address: cshieh@mail.ncku.edu.tw. CN - Taiwan Pediatric Infectious Disease Alliance (TPIDA) LA - eng PT - Journal Article DEP - 20250103 PL - England TA - J Microbiol Immunol Infect JT - Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi JID - 100956211 RN - 0 (BNT162 Vaccine) RN - 0 (Antibodies, Viral) RN - 0 (Antibodies, Neutralizing) RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - Adolescent MH - *Diabetes Mellitus, Type 1/immunology MH - BNT162 Vaccine/immunology MH - *Antibodies, Viral/immunology/blood MH - *CD8-Positive T-Lymphocytes/immunology MH - Male MH - Female MH - *COVID-19/prevention & control/immunology MH - Antibodies, Neutralizing/immunology/blood MH - *SARS-CoV-2/immunology MH - *Memory T Cells/immunology MH - *COVID-19 Vaccines/immunology/administration & dosage MH - Immunity, Innate MH - B-Lymphocytes/immunology MH - Longitudinal Studies MH - Immunologic Memory MH - Child OTO - NOTNLM OT - Adolescents OT - BNT162b2 vaccine OT - Innate immune response OT - T cell responses OT - Type 1 diabetes COIS- Declaration of competing interest The authors declare no conflicts of interest. EDAT- 2025/01/08 00:19 MHDA- 2025/05/16 11:43 CRDT- 2025/01/07 21:56 PHST- 2024/07/23 00:00 [received] PHST- 2024/11/27 00:00 [revised] PHST- 2024/12/31 00:00 [accepted] PHST- 2025/05/16 11:43 [medline] PHST- 2025/01/08 00:19 [pubmed] PHST- 2025/01/07 21:56 [entrez] AID - S1684-1182(25)00001-5 [pii] AID - 10.1016/j.jmii.2024.12.009 [doi] PST - ppublish SO - J Microbiol Immunol Infect. 2025 Jun;58(3):294-303. doi: 10.1016/j.jmii.2024.12.009. Epub 2025 Jan 3. PMID- 39742263 OWN - NLM STAT- MEDLINE DCOM- 20250101 LR - 20260717 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 15 DP - 2024 TI - Reduced durability of hybrid immunity to SARS-CoV-2 in immunocompromised children. PG - 1502598 LID - 10.3389/fimmu.2024.1502598 [doi] LID - 1502598 AB - BACKGROUND: In endemic COVID-19, immunocompromised children are vulnerable until vaccinated but the optimal primary vaccination regime and need for booster doses remains uncertain. METHODS: We recruited 19 immunocompromised children (post-solid organ transplantation, have autoimmune disease or were on current or recent chemotherapy for acute lymphoblastic leukemia), and followed them from the start of primary vaccination with BNT162b2 mRNA SARS-CoV-2 until 1-year post-vaccination. We investigated the quality of vaccine immunogenicity, and longevity of hybrid immunity, in comparison to healthy children. RESULTS: Immunocompromised children failed to produce T cell and memory B cell (MBC) responses reaching thresholds of protection after 2 doses; a third dose however improved both responses. Initially robust hybrid immunity demonstrated significantly more decline in T cell and MBC responses in immunocompromised compared to healthy children, to levels below the protective threshold by month 12. DISCUSSION: Immunocompromised children may benefit from a 3-dose primary vaccination regime, with yearly or twice-yearly booster doses for sustained immunity. CI - Copyright (c) 2024 Zhong, Kottaiswamy, Ang, Li, Yap, Tay, Osman, Roslan, Tan, Yap, Ang, Chan Ng, Yap, Lu, Aw, Karthik, Quak, Quah, Tham, Shek and Ooi. FAU - Zhong, Youjia AU - Zhong Y AD - Department of Pediatrics, Yong Loo Lin School of Medicine, National University of Singapore (NUS), Singapore, Singapore. AD - Program of Emerging Infectious Diseases, Duke-NUS Medical School, Singapore, Singapore. AD - Khoo Teck Puat-National University Children's Medical Institute, National University Health System, Singapore, Singapore. FAU - Kottaiswamy, Amuthavalli AU - Kottaiswamy A AD - Department of Pediatrics, Yong Loo Lin School of Medicine, National University of Singapore (NUS), Singapore, Singapore. FAU - Ang, Chen Xiang AU - Ang CX AD - Khoo Teck Puat-National University Children's Medical Institute, National University Health System, Singapore, Singapore. FAU - Li, Hui' En AU - Li HE AD - Department of Pediatrics, Yong Loo Lin School of Medicine, National University of Singapore (NUS), Singapore, Singapore. FAU - Yap, Gaik Chin AU - Yap GC AD - Department of Pediatrics, Yong Loo Lin School of Medicine, National University of Singapore (NUS), Singapore, Singapore. FAU - Tay, Carina J X AU - Tay CJX AD - Department of Pediatrics, Yong Loo Lin School of Medicine, National University of Singapore (NUS), Singapore, Singapore. FAU - Osman, Nurul Elyana AU - Osman NE AD - Department of Pediatrics, Yong Loo Lin School of Medicine, National University of Singapore (NUS), Singapore, Singapore. FAU - Roslan, Siti Namirah Binte AU - Roslan SNB AD - Department of Pediatrics, Yong Loo Lin School of Medicine, National University of Singapore (NUS), Singapore, Singapore. FAU - Tan, Chee Wah AU - Tan CW AD - Infectious Diseases Translational Research Program, Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, NUS, Singapore, Singapore. FAU - Yap, Wee Chee AU - Yap WC AD - Infectious Diseases Translational Research Program, Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, NUS, Singapore, Singapore. FAU - Ang, Elizabeth Y AU - Ang EY AD - Khoo Teck Puat-National University Children's Medical Institute, National University Health System, Singapore, Singapore. FAU - Chan Ng, Pauline P L AU - Chan Ng PPL AD - Department of Pediatrics, Yong Loo Lin School of Medicine, National University of Singapore (NUS), Singapore, Singapore. AD - Khoo Teck Puat-National University Children's Medical Institute, National University Health System, Singapore, Singapore. FAU - Yap, Hui Kim AU - Yap HK AD - Department of Pediatrics, Yong Loo Lin School of Medicine, National University of Singapore (NUS), Singapore, Singapore. AD - Khoo Teck Puat-National University Children's Medical Institute, National University Health System, Singapore, Singapore. FAU - Lu, Liangjian AU - Lu L AD - Khoo Teck Puat-National University Children's Medical Institute, National University Health System, Singapore, Singapore. FAU - Aw, Marion M AU - Aw MM AD - Department of Pediatrics, Yong Loo Lin School of Medicine, National University of Singapore (NUS), Singapore, Singapore. AD - Khoo Teck Puat-National University Children's Medical Institute, National University Health System, Singapore, Singapore. FAU - Karthik, Sivaraman V AU - Karthik SV AD - Khoo Teck Puat-National University Children's Medical Institute, National University Health System, Singapore, Singapore. FAU - Quak, Seng Hock AU - Quak SH AD - Khoo Teck Puat-National University Children's Medical Institute, National University Health System, Singapore, Singapore. FAU - Quah, Thuan Chong AU - Quah TC AD - Khoo Teck Puat-National University Children's Medical Institute, National University Health System, Singapore, Singapore. FAU - Tham, Elizabeth H AU - Tham EH AD - Department of Pediatrics, Yong Loo Lin School of Medicine, National University of Singapore (NUS), Singapore, Singapore. AD - Khoo Teck Puat-National University Children's Medical Institute, National University Health System, Singapore, Singapore. FAU - Shek, Lynette P AU - Shek LP AD - Department of Pediatrics, Yong Loo Lin School of Medicine, National University of Singapore (NUS), Singapore, Singapore. AD - Khoo Teck Puat-National University Children's Medical Institute, National University Health System, Singapore, Singapore. FAU - Ooi, Eng Eong AU - Ooi EE AD - Program of Emerging Infectious Diseases, Duke-NUS Medical School, Singapore, Singapore. AD - Viral Research and Experimental Medicine Center, SingHealth Duke-NUS Academic Medical Center, Singapore, Singapore. AD - Department of Clinical Translational Research, Singapore General Hospital, Singapore, Singapore. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20241217 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 RN - 0 (BNT162 Vaccine) RN - 0 (Antibodies, Viral) RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - *Immunocompromised Host MH - *COVID-19/immunology/prevention & control MH - Child MH - *SARS-CoV-2/immunology MH - Male MH - Female MH - Child, Preschool MH - *BNT162 Vaccine/immunology/administration & dosage MH - Adolescent MH - Antibodies, Viral/immunology/blood MH - Memory B Cells/immunology MH - Immunogenicity, Vaccine MH - Vaccination MH - COVID-19 Vaccines/immunology MH - T-Lymphocytes/immunology PMC - PMC11685208 OTO - NOTNLM OT - COVID-19 OT - T cells OT - adaptive immunity OT - correlates of protection OT - memory B cells OT - vaccine durability OT - vaccine immunogenicity COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2025/01/01 21:24 MHDA- 2025/01/01 21:25 PMCR- 2024/01/01 CRDT- 2025/01/01 04:37 PHST- 2024/09/27 00:00 [received] PHST- 2024/11/29 00:00 [accepted] PHST- 2025/01/01 21:25 [medline] PHST- 2025/01/01 21:24 [pubmed] PHST- 2025/01/01 04:37 [entrez] PHST- 2024/01/01 00:00 [pmc-release] AID - 10.3389/fimmu.2024.1502598 [doi] PST - epublish SO - Front Immunol. 2024 Dec 17;15:1502598. doi: 10.3389/fimmu.2024.1502598. eCollection 2024. PMID- 39740385 OWN - NLM STAT- MEDLINE DCOM- 20250429 LR - 20250905 IS - 1873-2518 (Electronic) IS - 0264-410X (Linking) VI - 46 DP - 2025 Feb 6 TI - Mucosal vaccination against SARS-CoV-2 using recombinant influenza viruses delivering self-assembling nanoparticles. PG - 126668 LID - S0264-410X(24)01350-1 [pii] LID - 10.1016/j.vaccine.2024.126668 [doi] AB - Recombinant influenza viruses are promising vectors that can bolster antibody and resident lymphocyte responses within mucosal sites. This study evaluates recombinant influenza viruses with SARS-CoV-2 RBD genes in eliciting mucosal and systemic responses. Using reverse genetics, we generated replication-competent recombinant influenza viruses carrying heterologous RBD genes in monomeric, trimeric, or ferritin-based nanoparticle forms. Following intranasal immunisation, mice developed potent serological anti-RBD responses, with ferritin nanoparticles superseding monomeric or trimeric RBD responses. While parenteral and mucosal immunisation elicited robust anti-RBD IgG in serum, mucosal immunisation seeded respiratory IgA, RBD-specific lung-resident memory and germinal centre (GC) B cells. In animals with prior intramuscular vaccination, intranasal boosting with recombinant influenza vectors augmented mucosal IgG, IgA, GC and memory B cells, and SARS-CoV-2 lung neutralising titres. Recall of RBD-specific memory B cells via antigen re-exposure in the lung increased antibody-secreting cells in the lung-draining lymph nodes, with maintenance of lung GC B cells. Recombinant influenza-based vaccines effectively deliver highly immunogenic self-assembling nanoparticles, generating antibodies and B cells in the respiratory mucosa. This strategy provides a tractable pathway to augment lung-localised responses against recurrent respiratory viral infections. CI - Copyright (c) 2024 The Authors. Published by Elsevier Ltd.. All rights reserved. FAU - Pilapitiya, Devaki AU - Pilapitiya D AD - Department of Microbiology and Immunology, University of Melbourne, at The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria 3000, Australia. FAU - Lee, Wen Shi AU - Lee WS AD - Department of Microbiology and Immunology, University of Melbourne, at The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria 3000, Australia. FAU - Vu, Mai N AU - Vu MN AD - Department of Microbiology and Immunology, University of Melbourne, at The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria 3000, Australia. FAU - Kelly, Andrew AU - Kelly A AD - Department of Microbiology and Immunology, University of Melbourne, at The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria 3000, Australia. FAU - Webster, Rosela H AU - Webster RH AD - Department of Microbiology and Immunology, University of Melbourne, at The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria 3000, Australia. FAU - Koutsakos, Marios AU - Koutsakos M AD - Department of Microbiology and Immunology, University of Melbourne, at The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria 3000, Australia. FAU - Kent, Stephen J AU - Kent SJ AD - Department of Microbiology and Immunology, University of Melbourne, at The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria 3000, Australia; Melbourne Sexual Health Centre and Department of Infectious Diseases, Alfred Hospital and Central Clinical School, Monash University, Melbourne, Victoria, Australia. FAU - Juno, Jennifer A AU - Juno JA AD - Department of Microbiology and Immunology, University of Melbourne, at The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria 3000, Australia. FAU - Tan, Hyon-Xhi AU - Tan HX AD - Department of Microbiology and Immunology, University of Melbourne, at The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria 3000, Australia. Electronic address: hxtan@unimelb.edu.au. FAU - Wheatley, Adam K AU - Wheatley AK AD - Department of Microbiology and Immunology, University of Melbourne, at The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria 3000, Australia. Electronic address: a.wheatley@unimelb.edu.au. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20241230 PL - Netherlands TA - Vaccine JT - Vaccine JID - 8406899 RN - 0 (Antibodies, Viral) RN - 0 (COVID-19 Vaccines) RN - 0 (Influenza Vaccines) RN - 0 (Immunoglobulin G) RN - 0 (Vaccines, Synthetic) RN - 0 (Antibodies, Neutralizing) RN - 0 (Immunoglobulin A) RN - 0 (Spike Glycoprotein, Coronavirus) SB - IM MH - Animals MH - *Nanoparticles/administration & dosage/chemistry MH - *SARS-CoV-2/immunology MH - *COVID-19/prevention & control/immunology MH - Antibodies, Viral/immunology/blood MH - Mice MH - *COVID-19 Vaccines/immunology/administration & dosage MH - *Influenza Vaccines/immunology/administration & dosage MH - Female MH - Administration, Intranasal MH - Immunity, Mucosal MH - Immunoglobulin G/immunology MH - Vaccines, Synthetic/immunology/administration & dosage MH - Mice, Inbred BALB C MH - Antibodies, Neutralizing/immunology MH - Immunoglobulin A/immunology MH - Spike Glycoprotein, Coronavirus/immunology/genetics MH - Vaccination/methods MH - Lung/immunology MH - B-Lymphocytes/immunology MH - Humans MH - Orthomyxoviridae/genetics/immunology OTO - NOTNLM OT - COVID-19 vaccines OT - Germinal centres OT - Memory B cells OT - Mucosal immunisation OT - Nanoparticle vaccines OT - Neutralising antibodies OT - Recombinant influenza viruses OT - Respiratory viral infections COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2025/01/01 12:42 MHDA- 2025/01/21 09:00 CRDT- 2024/12/31 18:05 PHST- 2024/08/30 00:00 [received] PHST- 2024/11/07 00:00 [revised] PHST- 2024/12/21 00:00 [accepted] PHST- 2025/01/21 09:00 [medline] PHST- 2025/01/01 12:42 [pubmed] PHST- 2024/12/31 18:05 [entrez] AID - S0264-410X(24)01350-1 [pii] AID - 10.1016/j.vaccine.2024.126668 [doi] PST - ppublish SO - Vaccine. 2025 Feb 6;46:126668. doi: 10.1016/j.vaccine.2024.126668. Epub 2024 Dec 30. PMID- 39717779 OWN - NLM STAT- MEDLINE DCOM- 20241224 LR - 20260803 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 15 DP - 2024 TI - Booster COVID-19 mRNA vaccination ameliorates impaired B-cell but not T-cell responses in older adults. PG - 1455334 LID - 10.3389/fimmu.2024.1455334 [doi] LID - 1455334 AB - Age-associated differences in the effect of repetitive vaccination, particularly on memory T-cell and B-cell responses, remain unclear. While older adults (aged >/=65 years) exhibited enhanced IgG responses following COVID-19 mRNA booster vaccination, they produced fewer spike-specific circulating follicular helper T cells-1 than younger adults. Similarly, the cytotoxic CD8(+) T-cell response remained diminished with reduced PD-1 expression even after booster vaccination compared with that in younger adults, suggesting impaired memory T-cell activation in older adults. In contrast, although B-cell responses in older adults were weaker than those in younger adults in the primary response, the responses were significantly enhanced upon booster vaccination, reaching levels comparable with that observed in younger adults. Therefore, while booster vaccination ameliorates impaired humoral immunity in older adults by efficiently stimulating memory B-cell responses, it may less effectively enhance T-cell-mediated cellular immunity. Our study provides insights for the development of effective therapeutic and vaccine strategies for the most vulnerable older population. CI - Copyright (c) 2024 Kometani, Yorimitsu, Jo, Yamaguchi, Kikuchi, Fukahori, Sawada, Tsujimoto, Sunami, Li, Ito, Pretemer, Gao, Hidaka, Yamamoto, Kaku, Nakagama, Kido, Grifoni, Sette, Nagao, Morita, Nakajima, Muto and Hamazaki. FAU - Kometani, Kohei AU - Kometani K AD - Department of Life Science Frontiers, Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan. FAU - Yorimitsu, Takaaki AU - Yorimitsu T AD - Department of Life Science Frontiers, Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan. AD - Department of Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan. FAU - Jo, Norihide AU - Jo N AD - Department of Life Science Frontiers, Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan. AD - Alliance Laboratory for Advanced Medical Research, Graduate School of Medicine, Kyoto University, Kyoto, Japan. FAU - Yamaguchi, Erina AU - Yamaguchi E AD - Department of Life Science Frontiers, Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan. FAU - Kikuchi, Osamu AU - Kikuchi O AD - Department of Medical Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan. AD - Clinical Bio-Resource Center, Kyoto University Hospital, Kyoto, Japan. AD - Center for Cancer Immunotherapy and Immunobiology, Kyoto University, Kyoto, Japan. FAU - Fukahori, Masaru AU - Fukahori M AD - Department of Early Clinical Development, Graduate School of Medicine, Kyoto University, Kyoto, Japan. AD - Kyoto Innovation Center for Next Generation Clinical Trials and iPS Cell Therapy (Ki-CONNECT), Kyoto University Hospital, Kyoto, Japan. FAU - Sawada, Takeshi AU - Sawada T AD - Department of Early Clinical Development, Graduate School of Medicine, Kyoto University, Kyoto, Japan. AD - Kyoto Innovation Center for Next Generation Clinical Trials and iPS Cell Therapy (Ki-CONNECT), Kyoto University Hospital, Kyoto, Japan. FAU - Tsujimoto, Yoshitaka AU - Tsujimoto Y AD - Department of Life Science Frontiers, Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan. AD - Department of Neurosurgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan. FAU - Sunami, Ayana AU - Sunami A AD - Department of Life Science Frontiers, Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan. AD - Laboratory of Immunobiology, Graduate School of Medicine, Kyoto University, Kyoto, Japan. FAU - Li, Mengqian AU - Li M AD - Department of Life Science Frontiers, Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan. FAU - Ito, Takeshi AU - Ito T AD - Department of Life Science Frontiers, Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan. FAU - Pretemer, Yann AU - Pretemer Y AD - Department of Life Science Frontiers, Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan. FAU - Gao, Yuxian AU - Gao Y AD - Department of Life Science Frontiers, Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan. AD - Laboratory of Immunobiology, Graduate School of Medicine, Kyoto University, Kyoto, Japan. FAU - Hidaka, Yu AU - Hidaka Y AD - Department of Biomedical Statistics and Bioinformatics, Graduate School of Medicine, Kyoto University, Kyoto, Japan. FAU - Yamamoto, Masaki AU - Yamamoto M AD - Department of Clinical Laboratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan. FAU - Kaku, Natsuko AU - Kaku N AD - Department of Virology and Parasitology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan. AD - Osaka International Research Center for Infectious Diseases, Osaka Metropolitan University, Osaka, Japan. FAU - Nakagama, Yu AU - Nakagama Y AD - Department of Virology and Parasitology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan. AD - Osaka International Research Center for Infectious Diseases, Osaka Metropolitan University, Osaka, Japan. FAU - Kido, Yasutoshi AU - Kido Y AD - Department of Virology and Parasitology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan. AD - Osaka International Research Center for Infectious Diseases, Osaka Metropolitan University, Osaka, Japan. FAU - Grifoni, Alba AU - Grifoni A AD - Center for Vaccine Innovation, La Jolla Institute for Immunology (LJI), La Jolla, CA, United States. FAU - Sette, Alessandro AU - Sette A AD - Center for Vaccine Innovation, La Jolla Institute for Immunology (LJI), La Jolla, CA, United States. AD - Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego (UCSD), La Jolla, United States. FAU - Nagao, Miki AU - Nagao M AD - Department of Clinical Laboratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan. FAU - Morita, Satoshi AU - Morita S AD - Department of Biomedical Statistics and Bioinformatics, Graduate School of Medicine, Kyoto University, Kyoto, Japan. FAU - Nakajima, Takako E AU - Nakajima TE AD - Department of Early Clinical Development, Graduate School of Medicine, Kyoto University, Kyoto, Japan. AD - Kyoto Innovation Center for Next Generation Clinical Trials and iPS Cell Therapy (Ki-CONNECT), Kyoto University Hospital, Kyoto, Japan. FAU - Muto, Manabu AU - Muto M AD - Department of Medical Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan. AD - Clinical Bio-Resource Center, Kyoto University Hospital, Kyoto, Japan. AD - Kyoto Innovation Center for Next Generation Clinical Trials and iPS Cell Therapy (Ki-CONNECT), Kyoto University Hospital, Kyoto, Japan. FAU - Hamazaki, Yoko AU - Hamazaki Y AD - Department of Life Science Frontiers, Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan. AD - Laboratory of Immunobiology, Graduate School of Medicine, Kyoto University, Kyoto, Japan. AD - Kyoto University Immunomonitoring Center, Kyoto, Japan. LA - eng GR - 75N93021C00016/AI/NIAID NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20241209 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 RN - 0 (COVID-19 Vaccines) RN - 0 (Antibodies, Viral) RN - 0 (Spike Glycoprotein, Coronavirus) RN - 0 (Immunoglobulin G) RN - 0 (mRNA Vaccines) SB - IM MH - Humans MH - Aged MH - *COVID-19/prevention & control/immunology MH - *SARS-CoV-2/immunology MH - *Immunization, Secondary MH - *COVID-19 Vaccines/immunology MH - Male MH - Female MH - *B-Lymphocytes/immunology MH - Antibodies, Viral/blood/immunology MH - Adult MH - Middle Aged MH - Spike Glycoprotein, Coronavirus/immunology MH - Aged, 80 and over MH - Immunoglobulin G/blood/immunology MH - Immunologic Memory MH - CD8-Positive T-Lymphocytes/immunology MH - Young Adult MH - Immunity, Humoral MH - Memory B Cells/immunology MH - mRNA Vaccines/immunology MH - Age Factors PMC - PMC11663736 OTO - NOTNLM OT - COVID-19 article type: original research article OT - booster vaccination OT - cTfh OT - immune aging OT - immunological memory OT - mRNA vaccine OT - memory B cells OT - memory T cells COIS- AlS is a consultant for Darwin Health, EmerVax, Gilead Sciences, Guggenheim Securities, RiverVest Venture Partners, and Arcturus. LJI has filed for patent protection for various aspects of T cell epitope and vaccine design work. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2024/12/24 11:24 MHDA- 2024/12/24 11:25 PMCR- 2024/01/01 CRDT- 2024/12/24 04:51 PHST- 2024/06/26 00:00 [received] PHST- 2024/11/05 00:00 [accepted] PHST- 2024/12/24 11:25 [medline] PHST- 2024/12/24 11:24 [pubmed] PHST- 2024/12/24 04:51 [entrez] PHST- 2024/01/01 00:00 [pmc-release] AID - 10.3389/fimmu.2024.1455334 [doi] PST - epublish SO - Front Immunol. 2024 Dec 9;15:1455334. doi: 10.3389/fimmu.2024.1455334. eCollection 2024. PMID- 39716551 OWN - NLM STAT- In-Process LR - 20250317 IS - 1469-0691 (Electronic) IS - 1198-743X (Linking) VI - 31 IP - 4 DP - 2025 Apr TI - Re: Neurodevelopmental outcomes of infants after in utero exposure to SARS-CoV-2 or mRNA COVID-19 vaccine compared to unexposed infants by Favre et al. PG - 664-665 LID - S1198-743X(24)00615-3 [pii] LID - 10.1016/j.cmi.2024.12.027 [doi] FAU - Liu, Xiangting AU - Liu X AD - Reproductive Medicine Center, The First People's Hospital of Chenzhou, Xiangnan University, Chenzhou, China. FAU - Wang, Xia AU - Wang X AD - Department of Pharmacy, The First People's Hospital of Chenzhou, Xiangnan University, Chenzhou, China. FAU - Zeng, Guangting AU - Zeng G AD - Department of Pharmacy, The First People's Hospital of Chenzhou, Xiangnan University, Chenzhou, China. Electronic address: 1090651185@qq.com. LA - eng PT - Letter DEP - 20241221 PL - England TA - Clin Microbiol Infect JT - Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases JID - 9516420 SB - IM OTO - NOTNLM OT - Infants OT - Neurodevelopment OT - Neurodevelopment questionnaire OT - SARS-CoV-2 OT - mRNA COVID-19 vaccine EDAT- 2024/12/24 06:20 MHDA- 2024/12/24 06:20 CRDT- 2024/12/24 01:42 PHST- 2024/12/12 00:00 [received] PHST- 2024/12/17 00:00 [accepted] PHST- 2024/12/24 06:20 [pubmed] PHST- 2024/12/24 06:20 [medline] PHST- 2024/12/24 01:42 [entrez] AID - S1198-743X(24)00615-3 [pii] AID - 10.1016/j.cmi.2024.12.027 [doi] PST - ppublish SO - Clin Microbiol Infect. 2025 Apr;31(4):664-665. doi: 10.1016/j.cmi.2024.12.027. Epub 2024 Dec 21. PMID- 39680178 OWN - NLM STAT- MEDLINE DCOM- 20241216 LR - 20261010 IS - 1432-1459 (Electronic) IS - 0340-5354 (Linking) VI - 272 IP - 1 DP - 2024 Dec 16 TI - Antibodies against SARS-CoV-2 spike protein in the cerebrospinal fluid of COVID-19 patients and vaccinated controls: a multicentre study. PG - 60 LID - 10.1007/s00415-024-12769-4 [doi] AB - INTRODUCTION: SARS-CoV-2 antibodies in the cerebrospinal fluid (CSF) of COVID-19 patients possibly reflect blood-cerebrospinal fluid barrier (BCB) disruption due to systemic inflammation. However, some studies indicate that CSF antibodies signal a neurotropic infection. Currently, larger studies are needed to clarify this, and it is unknown if CSF antibodies appear solely after infection or also after COVID-19 vaccination. Therefore, we aimed to investigate the CSF dynamics of SARS-CoV-2 antibodies in a multicenter study of COVID-19 patients and vaccinated controls. METHODS: A cohort study of Danish and Norwegian COVID-19 patients and controls investigated with a lumbar puncture (April 2020-December 2022). Serum and CSF were analysed locally for routine investigations, and centrally at Statens Serum Institut (Danish governmental public health institute) for SARS-CoV-2 IgG antibodies against the spike protein using the Euroimmun (quantitative) and Wantai (qualitative) assays. Primary outcome was the quantity of CSF SARS-CoV-2 antibodies post-COVID versus post-vaccination. Secondary outcomes included regression models examining the relationship between CSF antibodies and serum levels, albumin ratio, CSF pleocytosis, COVID-19 severity, and temporal antibody dynamics. RESULTS: We included 124 individuals (Mean [SD] age 47.2 [16.6]; 59.7% males surviving COVID-19 and controls. Of these, 86 had paired CSF-serum testing. Antibody-index calculations did not support a SARS-CoV-2 brain infection. Multi-variate regression revealed that CSF SARS-CoV-2 antibodies were most strongly influenced by serum antibody levels and BCB permeability, as measured by increasing albumin ratio. CSF antibody levels displayed a dose-response relationship (p < 0.0001) influenced by preceding vaccinations or infections. CSF antibody levels (median [IQR]) were highest among those both previously infected and vaccinated, 100.0 [25.0-174.0], and those vaccinated without prior infection, 85.0 [12.0-142.0], and lowest among previously infected individuals without preceding vaccination, 5.9 [2.7-55.1], (p = 0.003). SARS-CoV-2 antibodies in CSF were also detected via qualitative assays in the COVID-19 (46.8%) and vaccinated (78.6%) groups, p = 0.03. CONCLUSION: SARS-CoV-2 antibodies detected in CSF can be derived following both infection and vaccination for COVID-19. CSF antibody levels increase in a dose-response relationship with the number of prior infections and vaccinations and are most strongly influenced by serum antibody levels and BCB permeability. These findings stress the importance of carefully interpreting CSF antibody results when assessing neurological complications following infections not categorized as neurotropic. CI - (c) 2024. Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Nersesjan, Vardan AU - Nersesjan V AUID- ORCID: 0000-0001-7786-9626 AD - Copenhagen Research Center for Biological and Precision Psychiatry, Mental Health Centre Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark. vardan.nersesjan@regionh.dk. AD - Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. vardan.nersesjan@regionh.dk. FAU - Boldingh, Marion Ingeborg AU - Boldingh MI AD - Department of Neurology, Oslo University Hospital, Oslo, Norway. FAU - Paulsen, Else Quist AU - Paulsen EQ AD - Department of Microbiology, Oslo University Hospital, Oslo, Norway. FAU - Argren, Maria AU - Argren M AD - Department of Neurology, Oslo University Hospital, Oslo, Norway. FAU - Hogestol, Einar AU - Hogestol E AD - Department of Neurology, Oslo University Hospital, Oslo, Norway. AD - Department of Psychology, Oslo University Hospital, Oslo, Norway. AD - Institute of Clinical Medicine, University of Oslo, Oslo, Norway. FAU - Aamodt, Anne Hege AU - Aamodt AH AD - Department of Neurology, Oslo University Hospital, Oslo, Norway. AD - Department of Neuromedicine and Movement Science, The Norwegian University of Science and Technology, Trondheim, Norway. FAU - Popperud, Trine Haug AU - Popperud TH AD - Department of Neurology, Oslo University Hospital, Oslo, Norway. FAU - Kondziella, Daniel AU - Kondziella D AD - Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. AD - Department of Neurology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. FAU - Jorgensen, Charlotte Svaerke AU - Jorgensen CS AD - Department of Virus and Microbiological Special Diagnostics, Statens Serum Institut, Copenhagen, Denmark. FAU - Jensen, Veronika Vorobieva Solholm AU - Jensen VVS AD - Department of Virus and Microbiological Special Diagnostics, Statens Serum Institut, Copenhagen, Denmark. FAU - Benros, Michael E AU - Benros ME AD - Copenhagen Research Center for Biological and Precision Psychiatry, Mental Health Centre Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark. AD - Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. LA - eng GR - R349-2020-658/Lundbeck Foundation/ PT - Journal Article PT - Multicenter Study DEP - 20241216 PL - Germany TA - J Neurol JT - Journal of neurology JID - 0423161 RN - 0 (Antibodies, Viral) RN - 0 (Spike Glycoprotein, Coronavirus) RN - 0 (COVID-19 Vaccines) RN - 0 (spike protein, SARS-CoV-2) RN - 0 (Immunoglobulin G) SB - IM MH - Humans MH - *COVID-19/immunology/cerebrospinal fluid/prevention & control MH - Male MH - Female MH - Middle Aged MH - *Antibodies, Viral/cerebrospinal fluid/blood MH - *Spike Glycoprotein, Coronavirus/immunology MH - *COVID-19 Vaccines/immunology MH - Aged MH - Adult MH - *SARS-CoV-2/immunology MH - Cohort Studies MH - Norway/epidemiology MH - Immunoglobulin G/cerebrospinal fluid/blood MH - Denmark/epidemiology MH - Vaccination OTO - NOTNLM OT - Blood-brain-barrier OT - COVID-19 OT - CSF OT - Encephalitis OT - Vaccination COIS- Declarations. Ethics approval and consent to participate: Written and informed consent was obtained from participants or legal next of kin. Data collection was approved by The Regional Committee on Health Research Ethics (j.no: H-20026602), the Danish Data Protection Agency (j.no: P-2020-497), and the Regional Ethics Committee for Medical Research in South Eastern Norway Health Authority (j.no: 152727 and 351097). Conflicts of interest: None. EDAT- 2024/12/16 12:29 MHDA- 2024/12/16 18:18 CRDT- 2024/12/16 11:23 PHST- 2024/09/09 00:00 [received] PHST- 2024/10/24 00:00 [accepted] PHST- 2024/10/18 00:00 [revised] PHST- 2024/12/16 18:18 [medline] PHST- 2024/12/16 12:29 [pubmed] PHST- 2024/12/16 11:23 [entrez] AID - 10.1007/s00415-024-12769-4 [pii] AID - 10.1007/s00415-024-12769-4 [doi] PST - epublish SO - J Neurol. 2024 Dec 16;272(1):60. doi: 10.1007/s00415-024-12769-4. PMID- 39657038 OWN - NLM STAT- MEDLINE DCOM- 20250427 LR - 20250518 IS - 1537-6591 (Electronic) IS - 1058-4838 (Linking) VI - 80 IP - 3 DP - 2025 Mar 17 TI - Bivalent Boosters and Risk of Postacute Sequelae Following Vaccine-Breakthrough SARS-CoV-2 Omicron Infection: A Cohort Study. PG - 520-528 LID - 10.1093/cid/ciae598 [doi] AB - BACKGROUND: Vaccination has been shown to attenuate the risk of postacute sequelae following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. However, no prior population-based studies have evaluated if updated bivalent boosters reduce risk of postacute sequelae following Omicron variant infection, versus ancestral vaccines. METHODS: National databases were utilized to construct a population-based cohort of adult individuals infected during Omicron-predominant transmission. Risk and excess burden (EB) of prespecified multiorgan new-incident diagnoses at 31-365 days post-SARS-CoV-2 infection were compared between individuals who received prior bivalent boosters and those boosted with ancestral messenger RNA (mRNA) vaccines, using competing-risks regression. RESULTS: A total of 1 080 348 vaccine-breakthrough infections after an ancestral mRNA booster were contrasted against 9824 vaccine-breakthrough infections following a bivalent mRNA booster. There was an estimated 37.8% (hazard ratio [HR], 0.62 [95 confidence interval CI, .53-.73]) decrease in risk and lower overall EB per 1000 (-28.73 [95% CI, -40.47 to -16.99]) of any postacute sequelae, as well as a 39.9% (HR, 0.62 [95% CI, .52-.73]) decrease in risk and lower EB (-22.95 [95% CI, -32.71 to -13.19]) of any postacute neurological sequelae, among individuals who received prior bivalent boosters, versus those boosted with ancestral mRNA vaccines. Specifically, there was reduced risk of thrombotic disorders (HR, 0.54 [95% CI, .29-.99]), episodic neurological disorders (HR, 0.55 [95% CI, .43-.72]), movement disorders (HR, 0.57 [95% CI, .47-.70]), and autoimmune vasculitis (HR, 0.54 [95% CI, .29-.99]) 31-365 days postinfection among those who received prior bivalent boosters, versus those boosted with ancestral mRNA vaccines. CONCLUSIONS: Boosting with updated bivalent mRNA vaccines was associated with greater attenuation of risk for postacute sequelae following Omicron variant infection, compared with ancestral mRNA boosters. CI - (c) The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site-for further information please contact journals.permissions@oup.com. FAU - Wee, Liang En AU - Wee LE AD - National Centre for Infectious Diseases, Singapore, Singapore. AD - Duke-National University of Singapore Graduate Medical School, National University of Singapore, Singapore, Singapore. AD - Department of Infectious Diseases, Singapore General Hospital, Singapore, Singapore. FAU - Lim, Jue Tao AU - Lim JT AUID- ORCID: 0000-0002-2245-0331 AD - National Centre for Infectious Diseases, Singapore, Singapore. AD - Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore. FAU - Goel, Mayank AU - Goel M AD - National Centre for Infectious Diseases, Singapore, Singapore. FAU - Malek, Muhammad Ismail Abdul AU - Malek MIA AD - National Centre for Infectious Diseases, Singapore, Singapore. FAU - Chiew, Calvin J AU - Chiew CJ AUID- ORCID: 0000-0002-8217-7971 AD - National Centre for Infectious Diseases, Singapore, Singapore. AD - Ministry of Health, Singapore, Singapore. FAU - Ong, Benjamin AU - Ong B AD - Ministry of Health, Singapore, Singapore. AD - Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. FAU - Lye, David Chien Boon AU - Lye DCB AD - National Centre for Infectious Diseases, Singapore, Singapore. AD - Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore. AD - Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. AD - Department of Infectious Diseases, Tan Tock Seng Hospital, Singapore, Singapore. FAU - Tan, Kelvin Bryan AU - Tan KB AD - National Centre for Infectious Diseases, Singapore, Singapore. AD - Ministry of Health, Singapore, Singapore. AD - Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore. LA - eng GR - Singhealth Regional Health Systems PULSES Fellowship/ GR - Ministry of Education/ PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Clin Infect Dis JT - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America JID - 9203213 RN - 0 (COVID-19 Vaccines) RN - COVID-19 breakthrough infections RN - SARS-CoV-2 variants SB - IM MH - Humans MH - *COVID-19/prevention & control/complications/epidemiology MH - *COVID-19 Vaccines/immunology/administration & dosage MH - Male MH - Middle Aged MH - Female MH - Adult MH - *SARS-CoV-2/immunology MH - *Immunization, Secondary MH - Cohort Studies MH - Aged MH - Young Adult MH - Breakthrough Infections OTO - NOTNLM OT - COVID-19 OT - Delta OT - Omicron OT - bivalent vaccines OT - multiorgan sequelae COIS- Potential conflicts of interest. The authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. EDAT- 2024/12/15 19:30 MHDA- 2025/03/17 18:30 CRDT- 2024/12/10 15:43 PHST- 2024/08/09 00:00 [received] PHST- 2025/03/17 18:30 [medline] PHST- 2024/12/15 19:30 [pubmed] PHST- 2024/12/10 15:43 [entrez] AID - 7917536 [pii] AID - 10.1093/cid/ciae598 [doi] PST - ppublish SO - Clin Infect Dis. 2025 Mar 17;80(3):520-528. doi: 10.1093/cid/ciae598. PMID- 39667270 OWN - NLM STAT- MEDLINE DCOM- 20250427 LR - 20250518 IS - 2352-3964 (Electronic) IS - 2352-3964 (Linking) VI - 111 DP - 2025 Jan TI - Subunit protein CD40.SARS.CoV2 vaccine induces SARS-CoV-2-specific stem cell-like memory CD8(+) T cells. PG - 105479 LID - S2352-3964(24)00515-2 [pii] LID - 10.1016/j.ebiom.2024.105479 [doi] LID - 105479 AB - BACKGROUND: Ideally, vaccination should induce protective long-lived humoral and cellular immunity. Current licensed COVID-19 mRNA vaccines focused on the spike (S) region induce neutralizing antibodies that rapidly wane. METHODS: Herein, we show that a subunit vaccine (CD40.CoV2) targeting spike and nucleocapsid antigens to CD40-expressing cells elicits broad specific human (hu)Th1 CD4(+) and CD8(+) T cells in humanized mice. FINDINGS: CD40.CoV2 vaccination selectively enriched long-lived spike- and nucleocapsid-specific CD8(+) progenitors with stem-cell-like memory (Tscm) properties, whereas mRNA BNT162b2 induced effector memory CD8(+) T cells. CD8(+) Tscm cells produced IFNgamma and TNF upon antigenic restimulation and showed a high proliferation rate. We demonstrate that CD40 activation is specifically required for the generation of huCD8(+) Tscm cells. INTERPRETATION: These results support the development of a CD40-vaccine platform capable of eliciting long-lasting T-cell immunity. FUNDING: This work was supported by Inserm, Universite Paris-Est Creteil, and the Investissements d'Avenir program, Vaccine Research Institute (VRI), managed by the ANR. CI - Copyright (c) 2024 The Author(s). Published by Elsevier B.V. All rights reserved. FAU - Nguema, Laury AU - Nguema L AD - Vaccine Research Institute, Universite Paris-Est Creteil, Faculte de Medecine, INSERM U955, Team 16, Creteil, France. FAU - Picard, Florence AU - Picard F AD - Vaccine Research Institute, Universite Paris-Est Creteil, Faculte de Medecine, INSERM U955, Team 16, Creteil, France. FAU - El Hajj, Marwa AU - El Hajj M AD - Vaccine Research Institute, Universite Paris-Est Creteil, Faculte de Medecine, INSERM U955, Team 16, Creteil, France. FAU - Dupaty, Lea AU - Dupaty L AD - Vaccine Research Institute, Universite Paris-Est Creteil, Faculte de Medecine, INSERM U955, Team 16, Creteil, France. FAU - Fenwick, Craig AU - Fenwick C AD - Service of Immunology and Allergy Lausanne University Hospital, Swiss Vaccine Research Institute, University Hospital, University of Lausanne, Lausanne, Switzerland. FAU - Cardinaud, Sylvain AU - Cardinaud S AD - Vaccine Research Institute, Universite Paris-Est Creteil, Faculte de Medecine, INSERM U955, Team 16, Creteil, France. FAU - Wiedemann, Aurelie AU - Wiedemann A AD - Vaccine Research Institute, Universite Paris-Est Creteil, Faculte de Medecine, INSERM U955, Team 16, Creteil, France. FAU - Pantaleo, Giuseppe AU - Pantaleo G AD - Vaccine Research Institute, Universite Paris-Est Creteil, Faculte de Medecine, INSERM U955, Team 16, Creteil, France; Service of Immunology and Allergy Lausanne University Hospital, Swiss Vaccine Research Institute, University Hospital, University of Lausanne, Lausanne, Switzerland. FAU - Zurawski, Sandra AU - Zurawski S AD - Vaccine Research Institute, Universite Paris-Est Creteil, Faculte de Medecine, INSERM U955, Team 16, Creteil, France; Baylor Scott and White Research Institute, Dallas, TX, United States. FAU - Centlivre, Mireille AU - Centlivre M AD - Vaccine Research Institute, Universite Paris-Est Creteil, Faculte de Medecine, INSERM U955, Team 16, Creteil, France. FAU - Zurawski, Gerard AU - Zurawski G AD - Vaccine Research Institute, Universite Paris-Est Creteil, Faculte de Medecine, INSERM U955, Team 16, Creteil, France; Baylor Scott and White Research Institute, Dallas, TX, United States. FAU - Levy, Yves AU - Levy Y AD - Vaccine Research Institute, Universite Paris-Est Creteil, Faculte de Medecine, INSERM U955, Team 16, Creteil, France; Assistance Publique-Hopitaux de Paris, Groupe Henri-Mondor Albert-Chenevier, Service Immunologie Clinique, Creteil, France. Electronic address: yves.levy@inserm.fr. FAU - Godot, Veronique AU - Godot V AD - Vaccine Research Institute, Universite Paris-Est Creteil, Faculte de Medecine, INSERM U955, Team 16, Creteil, France. Electronic address: veronique.godot@inserm.fr. LA - eng PT - Journal Article DEP - 20241211 PL - Netherlands TA - EBioMedicine JT - EBioMedicine JID - 101647039 RN - 0 (COVID-19 Vaccines) RN - 0 (CD40 Antigens) RN - 0 (Spike Glycoprotein, Coronavirus) RN - 0 (Vaccines, Subunit) RN - 0 (spike protein, SARS-CoV-2) RN - 0 (BNT162 Vaccine) SB - IM MH - *CD8-Positive T-Lymphocytes/immunology MH - *SARS-CoV-2/immunology MH - Animals MH - Humans MH - Mice MH - *COVID-19 Vaccines/immunology MH - *COVID-19/immunology/prevention & control/virology MH - *CD40 Antigens/immunology MH - *Immunologic Memory MH - Spike Glycoprotein, Coronavirus/immunology MH - Vaccines, Subunit/immunology MH - BNT162 Vaccine MH - *Memory T Cells/immunology PMC - PMC11697708 OTO - NOTNLM OT - COVID-19 OT - Long-lasting T-cell immunity OT - Pre-clinical models OT - SARS-CoV-2 OT - Vaccine COIS- Declaration of interests The authors SZ, GZ, MC, SC, and YL are named inventors on patent applications based on this work held by Inserm Transfert. The remaining authors declare no competing interests. Inserm Transfert provided a license for CD40-targeting vaccines to the biotech company LinKinVax. EDAT- 2024/12/13 00:23 MHDA- 2025/01/17 00:20 PMCR- 2024/12/11 CRDT- 2024/12/12 18:13 PHST- 2023/09/10 00:00 [received] PHST- 2024/11/14 00:00 [revised] PHST- 2024/11/14 00:00 [accepted] PHST- 2025/01/17 00:20 [medline] PHST- 2024/12/13 00:23 [pubmed] PHST- 2024/12/12 18:13 [entrez] PHST- 2024/12/11 00:00 [pmc-release] AID - S2352-3964(24)00515-2 [pii] AID - 105479 [pii] AID - 10.1016/j.ebiom.2024.105479 [doi] PST - ppublish SO - EBioMedicine. 2025 Jan;111:105479. doi: 10.1016/j.ebiom.2024.105479. Epub 2024 Dec 11. PMID- 39662823 OWN - NLM STAT- MEDLINE DCOM- 20250427 LR - 20250518 IS - 1469-0691 (Electronic) IS - 1198-743X (Linking) VI - 31 IP - 4 DP - 2025 Apr TI - Booster vaccination and post-COVID-19 condition during the Omicron variant-dominant wave: a large population-based study. PG - 630-635 LID - S1198-743X(24)00588-3 [pii] LID - 10.1016/j.cmi.2024.12.002 [doi] AB - OBJECTIVES: The effect of the COVID-19 booster vaccination and the long-term consequences concerning preventing post-COVID-19 condition (PCC) remains unclear. We aimed to investigate the association of COVID-19 booster vaccination dose and vaccination timing before infection with the risk of PCC during the Omicron variant-dominant wave. METHODS: This population-based study included patients confirmed with COVID-19 (extracted from the Health Center Real-time Information-sharing System) aged 20-69 years, who were infected between 1 July and 31 August 2022. We used a self-report questionnaire to evaluate PCC and extracted information on vaccination from the municipal vaccine registry system. We calculated multiple propensity scores for COVID-19 vaccination status (unvaccinated, 1-2 doses and >/=3 doses) to control for baseline population differences. We then used a logistic regression model with inverse probability weighting to analyse the associations between the number of vaccine doses and the risk of PCC. Additionally, we conducted stratified analysis by gender and subgroup analysis for respiratory and neurological symptoms. Multivariable logistic regression was used to analyse the association between vaccination timing and PCC risk, adjusting for vaccination doses. RESULTS: Of the 7936 participants with COVID-19 (mean age 42.9 years, 4553 women), 940 (11.8%) had at least 1 PCC. Compared with people unvaccinated, those vaccinated >/=3 times before the infection had a lower probability of PCC with the OR of 0.69 (95% CI: 0.53-0.90), although we detected no association with one or two doses. This association was present in women (>/=3 doses vs. unvaccinated OR: 0.70, 95% CI: 0.51-0.95) but not in men. Those vaccinated >/=3 times had fewer neurological symptoms compared with those unvaccinated (OR: 0.61, 95% CI: 0.45-0.83); however, no significant association was found for respiratory symptoms. DISCUSSION: This study suggests that booster vaccination could lower the risk of PCC. CI - Copyright (c) 2024 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved. FAU - Iba, Arisa AU - Iba A AD - Institute of Global Health Policy Research, Bureau of International Health Cooperation, National Center for Global Health and Medicine, Shinjuku, Tokyo, Japan. Electronic address: aiba@it.ncgm.go.jp. FAU - Hosozawa, Mariko AU - Hosozawa M AD - Institute of Global Health Policy Research, Bureau of International Health Cooperation, National Center for Global Health and Medicine, Shinjuku, Tokyo, Japan. FAU - Hori, Miyuki AU - Hori M AD - Institute of Global Health Policy Research, Bureau of International Health Cooperation, National Center for Global Health and Medicine, Shinjuku, Tokyo, Japan. FAU - Muto, Yoko AU - Muto Y AD - Institute of Global Health Policy Research, Bureau of International Health Cooperation, National Center for Global Health and Medicine, Shinjuku, Tokyo, Japan. FAU - Kihara, Tomomi AU - Kihara T AD - Institute of Global Health Policy Research, Bureau of International Health Cooperation, National Center for Global Health and Medicine, Shinjuku, Tokyo, Japan; Department of Public Health Medicine, Institute of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan; Health Services Research and Development Center, University of Tsukuba, Tsukuba, Ibaraki, Japan. FAU - Muraki, Isao AU - Muraki I AD - Public Health, Department of Social and Environmental Medicine, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan. FAU - Masuda, Rie AU - Masuda R AD - Health Services Research and Development Center, University of Tsukuba, Tsukuba, Ibaraki, Japan. FAU - Tamiya, Nanako AU - Tamiya N AD - Health Services Research and Development Center, University of Tsukuba, Tsukuba, Ibaraki, Japan; Department of Health Services Research, Institute of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan. FAU - Iso, Hiroyasu AU - Iso H AD - Institute of Global Health Policy Research, Bureau of International Health Cooperation, National Center for Global Health and Medicine, Shinjuku, Tokyo, Japan. LA - eng PT - Journal Article DEP - 20241209 PL - England TA - Clin Microbiol Infect JT - Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases JID - 9516420 RN - 0 (COVID-19 Vaccines) RN - SARS-CoV-2 variants SB - IM MH - Humans MH - Middle Aged MH - Male MH - Female MH - *COVID-19/prevention & control/epidemiology/virology/complications MH - Adult MH - *Immunization, Secondary/statistics & numerical data MH - Aged MH - *SARS-CoV-2/immunology MH - *COVID-19 Vaccines/administration & dosage/immunology MH - Young Adult MH - Vaccination OTO - NOTNLM OT - Booster vaccine OT - Japan OT - Population study OT - Post-COVID-19 condition OT - Vaccination effect EDAT- 2024/12/12 00:24 MHDA- 2025/03/18 00:26 CRDT- 2024/12/11 19:32 PHST- 2024/05/09 00:00 [received] PHST- 2024/11/19 00:00 [revised] PHST- 2024/12/03 00:00 [accepted] PHST- 2025/03/18 00:26 [medline] PHST- 2024/12/12 00:24 [pubmed] PHST- 2024/12/11 19:32 [entrez] AID - S1198-743X(24)00588-3 [pii] AID - 10.1016/j.cmi.2024.12.002 [doi] PST - ppublish SO - Clin Microbiol Infect. 2025 Apr;31(4):630-635. doi: 10.1016/j.cmi.2024.12.002. Epub 2024 Dec 9. PMID- 39637971 OWN - NLM STAT- MEDLINE DCOM- 20250426 LR - 20250518 IS - 1878-3511 (Electronic) IS - 1201-9712 (Linking) VI - 151 DP - 2025 Feb TI - COVID-19 vaccination and cerebral small vessel disease progression-A prospective cohort study. PG - 107324 LID - S1201-9712(24)00399-0 [pii] LID - 10.1016/j.ijid.2024.107324 [doi] AB - OBJECTIVES: The association between SARS-CoV-2 spike protein and cerebrovascular diseases raised a concern of cerebrovascular safety of COVID-19 vaccines. We aimed to determine the risk of radiologic cerebral small vessel disease (cSVD) progression with BNT162b2 and CoronaVac. METHODS: In this community-based prospective cohort study, community-dwelling subjects underwent brain magnetic resonance imaging (MRI) before and 4 months after vaccination with BNT162b2 or CoronaVac. Unvaccinated subjects received serial brain MRI over a comparable interval. The primary outcome was progression of a composite of six standard cSVD biomarkers. We compared the risk of cSVD progression between vaccinated and unvaccinated subjects and identified predictors of primary outcome within each vaccine subgroup. RESULTS: Of the 415 subjects recruited, 190 received BNT162b2, 152 received CoronaVac, and 73 remained unvaccinated. A total of 60 (14.4%) had COVID-19 infection before follow-up MRI, and 109 (26.3%) developed the primary outcome. Neither BNT162b2 (adjusted odds ratio [aOR] 0.61, 95% confidence interval [CI] 0.30-1.26, P = 0.179) nor CoronaVac (aOR 0.71, 95% CI 0.34-1.47, P = 0.349) was associated with cSVD progression. Among the BNT162b2 recipients, a higher surrogate virus neutralization test was associated (aOR 0.97, 95% CI 0.95-0.99, P = 0.002) with a lower risk of cSVD progression. CONCLUSIONS: BNT162b2 and CoronaVac did not increase cSVD burden in community-dwelling citizens. The association between surrogate virus neutralization test and cSVD progression among BNT162b2 recipients requires further investigation. CI - Copyright (c) 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved. FAU - Ip, Yiu Ming Bonaventure AU - Ip YMB AD - Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, HKSAR; Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong, HKSAR; Gerald Choa Neuroscience Institute, The Chinese University of Hong Kong, Hong Kong, HKSAR. FAU - Pang, Sangqi AU - Pang S AD - Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, HKSAR. FAU - Yao, Alan AU - Yao A AD - Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, HKSAR. FAU - Lau, Lucas AU - Lau L AD - Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, HKSAR. FAU - Miu, Anki AU - Miu A AD - Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, HKSAR. FAU - Chiu, Katarina AU - Chiu K AD - Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, HKSAR. FAU - Ko, Ho AU - Ko H AD - Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, HKSAR; Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong, HKSAR; Gerald Choa Neuroscience Institute, The Chinese University of Hong Kong, Hong Kong, HKSAR. FAU - Kwok, Andrew AU - Kwok A AD - Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, HKSAR; Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong, HKSAR; Gerald Choa Neuroscience Institute, The Chinese University of Hong Kong, Hong Kong, HKSAR. FAU - Chan, Helen Y AU - Chan HY AD - Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, HKSAR. FAU - Lee, Sharon AU - Lee S AD - Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, HKSAR. FAU - Chan, Howard AU - Chan H AD - Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, HKSAR. FAU - Hung, Trista AU - Hung T AD - Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, HKSAR. FAU - Lam, Bonnie AU - Lam B AD - Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, HKSAR. FAU - Hui, Vincent AU - Hui V AD - Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, HKSAR. FAU - Li, Haipeng AU - Li H AD - Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, HKSAR. FAU - Shi, Lin AU - Shi L AD - Department of Imaging and Interventional Radiology, The Chinese University of Hong Kong, Shatin, HKSAR; BrainNow Research Institute, Shenzhen, China. FAU - Abrigo, Jill AU - Abrigo J AD - Department of Imaging and Interventional Radiology, The Chinese University of Hong Kong, Shatin, HKSAR. FAU - Leng, Xinyi AU - Leng X AD - Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, HKSAR; Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong, HKSAR. FAU - Soo, Yannie AU - Soo Y AD - Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, HKSAR. FAU - Ma, Sze Ho AU - Ma SH AD - Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, HKSAR. FAU - Mok, Vincent Ct AU - Mok VC AD - Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, HKSAR. FAU - Markus, Hugh S AU - Markus HS AD - Stroke Research Group, Department of Neurosciences, University of Cambridge, Cambridge, United Kingdom. FAU - Mok, Chris AU - Mok C AD - The JC School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong, HKSAR. FAU - Hui, David Sc AU - Hui DS AD - Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, HKSAR; The JC School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong, HKSAR. FAU - Leung, Thomas W AU - Leung TW AD - Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, HKSAR; Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong, HKSAR; Gerald Choa Neuroscience Institute, The Chinese University of Hong Kong, Hong Kong, HKSAR. Electronic address: drtleung@cuhk.edu.hk. LA - eng PT - Journal Article DEP - 20241203 PL - Canada TA - Int J Infect Dis JT - International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases JID - 9610933 RN - 0 (COVID-19 Vaccines) RN - 0 (BNT162 Vaccine) SB - IM MH - Humans MH - Male MH - Female MH - Prospective Studies MH - Middle Aged MH - *COVID-19/prevention & control MH - Disease Progression MH - *Cerebral Small Vessel Diseases/diagnostic imaging/etiology MH - Magnetic Resonance Imaging MH - Aged MH - *COVID-19 Vaccines/adverse effects/administration & dosage MH - BNT162 Vaccine/adverse effects MH - SARS-CoV-2/immunology MH - Vaccination/adverse effects MH - Adult MH - Brain/diagnostic imaging OTO - NOTNLM OT - BNT162b2 OT - COVID-19 OT - Cerebrovascular disease OT - CoronaVac OT - MRI COIS- Declarations of competing interest The authors have no competing interests to declare. EDAT- 2024/12/06 05:31 MHDA- 2025/01/18 15:10 CRDT- 2024/12/05 19:14 PHST- 2024/10/23 00:00 [received] PHST- 2024/11/28 00:00 [revised] PHST- 2024/12/01 00:00 [accepted] PHST- 2025/01/18 15:10 [medline] PHST- 2024/12/06 05:31 [pubmed] PHST- 2024/12/05 19:14 [entrez] AID - S1201-9712(24)00399-0 [pii] AID - 10.1016/j.ijid.2024.107324 [doi] PST - ppublish SO - Int J Infect Dis. 2025 Feb;151:107324. doi: 10.1016/j.ijid.2024.107324. Epub 2024 Dec 3. PMID- 39612651 OWN - NLM STAT- MEDLINE DCOM- 20241213 LR - 20260518 IS - 2352-3964 (Electronic) IS - 2352-3964 (Linking) VI - 110 DP - 2024 Dec TI - Bivalent Omicron BA.1 vaccine booster increases memory B cell breadth and neutralising antibodies against emerging SARS-CoV-2 variants. PG - 105461 LID - S2352-3964(24)00497-3 [pii] LID - 10.1016/j.ebiom.2024.105461 [doi] LID - 105461 AB - BACKGROUND: Current literature informs us that bivalent vaccines will generate a broader serum neutralizing antibody response to multiple SARS-CoV-2 variants, but studies on how this breadth relates to the memory B cell (MBC) and T cell responses are sparse. This study compared breadth of neutralising antibody, and memory B and T cell responses to monovalent or a bivalent ancestral/Omicron BA.1 COVID-19 booster vaccine. METHODS: At baseline and 1-month post-booster, neutralisation activity and frequencies of receptor binding domain (RBD)-specific MBCs and Spike-specific memory T cells were measured against a panel of variants. FINDINGS: Both vaccines boosted neutralising antibodies to 5 variants - Wuhan-Hu-1, Delta, BA.1, BA.5 and JN.1, the latter of which had not yet emerged at the time of sample collection. The bivalent vaccine induced a significantly larger increase in nAb against BA.1 and JN.1. Both vaccines boosted RBD-specific MBC responses to Wuhan-Hu-1, Delta, BA.1 and BA.5 variants with a significantly greater increase for BA.1 in the bivalent group. The breadth of MBCs was significantly higher in those who received the bivalent boost and correlated with nAb breadth. Both vaccines significantly boosted Spike-specific T cell responses to the Wuhan-Hu-1 and BA.5 variants, but only the bivalent vaccine boosted BA.1 responses. INTERPRETATION: These results suggest that the bivalent vaccine confers an advantage against future novel variants due to increased frequency of broadly reactive RBD-specific B cells. FUNDING: Work supported by NSW Health for the NSW Vaccine, Infection and Immunology Collaborative (VIIM). CI - Copyright (c) 2024 The Author(s). Published by Elsevier B.V. All rights reserved. FAU - Shrestha, Lok Bahadur AU - Shrestha LB AD - The Kirby Institute, University of New South Wales, Sydney, NSW, Australia; School of Biomedical Sciences, Faculty of Medicine & Health, University of New South Wales, Sydney, NSW, Australia. FAU - Tungatt, Katie AU - Tungatt K AD - Centre for Virus Research, The Westmead Institute for Medical Research, Westmead, NSW, Australia. FAU - Aggarwal, Anupriya AU - Aggarwal A AD - The Kirby Institute, University of New South Wales, Sydney, NSW, Australia. FAU - Stubis, Aija AU - Stubis A AD - Centre for Virus Research, The Westmead Institute for Medical Research, Westmead, NSW, Australia. FAU - Fewings, Nicole L AU - Fewings NL AD - Centre for Virus Research, The Westmead Institute for Medical Research, Westmead, NSW, Australia. FAU - Fichter, Christina AU - Fichter C AD - The Kirby Institute, University of New South Wales, Sydney, NSW, Australia. FAU - Akerman, Anouschka AU - Akerman A AD - The Kirby Institute, University of New South Wales, Sydney, NSW, Australia. FAU - Rodrigo, Chaturaka AU - Rodrigo C AD - School of Biomedical Sciences, Faculty of Medicine & Health, University of New South Wales, Sydney, NSW, Australia. FAU - Tedla, Nicodemus AU - Tedla N AD - School of Biomedical Sciences, Faculty of Medicine & Health, University of New South Wales, Sydney, NSW, Australia. FAU - Lee, Sharon AU - Lee S AD - Research & Education Network, Western Sydney Local Health District, Westmead, NSW, Australia. FAU - Lloyd, Andrew R AU - Lloyd AR AD - The Kirby Institute, University of New South Wales, Sydney, NSW, Australia. FAU - Brilot, Fabienne AU - Brilot F AD - Kids Neuroscience Centre, Kids Research at the Children's Hospital at Westmead, Westmead, NSW, Australia; Sydney Infectious Diseases Institute (Sydney ID), Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, Australia; School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, Australia. FAU - Britton, Warwick J AU - Britton WJ AD - Centenary Institute, The University of Sydney, Camperdown, NSW, Australia; RPAH Vaccination Centre, Sydney Local Health District, Sydney, NSW, Australia. FAU - Kelleher, Anthony AU - Kelleher A AD - The Kirby Institute, University of New South Wales, Sydney, NSW, Australia. FAU - Caterson, Ian D AU - Caterson ID AD - RPAH Vaccination Centre, Sydney Local Health District, Sydney, NSW, Australia. FAU - Douglas, Mark W AU - Douglas MW AD - Sydney Infectious Diseases Institute (Sydney ID), Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, Australia; Storr Liver Centre, The Westmead Institute for Medical Research, Westmead, NSW, Australia; Centre for Infectious Diseases and Microbiology, Westmead Hospital, Westmead, NSW, Australia. FAU - Rockett, Rebecca AU - Rockett R AD - Sydney Infectious Diseases Institute (Sydney ID), Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, Australia; School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, Australia. FAU - Tangye, Stuart G AU - Tangye SG AD - Garvan Institute of Medical Research, Darlinghurst, NSW, Australia; School of Clinical Medicine, Faculty of Medicine and Health, University of New South Wales, Sydney, NSW, Australia. FAU - Triccas, James A AU - Triccas JA AD - Sydney Infectious Diseases Institute (Sydney ID), Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, Australia; School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, Australia. FAU - Turville, Stuart G AU - Turville SG AD - The Kirby Institute, University of New South Wales, Sydney, NSW, Australia. FAU - Sandgren, Kerrie J AU - Sandgren KJ AD - Centre for Virus Research, The Westmead Institute for Medical Research, Westmead, NSW, Australia; Sydney Infectious Diseases Institute (Sydney ID), Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, Australia; School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, Australia. FAU - Bull, Rowena A AU - Bull RA AD - The Kirby Institute, University of New South Wales, Sydney, NSW, Australia; School of Biomedical Sciences, Faculty of Medicine & Health, University of New South Wales, Sydney, NSW, Australia. FAU - Cunningham, Anthony L AU - Cunningham AL AD - Centre for Virus Research, The Westmead Institute for Medical Research, Westmead, NSW, Australia; Sydney Infectious Diseases Institute (Sydney ID), Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, Australia; School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, Australia. Electronic address: tony.cunningham@sydney.edu.au. CN - VIIM Collaborative Research Group of NSW LA - eng PT - Journal Article DEP - 20241128 PL - Netherlands TA - EBioMedicine JT - EBioMedicine JID - 101647039 RN - 0 (COVID-19 Vaccines) RN - 0 (Antibodies, Viral) RN - 0 (Antibodies, Neutralizing) RN - 0 (Spike Glycoprotein, Coronavirus) RN - 0 (spike protein, SARS-CoV-2) RN - SARS-CoV-2 variants SB - IM MH - Humans MH - *COVID-19 Vaccines/immunology/administration & dosage MH - *SARS-CoV-2/immunology MH - *Memory B Cells/immunology MH - *COVID-19/immunology/prevention & control MH - *Antibodies, Viral/immunology MH - *Antibodies, Neutralizing/immunology MH - *Immunization, Secondary MH - *Spike Glycoprotein, Coronavirus/immunology MH - Adult MH - Female MH - Male MH - Middle Aged MH - Immunologic Memory MH - B-Lymphocytes/immunology PMC - PMC11647467 OTO - NOTNLM OT - Bivalent vaccine OT - JN.1 OT - Memory B cells OT - Omicron BA.1 OT - Receptor binding domain COIS- Declaration of interests The VIIM Collaborative Group of NSW was funded by NSW Health. A.L.C has received NSW Health grant and performed consultancies for Moderna with honoraria directed to his institution. K.J.S. has received honoraria for talks from Moderna. A.K. has grants from NSW Health, NHMRC, MRFF, NIH, Viiv, Unitaid, DFAT, received consulting fee from Merck and Viiv, travel support from HIN STRIVE investigators meeting, performed leadership and advisory role in Board member Scientia Clinical Research Phase 1 Unit, HIV-NAT Advisory Board ASCOT Trial, Chair of DSMB Aegros Advisory Board and pending patent for siRNA for COVID-19. F.B. has received support from NHMRC, Novartis and MRFF. W.J.B. has received support from NSW Vaccine Accelerator, NHMRC, MRFF and NSW Dust Diseases board. I.D.C. has clinical trials support from Eli Lilly and Boehringer. M.W.D has grants from NHMRC and Gilead Australia, payment from Roche Diagnostics for webinar, GSK travel grant and participated as advisor in Gilead and GSK. R.A.B. and R.R. have NHMRC Investigator grants. S.G.Ta has grants from NHMRC, Job Research Foundation and Allegry and Immunology Foundation of Australasia. S.G.Tu has received grants from MRFF, and New South Wales Health COVID-19 Research Grants Round 2. FIR - Cunningham, Anthony L IR - Cunningham AL FIR - Sorrell, Tania IR - Sorrell T FIR - Kelleher, Anthony IR - Kelleher A FIR - Britton, Warwick IR - Britton W FIR - Maclean, Mark IR - Maclean M FIR - Lee, Sharon IR - Lee S FIR - Camilleri, Joanne IR - Camilleri J FIR - Douglas, Mark IR - Douglas M FIR - Bull, Rowena IR - Bull R FIR - Sandgren, Kerrie IR - Sandgren K FIR - Song, Yang IR - Song Y FIR - Mao, Lijun IR - Mao L FIR - Phu, Amy IR - Phu A FIR - Sigmund, Allison IR - Sigmund A FIR - Beard, Sophie IR - Beard S FIR - Caterson, Ian IR - Caterson I FIR - Hunt, Stephanie IR - Hunt S FIR - Vande More, Anne Marie IR - Vande More AM FIR - Kandasamy, Rama IR - Kandasamy R FIR - Caterson, Ian IR - Caterson I FIR - Kok, Jen IR - Kok J FIR - Byrne, Jennifer IR - Byrne J FIR - Lloyd, Andrew IR - Lloyd A FIR - Triccas, James IR - Triccas J FIR - Tangye, Stuart IR - Tangye S FIR - Turville, Stuart IR - Turville S FIR - Brilot, Fabienne IR - Brilot F FIR - O'Sullivan, Matthew IR - O'Sullivan M FIR - Steain, Megan IR - Steain M FIR - Baird, Sarah IR - Baird S FIR - Phetsouphanh, Chansavath IR - Phetsouphanh C FIR - Zhao, Yanran IR - Zhao Y EDAT- 2024/11/30 11:17 MHDA- 2024/12/14 00:24 PMCR- 2024/11/28 CRDT- 2024/11/29 18:07 PHST- 2024/06/18 00:00 [received] PHST- 2024/10/30 00:00 [revised] PHST- 2024/11/05 00:00 [accepted] PHST- 2024/12/14 00:24 [medline] PHST- 2024/11/30 11:17 [pubmed] PHST- 2024/11/29 18:07 [entrez] PHST- 2024/11/28 00:00 [pmc-release] AID - S2352-3964(24)00497-3 [pii] AID - 105461 [pii] AID - 10.1016/j.ebiom.2024.105461 [doi] PST - ppublish SO - EBioMedicine. 2024 Dec;110:105461. doi: 10.1016/j.ebiom.2024.105461. Epub 2024 Nov 28. PMID- 39604225 OWN - NLM STAT- MEDLINE DCOM- 20250426 LR - 20260708 IS - 1521-4141 (Electronic) IS - 0014-2980 (Print) IS - 0014-2980 (Linking) VI - 55 IP - 1 DP - 2025 Jan TI - Distinct Requirements for CD4(+) T Cell Help for Immune Responses Induced by mRNA and Adenovirus-Vector SARS-CoV-2 Vaccines. PG - e202451142 LID - 10.1002/eji.202451142 [doi] LID - e202451142 AB - CD4(+) T cells have been established as central orchestrators of cellular and humoral immune responses to infection or vaccination. However, the need for CD4(+) T cell help to generate primary CD8(+) T cell responses is variable depending on the infectious agent or vaccine and yet consistently required for the recall of CD8(+) T cell memory responses or antibody responses. Given the deployment of new vaccine platforms such as nucleoside-modified mRNA vaccines, we sought to elucidate the requirement for CD4(+) T cell help in the induction of cellular and antibody responses to mRNA and adenovirus (Ad)-vectored vaccines against SARS-CoV-2. Using antibody-mediated depletion of CD4(+) T cells in a mouse immunization model, we observed that CD4(+) T cell help was dispensable for both primary and secondary CD8(+) T cell responses to the BNT162b2 and mRNA-1273 mRNA vaccines but required for the AZD1222 Ad-vectored vaccine. Nonetheless, CD4(+) T cell help was needed by both mRNA and Ad-vectored vaccine platforms for the generation of antibodies, demonstrating the centrality of CD4(+) T cells in vaccine-induced protective immunity against SARS-CoV-2. Ultimately, this highlights the shared and distinct regulation of humoral and cellular responses induced by these vaccine platforms. CI - (c) 2024 The Author(s). European Journal of Immunology published by Wiley-VCH GmbH. FAU - Yong, Lyn AU - Yong L AUID- ORCID: 0009-0008-0551-746X AD - Pandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK. AD - Translational Gastroenterology and Liver Unit, Nuffield Department of Medicine-Experimental Medicine, University of Oxford, Oxford, UK. FAU - Hutchings, Claire AU - Hutchings C AD - Peter Medawar Building for Pathogen Research, Nuffield Department of Medicine, University of Oxford, Oxford, UK. FAU - Barnes, Eleanor AU - Barnes E AD - Translational Gastroenterology and Liver Unit, Nuffield Department of Medicine-Experimental Medicine, University of Oxford, Oxford, UK. AD - Peter Medawar Building for Pathogen Research, Nuffield Department of Medicine, University of Oxford, Oxford, UK. FAU - Klenerman, Paul AU - Klenerman P AD - Pandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK. AD - Translational Gastroenterology and Liver Unit, Nuffield Department of Medicine-Experimental Medicine, University of Oxford, Oxford, UK. AD - Peter Medawar Building for Pathogen Research, Nuffield Department of Medicine, University of Oxford, Oxford, UK. FAU - Provine, Nicholas M AU - Provine NM AUID- ORCID: 0000-0002-9694-2216 AD - Pandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK. AD - Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK. LA - eng GR - WT_/Wellcome Trust/United Kingdom GR - 222426/Z/21/Z/WT_/Wellcome Trust/United Kingdom GR - U19 I082360/GF/NIH HHS/United States GR - 227217/Z/23/Z/WT_/Wellcome Trust/United Kingdom PT - Journal Article DEP - 20241127 PL - Germany TA - Eur J Immunol JT - European journal of immunology JID - 1273201 RN - 0 (COVID-19 Vaccines) RN - 0 (Antibodies, Viral) RN - 0 (BNT162 Vaccine) RN - EPK39PL4R4 (2019-nCoV Vaccine mRNA-1273) RN - 0 (RNA, Messenger) SB - IM MH - Animals MH - Mice MH - *SARS-CoV-2/immunology MH - *CD4-Positive T-Lymphocytes/immunology MH - Adenoviridae/genetics MH - *COVID-19 Vaccines/immunology MH - *COVID-19/immunology/prevention & control MH - CD8-Positive T-Lymphocytes/immunology MH - Antibodies, Viral/immunology MH - Genetic Vectors MH - BNT162 Vaccine/immunology MH - Mice, Inbred C57BL MH - 2019-nCoV Vaccine mRNA-1273/immunology MH - Humans MH - Female MH - RNA, Messenger/immunology MH - Immunity, Cellular PMC - PMC11739681 OTO - NOTNLM OT - CD4 T cell help OT - CD8 T cells OT - T cell memory OT - T cell priming OT - adenovirus vaccines OT - antibodies OT - mRNA vaccines OT - vaccination COIS- The authors note the following conflicts of interest: N.M.P. has received consulting fees from Infinitopes. P.K. has received consulting fees from UCB, Biomunex, AstraZeneca, and Infinitopes. E.B. consults for AstaZeneca, Roche, and Vaccitech and has patents in ChAdOx1 HBV and HCV vaccines. EDAT- 2024/11/28 06:35 MHDA- 2025/01/17 18:23 PMCR- 2025/01/17 CRDT- 2024/11/28 01:43 PHST- 2024/11/18 00:00 [revised] PHST- 2024/03/15 00:00 [received] PHST- 2024/11/20 00:00 [accepted] PHST- 2025/01/17 18:23 [medline] PHST- 2024/11/28 06:35 [pubmed] PHST- 2024/11/28 01:43 [entrez] PHST- 2025/01/17 00:00 [pmc-release] AID - EJI5886 [pii] AID - 10.1002/eji.202451142 [doi] PST - ppublish SO - Eur J Immunol. 2025 Jan;55(1):e202451142. doi: 10.1002/eji.202451142. Epub 2024 Nov 27. PMID- 39601170 OWN - NLM STAT- MEDLINE DCOM- 20250106 LR - 20250110 IS - 1875-5828 (Electronic) IS - 1567-2050 (Linking) VI - 21 IP - 7 DP - 2024 TI - Impact of the COVID-19 Pandemic on People with Dementia and their Caregivers: A Multiphase Observational Study from India. PG - 470-478 LID - 10.2174/0115672050346469241112115052 [doi] AB - INTRODUCTION: The COVID-19 pandemic has had multifaceted and enduring impacts on people with dementia and their caregivers; however, our understanding of the long-term outcomes remains limited. We aimed to explore the long-term effects of the COVID-19 pandemic on cognitive symptoms and vaccination rates in people living with dementia. METHODS: This study was conducted as a part of a longitudinal study design in two specialized hospitals in South India. In this study, patients with dementia and their caregivers assessed in earlier phases ('period of lockdown with phased relaxations - phase-I' and 'cluster of cases transmission phase - phase-II') were telephonically interviewed. We adopted a quantitative approach to understand disease progression during the three-year course of the pandemic. Changes in cognition and disease severity were measured using the Clinical Dementia Rating (CDR) scale. In brief, semistructured interviews were carried out with caregivers of people with dementia to gain insights into vaccination rates. Data obtained from the current study (phase III) were compared against phase I data, which served as the baseline. Among the 72 participants contacted in the current phase, 59 (81.9%) could be reevaluated for dementia severity and vaccination status, whereas 13 (18.0%) had died. Among the 59 participants, 33 (55.9%) had severe dementia (CDR 3). This is in contrast to phases I and II, when 17.6% and 19.2% of the participants, respectively, were classified as CDR 3. RESULTS: A significant difference in dementia severity between the two phases (phases I and III) was observed. In addition, we observed vaccination hesitancy among caregivers of patients with dementia. This study would provide valuable insights into the long-term impact of the COVID-19 pandemic on the cognitive outcomes and vaccination status of patients with dementia. CONCLUSION: This overall longitudinal study has compared dementia severity between different phases throughout the pandemic, with implications for future studies to tailor home-based support and healthcare interventions in order to meet these evolving needs. CI - Copyright(c) Bentham Science Publishers; For any queries, please email at epub@benthamscience.net. FAU - Arshad, Faheem AU - Arshad F AD - Department of Neurology, National Institute of Mental Health and Neurosciences (NIMHANS), Hosur Road, Bangalore, Karnataka, Bangalore, India. FAU - Hurzuk, Saadiya AU - Hurzuk S AD - Strengthening Responses to Dementia in Developing Countries (STRiDE), Psychology, India, Alzheimer's and Related Disorders Society of India, Hyderabad, India. FAU - Tiwari, Megha AU - Tiwari M AD - Department of Neurology, National Institute of Mental Health and Neurosciences (NIMHANS), Hosur Road, Bangalore, Karnataka, Bangalore, India. FAU - Varghese, Feba AU - Varghese F AD - Department of Neurology, National Institute of Mental Health and Neurosciences (NIMHANS), Hosur Road, Bangalore, Karnataka, Bangalore, India. FAU - Hoskeri, Rakshith Maneshwar AU - Hoskeri RM AD - Department of Neurology, National Institute of Mental Health and Neurosciences (NIMHANS), Hosur Road, Bangalore, Karnataka, Bangalore, India. FAU - Paplikar, Avanthi AU - Paplikar A AD - Department of Neurology, National Institute of Mental Health and Neurosciences (NIMHANS), Hosur Road, Bangalore, Karnataka, Bangalore, India. FAU - Goyal, Sheetal AU - Goyal S AD - Department of Neurology, National Institute of Mental Health and Neurosciences (NIMHANS), Hosur Road, Bangalore, Karnataka, Bangalore, India. FAU - Dhiren, Shah Rutul AU - Dhiren SR AD - Department of Neurology, National Institute of Mental Health and Neurosciences (NIMHANS), Hosur Road, Bangalore, Karnataka, Bangalore, India. FAU - Ganeshbhai, Patel Vishal AU - Ganeshbhai PV AD - Department of Neurology, National Institute of Mental Health and Neurosciences (NIMHANS), Hosur Road, Bangalore, Karnataka, Bangalore, India. FAU - Ansari, Mohammed Farhan AU - Ansari MF AD - Hosur Road, Bangalore, Karnataka, Bangalore. FAU - Komaravolu, Shashidhar AU - Komaravolu S AD - Alzheimer's and Related Disorders Society of India Hyderabad Deccan Chapter, Psychiatry, Hyderabad, India. FAU - Kammammettu, Chandrashekar AU - Kammammettu C AD - Department of Neuropsychiatry and Geriatric Psychiatry, Asha Hospital, Psychiatry, Hyderabad, India. FAU - Thomas, Priya Treesa AU - Thomas PT AD - Department of Psychiatric Social Work, National Institute of Mental Health and Neurosciences, Bangalore, India. FAU - Rao, Girish Nagaraja AU - Rao GN AD - Department of Epidemiology, National Institute of Mental Health and Neurosciences, Bangalore, India. FAU - Alladi, Suvarna AU - Alladi S AD - Department of Neurology, National Institute of Mental Health and Neurosciences (NIMHANS), Hosur Road, Bangalore, Karnataka, Bangalore, India. LA - eng PT - Journal Article PT - Observational Study PL - United Arab Emirates TA - Curr Alzheimer Res JT - Current Alzheimer research JID - 101208441 SB - IM MH - Aged MH - Aged, 80 and over MH - Female MH - Humans MH - Male MH - Middle Aged MH - *Caregivers/psychology MH - *COVID-19/psychology/epidemiology MH - *Dementia/psychology/epidemiology MH - Disease Progression MH - India/epidemiology MH - Longitudinal Studies MH - SARS-CoV-2 MH - Vaccination/psychology MH - *Pandemics OTO - NOTNLM OT - COVID-19 OT - Dementia OT - LMICs OT - cognition OT - pandemic. OT - vaccination EDAT- 2024/11/27 06:19 MHDA- 2025/01/07 00:21 CRDT- 2024/11/27 05:13 PHST- 2024/08/01 00:00 [received] PHST- 2024/10/27 00:00 [revised] PHST- 2024/10/30 00:00 [accepted] PHST- 2025/01/07 00:21 [medline] PHST- 2024/11/27 06:19 [pubmed] PHST- 2024/11/27 05:13 [entrez] AID - CAR-EPUB-144621 [pii] AID - 10.2174/0115672050346469241112115052 [doi] PST - ppublish SO - Curr Alzheimer Res. 2024;21(7):470-478. doi: 10.2174/0115672050346469241112115052. PMID- 39598316 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20241130 IS - 2075-1729 (Print) IS - 2075-1729 (Electronic) IS - 2075-1729 (Linking) VI - 14 IP - 11 DP - 2024 Nov 20 TI - Insights into the Risk Factors and Outcomes of Post-COVID-19 Syndrome-Results from a Retrospective, Cross-Sectional Study in Romania. LID - 10.3390/life14111519 [doi] LID - 1519 AB - Post-Coronavirus Disease 2019 (post-COVID-19) syndrome represents a cluster of persistent symptoms following Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection that can severely affect quality of life. The pathogenic mechanisms and epidemiology in different regions are still under evaluation. To assess the outcomes of post-COVID-19 syndrome, we performed a questionnaire-based, cross-sectional study in previously infected individuals. Out of 549 respondents, (male:female ratio: 0.32), 29.5% had persistent symptoms at 3 months, 23.5% had persistent symptoms at 6 months, and 18.3% had persistent symptoms at 12 months after the initial infection. The most common symptoms included fatigue (8.7%), sleep disturbances (7.1%), and cognitive impairment (6.4%). The risk of developing post-COVID-19 syndrome increased for those with more symptoms in the acute phase (OR 4.24, p < 0.001) and those experiencing reinfections (OR 2.405, p < 0.001), while SARS-CoV-2 vaccination halved the risk (OR = 0.489, p = 0.004). Individuals with post-COVID-19 syndrome had a 5.7-fold higher risk of being diagnosed with a new chronic condition, with 44% reporting cardiovascular disease, and a 6.8-fold higher likelihood of needing medical care or leave. Affected individuals reported significant impairments in mobility, pain/discomfort, and anxiety/depression, with 20.7% needing to adjust their work schedules. Overall, patients with post-COVID-19 syndrome require ongoing monitoring and rehabilitation, and further socio-economic impact studies are needed. FAU - Bejan, Ioana AU - Bejan I AD - Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 020956 Bucharest, Romania. FAU - Popescu, Corneliu Petru AU - Popescu CP AUID- ORCID: 0000-0001-6316-0333 AD - Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 020956 Bucharest, Romania. AD - Victor Babes Hospital for Infectious and Tropical Diseases, 030303 Bucharest, Romania. FAU - Ruta, Simona Maria AU - Ruta SM AUID- ORCID: 0000-0002-2492-6073 AD - Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 020956 Bucharest, Romania. AD - Stefan S Nicolau Institute of Virology, 030304 Bucharest, Romania. LA - eng PT - Journal Article DEP - 20241120 PL - Switzerland TA - Life (Basel) JT - Life (Basel, Switzerland) JID - 101580444 PMC - PMC11596014 OTO - NOTNLM OT - COVID-19 sequelae OT - SARS-CoV-2 vaccination OT - long COVID OT - post-COVID-19 syndrome COIS- The authors declare no conflicts of interest. EDAT- 2024/11/27 06:19 MHDA- 2024/11/27 06:20 PMCR- 2024/11/20 CRDT- 2024/11/27 01:34 PHST- 2024/10/16 00:00 [received] PHST- 2024/11/16 00:00 [revised] PHST- 2024/11/17 00:00 [accepted] PHST- 2024/11/27 06:20 [medline] PHST- 2024/11/27 06:19 [pubmed] PHST- 2024/11/27 01:34 [entrez] PHST- 2024/11/20 00:00 [pmc-release] AID - life14111519 [pii] AID - life-14-01519 [pii] AID - 10.3390/life14111519 [doi] PST - epublish SO - Life (Basel). 2024 Nov 20;14(11):1519. doi: 10.3390/life14111519. PMID- 39588905 OWN - NLM STAT- MEDLINE DCOM- 20250306 LR - 20250616 IS - 1460-2377 (Electronic) IS - 0953-8178 (Linking) VI - 37 IP - 4 DP - 2025 Mar 6 TI - The immune memory of innate immune systems. PG - 195-202 LID - 10.1093/intimm/dxae067 [doi] AB - Immune memory has long been considered a function specific to adaptive immune systems; however, adaptive immune memory alone has not fully explained the mechanism by which vaccines exert their protective effects against nontarget pathogens. Recently, trained immunity, in which human monocytes vaccinated with bacillus Calmette-Guerin become highly responsive to pathogens other than Mycobacterium tuberculosis, has been reported. However, a phenomenon called endotoxin tolerance is also known, in which monocyte responsiveness is attenuated after the first lipopolysaccharide stimulation. These phenomena represent an altered innate immune response after the initial exposure to the stimulus, indicating that memories are formed in the innate immune system. In this review, we discuss trained immunity and endotoxin tolerance, known as innate immune memory, and innate immune memory formation by mRNA vaccines, which have been newly used in the coronavirus disease 2019 (COVID-19) pandemic and are considered important vaccine modalities in the future. CI - (c) The Author(s) 2024. Published by Oxford University Press on behalf of The Japanese Society for Immunology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site-for further information please contact journals.permissions@oup.com. FAU - Kato, Yasuhiro AU - Kato Y AUID- ORCID: 0000-0002-4050-2350 AD - Department of Immunopathology, WPI Immunology Frontier Research Center, Osaka University, Suita, Osaka, Japan. AD - Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan. FAU - Kumanogoh, Atsushi AU - Kumanogoh A AD - Department of Immunopathology, WPI Immunology Frontier Research Center, Osaka University, Suita, Osaka, Japan. AD - Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan. AD - Center for Infectious Diseases Education and Research, Osaka University, Suita, Osaka, Japan. AD - Integrated Frontier Research for Medical Science Division, Institute for Open and Transdisciplinary Research Initiatives, Osaka University, Suita, Osaka, Japan. AD - Japan Agency for Medical Research and Development-Core Research for Evolutional Science and Technology (AMED-CREST), Osaka University, Suita, Osaka, Japan. AD - Center for Advanced Modalities and DDS, Osaka University, Suita, Osaka, Japan. LA - eng GR - Cloud founding of peace winds Japan/ GR - Ministry of Education, Culture, Sports, Science and Technology of Japan/ GR - JP18H05282/Japan Society for the Promotion of Science/ GR - Japan Agency for Medical Research and Development/ GR - 22gm1810003h0001/Japan Agency for Medical Research and Development-Core Research for Evolutional Science and Technology/ GR - Kansai Economic Federation/ GR - Mitsubishi Zaidan/ PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review PL - England TA - Int Immunol JT - International immunology JID - 8916182 RN - 0 (COVID-19 Vaccines) RN - 0 (Vaccines, Synthetic) SB - IM MH - Humans MH - *Immunity, Innate MH - *Immunologic Memory MH - *COVID-19/immunology/prevention & control MH - *SARS-CoV-2/immunology MH - *COVID-19 Vaccines/immunology MH - Animals MH - Monocytes/immunology MH - Vaccines, Synthetic/immunology OTO - NOTNLM OT - endotoxin tolerance OT - epigenetic reprogramming OT - trained immunity EDAT- 2024/11/26 12:31 MHDA- 2025/03/06 18:27 CRDT- 2024/11/26 07:22 PHST- 2024/07/09 00:00 [received] PHST- 2024/11/24 00:00 [accepted] PHST- 2025/03/06 18:27 [medline] PHST- 2024/11/26 12:31 [pubmed] PHST- 2024/11/26 07:22 [entrez] AID - 7908808 [pii] AID - 10.1093/intimm/dxae067 [doi] PST - ppublish SO - Int Immunol. 2025 Mar 6;37(4):195-202. doi: 10.1093/intimm/dxae067. PMID- 39560882 OWN - NLM STAT- MEDLINE DCOM- 20250103 LR - 20261010 IS - 1590-3478 (Electronic) IS - 1590-1874 (Linking) VI - 46 IP - 1 DP - 2025 Jan TI - Impact of COVID-19 disease and COVID-19 vaccinations on hospital admissions for neurological diseases in the Lombardia over-12 population. Data from a self-controlled case series analysis. PG - 25-32 LID - 10.1007/s10072-024-07870-5 [doi] AB - INTRODUCTION: The influence of COVID19 vaccination on the risk of different neurological diseases has been subject of intense investigation. No large scale results have been published so far in the population of around 10 million people of Lombardia in Italy. METHODS: Linkable administrative health databases from the Lombardia region were used. By using the adapted self controlled case series (SCCS) method for event dependent exposures, we estimated the relative incidence of different neurological diseases following pre-specified windows at risk after vaccination and after COVID-19 infection in the over-12 population of Lombardia. Follow-up time before vaccination (Pre-Vax period) was compared with follow-up time 0-28 days (high-risk period) from the day of vaccination as well as for COVID infection. The SCCS model was fitted using a conditional Poisson regression model to estimate the relative incidences (RI) and their 95% Confidence Intervals (CI). RESULTS: The 28-day post-vaccination period was associated with a significant increase in the occurrence of ischemic stroke, cerebral haemorrhage, TIAs and myelitis (IRR 1.44, 1.50, 1.67 and 2.65 respectively). When the risk conferred by COVID19 infection was assessed in the same cohort, significant IRR were greater in the occurrence of ischemic stroke, cerebral haemorrhage, and TIAs (IRR 5.6, 3.62, 6.83) and includes also Multiple Sclerosis, neuromyelitis, and polymyositis (5.25, 8.81, 5.67). CONCLUSIONS: Our data suggest that the increased risk of non-inflammatory CNS disorders following COVID-19 vaccination is lower than the risk conferred by COVID-19 infection, and that COVID-19 infection increases the risk of some inflammatory and non inflammatory neurological disorders. CI - (c) 2024. Fondazione Societa Italiana di Neurologia. FAU - Salmaggi, Andrea AU - Salmaggi A AUID- ORCID: 0000-0001-6925-3434 AD - Department of Neurosciences, ASST Lecco, Lecco, Italy. a.salmaggi@asst-lecco.it. FAU - Bortolan, Francesco AU - Bortolan F AD - Epidemiological Regional Observatory, Lombardy Region, Milan, Italy. FAU - Ercolanoni, Michele AU - Ercolanoni M AD - Epidemiological Regional Observatory, Lombardy Region, Milan, Italy. FAU - Vrabie, Paul Stefan AU - Vrabie PS AD - Epidemiological Regional Observatory, Lombardy Region, Milan, Italy. FAU - Cideni, Francesco AU - Cideni F AD - Epidemiological Regional Observatory, Lombardy Region, Milan, Italy. FAU - Leoni, Olivia AU - Leoni O AD - Epidemiological Regional Observatory, Lombardy Region, Milan, Italy. FAU - Boneschi, Filippo Martinelli AU - Boneschi FM AD - Department of Health Science, CRC Aldo Ravelli for Experimental Brain Therapeutics, University of Milan and San Paolo Hospital, ASST Santipaolocarlo, Milan, Italy. LA - eng PT - Journal Article DEP - 20241119 PL - Italy TA - Neurol Sci JT - Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology JID - 100959175 RN - 0 (COVID-19 Vaccines) SB - IM MH - Adolescent MH - Adult MH - Aged MH - Aged, 80 and over MH - Female MH - Humans MH - Male MH - Middle Aged MH - Young Adult MH - Cerebral Hemorrhage/epidemiology MH - *COVID-19/epidemiology/prevention & control MH - *COVID-19 Vaccines/adverse effects MH - Hospitalization/statistics & numerical data MH - Incidence MH - Italy/epidemiology MH - Myelitis/epidemiology MH - *Nervous System Diseases/epidemiology/etiology MH - Vaccination/statistics & numerical data/adverse effects OTO - NOTNLM OT - COVID19 OT - Incidence risk ratio OT - Lombardy OT - Neurological diseases OT - Vaccines COIS- Declarations. Competing interests: The authors have no competing interests. Informed consent: The informed consent was waived in as much it was not needed according to Italian law for analysis of aggregated administrative data. Ethical statement: This study was notified to EC Brianza with the SNO-COVID acronym, a non interventional study on neurological complications of COVID and COVID vaccinations. EDAT- 2024/11/19 13:18 MHDA- 2025/01/03 18:20 CRDT- 2024/11/19 11:21 PHST- 2024/08/02 00:00 [received] PHST- 2024/10/30 00:00 [accepted] PHST- 2025/01/03 18:20 [medline] PHST- 2024/11/19 13:18 [pubmed] PHST- 2024/11/19 11:21 [entrez] AID - 10.1007/s10072-024-07870-5 [pii] AID - 10.1007/s10072-024-07870-5 [doi] PST - ppublish SO - Neurol Sci. 2025 Jan;46(1):25-32. doi: 10.1007/s10072-024-07870-5. Epub 2024 Nov 19. PMID- 39524914 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20241114 IS - 1664-2295 (Print) IS - 1664-2295 (Electronic) IS - 1664-2295 (Linking) VI - 15 DP - 2024 TI - New insights into the increased risk of migraines from COVID-19 infection and vaccination: a Mendelian randomization study. PG - 1445649 LID - 10.3389/fneur.2024.1445649 [doi] LID - 1445649 AB - INTRODUCTION: Migraine is a prevalent neurological disorder characterized by recurrent attacks, leading to a substantial global disease burden. Recent observational studies have reported the onset and worsening of migraine following COVID-19 infection and vaccination. However, traditional observational study designs have limitations in controlling for confounding factors, potentially resulting in biased and inconsistent conclusions. To address this, we applied Mendelian randomization (MR) to investigate the causal relationship between COVID-19 infection and vaccination with migraine. METHODS: This study utilized summary-level genome-wide association study (GWAS) data from the GWAS catalog and FinnGen database to evaluate the effects of varying degrees of COVID-19 infection and vaccination on migraine. We employed inverse variance weighted (IVW) fixed-effect and random-effect models as the primary methods for MR analysis, with MR-Egger and other approaches as complementary methods. Sensitivity analyses, including Cochran's Q test, MR-Egger intercept regression, and MR-PRESSO, were conducted to ensure robustness of the results. RESULTS: Our MR analysis revealed no significant causal association between COVID-19 infection and migraine. However, a significant causal association was found between COVID-19 vaccination and migraine (beta = 0.071, P = 0.034). The results were confirmed through a series of sensitivity tests, demonstrating the robustness of the findings. DISCUSSION: This study provides novel evidence of a significant causal link between COVID-19 vaccination and migraine, while no such association was observed with COVID-19 infection. These findings may have important implications for clinical practice, particularly in planning treatment adjustments and optimizing patient care for individuals with migraines in the context of COVID-19 vaccination. CI - Copyright (c) 2024 Yang, Song, Shi, Du, Zhang, Huang, Zhou, Chi and Zhu. FAU - Yang, Jin AU - Yang J AD - First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China. AD - National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, China. FAU - Song, Xiaoli AU - Song X AD - First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China. AD - National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, China. FAU - Shi, Lei AU - Shi L AD - First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China. AD - National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, China. FAU - Du, Shuhao AU - Du S AD - First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China. AD - National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, China. FAU - Zhang, Jieying AU - Zhang J AD - First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China. AD - National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, China. FAU - Huang, Gang AU - Huang G AD - Clinical Medical College, Southwest Medical University, Luzhou, China. FAU - Zhou, Xuancheng AU - Zhou X AD - Clinical Medical College, Southwest Medical University, Luzhou, China. FAU - Chi, Hao AU - Chi H AD - Clinical Medical College, Southwest Medical University, Luzhou, China. FAU - Zhu, Qian AU - Zhu Q AD - First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China. AD - National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, China. LA - eng PT - Journal Article DEP - 20241025 PL - Switzerland TA - Front Neurol JT - Frontiers in neurology JID - 101546899 PMC - PMC11543403 OTO - NOTNLM OT - COVID-19 OT - COVID-19 vaccination OT - GWAS OT - Mendelian randomization study OT - migraine COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2024/11/14 03:58 MHDA- 2024/11/14 03:59 PMCR- 2024/10/25 CRDT- 2024/11/11 05:35 PHST- 2024/06/07 00:00 [received] PHST- 2024/10/14 00:00 [accepted] PHST- 2024/11/14 03:59 [medline] PHST- 2024/11/14 03:58 [pubmed] PHST- 2024/11/11 05:35 [entrez] PHST- 2024/10/25 00:00 [pmc-release] AID - 10.3389/fneur.2024.1445649 [doi] PST - epublish SO - Front Neurol. 2024 Oct 25;15:1445649. doi: 10.3389/fneur.2024.1445649. eCollection 2024. PMID- 39530340 OWN - NLM STAT- MEDLINE DCOM- 20241112 LR - 20260530 IS - 1096-9071 (Electronic) IS - 0146-6615 (Linking) VI - 96 IP - 11 DP - 2024 Nov TI - Memory B Cells Provide Long-Term Protection to Vaccinated Kidney Transplant Recipients Against SARS-CoV-2 Variants. PG - e70037 LID - 10.1002/jmv.70037 [doi] AB - Kidney transplant recipients (KTRs) are highly vulnerable to COVID-19. An intensified scheme of vaccination offers short-term protection to the 50%-75% of KTRs able to develop a germinal center reaction, required for the generation of neutralizing titers of antibodies (NAbs). However, the duration of this vaccinal protection is unknown. In-depth longitudinal analysis of the immune response to vaccination of 33 KTRs demonstrates that the low peak of IgGs, the progressive decline in antibody titers, and the emergence of a variant of concerns (VOC) of SARS-CoV2, synergize to let 2/3 of responders to vaccine without NAbs after only a few months. Yet, a retrospective study of an independent cohort of 274 KTRs, revealed that the risk of severe COVID-19 in the latter was low, similar to that of patients with serum neutralizing capacity against VOC. Our work links this late vaccine protection with the presence of memory B cells, which are generated during the initial vaccine-induced germinal center reaction, have a wide repertoire directed against conserved spike epitopes, and rapidly differentiate into IgG-producing plasma cells upon antigenic rechallenge. We conclude that in contrast with a serological layer that goes fading rapidly, the cellular layer of humoral memory provides an efficient long-term protection against VOC to KTRs. This illustration of the complementary roles of the two layers of the humoral memory has implications in immunopathology beyond the COVID-19 in KTRs. CI - (c) 2024 Wiley Periodicals LLC. FAU - Espi, Maxime AU - Espi M AUID- ORCID: 0000-0003-1000-4737 AD - CIRI, INSERM U1111, Universite Claude Bernard Lyon I, CNRS UMR5308, Ecole Normale Superieure de Lyon, Lyon, France. FAU - Charmetant, Xavier AU - Charmetant X AD - CIRI, INSERM U1111, Universite Claude Bernard Lyon I, CNRS UMR5308, Ecole Normale Superieure de Lyon, Lyon, France. AD - Department of Transplantation, Hospices Civils de Lyon, Edouard Herriot Hospital, Nephrology and Clinical Immunology, Lyon, France. AD - Claude Bernard University, Villeurbanne, France. FAU - Benotmane, Ilies AU - Benotmane I AD - Department of Nephrology Dialysis and Transplantation, Strasbourg University Hospital, Strasbourg, France. AD - Inserm UMR S1109, LabEx Transplantex, Federation de Medecine Translationnelle de Strasbourg (FMTS), Universite de Strasbourg, Strasbourg, France. FAU - Lefsihane, Katia AU - Lefsihane K AD - CIRI, INSERM U1111, Universite Claude Bernard Lyon I, CNRS UMR5308, Ecole Normale Superieure de Lyon, Lyon, France. FAU - Barateau, Veronique AU - Barateau V AD - CIRI, INSERM U1111, Universite Claude Bernard Lyon I, CNRS UMR5308, Ecole Normale Superieure de Lyon, Lyon, France. FAU - Gallais, Floriane AU - Gallais F AD - Department of Virology, Strasbourg University Hospital, Strasbourg, France. FAU - Boulenouar, Hafsa AU - Boulenouar H AD - Inserm UMR S1109, LabEx Transplantex, Federation de Medecine Translationnelle de Strasbourg (FMTS), Universite de Strasbourg, Strasbourg, France. FAU - Ovize, Anne AU - Ovize A AD - Eurofins Biomnis Laboratory, Lyon, France. FAU - Barbry, Alexia AU - Barbry A AD - Eurofins Biomnis Laboratory, Lyon, France. FAU - Bouz, Christine AU - Bouz C AD - Eurofins Biomnis Laboratory, Lyon, France. FAU - Morelon, Emmanuel AU - Morelon E AD - CIRI, INSERM U1111, Universite Claude Bernard Lyon I, CNRS UMR5308, Ecole Normale Superieure de Lyon, Lyon, France. AD - Department of Transplantation, Hospices Civils de Lyon, Edouard Herriot Hospital, Nephrology and Clinical Immunology, Lyon, France. AD - Claude Bernard University, Villeurbanne, France. FAU - Defrance, Thierry AU - Defrance T AD - CIRI, INSERM U1111, Universite Claude Bernard Lyon I, CNRS UMR5308, Ecole Normale Superieure de Lyon, Lyon, France. FAU - Fafi-Kremer, Samira AU - Fafi-Kremer S AD - Inserm UMR S1109, LabEx Transplantex, Federation de Medecine Translationnelle de Strasbourg (FMTS), Universite de Strasbourg, Strasbourg, France. AD - Department of Virology, Strasbourg University Hospital, Strasbourg, France. FAU - Caillard, Sophie AU - Caillard S AD - Department of Nephrology Dialysis and Transplantation, Strasbourg University Hospital, Strasbourg, France. AD - Inserm UMR S1109, LabEx Transplantex, Federation de Medecine Translationnelle de Strasbourg (FMTS), Universite de Strasbourg, Strasbourg, France. FAU - Thaunat, Olivier AU - Thaunat O AD - CIRI, INSERM U1111, Universite Claude Bernard Lyon I, CNRS UMR5308, Ecole Normale Superieure de Lyon, Lyon, France. AD - Department of Transplantation, Hospices Civils de Lyon, Edouard Herriot Hospital, Nephrology and Clinical Immunology, Lyon, France. AD - Claude Bernard University, Villeurbanne, France. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - J Med Virol JT - Journal of medical virology JID - 7705876 RN - 0 (Antibodies, Viral) RN - 0 (Antibodies, Neutralizing) RN - 0 (COVID-19 Vaccines) RN - 0 (Immunoglobulin G) RN - SARS-CoV-2 variants SB - IM MH - Humans MH - *Kidney Transplantation/adverse effects MH - *COVID-19/prevention & control/immunology MH - *SARS-CoV-2/immunology MH - *Antibodies, Viral/blood/immunology MH - *Antibodies, Neutralizing/immunology/blood MH - Middle Aged MH - Male MH - Female MH - *Transplant Recipients MH - *COVID-19 Vaccines/immunology/administration & dosage MH - Retrospective Studies MH - *Memory B Cells/immunology MH - Aged MH - Adult MH - Immunoglobulin G/blood/immunology MH - Vaccination MH - Longitudinal Studies OTO - NOTNLM OT - coronavirus OT - disease control OT - immune responses OT - vaccines/vaccine strains OT - virus classification EDAT- 2024/11/13 13:51 MHDA- 2024/11/13 13:52 CRDT- 2024/11/12 06:23 PHST- 2024/09/10 00:00 [revised] PHST- 2024/05/22 00:00 [received] PHST- 2024/10/10 00:00 [accepted] PHST- 2024/11/13 13:52 [medline] PHST- 2024/11/13 13:51 [pubmed] PHST- 2024/11/12 06:23 [entrez] AID - 10.1002/jmv.70037 [doi] PST - ppublish SO - J Med Virol. 2024 Nov;96(11):e70037. doi: 10.1002/jmv.70037. PMID- 39510068 OWN - NLM STAT- MEDLINE DCOM- 20241211 LR - 20260923 IS - 1097-4180 (Electronic) IS - 1074-7613 (Print) IS - 1074-7613 (Linking) VI - 57 IP - 12 DP - 2024 Dec 10 TI - Maintenance and functional regulation of immune memory to COVID-19 vaccines in tissues. PG - 2895-2913.e8 LID - S1074-7613(24)00483-7 [pii] LID - 10.1016/j.immuni.2024.10.003 [doi] AB - Memory T and B cells in tissues are essential for protective immunity. Here, we performed a comprehensive analysis of the tissue distribution, phenotype, durability, and transcriptional profile of COVID-19 mRNA vaccine-induced immune memory across blood, lymphoid organs, and lungs obtained from 63 vaccinated organ donors aged 23-86, some of whom experienced SARS-CoV-2 infection. Spike (S)-reactive memory T cells were detected in lymphoid organs and lungs and variably expressed tissue-resident markers based on infection history, and S-reactive B cells comprised class-switched memory cells resident in lymphoid organs. Compared with blood, S-reactive tissue memory T cells persisted for longer times post-vaccination and were more prevalent with age. S-reactive T cells displayed site-specific subset compositions and functions: regulatory cell profiles were enriched in tissues, while effector and cytolytic profiles were more abundant in circulation. Our findings reveal functional compartmentalization of vaccine-induced T cell memory where surveilling effectors and in situ regulatory responses confer protection with minimal tissue damage. CI - Copyright (c) 2024 Elsevier Inc. All rights reserved. FAU - Davis-Porada, Julia AU - Davis-Porada J AD - Department of Microbiology and Immunology, Columbia University Irving Medical Center, New York, NY 10032, USA; Medical Scientist Training Program, Columbia University Irving Medical Center, New York, NY 10032, USA. FAU - George, Alex B AU - George AB AD - Medical Scientist Training Program, Columbia University Irving Medical Center, New York, NY 10032, USA; Department of Systems Biology, Columbia University Irving Medical Center, New York, NY 10032, USA. FAU - Lam, Nora AU - Lam N AD - Department of Microbiology and Immunology, Columbia University Irving Medical Center, New York, NY 10032, USA; Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY 10032, USA. FAU - Caron, Daniel P AU - Caron DP AD - Department of Microbiology and Immunology, Columbia University Irving Medical Center, New York, NY 10032, USA. FAU - Gray, Joshua I AU - Gray JI AD - Department of Microbiology and Immunology, Columbia University Irving Medical Center, New York, NY 10032, USA. FAU - Huang, Jenny AU - Huang J AD - Department of Systems Biology, Columbia University Irving Medical Center, New York, NY 10032, USA. FAU - Hwu, Jennifer AU - Hwu J AD - Department of Systems Biology, Columbia University Irving Medical Center, New York, NY 10032, USA. FAU - Wells, Steven B AU - Wells SB AD - Department of Systems Biology, Columbia University Irving Medical Center, New York, NY 10032, USA. FAU - Matsumoto, Rei AU - Matsumoto R AD - Department of Surgery, Columbia University Irving Medical Center, New York, NY 10032, USA. FAU - Kubota, Masaru AU - Kubota M AD - Department of Surgery, Columbia University Irving Medical Center, New York, NY 10032, USA. FAU - Lee, YoonSeung AU - Lee Y AD - Department of Microbiology and Immunology, Columbia University Irving Medical Center, New York, NY 10032, USA. FAU - Morrison-Colvin, Rory AU - Morrison-Colvin R AD - Department of Microbiology and Immunology, Columbia University Irving Medical Center, New York, NY 10032, USA. FAU - Jensen, Isaac J AU - Jensen IJ AD - Department of Microbiology and Immunology, Columbia University Irving Medical Center, New York, NY 10032, USA. FAU - Ural, Basak B AU - Ural BB AD - Department of Microbiology and Immunology, Columbia University Irving Medical Center, New York, NY 10032, USA. FAU - Shaabani, Namir AU - Shaabani N AD - Department of Immunology and Microbiology, Scripps Research, La Jolla, CA 92037, USA. FAU - Weiskopf, Daniela AU - Weiskopf D AD - Center of Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA 92037, USA. FAU - Grifoni, Alba AU - Grifoni A AD - Center of Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA 92037, USA. FAU - Sette, Alessandro AU - Sette A AD - Center of Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA 92037, USA; Department of Pathology, University of California, San Diego, La Jolla, CA 92093, USA. FAU - Szabo, Peter A AU - Szabo PA AD - Department of Microbiology and Immunology, Columbia University Irving Medical Center, New York, NY 10032, USA. FAU - Teijaro, John R AU - Teijaro JR AD - Department of Immunology and Microbiology, Scripps Research, La Jolla, CA 92037, USA. FAU - Sims, Peter A AU - Sims PA AD - Department of Systems Biology, Columbia University Irving Medical Center, New York, NY 10032, USA; Department of Biochemistry and Molecular Biophysics, Columbia University Irving Medical Center, New York, NY 10032, USA. Electronic address: pas2182@cumc.columbia.edu. FAU - Farber, Donna L AU - Farber DL AD - Department of Microbiology and Immunology, Columbia University Irving Medical Center, New York, NY 10032, USA; Department of Surgery, Columbia University Irving Medical Center, New York, NY 10032, USA. Electronic address: df2396@cumc.columbia.edu. LA - eng GR - U19 AI128949/AI/NIAID NIH HHS/United States GR - T32 AI106711/AI/NIAID NIH HHS/United States GR - P01 AI106697/AI/NIAID NIH HHS/United States GR - U19 AI057266/AI/NIAID NIH HHS/United States GR - F30 AI174785/AI/NIAID NIH HHS/United States GR - R01 AI167372/AI/NIAID NIH HHS/United States GR - 75N93019C00065/AI/NIAID NIH HHS/United States GR - P30 CA013696/CA/NCI NIH HHS/United States GR - T32 GM145440/GM/NIGMS NIH HHS/United States GR - S10 OD030282/OD/NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, U.S. Gov't, Non-P.H.S. DEP - 20241106 PL - United States TA - Immunity JT - Immunity JID - 9432918 RN - 0 (COVID-19 Vaccines) RN - 0 (Spike Glycoprotein, Coronavirus) RN - 0 (spike protein, SARS-CoV-2) SB - IM MH - Humans MH - *Immunologic Memory/immunology MH - Aged MH - *SARS-CoV-2/immunology MH - *COVID-19/immunology/prevention & control MH - Middle Aged MH - *Memory T Cells/immunology MH - Adult MH - Aged, 80 and over MH - *COVID-19 Vaccines/immunology MH - Female MH - Male MH - Lung/immunology/virology MH - Young Adult MH - Spike Glycoprotein, Coronavirus/immunology MH - B-Lymphocytes/immunology MH - Lymphoid Tissue/immunology MH - Vaccination PMC - PMC11634668 MID - NIHMS2029874 OTO - NOTNLM OT - COVID-19 OT - SARS-CoV-2 OT - human immunology OT - immunologic memory OT - lung immunity OT - lymphoid organs OT - mRNA vaccines OT - memory B cells OT - regulatory T cells OT - tissue-resident memory T cells COIS- Declaration of interests A.S. is a consultant for Gritstone Bio, Flow Pharma, Moderna, AstraZeneca, Qiagen, Fortress, Gilead, Sanofi, Merck, RiverVest, MedaCorp, Turnstone, NA Vaccine Institute, Emervax, Gerson Lehrman Group, and Guggenheim. La Jolla Institute. has filed for patent protection for various aspects of T cell epitope and vaccine design work. Columbia University has filed patent applications related to vaccine tissue assays. EDAT- 2024/11/13 13:56 MHDA- 2024/12/12 05:26 PMCR- 2025/12/10 CRDT- 2024/11/07 18:42 PHST- 2024/03/05 00:00 [received] PHST- 2024/06/28 00:00 [revised] PHST- 2024/10/08 00:00 [accepted] PHST- 2024/12/12 05:26 [medline] PHST- 2024/11/13 13:56 [pubmed] PHST- 2024/11/07 18:42 [entrez] PHST- 2025/12/10 00:00 [pmc-release] AID - S1074-7613(24)00483-7 [pii] AID - 10.1016/j.immuni.2024.10.003 [doi] PST - ppublish SO - Immunity. 2024 Dec 10;57(12):2895-2913.e8. doi: 10.1016/j.immuni.2024.10.003. Epub 2024 Nov 6. PMID- 39489918 OWN - NLM STAT- MEDLINE DCOM- 20241205 LR - 20260904 IS - 1525-0024 (Electronic) IS - 1525-0016 (Print) IS - 1525-0016 (Linking) VI - 32 IP - 12 DP - 2024 Dec 4 TI - Enhanced mucosal SARS-CoV-2 immunity after heterologous intramuscular mRNA prime/intranasal protein boost vaccination with a combination adjuvant. PG - 4448-4466 LID - S1525-0016(24)00676-2 [pii] LID - 10.1016/j.ymthe.2024.10.016 [doi] AB - Current COVID-19 mRNA vaccines delivered intramuscularly (IM) induce effective systemic immunity, but with suboptimal immunity at mucosal sites, limiting their ability to impart sterilizing immunity. There is strong interest in rerouting immune responses induced in the periphery by parenteral vaccination to the portal entry site of respiratory viruses, such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), by mucosal vaccination. We previously demonstrated the combination adjuvant, NE/IVT, consisting of a nanoemulsion (NE) and an RNA-based RIG-I agonist (IVT) induces potent systemic and mucosal immune responses in protein-based SARS-CoV-2 vaccines administered intranasally (IN). Herein, we demonstrate priming IM with mRNA followed by heterologous IN boosting with NE/IVT adjuvanted recombinant antigen induces strong mucosal and systemic antibody responses and enhances antigen-specific T cell responses in mucosa-draining lymph nodes compared to IM/IM and IN/IN prime/boost regimens. While all regimens induced cross-neutralizing antibodies against divergent variants and sterilizing immunity in the lungs of challenged mice, mucosal vaccination, either as homologous prime/boost or heterologous IN boost after IM mRNA prime, was required to impart sterilizing immunity in the upper respiratory tract. Our data demonstrate the benefit of hybrid regimens whereby strong immune responses primed via IM vaccination are rerouted by IN vaccination to mucosal sites to provide optimal protection against SARS-CoV-2. CI - Copyright (c) 2024 The Author(s). Published by Elsevier Inc. All rights reserved. FAU - Laghlali, Gabriel AU - Laghlali G AD - Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Pharmaceutics, Ghent University, Ghent, Belgium. FAU - Wiest, Matthew J AU - Wiest MJ AD - Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA; Michigan Nanotechnology Institute for Medicine and Biological Sciences, University of Michigan Medical School, Ann Arbor, MI, USA. FAU - Karadag, Dilara AU - Karadag D AD - Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA; Michigan Nanotechnology Institute for Medicine and Biological Sciences, University of Michigan Medical School, Ann Arbor, MI, USA. FAU - Warang, Prajakta AU - Warang P AD - Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. FAU - O'Konek, Jessica J AU - O'Konek JJ AD - Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA; Michigan Nanotechnology Institute for Medicine and Biological Sciences, University of Michigan Medical School, Ann Arbor, MI, USA; Mary H. Weiser Food Allergy Center, University of Michigan Medical School, Ann Arbor, MI, USA. FAU - Chang, Lauren A AU - Chang LA AD - Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA. FAU - Park, Seok-Chan AU - Park SC AD - Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. FAU - Yan, Vivian AU - Yan V AD - Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA. FAU - Farazuddin, Mohammad AU - Farazuddin M AD - Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA; Michigan Nanotechnology Institute for Medicine and Biological Sciences, University of Michigan Medical School, Ann Arbor, MI, USA; Mary H. Weiser Food Allergy Center, University of Michigan Medical School, Ann Arbor, MI, USA. FAU - Janczak, Katarzyna W AU - Janczak KW AD - Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA; Michigan Nanotechnology Institute for Medicine and Biological Sciences, University of Michigan Medical School, Ann Arbor, MI, USA; Mary H. Weiser Food Allergy Center, University of Michigan Medical School, Ann Arbor, MI, USA. FAU - Garcia-Sastre, Adolfo AU - Garcia-Sastre A AD - Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Medicine, Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA; The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Icahn Genomics Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. FAU - Baker, James R Jr AU - Baker JR Jr AD - Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA; Michigan Nanotechnology Institute for Medicine and Biological Sciences, University of Michigan Medical School, Ann Arbor, MI, USA; Mary H. Weiser Food Allergy Center, University of Michigan Medical School, Ann Arbor, MI, USA. FAU - Wong, Pamela T AU - Wong PT AD - Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA; Michigan Nanotechnology Institute for Medicine and Biological Sciences, University of Michigan Medical School, Ann Arbor, MI, USA; Mary H. Weiser Food Allergy Center, University of Michigan Medical School, Ann Arbor, MI, USA. Electronic address: ptw@umich.edu. FAU - Schotsaert, Michael AU - Schotsaert M AD - Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Icahn Genomics Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Marc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address: michael.schotsaert@mssm.edu. LA - eng GR - R21 AI176069/AI/NIAID NIH HHS/United States GR - R01 DK130425/DK/NIDDK NIH HHS/United States GR - U19 AI135972/AI/NIAID NIH HHS/United States GR - G20 AI174733/AI/NIAID NIH HHS/United States GR - R01 AI160706/AI/NIAID NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20241028 PL - United States TA - Mol Ther JT - Molecular therapy : the journal of the American Society of Gene Therapy JID - 100890581 RN - 0 (COVID-19 Vaccines) RN - 0 (Antibodies, Viral) RN - 0 (Antibodies, Neutralizing) RN - 0 (Adjuvants, Immunologic) RN - 0 (mRNA Vaccines) RN - 0 (Adjuvants, Vaccine) RN - 0 (Spike Glycoprotein, Coronavirus) SB - IM UOF - bioRxiv. 2024 Mar 29:2024.03.28.587260. doi: 10.1101/2024.03.28.587260. PMID: 38586014 MH - Animals MH - *SARS-CoV-2/immunology MH - Mice MH - *COVID-19 Vaccines/immunology/administration & dosage MH - *COVID-19/prevention & control/immunology MH - *Administration, Intranasal MH - *Immunity, Mucosal MH - *Antibodies, Viral/immunology MH - Injections, Intramuscular MH - Female MH - Immunization, Secondary MH - Humans MH - Antibodies, Neutralizing/immunology MH - Adjuvants, Immunologic/administration & dosage MH - mRNA Vaccines/immunology MH - Vaccination/methods MH - Adjuvants, Vaccine/administration & dosage MH - Spike Glycoprotein, Coronavirus/immunology/genetics PMC - PMC11638833 OTO - NOTNLM OT - SARS-Cov-2 OT - intranasal vaccination OT - mRNA vaccines OT - mucosal adjuvants OT - mucosal immunization OT - prime/pull OT - tissue-resident memory T cells COIS- Declaration of interests P.T.W., M.S., J.R.B., and A.G.-S. are co-inventors on a patent for NE/IVT. The A.G.-S laboratory has received research support from GSK, Pfizer, Senhwa Biosciences, Kenall Manufacturing, Blade Therapeutics, Avimex, Johnson & Johnson, Dynavax, 7Hills Pharma, Pharmamar, ImmunityBio, Accurius, Nanocomposix, Hexamer, N-fold LLC, Model Medicines, Atea Pharma, Applied Biological Laboratories and Merck, outside of the reported work. A.G.-S. has consulting agreements with the following companies involving cash and/or stock: Castlevax, Amovir, Vivaldi Biosciences, Contrafect, 7Hills Pharma, Avimex, Pagoda, Accurius, Esperovax, Farmak, Applied Biological Laboratories, Pharmamar, CureLab Oncology, CureLab Veterinary, Synairgen, Paratus, Pfizer and Prosetta, outside of the reported work. A.G.-S. has been an invited speaker in meeting events organized by Seqirus, Janssen, Abbott, and Astrazeneca. A.G.-S. is inventor on patents and patent applications on the use of antivirals and vaccines for the treatment and prevention of virus infections and cancer, owned by the Icahn School of Medicine at Mount Sinai, New York. The M.S. laboratory received unrelated research support as sponsored research agreements from ArgenX BV, Phio Pharmaceuticals, 7Hills Pharma LLC and Moderna. EDAT- 2024/11/04 00:31 MHDA- 2024/12/06 05:31 PMCR- 2024/10/28 CRDT- 2024/11/03 23:28 PHST- 2024/03/28 00:00 [received] PHST- 2024/09/11 00:00 [revised] PHST- 2024/10/23 00:00 [accepted] PHST- 2024/12/06 05:31 [medline] PHST- 2024/11/04 00:31 [pubmed] PHST- 2024/11/03 23:28 [entrez] PHST- 2024/10/28 00:00 [pmc-release] AID - S1525-0016(24)00676-2 [pii] AID - 10.1016/j.ymthe.2024.10.016 [doi] PST - ppublish SO - Mol Ther. 2024 Dec 4;32(12):4448-4466. doi: 10.1016/j.ymthe.2024.10.016. Epub 2024 Oct 28. PMID- 39474707 OWN - NLM STAT- MEDLINE DCOM- 20241127 LR - 20250418 IS - 1557-8976 (Electronic) IS - 0882-8245 (Linking) VI - 37 IP - 9 DP - 2024 Nov TI - Memory T Cells Subpopulations in a Cohort of COVID-19 Vaccinated or Recovered Subjects. PG - 440-445 LID - 10.1089/vim.2024.0065 [doi] AB - Following viral infection, antigen-restricted T lymphocytes are activated and recognize infected cells to eliminate them. A subset of T cells differentiates into memory lymphocytes able to counteract viral rechallenge in a faster and enhanced way. SARS-CoV-2 can escape immune responses leading to a poor clinical outcome. Immune escape can be associated with the failure of the development of T cell memory compartments. The aim of this study is to characterize the T memory subsets and to test the immune response against class I- and II-restricted immunodominant epitopes shared by ancestral and SARS-CoV-2 variants strains. T memory subsets and recognition of SARS-CoV-2S Spike-specific epitopes were analyzed by flow cytometry on 14 fully vaccinated healthy donors (HDV) and 18 COVID-19 recovered patients (CD). The results obtained showed that CD8+ T naive subset numbers decreased in association with a significant increase of the effector memory T cell subset whereas there was a small increase in the percentage of SARS-CoV-2 antigen-restricted T clones in both CD4(+) and CD8+ subset in the CD compared to HDV sample. Collectively, these features may reflect a broader cytotoxic T cell repertoire stimulated by the virus during the natural infection compared to the spike-restricted response activated during vaccination. FAU - Iuliano, Marco AU - Iuliano M AUID- ORCID: 0000-0002-3862-9731 AD - Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy. FAU - Mongiovi, Roberta Maria AU - Mongiovi RM AD - Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy. AD - Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina, Italy. FAU - Parente, Alberico AU - Parente A AD - Department of Public Health and Infectious Disease, S. Maria Goretti Hospital, Sapienza University of Rome, Latina, Italy. FAU - Grimaldi, Lorenzo AU - Grimaldi L AD - Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy. FAU - Kertusha, Blerta AU - Kertusha B AD - Department of Public Health and Infectious Disease, S. Maria Goretti Hospital, Sapienza University of Rome, Latina, Italy. FAU - Carraro, Anna AU - Carraro A AD - Department of Public Health and Infectious Disease, S. Maria Goretti Hospital, Sapienza University of Rome, Latina, Italy. FAU - Marocco, Raffaella AU - Marocco R AD - Department of Public Health and Infectious Disease, S. Maria Goretti Hospital, Sapienza University of Rome, Latina, Italy. FAU - Mancarella, Giulia AU - Mancarella G AD - Department of Public Health and Infectious Disease, S. Maria Goretti Hospital, Sapienza University of Rome, Latina, Italy. FAU - Del Borgo, Cosmo AU - Del Borgo C AD - Department of Public Health and Infectious Disease, S. Maria Goretti Hospital, Sapienza University of Rome, Latina, Italy. FAU - Dorrucci, Maria AU - Dorrucci M AD - Department of Infectious Diseases, Istituto Superiore di Sanita, Rome, Italy. FAU - Lichtner, Miriam AU - Lichtner M AD - Department of General Surgery and Surgical Specialty, Sapienza University of Rome, Latina, Italy. FAU - Mangino, Giorgio AU - Mangino G AD - Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy. FAU - Romeo, Giovanna AU - Romeo G AD - Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20241030 PL - United States TA - Viral Immunol JT - Viral immunology JID - 8801552 RN - 0 (COVID-19 Vaccines) RN - 0 (Spike Glycoprotein, Coronavirus) RN - 0 (spike protein, SARS-CoV-2) RN - 0 (Epitopes, T-Lymphocyte) RN - 0 (Immunodominant Epitopes) RN - SARS-CoV-2 variants SB - IM MH - Humans MH - *COVID-19/immunology/prevention & control MH - *Memory T Cells/immunology MH - *SARS-CoV-2/immunology MH - *COVID-19 Vaccines/immunology MH - Male MH - Adult MH - *Spike Glycoprotein, Coronavirus/immunology MH - Female MH - Middle Aged MH - *CD8-Positive T-Lymphocytes/immunology MH - T-Lymphocyte Subsets/immunology MH - Immunologic Memory MH - Epitopes, T-Lymphocyte/immunology MH - CD4-Positive T-Lymphocytes/immunology MH - Immunodominant Epitopes/immunology MH - Cohort Studies MH - Vaccination MH - Aged OTO - NOTNLM OT - SARS-CoV-2 OT - memory T cells OT - vaccine EDAT- 2024/10/30 06:22 MHDA- 2024/11/27 12:36 CRDT- 2024/10/30 05:13 PHST- 2024/11/27 12:36 [medline] PHST- 2024/10/30 06:22 [pubmed] PHST- 2024/10/30 05:13 [entrez] AID - 10.1089/vim.2024.0065 [doi] PST - ppublish SO - Viral Immunol. 2024 Nov;37(9):440-445. doi: 10.1089/vim.2024.0065. Epub 2024 Oct 30. PMID- 39460293 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20241028 IS - 2076-393X (Print) IS - 2076-393X (Electronic) IS - 2076-393X (Linking) VI - 12 IP - 10 DP - 2024 Sep 30 TI - T-Cell Immune Responses to SARS-CoV-2 Infection and Vaccination. LID - 10.3390/vaccines12101126 [doi] LID - 1126 AB - The innate and adaptive immune systems collaborate to detect SARS-CoV-2 infection, minimize the viral spread, and kill infected cells, ultimately leading to the resolution of the infection. The adaptive immune system develops a memory of previous encounters with the virus, providing enhanced responses when rechallenged by the same pathogen. Such immunological memory is the basis of vaccine function. Here, we review the current knowledge on the immune response to SARS-CoV-2 infection and vaccination, focusing on the pivotal role of T cells in establishing protective immunity against the virus. After providing an overview of the immune response to SARS-CoV-2 infection, we describe the main features of SARS-CoV-2-specific CD4(+) and CD8(+) T cells, including cross-reactive T cells, generated in patients with different degrees of COVID-19 severity, and of Spike-specific CD4(+) and CD8(+) T cells induced by vaccines. Finally, we discuss T-cell responses to SARS-CoV-2 variants and hybrid immunity and conclude by highlighting possible strategies to improve the efficacy of COVID-19 vaccination. FAU - Notarbartolo, Samuele AU - Notarbartolo S AUID- ORCID: 0000-0001-5910-4910 AD - Infectious Diseases Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy. LA - eng GR - GR-2021-12374097/Ministero della Salute/ PT - Journal Article PT - Review DEP - 20240930 PL - Switzerland TA - Vaccines (Basel) JT - Vaccines JID - 101629355 PMC - PMC11511197 OTO - NOTNLM OT - COVID-19 vaccine OT - SARS-CoV-2 infection OT - antigen-specific T cells OT - cross-reactive T cells OT - human T cells OT - hybrid immunity OT - immunological memory OT - resident memory T cells OT - vaccine improvement COIS- The author declares no conflicts of interest. EDAT- 2024/10/26 19:21 MHDA- 2024/10/26 19:22 PMCR- 2024/09/30 CRDT- 2024/10/26 01:25 PHST- 2024/09/04 00:00 [received] PHST- 2024/09/25 00:00 [revised] PHST- 2024/09/27 00:00 [accepted] PHST- 2024/10/26 19:22 [medline] PHST- 2024/10/26 19:21 [pubmed] PHST- 2024/10/26 01:25 [entrez] PHST- 2024/09/30 00:00 [pmc-release] AID - vaccines12101126 [pii] AID - vaccines-12-01126 [pii] AID - 10.3390/vaccines12101126 [doi] PST - epublish SO - Vaccines (Basel). 2024 Sep 30;12(10):1126. doi: 10.3390/vaccines12101126. PMID- 39454753 OWN - NLM STAT- MEDLINE DCOM- 20250424 LR - 20250516 IS - 1469-0691 (Electronic) IS - 1198-743X (Linking) VI - 31 IP - 2 DP - 2025 Feb TI - Neurodevelopmental outcomes of infants after in utero exposure to SARS-CoV-2 or mRNA-COVID-19 vaccine compared with unexposed infants: a COVI-PREG prospective cohort study. PG - 266-273 LID - S1198-743X(24)00501-9 [pii] LID - 10.1016/j.cmi.2024.10.019 [doi] AB - OBJECTIVES: Data are lacking regarding the long-term consequences of SARS-CoV-2 and COVID-19 mRNA vaccine on infants exposed in utero. We aimed to evaluate the neurodevelopment of infants exposed prenatally to SARS-CoV-2 or mRNA-COVID-19 vaccine during pregnancy at 12 months after birth. METHODS: Infants born to mothers exposed to SARS-CoV-2 or mRNA-COVID-19 vaccine during pregnancy, or unexposed to either the virus or the vaccine were enrolled from 2021 to 2023. Infants with prenatal exposure to the virus or vaccine were compared with infants without prenatal exposure to the virus and/or vaccine. Parents received a neurodevelopmental questionnaire (ages and stages questionnaire third edition) at 12 months after birth assessing five subdomains: communication, gross motor, fine motor, problem-solving, and personal social development. A low score was defined as <2 standard deviations below the normative mean in at least one of the subdomains. RESULTS: A total of 330 infants were included (76 in the SARS-CoV-2 group, 153 in the mRNA-COVID-19 vaccine group, and 101 in the reference group). In utero exposure to the SARS-CoV-2 or mRNA-COVID-19 vaccine was not associated with an increased risk of a low score for at least one subdomain compared with the reference group. The crude ORs were 1.16 (95% CI, 0.59-2.28) and 1.04 (95% CI, 0.58-1.86), respectively. Results remained consistent in the multivariate analysis, showing no increased risk of a low score for at least one subdomain for infants exposed to the SARS-CoV-2 or mRNA-COVID-19 vaccine, compared with the reference group. The adjusted ORs were 1.74 (95% CI, 0.76-3.99) and 0.76 (95% CI, 0.39-1.49), respectively. DISCUSSION: In utero exposure to SARS-CoV-2 or mRNA-COVID-19 vaccine was not associated with an increased risk of a low score for at least one ages and stages questionnaire third edition subdomain at 12 months after birth. Additional studies are needed to confirm our results, especially longer-term evaluation of infant development. CI - Copyright (c) 2025 The Authors. Published by Elsevier Ltd.. All rights reserved. FAU - Favre, Guillaume AU - Favre G AD - Materno-Fetal and Obstetrics Research Unit, Woman-Mother-Child Department, Centre Hospitalier Universitaire Vaudois (CHUV), University Hospital, Lausanne, Switzerland. FAU - Bromley, Rebecca L AU - Bromley RL AD - Division of Neuroscience, School of Biological Sciences, Faculty of Medicine, Biology and Health, University of Manchester, Manchester, United Kingdom. FAU - Bluett-Duncan, Matthew AU - Bluett-Duncan M AD - Division of Neuroscience, School of Biological Sciences, Faculty of Medicine, Biology and Health, University of Manchester, Manchester, United Kingdom. FAU - Maisonneuve, Emeline AU - Maisonneuve E AD - Materno-Fetal and Obstetrics Research Unit, Woman-Mother-Child Department, Centre Hospitalier Universitaire Vaudois (CHUV), University Hospital, Lausanne, Switzerland; Institute of Primary Health Care Berner Institut fur Hausarztmedizin (BIHAM), University of Bern, Bern, Switzerland; Graduate School for Health Sciences (GHS), University of Bern, Bern, Switzerland. FAU - Pomar, Leo AU - Pomar L AD - Materno-Fetal and Obstetrics Research Unit, Woman-Mother-Child Department, Centre Hospitalier Universitaire Vaudois (CHUV), University Hospital, Lausanne, Switzerland; School of Health Sciences Haute Ecole de Sante Vaud (HESAV), University of Applied Sciences and Arts Western Switzerland, Lausanne, Switzerland. FAU - Daire, Charlotte AU - Daire C AD - Materno-Fetal and Obstetrics Research Unit, Woman-Mother-Child Department, Centre Hospitalier Universitaire Vaudois (CHUV), University Hospital, Lausanne, Switzerland. FAU - Radan, Anda-Petronela AU - Radan AP AD - Department of Obstetrics and Fetal-Maternal Medicine, University Hospital of Bern, University of Bern, Bern, Switzerland. FAU - Raio, Luigi AU - Raio L AD - Department of Obstetrics and Fetal-Maternal Medicine, University Hospital of Bern, University of Bern, Bern, Switzerland. FAU - Surbek, Daniel AU - Surbek D AD - Department of Obstetrics and Fetal-Maternal Medicine, University Hospital of Bern, University of Bern, Bern, Switzerland. FAU - Blume, Carolin AU - Blume C AD - Kantonsspital Graubunden, Frauenklinik Fontana, Chur, Switzerland. FAU - Kalimeris, Stylianos AU - Kalimeris S AD - Kantonsspital Graubunden, Frauenklinik Fontana, Chur, Switzerland. FAU - Madec, Yoann AU - Madec Y AD - Emerging Diseases Epidemiology Unit, Institut Pasteur, Paris, France. FAU - Schneider, Juliane AU - Schneider J AD - Clinic of Neonatology and Developmental Unit, Woman-Mother-Child Department, University Hospital Center and University of Lausanne, Lausanne, Switzerland. FAU - Bickle Graz, Myriam AU - Bickle Graz M AD - Clinic of Neonatology and Developmental Unit, Woman-Mother-Child Department, University Hospital Center and University of Lausanne, Lausanne, Switzerland. FAU - Winterfeld, Ursula AU - Winterfeld U AD - Swiss Teratogen Information Service, Clinical Pharmacology Unit, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Panchaud, Alice AU - Panchaud A AD - Institute of Primary Health Care Berner Institut fur Hausarztmedizin (BIHAM), University of Bern, Bern, Switzerland; Service of Pharmacy, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Baud, David AU - Baud D AD - Materno-Fetal and Obstetrics Research Unit, Woman-Mother-Child Department, Centre Hospitalier Universitaire Vaudois (CHUV), University Hospital, Lausanne, Switzerland. Electronic address: david.baud@chuv.ch. LA - eng PT - Journal Article DEP - 20241023 PL - England TA - Clin Microbiol Infect JT - Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases JID - 9516420 RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - Female MH - Pregnancy MH - Infant MH - Prospective Studies MH - *COVID-19 Vaccines/adverse effects MH - Male MH - *COVID-19/prevention & control MH - *Prenatal Exposure Delayed Effects/epidemiology MH - Adult MH - SARS-CoV-2/immunology MH - *Child Development MH - Infant, Newborn MH - *Neurodevelopmental Disorders/epidemiology/etiology MH - Surveys and Questionnaires OTO - NOTNLM OT - ASQ OT - COVI-PREG OT - COVID-19 OT - Child OT - Infant OT - Neurodevelopment OT - Neurologic OT - SARS-CoV-2 OT - Vaccine OT - mRNA EDAT- 2024/10/26 19:25 MHDA- 2025/01/20 22:53 CRDT- 2024/10/25 19:25 PHST- 2024/08/10 00:00 [received] PHST- 2024/10/15 00:00 [revised] PHST- 2024/10/20 00:00 [accepted] PHST- 2025/01/20 22:53 [medline] PHST- 2024/10/26 19:25 [pubmed] PHST- 2024/10/25 19:25 [entrez] AID - S1198-743X(24)00501-9 [pii] AID - 10.1016/j.cmi.2024.10.019 [doi] PST - ppublish SO - Clin Microbiol Infect. 2025 Feb;31(2):266-273. doi: 10.1016/j.cmi.2024.10.019. Epub 2024 Oct 23. PMID- 39446607 OWN - NLM STAT- MEDLINE DCOM- 20241212 LR - 20250617 IS - 1537-2995 (Electronic) IS - 0041-1132 (Linking) VI - 64 IP - 12 DP - 2024 Dec TI - Shared decision-making for patients with vaccine-related concerns of blood transfusion: A single institution experience. PG - 2247-2251 LID - 10.1111/trf.18052 [doi] AB - BACKGROUND: Some patients express concerns regarding receipt of allogeneic blood transfusions from donors potentially vaccinated against SARS-CoV-2 (COVID-19). However, limited information exists about patients' expression of these concerns or how to address them during the blood transfusion consent process. In this study, we describe our experience of working collaboratively with patients with vaccine-related transfusion concerns prior to elective surgery, summarizing treatment decisions and clinical outcomes. STUDY DESIGN AND METHODS: This observational descriptive study includes patients seen in our Bloodless Medicine and Surgery clinic between June 2022 and June 2024 for vaccine-related transfusion concerns prior to elective surgery. A shared decision-making framework was employed to foster conversation, share information, provide reassurance, reconcile conflict, and match preferences with available care options. Patient characteristics, treatment decisions, and surgical outcomes were reviewed and summarized. RESULTS: Thirty-five patients were included, with median (1st, 3rd quartile) age of 61 (53, 69) years. Cardiac surgery was the most common type of surgery (29%). Twelve patients (34%) were anemic preoperatively, and all received preoperative treatment. After discussion with a Bloodless Medicine specialist, 24 (68.6%) decided to consent to the use of all blood products, 5 (14.3%) accepted only red blood cells, and 6 (17.1%) declined all blood products. Among 28 patients undergoing surgery, only 4 (14%) received allogeneic transfusion perioperatively. CONCLUSION: Many patients concerned about the vaccination status of blood donors may ultimately consent to allogeneic blood products after shared decision-making with a Bloodless Medicine specialist, highlighting the importance of patient empowerment and collaborative care. CI - (c) 2024 AABB. FAU - Cho, David J AU - Cho DJ AUID- ORCID: 0000-0002-1351-4313 AD - Mayo Clinic Alix School of Medicine, Mayo Clinic, Rochester, Minnesota, USA. FAU - Klompas, Allan M AU - Klompas AM AUID- ORCID: 0000-0001-8852-4666 AD - Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, Minnesota, USA. AD - Patient Blood Management Program, Mayo Clinic, Rochester, Minnesota, USA. FAU - Gonzalez, Jessica A AU - Gonzalez JA AD - Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, Minnesota, USA. AD - Patient Blood Management Program, Mayo Clinic, Rochester, Minnesota, USA. FAU - Petsch, Jamie L AU - Petsch JL AD - Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, Minnesota, USA. AD - Patient Blood Management Program, Mayo Clinic, Rochester, Minnesota, USA. FAU - Burt, Jen M AU - Burt JM AD - Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, Minnesota, USA. AD - Patient Blood Management Program, Mayo Clinic, Rochester, Minnesota, USA. FAU - Kor, Daryl J AU - Kor DJ AD - Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, Minnesota, USA. AD - Patient Blood Management Program, Mayo Clinic, Rochester, Minnesota, USA. FAU - Winters, Jeffrey L AU - Winters JL AD - Division of Transfusion Medicine, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA. FAU - van Buskirk, Camille M AU - van Buskirk CM AD - Division of Transfusion Medicine, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA. FAU - Warner, Matthew A AU - Warner MA AUID- ORCID: 0000-0002-6625-8755 AD - Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, Minnesota, USA. AD - Patient Blood Management Program, Mayo Clinic, Rochester, Minnesota, USA. LA - eng GR - K23HL153310/HL/NHLBI NIH HHS/United States GR - National Institutes of Health (NIH)/ GR - K23HL153310/HL/NHLBI NIH HHS/United States PT - Journal Article PT - Observational Study PT - Research Support, N.I.H., Extramural DEP - 20241024 PL - United States TA - Transfusion JT - Transfusion JID - 0417360 RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - Middle Aged MH - Male MH - Female MH - Aged MH - *Blood Transfusion MH - *Decision Making, Shared MH - *COVID-19 Vaccines MH - *COVID-19/prevention & control MH - SARS-CoV-2 MH - Elective Surgical Procedures OTO - NOTNLM OT - RBC transfusion OT - consent OT - donors OT - patient blood management OT - platelet transfusion EDAT- 2024/10/25 07:20 MHDA- 2024/12/12 18:23 CRDT- 2024/10/24 12:43 PHST- 2024/09/20 00:00 [revised] PHST- 2024/08/12 00:00 [received] PHST- 2024/10/12 00:00 [accepted] PHST- 2024/12/12 18:23 [medline] PHST- 2024/10/25 07:20 [pubmed] PHST- 2024/10/24 12:43 [entrez] AID - 10.1111/trf.18052 [doi] PST - ppublish SO - Transfusion. 2024 Dec;64(12):2247-2251. doi: 10.1111/trf.18052. Epub 2024 Oct 24. PMID- 39439787 OWN - NLM STAT- MEDLINE DCOM- 20241023 LR - 20261020 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 15 DP - 2024 TI - Role of SARS-CoV-2-specific memory B cells promoting immune protection after booster vaccination in solid organ transplantation. PG - 1463769 LID - 10.3389/fimmu.2024.1463769 [doi] LID - 1463769 AB - INTRODUCTION: Solid organ transplant (SOT) recipients display weak seroconversion and neutralizing antibody (NAb) responses after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination and remain at risk of severe coronavirus disease 2019 (COVID-19). While B-cell memory is the hallmark of serological immunity, its role in driving successful vaccine responses and providing immune protection in SOT patients remains unclear. METHODS: We investigated the function and interplay of SARS-CoV-2-specific memory B cells (mBc), different cytokineproducing T cells, and cross-reactive NAb in driving seroconversion and protection against COVID-19 in two cohorts. First, we studied a large cohort of 148 SOT recipients and 32 immunocompetent individuals who underwent several vaccinations. Subsequently, we assessed 25 SOT patients participating in a randomized controlled trial to compare two different immunosuppressive strategies for allowing successful seroconversion and memory-cell responses after booster vaccination. RESULTS: We corroborate previous findings that B- and T-cell memory responses are weaker and more delayed in SOT patients than in immunocompetent (IC) individuals; however, within the SOT cohort, we found that these responses are relatively stronger and more robust in patients not receiving mycophenolate mofetil (MMF)-based therapies. Anti- spike IgG titers strongly correlated with RBD-specific IgG-producing mBc, with both displaying broad viral cross reactivity. Prebooster SARS-CoV-2-specific mBc and IL-2- producing T cells accurately predicted Nab seroconversion (AUC, 0.828) and protection against severe COVID-19. While switching unresponsive SOT patients from calcineurin inhibitors (CNI)/MMF to a low-exposure CNI/mTOR-i regimen favored wider SARS-CoV-2-specific immune responses after a fourth booster vaccination, preformed RBD-specific mBc predicted NAb seroconversion. DISCUSSION: Our study adds new insights into the pathobiology of immune memory and highlights the pivotal role of SARS-CoV-2-specific mBc in promoting immune protection inSOT patients. CI - Copyright (c) 2024 Donadeu, Gomez-Olles, Casanova, Torija, Lopez-Meseguer, Boada-Perez, Kervella, Crespo, Carrera-Munoz, Campos-Varela, Castells, Cortese, Esperalba, Fernandez-Naval, Quintero, Munoz, Aguero, Gonzalez-Costello, Llado, Fava, Canas, del Mar de la Hoz-Caballero, Meneghini, Torres, Juve, Hafkamp, Vila, Robles, Buzon, Toapanta, Zuniga, Monforte, Saez-Gimenez, Len, Arcos, Miret, Ariceta, Pardo, Martinez, Moreso and Bestard. FAU - Donadeu, Laura AU - Donadeu L AD - Laboratory of Nephrology and Transplantation, Vall d'Hebron Institut de Recerca (VHIR), Universitat Autonoma de Barcelona, Barcelona, Spain. AD - Vall d'Hebron for Solid Organ Transplantation Research Group, Vall d'Hebron Institut de Recerca (VHIR), Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - Gomez-Olles, Susana AU - Gomez-Olles S AD - Vall d'Hebron for Solid Organ Transplantation Research Group, Vall d'Hebron Institut de Recerca (VHIR), Universitat Autonoma de Barcelona, Barcelona, Spain. AD - Laboratory of Pneumology, Vall d'Hebron Institut de Recerca (VHIR), Universitat Autonoma de Barcelona, Barcelona, Spain. AD - Ciber Enfermedades Respiratorias (CIBERES), Madrid, Spain. FAU - Casanova, Franc AU - Casanova F AD - Laboratory of Nephrology and Transplantation, Vall d'Hebron Institut de Recerca (VHIR), Universitat Autonoma de Barcelona, Barcelona, Spain. AD - Vall d'Hebron for Solid Organ Transplantation Research Group, Vall d'Hebron Institut de Recerca (VHIR), Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - Torija, Alba AU - Torija A AD - Laboratory of Nephrology and Transplantation, Vall d'Hebron Institut de Recerca (VHIR), Universitat Autonoma de Barcelona, Barcelona, Spain. AD - Vall d'Hebron for Solid Organ Transplantation Research Group, Vall d'Hebron Institut de Recerca (VHIR), Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - Lopez-Meseguer, Manuel AU - Lopez-Meseguer M AD - Vall d'Hebron for Solid Organ Transplantation Research Group, Vall d'Hebron Institut de Recerca (VHIR), Universitat Autonoma de Barcelona, Barcelona, Spain. AD - Laboratory of Pneumology, Vall d'Hebron Institut de Recerca (VHIR), Universitat Autonoma de Barcelona, Barcelona, Spain. AD - Ciber Enfermedades Respiratorias (CIBERES), Madrid, Spain. AD - Lung Transplant Unit, Pneumology Department, Vall d'Hebron Hospital Universitari, Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - Boada-Perez, Meritxell AU - Boada-Perez M AD - Vall d'Hebron for Solid Organ Transplantation Research Group, Vall d'Hebron Institut de Recerca (VHIR), Universitat Autonoma de Barcelona, Barcelona, Spain. AD - Laboratory of Pneumology, Vall d'Hebron Institut de Recerca (VHIR), Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - Kervella, Delphine AU - Kervella D AD - Laboratory of Nephrology and Transplantation, Vall d'Hebron Institut de Recerca (VHIR), Universitat Autonoma de Barcelona, Barcelona, Spain. AD - Vall d'Hebron for Solid Organ Transplantation Research Group, Vall d'Hebron Institut de Recerca (VHIR), Universitat Autonoma de Barcelona, Barcelona, Spain. AD - Kidney Transplant Unit, Nephrology Department, Vall d'Hebron Hospital Universitari, Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - Crespo, Elena AU - Crespo E AD - Laboratory of Nephrology and Transplantation, Vall d'Hebron Institut de Recerca (VHIR), Universitat Autonoma de Barcelona, Barcelona, Spain. AD - Vall d'Hebron for Solid Organ Transplantation Research Group, Vall d'Hebron Institut de Recerca (VHIR), Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - Carrera-Munoz, Claudia AU - Carrera-Munoz C AD - Laboratory of Nephrology and Transplantation, Vall d'Hebron Institut de Recerca (VHIR), Universitat Autonoma de Barcelona, Barcelona, Spain. AD - Vall d'Hebron for Solid Organ Transplantation Research Group, Vall d'Hebron Institut de Recerca (VHIR), Universitat Autonoma de Barcelona, Barcelona, Spain. AD - Kidney Transplant Unit, Nephrology Department, Vall d'Hebron Hospital Universitari, Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - Campos-Varela, Isabel AU - Campos-Varela I AD - Vall d'Hebron for Solid Organ Transplantation Research Group, Vall d'Hebron Institut de Recerca (VHIR), Universitat Autonoma de Barcelona, Barcelona, Spain. AD - Liver Unit, Vall d'Hebron Hospital Universitari, Universitat Autonoma de Barcelona, Barcelona, Spain. AD - Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain. FAU - Castells, Lluis AU - Castells L AD - Vall d'Hebron for Solid Organ Transplantation Research Group, Vall d'Hebron Institut de Recerca (VHIR), Universitat Autonoma de Barcelona, Barcelona, Spain. AD - Liver Unit, Vall d'Hebron Hospital Universitari, Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - Cortese, Maria F AU - Cortese MF AD - Microbiology Department, Vall d'Hebron Hospital Universitari, Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - Esperalba, Juliana AU - Esperalba J AD - Vall d'Hebron for Solid Organ Transplantation Research Group, Vall d'Hebron Institut de Recerca (VHIR), Universitat Autonoma de Barcelona, Barcelona, Spain. AD - Microbiology Department, Vall d'Hebron Hospital Universitari, Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - Fernandez-Naval, Candela AU - Fernandez-Naval C AD - Microbiology Department, Vall d'Hebron Hospital Universitari, Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - Quintero, Jesus AU - Quintero J AD - Vall d'Hebron for Solid Organ Transplantation Research Group, Vall d'Hebron Institut de Recerca (VHIR), Universitat Autonoma de Barcelona, Barcelona, Spain. AD - Pediatric Hepatology and Liver Transplant Department, Vall d'Hebron Hospital Universitari, Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - Munoz, Marina AU - Munoz M AD - Vall d'Hebron for Solid Organ Transplantation Research Group, Vall d'Hebron Institut de Recerca (VHIR), Universitat Autonoma de Barcelona, Barcelona, Spain. AD - Department of Pediatric Nephrology, Vall d'Hebron Hospital Universitari, Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - Aguero, Fernando AU - Aguero F AD - Department of Preventive Medicine and Epidemiology, Bellvitge University Hospital, Barcelona, Spain. FAU - Gonzalez-Costello, Jose AU - Gonzalez-Costello J AD - Advanced Heart Failure and Heart Transplant Unit, Department of Cardiology, Hospital Universitari de Bellvitge, BIOHEART-Cardiovascular Diseases Research Group, Bellvitge Biomedical Research Institute (IDIBELL), Universitat de Barcelona, Ciber Cardiovascular (CIBERCV), Barcelona, Spain. FAU - Llado, Laura AU - Llado L AD - Liver Transplant Unit, Bellvitge University Hospital, Barcelona, Spain. FAU - Fava, Alexandre AU - Fava A AD - Kidney Transplant Unit, Bellvitge University Hospital, Barcelona, Spain. FAU - Canas, Laura AU - Canas L AD - Kidney Transplant Unit, Nephrology department, Germans Trias i Pujol Hospital, Badalona, Spain. FAU - Del Mar de la Hoz-Caballero, Maria AU - Del Mar de la Hoz-Caballero M AD - Equipo de Atencion Primaria Sant Rafael, Servei d'Atencio Primaria (SAP) Muntanya, Gerencia Territorial de Barcelona Ciutat, Institut Catala de la Salut, Barcelona, Spain. FAU - Meneghini, Maria AU - Meneghini M AD - Laboratory of Nephrology and Transplantation, Vall d'Hebron Institut de Recerca (VHIR), Universitat Autonoma de Barcelona, Barcelona, Spain. AD - Vall d'Hebron for Solid Organ Transplantation Research Group, Vall d'Hebron Institut de Recerca (VHIR), Universitat Autonoma de Barcelona, Barcelona, Spain. AD - Kidney Transplant Unit, Nephrology Department, Vall d'Hebron Hospital Universitari, Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - Torres, Irina B AU - Torres IB AD - Vall d'Hebron for Solid Organ Transplantation Research Group, Vall d'Hebron Institut de Recerca (VHIR), Universitat Autonoma de Barcelona, Barcelona, Spain. AD - Kidney Transplant Unit, Nephrology Department, Vall d'Hebron Hospital Universitari, Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - Juve, Mariona AU - Juve M AD - Laboratory of Nephrology and Transplantation, Vall d'Hebron Institut de Recerca (VHIR), Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - Hafkamp, Fmj AU - Hafkamp F AD - Laboratory of Nephrology and Transplantation, Vall d'Hebron Institut de Recerca (VHIR), Universitat Autonoma de Barcelona, Barcelona, Spain. AD - Vall d'Hebron for Solid Organ Transplantation Research Group, Vall d'Hebron Institut de Recerca (VHIR), Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - Vila, Marta AU - Vila M AD - Microbiology Department, Vall d'Hebron Hospital Universitari, Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - Robles, Alba G AU - Robles AG AD - Infectious Diseases Department, Vall d'Hebron Institut de Recerca (VHIR), Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - Buzon, Maria Jose AU - Buzon MJ AD - Infectious Diseases Department, Vall d'Hebron Institut de Recerca (VHIR), Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - Toapanta, Nestor AU - Toapanta N AD - Vall d'Hebron for Solid Organ Transplantation Research Group, Vall d'Hebron Institut de Recerca (VHIR), Universitat Autonoma de Barcelona, Barcelona, Spain. AD - Kidney Transplant Unit, Nephrology Department, Vall d'Hebron Hospital Universitari, Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - Zuniga, Jose Miguel AU - Zuniga JM AD - Laboratory of Nephrology and Transplantation, Vall d'Hebron Institut de Recerca (VHIR), Universitat Autonoma de Barcelona, Barcelona, Spain. AD - Vall d'Hebron for Solid Organ Transplantation Research Group, Vall d'Hebron Institut de Recerca (VHIR), Universitat Autonoma de Barcelona, Barcelona, Spain. AD - Kidney Transplant Unit, Nephrology Department, Vall d'Hebron Hospital Universitari, Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - Monforte, Victor AU - Monforte V AD - Vall d'Hebron for Solid Organ Transplantation Research Group, Vall d'Hebron Institut de Recerca (VHIR), Universitat Autonoma de Barcelona, Barcelona, Spain. AD - Laboratory of Pneumology, Vall d'Hebron Institut de Recerca (VHIR), Universitat Autonoma de Barcelona, Barcelona, Spain. AD - Lung Transplant Unit, Pneumology Department, Vall d'Hebron Hospital Universitari, Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - Saez-Gimenez, Berta AU - Saez-Gimenez B AD - Vall d'Hebron for Solid Organ Transplantation Research Group, Vall d'Hebron Institut de Recerca (VHIR), Universitat Autonoma de Barcelona, Barcelona, Spain. AD - Laboratory of Pneumology, Vall d'Hebron Institut de Recerca (VHIR), Universitat Autonoma de Barcelona, Barcelona, Spain. AD - Lung Transplant Unit, Pneumology Department, Vall d'Hebron Hospital Universitari, Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - Len, Oscar AU - Len O AD - Vall d'Hebron for Solid Organ Transplantation Research Group, Vall d'Hebron Institut de Recerca (VHIR), Universitat Autonoma de Barcelona, Barcelona, Spain. AD - Department of Infectious Diseases, Vall d'Hebron Hospital Universitari, Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - Arcos, Ibai Los AU - Arcos IL AD - Vall d'Hebron for Solid Organ Transplantation Research Group, Vall d'Hebron Institut de Recerca (VHIR), Universitat Autonoma de Barcelona, Barcelona, Spain. AD - Department of Infectious Diseases, Vall d'Hebron Hospital Universitari, Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - Miret, Enric AU - Miret E AD - Vall d'Hebron for Solid Organ Transplantation Research Group, Vall d'Hebron Institut de Recerca (VHIR), Universitat Autonoma de Barcelona, Barcelona, Spain. AD - Urology Department, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institut de Recerca (VHIR), Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - Ariceta, Gema AU - Ariceta G AD - Vall d'Hebron for Solid Organ Transplantation Research Group, Vall d'Hebron Institut de Recerca (VHIR), Universitat Autonoma de Barcelona, Barcelona, Spain. AD - Department of Pediatric Nephrology, Vall d'Hebron Hospital Universitari, Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - Pardo, Emma AU - Pardo E AD - Kidney Transplant Unit, Nephrology Department, Vall d'Hebron Hospital Universitari, Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - Martinez, Xavier AU - Martinez X AD - Department of Preventive Medicine and Epidemiology, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institut de Recerca (VHIR), Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - Moreso, Francesc AU - Moreso F AD - Vall d'Hebron for Solid Organ Transplantation Research Group, Vall d'Hebron Institut de Recerca (VHIR), Universitat Autonoma de Barcelona, Barcelona, Spain. AD - Kidney Transplant Unit, Nephrology Department, Vall d'Hebron Hospital Universitari, Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - Bestard, Oriol AU - Bestard O AD - Laboratory of Nephrology and Transplantation, Vall d'Hebron Institut de Recerca (VHIR), Universitat Autonoma de Barcelona, Barcelona, Spain. AD - Vall d'Hebron for Solid Organ Transplantation Research Group, Vall d'Hebron Institut de Recerca (VHIR), Universitat Autonoma de Barcelona, Barcelona, Spain. AD - Kidney Transplant Unit, Nephrology Department, Vall d'Hebron Hospital Universitari, Universitat Autonoma de Barcelona, Barcelona, Spain. LA - eng SI - EudraCT/2022-000617-13 PT - Journal Article PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't DEP - 20241008 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 RN - 0 (Antibodies, Viral) RN - 0 (COVID-19 Vaccines) RN - 0 (Antibodies, Neutralizing) RN - 0 (Immunosuppressive Agents) SB - IM MH - Humans MH - *COVID-19/immunology/prevention & control MH - *SARS-CoV-2/immunology MH - Male MH - Middle Aged MH - *Antibodies, Viral/blood/immunology MH - Female MH - *Memory B Cells/immunology MH - *COVID-19 Vaccines/immunology MH - *Antibodies, Neutralizing/immunology/blood MH - *Organ Transplantation/adverse effects MH - *Immunization, Secondary MH - Aged MH - Adult MH - Immunosuppressive Agents/therapeutic use MH - Immunologic Memory MH - Seroconversion MH - Vaccination PMC - PMC11493670 OTO - NOTNLM OT - SARS-CoV-2 OT - adaptive immunity OT - booster vaccination OT - neutralizing antibodies OT - solid organ transplantation COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision. EDAT- 2024/10/23 10:55 MHDA- 2024/10/23 10:56 PMCR- 2024/01/01 CRDT- 2024/10/23 04:19 PHST- 2024/07/12 00:00 [received] PHST- 2024/09/09 00:00 [accepted] PHST- 2024/10/23 10:56 [medline] PHST- 2024/10/23 10:55 [pubmed] PHST- 2024/10/23 04:19 [entrez] PHST- 2024/01/01 00:00 [pmc-release] AID - 10.3389/fimmu.2024.1463769 [doi] PST - epublish SO - Front Immunol. 2024 Oct 8;15:1463769. doi: 10.3389/fimmu.2024.1463769. eCollection 2024. PMID- 39434214 OWN - NLM STAT- MEDLINE DCOM- 20241022 LR - 20241203 IS - 2164-554X (Electronic) IS - 2164-5515 (Print) IS - 2164-5515 (Linking) VI - 20 IP - 1 DP - 2024 Dec 31 TI - Humoral and cellular immune response to AZD1222 /Covishield and BV152/Covaxin COVID-19 vaccines among adults in India. PG - 2410579 LID - 10.1080/21645515.2024.2410579 [doi] LID - 2410579 AB - Several COVID-19 vaccines were developed using different approaches to prevent both symptomatic COVID-19 cases and fatalities. The adults were vaccinated with two doses of AZD1222/Covishield (n = 77) [manufactured by Serum Institute of India Pvt Ltd] vaccine and BV152/Covaxin (n = 99) [manufactured by Bharat Biotech] vaccine. They were assessed for immune response at pre-vaccination, 1 month post first and 6 months post second dose for anti-SARS-CoV-2 IgG antibody, surrogate neutralizing antibody (NAbs), immune phenotypes, antigen specific NK, B and T cell response, their effector functionality by ELISPOT and plasma cytokine profile. Both vaccines elicited enhanced IgG antibody and Nab levels compared to the baseline. BV152/Covaxin, the whole virus inactivated vaccine exhibited higher IgG (70% vs 100%), Nab (90% vs 100%), and robust T cell (31% vs 96%) responses at 6 months post second dose compared to 1 month post first dose justifying the utility of the second dose. Detection of SARS-CoV-2 WV and S1 specific CD4+ central T cell memory response in AZD1222/Covishield vaccinee at 6 months post second dose and higher CD4+ and CD8+ naive and central memory T cell response in BV152/Covaxin vaccinee at 1 month post first dose indicated the involvement of memory T cells. Persistent IgG and NAb responses along with IgG+B and IgG+memory B cells in AZD1222/Covishield recipients at 6 months post second dose indicated sustained immune memory response. Continued heightened IFN-gamma secreting T cell response (ELISPOT) displayed by both the vaccine platforms could serve as a co correlate of protection, further to evaluation in follow up studies. Overall, our data suggest that coordinated functions of humoral and cellular branches of adaptive immunity may pave ways toward protective immunity against COVID-19. FAU - Tripathy, Anuradha S AU - Tripathy AS AUID- ORCID: 0000-0002-8919-3819 AD - ICMR-National Institute of Virology, Pune, India. FAU - Singh, Dharmendra AU - Singh D AD - ICMR-National Institute of Virology, Pune, India. FAU - Trimbake, Diptee AU - Trimbake D AD - ICMR-National Institute of Virology, Pune, India. FAU - Salwe, Sukeshani AU - Salwe S AD - ICMR-National Institute of Virology, Pune, India. FAU - Tripathy, Srikanth AU - Tripathy S AD - Dr. D. Y. Patil Medical College, Hospital & Research Centre, Pune, India. FAU - Kakrani, Arjun AU - Kakrani A AD - Dr. D. Y. Patil Medical College, Hospital & Research Centre, Pune, India. FAU - Jali, Priyanka AU - Jali P AD - Dr. D. Y. Patil Medical College, Hospital & Research Centre, Pune, India. FAU - Chavan, Hanmant AU - Chavan H AD - Dr. D. Y. Patil Medical College, Hospital & Research Centre, Pune, India. FAU - Yadav, Pragya AU - Yadav P AD - ICMR-National Institute of Virology, Pune, India. FAU - Sahay, Rima AU - Sahay R AD - ICMR-National Institute of Virology, Pune, India. FAU - Sarje, Prakash AU - Sarje P AD - ICMR-National Institute of Virology, Pune, India. FAU - Babar, Prasad AU - Babar P AD - ICMR-National Institute of Virology, Pune, India. FAU - Shete, Anita AU - Shete A AD - ICMR-National Institute of Virology, Pune, India. FAU - Nandapurkar, Ashok AU - Nandapurkar A AD - Aundh Chest Hospital, Pune, India. FAU - Kulkarni, Milind AU - Kulkarni M AD - Aundh Chest Hospital, Pune, India. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20241021 PL - United States TA - Hum Vaccin Immunother JT - Human vaccines & immunotherapeutics JID - 101572652 RN - 0 (COVID-19 Vaccines) RN - 0 (Antibodies, Viral) RN - 0 (Antibodies, Neutralizing) RN - 0 (Immunoglobulin G) RN - 0 (Cytokines) RN - 0 (Vaccines, Inactivated) RN - 76JZE5DSN6 (BBV152 COVID-19 vaccine) SB - IM MH - Humans MH - *COVID-19 Vaccines/immunology/administration & dosage MH - *Antibodies, Viral/blood MH - India MH - Adult MH - *COVID-19/prevention & control/immunology MH - *Antibodies, Neutralizing/blood MH - *Immunity, Cellular MH - *Immunity, Humoral MH - *Immunoglobulin G/blood MH - *SARS-CoV-2/immunology MH - Male MH - Female MH - Middle Aged MH - Cytokines MH - Young Adult MH - Vaccines, Inactivated/immunology/administration & dosage MH - T-Lymphocytes/immunology PMC - PMC11497953 OTO - NOTNLM OT - AZD1222/Covishield OT - BV152/Covaxin OT - SARS CoV-2 specific IgG and "Neutralizing antibodies" OT - longitudinal follow-up at 6 months post second dose OT - "B-lymphocytes memory" OT - "T cell response" OT - "T-lymphocytes memory" COIS- No potential conflict of interest was reported by the author(s). EDAT- 2024/10/22 06:27 MHDA- 2024/10/22 06:28 PMCR- 2024/10/21 CRDT- 2024/10/22 00:03 PHST- 2024/10/22 06:28 [medline] PHST- 2024/10/22 06:27 [pubmed] PHST- 2024/10/22 00:03 [entrez] PHST- 2024/10/21 00:00 [pmc-release] AID - 2410579 [pii] AID - 10.1080/21645515.2024.2410579 [doi] PST - ppublish SO - Hum Vaccin Immunother. 2024 Dec 31;20(1):2410579. doi: 10.1080/21645515.2024.2410579. Epub 2024 Oct 21. PMID- 39431229 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20260923 IS - 2717-011X (Electronic) IS - 2717-011X (Linking) VI - 23 IP - 1 DP - 2024 Jan 5 TI - New diagnosis of multiple sclerosis in the setting of recent Sinopharm COVID-19 vaccine (BBIBP-CorV) exposure: A series of clinical cases and updated review of the literature. PG - 21-38 LID - 10.18502/cjn.v23i1.16430 [doi] AB - Background: Multiple sclerosis (MS) is the most common cause of non-traumatic disability in young individuals. There are limited reports of developing demyelinating events following the coronavirus disease 2019 (COVID-19) vaccination. Methods: We reported all individuals (n = 8) with new MS diagnoses with recent exposure (/=60 who received at least 1 anti-SARS-CoV-2 vaccine dose. METHODS: Baseline data covered sociodemographic details, chronic diseases, medications, nutritional status, cognitive and functional assessments, mobility, and frailty. Delirium was assessed post-first, second, and booster vaccine doses using DSM-5 criteria. Data analysis involved descriptive statistics, multivariate logistic regression, and network analysis. RESULTS: A total of 2521 participants (mean age 83.10 +/- 9.21 years, 70.7% female) were analyzed. Delirium incidence post-first, second, and booster doses was 3.5%, 1.6%, and 1.5%, respectively. Age, preexisting cognitive disorders, and frailty were significant predictors of delirium, with odds ratios (ORs) of 1.70 (95% CI, 1.08-2.77), 2.05 (95% CI, 1.40-2.97), and 1.77 (95% CI, 1.25-2.52), respectively. Prior use of antipsychotics (OR, 1.75; 95% CI, 1.22-2.51) and antidepressants (OR, 1.77; 95% CI, 1.25-2.52) correlated significantly with delirium. Network analysis indicated a strong association between anorexia and delirium. CONCLUSION AND IMPLICATIONS: Post-vaccination delirium is infrequent and decreases with subsequent doses. Timely assessments for frailty and cognitive impairment could aid in stratifying delirium risk among LTCF residents, facilitating enhanced prevention measures and close monitoring for delirium indicators. CI - Copyright (c) 2024 The Author(s). Published by Elsevier Inc. All rights reserved. FAU - Okoye, Chukwuma AU - Okoye C AD - Department of Medicine and Surgery, University of Milano-Bicocca, Milano, Italy; Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy; Department of Neurobiology, Care Sciences and Society, Aging Research Center, Karolinska Institutet and Stockholm University, Stockholm, Sweden. FAU - Zazzara, Maria Beatrice AU - Zazzara MB AD - Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy; Universita Cattolica del Sacro Cuore, Rome, Italy. FAU - Ceolin, Chiara AU - Ceolin C AD - Department of Neurobiology, Care Sciences and Society, Aging Research Center, Karolinska Institutet and Stockholm University, Stockholm, Sweden; Department of Medicine (DIMED), Geriatrics Division, University of Padova, Padova, Italy. Electronic address: chiara.ceolin.1@phd.unipd.it. FAU - Fedele, Giorgio AU - Fedele G AD - Department of Infectious Diseases, Istituto Superiore di Sanita, Rome, Italy. FAU - Palmieri, Annapina AU - Palmieri A AD - Department of Cardiovascular, Endocrine-Metabolic Diseases and Aging, Istituto Superiore di Sanita, Rome, Italy. FAU - Abbatecola, Angela Marie AU - Abbatecola AM AD - Alzheimer's Disease Day Clinic, Azienda Sanitaria Locale, Frosinone, Italy. FAU - Malara, Alba AU - Malara A AD - ANASTE Humanitas Foundation, Rome, Italy. FAU - Trevisan, Caterina AU - Trevisan C AD - Department of Medical Sciences, University of Ferrara, Ferrara, Italy. FAU - Timmons, Suzanne AU - Timmons S AD - Centre for Gerontology and Rehabilitation, School of Medicine, University College Cork, Cork, Ireland. FAU - Prato, Rosa AU - Prato R AD - Hygiene Unit, Policlinico Foggia Hospital, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy. FAU - Fortunato, Francesca AU - Fortunato F AD - Hygiene Unit, Policlinico Foggia Hospital, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy. FAU - Del Signore, Susanna AU - Del Signore S AD - Bluecompanion Ltd, Londra, UK. FAU - Bellelli, Giuseppe AU - Bellelli G AD - Department of Medicine and Surgery, University of Milano-Bicocca, Milano, Italy; Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy. FAU - Incalzi, Raffaele Antonelli AU - Incalzi RA AD - Campus Bio-Medico University, Rome, Italy. FAU - Onder, Graziano AU - Onder G AD - Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy; Universita Cattolica del Sacro Cuore, Rome, Italy. FAU - Coin, Alessandra AU - Coin A AD - Department of Medicine (DIMED), Geriatrics Division, University of Padova, Padova, Italy. CN - GeroCovid Vax Working Group LA - eng PT - Journal Article PT - Multicenter Study PT - Research Support, Non-U.S. Gov't DEP - 20240905 PL - United States TA - J Am Med Dir Assoc JT - Journal of the American Medical Directors Association JID - 100893243 RN - 0 (COVID-19 Vaccines) SB - IM MH - Aged MH - Aged, 80 and over MH - Female MH - Humans MH - Male MH - *COVID-19/prevention & control/epidemiology MH - *COVID-19 Vaccines/administration & dosage MH - *Delirium/epidemiology/prevention & control MH - Incidence MH - Italy/epidemiology MH - *Long-Term Care MH - Prospective Studies MH - SARS-CoV-2 OTO - NOTNLM OT - COVID-19 OT - frailty OT - long-term facilities OT - older adults OT - vaccine COIS- Disclosures The authors declare no conflicts of interest. EDAT- 2024/09/09 00:50 MHDA- 2024/11/13 13:55 CRDT- 2024/09/08 19:24 PHST- 2024/04/15 00:00 [received] PHST- 2024/07/30 00:00 [revised] PHST- 2024/08/02 00:00 [accepted] PHST- 2024/11/13 13:55 [medline] PHST- 2024/09/09 00:50 [pubmed] PHST- 2024/09/08 19:24 [entrez] AID - S1525-8610(24)00673-X [pii] AID - 10.1016/j.jamda.2024.105251 [doi] PST - ppublish SO - J Am Med Dir Assoc. 2024 Nov;25(11):105251. doi: 10.1016/j.jamda.2024.105251. Epub 2024 Sep 5. PMID- 39240335 OWN - NLM STAT- MEDLINE DCOM- 20240906 LR - 20260625 IS - 1540-9538 (Electronic) IS - 0022-1007 (Print) IS - 0022-1007 (Linking) VI - 221 IP - 10 DP - 2024 Oct 7 TI - Modeling memory B cell responses in a lymphoid organ-chip to evaluate mRNA vaccine boosting. LID - 10.1084/jem.20240289 [doi] LID - e20240289 AB - Predicting the immunogenicity of candidate vaccines in humans remains a challenge. To address this issue, we developed a lymphoid organ-chip (LO chip) model based on a microfluidic chip seeded with human PBMC at high density within a 3D collagen matrix. Perfusion of the SARS-CoV-2 spike protein mimicked a vaccine boost by inducing a massive amplification of spike-specific memory B cells, plasmablast differentiation, and spike-specific antibody secretion. Features of lymphoid tissue, including the formation of activated CD4+ T cell/B cell clusters and the emigration of matured plasmablasts, were recapitulated in the LO chip. Importantly, myeloid cells were competent at capturing and expressing mRNA vectored by lipid nanoparticles, enabling the assessment of responses to mRNA vaccines. Comparison of on-chip responses to Wuhan monovalent and Wuhan/Omicron bivalent mRNA vaccine boosts showed equivalent induction of Omicron neutralizing antibodies, pointing at immune imprinting as reported in vivo. The LO chip thus represents a versatile platform suited to the preclinical evaluation of vaccine-boosting strategies. CI - (c) 2024 Jeger-Madiot et al. FAU - Jeger-Madiot, Raphael AU - Jeger-Madiot R AUID- ORCID: 0009-0009-3444-8536 AD - Control of Chronic Viral Infections Group, Virus and Immunity Unit, Institut Pasteur, Universite de Paris Cite, Centre National de la Recherche Scientifique UMR3569 , Paris, France. FAU - Planas, Delphine AU - Planas D AUID- ORCID: 0000-0002-2509-9954 AD - Virus and Immunity Unit, Institut Pasteur, Universite de Paris Cite, Centre National de la Recherche Scientifique UMR3569 , Paris, France. FAU - Staropoli, Isabelle AU - Staropoli I AUID- ORCID: 0000-0001-8637-4545 AD - Virus and Immunity Unit, Institut Pasteur, Universite de Paris Cite, Centre National de la Recherche Scientifique UMR3569 , Paris, France. FAU - Debarnot, Hippolyte AU - Debarnot H AUID- ORCID: 0009-0001-7261-8470 AD - Control of Chronic Viral Infections Group, Virus and Immunity Unit, Institut Pasteur, Universite de Paris Cite, Centre National de la Recherche Scientifique UMR3569 , Paris, France. FAU - Kervevan, Jerome AU - Kervevan J AUID- ORCID: 0000-0002-5070-022X AD - Control of Chronic Viral Infections Group, Virus and Immunity Unit, Institut Pasteur, Universite de Paris Cite, Centre National de la Recherche Scientifique UMR3569 , Paris, France. FAU - Mary, Heloise AU - Mary H AUID- ORCID: 0000-0003-1171-3260 AD - Biomaterials and Microfluidics Core Facility, Institut Pasteur, Universite de Paris Cite , Paris, France. FAU - Collina, Camilla AU - Collina C AUID- ORCID: 0009-0002-2632-0136 AD - Control of Chronic Viral Infections Group, Virus and Immunity Unit, Institut Pasteur, Universite de Paris Cite, Centre National de la Recherche Scientifique UMR3569 , Paris, France. FAU - Fonseca, Barbara F AU - Fonseca BF AUID- ORCID: 0000-0001-6403-4099 AD - Control of Chronic Viral Infections Group, Virus and Immunity Unit, Institut Pasteur, Universite de Paris Cite, Centre National de la Recherche Scientifique UMR3569 , Paris, France. AD - Biomaterials and Microfluidics Core Facility, Institut Pasteur, Universite de Paris Cite , Paris, France. FAU - Robinot, Remy AU - Robinot R AUID- ORCID: 0000-0002-3651-0171 AD - Control of Chronic Viral Infections Group, Virus and Immunity Unit, Institut Pasteur, Universite de Paris Cite, Centre National de la Recherche Scientifique UMR3569 , Paris, France. FAU - Gellenoncourt, Stacy AU - Gellenoncourt S AUID- ORCID: 0000-0003-1896-7212 AD - Control of Chronic Viral Infections Group, Virus and Immunity Unit, Institut Pasteur, Universite de Paris Cite, Centre National de la Recherche Scientifique UMR3569 , Paris, France. FAU - Schwartz, Olivier AU - Schwartz O AUID- ORCID: 0000-0002-0729-1475 AD - Virus and Immunity Unit, Institut Pasteur, Universite de Paris Cite, Centre National de la Recherche Scientifique UMR3569 , Paris, France. FAU - Ewart, Lorna AU - Ewart L AUID- ORCID: 0000-0002-8258-7460 AD - Emulate Inc , Boston, USA. FAU - Bscheider, Michael AU - Bscheider M AUID- ORCID: 0000-0001-7808-3270 AD - Roche Pharma Research & Early Development, Roche Innovation Center Basel , Basel, Switzerland. FAU - Gobaa, Samy AU - Gobaa S AUID- ORCID: 0000-0002-0125-8674 AD - Biomaterials and Microfluidics Core Facility, Institut Pasteur, Universite de Paris Cite , Paris, France. FAU - Chakrabarti, Lisa A AU - Chakrabarti LA AUID- ORCID: 0000-0002-1895-3630 AD - Control of Chronic Viral Infections Group, Virus and Immunity Unit, Institut Pasteur, Universite de Paris Cite, Centre National de la Recherche Scientifique UMR3569 , Paris, France. LA - eng GR - S-RD21002/Emulate/ GR - Pasteur COVID-19 RP call/ GR - PR-166156/Fondation de France/ GR - PFR7/Institut Pasteur/ GR - ECTZ213626/French Agency for AIDS and Emerging Diseases Research (ANRS-MIE)/ GR - Institut Carnot Pasteur Microbe & Sante/ PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20240906 PL - United States TA - J Exp Med JT - The Journal of experimental medicine JID - 2985109R RN - 0 (COVID-19 Vaccines) RN - 0 (mRNA Vaccines) RN - 0 (Spike Glycoprotein, Coronavirus) RN - 0 (spike protein, SARS-CoV-2) RN - 0 (Antibodies, Neutralizing) RN - 0 (Antibodies, Viral) RN - 0 (Vaccines, Synthetic) RN - 0 (RNA, Messenger) RN - 0 (Lipid Nanoparticles) RN - 0 (Liposomes) SB - IM MH - Humans MH - *COVID-19 Vaccines/immunology MH - *mRNA Vaccines/immunology MH - *SARS-CoV-2/immunology MH - *Spike Glycoprotein, Coronavirus/immunology/genetics MH - *Memory B Cells/immunology MH - *COVID-19/prevention & control/immunology MH - Antibodies, Neutralizing/immunology MH - Antibodies, Viral/immunology MH - Lymphoid Tissue/immunology MH - Lab-On-A-Chip Devices MH - Vaccines, Synthetic/immunology MH - RNA, Messenger/genetics/immunology/metabolism MH - B-Lymphocytes/immunology MH - CD4-Positive T-Lymphocytes/immunology MH - Liposomes MH - Nanoparticles PMC - PMC11383861 COIS- Disclosures: R. Jeger-Madiot received a fellowship from F. Hoffmann-LaRoche and Emulate during the conduct of the study. M. Bscheider reported personal fees from F. Hoffmann-LaRoche during the conduct of the study. L.A. Chakrabarti reported grants from F. Hoffmann-LaRoche and Emulate during the conduct of the study. No other disclosures were reported. EDAT- 2024/09/06 12:44 MHDA- 2024/09/06 12:45 PMCR- 2025/03/06 CRDT- 2024/09/06 11:14 PHST- 2024/02/14 00:00 [received] PHST- 2024/06/26 00:00 [revised] PHST- 2024/08/12 00:00 [accepted] PHST- 2024/09/06 12:45 [medline] PHST- 2024/09/06 12:44 [pubmed] PHST- 2024/09/06 11:14 [entrez] PHST- 2025/03/06 00:00 [pmc-release] AID - 276956 [pii] AID - jem.20240289 [pii] AID - 10.1084/jem.20240289 [doi] PST - ppublish SO - J Exp Med. 2024 Oct 7;221(10):e20240289. doi: 10.1084/jem.20240289. Epub 2024 Sep 6. PMID- 39225797 OWN - NLM STAT- MEDLINE DCOM- 20241018 LR - 20260504 IS - 1432-0738 (Electronic) IS - 0340-5761 (Print) IS - 0340-5761 (Linking) VI - 98 IP - 11 DP - 2024 Nov TI - A review of the scientific literature on experimental toxicity studies of COVID-19 vaccines, with special attention to publications in toxicology journals. PG - 3603-3617 LID - 10.1007/s00204-024-03854-8 [doi] AB - Since the reports of the first cases of COVID-19, in less than 5 years, a huge number of documents regarding that disease and the coronavirus (SARS-CoV-2), responsible for the infection, have been published. The tremendous number of scientific documents covers many topics on different issues directly related to COVID-19/SARS-CoV-2. The number of articles-including reviews-reporting adverse/side effects of the approved COVID-19 vaccines is considerable. A wide range of adverse/side effects have been reported in humans after COVID-19 vaccination: thrombotic events/thrombocytopenia, myocarditis/pericarditis, cutaneous reactions, immune-mediated effects, psychiatric adverse events, systemic lupus erythematosus, reproductive toxicity, and other miscellaneous adverse effects. In contrast, information on nonclinical studies conducted to assess the potential toxicity/adverse effects of the COVID-19 vaccines in laboratory animals, is comparatively very scarce. The present review was aimed at revising the scientific literature regarding the studies in laboratory animals on the toxic/adverse effects of COVID-19 vaccines. In addition, the investigations reported in those specific toxicology journals with the highest impact factors have been examined one by one. The results of the present review indicate that most nonclinical/experimental studies on the adverse/toxic effects of the COVID-19 vaccines and/or potential candidates showed-in general terms-a good safety profile. Only in some animal studies were certain adverse effects found. However, a rather surprising result has been the limited number of available (in the databases PubMed and Scopus) nonclinical studies performed by the companies that have been the largest manufacturers of mRNA vaccines in the world. It is assumed that these studies have been conducted. However, they have not been published in scientific journals, which does not allow the judgment of the international scientific community, including toxicologists. CI - (c) 2024. The Author(s). FAU - Domingo, Jose L AU - Domingo JL AUID- ORCID: 0000-0001-6647-9470 AD - Laboratory of Toxicology and Environmental Health, School of Medicine, Universitat Rovira i Virgili, Sant Llorens 21, 43201, Reus, Catalonia, Spain. joseluis.domingo@urv.cat. LA - eng PT - Journal Article PT - Review DEP - 20240903 PL - Germany TA - Arch Toxicol JT - Archives of toxicology JID - 0417615 RN - 0 (COVID-19 Vaccines) SB - IM MH - Animals MH - Humans MH - COVID-19/prevention & control MH - *COVID-19 Vaccines/toxicity MH - Periodicals as Topic MH - Toxicity Tests MH - Toxicology/methods PMC - PMC11489230 OTO - NOTNLM OT - Adverse effects OT - COVID-19 OT - Experimental animals OT - Nonclinical studies OT - Toxicity OT - Vaccines COIS- The author declares no known competing financial interests or personal relationships that influenced the work here reported. EDAT- 2024/09/03 12:44 MHDA- 2024/10/18 12:26 PMCR- 2024/09/03 CRDT- 2024/09/03 11:13 PHST- 2024/07/04 00:00 [received] PHST- 2024/08/22 00:00 [accepted] PHST- 2024/10/18 12:26 [medline] PHST- 2024/09/03 12:44 [pubmed] PHST- 2024/09/03 11:13 [entrez] PHST- 2024/09/03 00:00 [pmc-release] AID - 10.1007/s00204-024-03854-8 [pii] AID - 3854 [pii] AID - 10.1007/s00204-024-03854-8 [doi] PST - ppublish SO - Arch Toxicol. 2024 Nov;98(11):3603-3617. doi: 10.1007/s00204-024-03854-8. Epub 2024 Sep 3. PMID- 39207904 OWN - NLM STAT- MEDLINE DCOM- 20240926 LR - 20251027 IS - 2211-1247 (Electronic) VI - 43 IP - 9 DP - 2024 Sep 24 TI - Antigenic sin and multiple breakthrough infections drive converging evolution of COVID-19 neutralizing responses. PG - 114645 LID - S2211-1247(24)00996-3 [pii] LID - 10.1016/j.celrep.2024.114645 [doi] LID - 114645 AB - Understanding the evolution of the B cell response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants is fundamental to design the next generation of vaccines and therapeutics. We longitudinally analyze at the single-cell level almost 900 neutralizing human monoclonal antibodies (nAbs) isolated from vaccinated people and from individuals with hybrid and super hybrid immunity (SH), developed after three mRNA vaccine doses and two breakthrough infections. The most potent neutralization and Fc functions against highly mutated variants belong to the SH cohort. Repertoire analysis shows that the original Wuhan antigenic sin drives the convergent expansion of the same B cell germlines in vaccinated and SH cohorts. Only Omicron breakthrough infections expand previously unseen germ lines and generate broadly nAbs by restoring IGHV3-53/3-66 germ lines. Our analyses find that B cells initially expanded by the original antigenic sin continue to play a fundamental role in the evolution of the immune response toward an evolving virus. CI - Copyright (c) 2024 The Author(s). Published by Elsevier Inc. All rights reserved. FAU - Paciello, Ida AU - Paciello I AD - Monoclonal Antibody Discovery (MAD) Lab, Fondazione Toscana Life Sciences, Siena, Italy. FAU - Pierleoni, Giulio AU - Pierleoni G AD - Monoclonal Antibody Discovery (MAD) Lab, Fondazione Toscana Life Sciences, Siena, Italy; Department of Biotechnology, Chemistry, and Pharmacy, University of Siena, Siena, Italy. FAU - Pantano, Elisa AU - Pantano E AD - Monoclonal Antibody Discovery (MAD) Lab, Fondazione Toscana Life Sciences, Siena, Italy; Department of Biotechnology, Chemistry, and Pharmacy, University of Siena, Siena, Italy. FAU - Antonelli, Giada AU - Antonelli G AD - Monoclonal Antibody Discovery (MAD) Lab, Fondazione Toscana Life Sciences, Siena, Italy. FAU - Pileri, Piero AU - Pileri P AD - Monoclonal Antibody Discovery (MAD) Lab, Fondazione Toscana Life Sciences, Siena, Italy. FAU - Maccari, Giuseppe AU - Maccari G AD - Data Science for Health (DaScH) Lab, Fondazione Toscana Life Sciences, Siena, Italy. FAU - Cardamone, Dario AU - Cardamone D AD - Data Science for Health (DaScH) Lab, Fondazione Toscana Life Sciences, Siena, Italy. FAU - Realini, Giulia AU - Realini G AD - Monoclonal Antibody Discovery (MAD) Lab, Fondazione Toscana Life Sciences, Siena, Italy. FAU - Perrone, Federica AU - Perrone F AD - Monoclonal Antibody Discovery (MAD) Lab, Fondazione Toscana Life Sciences, Siena, Italy; Department of Biotechnology, Chemistry, and Pharmacy, University of Siena, Siena, Italy. FAU - Neto, Martin Mayora AU - Neto MM AD - Viral Pseudotype Unit, Medway School of Pharmacy, Universities of Kent and Greenwich, Chatham Maritime, Kent, UK. FAU - Pozzessere, Simone AU - Pozzessere S AD - Department of Cellular Therapies, Hematology, and Laboratory Medicine, University Hospital of Siena, Siena, Italy. FAU - Fabbiani, Massimiliano AU - Fabbiani M AD - Department of Medical Sciences, Infectious and Tropical Diseases Unit, Siena University Hospital, Siena, Italy; Department of Medical Biotechnologies, University of Siena, Siena, Italy. FAU - Panza, Francesca AU - Panza F AD - Department of Medical Sciences, Infectious and Tropical Diseases Unit, Siena University Hospital, Siena, Italy. FAU - Rancan, Ilaria AU - Rancan I AD - Department of Medical Sciences, Infectious and Tropical Diseases Unit, Siena University Hospital, Siena, Italy. FAU - Tumbarello, Mario AU - Tumbarello M AD - Department of Medical Sciences, Infectious and Tropical Diseases Unit, Siena University Hospital, Siena, Italy; Department of Medical Biotechnologies, University of Siena, Siena, Italy. FAU - Montagnani, Francesca AU - Montagnani F AD - Department of Medical Sciences, Infectious and Tropical Diseases Unit, Siena University Hospital, Siena, Italy; Department of Medical Biotechnologies, University of Siena, Siena, Italy. FAU - Medini, Duccio AU - Medini D AD - Data Science for Health (DaScH) Lab, Fondazione Toscana Life Sciences, Siena, Italy. FAU - Maes, Piet AU - Maes P AD - KU Leuven, Rega Institute, Department of Microbiology, Immunology, and Transplantation, Laboratory of Clinical and Epidemiological Virology, Leuven, Belgium. FAU - Temperton, Nigel AU - Temperton N AD - Viral Pseudotype Unit, Medway School of Pharmacy, Universities of Kent and Greenwich, Chatham Maritime, Kent, UK. FAU - Simon-Loriere, Etienne AU - Simon-Loriere E AD - G5 Evolutionary Genomics of RNA Viruses, Institut Pasteur, Universite Paris Cite, Paris, France; National Reference Center for Respiratory Viruses, Institut Pasteur, Paris, France. FAU - Schwartz, Olivier AU - Schwartz O AD - Virus and Immunity Unit, Department of Virology, Institut Pasteur, Paris, France; Vaccine Research Institute, Creteil, France. FAU - Rappuoli, Rino AU - Rappuoli R AD - Department of Biotechnology, Chemistry, and Pharmacy, University of Siena, Siena, Italy; Fondazione Biotecnopolo di Siena, Siena, Italy. FAU - Andreano, Emanuele AU - Andreano E AD - Monoclonal Antibody Discovery (MAD) Lab, Fondazione Toscana Life Sciences, Siena, Italy. Electronic address: e.andreano@toscanalifesciences.org. LA - eng GR - WT_/Wellcome Trust/United Kingdom GR - U01 AI151758/AI/NIAID NIH HHS/United States PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20240827 PL - United States TA - Cell Rep JT - Cell reports JID - 101573691 RN - 0 (Antibodies, Neutralizing) RN - 0 (Antibodies, Viral) RN - 0 (COVID-19 Vaccines) RN - 0 (Antibodies, Monoclonal) RN - 0 (Spike Glycoprotein, Coronavirus) RN - 0 (Antigens, Viral) RN - SARS-CoV-2 variants SB - IM MH - Humans MH - *SARS-CoV-2/immunology/genetics MH - *Antibodies, Neutralizing/immunology MH - *COVID-19/immunology/virology/prevention & control MH - *Antibodies, Viral/immunology MH - *B-Lymphocytes/immunology MH - COVID-19 Vaccines/immunology MH - Antibodies, Monoclonal/immunology MH - Spike Glycoprotein, Coronavirus/immunology/genetics MH - Antigens, Viral/immunology MH - Breakthrough Infections PMC - PMC11422482 OTO - NOTNLM OT - B cell germlines OT - COVID-19 OT - CP: Immunology OT - Fc functions OT - SARS-CoV-2 OT - V(D)J genes OT - antigenic sin OT - breakthrough infection OT - memory B cells OT - neutralizing antibodies COIS- Declaration of interests I.P., G.P., E.P., P.P., R.R., and E.A. are listed as inventors of full-length human mAbs described in Italian patent application nos. 102020000015754 filed on June 30, 2020, 102020000018955 filed on August 3, 2020, and 102020000029969 filed on December 4, 2020, and the international patent system no. PCT/IB2021/055755 filed on June 28, 2021. I.P., E.P., G.A., P.P., R.R., and E.A. are listed as inventors of full-length human mAbs described in the international patent system no. PCT/IB2022/061257 filed on November 22, 2022. All patents were submitted by Fondazione Toscana Life Sciences, Siena, Italy. EDAT- 2024/08/31 09:51 MHDA- 2024/09/27 00:42 PMCR- 2024/08/27 CRDT- 2024/08/29 12:36 PHST- 2024/04/29 00:00 [received] PHST- 2024/07/19 00:00 [revised] PHST- 2024/07/31 00:00 [accepted] PHST- 2024/09/27 00:42 [medline] PHST- 2024/08/31 09:51 [pubmed] PHST- 2024/08/29 12:36 [entrez] PHST- 2024/08/27 00:00 [pmc-release] AID - S2211-1247(24)00996-3 [pii] AID - 114645 [pii] AID - 10.1016/j.celrep.2024.114645 [doi] PST - ppublish SO - Cell Rep. 2024 Sep 24;43(9):114645. doi: 10.1016/j.celrep.2024.114645. Epub 2024 Aug 27. PMID- 39201981 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240901 IS - 2075-4426 (Print) IS - 2075-4426 (Electronic) IS - 2075-4426 (Linking) VI - 14 IP - 8 DP - 2024 Jul 25 TI - Small Fiber Neuropathy Associated with Post-COVID-19 and Post-COVID-19 Vaccination Arthritis: A Rare Post-Infective Syndrome or a New-Onset Disease? LID - 10.3390/jpm14080789 [doi] LID - 789 AB - Post-COVID-19 (PC) and post-COVID-19 vaccination (PCV) syndromes are considered emergent multidisciplinary disorders. PC/PCV small fiber neuropathy (SFN) was rarely described and its association with undifferentiated arthritis (UA) was never defined. We aimed to evaluate PC/PCV-UA associated with the recent onset of severe lower limb paresthesia, compare SFN positive (+) to negative (-) patients, and evaluate changes in biomarkers in SFN+ during treatments. Nineteen PC/PCV-UA-patients with possible SFN underwent skin biopsy at the Usl Tuscany Center (Florence) early arthritis outpatient clinic from September 2021 to March 2024. Eight selected SFN+ were compared to ten SFN- patients. In SFN+ patients, baseline joint ultrasound (US), electromyography (EMG), optical coherence tomography (OCT), and skin biopsy were repeated at six months. Moreover, SFN+ patients were clinically assessed by a 0-10 numeric rating scale for neurological symptoms and DAS28/ESR up to 12 months follow-up. SFN+ patients showed a lower intraepidermal nerve fiber density at histopathological examination of skin biopsies and a higher frequency of OCT and EMG abnormalities in comparison to SFN- patients. In SFN+ patients, US and DAS28/ESR significantly improved, while intraepidermal nerve fiber density did not significantly change at the six-month follow-up. Fatigue, motor impairment, burning pain, brain fog, and sensitivity disorders decreased at long-term follow-up (12 months). FAU - Bandinelli, Francesca AU - Bandinelli F AUID- ORCID: 0000-0002-6874-4941 AD - Rheumatology Department, San Giovanni di Dio Hospital, Usl Tuscany Center, 50143 Florence, Italy. FAU - Nassini, Romina AU - Nassini R AUID- ORCID: 0000-0002-9223-8395 AD - Section of Clinical Pharmacology and Oncology, Department of Health Sciences, University of Florence, 50139 Florence, Italy. AD - Headache Center and Clinical Pharmacology Unit, Careggi University Hospital, 50139 Florence, Italy. FAU - Gherardi, Eleonora AU - Gherardi E AD - Section of Dermatology, Department of Health Sciences, University of Florence, 50125 Florence, Italy. FAU - Chiocchetti, Barbara AU - Chiocchetti B AD - Neurology Department, San Giovanni di Dio Hospital, Usl Tuscany Center, 50143 Florence, Italy. FAU - Manetti, Mirko AU - Manetti M AUID- ORCID: 0000-0003-3956-8480 AD - Section of Anatomy and Histology, Department of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy. FAU - Cincotta, Massimo AU - Cincotta M AD - Neurology Department, San Giovanni di Dio Hospital, Usl Tuscany Center, 50143 Florence, Italy. FAU - Nozzoli, Filippo AU - Nozzoli F AD - Section of Pathological Anatomy, Department of Health Sciences, University of Florence, 50139 Florence, Italy. FAU - Nucci, Elena AU - Nucci E AD - Histopathology and Molecular Diagnostics Unit, Careggi University Hospital, University of Florence, 50139 Florence, Italy. FAU - De Logu, Francesco AU - De Logu F AD - Section of Clinical Pharmacology and Oncology, Department of Health Sciences, University of Florence, 50139 Florence, Italy. FAU - Pimpinelli, Nicola AU - Pimpinelli N AD - Section of Dermatology, Department of Health Sciences, University of Florence, 50125 Florence, Italy. LA - eng PT - Journal Article DEP - 20240725 PL - Switzerland TA - J Pers Med JT - Journal of personalized medicine JID - 101602269 PMC - PMC11355276 OTO - NOTNLM OT - COVID-19 OT - arthritis OT - small fiber neuropathy COIS- The authors declare no conflicts of interest. EDAT- 2024/08/31 09:43 MHDA- 2024/08/31 09:44 PMCR- 2024/07/25 CRDT- 2024/08/29 01:16 PHST- 2024/06/26 00:00 [received] PHST- 2024/07/12 00:00 [revised] PHST- 2024/07/23 00:00 [accepted] PHST- 2024/08/31 09:44 [medline] PHST- 2024/08/31 09:43 [pubmed] PHST- 2024/08/29 01:16 [entrez] PHST- 2024/07/25 00:00 [pmc-release] AID - jpm14080789 [pii] AID - jpm-14-00789 [pii] AID - 10.3390/jpm14080789 [doi] PST - epublish SO - J Pers Med. 2024 Jul 25;14(8):789. doi: 10.3390/jpm14080789. PMID- 39168129 OWN - NLM STAT- MEDLINE DCOM- 20240911 LR - 20250123 IS - 1097-4180 (Electronic) IS - 1074-7613 (Linking) VI - 57 IP - 9 DP - 2024 Sep 10 TI - Affinity-independent memory B cell origin of the early antibody-secreting cell response in naive individuals upon SARS-CoV-2 vaccination. PG - 2191-2201.e5 LID - S1074-7613(24)00372-8 [pii] LID - 10.1016/j.immuni.2024.07.023 [doi] AB - Memory B cells (MBCs) formed over the individual's lifetime constitute nearly half of the circulating B cell repertoire in humans. These pre-existing MBCs dominate recall responses to their cognate antigens, but how they respond to recognition of novel antigens is not well understood. Here, we tracked the origin and followed the differentiation paths of MBCs in the early anti-spike (S) response to mRNA vaccination in SARS-CoV-2-naive individuals on single-cell and monoclonal antibody levels. Pre-existing, highly mutated MBCs showed no signs of germinal center re-entry and rapidly developed into mature antibody-secreting cells (ASCs). By contrast, and despite similar levels of S reactivity, naive B cells showed strong signs of antibody affinity maturation before differentiating into MBCs and ASCs. Thus, pre-existing human MBCs differentiate into ASCs in response to novel antigens, but the quality of the humoral and cellular anti-S response improved through the clonal selection and affinity maturation of naive precursors. CI - Copyright (c) 2024 The Author(s). Published by Elsevier Inc. All rights reserved. FAU - Li, Zhe AU - Li Z AD - B Cell Immunology, German Cancer Research Center, Heidelberg 69120, Germany. FAU - Obraztsova, Anna AU - Obraztsova A AD - B Cell Immunology, German Cancer Research Center, Heidelberg 69120, Germany; Faculty of Biosciences, University of Heidelberg, Heidelberg 69120, Germany. Electronic address: a.obraztsova@dkfz.de. FAU - Shang, Fuwei AU - Shang F AD - Cellular Immunology, German Cancer Research Center, Heidelberg 69120, Germany; Faculty of Medicine, University of Heidelberg, Heidelberg 69120, Germany. FAU - Oludada, Opeyemi Ernest AU - Oludada OE AD - B Cell Immunology, German Cancer Research Center, Heidelberg 69120, Germany; Faculty of Biosciences, University of Heidelberg, Heidelberg 69120, Germany. FAU - Malapit, Joshua AU - Malapit J AD - B Cell Immunology, German Cancer Research Center, Heidelberg 69120, Germany; Faculty of Biosciences, University of Heidelberg, Heidelberg 69120, Germany. FAU - Busch, Katrin AU - Busch K AD - Cellular Immunology, German Cancer Research Center, Heidelberg 69120, Germany. FAU - van Straaten, Monique AU - van Straaten M AD - Structural Biology of Infection and Immunity, German Cancer Research Center, Heidelberg 69120, Germany. FAU - Stebbins, Erec AU - Stebbins E AD - Structural Biology of Infection and Immunity, German Cancer Research Center, Heidelberg 69120, Germany. FAU - Murugan, Rajagopal AU - Murugan R AD - B Cell Immunology, German Cancer Research Center, Heidelberg 69120, Germany. FAU - Wardemann, Hedda AU - Wardemann H AD - B Cell Immunology, German Cancer Research Center, Heidelberg 69120, Germany. Electronic address: h.wardemann@dkfz.de. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20240820 PL - United States TA - Immunity JT - Immunity JID - 9432918 RN - 0 (Antibodies, Viral) RN - 0 (Spike Glycoprotein, Coronavirus) RN - 0 (COVID-19 Vaccines) RN - 0 (spike protein, SARS-CoV-2) RN - 0 (Antibodies, Monoclonal) SB - IM MH - Humans MH - *SARS-CoV-2/immunology MH - *Memory B Cells/immunology MH - *COVID-19/immunology/prevention & control MH - *Antibodies, Viral/immunology MH - *Spike Glycoprotein, Coronavirus/immunology MH - *Antibody-Producing Cells/immunology MH - *COVID-19 Vaccines/immunology MH - Vaccination MH - Antibody Affinity/immunology MH - Cell Differentiation/immunology MH - Germinal Center/immunology MH - Immunologic Memory/immunology MH - Antibodies, Monoclonal/immunology MH - Adult MH - Female OTO - NOTNLM OT - SARS-CoV-2 OT - affinity maturation OT - germinal center OT - humoral immunity OT - mRNA vaccination OT - pre-existing memory B cells OT - somatic hypermutation COIS- Declaration of interests The authors declare no competing interests. EDAT- 2024/08/22 00:42 MHDA- 2024/09/12 00:42 CRDT- 2024/08/21 18:42 PHST- 2023/12/18 00:00 [received] PHST- 2024/02/02 00:00 [revised] PHST- 2024/07/24 00:00 [accepted] PHST- 2024/09/12 00:42 [medline] PHST- 2024/08/22 00:42 [pubmed] PHST- 2024/08/21 18:42 [entrez] AID - S1074-7613(24)00372-8 [pii] AID - 10.1016/j.immuni.2024.07.023 [doi] PST - ppublish SO - Immunity. 2024 Sep 10;57(9):2191-2201.e5. doi: 10.1016/j.immuni.2024.07.023. Epub 2024 Aug 20. PMID- 39165041 OWN - NLM STAT- MEDLINE DCOM- 20240821 LR - 20260604 IS - 1096-9071 (Electronic) IS - 0146-6615 (Linking) VI - 96 IP - 8 DP - 2024 Aug TI - SARS-CoV-2 reinfection broadens the antibody responses and promotes the phenotypic differentiation of virus-specific memory T cells in adolescents. PG - e29873 LID - 10.1002/jmv.29873 [doi] AB - The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron subvariants raises concerns regarding the effectiveness of immunity acquired from previous Omicron subvariants breakthrough infections (BTIs) or reinfections (RIs) against the current circulating Omicron subvariants. In this study, we prospectively investigate the dynamic changes of virus-specific antibody and T cell responses among 77 adolescents following Omicron BA.2.3 BTI with or without subsequent Omicron BA.5 RI. Notably, the neutralizing antibodies (NAbs) titers against various detected SARS-CoV-2 variants, especially the emerging Omicron CH.1.1, XBB.1.5, XBB.1.16, EG.5.1, and JN.1 subvariants, exhibited a significant decrease along the time. A lower level of IgG and NAbs titers post-BTI was found to be closely associated with subsequent RI. Elevated NAbs levels and shortened antigenic distances were observed following Omicron BA.5 RI. Robust T cell responses against both Omicron BA.2- and CH.1.1-spike peptides were observed at each point visited. The exposure to Omicron BA.5 promoted phenotypic differentiation of virus-specific memory T cells, even among the non-seroconversion adolescents. Therefore, updated vaccines are needed to provide effective protection against newly emerging SARS-CoV-2 variants among adolescents. CI - (c) 2024 The Author(s). Journal of Medical Virology published by Wiley Periodicals LLC. FAU - Zhao, Xin-Jing AU - Zhao XJ AD - Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, China. AD - State Key Laboratory of Pathogen and Biosecurity, Academy of Military Medical Science, Beijing, China. FAU - Liu, Xiao-Lin AU - Liu XL AD - Institute of Infectious Disease Control and Prevention, Shandong Center for Disease Control and Prevention, Jinan, China. FAU - Gu, Hong-Jing AU - Gu HJ AD - State Key Laboratory of Pathogen and Biosecurity, Academy of Military Medical Science, Beijing, China. FAU - Liu, Ti AU - Liu T AD - Institute of Infectious Disease Control and Prevention, Shandong Center for Disease Control and Prevention, Jinan, China. FAU - Li, De-Yu AU - Li DY AD - State Key Laboratory of Pathogen and Biosecurity, Academy of Military Medical Science, Beijing, China. FAU - Zhang, Sheng AU - Zhang S AD - State Key Laboratory of Pathogen and Biosecurity, Academy of Military Medical Science, Beijing, China. FAU - Wu, Jie AU - Wu J AD - Department of Infectious Disease Control and Prevention, Binzhou Center for Disease Control and Prevention, Jinan, China. FAU - Du, Kai-Ge AU - Du KG AD - Institute of Infectious Disease Control and Prevention, Shandong Center for Disease Control and Prevention, Jinan, China. FAU - Tian, Shen AU - Tian S AD - State Key Laboratory of Pathogen and Biosecurity, Academy of Military Medical Science, Beijing, China. FAU - Chen, Jin-Jin AU - Chen JJ AD - State Key Laboratory of Pathogen and Biosecurity, Academy of Military Medical Science, Beijing, China. FAU - Xu, Qiang AU - Xu Q AD - State Key Laboratory of Pathogen and Biosecurity, Academy of Military Medical Science, Beijing, China. FAU - Lv, Chen-Long AU - Lv CL AD - State Key Laboratory of Pathogen and Biosecurity, Academy of Military Medical Science, Beijing, China. FAU - Jiang, Bao-Gui AU - Jiang BG AD - State Key Laboratory of Pathogen and Biosecurity, Academy of Military Medical Science, Beijing, China. FAU - Wang, Hui AU - Wang H AD - State Key Laboratory of Pathogen and Biosecurity, Academy of Military Medical Science, Beijing, China. FAU - Kou, Zeng-Qiang AU - Kou ZQ AD - Institute of Infectious Disease Control and Prevention, Shandong Center for Disease Control and Prevention, Jinan, China. FAU - Wang, Guo-Lin AU - Wang GL AUID- ORCID: 0000-0002-5393-9500 AD - State Key Laboratory of Pathogen and Biosecurity, Academy of Military Medical Science, Beijing, China. FAU - Fang, Li-Qun AU - Fang LQ AUID- ORCID: 0000-0002-4981-1483 AD - Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, China. AD - State Key Laboratory of Pathogen and Biosecurity, Academy of Military Medical Science, Beijing, China. LA - eng GR - Natural Science Foundation of Beijing Municipality/ GR - National Natural Science Foundation of China/ GR - China Mega-Project on Infectious Disease Prevention/ GR - Natural Science Foundation of Shandong Province/ GR - State Key Laboratory of Pathogen and Biosecurity/ PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - J Med Virol JT - Journal of medical virology JID - 7705876 RN - 0 (Antibodies, Viral) RN - 0 (Antibodies, Neutralizing) RN - 0 (Immunoglobulin G) RN - 0 (Spike Glycoprotein, Coronavirus) RN - SARS-CoV-2 variants SB - IM MH - Humans MH - Adolescent MH - *COVID-19/immunology/virology MH - *SARS-CoV-2/immunology MH - *Antibodies, Viral/blood/immunology MH - *Antibodies, Neutralizing/immunology/blood MH - Male MH - *Reinfection/immunology/virology MH - Female MH - *Memory T Cells/immunology MH - Prospective Studies MH - Immunoglobulin G/blood/immunology MH - Antibody Formation MH - Spike Glycoprotein, Coronavirus/immunology MH - Immunologic Memory MH - Child MH - T-Lymphocytes/immunology OTO - NOTNLM OT - SARS-CoV-2 OT - T cell responses OT - breakthrough infection OT - differentiation of memory T cells OT - neutralizing antibody OT - reinfection EDAT- 2024/08/21 11:41 MHDA- 2024/08/21 11:42 CRDT- 2024/08/21 02:33 PHST- 2024/07/10 00:00 [revised] PHST- 2024/02/19 00:00 [received] PHST- 2024/08/10 00:00 [accepted] PHST- 2024/08/21 11:42 [medline] PHST- 2024/08/21 11:41 [pubmed] PHST- 2024/08/21 02:33 [entrez] AID - 10.1002/jmv.29873 [doi] PST - ppublish SO - J Med Virol. 2024 Aug;96(8):e29873. doi: 10.1002/jmv.29873. PMID- 39156891 OWN - NLM STAT- MEDLINE DCOM- 20240819 LR - 20260812 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 15 DP - 2024 TI - High serum prevalence of autoreactive IgG antibodies against peripheral nerve structures in patients with neurological post-COVID-19 vaccination syndrome. PG - 1404800 LID - 10.3389/fimmu.2024.1404800 [doi] LID - 1404800 AB - BACKGROUND: Patients suffering from neurological symptoms after COVID-19 vaccination (post-COVID-19 vaccination syndrome (PCVS)) have imposed an increasing challenge on medical practice, as diagnostic precision and therapeutic options are lacking. Underlying autoimmune dysfunctions, including autoantibodies, have been discussed in neurological disorders after SARS-CoV-2 infection and vaccination. Here, we describe the frequency and targets of autoantibodies against peripheral nervous system tissues in PCVS. METHODS: Sera from 50 PCVS patients with peripheral neurological symptoms after COVID-19 vaccination and 35 vaccinated healthy controls were used in this study. IgG autoreactivity was measured via indirect immunofluorescence assays on mouse sciatic nerve teased fibers. The frequencies of autoantibodies were compared between groups using Fisher's exact test. Serum anti-ganglioside antibodies were measured in ganglioside blots. Autoantibody target identification was performed using immunoprecipitation coupled to mass spectrometry. Subsequent target confirmation was conducted via cell-based assays and ELISA. RESULTS: Compared with controls, PCVS patients had a significantly greater frequency of autoantibodies against peripheral nervous system structures (9/50(18%) vs 1/35(3%); p=0.04). Autoantibodies bound to paranodes (n=5), axons (n=4), Schmidt-Lanterman incisures (n=2) and Schwann cell nuclei (n=1). Conversely, antibodies against gangliosides were absent in PCVS patients. Target identification and subsequent confirmation revealed various subunits of neurofilaments as well as DFS-70 as autoantibody epitopes. CONCLUSION: Our data suggest that autoantibodies against nervous system tissue could be relevant in PCVS patients. Autoantibodies against neurofilaments and cell nuclei with so far non-established links to this disease spectrum should be further elucidated to determine their biomarker potential. CI - Copyright (c) 2024 Arlt, Breuer, Trampenau, Boesl, Kirchner, Mertins, Sanchez-Sendin, Nasouti, Mayrhofer, Bluthner, Endres, Pruss and Franke. FAU - Arlt, Friederike A AU - Arlt FA AD - Department of Neurology and Experimental Neurology, Charite-Universitatsmedizin Berlin, corporate member of Freie Universitat and Humboldt-Universitat zu Berlin, Berlin, Germany. AD - German Center for Neurodegenerative Diseases (DZNE) Berlin, Berlin, Germany. FAU - Breuer, Ameli AU - Breuer A AD - Department of Neurology and Experimental Neurology, Charite-Universitatsmedizin Berlin, corporate member of Freie Universitat and Humboldt-Universitat zu Berlin, Berlin, Germany. FAU - Trampenau, Elli AU - Trampenau E AD - Department of Neurology and Experimental Neurology, Charite-Universitatsmedizin Berlin, corporate member of Freie Universitat and Humboldt-Universitat zu Berlin, Berlin, Germany. AD - German Center for Neurodegenerative Diseases (DZNE) Berlin, Berlin, Germany. FAU - Boesl, Fabian AU - Boesl F AD - Department of Neurology and Experimental Neurology, Charite-Universitatsmedizin Berlin, corporate member of Freie Universitat and Humboldt-Universitat zu Berlin, Berlin, Germany. FAU - Kirchner, Marieluise AU - Kirchner M AD - Core Unit Proteomics, Berlin Institute of Health at Charite - Universitatsmedizin Berlin and Max Delbruck Center for Molecular Medicine, Berlin, Germany. FAU - Mertins, Philipp AU - Mertins P AD - Core Unit Proteomics, Berlin Institute of Health at Charite - Universitatsmedizin Berlin and Max Delbruck Center for Molecular Medicine, Berlin, Germany. FAU - Sanchez-Sendin, Elisa AU - Sanchez-Sendin E AD - Department of Neurology and Experimental Neurology, Charite-Universitatsmedizin Berlin, corporate member of Freie Universitat and Humboldt-Universitat zu Berlin, Berlin, Germany. AD - German Center for Neurodegenerative Diseases (DZNE) Berlin, Berlin, Germany. FAU - Nasouti, Mahoor AU - Nasouti M AD - Department of Neurology and Experimental Neurology, Charite-Universitatsmedizin Berlin, corporate member of Freie Universitat and Humboldt-Universitat zu Berlin, Berlin, Germany. AD - German Center for Neurodegenerative Diseases (DZNE) Berlin, Berlin, Germany. FAU - Mayrhofer, Marie AU - Mayrhofer M AD - Department of Autoimmune Diagnostics, Medizinisches Versorgungszentrum (MVZ) Laboratory PD Dr. Volkmann & Colleagues, Karlsruhe, Germany. FAU - Bluthner, Martin AU - Bluthner M AD - Department of Autoimmune Diagnostics, Medizinisches Versorgungszentrum (MVZ) Laboratory PD Dr. Volkmann & Colleagues, Karlsruhe, Germany. FAU - Endres, Matthias AU - Endres M AD - Department of Neurology and Experimental Neurology, Charite-Universitatsmedizin Berlin, corporate member of Freie Universitat and Humboldt-Universitat zu Berlin, Berlin, Germany. AD - German Center for Neurodegenerative Diseases (DZNE) Berlin, Berlin, Germany. AD - German Center for Cardiovascular Diseases (DZHK), Berlin, Germany. AD - Center for Stroke Research Berlin (CSB), Charite-Universitatsmedizin Berlin, corporate member of Freie Universitat and Humboldt-Universitat zu Berlin, Berlin, Germany. AD - German Center for Mental Health (DZPG), Berlin, Germany. FAU - Pruss, Harald AU - Pruss H AD - Department of Neurology and Experimental Neurology, Charite-Universitatsmedizin Berlin, corporate member of Freie Universitat and Humboldt-Universitat zu Berlin, Berlin, Germany. AD - German Center for Neurodegenerative Diseases (DZNE) Berlin, Berlin, Germany. FAU - Franke, Christiana AU - Franke C AD - Department of Neurology and Experimental Neurology, Charite-Universitatsmedizin Berlin, corporate member of Freie Universitat and Humboldt-Universitat zu Berlin, Berlin, Germany. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20240802 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 RN - 0 (Autoantibodies) RN - 0 (Immunoglobulin G) RN - 0 (COVID-19 Vaccines) RN - 0 (Gangliosides) SB - IM MH - Humans MH - *Autoantibodies/immunology/blood MH - Male MH - Female MH - *Immunoglobulin G/immunology/blood MH - Middle Aged MH - *COVID-19/immunology MH - *SARS-CoV-2/immunology MH - *COVID-19 Vaccines/immunology/administration & dosage MH - Aged MH - Mice MH - Animals MH - Adult MH - Vaccination MH - Gangliosides/immunology MH - Peripheral Nerves/immunology PMC - PMC11327052 OTO - NOTNLM OT - COVID-19 vaccination OT - DFS-70 OT - SARS-CoV-2 vaccination OT - autoantibody OT - neurofilament autoantibodies OT - peripheral nerve OT - post-COVID-19 vaccination syndrome (PCVS) COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2024/08/19 06:42 MHDA- 2024/08/19 06:43 PMCR- 2024/01/01 CRDT- 2024/08/19 05:16 PHST- 2024/03/21 00:00 [received] PHST- 2024/07/11 00:00 [accepted] PHST- 2024/08/19 06:43 [medline] PHST- 2024/08/19 06:42 [pubmed] PHST- 2024/08/19 05:16 [entrez] PHST- 2024/01/01 00:00 [pmc-release] AID - 10.3389/fimmu.2024.1404800 [doi] PST - epublish SO - Front Immunol. 2024 Aug 2;15:1404800. doi: 10.3389/fimmu.2024.1404800. eCollection 2024. PMID- 39127451 OWN - NLM STAT- MEDLINE DCOM- 20240920 LR - 20240920 IS - 1532-2742 (Electronic) IS - 0163-4453 (Linking) VI - 89 IP - 4 DP - 2024 Oct TI - Fourth dose bivalent COVID-19 vaccines outperform monovalent boosters in eliciting cross-reactive memory B cells to Omicron subvariants. PG - 106246 LID - S0163-4453(24)00180-4 [pii] LID - 10.1016/j.jinf.2024.106246 [doi] AB - Bivalent COVID-19 vaccines comprising ancestral Wuhan-Hu-1 (WH1) and the Omicron BA.1 or BA.5 subvariant elicit enhanced serum antibody responses to emerging Omicron subvariants. Here, we characterized the RBD-specific memory B cell (Bmem) response following a fourth dose with a BA.1 or BA.5 bivalent vaccine, in direct comparison with a WH1 monovalent fourth dose. Healthcare workers previously immunized with mRNA or adenoviral vector monovalent vaccines were sampled before and one month after a fourth dose with a monovalent or a BA.1 or BA.5 bivalent vaccine. Serum neutralizing antibodies (NAb) were quantified, as well as RBD-specific Bmem with an in-depth spectral flow cytometry panel including recombinant RBD proteins of the WH1, BA.1, BA.5, BQ.1.1, and XBB.1.5 variants. Both bivalent vaccines elicited higher NAb titers against Omicron subvariants compared to the monovalent vaccine. Following either vaccine type, recipients had slightly increased WH1 RBD-specific Bmem numbers. Both bivalent vaccines significantly increased WH1 RBD-specific Bmem binding of all Omicron subvariants tested by flow cytometry, while recognition of Omicron subvariants was not enhanced following monovalent vaccination. IgG1(+) Bmem dominated the response, with substantial IgG4(+) Bmem only detected in recipients of an mRNA vaccine for their primary dose. Thus, Omicron-based bivalent vaccines can significantly boost NAb and Bmem specific for ancestral WH1 and Omicron variants and improve recognition of descendent subvariants by pre-existing, WH1-specific Bmem beyond that of a monovalent vaccine. This provides new insights into the capacity of variant-based mRNA booster vaccines to improve immune memory against emerging SARS-CoV-2 variants and potentially protect against severe disease. ONE-SENTENCE SUMMARY: Omicron BA.1 and BA.5 bivalent COVID-19 boosters, used as a fourth dose, increase RBD-specific Bmem cross-recognition of Omicron subvariants, both those encoded by the vaccines and antigenically distinct subvariants, further than a monovalent booster. CI - Copyright (c) 2024 The Authors. Published by Elsevier Ltd.. All rights reserved. FAU - Fryer, Holly A AU - Fryer HA AD - Dept. Immunology, School of Translational Medicine, Monash University, Melbourne, Victoria, Australia. FAU - Geers, Daryl AU - Geers D AD - Dept. Viroscience, Erasmus MC, University Medical Center, Rotterdam, the Netherlands. FAU - Gommers, Lennert AU - Gommers L AD - Dept. Viroscience, Erasmus MC, University Medical Center, Rotterdam, the Netherlands. FAU - Zaeck, Luca M AU - Zaeck LM AD - Dept. Viroscience, Erasmus MC, University Medical Center, Rotterdam, the Netherlands. FAU - Tan, Ngoc H AU - Tan NH AD - Dept. Hospital Pharmacy, Erasmus MC, University Medical Center, Rotterdam, the Netherlands. FAU - Jones-Freeman, Bernadette AU - Jones-Freeman B AD - Dept. Immunology, School of Translational Medicine, Monash University, Melbourne, Victoria, Australia. FAU - Goorhuis, Abraham AU - Goorhuis A AD - Center of Tropical Medicine and Travel Medicine, Department of Infectious Diseases, Amsterdam University Medical Centers, Amsterdam, the Netherlands; Infection and Immunity, Amsterdam Public Health, University of Amsterdam, Amsterdam, the Netherlands. FAU - Postma, Douwe F AU - Postma DF AD - Department of Internal Medicine and Infectious Diseases, University Medical Center Groningen, Groningen, the Netherlands. FAU - Visser, Leo G AU - Visser LG AD - Department of Infectious Diseases, Leiden University Medical Center, Leiden, Netherlands. FAU - Hogarth, P Mark AU - Hogarth PM AD - Dept. Immunology, School of Translational Medicine, Monash University, Melbourne, Victoria, Australia; Immune Therapies Group, Burnet Institute, Melbourne, Victoria, Australia. FAU - Koopmans, Marion P G AU - Koopmans MPG AD - Dept. Viroscience, Erasmus MC, University Medical Center, Rotterdam, the Netherlands. FAU - GeurtsvanKessel, Corine H AU - GeurtsvanKessel CH AD - Dept. Viroscience, Erasmus MC, University Medical Center, Rotterdam, the Netherlands. FAU - O'Hehir, Robyn E AU - O'Hehir RE AD - Dept. Immunology, School of Translational Medicine, Monash University, Melbourne, Victoria, Australia; Allergy, Asthma and Clinical Immunology Service, Alfred Hospital, Melbourne, Victoria, Australia. FAU - van der Kuy, P Hugo M AU - van der Kuy PHM AD - Dept. Hospital Pharmacy, Erasmus MC, University Medical Center, Rotterdam, the Netherlands. FAU - de Vries, Rory D AU - de Vries RD AD - Dept. Viroscience, Erasmus MC, University Medical Center, Rotterdam, the Netherlands. FAU - van Zelm, Menno C AU - van Zelm MC AD - Dept. Immunology, School of Translational Medicine, Monash University, Melbourne, Victoria, Australia; Allergy, Asthma and Clinical Immunology Service, Alfred Hospital, Melbourne, Victoria, Australia; Dept. Immunology, Erasmus MC, University Medical Center, Rotterdam, the Netherlands. Electronic address: m.vanzelm@erasmusmc.nl. LA - eng PT - Journal Article DEP - 20240808 PL - England TA - J Infect JT - The Journal of infection JID - 7908424 RN - 0 (COVID-19 Vaccines) RN - 0 (Antibodies, Neutralizing) RN - 0 (Antibodies, Viral) RN - 0 (Spike Glycoprotein, Coronavirus) RN - 0 (spike protein, SARS-CoV-2) RN - SARS-CoV-2 variants SB - IM MH - Humans MH - *COVID-19 Vaccines/immunology/administration & dosage MH - *SARS-CoV-2/immunology MH - *COVID-19/prevention & control/immunology MH - *Antibodies, Neutralizing/blood/immunology MH - *Antibodies, Viral/blood/immunology MH - *Immunization, Secondary MH - *Memory B Cells/immunology MH - *Cross Reactions MH - Spike Glycoprotein, Coronavirus/immunology MH - Adult MH - Middle Aged MH - Male MH - Female MH - Health Personnel OTO - NOTNLM OT - Adenoviral vector vaccine OT - Bivalent vaccine OT - COVID-19 vaccine OT - MRNA vaccine OT - Memory B cells OT - Neutralizing antibodies COIS- Declaration of Competing Interest MCvZ, REO'H and PMH are inventors on a patent application related to this work. All the other authors declare no conflict of interest. EDAT- 2024/08/11 04:43 MHDA- 2024/09/21 13:19 CRDT- 2024/08/10 19:21 PHST- 2024/05/15 00:00 [received] PHST- 2024/08/05 00:00 [accepted] PHST- 2024/09/21 13:19 [medline] PHST- 2024/08/11 04:43 [pubmed] PHST- 2024/08/10 19:21 [entrez] AID - S0163-4453(24)00180-4 [pii] AID - 10.1016/j.jinf.2024.106246 [doi] PST - ppublish SO - J Infect. 2024 Oct;89(4):106246. doi: 10.1016/j.jinf.2024.106246. Epub 2024 Aug 8. PMID- 39122676 OWN - NLM STAT- MEDLINE DCOM- 20240809 LR - 20260526 IS - 2041-1723 (Electronic) IS - 2041-1723 (Linking) VI - 15 IP - 1 DP - 2024 Aug 9 TI - Atypical and non-classical CD45RB(lo) memory B cells are the majority of circulating SARS-CoV-2 specific B cells following mRNA vaccination or COVID-19. PG - 6811 LID - 10.1038/s41467-024-50997-4 [doi] LID - 6811 AB - Resting memory B cells can be divided into classical or atypical groups, but the heterogenous marker expression on activated memory B cells makes similar classification difficult. Here, by longitudinal analysis of mass cytometry and CITE-seq data from cohorts with COVID-19, bacterial sepsis, or BNT162b2 mRNA vaccine, we observe that resting B cell memory consist of classical CD45RB(+) memory and CD45RB(lo) memory, of which the latter contains of two distinct groups of CD11c(+) atypical and CD23(+) non-classical memory cells. CD45RB levels remain stable in these cells after activation, thereby enabling the tracking of activated B cells and plasmablasts derived from either CD45RB(+) or CD45RB(lo) memory B cells. Moreover, in both COVID-19 patients and mRNA vaccination, CD45RB(lo) B cells formed the majority of SARS-CoV2 specific memory B cells and correlated with serum antibodies, while CD45RB(+) memory are activated by bacterial sepsis. Our results thus identify that stably expressed CD45RB levels can be exploited to trace resting memory B cells and their activated progeny, and suggest that atypical and non-classical CD45RB(lo) memory B cells contribute to SARS-CoV-2 infection and vaccination. CI - (c) 2024. The Author(s). FAU - Priest, David G AU - Priest DG AUID- ORCID: 0000-0003-0095-6718 AD - Laboratory of Human Single Cell Immunology, World Premier International Research Center Initiative Immunology Frontier Research Center (WPI-IFReC), Osaka University, Suita, Osaka, 563-0793, Japan. FAU - Ebihara, Takeshi AU - Ebihara T AD - Center for Infectious Disease Education and Research (CiDER), Osaka University, Suita, Osaka, 565-0871, Japan. AD - Department of Traumatology and Acute Critical Medicine, Osaka University Graduate School of Medicine, Suita, Osaka, 565-0871, Japan. FAU - Tulyeu, Janyerkye AU - Tulyeu J AUID- ORCID: 0000-0003-1473-5561 AD - Human Single Cell Immunology Team, Center for Infectious Disease Education and Research (CiDER), Osaka University, Suita, Osaka, 565-0871, Japan. FAU - Sondergaard, Jonas N AU - Sondergaard JN AUID- ORCID: 0000-0002-4438-6756 AD - Human Single Cell Immunology Team, Center for Infectious Disease Education and Research (CiDER), Osaka University, Suita, Osaka, 565-0871, Japan. FAU - Sakakibara, Shuhei AU - Sakakibara S AUID- ORCID: 0000-0003-3157-5870 AD - Laboratory of Immune Regulation, IFReC, Osaka University, Suita, Osaka, 563-0793, Japan. AD - Graduate School of Medical Safety Management, Jikei University of Health Care Sciences, Osaka, 532-0003, Japan. FAU - Sugihara, Fuminori AU - Sugihara F AD - Core Instrumentation Facility, Immunology Frontier Research Center and Research Institute for Microbial Disease, Osaka University, Suita, Osaka, 563-0793, Japan. AD - Research Institute for Microbial Disease, Osaka University, Suita, Osaka, 563-0793, Japan. FAU - Nakao, Shunichiro AU - Nakao S AD - Department of Traumatology and Acute Critical Medicine, Osaka University Graduate School of Medicine, Suita, Osaka, 565-0871, Japan. FAU - Togami, Yuki AU - Togami Y AD - Department of Traumatology and Acute Critical Medicine, Osaka University Graduate School of Medicine, Suita, Osaka, 565-0871, Japan. FAU - Yoshimura, Jumpei AU - Yoshimura J AD - Department of Traumatology and Acute Critical Medicine, Osaka University Graduate School of Medicine, Suita, Osaka, 565-0871, Japan. FAU - Ito, Hiroshi AU - Ito H AD - Department of Traumatology and Acute Critical Medicine, Osaka University Graduate School of Medicine, Suita, Osaka, 565-0871, Japan. FAU - Onishi, Shinya AU - Onishi S AD - Department of Traumatology and Acute Critical Medicine, Osaka University Graduate School of Medicine, Suita, Osaka, 565-0871, Japan. FAU - Muratsu, Arisa AU - Muratsu A AD - Department of Traumatology and Acute Critical Medicine, Osaka University Graduate School of Medicine, Suita, Osaka, 565-0871, Japan. FAU - Mitsuyama, Yumi AU - Mitsuyama Y AD - Department of Traumatology and Acute Critical Medicine, Osaka University Graduate School of Medicine, Suita, Osaka, 565-0871, Japan. AD - Division of Trauma and Surgical Critical Care, Osaka General Medical Center, Osaka, 558-8558, Japan. FAU - Ogura, Hiroshi AU - Ogura H AD - Center for Infectious Disease Education and Research (CiDER), Osaka University, Suita, Osaka, 565-0871, Japan. AD - Department of Traumatology and Acute Critical Medicine, Osaka University Graduate School of Medicine, Suita, Osaka, 565-0871, Japan. FAU - Oda, Jun AU - Oda J AUID- ORCID: 0000-0002-8254-3716 AD - Center for Infectious Disease Education and Research (CiDER), Osaka University, Suita, Osaka, 565-0871, Japan. AD - Department of Traumatology and Acute Critical Medicine, Osaka University Graduate School of Medicine, Suita, Osaka, 565-0871, Japan. FAU - Okusaki, Daisuke AU - Okusaki D AUID- ORCID: 0000-0002-4552-783X AD - Center for Infectious Disease Education and Research (CiDER), Osaka University, Suita, Osaka, 565-0871, Japan. AD - Laboratory of Human Immunology (Single Cell Genomics), WPI-IFReC, Osaka University, Suita, 565-0871, Japan. AD - Genome Information Research Center, Research Institute for Microbial Diseases, Osaka University, Suita, 565-0871, Japan. AD - Integrated Frontier Research for Medical Science Division, Institute for Open and Transdisciplinary Research Initiatives, Osaka University, Suita, 565-0871, Japan. FAU - Matsumoto, Hisatake AU - Matsumoto H AD - Center for Infectious Disease Education and Research (CiDER), Osaka University, Suita, Osaka, 565-0871, Japan. h-matsumoto@hp-emerg.med.osaka-u.ac.jp. AD - Department of Traumatology and Acute Critical Medicine, Osaka University Graduate School of Medicine, Suita, Osaka, 565-0871, Japan. h-matsumoto@hp-emerg.med.osaka-u.ac.jp. FAU - Wing, James B AU - Wing JB AUID- ORCID: 0000-0002-3462-1003 AD - Laboratory of Human Single Cell Immunology, World Premier International Research Center Initiative Immunology Frontier Research Center (WPI-IFReC), Osaka University, Suita, Osaka, 563-0793, Japan. jbwing@ifrec.osaka-u.ac.jp. AD - Human Single Cell Immunology Team, Center for Infectious Disease Education and Research (CiDER), Osaka University, Suita, Osaka, 565-0871, Japan. jbwing@ifrec.osaka-u.ac.jp. AD - Center for Advanced Modalities and DDS (CAMaD), Osaka University, Osaka, Japan. jbwing@ifrec.osaka-u.ac.jp. LA - eng SI - GEO/GSE247488 GR - 2021 High-Risk Emerging Infectious Disease Research Gran/Takeda Science Foundation/ GR - JP223fa627002/Japan Agency for Medical Research and Development (AMED)/ GR - Osaka University Project for Infectious Disease Prevention/Nippon Foundation/ PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20240809 PL - England TA - Nat Commun JT - Nature communications JID - 101528555 RN - EC 3.1.3.48 (Leukocyte Common Antigens) RN - 0 (BNT162 Vaccine) RN - 0 (Antibodies, Viral) RN - 0 (COVID-19 Vaccines) RN - 0 (mRNA Vaccines) SB - IM MH - Humans MH - *COVID-19/immunology MH - *Leukocyte Common Antigens/metabolism MH - *SARS-CoV-2/immunology MH - *Memory B Cells/immunology MH - *BNT162 Vaccine/immunology MH - Male MH - Antibodies, Viral/immunology/blood MH - Middle Aged MH - Female MH - COVID-19 Vaccines/immunology MH - Vaccination MH - Adult MH - Immunologic Memory/immunology MH - mRNA Vaccines/immunology MH - B-Lymphocytes/immunology MH - Aged PMC - PMC11315995 COIS- The authors declare no competing interests. EDAT- 2024/08/10 15:44 MHDA- 2024/08/10 15:45 PMCR- 2024/08/09 CRDT- 2024/08/09 23:14 PHST- 2023/11/27 00:00 [received] PHST- 2024/07/29 00:00 [accepted] PHST- 2024/08/10 15:45 [medline] PHST- 2024/08/10 15:44 [pubmed] PHST- 2024/08/09 23:14 [entrez] PHST- 2024/08/09 00:00 [pmc-release] AID - 10.1038/s41467-024-50997-4 [pii] AID - 50997 [pii] AID - 10.1038/s41467-024-50997-4 [doi] PST - epublish SO - Nat Commun. 2024 Aug 9;15(1):6811. doi: 10.1038/s41467-024-50997-4. PMID- 39116861 OWN - NLM STAT- MEDLINE DCOM- 20240808 LR - 20240808 IS - 0016-3813 (Print) IS - 0016-3813 (Linking) VI - 160 IP - 2 DP - 2024 TI - Contribution of memory T cells to the generation of long-lasting immunity against COVID-19. PG - 128-135 LID - 10.24875/GMM.M24000878 [doi] AB - Humans are exposed every day to innumerable external stimuli, both environmental and microbial. Immunological memory recalls each specific stimulus and mounts a secondary response that is faster and of a larger magnitude than the primary response; this process constitutes the basis for vaccine development. The COVID-19 pandemic offers a unique opportunity to study the development of immune memory against an emergent microorganism. Memory T cells have an important role in the resolution of COVID-19, and they are key pillars of immunological memory. In this review, we summarize the main findings regarding anti-SARS-CoV-2 memory T cells after infection, after vaccination, and after the combination of these two events ("hybrid immunity"), and analyze how these cells can contribute to long-term protection against the infection with SARS-CoV-2 variants. CI - Copyright: (c) 2024 Permanyer. FAU - Torres-Flores, Alejandro AU - Torres-Flores A AD - Medical Research Unit in Immunochemistry, High Specialty Medical Unit, Specialty Hospital, National Medical Center Siglo XXI, Mexican Institute of Social Security. AD - Department of Immunology, National School of Biological Sciences, Instituto Politecnico Nacional. Mexico City, Mexico. FAU - Wong-Baeza, Isabel AU - Wong-Baeza I AD - Department of Immunology, National School of Biological Sciences, Instituto Politecnico Nacional. Mexico City, Mexico. FAU - Lopez-Macias, Constantino AU - Lopez-Macias C AD - Medical Research Unit in Immunochemistry, High Specialty Medical Unit, Specialty Hospital, National Medical Center Siglo XXI, Mexican Institute of Social Security. LA - eng PT - Journal Article PT - Review TT - Contribucion de las celulas T de memoria en la generacion de inmunidad de larga duracion contra COVID-19. PL - Mexico TA - Gac Med Mex JT - Gaceta medica de Mexico JID - 0010333 RN - 0 (COVID-19 Vaccines) RN - SARS-CoV-2 variants SB - IM MH - Humans MH - *COVID-19/immunology/prevention & control MH - *Immunologic Memory/immunology MH - *Memory T Cells/immunology MH - *COVID-19 Vaccines/immunology MH - *SARS-CoV-2/immunology OTO - NOTNLM OT - Celulas T OT - Immunological memory OT - Memoria inmunologica OT - SARS-CoV-2 OT - T cells EDAT- 2024/08/09 00:43 MHDA- 2024/08/09 00:44 CRDT- 2024/08/08 18:33 PHST- 2024/08/09 00:44 [medline] PHST- 2024/08/09 00:43 [pubmed] PHST- 2024/08/08 18:33 [entrez] AID - j160/2/128 [pii] AID - 10.24875/GMM.M24000878 [doi] PST - ppublish SO - Gac Med Mex. 2024;160(2):128-135. doi: 10.24875/GMM.M24000878. PMID- 39097927 OWN - NLM STAT- MEDLINE DCOM- 20240830 LR - 20250121 IS - 2211-1247 (Electronic) VI - 43 IP - 8 DP - 2024 Aug 27 TI - Immunity against conserved epitopes dominates after two consecutive exposures to SARS-CoV-2 Omicron BA.1. PG - 114567 LID - S2211-1247(24)00896-9 [pii] LID - 10.1016/j.celrep.2024.114567 [doi] AB - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exposure histories become increasingly complex through original and variant-adapted vaccines and infections with viral variants. Upon exposure to the highly altered Omicron spike glycoprotein, pre-immunized individuals predominantly mount recall responses of Wuhan-Hu-1 (wild-type)-imprinted memory B (B(MEM)) cells mostly targeting conserved non-neutralizing epitopes, leading to diminished Omicron neutralization. We investigated the impact of imprinting in individuals double/triple vaccinated with a wild-type-strain-based mRNA vaccine who, thereafter, had two consecutive exposures to Omicron BA.1 spike (breakthrough infection followed by BA.1-adapted vaccine). We found that depletion of conserved epitope-recognizing antibodies using a wild-type spike bait results in strongly diminished BA.1 neutralization. Furthermore, spike-specific B(MEM) cells recognizing conserved epitopes are much more prevalent than BA.1-specific B(MEM) cells. Our observations suggest that imprinted B(MEM) cell recall responses limit the induction of strain-specific responses even after two consecutive BA.1 spike exposures. Vaccine adaptation strategies need to consider that prior SARS-CoV-2 infections and vaccinations may cause persistent immune imprinting. CI - Copyright (c) 2024. Published by Elsevier Inc. FAU - Muik, Alexander AU - Muik A AD - BioNTech, An der Goldgrube 12, 55131 Mainz, Germany. FAU - Quandt, Jasmin AU - Quandt J AD - BioNTech, An der Goldgrube 12, 55131 Mainz, Germany. FAU - Lui, Bonny Gaby AU - Lui BG AD - BioNTech, An der Goldgrube 12, 55131 Mainz, Germany. FAU - Bacher, Maren AU - Bacher M AD - BioNTech, An der Goldgrube 12, 55131 Mainz, Germany. FAU - Lutz, Sebastian AU - Lutz S AD - BioNTech, An der Goldgrube 12, 55131 Mainz, Germany. FAU - Grunenthal, Maika AU - Grunenthal M AD - BioNTech, An der Goldgrube 12, 55131 Mainz, Germany. FAU - Toker, Aras AU - Toker A AD - BioNTech, An der Goldgrube 12, 55131 Mainz, Germany. FAU - Grosser, Jessica AU - Grosser J AD - BioNTech, An der Goldgrube 12, 55131 Mainz, Germany. FAU - Ozhelvaci, Orkun AU - Ozhelvaci O AD - BioNTech, An der Goldgrube 12, 55131 Mainz, Germany. FAU - Blokhina, Olga AU - Blokhina O AD - BioNTech, An der Goldgrube 12, 55131 Mainz, Germany. FAU - Shpyro, Svetlana AU - Shpyro S AD - BioNTech, An der Goldgrube 12, 55131 Mainz, Germany. FAU - Vogler, Isabel AU - Vogler I AD - BioNTech, An der Goldgrube 12, 55131 Mainz, Germany. FAU - Salisch, Nadine AU - Salisch N AD - BioNTech, An der Goldgrube 12, 55131 Mainz, Germany. FAU - Tureci, Ozlem AU - Tureci O AD - BioNTech, An der Goldgrube 12, 55131 Mainz, Germany; HI-TRON - Helmholtz Institute for Translational Oncology Mainz by DKFZ, Obere Zahlbacherstr. 63, 55131 Mainz, Germany. FAU - Sahin, Ugur AU - Sahin U AD - BioNTech, An der Goldgrube 12, 55131 Mainz, Germany; TRON gGmbH - Translational Oncology at the University Medical Center of the Johannes Gutenberg University, Freiligrathstrasse 12, 55131 Mainz, Germany. Electronic address: ugur.sahin@biontech.de. LA - eng SI - ClinicalTrials.gov/NCT05004181 PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20240803 PL - United States TA - Cell Rep JT - Cell reports JID - 101573691 RN - 0 (Spike Glycoprotein, Coronavirus) RN - 0 (Antibodies, Viral) RN - 0 (Antibodies, Neutralizing) RN - 0 (spike protein, SARS-CoV-2) RN - 0 (COVID-19 Vaccines) RN - 0 (Epitopes) RN - SARS-CoV-2 variants SB - IM MH - Humans MH - *SARS-CoV-2/immunology MH - *COVID-19/immunology/virology MH - *Spike Glycoprotein, Coronavirus/immunology MH - *Antibodies, Viral/immunology MH - *Antibodies, Neutralizing/immunology MH - COVID-19 Vaccines/immunology MH - Epitopes/immunology MH - Female MH - Middle Aged MH - Adult MH - Male MH - Memory B Cells/immunology OTO - NOTNLM OT - BNT162b2 OT - CP: Immunology OT - Omicron OT - SARS-CoV-2 OT - breakthrough infection OT - immune imprinting OT - memory B cells OT - neutralizing antibody OT - original antigenic sin COIS- Declaration of interests U.S. and O.T. are management board members and employees at BioNTech SE. A.M., B.G.L., J.Q., M.B., S.L., M.G., A.T., J.G., I.V., O.B., S.S., N.S., and O.O. are employees at BioNTech SE. U.S., O.T., and A.M. are inventors on patents and patent applications related to RNA technology and COVID-19 vaccines. U.S., O.T., A.M., B.G.L., J.Q., M.B., S.L., A.T., M.G., J.G., I.V., O.B., S.S., N.S., and O.O. have securities from BioNTech SE. EDAT- 2024/08/04 18:42 MHDA- 2024/08/31 09:51 CRDT- 2024/08/04 13:30 PHST- 2024/02/23 00:00 [received] PHST- 2024/06/07 00:00 [revised] PHST- 2024/07/17 00:00 [accepted] PHST- 2024/08/31 09:51 [medline] PHST- 2024/08/04 18:42 [pubmed] PHST- 2024/08/04 13:30 [entrez] AID - S2211-1247(24)00896-9 [pii] AID - 10.1016/j.celrep.2024.114567 [doi] PST - ppublish SO - Cell Rep. 2024 Aug 27;43(8):114567. doi: 10.1016/j.celrep.2024.114567. Epub 2024 Aug 3. PMID- 39095276 OWN - NLM STAT- MEDLINE DCOM- 20240913 LR - 20250904 IS - 1873-2518 (Electronic) IS - 0264-410X (Linking) VI - 42 IP - 25 DP - 2024 Nov 14 TI - Immunization-related stress and stress-related responses of mucosal versus intramuscular COVID-19 vaccination among adults in China. PG - 126150 LID - S0264-410X(24)00811-9 [pii] LID - 10.1016/j.vaccine.2024.07.051 [doi] AB - BACKGROUND: In late 2022, China became the first country to roll out mucosal COVID-19 vaccines. No prior study has yet compared the immunization stress-related responses (ISRR) among different routes of COVID-19 vaccine delivery. We aimed to compare the immunization-related psychological stress and ISRR between mucosal and intramuscular COVID-19 vaccines. METHODS: A cross-sectional questionnaire survey using a biopsychosocial framework design was performed from January 11 to 20, 2023. Adults with COVID-19 vaccination were eligible for the study, and a total of 1073 adults participated with community-based sample. Primary outcomes were the psychological stress levels and prevalence of ISRR. Multivariate regression models were employed to compare these outcomes between the two vaccination groups. The potential mediating effects of stress on vaccination and ISRR were examined using bootstrap sampling method. To further ensure the robustness of our results, sensitivity analysis with propensity score matching was performed. FINDINGS: In the univariate analysis, participants who received mucosal vaccination reported significantly lower stress levels compared to those who received intramuscular vaccination (3.39 +/- 3.02 vs. 3.93 +/- 3.24, P = .006). The prevalence of overall ISRR was significantly lower in the mucosal group compared to the intramuscular group (38.4% vs. 47.9%, P = .002). Multivariate regression models revealed that participants who received mucosal vaccination had a significantly lower stress level (beta = -0.516, 95% CI: -0.852 to -0.180; P = .003) and 38.7% fewer overall ISRR (OR = 0.613, 95% CI: 0.427 to 0.881; P = .008), particularly in terms of neurological symptoms. The immunization-related stress mediated the association between vaccination type and ISRR, with indirect effects estimated at 0.0663 (95% CI: 0.0195 to 0.1346) for overall ISRR. CONCLUSIONS: Mucosal COVID-19 vaccination was associated with reduced psychological stress and physical responses, as compared to intramuscular vaccination, which may contribute to increased trust and compliance with routine or mass vaccination efforts in the future. CI - Copyright (c) 2024. Published by Elsevier Ltd. FAU - Jiang, Minghuan AU - Jiang M AD - Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmacy, Xi'an Jiaotong University, Xi'an, China; Center for Drug Safety and Policy Research, Xi'an Jiaotong University, Xi'an, China; Institute for Global Health and Development, Peking University, Beijing, China. FAU - Zhang, Haijun AU - Zhang H AD - Department of Health Policy and Management, School of Public Health, Peking University, Beijing, China; China Center for Health Development Studies, Peking University, Beijing, China; Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, USA; International Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health, Baltimore, USA. FAU - Yao, Xuelin AU - Yao X AD - Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmacy, Xi'an Jiaotong University, Xi'an, China; Center for Drug Safety and Policy Research, Xi'an Jiaotong University, Xi'an, China. FAU - Wang, Yang AU - Wang Y AD - China Center for Health Development Studies, Peking University, Beijing, China. FAU - Lai, Xiaozhen AU - Lai X AD - Department of Health Policy and Management, School of Public Health, Peking University, Beijing, China; China Center for Health Development Studies, Peking University, Beijing, China; Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford, Oxford, UK. FAU - Fang, Hai AU - Fang H AD - China Center for Health Development Studies, Peking University, Beijing, China; Peking University Health Science Center - Chinese Center for Disease Control and Prevention Joint Research Center for Vaccine Economics, Beijing, China. Electronic address: hfang@hsc.pku.edu.cn. LA - eng PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20240801 PL - Netherlands TA - Vaccine JT - Vaccine JID - 8406899 RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - Male MH - Female MH - Cross-Sectional Studies MH - China/epidemiology MH - Adult MH - *COVID-19/prevention & control/epidemiology MH - Injections, Intramuscular MH - Middle Aged MH - *COVID-19 Vaccines/administration & dosage MH - *Stress, Psychological MH - Vaccination/psychology/statistics & numerical data MH - Surveys and Questionnaires MH - SARS-CoV-2/immunology MH - Administration, Mucosal MH - Young Adult OTO - NOTNLM OT - COVID-19 vaccination OT - Immunization-related stress OT - Intramuscular vaccination OT - Mucosal vaccination COIS- Declaration of competing interest Authors declare no conflict of interests. EDAT- 2024/08/03 10:42 MHDA- 2024/09/14 10:43 CRDT- 2024/08/02 21:54 PHST- 2023/07/12 00:00 [received] PHST- 2024/07/15 00:00 [revised] PHST- 2024/07/15 00:00 [accepted] PHST- 2024/09/14 10:43 [medline] PHST- 2024/08/03 10:42 [pubmed] PHST- 2024/08/02 21:54 [entrez] AID - S0264-410X(24)00811-9 [pii] AID - 10.1016/j.vaccine.2024.07.051 [doi] PST - ppublish SO - Vaccine. 2024 Nov 14;42(25):126150. doi: 10.1016/j.vaccine.2024.07.051. Epub 2024 Aug 1. PMID- 39066428 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240729 IS - 2076-393X (Print) IS - 2076-393X (Electronic) IS - 2076-393X (Linking) VI - 12 IP - 7 DP - 2024 Jul 18 TI - Clinical and Diagnostic Features of Post-Acute COVID-19 Vaccination Syndrome (PACVS). LID - 10.3390/vaccines12070790 [doi] LID - 790 AB - Post-acute COVID-19 vaccination syndrome (PACVS) is a chronic disease triggered by SARS-CoV-2 vaccination (estimated prevalence 0.02%). PACVS is discriminated from the normal post-vaccination state by altered receptor antibodies, most notably angiotensin II type 1 and alpha-2B adrenergic receptor antibodies. Here, we investigate the clinical phenotype using a study registry encompassing 191 PACVS-affected persons (159 females/32 males; median ages: 39/42 years). Unbiased clustering (modified Jaccard index) of reported symptoms revealed a prevalent cross-cohort symptomatology of malaise and chronic fatigue (>80% of cases). Overlapping clusters of (i) peripheral nerve dysfunction, dysesthesia, motor weakness, pain, and vasomotor dysfunction; (ii) cardiovascular impairment; and (iii) cognitive impairment, headache, and visual and acoustic dysfunctions were also frequently represented. Notable abnormalities of standard serum markers encompassing increased interleukins 6 and 8 (>80%), low free tri-iodine thyroxine (>80%), IgG subclass imbalances (>50%), impaired iron storage (>50%), and increased soluble neurofilament light chains (>30%) were not associated with specific symptoms. Based on these data, 131/191 participants fit myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and simultaneously also several other established dysautonomia syndromes. Furthermore, 31/191 participants fit none of these syndromes. In conclusion, PACVS could either be an outlier of ME/CFS or a dysautonomia syndrome sui generis. FAU - Mundorf, Anna Katharina AU - Mundorf AK AD - Central Institute for Clinical Chemistry and Laboratory Diagnostics, Medical Faculty, University Hospital Dusseldorf, Heinrich-Heine-University, 40225 Dusseldorf, Germany. FAU - Semmler, Amelie AU - Semmler A AD - Central Institute for Clinical Chemistry and Laboratory Diagnostics, Medical Faculty, University Hospital Dusseldorf, Heinrich-Heine-University, 40225 Dusseldorf, Germany. FAU - Heidecke, Harald AU - Heidecke H AD - CellTrend GmbH, 14943 Luckenwalde, Germany. FAU - Schott, Matthias AU - Schott M AD - Division for Specific Endocrinology, Medical Faculty, University Hospital Dusseldorf, Heinrich-Heine-University, 40225 Dusseldorf, Germany. FAU - Steffen, Falk AU - Steffen F AD - Department of Neurology, Focus Program Translational Neuroscience (FTN) and Immunotherapy (FZI), Rhine Main Neuroscience Network (RMN2), Medical Center, Johannes Gutenberg University Mainz, 55131 Mainz, Germany. FAU - Bittner, Stefan AU - Bittner S AD - Department of Neurology, Focus Program Translational Neuroscience (FTN) and Immunotherapy (FZI), Rhine Main Neuroscience Network (RMN2), Medical Center, Johannes Gutenberg University Mainz, 55131 Mainz, Germany. FAU - Lackner, Karl J AU - Lackner KJ AD - University Medical Center, Johannes Gutenberg University Mainz, 55122 Mainz, Germany. FAU - Schulze-Bosse, Karin AU - Schulze-Bosse K AD - Central Institute for Clinical Chemistry and Laboratory Diagnostics, Medical Faculty, University Hospital Dusseldorf, Heinrich-Heine-University, 40225 Dusseldorf, Germany. FAU - Pawlitzki, Marc AU - Pawlitzki M AD - Department of Neurology, Medical Faculty, Heinrich-Heine-University, 40225 Dusseldorf, Germany. FAU - Meuth, Sven Guenther AU - Meuth SG AUID- ORCID: 0000-0003-2571-3501 AD - Department of Neurology, Medical Faculty, Heinrich-Heine-University, 40225 Dusseldorf, Germany. FAU - Klawonn, Frank AU - Klawonn F AUID- ORCID: 0000-0001-9613-182X AD - Biostatistics Research Group, Helmholtz Centre for Infection Research, 38124 Braunschweig, Germany. AD - Department of Computer Science, Ostfalia University, 38302 Wolfenbuttel, Germany. FAU - Ruhrlander, Jana AU - Ruhrlander J AUID- ORCID: 0009-0006-9537-8138 AD - Selbsthilfegruppe Post-Vac-Syndrom Deutschland e.V., 34121 Kassel, Germany. FAU - Boege, Fritz AU - Boege F AUID- ORCID: 0000-0002-0780-1033 AD - Central Institute for Clinical Chemistry and Laboratory Diagnostics, Medical Faculty, University Hospital Dusseldorf, Heinrich-Heine-University, 40225 Dusseldorf, Germany. LA - eng PT - Journal Article DEP - 20240718 PL - Switzerland TA - Vaccines (Basel) JT - Vaccines JID - 101629355 PMC - PMC11281408 OTO - NOTNLM OT - PACVS OT - cognitive impairment OT - interleukin-6 OT - interleukin-8 OT - malaise/chronic fatigue OT - peripheral nerve dysfunction OT - post-acute COVID-19 vaccination syndrome COIS- Harald Heidecke is co-owner and chief executive officer of CellTrend GmbH, Luckenwalde, Germany. The other authors have no conflicts of interest to declare. EDAT- 2024/07/27 10:46 MHDA- 2024/07/27 10:47 PMCR- 2024/07/18 CRDT- 2024/07/27 01:31 PHST- 2024/06/03 00:00 [received] PHST- 2024/07/10 00:00 [revised] PHST- 2024/07/10 00:00 [accepted] PHST- 2024/07/27 10:47 [medline] PHST- 2024/07/27 10:46 [pubmed] PHST- 2024/07/27 01:31 [entrez] PHST- 2024/07/18 00:00 [pmc-release] AID - vaccines12070790 [pii] AID - vaccines-12-00790 [pii] AID - 10.3390/vaccines12070790 [doi] PST - epublish SO - Vaccines (Basel). 2024 Jul 18;12(7):790. doi: 10.3390/vaccines12070790. PMID- 39063925 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240729 IS - 2075-4426 (Print) IS - 2075-4426 (Electronic) IS - 2075-4426 (Linking) VI - 14 IP - 7 DP - 2024 Jun 21 TI - Association of Coronavirus Disease 2019 Vaccination with Facial-Related Neurological Disorders: A Nationwide Retrospective Cohort Study. LID - 10.3390/jpm14070671 [doi] LID - 671 AB - Neurological complications after the coronavirus disease 2019 (COVID-19) vaccine administration have been reported. However, the incidence rates of these complications have not been compared in vaccinated and unvaccinated individuals. This study used a nationwide cohort from South Korea to investigate the incidence and prognostic factors of facial-related neurological disorders, such as facial palsy, trigeminal neuralgia, and hemifacial spasms, after COVID-19 vaccination. A population-based cohort design was used to examine data from a randomly selected 50% of the adult population in Seoul, South Korea. Information on demographics, vaccination status, vaccination type, and medical history was collected. The incidence rates and adjusted hazard ratios (aHRs) for facial-related neurological disorders were calculated. This study included 2,482,481 adults, 85.94% of whom were vaccinated. Vaccinated individuals showed a higher incidence of facial palsy, hemifacial spasm, and trigeminal neuralgia than unvaccinated individuals, with significant aHRs of 1.821, 3.203, and 6.621, respectively. Dyslipidemia, female sex, and young age were identified as risk factors for hemifacial spasms and trigeminal neuralgia. This study demonstrates an increased incidence of facial-related neurological disorders after COVID-19 vaccination, particularly among individuals with dyslipidemia and younger women. These findings underscore the need for further investigations into the mechanisms and management of vaccine-related neurological issues. FAU - Kim, Younggoo AU - Kim Y AUID- ORCID: 0000-0003-1496-433X AD - Department of Neurosurgery, Mokdong Hospital, College of Medicine, Ewha Womans University, Seoul 07985, Republic of Korea. FAU - Kim, Min-Ho AU - Kim MH AD - Informatization Department, Seoul Hospital, College of Medicine, Ewha Womans University, Seoul 07804, Republic of Korea. FAU - Chun, Eunmi AU - Chun E AD - Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Mokdong Hospital, College of Medicine, Ewha Womans University, Seoul 07985, Republic of Korea. FAU - Cho, Dosang AU - Cho D AUID- ORCID: 0000-0002-7116-9052 AD - Department of Neurosurgery, Seoul Hospital, College of Medicine, Ewha Womans University, Seoul 07804, Republic of Korea. LA - eng GR - RS-2023-00245620/National Research Foundation of Korea/ GR - RS-2023-00245620/the National Research Foundation of Korea/ PT - Journal Article DEP - 20240621 PL - Switzerland TA - J Pers Med JT - Journal of personalized medicine JID - 101602269 PMC - PMC11277844 OTO - NOTNLM OT - COVID-19 OT - SARS-CoV-2 OT - facial palsy OT - hemifacial spasm OT - mRNA OT - trigeminal neuralgia COIS- The authors declare no conflicts of interest. EDAT- 2024/07/27 10:45 MHDA- 2024/07/27 10:46 PMCR- 2024/06/21 CRDT- 2024/07/27 01:18 PHST- 2024/05/27 00:00 [received] PHST- 2024/06/16 00:00 [revised] PHST- 2024/06/19 00:00 [accepted] PHST- 2024/07/27 10:46 [medline] PHST- 2024/07/27 10:45 [pubmed] PHST- 2024/07/27 01:18 [entrez] PHST- 2024/06/21 00:00 [pmc-release] AID - jpm14070671 [pii] AID - jpm-14-00671 [pii] AID - 10.3390/jpm14070671 [doi] PST - epublish SO - J Pers Med. 2024 Jun 21;14(7):671. doi: 10.3390/jpm14070671. PMID- 39036987 OWN - NLM STAT- MEDLINE DCOM- 20241115 LR - 20260925 IS - 1537-6613 (Electronic) IS - 0022-1899 (Print) IS - 0022-1899 (Linking) VI - 230 IP - 5 DP - 2024 Nov 15 TI - SARS-CoV-2 Monoclonal Antibody Treatment Followed by Vaccination Shifts Human Memory B-Cell Epitope Recognition, Suggesting Antibody Feedback. PG - 1187-1196 LID - 10.1093/infdis/jiae371 [doi] AB - Therapeutic monoclonal antibodies (mAbs) have been studied in humans, but the impact on immune memory of mAb treatment during an ongoing infection remains unclear. We evaluated the effect of infusion of the anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike receptor-binding domain (RBD) mAb bamlanivimab on memory B cells (MBCs) in SARS-CoV-2-infected individuals. Bamlanivimab treatment skewed the repertoire of MBCs targeting spike toward non-RBD epitopes. Furthermore, the relative affinity of RBD MBCs was weaker in mAb-treated individuals compared to placebo-treated individuals over time. Subsequently, after mRNA coronavirus disease 2019 vaccination, MBC differences persisted and mapped to a specific reduction in recognition of the class II RBD site, the same RBD epitope recognized by bamlanivimab. These findings indicate a substantial role of antibody feedback in regulating MBC responses to infection, and single mAb administration can continue to impact MBC responses to additional antigen exposures months later. CI - (c) The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site-for further information please contact journals.permissions@oup.com. FAU - Bloom, Nathaniel AU - Bloom N AD - Center for Vaccine Innovation, La Jolla Institute for Immunology. FAU - Ramirez, Sydney I AU - Ramirez SI AD - Center for Vaccine Innovation, La Jolla Institute for Immunology. AD - Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California, San Diego, La Jolla. FAU - Cohn, Hallie AU - Cohn H AD - Department of Microbiology. AD - Center for Vaccine Research and Pandemic Preparedness, Icahn School of Medicine at Mount Sinai, New York, New York. FAU - Parikh, Urvi M AU - Parikh UM AD - Division of Infectious Diseases, Department of Medicine, University of Pittsburgh School of Medicine, Pennsylvania. FAU - Heaps, Amy AU - Heaps A AD - Division of Infectious Diseases, Department of Medicine, University of Pittsburgh School of Medicine, Pennsylvania. FAU - Sieg, Scott F AU - Sieg SF AD - Division of Infectious Diseases and HIV Medicine, Department of Medicine, Case Western Reserve School of Medicine, Cleveland, Ohio. FAU - Greninger, Alex AU - Greninger A AUID- ORCID: 0000-0002-7443-0527 AD - Department of Medicine, University of Washington, Seattle. FAU - Ritz, Justin AU - Ritz J AD - Center for Biostatistics in AIDS Research, Harvard T. H. Chan School of Public Health, Boston, Massachusetts. FAU - Moser, Carlee AU - Moser C AUID- ORCID: 0000-0001-5601-9112 AD - Center for Biostatistics in AIDS Research, Harvard T. H. Chan School of Public Health, Boston, Massachusetts. FAU - Eron, Joseph J AU - Eron JJ AD - Department of Medicine, University of North Carolina at Chapel Hill School of Medicine. FAU - Bajic, Goran AU - Bajic G AD - Department of Microbiology. FAU - Currier, Judith S AU - Currier JS AD - Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles. FAU - Klekotka, Paul AU - Klekotka P AD - Eli Lilly and Company, San Diego. FAU - Wohl, David A AU - Wohl DA AD - Department of Medicine, University of North Carolina at Chapel Hill School of Medicine. FAU - Daar, Eric S AU - Daar ES AD - Lundquist Institute at Harbor, University of California, Los Angeles Medical Center, Torrance. FAU - Li, Jonathan AU - Li J AD - Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. FAU - Hughes, Michael D AU - Hughes MD AD - Center for Biostatistics in AIDS Research, Harvard T. H. Chan School of Public Health, Boston, Massachusetts. FAU - Chew, Kara W AU - Chew KW AD - Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles. FAU - Smith, Davey M AU - Smith DM AD - Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California, San Diego, La Jolla. FAU - Crotty, Shane AU - Crotty S AD - Center for Vaccine Innovation, La Jolla Institute for Immunology. AD - Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California, San Diego, La Jolla. FAU - Coelho, Camila H AU - Coelho CH AUID- ORCID: 0000-0002-7885-9996 AD - Department of Microbiology. AD - Center for Vaccine Research and Pandemic Preparedness, Icahn School of Medicine at Mount Sinai, New York, New York. AD - Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York. CN - Accelerating COVID-19 Therapeutic Interventions and Vaccines-2/A5401 (ACTIV-2/A5401) Study Team LA - eng GR - UM1 AI069423/AI/NIAID NIH HHS/United States GR - R25 AI147376/AI/NIAID NIH HHS/United States GR - UM1 AI069424/AI/NIAID NIH HHS/United States GR - UM1 AI069481/AI/NIAID NIH HHS/United States GR - AI142742/Collaborative Center for Human Immunology/ GR - U01 AI068636/AI/NIAID NIH HHS/United States GR - 75N93019C00065/AI/NIAID NIH HHS/United States GR - UM1 AI069463/AI/NIAID NIH HHS/United States GR - U54 CA267776/CA/NCI NIH HHS/United States GR - A. P. Giannini Foundation/ GR - U54CA267776/NIH Faculty Institutional Recruitment for Sustainable Transformation/ GR - U19 AI142742/AI/NIAID NIH HHS/United States GR - National Institute of Allergy and Infectious Diseases/ GR - T32 AI007036/AI/NIAID NIH HHS/United States GR - U01 AI069463/AI/NIAID NIH HHS/United States GR - UM1 AI069432/AI/NIAID NIH HHS/United States GR - UM1 AI069412/AI/NIAID NIH HHS/United States GR - UM1 AI068634/AI/NIAID NIH HHS/United States GR - NH/NIH HHS/United States GR - 75N93019C00065/GF/NIH HHS/United States GR - La Jolla Institute for Immunology institutional funds/ GR - U01 AI069424/AI/NIAID NIH HHS/United States PT - Clinical Trial, Phase II PT - Clinical Trial, Phase III PT - Journal Article PT - Multicenter Study PT - Randomized Controlled Trial PL - United States TA - J Infect Dis JT - The Journal of infectious diseases JID - 0413675 RN - 0 (Antibodies, Monoclonal) RN - 0 (Antibodies, Monoclonal, Humanized) RN - 0 (Antibodies, Viral) RN - 0 (COVID-19 Vaccines) RN - 0 (Epitopes, B-Lymphocyte) RN - 0 (Spike Glycoprotein, Coronavirus) RN - 45I6OFJ8QH (bamlanivimab) RN - 0 (Antibodies, Neutralizing) RN - 0 (spike protein, SARS-CoV-2) SB - IM UOF - bioRxiv. 2023 Nov 22:2023.11.21.567575. doi: 10.1101/2023.11.21.567575. PMID: 38045374 MH - Adult MH - Female MH - Humans MH - Male MH - Middle Aged MH - *Antibodies, Monoclonal/immunology/therapeutic use MH - Antibodies, Monoclonal, Humanized/therapeutic use/immunology MH - Antibodies, Viral/immunology MH - *COVID-19/immunology/prevention & control/virology MH - COVID-19 Vaccines/immunology/administration & dosage MH - *Epitopes, B-Lymphocyte/immunology MH - *Memory B Cells/immunology MH - *SARS-CoV-2/immunology MH - Spike Glycoprotein, Coronavirus/immunology MH - *Vaccination MH - *Feedback, Physiological MH - Antibodies, Neutralizing PMC - PMC11566236 OTO - NOTNLM OT - COVID-19 OT - SARS-CoV-2 OT - bamlanivimab OT - mAb therapy OT - memory B cells COIS- Potential conflicts of interest. S. C. has consulted for GSK, JP Morgan, Citi, Morgan Stanley, Avalia NZ, Nutcracker Therapeutics, University of California, California State Universities, United Airlines, Adagio, Sanofi, and Roche. J. S. C. has consulted for Merck and Company. P. K. is an employee and shareholder of Eli Lilly and Company. K. W. C. has consulted for Pardes Biosciences. D. M. S. has consulted for and has equity stake in Linear Therapies, Model Medicines, and Vx Biosciences and has consulted for Bayer, Kiadis, Signant Health, and Brio Clinical. All other authors report no potential conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed. FIR - Hosey, Lara IR - Hosey L FIR - Roa, Jhoanna IR - Roa J FIR - Patel, Nilam IR - Patel N FIR - Erhardt, Bill IR - Erhardt B FIR - Adams, Stacey IR - Adams S EDAT- 2024/07/22 12:44 MHDA- 2024/11/16 09:59 PMCR- 2025/07/22 CRDT- 2024/07/22 06:53 PHST- 2024/05/29 00:00 [received] PHST- 2024/07/18 00:00 [accepted] PHST- 2024/11/16 09:59 [medline] PHST- 2024/07/22 12:44 [pubmed] PHST- 2024/07/22 06:53 [entrez] PHST- 2025/07/22 00:00 [pmc-release] AID - 7717844 [pii] AID - jiae371 [pii] AID - 10.1093/infdis/jiae371 [doi] PST - ppublish SO - J Infect Dis. 2024 Nov 15;230(5):1187-1196. doi: 10.1093/infdis/jiae371. PMID- 39013656 OWN - NLM STAT- MEDLINE DCOM- 20240716 LR - 20250204 IS - 2044-6055 (Electronic) IS - 2044-6055 (Linking) VI - 14 IP - 7 DP - 2024 Jul 16 TI - Comparing COVID-19 vaccination coverage, adverse reactions and impact of social determinants of health on vaccine hesitancy in ADRD/MCI and non-ADRD/MCI population: protocol for a retrospective cross-sectional study. PG - e082988 LID - 10.1136/bmjopen-2023-082988 [doi] LID - e082988 AB - INTRODUCTION: COVID-19 vaccination is crucial for vulnerable people with underlying chronic conditions such as Alzheimer's disease and related dementias (ADRD) and mild cognitive impairment (MCI). These individuals face unique challenges, including higher risk of COVID-19, difficulties in adopting preventive behaviours and vaccine hesitancy due to concerns about adverse reactions. Therefore, efforts to promote vaccination, including boosters tailored to the currently circulating virus, are essential for people with ADRD/MCI. OBJECTIVE: The primary purpose of this study protocol is to conduct a comprehensive analysis of COVID-19 vaccination coverage and adverse reactions among individuals with ADRD/MCI in comparison to those without ADRD/MCI. Additionally, the proposed study aims to investigate the impact of social determinants of health on COVID-19 vaccination and vaccine hesitancy in individuals with ADRD/MCI. METHODS AND ANALYSIS: A retrospective cross-sectional study will be conducted utilising data from the All of Us (AoU) Researcher Workbench. Relevant data fields are extracted from sources including demographic information, COVID-19 Vaccine Survey, Basic Survey, Health Access & Utilization, Social Determinants of Health, and Electronic Health Record (EHR) data. Data on vaccination, adverse reactions and vaccine hesitancy will be collected through COVID-19 vaccine survey questionnaires. Propensity score matching and binary logistic regression will be applied to assess the vaccination rates and vaccine hesitancy, while controlling for demographic characteristics and social determinants of health factors. ETHICS AND DISSEMINATION: This study protocol received approval from the Institutional Review Board at Florida State University (STUDY00004571). Results will be disseminated through publication in peer-reviewed journals and presented at scientific conferences. CI - (c) Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Yang, Yijiong AU - Yang Y AUID- ORCID: 0000-0002-6644-4179 AD - College of Nursing, Florida State University, Tallahassee, Florida, USA yijiongyang@gmail.com. FAU - Park, Hyejin AU - Park H AD - College of Nursing, Florida State University, Tallahassee, Florida, USA. FAU - Li, Chengdong AU - Li C AD - College of Nursing, Florida State University, Tallahassee, Florida, USA. FAU - Song, Dan AU - Song D AD - College of Nursing, Florida State University, Tallahassee, Florida, USA. FAU - Wang, Jing AU - Wang J AD - College of Nursing, Florida State University, Tallahassee, Florida, USA. LA - eng PT - Journal Article DEP - 20240716 PL - England TA - BMJ Open JT - BMJ open JID - 101552874 RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - Cross-Sectional Studies MH - Retrospective Studies MH - *COVID-19/prevention & control/epidemiology/psychology MH - *Vaccination Hesitancy/psychology/statistics & numerical data MH - *Social Determinants of Health MH - *COVID-19 Vaccines/adverse effects/administration & dosage MH - SARS-CoV-2 MH - Vaccination Coverage/statistics & numerical data MH - Cognitive Dysfunction/prevention & control MH - Alzheimer Disease/psychology MH - Dementia/psychology MH - Research Design MH - Male MH - Female PMC - PMC11253747 OTO - NOTNLM OT - COVID-19 OT - Chronic Disease OT - Dementia OT - GERIATRIC MEDICINE OT - PUBLIC HEALTH COIS- Competing interests: None declared. EDAT- 2024/07/17 00:41 MHDA- 2024/07/17 00:42 PMCR- 2024/07/16 CRDT- 2024/07/16 21:53 PHST- 2024/07/17 00:42 [medline] PHST- 2024/07/17 00:41 [pubmed] PHST- 2024/07/16 21:53 [entrez] PHST- 2024/07/16 00:00 [pmc-release] AID - bmjopen-2023-082988 [pii] AID - 10.1136/bmjopen-2023-082988 [doi] PST - epublish SO - BMJ Open. 2024 Jul 16;14(7):e082988. doi: 10.1136/bmjopen-2023-082988. PMID- 38940313 OWN - NLM STAT- MEDLINE DCOM- 20240628 LR - 20260922 IS - 2162-3279 (Electronic) VI - 14 IP - 7 DP - 2024 Jul TI - The effect of COVID-19 vaccination on multiple sclerosis activity as reflected by MRI. PG - e3587 LID - 10.1002/brb3.3587 [doi] LID - e3587 AB - INTRODUCTION: Examining the safety of theBNT162b2 mRNA vaccine in multiple sclerosis (MS) patients remains inconclusive, particularly regarding the potential for disease exacerbations. This study aims to assess the effects of BNT162b2 COVID-19 vaccination on disease activity in MS patients through sequential MRI imaging. METHODS: A retrospective study of 84 MS patients from five Israeli hospitals was conducted. MS lesion load was determined from three brain MRI scans, one postvaccination and two prevaccination scans. A post hoc analysis compared subgroups featuring vaccinated and unvaccinated patients respectively, with early onset MS. RESULTS: The cohort included 70 women with early onset (mean age 16.4 +/- 0.8 years) and adult onset (mean age 34.9 +/- 1.1 years) MS. Among the early onset group, vaccinated patients showed an increased risk of new lesions (p = .00026), while there was no increased risk among adult-onset patients. Additionally, a comparison between early onset vaccinated and nonvaccinated groups revealed a higher risk of increased lesions in the vaccinated group (p = .024). DISCUSSION: Overall, the study suggests that the BNT162b2 vaccine is generally safe in MS patients, with no association found between vaccination and new lesions in most patients. However, close MRI follow-up is recommended for early-onset MS cases to monitor lesion development. CI - (c) 2024 The Author(s). Brain and Behavior published by Wiley Periodicals LLC. FAU - Ganelin-Cohen, Esther AU - Ganelin-Cohen E AD - Neuroimmunological Clinic, Institute of Pediatric Neurology, Schneider Children's Medical Center of Israel, Petah Tikva, Israel. AD - Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. FAU - Buxbaum, Chen AU - Buxbaum C AD - Department of Neurology, Rambam Health Care Campus, Haifa, Israel. FAU - Bosak, Noam AU - Bosak N AD - Department of Neurology, Rambam Health Care Campus, Haifa, Israel. FAU - Sobol, Shani AU - Sobol S AD - Department of Neurology, Rambam Health Care Campus, Haifa, Israel. FAU - Vaknin-Dembinsky, Adi AU - Vaknin-Dembinsky A AD - Unit for Neuro-Immunology, Multiple Sclerosis & Cell Therapy, Department of Neurology, Hadassah Medical Center, Jerusalem, Israel. FAU - Hellmann, Mark A AU - Hellmann MA AD - Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. AD - Department of Neurology, Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel. FAU - Wilf-Yarkoni, Adi AU - Wilf-Yarkoni A AD - Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. AD - Department of Neurology, Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel. FAU - Regev, Keren AU - Regev K AD - The Neuroimmunology and Multiple Sclerosis Unit, Neurology Institute, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. FAU - Pustovoyt, Elizaveta AU - Pustovoyt E AD - The Neuroimmunology and Multiple Sclerosis Unit, Neurology Institute, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. FAU - Shifrin, Alla AU - Shifrin A AD - Department of Neurology, Rambam Health Care Campus, Haifa, Israel. FAU - Wexler, Yair AU - Wexler Y AD - School of Neurobiology, Biochemistry and Biophysics, The George S. Wise Faculty of Life Sciences, Tel-Aviv University, Tel Aviv, Israel. FAU - Rozenberg, Ayal AU - Rozenberg A AUID- ORCID: 0000-0002-9914-9715 AD - Department of Neurology, Rambam Health Care Campus, Haifa, Israel. AD - Neuroimmunology Laboratory, Department of Neurology, Rambam Health Care Campus and Ruth and Bruce Rapaport Faculty of Medicine, Technion, Israel Institute of Technology, Haifa, Israel. LA - eng PT - Journal Article PL - United States TA - Brain Behav JT - Brain and behavior JID - 101570837 RN - 0 (BNT162 Vaccine) RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - Female MH - *Magnetic Resonance Imaging/methods MH - Adult MH - *BNT162 Vaccine MH - *Multiple Sclerosis/diagnostic imaging MH - Retrospective Studies MH - *COVID-19/prevention & control MH - *COVID-19 Vaccines/adverse effects/administration & dosage MH - Adolescent MH - Brain/diagnostic imaging/pathology MH - Israel/epidemiology MH - Male MH - Vaccination/adverse effects MH - Young Adult PMC - PMC11212002 OTO - NOTNLM OT - COVID-19 OT - disease-modifying therapy OT - expanded disability status scale OT - mRNA vaccine OT - relapsing-remitting multiple sclerosis COIS- On behalf of all authors, the corresponding author states that there is no conflict of interest. EDAT- 2024/06/28 12:42 MHDA- 2024/06/28 12:43 PMCR- 2024/06/28 CRDT- 2024/06/28 07:03 PHST- 2023/12/23 00:00 [revised] PHST- 2023/07/06 00:00 [received] PHST- 2024/05/04 00:00 [accepted] PHST- 2024/06/28 12:43 [medline] PHST- 2024/06/28 12:42 [pubmed] PHST- 2024/06/28 07:03 [entrez] PHST- 2024/06/28 00:00 [pmc-release] AID - BRB33587 [pii] AID - 10.1002/brb3.3587 [doi] PST - ppublish SO - Brain Behav. 2024 Jul;14(7):e3587. doi: 10.1002/brb3.3587. PMID- 38932303 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240629 IS - 2076-393X (Print) IS - 2076-393X (Electronic) IS - 2076-393X (Linking) VI - 12 IP - 6 DP - 2024 May 24 TI - Cardiac and Neurological Complications Post COVID-19 Vaccination: A Systematic Review of Case Reports and Case Series. LID - 10.3390/vaccines12060575 [doi] LID - 575 AB - Following mass vaccinations for the control of the COVID-19 epidemic, a spectrum of cardiac and neurological disorders was reported among vaccinated individuals. This study examined the range of complications documented and factors related to their occurrence. Three electronic databases were searched for case reports and case series with descriptions of cardiac and/or neurological complications in COVID-19 vaccine recipients. A total of 698 vaccinees were included in this review, of which 259 (37.1%) had cardiac and 439 (62.9%) had neurological complications. Inflammatory conditions were the commonest among the cardiac complications; while polyneuropathy, demyelinating diseases and cerebrovascular disorders were the more common neurological complications. The mean age of those with cardiac complications (33.8 years) was much younger than those with neurological complications (49.7 years). There was no notable difference in the gender distribution between these two groups of vaccine recipients. mRNA vaccines (all brands) were associated with almost 90.0% of the cardiac complications, whereas viral vector vaccines were associated with slightly over half (52.6%) of the neurological complications. With regard to the dose, cardiac complications were more common after the second (69.1%), whereas neurological complications were more common after the first dose (63.6%). The majority of the cases had an uncomplicated clinical course. Nevertheless, 5.9% of cases with neurological complications and 2.5% of those with cardiac complications were fatal, underscoring the significance of the consistent surveillance and vigilant monitoring of vaccinated individuals to mitigate these occurrences. FAU - Lee, Kai Wei AU - Lee KW AUID- ORCID: 0000-0001-9737-8066 AD - Department of Medical Microbiology, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Serdang 43400, Selangor, Malaysia. FAU - Yap, Sook Fan AU - Yap SF AD - Department of Pre-Clinical Sciences, M. Kandiah Faculty of Medicine and Health Sciences, Universiti Tunku Abdul Rahman, Kajang 43200, Selangor, Malaysia. AD - Dr. Wu Lien-Teh Centre of Research in Communicable Diseases, Universiti Tunku Abdul Rahman, Kajang 43200, Selangor, Malaysia. FAU - Amin-Nordin, Syafinaz AU - Amin-Nordin S AUID- ORCID: 0000-0002-6054-2368 AD - Department of Medical Microbiology, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Serdang 43400, Selangor, Malaysia. FAU - Ngeow, Yun Fong AU - Ngeow YF AD - Department of Pre-Clinical Sciences, M. Kandiah Faculty of Medicine and Health Sciences, Universiti Tunku Abdul Rahman, Kajang 43200, Selangor, Malaysia. AD - Dr. Wu Lien-Teh Centre of Research in Communicable Diseases, Universiti Tunku Abdul Rahman, Kajang 43200, Selangor, Malaysia. LA - eng PT - Journal Article PT - Review DEP - 20240524 PL - Switzerland TA - Vaccines (Basel) JT - Vaccines JID - 101629355 PMC - PMC11209191 OTO - NOTNLM OT - cardiac OT - complications OT - neurological OT - public health OT - sequelae OT - vaccines COIS- The authors declare no conflicts of interest. EDAT- 2024/06/27 06:42 MHDA- 2024/06/27 06:43 PMCR- 2024/05/24 CRDT- 2024/06/27 01:28 PHST- 2024/04/08 00:00 [received] PHST- 2024/05/14 00:00 [revised] PHST- 2024/05/15 00:00 [accepted] PHST- 2024/06/27 06:43 [medline] PHST- 2024/06/27 06:42 [pubmed] PHST- 2024/06/27 01:28 [entrez] PHST- 2024/05/24 00:00 [pmc-release] AID - vaccines12060575 [pii] AID - vaccines-12-00575 [pii] AID - 10.3390/vaccines12060575 [doi] PST - epublish SO - Vaccines (Basel). 2024 May 24;12(6):575. doi: 10.3390/vaccines12060575. PMID- 38918610 OWN - NLM STAT- MEDLINE DCOM- 20240704 LR - 20261010 IS - 1529-2916 (Electronic) IS - 1529-2908 (Linking) VI - 25 IP - 7 DP - 2024 Jul TI - Vaccination prevents cognitive impairment after breakthrough infection with SARS-CoV-2. PG - 1136-1137 LID - 10.1038/s41590-024-01869-y [doi] LA - eng PT - Journal Article PL - United States TA - Nat Immunol JT - Nature immunology JID - 100941354 RN - 0 (COVID-19 Vaccines) RN - COVID-19 breakthrough infections SB - IM MH - Humans MH - *COVID-19/prevention & control/immunology MH - *SARS-CoV-2/immunology MH - *Cognitive Dysfunction/prevention & control/immunology MH - *COVID-19 Vaccines/immunology MH - *Vaccination MH - Breakthrough Infections EDAT- 2024/06/26 00:42 MHDA- 2024/07/05 00:42 CRDT- 2024/06/25 23:42 PHST- 2024/07/05 00:42 [medline] PHST- 2024/06/26 00:42 [pubmed] PHST- 2024/06/25 23:42 [entrez] AID - 10.1038/s41590-024-01869-y [pii] AID - 10.1038/s41590-024-01869-y [doi] PST - ppublish SO - Nat Immunol. 2024 Jul;25(7):1136-1137. doi: 10.1038/s41590-024-01869-y. PMID- 38902860 OWN - NLM STAT- MEDLINE DCOM- 20250228 LR - 20260923 IS - 1534-6080 (Electronic) IS - 0041-1337 (Print) IS - 0041-1337 (Linking) VI - 108 IP - 12 DP - 2024 Dec 1 TI - Repeated COVID-19 Vaccination Drives Memory T- and B-cell Responses in Kidney Transplant Recipients: Results From a Multicenter Randomized Controlled Trial. PG - 2420-2433 LID - 10.1097/TP.0000000000005119 [doi] AB - BACKGROUND: Insight into cellular immune responses to COVID-19 vaccinations is crucial for optimizing booster programs in kidney transplant recipients (KTRs). METHODS: In an immunologic substudy of a multicenter randomized controlled trial (NCT05030974) investigating different repeated vaccination strategies in KTR who showed poor serological responses after 2 or 3 doses of an messenger RNA (mRNA)-based vaccine, we compared SARS-CoV-2-specific interleukin-21 memory T-cell and B-cell responses by enzyme-linked immunosorbent spot (ELISpot) assays and serum IgG antibody levels. Patients were randomized to receive: a single dose of mRNA-1273 (100 mug, n = 25), a double dose of mRNA-1273 (2 x 100 mug, n = 25), or a single dose of adenovirus type 26 encoding the SARS-CoV-2 spike glycoprotein (Ad26.COV2.S) (n = 25). In parallel, we also examined responses in 50 KTR receiving 100 mug mRNA-1273, randomized to continue (n = 25) or discontinue (n = 25) mycophenolate mofetil/mycophenolic acid. As a reference, the data were compared with KTR who received 2 primary mRNA-1273 vaccinations. RESULTS: Repeated vaccination increased the seroconversion rate from 21% to 66% in all patients, which was strongly associated with enhanced levels of SARS-CoV-2-specific interleukin-21 memory T cells (odd ratio, 3.84 [1.89-7.78]; P < 0.001) and B cells (odd ratio, 35.93 [6.94-186.04]; P < 0.001). There were no significant differences observed in these responses among various vaccination strategies. In contrast to KTR vaccinated with 2 primary vaccinations, the number of antigen-specific memory B cells demonstrated potential for classifying seroconversion after repeated vaccination (area under the curve, 0.64; 95% confidence interval, 0.37-0.90; P = 0.26 and area under the curve, 0.95; confidence interval, 0.87-0.97; P < 0.0001, respectively). CONCLUSIONS: Our study emphasizes the importance of virus-specific memory T- and B-cell responses for comprehensive understanding of COVID-19 vaccine efficacy among KTR. CI - Copyright (c) 2024 The Author(s). Published by Wolters Kluwer Health, Inc. FAU - Malahe, S Reshwan K AU - Malahe SRK AD - Department of Internal Medicine, Nephrology and Transplantation, Erasmus MC Transplant Institute, Erasmus University Medical Center, Rotterdam, the Netherlands. FAU - den Hartog, Yvette AU - den Hartog Y AD - Department of Internal Medicine, Nephrology and Transplantation, Erasmus MC Transplant Institute, Erasmus University Medical Center, Rotterdam, the Netherlands. FAU - Rietdijk, Wim J R AU - Rietdijk WJR AD - Department of Hospital Pharmacy, Erasmus University Medical Center, Rotterdam, the Netherlands. FAU - van Baarle, Debbie AU - van Baarle D AD - Department of Medical Microbiology and Infection Prevention, Virology and Immunology Research Group, University Medical Center Groningen, Groningen, the Netherlands. AD - Center for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, the Netherlands. FAU - de Kuiper, Ronella AU - de Kuiper R AD - Department of Internal Medicine, Nephrology and Transplantation, Erasmus MC Transplant Institute, Erasmus University Medical Center, Rotterdam, the Netherlands. FAU - Reijerkerk, Derek AU - Reijerkerk D AD - Department of Internal Medicine, Nephrology and Transplantation, Erasmus MC Transplant Institute, Erasmus University Medical Center, Rotterdam, the Netherlands. FAU - Ras, Alicia M AU - Ras AM AD - Department of Internal Medicine, Nephrology and Transplantation, Erasmus MC Transplant Institute, Erasmus University Medical Center, Rotterdam, the Netherlands. FAU - Geers, Daryl AU - Geers D AD - Department of Viroscience, Erasmus University Medical Center, Rotterdam, the Netherlands. FAU - Diavatopoulos, Dimitri A AU - Diavatopoulos DA AD - Radboud Institute for Molecular Life Sciences, Department of Laboratory Medicine, Laboratory of Medical Immunology, Radboud University Medical Center Nijmegen, Nijmegen, the Netherlands. AD - Radboud Center for Infectious Diseases, Radboud University Medical Center Nijmegen, Nijmegen, the Netherlands. FAU - Messchendorp, A Lianne AU - Messchendorp AL AD - Department of Internal Medicine, Division of Nephrology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands. FAU - van der Molen, Renate G AU - van der Molen RG AD - Radboud Institute for Molecular Life Sciences, Department of Laboratory Medicine, Laboratory of Medical Immunology, Radboud University Medical Center Nijmegen, Nijmegen, the Netherlands. FAU - Imhof, Celine AU - Imhof C AD - Department of Internal Medicine, Division of Nephrology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands. FAU - Frolke, Sophie C AU - Frolke SC AD - Department of Experimental Immunology, Amsterdam Infection and Immunity Institute, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands. AD - Renal Transplant Unit, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands. FAU - Bemelman, Frederike J AU - Bemelman FJ AD - Renal Transplant Unit, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands. FAU - Gansevoort, Ron T AU - Gansevoort RT AD - Department of Internal Medicine, Division of Nephrology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands. FAU - Hilbrands, Luuk B AU - Hilbrands LB AD - Department of Nephrology, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, the Netherlands. FAU - Sanders, Jan-Stephan F AU - Sanders JF AD - Department of Internal Medicine, Division of Nephrology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands. FAU - GeurtsvanKessel, Corine H AU - GeurtsvanKessel CH AD - Department of Viroscience, Erasmus University Medical Center, Rotterdam, the Netherlands. FAU - Kho, Marcia M L AU - Kho MML AD - Department of Internal Medicine, Nephrology and Transplantation, Erasmus MC Transplant Institute, Erasmus University Medical Center, Rotterdam, the Netherlands. FAU - de Vries, Rory D AU - de Vries RD AD - Department of Viroscience, Erasmus University Medical Center, Rotterdam, the Netherlands. FAU - Reinders, Marlies E J AU - Reinders MEJ AD - Department of Internal Medicine, Nephrology and Transplantation, Erasmus MC Transplant Institute, Erasmus University Medical Center, Rotterdam, the Netherlands. FAU - Baan, Carla C AU - Baan CC AD - Department of Internal Medicine, Nephrology and Transplantation, Erasmus MC Transplant Institute, Erasmus University Medical Center, Rotterdam, the Netherlands. CN - On behalf of RECOVAC Consortium LA - eng SI - ClinicalTrials.gov/NCT05030974 PT - Journal Article PT - Multicenter Study PT - Randomized Controlled Trial DEP - 20241121 PL - United States TA - Transplantation JT - Transplantation JID - 0132144 RN - MKM3CA6LT1 (Interleukin-21) RN - 0 (COVID-19 Vaccines) RN - 0 (Interleukins) RN - EPK39PL4R4 (2019-nCoV Vaccine mRNA-1273) RN - 0 (Antibodies, Viral) RN - 0 (Immunosuppressive Agents) RN - 0 (Immunoglobulin G) SB - IM MH - Humans MH - *Kidney Transplantation/adverse effects MH - Male MH - Female MH - *COVID-19/prevention & control/immunology MH - Middle Aged MH - *SARS-CoV-2/immunology MH - Adult MH - *Memory T Cells/immunology MH - *B-Lymphocytes/immunology MH - Immunization, Secondary/methods MH - Aged MH - Interleukin-21 MH - *COVID-19 Vaccines/administration & dosage/immunology MH - Interleukins/immunology MH - 2019-nCoV Vaccine mRNA-1273/administration & dosage MH - Antibodies, Viral/blood MH - Vaccination/methods MH - Immunologic Memory MH - Immunosuppressive Agents MH - Transplant Recipients MH - Immunoglobulin G/blood PMC - PMC11581438 COIS- The authors declare no conflicts of interest. FIR - Abrahams, Alferso C IR - Abrahams AC IRAD- Department of Nephrology and Hypertension, University Medical Center Utrecht, Utrecht, the Netherlands. FIR - Baas, Marije C IR - Baas MC IRAD- Department of Nephrology, Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, the Netherlands. FIR - Bouwmans, Pim IR - Bouwmans P IRAD- Department of Internal Medicine, Division of Nephrology, Maastricht University Medical Center and CARIM School for Cardiovascular Disease, University of Maastricht, Maastricht, the Netherlands. FIR - Ten Dam, Marc A G J IR - Ten Dam MAGJ IRAD- Dutch Registry RENINE, Nefrovisie, Utrecht, the Netherlands. FIR - Gommers, Lennert IR - Gommers L IRAD- Department Viroscience, Erasmus Medical Center, Rotterdam, the Netherlands. FIR - Standaar, Dorien IR - Standaar D IRAD- Renal Transplant Unit, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands. FIR - van der Heiden, Marieke IR - van der Heiden M IRAD- Department of Medical Microbiology and Infection Prevention, University Medical Center Groningen, Groningen, the Netherlands. FIR - Adema, Yvonne M R IR - Adema YMR IRAD- Department of Internal Medicine, Division of Nephrology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands. FIR - Boer-Verschragen, Marieken J IR - Boer-Verschragen MJ IRAD- Department of Internal Medicine, Nephrology and Transplantation, Erasmus MC Transplant Institute, Erasmus Medical Center, Rotterdam, the Netherlands. FIR - Mattheussens, Wouter B IR - Mattheussens WB IRAD- Department of Nephrology, Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, the Netherlands. FIR - Philipsen, Ria H L A IR - Philipsen RHLA IRAD- Department of Nephrology, Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, the Netherlands. FIR - van Mourik, Djenolan IR - van Mourik D IRAD- Department Viroscience, Erasmus Medical Center, Rotterdam, the Netherlands. FIR - Bogers, Susanne IR - Bogers S IRAD- Department Viroscience, Erasmus Medical Center, Rotterdam, the Netherlands. FIR - van Dijk, Laura L A IR - van Dijk LLA IRAD- Department Viroscience, Erasmus Medical Center, Rotterdam, the Netherlands. FIR - Rots, Nynke IR - Rots N IRAD- Center for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, the Netherlands. FIR - Hemmelder, Marc H IR - Hemmelder MH IRAD- Department of Internal Medicine, Division of Nephrology, Maastricht University Medical Center and CARIM School for Cardiovascular Disease, University of Maastricht, Maastricht, the Netherlands. FIR - de Vries, Aiko P J IR - de Vries APJ IRAD- Department of Nephrology, Leiden University Medical Center, Leiden, the Netherlands. EDAT- 2024/06/21 06:42 MHDA- 2025/02/28 18:22 PMCR- 2024/11/21 CRDT- 2024/06/21 00:03 PHST- 2025/02/28 18:22 [medline] PHST- 2024/06/21 06:42 [pubmed] PHST- 2024/06/21 00:03 [entrez] PHST- 2024/11/21 00:00 [pmc-release] AID - 00007890-202412000-00024 [pii] AID - TPA-2024-0443 [pii] AID - 10.1097/TP.0000000000005119 [doi] PST - ppublish SO - Transplantation. 2024 Dec 1;108(12):2420-2433. doi: 10.1097/TP.0000000000005119. Epub 2024 Nov 21. PMID- 38902519 OWN - NLM STAT- MEDLINE DCOM- 20240704 LR - 20260813 IS - 1529-2916 (Electronic) IS - 1529-2908 (Print) IS - 1529-2908 (Linking) VI - 25 IP - 7 DP - 2024 Jul TI - Vaccination reduces central nervous system IL-1beta and memory deficits after COVID-19 in mice. PG - 1158-1171 LID - 10.1038/s41590-024-01868-z [doi] AB - Up to 25% of individuals infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exhibit postacute cognitive sequelae. Although millions of cases of coronavirus disease 2019 (COVID-19)-mediated memory dysfunction are accumulating worldwide, the underlying mechanisms and how vaccination lowers risk are unknown. Interleukin-1 (IL-1), a key component of innate immune defense against SARS-CoV-2 infection, is elevated in the hippocampi of individuals with COVID-19. Here we show that intranasal infection of C57BL/6J mice with SARS-CoV-2 Beta variant leads to central nervous system infiltration of Ly6C(hi) monocytes and microglial activation. Accordingly, SARS-CoV-2, but not H1N1 influenza virus, increases levels of brain IL-1beta and induces persistent IL-1R1-mediated loss of hippocampal neurogenesis, which promotes postacute cognitive deficits. Vaccination with a low dose of adenoviral-vectored spike protein prevents hippocampal production of IL-1beta during breakthrough SARS-CoV-2 infection, loss of neurogenesis and subsequent memory deficits. Our study identifies IL-1beta as one potential mechanism driving SARS-CoV-2-induced cognitive impairment in a new mouse model that is prevented by vaccination. CI - (c) 2024. The Author(s), under exclusive licence to Springer Nature America, Inc. FAU - Vanderheiden, Abigail AU - Vanderheiden A AUID- ORCID: 0000-0003-1321-4510 AD - Center for Neuroimmunology and Neuroinfectious Diseases, Washington University School of Medicine, St. Louis, MO, USA. AD - Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA. FAU - Hill, Jeremy D AU - Hill JD AD - Center for Neuroimmunology and Neuroinfectious Diseases, Washington University School of Medicine, St. Louis, MO, USA. AD - Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA. FAU - Jiang, Xiaoping AU - Jiang X AD - Center for Neuroimmunology and Neuroinfectious Diseases, Washington University School of Medicine, St. Louis, MO, USA. AD - Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA. FAU - Deppen, Ben AU - Deppen B AD - Center for Neuroimmunology and Neuroinfectious Diseases, Washington University School of Medicine, St. Louis, MO, USA. AD - Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA. FAU - Bamunuarachchi, Gayan AU - Bamunuarachchi G AD - Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA. FAU - Soudani, Nadia AU - Soudani N AD - Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA. FAU - Joshi, Astha AU - Joshi A AD - Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA. FAU - Cain, Matthew D AU - Cain MD AD - Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA. FAU - Boon, Adrianus C M AU - Boon ACM AUID- ORCID: 0000-0002-4700-8224 AD - Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA. AD - Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO, USA. FAU - Klein, Robyn S AU - Klein RS AUID- ORCID: 0000-0003-0281-1352 AD - Schulich School of Medicine and Dentistry, Department of Microbiology and Immunology, Western University, London, Ontario, Canada. rklein@wustl.edu. AD - Schulich School of Medicine and Dentistry, Western Institute of Neuroscience, Western University, London, Ontario, Canada. rklein@wustl.edu. LA - eng GR - R35NS122310/U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NINDS)/ GR - R35 NS122310/NS/NINDS NIH HHS/United States GR - R01NS104471/U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NINDS)/ GR - R01AI139251/U.S. Department of Health & Human Services | National Institutes of Health (NIH)/ GR - F32NS128065/Division of Intramural Research, National Institute of Allergy and Infectious Diseases (Division of Intramural Research of the NIAID)/ GR - F32 NS128065/NS/NINDS NIH HHS/United States PT - Journal Article DEP - 20240620 PL - United States TA - Nat Immunol JT - Nature immunology JID - 100941354 RN - 0 (Interleukin-1beta) RN - 0 (Spike Glycoprotein, Coronavirus) RN - 0 (COVID-19 Vaccines) RN - 0 (spike protein, SARS-CoV-2) RN - 0 (IL1B protein, mouse) RN - 0 (Receptors, Interleukin-1 Type I) RN - SARS-CoV-2 variants SB - IM MH - Animals MH - *Interleukin-1beta/metabolism/immunology MH - Mice MH - *COVID-19/immunology/prevention & control MH - *SARS-CoV-2/immunology MH - *Hippocampus/immunology/metabolism MH - *Mice, Inbred C57BL MH - *Memory Disorders/immunology MH - *Neurogenesis/immunology MH - Vaccination MH - Spike Glycoprotein, Coronavirus/immunology MH - COVID-19 Vaccines/immunology MH - Male MH - Humans MH - Microglia/immunology/metabolism MH - Disease Models, Animal MH - Receptors, Interleukin-1 Type I/metabolism/genetics MH - Monocytes/immunology/metabolism MH - Female PMC - PMC13148132 MID - NIHMS2004192 COIS- Competing interests The authors declare no competing interests. EDAT- 2024/06/21 00:42 MHDA- 2024/07/05 00:42 PMCR- 2026/05/06 CRDT- 2024/06/20 23:28 PHST- 2023/11/21 00:00 [received] PHST- 2024/05/13 00:00 [accepted] PHST- 2024/07/05 00:42 [medline] PHST- 2024/06/21 00:42 [pubmed] PHST- 2024/06/20 23:28 [entrez] PHST- 2026/05/06 00:00 [pmc-release] AID - 10.1038/s41590-024-01868-z [pii] AID - 10.1038/s41590-024-01868-z [doi] PST - ppublish SO - Nat Immunol. 2024 Jul;25(7):1158-1171. doi: 10.1038/s41590-024-01868-z. Epub 2024 Jun 20. PMID- 38886142 OWN - NLM STAT- MEDLINE DCOM- 20240913 LR - 20250902 IS - 1873-2518 (Electronic) IS - 0264-410X (Linking) VI - 42 IP - 23 DP - 2024 Oct 3 TI - Comparing the consequences of COVID-19 vaccination between central nervous system (CNS) demyelinating diseases and other neurological disorders. PG - 126061 LID - S0264-410X(24)00702-3 [pii] LID - 10.1016/j.vaccine.2024.06.028 [doi] AB - BACKGROUND: Vaccination constitutes a crucial preventive measure against COVID-19 infection. Concerns have been raised regarding the efficacy of vaccines in multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) patients due to various immunomodulatory medications and potential adverse events that may impact neurological function. This study aimed to explore the implications of COVID-19 vaccination within MS and NMSOD patients and compare it with other neurological disorders (OND). METHOD: In this cross-sectional study conducted in Isfahan, Iran, baseline data and information on COVID-19 infections and vaccinations were collected from MS, NMOSD, and OND patients between September 2021 and September 2022. The predominant neurological disorders identified among OND patients encompassed headache, epilepsy, and Parkinson's disease. Logistic regression analysis was employed to compare COVID-19 vaccination outcomes among different patient groups, presenting odds ratios (OR) with 95% confidence intervals (CI). RESULTS: The study included 1,307 participants, with 738 having MS, 96 having NMOSD, 76 having clinically isolated syndrome (CIS), and 397 having OND. Significantly higher odds of post-vaccination COVID-19 infection were detected in MS (OR = 3.86, p < 0.001) NMOSD (OR = 2.77, p = 0.015) patients than OND patients. The prior history of COVID-19 infection and the type of vaccine administered did not demonstrate significant associations with the likelihood of post-vaccination COVID-19 infection in MS and NMOSD patients (p > 0.05 for all). There were no significant differences in the rates of adverse events in MS, NMOSD, and OND patients, except the second dose, where NMOSD patients had lower odds than OND patients (OR = 0.55, p = 0.019). CONCLUSION: Although the safety profile of COVID-19 vaccination in MS and NMOSD was similar to that in OND, the rates of post-vaccination COVID-19 infection in MS and NMOSD seem higher than OND. These findings highlight the importance of regular serological monitoring and the potential advantages of supplementary vaccine doses in MS and NMOSD patients. CI - Copyright (c) 2024 Elsevier Ltd. All rights reserved. FAU - Yazdan Panah, Mohammad AU - Yazdan Panah M AD - Student Research Committee, Shahrekord University of Medical Sciences, Shahrekord, Iran; Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran. FAU - Vaheb, Saeed AU - Vaheb S AD - Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran. FAU - Mokary, Yousef AU - Mokary Y AD - Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran. FAU - Afshari-Safavi, Alireza AU - Afshari-Safavi A AD - Department of Biostatistics and Epidemiology, Faculty of Health, North Khorasan University of Medical Sciences, Bojnurd, Iran. FAU - Shaygannejad, Aysa AU - Shaygannejad A AD - Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran. FAU - Ebrahimi, Narges AU - Ebrahimi N AD - Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran. FAU - Shaygannejad, Vahid AU - Shaygannejad V AD - Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran; Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran. Electronic address: v.shaygannejad@gmail.com. FAU - Mirmosayyeb, Omid AU - Mirmosayyeb O AD - Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran; Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran. LA - eng PT - Comparative Study PT - Journal Article DEP - 20240616 PL - Netherlands TA - Vaccine JT - Vaccine JID - 8406899 RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - *COVID-19/prevention & control MH - Male MH - *COVID-19 Vaccines/adverse effects/administration & dosage/immunology MH - Female MH - Cross-Sectional Studies MH - Adult MH - Middle Aged MH - Iran/epidemiology MH - *Multiple Sclerosis/immunology MH - *Vaccination/adverse effects/methods MH - SARS-CoV-2/immunology MH - Aged MH - Nervous System Diseases/etiology MH - Neuromyelitis Optica/immunology/prevention & control MH - Young Adult MH - Demyelinating Diseases/immunology/prevention & control OTO - NOTNLM OT - COVID-19 OT - Multiple sclerosis OT - Neuromyelitis optica spectrum disorder OT - SARS-CoV-2 OT - Vaccine COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2024/06/18 00:43 MHDA- 2024/09/14 10:43 CRDT- 2024/06/17 21:54 PHST- 2023/12/25 00:00 [received] PHST- 2024/05/27 00:00 [revised] PHST- 2024/06/10 00:00 [accepted] PHST- 2024/09/14 10:43 [medline] PHST- 2024/06/18 00:43 [pubmed] PHST- 2024/06/17 21:54 [entrez] AID - S0264-410X(24)00702-3 [pii] AID - 10.1016/j.vaccine.2024.06.028 [doi] PST - ppublish SO - Vaccine. 2024 Oct 3;42(23):126061. doi: 10.1016/j.vaccine.2024.06.028. Epub 2024 Jun 16. PMID- 38878020 OWN - NLM STAT- MEDLINE DCOM- 20240807 LR - 20260922 IS - 1097-6825 (Electronic) IS - 0091-6749 (Print) IS - 0091-6749 (Linking) VI - 154 IP - 2 DP - 2024 Aug TI - Patients taking benralizumab, dupilumab, or mepolizumab have lower postvaccination SARS-CoV-2 immunity. PG - 435-446 LID - S0091-6749(24)00420-2 [pii] LID - 10.1016/j.jaci.2024.03.029 [doi] AB - BACKGROUND: Biologic therapies inhibiting the IL-4 or IL-5 pathways are very effective in the treatment of asthma and other related conditions. However, the cytokines IL-4 and IL-5 also play a role in the generation of adaptive immune responses. Although these biologics do not cause overt immunosuppression, their effect in primary severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunization has not been studied completely. OBJECTIVE: Our aim was to evaluate the antibody and cellular immunity after SARS-CoV-2 mRNA vaccination in patients on biologics (PoBs). METHODS: Patients with severe asthma or atopic dermatitis who were taking benralizumab, dupilumab, or mepolizumab and had received the initial dose of the 2-dose adult SARS-CoV-2 mRNA vaccine were enrolled in a prospective, observational study. As our control group, we used a cohort of immunologically healthy subjects (with no significant immunosuppression) who were not taking biologics (NBs). We used a multiplexed immunoassay to measure antibody levels, neutralization assays to assess antibody function, and flow cytometry to quantitate Spike-specific lymphocytes. RESULTS: We analyzed blood from 57 patients in the PoB group and 46 control subjects from the NB group. The patients in the PoB group had lower levels of SARS-CoV-2 antibodies, pseudovirus neutralization, live virus neutralization, and frequencies of Spike-specific B and CD8 T cells at 6 months after vaccination. In subgroup analyses, patients with asthma who were taking biologics had significantly lower pseudovirus neutralization than did subjects with asthma who were not taking biologics. CONCLUSION: The patients in the PoB group had reduced SARS-CoV-2-specific antibody titers, neutralizing activity, and virus-specific B- and CD8 T-cell counts. These results have implications when considering development of a more individualized immunization strategy in patients who receive biologic medications blocking IL-4 or IL-5 pathways. CI - Copyright (c) 2024 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Runnstrom, Martin C AU - Runnstrom MC AD - Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Department of Medicine, Emory University School of Medicine, Atlanta, Ga; Department of Medicine, Atlanta Veterans Affairs Healthcare System, Atlanta, Ga. FAU - Lamothe, Pedro A AU - Lamothe PA AD - Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Department of Medicine, Emory University School of Medicine, Atlanta, Ga. FAU - Faliti, Caterina E AU - Faliti CE AD - Division of Rheumatology, Department of Medicine, Emory University School of Medicine, Atlanta, Ga; Lowance Center for Human Immunology, Atlanta, Ga. FAU - Cheedarla, Narayanaiah AU - Cheedarla N AD - Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Ga. FAU - Moreno, Alberto AU - Moreno A AD - Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Ga; Yerkes National Primate Research Center, Atlanta, Ga. FAU - Suthar, Mehul S AU - Suthar MS AD - Emory Vaccine Center, Emory University School of Medicine, Atlanta, Ga; Center for Childhood Infections and Vaccines of Children's Healthcare of Atlanta, Department of Pediatrics, Emory University School of Medicine, Atlanta, Ga. FAU - Nahata, Rishika AU - Nahata R AD - Emory College of Arts and Sciences, Emory University, Atlanta, Ga. FAU - Ravindran, Mayuran AU - Ravindran M AD - J. Willis Hurst Internal Medicine Residency Program, Emory University School of Medicine, Atlanta, Ga. FAU - Haddad, Natalie S AU - Haddad NS AD - Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Department of Medicine, Emory University School of Medicine, Atlanta, Ga. FAU - Morrison-Porter, Andrea AU - Morrison-Porter A AD - Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Department of Medicine, Emory University School of Medicine, Atlanta, Ga. FAU - Quehl, Hannah AU - Quehl H AD - Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Department of Medicine, Emory University School of Medicine, Atlanta, Ga. FAU - Ramonell, Richard P AU - Ramonell RP AD - Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pa. FAU - Woodruff, Matthew AU - Woodruff M AD - Division of Rheumatology, Department of Medicine, Emory University School of Medicine, Atlanta, Ga; Lowance Center for Human Immunology, Atlanta, Ga. FAU - Anam, Fabliha AU - Anam F AD - Division of Rheumatology, Department of Medicine, Emory University School of Medicine, Atlanta, Ga; Lowance Center for Human Immunology, Atlanta, Ga. FAU - Zhang, Rebeca AU - Zhang R AD - Department of Biostatistics and Bioinformatics, Emory University, Atlanta, Ga. FAU - Swenson, Colin AU - Swenson C AD - Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Department of Medicine, Emory University School of Medicine, Atlanta, Ga. FAU - Polito, Carmen AU - Polito C AD - Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Department of Medicine, Emory University School of Medicine, Atlanta, Ga. FAU - Neveu, Wendy AU - Neveu W AD - Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Department of Medicine, Emory University School of Medicine, Atlanta, Ga. FAU - Patel, Rahulkumar AU - Patel R AD - Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Department of Medicine, Emory University School of Medicine, Atlanta, Ga. FAU - Smirnova, Natalia AU - Smirnova N AD - Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Department of Medicine, Emory University School of Medicine, Atlanta, Ga. FAU - Nguyen, Doan C AU - Nguyen DC AD - Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Department of Medicine, Emory University School of Medicine, Atlanta, Ga; Lowance Center for Human Immunology, Atlanta, Ga. FAU - Kim, Caroline AU - Kim C AD - Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Department of Medicine, Emory University School of Medicine, Atlanta, Ga. FAU - Hentenaar, Ian AU - Hentenaar I AD - Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Department of Medicine, Emory University School of Medicine, Atlanta, Ga. FAU - Kyu, Shuya AU - Kyu S AD - Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Department of Medicine, Emory University School of Medicine, Atlanta, Ga. FAU - Usman, Sabeena AU - Usman S AD - Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Department of Medicine, Emory University School of Medicine, Atlanta, Ga. FAU - Ngo, Thuy AU - Ngo T AD - Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Department of Medicine, Emory University School of Medicine, Atlanta, Ga. FAU - Guo, Zhenxing AU - Guo Z AD - Department of Biostatistics and Bioinformatics, Emory University, Atlanta, Ga. FAU - Wu, Hao AU - Wu H AD - Department of Biostatistics and Bioinformatics, Emory University, Atlanta, Ga. FAU - Daiss, John L AU - Daiss JL AD - Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Department of Medicine, Emory University School of Medicine, Atlanta, Ga. FAU - Park, Jiwon AU - Park J AD - Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Department of Medicine, Emory University School of Medicine, Atlanta, Ga. FAU - Manning, Kelly E AU - Manning KE AD - Emory Vaccine Center, Emory University School of Medicine, Atlanta, Ga; Center for Childhood Infections and Vaccines of Children's Healthcare of Atlanta, Department of Pediatrics, Emory University School of Medicine, Atlanta, Ga. FAU - Wali, Bursha AU - Wali B AD - Emory Vaccine Center, Emory University School of Medicine, Atlanta, Ga; Center for Childhood Infections and Vaccines of Children's Healthcare of Atlanta, Department of Pediatrics, Emory University School of Medicine, Atlanta, Ga. FAU - Ellis, Madison L AU - Ellis ML AD - Emory Vaccine Center, Emory University School of Medicine, Atlanta, Ga; Center for Childhood Infections and Vaccines of Children's Healthcare of Atlanta, Department of Pediatrics, Emory University School of Medicine, Atlanta, Ga. FAU - Sharma, Sunita AU - Sharma S AD - Division of Pulmonary Sciences and Critical Care Medicine, Department of Medicine, University of Colorado, Denver, Colo. FAU - Holguin, Fernando AU - Holguin F AD - Division of Pulmonary Sciences and Critical Care Medicine, Department of Medicine, University of Colorado, Denver, Colo. FAU - Cheedarla, Suneethamma AU - Cheedarla S AD - Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Ga. FAU - Neish, Andrew S AU - Neish AS AD - Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Ga. FAU - Roback, John D AU - Roback JD AD - Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Ga. FAU - Sanz, Ignacio AU - Sanz I AD - Division of Rheumatology, Department of Medicine, Emory University School of Medicine, Atlanta, Ga; Lowance Center for Human Immunology, Atlanta, Ga. FAU - Eun-Hyung Lee, F AU - Eun-Hyung Lee F AD - Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Department of Medicine, Emory University School of Medicine, Atlanta, Ga. Electronic address: f.e.lee@emory.edu. LA - eng GR - T32 HL116271/HL/NHLBI NIH HHS/United States GR - U01 AI141993/AI/NIAID NIH HHS/United States GR - P51 OD011132/OD/NIH HHS/United States GR - R01 AI121252/AI/NIAID NIH HHS/United States GR - P01 AI125180/AI/NIAID NIH HHS/United States GR - U54 CA260563/CA/NCI NIH HHS/United States GR - UL1 TR002378/TR/NCATS NIH HHS/United States GR - 75N93021C00017/AI/NIAID NIH HHS/United States GR - R01 AI172254/AI/NIAID NIH HHS/United States PT - Journal Article PT - Observational Study PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20240613 PL - United States TA - J Allergy Clin Immunol JT - The Journal of allergy and clinical immunology JID - 1275002 RN - 0 (Antibodies, Monoclonal, Humanized) RN - 420K487FSG (dupilumab) RN - 71492GE1FX (benralizumab) RN - 90Z2UF0E52 (mepolizumab) RN - 0 (COVID-19 Vaccines) RN - 0 (Antibodies, Viral) RN - 0 (Interleukin-5) SB - IM MH - Humans MH - *Antibodies, Monoclonal, Humanized/therapeutic use/administration & dosage MH - Male MH - Female MH - *SARS-CoV-2/immunology MH - Middle Aged MH - Adult MH - *COVID-19/immunology/prevention & control MH - *Asthma/drug therapy/immunology MH - *COVID-19 Vaccines/immunology/administration & dosage MH - Antibodies, Viral/blood/immunology MH - Dermatitis, Atopic/drug therapy/immunology MH - Prospective Studies MH - Aged MH - Vaccination MH - Interleukin-5/antagonists & inhibitors/immunology PMC - PMC11305925 MID - NIHMS1990255 OTO - NOTNLM OT - Asthma biologics OT - COVID-19 OT - SARS-CoV-2 OT - antibody neutralization OT - benralizumab OT - dupilumab OT - mRNA vaccines OT - memory B cells OT - memory T cells OT - mepolizumab COIS- Disclosure statement Supported by the National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID) (grants NIH/NHLBI T32HL116271 [to M.C.R., P.A.L., and N.S.]; the National Center for Advancing Translational Sciences of the NIH (UL1TR002378 [to N.S.]; P01AI125180 [to I.S. and F.E.L.]; U54CA260563 [to I.S. and F.E.L.]; R01AI121252 [to F.E.L.]; R01AI172254 [to F.E.L.]; U01AI141993 [to F.E.L.]; and NIH P51OD011132, 1U54CA260563, and the NIH/NIAID Centers of Excellence for Influenza Research and Response (under contract 75N93021C00017 to Emory University). This work does not necessarily represent the views of the US government or Department of Veterans Affairs. Disclosure of potential conflict of interest: N. S. Haddad is employed by MicroB-plex, Inc, but did not receive any payments for this article. C. Swenson receives compensation and consulting fees from Insmed, Inc, that are unrelated to this article. F. Holguin is a member of the adjudication committee of the ASPEN (A Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib in Participants With Non-Cystic Fibrosis Bronchiectasis) trial at Insmed, Inc. J. D. Roback received funding from an NIH grant in the past 36 months. I. Sanz receives royalties from BLI INC for plasma cell survival media; consulting fees from GSK, Pfizer, Kayverna, Johnson & Johnson, Celgene, Bristol-Myer Squibb, and Visterra; and honoraria for presentations from Yale and Harvard Universities. In addition, I. Sanz has a patent on plasma cell survival media. F. Eun-Hyung Lee receives or has received research grants from Genentech and the Gates Foundation; royalties from BLI INC for plasma cell survival media; consulting fees from Be Bio Pharma; honoraria for presentations at the University of Pennsylvania, the University of Cincinnati, and the Gerontological Advanced Practice Nurses Association; has patents on plasma cell survival media and media of elaborated newly synthesized antibodies (MENSA); and is the founder and owner of MicroB-plex, Inc. The rest of the authors declare that they have no relevant conflicts of interest. EDAT- 2024/06/15 14:44 MHDA- 2024/08/08 05:42 PMCR- 2024/08/08 CRDT- 2024/06/15 10:32 PHST- 2023/09/22 00:00 [received] PHST- 2024/02/27 00:00 [revised] PHST- 2024/03/15 00:00 [accepted] PHST- 2024/08/08 05:42 [medline] PHST- 2024/06/15 14:44 [pubmed] PHST- 2024/06/15 10:32 [entrez] PHST- 2024/08/08 00:00 [pmc-release] AID - S0091-6749(24)00420-2 [pii] AID - 10.1016/j.jaci.2024.03.029 [doi] PST - ppublish SO - J Allergy Clin Immunol. 2024 Aug;154(2):435-446. doi: 10.1016/j.jaci.2024.03.029. Epub 2024 Jun 13. PMID- 38864816 OWN - NLM STAT- MEDLINE DCOM- 20240612 LR - 20250129 IS - 2573-7732 (Electronic) IS - 2573-7732 (Linking) VI - 8 IP - 6 DP - 2024 Jun 1 TI - Appropriate Sampling and Longer Follow-Up Are Required to Rigorously Evaluate Longevity of Humoral Memory After Vaccination. PG - 397-403 LID - 10.4049/immunohorizons.2300057 [doi] AB - One of the goals of vaccination is to induce long-lived immunity against the infection and/or disease. Many studies have followed the generation of humoral immunity to SARS-CoV-2 after vaccination; however, such studies typically varied by the duration of the follow-up and the number of time points at which immune response measurements were done. How these parameters (the number of time points and the overall duration of the follow-up) impact estimates of immunity longevity remain largely unknown. Several studies, including one by Arunachalam et al. (2023. J. Clin. Invest. 133: e167955), evaluated the humoral immune response in individuals receiving either a third or fourth dose of mRNA COVID-19 vaccine; by measuring Ab levels at three time points (prior to vaccination and at 1 and 6 mo), Arunachalam et al. found similar half-life times for serum Abs in the two groups and thus suggested that additional boosting is unnecessary to prolong immunity to SARS-CoV-2. I demonstrate that measuring Ab levels at these three time points and only for 6 mo does not allow one to accurately evaluate the long-term half-life of vaccine-induced Abs. By using the data from a cohort of blood donors followed for several years, I show that after revaccination with vaccinia virus, vaccinia virus-specific Abs decay biphasically, and even the late decay rate exceeds the true slow loss rate of humoral memory observed years prior to the boosting. Mathematical models of Ab response kinetics, parameterized using preliminary data, should be used for power analysis to determine the most appropriate timing and duration of sampling to rigorously determine the duration of humoral immunity after vaccination. CI - Copyright (c) 2024 The Authors. FAU - Ganusov, Vitaly V AU - Ganusov VV AUID- ORCID: 0000-0001-6572-1691 LA - eng GR - R01 AI158963/AI/NIAID NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PL - England TA - Immunohorizons JT - ImmunoHorizons JID - 101708159 RN - 0 (Antibodies, Viral) RN - 0 (COVID-19 Vaccines) SB - IM UOF - medRxiv. 2023 Jun 29:2023.06.28.23291950. doi: 10.1101/2023.06.28.23291950. PMID: 37425815 MH - Humans MH - *Immunity, Humoral MH - *COVID-19/immunology/prevention & control MH - *Antibodies, Viral/blood/immunology MH - *COVID-19 Vaccines/immunology/administration & dosage MH - *SARS-CoV-2/immunology MH - *Immunologic Memory/immunology MH - *Vaccination MH - Follow-Up Studies MH - Immunization, Secondary PMC - PMC11220738 COIS- The author has no financial conflicts of interest. EDAT- 2024/06/12 12:43 MHDA- 2024/06/12 12:44 PMCR- 2024/06/10 CRDT- 2024/06/12 10:34 PHST- 2023/07/18 00:00 [received] PHST- 2024/04/25 00:00 [accepted] PHST- 2024/06/12 12:44 [medline] PHST- 2024/06/12 12:43 [pubmed] PHST- 2024/06/12 10:34 [entrez] PHST- 2024/06/10 00:00 [pmc-release] AID - 266934 [pii] AID - immunohorizons_2300057 [pii] AID - 10.4049/immunohorizons.2300057 [doi] PST - ppublish SO - Immunohorizons. 2024 Jun 1;8(6):397-403. doi: 10.4049/immunohorizons.2300057. PMID- 38842630 OWN - NLM STAT- MEDLINE DCOM- 20240728 LR - 20241216 IS - 1865-3774 (Electronic) IS - 0925-5710 (Print) IS - 0925-5710 (Linking) VI - 120 IP - 2 DP - 2024 Aug TI - Cellular and humoral immunogenicity against SARS-CoV-2 vaccination or infection is associated with the memory phenotype of T- and B-lymphocytes in adult allogeneic hematopoietic cell transplant recipients. PG - 229-240 LID - 10.1007/s12185-024-03802-3 [doi] AB - We conducted a cross-sectional study to evaluate cellular and humoral immunogenicity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination or infection and examine how lymphocyte subpopulations in peripheral blood correlate with cellular and humoral immunogenicity in adult allogeneic hematopoietic cell transplantation (HCT) recipients. The median period from SARS-CoV-2 vaccination or infection to sample collection was 110.5 days (range, 6-345 days). The median SARS-CoV-2 spike-specific antibody level was 1761 binding antibody units (BAU)/ml (range, 0 to > 11,360 BAU/ml). Enzyme-linked immunosorbent spot (ELISpot) assay of T cells stimulated with SARS-CoV-2 spike antigens showed that interferon-gamma (IFN-gamma)-, interleukin-2 (IL-2)-, and IFN-gamma + IL-2-producing T cells were present in 68.9%, 62.0%, and 56.8% of patients, respectively. The antibody level was significantly correlated with frequency of IL-2-producing T cells (P = 0.001) and IFN-gamma + IL-2-producing T cells (P = 0.006) but not IFN-gamma-producing T cells (P = 0.970). Absolute counts of CD8+ and CD4+ central memory T cells were higher in both IL-2- and IFN-gamma + IL-2-producing cellular responders compared with non-responders. These data suggest that cellular and humoral immunogenicity against SARS-CoV-2 vaccination or infection is associated with the memory phenotype of T cells and B cells in adult allogeneic HCT recipients. CI - (c) 2024. The Author(s). FAU - Konuma, Takaaki AU - Konuma T AUID- ORCID: 0000-0002-1953-8463 AD - Department of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, 4-6-1, Shirokanedai, Minato-ku, Tokyo, Japan. tkonuma@ims.u-tokyo.ac.jp. FAU - Hamatani-Asakura, Megumi AU - Hamatani-Asakura M AD - Department of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, 4-6-1, Shirokanedai, Minato-ku, Tokyo, Japan. FAU - Nagai, Etsuko AU - Nagai E AD - Department of Laboratory Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan. FAU - Adachi, Eisuke AU - Adachi E AD - Department of Infectious Diseases and Applied Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan. FAU - Kato, Seiko AU - Kato S AD - Department of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, 4-6-1, Shirokanedai, Minato-ku, Tokyo, Japan. FAU - Isobe, Masamichi AU - Isobe M AD - Department of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, 4-6-1, Shirokanedai, Minato-ku, Tokyo, Japan. FAU - Monna-Oiwa, Maki AU - Monna-Oiwa M AD - Department of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, 4-6-1, Shirokanedai, Minato-ku, Tokyo, Japan. FAU - Takahashi, Satoshi AU - Takahashi S AD - Division of Clinical Precision Research Platform, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan. FAU - Yotsuyanagi, Hiroshi AU - Yotsuyanagi H AD - Department of Infectious Diseases and Applied Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan. FAU - Nannya, Yasuhito AU - Nannya Y AD - Department of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, 4-6-1, Shirokanedai, Minato-ku, Tokyo, Japan. LA - eng PT - Journal Article DEP - 20240606 PL - Japan TA - Int J Hematol JT - International journal of hematology JID - 9111627 RN - 0 (Antibodies, Viral) RN - 0 (COVID-19 Vaccines) RN - 0 (Spike Glycoprotein, Coronavirus) RN - 0 (spike protein, SARS-CoV-2) RN - 82115-62-6 (Interferon-gamma) SB - IM MH - Humans MH - *Hematopoietic Stem Cell Transplantation MH - Middle Aged MH - Adult MH - Male MH - Female MH - *COVID-19/immunology/prevention & control MH - Cross-Sectional Studies MH - *SARS-CoV-2/immunology MH - Aged MH - *Immunity, Humoral MH - *Antibodies, Viral/blood/immunology MH - COVID-19 Vaccines/immunology MH - B-Lymphocytes/immunology MH - Immunologic Memory MH - Transplantation, Homologous MH - Vaccination MH - Spike Glycoprotein, Coronavirus/immunology MH - Young Adult MH - Immunity, Cellular MH - T-Lymphocytes/immunology MH - Interferon-gamma PMC - PMC11284193 OTO - NOTNLM OT - Allogeneic hematopoietic cell transplantation OT - Coronavirus disease 2019 (COVID-19) OT - Memory B cells OT - Memory T cells OT - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) COIS- There are no conflicts of interest to report. EDAT- 2024/06/06 12:44 MHDA- 2024/07/28 14:53 PMCR- 2024/06/06 CRDT- 2024/06/06 11:06 PHST- 2023/10/06 00:00 [received] PHST- 2024/05/22 00:00 [accepted] PHST- 2024/05/10 00:00 [revised] PHST- 2024/07/28 14:53 [medline] PHST- 2024/06/06 12:44 [pubmed] PHST- 2024/06/06 11:06 [entrez] PHST- 2024/06/06 00:00 [pmc-release] AID - 10.1007/s12185-024-03802-3 [pii] AID - 3802 [pii] AID - 10.1007/s12185-024-03802-3 [doi] PST - ppublish SO - Int J Hematol. 2024 Aug;120(2):229-240. doi: 10.1007/s12185-024-03802-3. Epub 2024 Jun 6. PMID- 38823086 OWN - NLM STAT- MEDLINE DCOM- 20240620 LR - 20240620 IS - 1876-035X (Electronic) IS - 1876-0341 (Linking) VI - 17 IP - 7 DP - 2024 Jul TI - Risk factors for COVID-19 hospitalisation after booster vaccination during the Omicron period: A French nationwide cohort study. PG - 102450 LID - S1876-0341(24)00147-3 [pii] LID - 10.1016/j.jiph.2024.05.007 [doi] AB - BACKGROUND: In spite of major effectiveness, a residual risk after COVID-19 primary vaccination was identified, in particular, for vulnerable individuals of advanced age or with comorbidities. Less is known about the Omicron period in people protected by a booster dose. We aimed to identify the characteristics associated with severe COVID-19 during the Omicron period in a population that had received a booster dose in France and to compare differences with the previous periods of the pandemic. METHODS: This study was carried out using the French national COVID-19 vaccination database (VAC-SI) coupled with the National Health Data System (SNDS). Individuals aged 12 years or over who received at least one booster dose were identified. Associations between socio-demographic and clinical characteristics and the risk of COVID-19 hospitalisation occurring at least 14 days after receiving a third dose of vaccine during the period of Omicron predominance, i.e., from 1 January 2022 to 10 November 2022, were assessed using Cox proportional hazard models adjusted for age, sex, time since booster dose and vaccination schedule. Analyses were performed overall and by sub-period of circulation of the strains BA.1, BA.2, and BA.4/BA.5, defined as periods where the main sub-variant accounted for more than 80 % of genotyped samples. FINDINGS: In total, 35,640,387 individuals received a booster dose (mean follow-up of 291 days) and 73,989 were hospitalised for COVID-19 during the total period. Older age (aHR 20.5 95 % CI [19.6-21.5] for 90 years of age or older versus 45-54 years of age), being male (aHR 1.52 [1.50-1.55]), and social deprivation (aHR 1.33 [1.30-1.37] for the most deprived areas versus the least deprived) were associated with an increased risk of hospitalisation for COVID-19. Most of the chronic diseases considered were also positively associated with a residual risk, in particular, cystic fibrosis (aHR 9.83 [7.68-12.56]), active lung cancer (aHR 3.26 [3.06-3.47]), chronic dialysis (aHR 3.79 [3.49-4.11]), psychological and neurodegenerative diseases (more markedly than during the periods of circulation of the alpha and delta variants), and organ transplantation. The use of immunosuppressants was also associated with an increased risk (aHR 2.24 [2.14-2.35], including oral corticosteroids aHR (2.58 [2.50-2.67]). CONCLUSION: Despite an effective booster and a generally less virulent circulating variant, a residual risk of severe COVID-19 still exists in vulnerable populations, especially those with neurological disorders. CI - Copyright (c) 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved. FAU - Turpin, Agathe AU - Turpin A AD - EPI-PHARE Scientific Interest Group in Epidemiology of Health Products from the French National, Agency for the Safety of Medicines and Health Products and the French National Health Insurance, France. FAU - Semenzato, Laura AU - Semenzato L AD - EPI-PHARE Scientific Interest Group in Epidemiology of Health Products from the French National, Agency for the Safety of Medicines and Health Products and the French National Health Insurance, France. FAU - Le Vu, Stephane AU - Le Vu S AD - EPI-PHARE Scientific Interest Group in Epidemiology of Health Products from the French National, Agency for the Safety of Medicines and Health Products and the French National Health Insurance, France. FAU - Jabagi, Marie-Joelle AU - Jabagi MJ AD - EPI-PHARE Scientific Interest Group in Epidemiology of Health Products from the French National, Agency for the Safety of Medicines and Health Products and the French National Health Insurance, France. FAU - Bouillon, Kim AU - Bouillon K AD - EPI-PHARE Scientific Interest Group in Epidemiology of Health Products from the French National, Agency for the Safety of Medicines and Health Products and the French National Health Insurance, France. FAU - Drouin, Jerome AU - Drouin J AD - EPI-PHARE Scientific Interest Group in Epidemiology of Health Products from the French National, Agency for the Safety of Medicines and Health Products and the French National Health Insurance, France. FAU - Bertrand, Marion AU - Bertrand M AD - EPI-PHARE Scientific Interest Group in Epidemiology of Health Products from the French National, Agency for the Safety of Medicines and Health Products and the French National Health Insurance, France. FAU - Kanagaratnam, Lukshe AU - Kanagaratnam L AD - EPI-PHARE Scientific Interest Group in Epidemiology of Health Products from the French National, Agency for the Safety of Medicines and Health Products and the French National Health Insurance, France. FAU - Weill, Alain AU - Weill A AD - EPI-PHARE Scientific Interest Group in Epidemiology of Health Products from the French National, Agency for the Safety of Medicines and Health Products and the French National Health Insurance, France. FAU - Dray-Spira, Rosemary AU - Dray-Spira R AD - EPI-PHARE Scientific Interest Group in Epidemiology of Health Products from the French National, Agency for the Safety of Medicines and Health Products and the French National Health Insurance, France. FAU - Zureik, Mahmoud AU - Zureik M AD - EPI-PHARE Scientific Interest Group in Epidemiology of Health Products from the French National, Agency for the Safety of Medicines and Health Products and the French National Health Insurance, France; University Paris-Saclay, UVSQ, University Paris-Sud, Inserm, Anti-infective evasion and Pharmacoepidemiology Unit/Team, CESP, 78180 Montigny le Bretonneux, France. FAU - Botton, Jeremie AU - Botton J AD - EPI-PHARE Scientific Interest Group in Epidemiology of Health Products from the French National, Agency for the Safety of Medicines and Health Products and the French National Health Insurance, France; Faculty of Pharmacy, Paris-Saclay University, Orsay, France. Electronic address: jeremie.botton@ansm.sante.fr. LA - eng PT - Journal Article DEP - 20240514 PL - England TA - J Infect Public Health JT - Journal of infection and public health JID - 101487384 RN - 0 (COVID-19 Vaccines) RN - SARS-CoV-2 variants SB - IM MH - Humans MH - *COVID-19/prevention & control/epidemiology MH - France/epidemiology MH - Male MH - Female MH - Middle Aged MH - *Hospitalization/statistics & numerical data MH - Adult MH - Aged MH - Risk Factors MH - *Immunization, Secondary MH - *COVID-19 Vaccines/administration & dosage/immunology MH - *SARS-CoV-2/immunology MH - Young Adult MH - Cohort Studies MH - Adolescent MH - Child MH - Aged, 80 and over MH - Vaccination/statistics & numerical data OTO - NOTNLM OT - Booster dose OT - COVID-19 OT - Chronic diseases OT - Hospitalisation OT - Omicron OT - SNDS OT - Vaccination COIS- Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2024/06/02 00:43 MHDA- 2024/06/21 00:42 CRDT- 2024/06/01 18:01 PHST- 2024/01/13 00:00 [received] PHST- 2024/04/22 00:00 [revised] PHST- 2024/05/08 00:00 [accepted] PHST- 2024/06/21 00:42 [medline] PHST- 2024/06/02 00:43 [pubmed] PHST- 2024/06/01 18:01 [entrez] AID - S1876-0341(24)00147-3 [pii] AID - 10.1016/j.jiph.2024.05.007 [doi] PST - ppublish SO - J Infect Public Health. 2024 Jul;17(7):102450. doi: 10.1016/j.jiph.2024.05.007. Epub 2024 May 14. PMID- 38818372 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250112 IS - 2666-3546 (Electronic) IS - 2666-3546 (Linking) VI - 38 DP - 2024 Jul TI - Central nervous system manifestations following vaccination against COVID-19. PG - 100788 LID - 10.1016/j.bbih.2024.100788 [doi] LID - 100788 AB - Coronavirus disease 2019 (COVID-19) vaccination has become the most effective countermeasure in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. However, vaccination is associated with side effects. This narrative review focuses on central nervous system (CNS) manifestations following COVID-19 vaccination and provides a summary of the potential underlying mechanisms and methods of diagnosis and management of the vaccination-related CNS manifestations. Headache, myalgia, optic neuritis, seizure, multiple sclerosis, acute disseminated encephalomyelitis and encephalitis, delirium, acute transverse myelitis, and stroke have been reported after COVID-19 vaccination. Constant headache and myalgia are common manifestations that may necessitate further clinical investigation for stroke. To limit consequences, it is imperative to follow standard treatment protocols for each neurological disorder following COVID-19 vaccination. Immunosuppressive medication can be helpful in the treatment of seizures following vaccination since the immune response is involved in their etiology. Clinicians should be aware of the manifestations after COVID-19 vaccination to respond promptly and effectively. Clinical guidelines for the management of CNS manifestations following COVID-19 vaccination are in high demand and would be useful in each new SARS-CoV-2 variant pandemic. CI - (c) 2024 The Authors. FAU - Khatami, Seyed Sepehr AU - Khatami SS AD - Department of Neurology, University of California Irvine, California, USA. FAU - Revheim, Mona-Elisabeth AU - Revheim ME AD - The Intervention Center, Division of Technology and Innovation, Oslo University Hospital, Oslo, Norway. AD - Institute of Clinical Medicine, University of Oslo, Oslo, Norway. FAU - Hoilund-Carlsen, Poul Flemming AU - Hoilund-Carlsen PF AD - Department of Nuclear Medicine, Odense University Hospital, University of Southern Denmark, Odense, Denmark. AD - Research Unit of Clinical Physiology and Nuclear Medicine, Department of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark. FAU - Alavi, Abass AU - Alavi A AD - Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Pennsylvania, USA. FAU - Ghorbani Shirkouhi, Samaneh AU - Ghorbani Shirkouhi S AD - School of Medicine, Shahroud University of Medical Sciences, Shahroud, Iran. FAU - Andalib, Sasan AU - Andalib S AD - Research Unit of Neurology, Department of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark. AD - Department of Neurology, Odense University Hospital, Odense, Denmark. LA - eng PT - Journal Article PT - Review DEP - 20240503 PL - United States TA - Brain Behav Immun Health JT - Brain, behavior, & immunity - health JID - 101759062 PMC - PMC11137405 OTO - NOTNLM OT - COVID-19 OT - Central nervous system OT - Complications OT - Neurology OT - SARS-CoV-2 OT - Vaccination COIS- The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2024/05/31 06:42 MHDA- 2024/05/31 06:43 PMCR- 2024/05/03 CRDT- 2024/05/31 04:00 PHST- 2023/09/10 00:00 [received] PHST- 2024/03/03 00:00 [revised] PHST- 2024/05/02 00:00 [accepted] PHST- 2024/05/31 06:43 [medline] PHST- 2024/05/31 06:42 [pubmed] PHST- 2024/05/31 04:00 [entrez] PHST- 2024/05/03 00:00 [pmc-release] AID - S2666-3546(24)00066-8 [pii] AID - 100788 [pii] AID - 10.1016/j.bbih.2024.100788 [doi] PST - epublish SO - Brain Behav Immun Health. 2024 May 3;38:100788. doi: 10.1016/j.bbih.2024.100788. eCollection 2024 Jul. PMID- 38818170 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240601 IS - 2405-8440 (Print) IS - 2405-8440 (Electronic) IS - 2405-8440 (Linking) VI - 10 IP - 10 DP - 2024 May 30 TI - COVID-19 vaccination may prevent postoperative delirium in elderly patients undergoing elective non-cardiac surgery: The PNDRFAP and PNDABLE studies. PG - e30414 LID - 10.1016/j.heliyon.2024.e30414 [doi] LID - e30414 AB - BACKGROUND: Postoperative delirium (POD) often occurs in elderly patients after surgery. We conducted two clinical studies to determine whether COVID-19 vaccination has a protective effect on POD and to explore the role of CSF biomarkers in this process. METHODS: We conducted two clinical studies, Perioperative Neurocognitive Disorder Risk Factor and Prognosis (PNDRFAP) and Perioperative Neurocognitive Disorder and Biomarker Lifestyle (PNDABLE), in which patients more than or equal to 65 years old who have had elective non-cardiac surgery were enrolled. The preoperative cognitive status of patients were evaluated by Mini-Mental State Examination (MMSE) one day preoperatively. Confusion Assessment Method (CAM) was used to diagnose POD. We used the mediation model to analyze the relationship between CSF biomarkers, COVID-19 vaccination and POD, as well as Dynamic Nomogram to calculate the incidence of Non-Postoperative Delirium (NPOD). The main outcome of these studies was the incidence of POD during seven days postoperatively or before discharge, which was assessed by CAM. RESULTS: In the final, 705 participants were enrolled in the PNDRFAP study, and 638 patients in the PNDABLE. In both studies, we found that the occurrence of POD was lower in patients who had injected COVID-19 vaccination before surgery compared with those without vaccination (PNDRFAP: 10.20 % [21/205] vs 25.80 % [129/500], P < 0.001; PNDABLE: 2.40 % [4/164] vs 34.60 % [164/474], P < 0.001). Mediation analysis showed that the protective effect of preoperative COVID-19 vaccine on POD was significantly mediated by CSF Abeta42 (proportion = 17.56 %), T-tau (proportion = 19.64 %), Abeta42/T-tau (proportion = 29.67 %), and Abeta42/P-tau (proportion = 12.26 %). CONCLUSIONS: COVID-19 vaccine is a protective factor for POD in old patients, which is associated with CSF biomarkers. CI - (c) 2024 Published by Elsevier Ltd. FAU - Zhang, Haoran AU - Zhang H AD - Department of Anesthesiology, Qingdao Municipal Hospital, Qingdao, Shandong, China. FAU - Zhang, Aihua AU - Zhang A AD - Department of Anesthesiology, Qingdao Municipal Hospital, Qingdao, Shandong, China. FAU - Lin, Yanan AU - Lin Y AD - Department of Anesthesiology, Qingdao Municipal Hospital, Qingdao, Shandong, China. FAU - Li, Chuan AU - Li C AD - Department of Anesthesiology, Qingdao Municipal Hospital, Qingdao, Shandong, China. FAU - Yang, Yunchao AU - Yang Y AD - Department of Anesthesiology, Qingdao University Medical College, Qingdao, Shandong, China. FAU - Dong, Rui AU - Dong R AD - Department of Anesthesiology, Qingdao Municipal Hospital, Qingdao, Shandong, China. FAU - Lin, Xu AU - Lin X AD - Department of Anesthesiology, Qingdao Municipal Hospital, Qingdao, Shandong, China. FAU - Wang, Bin AU - Wang B AD - Department of Anesthesiology, Qingdao Municipal Hospital, Qingdao, Shandong, China. FAU - Bi, Yanlin AU - Bi Y AD - Department of Anesthesiology, Qingdao Municipal Hospital, Qingdao, Shandong, China. LA - eng PT - Journal Article DEP - 20240507 PL - England TA - Heliyon JT - Heliyon JID - 101672560 PMC - PMC11137356 OTO - NOTNLM OT - COVID-19 vaccine OT - CSF biomarkers OT - Mediation analysis OT - Perioperative neurocognitive disorders OT - Postoperative delirium COIS- The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2024/05/31 06:41 MHDA- 2024/05/31 06:42 PMCR- 2024/05/07 CRDT- 2024/05/31 03:57 PHST- 2023/11/16 00:00 [received] PHST- 2024/04/22 00:00 [revised] PHST- 2024/04/25 00:00 [accepted] PHST- 2024/05/31 06:42 [medline] PHST- 2024/05/31 06:41 [pubmed] PHST- 2024/05/31 03:57 [entrez] PHST- 2024/05/07 00:00 [pmc-release] AID - S2405-8440(24)06445-4 [pii] AID - e30414 [pii] AID - 10.1016/j.heliyon.2024.e30414 [doi] PST - epublish SO - Heliyon. 2024 May 7;10(10):e30414. doi: 10.1016/j.heliyon.2024.e30414. eCollection 2024 May 30. PMID- 38807606 OWN - NLM STAT- MEDLINE DCOM- 20240529 LR - 20260629 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 15 DP - 2024 TI - Non-cross-reactive epitopes dominate the humoral immune response to COVID-19 vaccination - kinetics of plasma antibodies, plasmablasts and memory B cells. PG - 1382911 LID - 10.3389/fimmu.2024.1382911 [doi] LID - 1382911 AB - INTRODUCTION: COVID-19 vaccines are highly effective in inducing protective immunity. While the serum antibody response to COVID-19 vaccination has been studied in depth, our knowledge of the underlying plasmablast and memory B cell (Bmem) responses is still incomplete. Here, we determined the antibody and B cell response to COVID-19 vaccination in a naive population and contrasted it with the response to a single influenza vaccination in a primed cohort. In addition, we analyzed the antibody and B cell responses against the four endemic human coronaviruses (HCoVs). METHODS: Measurement of specific plasma IgG antibodies was combined with functional analyses of antibody-secreting plasmablasts and Bmems. SARS-CoV-2- and HCoV-specific IgG antibodies were quantified with an in-house bead-based multiplexed immunoassay. RESULTS: The antibody and B cell responses to COVID-19 vaccination reflected the kinetics of a prime-boost immunization, characterized by a slow and moderate primary response and a faster and stronger secondary response. In contrast, the influenza vaccinees possessed robust immune memory for the vaccine antigens prior to vaccination, and the recall vaccination moderately boosted antibody production and Bmem responses. Antibody levels and Bmem responses waned several months after the 2(nd) COVID-19 vaccination, but were restored upon the 3(rd) vaccination. The COVID-19 vaccine-induced antibodies mainly targeted novel, non-cross-reactive S1 epitopes of the viral spike protein, while cross-reactive S2 epitopes were less immunogenic. Booster vaccination not only strongly enhanced neutralizing antibodies against an original SARS-CoV-2 strain, but also induced neutralizing antibodies against the Omicron BA.2 variant. We observed a 100% plasma antibody prevalence against the S1 subunits of HCoVs, which was not affected by vaccination. DISCUSSION: Overall, by complementing classical serology with a functional evaluation of plasmablasts and memory B cells we provide new insights into the specificity of COVID-19 vaccine-induced antibody and B cell responses. CI - Copyright (c) 2024 Wietschel, Fechtner, Antileo, Abdurrahman, Drechsler, Makuvise, Rose, Voss, Krumbholz, Michalik, Weiss, Ulm, Franikowski, Fickenscher, Broker, Raafat and Holtfreter. FAU - Wietschel, Kilian A AU - Wietschel KA AD - Institute of Immunology, University Medicine Greifswald, Greifswald, Germany. FAU - Fechtner, Kevin AU - Fechtner K AD - Institute of Immunology, University Medicine Greifswald, Greifswald, Germany. FAU - Antileo, Elmer AU - Antileo E AD - Institute of Immunology, University Medicine Greifswald, Greifswald, Germany. FAU - Abdurrahman, Goran AU - Abdurrahman G AD - Institute of Immunology, University Medicine Greifswald, Greifswald, Germany. FAU - Drechsler, Chiara A AU - Drechsler CA AD - Institute of Immunology, University Medicine Greifswald, Greifswald, Germany. FAU - Makuvise, Michelle Kudzayi AU - Makuvise MK AD - Institute of Immunology, University Medicine Greifswald, Greifswald, Germany. FAU - Rose, Ruben AU - Rose R AD - Institute for Infection Medicine, Kiel University and University Medical Center Schleswig-Holstein, Kiel, Germany. FAU - Voss, Mathias AU - Voss M AD - Institute for Infection Medicine, Kiel University and University Medical Center Schleswig-Holstein, Kiel, Germany. FAU - Krumbholz, Andi AU - Krumbholz A AD - Institute for Infection Medicine, Kiel University and University Medical Center Schleswig-Holstein, Kiel, Germany. AD - Labor Dr. Krause und Kollegen MVZ GmbH, Kiel, Germany. FAU - Michalik, Stephan AU - Michalik S AD - Interfaculty Institute for Genetics and Functional Genomics, Department of Functional Genomics, University Medicine Greifswald, Greifswald, Germany. FAU - Weiss, Stefan AU - Weiss S AD - Interfaculty Institute for Genetics and Functional Genomics, Department of Functional Genomics, University Medicine Greifswald, Greifswald, Germany. FAU - Ulm, Lena AU - Ulm L AD - Friedrich Loeffler-Institute of Medical Microbiology, University Medicine Greifswald, Greifswald, Germany. FAU - Franikowski, Philipp AU - Franikowski P AD - Institute for Educational Quality Improvement, Humboldt University of Berlin, Berlin, Germany. FAU - Fickenscher, Helmut AU - Fickenscher H AD - Institute for Infection Medicine, Kiel University and University Medical Center Schleswig-Holstein, Kiel, Germany. FAU - Broker, Barbara M AU - Broker BM AD - Institute of Immunology, University Medicine Greifswald, Greifswald, Germany. FAU - Raafat, Dina AU - Raafat D AD - Institute of Immunology, University Medicine Greifswald, Greifswald, Germany. AD - Department of Microbiology and Immunology, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt. FAU - Holtfreter, Silva AU - Holtfreter S AD - Institute of Immunology, University Medicine Greifswald, Greifswald, Germany. LA - eng PT - Journal Article DEP - 20240514 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 RN - 0 (Antibodies, Viral) RN - 0 (COVID-19 Vaccines) RN - 0 (Immunoglobulin G) RN - 0 (Influenza Vaccines) RN - 0 (Antibodies, Neutralizing) RN - 0 (Epitopes, B-Lymphocyte) RN - 0 (Spike Glycoprotein, Coronavirus) SB - IM MH - Humans MH - *Antibodies, Viral/blood/immunology MH - *COVID-19/immunology/prevention & control MH - *Memory B Cells/immunology MH - *SARS-CoV-2/immunology MH - *COVID-19 Vaccines/immunology MH - *Immunity, Humoral MH - Male MH - Adult MH - *Cross Reactions/immunology MH - Female MH - *Plasma Cells/immunology MH - Middle Aged MH - *Immunoglobulin G/immunology/blood MH - Vaccination MH - Influenza Vaccines/immunology MH - Immunologic Memory/immunology MH - Antibodies, Neutralizing/immunology/blood MH - Epitopes, B-Lymphocyte/immunology MH - B-Lymphocytes/immunology MH - Spike Glycoprotein, Coronavirus/immunology MH - Kinetics PMC - PMC11130424 OTO - NOTNLM OT - COVID-19 vaccination OT - HCoV OT - cross-reactive antibodies OT - dynamics OT - influenza OT - memory B cell OT - original antigenic sin OT - plasmablast COIS- Author AK was employed by Labor Dr. Krause und Kollegen MVZ GmbH. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2024/05/29 06:42 MHDA- 2024/05/29 06:43 PMCR- 2024/01/01 CRDT- 2024/05/29 03:34 PHST- 2024/02/06 00:00 [received] PHST- 2024/04/15 00:00 [accepted] PHST- 2024/05/29 06:43 [medline] PHST- 2024/05/29 06:42 [pubmed] PHST- 2024/05/29 03:34 [entrez] PHST- 2024/01/01 00:00 [pmc-release] AID - 10.3389/fimmu.2024.1382911 [doi] PST - epublish SO - Front Immunol. 2024 May 14;15:1382911. doi: 10.3389/fimmu.2024.1382911. eCollection 2024. PMID- 38806183 OWN - NLM STAT- MEDLINE DCOM- 20241128 LR - 20241129 IS - 1460-2393 (Electronic) IS - 1460-2393 (Linking) VI - 117 IP - 10 DP - 2024 Oct 1 TI - A potential association between COVID-19 vaccination and development of Alzheimer's disease. PG - 709-716 LID - 10.1093/qjmed/hcae103 [doi] AB - BACKGROUND: The challenges of the COVID-19 pandemic extend to concerns about vaccine side effects, particularly potential links to neurodegenerative diseases such as Alzheimer's disease (AD). AIM: This study investigates the association between COVID-19 vaccination and the onset of AD and its prodromal state, mild cognitive impairment (MCI). DESIGN: A nationwide, retrospective cohort study leveraging data from the Korean National Health Insurance Service was conducted. METHODS: The study, conducted in Seoul, South Korea, analyzed data from a random 50% sample of city residents aged 65 and above, totaling 558 017 individuals. Participants were divided into vaccinated and unvaccinated groups, with vaccinations including mRNA and cDNA vaccines. The study focused on AD and MCI incidences post-vaccination, identified via ICD-10 codes, using multivariable logistic and Cox regression analyses. Patients with vascular dementia or Parkinson's disease served as controls. RESULTS: Findings showed an increased incidence of MCI and AD in vaccinated individuals, particularly those receiving mRNA vaccines, within three months post-vaccination. The mRNA vaccine group exhibited a significantly higher incidence of AD (odds ratio [OR]: 1.225; 95% confidence interval [CI]: 1.025-1.464; P = 0.026) and MCI (OR: 2.377; CI: 1.845-3.064; P < 0.001) compared to the unvaccinated group. No significant relationship was found with vascular dementia or Parkinson's disease. CONCLUSIONS: Preliminary evidence suggests a potential link between COVID-19 vaccination, particularly mRNA vaccines, and increased incidences of AD and MCI. This warrants the need for further research to elucidate the relationship between vaccine-induced immune responses and neurodegenerative processes, advocating for continuous monitoring and investigation into the vaccines' long-term neurological impacts. CI - (c) The Author(s) 2024. Published by Oxford University Press on behalf of the Association of Physicians. All rights reserved. For permissions, please email: journals.permissions@oup.com. FAU - Roh, Jee Hoon AU - Roh JH AUID- ORCID: 0000-0002-3243-0529 AD - Department of Biomedical Sciences, Korea University College of Medicine, Seoul, Republic of Korea. AD - Department of Physiology, Korea University College of Medicine, Seoul, Republic of Korea. AD - Department of Neurology, Anam Hospital, Korea University College of Medicine, Seoul, Republic of Korea. FAU - Jung, Inha AU - Jung I AD - Department of Biomedical Sciences, Korea University College of Medicine, Seoul, Republic of Korea. AD - Department of Physiology, Korea University College of Medicine, Seoul, Republic of Korea. FAU - Suh, Yunsun AU - Suh Y AD - Department of Biomedical Sciences, Korea University College of Medicine, Seoul, Republic of Korea. AD - Department of Physiology, Korea University College of Medicine, Seoul, Republic of Korea. AD - Steinhardt School of Culture, Education, and Human Development, New York University, New York, NY, USA. FAU - Kim, Min-Ho AU - Kim MH AD - Informatization Department, Ewha Womans University Seoul Hospital, Seoul, Republic of Korea. LA - eng GR - RS-2023-00220894/National Research Foundation/ GR - Korea Dementia Research/ GR - Korea Dementia Research Center/ GR - HU21C0066/Ministry of Health & Welfare and Ministry of Science and ICT/ GR - K2123751/Korea University/ GR - Republic of Korea/ PT - Journal Article PL - England TA - QJM JT - QJM : monthly journal of the Association of Physicians JID - 9438285 RN - 0 (COVID-19 Vaccines) SB - IM MH - Aged MH - Aged, 80 and over MH - Female MH - Humans MH - Male MH - *Alzheimer Disease/epidemiology MH - *Cognitive Dysfunction/epidemiology/etiology MH - *COVID-19/prevention & control/epidemiology MH - *COVID-19 Vaccines/adverse effects MH - Incidence MH - Republic of Korea/epidemiology MH - Retrospective Studies MH - Vaccination/adverse effects EDAT- 2024/05/29 00:49 MHDA- 2024/11/29 05:20 CRDT- 2024/05/28 20:34 PHST- 2024/03/02 00:00 [received] PHST- 2024/05/06 00:00 [revised] PHST- 2024/11/29 05:20 [medline] PHST- 2024/05/29 00:49 [pubmed] PHST- 2024/05/28 20:34 [entrez] AID - 7684274 [pii] AID - 10.1093/qjmed/hcae103 [doi] PST - ppublish SO - QJM. 2024 Oct 1;117(10):709-716. doi: 10.1093/qjmed/hcae103. PMID- 38789939 OWN - NLM STAT- MEDLINE DCOM- 20240525 LR - 20261020 IS - 1471-2318 (Electronic) IS - 1471-2318 (Linking) VI - 24 IP - 1 DP - 2024 May 24 TI - Modeling mortality prediction in older adults with dementia receiving COVID-19 vaccination. PG - 454 LID - 10.1186/s12877-024-04982-7 [doi] LID - 454 AB - OBJECTIVE: This study compared COVID-19 outcomes between vaccinated and unvaccinated older adults with and without cognitive impairment. METHOD: Electronic health records from Israel from March 2020-February 2022 were analyzed for a large cohort (N = 85,288) aged 65 + . Machine learning constructed models to predict mortality risk from patient factors. Outcomes examined were COVID-19 mortality and hospitalization post-vaccination. RESULTS: Our study highlights the significant reduction in mortality risk among older adults with cognitive disorders following COVID-19 vaccination, showcasing a survival rate improvement to 93%. Utilizing machine learning for mortality prediction, we found the XGBoost model, enhanced with inverse probability of treatment weighting, to be the most effective, achieving an AUC-PR value of 0.89. This underscores the importance of predictive analytics in identifying high-risk individuals, emphasizing the critical role of vaccination in mitigating mortality and supporting targeted healthcare interventions. CONCLUSIONS: COVID-19 vaccination strongly reduced poor outcomes in older adults with cognitive impairment. Predictive analytics can help identify highest-risk cases requiring targeted interventions. CI - (c) 2024. The Author(s). FAU - Radomyslsky, Zorian AU - Radomyslsky Z AD - Maccabi Healthcare Services, 6812509, Tel Aviv-Jaffa, Israel. radomysl_z@mac.org.il. AD - Ariel University, School of Health Sciences, Ariel, Israel. radomysl_z@mac.org.il. FAU - Kivity, Sara AU - Kivity S AD - Maccabi Healthcare Services, 6812509, Tel Aviv-Jaffa, Israel. dejav_s@mac.org.il. FAU - Alon, Yaniv AU - Alon Y AD - Nursing Department, School of Health Professions, Faculty of Medical & Health Sciences, Tel Aviv University, Ramat Aviv, Tel Aviv, 69978, Israel. FAU - Saban, Mor AU - Saban M AD - Nursing Department, School of Health Professions, Faculty of Medical & Health Sciences, Tel Aviv University, Ramat Aviv, Tel Aviv, 69978, Israel. LA - eng PT - Journal Article DEP - 20240524 PL - England TA - BMC Geriatr JT - BMC geriatrics JID - 100968548 RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - Aged MH - *COVID-19/prevention & control/mortality/epidemiology MH - Male MH - Female MH - *COVID-19 Vaccines/administration & dosage MH - Israel/epidemiology MH - Aged, 80 and over MH - *Dementia/mortality MH - *Machine Learning MH - Vaccination MH - Hospitalization/trends MH - Cohort Studies MH - Cognitive Dysfunction/epidemiology PMC - PMC11127399 OTO - NOTNLM OT - COVID-19 vaccination OT - Cognitive impairment OT - Mortality OT - Older adults OT - Predictive analytics COIS- The authors declare no competing interests. EDAT- 2024/05/25 05:43 MHDA- 2024/05/25 10:54 PMCR- 2024/05/24 CRDT- 2024/05/24 23:44 PHST- 2023/10/21 00:00 [received] PHST- 2024/04/16 00:00 [accepted] PHST- 2024/05/25 10:54 [medline] PHST- 2024/05/25 05:43 [pubmed] PHST- 2024/05/24 23:44 [entrez] PHST- 2024/05/24 00:00 [pmc-release] AID - 10.1186/s12877-024-04982-7 [pii] AID - 4982 [pii] AID - 10.1186/s12877-024-04982-7 [doi] PST - epublish SO - BMC Geriatr. 2024 May 24;24(1):454. doi: 10.1186/s12877-024-04982-7. PMID- 38761322 OWN - NLM STAT- MEDLINE DCOM- 20241210 LR - 20250711 IS - 1573-7403 (Electronic) IS - 1386-341X (Print) IS - 1386-341X (Linking) VI - 27 IP - 6 DP - 2024 Dec TI - Pituitary and COVID-19 vaccination: a systematic review. PG - 970-985 LID - 10.1007/s11102-024-01402-2 [doi] AB - PURPOSE: This systematic review aims to examine the latest research findings and assess the impact of COVID-19 vaccination on the pituitary gland. METHOD: PubMed and Tripdatabase were searched from January 1st, 2020 to February 12th, 2024. Case reports, case series and reviews related to post COVID-19 vaccination pituitary disease were included. Eligible articles were tabulated and analysed in the attempt to provide an overview on the epidemiology, clinical presentation, imaging, treatment, outcomes and pathophysiological background of post COVID-19 vaccination pituitary disease. RESULTS: Among the 23 case reports included in this review, post COVID-19 vaccination hypophysitis was reported in 9 patients, pituitary apoplexy (PA) in 6 cases, SIADH in 5 cases and Isolated ACTH deficiency in 2 cases. Additionally, precipitating adrenal crisis was registered in 7 patients and pituitary tumor enlargement in 1 patient after receiving COVID-19 vaccination. CONCLUSION: Despite the rarity of these events, our research findings suggest an association between COVID-19 vaccination and the subsequent development of pituitary diseases. The most common manifestations include hypophysitis with ADH deficiency, PA and SIADH, with symptoms typically emerging shortly after vaccine administration. Potential pathogenetic mechanisms include molecular mimicry, vaccine adjuvants and vaccine-induced thrombotic thrombocytopenia (VITT), with the presence of ACE2 receptors in the hypothalamus-pituitary system contributing to the process. These findings can aid in diagnostic and treatment decisions for patients presenting with these syndromes. Nevertheless, given the rarity of these events, safety and efficacy of the currently available COVID-19 vaccines remain robust and we strongly advocate continuing pursuing vaccination efforts. CI - (c) 2024. The Author(s). FAU - Verrienti, Martina AU - Verrienti M AUID- ORCID: 0000-0001-8408-7796 AD - Unit of Endocrinology and Metabolic Diseases, Department of Specialty Medicines, University Hospital of Ferrara, Ferrara, Italy. FAU - Marino Picciola, Valentino AU - Marino Picciola V AUID- ORCID: 0009-0005-5687-2208 AD - Section of Endocrinology, Geriatrics and Internal Medicine, Department of Medical Sciences, University of Ferrara, Via Ariosto 35, Ferrara, 44100, Italy. FAU - Ambrosio, Maria Rosaria AU - Ambrosio MR AUID- ORCID: 0009-0003-1370-8438 AD - Unit of Endocrinology and Metabolic Diseases, Department of Specialty Medicines, University Hospital of Ferrara, Ferrara, Italy. AD - Section of Endocrinology, Geriatrics and Internal Medicine, Department of Medical Sciences, University of Ferrara, Via Ariosto 35, Ferrara, 44100, Italy. FAU - Zatelli, Maria Chiara AU - Zatelli MC AUID- ORCID: 0000-0002-7911-9770 AD - Unit of Endocrinology and Metabolic Diseases, Department of Specialty Medicines, University Hospital of Ferrara, Ferrara, Italy. ztlmch@unife.it. AD - Section of Endocrinology, Geriatrics and Internal Medicine, Department of Medical Sciences, University of Ferrara, Via Ariosto 35, Ferrara, 44100, Italy. ztlmch@unife.it. LA - eng PT - Journal Article PT - Systematic Review DEP - 20240518 PL - United States TA - Pituitary JT - Pituitary JID - 9814578 RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - *COVID-19/prevention & control/epidemiology MH - *COVID-19 Vaccines/adverse effects MH - Pituitary Apoplexy/epidemiology/etiology MH - Pituitary Diseases/epidemiology MH - Pituitary Gland/pathology MH - SARS-CoV-2/immunology MH - Vaccination/adverse effects PMC - PMC11632052 OTO - NOTNLM OT - COVID-19 OT - Hypophysitis OT - Pituitary OT - Pituitary apoplexy OT - Vaccine COIS- Declarations. Ethics approval: An ethics statement was not required for this study type since no human or animal subjects or materials were used. Competing interests: The authors declare no competing interests. EDAT- 2024/05/18 19:47 MHDA- 2024/12/11 00:23 PMCR- 2024/05/18 CRDT- 2024/05/18 11:08 PHST- 2024/05/07 00:00 [accepted] PHST- 2024/12/11 00:23 [medline] PHST- 2024/05/18 19:47 [pubmed] PHST- 2024/05/18 11:08 [entrez] PHST- 2024/05/18 00:00 [pmc-release] AID - 10.1007/s11102-024-01402-2 [pii] AID - 1402 [pii] AID - 10.1007/s11102-024-01402-2 [doi] PST - ppublish SO - Pituitary. 2024 Dec;27(6):970-985. doi: 10.1007/s11102-024-01402-2. Epub 2024 May 18. PMID- 38717738 OWN - NLM STAT- MEDLINE DCOM- 20240628 LR - 20250708 IS - 1938-3673 (Electronic) IS - 0741-5400 (Linking) VI - 116 IP - 1 DP - 2024 Jun 28 TI - Presence of SARS-CoV-2-specific T cells before vaccination in the Mexican population. PG - 95-102 LID - 10.1093/jleuko/qiae111 [doi] AB - The immune response to SARS-CoV-2 has been extensively studied following the pandemic outbreak in 2020; however, the presence of specific T cells against SARS-CoV-2 before vaccination has not been evaluated in Mexico. In this study, we estimated the frequency of T CD4+ and T CD8+ cells that exhibit a specific response to S (spike) and N (nucleocapsid) proteins in a Mexican population. We collected 78 peripheral blood samples from unvaccinated subjects, and the presence of antibodies against spike (RBD) and N protein was determined. Peripheral blood mononuclear cells were isolated and stimulated with a pool of S or N protein peptides (Wuhan-Hu-1 strain). IL-1beta, IL-4, IL-6, IL-10, IL-2, IL-8, TNF-alpha, IFN-gamma, and GM-CSF levels were quantified in the supernatant of the activated cells, and the cells were stained to assess the activation and memory phenotypes. Differential activation frequency dependent on serological status was observed in CD4+ cells but not in CD8+ cells. The predominantly activated population was the central memory T CD4+ cells. Only 10% of the population exhibited the same phenotype with respect to the response to nucleocapsid peptides. The cytokine profile differed between the S and N responses. S peptides induced a more proinflammatory response compared with the N peptides. In conclusion, in a Mexican cohort before vaccination, there was a significant response to the S and N SARS-CoV-2 proteins resulting from previous infections with seasonal coronaviruses or previous undetected exposure to SARS-CoV-2. CI - (c) The Author(s) 2024. Published by Oxford University Press on behalf of Society for Leukocyte Biology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site-for further information please contact journals.permissions@oup.com. FAU - Hernandez-Galicia, Gabriela AU - Hernandez-Galicia G AD - Department of Molecular Biomedicine, Center for Research and Advanced Studies of the National Polytechnic Institute, 2508 Instituto Politecnico Nacional Avenue, 07360, Mexico City, Mexico. FAU - Gomez-Morales, Luis AU - Gomez-Morales L AD - Department of Molecular Biomedicine, Center for Research and Advanced Studies of the National Polytechnic Institute, 2508 Instituto Politecnico Nacional Avenue, 07360, Mexico City, Mexico. AD - Department of Immunology, National School of Biological Sciences, National Polytechnic Institute, Manuel Carpio and Plan de Ayala St, 11340, Mexico City, Mexico. FAU - Lopez-Bailon, Luis Uriel AU - Lopez-Bailon LU AD - Department of Molecular Biomedicine, Center for Research and Advanced Studies of the National Polytechnic Institute, 2508 Instituto Politecnico Nacional Avenue, 07360, Mexico City, Mexico. AD - Department of Immunology, National School of Biological Sciences, National Polytechnic Institute, Manuel Carpio and Plan de Ayala St, 11340, Mexico City, Mexico. FAU - Valdovinos-Torres, Humberto AU - Valdovinos-Torres H AD - Center for Infectious Diseases Research, National Institute of Public Health, 655 Universidad Avenue, 62100, Cuernavaca, Mexico. FAU - Contreras-Ochoa, Carla O AU - Contreras-Ochoa CO AD - Center for Infectious Diseases Research, National Institute of Public Health, 655 Universidad Avenue, 62100, Cuernavaca, Mexico. FAU - Diaz Benitez, Cinthya Estefhany AU - Diaz Benitez CE AD - Center for Infectious Diseases Research, National Institute of Public Health, 655 Universidad Avenue, 62100, Cuernavaca, Mexico. FAU - Martinez-Barnetche, Jesus AU - Martinez-Barnetche J AD - Center for Infectious Diseases Research, National Institute of Public Health, 655 Universidad Avenue, 62100, Cuernavaca, Mexico. FAU - Alpuche-Aranda, Celia AU - Alpuche-Aranda C AD - Center for Infectious Diseases Research, National Institute of Public Health, 655 Universidad Avenue, 62100, Cuernavaca, Mexico. FAU - Ortiz-Navarrete, Vianney AU - Ortiz-Navarrete V AUID- ORCID: 0000-0001-6546-9713 AD - Department of Molecular Biomedicine, Center for Research and Advanced Studies of the National Polytechnic Institute, 2508 Instituto Politecnico Nacional Avenue, 07360, Mexico City, Mexico. LA - eng PT - Journal Article PL - England TA - J Leukoc Biol JT - Journal of leukocyte biology JID - 8405628 RN - 0 (Spike Glycoprotein, Coronavirus) RN - 0 (spike protein, SARS-CoV-2) RN - 0 (Cytokines) RN - 0 (COVID-19 Vaccines) RN - 0 (Coronavirus Nucleocapsid Proteins) RN - 0 (Antibodies, Viral) RN - 0 (nucleocapsid phosphoprotein, SARS-CoV-2) RN - 0 (Phosphoproteins) SB - IM MH - Humans MH - Mexico/epidemiology MH - *SARS-CoV-2/immunology MH - *COVID-19/immunology/epidemiology/prevention & control MH - Female MH - Male MH - Adult MH - *CD8-Positive T-Lymphocytes/immunology MH - Middle Aged MH - *CD4-Positive T-Lymphocytes/immunology MH - *Spike Glycoprotein, Coronavirus/immunology MH - *Vaccination MH - Cytokines/metabolism MH - COVID-19 Vaccines/immunology MH - Coronavirus Nucleocapsid Proteins/immunology MH - Antibodies, Viral/blood/immunology MH - Young Adult MH - Phosphoproteins/immunology MH - Aged MH - Lymphocyte Activation/immunology OTO - NOTNLM OT - Mexican population OT - SARS-CoV-2 OT - T cell OT - immune memory OT - vaccination COIS- Conflict of interest statement. None declared. EDAT- 2024/05/08 12:44 MHDA- 2024/06/28 18:42 CRDT- 2024/05/08 11:22 PHST- 2023/08/01 00:00 [received] PHST- 2024/04/04 00:00 [revised] PHST- 2024/04/17 00:00 [accepted] PHST- 2024/06/28 18:42 [medline] PHST- 2024/05/08 12:44 [pubmed] PHST- 2024/05/08 11:22 [entrez] AID - 7667143 [pii] AID - 10.1093/jleuko/qiae111 [doi] PST - ppublish SO - J Leukoc Biol. 2024 Jun 28;116(1):95-102. doi: 10.1093/jleuko/qiae111. PMID- 38713366 OWN - NLM STAT- MEDLINE DCOM- 20241024 LR - 20250303 IS - 1867-0687 (Electronic) IS - 1708-8569 (Print) VI - 20 IP - 10 DP - 2024 Oct TI - Specific convulsions and brain damage in children hospitalized for Omicron BA.5 infection: an observational study using two cohorts. PG - 1079-1089 LID - 10.1007/s12519-024-00808-z [doi] AB - BACKGROUND: SARS-CoV-2 continues to mutate over time, and reports on children infected with Omicron BA.5 are limited. We aimed to analyze the specific symptoms of Omicron-infected children and to improve patient care. METHODS: We selected 315 consecutively hospitalized children with Omicron BA.5 and 16,744 non-Omicron-infected febrile children visiting the fever clinic at our hospital between December 8 and 30, 2022. Specific convulsions and body temperatures were compared between the two cohorts. We analyzed potential associations between convulsions and vaccination, and additionally evaluated the brain damage among severe Omicron-infected children. RESULTS: Convulsion rates (97.5% vs. 4.3%, P < 0.001) and frequencies (median: 2.0 vs. 1.6, P < 0.001) significantly differed between Omicron-infected and non-Omicron-infected febrile children. The body temperatures of Omicron-infected children were significantly higher during convulsions than when they were not convulsing and those of non-Omicron-infected febrile children during convulsions (median: 39.5 vs. 38.2 and 38.6 degrees C, both P < 0.001). In the three Omicron-subgroups, the temperature during convulsions was proportional to the percentage of patients and significantly differed ( P < 0.001), while not in the three non-Omicron-subgroups (P = 0.244). The convulsion frequency was lower in the 55 vaccinated children compared to the 260 non-vaccinated children (average: 1.8 vs. 2.1, P < 0.001). The vaccination dose and convulsion frequency in Omicron-infected children were significantly correlated ( P < 0.001). Fifteen of the 112 severe Omicron cases had brain damage. CONCLUSIONS: Omicron-infected children experience higher body temperatures and frequencies during convulsions than those of non-Omicron-infected febrile children. We additionally found evidence of brain damage caused by infection with omicron BA.5. Vaccination and prompt fever reduction may relieve symptoms. CI - (c) 2024. The Author(s). FAU - Pei, Yuan-Yuan AU - Pei YY AD - Clinical Data Center, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, 510623, China. FAU - Wang, Hong-Li AU - Wang HL AD - Department of Gastroenterology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, 510623, China. FAU - Yin, Gen-Quan AU - Yin GQ AD - Department of Internal Medicine, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, 510623, China. FAU - Xu, Yi AU - Xu Y AD - Department of Infectious Diseases, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, 510623, China. FAU - Tan, Jian-Hao AU - Tan JH AD - Information Department, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, 510623, China. FAU - Liang, Xin-Hua AU - Liang XH AD - School of Pediatrics, Guangzhou Medical University, Guangzhou, 510623, China. FAU - Wu, Hui-Ying AU - Wu HY AD - Imaging Department, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, 510623, China. FAU - Yin, Xun-Tao AU - Yin XT AD - Imaging Department, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, 510623, China. FAU - Fang, Chun-Xiao AU - Fang CX AD - Department of Infectious Diseases, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, 510623, China. FAU - Peng, Jun-Zheng AU - Peng JZ AD - Respiratory Department, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, 510623, China. FAU - Wu, Zhi-Yuan AU - Wu ZY AD - Pediatric Intensive Care Unit, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, 510623, China. FAU - Sun, Yi AU - Sun Y AD - Neonatal Intensive Care Unit, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, 510623, China. FAU - Dang, Run AU - Dang R AD - Pediatric Intensive Care Unit, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, 510623, China. FAU - Liang, Yu-Feng AU - Liang YF AD - Pediatric Intensive Care Unit, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, 510623, China. FAU - Tang, Hong-Mei AU - Tang HM AD - Rehabilitation Department, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, 510623, China. FAU - Li, You-Yi AU - Li YY AD - General Pediatrics, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, 510623, China. FAU - Qiao, Zhong-Xiang AU - Qiao ZX AD - Rehabilitation Department, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, 510623, China. FAU - Liang, Zhi-Cheng AU - Liang ZC AD - Emergency Department, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, 510623, China. FAU - Tang, Jian-Ping AU - Tang JP AD - Neonatal Intensive Care Unit, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, 510623, China. FAU - Zeng, Fan-Sen AU - Zeng FS AD - Department of Infectious Diseases, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, 510623, China. FAU - Zheng, Ke-Lu AU - Zheng KL AD - Department of Neurology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, 510623, China. FAU - Zeng, Yi-Ru AU - Zeng YR AD - Department of Neurology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, 510623, China. FAU - Cao, Xiao-Jun AU - Cao XJ AD - Information Department, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, 510623, China. FAU - Xia, Hui-Min AU - Xia HM AD - Key Laboratory of Structural Birth Defects Research in Guangdong Province, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, 510623, China. FAU - Wei, Jian-Rui AU - Wei JR AD - Cardiovascular Department, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, 510623, China. FAU - Tang, Jin-Ling AU - Tang JL AD - Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 518055, China. jltang@cuhk.edu.hk. FAU - Gong, Si-Tang AU - Gong ST AUID- ORCID: 0000-0002-6899-0616 AD - General Pediatrics, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, 510623, China. sitangg@126.com. LA - eng GR - No. 2020B1111170001/Science and Technology Planning Project of Guangdong Province/ PT - Journal Article PT - Observational Study DEP - 20240507 PL - Switzerland TA - World J Pediatr JT - World journal of pediatrics : WJP JID - 101278599 RN - SARS-CoV-2 variants SB - IM MH - Humans MH - *COVID-19/complications/epidemiology MH - Male MH - Female MH - *Seizures/etiology MH - Child, Preschool MH - Child MH - Infant MH - Hospitalization/statistics & numerical data MH - Cohort Studies MH - SARS-CoV-2 MH - Body Temperature MH - Fever PMC - PMC11502579 OTO - NOTNLM OT - Body temperature OT - Brain damage OT - Children OT - Convulsion OT - Omicron BA.5 OT - Vaccination COIS- No financial or non-financial benefits have been received or will be received from any party related directly or indirectly to the subject of this article. Si-tang Gong is a member of the Editorial Board for World Journal of Pediatrics. The paper was handled by the other Editor and has undergone rigorous peer review process. Si-tang Gong was not involved in the journal's review of, or decisions related to, this manuscript. EDAT- 2024/05/07 13:45 MHDA- 2024/10/24 12:31 PMCR- 2024/05/07 CRDT- 2024/05/07 11:11 PHST- 2023/11/16 00:00 [received] PHST- 2024/03/22 00:00 [accepted] PHST- 2024/10/24 12:31 [medline] PHST- 2024/05/07 13:45 [pubmed] PHST- 2024/05/07 11:11 [entrez] PHST- 2024/05/07 00:00 [pmc-release] AID - 10.1007/s12519-024-00808-z [pii] AID - 808 [pii] AID - 10.1007/s12519-024-00808-z [doi] PST - ppublish SO - World J Pediatr. 2024 Oct;20(10):1079-1089. doi: 10.1007/s12519-024-00808-z. Epub 2024 May 7. PMID- 38607521 OWN - NLM STAT- MEDLINE DCOM- 20240729 LR - 20240801 IS - 1179-1942 (Electronic) IS - 0114-5916 (Print) IS - 0114-5916 (Linking) VI - 47 IP - 8 DP - 2024 Aug TI - COVID-19 Vaccines and Heavy Menstrual Bleeding: The Impact of Media Attention on Reporting to EudraVigilance. PG - 783-798 LID - 10.1007/s40264-024-01426-4 [doi] AB - BACKGROUND AND OBJECTIVE: During the COVID-19 vaccination campaign, over 34,000 reports of heavy menstrual bleeding following the administration of COVID-19 vaccines originating in the Economic European Area were submitted to EudraVigilance, the European Union database of suspected adverse drug reactions. More than 90% of these reports were sent by consumers while the remaining by healthcare professionals. Public concerns regarding menstruation disorders in COVID-19 vaccinees were also covered by the media. We investigated the impact of media attention on the reporting trends of heavy menstrual bleeding to EudraVigilance. METHODS: We used media outlets published in the Economic European Area on menstrual disorders and COVID-19 vaccines from the beginning of the vaccination campaign in the Economic European Area (1 January, 2021) until December 2022 (i.e., after the regulatory request to add the adverse event to the product information) and spontaneous reports from EudraVigilance. RESULTS: We found that the publication of safety updates from regulatory authorities and subsequent coverage in media outlets preceded increased reporting to EudraVigilance. Furthermore, the heavy menstrual bleeding reported in the cases occurred several weeks or months earlier and were not submitted to the respective date. The analysis suggests that the spikes in reporting of heavy menstrual bleeding were to some extent influenced by media coverage in some countries. CONCLUSIONS: Consumer reporting to the European Union spontaneous data collection system, EudraVigilance, was of high value for regulatory safety reviews, albeit the reporting behaviours were not free of the influence of the media. These sources of information can be investigated to understand the context of safety concerns of public health interest. CI - (c) 2024. The Author(s). FAU - Gordillo-Maranon, Maria AU - Gordillo-Maranon M AUID- ORCID: 0000-0003-2993-6577 AD - Data Analytics and Methods Task Force, European Medicines Agency, Amsterdam, The Netherlands. AD - Institute of Cardiovascular Science, Faculty of Population Health, University College London, London, UK. FAU - Szmigiel, Agnieszka AU - Szmigiel A AUID- ORCID: 0009-0006-6049-9634 AD - Pharmacovigilance Office, European Medicines Agency, Domenico Scarlattilaan 6, 1083 HS, Amsterdam, The Netherlands. agnieszka.szmigiel@ema.europa.eu. FAU - Yalmanova, Vladimira AU - Yalmanova V AUID- ORCID: 0009-0002-4947-0479 AD - Stakeholders and Communication, European Medicines Agency, Amsterdam, The Netherlands. FAU - Caplanusi, Irina AU - Caplanusi I AUID- ORCID: 0009-0006-0694-4469 AD - Pharmacovigilance Office, European Medicines Agency, Domenico Scarlattilaan 6, 1083 HS, Amsterdam, The Netherlands. FAU - Genov, Georgy AU - Genov G AUID- ORCID: 0009-0000-5139-3981 AD - Pharmacovigilance Office, European Medicines Agency, Domenico Scarlattilaan 6, 1083 HS, Amsterdam, The Netherlands. FAU - Olsen, David Benee AU - Olsen DB AUID- ORCID: 0009-0006-7117-8182 AD - Department of Pharmacovigilance, Norwegian Medical Products Agency, Oslo, Norway. FAU - Straus, Sabine AU - Straus S AUID- ORCID: 0009-0006-9266-3312 AD - Medicines Evaluation Board (MEB), Utrecht, The Netherlands. AD - Department of Medical Informatics, Erasmus Medical Centre, Rotterdam, The Netherlands. LA - eng PT - Journal Article DEP - 20240412 PL - New Zealand TA - Drug Saf JT - Drug safety JID - 9002928 RN - 0 (COVID-19 Vaccines) SB - IM MH - Female MH - Humans MH - *Adverse Drug Reaction Reporting Systems MH - *COVID-19/prevention & control/epidemiology MH - *COVID-19 Vaccines/adverse effects MH - Databases, Factual MH - European Union MH - Mass Media MH - *Menorrhagia/epidemiology MH - Pharmacovigilance PMC - PMC11286647 COIS- Maria Gordillo-Maranon, Agnieszka Szmigiel, Vladimira Yalmanova, Irina Caplanusi, Georgy Genov, David Benee Olsen and Sabine Straus have no conflicts of interest that are directly relevant to the content of this article. Maria Gordillo-Maranon, Agnieszka Szmigiel, Vladimira Yalmanova, Irina Caplanusi and Georgy Genov are employees of the European Medicines Agency. Sabine Straus is the Chair of European Medicines Agency's Pharmacovigilance Risk Assessment Committee and employee of the Medicines Evaluation Board, the Netherlands. David Benee Olsen is a member of the European Medicines Agency Pharmacovigilance Risk Assessment Committee and employee of the Norwegian Medical Products Agency, Norway. EDAT- 2024/04/12 12:42 MHDA- 2024/07/29 12:44 PMCR- 2024/04/12 CRDT- 2024/04/12 11:10 PHST- 2024/03/20 00:00 [accepted] PHST- 2024/07/29 12:44 [medline] PHST- 2024/04/12 12:42 [pubmed] PHST- 2024/04/12 11:10 [entrez] PHST- 2024/04/12 00:00 [pmc-release] AID - 10.1007/s40264-024-01426-4 [pii] AID - 1426 [pii] AID - 10.1007/s40264-024-01426-4 [doi] PST - ppublish SO - Drug Saf. 2024 Aug;47(8):783-798. doi: 10.1007/s40264-024-01426-4. Epub 2024 Apr 12. PMID- 38579013 OWN - NLM STAT- MEDLINE DCOM- 20240408 LR - 20260919 IS - 2470-9468 (Electronic) IS - 2470-9468 (Linking) VI - 9 IP - 94 DP - 2024 Apr 5 TI - AS03 adjuvant enhances the magnitude, persistence, and clonal breadth of memory B cell responses to a plant-based COVID-19 vaccine in humans. PG - eadi8039 LID - 10.1126/sciimmunol.adi8039 [doi] AB - Vaccine adjuvants increase the breadth of serum antibody responses, but whether this is due to the generation of antigen-specific B cell clones with distinct specificities or the maturation of memory B cell clones that produce broadly cross-reactive antibodies is unknown. Here, we longitudinally analyzed immune responses in healthy adults after two-dose vaccination with either a virus-like particle COVID-19 vaccine (CoVLP), CoVLP adjuvanted with AS03 (CoVLP+AS03), or a messenger RNA vaccination (mRNA-1273). CoVLP+AS03 enhanced the magnitude and durability of circulating antibodies and antigen-specific CD4(+) T cell and memory B cell responses. Antigen-specific CD4(+) T cells in the CoVLP+AS03 group at day 42 correlated with antigen-specific memory B cells at 6 months. CoVLP+AS03 induced memory B cell responses, which accumulated somatic hypermutations over 6 months, resulting in enhanced neutralization breadth of monoclonal antibodies. Furthermore, the fraction of broadly neutralizing antibodies encoded by memory B cells increased between day 42 and 6 months. These results indicate that AS03 enhances the antigenic breadth of B cell memory at the clonal level and induces progressive maturation of the B cell response. FAU - Grigoryan, Lilit AU - Grigoryan L AUID- ORCID: 0000-0002-9255-1453 AD - Institute for Immunity, Transplantation, and Infection, Stanford University School of Medicine, Stanford University, Stanford, CA 94305, USA. FAU - Feng, Yupeng AU - Feng Y AUID- ORCID: 0000-0001-8550-2787 AD - Institute for Immunity, Transplantation, and Infection, Stanford University School of Medicine, Stanford University, Stanford, CA 94305, USA. FAU - Bellusci, Lorenza AU - Bellusci L AUID- ORCID: 0000-0001-9945-1706 AD - Food and Drug Administration, Silver Spring, MD 20993, USA. FAU - Lai, Lilin AU - Lai L AD - Department of Pediatrics and Department of Microbiology and Immunology, Emory Vaccine Center, Emory National Primate Research Center, Emory School of Medicine, Atlanta, GA 30329, USA. FAU - Wali, Bushra AU - Wali B AD - Department of Pediatrics and Department of Microbiology and Immunology, Emory Vaccine Center, Emory National Primate Research Center, Emory School of Medicine, Atlanta, GA 30329, USA. FAU - Ellis, Madison AU - Ellis M AUID- ORCID: 0000-0002-0325-5477 AD - Department of Pediatrics and Department of Microbiology and Immunology, Emory Vaccine Center, Emory National Primate Research Center, Emory School of Medicine, Atlanta, GA 30329, USA. FAU - Yuan, Meng AU - Yuan M AUID- ORCID: 0000-0001-9754-4503 AD - Department of Integrative Structural and Computational Biology, Scripps Research Institute, La Jolla, CA 92037, USA. FAU - Arunachalam, Prabhu S AU - Arunachalam PS AUID- ORCID: 0000-0003-0090-5689 AD - Institute for Immunity, Transplantation, and Infection, Stanford University School of Medicine, Stanford University, Stanford, CA 94305, USA. FAU - Hu, Mengyun AU - Hu M AUID- ORCID: 0000-0003-4495-7501 AD - Institute for Immunity, Transplantation, and Infection, Stanford University School of Medicine, Stanford University, Stanford, CA 94305, USA. FAU - Kowli, Sangeeta AU - Kowli S AUID- ORCID: 0000-0003-0362-572X AD - Institute for Immunity, Transplantation, and Infection, Stanford University School of Medicine, Stanford University, Stanford, CA 94305, USA. FAU - Gupta, Sheena AU - Gupta S AUID- ORCID: 0000-0002-6126-1170 AD - Institute for Immunity, Transplantation, and Infection, Stanford University School of Medicine, Stanford University, Stanford, CA 94305, USA. FAU - Maysel-Auslender, Sofia AU - Maysel-Auslender S AD - Institute for Immunity, Transplantation, and Infection, Stanford University School of Medicine, Stanford University, Stanford, CA 94305, USA. FAU - Maecker, Holden T AU - Maecker HT AUID- ORCID: 0000-0003-0795-9946 AD - Institute for Immunity, Transplantation, and Infection, Stanford University School of Medicine, Stanford University, Stanford, CA 94305, USA. FAU - Samaha, Hady AU - Samaha H AUID- ORCID: 0000-0002-9124-7820 AD - Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA. FAU - Rouphael, Nadine AU - Rouphael N AUID- ORCID: 0000-0002-2512-7919 AD - Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA. AD - Hope Clinic of Emory Vaccine Center, Emory University, Decatur, GA 30030, USA. FAU - Wilson, Ian A AU - Wilson IA AUID- ORCID: 0000-0002-6469-2419 AD - Department of Integrative Structural and Computational Biology, Scripps Research Institute, La Jolla, CA 92037, USA. FAU - Moreno, Alberto C AU - Moreno AC AUID- ORCID: 0000-0002-3031-7194 AD - Department of Medicine, Emory Vaccine Center, Emory National Primate Research Center, Emory University School of Medicine, Atlanta, GA 30329, USA. FAU - Suthar, Mehul S AU - Suthar MS AUID- ORCID: 0000-0002-2686-8380 AD - Department of Pediatrics and Department of Microbiology and Immunology, Emory Vaccine Center, Emory National Primate Research Center, Emory School of Medicine, Atlanta, GA 30329, USA. FAU - Khurana, Surender AU - Khurana S AUID- ORCID: 0000-0002-0593-7965 AD - Food and Drug Administration, Silver Spring, MD 20993, USA. FAU - Pillet, Stephane AU - Pillet S AUID- ORCID: 0000-0002-7604-7855 AD - Medicago Inc., Quebec, QC G1V 3V9, Canada. AD - Research Institute of the McGill University Health Center, 1001 Decarie St., Montreal, QC H4A 3J1, Canada. FAU - Charland, Nathalie AU - Charland N AD - Medicago Inc., Quebec, QC G1V 3V9, Canada. FAU - Ward, Brian J AU - Ward BJ AUID- ORCID: 0000-0003-3251-958X AD - Medicago Inc., Quebec, QC G1V 3V9, Canada. AD - Research Institute of the McGill University Health Center, 1001 Decarie St., Montreal, QC H4A 3J1, Canada. FAU - Pulendran, Bali AU - Pulendran B AUID- ORCID: 0000-0001-6517-4333 AD - Institute for Immunity, Transplantation, and Infection, Stanford University School of Medicine, Stanford University, Stanford, CA 94305, USA. LA - eng GR - P51 OD011132/OD/NIH HHS/United States GR - 75N93021C00017/AI/NIAID NIH HHS/United States GR - U19 AI057266/AI/NIAID NIH HHS/United States GR - P01 AI167966/AI/NIAID NIH HHS/United States GR - INV-004923/Bill & Melinda Gates Foundation/United States GR - U19 AI167903/AI/NIAID NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20240405 PL - United States TA - Sci Immunol JT - Science immunology JID - 101688624 RN - A7YT618XBV (AS03 adjuvant) RN - 0 (Influenza Vaccines) RN - 0 (COVID-19 Vaccines) RN - 0 (Antibodies, Viral) RN - 0 (Drug Combinations) RN - 0 (Polysorbates) RN - 7QWM220FJH (Squalene) RN - H4N855PNZ1 (alpha-Tocopherol) SB - IM MH - Adult MH - Humans MH - *Influenza Vaccines MH - Memory B Cells MH - COVID-19 Vaccines MH - *Influenza, Human MH - Antibodies, Viral MH - *COVID-19/prevention & control MH - Drug Combinations MH - *Polysorbates MH - *Squalene MH - *alpha-Tocopherol PMC - PMC11732256 MID - NIHMS2036405 COIS- Competing interests B.P. serves on the External Immunology Board of GlaxoSmithKline, and on the Scientific Advisory Board of Sanofi, Medicago, CircBio, Boehringer-Ingelheim, Icosavax, and EdJen. M.S.S. serves in a consulting role for Moderna and Ocugen. S.P., N.C. and B.J.W. are employees of Medicago. All other authors declare no competing interests. EDAT- 2024/04/05 18:42 MHDA- 2024/04/08 06:42 PMCR- 2025/04/05 CRDT- 2024/04/05 14:03 PHST- 2024/04/08 06:42 [medline] PHST- 2024/04/05 18:42 [pubmed] PHST- 2024/04/05 14:03 [entrez] PHST- 2025/04/05 00:00 [pmc-release] AID - 10.1126/sciimmunol.adi8039 [doi] PST - ppublish SO - Sci Immunol. 2024 Apr 5;9(94):eadi8039. doi: 10.1126/sciimmunol.adi8039. Epub 2024 Apr 5. PMID- 38572438 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240405 IS - 2341-4545 (Print) IS - 2387-1954 (Electronic) IS - 2387-1954 (Linking) VI - 31 IP - 2 DP - 2024 Apr TI - Persistent Fever after COVID-19 Vaccination in a Patient with Ulcerative Colitis: A Call for Attention. PG - 129-135 LID - 10.1159/000530834 [doi] AB - The development of vaccinations has been game-changing in the ongoing effort to combat the COVID-19 pandemic. Until now, adverse effects are being reported at low frequency, including thrombocytopenia and myocarditis. Careful monitoring for any suspicious symptoms and signs following vaccination is necessary. We report a case of hemophagocytic lymphohistiocytosis (HLH) after mRNA COVID-19 vaccine in a 23-year-old female with ulcerative colitis. Diagnosis was made according to HLH-2004 criteria and the patient was treated with dexamethasone with response. Our report aimed to draw attention to the potential relation between COVID-19 vaccines and HLH and the necessity of continued surveillance, especially in at-risk populations such as those with underlying immune dysregulation. CI - (c) 2023 The Author(s).Published by S. Karger AG, Basel. FAU - Rodrigues, Claudio Melo AU - Rodrigues CM AD - Department of Gastroenterology, Centro Hospitalar Tondela-Viseu, Viseu, Portugal. FAU - Carvalho, Ana Catarina AU - Carvalho AC AD - Department of Gastroenterology, Centro Hospitalar Tondela-Viseu, Viseu, Portugal. FAU - Ventura, Sofia AU - Ventura S AD - Department of Gastroenterology, Centro Hospitalar Tondela-Viseu, Viseu, Portugal. FAU - Domingues, Angela Pinto AU - Domingues AP AD - Department of Gastroenterology, Centro Hospitalar Tondela-Viseu, Viseu, Portugal. FAU - Silva, Americo AU - Silva A AD - Department of Gastroenterology, Centro Hospitalar Tondela-Viseu, Viseu, Portugal. FAU - Ministro, Paula AU - Ministro P AD - Department of Gastroenterology, Centro Hospitalar Tondela-Viseu, Viseu, Portugal. LA - eng PT - Journal Article DEP - 20230615 PL - Switzerland TA - GE Port J Gastroenterol JT - GE Portuguese journal of gastroenterology JID - 101685861 PMC - PMC10987068 OTO - NOTNLM OT - COVID-19 vaccination OT - Hemophagocytic lymphohistiocytosis OT - Ulcerative colitis COIS- Paula Ministro received consulting fees and support to travel to meetings from the following companies: AbbVie, Falk Pharma, Ferring, Pfizer, Takeda, and Janssen. The remaining authors have no conflict of interests to declare. EDAT- 2024/04/04 06:44 MHDA- 2024/04/04 06:45 PMCR- 2023/06/15 CRDT- 2024/04/04 04:13 PHST- 2022/11/04 00:00 [received] PHST- 2023/02/06 00:00 [accepted] PHST- 2024/04/04 06:45 [medline] PHST- 2024/04/04 06:44 [pubmed] PHST- 2024/04/04 04:13 [entrez] PHST- 2023/06/15 00:00 [pmc-release] AID - 530834 [pii] AID - 10.1159/000530834 [doi] PST - epublish SO - GE Port J Gastroenterol. 2023 Jun 15;31(2):129-135. doi: 10.1159/000530834. eCollection 2024 Apr. PMID- 38549052 OWN - NLM STAT- MEDLINE DCOM- 20240401 LR - 20260318 IS - 1471-2458 (Electronic) IS - 1471-2458 (Linking) VI - 24 IP - 1 DP - 2024 Mar 28 TI - How do people with long COVID utilize COVID-19 vaccination and rehabilitation services and what are their experiences with these services? results of a qualitative study with 48 participants from Germany. PG - 915 LID - 10.1186/s12889-024-18380-6 [doi] LID - 915 AB - BACKGROUND: Studies estimate that at least 7.5% of adults are affected by long-term symptoms such as fatigue or cognitive impairment after the acute phase of COVID-19. COVID-19 vaccination may reduce the risk of long COVID. Rehabilitation can have a positive impact on recovery. This study aims to present the experiences of people with long COVID with COVID-19 vaccination and rehabilitation. Such research is important because perceptions of these measures can impact healthcare utilization and health status. METHODS: 48 adults with long COVID participated in this qualitative study, 25 of them in one-on-one interviews and 23 in focus groups. Participants were recruited via calls for participation on the websites and social media channels of two university hospitals and with the help of respondents' networks. The conversations were audio-recorded, transcribed, and analyzed using qualitative content analysis. Subsequently, the results were compared, interpreted, and discussed by scientific literature. RESULTS: 35 study participants reported that they had received a COVID-19 vaccination and 16 of them stated that they had utilized a rehabilitation service. These participants had varying experiences with COVID-19 vaccination and rehabilitation. Nine of them stated that they developed long COVID despite vaccination before COVID-19. Ten participants reported vaccine reactions, and two participants reported severe side effects. Two participants reported persistent deterioration of their long COVID symptoms after vaccination. This led to uncertainty about the safety, benefits, and handling of COVID-19 vaccination. However, most participants perceived the vaccine as effective regarding milder COVID-19 sequelae. Four participants felt their rehabilitation was helpful and four participants felt it was unhelpful. Two persons found the combination of inpatient rehabilitation and rehabilitation sport helpful. CONCLUSIONS: Several implications can be derived from this study: (1) researchers should explore the effects of COVID-19 vaccination on long COVID symptoms; (2) vaccination campaigns should be more responsive to the perspectives of people with long COVID on vaccination; (3) care planners should build rehabilitation facilities specialized in long COVID; (4) rehabilitation providers should train their professionals regarding long COVID and develop rehabilitation programs tailored to different clinical pictures. TRIAL REGISTRATION: German register for clinical trials DRKS00026007, 09 September 2021. CI - (c) 2024. The Author(s). FAU - Schmachtenberg, Tim AU - Schmachtenberg T AD - Department of General Practice, University Medical Center Gottingen, Humboldtallee 38, 37073, Gottingen, Germany. tim.schmachtenberg@med.uni-goettingen.de. AD - Department of Rheumatology and Immunology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany. tim.schmachtenberg@med.uni-goettingen.de. FAU - Konigs, Gloria AU - Konigs G AD - Department of General Practice, University Medical Center Gottingen, Humboldtallee 38, 37073, Gottingen, Germany. FAU - Roder, Sascha AU - Roder S AD - Department of General Practice, University Medical Center Gottingen, Humboldtallee 38, 37073, Gottingen, Germany. AD - Department of Social Work, University of Applied Sciences and Arts Bielefeld, Interaktion 1, 33619, Bielefeld, Germany. FAU - Muller, Frank AU - Muller F AD - Department of General Practice, University Medical Center Gottingen, Humboldtallee 38, 37073, Gottingen, Germany. AD - Department of Family Medicine, College of Human Medicine, Michigan State University, 15 Michigan St NE, Grand Rapids, 49503, East Lansing, MI, USA. FAU - Mullenmeister, Christina AU - Mullenmeister C AD - Department of General Practice, University Medical Center Gottingen, Humboldtallee 38, 37073, Gottingen, Germany. FAU - Schroder, Dominik AU - Schroder D AD - Department of General Practice, University Medical Center Gottingen, Humboldtallee 38, 37073, Gottingen, Germany. FAU - El-Sayed, Iman AU - El-Sayed I AD - Department of General Practice, University Medical Center Gottingen, Humboldtallee 38, 37073, Gottingen, Germany. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20240328 PL - England TA - BMC Public Health JT - BMC public health JID - 100968562 RN - 0 (COVID-19 Vaccines) RN - 0 (Vaccines) RN - German people SB - IM MH - Adult MH - Humans MH - *COVID-19/prevention & control MH - COVID-19 Vaccines MH - Post-Acute COVID-19 Syndrome MH - Vaccination MH - *Vaccines MH - European People PMC - PMC10976759 OTO - NOTNLM OT - COVID-19 vaccination OT - Germany OT - Long COVID OT - Qualitative study OT - Rehabilitation OT - SARS-CoV-2 COIS- The authors declare no competing interests. EDAT- 2024/03/29 06:45 MHDA- 2024/04/01 06:43 PMCR- 2024/03/28 CRDT- 2024/03/29 00:35 PHST- 2023/10/09 00:00 [received] PHST- 2024/03/18 00:00 [accepted] PHST- 2024/04/01 06:43 [medline] PHST- 2024/03/29 06:45 [pubmed] PHST- 2024/03/29 00:35 [entrez] PHST- 2024/03/28 00:00 [pmc-release] AID - 10.1186/s12889-024-18380-6 [pii] AID - 18380 [pii] AID - 10.1186/s12889-024-18380-6 [doi] PST - epublish SO - BMC Public Health. 2024 Mar 28;24(1):915. doi: 10.1186/s12889-024-18380-6. PMID- 38533494 OWN - NLM STAT- MEDLINE DCOM- 20240328 LR - 20240410 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 15 DP - 2024 TI - Long-term analysis of humoral responses and spike-specific T cell memory to Omicron variants after different COVID-19 vaccine regimens. PG - 1340645 LID - 10.3389/fimmu.2024.1340645 [doi] LID - 1340645 AB - BACKGROUND: The emergence of SARS-CoV-2 variants has raised concerns about the sustainability of vaccine-induced immunity. Little is known about the long-term humoral responses and spike-specific T cell memory to Omicron variants, with specific attention to BA.4/5, BQ.1.1, and XBB.1. METHODS: We assessed immune responses in 50 uninfected individuals who received varying three-dose vaccination combinations (2X AstraZeneca + 1X Moderna, 1X AstraZeneca + 2X Moderna, and 3X Moderna) against wild-type (WT) and Omicron variants at eight months post-vaccination. The serum antibody titers were analyzed by enzyme-linked immunosorbent assays (ELISA), and neutralizing activities were examined by pseudovirus and infectious SARS-CoV-2 neutralization assays. T cell reactivities and their memory phenotypes were determined by flow cytometry. RESULTS: We found that RBD-specific antibody titers, neutralizing activities, and CD4+ T cell reactivities were reduced against Omicron variants compared to WT. In contrast, CD8+ T cell responses, central memory, effector memory, and CD45RA+ effector memory T cells remained unaffected upon stimulation with the Omicron peptide pool. Notably, CD4+ effector memory T cells even exhibited a higher proportion of reactivity against Omicron variants. Furthermore, participants who received three doses of the Moderna showed a more robust response regarding neutralization and CD8+ T cell reactions than other three-dose vaccination groups. CONCLUSION: Reduction of humoral and CD4+ T cell responses against Omicron variants in vaccinees suggested that vaccine effectiveness after eight months may not have sufficient protection against the new emerging variants, which provides valuable information for future vaccination strategies such as receiving BA.4/5 or XBB.1-based bivalent vaccines. CI - Copyright (c) 2024 Ho, Yen, Huang, Lu, Hung, Liao, Hung and Chiu. FAU - Ho, Chia-Lo AU - Ho CL AD - Institute of Life Sciences, National Defense Medical Center, Taipei, Taiwan. FAU - Yen, Li-Chen AU - Yen LC AD - Department of Microbiology and Immunology, National Defense Medical Center, Taipei, Taiwan. FAU - Huang, Hong-Wei AU - Huang HW AD - Department of Microbiology and Immunology, National Defense Medical Center, Taipei, Taiwan. FAU - Lu, Chun-Chi AU - Lu CC AD - Division of Rheumatology/Immunology and Allergy, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan. FAU - Hung, Yi-Jen AU - Hung YJ AD - Division of Endocrinology and Metabolism, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan. FAU - Liao, Ching-Len AU - Liao CL AD - Department of Microbiology and Immunology, National Defense Medical Center, Taipei, Taiwan. AD - National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Miaoli, Taiwan. FAU - Hung, Chin-Mao AU - Hung CM AD - Institute of Preventive Medicine, National Defense Medical Center, Taipei, Taiwan. FAU - Chiu, Kuo-Chou AU - Chiu KC AD - Division of General Dentistry, Taichung Armed Forces General Hospital, Taichung, Taiwan. AD - School of Dentistry, China Medical University, Taichung, Taiwan. AD - School of Dentistry, National Defense Medical Center, Taipei, Taiwan. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20240312 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 RN - 0 (COVID-19 Vaccines) RN - SARS-CoV-2 variants SB - IM MH - Humans MH - *COVID-19 Vaccines MH - Memory T Cells MH - *COVID-19 MH - SARS-CoV-2 PMC - PMC10963495 OTO - NOTNLM OT - Omicron variant OT - SARS-CoV-2 OT - cellular immune response OT - neutralizing antibody OT - vaccination COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2024/03/27 06:44 MHDA- 2024/03/28 06:44 PMCR- 2024/01/01 CRDT- 2024/03/27 03:59 PHST- 2023/11/18 00:00 [received] PHST- 2024/02/27 00:00 [accepted] PHST- 2024/03/28 06:44 [medline] PHST- 2024/03/27 06:44 [pubmed] PHST- 2024/03/27 03:59 [entrez] PHST- 2024/01/01 00:00 [pmc-release] AID - 10.3389/fimmu.2024.1340645 [doi] PST - epublish SO - Front Immunol. 2024 Mar 12;15:1340645. doi: 10.3389/fimmu.2024.1340645. eCollection 2024. PMID- 38522148 OWN - NLM STAT- MEDLINE DCOM- 20240427 LR - 20250408 IS - 1873-5347 (Electronic) IS - 0277-9536 (Linking) VI - 348 DP - 2024 May TI - One-size fits all? Evaluating group differences in an integrated social cognition model to understand COVID-19 vaccine intention and uptake. PG - 116780 LID - S0277-9536(24)00224-7 [pii] LID - 10.1016/j.socscimed.2024.116780 [doi] AB - Vaccine programs significantly reduce disease burden within a population. The COVID-19 vaccine facilitated a return to "normal"; however, vaccine coverage remains below target levels. Identifying predictors of vaccine uptake is vital for individual and community health. The present study used the Reasoned Action Approach and integrated hazard-specific risk perception, to predict COVID-19 vaccine intention and uptake behavior. Informed by the diffusion of innovations theory, differences in associations and model effects were tested by early adopter status of the seasonal influenza vaccine. We recruited participants online within the United States for a longitudinal survey study. The integrated social cognition model provided an acceptable to ideal fit for both groups but performed better among the not early adopter group with better fit statistics, mostly stronger effect sizes, and greater variance accounted for in intention to vaccinate against COVID-19. Instrumental attitudes toward the COVID-19 vaccine predicted intention for both groups, and uptake among the non-early adopters. Capacity predicted intention among early adopters, and behavior among non-early adopters. Among non-early adopters, subjective norms had a direct effect on intention and an indirect effect on vaccine uptake behavior. Intervention research to support COVID-19 vaccine uptake focusing on the utility of vaccines, fostering self-efficacy, and providing normative information is warranted. CI - Copyright (c) 2024 The Authors. Published by Elsevier Ltd.. All rights reserved. FAU - Kowalsky, Jennifer M AU - Kowalsky JM AD - Department of Psychology, The Ohio State University, USA. Electronic address: kowalsky.9@osu.edu. FAU - Buelow, Melissa T AU - Buelow MT AD - Department of Psychology, The Ohio State University, USA. FAU - Brunell, Amy B AU - Brunell AB AD - Department of Psychology, The Ohio State University, USA. LA - eng PT - Journal Article DEP - 20240318 PL - England TA - Soc Sci Med JT - Social science & medicine (1982) JID - 8303205 RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - *Intention MH - *COVID-19 Vaccines/administration & dosage MH - Male MH - Female MH - *COVID-19/prevention & control/psychology MH - Adult MH - Longitudinal Studies MH - *Social Cognition MH - United States MH - Middle Aged MH - SARS-CoV-2 MH - Health Knowledge, Attitudes, Practice MH - Surveys and Questionnaires OTO - NOTNLM OT - Behavior OT - COVID-19 OT - Early adopter OT - Reasoned action approach OT - Risk perception OT - United States OT - Vaccine COIS- Declaration of competing interest The Authors declare that there is no conflict of interest. EDAT- 2024/03/25 00:42 MHDA- 2024/04/28 07:25 CRDT- 2024/03/24 19:01 PHST- 2023/10/04 00:00 [received] PHST- 2024/03/06 00:00 [revised] PHST- 2024/03/10 00:00 [accepted] PHST- 2024/04/28 07:25 [medline] PHST- 2024/03/25 00:42 [pubmed] PHST- 2024/03/24 19:01 [entrez] AID - S0277-9536(24)00224-7 [pii] AID - 10.1016/j.socscimed.2024.116780 [doi] PST - ppublish SO - Soc Sci Med. 2024 May;348:116780. doi: 10.1016/j.socscimed.2024.116780. Epub 2024 Mar 18. PMID- 38514925 OWN - NLM STAT- MEDLINE DCOM- 20241111 LR - 20260518 IS - 1532-7027 (Electronic) IS - 1041-0236 (Linking) VI - 39 IP - 13 DP - 2024 Nov TI - Why Do People Believe in Vaccine Misinformation? The Roles of Perceived Familiarity and Evidence Type. PG - 3480-3492 LID - 10.1080/10410236.2024.2328455 [doi] AB - The proliferation of health misinformation poses a significant threat to public health, making it increasingly important to understand why misinformation is accepted. The illusory truth effect, which refers to the increased believability of a message due to repeated exposure, has been widely studied. However, there is limited research on this effect in the context of COVID-19 vaccine misinformation. This paper aims to examine the role of perceived familiarity with COVID-19 vaccine misinformation on various message perceptions, including perceived accuracy, agreement, perceived message effectiveness, and determinants of vaccination, including vaccine attitude and vaccination intention. Furthermore, it explores the impact of misinformation evidence (statistical vs. narrative) on the magnitude of the effects of perceived familiarity. To investigate these factors, a between-subjects experimental study was conducted, employing a 2 (Familiarity: strong vs. weak) x 3 (Evidence type: statistical, narrative, and both evidence) + 1 (Control: a message about drinking water) design. The results revealed that perceived familiarity with COVID-19 vaccine misinformation significantly predicted perceived accuracy, which was found to be negatively correlated with vaccine attitudes and vaccination intentions. Moreover, statistical evidence presented in misinformation was perceived as more persuasive in perceived message effectiveness, compared to narrative and mixed evidence. Interestingly, the effects of perceived familiarity were not contingent on the type of evidence used in COVID-19 vaccine misinformation. These findings emphasize the importance of avoiding the repetition of misinformation, reducing the processing fluency associated with misinformation correction, and educating individuals on how to critically evaluate statistical evidence when encountering (mis)information. FAU - Fang, Yuming AU - Fang Y AD - Hubbard School of Journalism and Mass Communication, University of Minnesota. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20240321 PL - England TA - Health Commun JT - Health communication JID - 8908762 RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - *COVID-19 Vaccines MH - Female MH - Male MH - Adult MH - *COVID-19/prevention & control MH - *Communication MH - Young Adult MH - Health Knowledge, Attitudes, Practice MH - Health Communication MH - Vaccination/psychology MH - Intention MH - Recognition, Psychology MH - SARS-CoV-2 MH - Adolescent EDAT- 2024/03/22 06:44 MHDA- 2024/11/13 13:55 CRDT- 2024/03/22 01:02 PHST- 2024/11/13 13:55 [medline] PHST- 2024/03/22 06:44 [pubmed] PHST- 2024/03/22 01:02 [entrez] AID - 10.1080/10410236.2024.2328455 [doi] PST - ppublish SO - Health Commun. 2024 Nov;39(13):3480-3492. doi: 10.1080/10410236.2024.2328455. Epub 2024 Mar 21. PMID- 38501661 OWN - NLM STAT- MEDLINE DCOM- 20240417 LR - 20260319 IS - 1098-5514 (Electronic) IS - 0022-538X (Print) IS - 0022-538X (Linking) VI - 98 IP - 4 DP - 2024 Apr 16 TI - The varying extent of humoral and cellular immune responses to either vector- or RNA-based SARS-CoV-2 vaccines persists for at least 18 months and is independent of infection. PG - e0191223 LID - 10.1128/jvi.01912-23 [doi] LID - e01912-23 AB - The corona virus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome corona-virus 2 (SARS-CoV-2) spurred a worldwide race for the development of an efficient vaccine. Various strategies were pursued; however, the first vaccines to be licensed presented the SARS-CoV-2 spike protein either in the context of a non-replicating adenoviral vector or as an mRNA construct. While short-term efficacies have extensively been characterized, the duration of protection, the need for repeated boosting, and reasonable vaccination intervals have yet to be defined. We here describe the adaptive immune response resulting from homologous and heterologous vaccination regimen at 18 months after primary vaccination. To that extent, we monitored 176 healthcare workers, the majority of whom had recovered from previous SARS-CoV-2 infection. In summary, we find that differences depending on primary immunization continue to exist 18 months after the first vaccination and these findings hold true irrespective of previous infection with the virus. Homologous primary immunization with BNT162b2 was repeatedly shown to produce higher antibody levels and slower antibody decline, leading to more effective in vitro neutralization capacities. Likewise, cellular responses resulting from in vitro re-stimulation were more pronounced after primary immunization involving BNT162b2. In contrast, IL-2 producing memory T helper and cytotoxic T cells appeared independent from the primary vaccination regimen. Despite these differences, comparable infection rates among all vaccination groups suggest comparable real-life protection.IMPORTANCEVaccination against the severe acute respiratory syndrome corona-virus 2 (SARS-CoV-2) was shown to avert severe courses of corona virus disease 2019 (COVID-19) and to mitigate spreading of the virus. However, the duration of protection and need for repeated boosting have yet to be defined. Monitoring and comparing the immune responses resulting from various vaccine strategies are therefore important to fill knowledge gaps and prepare for future pandemics. FAU - Mai, Franz AU - Mai F AUID- ORCID: 0009-0006-2350-8319 AD - Core Facility for Cell Sorting and Cell Analysis, University Medical Center, Rostock, Germany. FAU - Bergmann, Wendy AU - Bergmann W AD - Core Facility for Cell Sorting and Cell Analysis, University Medical Center, Rostock, Germany. FAU - Reisinger, Emil C AU - Reisinger EC AD - Division of Tropical Medicine and Infectious Diseases, Center of Internal Medicine II, University Medical Center, Rostock, Germany. FAU - Muller-Hilke, Brigitte AU - Muller-Hilke B AUID- ORCID: 0000-0002-6575-6824 AD - Core Facility for Cell Sorting and Cell Analysis, University Medical Center, Rostock, Germany. AD - Institute of Immunology, University Medical Center, Rostock, Germany. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20240319 PL - United States TA - J Virol JT - Journal of virology JID - 0113724 RN - 0 (Antibodies, Neutralizing) RN - 0 (Antibodies, Viral) RN - 0 (BNT162 Vaccine) RN - 0 (COVID-19 Vaccines) RN - 63231-63-0 (RNA) RN - 0 (Spike Glycoprotein, Coronavirus) RN - 0 (spike protein, SARS-CoV-2) SB - IM MH - Humans MH - Antibodies, Neutralizing MH - Antibodies, Viral MH - BNT162 Vaccine MH - *COVID-19/immunology/prevention & control MH - *COVID-19 Vaccines/administration & dosage/immunology MH - Immunity, Cellular MH - Immunity, Humoral MH - RNA MH - SARS-CoV-2/physiology MH - Spike Glycoprotein, Coronavirus PMC - PMC11019912 OTO - NOTNLM OT - COVID-19 OT - SARS-CoV-2 OT - T cell memory OT - antibodies OT - homologous and heterologous vaccination regime COIS- The authors declare no conflict of interest. EDAT- 2024/03/19 12:42 MHDA- 2024/04/17 06:42 PMCR- 2024/03/19 CRDT- 2024/03/19 08:03 PHST- 2024/04/17 06:42 [medline] PHST- 2024/03/19 12:42 [pubmed] PHST- 2024/03/19 08:03 [entrez] PHST- 2024/03/19 00:00 [pmc-release] AID - 01912-23 [pii] AID - jvi.01912-23 [pii] AID - 10.1128/jvi.01912-23 [doi] PST - ppublish SO - J Virol. 2024 Apr 16;98(4):e0191223. doi: 10.1128/jvi.01912-23. Epub 2024 Mar 19. PMID- 38491112 OWN - NLM STAT- MEDLINE DCOM- 20240318 LR - 20240318 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 14 IP - 1 DP - 2024 Mar 15 TI - Picture analysis of billboards and infographic graphics advertising COVID-19 on promoting preventive behaviors and taking vaccination against the Coronavirus disease pandemic. PG - 6310 LID - 10.1038/s41598-024-56758-z [doi] LID - 6310 AB - Today, advertising science is a tool that helps advertisers to design their advertising to meet the needs of the audience. In this regard, knowing and understanding the audience is one of the most important points that advertisers should pay attention to before advertising in order to better attract the audience. This study has been done with the aim of billboards and infographics analysis related to promoting preventive behaviors and vaccination against the Coronavirus disease pandemic and investigating the opinion of the general adult population of Iran. The method used in this research is the qualitative method. In this research, according to the type of data and research goals, Kress and Van Leeuwen's discourse theory method has been used. The sample size includes 36 advertising billboards and infographics. Data collection has been done through searching the sites and websites of health networks and medical education centers in Iran, taking pictures of infographics and billboards in public places, and also receiving archive files of pictures from the public relations of health networks and medical services. The data was collected from February 19, 2020 to December 30, 2022 (the time frame of the pandemic and public vaccination program in Iran). Then, an online survey about promoting preventive behaviors and taking vaccination against the Coronavirus disease pandemic was designed in SurveyMonkey and its link was provided to the audience through virtual networks and other platforms. The assessment of validity involved experts in infection control and linguistics. The reliability of the measurement, determined through the Cronbach's alpha internal consistency coefficient, yielded a coefficient of 0.968. In this study, data analysis was conducted using IBM SPSS Statistics software, version 15.0 (IBM Corp., Armonk, NY, USA). Finally, users' opinions about of billboards and infographics were analyzed using descriptive statistics. The results of component analysis and surveys show that visual components such as <>, <>, <>, <>, <> and <> in medical advertising has had a great impact in arousing public opinion to create a positive attitude towards preventive measures and vaccination during the Coronavirus disease epidemic. The results of this research show that in visual communication, visual components play a significant role in creating and maintaining target ideologies. Also, advertising in the field of preventive measures in medical sciences requires certain rules that determine people's culture and the main foundation of their attitude and thinking. Therefore, it is necessary to know such knowledge and learn it by the medical staff to deal with critical situations. CI - (c) 2024. The Author(s). FAU - Mohamadpour, Fereshteh AU - Mohamadpour F AD - Department of Community Medicine, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. FAU - Askarian, Ardalan AU - Askarian A AD - College of Arts and Science, University of Saskatchewan, Saskatoon, Canada. FAU - Askarian, Mehrdad AU - Askarian M AD - Department of Community Medicine, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. askariam@sums.ac.ir. LA - eng PT - Journal Article DEP - 20240315 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 SB - IM MH - Adult MH - Humans MH - *Advertising/methods MH - *COVID-19/epidemiology/prevention & control MH - Pandemics MH - Reproducibility of Results MH - Data Visualization MH - Vaccination PMC - PMC10943230 OTO - NOTNLM OT - Billboard OT - COVID-19 OT - Infographic OT - Prevention OT - Public attention OT - Vaccination COIS- The authors declare no competing interests. EDAT- 2024/03/16 21:43 MHDA- 2024/03/18 06:44 PMCR- 2024/03/15 CRDT- 2024/03/16 00:25 PHST- 2023/11/17 00:00 [received] PHST- 2024/03/11 00:00 [accepted] PHST- 2024/03/18 06:44 [medline] PHST- 2024/03/16 21:43 [pubmed] PHST- 2024/03/16 00:25 [entrez] PHST- 2024/03/15 00:00 [pmc-release] AID - 10.1038/s41598-024-56758-z [pii] AID - 56758 [pii] AID - 10.1038/s41598-024-56758-z [doi] PST - epublish SO - Sci Rep. 2024 Mar 15;14(1):6310. doi: 10.1038/s41598-024-56758-z. PMID- 38490197 OWN - NLM STAT- MEDLINE DCOM- 20240412 LR - 20250820 IS - 1097-4180 (Electronic) IS - 1074-7613 (Print) IS - 1074-7613 (Linking) VI - 57 IP - 4 DP - 2024 Apr 9 TI - Persistent immune imprinting occurs after vaccination with the COVID-19 XBB.1.5 mRNA booster in humans. PG - 904-911.e4 LID - S1074-7613(24)00092-X [pii] LID - 10.1016/j.immuni.2024.02.016 [doi] AB - Immune imprinting describes how the first exposure to a virus shapes immunological outcomes of subsequent exposures to antigenically related strains. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) Omicron breakthrough infections and bivalent COVID-19 vaccination primarily recall cross-reactive memory B cells induced by prior Wuhan-Hu-1 spike mRNA vaccination rather than priming Omicron-specific naive B cells. These findings indicate that immune imprinting occurs after repeated Wuhan-Hu-1 spike exposures, but whether it can be overcome remains unclear. To understand the persistence of immune imprinting, we investigated memory and plasma antibody responses after administration of the updated XBB.1.5 COVID-19 mRNA vaccine booster. We showed that the XBB.1.5 booster elicited neutralizing antibody responses against current variants that were dominated by recall of pre-existing memory B cells previously induced by the Wuhan-Hu-1 spike. Therefore, immune imprinting persists after multiple exposures to Omicron spikes through vaccination and infection, including post XBB.1.5 booster vaccination, which will need to be considered to guide future vaccination. CI - Copyright (c) 2024 The Author(s). Published by Elsevier Inc. All rights reserved. FAU - Tortorici, M Alejandra AU - Tortorici MA AD - Department of Biochemistry, University of Washington, Seattle, WA 98195, USA. FAU - Addetia, Amin AU - Addetia A AD - Department of Biochemistry, University of Washington, Seattle, WA 98195, USA. FAU - Seo, Albert J AU - Seo AJ AD - Department of Biochemistry, University of Washington, Seattle, WA 98195, USA. FAU - Brown, Jack AU - Brown J AD - Department of Biochemistry, University of Washington, Seattle, WA 98195, USA. FAU - Sprouse, Kaiti AU - Sprouse K AD - Department of Biochemistry, University of Washington, Seattle, WA 98195, USA. FAU - Logue, Jenni AU - Logue J AD - Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA 98195, USA. FAU - Clark, Erica AU - Clark E AD - Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA 98195, USA. FAU - Franko, Nicholas AU - Franko N AD - Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA 98195, USA. FAU - Chu, Helen AU - Chu H AD - Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA 98195, USA. FAU - Veesler, David AU - Veesler D AD - Department of Biochemistry, University of Washington, Seattle, WA 98195, USA; Howard Hughes Medical Institute, University of Washington, Seattle, WA 98195, USA. Electronic address: dveesler@uw.edu. LA - eng GR - S10 OD023476/OD/NIH HHS/United States GR - P01 AI167966/AI/NIAID NIH HHS/United States GR - HHMI/Howard Hughes Medical Institute/United States GR - 75N93022C00036/AI/NIAID NIH HHS/United States GR - WT_/Wellcome Trust/United Kingdom GR - DP1 AI158186/AI/NIAID NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20240314 PL - United States TA - Immunity JT - Immunity JID - 9432918 RN - 0 (COVID-19 Vaccines) RN - 0 (Antibodies, Neutralizing) RN - 0 (RNA, Messenger) RN - 0 (Antibodies, Viral) SB - IM UOF - bioRxiv. 2023 Nov 30:2023.11.28.569129. doi: 10.1101/2023.11.28.569129. PMID: 38076876 MH - Humans MH - *COVID-19 Vaccines MH - *COVID-19/prevention & control MH - SARS-CoV-2 MH - Antibodies, Neutralizing MH - RNA, Messenger/genetics MH - Vaccination MH - Antibodies, Viral PMC - PMC12360627 MID - NIHMS2101333 OTO - NOTNLM OT - COVID-19 mRNA vaccines OT - SARS-CoV-2 OT - SARS-CoV-2 variants OT - coronaviruses OT - depletion assays OT - immune imprinting OT - memory B cells OT - neutralizing antibodies OT - spike glycoprotein COIS- Declaration of interests H.C. reports consulting with Ellume, Pfizer, and the Bill and Melinda Gates Foundation. She has served on advisory boards for Vir, Merck, and Abbvie. She has conducted continuing medical education teaching with Medscape, Vindico, and Clinical Care Options. She has received research funding from Gates Ventures and support and reagents from Ellume and Cepheid, all outside of the submitted work. D.V. is named as inventor on patents for coronavirus vaccines filed by the University of Washington. EDAT- 2024/03/16 05:42 MHDA- 2024/04/12 06:44 PMCR- 2025/08/18 CRDT- 2024/03/15 19:42 PHST- 2023/12/01 00:00 [received] PHST- 2024/01/25 00:00 [revised] PHST- 2024/02/20 00:00 [accepted] PHST- 2024/04/12 06:44 [medline] PHST- 2024/03/16 05:42 [pubmed] PHST- 2024/03/15 19:42 [entrez] PHST- 2025/08/18 00:00 [pmc-release] AID - S1074-7613(24)00092-X [pii] AID - 10.1016/j.immuni.2024.02.016 [doi] PST - ppublish SO - Immunity. 2024 Apr 9;57(4):904-911.e4. doi: 10.1016/j.immuni.2024.02.016. Epub 2024 Mar 14. PMID- 38489974 OWN - NLM STAT- MEDLINE DCOM- 20240410 LR - 20240410 IS - 1878-1705 (Electronic) IS - 1567-5769 (Linking) VI - 131 DP - 2024 Apr 20 TI - A prognostic model for SARS-CoV-2 breakthrough infection: Analyzing a prospective cellular immunity cohort. PG - 111829 LID - S1567-5769(24)00347-3 [pii] LID - 10.1016/j.intimp.2024.111829 [doi] AB - BACKGROUND: Following the COVID-19 pandemic, studies have identified several prevalent characteristics, especially related to lymphocyte subsets. However, limited research is available on the focus of this study, namely, the specific memory cell subsets among individuals who received COVID-19 vaccine boosters and subsequently experienced a SARS-CoV-2 breakthrough infection. METHODS: Flow cytometry (FCM) was employed to investigate the early and longitudinal pattern changes of cellular immunity in patients with SARS-CoV-2 breakthrough infections following COVID-19 vaccine boosters. XGBoost (a machine learning algorithm) was employed to analyze cellular immunity prior to SARS-CoV-2 breakthrough, aiming to establish a prognostic model for SARS-CoV-2 breakthrough infections. RESULTS: Following SARS-CoV-2 breakthrough infection, naive T cells and T(EMRA) subsets increased while the percentage of T(CM) and T(EM) cells decreased. Naive and non-switched memory B cells increased while switched and double-negative memory B cells decreased. The XGBoost model achieved an area under the curve (AUC) of 0.78, with an accuracy rate of 81.8 %, a sensitivity of 75 %, and specificity of 85.7 %. TNF-alpha, CD27(-)CD19(+)cells, and T(EMRA) subsets were identified as high predictors. An increase in TNF-alpha, cTfh, double-negative memory B cells, IL-6, IL-10, and IFN-gamma prior to SARS-CoV-2 infection was associated with enduring clinical symptoms; conversely, an increase in CD3(+) T cells, CD4(+) T cells, and IL-2 was associated with clinical with non-enduring clinical symptoms. CONCLUSION: SARS-CoV-2 breakthrough infection leads to disturbances in cellular immunity. Assessing cellular immunity prior to breakthrough infection serves as a valuable prognostic tool for SARS-CoV-2 infection, which facilitates clinical decision-making. CI - Copyright (c) 2024 Elsevier B.V. All rights reserved. FAU - Yang, Mei AU - Yang M AD - Department of Laboratory Medicine, Shengjing Hospital of China Medical University, Shenyang, Liaoning, People's Republic of China. FAU - Meng, Yuan AU - Meng Y AD - Department of Laboratory Medicine, Shengjing Hospital of China Medical University, Shenyang, Liaoning, People's Republic of China. FAU - Hao, Wudi AU - Hao W AD - Department of Laboratory Medicine, Shengjing Hospital of China Medical University, Shenyang, Liaoning, People's Republic of China. FAU - Zhang, Jin AU - Zhang J AD - Department of Laboratory Medicine, Shengjing Hospital of China Medical University, Shenyang, Liaoning, People's Republic of China. FAU - Liu, Jianhua AU - Liu J AD - Department of Laboratory Medicine, Shengjing Hospital of China Medical University, Shenyang, Liaoning, People's Republic of China. FAU - Wu, Lina AU - Wu L AD - Department of Laboratory Medicine, Shengjing Hospital of China Medical University, Shenyang, Liaoning, People's Republic of China. FAU - Lin, Baoxu AU - Lin B AD - Department of Laboratory Medicine, Shengjing Hospital of China Medical University, Shenyang, Liaoning, People's Republic of China. FAU - Liu, Yong AU - Liu Y AD - Department of Laboratory Medicine, Shengjing Hospital of China Medical University, Shenyang, Liaoning, People's Republic of China. FAU - Zhang, Yue AU - Zhang Y AD - Department of Laboratory Medicine, Shengjing Hospital of China Medical University, Shenyang, Liaoning, People's Republic of China. FAU - Yu, Xiaojun AU - Yu X AD - Department of Laboratory Medicine, Shengjing Hospital of China Medical University, Shenyang, Liaoning, People's Republic of China. FAU - Wang, Xiaoqian AU - Wang X AD - Department of Laboratory Medicine, Shengjing Hospital of China Medical University, Shenyang, Liaoning, People's Republic of China. FAU - Gong, Yu AU - Gong Y AD - Department of Laboratory Medicine, Shengjing Hospital of China Medical University, Shenyang, Liaoning, People's Republic of China. FAU - Ge, Lili AU - Ge L AD - Department of Laboratory Medicine, Shengjing Hospital of China Medical University, Shenyang, Liaoning, People's Republic of China. FAU - Fan, Yan AU - Fan Y AD - Department of Laboratory Medicine, Shengjing Hospital of China Medical University, Shenyang, Liaoning, People's Republic of China. FAU - Xie, Conghong AU - Xie C AD - Department of Laboratory Medicine, Shengjing Hospital of China Medical University, Shenyang, Liaoning, People's Republic of China. FAU - Xu, Yiyun AU - Xu Y AD - Department of Laboratory Medicine, Shengjing Hospital of China Medical University, Shenyang, Liaoning, People's Republic of China. FAU - Chang, Qing AU - Chang Q AD - Department of Clinical Epidemiology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, People's Republic of China. FAU - Zhang, Yixiao AU - Zhang Y AD - Department of Urology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, People's Republic of China. Electronic address: zhangyx@sj-hospital.org. FAU - Qin, Xiaosong AU - Qin X AD - Department of Laboratory Medicine, Shengjing Hospital of China Medical University, Shenyang, Liaoning, People's Republic of China. Electronic address: qinxs@sj-hospital.org. LA - eng PT - Journal Article DEP - 20240314 PL - Netherlands TA - Int Immunopharmacol JT - International immunopharmacology JID - 100965259 RN - 0 (COVID-19 Vaccines) RN - 0 (Tumor Necrosis Factor-alpha) RN - 0 (Antibodies, Viral) RN - COVID-19 breakthrough infections SB - IM MH - Humans MH - *COVID-19 Vaccines MH - *COVID-19 MH - SARS-CoV-2 MH - Breakthrough Infections MH - Pandemics MH - Prognosis MH - Prospective Studies MH - Tumor Necrosis Factor-alpha MH - Immunity, Cellular MH - Antibodies, Viral OTO - NOTNLM OT - Cellular immunity OT - Machine learning OT - Memory cells OT - Model OT - SARS-CoV-2 COIS- Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2024/03/16 05:42 MHDA- 2024/04/10 06:43 CRDT- 2024/03/15 19:07 PHST- 2023/12/08 00:00 [received] PHST- 2024/03/03 00:00 [revised] PHST- 2024/03/06 00:00 [accepted] PHST- 2024/04/10 06:43 [medline] PHST- 2024/03/16 05:42 [pubmed] PHST- 2024/03/15 19:07 [entrez] AID - S1567-5769(24)00347-3 [pii] AID - 10.1016/j.intimp.2024.111829 [doi] PST - ppublish SO - Int Immunopharmacol. 2024 Apr 20;131:111829. doi: 10.1016/j.intimp.2024.111829. Epub 2024 Mar 14. PMID- 38469293 OWN - NLM STAT- MEDLINE DCOM- 20240313 LR - 20241031 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 15 DP - 2024 TI - The immunobiology of SARS-CoV-2 infection and vaccine responses: potential influences of cross-reactive memory responses and aging on efficacy and off-target effects. PG - 1345499 LID - 10.3389/fimmu.2024.1345499 [doi] LID - 1345499 AB - Immune responses to both SARS-CoV-2 infection and its associated vaccines have been highly variable within the general population. The increasing evidence of long-lasting symptoms after resolution of infection, called post-acute sequelae of COVID-19 (PASC) or "Long COVID," suggests that immune-mediated mechanisms are at play. Closely related endemic common human coronaviruses (hCoV) can induce pre-existing and potentially cross-reactive immunity, which can then affect primary SARS-CoV-2 infection, as well as vaccination responses. The influence of pre-existing immunity from these hCoVs, as well as responses generated from original CoV2 strains or vaccines on the development of new high-affinity responses to CoV2 antigenic viral variants, needs to be better understood given the need for continuous vaccine adaptation and application in the population. Due in part to thymic involution, normal aging is associated with reduced naive T cell compartments and impaired primary antigen responsiveness, resulting in a reliance on the pre-existing cross-reactive memory cell pool which may be of lower affinity, restricted in diversity, or of shorter duration. These effects can also be mediated by the presence of down-regulatory anti-idiotype responses which also increase in aging. Given the tremendous heterogeneity of clinical data, utilization of preclinical models offers the greatest ability to assess immune responses under a controlled setting. These models should now involve prior antigen/viral exposure combined with incorporation of modifying factors such as age on immune responses and effects. This will also allow for mechanistic dissection and understanding of the different immune pathways involved in both SARS-CoV-2 pathogen and potential vaccine responses over time and how pre-existing memory responses, including potential anti-idiotype responses, can affect efficacy as well as potential off-target effects in different tissues as well as modeling PASC. CI - Copyright (c) 2024 Collins, Longo and Murphy. FAU - Collins, Craig P AU - Collins CP AD - Graduate Program in Immunology, University of California (UC) Davis, Davis, CA, United States. FAU - Longo, Dan L AU - Longo DL AD - Harvard Medical School, Brigham and Women's Hospital, Boston, MA, United States. FAU - Murphy, William J AU - Murphy WJ AD - Departments of Dermatology and Internal Medicine (Hematology/Oncology), University of California (UC) Davis School of Medicine, Sacramento, CA, United States. LA - eng PT - Journal Article PT - Review DEP - 20240226 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 RN - 0 (Vaccines) RN - 0 (Immunoglobulin Idiotypes) SB - IM MH - Humans MH - *COVID-19 MH - Post-Acute COVID-19 Syndrome MH - SARS-CoV-2 MH - *Vaccines MH - Aging MH - Immunoglobulin Idiotypes PMC - PMC10925677 OTO - NOTNLM OT - SARS-CoV-2 OT - aging OT - anti-idiotype antibodies OT - immunology OT - vaccination COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2024/03/12 06:43 MHDA- 2024/03/13 06:47 PMCR- 2024/01/01 CRDT- 2024/03/12 03:54 PHST- 2023/11/27 00:00 [received] PHST- 2024/02/12 00:00 [accepted] PHST- 2024/03/13 06:47 [medline] PHST- 2024/03/12 06:43 [pubmed] PHST- 2024/03/12 03:54 [entrez] PHST- 2024/01/01 00:00 [pmc-release] AID - 10.3389/fimmu.2024.1345499 [doi] PST - epublish SO - Front Immunol. 2024 Feb 26;15:1345499. doi: 10.3389/fimmu.2024.1345499. eCollection 2024. PMID- 38458195 OWN - NLM STAT- MEDLINE DCOM- 20240401 LR - 20250115 IS - 2211-1247 (Electronic) VI - 43 IP - 3 DP - 2024 Mar 26 TI - CD8(+) T cell memory induced by successive SARS-CoV-2 mRNA vaccinations is characterized by shifts in clonal dominance. PG - 113887 LID - S2211-1247(24)00215-8 [pii] LID - 10.1016/j.celrep.2024.113887 [doi] AB - mRNA vaccines against the spike glycoprotein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) elicit strong T cell responses. However, a clonal-resolution analysis of T cell responses to mRNA vaccination has not been performed. Here, we temporally track the CD8(+) T cell repertoire in individuals who received three shots of the BNT162b2 mRNA vaccine through longitudinal T cell receptor sequencing with peptide-human leukocyte antigen (HLA) tetramer analysis. We demonstrate a shift in T cell responses between the clonotypes with different kinetics: from early responders that expand rapidly after the first shot to main responders that greatly expand after the second shot. Although the main responders re-expand after the third shot, their clonal diversity is skewed, and newly elicited third responders partially replace them. Furthermore, this shift in clonal dominance occurs not only between, but also within, clonotypes specific for spike epitopes. Our study will be a valuable resource for understanding vaccine-induced T cell responses in general. CI - Copyright (c) 2024 The Author(s). Published by Elsevier Inc. All rights reserved. FAU - Aoki, Hiroyasu AU - Aoki H AD - Division of Molecular Regulation of Inflammatory and Immune Diseases, Research Institute for Biomedical Sciences, Tokyo University of Science, Noda City, Chiba 2780022, Japan; Department of Preventive Medicine, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo 1130033, Japan. FAU - Kitabatake, Masahiro AU - Kitabatake M AD - Department of Immunology, Nara Medical University, Kashihara City, Nara 6348521, Japan. FAU - Abe, Haruka AU - Abe H AD - Division of Molecular Regulation of Inflammatory and Immune Diseases, Research Institute for Biomedical Sciences, Tokyo University of Science, Noda City, Chiba 2780022, Japan. FAU - Xu, Peng AU - Xu P AD - Division of Molecular Regulation of Inflammatory and Immune Diseases, Research Institute for Biomedical Sciences, Tokyo University of Science, Noda City, Chiba 2780022, Japan. FAU - Tsunoda, Mikiya AU - Tsunoda M AD - Division of Molecular Regulation of Inflammatory and Immune Diseases, Research Institute for Biomedical Sciences, Tokyo University of Science, Noda City, Chiba 2780022, Japan. FAU - Shichino, Shigeyuki AU - Shichino S AD - Division of Molecular Regulation of Inflammatory and Immune Diseases, Research Institute for Biomedical Sciences, Tokyo University of Science, Noda City, Chiba 2780022, Japan. FAU - Hara, Atsushi AU - Hara A AD - Department of Immunology, Nara Medical University, Kashihara City, Nara 6348521, Japan. FAU - Ouji-Sageshima, Noriko AU - Ouji-Sageshima N AD - Department of Immunology, Nara Medical University, Kashihara City, Nara 6348521, Japan. FAU - Motozono, Chihiro AU - Motozono C AD - Division of Infection and Immunity, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto City, Kumamoto 8600811, Japan. FAU - Ito, Toshihiro AU - Ito T AD - Department of Immunology, Nara Medical University, Kashihara City, Nara 6348521, Japan. FAU - Matsushima, Kouji AU - Matsushima K AD - Division of Molecular Regulation of Inflammatory and Immune Diseases, Research Institute for Biomedical Sciences, Tokyo University of Science, Noda City, Chiba 2780022, Japan. FAU - Ueha, Satoshi AU - Ueha S AD - Division of Molecular Regulation of Inflammatory and Immune Diseases, Research Institute for Biomedical Sciences, Tokyo University of Science, Noda City, Chiba 2780022, Japan. Electronic address: ueha@rs.tus.ac.jp. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20240307 PL - United States TA - Cell Rep JT - Cell reports JID - 101573691 RN - 0 (BNT162 Vaccine) SB - IM MH - Humans MH - *SARS-CoV-2 MH - BNT162 Vaccine MH - *COVID-19/prevention & control MH - CD8-Positive T-Lymphocytes MH - Vaccination OTO - NOTNLM OT - CD8(+) T cells OT - CP: Immunology OT - CP: Microbiology OT - SARS-CoV-2 OT - TCR motif OT - TCR repertoire OT - longitudinal repertoire analysis OT - mRNA vaccination OT - pHLA tetramer OT - pre-existing memory OT - single-cell TCRseq OT - spike epitopes COIS- Declaration of interests H. Aoki reports stock for ImmunoGeneTeqs, Inc. S.S. reports an advisory role for ImmunoGeneTeqs, Inc. and stock for ImmunoGeneTeqs, Inc. T.I. reports research funding from Rohto Pharmaceutical Co., Ltd., and Biometrics Sympathies Inc. K.M. reports a consulting or advisory role for Kyowa-Hakko Kirin and ImmunoGeneTeqs, Inc; research funding from Kyowa-Hakko Kirin and Ono; and stock for ImmunoGeneTeqs, Inc. and IDAC Theranostics, Inc. S.U. reports an advisory role for ImmunoGeneTeqs, Inc. and stock for ImmunoGeneTeqs, Inc. and IDAC Theranostics, Inc. EDAT- 2024/03/09 10:42 MHDA- 2024/04/01 06:42 CRDT- 2024/03/08 18:42 PHST- 2023/07/20 00:00 [received] PHST- 2023/12/27 00:00 [revised] PHST- 2024/02/14 00:00 [accepted] PHST- 2024/04/01 06:42 [medline] PHST- 2024/03/09 10:42 [pubmed] PHST- 2024/03/08 18:42 [entrez] AID - S2211-1247(24)00215-8 [pii] AID - 10.1016/j.celrep.2024.113887 [doi] PST - ppublish SO - Cell Rep. 2024 Mar 26;43(3):113887. doi: 10.1016/j.celrep.2024.113887. Epub 2024 Mar 7. PMID- 38442743 OWN - NLM STAT- MEDLINE DCOM- 20240425 LR - 20240920 IS - 1839-3551 (Electronic) IS - 1446-1242 (Linking) VI - 33 IP - 1 DP - 2024 Mar TI - Leaky bodies, vaccination and three layers of memory: bio-immune, social-collective and lived experience. PG - 73-88 LID - 10.1080/14461242.2024.2320223 [doi] AB - This paper focuses on the omnipresent yet analytically almost invisible role of memory and bodily experiences in childhood vaccination. Previous scholarship on the sociocultural aspects of vaccination has primarily focused on the individual and sociodemographic factors underpinning vaccine hesitancy, the role of healthcare professionals and the politicisation or mediatisation of vaccination. Social practices considering vaccination were primarily explored as a matter of the present. Only little consideration was given to the past, individual biographies and sociohistorical temporalities. To complement this body of work, we focus on cognitively-based, embodied and emotionally-experienced memory related to vaccination. Based on a qualitative study of childhood vaccination conducted in Czechia between 2017 and 2019 consisting of ethnographic observations, in-depth interviews and a document review, we identified three interconnected forms of vaccination memory: bio-immune, social-collective and lived experience. Bio-immune memory refers to the body's physical memory, gained to protect itself from diseases. Social-collective memory focuses on socially shared narratives about diseases and vaccination in the past. The memory of lived experience refers to feelings, embodied knowledge and pain. Our findings may inspire further analysis of childhood vaccination in other geographical contexts and amidst the reconfiguration of attitudes and newly established memories following the COVID-19 pandemic. FAU - Divisek, Tereza AU - Divisek T AUID- ORCID: 0000-0002-3501-6964 AD - Institute of Sociological Studies, Faculty of Social Sciences, Charles University, Prague. FAU - Numerato, Dino AU - Numerato D AUID- ORCID: 0000-0002-4821-6471 AD - Institute of Sociological Studies, Faculty of Social Sciences, Charles University, Prague. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20240305 PL - United States TA - Health Sociol Rev JT - Health sociology review : the journal of the Health Section of the Australian Sociological Association JID - 101156268 RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - *Vaccination/psychology MH - *COVID-19/prevention & control/psychology MH - Vaccination Hesitancy/psychology/statistics & numerical data MH - Qualitative Research MH - Memory MH - Czech Republic MH - Child MH - Female MH - SARS-CoV-2 MH - Male MH - COVID-19 Vaccines/administration & dosage OTO - NOTNLM OT - Vaccination OT - embodied memory OT - leakiness OT - leaky body OT - memory EDAT- 2024/03/06 00:42 MHDA- 2024/04/25 06:48 CRDT- 2024/03/05 19:03 PHST- 2024/04/25 06:48 [medline] PHST- 2024/03/06 00:42 [pubmed] PHST- 2024/03/05 19:03 [entrez] AID - 10.1080/14461242.2024.2320223 [doi] PST - ppublish SO - Health Sociol Rev. 2024 Mar;33(1):73-88. doi: 10.1080/14461242.2024.2320223. Epub 2024 Mar 5. PMID- 38425890 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240302 IS - 2353-5571 (Electronic) IS - 2353-4184 (Print) IS - 2353-5571 (Linking) VI - 12 IP - 1 DP - 2024 TI - Priming congruence and COVID-19 vaccination intention: a mediation analysis. PG - 79-86 LID - 10.5114/hpr/157228 [doi] AB - BACKGROUND: This study took place at the height of the fifth wave of COVID-19 in France, coinciding with stigmatizing communication toward the unvaccinated. We hypothesized that adherence to this communication would facilitate or inhibit the effects of priming on vaccination intention, depending on whether the priming included a dimension of connection to others. PARTICIPANTS AND PROCEDURE: In a convenience online French sample (N = 1800, M age = 26.30), vaccination intention was asked after love priming, no love/prejudice priming, materialism priming, or a control condition. Participants also reported their adherence to restrictive measures, i.e., media control, vaccination pass, and mandatory vaccination. RESULTS: Vaccination intention was higher in the no love/prejudice and materialism conditions than in the love and control conditions. Adherence to restrictive measures mediated the effect of prejudice or materialism priming on intention to get vaccinated. CONCLUSIONS: Implications of these results are discussed in light of the socially situated cognition perspective and the congruence of (a) a societal context of communication toward the vaccine and the unvaccinated, (b) the participant's degree of adherence to that communication, (c) the theme of priming, whether or not related to feeling connected to others. Implications of materialism priming are discussed, and the effect of commitment on intention to get vaccinated. CI - Copyright (c) Institute of Psychology, University of Gdansk. FAU - Lamy, Lubomir AU - Lamy L AUID- ORCID: 0000-0001-6114-2641 AD - Paris Cite University, Paris, France. FAU - Fischer-Lokou, Jacques AU - Fischer-Lokou J AUID- ORCID: 0000-0001-8601-6772 AD - Southern Brittany University, Rennes, France. FAU - Gueguen, Nicolas AU - Gueguen N AUID- ORCID: 0000-0002-8963-1751 AD - Southern Brittany University, Rennes, France. FAU - Guegan, Jerome AU - Guegan J AUID- ORCID: 0000-0002-6275-7258 AD - Paris Cite University, Paris, France. LA - eng PT - Journal Article DEP - 20230321 PL - Poland TA - Health Psychol Rep JT - Health psychology report JID - 101677269 PMC - PMC10900976 OTO - NOTNLM OT - love OT - materialism OT - prejudice OT - socially situated cognition EDAT- 2024/03/01 06:44 MHDA- 2024/03/01 06:45 PMCR- 2023/03/21 CRDT- 2024/03/01 03:55 PHST- 2022/07/23 00:00 [received] PHST- 2022/09/19 00:00 [revised] PHST- 2022/12/07 00:00 [accepted] PHST- 2024/03/01 06:45 [medline] PHST- 2024/03/01 06:44 [pubmed] PHST- 2024/03/01 03:55 [entrez] PHST- 2023/03/21 00:00 [pmc-release] AID - 157228 [pii] AID - 10.5114/hpr/157228 [doi] PST - epublish SO - Health Psychol Rep. 2023 Mar 21;12(1):79-86. doi: 10.5114/hpr/157228. eCollection 2024. PMID- 38420128 OWN - NLM STAT- MEDLINE DCOM- 20240301 LR - 20240412 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 15 DP - 2024 TI - SARS-CoV-2 spike-reactive naive B cells and pre-existing memory B cells contribute to antibody responses in unexposed individuals after vaccination. PG - 1355949 LID - 10.3389/fimmu.2024.1355949 [doi] LID - 1355949 AB - INTRODUCTION: Since December 2019, the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing coronavirus disease 2019 (COVID-19) has presented considerable public health challenges. Multiple vaccines have been used to induce neutralizing antibodies (nAbs) and memory B-cell responses against the viral spike (S) glycoprotein, and many essential epitopes have been defined. Previous reports have identified severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike-reactive naive B cells and preexisting memory B cells in unexposed individuals. However, the role of these spike-reactive B cells in vaccine-induced immunity remains unknown. METHODS: To elucidate the characteristics of preexisting SARS-CoV-2 S-reactive B cells as well as their maturation after antigen encounter, we assessed the relationship of spike-reactive B cells before and after vaccination in unexposed human individuals. We further characterized the sequence identity, targeting domain, broad-spectrum binding activity and neutralizing activity of these SARS-CoV-2 S-reactive B cells by isolating monoclonal antibodies (mAbs) from these B cells. RESULTS: The frequencies of both spike-reactive naive B cells and preexisting memory B cells before vaccination correlated with the frequencies of spike-reactive memory B cells after vaccination. Isolated mAbs from spike-reactive naive B cells before vaccination had fewer somatic hypermutations (SHMs) than mAbs isolated from spike-reactive memory B cells before and after vaccination, but bound SARS-CoV-2 spike in vitro. Intriguingly, these germline-like mAbs possessed broad binding profiles for SARS-CoV-2 and its variants, although with low or no neutralizing capacity. According to tracking of the evolution of IGHV4-4/IGKV3-20 lineage antibodies from a single donor, the lineage underwent SHMs and developed increased binding activity after vaccination. DISCUSSION: Our findings suggest that spike-reactive naive B cells can be expanded and matured by vaccination and cocontribute to vaccine-elicited antibody responses with preexisting memory B cells. Selectively and precisely targeting spike-reactive B cells by rational antigen design may provide a novel strategy for next-generation SARS-CoV-2 vaccine development. CI - Copyright (c) 2024 Teng, Hu, Wang, Tang, Wu, Zheng, Lu, Pan, Liu, Xie, Wu, Li, Liu and Qu. FAU - Teng, Shishan AU - Teng S AD - School of Public Health & School of Basic Medicine Sciences, Hengyang Medical School & Ministry of Education Key Laboratory of Rare Pediatric Diseases, University of South China, Hengyang, China. AD - Translational Medicine Institute, The First People's Hospital of Chenzhou, Hengyang Medical School, University of South China, Chenzhou, China. FAU - Hu, Yabin AU - Hu Y AD - School of Public Health & School of Basic Medicine Sciences, Hengyang Medical School & Ministry of Education Key Laboratory of Rare Pediatric Diseases, University of South China, Hengyang, China. AD - Translational Medicine Institute, The First People's Hospital of Chenzhou, Hengyang Medical School, University of South China, Chenzhou, China. FAU - Wang, You AU - Wang Y AD - School of Public Health & School of Basic Medicine Sciences, Hengyang Medical School & Ministry of Education Key Laboratory of Rare Pediatric Diseases, University of South China, Hengyang, China. AD - Translational Medicine Institute, The First People's Hospital of Chenzhou, Hengyang Medical School, University of South China, Chenzhou, China. FAU - Tang, Yinggen AU - Tang Y AD - School of Public Health & School of Basic Medicine Sciences, Hengyang Medical School & Ministry of Education Key Laboratory of Rare Pediatric Diseases, University of South China, Hengyang, China. AD - Translational Medicine Institute, The First People's Hospital of Chenzhou, Hengyang Medical School, University of South China, Chenzhou, China. FAU - Wu, Qian AU - Wu Q AD - Institute of Human Virology, Zhongshan School of Medicine, and Key Laboratory of Tropical Disease Control of the Ministry of Education, Sun Yat-sen University, Guangzhou, China. FAU - Zheng, Xingyu AU - Zheng X AD - School of Public Health & School of Basic Medicine Sciences, Hengyang Medical School & Ministry of Education Key Laboratory of Rare Pediatric Diseases, University of South China, Hengyang, China. AD - Translational Medicine Institute, The First People's Hospital of Chenzhou, Hengyang Medical School, University of South China, Chenzhou, China. FAU - Lu, Rui AU - Lu R AD - School of Public Health & School of Basic Medicine Sciences, Hengyang Medical School & Ministry of Education Key Laboratory of Rare Pediatric Diseases, University of South China, Hengyang, China. AD - Translational Medicine Institute, The First People's Hospital of Chenzhou, Hengyang Medical School, University of South China, Chenzhou, China. FAU - Pan, Dong AU - Pan D AD - School of Public Health & School of Basic Medicine Sciences, Hengyang Medical School & Ministry of Education Key Laboratory of Rare Pediatric Diseases, University of South China, Hengyang, China. AD - Translational Medicine Institute, The First People's Hospital of Chenzhou, Hengyang Medical School, University of South China, Chenzhou, China. FAU - Liu, Fen AU - Liu F AD - School of Public Health & School of Basic Medicine Sciences, Hengyang Medical School & Ministry of Education Key Laboratory of Rare Pediatric Diseases, University of South China, Hengyang, China. AD - Translational Medicine Institute, The First People's Hospital of Chenzhou, Hengyang Medical School, University of South China, Chenzhou, China. FAU - Xie, Tianyi AU - Xie T AD - School of Public Health & School of Basic Medicine Sciences, Hengyang Medical School & Ministry of Education Key Laboratory of Rare Pediatric Diseases, University of South China, Hengyang, China. AD - Translational Medicine Institute, The First People's Hospital of Chenzhou, Hengyang Medical School, University of South China, Chenzhou, China. FAU - Wu, Chanfeng AU - Wu C AD - School of Public Health & School of Basic Medicine Sciences, Hengyang Medical School & Ministry of Education Key Laboratory of Rare Pediatric Diseases, University of South China, Hengyang, China. AD - Translational Medicine Institute, The First People's Hospital of Chenzhou, Hengyang Medical School, University of South China, Chenzhou, China. FAU - Li, Yi-Ping AU - Li YP AD - Institute of Human Virology, Zhongshan School of Medicine, and Key Laboratory of Tropical Disease Control of the Ministry of Education, Sun Yat-sen University, Guangzhou, China. FAU - Liu, Wenpei AU - Liu W AD - School of Public Health & School of Basic Medicine Sciences, Hengyang Medical School & Ministry of Education Key Laboratory of Rare Pediatric Diseases, University of South China, Hengyang, China. FAU - Qu, Xiaowang AU - Qu X AD - School of Public Health & School of Basic Medicine Sciences, Hengyang Medical School & Ministry of Education Key Laboratory of Rare Pediatric Diseases, University of South China, Hengyang, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20240214 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 RN - 0 (COVID-19 Vaccines) RN - 0 (Antibodies, Monoclonal) SB - IM MH - Humans MH - *Memory B Cells MH - SARS-CoV-2 MH - Antibody Formation MH - COVID-19 Vaccines MH - *COVID-19/prevention & control MH - Vaccination MH - Antibodies, Monoclonal PMC - PMC10899457 OTO - NOTNLM OT - SARS-CoV-2 OT - monoclonal antibody OT - naive B cell OT - preexisting memory B cell OT - vaccination COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2024/02/29 06:43 MHDA- 2024/03/01 06:44 PMCR- 2024/01/01 CRDT- 2024/02/29 04:08 PHST- 2023/12/14 00:00 [received] PHST- 2024/01/30 00:00 [accepted] PHST- 2024/03/01 06:44 [medline] PHST- 2024/02/29 06:43 [pubmed] PHST- 2024/02/29 04:08 [entrez] PHST- 2024/01/01 00:00 [pmc-release] AID - 10.3389/fimmu.2024.1355949 [doi] PST - epublish SO - Front Immunol. 2024 Feb 14;15:1355949. doi: 10.3389/fimmu.2024.1355949. eCollection 2024. PMID- 38417765 OWN - NLM STAT- MEDLINE DCOM- 20240318 LR - 20240410 IS - 1521-7035 (Electronic) IS - 1521-6616 (Linking) VI - 261 DP - 2024 Apr TI - Tracking the immune response profiles elicited by the BNT162b2 vaccine in COVID-19 unexperienced and experienced individuals. PG - 110164 LID - S1521-6616(24)00055-X [pii] LID - 10.1016/j.clim.2024.110164 [doi] AB - Multiple vaccines have been approved to control COVID-19 pandemic, with Pfizer/BioNTech (BNT162b2) being widely used. We conducted a longitudinal analysis of the immune response elicited after three doses of the BNT162b2 vaccine in individuals who have previously experienced SARS-CoV-2 infection and in unexperienced ones. We conducted immunological analyses and single-cell transcriptomics of circulating T and B lymphocytes, combined to CITE-seq or LIBRA-seq, and VDJ-seq. We found that antibody levels against SARS-CoV-2 Spike, NTD and RBD from wild-type, delta and omicron VoCs show comparable dynamics in both vaccination groups, with a peak after the second dose, a decline after six months and a restoration after the booster dose. The antibody neutralization activity was maintained, with lower titers against the omicron variant. Spike-specific memory B cell response was sustained over the vaccination schedule. Clonal analysis revealed that Spike-specific B cells were polyclonal, with a partial clone conservation from natural infection to vaccination. Spike-specific T cell responses were oriented towards effector and effector memory phenotypes, with similar trends in unexperienced and experienced individuals. The CD8 T cell compartment showed a higher clonal expansion and persistence than CD4 T cells. The first two vaccinations doses tended to induce new clones rather than promoting expansion of pre-existing clones. However, we identified a fraction of Spike-specific CD8 T cell clones persisting from natural infection that were boosted by vaccination and clones specifically induced by vaccination. Collectively, our observations revealed a moderate effect of the second dose in enhancing the immune responses elicited after the first vaccination. Differently, we found that a third dose was necessary to restore comparable levels of neutralizing antibodies and Spike-specific T and B cell responses in individuals who experienced a natural SARS-CoV-2 infection. CI - Copyright (c) 2024. Published by Elsevier Inc. FAU - Galeota, Eugenia AU - Galeota E AD - INGM, Istituto Nazionale Genetica Molecolare "Romeo ed Enrica Invernizzi", Milan, Italy. FAU - Bevilacqua, Valeria AU - Bevilacqua V AD - INGM, Istituto Nazionale Genetica Molecolare "Romeo ed Enrica Invernizzi", Milan, Italy. FAU - Gobbini, Andrea AU - Gobbini A AD - INGM, Istituto Nazionale Genetica Molecolare "Romeo ed Enrica Invernizzi", Milan, Italy. FAU - Gruarin, Paola AU - Gruarin P AD - INGM, Istituto Nazionale Genetica Molecolare "Romeo ed Enrica Invernizzi", Milan, Italy. FAU - Bombaci, Mauro AU - Bombaci M AD - INGM, Istituto Nazionale Genetica Molecolare "Romeo ed Enrica Invernizzi", Milan, Italy. FAU - Pesce, Elisa AU - Pesce E AD - INGM, Istituto Nazionale Genetica Molecolare "Romeo ed Enrica Invernizzi", Milan, Italy; Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy. FAU - Favalli, Andrea AU - Favalli A AD - INGM, Istituto Nazionale Genetica Molecolare "Romeo ed Enrica Invernizzi", Milan, Italy; Ph.D. Program in Translational and Molecular Medicine, Dottorato in Medicina Molecolare e Traslazionale (DIMET), University of Milan-Bicocca, Monza, Italy. FAU - Lombardi, Andrea AU - Lombardi A AD - Infectious Diseases Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan 20122, Italy; Centre for Multidisciplinary Research in Health Science (MACH), University of Milano, Milan 20122, Italy; Department of Pathophysiology and Transplantation, University of Milan, Milan 20122, Italy. FAU - Vincenti, Francesca AU - Vincenti F AD - INGM, Istituto Nazionale Genetica Molecolare "Romeo ed Enrica Invernizzi", Milan, Italy. FAU - Ongaro, Jessica AU - Ongaro J AD - INGM, Istituto Nazionale Genetica Molecolare "Romeo ed Enrica Invernizzi", Milan, Italy. FAU - Fabbris, Tanya AU - Fabbris T AD - INGM, Istituto Nazionale Genetica Molecolare "Romeo ed Enrica Invernizzi", Milan, Italy. FAU - Curti, Serena AU - Curti S AD - INGM, Istituto Nazionale Genetica Molecolare "Romeo ed Enrica Invernizzi", Milan, Italy. FAU - Martinovic, Martina AU - Martinovic M AD - INGM, Istituto Nazionale Genetica Molecolare "Romeo ed Enrica Invernizzi", Milan, Italy. FAU - Toccafondi, Mirco AU - Toccafondi M AD - INGM, Istituto Nazionale Genetica Molecolare "Romeo ed Enrica Invernizzi", Milan, Italy. FAU - Lorenzo, Mariangela AU - Lorenzo M AD - INGM, Istituto Nazionale Genetica Molecolare "Romeo ed Enrica Invernizzi", Milan, Italy. FAU - Critelli, Angelica AU - Critelli A AD - INGM, Istituto Nazionale Genetica Molecolare "Romeo ed Enrica Invernizzi", Milan, Italy. FAU - Clemente, Francesca AU - Clemente F AD - INGM, Istituto Nazionale Genetica Molecolare "Romeo ed Enrica Invernizzi", Milan, Italy. FAU - Crosti, Mariacristina AU - Crosti M AD - INGM, Istituto Nazionale Genetica Molecolare "Romeo ed Enrica Invernizzi", Milan, Italy. FAU - Sarnicola, Maria Lucia AU - Sarnicola ML AD - INGM, Istituto Nazionale Genetica Molecolare "Romeo ed Enrica Invernizzi", Milan, Italy. FAU - Martinelli, Manuele AU - Martinelli M AD - CheckmAb Srl, Milan, Italy. FAU - La Sala, Lucia AU - La Sala L AD - IRCCS MultiMedica, Milan 20138, Italy. FAU - Espadas, Alejandro AU - Espadas A AD - Laboratory of Transplant Immunology - North Italy Transplant program (NITp) - Foundation IRCCS Ca Granda Ospedale Maggiore Policlinico of Milan, Italy. FAU - Donnici, Lorena AU - Donnici L AD - INGM, Istituto Nazionale Genetica Molecolare "Romeo ed Enrica Invernizzi", Milan, Italy. FAU - Borghi, Maria Orietta AU - Borghi MO AD - Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy; IRCCS Istituto Auxologico Italiano, Immunorheumatology Research Laboratory, Milan, Italy. FAU - De Feo, Tullia AU - De Feo T AD - Laboratory of Transplant Immunology - North Italy Transplant program (NITp) - Foundation IRCCS Ca Granda Ospedale Maggiore Policlinico of Milan, Italy. FAU - De Francesco, Raffaele AU - De Francesco R AD - INGM, Istituto Nazionale Genetica Molecolare "Romeo ed Enrica Invernizzi", Milan, Italy; Department of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy. FAU - Prati, Daniele AU - Prati D AD - Department of Transfusion Medicine and Hematology, Foundation IRCCS Ca Granda Ospedale Maggiore Policlinico of Milan, Italy. FAU - Meroni, Pier Luigi AU - Meroni PL AD - IRCCS Istituto Auxologico Italiano, Immunorheumatology Research Laboratory, Milan, Italy. FAU - Notarbartolo, Samuele AU - Notarbartolo S AD - INGM, Istituto Nazionale Genetica Molecolare "Romeo ed Enrica Invernizzi", Milan, Italy; Infectious Diseases Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan 20122, Italy. FAU - Geginat, Jens AU - Geginat J AD - INGM, Istituto Nazionale Genetica Molecolare "Romeo ed Enrica Invernizzi", Milan, Italy; Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy. FAU - Gori, Andrea AU - Gori A AD - Centre for Multidisciplinary Research in Health Science (MACH), University of Milano, Milan 20122, Italy; Infectious Diseases Unit, Ospedale "Luigi Sacco", Milan, Italy. FAU - Bandera, Alessandra AU - Bandera A AD - Infectious Diseases Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan 20122, Italy; Centre for Multidisciplinary Research in Health Science (MACH), University of Milano, Milan 20122, Italy; Department of Pathophysiology and Transplantation, University of Milan, Milan 20122, Italy. FAU - Abrignani, Sergio AU - Abrignani S AD - INGM, Istituto Nazionale Genetica Molecolare "Romeo ed Enrica Invernizzi", Milan, Italy; Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy. FAU - Grifantini, Renata AU - Grifantini R AD - INGM, Istituto Nazionale Genetica Molecolare "Romeo ed Enrica Invernizzi", Milan, Italy; CheckmAb Srl, Milan, Italy. Electronic address: grifantini@ingm.org. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20240228 PL - United States TA - Clin Immunol JT - Clinical immunology (Orlando, Fla.) JID - 100883537 RN - 0 (BNT162 Vaccine) RN - 0 (Vaccines) RN - 0 (Antibodies, Neutralizing) RN - 0 (Antibodies, Viral) RN - SARS-CoV-2 variants SB - IM MH - Humans MH - *COVID-19/prevention & control MH - BNT162 Vaccine MH - SARS-CoV-2 MH - Pandemics MH - *Vaccines MH - Vaccination MH - Antibodies, Neutralizing MH - Antibodies, Viral OTO - NOTNLM OT - SARS-CoV-2 vaccination OT - Single-cell multimodal longitudinal analysis OT - T and B cell memory to SARS-CoV-2 infection and vaccination COIS- Declaration of competing interest Author Renata Grifantini is currently employed by CheckmAb Srl. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2024/02/29 00:43 MHDA- 2024/03/18 06:43 CRDT- 2024/02/28 19:19 PHST- 2023/10/02 00:00 [received] PHST- 2024/02/13 00:00 [revised] PHST- 2024/02/23 00:00 [accepted] PHST- 2024/03/18 06:43 [medline] PHST- 2024/02/29 00:43 [pubmed] PHST- 2024/02/28 19:19 [entrez] AID - S1521-6616(24)00055-X [pii] AID - 10.1016/j.clim.2024.110164 [doi] PST - ppublish SO - Clin Immunol. 2024 Apr;261:110164. doi: 10.1016/j.clim.2024.110164. Epub 2024 Feb 28. PMID- 38415282 OWN - NLM STAT- MEDLINE DCOM- 20240508 LR - 20260626 IS - 1468-1331 (Electronic) IS - 1351-5101 (Print) IS - 1351-5101 (Linking) VI - 31 IP - 6 DP - 2024 Jun TI - Headaches and facial pain attributed to SARS-CoV-2 infection and vaccination: a systematic review. PG - e16251 LID - 10.1111/ene.16251 [doi] LID - e16251 AB - BACKGROUND AND PURPOSE: The aim was to provide insights to the characteristics of headache in the context of COVID-19 on behalf of the Headache Scientific Panel and the Neuro-COVID-19 Task Force of the European Academy of Neurology (EAN) and the European Headache Federation (EHF). METHODS: Following the Delphi method the Task Force identified six relevant questions and then conducted a systematic literature review to provide evidence-based answers and suggest specific diagnostic criteria. RESULTS: No data for facial pain were identified in the literature search. (1) Headache incidence during acute COVID-19 varies considerably, with higher prevalence rates in prospective compared to retrospective studies (28.9%-74.6% vs. 6.5%-34.0%). (2) Acute COVID-19 headache is usually bilateral or holocranial and often moderate to severe with throbbing pain quality lasting 2-14 days after first signs of COVID-19; photo-phonophobia, nausea, anosmia and ageusia are common associated features; persistent headache shares similar clinical characteristics. (3) Acute COVID-19 headache is presumably caused by immune-mediated mechanisms that activate the trigeminovascular system. (4) Headache occurs in 13.3%-76.9% following SARS-CoV-2 vaccination and occurs more often amongst women with a pre-existing primary headache; the risk of developing headache is higher with the adenoviral-vector-type vaccines than with other preparations. (5) Headache related to SARS-CoV-2 vaccination is mostly bilateral, and throbbing, pressing, jolting or stabbing. (6) No studies have been conducted investigating the underlying mechanism of headache attributed to SARS-CoV-2 vaccines. CONCLUSION: The results of this joint EAN/EHF initiative provide a framework for a better understanding of headache in the context of SARS-CoV-2 infection and vaccination. CI - (c) 2024 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology. FAU - Mitsikostas, Dimos-Dimtirios D AU - Mitsikostas DD AUID- ORCID: 0000-0002-4691-3388 AD - Neurology Department, Aeginition Hospital, Medical School, National & Kapodistrian University of Athens, Athens, Greece. FAU - Caronna, Edoardo AU - Caronna E AUID- ORCID: 0000-0001-5525-0267 AD - Headache Unit, Neurology Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain. AD - Headache and Neurological Pain Research Group, Department of Medicine, Vall d'Hebron Research Institute, Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - De Tommaso, Marina AU - De Tommaso M AUID- ORCID: 0000-0001-6567-5373 AD - Neurophysiopathology Unit, DiBrain Department, Aldo Moro University, Bari, Italy. FAU - Deligianni, Christina I AU - Deligianni CI AUID- ORCID: 0000-0002-6208-1059 AD - Athens Naval Hospital, Athens, Greece. FAU - Ekizoglu, Esme AU - Ekizoglu E AUID- ORCID: 0000-0002-4904-9994 AD - Department of Neurology, Faculty of Medicine, Istanbul University, Istanbul, Istanbul, Turkey. FAU - Bolay, Hayrunnisa AU - Bolay H AUID- ORCID: 0000-0002-3357-7733 AD - Department of Neurology and Algology, NOROM, Gazi University Ankara, Ankara, Turkey. FAU - Gobel, Carl H AU - Gobel CH AD - Department of Neurology, University Hospital Schleswig-Holstein, Lubeck, Germany. FAU - Kristoffersen, Espen Saxhaug AU - Kristoffersen ES AUID- ORCID: 0000-0002-8999-5424 AD - Department of Neurology, Akershus University Hospital, Lorenskog, Norway. AD - NorHEAD, Norwegian Centre for Headache Research, Akershus University Hospital, Lorenskog, Norway. AD - Department of General Practice, HELSAM, University of Oslo, Oslo, Norway. FAU - Lampl, Christian AU - Lampl C AUID- ORCID: 0000-0003-1756-1181 AD - Department of Neurology and Stroke Unit, Konventhospital Barmherzige Bruder Linz, Linz, Austria. AD - Headache Medical Center Linz, Linz, Austria. FAU - Moro, Elena AU - Moro E AUID- ORCID: 0000-0002-7968-5908 AD - Division of Neurology, CHU of Grenoble, Grenoble Institute of Neurosciences, Grenoble Alpes University, Grenoble, France. FAU - Pozo-Rosich, Patricia AU - Pozo-Rosich P AUID- ORCID: 0000-0003-0796-4702 AD - Headache Unit, Neurology Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain. AD - Headache and Neurological Pain Research Group, Department of Medicine, Vall d'Hebron Research Institute, Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - Sellner, Johann AU - Sellner J AUID- ORCID: 0000-0001-8749-5533 AD - Department of Neurology, Landesklinikum Mistelbach-Ganserndorf, Mistelbach, Austria. FAU - Terwindt, Gisela AU - Terwindt G AUID- ORCID: 0000-0003-3140-6882 AD - Department of Neurology, Leiden University Medical Center, Leiden, The Netherlands. FAU - Irimia-Sieira, Pablo AU - Irimia-Sieira P AUID- ORCID: 0000-0002-7238-0036 AD - Neurology Department, Clinica Universidad de Navarra, Pamplona, Spain. LA - eng PT - Journal Article PT - Systematic Review DEP - 20240228 PL - England TA - Eur J Neurol JT - European journal of neurology JID - 9506311 RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - *COVID-19/complications/epidemiology MH - *COVID-19 Vaccines/adverse effects MH - *Facial Pain/etiology/epidemiology MH - *Headache/etiology/epidemiology MH - SARS-CoV-2 MH - Vaccination/adverse effects PMC - PMC11235838 OTO - NOTNLM OT - chronic daily headache OT - headache OT - neurological disorders COIS- The authors declare no conflicts of interest. EDAT- 2024/02/28 06:45 MHDA- 2024/05/08 12:44 PMCR- 2024/02/28 CRDT- 2024/02/28 04:01 PHST- 2024/01/23 00:00 [revised] PHST- 2023/09/12 00:00 [received] PHST- 2024/02/01 00:00 [accepted] PHST- 2024/05/08 12:44 [medline] PHST- 2024/02/28 06:45 [pubmed] PHST- 2024/02/28 04:01 [entrez] PHST- 2024/02/28 00:00 [pmc-release] AID - ENE16251 [pii] AID - 10.1111/ene.16251 [doi] PST - ppublish SO - Eur J Neurol. 2024 Jun;31(6):e16251. doi: 10.1111/ene.16251. Epub 2024 Feb 28. PMID- 38398733 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240227 IS - 2075-1729 (Print) IS - 2075-1729 (Electronic) IS - 2075-1729 (Linking) VI - 14 IP - 2 DP - 2024 Feb 5 TI - How Much Does SARS-CoV-2 Infection during Pregnancy Affect the Neonatal Brain, Heart, and Kidney? A Parallel between COVID-19, Vaccination, and Normal Pregnancy. LID - 10.3390/life14020224 [doi] LID - 224 AB - During the last decades, a growing number of studies have shown that infections during pregnancy have an important impact on both pregnant women and their fetuses. Our goal was to include newborns from pregnancies with SARS-CoV-2 infection and to investigate the extension of neonatal complications using cardiac, abdominal, and cerebral ultrasonography; hearing testing; and indirect ophthalmoscopy. Likewise, neonates whose mothers were vaccinated against COVID-19 during pregnancy and those from pathology-free pregnancies were examined. A total of 458 mother-newborn dyads were included over a period of 10 months and divided into three groups: the COVID-19 group, vaccine group, and control group. Although six cardiac malformations were found in the COVID-19 group, no correlation was made compared to the vaccine and control group (p = 0.07). Grade 1 intraventricular hemorrhage and hypoxic ischemic encephalopathy were the most prevalent among neonates from mothers with SARS-CoV-2 infection (p = 0.002 and p < 0.001, respectively). The kidney anomaly found to be most frequent in this group was grade 1 unilateral hydronephrosis (p < 0.001). COVID-19 disease during the gestational period had no effect on the auditory or visual function. Our findings highlight the importance of implementing proper infection control practices for future mothers, and by continuing to investigate this topic, we can gather valuable insights that will improve neonatal health in this context. FAU - Popescu, Daniela Eugenia AU - Popescu DE AUID- ORCID: 0000-0002-4986-8025 AD - Department of Obstetrics and Gynecology, "Victor Babes" University of Medicine and Pharmacy, Eftimie Murgu Sq. No. 2, 300041 Timisoara, Romania. AD - Department of Neonatology, Premiere Hospital, Regina Maria Health Network, Calea Aradului, No. 113, 300645 Timisoara, Romania. FAU - Jura, Ana Maria Cristina AU - Jura AMC AD - Department of Obstetrics and Gynecology, "Victor Babes" University of Medicine and Pharmacy, Eftimie Murgu Sq. No. 2, 300041 Timisoara, Romania. FAU - Stiube, Dana AU - Stiube D AD - Department of Neonatology, Premiere Hospital, Regina Maria Health Network, Calea Aradului, No. 113, 300645 Timisoara, Romania. FAU - Ciulpan, Adrian AU - Ciulpan A AUID- ORCID: 0000-0001-5796-4028 AD - Department of Pediatrics, Victor Babes University of Medicine and Pharmacy, 300041 Timisoara, Romania. FAU - Stoica, Florina AU - Stoica F AD - Department of Ophthalmology, Emergency Municipal Clinical Hospital, Gheorghe Dima Street 5, 300254 Timisoara, Romania. FAU - Sipos, Simona Ioana AU - Sipos SI AD - Department of Pharmacology, 'Victor Babes' University of Medicine and Pharmacy of Timisoara, 300041 Timisoara, Romania. FAU - Citu, Cosmin AU - Citu C AUID- ORCID: 0000-0002-3730-6527 AD - Department of Obstetrics and Gynecology, "Victor Babes" University of Medicine and Pharmacy, Eftimie Murgu Sq. No. 2, 300041 Timisoara, Romania. FAU - Gorun, Florin AU - Gorun F AUID- ORCID: 0000-0002-8882-7381 AD - Department of Obstetrics and Gynecology, "Victor Babes" University of Medicine and Pharmacy, Eftimie Murgu Sq. No. 2, 300041 Timisoara, Romania. FAU - Boia, Marioara AU - Boia M AD - Department of Obstetrics and Gynecology, "Victor Babes" University of Medicine and Pharmacy, Eftimie Murgu Sq. No. 2, 300041 Timisoara, Romania. LA - eng PT - Journal Article DEP - 20240205 PL - Switzerland TA - Life (Basel) JT - Life (Basel, Switzerland) JID - 101580444 PMC - PMC10889919 OTO - NOTNLM OT - COVID-19 OT - SARS-CoV-2 OT - disease course OT - infectious diseases OT - neonatal OT - pregnancy OT - ultrasound OT - vaccine COIS- The authors declare no conflicts of interest. EDAT- 2024/02/24 11:44 MHDA- 2024/02/24 11:45 PMCR- 2024/02/05 CRDT- 2024/02/24 01:15 PHST- 2024/01/02 00:00 [received] PHST- 2024/02/03 00:00 [revised] PHST- 2024/02/04 00:00 [accepted] PHST- 2024/02/24 11:45 [medline] PHST- 2024/02/24 11:44 [pubmed] PHST- 2024/02/24 01:15 [entrez] PHST- 2024/02/05 00:00 [pmc-release] AID - life14020224 [pii] AID - life-14-00224 [pii] AID - 10.3390/life14020224 [doi] PST - epublish SO - Life (Basel). 2024 Feb 5;14(2):224. doi: 10.3390/life14020224. PMID- 38359587 OWN - NLM STAT- MEDLINE DCOM- 20240318 LR - 20260422 IS - 1879-1646 (Electronic) IS - 0167-6296 (Linking) VI - 94 DP - 2024 Mar TI - The causal effect of a health treatment on beliefs, stated preferences and memories. PG - 102864 LID - S0167-6296(24)00009-2 [pii] LID - 10.1016/j.jhealeco.2024.102864 [doi] AB - The paper estimates the causal effect of a health treatment on patients' beliefs, preferences and memories about the treatment. It exploits a natural experiment which occurred in the United Kingdom during the COVID-19 vaccination campaign. UK residents could choose to opt into the vaccination program, but not which vaccine they received. The assignment to a vaccine offered little objective information for learning about its qualities, but triggered strong psychological demand for reassuring beliefs. We surveyed a sample of UK residents about their beliefs on the different COVID-19 vaccines before and after receiving their jab. Before vaccination, individuals exhibit similar prior beliefs and stated preferences about the different vaccines. After vaccination, however, they update their beliefs overly optimistically about the safety and effectiveness of the vaccine they received, state that they would have chosen it if they could, and have distorted memories about their past beliefs. These results cannot be explained by conventional experience effects. At the aggregated level, they show that random assignment to a health treatment predicts a polarization of opinions about its quality. At the individual level, these findings provide evidence in line with the predictions of motivated beliefs and over-inference from weak signals in a real-world health setting. CI - Copyright (c) 2024 The Author(s). Published by Elsevier B.V. All rights reserved. FAU - Prati, Alberto AU - Prati A AD - University College London, United Kingdom; University of Oxford, United Kingdom; London School of Economics, United Kingdom. Electronic address: a.prati@ucl.ac.uk. FAU - Saucet, Charlotte AU - Saucet C AD - University of Paris 1 Pantheon-Sorbonne, France. Electronic address: charlotte.saucet@univ-paris1.fr. LA - eng PT - Journal Article DEP - 20240206 PL - Netherlands TA - J Health Econ JT - Journal of health economics JID - 8410622 RN - 0 (COVID-19 Vaccines) MH - Humans MH - *COVID-19 Vaccines MH - Causality MH - *COVID-19 MH - Immunization Programs MH - Motivation MH - Vaccination OTO - NOTNLM OT - Behavioral health economics OT - COVID-19 OT - Motivated beliefs OT - Motivated memory OT - Natural experiment OT - Over-inference COIS- Declaration of competing interest We do not have any conflict of interest to disclose. EDAT- 2024/02/16 00:42 MHDA- 2024/03/18 06:44 CRDT- 2024/02/15 18:07 PHST- 2023/09/05 00:00 [received] PHST- 2024/02/01 00:00 [revised] PHST- 2024/02/02 00:00 [accepted] PHST- 2024/03/18 06:44 [medline] PHST- 2024/02/16 00:42 [pubmed] PHST- 2024/02/15 18:07 [entrez] AID - S0167-6296(24)00009-2 [pii] AID - 10.1016/j.jhealeco.2024.102864 [doi] PST - ppublish SO - J Health Econ. 2024 Mar;94:102864. doi: 10.1016/j.jhealeco.2024.102864. Epub 2024 Feb 6. PMID- 38347305 OWN - NLM STAT- MEDLINE DCOM- 20251202 LR - 20251205 IS - 1532-7558 (Electronic) IS - 1070-5503 (Print) IS - 1070-5503 (Linking) VI - 32 IP - 5 DP - 2025 Oct TI - The Effect of Being Vaccinated and National Vaccination Rates on Individuals' Cognitions, Emotions, and Economic Expectations: Evidence from Israel. PG - 788-797 LID - 10.1007/s12529-024-10269-3 [doi] AB - BACKGROUND: Israel was the first nation to establish a vaccination program during the COVID-19 pandemic. Thus, its citizens could look to no other country to help them judge its influence. People's predictions of their safety should depend on whether they were vaccinated, whereas their predictions regarding the COVID-19 pandemic should be based on the degree of progress of the vaccination program. We expected people to understand that the program would improve their safety by reducing the number of infected people around them. METHOD: An original panel survey was conducted covering the pandemic's first year. Respondents reported their vaccination status, emotions, evaluations of their safety, and predictions about the spread of COVID-19 and the Israeli gross domestic product. RESULTS: Estimates of fixed-effects models using the survey data suggest that being vaccinated affected people's cognitions about their own safety and their emotions but not their expectations regarding the situation in Israel as a whole. In contrast, the vaccination rate in Israel affected only the respondents' expectations about the spread of COVID-19, their own income, and Israel's gross domestic product. CONCLUSIONS: Being vaccinated is important for people's personal emotional and cognitive relief during a pandemic. A high vaccination rate improves people's economic expectations, which is important to the recovery of economic activity. CI - (c) 2024. The Author(s). FAU - Lahav, Eyal AU - Lahav E AUID- ORCID: 0000-0002-7840-9506 AD - The Open University of Israel, University Road 1, Raanana, Israel. eyalla@openu.ac.il. FAU - Shahrabani, Shosh AU - Shahrabani S AD - Economics and Management Department, The Max Stern Yezreel Valley College, Emek Yezreel, Israel. FAU - Rosenboim, Mosi AU - Rosenboim M AD - Guilford Glazer Faculty of Business and Management, Ben Gurion University of the Negev, Beer Sheva, Israel. FAU - Tsutsui, Yoshiro AU - Tsutsui Y AD - Kyoto Bunkyo University, Kyoto, Japan. LA - eng PT - Journal Article DEP - 20240212 PL - England TA - Int J Behav Med JT - International journal of behavioral medicine JID - 9421097 RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - Israel MH - *COVID-19/prevention & control/psychology MH - *Emotions MH - Male MH - Female MH - Adult MH - *Vaccination/psychology/statistics & numerical data MH - Middle Aged MH - *COVID-19 Vaccines MH - *Cognition MH - SARS-CoV-2 MH - Surveys and Questionnaires MH - Young Adult MH - Aged MH - *Health Knowledge, Attitudes, Practice PMC - PMC12672598 OTO - NOTNLM OT - COVID-19 OT - Emotions OT - Perceived risk OT - Prevention behavior OT - Vaccination COIS- Declarations. Informed Consent: Informed Consent was obtained from all individual participants included in the study. Ethical Approval: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Research Involving Human Participants and/or Animals: Not applicable. Competing Interests: The authors declare no conflict of interest. EDAT- 2024/02/13 00:42 MHDA- 2025/12/02 12:57 PMCR- 2024/02/12 CRDT- 2024/02/12 23:34 PHST- 2024/02/04 00:00 [accepted] PHST- 2025/12/02 12:57 [medline] PHST- 2024/02/13 00:42 [pubmed] PHST- 2024/02/12 23:34 [entrez] PHST- 2024/02/12 00:00 [pmc-release] AID - 10.1007/s12529-024-10269-3 [pii] AID - 10269 [pii] AID - 10.1007/s12529-024-10269-3 [doi] PST - ppublish SO - Int J Behav Med. 2025 Oct;32(5):788-797. doi: 10.1007/s12529-024-10269-3. Epub 2024 Feb 12. PMID- 38327486 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240211 IS - 2821-1723 (Electronic) IS - 2821-1723 (Linking) VI - 2 IP - 1 DP - 2023 Apr TI - COVID-19 vaccine-hesitancy is associated with lower cortical volume in elderly individuals. PG - 35-41 LID - 10.52547/nl.2.1.35 [doi] AB - BACKGROUND: According to a large number of scientific reports, the main problem is COVID-19 vaccine hesitancy which slowed down the vaccination program. Previous studies revealed that COVID-19 vaccine hesitancy is associated with lower cognitive performance. However, the neurobiology of such behavior is less known, and investigating the brain structural patterns in this regard can extend our knowledge on the basis of this behavior. This study aimed to investigate the link between brain structural features including cortical and subcortical volume with COVID-19 vaccine hesitancy in elderly individuals. METHODS: A total of 221 healthy subjects without any cognitive impairment with a mean age of 63.7 +/- 6.1 were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database. Overall, 87 vaccine-hesitant (VH) and 134 vaccine-accepted (VA) were entered into this study. The difference in the volume of cortical and subcortical regions was investigated between VH and VA groups. RESULTS: There was no significant difference in cognitive status measured by MMSE, MoCA, ADAS-cog, and RAVLT between VA and VH groups (P>0.05). The analysis showed that VA subjects had significantly higher left pars orbitalis (P: 0.013), left precentral (P: 0.042), right caudal anterior cingulate (P: 0.044), and right isthmus cingulate (P: 0.013) volume compared to the VH group. There was no significant difference in other cortical and subcortical regions. CONCLUSION: In conclusion, this finding demonstrated that in the era of complicated decision-making due to social media reports, elderly adults with smaller frontal and cingulate regions are more likely to be vaccine-hesitant. These findings can highlight the link between cortical regions and health-protective behaviors such as taking up the offer of vaccination. FAU - Nabizadeh, Fardin AU - Nabizadeh F AD - Neuroscience Research Group (NRG), Universal Scientific Education and Research Network (USERN), Tehran, Iran. AD - School of Medicine, Iran University of Medical Sciences, Tehran, Iran. CN - Alzheimer's disease Neuroimaging Initiative (ADNI) LA - eng GR - P30 AG010129/AG/NIA NIH HHS/United States GR - U01 AG024904/AG/NIA NIH HHS/United States PT - Journal Article DEP - 20220415 PL - Iran TA - Neurol Lett JT - Neurology letters JID - 9918752185506676 PMC - PMC10847881 MID - NIHMS1962532 OTO - NOTNLM OT - COVID-19 OT - brain OT - cingulate OT - cognition OT - hesitancy OT - vaccine COIS- Conflict of interest The author declares no conflict of interest regarding the publication of this paper. EDAT- 2024/02/08 06:42 MHDA- 2024/02/08 06:43 PMCR- 2024/02/07 CRDT- 2024/02/08 04:05 PHST- 2024/02/08 06:43 [medline] PHST- 2024/02/08 06:42 [pubmed] PHST- 2024/02/08 04:05 [entrez] PHST- 2024/02/07 00:00 [pmc-release] AID - 10.52547/nl.2.1.35 [doi] PST - ppublish SO - Neurol Lett. 2023 Apr;2(1):35-41. doi: 10.52547/nl.2.1.35. Epub 2022 Apr 15. PMID- 38281402 OWN - NLM STAT- MEDLINE DCOM- 20240219 LR - 20250317 IS - 1878-5883 (Electronic) IS - 0022-510X (Linking) VI - 457 DP - 2024 Feb 15 TI - Neurological disorders throughout acute SARS-CoV2 infection: A comparative study between vaccinated and non-vaccinated patients. PG - 122898 LID - S0022-510X(24)00033-9 [pii] LID - 10.1016/j.jns.2024.122898 [doi] AB - BACKGROUND: The role of vaccination on Covid-19 severity in neurological patients is still unknown. We aim at describing clinical characteristics and outcomes of breakthrough and unvaccinated Covid-19 patients hospitalized for neurological disorders. METHODS: Two hundred thirty-two Covid-19 patients were admitted to a neuro-Covid Unit form March 1st 2021 to February 28th 2022. Out of the total sample, 74 (32%) were full vaccinated. The prevalence, clinical characteristics, disease severity, expressed by Brescia-COVID Respiratory Severity Scale (BCRSS) and National Early Warning Score 2 (NEWS2), and final outcomes of neurological syndromes were compared between vaccinated and unvaccinated cases. Cox regression analysis was implemented in order to investigate the combined effect of predictors of mortality. RESULTS: Breakthrough vaccinated cases were older (years 72.4 +/- 16.3 vs 67.0 +/- 18.9 years, p = 0.029), showed higher pre-admission comorbidity score and Clinical Frailty scale score (4.46 +/- 1.6 vs 3.75 +/- 2.0, p = 0.008) with no differences in terms of disease progression or mortality rate (16.2% vs 15.2%), compared to full-dose vaccinated patients. Cox-regression analysis showed age and NEWS2 score as the variables with a significant relation to mortality between the two groups, independently from pre-morbid conditions and inflammatory response. CONCLUSION: This study on breakthrough COVID-19 infection could help identify vulnerable neurological patients with higher risk of poor outcomes. CI - Copyright (c) 2024 Elsevier B.V. All rights reserved. FAU - Cristillo, Viviana AU - Cristillo V AD - Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Italy. Electronic address: viviana.cristillo@gmail.com. FAU - Pilotto, Andrea AU - Pilotto A AD - Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Italy. FAU - Piccinelli, Stefano Cotti AU - Piccinelli SC AD - Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Italy. FAU - Libri, Ilenia AU - Libri I AD - Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Italy. FAU - Locatelli, Martina AU - Locatelli M AD - Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Italy. FAU - Giunta, Marcello AU - Giunta M AD - Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Italy. FAU - Mazzoleni, Valentina AU - Mazzoleni V AD - Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Italy. FAU - Pezzini, Debora AU - Pezzini D AD - Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Italy. FAU - Arici, Davide AU - Arici D AD - Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Italy. FAU - Gipponi, Stefano AU - Gipponi S AD - Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Italy. FAU - di Cola, Francesca Schiano AU - di Cola FS AD - Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Italy. FAU - Cottini, Elisabetta AU - Cottini E AD - Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Italy. FAU - Gamba, Massimo AU - Gamba M AD - Stroke Unit, Azienda Socio Sanitaria Territoriale Spedali Civili, Spedali Civili Hospital, Brescia, Italy. FAU - Magoni, Mauro AU - Magoni M AD - Stroke Unit, Azienda Socio Sanitaria Territoriale Spedali Civili, Spedali Civili Hospital, Brescia, Italy. FAU - Padovani, Alessandro AU - Padovani A AD - Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Italy. LA - eng PT - Journal Article DEP - 20240123 PL - Netherlands TA - J Neurol Sci JT - Journal of the neurological sciences JID - 0375403 RN - 0 (RNA, Viral) RN - COVID-19 breakthrough infections SB - IM MH - Humans MH - *COVID-19/prevention & control MH - RNA, Viral MH - SARS-CoV-2 MH - *Nervous System Diseases/epidemiology/etiology MH - *Breakthrough Infections OTO - NOTNLM OT - COVID-19 OT - Mortality OT - Neurological disease OT - Vaccine COIS- Declaration of competing interest The authors declare no competing interests. EDAT- 2024/01/29 00:42 MHDA- 2024/02/19 06:42 CRDT- 2024/01/28 18:06 PHST- 2023/11/06 00:00 [received] PHST- 2023/12/30 00:00 [revised] PHST- 2024/01/21 00:00 [accepted] PHST- 2024/02/19 06:42 [medline] PHST- 2024/01/29 00:42 [pubmed] PHST- 2024/01/28 18:06 [entrez] AID - S0022-510X(24)00033-9 [pii] AID - 10.1016/j.jns.2024.122898 [doi] PST - ppublish SO - J Neurol Sci. 2024 Feb 15;457:122898. doi: 10.1016/j.jns.2024.122898. Epub 2024 Jan 23. PMID- 38274635 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20241023 IS - 2168-8184 (Print) IS - 2168-8184 (Electronic) IS - 2168-8184 (Linking) VI - 16 IP - 1 DP - 2024 Jan TI - COVID-19 mRNA Vaccines: Lessons Learned from the Registrational Trials and Global Vaccination Campaign. PG - e52876 LID - 10.7759/cureus.52876 [doi] LID - e52876 AB - Our understanding of COVID-19 vaccinations and their impact on health and mortality has evolved substantially since the first vaccine rollouts. Published reports from the original randomized phase 3 trials concluded that the COVID-19 mRNA vaccines could greatly reduce COVID-19 symptoms. In the interim, problems with the methods, execution, and reporting of these pivotal trials have emerged. Re-analysis of the Pfizer trial data identified statistically significant increases in serious adverse events (SAEs) in the vaccine group. Numerous SAEs were identified following the Emergency Use Authorization (EUA), including death, cancer, cardiac events, and various autoimmune, hematological, reproductive, and neurological disorders. Furthermore, these products never underwent adequate safety and toxicological testing in accordance with previously established scientific standards. Among the other major topics addressed in this narrative review are the published analyses of serious harms to humans, quality control issues and process-related impurities, mechanisms underlying adverse events (AEs), the immunologic basis for vaccine inefficacy, and concerning mortality trends based on the registrational trial data. The risk-benefit imbalance substantiated by the evidence to date contraindicates further booster injections and suggests that, at a minimum, the mRNA injections should be removed from the childhood immunization program until proper safety and toxicological studies are conducted. Federal agency approval of the COVID-19 mRNA vaccines on a blanket-coverage population-wide basis had no support from an honest assessment of all relevant registrational data and commensurate consideration of risks versus benefits. Given the extensive, well-documented SAEs and unacceptably high harm-to-reward ratio, we urge governments to endorse a global moratorium on the modified mRNA products until all relevant questions pertaining to causality, residual DNA, and aberrant protein production are answered. CI - Copyright (c) 2024, Mead et al. FAU - Mead, M Nathaniel AU - Mead MN AD - Biology and Nutritional Epidemiology, Independent Research, Copper Hill, USA. FAU - Seneff, Stephanie AU - Seneff S AD - Computer Science and Artificial Intelligence Laboratory, Massachusetts Institute of Technology, Cambridge, USA. FAU - Wolfinger, Russ AU - Wolfinger R AD - Biostatistics and Epidemiology, Independent Research, Research Triangle Park, USA. FAU - Rose, Jessica AU - Rose J AD - Immunology and Public Health Research, Independent Research, Ottawa, CAN. FAU - Denhaerynck, Kris AU - Denhaerynck K AD - Epidemiology and Biostatistics, Independent Research, Basel, CHE. FAU - Kirsch, Steve AU - Kirsch S AD - Data Science, Independent Research, Los Angeles, USA. FAU - McCullough, Peter A AU - McCullough PA AD - Cardiology, Epidemiology, and Public Health, McCullough Foundation, Dallas, USA. AD - Cardiology, Epidemiology, and Public Health, Truth for Health Foundation, Tucson, USA. LA - eng PT - Journal Article PT - Retracted Publication PT - Review DEP - 20240124 PL - United States TA - Cureus JT - Cureus JID - 101596737 RIN - Cureus. 2024 Feb 26;16(2):r137. doi: 10.7759/cureus.r137. PMID: 38414517 PMC - PMC10810638 OTO - NOTNLM OT - autoimmune OT - cardiovascular OT - covid-19 mrna vaccines OT - gene therapy products OT - immunity OT - mortality OT - registrational trials OT - risk-benefit assessment OT - sars-cov-2 (severe acute respiratory syndrome coronavirus -2) OT - serious adverse events COIS- Steve Kirsch is the founder of the Vaccine Safety Research Foundation or VSRF (vacsafety.org) but receives no income from this entity EDAT- 2024/01/26 06:43 MHDA- 2024/01/26 06:44 PMCR- 2024/01/24 CRDT- 2024/01/26 03:57 PHST- 2024/01/24 00:00 [accepted] PHST- 2024/01/26 06:44 [medline] PHST- 2024/01/26 06:43 [pubmed] PHST- 2024/01/26 03:57 [entrez] PHST- 2024/01/24 00:00 [pmc-release] AID - 10.7759/cureus.52876 [doi] PST - epublish SO - Cureus. 2024 Jan 24;16(1):e52876. doi: 10.7759/cureus.52876. eCollection 2024 Jan. PMID- 38252445 OWN - NLM STAT- MEDLINE DCOM- 20240305 LR - 20250819 IS - 2168-6211 (Electronic) IS - 2168-6203 (Print) IS - 2168-6203 (Linking) VI - 178 IP - 3 DP - 2024 Mar 1 TI - In Utero Exposure to Maternal COVID-19 Vaccination and Offspring Neurodevelopment at 12 and 18 Months. PG - 258-265 LID - 10.1001/jamapediatrics.2023.5743 [doi] AB - IMPORTANCE: Uptake of COVID-19 vaccines among pregnant individuals was hampered by safety concerns around potential risks to unborn children. Data clarifying early neurodevelopmental outcomes of offspring exposed to COVID-19 vaccination in utero are lacking. OBJECTIVE: To determine whether in utero exposure to maternal COVID-19 vaccination was associated with differences in scores on the Ages and Stages Questionnaire, third edition (ASQ-3), at 12 and 18 months of age. DESIGN, SETTING, AND PARTICIPANTS: This prospective cohort study, Assessing the Safety of Pregnancy During the Coronavirus Pandemic (ASPIRE), enrolled pregnant participants from May 2020 to August 2021; follow-up of children from these pregnancies is ongoing. Participants, which included pregnant individuals and their offspring from all 50 states, self-enrolled online. Study activities were performed remotely. EXPOSURE: In utero exposure of the fetus to maternal COVID-19 vaccination during pregnancy was compared with those unexposed. MAIN OUTCOMES AND MEASURES: Neurodevelopmental scores on validated ASQ-3, completed by birth mothers at 12 and 18 months. A score below the established cutoff in any of 5 subdomains (communication, gross motor, fine motor, problem solving, social skills) constituted an abnormal screen for developmental delay. RESULTS: A total of 2487 pregnant individuals (mean [SD] age, 33.3 [4.2] years) enrolled at less than 10 weeks' gestation and completed research activities, yielding a total of 2261 and 1940 infants aged 12 and 18 months, respectively, with neurodevelopmental assessments. In crude analyses, 471 of 1541 exposed infants (30.6%) screened abnormally for developmental delay at 12 months vs 203 of 720 unexposed infants (28.2%; chi2 = 1.32; P = .25); the corresponding prevalences at 18 months were 262 of 1301 (20.1%) vs 148 of 639 (23.2%), respectively (chi2 = 2.35; P = .13). In multivariable mixed-effects logistic regression models adjusting for maternal age, race, ethnicity, education, income, maternal depression, and anxiety, no difference in risk for abnormal ASQ-3 screens was observed at either time point (12 months: adjusted risk ratio [aRR], 1.14; 95% CI, 0.97-1.33; 18 months: aRR, 0.88; 95% CI, 0.72-1.07). Further adjustment for preterm birth and infant sex did not affect results (12 months: aRR, 1.16; 95% CI, 0.98-1.36; 18 months: aRR, 0.87; 95% CI, 0.71-1.07). CONCLUSIONS AND RELEVANCE: Results of this cohort study suggest that COVID-19 vaccination was safe during pregnancy from the perspective of infant neurodevelopment to 18 months of age. Additional longer-term research should be conducted to corroborate these findings and buttress clinical guidance with a strong evidence base. FAU - Jaswa, Eleni G AU - Jaswa EG AD - Department of Obstetrics, Gynecology and Reproductive Sciences, Division of Reproductive Endocrinology and Infertility, University of California, San Francisco, San Francisco. FAU - Cedars, Marcelle I AU - Cedars MI AD - Department of Obstetrics, Gynecology and Reproductive Sciences, Division of Reproductive Endocrinology and Infertility, University of California, San Francisco, San Francisco. FAU - Lindquist, Karla J AU - Lindquist KJ AD - Department of Epidemiology & Biostatistics, University of California, San Francisco, San Francisco. FAU - Bishop, Somer L AU - Bishop SL AD - Department of Psychiatry, University of California, San Francisco, San Francisco. FAU - Kim, Young-Shin AU - Kim YS AD - Department of Psychiatry, University of California, San Francisco, San Francisco. FAU - Kaing, Amy AU - Kaing A AD - Department of Obstetrics, Gynecology and Reproductive Sciences, Division of Reproductive Endocrinology and Infertility, University of California, San Francisco, San Francisco. FAU - Prahl, Mary AU - Prahl M AD - Department of Pediatrics, Division of Pediatric Infectious Disease and Global Health, University of California, San Francisco, San Francisco. FAU - Gaw, Stephanie L AU - Gaw SL AD - Department of Obstetrics, Gynecology and Reproductive Sciences, Division of Maternal Fetal Medicine, University of California, San Francisco, San Francisco. FAU - Corley, Jamie AU - Corley J AD - Department of Obstetrics, Gynecology and Reproductive Sciences, Division of Reproductive Endocrinology and Infertility, University of California, San Francisco, San Francisco. FAU - Hoskin, Elena AU - Hoskin E AD - Department of Obstetrics, Gynecology and Reproductive Sciences, Division of Reproductive Endocrinology and Infertility, University of California, San Francisco, San Francisco. FAU - Cho, Yoon Jae AU - Cho YJ AD - Department of Psychiatry, University of California, San Francisco, San Francisco. FAU - Rogers, Elizabeth AU - Rogers E AD - Department of Pediatrics, Division of Neonatology, University of California, San Francisco, San Francisco. FAU - Huddleston, Heather G AU - Huddleston HG AD - Department of Obstetrics, Gynecology and Reproductive Sciences, Division of Reproductive Endocrinology and Infertility, University of California, San Francisco, San Francisco. LA - eng GR - K08 AI141728/AI/NIAID NIH HHS/United States GR - K23 AI127886/AI/NIAID NIH HHS/United States GR - R01 HD111582/HD/NICHD NIH HHS/United States GR - R01 HD112339/HD/NICHD NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't PL - United States TA - JAMA Pediatr JT - JAMA pediatrics JID - 101589544 RN - 0 (COVID-19 Vaccines) SB - IM MH - Adult MH - Female MH - Humans MH - Infant MH - Infant, Newborn MH - Pregnancy MH - Cohort Studies MH - *COVID-19/epidemiology/prevention & control MH - *COVID-19 Vaccines/adverse effects MH - *Premature Birth MH - Prospective Studies PMC - PMC10804280 COIS- Conflict of Interest Disclosures: Dr Jaswa reported receiving grants from the California Breast Cancer Research Program and the Start Small Foundation during the conduct of the study. Dr Cedars reported receiving grants from Reproductive Medicine Network; serving on the presidential chain of the American Society of Reproductive Medicine, for which payment was received, and serving as treasurer of the American Gynecological and Obstetrical Society, for which no payment was received, outside the submitted work. Dr Kim reported receiving grants from the University of California, San Francisco, during the conduct of the study. Dr Prahl reported receiving grants from the National Institute of Allery and Infectious Diseases during the conduct of the study. No other disclosures were reported. EDAT- 2024/01/22 12:42 MHDA- 2024/03/05 06:47 PMCR- 2025/01/22 CRDT- 2024/01/22 11:37 PHST- 2024/03/05 06:47 [medline] PHST- 2024/01/22 12:42 [pubmed] PHST- 2024/01/22 11:37 [entrez] PHST- 2025/01/22 00:00 [pmc-release] AID - 2814106 [pii] AID - poi230088 [pii] AID - 10.1001/jamapediatrics.2023.5743 [doi] PST - ppublish SO - JAMA Pediatr. 2024 Mar 1;178(3):258-265. doi: 10.1001/jamapediatrics.2023.5743. PMID- 38233288 OWN - NLM STAT- MEDLINE DCOM- 20240214 LR - 20250827 IS - 1873-2518 (Electronic) IS - 0264-410X (Print) IS - 0264-410X (Linking) VI - 42 IP - 4 DP - 2024 Feb 6 TI - Restricted Omicron-specific cross-variant memory B-cell immunity after a 3rd dose/booster of monovalent Wuhan-Hu-1-containing COVID-19 mRNA vaccine. PG - 912-917 LID - S0264-410X(24)00032-X [pii] LID - 10.1016/j.vaccine.2024.01.032 [doi] AB - The responsiveness/cross-binding of vaccine-induced memory B cells/MBCs to previous and emerging divergent SARS-CoV-2 variants (e.g., Omicron) is understudied. In this longitudinal study subjects receiving two or three doses of monovalent ancestral strain-containing COVID-19 mRNA vaccine were evaluated. In contrast to others, we observed significantly lower frequencies of MBCs reactive to the receptor-binding domain/RBD, the N-terminal domain/NTD, and the S1 of Omicron/BA.1, compared to Wuhan and Delta, even after a 3rd vaccine dose/booster. Our study is a proof of concept that MBC cross-reactivity to variants with greater sequence divergence from the vaccine strain may be overestimated and suggests that these variants may exhibit immune escape with reduced recognition by circulating pre-existing MBCs upon infection. CI - Copyright (c) 2024 Elsevier Ltd. All rights reserved. FAU - Haralambieva, Iana H AU - Haralambieva IH AD - Mayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, MN, United States. FAU - Monroe, Jonathon M AU - Monroe JM AD - Mayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, MN, United States. FAU - Ovsyannikova, Inna G AU - Ovsyannikova IG AD - Mayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, MN, United States. FAU - Warner, Nathaniel D AU - Warner ND AD - Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, United States. FAU - Grill, Diane E AU - Grill DE AD - Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, United States. FAU - Poland, Gregory A AU - Poland GA AD - Mayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, MN, United States. FAU - Kennedy, Richard B AU - Kennedy RB AD - Mayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, MN, United States. Electronic address: kennedy.rick@mayo.edu. LA - eng GR - R01 AI048793/AI/NIAID NIH HHS/United States GR - R37 AI048793/AI/NIAID NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20240117 PL - Netherlands TA - Vaccine JT - Vaccine JID - 8406899 RN - 0 (COVID-19 Vaccines) RN - 0 (mRNA Vaccines) RN - 0 (Antibodies, Neutralizing) RN - 0 (Antibodies, Viral) RN - SARS-CoV-2 variants SB - IM MH - Humans MH - *COVID-19 Vaccines MH - Longitudinal Studies MH - Memory B Cells MH - mRNA Vaccines MH - *COVID-19/prevention & control MH - SARS-CoV-2 MH - Antibodies, Neutralizing MH - Antibodies, Viral PMC - PMC10922459 MID - NIHMS1960154 OTO - NOTNLM OT - Antibodies, neutralizing OT - B cells OT - COVID-19 OT - Humoral immune responses OT - Immunological memory OT - SARS-CoV-2 OT - Vaccine OT - Variants of concern COIS- Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Rick Kennedy reports financial support was provided by Mayo Clinic for SARS-CoV-2 research. Gregory Poland reports financial support was provided by National Institutes of Health (R01 AI48793: Poland PI). Dr. Poland is the chair of a Safety Evaluation Committee for novel investigational vaccine trials being conducted by Merck Research Laboratories. Dr. Poland provides consultative advice to AiZtech; Atria; GlaxoSmithKline; Invivyd; Janssen Global Services, LLC; Merck & Co. Inc.; Moderna; Novavax; and Syneos Health. Drs. Poland and Ovsyannikova hold patents related to vaccinia and measles peptide vaccines. Drs. Kennedy, Poland, and Ovsyannikova hold a patent related to vaccinia peptide vaccines. Drs. Poland, Kennedy, and Ovsyannikova have received grant funding and royalties from ICW Ventures for pre-clinical studies on a peptide-based COVID-19 vaccine. Drs. Poland, Kennedy, Ovsyannikova and Haralambieva hold a patent related to the impact of single nucleotide polymorphisms on measles vaccine immunity. Dr. Kennedy has received funding from Merck Research Laboratories to study waning immunity to mumps vaccine. These activities have been reviewed by the Mayo Clinic Conflict of Interest Review Board and are conducted in compliance with Mayo Clinic Conflict of Interest policies. This research has been reviewed by the Mayo Clinic Conflict of Interest Review Board and was conducted in compliance with Mayo Clinic Conflict of Interest policy. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2024/01/18 00:42 MHDA- 2024/02/09 12:44 PMCR- 2025/02/06 CRDT- 2024/01/17 21:58 PHST- 2023/06/09 00:00 [received] PHST- 2024/01/08 00:00 [revised] PHST- 2024/01/09 00:00 [accepted] PHST- 2024/02/09 12:44 [medline] PHST- 2024/01/18 00:42 [pubmed] PHST- 2024/01/17 21:58 [entrez] PHST- 2025/02/06 00:00 [pmc-release] AID - S0264-410X(24)00032-X [pii] AID - 10.1016/j.vaccine.2024.01.032 [doi] PST - ppublish SO - Vaccine. 2024 Feb 6;42(4):912-917. doi: 10.1016/j.vaccine.2024.01.032. Epub 2024 Jan 17. PMID- 38228087 OWN - NLM STAT- MEDLINE DCOM- 20240402 LR - 20240827 IS - 2092-7193 (Electronic) IS - 2092-7193 (Linking) VI - 46 DP - 2024 TI - The bounds of meta-analytics and an alternative method. PG - e2024016 LID - 10.4178/epih.e2024016 [doi] LID - e2024016 AB - OBJECTIVES: Meta-analysis is a statistical appraisal of the data analytic implications of published articles (Y), estimating parameters including the odds ratio and relative risk. This information is helpful for evaluating the significance of the findings. The Higgins I2 index is often used to measure heterogeneity among studies. The objectives of this article are to amend the Higgins I2 index score in a novel and innovative way and to make it more useful in practice. METHODS: Heterogeneity among study populations can be affected by many sources, including the sample size and study design. They influence the Cochran Q score and, thus, the Higgins I2 score. In this regard, the I2 score is not an absolute indicator of heterogeneity. Q changes by bound as Y increases unboundedly. An innovative methodology is devised to show the conditional and unconditional probability structures. RESULTS: Various properties are derived, including showing that a zero correlation between Q and Y does not necessarily mean that they are independent. A new alternative statistic, S2, is derived and applied to mild cognitive impairment and coronavirus disease 2019 vaccination for meta-analysis. CONCLUSIONS: A hidden shortcoming of the Higgins I2 index is overcome in this article by amending the Higgins I2 score. The usefulness of the proposed methodology is illustrated using 2 examples. The findings have potential health policy implications. FAU - Shanmugam, Ramalingam AU - Shanmugam R AD - School of Health Administration, Texas State University, San Marcos, TX, USA. FAU - Tabatabai, Mohammad AU - Tabatabai M AD - Meharry Medical College, School of Graduate Studies, Nashville, TN, USA. FAU - Wilus, Derek AU - Wilus D AD - Meharry Medical College, School of Graduate Studies, Nashville, TN, USA. FAU - Singh, Karan P AU - Singh KP AD - Department of Epidemiology and Biostatistics, School of Medicine, The University of Texas at Tyler, Tyler, TX, USA. LA - eng GR - G12 MD007586/MD/NIMHD NIH HHS/United States GR - U54 MD007586/MD/NIMHD NIH HHS/United States PT - Journal Article PT - Meta-Analysis DEP - 20240107 PL - Korea (South) TA - Epidemiol Health JT - Epidemiology and health JID - 101519472 SB - IM MH - Humans MH - *COVID-19/epidemiology MH - *Cognitive Dysfunction PMC - PMC11040225 OTO - NOTNLM OT - COVID-19 OT - Cognitive impairment OT - Heterogeneity OT - Risk OT - Vaccination COIS- Conflict of interest The authors have no conflicts of interest to declare for this study. EDAT- 2024/01/17 00:41 MHDA- 2024/04/02 06:46 PMCR- 2024/01/07 CRDT- 2024/01/16 18:10 PHST- 2023/08/25 00:00 [received] PHST- 2023/12/25 00:00 [accepted] PHST- 2024/04/02 06:46 [medline] PHST- 2024/01/17 00:41 [pubmed] PHST- 2024/01/16 18:10 [entrez] PHST- 2024/01/07 00:00 [pmc-release] AID - epih.e2024016 [pii] AID - epih-46-e2024016 [pii] AID - 10.4178/epih.e2024016 [doi] PST - ppublish SO - Epidemiol Health. 2024;46:e2024016. doi: 10.4178/epih.e2024016. Epub 2024 Jan 7. PMID- 38166817 OWN - NLM STAT- MEDLINE DCOM- 20240105 LR - 20240106 IS - 1471-2334 (Electronic) IS - 1471-2334 (Linking) VI - 24 IP - 1 DP - 2024 Jan 2 TI - Factors affecting subsequent dose of COVID-19 vaccine uptake based on BASNEF model among older adults. PG - 18 LID - 10.1186/s12879-023-08903-8 [doi] LID - 18 AB - BACKGROUND: Vaccination is a primary prevention approach to preventing disease by disconnecting the transmission chain. The current study utilized a BASNEF model framework to identify factors influencing subsequent doses of COVID-19 vaccination among older adults. METHODS: This cross-sectional study was performed in the west of Iran in May 2022. The participants were selected via multi-stage sampling. Finally, 1120 participants contributed to the present study. The questionnaire consisted of three sections: a) Socio-demographic characteristics, b) cognitive impairments tests, and c) Questionnaire about the subsequent dose of COVID-19 vaccine uptake based on the BASNEF model. Data were analyzed using the software IBM AMOS-20 and SPSS-23 via one-way analysis of variance (ANOVA) and independent sample T-tests were used, too. The significance level of statistical tests was regarded as less than 0.05. RESULTS: The presented results of analyzing 50% of the variance of vaccination intention as the dependent variable (R square = 0.497) and 10% of the behavior variance as the dependent variable (R square = 0.104) can be explained based on the BASNEF model. The enabling factors (beta = 0.636, p < 0.001) and the intention (beta = 0.322, p < 0.001) were important factors for subsequent doses of COVID-19 vaccine uptake in older adults. CONCLUSION: So, planning and implementing promotional intervention programs for older people (over 65; 80), females, illiterate, widows and divorced, good economic status, and urban areas is essential. It seems that enabling factors such as free vaccinations, vaccination inaccessible places such as public social security agencies, social supports such as involvement of the government and physicians, and improving information by the medium or knowledge-sharing experience, which can be further used to enhance the acceptance of subsequent doses of COVID-19 uptake in older adults. CI - (c) 2023. The Author(s). FAU - Barati, Majid AU - Barati M AD - Social Determinants of Health Research Center, Hamadan University of Medical Sciences and Department of Public Health, Asadabad School of Medical sciences, Asadabad, Iran, Hamadan, IR, Iran. FAU - Jormand, Hanieh AU - Jormand H AUID- ORCID: 0000-0002-4582-1473 AD - Urology and Nephrology Research Center, Hamadan University of Medical Sciences, Hamadan, IR, Iran. jormand69h@gmail.com. FAU - Khazaei, Salman AU - Khazaei S AD - Department of Epidemiology, School of Public and Social Determinants of Health Research Center, Hamadan University of Medical Sciences, Hamadan, IR, Iran. FAU - Bashirian, Saeed AU - Bashirian S AD - Department of Public Health, School of Public Health and Social Determinants of Health Research Center, Hamadan University of Medical Sciences, Hamadan, IR, Iran. FAU - Sadri, Mohadeseh AU - Sadri M AD - Iranian Research Center on Aging, University of Social Walfare and Rehablitation Sciences, Tehran, IR, Iran. FAU - Afshari, Maryam AU - Afshari M AD - Department of Public Health, School of Public Health and Social Determinants of Health Research Center, Hamadan University of Medical Sciences, Hamadan, IR, Iran. LA - eng GR - 140002281477/Hamadan University of Medical Sciences/ PT - Journal Article DEP - 20240102 PL - England TA - BMC Infect Dis JT - BMC infectious diseases JID - 100968551 RN - 0 (COVID-19 Vaccines) SB - IM MH - Female MH - Humans MH - Aged MH - COVID-19 Vaccines MH - *COVID-19/prevention & control MH - Cross-Sectional Studies MH - Analysis of Variance MH - *Cognitive Dysfunction MH - Vaccination PMC - PMC10763401 OTO - NOTNLM OT - Aging OT - COVID-19 vaccines OT - Immunosenescence OT - Intention COIS- The authors declare that they have no competing interests. EDAT- 2024/01/04 01:18 MHDA- 2024/01/05 06:43 PMCR- 2024/01/02 CRDT- 2024/01/03 09:16 PHST- 2023/09/04 00:00 [received] PHST- 2023/12/13 00:00 [accepted] PHST- 2024/01/05 06:43 [medline] PHST- 2024/01/04 01:18 [pubmed] PHST- 2024/01/03 09:16 [entrez] PHST- 2024/01/02 00:00 [pmc-release] AID - 10.1186/s12879-023-08903-8 [pii] AID - 8903 [pii] AID - 10.1186/s12879-023-08903-8 [doi] PST - epublish SO - BMC Infect Dis. 2024 Jan 2;24(1):18. doi: 10.1186/s12879-023-08903-8. PMID- 38165067 OWN - NLM STAT- MEDLINE DCOM- 20240314 LR - 20260616 IS - 1468-1331 (Electronic) IS - 1351-5101 (Print) IS - 1351-5101 (Linking) VI - 31 IP - 4 DP - 2024 Apr TI - Increased risk of functional neurological disorders following SARS-CoV-2 vaccination. PG - e16191 LID - 10.1111/ene.16191 [doi] LID - e16191 AB - BACKGROUND AND PURPOSE: The purpose of this study was to evaluate the possible correlation between SARS-CoV-2 vaccines and the onset of neurological syndromes. The aim was to challenge the association between SARS-CoV-2 vaccinations and the onset of acute functional neurological disorders (FNDs) compared to other neurological syndromes in hospitalized patients. METHODS: In this prospective cohort study, all adult inpatients consecutively admitted to a tertiary neurological centre were included. The prevalence and characteristics of neurological syndromes were compared between unvaccinated and vaccinated cases stratified according to the onset from vaccination. The study involved 843 subjects, namely 411 unvaccinated (UVC) and 432 vaccinated cases; these groups were comparable for demographics and clinical diagnosis distribution. RESULTS: Compared to UVC, subjects hospitalized within the first 30 days from vaccine exhibited higher prevalence of FNDs (12.3% vs. 3.6%; odds ratio 4.2, 95% confidence interval 1.6-11.1) and headache (10.8% vs. 5%; odds ratio 4.1, 95% confidence interval 1.9-8.8) but no other neurological syndromes. The FND cases following vaccinations showed similar premorbid conditions and severity but a higher percentage of sensory symptoms and pain compared to UVC FND cases. CONCLUSIONS: SARS-CoV-2 vaccination is associated with a significant short-term increased risk of FND and headache requiring hospitalization in an acute neurological setting. CI - (c) 2023 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology. FAU - Pilotto, Andrea AU - Pilotto A AUID- ORCID: 0000-0003-2029-6606 AD - Neurology Unit, Department of Continuity of Care and Frailty, ASST Spedali Civili Brescia Hospital, Brescia, Italy. AD - Laboratory of Digital Neurology and Biosensors, University of Brescia, Brescia, Italy. AD - Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy. FAU - Catania, Marcello AU - Catania M AD - Neurology Unit, Department of Continuity of Care and Frailty, ASST Spedali Civili Brescia Hospital, Brescia, Italy. AD - Laboratory of Digital Neurology and Biosensors, University of Brescia, Brescia, Italy. AD - Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy. FAU - Mattioli, Irene AU - Mattioli I AD - Neurology Unit, Department of Continuity of Care and Frailty, ASST Spedali Civili Brescia Hospital, Brescia, Italy. AD - Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy. FAU - Zoppi, Nicola AU - Zoppi N AD - Neurology Unit, Department of Continuity of Care and Frailty, ASST Spedali Civili Brescia Hospital, Brescia, Italy. AD - Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy. FAU - Ceccardi, Giulia AU - Ceccardi G AD - Neurology Unit, Department of Continuity of Care and Frailty, ASST Spedali Civili Brescia Hospital, Brescia, Italy. AD - Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy. FAU - Rao, Renata AU - Rao R AD - Neurology Unit, Department of Continuity of Care and Frailty, ASST Spedali Civili Brescia Hospital, Brescia, Italy. FAU - Gipponi, Stefano AU - Gipponi S AD - Neurology Unit, Department of Continuity of Care and Frailty, ASST Spedali Civili Brescia Hospital, Brescia, Italy. FAU - Magoni, Mauro AU - Magoni M AD - Stroke Unit, ASST Spedali Civili of Brescia, Brescia, Italy. FAU - Gamba, Massimo AU - Gamba M AD - Stroke Unit, ASST Spedali Civili of Brescia, Brescia, Italy. FAU - Padovani, Alessandro AU - Padovani A AD - Neurology Unit, Department of Continuity of Care and Frailty, ASST Spedali Civili Brescia Hospital, Brescia, Italy. AD - Laboratory of Digital Neurology and Biosensors, University of Brescia, Brescia, Italy. AD - Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy. AD - Brain Health Center, University of Brescia, Brescia, Italy. LA - eng PT - Journal Article DEP - 20240102 PL - England TA - Eur J Neurol JT - European journal of neurology JID - 9506311 RN - 0 (COVID-19 Vaccines) SB - IM MH - Adult MH - Humans MH - *COVID-19 MH - COVID-19 Vaccines MH - Prospective Studies MH - SARS-CoV-2 MH - Vaccination MH - *Conversion Disorder MH - Headache MH - Syndrome PMC - PMC11235690 OTO - NOTNLM OT - SARS-CoV-2 vaccination OT - acute neurology OT - medical unexplained symptoms, functional neurological disorders COIS- Andrea Pilotto, Marcello Catania, Irene Mattioli, Giulia Ceccardi, Renata Rao, Stefano Gipponi Mauro Magoni, Massimo Gamba and Alessandro Padovani report no disclosures relevant to the submitted work. EDAT- 2024/01/02 11:45 MHDA- 2024/03/14 06:47 PMCR- 2024/01/02 CRDT- 2024/01/02 08:02 PHST- 2023/12/02 00:00 [revised] PHST- 2023/08/22 00:00 [received] PHST- 2023/12/12 00:00 [accepted] PHST- 2024/03/14 06:47 [medline] PHST- 2024/01/02 11:45 [pubmed] PHST- 2024/01/02 08:02 [entrez] PHST- 2024/01/02 00:00 [pmc-release] AID - ENE16191 [pii] AID - 10.1111/ene.16191 [doi] PST - ppublish SO - Eur J Neurol. 2024 Apr;31(4):e16191. doi: 10.1111/ene.16191. Epub 2024 Jan 2. PMID- 38134199 OWN - NLM STAT- MEDLINE DCOM- 20231225 LR - 20260105 IS - 1091-6490 (Electronic) IS - 0027-8424 (Print) IS - 0027-8424 (Linking) VI - 120 IP - 52 DP - 2023 Dec 26 TI - Monovalent SARS-COV-2 mRNA vaccine using optimal UTRs and LNPs is highly immunogenic and broadly protective against Omicron variants. PG - e2311752120 LID - 10.1073/pnas.2311752120 [doi] LID - e2311752120 AB - The emergence of highly transmissible severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) that are resistant to the current COVID-19 vaccines highlights the need for continued development of broadly protective vaccines for the future. Here, we developed two messenger RNA (mRNA)-lipid nanoparticle (LNP) vaccines, TU88mCSA and ALCmCSA, using the ancestral SARS-CoV-2 spike sequence, optimized 5' and 3' untranslated regions (UTRs), and LNP combinations. Our data showed that these nanocomplexes effectively activate CD4(+) and CD8(+) T cell responses and humoral immune response and provide complete protection against WA1/2020, Omicron BA.1 and BQ.1 infection in hamsters. Critically, in Omicron BQ.1 challenge hamster models, TU88mCSA and ALCmCSA not only induced robust control of virus load in the lungs but also enhanced protective efficacy in the upper respiratory airways. Antigen-specific immune analysis in mice revealed that the observed cross-protection is associated with superior UTRs [Carboxylesterase 1d (Ces1d)/adaptor protein-3beta (AP3B1)] and LNP formulations that elicit robust lung tissue-resident memory T cells. Strong protective effects of TU88mCSA or ALCmCSA against both WA1/2020 and VOCs suggest that this mRNA-LNP combination can be a broadly protective vaccine platform in which mRNA cargo uses the ancestral antigen sequence regardless of the antigenic drift. This approach could be rapidly adapted for clinical use and timely deployment of vaccines against emerging and reemerging VOCs. FAU - Ye, Zhongfeng AU - Ye Z AUID- ORCID: 0000-0003-0383-7247 AD - Department of Biomedical Engineering, Tufts University, Medford, MA 02155. FAU - Bonam, Srinivasa Reddy AU - Bonam SR AUID- ORCID: 0000-0002-2888-2418 AD - Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555. FAU - McKay, Lindsay G A AU - McKay LGA AUID- ORCID: 0000-0003-0369-9067 AD - National Emerging Infectious Diseases Laboratories and Department of Virology, Immunology, and Microbiology, Chobanian & Avedisian School of Medicine, Boston University, Boston, MA 02215. FAU - Plante, Jessica A AU - Plante JA AUID- ORCID: 0000-0002-4768-7458 AD - Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555. AD - World Reference Center for Emerging Viruses and Arboviruses, University of Texas Medical Branch, Galveston, TX 77555. FAU - Walker, Jordyn AU - Walker J AD - Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555. AD - World Reference Center for Emerging Viruses and Arboviruses, University of Texas Medical Branch, Galveston, TX 77555. FAU - Zhao, Yu AU - Zhao Y AD - Department of Biomedical Engineering, Tufts University, Medford, MA 02155. FAU - Huang, Changfeng AU - Huang C AD - Department of Biomedical Engineering, Tufts University, Medford, MA 02155. FAU - Chen, Jinjin AU - Chen J AD - Department of Biomedical Engineering, Tufts University, Medford, MA 02155. FAU - Xu, Chutian AU - Xu C AD - Department of Biomedical Engineering, Tufts University, Medford, MA 02155. FAU - Li, Yamin AU - Li Y AUID- ORCID: 0000-0002-5535-1807 AD - Department of Pharmacology, State University of New York Upstate Medical University, Syracuse, NY 13210. FAU - Liu, Lihan AU - Liu L AD - Department of Biomedical Engineering, Tufts University, Medford, MA 02155. FAU - Harmon, Joseph AU - Harmon J AUID- ORCID: 0000-0002-6445-2191 AD - Department of Biomedical Engineering, Tufts University, Medford, MA 02155. FAU - Gao, Shuliang AU - Gao S AD - Department of Biomedical Engineering, Tufts University, Medford, MA 02155. FAU - Song, Donghui AU - Song D AUID- ORCID: 0000-0001-9081-4275 AD - Department of Biomedical Engineering, Tufts University, Medford, MA 02155. FAU - Zhang, Zhibo AU - Zhang Z AUID- ORCID: 0009-0007-7320-3983 AD - Department of Biomedical Engineering, Tufts University, Medford, MA 02155. FAU - Plante, Kenneth S AU - Plante KS AUID- ORCID: 0000-0002-7485-3167 AD - Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555. AD - World Reference Center for Emerging Viruses and Arboviruses, University of Texas Medical Branch, Galveston, TX 77555. FAU - Griffiths, Anthony AU - Griffiths A AUID- ORCID: 0000-0001-5435-8364 AD - National Emerging Infectious Diseases Laboratories and Department of Virology, Immunology, and Microbiology, Chobanian & Avedisian School of Medicine, Boston University, Boston, MA 02215. FAU - Chen, Jianzhu AU - Chen J AUID- ORCID: 0000-0002-5687-6154 AD - Koch Institute for Integrative Cancer Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139. FAU - Hu, Haitao AU - Hu H AD - Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555. FAU - Xu, Qiaobing AU - Xu Q AD - Department of Biomedical Engineering, Tufts University, Medford, MA 02155. LA - eng GR - R24 AI120942/AI/NIAID NIH HHS/United States PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20231222 PL - United States TA - Proc Natl Acad Sci U S A JT - Proceedings of the National Academy of Sciences of the United States of America JID - 7505876 RN - 0 (RNA, Messenger) RN - 0 (COVID-19 Vaccines) RN - 0 (mRNA Vaccines) RN - 0 (3' Untranslated Regions) RN - 0 (Antibodies, Neutralizing) RN - 0 (Antibodies, Viral) RN - SARS-CoV-2 variants SB - IM MH - Cricetinae MH - Animals MH - Humans MH - Mice MH - RNA, Messenger/genetics MH - *COVID-19 Vaccines/genetics MH - mRNA Vaccines MH - SARS-CoV-2/genetics MH - *COVID-19/prevention & control MH - 3' Untranslated Regions MH - Antibodies, Neutralizing MH - Antibodies, Viral PMC - PMC10756290 OTO - NOTNLM OT - lipid nanoparticle OT - lung tissue-resident memory T cells OT - mRNA vaccine OT - untranslated region COIS- Competing interests statement:Q.X. and Z.Y. are inventors on a provisional patent from Tufts University. Q.X. is a founder and consultant (with Chief Technology Officer title) of Hopewell Therapeutics Inc. EDAT- 2023/12/22 19:43 MHDA- 2023/12/25 06:42 PMCR- 2023/12/22 CRDT- 2023/12/22 13:45 PHST- 2023/12/25 06:42 [medline] PHST- 2023/12/22 19:43 [pubmed] PHST- 2023/12/22 13:45 [entrez] PHST- 2023/12/22 00:00 [pmc-release] AID - 202311752 [pii] AID - 10.1073/pnas.2311752120 [doi] PST - ppublish SO - Proc Natl Acad Sci U S A. 2023 Dec 26;120(52):e2311752120. doi: 10.1073/pnas.2311752120. Epub 2023 Dec 22. PMID- 38130975 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240103 IS - 2396-8923 (Electronic) IS - 2396-8923 (Linking) VI - 8 IP - 1 DP - 2023 TI - COVID's long shadow: How SARS-CoV-2 infection, COVID-19 severity, and vaccination status affect long-term cognitive performance and health. PG - bpad038 LID - 10.1093/biomethods/bpad038 [doi] LID - bpad038 AB - COVID-19 affects a variety of organs and systems of the body including the central nervous system. Recent research has shown that COVID-19 survivors often experience neurological and psychiatric complications that can last for months after infection. We conducted a large Internet study using online tests to analyze the effects of SARS-CoV-2 infection, COVID-19 severity, and vaccination on health, intelligence, memory, and information processing precision and speed in a cohort of 4445 subjects. We found that both SARS-CoV-2 infection and COVID-19 severity were associated with negative impacts on patients' health. Furthermore, we observed a negative association between COVID-19 severity and cognitive performance. Younger participants had a higher likelihood of SARS-CoV-2 contraction, while the elderly had a higher likelihood of severe COVID-19 and vaccination. The association between age and COVID-19 severity was primarily mediated by older participants' impaired long-term health. Vaccination was positively associated with intelligence and the precision of information processing. However, the positive association between vaccination and intelligence was likely mediated by achieved education, which was itself strongly associated with the likelihood of being vaccinated. CI - (c) The Author(s) 2023. Published by Oxford University Press. FAU - Flegr, Jaroslav AU - Flegr J AUID- ORCID: 0000-0002-0822-0126 AD - Department of Philosophy and History of Sciences, Faculty of Science, Laboratory of Evolutionary Biology, Charles University, Prague 128 00, Czechia. FAU - Latifi, Ashkan AU - Latifi A AD - Department of Philosophy and History of Sciences, Faculty of Science, Laboratory of Evolutionary Biology, Charles University, Prague 128 00, Czechia. LA - eng SI - figshare/10.6084/m9.figshare.22586446.v1 PT - Journal Article DEP - 20231207 PL - England TA - Biol Methods Protoc JT - Biology methods & protocols JID - 101693064 PMC - PMC10733723 OTO - NOTNLM OT - COVID-19 OT - SARS-CoV-2 OT - cognition OT - cognitive performance OT - long-term effects OT - mental health COIS- The authors declare no competing interests. EDAT- 2023/12/22 06:42 MHDA- 2023/12/22 06:43 PMCR- 2023/12/07 CRDT- 2023/12/22 04:08 PHST- 2023/11/09 00:00 [received] PHST- 2023/11/30 00:00 [revised] PHST- 2023/12/05 00:00 [accepted] PHST- 2023/12/22 06:43 [medline] PHST- 2023/12/22 06:42 [pubmed] PHST- 2023/12/22 04:08 [entrez] PHST- 2023/12/07 00:00 [pmc-release] AID - bpad038 [pii] AID - 10.1093/biomethods/bpad038 [doi] PST - epublish SO - Biol Methods Protoc. 2023 Dec 7;8(1):bpad038. doi: 10.1093/biomethods/bpad038. eCollection 2023. PMID- 38113758 OWN - NLM STAT- MEDLINE DCOM- 20240122 LR - 20250310 IS - 2352-3964 (Electronic) IS - 2352-3964 (Linking) VI - 99 DP - 2024 Jan TI - Mucosal SARS-CoV-2 vaccination of rodents elicits superior systemic T central memory function and cross-neutralising antibodies against variants of concern. PG - 104924 LID - S2352-3964(23)00490-5 [pii] LID - 10.1016/j.ebiom.2023.104924 [doi] LID - 104924 AB - BACKGROUND: COVID-19 vaccines used in humans are highly effective in limiting disease and death caused by the SARS-CoV-2 virus, yet improved vaccines that provide greater protection at mucosal surfaces, which could reduce break-through infections and subsequent transmission, are still needed. METHODS: Here we tested an intranasal (I.N.) vaccination with the receptor binding domain of Spike antigen of SARS-CoV-2 (S-RBD) in combination with the mucosal adjuvant mastoparan-7 compared with the sub-cutaneous (S.C.) route, adjuvanted by either M7 or the gold-standard adjuvant, alum, in mice, for immunological read-outs. The same formulation delivered I.N. or S.C. was tested in hamsters to assess efficacy. FINDINGS: I.N. vaccination improved systemic T cell responses compared to an equivalent dose of antigen delivered S.C. and T cell phenotypes induced by I.N. vaccine administration included enhanced polyfunctionality (combined IFN-gamma and TNF expression) and greater numbers of T central memory (T(CM)) cells. These phenotypes were T cell-intrinsic and could be recalled in the lungs and/or brachial LNs upon antigen challenge after adoptive T cell transfer to naive recipients. Furthermore, mucosal vaccination induced antibody responses that were similarly effective in neutralising the binding of the parental strain of S-RBD to its ACE2 receptor, but showed greater cross-neutralising capacity against multiple variants of concern (VOC), compared to S.C. vaccination. I.N. vaccination provided significant protection from lung pathology compared to unvaccinated animals upon challenge with homologous and heterologous SARS-CoV-2 strains in a hamster model. INTERPRETATION: These results highlight the role of nasal vaccine administration in imprinting an immune profile associated with long-term T cell retention and diversified neutralising antibody responses, which could be applied to improve vaccines for COVID-19 and other infectious diseases. FUNDING: This study was funded by Duke-NUS Medical School, the Singapore Ministry of Education, the National Medical Research Council of Singapore and a DBT-BIRAC Grant. CI - Copyright (c) 2023 The Author(s). Published by Elsevier B.V. All rights reserved. FAU - O'Neill, Aled AU - O'Neill A AD - Program in Emerging Infectious Diseases, Duke-National University of Singapore Medical School, 169857, Singapore. FAU - Mantri, Chinmay Kumar AU - Mantri CK AD - Program in Emerging Infectious Diseases, Duke-National University of Singapore Medical School, 169857, Singapore. FAU - Tan, Chee Wah AU - Tan CW AD - Program in Emerging Infectious Diseases, Duke-National University of Singapore Medical School, 169857, Singapore; Infectious Diseases Translational Research Programme, Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, 117545, Singapore. FAU - Saron, Wilfried A A AU - Saron WAA AD - Program in Emerging Infectious Diseases, Duke-National University of Singapore Medical School, 169857, Singapore. FAU - Nagaraj, Santhosh Kambaiah AU - Nagaraj SK AD - Centre for Infectious Disease Research, Microbiology and Cell Biology Department, Indian Institute of Science, Bengaluru, 560012, India. FAU - Kala, Monica Palanichamy AU - Kala MP AD - Program in Emerging Infectious Diseases, Duke-National University of Singapore Medical School, 169857, Singapore. FAU - Joy, Christy Margarat AU - Joy CM AD - Centre for Infectious Disease Research, Microbiology and Cell Biology Department, Indian Institute of Science, Bengaluru, 560012, India. FAU - Rathore, Abhay P S AU - Rathore APS AD - Program in Emerging Infectious Diseases, Duke-National University of Singapore Medical School, 169857, Singapore; Department of Pathology, Duke University Medical Centre, Durham, North Carolina, 27705, USA. FAU - Tripathi, Shashank AU - Tripathi S AD - Centre for Infectious Disease Research, Microbiology and Cell Biology Department, Indian Institute of Science, Bengaluru, 560012, India. FAU - Wang, Lin-Fa AU - Wang LF AD - Program in Emerging Infectious Diseases, Duke-National University of Singapore Medical School, 169857, Singapore; SingHealth Duke-NUS Global Health Institute, Singapore. FAU - St John, Ashley L AU - St John AL AD - Program in Emerging Infectious Diseases, Duke-National University of Singapore Medical School, 169857, Singapore; Department of Pathology, Duke University Medical Centre, Durham, North Carolina, 27705, USA; SingHealth Duke-NUS Global Health Institute, Singapore; Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore. Electronic address: ashley.st.john@duke-nus.edu.sg. LA - eng PT - Journal Article DEP - 20231218 PL - Netherlands TA - EBioMedicine JT - EBioMedicine JID - 101647039 RN - 0 (COVID-19 Vaccines) RN - 0 (Broadly Neutralizing Antibodies) RN - 0 (Adjuvants, Immunologic) RN - 0 (Antibodies, Neutralizing) RN - 0 (Antibodies, Viral) SB - IM MH - Cricetinae MH - Humans MH - Animals MH - Mice MH - *COVID-19 Vaccines MH - Rodentia MH - Broadly Neutralizing Antibodies MH - SARS-CoV-2 MH - *COVID-19/prevention & control MH - Vaccination MH - Adjuvants, Immunologic MH - Antibodies, Neutralizing MH - Antibodies, Viral PMC - PMC10772395 OTO - NOTNLM OT - COVID-19 OT - Mucosal vaccine OT - SARS-CoV-2 OT - T cell COIS- Declaration of interests ALS is an inventor on a patent relating to mucosal vaccination against COVID-19. LFW and TCW are co-inventors on a patent for the sVNT assay and receive royalties from the cPass kit. EDAT- 2023/12/19 19:52 MHDA- 2024/01/22 06:43 PMCR- 2023/12/18 CRDT- 2023/12/19 18:12 PHST- 2023/02/08 00:00 [received] PHST- 2023/11/27 00:00 [revised] PHST- 2023/12/02 00:00 [accepted] PHST- 2024/01/22 06:43 [medline] PHST- 2023/12/19 19:52 [pubmed] PHST- 2023/12/19 18:12 [entrez] PHST- 2023/12/18 00:00 [pmc-release] AID - S2352-3964(23)00490-5 [pii] AID - 104924 [pii] AID - 10.1016/j.ebiom.2023.104924 [doi] PST - ppublish SO - EBioMedicine. 2024 Jan;99:104924. doi: 10.1016/j.ebiom.2023.104924. Epub 2023 Dec 18. PMID- 38046447 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231205 IS - 2405-6502 (Electronic) IS - 2405-6502 (Linking) VI - 33 DP - 2023 Dec TI - Clinical characteristics of motor functional neurological disorder manifesting as limb weakness after vaccination against coronavirus disease 2019: A case series. PG - 100487 LID - 10.1016/j.ensci.2023.100487 [doi] LID - 100487 AB - BACKGROUND: The characteristics of functional limb weakness (FLW) as one of the manifestations of functional neurological disorder after vaccination against coronavirus disease 2019 (COVID-19) remain controversial. METHODS: In this descriptive case series, we aimed to elucidate the characteristics of Japanese patients with FLW who claimed muscle weakness after COVID-19 vaccination among patients who visited our outpatient clinic between 1 June 2021 and 31 December 2022. RESULTS: Nine patients were diagnosed with FLW (mean age: 30.8 years), including two men and seven women. Seven patients were vaccinated with the BioNTech/Pfizer vaccine and two with the mRNA-1273 Moderna vaccine. All patients demonstrated various positive signs for FLW. Magnetic resonance imaging or computed tomography indicated no abnormality that could explain their symptoms. At the time of the clinic visit, five patients were treated for psychiatric disorders, including depression, insomnia, attention-deficit hyperactivity disorder, and Asperger's syndrome. Muscle weakness spread to the limbs beyond the vaccinated arm in seven patients. CONCLUSIONS: We describe the basic characteristics of FLW in Japanese patients after COVID-19 vaccination. Further recognition of these characteristics could aid the diagnosis of FLW by physicians allowing them to support these patients effectively. CI - (c) 2023 The Authors. Published by Elsevier B.V. FAU - Ohira, Masayuki AU - Ohira M AD - Department of General Internal Medicine and Clinical Laboratory, National Center of Neurology and Psychiatry National Center Hospital, Kodaira, Tokyo, Japan. FAU - Osada, Takashi AU - Osada T AD - Department of General Internal Medicine, National Center of Neurology and Psychiatry National Center Hospital, Kodaira, Tokyo, Japan. FAU - Kimura, Hiroaki AU - Kimura H AD - Department of General Internal Medicine, National Center of Neurology and Psychiatry National Center Hospital, Kodaira, Tokyo, Japan. FAU - Sano, Terunori AU - Sano T AD - Department of General Internal Medicine and Clinical Laboratory, National Center of Neurology and Psychiatry National Center Hospital, Kodaira, Tokyo, Japan. FAU - Takao, Masaki AU - Takao M AD - Department of General Internal Medicine, National Center of Neurology and Psychiatry National Center Hospital, Kodaira, Tokyo, Japan. LA - eng PT - Journal Article DEP - 20231113 PL - Netherlands TA - eNeurologicalSci JT - eNeurologicalSci JID - 101667077 PMC - PMC10692754 OTO - NOTNLM OT - COVID-19 OT - Epidemiological survey OT - Functional neurological disorder OT - Vaccination COIS- The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Masayuki Ohira and Masaki Takao received research funding from Pfizer for tick-borne encephalitis. Masaki Takao received lecture fees from Pfizer EDAT- 2023/12/04 06:42 MHDA- 2023/12/04 06:43 PMCR- 2023/11/13 CRDT- 2023/12/04 04:59 PHST- 2023/07/05 00:00 [received] PHST- 2023/11/04 00:00 [revised] PHST- 2023/11/11 00:00 [accepted] PHST- 2023/12/04 06:43 [medline] PHST- 2023/12/04 06:42 [pubmed] PHST- 2023/12/04 04:59 [entrez] PHST- 2023/11/13 00:00 [pmc-release] AID - S2405-6502(23)00045-X [pii] AID - 100487 [pii] AID - 10.1016/j.ensci.2023.100487 [doi] PST - epublish SO - eNeurologicalSci. 2023 Nov 13;33:100487. doi: 10.1016/j.ensci.2023.100487. eCollection 2023 Dec. PMID- 38045702 OWN - NLM STAT- MEDLINE DCOM- 20231205 LR - 20240327 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 14 DP - 2023 TI - Impact of SARS-CoV-2 vaccination on FcgammaRIIIA/CD16 dynamics in Natural Killer cells: relevance for antibody-dependent functions. PG - 1285203 LID - 10.3389/fimmu.2023.1285203 [doi] LID - 1285203 AB - INTRODUCTION: Natural Killer (NK) cells contribute to the protective effects of vaccine-induced antibodies thanks to the low affinity receptor for IgG, FcgammaRIIIA/CD16, whose aggregation leads to the killing of infected cells and IFNgamma release, through which they potentiate adaptive immune responses. METHODS: Forty-seven healthy young individuals undergoing either homologous (ChAdOx1-S/ChAdOx1-S) or heterologous (ChAdOx1-S/BNT162B2) SARS-CoV-2 vaccination settings were recruited. Peripheral blood samples were collected immediately prior to vaccination and 8 weeks after the booster dose. The phenotypic and functional profile of NK cells was evaluated by flow cytometry at both time points. Serum samples were tested to evaluate circulating anti-Spike IgG levels and cytomegalovirus serostatus. CD16 F158V polymorphism was assessed by sequencing analysis. RESULTS: The downregulation of CD16 and the selective impairment of antibody-dependent cytotoxicity and IFNgamma production in CD56(dim) NK population, persisting 8 weeks after boosting, were observed in heterologous, but not in homologous SARS-CoV-2 vaccination scheme. While the magnitude of CD16-dependent functions of the global CD56(dim) pool correlated with receptor levels before and after vaccination, the responsivity of NKG2C(+) subset, that displays amplified size and functionality in HCMV(+) individuals, resulted intrinsically insensitive to CD16 levels. Individual CD16 responsiveness was also affected by CD16F158V polymorphism; F/F low affinity individuals, characterized by reduced CD16 levels and functions independently of vaccination, did not show post-vaccinal functional impairment with respect to intermediate and high affinity ones, despite a comparable CD16 downregulation. Further, CD16 high affinity ligation conditions by means of afucosylated mAb overcame vaccine-induced and genotype-dependent functional defects. Finally, the preservation of CD16 expression directly correlated with anti-Spike IgG titer, hinting that the individual magnitude of receptor-dependent functions may contribute to the amplification of the vaccinal response. CONCLUSION: This study demonstrates a durable downmodulation of CD16 levels and Ab-dependent NK functions after SARS-CoV-2 heterologous vaccination, and highlights the impact of genetic and environmental host-related factors in modulating NK cell susceptibility to post-vaccinal Fc-dependent functional impairment. CI - Copyright (c) 2023 Capuano, De Federicis, Ciuti, Turriziani, Angeloni, Anastasi, Giannini, Belardinilli, Molfetta, Alvaro, Palmieri and Galandrini. FAU - Capuano, Cristina AU - Capuano C AD - Departmental Faculty of Medicine and Surgery, UniCamillus-Saint Camillus International University of Health and Medical Sciences, Rome, Italy. FAU - De Federicis, Davide AU - De Federicis D AD - Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy. AD - Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy. FAU - Ciuti, Daniel AU - Ciuti D AD - Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy. FAU - Turriziani, Ombretta AU - Turriziani O AD - Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy. FAU - Angeloni, Antonio AU - Angeloni A AD - Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy. FAU - Anastasi, Emanuela AU - Anastasi E AD - Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy. FAU - Giannini, Giuseppe AU - Giannini G AD - Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy. FAU - Belardinilli, Francesca AU - Belardinilli F AD - Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy. FAU - Molfetta, Rosa AU - Molfetta R AD - Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy. FAU - Alvaro, Domenico AU - Alvaro D AD - Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy. FAU - Palmieri, Gabriella AU - Palmieri G AD - Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy. FAU - Galandrini, Ricciarda AU - Galandrini R AD - Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20231116 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 RN - 0 (COVID-19 Vaccines) RN - 0 (BNT162 Vaccine) RN - 0 (Antibodies, Viral) RN - 0 (Immunoglobulin G) SB - IM MH - Humans MH - *COVID-19 Vaccines/metabolism MH - SARS-CoV-2 MH - Antibody-Dependent Cell Cytotoxicity MH - BNT162 Vaccine MH - *COVID-19/prevention & control/metabolism MH - Killer Cells, Natural MH - Antibodies, Viral/metabolism MH - Vaccination MH - Immunoglobulin G/metabolism PMC - PMC10693335 OTO - NOTNLM OT - ADCC OT - CD16 OT - CD16 polymorphism OT - IFNgamma OT - NK cells OT - SARS-CoV-2 vaccine OT - memory NK cells COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationship that could be constructed as a potential conflict of interest. EDAT- 2023/12/04 06:42 MHDA- 2023/12/05 17:44 PMCR- 2023/01/01 CRDT- 2023/12/04 04:43 PHST- 2023/08/29 00:00 [received] PHST- 2023/10/27 00:00 [accepted] PHST- 2023/12/05 17:44 [medline] PHST- 2023/12/04 06:42 [pubmed] PHST- 2023/12/04 04:43 [entrez] PHST- 2023/01/01 00:00 [pmc-release] AID - 10.3389/fimmu.2023.1285203 [doi] PST - epublish SO - Front Immunol. 2023 Nov 16;14:1285203. doi: 10.3389/fimmu.2023.1285203. eCollection 2023. PMID- 38038432 OWN - NLM STAT- MEDLINE DCOM- 20240104 LR - 20250415 IS - 1098-5514 (Electronic) IS - 0022-538X (Print) IS - 0022-538X (Linking) VI - 97 IP - 12 DP - 2023 Dec 21 TI - A multi-epitope/CXCL11 prime/pull coronavirus mucosal vaccine boosts the frequency and the function of lung-resident memory CD4(+) and CD8(+) T cells and enhanced protection against COVID-19-like symptoms and death caused by SARS-CoV-2 infection. PG - e0109623 LID - 10.1128/jvi.01096-23 [doi] LID - e01096-23 AB - Although the current rate of SARS-CoV-2 infections has decreased significantly, COVID-19 still ranks very high as a cause of death worldwide. As of October 2023, the weekly mortality rate is still at 600 deaths in the United States alone, which surpasses even the worst mortality rates recorded for influenza. Thus, the long-term outlook of COVID-19 is still a serious concern outlining the need for the next-generation vaccine. This study found that a prime/pull coronavirus vaccine strategy increased the frequency of functional SARS-CoV-2-specific CD4(+) and CD8(+) memory T cells in the lungs of SARS-CoV-2-infected triple transgenic HLA-DR*0101/HLA-A*0201/hACE2 mouse model, thereby resulting in low viral titer and reduced COVID-19-like symptoms. FAU - Zayou, Latifa AU - Zayou L AUID- ORCID: 0009-0008-3049-4140 AD - Laboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, School of Medicine, University of California Irvine, Irvine, California, USA. AD - Laboratory of Cell Biology and Molecular Genetics, Faculty of Sciences, Ibn Zohr University, Agadir, Morocco. FAU - Prakash, Swayam AU - Prakash S AUID- ORCID: 0000-0003-3986-890X AD - Laboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, School of Medicine, University of California Irvine, Irvine, California, USA. FAU - Dhanushkodi, Nisha Rajeswari AU - Dhanushkodi NR AD - Laboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, School of Medicine, University of California Irvine, Irvine, California, USA. FAU - Quadiri, Afshana AU - Quadiri A AD - Laboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, School of Medicine, University of California Irvine, Irvine, California, USA. FAU - Ibraim, Izabela Coimbra AU - Ibraim IC AD - High containment facility, School of Medicine, University of California Irvine, Irvine, California, USA. FAU - Singer, Mahmoud AU - Singer M AD - Laboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, School of Medicine, University of California Irvine, Irvine, California, USA. FAU - Salem, Amirah AU - Salem A AD - Laboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, School of Medicine, University of California Irvine, Irvine, California, USA. FAU - Shaik, Amin Mohammed AU - Shaik AM AD - Laboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, School of Medicine, University of California Irvine, Irvine, California, USA. FAU - Suzer, Berfin AU - Suzer B AD - Laboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, School of Medicine, University of California Irvine, Irvine, California, USA. FAU - Chilukuri, Amruth AU - Chilukuri A AD - Laboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, School of Medicine, University of California Irvine, Irvine, California, USA. FAU - Tran, Jennifer AU - Tran J AD - Laboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, School of Medicine, University of California Irvine, Irvine, California, USA. FAU - Nguyen, Pauline Chau AU - Nguyen PC AD - Laboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, School of Medicine, University of California Irvine, Irvine, California, USA. FAU - Sun, Miyo AU - Sun M AD - Laboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, School of Medicine, University of California Irvine, Irvine, California, USA. FAU - Hormi-Carver, Kathy K AU - Hormi-Carver KK AD - Laboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, School of Medicine, University of California Irvine, Irvine, California, USA. FAU - Belmouden, Ahmed AU - Belmouden A AD - Laboratory of Cell Biology and Molecular Genetics, Faculty of Sciences, Ibn Zohr University, Agadir, Morocco. FAU - Vahed, Hawa AU - Vahed H AD - Department of Vaccines and Immunotherapies, TechImmune, LLC, University Lab Partners, Irvine, California, USA. FAU - Gil, Daniel AU - Gil D AD - Department of Vaccines and Immunotherapies, TechImmune, LLC, University Lab Partners, Irvine, California, USA. FAU - Ulmer, Jeffrey B AU - Ulmer JB AD - Department of Vaccines and Immunotherapies, TechImmune, LLC, University Lab Partners, Irvine, California, USA. FAU - BenMohamed, Lbachir AU - BenMohamed L AUID- ORCID: 0000-0001-9468-2521 AD - Laboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, School of Medicine, University of California Irvine, Irvine, California, USA. AD - Department of Vaccines and Immunotherapies, TechImmune, LLC, University Lab Partners, Irvine, California, USA. AD - Department of Molecular Biology and Biochemistry, University of California Irvine, Irvine, California, USA. AD - Institute for Immunology, School of Medicine, University of California Irvine, Irvine, California, USA. LA - eng GR - R41 AI138764/AI/NIAID NIH HHS/United States GR - R01 AI143348/AI/NIAID NIH HHS/United States GR - R43 AI174383/AI/NIAID NIH HHS/United States GR - R01 AI158060/AI/NIAID NIH HHS/United States GR - R43 AI124911/AI/NIAID NIH HHS/United States GR - R01 AI150091/AI/NIAID NIH HHS/United States GR - R21 AI143326/AI/NIAID NIH HHS/United States GR - R21 AI110902/AI/NIAID NIH HHS/United States GR - R21 AI147499/AI/NIAID NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20231201 PL - United States TA - J Virol JT - Journal of virology JID - 0113724 RN - 0 (Chemokine CXCL11) RN - 0 (COVID-19 Vaccines) RN - 0 (CXCL11 protein, human) RN - 0 (Epitopes) RN - 0 (Spike Glycoprotein, Coronavirus) RN - 0 (spike protein, SARS-CoV-2) SB - IM MH - Animals MH - Humans MH - Mice MH - CD4-Positive T-Lymphocytes/immunology MH - CD8-Positive T-Lymphocytes/immunology MH - Chemokine CXCL11/immunology MH - *COVID-19/immunology/prevention & control MH - *COVID-19 Vaccines/immunology MH - Epitopes MH - Lung/immunology/virology MH - SARS-CoV-2/physiology MH - Spike Glycoprotein, Coronavirus MH - Disease Models, Animal PMC - PMC10734477 OTO - NOTNLM OT - CD8+ T cells OT - COVID-19 OT - CXCL-11 OT - SARS-CoV-2 OT - lungs OT - memory CD4+ COIS- L.B.M. has an equity interest in TechImmune, LLC, a company that may potentially benefit from the research results and serves on the company's Scientific Advisory Board. L.B.M.'s relationship with TechImmune, LLC has been reviewed and approved by the University of California, Irvine, in accordance with its conflict-of-interest policies. EDAT- 2023/12/01 12:42 MHDA- 2023/12/22 06:42 PMCR- 2023/12/01 CRDT- 2023/12/01 09:02 PHST- 2023/12/22 06:42 [medline] PHST- 2023/12/01 12:42 [pubmed] PHST- 2023/12/01 09:02 [entrez] PHST- 2023/12/01 00:00 [pmc-release] AID - 01096-23 [pii] AID - jvi.01096-23 [pii] AID - 10.1128/jvi.01096-23 [doi] PST - ppublish SO - J Virol. 2023 Dec 21;97(12):e0109623. doi: 10.1128/jvi.01096-23. Epub 2023 Dec 1. PMID- 38027416 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250530 IS - 2754-0413 (Electronic) IS - 2754-0413 (Linking) VI - 2 IP - 1 DP - 2023 TI - T cell immune memory after covid-19 and vaccination. PG - e000468 LID - 10.1136/bmjmed-2022-000468 [doi] LID - e000468 AB - The T cell memory response is a crucial component of adaptive immunity responsible for limiting or preventing viral reinfection. T cell memory after infection with the SARS-CoV-2 virus or vaccination is broad, and spans multiple viral proteins and epitopes, about 20 in each individual. So far the T cell memory response is long lasting and provides a high level of cross reactivity and hence resistance to viral escape by variants of the SARS-CoV-2 virus, such as the omicron variant. All current vaccine regimens tested produce robust T cell memory responses, and heterologous regimens will probably enhance protective responses through increased breadth. T cell memory could have a major role in protecting against severe covid-19 disease through rapid viral clearance and early presentation of epitopes, and the presence of cross reactive T cells might enhance this protection. T cell memory is likely to provide ongoing protection against admission to hospital and death, and the development of a pan-coronovirus vaccine might future proof against new pandemic strains. CI - (c) Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY. Published by BMJ. FAU - Wang, Lulu AU - Wang L AUID- ORCID: 0009-0009-7437-5968 AD - Translational and Clinical Research Institute, Immunity and Inflammation Theme, Newcastle University, Newcastle upon Tyne, UK. FAU - Nicols, Alex AU - Nicols A AD - Translational and Clinical Research Institute, Immunity and Inflammation Theme, Newcastle University, Newcastle upon Tyne, UK. FAU - Turtle, Lance AU - Turtle L AD - NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, UK. AD - Tropical and Infectious Disease Unit, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK. FAU - Richter, Alex AU - Richter A AUID- ORCID: 0000-0003-2885-1299 AD - Institute of Immunology and Immunotherapy, College of Medical and Dental Science, University of Birmingham, Birmingham, UK. FAU - Duncan, Christopher Ja AU - Duncan CJ AD - Translational and Clinical Research Institute, Immunity and Inflammation Theme, Newcastle University, Newcastle upon Tyne, UK. AD - Department of Infection and Tropical Medicine, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, UK. FAU - Dunachie, Susanna J AU - Dunachie SJ AD - NDM Centre For Global Health Research, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK. AD - Mahidol-Oxford Tropical Medicine Research Unit, Mahidol University Faculty of Science, Bangkok, Thailand. FAU - Klenerman, Paul AU - Klenerman P AD - Oxford University Hospitals NHS Foundation Trust, Oxford NIHR Biomedical Research Centre, University of Oxford, Oxford, Oxfordshire, UK. AD - Translational Gastroenterology Unit, University of Oxford, Oxford, UK. FAU - Payne, Rebecca P AU - Payne RP AUID- ORCID: 0000-0002-9037-7367 AD - Translational and Clinical Research Institute, Immunity and Inflammation Theme, Newcastle University, Newcastle upon Tyne, UK. LA - eng GR - WT_/Wellcome Trust/United Kingdom GR - MR/W020653/1/MRC_/Medical Research Council/United Kingdom GR - MR/W02067X/1/MRC_/Medical Research Council/United Kingdom PT - Journal Article PT - Review DEP - 20231122 PL - England TA - BMJ Med JT - BMJ medicine JID - 9918487584306676 PMC - PMC10668147 OTO - NOTNLM OT - COVID-19 OT - Covid-19 OT - Immunology OT - Respiratory tract infections COIS- Competing interests: We have read and understood the BMJ policy on declaration of interests and declare the following interests: CJAD has done consultancy for Synairgen and Moderna, has been an investigator on commercial SARS-CoV-2 vaccine studies (AstraZeneca, Moderna, and Valneva), receives current research funding from UK MRC, and previous funding from DHSC, Wellcome, and Barbour Foundation; LT has received consulting fees from MHRA, and from AstraZeneca and Synairgen, paid to the University of Liverpool, speakers' fees from Eisai Ltd, and support for conference attendance from AstraZeneca. PK has done consultancy work for Astra Zeneca, UCB, MedImmuneBio, GlaxoSimthKline, Ysios, Biomunex, and Infinitopes, has received competitive grant funding for basic science investigations of inflammatory bowel disease from Pfizer and Johnson&Jonhson through external grant award schemes, and has been granted a patent to generate anticancer vaccines using adenovirus vectors with CRUK; SJD is a member of the UK government's New and Emerging Respiratory Virus Threats Advisory Group; AR is co-investigator in a phase III study evaluation of a monoclonal antibody for pre-exposure prophylaxis with GlaxoSmithKline and received compensation from Takaeda and CSL Biotechnology for conference attendances invited talks. EDAT- 2023/11/29 18:43 MHDA- 2023/11/29 18:44 PMCR- 2023/11/22 CRDT- 2023/11/29 17:04 PHST- 2023/04/26 00:00 [received] PHST- 2023/10/23 00:00 [accepted] PHST- 2023/11/29 18:44 [medline] PHST- 2023/11/29 18:43 [pubmed] PHST- 2023/11/29 17:04 [entrez] PHST- 2023/11/22 00:00 [pmc-release] AID - bmjmed-2022-000468 [pii] AID - 10.1136/bmjmed-2022-000468 [doi] PST - epublish SO - BMJ Med. 2023 Nov 22;2(1):e000468. doi: 10.1136/bmjmed-2022-000468. eCollection 2023. PMID- 38016931 OWN - NLM STAT- MEDLINE DCOM- 20241021 LR - 20260519 IS - 1532-7027 (Electronic) IS - 1041-0236 (Linking) VI - 39 IP - 12 DP - 2024 Nov TI - Heuristic Information Processing as a Mediating Factor in the Process of Exposure to COVID-19 Vaccine Information and Misinformation Sharing on Social Media. PG - 2779-2792 LID - 10.1080/10410236.2023.2288373 [doi] AB - Social media use for risk communication during the COVID-19 pandemic has caused considerable concerns about an overabundance of information, particularly misinformation. However, how exposure to COVID-19 information on social media can lead to subsequent misinformation sharing during the pandemic has received little research attention. This study adopted the social amplification of risk framework to delineate how exposure to COVID-19 vaccine information on social media can be associated with individuals' misinformation sharing through heuristic information processing. The role of social media trust was also examined. Results from an online survey (N = 1488) of Chinese Internet users revealed that exposure to COVID-19 vaccine information on social media was associated with misinformation sharing, mediated by both affect heuristics (i.e., negative affect toward the COVID-19 pandemic in general) and availability heuristics (i.e., perceived misinformation availability). Importantly, both high and low levels of trust in social media strengthened the mediating associations. While a low level of trust strengthened the association between exposure to COVID-19 vaccine information on social media and the affect heuristics, a high level of trust strengthened its association with the availability heuristics, both of which were associated with misinformation sharing. Our findings suggest that heuristic information processing is essential in amplifying the spread of misinformation after exposure to risk information on social media. It is also suggested that individuals should maintain a middle level of trust in social media, being open while critical of risk information on social media. FAU - Lu, Jiahui AU - Lu J AUID- ORCID: 0000-0003-2984-7435 AD - School of New Media and Communication, Tianjin University. FAU - Xiao, Yi AU - Xiao Y AUID- ORCID: 0000-0001-8477-5337 AD - School of New Media and Communication, Tianjin University. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20231128 PL - England TA - Health Commun JT - Health communication JID - 8908762 RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - *Social Media MH - Female MH - *Trust MH - *COVID-19/prevention & control MH - *COVID-19 Vaccines MH - *Communication MH - Male MH - Adult MH - *Heuristics MH - Surveys and Questionnaires MH - Middle Aged MH - China MH - SARS-CoV-2 MH - Young Adult MH - Information Dissemination MH - Health Communication/methods MH - Adolescent EDAT- 2023/11/29 00:42 MHDA- 2024/10/21 10:51 CRDT- 2023/11/28 22:52 PHST- 2024/10/21 10:51 [medline] PHST- 2023/11/29 00:42 [pubmed] PHST- 2023/11/28 22:52 [entrez] AID - 10.1080/10410236.2023.2288373 [doi] PST - ppublish SO - Health Commun. 2024 Nov;39(12):2779-2792. doi: 10.1080/10410236.2023.2288373. Epub 2023 Nov 28. PMID- 38010939 OWN - NLM STAT- MEDLINE DCOM- 20231206 LR - 20240125 IS - 1744-8395 (Electronic) IS - 1476-0584 (Linking) VI - 22 IP - 1 DP - 2023 Jan-Dec TI - A retrospective cohort study: vaccination status and safety analysis of SARS-CoV-2 vaccine in patients with Wilson's disease. PG - 1185-1195 LID - 10.1080/14760584.2023.2288630 [doi] AB - BACKGROUND: Wilson's disease (WD) is a rare hepatic and neurological disorder, which can dramatically worsen by traumatic injuries, surgeries, and infections. No studies have reported safety data of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination in WD patients. We aimed to investigate the SARS-CoV-2 vaccination status and post-vaccination adverse events in WD patients. METHODS: This is a multicenter, retrospective, observational study. We investigated the vaccination rates, the type of vaccine, subjective reasons for non-vaccination, and the adverse events following vaccination. Logistic regression analysis was used to assess the correlation between vaccination status and increased Unified Wilson's Disease Rating Scale (UWDRS) scores. RESULTS: A total of 554 WD patients with a mean (SD) age of 25.3 (10.85) years were included in this study, of whom 336 (60.6%) were males and 218 (39.4%) were females. 368 (66.4%) patients received at least one dose of the SARS-CoV-2 vaccine.186 (33.6%) patients were unvaccinated. Logistic regression analysis showed that vaccination against SARS-CoV-2 was not significantly associated with increased UWDRS scores. The safety analysis demonstrated that 21.2% had post-vaccination adverse events. CONCLUSIONS: In this study, vaccination against SARS-CoV-2 was safe in WD patients, providing evidence for the safety of vaccination in WD patients. FAU - Han, Hui AU - Han H AD - Neurology Department, The First Affiliated Hospital, Anhui University of Traditional Chinese Medicine, Hefei, Anhui, People's Republic of China. FAU - Zhao, Dan AU - Zhao D AD - Neurology Department, The First Affiliated Hospital, Anhui University of Traditional Chinese Medicine, Hefei, Anhui, People's Republic of China. FAU - Fang, Xinru AU - Fang X AD - Neurology Department, The First Affiliated Hospital, Anhui University of Traditional Chinese Medicine, Hefei, Anhui, People's Republic of China. FAU - Yang, Wenming AU - Yang W AD - Neurology Department, The First Affiliated Hospital, Anhui University of Traditional Chinese Medicine, Hefei, Anhui, People's Republic of China. FAU - Wang, Mengli AU - Wang M AD - The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, People's Republic of China. FAU - Liu, Qianzhuo AU - Liu Q AD - Neurology Department, The First Affiliated Hospital, Anhui University of Traditional Chinese Medicine, Hefei, Anhui, People's Republic of China. FAU - Wang, Luyao AU - Wang L AD - Neurology Department, The First Affiliated Hospital, Anhui University of Traditional Chinese Medicine, Hefei, Anhui, People's Republic of China. FAU - Ji, Zhihui AU - Ji Z AD - Neurology Department, The First Affiliated Hospital, Anhui University of Traditional Chinese Medicine, Hefei, Anhui, People's Republic of China. FAU - Zhang, Juan AU - Zhang J AD - Neurology Department, The First Affiliated Hospital, Anhui University of Traditional Chinese Medicine, Hefei, Anhui, People's Republic of China. FAU - Hou, Zhifeng AU - Hou Z AD - Neurology Department, Anhui integrated traditional Chinese and Western Medicine Hospital, Hefei, Anhui, People's Republic of China. FAU - Hua, Lei AU - Hua L AD - Institute of Neurology, Anhui University of Traditional Chinese Medicine, Hefei, Anhui, People's Republic of China. FAU - Wang, Yu AU - Wang Y AD - Institute of Neurology, Anhui University of Traditional Chinese Medicine, Hefei, Anhui, People's Republic of China. FAU - Wu, Limin AU - Wu L AD - The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, People's Republic of China. LA - eng PT - Journal Article PT - Multicenter Study PT - Observational Study PT - Research Support, Non-U.S. Gov't DEP - 20231201 PL - England TA - Expert Rev Vaccines JT - Expert review of vaccines JID - 101155475 RN - 0 (COVID-19 Vaccines) SB - IM MH - Adult MH - Female MH - Humans MH - Male MH - *COVID-19/prevention & control MH - *COVID-19 Vaccines/adverse effects MH - *Hepatolenticular Degeneration MH - Retrospective Studies MH - SARS-CoV-2 MH - Vaccination/adverse effects OTO - NOTNLM OT - COVID-19 OT - SARS-CoV-2 OT - UWDRS OT - Wilson's disease OT - vaccine EDAT- 2023/11/27 18:42 MHDA- 2023/12/04 12:41 CRDT- 2023/11/27 12:35 PHST- 2023/12/04 12:41 [medline] PHST- 2023/11/27 18:42 [pubmed] PHST- 2023/11/27 12:35 [entrez] AID - 10.1080/14760584.2023.2288630 [doi] PST - ppublish SO - Expert Rev Vaccines. 2023 Jan-Dec;22(1):1185-1195. doi: 10.1080/14760584.2023.2288630. Epub 2023 Dec 1. PMID- 37976348 OWN - NLM STAT- MEDLINE DCOM- 20231120 LR - 20231214 IS - 2470-9468 (Electronic) IS - 2470-9468 (Linking) VI - 8 IP - 89 DP - 2023 Nov 17 TI - Enhanced SARS-CoV-2 humoral immunity following breakthrough infection builds upon the preexisting memory B cell pool. PG - eadk5845 LID - 10.1126/sciimmunol.adk5845 [doi] AB - The human immune response must continuously adapt to newly emerging SARS-CoV-2 variants. To investigate how B cells respond to repeated SARS-CoV-2 antigen exposure by Wu01 booster vaccination and Omicron breakthrough infection, we performed a molecular longitudinal analysis of the memory B cell pool. We demonstrate that a subsequent breakthrough infection substantially increases the frequency of B cells encoding SARS-CoV-2-neutralizing antibodies. However, this is not primarily attributable to maturation, but to selection of preexisting B cell clones. Moreover, broadly reactive memory B cells arose early and even neutralized highly mutated variants like XBB.1.5 that the individuals had not encountered. Together, our data show that SARS-CoV-2 immunity is largely imprinted on Wu01 over the course of multiple antigen contacts but can respond to new variants through preexisting diversity. FAU - Weber, Timm AU - Weber T AUID- ORCID: 0000-0003-2079-842X AD - Institute of Virology, Faculty of Medicine, University Hospital Cologne, University of Cologne, Cologne, Germany. FAU - Dahling, Sabrina AU - Dahling S AD - Institute of Virology, Faculty of Medicine, University Hospital Cologne, University of Cologne, Cologne, Germany. FAU - Rose, Svea AU - Rose S AUID- ORCID: 0000-0003-1993-8034 AD - Institute of Virology, Faculty of Medicine, University Hospital Cologne, University of Cologne, Cologne, Germany. AD - German Center for Infection Research (DZIF), Partner Site Bonn-Cologne, Cologne, Germany. FAU - Affeldt, Patrick AU - Affeldt P AD - Institute of Virology, Faculty of Medicine, University Hospital Cologne, University of Cologne, Cologne, Germany. AD - Department II of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany. FAU - Vanshylla, Kanika AU - Vanshylla K AUID- ORCID: 0000-0003-4552-9170 AD - Institute of Virology, Faculty of Medicine, University Hospital Cologne, University of Cologne, Cologne, Germany. FAU - Ullrich, Leon AU - Ullrich L AUID- ORCID: 0000-0002-4358-0717 AD - Institute of Virology, Faculty of Medicine, University Hospital Cologne, University of Cologne, Cologne, Germany. FAU - Gieselmann, Lutz AU - Gieselmann L AD - Institute of Virology, Faculty of Medicine, University Hospital Cologne, University of Cologne, Cologne, Germany. AD - German Center for Infection Research (DZIF), Partner Site Bonn-Cologne, Cologne, Germany. FAU - Teipel, Finn AU - Teipel F AUID- ORCID: 0000-0001-8672-7443 AD - Institute of Virology, Faculty of Medicine, University Hospital Cologne, University of Cologne, Cologne, Germany. AD - German Center for Infection Research (DZIF), Partner Site Bonn-Cologne, Cologne, Germany. FAU - Gruell, Henning AU - Gruell H AUID- ORCID: 0000-0002-0725-7138 AD - Institute of Virology, Faculty of Medicine, University Hospital Cologne, University of Cologne, Cologne, Germany. FAU - Di Cristanziano, Veronica AU - Di Cristanziano V AUID- ORCID: 0000-0003-1604-8386 AD - Institute of Virology, Faculty of Medicine, University Hospital Cologne, University of Cologne, Cologne, Germany. FAU - Kim, Dae Sung AU - Kim DS AUID- ORCID: 0000-0002-3191-437X AD - Department of Biomedical Engineering, University of Texas at Austin, Austin, Texas, USA. FAU - Georgiou, George AU - Georgiou G AUID- ORCID: 0000-0002-8823-3073 AD - Department of Biomedical Engineering, University of Texas at Austin, Austin, Texas, USA. AD - Department of Chemical Engineering and Department of Molecular Biosciences and Institute for Cellular and Molecular Biology, University of Texas at Austin, Austin, Texas, USA. AD - Department of Oncology, University of Texas Dell Medical School, Austin, Texas, USA. FAU - Koch, Manuel AU - Koch M AUID- ORCID: 0000-0002-2962-7814 AD - Institute for Dental Research and Oral Musculoskeletal Biology, Center for Biochemistry, Medical Faculty and University of Cologne, Cologne, Germany. FAU - Kreer, Christoph AU - Kreer C AUID- ORCID: 0000-0002-9140-9850 AD - Institute of Virology, Faculty of Medicine, University Hospital Cologne, University of Cologne, Cologne, Germany. FAU - Klein, Florian AU - Klein F AUID- ORCID: 0000-0003-1376-1792 AD - Institute of Virology, Faculty of Medicine, University Hospital Cologne, University of Cologne, Cologne, Germany. AD - German Center for Infection Research (DZIF), Partner Site Bonn-Cologne, Cologne, Germany. AD - Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany. LA - eng PT - Journal Article DEP - 20231117 PL - United States TA - Sci Immunol JT - Science immunology JID - 101688624 RN - 0 (Antibodies, Viral) RN - SARS-CoV-2 variants SB - IM MH - Humans MH - *Memory B Cells MH - Immunity, Humoral MH - Breakthrough Infections MH - SARS-CoV-2 MH - *COVID-19 MH - Antibodies, Viral EDAT- 2023/11/17 18:42 MHDA- 2023/11/20 06:54 CRDT- 2023/11/17 14:03 PHST- 2023/11/20 06:54 [medline] PHST- 2023/11/17 18:42 [pubmed] PHST- 2023/11/17 14:03 [entrez] AID - 10.1126/sciimmunol.adk5845 [doi] PST - ppublish SO - Sci Immunol. 2023 Nov 17;8(89):eadk5845. doi: 10.1126/sciimmunol.adk5845. Epub 2023 Nov 17. PMID- 37945737 OWN - NLM STAT- MEDLINE DCOM- 20240125 LR - 20250319 IS - 2042-0226 (Electronic) IS - 1672-7681 (Print) IS - 1672-7681 (Linking) VI - 21 IP - 2 DP - 2024 Feb TI - B-cell and antibody responses to SARS-CoV-2: infection, vaccination, and hybrid immunity. PG - 144-158 LID - 10.1038/s41423-023-01095-w [doi] AB - The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 2019 prompted scientific, medical, and biotech communities to investigate infection- and vaccine-induced immune responses in the context of this pathogen. B-cell and antibody responses are at the center of these investigations, as neutralizing antibodies (nAbs) are an important correlate of protection (COP) from infection and the primary target of SARS-CoV-2 vaccine modalities. In addition to absolute levels, nAb longevity, neutralization breadth, immunoglobulin isotype and subtype composition, and presence at mucosal sites have become important topics for scientists and health policy makers. The recent pandemic was and still is a unique setting in which to study de novo and memory B-cell (MBC) and antibody responses in the dynamic interplay of infection- and vaccine-induced immunity. It also provided an opportunity to explore new vaccine platforms, such as mRNA or adenoviral vector vaccines, in unprecedented cohort sizes. Combined with the technological advances of recent years, this situation has provided detailed mechanistic insights into the development of B-cell and antibody responses but also revealed some unexpected findings. In this review, we summarize the key findings of the last 2.5 years regarding infection- and vaccine-induced B-cell immunity, which we believe are of significant value not only in the context of SARS-CoV-2 but also for future vaccination approaches in endemic and pandemic settings. CI - (c) 2023. The Author(s). FAU - Lapuente, Dennis AU - Lapuente D AUID- ORCID: 0000-0002-9833-5313 AD - Institut fur klinische und molekulare Virologie, Universitatsklinikum Erlangen und Friedrich-Alexander-Universitat (FAU) Erlangen-Nurnberg, Schlossgarten 4, 91054, Erlangen, Germany. FAU - Winkler, Thomas H AU - Winkler TH AUID- ORCID: 0000-0002-1860-0528 AD - Department of Biology, Division of Genetics, Nikolaus-Fiebiger-Center for Molecular Medicine, Friedrich-Alexander-Universitat Erlangen-Nurnberg (FAU), Erlangen, Germany. thomas.winkler@fau.de. AD - Medical Immunology Campus Erlangen, Friedrich-Alexander-Universitat (FAU) Erlangen-Nurnberg, Schlossplatz 1, 91054, Erlangen, Germany. thomas.winkler@fau.de. FAU - Tenbusch, Matthias AU - Tenbusch M AUID- ORCID: 0000-0003-3951-9056 AD - Institut fur klinische und molekulare Virologie, Universitatsklinikum Erlangen und Friedrich-Alexander-Universitat (FAU) Erlangen-Nurnberg, Schlossgarten 4, 91054, Erlangen, Germany. AD - Medical Immunology Campus Erlangen, Friedrich-Alexander-Universitat (FAU) Erlangen-Nurnberg, Schlossplatz 1, 91054, Erlangen, Germany. LA - eng GR - Projektnummer 215346292/Deutsche Forschungsgemeinschaft (German Research Foundation)/ PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20231110 PL - China TA - Cell Mol Immunol JT - Cellular & molecular immunology JID - 101242872 RN - 0 (COVID-19 Vaccines) RN - 0 (Antibodies, Neutralizing) RN - 0 (Antibodies, Viral) SB - IM MH - Humans MH - *SARS-CoV-2 MH - Antibody Formation MH - COVID-19 Vaccines MH - *COVID-19 MH - Vaccination MH - Antibodies, Neutralizing MH - Antibodies, Viral PMC - PMC10805925 OTO - NOTNLM OT - IgG4 OT - SARS-CoV-2 OT - memory responses OT - neutralizing antibodies OT - vaccines COIS- The authors declare no competing interests. EDAT- 2023/11/10 00:44 MHDA- 2024/01/25 06:43 PMCR- 2023/11/10 CRDT- 2023/11/09 23:41 PHST- 2023/09/17 00:00 [received] PHST- 2023/10/13 00:00 [accepted] PHST- 2024/01/25 06:43 [medline] PHST- 2023/11/10 00:44 [pubmed] PHST- 2023/11/09 23:41 [entrez] PHST- 2023/11/10 00:00 [pmc-release] AID - 10.1038/s41423-023-01095-w [pii] AID - 1095 [pii] AID - 10.1038/s41423-023-01095-w [doi] PST - ppublish SO - Cell Mol Immunol. 2024 Feb;21(2):144-158. doi: 10.1038/s41423-023-01095-w. Epub 2023 Nov 10. PMID- 37942335 OWN - NLM STAT- MEDLINE DCOM- 20231110 LR - 20231113 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 14 DP - 2023 TI - Low switched memory B cells are associated with no humoral response after SARS-CoV-2 vaccine boosters in kidney transplant recipients. PG - 1202630 LID - 10.3389/fimmu.2023.1202630 [doi] LID - 1202630 AB - INTRODUCTION: The humoral response after SARS-CoV-2 vaccination and boosters in kidney transplant recipients (KTRs) is heterogeneous and depends on immunosuppression status. There is no validated immune measurement associated with serological response in clinical practice. Multicolor flow cytometric immunophenotyping could be useful for measuring immune response. This study aimed to study B- and T-cell compartments through Standardized EuroFlow PID Orientation after SARS-CoV-2 vaccination and their association with IgG SARS-CoV-2 seropositivity status after two doses or boosters. METHODS: We conducted a multicenter prospective study to evaluate humoral response after SARS-CoV-2 vaccination in KTRs. Heterologous regimen: two doses of inactivated SARS-CoV-2 and two boosters of BNT162b2 mRNA (n=75). Homologous vaccination: two doses of BNT162b2 mRNA and one BNT162b2 mRNA booster (n=13). Booster doses were administrated to KTRs without taking into account their IgG SARS-CoV-2 seropositivity status. Peripheral blood samples were collected 30 days after the second dose and after the last heterologous or homologous booster. A standardized EuroFlow PID Orientation Tube (PIDOT) and a supervised automated analysis were used for immune monitoring cellular subsets after boosters. RESULTS: A total of 88 KTRs were included and divided into three groups according to the time of the first detected IgG SARS-CoV-2 seropositivity: non-responders (NRs, n=23), booster responders (BRs, n=41), and two-dose responders (2DRs, n=24). The NR group was more frequent on mycophenolate than the responder groups (NRs, 96%; BRs, 80%; 2DRs, 42%; p=0.000). Switched memory B cells in the 2DR group were higher than those in the BR and NR groups (medians of 30, 17, and 10 cells/ul, respectively; p=0.017). Additionally, the absolute count of central memory/terminal memory CD8 T cells was higher in the 2DR group than in the BR and NR groups. (166, 98, and 93 cells/ul, respectively; p=0.041). The rest of the T-cell populations studied did not show a statistical difference. CONCLUSION: switched memory B cells and memory CD8 T-cell populations in peripheral blood were associated with the magnitude of the humoral response after SARS-CoV-2 vaccination. Boosters increased IgG anti-SARS-CoV-2 levels, CM/TM CD8 T cells, and switched MBCs in patients with seropositivity after two doses. Interestingly, no seropositivity after boosters was associated with the use of mycophenolate and a lower number of switched MBCs and CM/TM CD8 T cells in peripheral blood. CI - Copyright (c) 2023 Seija, Garcia-Luna, Rammauro, Brugnini, Trias, Astesiano, Santiago, Orihuela, Zulberti, Machado, Recalde, Yandian, Guerisoli, Noboa, Orihuela, Curi, Bugstaller, Noboa, Nin, Bianchi, Tiscornia and Lens. FAU - Seija, Mariana AU - Seija M AD - Centro de Nefrologia, Hospital de Clinicas, Facultad de Medicina, Universidad de la Republica, Montevideo, Uruguay. AD - Departamento de Fisiopatologia, Hospital de Clinicas, Facultad de Medicina, Universidad de la Republica, Montevideo, Uruguay. FAU - Garcia-Luna, Joaquin AU - Garcia-Luna J AD - Laboratorio de Citometria de Flujo, Departamento Basico de Medicina, Facultad de Medicina, Universidad de la Republica, Montevideo, Uruguay. FAU - Rammauro, Florencia AU - Rammauro F AD - Departamento de Inmunobiologia, Facultad de Medicina, Universidad de la Republica, Montevideo, Uruguay. AD - Institut Pasteur de Montevideo, Montevideo, Uruguay. FAU - Brugnini, Andreina AU - Brugnini A AD - Laboratorio de Citometria de Flujo, Departamento Basico de Medicina, Facultad de Medicina, Universidad de la Republica, Montevideo, Uruguay. FAU - Trias, Natalia AU - Trias N AD - Laboratorio de Citometria de Flujo, Departamento Basico de Medicina, Facultad de Medicina, Universidad de la Republica, Montevideo, Uruguay. FAU - Astesiano, Rossana AU - Astesiano R AD - Centro de Nefrologia, Hospital de Clinicas, Facultad de Medicina, Universidad de la Republica, Montevideo, Uruguay. FAU - Santiago, Jose AU - Santiago J AD - Centro de Nefrologia, Hospital de Clinicas, Facultad de Medicina, Universidad de la Republica, Montevideo, Uruguay. FAU - Orihuela, Natalia AU - Orihuela N AD - Centro de Trasplante INU, Hospital Italiano, Montevideo, Uruguay. FAU - Zulberti, Catherine AU - Zulberti C AD - Centro de Trasplante INU, Hospital Italiano, Montevideo, Uruguay. FAU - Machado, Danilo AU - Machado D AD - Centro de Trasplante, Hospital Evangelico, Montevideo, Uruguay. FAU - Recalde, Cecilia AU - Recalde C AD - Centro de Trasplante, Hospital Evangelico, Montevideo, Uruguay. FAU - Yandian, Federico AU - Yandian F AD - Centro de Nefrologia, Hospital de Clinicas, Facultad de Medicina, Universidad de la Republica, Montevideo, Uruguay. FAU - Guerisoli, Ana AU - Guerisoli A AD - Centro de Nefrologia, Hospital de Clinicas, Facultad de Medicina, Universidad de la Republica, Montevideo, Uruguay. FAU - Noboa, Javier AU - Noboa J AD - Centro de Nefrologia, Hospital de Clinicas, Facultad de Medicina, Universidad de la Republica, Montevideo, Uruguay. AD - Departamento de Inmunobiologia, Facultad de Medicina, Universidad de la Republica, Montevideo, Uruguay. FAU - Orihuela, Sergio AU - Orihuela S AD - Centro de Trasplante INU, Hospital Italiano, Montevideo, Uruguay. FAU - Curi, Lilian AU - Curi L AD - Centro de Trasplante INU, Hospital Italiano, Montevideo, Uruguay. FAU - Bugstaller, Emma AU - Bugstaller E AD - Centro de Trasplante, Hospital Evangelico, Montevideo, Uruguay. FAU - Noboa, Oscar AU - Noboa O AD - Centro de Nefrologia, Hospital de Clinicas, Facultad de Medicina, Universidad de la Republica, Montevideo, Uruguay. FAU - Nin, Marcelo AU - Nin M AD - Centro de Nefrologia, Hospital de Clinicas, Facultad de Medicina, Universidad de la Republica, Montevideo, Uruguay. AD - Centro de Trasplante INU, Hospital Italiano, Montevideo, Uruguay. FAU - Bianchi, Sergio AU - Bianchi S AD - Departamento de Fisiopatologia, Hospital de Clinicas, Facultad de Medicina, Universidad de la Republica, Montevideo, Uruguay. AD - Institut Pasteur de Montevideo, Montevideo, Uruguay. FAU - Tiscornia, Adriana AU - Tiscornia A AD - Instituto Nacional de Donacion y Trasplante, Hospital de Clinicas, Facultad de Medicina, Universidad de la Republica y Ministerio de Salud Publica, Montevideo, Uruguay. FAU - Lens, Daniela AU - Lens D AD - Laboratorio de Citometria de Flujo, Departamento Basico de Medicina, Facultad de Medicina, Universidad de la Republica, Montevideo, Uruguay. LA - eng PT - Journal Article PT - Multicenter Study PT - Research Support, Non-U.S. Gov't DEP - 20231024 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 RN - 0 (COVID-19 Vaccines) RN - 0 (BNT162 Vaccine) RN - 0 (Immunosuppressive Agents) RN - 0 (RNA, Messenger) RN - 0 (Immunoglobulin G) SB - IM MH - Humans MH - COVID-19 Vaccines MH - BNT162 Vaccine MH - *Kidney Transplantation MH - Memory B Cells MH - Prospective Studies MH - *COVID-19/prevention & control MH - SARS-CoV-2 MH - Immunosuppressive Agents/therapeutic use MH - RNA, Messenger MH - Immunoglobulin G PMC - PMC10628322 OTO - NOTNLM OT - SARS-CoV-2 OT - boosters OT - kidney transplant OT - memory B cell OT - vaccine COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2023/11/09 06:42 MHDA- 2023/11/10 06:45 PMCR- 2023/01/01 CRDT- 2023/11/09 04:27 PHST- 2023/04/09 00:00 [received] PHST- 2023/10/09 00:00 [accepted] PHST- 2023/11/10 06:45 [medline] PHST- 2023/11/09 06:42 [pubmed] PHST- 2023/11/09 04:27 [entrez] PHST- 2023/01/01 00:00 [pmc-release] AID - 10.3389/fimmu.2023.1202630 [doi] PST - epublish SO - Front Immunol. 2023 Oct 24;14:1202630. doi: 10.3389/fimmu.2023.1202630. eCollection 2023. PMID- 37884506 OWN - NLM STAT- MEDLINE DCOM- 20231030 LR - 20240927 IS - 2041-1723 (Electronic) IS - 2041-1723 (Linking) VI - 14 IP - 1 DP - 2023 Oct 26 TI - Respiratory mucosal immune memory to SARS-CoV-2 after infection and vaccination. PG - 6815 LID - 10.1038/s41467-023-42433-w [doi] LID - 6815 AB - Respiratory mucosal immunity induced by vaccination is vital for protection from coronavirus infection in animal models. In humans, the capacity of peripheral vaccination to generate sustained immunity in the lung mucosa, and how this is influenced by prior SARS-CoV-2 infection, is unknown. Here we show using bronchoalveolar lavage samples that donors with history of both infection and vaccination have more airway mucosal SARS-CoV-2 antibodies and memory B cells than those only vaccinated. Infection also induces populations of airway spike-specific memory CD4+ and CD8+ T cells that are not expanded by vaccination alone. Airway mucosal T cells induced by infection have a distinct hierarchy of antigen specificity compared to the periphery. Spike-specific T cells persist in the lung mucosa for 7 months after the last immunising event. Thus, peripheral vaccination alone does not appear to induce durable lung mucosal immunity against SARS-CoV-2, supporting an argument for the need for vaccines targeting the airways. CI - (c) 2023. The Author(s). FAU - Mitsi, Elena AU - Mitsi E AUID- ORCID: 0000-0001-7586-6050 AD - Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK. elena.mitsi@paediatrics.ox.ac.uk. AD - Department of Clinical Science, Liverpool School of Tropical Medicine, Liverpool, UK. elena.mitsi@paediatrics.ox.ac.uk. FAU - Diniz, Mariana O AU - Diniz MO AD - Division of Infection and Immunity and Institute of Immunity and Transplantation, UCL, London, UK. FAU - Reine, Jesus AU - Reine J AD - Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK. AD - Department of Clinical Science, Liverpool School of Tropical Medicine, Liverpool, UK. FAU - Collins, Andrea M AU - Collins AM AD - Department of Clinical Science, Liverpool School of Tropical Medicine, Liverpool, UK. FAU - Robinson, Ryan E AU - Robinson RE AD - Department of Clinical Science, Liverpool School of Tropical Medicine, Liverpool, UK. FAU - Hyder-Wright, Angela AU - Hyder-Wright A AD - Department of Clinical Science, Liverpool School of Tropical Medicine, Liverpool, UK. FAU - Farrar, Madlen AU - Farrar M AD - Department of Clinical Science, Liverpool School of Tropical Medicine, Liverpool, UK. FAU - Liatsikos, Konstantinos AU - Liatsikos K AUID- ORCID: 0000-0003-2061-8329 AD - Department of Clinical Science, Liverpool School of Tropical Medicine, Liverpool, UK. FAU - Hamilton, Josh AU - Hamilton J AUID- ORCID: 0000-0002-8523-3326 AD - Department of Clinical Science, Liverpool School of Tropical Medicine, Liverpool, UK. FAU - Onyema, Onyia AU - Onyema O AD - Department of Clinical Science, Liverpool School of Tropical Medicine, Liverpool, UK. FAU - Urban, Britta C AU - Urban BC AD - Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK. AD - Department of Clinical Science, Liverpool School of Tropical Medicine, Liverpool, UK. FAU - Solorzano, Carla AU - Solorzano C AD - Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK. AD - Department of Clinical Science, Liverpool School of Tropical Medicine, Liverpool, UK. FAU - Belij-Rammerstorfer, Sandra AU - Belij-Rammerstorfer S AD - Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK. FAU - Sheehan, Emma AU - Sheehan E AD - Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK. FAU - Lambe, Teresa AU - Lambe T AUID- ORCID: 0000-0001-7711-897X AD - Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK. AD - Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, Oxford, UK. FAU - Draper, Simon J AU - Draper SJ AUID- ORCID: 0000-0002-9415-1357 AD - Department of Biochemistry, University of Oxford, Oxford, UK. FAU - Weiskopf, Daniela AU - Weiskopf D AD - Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, USA. FAU - Sette, Alessandro AU - Sette A AUID- ORCID: 0000-0001-7013-2250 AD - Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, USA. AD - Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego, La Jolla, USA. FAU - Maini, Mala K AU - Maini MK AUID- ORCID: 0000-0001-6384-1462 AD - Division of Infection and Immunity and Institute of Immunity and Transplantation, UCL, London, UK. FAU - Ferreira, Daniela M AU - Ferreira DM AUID- ORCID: 0000-0002-0594-0902 AD - Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK. daniela.ferreira@paediatrics.ox.ac.uk. AD - Department of Clinical Science, Liverpool School of Tropical Medicine, Liverpool, UK. daniela.ferreira@paediatrics.ox.ac.uk. LA - eng GR - WT_/Wellcome Trust/United Kingdom PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20231026 PL - England TA - Nat Commun JT - Nature communications JID - 101528555 RN - 0 (Antibodies, Viral) RN - 0 (Spike Glycoprotein, Coronavirus) RN - 0 (spike protein, SARS-CoV-2) SB - IM MH - Animals MH - Humans MH - *Immunologic Memory MH - SARS-CoV-2 MH - *COVID-19/prevention & control MH - Respiratory Mucosa MH - Vaccination MH - Antibodies, Viral MH - Spike Glycoprotein, Coronavirus PMC - PMC10603102 COIS- A.S. is a consultant for Gritstone Bio, Flow Pharma, Moderna, AstraZeneca, Qiagen, Fortress, Gilead, Sanofi, Merck, RiverVest, MedaCorp, Turnstone, NA Vaccine Institute, Emervax, Gerson Lehrman Group and Guggenheim. La Jolla Institute has filed for patent protection for various aspects of T cell epitope and vaccine design work. The remaining authors declare no competing interests. EDAT- 2023/10/27 00:43 MHDA- 2023/10/30 06:47 PMCR- 2023/10/26 CRDT- 2023/10/26 23:17 PHST- 2023/07/14 00:00 [received] PHST- 2023/10/10 00:00 [accepted] PHST- 2023/10/30 06:47 [medline] PHST- 2023/10/27 00:43 [pubmed] PHST- 2023/10/26 23:17 [entrez] PHST- 2023/10/26 00:00 [pmc-release] AID - 10.1038/s41467-023-42433-w [pii] AID - 42433 [pii] AID - 10.1038/s41467-023-42433-w [doi] PST - epublish SO - Nat Commun. 2023 Oct 26;14(1):6815. doi: 10.1038/s41467-023-42433-w. PMID- 37849724 OWN - NLM STAT- MEDLINE DCOM- 20231023 LR - 20231023 IS - 2296-2565 (Electronic) IS - 2296-2565 (Linking) VI - 11 DP - 2023 TI - Association between COVID-19 vaccination and critical outcomes among older adults with dementia: a comparative cohort study. PG - 1281266 LID - 10.3389/fpubh.2023.1281266 [doi] LID - 1281266 AB - BACKGROUND: As COVID-19 vaccines became available, understanding their potential benefits in vulnerable populations has gained significance. This study explored the advantages of COVID-19 vaccination in individuals with cognitive disorders by analyzing health-related variables and outcomes. METHODS: A prospective cohort study analyzed electronic medical records of 25,733 older adults with cognitive disorders and 65,544 older adults without cognitive disorders from March 2020 to February 2022. COVID-19 vaccination status was the primary exposure variable, categorized as fully vaccinated or unvaccinated. The primary outcomes measured were all-cause mortality and hospitalization rates within 14 and 400 days post-vaccination. Data on vaccination status, demographics, comorbidities, testing history, and clinical outcomes were collected from electronic health records. The study was ethically approved by the relevant medical facility's Institutional Review Board (0075-22-MHS). RESULTS: Vaccinated individuals had significantly lower mortality rates in both groups. In the research group, the mortality rate was 52% (n = 1852) for unvaccinated individuals and 7% (n = 1,241) for vaccinated individuals (p < 0.001). Similarly, in the control group, the mortality rate was 13.58% (n = 1,508) for unvaccinated individuals and 1.85% (n = 936) for vaccinated individuals (p < 0.001), despite higher COVID-19 positivity rates. In the research group, 30.26% (n = 1,072) of unvaccinated individuals tested positive for COVID-19, compared to 37.16% (n = 6,492) of vaccinated individuals (p < 0.001). In the control group, 17.31% (n = 1922) of unvaccinated individuals were COVID-19 positive, while 37.25% (n = 18,873) of vaccinated individuals tested positive (p < 0.001). Vaccination also showed potential benefits in mental health support. The usage of antipsychotic drugs was lower in vaccinated individuals (28.43%, n = 4,967) compared to unvaccinated individuals (37.48%, n = 1,328; 95% CI [0.92-1.28], p < 0.001). Moreover, vaccinated individuals had lower antipsychotic drug prescription rates (23.88%, n = 4,171) compared to unvaccinated individuals (27.83%, n = 968; 95% CI [-1.02 to -0.63], p < 0.001). Vaccination appeared to have a positive impact on managing conditions like diabetes, with 38.63% (n = 6,748) of vaccinated individuals having diabetes compared to 41.55% (n = 1,472) of unvaccinated individuals (95% CI [0.24, 0.48], p < 0.001). DISCUSSION: The findings highlight the importance of vaccination in safeguarding vulnerable populations during the pandemic and call for further research to optimize healthcare strategies for individuals with cognitive disorders. CI - Copyright (c) 2023 Radomyslsky, Kivity, Lidar, Bentur, Korn, Nissanholtz-Gannot, Sternberg, Halevi Hochwald, Reges, Alon and Saban. FAU - Radomyslsky, Zorian AU - Radomyslsky Z AD - Department of Health System Management, Ariel University, Ariel, Israel. FAU - Kivity, Sara AU - Kivity S AD - Department of Health System Management, Ariel University, Ariel, Israel. FAU - Lidar, Shira AU - Lidar S AD - Department of Health System Management, Ariel University, Ariel, Israel. FAU - Bentur, Netta AU - Bentur N AD - Department of Occupational Therapy, School of Health Sciences, Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. FAU - Korn, Liat AU - Korn L AD - Department of Health System Management, Ariel University, Ariel, Israel. FAU - Nissanholtz-Gannot, Rachel AU - Nissanholtz-Gannot R AD - Department of Health System Management, Ariel University, Ariel, Israel. AD - Mayers-JDC-Brookdale Institute, Jerusalem, Israel. FAU - Sternberg, Shelley AU - Sternberg S AD - Department of Health System Management, Ariel University, Ariel, Israel. FAU - Halevi Hochwald, Inbal AU - Halevi Hochwald I AD - School of Nursing, Max Stern Yezreel Valley College, Emek Yezreel, Israel. FAU - Reges, Orna AU - Reges O AD - Department of Health System Management, Ariel University, Ariel, Israel. FAU - Alon, Yaniv AU - Alon Y AD - Nursing Department, School of Health Sciences, Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. FAU - Saban, Mor AU - Saban M AD - Nursing Department, School of Health Sciences, Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. LA - eng PT - Journal Article DEP - 20231002 PL - Switzerland TA - Front Public Health JT - Frontiers in public health JID - 101616579 RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - Aged MH - *COVID-19/epidemiology/prevention & control MH - COVID-19 Vaccines MH - Cohort Studies MH - Prospective Studies MH - Vaccination MH - *Diabetes Mellitus MH - *Dementia/epidemiology PMC - PMC10578450 OTO - NOTNLM OT - COVID-19 OT - dementia OT - mild cognitive impairment OT - psychiatric disorder diagnosis OT - vaccination COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2023/10/18 06:43 MHDA- 2023/10/23 01:18 PMCR- 2023/10/02 CRDT- 2023/10/18 03:55 PHST- 2023/08/22 00:00 [received] PHST- 2023/09/15 00:00 [accepted] PHST- 2023/10/23 01:18 [medline] PHST- 2023/10/18 06:43 [pubmed] PHST- 2023/10/18 03:55 [entrez] PHST- 2023/10/02 00:00 [pmc-release] AID - 10.3389/fpubh.2023.1281266 [doi] PST - epublish SO - Front Public Health. 2023 Oct 2;11:1281266. doi: 10.3389/fpubh.2023.1281266. eCollection 2023. PMID- 37832345 OWN - NLM STAT- MEDLINE DCOM- 20231223 LR - 20250617 IS - 1873-5134 (Electronic) IS - 0738-3991 (Linking) VI - 118 DP - 2024 Jan TI - Perspectives and experiences of COVID-19 vaccination in people with autoimmune and inflammatory rheumatic disease. PG - 107996 LID - S0738-3991(23)00377-4 [pii] LID - 10.1016/j.pec.2023.107996 [doi] AB - OBJECTIVE: People with autoimmune and inflammatory rheumatic disease (AIIRD) are at an increased risk of morbidity from COVID-19. While COVID-19 vaccination is effective at reducing disease complications, there have been significant levels of vaccine hesitancy in people with AIIRD. We aimed to understand vaccine hesitancy and promote shared decision-making by describing the experiences and perspectives of people with AIIRD who had concerns with COVID-19 vaccinations. METHODS: Adults with AIIRD on immunosuppressive medications who expressed concerns regarding the COVID-19 vaccination were purposively sampled until thematic saturation. Individual semi-structured interviews were conducted and analysed using reflexive thematic analysis. RESULTS: Sixteen adults with an AIIRD were interviewed. Thematic analysis yielded four themes: heightened sense of vulnerability; determining individual suitability; desperate for freedom and relief; deterred by scepticism. CONCLUSIONS: The perspectives of people with AIIRD towards the COVID-19 vaccination were shaped by a sense of vulnerability. The decision-making experience was challenging, resulting from struggles with handling information, dealing with external pressures, and facing negativity. PRACTICE IMPLICATIONS: A collaborative approach, involving close family and friends and avoiding negativity and pressure can improve engagement and support decision-making around COVID-19 vaccination. Clearly addressing potential risks of vaccination may prevent subsequent regret and hesitancy if they arise. CI - Copyright (c) 2023 The Authors. Published by Elsevier B.V. All rights reserved. FAU - Peng, David AU - Peng D AD - Rheumatology department, Liverpool Hospital, Liverpool, NSW, Australia; University of NSW, Sydney, Australia. Electronic address: David.Peng@health.nsw.gov.au. FAU - Kelly, Ayano AU - Kelly A AD - Rheumatology department, Liverpool Hospital, Liverpool, NSW, Australia; University of NSW, Sydney, Australia. FAU - Brady, Bernadette AU - Brady B AD - Rheumatology department, Liverpool Hospital, Liverpool, NSW, Australia. FAU - Faasse, Kate AU - Faasse K AD - University of NSW, Sydney, Australia. FAU - El-Haddad, Carlos AU - El-Haddad C AD - Rheumatology department, Liverpool Hospital, Liverpool, NSW, Australia; University of NSW, Sydney, Australia; Western Sydney University, Sydney, Australia. FAU - Frade, Stephanie AU - Frade S AD - Rheumatology department, Liverpool Hospital, Liverpool, NSW, Australia. LA - eng PT - Journal Article DEP - 20230930 PL - Ireland TA - Patient Educ Couns JT - Patient education and counseling JID - 8406280 RN - 0 (COVID-19 Vaccines) SB - IM MH - Adult MH - Humans MH - *COVID-19/prevention & control MH - COVID-19 Vaccines MH - Decision Making, Shared MH - *Rheumatic Diseases MH - Vaccination MH - *Autoimmune Diseases OTO - NOTNLM OT - Autoimmune diseases OT - COVID-19 OT - Rheumatic Disease OT - Vaccination OT - Vaccine hesitancy COIS- Declaration of Competing Interest There are no conflicts of interest to report from the authors. EDAT- 2023/10/14 10:43 MHDA- 2023/12/04 12:42 CRDT- 2023/10/13 18:08 PHST- 2023/05/17 00:00 [received] PHST- 2023/09/15 00:00 [revised] PHST- 2023/09/29 00:00 [accepted] PHST- 2023/12/04 12:42 [medline] PHST- 2023/10/14 10:43 [pubmed] PHST- 2023/10/13 18:08 [entrez] AID - S0738-3991(23)00377-4 [pii] AID - 10.1016/j.pec.2023.107996 [doi] PST - ppublish SO - Patient Educ Couns. 2024 Jan;118:107996. doi: 10.1016/j.pec.2023.107996. Epub 2023 Sep 30. PMID- 37815874 OWN - NLM STAT- MEDLINE DCOM- 20231216 LR - 20240710 IS - 1558-8238 (Electronic) IS - 0021-9738 (Print) IS - 0021-9738 (Linking) VI - 133 IP - 24 DP - 2023 Dec 15 TI - SARS-CoV-2 mRNA vaccination-induced immunological memory in human nonlymphoid and lymphoid tissues. LID - 10.1172/JCI171797 [doi] LID - e171797 AB - Tissue-resident lymphocytes provide organ-adapted protection against invading pathogens. Whereas their biology has been examined in great detail in various infection models, their generation and functionality in response to vaccination have not been comprehensively analyzed in humans. We therefore studied SARS-CoV-2 mRNA vaccine-specific T cells in surgery specimens of kidney, liver, lung, bone marrow, and spleen compared with paired blood samples from largely virus-naive individuals. As opposed to lymphoid tissues, nonlymphoid organs harbored significantly elevated frequencies of spike-specific CD4+ T cells compared with blood showing hallmarks of tissue residency and an expanded memory pool. Organ-derived CD4+ T cells further exhibited increased polyfunctionality over those detected in blood. Single-cell RNA-Seq together with T cell receptor repertoire analysis indicated that the clonotype rather than organ origin is a major determinant of transcriptomic state in vaccine-specific CD4+ T cells. In summary, our data demonstrate that SARS-CoV-2 vaccination entails acquisition of tissue memory and residency features in organs distant from the inoculation site, thereby contributing to our understanding of how local tissue protection might be accomplished. FAU - Pross, Vanessa AU - Pross V AD - Department of General and Visceral Surgery, Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of Health, Berlin, Germany. FAU - Sattler, Arne AU - Sattler A AD - Department of General and Visceral Surgery, Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of Health, Berlin, Germany. FAU - Lukassen, Soren AU - Lukassen S AD - Center of Digital Health, Berlin Institute of Health and Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany. FAU - Toth, Laura AU - Toth L AD - Department of General and Visceral Surgery, Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of Health, Berlin, Germany. FAU - Thole, Linda Marie Laura AU - Thole LML AD - Department of General and Visceral Surgery, Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of Health, Berlin, Germany. FAU - Siegle, Janine AU - Siegle J AD - Department of General and Visceral Surgery, Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of Health, Berlin, Germany. FAU - Stahl, Carolin AU - Stahl C AD - Department of General and Visceral Surgery, Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of Health, Berlin, Germany. FAU - He, An AU - He A AD - Department of General and Visceral Surgery, Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of Health, Berlin, Germany. FAU - Damm, Georg AU - Damm G AD - Department of Hepatobiliary Surgery and Visceral Transplantation, University Hospital, Leipzig University, Leipzig, Germany. FAU - Seehofer, Daniel AU - Seehofer D AD - Department of Hepatobiliary Surgery and Visceral Transplantation, University Hospital, Leipzig University, Leipzig, Germany. FAU - Gotz, Christina AU - Gotz C AD - Department of Hepatobiliary Surgery and Visceral Transplantation, University Hospital, Leipzig University, Leipzig, Germany. FAU - Bayerl, Christian AU - Bayerl C AD - Department of Radiology, Charite - Universitatsmedizin Berlin, Campus Benjamin Franklin, Corporate Member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of Health, Berlin, Germany. FAU - Jager, Pia AU - Jager P AD - Department of General and Visceral Surgery, Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of Health, Berlin, Germany. FAU - Macke, Alexander AU - Macke A AD - Department of Visceral Surgery. FAU - Eggeling, Stephan AU - Eggeling S AD - Department of Thoracic Surgery, and. FAU - Kirzinger, Bernadette AU - Kirzinger B AD - Department of Thoracic Surgery, and. FAU - Mayr, Thomas AU - Mayr T AD - Department of Thoracic Surgery, and. FAU - Herbst, Hermann AU - Herbst H AD - Department of Pathology, Vivantes Klinikum Neukolln, Berlin, Germany. FAU - Beyer, Katharina AU - Beyer K AD - Department of General and Visceral Surgery, Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of Health, Berlin, Germany. FAU - Laue, Dominik AU - Laue D AD - Department of Traumatology and Reconstructive Surgery, Campus Benjamin Franklin, Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of Health, Berlin, Germany. FAU - Kronke, Jan AU - Kronke J AD - Department of Hematology, Oncology and Cancer Immunology, Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany. FAU - Braune, Jan AU - Braune J AD - Department of Hematology, Oncology and Cancer Immunology, Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany. FAU - Rosseck, Friederike AU - Rosseck F AD - Institute of Pathology, Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of Health, Berlin, Germany. FAU - Kittner, Beatrice AU - Kittner B AD - Department of Urology, Evangelisches Krankenhaus Konigin Elisabeth Herzberge, Berlin, Germany. FAU - Friedersdorff, Frank AU - Friedersdorff F AD - Department of Urology, Evangelisches Krankenhaus Konigin Elisabeth Herzberge, Berlin, Germany. FAU - Hubatsch, Mandy AU - Hubatsch M AD - Department of Urology, Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of Health, Berlin, Germany. FAU - Weinberger, Sarah AU - Weinberger S AD - Department of Urology, Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of Health, Berlin, Germany. FAU - Lachmann, Nils AU - Lachmann N AD - Institute of Transfusion Medicine, Berlin Institute of Health, Charite - Universitatsmedizin Berlin, Humboldt-Universitat zu Berlin, Berlin, Germany. FAU - Hofmann, Veit Maria AU - Hofmann VM AD - Department of Otolaryngology, Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of Health, Berlin, Germany. FAU - Schrezenmeier, Eva AU - Schrezenmeier E AD - Department of Nephrology and Medical Intensive Care, Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany. AD - BIH Charite Clinician Scientist Program, BIH Biomedical Innovation Academy, Berlin Institute of Health at Charite - Universitatsmedizin Berlin, Berlin, Germany. FAU - Ludwig, Carolin AU - Ludwig C AD - Institute for Clinical Transfusion Medicine and Immunogenetics, German Red Cross Blood Transfusion Service Baden-Wurttemberg-Hessen and University Hospital Ulm, Ulm, Germany. FAU - Schrezenmeier, Hubert AU - Schrezenmeier H AD - Institute for Clinical Transfusion Medicine and Immunogenetics, German Red Cross Blood Transfusion Service Baden-Wurttemberg-Hessen and University Hospital Ulm, Ulm, Germany. FAU - Jechow, Katharina AU - Jechow K AD - Center of Digital Health, Berlin Institute of Health and Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany. FAU - Conrad, Christian AU - Conrad C AD - Center of Digital Health, Berlin Institute of Health and Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany. FAU - Kotsch, Katja AU - Kotsch K AD - Department of General and Visceral Surgery, Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of Health, Berlin, Germany. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20231215 PL - United States TA - J Clin Invest JT - The Journal of clinical investigation JID - 7802877 RN - 0 (COVID-19 Vaccines) RN - 0 (RNA, Messenger) RN - 0 (Antibodies, Viral) SB - IM MH - Humans MH - *COVID-19 Vaccines MH - SARS-CoV-2/genetics MH - Immunologic Memory MH - *COVID-19/prevention & control MH - Lymphoid Tissue MH - Vaccination MH - RNA, Messenger MH - Antibodies, Viral PMC - PMC10721158 OTO - NOTNLM OT - Adaptive immunity OT - Immunology OT - T cells OT - Vaccines EDAT- 2023/10/10 18:42 MHDA- 2023/12/17 09:42 PMCR- 2023/12/15 CRDT- 2023/10/10 12:03 PHST- 2023/04/26 00:00 [received] PHST- 2023/10/05 00:00 [accepted] PHST- 2023/12/17 09:42 [medline] PHST- 2023/10/10 18:42 [pubmed] PHST- 2023/10/10 12:03 [entrez] PHST- 2023/12/15 00:00 [pmc-release] AID - 171797 [pii] AID - 10.1172/JCI171797 [doi] PST - epublish SO - J Clin Invest. 2023 Dec 15;133(24):e171797. doi: 10.1172/JCI171797. PMID- 37807809 OWN - NLM STAT- MEDLINE DCOM- 20240118 LR - 20250626 IS - 1099-1654 (Electronic) IS - 1052-9276 (Linking) VI - 33 IP - 6 DP - 2023 Nov TI - Electroencephalographic findings post-COVID-19 vaccination: A systematic review of case reports and case series. PG - e2484 LID - 10.1002/rmv.2484 [doi] AB - A number of different neurological complications have been reported following vaccination against the coronavirus disease 2019 (COVID-19). Electroencephalogram (EEG) is one of the modalities used to evaluate the neurological complications of diseases. The aim of the present study was to identify the EEG changes in participants vaccinated against COVID-19. PubMed, Scopus, Web of Science, medRxiv, and Google Scholar were searched up to 1 September 2022, with terms related to COVID-19 vaccines, EEG, neurological signs/symptoms, or neurological disorders. All case reports and case series were included if the participants had received at least one dose of a COVID-19 vaccine and a post vaccination EEG report was also reported. We used the Joanna Briggs Institute (JBI) Critical Appraisal Checklist for case reports and case series to appraise the methodological quality of the included studies. Thirty-one studies were included, which were comprised of 24 case reports and seven case series and a total of 36 participants. Generalised slowing and non-convulsive focal status epilepticus were the most common EEG findings post-COVID-19 vaccination. The most frequent symptoms were headache, fatigue, generalised weakness, and vomiting. In addition, the most common signs were encephalopathy, post-ictal phases, and confusion. Encephalitis, acute disseminated encephalomyelitis, and post-vaccinal encephalopathy were the most commonly diagnosed adverse events. Furthermore, most of the imaging studies appeared normal. The EEG reports mainly showed background slowing and epileptiform discharges, encephalitis, encephalopathies, and demyelinating disorders. Future studies with larger samples and more vaccine types may help to further unravel the potential neurological effects of COVID-19 vaccinations on recipients. CI - (c) 2023 John Wiley & Sons Ltd. FAU - Fazlollahi, Asra AU - Fazlollahi A AD - Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran. AD - Neurosciences Research Center, Aging Research Institute, Tabriz University of Medical Sciences, Tabriz, Iran. FAU - Zahmatyar, Mahdi AU - Zahmatyar M AUID- ORCID: 0000-0001-9719-6844 AD - Neurosciences Research Center, Aging Research Institute, Tabriz University of Medical Sciences, Tabriz, Iran. FAU - Shamekh, Ali AU - Shamekh A AD - Neurosciences Research Center, Aging Research Institute, Tabriz University of Medical Sciences, Tabriz, Iran. FAU - Motamedi, Alireza AU - Motamedi A AD - Neurosciences Research Center, Aging Research Institute, Tabriz University of Medical Sciences, Tabriz, Iran. FAU - Seyedi, Fatemeh AU - Seyedi F AD - Neurosciences Research Center, Aging Research Institute, Tabriz University of Medical Sciences, Tabriz, Iran. FAU - Seyedmirzaei, Homa AU - Seyedmirzaei H AD - School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. AD - Interdisciplinary Neuroscience Research Program (INRP), Tehran University of Medical Sciences, Tehran, Iran. FAU - Mousavi, Seyed Ehsan AU - Mousavi SE AD - Neurosciences Research Center, Aging Research Institute, Tabriz University of Medical Sciences, Tabriz, Iran. AD - Tuberculosis and Lung Diseases Research Centre, Tabriz University of Medical Sciences, Tabriz, Iran. FAU - Nejadghaderi, Seyed Aria AU - Nejadghaderi SA AUID- ORCID: 0000-0002-8692-9720 AD - Endocrinology and Metabolism Research Center, Institute of Basic and Clinical Physiology Sciences, Kerman University of Medical Sciences, Kerman, Iran. AD - Systematic Review and Meta-analysis Expert Group (SRMEG), Universal Scientific Education and Research Network (USERN), Tehran, Iran. FAU - Sullman, Mark J M AU - Sullman MJM AD - Department of Life and Health Sciences, University of Nicosia, Nicosia, Cyprus. AD - Department of Social Sciences, University of Nicosia, Nicosia, Cyprus. FAU - Kolahi, Ali-Asghar AU - Kolahi AA AD - Social Determinants of Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. FAU - Arshi, Shahnam AU - Arshi S AD - Social Determinants of Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. FAU - Safiri, Saeid AU - Safiri S AUID- ORCID: 0000-0001-7986-9072 AD - Neurosciences Research Center, Aging Research Institute, Tabriz University of Medical Sciences, Tabriz, Iran. AD - Clinical Research Development Unit of Tabriz Valiasr Hospital, Tabriz University of Medical Sciences, Tabriz, Iran. LA - eng GR - 43004465/Shahid Beheshti University of Medical Sciences/ PT - Journal Article PT - Systematic Review DEP - 20231009 PL - England TA - Rev Med Virol JT - Reviews in medical virology JID - 9112448 RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - *Brain Diseases MH - *COVID-19/prevention & control MH - COVID-19 Vaccines/adverse effects MH - Electroencephalography MH - *Encephalitis MH - Vaccination/adverse effects MH - Case Reports as Topic OTO - NOTNLM OT - COVID-19 vaccines OT - EEG OT - coronavirus disease 2019 OT - electroencephalogram OT - systematic review EDAT- 2023/10/09 06:42 MHDA- 2023/11/06 06:42 CRDT- 2023/10/09 03:44 PHST- 2023/08/14 00:00 [revised] PHST- 2023/04/13 00:00 [received] PHST- 2023/09/20 00:00 [accepted] PHST- 2023/11/06 06:42 [medline] PHST- 2023/10/09 06:42 [pubmed] PHST- 2023/10/09 03:44 [entrez] AID - 10.1002/rmv.2484 [doi] PST - ppublish SO - Rev Med Virol. 2023 Nov;33(6):e2484. doi: 10.1002/rmv.2484. Epub 2023 Oct 9. PMID- 37806865 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240419 IS - 1090-2139 (Electronic) IS - 0889-1591 (Print) IS - 0889-1591 (Linking) VI - 115 DP - 2024 Jan TI - Corrigendum to "COVID-19 vaccination for the prevention and treatment of long COVID: A systematic review and meta-analysis" [Brain Behav. Immun. 111 (2023) 211-229]. PG - 758 LID - S0889-1591(23)00284-2 [pii] LID - 10.1016/j.bbi.2023.09.020 [doi] FAU - Ceban, Felicia AU - Ceban F AD - Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada; Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada; Brain and Cognition Discovery Foundation, Toronto, Ontario, Canada. FAU - Kulzhabayeva, Dana AU - Kulzhabayeva D AD - Department of Psychology, University of Toronto, Toronto, Ontario, Canada. FAU - Rodrigues, Nelson B AU - Rodrigues NB AD - Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada. FAU - Di Vincenzo, Joshua D AU - Di Vincenzo JD AD - Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada. FAU - Gill, Hartej AU - Gill H AD - Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada; Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada. FAU - Subramaniapillai, Mehala AU - Subramaniapillai M AD - Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada; Brain and Cognition Discovery Foundation, Toronto, Ontario, Canada. FAU - Lui, Leanna M W AU - Lui LMW AD - Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada; Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada. FAU - Cao, Bing AU - Cao B AD - Key Laboratory of Cognition and Personality, Faculty of Psychology, Ministry of Education, Southwest University, Chongqing 400715, China. FAU - Mansur, Rodrigo B AU - Mansur RB AD - Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada; Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada. FAU - Ho, Roger C AU - Ho RC AD - Department of Psychological Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228, Singapore; Institute for Health Innovation and Technology (iHealthtech), National University of Singapore, Singapore 119077, Singapore. FAU - Burke, Matthew J AU - Burke MJ AD - Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada; Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Canada; Department of Neurology, Division of Cognitive Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. FAU - Rhee, Taeho Greg AU - Rhee TG AD - Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA; Department of Public Health Sciences, University of Connecticut School of Medicine, Farmington, CT, USA. FAU - Rosenblat, Joshua D AU - Rosenblat JD AD - Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada; Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada. FAU - McIntyre, Roger S AU - McIntyre RS AD - Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada; Brain and Cognition Discovery Foundation, Toronto, Ontario, Canada; Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada; Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada; Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada. Electronic address: Roger.mcintyre@bcdf.org. LA - eng PT - Published Erratum DEP - 20231007 PL - Netherlands TA - Brain Behav Immun JT - Brain, behavior, and immunity JID - 8800478 SB - IM EFR - Brain Behav Immun. 2023 Jul;111:211-229. doi: 10.1016/j.bbi.2023.03.022. PMID: 36990297 PMC - PMC11021210 EDAT- 2023/10/09 00:41 MHDA- 2023/10/09 00:42 PMCR- 2024/01/01 CRDT- 2023/10/08 22:01 PHST- 2023/10/09 00:42 [medline] PHST- 2023/10/09 00:41 [pubmed] PHST- 2023/10/08 22:01 [entrez] PHST- 2024/01/01 00:00 [pmc-release] AID - S0889-1591(23)00284-2 [pii] AID - 10.1016/j.bbi.2023.09.020 [doi] PST - ppublish SO - Brain Behav Immun. 2024 Jan;115:758. doi: 10.1016/j.bbi.2023.09.020. Epub 2023 Oct 7. PMID- 37796612 OWN - NLM STAT- MEDLINE DCOM- 20231127 LR - 20250130 IS - 2379-3708 (Electronic) IS - 2379-3708 (Linking) VI - 8 IP - 22 DP - 2023 Nov 22 TI - Airway surveillance and lung viral control by memory T cells induced by COVID-19 mRNA vaccine. LID - 10.1172/jci.insight.172510 [doi] LID - e172510 AB - Although SARS-CoV-2 evolution seeds a continuous stream of antibody-evasive viral variants, COVID-19 mRNA vaccines provide robust protection against severe disease and hospitalization. Here, we asked whether mRNA vaccine-induced memory T cells limit lung SARS-CoV-2 replication and severe disease. We show that mice and humans receiving booster BioNTech mRNA vaccine developed potent CD8 T cell responses and showed similar kinetics of expansion and contraction of granzyme B/perforin-expressing effector CD8 T cells. Both monovalent and bivalent mRNA vaccines elicited strong expansion of a heterogeneous pool of terminal effectors and memory precursor effector CD8 T cells in spleen, inguinal and mediastinal lymph nodes, pulmonary vasculature, and most surprisingly in the airways, suggestive of systemic and regional surveillance. Furthermore, we document that: (a) CD8 T cell memory persists in multiple tissues for > 200 days; (b) following challenge with pathogenic SARS-CoV-2, circulating memory CD8 T cells rapidly extravasate to the lungs and promote expeditious viral clearance, by mechanisms that require CD4 T cell help; and (c) adoptively transferred splenic memory CD8 T cells traffic to the airways and promote lung SARS-CoV-2 clearance. These findings provide insights into the critical role of memory T cells in preventing severe lung disease following breakthrough infections with antibody-evasive SARS-CoV-2 variants. FAU - Kingstad-Bakke, Brock AU - Kingstad-Bakke B AD - Department of Pathobiological Sciences, University of Wisconsin-Madison, Madison, Wisconsin, USA. FAU - Cleven, Thomas AU - Cleven T AD - Department of Pathobiological Sciences, University of Wisconsin-Madison, Madison, Wisconsin, USA. FAU - Bussan, Hailey AU - Bussan H AD - Department of Pathobiological Sciences, University of Wisconsin-Madison, Madison, Wisconsin, USA. FAU - Yount, Boyd L Jr AU - Yount BL Jr AD - Department of Microbiology and Immunology, University of North Carolina-Chapel Hill, Chapel Hill, North Carolina, USA. FAU - Uraki, Ryuta AU - Uraki R AD - Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo, Japan. AD - The Research Center for Global Viral Diseases, National Center for Global Health and Medicine Research Institute, Tokyo, Japan. FAU - Iwatsuki-Horimoto, Kiyoko AU - Iwatsuki-Horimoto K AD - Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo, Japan. FAU - Koga, Michiko AU - Koga M AD - Department of Infectious Diseases and Applied Immunology, IMSUT Hospital of The Institute of Medical Science, and. AD - Division of Infectious Diseases, Advanced Clinical Research Center, Institute of Medical Science, University of Tokyo, Tokyo, Japan. FAU - Yamamoto, Shinya AU - Yamamoto S AD - Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo, Japan. AD - Division of Infectious Diseases, Advanced Clinical Research Center, Institute of Medical Science, University of Tokyo, Tokyo, Japan. FAU - Yotsuyanagi, Hiroshi AU - Yotsuyanagi H AD - Department of Infectious Diseases and Applied Immunology, IMSUT Hospital of The Institute of Medical Science, and. AD - Division of Infectious Diseases, Advanced Clinical Research Center, Institute of Medical Science, University of Tokyo, Tokyo, Japan. FAU - Park, Hongtae AU - Park H AD - Department of Pathobiological Sciences, University of Wisconsin-Madison, Madison, Wisconsin, USA. FAU - Mishra, Jay S AU - Mishra JS AD - Department of Comparative Biosciences, University of Wisconsin-Madison, Madison, Wisconsin, USA. FAU - Kumar, Sathish AU - Kumar S AD - Department of Comparative Biosciences, University of Wisconsin-Madison, Madison, Wisconsin, USA. FAU - Baric, Ralph S AU - Baric RS AD - Department of Microbiology and Immunology, University of North Carolina-Chapel Hill, Chapel Hill, North Carolina, USA. FAU - Halfmann, Peter J AU - Halfmann PJ AD - Department of Pathobiological Sciences, University of Wisconsin-Madison, Madison, Wisconsin, USA. FAU - Kawaoka, Yoshihiro AU - Kawaoka Y AD - Department of Pathobiological Sciences, University of Wisconsin-Madison, Madison, Wisconsin, USA. AD - Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo, Japan. AD - The Research Center for Global Viral Diseases, National Center for Global Health and Medicine Research Institute, Tokyo, Japan. AD - The University of Tokyo, Pandemic Preparedness, Infection and Advanced Research Center (UTOPIA), Tokyo, Japan. FAU - Suresh, M AU - Suresh M AD - Department of Pathobiological Sciences, University of Wisconsin-Madison, Madison, Wisconsin, USA. LA - eng GR - R21 AI149793/AI/NIAID NIH HHS/United States GR - R21 AI173757/AI/NIAID NIH HHS/United States GR - U01 AI124299/AI/NIAID NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20231122 PL - United States TA - JCI Insight JT - JCI insight JID - 101676073 RN - 0 (COVID-19 Vaccines) RN - SARS-CoV-2 variants SB - IM MH - Humans MH - Animals MH - Mice MH - *COVID-19 Vaccines MH - Memory T Cells MH - *COVID-19/prevention & control MH - SARS-CoV-2 MH - Lung PMC - PMC10721330 OTO - NOTNLM OT - COVID-19 OT - Cellular immune response OT - Immunology OT - Memory OT - T cells EDAT- 2023/10/05 18:42 MHDA- 2023/11/27 12:42 PMCR- 2023/11/22 CRDT- 2023/10/05 12:03 PHST- 2023/05/23 00:00 [received] PHST- 2023/10/02 00:00 [accepted] PHST- 2023/11/27 12:42 [medline] PHST- 2023/10/05 18:42 [pubmed] PHST- 2023/10/05 12:03 [entrez] PHST- 2023/11/22 00:00 [pmc-release] AID - 172510 [pii] AID - 10.1172/jci.insight.172510 [doi] PST - epublish SO - JCI Insight. 2023 Nov 22;8(22):e172510. doi: 10.1172/jci.insight.172510. PMID- 37762029 OWN - NLM STAT- MEDLINE DCOM- 20230929 LR - 20230930 IS - 1422-0067 (Electronic) IS - 1422-0067 (Linking) VI - 24 IP - 18 DP - 2023 Sep 6 TI - Humoral and Cellular Immune Response Elicited by the BNT162b2 COVID-19 Vaccine Booster in Elderly. LID - 10.3390/ijms241813728 [doi] LID - 13728 AB - Although the safety and efficacy of COVID-19 vaccines in older people are critical to their success, little is known about their immunogenicity among elderly residents of long-term care facilities (LTCFs). A single-center prospective cohort study was conducted: a total IgG antibody titer, neutralizing antibodies against Wild-type, Delta Plus, and Omicron BA.2 variants and T cell response, were measured eight months after the second dose of BNT162b2 vaccine (T0) and at least 15 days after the booster (T1). Forty-nine LTCF residents, with a median age of 84.8 +/- 10.6 years, were enrolled. Previous COVID-19 infection was documented in 42.9% of the subjects one year before T0. At T1, the IgG titers increased up to 10-fold. This ratio was lower in the subjects with previous COVID-19 infection. At T1, IgG levels were similar in both groups. The neutralizing activity against Omicron BA.2 was significantly lower (65%) than that measured against Wild-type and Delta Plus (90%). A significant increase of T cell-specific immune response was observed after the booster. Frailty, older age, sex, cognitive impairment, and comorbidities did not affect antibody titers or T cell response. In the elderly sample analyzed, the BNT162b2 mRNA COVID-19 vaccine produced immunogenicity regardless of frailty. FAU - Dalla Gasperina, Daniela AU - Dalla Gasperina D AUID- ORCID: 0000-0002-1187-6222 AD - Department of Medicine and Technological Innovation, University of Insubria, ASST Sette Laghi, 21100 Varese, Italy. FAU - Veronesi, Giovanni AU - Veronesi G AUID- ORCID: 0000-0002-4119-6615 AD - Research Centre in Epidemiology and Preventive Medicine (EPIMED), Department of Medicine and Surgery, University of Insubria, 21100 Varese, Italy. FAU - Castelletti, Carlo M AU - Castelletti CM AD - Molina's Foundation, 21100 Varese, Italy. FAU - Varchetta, Stefania AU - Varchetta S AUID- ORCID: 0000-0002-0289-2896 AD - Clinical Immunology-Infectious Diseases, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy. FAU - Ottolini, Sabrina AU - Ottolini S AD - Department of Internal Medicine and Therapeutics, University of Pavia, 27100 Pavia, Italy. FAU - Mele, Dalila AU - Mele D AUID- ORCID: 0000-0002-5217-2766 AD - Microbiology and Molecular Virology Unit, Fondazione IRCCS Policlinico S. Matteo, 27100 Pavia, Italy. FAU - Ferrari, Giuseppe AU - Ferrari G AD - Molina's Foundation, 21100 Varese, Italy. FAU - Shaik, Amruth K B AU - Shaik AKB AD - Laboratory of General Pathology and Immunology "Giovanna Tosi", Department of Medicine and Technological Innovation, University of Insubria, 21100 Varese, Italy. FAU - Celesti, Fabrizio AU - Celesti F AD - Center for Immuno-Oncology, Department of Medicine, Surgery and Neurosciences, University of Siena, 53100 Siena, Italy. FAU - Dentali, Francesco AU - Dentali F AD - Department of Medicine and Surgery, University of Insubria, ASST Sette Laghi, 21100 Varese, Italy. FAU - Accolla, Roberto S AU - Accolla RS AD - Laboratory of General Pathology and Immunology "Giovanna Tosi", Department of Medicine and Technological Innovation, University of Insubria, 21100 Varese, Italy. FAU - Forlani, Greta AU - Forlani G AUID- ORCID: 0000-0003-1987-7761 AD - Laboratory of General Pathology and Immunology "Giovanna Tosi", Department of Medicine and Technological Innovation, University of Insubria, 21100 Varese, Italy. LA - eng GR - NA/FONDAZIONE MOLINA/ PT - Journal Article DEP - 20230906 PL - Switzerland TA - Int J Mol Sci JT - International journal of molecular sciences JID - 101092791 RN - 0 (COVID-19 Vaccines) RN - 0 (BNT162 Vaccine) RN - 0 (Immunoglobulin G) RN - COVID-19 vaccine booster shot SB - IM MH - *COVID-19/prevention & control MH - Immunization, Secondary MH - Immunoglobulin G MH - Prospective Studies MH - Humans MH - *Frailty MH - Immunity, Cellular MH - Aged, 80 and over MH - BNT162 Vaccine MH - COVID-19 Vaccines MH - Aged PMC - PMC10530943 OTO - NOTNLM OT - BNT162b2 mRNA COVID-19 vaccine OT - Omicron BA.2 OT - cellular immunity OT - long-term care facilities elderly residents OT - neutralizing antibodies COIS- The authors declare no conflict of interest. The funders had no role in the study's design; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results. EDAT- 2023/09/28 06:42 MHDA- 2023/09/29 06:44 PMCR- 2023/09/06 CRDT- 2023/09/28 01:16 PHST- 2023/08/04 00:00 [received] PHST- 2023/08/22 00:00 [revised] PHST- 2023/08/26 00:00 [accepted] PHST- 2023/09/29 06:44 [medline] PHST- 2023/09/28 06:42 [pubmed] PHST- 2023/09/28 01:16 [entrez] PHST- 2023/09/06 00:00 [pmc-release] AID - ijms241813728 [pii] AID - ijms-24-13728 [pii] AID - 10.3390/ijms241813728 [doi] PST - epublish SO - Int J Mol Sci. 2023 Sep 6;24(18):13728. doi: 10.3390/ijms241813728. PMID- 37735592 OWN - NLM STAT- MEDLINE DCOM- 20260310 LR - 20261010 IS - 1529-2916 (Electronic) IS - 1529-2908 (Linking) VI - 24 IP - 10 DP - 2023 Oct TI - Prior vaccination promotes early activation of memory T cells and enhances immune responses during SARS-CoV-2 breakthrough infection. PG - 1711-1724 LID - 10.1038/s41590-023-01613-y [doi] AB - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection of vaccinated individuals is increasingly common but rarely results in severe disease, likely due to the enhanced potency and accelerated kinetics of memory immune responses. However, there have been few opportunities to rigorously study early recall responses during human viral infection. To better understand human immune memory and identify potential mediators of lasting vaccine efficacy, we used high-dimensional flow cytometry and SARS-CoV-2 antigen probes to examine immune responses in longitudinal samples from vaccinated individuals infected during the Omicron wave. These studies revealed heightened spike-specific responses during infection of vaccinated compared to unvaccinated individuals. Spike-specific cluster of differentiation (CD)4 T cells and plasmablasts expanded and CD8 T cells were robustly activated during the first week. In contrast, memory B cell activation, neutralizing antibody production and primary responses to nonspike antigens occurred during the second week. Collectively, these data demonstrate the functionality of vaccine-primed immune memory and highlight memory T cells as rapid responders during SARS-CoV-2 infection. CI - (c) 2023. The Author(s), under exclusive licence to Springer Nature America, Inc. FAU - Painter, Mark M AU - Painter MM AUID- ORCID: 0000-0002-0180-2748 AD - Institute for Immunology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA. AD - Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA. AD - Immune Health, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA. FAU - Johnston, Timothy S AU - Johnston TS AD - Institute for Immunology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA. AD - Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA. AD - Immunology Graduate Group, University of Pennsylvania, Philadelphia, PA, USA. FAU - Lundgreen, Kendall A AU - Lundgreen KA AD - Department of Microbiology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA. FAU - Santos, Jefferson J S AU - Santos JJS AUID- ORCID: 0000-0001-5895-4163 AD - Department of Microbiology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA. FAU - Qin, Juliana S AU - Qin JS AUID- ORCID: 0000-0002-6352-9601 AD - Immune Health, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA. FAU - Goel, Rishi R AU - Goel RR AD - Institute for Immunology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA. AD - Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA. AD - Immune Health, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA. FAU - Apostolidis, Sokratis A AU - Apostolidis SA AUID- ORCID: 0000-0002-0224-0097 AD - Institute for Immunology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA. AD - Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA. AD - Immune Health, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA. AD - Division of Rheumatology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA. FAU - Mathew, Divij AU - Mathew D AD - Institute for Immunology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA. AD - Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA. FAU - Fulmer, Bria AU - Fulmer B AD - Institute for Immunology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA. AD - Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA. FAU - Williams, Justine C AU - Williams JC AD - Immune Health, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA. FAU - McKeague, Michelle L AU - McKeague ML AD - Immune Health, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA. FAU - Pattekar, Ajinkya AU - Pattekar A AD - Immune Health, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA. FAU - Goode, Ahmad AU - Goode A AD - Immune Health, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA. FAU - Nasta, Sean AU - Nasta S AD - Immune Health, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA. FAU - Baxter, Amy E AU - Baxter AE AUID- ORCID: 0000-0002-1555-0713 AD - Institute for Immunology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA. AD - Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA. FAU - Giles, Josephine R AU - Giles JR AD - Institute for Immunology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA. AD - Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA. AD - Parker Institute for Cancer Immunotherapy, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA. FAU - Skelly, Ashwin N AU - Skelly AN AUID- ORCID: 0000-0002-1565-3376 AD - Institute for Immunology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA. AD - Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA. FAU - Felley, Laura E AU - Felley LE AD - Division of Infectious Disease, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA. FAU - McLaughlin, Maura AU - McLaughlin M AD - Institute for Immunology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA. AD - Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA. FAU - Weaver, Joellen AU - Weaver J AD - Department of Genetics, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA. CN - Penn Medicine BioBank FAU - Kuthuru, Oliva AU - Kuthuru O AD - Institute for Immunology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA. AD - Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA. FAU - Dougherty, Jeanette AU - Dougherty J AD - Immune Health, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA. FAU - Adamski, Sharon AU - Adamski S AD - Immune Health, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA. FAU - Long, Sherea AU - Long S AD - Immune Health, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA. FAU - Kee, Macy AU - Kee M AD - Immune Health, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA. FAU - Clendenin, Cynthia AU - Clendenin C AUID- ORCID: 0000-0003-4535-2088 AD - Immune Health, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA. FAU - da Silva Antunes, Ricardo AU - da Silva Antunes R AUID- ORCID: 0000-0001-9785-5272 AD - Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA, USA. FAU - Grifoni, Alba AU - Grifoni A AUID- ORCID: 0000-0002-2209-5966 AD - Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA, USA. FAU - Weiskopf, Daniela AU - Weiskopf D AD - Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA, USA. FAU - Sette, Alessandro AU - Sette A AUID- ORCID: 0000-0001-7013-2250 AD - Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA, USA. AD - Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego (UCSD), La Jolla, CA, USA. FAU - Huang, Alexander C AU - Huang AC AUID- ORCID: 0000-0002-0099-0492 AD - Institute for Immunology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA. AD - Parker Institute for Cancer Immunotherapy, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA. AD - Division of Hematology/Oncology, Department of Medicine, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA. FAU - Rader, Daniel J AU - Rader DJ AD - Department of Genetics, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA. AD - Penn Medicine Biobank, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA. FAU - Hensley, Scott E AU - Hensley SE AUID- ORCID: 0000-0002-2928-7506 AD - Department of Microbiology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA. FAU - Bates, Paul AU - Bates P AD - Department of Microbiology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA. FAU - Greenplate, Allison R AU - Greenplate AR AUID- ORCID: 0000-0002-2614-3072 AD - Institute for Immunology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA. AD - Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA. AD - Immune Health, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA. FAU - Wherry, E John AU - Wherry EJ AUID- ORCID: 0000-0003-0477-1956 AD - Institute for Immunology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA. wherry@pennmedicine.upenn.edu. AD - Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA. wherry@pennmedicine.upenn.edu. AD - Immune Health, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA. wherry@pennmedicine.upenn.edu. AD - Parker Institute for Cancer Immunotherapy, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA. wherry@pennmedicine.upenn.edu. LA - eng GR - AI082630/U.S. Department of Health & Human Services | National Institutes of Health (NIH)/ GR - AI108545/U.S. Department of Health & Human Services | National Institutes of Health (NIH)/ GR - AI155577/U.S. Department of Health & Human Services | National Institutes of Health (NIH)/ GR - AI149680/U.S. Department of Health & Human Services | National Institutes of Health (NIH)/ GR - U19AI082630/U.S. Department of Health & Human Services | National Institutes of Health (NIH)/ GR - 75N9301900065/U.S. Department of Health & Human Services | National Institutes of Health (NIH)/ GR - AI152236/U.S. Department of Health & Human Services | National Institutes of Health (NIH)/ GR - UL1TR001878/U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences (NCATS)/ PT - Journal Article DEP - 20230921 PL - United States TA - Nat Immunol JT - Nature immunology JID - 100941354 RN - 0 (COVID-19 Vaccines) RN - 0 (Antibodies, Neutralizing) RN - 0 (Antibodies, Viral) RN - 0 (Spike Glycoprotein, Coronavirus) RN - 0 (spike protein, SARS-CoV-2) RN - COVID-19 breakthrough infections SB - IM UOF - bioRxiv. 2023 Feb 06:2023.02.05.527215. doi: 10.1101/2023.02.05.527215. PMID: 36798171 MH - Humans MH - *COVID-19/immunology/prevention & control MH - *SARS-CoV-2/immunology MH - *Memory T Cells/immunology MH - *COVID-19 Vaccines/immunology MH - Antibodies, Neutralizing/immunology MH - Vaccination MH - Antibodies, Viral/immunology MH - *Immunologic Memory MH - Spike Glycoprotein, Coronavirus/immunology MH - Lymphocyte Activation/immunology MH - CD8-Positive T-Lymphocytes/immunology MH - Female MH - Memory B Cells/immunology MH - Adult MH - Male MH - Middle Aged MH - Breakthrough Infections FIR - Ritchie, Marylyn D IR - Ritchie MD FIR - Feldman, Michael D IR - Feldman MD FIR - Weaver, JoEllen IR - Weaver J FIR - Naseer, Nawar IR - Naseer N FIR - Poindexter, Afiya IR - Poindexter A FIR - Brock, Ashlei IR - Brock A FIR - Hu-Sain, Khadijah IR - Hu-Sain K FIR - Ko, Yi-An IR - Ko YA FIR - Livingstone, Meghan IR - Livingstone M FIR - Vadivieso, Fred IR - Vadivieso F FIR - Kloter, Ashley IR - Kloter A FIR - DerOhannessian, Stephanie IR - DerOhannessian S FIR - Tran, Teo IR - Tran T FIR - Morrel, Linda IR - Morrel L FIR - Haubein, Ned IR - Haubein N FIR - Dunn, Joseph IR - Dunn J FIR - Verma, Anurag IR - Verma A FIR - Morse, Colleen IR - Morse C FIR - Risman, Marjorie IR - Risman M FIR - Judy, Renae IR - Judy R FIR - Verma, Shefali S IR - Verma SS FIR - Bradford, Yuki IR - Bradford Y FIR - Dudek, Scott IR - Dudek S FIR - Drivas, Theodore IR - Drivas T EDAT- 2023/09/22 06:42 MHDA- 2026/03/10 18:37 CRDT- 2023/09/22 01:32 PHST- 2023/02/05 00:00 [received] PHST- 2023/08/07 00:00 [accepted] PHST- 2026/03/10 18:37 [medline] PHST- 2023/09/22 06:42 [pubmed] PHST- 2023/09/22 01:32 [entrez] AID - 10.1038/s41590-023-01613-y [pii] AID - 10.1038/s41590-023-01613-y [doi] PST - ppublish SO - Nat Immunol. 2023 Oct;24(10):1711-1724. doi: 10.1038/s41590-023-01613-y. Epub 2023 Sep 21. PMID- 37710966 OWN - NLM STAT- MEDLINE DCOM- 20230918 LR - 20231009 IS - 1607-842X (Electronic) IS - 0891-6934 (Linking) VI - 56 IP - 1 DP - 2023 Dec TI - Autoimmune inflammatory reactions triggered by the COVID-19 genetic vaccines in terminally differentiated tissues. PG - 2259123 LID - 10.1080/08916934.2023.2259123 [doi] AB - As a result of the spread of SARS-CoV-2, a global pandemic was declared. Indiscriminate COVID-19 vaccination has been extended to include age groups and naturally immune people with minimal danger of suffering serious complications due to COVID-19. Solid immuno-histopathological evidence demonstrates that the COVID-19 genetic vaccines can display a wide distribution within the body, affecting tissues that are terminally differentiated and far away from the injection site. These include the heart and brain, which may incur in situ production of spike protein eliciting a strong autoimmunological inflammatory response. Due to the fact that every human cell which synthesises non-self antigens, inevitably becomes the target of the immune system, and since the human body is not a strictly compartmentalised system, accurate pharmacokinetic and pharmacodynamic studies are needed in order to determine precisely which tissues can be harmed. Therefore, our article aims to draw the attention of the scientific and regulatory communities to the critical need for biodistribution studies for the genetic vaccines against COVID-19, as well as for rational harm-benefit assessments by age group. FAU - Polykretis, Panagis AU - Polykretis P AD - "Allineare Sanita e Salute" Foundation, Milano, Italy. AD - Independent Medical Scientific Commission (CMSi), Milano, Italy. FAU - Donzelli, Alberto AU - Donzelli A AD - "Allineare Sanita e Salute" Foundation, Milano, Italy. AD - Independent Medical Scientific Commission (CMSi), Milano, Italy. FAU - Lindsay, Janci C AU - Lindsay JC AD - Toxicology & Molecular Biology, Toxicology Support Services, LLC, Sealy, TX, USA. FAU - Wiseman, David AU - Wiseman D AUID- ORCID: 0000-0002-8367-6158 AD - Synechion, Inc, Dallas, TX, USA. FAU - Kyriakopoulos, Anthony M AU - Kyriakopoulos AM AD - Infectious Disease, Nasco AD Biotechnology Laboratory, Piraeus, Greece. FAU - Morz, Michael AU - Morz M AD - Independent researcher, Dresden, Germany. FAU - Bellavite, Paolo AU - Bellavite P AD - Independent medical researcher, Verona, Italy. FAU - Fukushima, Masanori AU - Fukushima M AD - Foundation of Learning Health Society Institute, Nagoya, Japan. FAU - Seneff, Stephanie AU - Seneff S AD - Computer Science and Artificial Intelligence Laboratory, MIT, Cambridge, MA, USA. FAU - McCullough, Peter A AU - McCullough PA AD - Cardiology, Truth for Health Foundation, Tucson, AZ, USA. LA - eng PT - Journal Article PT - Review PL - England TA - Autoimmunity JT - Autoimmunity JID - 8900070 RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - *COVID-19 Vaccines/adverse effects MH - *COVID-19/prevention & control MH - Tissue Distribution MH - SARS-CoV-2 MH - Brain OTO - NOTNLM OT - COVID-19 genetic vaccines OT - antigen presentation OT - autoimmunity OT - histopathology OT - immunohistochemistry OT - spike protein EDAT- 2023/09/15 06:42 MHDA- 2023/09/18 12:42 CRDT- 2023/09/15 02:10 PHST- 2023/09/18 12:42 [medline] PHST- 2023/09/15 06:42 [pubmed] PHST- 2023/09/15 02:10 [entrez] AID - 10.1080/08916934.2023.2259123 [doi] PST - ppublish SO - Autoimmunity. 2023 Dec;56(1):2259123. doi: 10.1080/08916934.2023.2259123. PMID- 37683546 OWN - NLM STAT- MEDLINE DCOM- 20230914 LR - 20231212 IS - 1980-5322 (Electronic) IS - 1807-5932 (Print) IS - 1807-5932 (Linking) VI - 78 DP - 2023 TI - First tonic-clonic seizure five hours after Ad26.COV2.S vaccination without acute brain lesion but long-term chorea. PG - 100281 LID - S1807-5932(23)00117-5 [pii] LID - 10.1016/j.clinsp.2023.100281 [doi] LID - 100281 FAU - de Almeida, Antonio-Carlos M AU - de Almeida AM AD - Centro de Neurociencias e Saude da Mulher "Professor Geraldo Rodrigues de Lima", Escola Paulista de Medicina, Universidade Federal de Sao Paulo (EPM/UNIFESP), Sao Paulo, SP, Brazil. FAU - Fiorini, Ana C AU - Fiorini AC AD - Programa de Estudos Pos-Graduado em Fonoaudiologia, Pontificia Universidade Catolica de Sao Paulo (PUC-SP), Sao Paulo, SP, Brazil; Departamento de Fonoaudiologia, Escola Paulista de Medicina, Universidade Federal de Sao Paulo (EPM/UNIFESP), Sao Paulo, SP, Brazil. FAU - Scorza, Fulvio A AU - Scorza FA AD - Disciplina de Neurociencia, Universidade Federal de Sao Paulo, Escola Paulista de Medicina (UNIFESP/EPM), Sao Paulo, SP, Brazil. FAU - Finsterer, Josef AU - Finsterer J AD - Neurology & Neurophysiology Center, Vienna, Austria. Electronic address: fifigs1@yahoo.de. LA - eng PT - Letter DEP - 20230906 PL - United States TA - Clinics (Sao Paulo) JT - Clinics (Sao Paulo, Brazil) JID - 101244734 RN - JT2NS6183B (Ad26COVS1) SB - IM MH - Humans MH - Ad26COVS1 MH - *Chorea/etiology MH - *COVID-19 MH - Seizures/etiology MH - Brain PMC - PMC10497981 COIS- Declaration of Competing Interest The authors declare no conflicts of interest. EDAT- 2023/09/09 10:41 MHDA- 2023/09/14 06:42 PMCR- 2023/09/07 CRDT- 2023/09/08 18:09 PHST- 2023/07/04 00:00 [received] PHST- 2023/08/22 00:00 [accepted] PHST- 2023/09/14 06:42 [medline] PHST- 2023/09/09 10:41 [pubmed] PHST- 2023/09/08 18:09 [entrez] PHST- 2023/09/07 00:00 [pmc-release] AID - S1807-5932(23)00117-5 [pii] AID - 100281 [pii] AID - 10.1016/j.clinsp.2023.100281 [doi] PST - epublish SO - Clinics (Sao Paulo). 2023 Sep 6;78:100281. doi: 10.1016/j.clinsp.2023.100281. eCollection 2023. PMID- 37679040 OWN - NLM STAT- MEDLINE DCOM- 20230911 LR - 20231004 IS - 2332-7812 (Electronic) IS - 2332-7812 (Linking) VI - 10 IP - 6 DP - 2023 Nov TI - mRNA COVID-19 Vaccination Does Not Exacerbate Symptoms or Trigger Neural Antibody Responses in Multiple Sclerosis. LID - 10.1212/NXI.0000000000200163 [doi] LID - e200163 AB - BACKGROUND AND OBJECTIVE: In people with multiple sclerosis (pwMS), concern for potential disease exacerbation or triggering of other autoimmune disorders contributes to vaccine hesitancy. We assessed the humoral and T-cell responses to SARS-CoV-2 after mRNA vaccination, changes in disease activity, and development of antibodies against central or peripheral nervous system antigens. METHODS: This was a prospective 1-year longitudinal observational study of pwMS and a control group of patients with other inflammatory neurologic disorders (OIND) who received an mRNA vaccine. Blood samples were obtained before the first dose (T1), 1 month after the first dose (T2), 1 month after the second dose (T3), and 6 (T4), 9 (T5), and 12 (T6) months after the first dose. Patients were assessed for the immune-specific response, annualized relapse rate (ARR), and antibodies to onconeuronal, neural surface, glial, ganglioside, and nodo-paranodal antigens. RESULTS: Among 454 patients studied, 390 had MS (22 adolescents) and 64 OIND; the mean (SD) age was 44 (14) years; 315 (69%) were female; and 392 (87%) were on disease-modifying therapies. Antibodies to the receptor-binding domain were detected in 367 (86%) patients at T3 and 276 (83%) at T4. After a third dose, only 13 (22%) of 60 seronegative patients seroconverted, and 255 (92%) remained seropositive at T6. Cellular responses were present in 381 (93%) patients at T3 and in 235 (91%) patients at T6 including all those receiving anti-CD20 therapies and in 79% of patients receiving fingolimod. At T3 (429 patients) or T6 (395 patients), none of the patients had developed CNS autoantibodies. Seven patients had neural antibodies that were already present before immunization (3 adult patients with MS had MOG-IgG, 2 with MG and 1 with MS had neuronal cell surface antibodies [unknown antigen], and 1 with MS had myelin antibody reactivity [unknown antigen]. Similarly, no antibodies against PNS antigens were identified at T3 (427 patients). ARR was lower in MS and not significantly different in patients with OIND. Although 182 (40%) patients developed SARS-CoV-2 infection, no cases of severe COVID-19 or serious adverse events occurred. DISCUSSION: In this study, mRNA COVID-19 vaccination was safe and did not exacerbate the autoimmune disease nor triggered neural autoantibodies or immune-mediated neurologic disorders. The outcome of patients who developed SARS-CoV-2 infection was favorable. CI - Copyright (c) 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. FAU - Blanco, Yolanda AU - Blanco Y AD - From the Neuroimmunology and Multiple Sclerosis Unit (Y.B., D.E., S.L., R.R.G., M.A., S.A., J.M.C.-M., M.G., A.H., E.M.-H., M.S., T.A., J.D., A.S.), Hospital Clinic de Barcelona, and Universitat de Barcelona; Neurommunology Program, Fundacio de Recerca Clinic Barcelona-IDIBAPS (Y.B., S.L., R.R.G., M.A., E.A., M.A., E.C., J.M.C.-M., E.F., M.G., E.M.-H., G.O.-C., M.R., L.S., M.S., E.S., T.A., J.D., A.S.), Barcelona; Neuromuscular Diseases Unit, Neurology Department (C.L., L.M.-A., C.T.-I., N.V.-F., L.Q.), Hospital de Sant Pau, Barcelona; Centro para la Investigacion en Red en Enfermedades Raras (CIBERER) (C.L., M.G., C.T.-I., J.D., L.Q.), Madrid; Department of Immunology (N.E., R.R.G.), Hospital Clinic de Barcelona; Department of Preventive Medicine and Epidemiology (M.A., A.V.), Hospital Clinic de Barcelona, Spain; Department of Neurology (E.F.), School of Medicine, Pontificia Universidad Catolica de Chile, Santiago de Chile; Pediatric Neurology Unit (G.O.-C.), Hospital Parc Tauli de Sabadell, Barcelona; Infectious Diseases Unit, Department of Internal Medicine, (J.L.-C., A.R.) Hospital de Sant Pau, Universitat Autonoma de Barcelona, Barcelona; Immunology Department (L.M.-M.), Sant Pau, Institut de Recerca del Hospital de Sant Pau, Universitat Autonoma de Barcelona, Barcelona; Department of Pediatrics, and Infectious Diseases Department (C.F.), Institut de Recerca Pediatrica Hospital de Sant Joan de Deu, Esplugues de Llobregat, Barcelona; Pediatric Neuroimmunology Unit, Department of Neurology (S.J.D.), Sant Joan de Deu Children s Hospital (T.A), University of Barcelona, Spain; Department of Neurology, (J.D.) Perelman School of Medicine, University of Pennsylvania, Philadelphia; and Catalan Institute for Research and Advanced Studies (ICREA) (J.D.), Barcelona, Spain. FAU - Escudero, Domingo AU - Escudero D AD - From the Neuroimmunology and Multiple Sclerosis Unit (Y.B., D.E., S.L., R.R.G., M.A., S.A., J.M.C.-M., M.G., A.H., E.M.-H., M.S., T.A., J.D., A.S.), Hospital Clinic de Barcelona, and Universitat de Barcelona; Neurommunology Program, Fundacio de Recerca Clinic Barcelona-IDIBAPS (Y.B., S.L., R.R.G., M.A., E.A., M.A., E.C., J.M.C.-M., E.F., M.G., E.M.-H., G.O.-C., M.R., L.S., M.S., E.S., T.A., J.D., A.S.), Barcelona; Neuromuscular Diseases Unit, Neurology Department (C.L., L.M.-A., C.T.-I., N.V.-F., L.Q.), Hospital de Sant Pau, Barcelona; Centro para la Investigacion en Red en Enfermedades Raras (CIBERER) (C.L., M.G., C.T.-I., J.D., L.Q.), Madrid; Department of Immunology (N.E., R.R.G.), Hospital Clinic de Barcelona; Department of Preventive Medicine and Epidemiology (M.A., A.V.), Hospital Clinic de Barcelona, Spain; Department of Neurology (E.F.), School of Medicine, Pontificia Universidad Catolica de Chile, Santiago de Chile; Pediatric Neurology Unit (G.O.-C.), Hospital Parc Tauli de Sabadell, Barcelona; Infectious Diseases Unit, Department of Internal Medicine, (J.L.-C., A.R.) Hospital de Sant Pau, Universitat Autonoma de Barcelona, Barcelona; Immunology Department (L.M.-M.), Sant Pau, Institut de Recerca del Hospital de Sant Pau, Universitat Autonoma de Barcelona, Barcelona; Department of Pediatrics, and Infectious Diseases Department (C.F.), Institut de Recerca Pediatrica Hospital de Sant Joan de Deu, Esplugues de Llobregat, Barcelona; Pediatric Neuroimmunology Unit, Department of Neurology (S.J.D.), Sant Joan de Deu Children s Hospital (T.A), University of Barcelona, Spain; Department of Neurology, (J.D.) Perelman School of Medicine, University of Pennsylvania, Philadelphia; and Catalan Institute for Research and Advanced Studies (ICREA) (J.D.), Barcelona, Spain. FAU - Lleixa, Cinta AU - Lleixa C AD - From the Neuroimmunology and Multiple Sclerosis Unit (Y.B., D.E., S.L., R.R.G., M.A., S.A., J.M.C.-M., M.G., A.H., E.M.-H., M.S., T.A., J.D., A.S.), Hospital Clinic de Barcelona, and Universitat de Barcelona; Neurommunology Program, Fundacio de Recerca Clinic Barcelona-IDIBAPS (Y.B., S.L., R.R.G., M.A., E.A., M.A., E.C., J.M.C.-M., E.F., M.G., E.M.-H., G.O.-C., M.R., L.S., M.S., E.S., T.A., J.D., A.S.), Barcelona; Neuromuscular Diseases Unit, Neurology Department (C.L., L.M.-A., C.T.-I., N.V.-F., L.Q.), Hospital de Sant Pau, Barcelona; Centro para la Investigacion en Red en Enfermedades Raras (CIBERER) (C.L., M.G., C.T.-I., J.D., L.Q.), Madrid; Department of Immunology (N.E., R.R.G.), Hospital Clinic de Barcelona; Department of Preventive Medicine and Epidemiology (M.A., A.V.), Hospital Clinic de Barcelona, Spain; Department of Neurology (E.F.), School of Medicine, Pontificia Universidad Catolica de Chile, Santiago de Chile; Pediatric Neurology Unit (G.O.-C.), Hospital Parc Tauli de Sabadell, Barcelona; Infectious Diseases Unit, Department of Internal Medicine, (J.L.-C., A.R.) Hospital de Sant Pau, Universitat Autonoma de Barcelona, Barcelona; Immunology Department (L.M.-M.), Sant Pau, Institut de Recerca del Hospital de Sant Pau, Universitat Autonoma de Barcelona, Barcelona; Department of Pediatrics, and Infectious Diseases Department (C.F.), Institut de Recerca Pediatrica Hospital de Sant Joan de Deu, Esplugues de Llobregat, Barcelona; Pediatric Neuroimmunology Unit, Department of Neurology (S.J.D.), Sant Joan de Deu Children s Hospital (T.A), University of Barcelona, Spain; Department of Neurology, (J.D.) Perelman School of Medicine, University of Pennsylvania, Philadelphia; and Catalan Institute for Research and Advanced Studies (ICREA) (J.D.), Barcelona, Spain. FAU - Llufriu, Sara AU - Llufriu S AD - From the Neuroimmunology and Multiple Sclerosis Unit (Y.B., D.E., S.L., R.R.G., M.A., S.A., J.M.C.-M., M.G., A.H., E.M.-H., M.S., T.A., J.D., A.S.), Hospital Clinic de Barcelona, and Universitat de Barcelona; Neurommunology Program, Fundacio de Recerca Clinic Barcelona-IDIBAPS (Y.B., S.L., R.R.G., M.A., E.A., M.A., E.C., J.M.C.-M., E.F., M.G., E.M.-H., G.O.-C., M.R., L.S., M.S., E.S., T.A., J.D., A.S.), Barcelona; Neuromuscular Diseases Unit, Neurology Department (C.L., L.M.-A., C.T.-I., N.V.-F., L.Q.), Hospital de Sant Pau, Barcelona; Centro para la Investigacion en Red en Enfermedades Raras (CIBERER) (C.L., M.G., C.T.-I., J.D., L.Q.), Madrid; Department of Immunology (N.E., R.R.G.), Hospital Clinic de Barcelona; Department of Preventive Medicine and Epidemiology (M.A., A.V.), Hospital Clinic de Barcelona, Spain; Department of Neurology (E.F.), School of Medicine, Pontificia Universidad Catolica de Chile, Santiago de Chile; Pediatric Neurology Unit (G.O.-C.), Hospital Parc Tauli de Sabadell, Barcelona; Infectious Diseases Unit, Department of Internal Medicine, (J.L.-C., A.R.) Hospital de Sant Pau, Universitat Autonoma de Barcelona, Barcelona; Immunology Department (L.M.-M.), Sant Pau, Institut de Recerca del Hospital de Sant Pau, Universitat Autonoma de Barcelona, Barcelona; Department of Pediatrics, and Infectious Diseases Department (C.F.), Institut de Recerca Pediatrica Hospital de Sant Joan de Deu, Esplugues de Llobregat, Barcelona; Pediatric Neuroimmunology Unit, Department of Neurology (S.J.D.), Sant Joan de Deu Children s Hospital (T.A), University of Barcelona, Spain; Department of Neurology, (J.D.) Perelman School of Medicine, University of Pennsylvania, Philadelphia; and Catalan Institute for Research and Advanced Studies (ICREA) (J.D.), Barcelona, Spain. FAU - Egri, Natalia AU - Egri N AUID- ORCID: 0000-0001-7698-0672 AD - From the Neuroimmunology and Multiple Sclerosis Unit (Y.B., D.E., S.L., R.R.G., M.A., S.A., J.M.C.-M., M.G., A.H., E.M.-H., M.S., T.A., J.D., A.S.), Hospital Clinic de Barcelona, and Universitat de Barcelona; Neurommunology Program, Fundacio de Recerca Clinic Barcelona-IDIBAPS (Y.B., S.L., R.R.G., M.A., E.A., M.A., E.C., J.M.C.-M., E.F., M.G., E.M.-H., G.O.-C., M.R., L.S., M.S., E.S., T.A., J.D., A.S.), Barcelona; Neuromuscular Diseases Unit, Neurology Department (C.L., L.M.-A., C.T.-I., N.V.-F., L.Q.), Hospital de Sant Pau, Barcelona; Centro para la Investigacion en Red en Enfermedades Raras (CIBERER) (C.L., M.G., C.T.-I., J.D., L.Q.), Madrid; Department of Immunology (N.E., R.R.G.), Hospital Clinic de Barcelona; Department of Preventive Medicine and Epidemiology (M.A., A.V.), Hospital Clinic de Barcelona, Spain; Department of Neurology (E.F.), School of Medicine, Pontificia Universidad Catolica de Chile, Santiago de Chile; Pediatric Neurology Unit (G.O.-C.), Hospital Parc Tauli de Sabadell, Barcelona; Infectious Diseases Unit, Department of Internal Medicine, (J.L.-C., A.R.) Hospital de Sant Pau, Universitat Autonoma de Barcelona, Barcelona; Immunology Department (L.M.-M.), Sant Pau, Institut de Recerca del Hospital de Sant Pau, Universitat Autonoma de Barcelona, Barcelona; Department of Pediatrics, and Infectious Diseases Department (C.F.), Institut de Recerca Pediatrica Hospital de Sant Joan de Deu, Esplugues de Llobregat, Barcelona; Pediatric Neuroimmunology Unit, Department of Neurology (S.J.D.), Sant Joan de Deu Children s Hospital (T.A), University of Barcelona, Spain; Department of Neurology, (J.D.) Perelman School of Medicine, University of Pennsylvania, Philadelphia; and Catalan Institute for Research and Advanced Studies (ICREA) (J.D.), Barcelona, Spain. FAU - Garcia, Raquel Ruiz AU - Garcia RR AUID- ORCID: 0000-0002-8403-3613 AD - From the Neuroimmunology and Multiple Sclerosis Unit (Y.B., D.E., S.L., R.R.G., M.A., S.A., J.M.C.-M., M.G., A.H., E.M.-H., M.S., T.A., J.D., A.S.), Hospital Clinic de Barcelona, and Universitat de Barcelona; Neurommunology Program, Fundacio de Recerca Clinic Barcelona-IDIBAPS (Y.B., S.L., R.R.G., M.A., E.A., M.A., E.C., J.M.C.-M., E.F., M.G., E.M.-H., G.O.-C., M.R., L.S., M.S., E.S., T.A., J.D., A.S.), Barcelona; Neuromuscular Diseases Unit, Neurology Department (C.L., L.M.-A., C.T.-I., N.V.-F., L.Q.), Hospital de Sant Pau, Barcelona; Centro para la Investigacion en Red en Enfermedades Raras (CIBERER) (C.L., M.G., C.T.-I., J.D., L.Q.), Madrid; Department of Immunology (N.E., R.R.G.), Hospital Clinic de Barcelona; Department of Preventive Medicine and Epidemiology (M.A., A.V.), Hospital Clinic de Barcelona, Spain; Department of Neurology (E.F.), School of Medicine, Pontificia Universidad Catolica de Chile, Santiago de Chile; Pediatric Neurology Unit (G.O.-C.), Hospital Parc Tauli de Sabadell, Barcelona; Infectious Diseases Unit, Department of Internal Medicine, (J.L.-C., A.R.) Hospital de Sant Pau, Universitat Autonoma de Barcelona, Barcelona; Immunology Department (L.M.-M.), Sant Pau, Institut de Recerca del Hospital de Sant Pau, Universitat Autonoma de Barcelona, Barcelona; Department of Pediatrics, and Infectious Diseases Department (C.F.), Institut de Recerca Pediatrica Hospital de Sant Joan de Deu, Esplugues de Llobregat, Barcelona; Pediatric Neuroimmunology Unit, Department of Neurology (S.J.D.), Sant Joan de Deu Children s Hospital (T.A), University of Barcelona, Spain; Department of Neurology, (J.D.) Perelman School of Medicine, University of Pennsylvania, Philadelphia; and Catalan Institute for Research and Advanced Studies (ICREA) (J.D.), Barcelona, Spain. FAU - Alba, Mercedes AU - Alba M AD - From the Neuroimmunology and Multiple Sclerosis Unit (Y.B., D.E., S.L., R.R.G., M.A., S.A., J.M.C.-M., M.G., A.H., E.M.-H., M.S., T.A., J.D., A.S.), Hospital Clinic de Barcelona, and Universitat de Barcelona; Neurommunology Program, Fundacio de Recerca Clinic Barcelona-IDIBAPS (Y.B., S.L., R.R.G., M.A., E.A., M.A., E.C., J.M.C.-M., E.F., M.G., E.M.-H., G.O.-C., M.R., L.S., M.S., E.S., T.A., J.D., A.S.), Barcelona; Neuromuscular Diseases Unit, Neurology Department (C.L., L.M.-A., C.T.-I., N.V.-F., L.Q.), Hospital de Sant Pau, Barcelona; Centro para la Investigacion en Red en Enfermedades Raras (CIBERER) (C.L., M.G., C.T.-I., J.D., L.Q.), Madrid; Department of Immunology (N.E., R.R.G.), Hospital Clinic de Barcelona; Department of Preventive Medicine and Epidemiology (M.A., A.V.), Hospital Clinic de Barcelona, Spain; Department of Neurology (E.F.), School of Medicine, Pontificia Universidad Catolica de Chile, Santiago de Chile; Pediatric Neurology Unit (G.O.-C.), Hospital Parc Tauli de Sabadell, Barcelona; Infectious Diseases Unit, Department of Internal Medicine, (J.L.-C., A.R.) Hospital de Sant Pau, Universitat Autonoma de Barcelona, Barcelona; Immunology Department (L.M.-M.), Sant Pau, Institut de Recerca del Hospital de Sant Pau, Universitat Autonoma de Barcelona, Barcelona; Department of Pediatrics, and Infectious Diseases Department (C.F.), Institut de Recerca Pediatrica Hospital de Sant Joan de Deu, Esplugues de Llobregat, Barcelona; Pediatric Neuroimmunology Unit, Department of Neurology (S.J.D.), Sant Joan de Deu Children s Hospital (T.A), University of Barcelona, Spain; Department of Neurology, (J.D.) Perelman School of Medicine, University of Pennsylvania, Philadelphia; and Catalan Institute for Research and Advanced Studies (ICREA) (J.D.), Barcelona, Spain. FAU - Aguilar, Esther AU - Aguilar E AD - From the Neuroimmunology and Multiple Sclerosis Unit (Y.B., D.E., S.L., R.R.G., M.A., S.A., J.M.C.-M., M.G., A.H., E.M.-H., M.S., T.A., J.D., A.S.), Hospital Clinic de Barcelona, and Universitat de Barcelona; Neurommunology Program, Fundacio de Recerca Clinic Barcelona-IDIBAPS (Y.B., S.L., R.R.G., M.A., E.A., M.A., E.C., J.M.C.-M., E.F., M.G., E.M.-H., G.O.-C., M.R., L.S., M.S., E.S., T.A., J.D., A.S.), Barcelona; Neuromuscular Diseases Unit, Neurology Department (C.L., L.M.-A., C.T.-I., N.V.-F., L.Q.), Hospital de Sant Pau, Barcelona; Centro para la Investigacion en Red en Enfermedades Raras (CIBERER) (C.L., M.G., C.T.-I., J.D., L.Q.), Madrid; Department of Immunology (N.E., R.R.G.), Hospital Clinic de Barcelona; Department of Preventive Medicine and Epidemiology (M.A., A.V.), Hospital Clinic de Barcelona, Spain; Department of Neurology (E.F.), School of Medicine, Pontificia Universidad Catolica de Chile, Santiago de Chile; Pediatric Neurology Unit (G.O.-C.), Hospital Parc Tauli de Sabadell, Barcelona; Infectious Diseases Unit, Department of Internal Medicine, (J.L.-C., A.R.) Hospital de Sant Pau, Universitat Autonoma de Barcelona, Barcelona; Immunology Department (L.M.-M.), Sant Pau, Institut de Recerca del Hospital de Sant Pau, Universitat Autonoma de Barcelona, Barcelona; Department of Pediatrics, and Infectious Diseases Department (C.F.), Institut de Recerca Pediatrica Hospital de Sant Joan de Deu, Esplugues de Llobregat, Barcelona; Pediatric Neuroimmunology Unit, Department of Neurology (S.J.D.), Sant Joan de Deu Children s Hospital (T.A), University of Barcelona, Spain; Department of Neurology, (J.D.) Perelman School of Medicine, University of Pennsylvania, Philadelphia; and Catalan Institute for Research and Advanced Studies (ICREA) (J.D.), Barcelona, Spain. FAU - Artola, Montse AU - Artola M AD - From the Neuroimmunology and Multiple Sclerosis Unit (Y.B., D.E., S.L., R.R.G., M.A., S.A., J.M.C.-M., M.G., A.H., E.M.-H., M.S., T.A., J.D., A.S.), Hospital Clinic de Barcelona, and Universitat de Barcelona; Neurommunology Program, Fundacio de Recerca Clinic Barcelona-IDIBAPS (Y.B., S.L., R.R.G., M.A., E.A., M.A., E.C., J.M.C.-M., E.F., M.G., E.M.-H., G.O.-C., M.R., L.S., M.S., E.S., T.A., J.D., A.S.), Barcelona; Neuromuscular Diseases Unit, Neurology Department (C.L., L.M.-A., C.T.-I., N.V.-F., L.Q.), Hospital de Sant Pau, Barcelona; Centro para la Investigacion en Red en Enfermedades Raras (CIBERER) (C.L., M.G., C.T.-I., J.D., L.Q.), Madrid; Department of Immunology (N.E., R.R.G.), Hospital Clinic de Barcelona; Department of Preventive Medicine and Epidemiology (M.A., A.V.), Hospital Clinic de Barcelona, Spain; Department of Neurology (E.F.), School of Medicine, Pontificia Universidad Catolica de Chile, Santiago de Chile; Pediatric Neurology Unit (G.O.-C.), Hospital Parc Tauli de Sabadell, Barcelona; Infectious Diseases Unit, Department of Internal Medicine, (J.L.-C., A.R.) Hospital de Sant Pau, Universitat Autonoma de Barcelona, Barcelona; Immunology Department (L.M.-M.), Sant Pau, Institut de Recerca del Hospital de Sant Pau, Universitat Autonoma de Barcelona, Barcelona; Department of Pediatrics, and Infectious Diseases Department (C.F.), Institut de Recerca Pediatrica Hospital de Sant Joan de Deu, Esplugues de Llobregat, Barcelona; Pediatric Neuroimmunology Unit, Department of Neurology (S.J.D.), Sant Joan de Deu Children s Hospital (T.A), University of Barcelona, Spain; Department of Neurology, (J.D.) Perelman School of Medicine, University of Pennsylvania, Philadelphia; and Catalan Institute for Research and Advanced Studies (ICREA) (J.D.), Barcelona, Spain. FAU - Aldea Novo, Marta AU - Aldea Novo M AD - From the Neuroimmunology and Multiple Sclerosis Unit (Y.B., D.E., S.L., R.R.G., M.A., S.A., J.M.C.-M., M.G., A.H., E.M.-H., M.S., T.A., J.D., A.S.), Hospital Clinic de Barcelona, and Universitat de Barcelona; Neurommunology Program, Fundacio de Recerca Clinic Barcelona-IDIBAPS (Y.B., S.L., R.R.G., M.A., E.A., M.A., E.C., J.M.C.-M., E.F., M.G., E.M.-H., G.O.-C., M.R., L.S., M.S., E.S., T.A., J.D., A.S.), Barcelona; Neuromuscular Diseases Unit, Neurology Department (C.L., L.M.-A., C.T.-I., N.V.-F., L.Q.), Hospital de Sant Pau, Barcelona; Centro para la Investigacion en Red en Enfermedades Raras (CIBERER) (C.L., M.G., C.T.-I., J.D., L.Q.), Madrid; Department of Immunology (N.E., R.R.G.), Hospital Clinic de Barcelona; Department of Preventive Medicine and Epidemiology (M.A., A.V.), Hospital Clinic de Barcelona, Spain; Department of Neurology (E.F.), School of Medicine, Pontificia Universidad Catolica de Chile, Santiago de Chile; Pediatric Neurology Unit (G.O.-C.), Hospital Parc Tauli de Sabadell, Barcelona; Infectious Diseases Unit, Department of Internal Medicine, (J.L.-C., A.R.) Hospital de Sant Pau, Universitat Autonoma de Barcelona, Barcelona; Immunology Department (L.M.-M.), Sant Pau, Institut de Recerca del Hospital de Sant Pau, Universitat Autonoma de Barcelona, Barcelona; Department of Pediatrics, and Infectious Diseases Department (C.F.), Institut de Recerca Pediatrica Hospital de Sant Joan de Deu, Esplugues de Llobregat, Barcelona; Pediatric Neuroimmunology Unit, Department of Neurology (S.J.D.), Sant Joan de Deu Children s Hospital (T.A), University of Barcelona, Spain; Department of Neurology, (J.D.) Perelman School of Medicine, University of Pennsylvania, Philadelphia; and Catalan Institute for Research and Advanced Studies (ICREA) (J.D.), Barcelona, Spain. FAU - Alvarez, Silvia AU - Alvarez S AD - From the Neuroimmunology and Multiple Sclerosis Unit (Y.B., D.E., S.L., R.R.G., M.A., S.A., J.M.C.-M., M.G., A.H., E.M.-H., M.S., T.A., J.D., A.S.), Hospital Clinic de Barcelona, and Universitat de Barcelona; Neurommunology Program, Fundacio de Recerca Clinic Barcelona-IDIBAPS (Y.B., S.L., R.R.G., M.A., E.A., M.A., E.C., J.M.C.-M., E.F., M.G., E.M.-H., G.O.-C., M.R., L.S., M.S., E.S., T.A., J.D., A.S.), Barcelona; Neuromuscular Diseases Unit, Neurology Department (C.L., L.M.-A., C.T.-I., N.V.-F., L.Q.), Hospital de Sant Pau, Barcelona; Centro para la Investigacion en Red en Enfermedades Raras (CIBERER) (C.L., M.G., C.T.-I., J.D., L.Q.), Madrid; Department of Immunology (N.E., R.R.G.), Hospital Clinic de Barcelona; Department of Preventive Medicine and Epidemiology (M.A., A.V.), Hospital Clinic de Barcelona, Spain; Department of Neurology (E.F.), School of Medicine, Pontificia Universidad Catolica de Chile, Santiago de Chile; Pediatric Neurology Unit (G.O.-C.), Hospital Parc Tauli de Sabadell, Barcelona; Infectious Diseases Unit, Department of Internal Medicine, (J.L.-C., A.R.) Hospital de Sant Pau, Universitat Autonoma de Barcelona, Barcelona; Immunology Department (L.M.-M.), Sant Pau, Institut de Recerca del Hospital de Sant Pau, Universitat Autonoma de Barcelona, Barcelona; Department of Pediatrics, and Infectious Diseases Department (C.F.), Institut de Recerca Pediatrica Hospital de Sant Joan de Deu, Esplugues de Llobregat, Barcelona; Pediatric Neuroimmunology Unit, Department of Neurology (S.J.D.), Sant Joan de Deu Children s Hospital (T.A), University of Barcelona, Spain; Department of Neurology, (J.D.) Perelman School of Medicine, University of Pennsylvania, Philadelphia; and Catalan Institute for Research and Advanced Studies (ICREA) (J.D.), Barcelona, Spain. FAU - Caballero, Eva AU - Caballero E AD - From the Neuroimmunology and Multiple Sclerosis Unit (Y.B., D.E., S.L., R.R.G., M.A., S.A., J.M.C.-M., M.G., A.H., E.M.-H., M.S., T.A., J.D., A.S.), Hospital Clinic de Barcelona, and Universitat de Barcelona; Neurommunology Program, Fundacio de Recerca Clinic Barcelona-IDIBAPS (Y.B., S.L., R.R.G., M.A., E.A., M.A., E.C., J.M.C.-M., E.F., M.G., E.M.-H., G.O.-C., M.R., L.S., M.S., E.S., T.A., J.D., A.S.), Barcelona; Neuromuscular Diseases Unit, Neurology Department (C.L., L.M.-A., C.T.-I., N.V.-F., L.Q.), Hospital de Sant Pau, Barcelona; Centro para la Investigacion en Red en Enfermedades Raras (CIBERER) (C.L., M.G., C.T.-I., J.D., L.Q.), Madrid; Department of Immunology (N.E., R.R.G.), Hospital Clinic de Barcelona; Department of Preventive Medicine and Epidemiology (M.A., A.V.), Hospital Clinic de Barcelona, Spain; Department of Neurology (E.F.), School of Medicine, Pontificia Universidad Catolica de Chile, Santiago de Chile; Pediatric Neurology Unit (G.O.-C.), Hospital Parc Tauli de Sabadell, Barcelona; Infectious Diseases Unit, Department of Internal Medicine, (J.L.-C., A.R.) Hospital de Sant Pau, Universitat Autonoma de Barcelona, Barcelona; Immunology Department (L.M.-M.), Sant Pau, Institut de Recerca del Hospital de Sant Pau, Universitat Autonoma de Barcelona, Barcelona; Department of Pediatrics, and Infectious Diseases Department (C.F.), Institut de Recerca Pediatrica Hospital de Sant Joan de Deu, Esplugues de Llobregat, Barcelona; Pediatric Neuroimmunology Unit, Department of Neurology (S.J.D.), Sant Joan de Deu Children s Hospital (T.A), University of Barcelona, Spain; Department of Neurology, (J.D.) Perelman School of Medicine, University of Pennsylvania, Philadelphia; and Catalan Institute for Research and Advanced Studies (ICREA) (J.D.), Barcelona, Spain. FAU - Cabrera-Maqueda, Jose Maria AU - Cabrera-Maqueda JM AD - From the Neuroimmunology and Multiple Sclerosis Unit (Y.B., D.E., S.L., R.R.G., M.A., S.A., J.M.C.-M., M.G., A.H., E.M.-H., M.S., T.A., J.D., A.S.), Hospital Clinic de Barcelona, and Universitat de Barcelona; Neurommunology Program, Fundacio de Recerca Clinic Barcelona-IDIBAPS (Y.B., S.L., R.R.G., M.A., E.A., M.A., E.C., J.M.C.-M., E.F., M.G., E.M.-H., G.O.-C., M.R., L.S., M.S., E.S., T.A., J.D., A.S.), Barcelona; Neuromuscular Diseases Unit, Neurology Department (C.L., L.M.-A., C.T.-I., N.V.-F., L.Q.), Hospital de Sant Pau, Barcelona; Centro para la Investigacion en Red en Enfermedades Raras (CIBERER) (C.L., M.G., C.T.-I., J.D., L.Q.), Madrid; Department of Immunology (N.E., R.R.G.), Hospital Clinic de Barcelona; Department of Preventive Medicine and Epidemiology (M.A., A.V.), Hospital Clinic de Barcelona, Spain; Department of Neurology (E.F.), School of Medicine, Pontificia Universidad Catolica de Chile, Santiago de Chile; Pediatric Neurology Unit (G.O.-C.), Hospital Parc Tauli de Sabadell, Barcelona; Infectious Diseases Unit, Department of Internal Medicine, (J.L.-C., A.R.) Hospital de Sant Pau, Universitat Autonoma de Barcelona, Barcelona; Immunology Department (L.M.-M.), Sant Pau, Institut de Recerca del Hospital de Sant Pau, Universitat Autonoma de Barcelona, Barcelona; Department of Pediatrics, and Infectious Diseases Department (C.F.), Institut de Recerca Pediatrica Hospital de Sant Joan de Deu, Esplugues de Llobregat, Barcelona; Pediatric Neuroimmunology Unit, Department of Neurology (S.J.D.), Sant Joan de Deu Children s Hospital (T.A), University of Barcelona, Spain; Department of Neurology, (J.D.) Perelman School of Medicine, University of Pennsylvania, Philadelphia; and Catalan Institute for Research and Advanced Studies (ICREA) (J.D.), Barcelona, Spain. FAU - Fonseca, Elianet AU - Fonseca E AD - From the Neuroimmunology and Multiple Sclerosis Unit (Y.B., D.E., S.L., R.R.G., M.A., S.A., J.M.C.-M., M.G., A.H., E.M.-H., M.S., T.A., J.D., A.S.), Hospital Clinic de Barcelona, and Universitat de Barcelona; Neurommunology Program, Fundacio de Recerca Clinic Barcelona-IDIBAPS (Y.B., S.L., R.R.G., M.A., E.A., M.A., E.C., J.M.C.-M., E.F., M.G., E.M.-H., G.O.-C., M.R., L.S., M.S., E.S., T.A., J.D., A.S.), Barcelona; Neuromuscular Diseases Unit, Neurology Department (C.L., L.M.-A., C.T.-I., N.V.-F., L.Q.), Hospital de Sant Pau, Barcelona; Centro para la Investigacion en Red en Enfermedades Raras (CIBERER) (C.L., M.G., C.T.-I., J.D., L.Q.), Madrid; Department of Immunology (N.E., R.R.G.), Hospital Clinic de Barcelona; Department of Preventive Medicine and Epidemiology (M.A., A.V.), Hospital Clinic de Barcelona, Spain; Department of Neurology (E.F.), School of Medicine, Pontificia Universidad Catolica de Chile, Santiago de Chile; Pediatric Neurology Unit (G.O.-C.), Hospital Parc Tauli de Sabadell, Barcelona; Infectious Diseases Unit, Department of Internal Medicine, (J.L.-C., A.R.) Hospital de Sant Pau, Universitat Autonoma de Barcelona, Barcelona; Immunology Department (L.M.-M.), Sant Pau, Institut de Recerca del Hospital de Sant Pau, Universitat Autonoma de Barcelona, Barcelona; Department of Pediatrics, and Infectious Diseases Department (C.F.), Institut de Recerca Pediatrica Hospital de Sant Joan de Deu, Esplugues de Llobregat, Barcelona; Pediatric Neuroimmunology Unit, Department of Neurology (S.J.D.), Sant Joan de Deu Children s Hospital (T.A), University of Barcelona, Spain; Department of Neurology, (J.D.) Perelman School of Medicine, University of Pennsylvania, Philadelphia; and Catalan Institute for Research and Advanced Studies (ICREA) (J.D.), Barcelona, Spain. FAU - Guasp, Mar AU - Guasp M AUID- ORCID: 0000-0002-0110-5213 AD - From the Neuroimmunology and Multiple Sclerosis Unit (Y.B., D.E., S.L., R.R.G., M.A., S.A., J.M.C.-M., M.G., A.H., E.M.-H., M.S., T.A., J.D., A.S.), Hospital Clinic de Barcelona, and Universitat de Barcelona; Neurommunology Program, Fundacio de Recerca Clinic Barcelona-IDIBAPS (Y.B., S.L., R.R.G., M.A., E.A., M.A., E.C., J.M.C.-M., E.F., M.G., E.M.-H., G.O.-C., M.R., L.S., M.S., E.S., T.A., J.D., A.S.), Barcelona; Neuromuscular Diseases Unit, Neurology Department (C.L., L.M.-A., C.T.-I., N.V.-F., L.Q.), Hospital de Sant Pau, Barcelona; Centro para la Investigacion en Red en Enfermedades Raras (CIBERER) (C.L., M.G., C.T.-I., J.D., L.Q.), Madrid; Department of Immunology (N.E., R.R.G.), Hospital Clinic de Barcelona; Department of Preventive Medicine and Epidemiology (M.A., A.V.), Hospital Clinic de Barcelona, Spain; Department of Neurology (E.F.), School of Medicine, Pontificia Universidad Catolica de Chile, Santiago de Chile; Pediatric Neurology Unit (G.O.-C.), Hospital Parc Tauli de Sabadell, Barcelona; Infectious Diseases Unit, Department of Internal Medicine, (J.L.-C., A.R.) Hospital de Sant Pau, Universitat Autonoma de Barcelona, Barcelona; Immunology Department (L.M.-M.), Sant Pau, Institut de Recerca del Hospital de Sant Pau, Universitat Autonoma de Barcelona, Barcelona; Department of Pediatrics, and Infectious Diseases Department (C.F.), Institut de Recerca Pediatrica Hospital de Sant Joan de Deu, Esplugues de Llobregat, Barcelona; Pediatric Neuroimmunology Unit, Department of Neurology (S.J.D.), Sant Joan de Deu Children s Hospital (T.A), University of Barcelona, Spain; Department of Neurology, (J.D.) Perelman School of Medicine, University of Pennsylvania, Philadelphia; and Catalan Institute for Research and Advanced Studies (ICREA) (J.D.), Barcelona, Spain. FAU - Hernando, Ana AU - Hernando A AD - From the Neuroimmunology and Multiple Sclerosis Unit (Y.B., D.E., S.L., R.R.G., M.A., S.A., J.M.C.-M., M.G., A.H., E.M.-H., M.S., T.A., J.D., A.S.), Hospital Clinic de Barcelona, and Universitat de Barcelona; Neurommunology Program, Fundacio de Recerca Clinic Barcelona-IDIBAPS (Y.B., S.L., R.R.G., M.A., E.A., M.A., E.C., J.M.C.-M., E.F., M.G., E.M.-H., G.O.-C., M.R., L.S., M.S., E.S., T.A., J.D., A.S.), Barcelona; Neuromuscular Diseases Unit, Neurology Department (C.L., L.M.-A., C.T.-I., N.V.-F., L.Q.), Hospital de Sant Pau, Barcelona; Centro para la Investigacion en Red en Enfermedades Raras (CIBERER) (C.L., M.G., C.T.-I., J.D., L.Q.), Madrid; Department of Immunology (N.E., R.R.G.), Hospital Clinic de Barcelona; Department of Preventive Medicine and Epidemiology (M.A., A.V.), Hospital Clinic de Barcelona, Spain; Department of Neurology (E.F.), School of Medicine, Pontificia Universidad Catolica de Chile, Santiago de Chile; Pediatric Neurology Unit (G.O.-C.), Hospital Parc Tauli de Sabadell, Barcelona; Infectious Diseases Unit, Department of Internal Medicine, (J.L.-C., A.R.) Hospital de Sant Pau, Universitat Autonoma de Barcelona, Barcelona; Immunology Department (L.M.-M.), Sant Pau, Institut de Recerca del Hospital de Sant Pau, Universitat Autonoma de Barcelona, Barcelona; Department of Pediatrics, and Infectious Diseases Department (C.F.), Institut de Recerca Pediatrica Hospital de Sant Joan de Deu, Esplugues de Llobregat, Barcelona; Pediatric Neuroimmunology Unit, Department of Neurology (S.J.D.), Sant Joan de Deu Children s Hospital (T.A), University of Barcelona, Spain; Department of Neurology, (J.D.) Perelman School of Medicine, University of Pennsylvania, Philadelphia; and Catalan Institute for Research and Advanced Studies (ICREA) (J.D.), Barcelona, Spain. FAU - Martinez-Hernandez, Eugenia AU - Martinez-Hernandez E AD - From the Neuroimmunology and Multiple Sclerosis Unit (Y.B., D.E., S.L., R.R.G., M.A., S.A., J.M.C.-M., M.G., A.H., E.M.-H., M.S., T.A., J.D., A.S.), Hospital Clinic de Barcelona, and Universitat de Barcelona; Neurommunology Program, Fundacio de Recerca Clinic Barcelona-IDIBAPS (Y.B., S.L., R.R.G., M.A., E.A., M.A., E.C., J.M.C.-M., E.F., M.G., E.M.-H., G.O.-C., M.R., L.S., M.S., E.S., T.A., J.D., A.S.), Barcelona; Neuromuscular Diseases Unit, Neurology Department (C.L., L.M.-A., C.T.-I., N.V.-F., L.Q.), Hospital de Sant Pau, Barcelona; Centro para la Investigacion en Red en Enfermedades Raras (CIBERER) (C.L., M.G., C.T.-I., J.D., L.Q.), Madrid; Department of Immunology (N.E., R.R.G.), Hospital Clinic de Barcelona; Department of Preventive Medicine and Epidemiology (M.A., A.V.), Hospital Clinic de Barcelona, Spain; Department of Neurology (E.F.), School of Medicine, Pontificia Universidad Catolica de Chile, Santiago de Chile; Pediatric Neurology Unit (G.O.-C.), Hospital Parc Tauli de Sabadell, Barcelona; Infectious Diseases Unit, Department of Internal Medicine, (J.L.-C., A.R.) Hospital de Sant Pau, Universitat Autonoma de Barcelona, Barcelona; Immunology Department (L.M.-M.), Sant Pau, Institut de Recerca del Hospital de Sant Pau, Universitat Autonoma de Barcelona, Barcelona; Department of Pediatrics, and Infectious Diseases Department (C.F.), Institut de Recerca Pediatrica Hospital de Sant Joan de Deu, Esplugues de Llobregat, Barcelona; Pediatric Neuroimmunology Unit, Department of Neurology (S.J.D.), Sant Joan de Deu Children s Hospital (T.A), University of Barcelona, Spain; Department of Neurology, (J.D.) Perelman School of Medicine, University of Pennsylvania, Philadelphia; and Catalan Institute for Research and Advanced Studies (ICREA) (J.D.), Barcelona, Spain. FAU - Olive-Cirera, Gemma AU - Olive-Cirera G AD - From the Neuroimmunology and Multiple Sclerosis Unit (Y.B., D.E., S.L., R.R.G., M.A., S.A., J.M.C.-M., M.G., A.H., E.M.-H., M.S., T.A., J.D., A.S.), Hospital Clinic de Barcelona, and Universitat de Barcelona; Neurommunology Program, Fundacio de Recerca Clinic Barcelona-IDIBAPS (Y.B., S.L., R.R.G., M.A., E.A., M.A., E.C., J.M.C.-M., E.F., M.G., E.M.-H., G.O.-C., M.R., L.S., M.S., E.S., T.A., J.D., A.S.), Barcelona; Neuromuscular Diseases Unit, Neurology Department (C.L., L.M.-A., C.T.-I., N.V.-F., L.Q.), Hospital de Sant Pau, Barcelona; Centro para la Investigacion en Red en Enfermedades Raras (CIBERER) (C.L., M.G., C.T.-I., J.D., L.Q.), Madrid; Department of Immunology (N.E., R.R.G.), Hospital Clinic de Barcelona; Department of Preventive Medicine and Epidemiology (M.A., A.V.), Hospital Clinic de Barcelona, Spain; Department of Neurology (E.F.), School of Medicine, Pontificia Universidad Catolica de Chile, Santiago de Chile; Pediatric Neurology Unit (G.O.-C.), Hospital Parc Tauli de Sabadell, Barcelona; Infectious Diseases Unit, Department of Internal Medicine, (J.L.-C., A.R.) Hospital de Sant Pau, Universitat Autonoma de Barcelona, Barcelona; Immunology Department (L.M.-M.), Sant Pau, Institut de Recerca del Hospital de Sant Pau, Universitat Autonoma de Barcelona, Barcelona; Department of Pediatrics, and Infectious Diseases Department (C.F.), Institut de Recerca Pediatrica Hospital de Sant Joan de Deu, Esplugues de Llobregat, Barcelona; Pediatric Neuroimmunology Unit, Department of Neurology (S.J.D.), Sant Joan de Deu Children s Hospital (T.A), University of Barcelona, Spain; Department of Neurology, (J.D.) Perelman School of Medicine, University of Pennsylvania, Philadelphia; and Catalan Institute for Research and Advanced Studies (ICREA) (J.D.), Barcelona, Spain. FAU - Lopez-Contreras, Joaquin AU - Lopez-Contreras J AUID- ORCID: 0000-0002-3166-4016 AD - From the Neuroimmunology and Multiple Sclerosis Unit (Y.B., D.E., S.L., R.R.G., M.A., S.A., J.M.C.-M., M.G., A.H., E.M.-H., M.S., T.A., J.D., A.S.), Hospital Clinic de Barcelona, and Universitat de Barcelona; Neurommunology Program, Fundacio de Recerca Clinic Barcelona-IDIBAPS (Y.B., S.L., R.R.G., M.A., E.A., M.A., E.C., J.M.C.-M., E.F., M.G., E.M.-H., G.O.-C., M.R., L.S., M.S., E.S., T.A., J.D., A.S.), Barcelona; Neuromuscular Diseases Unit, Neurology Department (C.L., L.M.-A., C.T.-I., N.V.-F., L.Q.), Hospital de Sant Pau, Barcelona; Centro para la Investigacion en Red en Enfermedades Raras (CIBERER) (C.L., M.G., C.T.-I., J.D., L.Q.), Madrid; Department of Immunology (N.E., R.R.G.), Hospital Clinic de Barcelona; Department of Preventive Medicine and Epidemiology (M.A., A.V.), Hospital Clinic de Barcelona, Spain; Department of Neurology (E.F.), School of Medicine, Pontificia Universidad Catolica de Chile, Santiago de Chile; Pediatric Neurology Unit (G.O.-C.), Hospital Parc Tauli de Sabadell, Barcelona; Infectious Diseases Unit, Department of Internal Medicine, (J.L.-C., A.R.) Hospital de Sant Pau, Universitat Autonoma de Barcelona, Barcelona; Immunology Department (L.M.-M.), Sant Pau, Institut de Recerca del Hospital de Sant Pau, Universitat Autonoma de Barcelona, Barcelona; Department of Pediatrics, and Infectious Diseases Department (C.F.), Institut de Recerca Pediatrica Hospital de Sant Joan de Deu, Esplugues de Llobregat, Barcelona; Pediatric Neuroimmunology Unit, Department of Neurology (S.J.D.), Sant Joan de Deu Children s Hospital (T.A), University of Barcelona, Spain; Department of Neurology, (J.D.) Perelman School of Medicine, University of Pennsylvania, Philadelphia; and Catalan Institute for Research and Advanced Studies (ICREA) (J.D.), Barcelona, Spain. FAU - Martin-Aguilar, Lorena AU - Martin-Aguilar L AD - From the Neuroimmunology and Multiple Sclerosis Unit (Y.B., D.E., S.L., R.R.G., M.A., S.A., J.M.C.-M., M.G., A.H., E.M.-H., M.S., T.A., J.D., A.S.), Hospital Clinic de Barcelona, and Universitat de Barcelona; Neurommunology Program, Fundacio de Recerca Clinic Barcelona-IDIBAPS (Y.B., S.L., R.R.G., M.A., E.A., M.A., E.C., J.M.C.-M., E.F., M.G., E.M.-H., G.O.-C., M.R., L.S., M.S., E.S., T.A., J.D., A.S.), Barcelona; Neuromuscular Diseases Unit, Neurology Department (C.L., L.M.-A., C.T.-I., N.V.-F., L.Q.), Hospital de Sant Pau, Barcelona; Centro para la Investigacion en Red en Enfermedades Raras (CIBERER) (C.L., M.G., C.T.-I., J.D., L.Q.), Madrid; Department of Immunology (N.E., R.R.G.), Hospital Clinic de Barcelona; Department of Preventive Medicine and Epidemiology (M.A., A.V.), Hospital Clinic de Barcelona, Spain; Department of Neurology (E.F.), School of Medicine, Pontificia Universidad Catolica de Chile, Santiago de Chile; Pediatric Neurology Unit (G.O.-C.), Hospital Parc Tauli de Sabadell, Barcelona; Infectious Diseases Unit, Department of Internal Medicine, (J.L.-C., A.R.) Hospital de Sant Pau, Universitat Autonoma de Barcelona, Barcelona; Immunology Department (L.M.-M.), Sant Pau, Institut de Recerca del Hospital de Sant Pau, Universitat Autonoma de Barcelona, Barcelona; Department of Pediatrics, and Infectious Diseases Department (C.F.), Institut de Recerca Pediatrica Hospital de Sant Joan de Deu, Esplugues de Llobregat, Barcelona; Pediatric Neuroimmunology Unit, Department of Neurology (S.J.D.), Sant Joan de Deu Children s Hospital (T.A), University of Barcelona, Spain; Department of Neurology, (J.D.) Perelman School of Medicine, University of Pennsylvania, Philadelphia; and Catalan Institute for Research and Advanced Studies (ICREA) (J.D.), Barcelona, Spain. FAU - Martinez-Martinez, Laura AU - Martinez-Martinez L AD - From the Neuroimmunology and Multiple Sclerosis Unit (Y.B., D.E., S.L., R.R.G., M.A., S.A., J.M.C.-M., M.G., A.H., E.M.-H., M.S., T.A., J.D., A.S.), Hospital Clinic de Barcelona, and Universitat de Barcelona; Neurommunology Program, Fundacio de Recerca Clinic Barcelona-IDIBAPS (Y.B., S.L., R.R.G., M.A., E.A., M.A., E.C., J.M.C.-M., E.F., M.G., E.M.-H., G.O.-C., M.R., L.S., M.S., E.S., T.A., J.D., A.S.), Barcelona; Neuromuscular Diseases Unit, Neurology Department (C.L., L.M.-A., C.T.-I., N.V.-F., L.Q.), Hospital de Sant Pau, Barcelona; Centro para la Investigacion en Red en Enfermedades Raras (CIBERER) (C.L., M.G., C.T.-I., J.D., L.Q.), Madrid; Department of Immunology (N.E., R.R.G.), Hospital Clinic de Barcelona; Department of Preventive Medicine and Epidemiology (M.A., A.V.), Hospital Clinic de Barcelona, Spain; Department of Neurology (E.F.), School of Medicine, Pontificia Universidad Catolica de Chile, Santiago de Chile; Pediatric Neurology Unit (G.O.-C.), Hospital Parc Tauli de Sabadell, Barcelona; Infectious Diseases Unit, Department of Internal Medicine, (J.L.-C., A.R.) Hospital de Sant Pau, Universitat Autonoma de Barcelona, Barcelona; Immunology Department (L.M.-M.), Sant Pau, Institut de Recerca del Hospital de Sant Pau, Universitat Autonoma de Barcelona, Barcelona; Department of Pediatrics, and Infectious Diseases Department (C.F.), Institut de Recerca Pediatrica Hospital de Sant Joan de Deu, Esplugues de Llobregat, Barcelona; Pediatric Neuroimmunology Unit, Department of Neurology (S.J.D.), Sant Joan de Deu Children s Hospital (T.A), University of Barcelona, Spain; Department of Neurology, (J.D.) Perelman School of Medicine, University of Pennsylvania, Philadelphia; and Catalan Institute for Research and Advanced Studies (ICREA) (J.D.), Barcelona, Spain. FAU - Rombauts, Alexander AU - Rombauts A AD - From the Neuroimmunology and Multiple Sclerosis Unit (Y.B., D.E., S.L., R.R.G., M.A., S.A., J.M.C.-M., M.G., A.H., E.M.-H., M.S., T.A., J.D., A.S.), Hospital Clinic de Barcelona, and Universitat de Barcelona; Neurommunology Program, Fundacio de Recerca Clinic Barcelona-IDIBAPS (Y.B., S.L., R.R.G., M.A., E.A., M.A., E.C., J.M.C.-M., E.F., M.G., E.M.-H., G.O.-C., M.R., L.S., M.S., E.S., T.A., J.D., A.S.), Barcelona; Neuromuscular Diseases Unit, Neurology Department (C.L., L.M.-A., C.T.-I., N.V.-F., L.Q.), Hospital de Sant Pau, Barcelona; Centro para la Investigacion en Red en Enfermedades Raras (CIBERER) (C.L., M.G., C.T.-I., J.D., L.Q.), Madrid; Department of Immunology (N.E., R.R.G.), Hospital Clinic de Barcelona; Department of Preventive Medicine and Epidemiology (M.A., A.V.), Hospital Clinic de Barcelona, Spain; Department of Neurology (E.F.), School of Medicine, Pontificia Universidad Catolica de Chile, Santiago de Chile; Pediatric Neurology Unit (G.O.-C.), Hospital Parc Tauli de Sabadell, Barcelona; Infectious Diseases Unit, Department of Internal Medicine, (J.L.-C., A.R.) Hospital de Sant Pau, Universitat Autonoma de Barcelona, Barcelona; Immunology Department (L.M.-M.), Sant Pau, Institut de Recerca del Hospital de Sant Pau, Universitat Autonoma de Barcelona, Barcelona; Department of Pediatrics, and Infectious Diseases Department (C.F.), Institut de Recerca Pediatrica Hospital de Sant Joan de Deu, Esplugues de Llobregat, Barcelona; Pediatric Neuroimmunology Unit, Department of Neurology (S.J.D.), Sant Joan de Deu Children s Hospital (T.A), University of Barcelona, Spain; Department of Neurology, (J.D.) Perelman School of Medicine, University of Pennsylvania, Philadelphia; and Catalan Institute for Research and Advanced Studies (ICREA) (J.D.), Barcelona, Spain. FAU - Rodes, Maria AU - Rodes M AD - From the Neuroimmunology and Multiple Sclerosis Unit (Y.B., D.E., S.L., R.R.G., M.A., S.A., J.M.C.-M., M.G., A.H., E.M.-H., M.S., T.A., J.D., A.S.), Hospital Clinic de Barcelona, and Universitat de Barcelona; Neurommunology Program, Fundacio de Recerca Clinic Barcelona-IDIBAPS (Y.B., S.L., R.R.G., M.A., E.A., M.A., E.C., J.M.C.-M., E.F., M.G., E.M.-H., G.O.-C., M.R., L.S., M.S., E.S., T.A., J.D., A.S.), Barcelona; Neuromuscular Diseases Unit, Neurology Department (C.L., L.M.-A., C.T.-I., N.V.-F., L.Q.), Hospital de Sant Pau, Barcelona; Centro para la Investigacion en Red en Enfermedades Raras (CIBERER) (C.L., M.G., C.T.-I., J.D., L.Q.), Madrid; Department of Immunology (N.E., R.R.G.), Hospital Clinic de Barcelona; Department of Preventive Medicine and Epidemiology (M.A., A.V.), Hospital Clinic de Barcelona, Spain; Department of Neurology (E.F.), School of Medicine, Pontificia Universidad Catolica de Chile, Santiago de Chile; Pediatric Neurology Unit (G.O.-C.), Hospital Parc Tauli de Sabadell, Barcelona; Infectious Diseases Unit, Department of Internal Medicine, (J.L.-C., A.R.) Hospital de Sant Pau, Universitat Autonoma de Barcelona, Barcelona; Immunology Department (L.M.-M.), Sant Pau, Institut de Recerca del Hospital de Sant Pau, Universitat Autonoma de Barcelona, Barcelona; Department of Pediatrics, and Infectious Diseases Department (C.F.), Institut de Recerca Pediatrica Hospital de Sant Joan de Deu, Esplugues de Llobregat, Barcelona; Pediatric Neuroimmunology Unit, Department of Neurology (S.J.D.), Sant Joan de Deu Children s Hospital (T.A), University of Barcelona, Spain; Department of Neurology, (J.D.) Perelman School of Medicine, University of Pennsylvania, Philadelphia; and Catalan Institute for Research and Advanced Studies (ICREA) (J.D.), Barcelona, Spain. FAU - Sabater, Lidia AU - Sabater L AD - From the Neuroimmunology and Multiple Sclerosis Unit (Y.B., D.E., S.L., R.R.G., M.A., S.A., J.M.C.-M., M.G., A.H., E.M.-H., M.S., T.A., J.D., A.S.), Hospital Clinic de Barcelona, and Universitat de Barcelona; Neurommunology Program, Fundacio de Recerca Clinic Barcelona-IDIBAPS (Y.B., S.L., R.R.G., M.A., E.A., M.A., E.C., J.M.C.-M., E.F., M.G., E.M.-H., G.O.-C., M.R., L.S., M.S., E.S., T.A., J.D., A.S.), Barcelona; Neuromuscular Diseases Unit, Neurology Department (C.L., L.M.-A., C.T.-I., N.V.-F., L.Q.), Hospital de Sant Pau, Barcelona; Centro para la Investigacion en Red en Enfermedades Raras (CIBERER) (C.L., M.G., C.T.-I., J.D., L.Q.), Madrid; Department of Immunology (N.E., R.R.G.), Hospital Clinic de Barcelona; Department of Preventive Medicine and Epidemiology (M.A., A.V.), Hospital Clinic de Barcelona, Spain; Department of Neurology (E.F.), School of Medicine, Pontificia Universidad Catolica de Chile, Santiago de Chile; Pediatric Neurology Unit (G.O.-C.), Hospital Parc Tauli de Sabadell, Barcelona; Infectious Diseases Unit, Department of Internal Medicine, (J.L.-C., A.R.) Hospital de Sant Pau, Universitat Autonoma de Barcelona, Barcelona; Immunology Department (L.M.-M.), Sant Pau, Institut de Recerca del Hospital de Sant Pau, Universitat Autonoma de Barcelona, Barcelona; Department of Pediatrics, and Infectious Diseases Department (C.F.), Institut de Recerca Pediatrica Hospital de Sant Joan de Deu, Esplugues de Llobregat, Barcelona; Pediatric Neuroimmunology Unit, Department of Neurology (S.J.D.), Sant Joan de Deu Children s Hospital (T.A), University of Barcelona, Spain; Department of Neurology, (J.D.) Perelman School of Medicine, University of Pennsylvania, Philadelphia; and Catalan Institute for Research and Advanced Studies (ICREA) (J.D.), Barcelona, Spain. FAU - Sepulveda, Maria AU - Sepulveda M AUID- ORCID: 0000-0002-3078-645X AD - From the Neuroimmunology and Multiple Sclerosis Unit (Y.B., D.E., S.L., R.R.G., M.A., S.A., J.M.C.-M., M.G., A.H., E.M.-H., M.S., T.A., J.D., A.S.), Hospital Clinic de Barcelona, and Universitat de Barcelona; Neurommunology Program, Fundacio de Recerca Clinic Barcelona-IDIBAPS (Y.B., S.L., R.R.G., M.A., E.A., M.A., E.C., J.M.C.-M., E.F., M.G., E.M.-H., G.O.-C., M.R., L.S., M.S., E.S., T.A., J.D., A.S.), Barcelona; Neuromuscular Diseases Unit, Neurology Department (C.L., L.M.-A., C.T.-I., N.V.-F., L.Q.), Hospital de Sant Pau, Barcelona; Centro para la Investigacion en Red en Enfermedades Raras (CIBERER) (C.L., M.G., C.T.-I., J.D., L.Q.), Madrid; Department of Immunology (N.E., R.R.G.), Hospital Clinic de Barcelona; Department of Preventive Medicine and Epidemiology (M.A., A.V.), Hospital Clinic de Barcelona, Spain; Department of Neurology (E.F.), School of Medicine, Pontificia Universidad Catolica de Chile, Santiago de Chile; Pediatric Neurology Unit (G.O.-C.), Hospital Parc Tauli de Sabadell, Barcelona; Infectious Diseases Unit, Department of Internal Medicine, (J.L.-C., A.R.) Hospital de Sant Pau, Universitat Autonoma de Barcelona, Barcelona; Immunology Department (L.M.-M.), Sant Pau, Institut de Recerca del Hospital de Sant Pau, Universitat Autonoma de Barcelona, Barcelona; Department of Pediatrics, and Infectious Diseases Department (C.F.), Institut de Recerca Pediatrica Hospital de Sant Joan de Deu, Esplugues de Llobregat, Barcelona; Pediatric Neuroimmunology Unit, Department of Neurology (S.J.D.), Sant Joan de Deu Children s Hospital (T.A), University of Barcelona, Spain; Department of Neurology, (J.D.) Perelman School of Medicine, University of Pennsylvania, Philadelphia; and Catalan Institute for Research and Advanced Studies (ICREA) (J.D.), Barcelona, Spain. FAU - Solana, Elisabeth AU - Solana E AD - From the Neuroimmunology and Multiple Sclerosis Unit (Y.B., D.E., S.L., R.R.G., M.A., S.A., J.M.C.-M., M.G., A.H., E.M.-H., M.S., T.A., J.D., A.S.), Hospital Clinic de Barcelona, and Universitat de Barcelona; Neurommunology Program, Fundacio de Recerca Clinic Barcelona-IDIBAPS (Y.B., S.L., R.R.G., M.A., E.A., M.A., E.C., J.M.C.-M., E.F., M.G., E.M.-H., G.O.-C., M.R., L.S., M.S., E.S., T.A., J.D., A.S.), Barcelona; Neuromuscular Diseases Unit, Neurology Department (C.L., L.M.-A., C.T.-I., N.V.-F., L.Q.), Hospital de Sant Pau, Barcelona; Centro para la Investigacion en Red en Enfermedades Raras (CIBERER) (C.L., M.G., C.T.-I., J.D., L.Q.), Madrid; Department of Immunology (N.E., R.R.G.), Hospital Clinic de Barcelona; Department of Preventive Medicine and Epidemiology (M.A., A.V.), Hospital Clinic de Barcelona, Spain; Department of Neurology (E.F.), School of Medicine, Pontificia Universidad Catolica de Chile, Santiago de Chile; Pediatric Neurology Unit (G.O.-C.), Hospital Parc Tauli de Sabadell, Barcelona; Infectious Diseases Unit, Department of Internal Medicine, (J.L.-C., A.R.) Hospital de Sant Pau, Universitat Autonoma de Barcelona, Barcelona; Immunology Department (L.M.-M.), Sant Pau, Institut de Recerca del Hospital de Sant Pau, Universitat Autonoma de Barcelona, Barcelona; Department of Pediatrics, and Infectious Diseases Department (C.F.), Institut de Recerca Pediatrica Hospital de Sant Joan de Deu, Esplugues de Llobregat, Barcelona; Pediatric Neuroimmunology Unit, Department of Neurology (S.J.D.), Sant Joan de Deu Children s Hospital (T.A), University of Barcelona, Spain; Department of Neurology, (J.D.) Perelman School of Medicine, University of Pennsylvania, Philadelphia; and Catalan Institute for Research and Advanced Studies (ICREA) (J.D.), Barcelona, Spain. FAU - Tejada-Illa, Clara AU - Tejada-Illa C AD - From the Neuroimmunology and Multiple Sclerosis Unit (Y.B., D.E., S.L., R.R.G., M.A., S.A., J.M.C.-M., M.G., A.H., E.M.-H., M.S., T.A., J.D., A.S.), Hospital Clinic de Barcelona, and Universitat de Barcelona; Neurommunology Program, Fundacio de Recerca Clinic Barcelona-IDIBAPS (Y.B., S.L., R.R.G., M.A., E.A., M.A., E.C., J.M.C.-M., E.F., M.G., E.M.-H., G.O.-C., M.R., L.S., M.S., E.S., T.A., J.D., A.S.), Barcelona; Neuromuscular Diseases Unit, Neurology Department (C.L., L.M.-A., C.T.-I., N.V.-F., L.Q.), Hospital de Sant Pau, Barcelona; Centro para la Investigacion en Red en Enfermedades Raras (CIBERER) (C.L., M.G., C.T.-I., J.D., L.Q.), Madrid; Department of Immunology (N.E., R.R.G.), Hospital Clinic de Barcelona; Department of Preventive Medicine and Epidemiology (M.A., A.V.), Hospital Clinic de Barcelona, Spain; Department of Neurology (E.F.), School of Medicine, Pontificia Universidad Catolica de Chile, Santiago de Chile; Pediatric Neurology Unit (G.O.-C.), Hospital Parc Tauli de Sabadell, Barcelona; Infectious Diseases Unit, Department of Internal Medicine, (J.L.-C., A.R.) Hospital de Sant Pau, Universitat Autonoma de Barcelona, Barcelona; Immunology Department (L.M.-M.), Sant Pau, Institut de Recerca del Hospital de Sant Pau, Universitat Autonoma de Barcelona, Barcelona; Department of Pediatrics, and Infectious Diseases Department (C.F.), Institut de Recerca Pediatrica Hospital de Sant Joan de Deu, Esplugues de Llobregat, Barcelona; Pediatric Neuroimmunology Unit, Department of Neurology (S.J.D.), Sant Joan de Deu Children s Hospital (T.A), University of Barcelona, Spain; Department of Neurology, (J.D.) Perelman School of Medicine, University of Pennsylvania, Philadelphia; and Catalan Institute for Research and Advanced Studies (ICREA) (J.D.), Barcelona, Spain. FAU - Vidal-Fernandez, Nuria AU - Vidal-Fernandez N AD - From the Neuroimmunology and Multiple Sclerosis Unit (Y.B., D.E., S.L., R.R.G., M.A., S.A., J.M.C.-M., M.G., A.H., E.M.-H., M.S., T.A., J.D., A.S.), Hospital Clinic de Barcelona, and Universitat de Barcelona; Neurommunology Program, Fundacio de Recerca Clinic Barcelona-IDIBAPS (Y.B., S.L., R.R.G., M.A., E.A., M.A., E.C., J.M.C.-M., E.F., M.G., E.M.-H., G.O.-C., M.R., L.S., M.S., E.S., T.A., J.D., A.S.), Barcelona; Neuromuscular Diseases Unit, Neurology Department (C.L., L.M.-A., C.T.-I., N.V.-F., L.Q.), Hospital de Sant Pau, Barcelona; Centro para la Investigacion en Red en Enfermedades Raras (CIBERER) (C.L., M.G., C.T.-I., J.D., L.Q.), Madrid; Department of Immunology (N.E., R.R.G.), Hospital Clinic de Barcelona; Department of Preventive Medicine and Epidemiology (M.A., A.V.), Hospital Clinic de Barcelona, Spain; Department of Neurology (E.F.), School of Medicine, Pontificia Universidad Catolica de Chile, Santiago de Chile; Pediatric Neurology Unit (G.O.-C.), Hospital Parc Tauli de Sabadell, Barcelona; Infectious Diseases Unit, Department of Internal Medicine, (J.L.-C., A.R.) Hospital de Sant Pau, Universitat Autonoma de Barcelona, Barcelona; Immunology Department (L.M.-M.), Sant Pau, Institut de Recerca del Hospital de Sant Pau, Universitat Autonoma de Barcelona, Barcelona; Department of Pediatrics, and Infectious Diseases Department (C.F.), Institut de Recerca Pediatrica Hospital de Sant Joan de Deu, Esplugues de Llobregat, Barcelona; Pediatric Neuroimmunology Unit, Department of Neurology (S.J.D.), Sant Joan de Deu Children s Hospital (T.A), University of Barcelona, Spain; Department of Neurology, (J.D.) Perelman School of Medicine, University of Pennsylvania, Philadelphia; and Catalan Institute for Research and Advanced Studies (ICREA) (J.D.), Barcelona, Spain. FAU - Vilella, Anna AU - Vilella A AD - From the Neuroimmunology and Multiple Sclerosis Unit (Y.B., D.E., S.L., R.R.G., M.A., S.A., J.M.C.-M., M.G., A.H., E.M.-H., M.S., T.A., J.D., A.S.), Hospital Clinic de Barcelona, and Universitat de Barcelona; Neurommunology Program, Fundacio de Recerca Clinic Barcelona-IDIBAPS (Y.B., S.L., R.R.G., M.A., E.A., M.A., E.C., J.M.C.-M., E.F., M.G., E.M.-H., G.O.-C., M.R., L.S., M.S., E.S., T.A., J.D., A.S.), Barcelona; Neuromuscular Diseases Unit, Neurology Department (C.L., L.M.-A., C.T.-I., N.V.-F., L.Q.), Hospital de Sant Pau, Barcelona; Centro para la Investigacion en Red en Enfermedades Raras (CIBERER) (C.L., M.G., C.T.-I., J.D., L.Q.), Madrid; Department of Immunology (N.E., R.R.G.), Hospital Clinic de Barcelona; Department of Preventive Medicine and Epidemiology (M.A., A.V.), Hospital Clinic de Barcelona, Spain; Department of Neurology (E.F.), School of Medicine, Pontificia Universidad Catolica de Chile, Santiago de Chile; Pediatric Neurology Unit (G.O.-C.), Hospital Parc Tauli de Sabadell, Barcelona; Infectious Diseases Unit, Department of Internal Medicine, (J.L.-C., A.R.) Hospital de Sant Pau, Universitat Autonoma de Barcelona, Barcelona; Immunology Department (L.M.-M.), Sant Pau, Institut de Recerca del Hospital de Sant Pau, Universitat Autonoma de Barcelona, Barcelona; Department of Pediatrics, and Infectious Diseases Department (C.F.), Institut de Recerca Pediatrica Hospital de Sant Joan de Deu, Esplugues de Llobregat, Barcelona; Pediatric Neuroimmunology Unit, Department of Neurology (S.J.D.), Sant Joan de Deu Children s Hospital (T.A), University of Barcelona, Spain; Department of Neurology, (J.D.) Perelman School of Medicine, University of Pennsylvania, Philadelphia; and Catalan Institute for Research and Advanced Studies (ICREA) (J.D.), Barcelona, Spain. FAU - Fortuny, Claudia AU - Fortuny C AD - From the Neuroimmunology and Multiple Sclerosis Unit (Y.B., D.E., S.L., R.R.G., M.A., S.A., J.M.C.-M., M.G., A.H., E.M.-H., M.S., T.A., J.D., A.S.), Hospital Clinic de Barcelona, and Universitat de Barcelona; Neurommunology Program, Fundacio de Recerca Clinic Barcelona-IDIBAPS (Y.B., S.L., R.R.G., M.A., E.A., M.A., E.C., J.M.C.-M., E.F., M.G., E.M.-H., G.O.-C., M.R., L.S., M.S., E.S., T.A., J.D., A.S.), Barcelona; Neuromuscular Diseases Unit, Neurology Department (C.L., L.M.-A., C.T.-I., N.V.-F., L.Q.), Hospital de Sant Pau, Barcelona; Centro para la Investigacion en Red en Enfermedades Raras (CIBERER) (C.L., M.G., C.T.-I., J.D., L.Q.), Madrid; Department of Immunology (N.E., R.R.G.), Hospital Clinic de Barcelona; Department of Preventive Medicine and Epidemiology (M.A., A.V.), Hospital Clinic de Barcelona, Spain; Department of Neurology (E.F.), School of Medicine, Pontificia Universidad Catolica de Chile, Santiago de Chile; Pediatric Neurology Unit (G.O.-C.), Hospital Parc Tauli de Sabadell, Barcelona; Infectious Diseases Unit, Department of Internal Medicine, (J.L.-C., A.R.) Hospital de Sant Pau, Universitat Autonoma de Barcelona, Barcelona; Immunology Department (L.M.-M.), Sant Pau, Institut de Recerca del Hospital de Sant Pau, Universitat Autonoma de Barcelona, Barcelona; Department of Pediatrics, and Infectious Diseases Department (C.F.), Institut de Recerca Pediatrica Hospital de Sant Joan de Deu, Esplugues de Llobregat, Barcelona; Pediatric Neuroimmunology Unit, Department of Neurology (S.J.D.), Sant Joan de Deu Children s Hospital (T.A), University of Barcelona, Spain; Department of Neurology, (J.D.) Perelman School of Medicine, University of Pennsylvania, Philadelphia; and Catalan Institute for Research and Advanced Studies (ICREA) (J.D.), Barcelona, Spain. FAU - Armangue, Thais AU - Armangue T AUID- ORCID: 0000-0001-6192-6171 AD - From the Neuroimmunology and Multiple Sclerosis Unit (Y.B., D.E., S.L., R.R.G., M.A., S.A., J.M.C.-M., M.G., A.H., E.M.-H., M.S., T.A., J.D., A.S.), Hospital Clinic de Barcelona, and Universitat de Barcelona; Neurommunology Program, Fundacio de Recerca Clinic Barcelona-IDIBAPS (Y.B., S.L., R.R.G., M.A., E.A., M.A., E.C., J.M.C.-M., E.F., M.G., E.M.-H., G.O.-C., M.R., L.S., M.S., E.S., T.A., J.D., A.S.), Barcelona; Neuromuscular Diseases Unit, Neurology Department (C.L., L.M.-A., C.T.-I., N.V.-F., L.Q.), Hospital de Sant Pau, Barcelona; Centro para la Investigacion en Red en Enfermedades Raras (CIBERER) (C.L., M.G., C.T.-I., J.D., L.Q.), Madrid; Department of Immunology (N.E., R.R.G.), Hospital Clinic de Barcelona; Department of Preventive Medicine and Epidemiology (M.A., A.V.), Hospital Clinic de Barcelona, Spain; Department of Neurology (E.F.), School of Medicine, Pontificia Universidad Catolica de Chile, Santiago de Chile; Pediatric Neurology Unit (G.O.-C.), Hospital Parc Tauli de Sabadell, Barcelona; Infectious Diseases Unit, Department of Internal Medicine, (J.L.-C., A.R.) Hospital de Sant Pau, Universitat Autonoma de Barcelona, Barcelona; Immunology Department (L.M.-M.), Sant Pau, Institut de Recerca del Hospital de Sant Pau, Universitat Autonoma de Barcelona, Barcelona; Department of Pediatrics, and Infectious Diseases Department (C.F.), Institut de Recerca Pediatrica Hospital de Sant Joan de Deu, Esplugues de Llobregat, Barcelona; Pediatric Neuroimmunology Unit, Department of Neurology (S.J.D.), Sant Joan de Deu Children s Hospital (T.A), University of Barcelona, Spain; Department of Neurology, (J.D.) Perelman School of Medicine, University of Pennsylvania, Philadelphia; and Catalan Institute for Research and Advanced Studies (ICREA) (J.D.), Barcelona, Spain. FAU - Dalmau, Josep O AU - Dalmau JO AD - From the Neuroimmunology and Multiple Sclerosis Unit (Y.B., D.E., S.L., R.R.G., M.A., S.A., J.M.C.-M., M.G., A.H., E.M.-H., M.S., T.A., J.D., A.S.), Hospital Clinic de Barcelona, and Universitat de Barcelona; Neurommunology Program, Fundacio de Recerca Clinic Barcelona-IDIBAPS (Y.B., S.L., R.R.G., M.A., E.A., M.A., E.C., J.M.C.-M., E.F., M.G., E.M.-H., G.O.-C., M.R., L.S., M.S., E.S., T.A., J.D., A.S.), Barcelona; Neuromuscular Diseases Unit, Neurology Department (C.L., L.M.-A., C.T.-I., N.V.-F., L.Q.), Hospital de Sant Pau, Barcelona; Centro para la Investigacion en Red en Enfermedades Raras (CIBERER) (C.L., M.G., C.T.-I., J.D., L.Q.), Madrid; Department of Immunology (N.E., R.R.G.), Hospital Clinic de Barcelona; Department of Preventive Medicine and Epidemiology (M.A., A.V.), Hospital Clinic de Barcelona, Spain; Department of Neurology (E.F.), School of Medicine, Pontificia Universidad Catolica de Chile, Santiago de Chile; Pediatric Neurology Unit (G.O.-C.), Hospital Parc Tauli de Sabadell, Barcelona; Infectious Diseases Unit, Department of Internal Medicine, (J.L.-C., A.R.) Hospital de Sant Pau, Universitat Autonoma de Barcelona, Barcelona; Immunology Department (L.M.-M.), Sant Pau, Institut de Recerca del Hospital de Sant Pau, Universitat Autonoma de Barcelona, Barcelona; Department of Pediatrics, and Infectious Diseases Department (C.F.), Institut de Recerca Pediatrica Hospital de Sant Joan de Deu, Esplugues de Llobregat, Barcelona; Pediatric Neuroimmunology Unit, Department of Neurology (S.J.D.), Sant Joan de Deu Children s Hospital (T.A), University of Barcelona, Spain; Department of Neurology, (J.D.) Perelman School of Medicine, University of Pennsylvania, Philadelphia; and Catalan Institute for Research and Advanced Studies (ICREA) (J.D.), Barcelona, Spain. FAU - Querol, Luis AU - Querol L AUID- ORCID: 0000-0002-4289-8264 AD - From the Neuroimmunology and Multiple Sclerosis Unit (Y.B., D.E., S.L., R.R.G., M.A., S.A., J.M.C.-M., M.G., A.H., E.M.-H., M.S., T.A., J.D., A.S.), Hospital Clinic de Barcelona, and Universitat de Barcelona; Neurommunology Program, Fundacio de Recerca Clinic Barcelona-IDIBAPS (Y.B., S.L., R.R.G., M.A., E.A., M.A., E.C., J.M.C.-M., E.F., M.G., E.M.-H., G.O.-C., M.R., L.S., M.S., E.S., T.A., J.D., A.S.), Barcelona; Neuromuscular Diseases Unit, Neurology Department (C.L., L.M.-A., C.T.-I., N.V.-F., L.Q.), Hospital de Sant Pau, Barcelona; Centro para la Investigacion en Red en Enfermedades Raras (CIBERER) (C.L., M.G., C.T.-I., J.D., L.Q.), Madrid; Department of Immunology (N.E., R.R.G.), Hospital Clinic de Barcelona; Department of Preventive Medicine and Epidemiology (M.A., A.V.), Hospital Clinic de Barcelona, Spain; Department of Neurology (E.F.), School of Medicine, Pontificia Universidad Catolica de Chile, Santiago de Chile; Pediatric Neurology Unit (G.O.-C.), Hospital Parc Tauli de Sabadell, Barcelona; Infectious Diseases Unit, Department of Internal Medicine, (J.L.-C., A.R.) Hospital de Sant Pau, Universitat Autonoma de Barcelona, Barcelona; Immunology Department (L.M.-M.), Sant Pau, Institut de Recerca del Hospital de Sant Pau, Universitat Autonoma de Barcelona, Barcelona; Department of Pediatrics, and Infectious Diseases Department (C.F.), Institut de Recerca Pediatrica Hospital de Sant Joan de Deu, Esplugues de Llobregat, Barcelona; Pediatric Neuroimmunology Unit, Department of Neurology (S.J.D.), Sant Joan de Deu Children s Hospital (T.A), University of Barcelona, Spain; Department of Neurology, (J.D.) Perelman School of Medicine, University of Pennsylvania, Philadelphia; and Catalan Institute for Research and Advanced Studies (ICREA) (J.D.), Barcelona, Spain. FAU - Saiz, Albert AU - Saiz A AD - From the Neuroimmunology and Multiple Sclerosis Unit (Y.B., D.E., S.L., R.R.G., M.A., S.A., J.M.C.-M., M.G., A.H., E.M.-H., M.S., T.A., J.D., A.S.), Hospital Clinic de Barcelona, and Universitat de Barcelona; Neurommunology Program, Fundacio de Recerca Clinic Barcelona-IDIBAPS (Y.B., S.L., R.R.G., M.A., E.A., M.A., E.C., J.M.C.-M., E.F., M.G., E.M.-H., G.O.-C., M.R., L.S., M.S., E.S., T.A., J.D., A.S.), Barcelona; Neuromuscular Diseases Unit, Neurology Department (C.L., L.M.-A., C.T.-I., N.V.-F., L.Q.), Hospital de Sant Pau, Barcelona; Centro para la Investigacion en Red en Enfermedades Raras (CIBERER) (C.L., M.G., C.T.-I., J.D., L.Q.), Madrid; Department of Immunology (N.E., R.R.G.), Hospital Clinic de Barcelona; Department of Preventive Medicine and Epidemiology (M.A., A.V.), Hospital Clinic de Barcelona, Spain; Department of Neurology (E.F.), School of Medicine, Pontificia Universidad Catolica de Chile, Santiago de Chile; Pediatric Neurology Unit (G.O.-C.), Hospital Parc Tauli de Sabadell, Barcelona; Infectious Diseases Unit, Department of Internal Medicine, (J.L.-C., A.R.) Hospital de Sant Pau, Universitat Autonoma de Barcelona, Barcelona; Immunology Department (L.M.-M.), Sant Pau, Institut de Recerca del Hospital de Sant Pau, Universitat Autonoma de Barcelona, Barcelona; Department of Pediatrics, and Infectious Diseases Department (C.F.), Institut de Recerca Pediatrica Hospital de Sant Joan de Deu, Esplugues de Llobregat, Barcelona; Pediatric Neuroimmunology Unit, Department of Neurology (S.J.D.), Sant Joan de Deu Children s Hospital (T.A), University of Barcelona, Spain; Department of Neurology, (J.D.) Perelman School of Medicine, University of Pennsylvania, Philadelphia; and Catalan Institute for Research and Advanced Studies (ICREA) (J.D.), Barcelona, Spain. LA - eng PT - Journal Article PT - Observational Study PT - Research Support, Non-U.S. Gov't DEP - 20230907 PL - United States TA - Neurol Neuroimmunol Neuroinflamm JT - Neurology(R) neuroimmunology & neuroinflammation JID - 101636388 RN - 0 (COVID-19 Vaccines) RN - 0 (Autoantibodies) SB - IM MH - Adolescent MH - Adult MH - Humans MH - Female MH - Male MH - *Multiple Sclerosis MH - COVID-19 Vaccines/adverse effects MH - Antibody Formation MH - Prospective Studies MH - *COVID-19/prevention & control MH - SARS-CoV-2 MH - Vaccination MH - *Autoimmune Diseases MH - Autoantibodies PMC - PMC10484689 COIS- Y. Blanco received speaker honoraria from Novartis, Roche, Sanofi, Merck, and Biogen; S. Llufriu received compensation for consulting services and speaker honoraria from Biogen Idec, Novartis, TEVA, Genzyme, Sanofi, Merck, and Bristol-Myers Squibb and holds grants from the Instituto de Salud Carlos III; M. Artola received financial honoraria for presentations and attendance at conferences by Almirall, Biogen idec, Sanofi, Novartis, and Merck; J.M. Cabrera-Maqueda received speaking honoraria and travel expenses for participation in scientific meetings from Sanofi. A. Hernando received financial speaker honoraria from Merck and attendance at conferences by Almirall, Bayer, Biogen, Novartis, Roche, Sanofi, and Teva. J. Lopez-Contreras has received grants from Instituto de Salud Carlos III - Ministry of Economy and Innovation (Spain)and Fundacio La Marato, speaking honoraria from Pfizer, MSD, Astra-Zeneca, Guerbet, and Hartmann, funding for clinical trials from Pfizer, Shionogi, MSD, Arsanis, Summit, GSK, Actelion, and Angelini, and for educational activities from MSD, Pfizer, Angelini, Gilead, and Guerbet; L. Martin-Aguilar received speaking honoraria from Roche; E. Martinez-Hernandez received speaking compensation from Biogen; M. Sepulveda received speaking honoraria from Roche, Biogen, and UCB Pharma and travel reimbursement from Biogen, Sanofi, Merck, and Roche for national and international meetings. E. Solana received travel reimbursement and congress assistance from Sanofi and Merck and reports personal fees from Roche Spain; T. Armangue received personal compensation for speaking fees from Sanofi and Roche. J.O. Dalmau holds patents for the use of NMDAR, GABAaR, GABAbR, DPPX, and IgLON5 as autoantibody tests and receives royalties related to autoantibody tests from Athena Diagnostics and Euroimmun Inc. L. Querol received research grants from Instituto de Salud Carlos III - Ministry of Economy and Innovation (Spain), CIBERER, Fundacio La Marato, GBS-CIDP Foundation International, UCB, and Grifols, received speaker or expert testimony honoraria from CSL Behring, Novartis, Sanofi-Genzyme, Merck, Annexon, Alnylam, Biogen, Janssen, Lundbeck, ArgenX, UCB, LFB, Octapharma, and Roche, serves at Clinical Trial Steering Committee for Sanofi Genzyme and Roche, and is Principal Investigator for UCB's CIDP01 trial. A. Saiz received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Merck, Sanofi, Biogen, Roche, Novartis, Janssen, and Horizon Therapeutics. The other authors report no disclosures. Go to Neurology.org/NN for full disclosures. EDAT- 2023/09/08 00:42 MHDA- 2023/09/11 06:43 PMCR- 2023/09/07 CRDT- 2023/09/07 21:22 PHST- 2023/05/01 00:00 [received] PHST- 2023/07/17 00:00 [accepted] PHST- 2023/09/11 06:43 [medline] PHST- 2023/09/08 00:42 [pubmed] PHST- 2023/09/07 21:22 [entrez] PHST- 2023/09/07 00:00 [pmc-release] AID - 10/6/e200163 [pii] AID - NXI-2023-000273 [pii] AID - 10.1212/NXI.0000000000200163 [doi] PST - epublish SO - Neurol Neuroimmunol Neuroinflamm. 2023 Sep 7;10(6):e200163. doi: 10.1212/NXI.0000000000200163. Print 2023 Nov. PMID- 37672867 OWN - NLM STAT- MEDLINE DCOM- 20260311 LR - 20260311 IS - 2352-3964 (Electronic) IS - 2352-3964 (Linking) VI - 96 DP - 2023 Oct TI - Lower magnitude and faster waning of antibody responses to SARS-CoV-2 vaccination in anti-TNF-alpha-treated IBD patients are linked to lack of activation and expansion of cTfh1 cells and impaired B memory cell formation. PG - 104788 LID - S2352-3964(23)00354-7 [pii] LID - 10.1016/j.ebiom.2023.104788 [doi] LID - 104788 AB - BACKGROUND: Patients with inflammatory bowel disease (IBD) and healthy controls received primary SARS-CoV-2-mRNA vaccination and a booster after six months. Anti-TNF-alpha-treated patients showed significantly lower antibody (Ab) levels and faster waning than alpha4beta7-integrin-antagonist recipients and controls. This prospective cohort study aimed to elucidate the underlying mechanisms on the basis of circulating T-follicular helper cells (cTfh) and B memory cells. METHODS: We measured SARS-CoV-2- Wuhan and Omicron specific Abs, B- and T-cell subsets at baseline and kinetics of Spike (S)-specific B memory cells along with distributions of activated cTfh subsets before and after primary and booster vaccination. FINDINGS: Lower and faster waning of Ab levels in anti-TNF-alpha treated IBD patients was associated with low numbers of total and naive B cells vs. expanded plasmablasts prior to vaccination. Along with their low Ab levels against Wuhan and Omicron VOCs, reduced S-specific B memory cells were identified after the 2nd dose which declined to non-detectable after 6 months. In contrast, IBD patients with alpha4beta7-integrin-antagonists and controls mounted and retained high Ab levels after the 2nd dose, which was associated with a pronounced increase in S-specific B memory cells that were maintained or expanded up to 6 months. Booster vaccination led to a strong increase of Abs with neutralizing capacity and S-specific B memory cells in these groups, which was not the case in anti-TNF-alpha treated IBD patients. Of note, Ab levels and S-specific B memory cells in particular post-booster correlated with the activation of cTfh1 cells after primary vaccination. INTERPRETATIONS: The reduced magnitude, persistence and neutralization capacity of SARS-CoV-2 specific Abs after vaccination in anti-TNF-alpha-treated IBD patients were associated with impaired formation and maintenance of S-specific B memory cells, likely due to absent cTfh1 activation leading to extra-follicular immune responses and diminished B memory cell diversification. These observations have implications for patient-tailored vaccination schedules/vaccines in anti-TNF-alpha-treated patients, irrespective of their underlying disease. FUNDING: The study was funded by third party funding of the Institute of Specific Prophylaxis and Tropical Medicine at the Medical University Vienna. The funders had no role in study design, data collection, data analyses, interpretation, or writing of report. CI - Copyright (c) 2023. Published by Elsevier B.V. FAU - Garner-Spitzer, Erika AU - Garner-Spitzer E AD - Medical University of Vienna, Center of Pathophysiology, Infectiology and Immunology, Institute of Specific Prophylaxis and Tropical Medicine, Vienna, Austria. Electronic address: erika.garner-spitzer@meduniwien.ac.at. FAU - Wagner, Angelika AU - Wagner A AD - Medical University of Vienna, Center of Pathophysiology, Infectiology and Immunology, Institute of Specific Prophylaxis and Tropical Medicine, Vienna, Austria. FAU - Gudipati, Venugopal AU - Gudipati V AD - Medical University of Vienna, Center of Pathophysiology, Infectiology and Immunology, Institute for Hygiene and Applied Immunology, Vienna, Austria. FAU - Schoetta, Anna-Margarita AU - Schoetta AM AD - Medical University of Vienna, Center of Pathophysiology, Infectiology and Immunology, Institute for Hygiene and Applied Immunology, Vienna, Austria. FAU - Orola-Taus, Maria AU - Orola-Taus M AD - Medical University of Vienna, Center of Pathophysiology, Infectiology and Immunology, Institute of Specific Prophylaxis and Tropical Medicine, Vienna, Austria. FAU - Kundi, Michael AU - Kundi M AD - Medical University of Vienna, Center for Public Health, Vienna, Austria. FAU - Kunert, Renate AU - Kunert R AD - Department of Biotechnology, University of Natural Resources and Life Sciences Vienna, Vienna, Austria. FAU - Mayrhofer, Patrick AU - Mayrhofer P AD - Department of Biotechnology, University of Natural Resources and Life Sciences Vienna, Vienna, Austria. FAU - Huppa, Johannes B AU - Huppa JB AD - Medical University of Vienna, Center of Pathophysiology, Infectiology and Immunology, Institute for Hygiene and Applied Immunology, Vienna, Austria. FAU - Stockinger, Hannes AU - Stockinger H AD - Medical University of Vienna, Center of Pathophysiology, Infectiology and Immunology, Institute for Hygiene and Applied Immunology, Vienna, Austria. FAU - Carsetti, Rita AU - Carsetti R AD - B Cell Research Unit, Immunology Research Area, Bambino Gesu Children's Hospital, IRCCS; Rome, Italy. FAU - Gattinger, Pia AU - Gattinger P AD - Medical University of Vienna, Center for Pathophysiology, Infectiology and Immunology, Department of Pathophysiology and Allergy Research, Division of Immunopathology, Vienna, Austria. FAU - Valenta, Rudolf AU - Valenta R AD - Medical University of Vienna, Center for Pathophysiology, Infectiology and Immunology, Department of Pathophysiology and Allergy Research, Division of Immunopathology, Vienna, Austria; Karl Landsteiner University of Health Sciences, Krems, Austria. FAU - Kratzer, Bernhard AU - Kratzer B AD - Medical University of Vienna, Center for Pathophysiology, Infectiology and Immunology, Institute of Immunology, Vienna, Austria. FAU - Sehgal, Al Nasar Ahmed AU - Sehgal ANA AD - Medical University of Vienna, Center for Pathophysiology, Infectiology and Immunology, Institute of Immunology, Vienna, Austria. FAU - Pickl, Winfried F AU - Pickl WF AD - Karl Landsteiner University of Health Sciences, Krems, Austria; Medical University of Vienna, Center for Pathophysiology, Infectiology and Immunology, Institute of Immunology, Vienna, Austria. FAU - Reinisch, Walter AU - Reinisch W AD - Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria. FAU - Novacek, Gottfried AU - Novacek G AD - Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria. FAU - Wiedermann, Ursula AU - Wiedermann U AD - Medical University of Vienna, Center of Pathophysiology, Infectiology and Immunology, Institute of Specific Prophylaxis and Tropical Medicine, Vienna, Austria. Electronic address: ursula.wiedermann@meduniwien.ac.at. LA - eng PT - Journal Article DEP - 20230904 PL - Netherlands TA - EBioMedicine JT - EBioMedicine JID - 101647039 RN - 0 (COVID-19 Vaccines) RN - 0 (Antibodies, Viral) RN - 0 (Tumor Necrosis Factor-alpha) RN - 0 (Spike Glycoprotein, Coronavirus) SB - IM MH - Humans MH - *Inflammatory Bowel Diseases/immunology/drug therapy MH - *SARS-CoV-2/immunology MH - Female MH - Male MH - Adult MH - *Memory B Cells/immunology MH - *COVID-19/prevention & control/immunology MH - Middle Aged MH - *COVID-19 Vaccines/immunology/administration & dosage MH - *Antibodies, Viral/immunology/blood MH - *Antibody Formation/immunology MH - *Tumor Necrosis Factor-alpha/antagonists & inhibitors MH - *T-Lymphocytes, Helper-Inducer/immunology MH - Vaccination MH - Immunologic Memory MH - Prospective Studies MH - Spike Glycoprotein, Coronavirus/immunology PMC - PMC10485594 OTO - NOTNLM OT - B memory cells OT - Immune response OT - Immunosuppression OT - Inflammatory bowel disease OT - SARS-CoV-2 vaccination OT - T follicular helper cells COIS- Declaration of interests EGS: none; AW: received fees from AbbVie and Astra Zeneca; VG: none; AS: none; MOT: none; MK: received an investigator initiated research contract from Pfizer outside the present work; RK: none; PM: none; JBH: Boehringer Ingelheim; HS: none; GN has received fees from AbbVie, MSD, Takeda, Janssen, Sandoz, Pfizer, Astro Pharma, Falk Pharma, Ferring Galapagos, Bristol-Myers Squibb, and Vifor; PG: none; RV: has received research grants from Worg Pharmaceuticals, Hangzhou, China, HVD Biotech, Vienna, Austria and Viravaxx, Vienna, Austria. He serves as consultant for Viravaxx and Worg; BK: none; ANAS: none; WFP: has received fees from Novartis, Astra Zeneca, Medical Dialogue, BMS; WR has served as speaker for AbbVie, Celltrion, Falk Pharma GmbH, Ferring, Janssen, Galapagos Medice, MSD, Roche, Pfizer, Pharmacosmos, Shire, Takeda, Therakos, as consultant for AbbVie, Amgen, AOP Orphan, Arena Pharmaceuticals, Astellas, Astra Zeneca, Bioclinica, Boehringer Ingelheim, Bristol Myers Squibb, Calyx, Celgene, Celltrion, Eli Lilly, Falk Pharma GmbH, Ferring, Galapagos, Gatehouse Bio Inc., Genentech, Gilead, Grunenthal, ICON, Index Pharma, Inova, Janssen, Landos Biopharma, Medahead, MedImmune, Microbiotica, Mitsubishi Tanabe Pharma Corporation, MSD, Novartis, OMass, Otsuka, Parexel, Periconsulting, Pharmacosmos, Pfizer, Protagonist, Provention, Quell Therapeutics, Sandoz, Seres Therapeutics, Setpointmedical, Sigmoid, Sublimity, Takeda, Teva Pharma, Therakos, Theravance, Zealand, as advisory board member for AbbVie, Amgen, Astra Zeneca, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Celltrion, Galapagos, Janssen, Mitsubishi Tanabe Pharma Corporation, MSD, Pharmacosmos, Pfizer, Sandoz, Takeda, and has received research funding from AbbVie, Janssen, MSD, Sandoz, Sanofi, Takeda; RC: none; UW is PI of clinical studies sponsored by GSK, Novartis and Pfizer. No conflict of interest regarding the presented clinical study. EDAT- 2023/09/07 00:41 MHDA- 2026/03/11 13:20 PMCR- 2023/09/04 CRDT- 2023/09/06 18:08 PHST- 2022/12/02 00:00 [received] PHST- 2023/08/08 00:00 [revised] PHST- 2023/08/22 00:00 [accepted] PHST- 2026/03/11 13:20 [medline] PHST- 2023/09/07 00:41 [pubmed] PHST- 2023/09/06 18:08 [entrez] PHST- 2023/09/04 00:00 [pmc-release] AID - S2352-3964(23)00354-7 [pii] AID - 104788 [pii] AID - 10.1016/j.ebiom.2023.104788 [doi] PST - ppublish SO - EBioMedicine. 2023 Oct;96:104788. doi: 10.1016/j.ebiom.2023.104788. Epub 2023 Sep 4. PMID- 37629320 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230828 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 12 IP - 16 DP - 2023 Aug 14 TI - Efficacy of Non-Enhanced Brain Computed Tomography in Patients Presenting to the Emergency Department with Headache after COVID-19 Vaccination. LID - 10.3390/jcm12165279 [doi] LID - 5279 AB - Headaches are a common side effect of vaccination against the severe acute respiratory syndrome, coronavirus 2; however, it is usually not necessary to seek emergency medical attention or undergo brain imaging such as non-enhanced brain computed tomography (CT) for routine evaluation of vaccine-related headaches. This study aimed to demonstrate that brain CT is of no clinical benefit to patients presenting to the emergency department (ED) with post-coronavirus disease 2019 (COVID-19) vaccination headaches. This retrospective, single-center observational study used electronic medical record (EMR) data of patients who received the COVID-19 vaccination during the first year of the vaccination program. In total, 914 patients were analyzed, of whom 435 underwent CT (CT group, n = 435; no CT group, n = 475). More female patients visited the ED, and there was no significant sex difference between the CT and no-CT groups. The type of vaccine affected the clinical decision to perform brain CT, but the number of doses did not. The CT rate was relatively high for patients who had received the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) and Johnson and Johnson Janssen (Jansen) vaccines (p = 0.004). Focal neurological deficits were present in all cases of abnormalities on non-enhanced brain CT in patients complaining of headaches. Two out of the 435 patients had abnormal brain CT findings (glioblastoma and Rathke's pouch cyst) at 35 and 32 days after vaccination, respectively. Non-enhanced brain CT should be performed cautiously in patients visiting the ED for post-vaccination headaches only. FAU - Lee, Yongtack AU - Lee Y AD - Department of Emergency Medicine, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam 13496, Republic of Korea. FAU - Kim, Kyuseok AU - Kim K AUID- ORCID: 0000-0002-7991-9428 AD - Department of Emergency Medicine, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam 13496, Republic of Korea. FAU - Paek, So-Hyun AU - Paek SH AD - Department of Emergency Medicine, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam 13496, Republic of Korea. FAU - Chang, Hyunglan AU - Chang H AUID- ORCID: 0000-0003-4829-8902 AD - Department of Emergency Medicine, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam 13496, Republic of Korea. LA - eng PT - Journal Article DEP - 20230814 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC10455817 OTO - NOTNLM OT - COVID-19 OT - COVID-19 vaccination OT - brain CT OT - headache OT - vaccination side effect COIS- The authors declare no conflict of interest. EDAT- 2023/08/26 10:46 MHDA- 2023/08/26 10:47 PMCR- 2023/08/14 CRDT- 2023/08/26 01:18 PHST- 2023/07/11 00:00 [received] PHST- 2023/07/30 00:00 [revised] PHST- 2023/08/10 00:00 [accepted] PHST- 2023/08/26 10:47 [medline] PHST- 2023/08/26 10:46 [pubmed] PHST- 2023/08/26 01:18 [entrez] PHST- 2023/08/14 00:00 [pmc-release] AID - jcm12165279 [pii] AID - jcm-12-05279 [pii] AID - 10.3390/jcm12165279 [doi] PST - epublish SO - J Clin Med. 2023 Aug 14;12(16):5279. doi: 10.3390/jcm12165279. PMID- 37561647 OWN - NLM STAT- MEDLINE DCOM- 20230905 LR - 20230907 IS - 1543-8392 (Electronic) IS - 1543-8384 (Linking) VI - 20 IP - 9 DP - 2023 Sep 4 TI - Complex Coacervates as a Promising Vehicle for mRNA Delivery: A Comprehensive Review of Recent Advances and Challenges. PG - 4387-4403 LID - 10.1021/acs.molpharmaceut.3c00439 [doi] AB - Messenger RNA (mRNA)-based therapies have gained significant attention, following the successful deployment of mRNA-based COVID-19 vaccines. Compared with traditional methods of genetic modification, mRNA-based therapies offer several advantages, including a lower risk of genetic mutations, temporary and controlled therapeutic gene expression, and a shorter production time, which facilitates rapid responses to emerging health challenges. Moreover, mRNA-based therapies have shown immense potential in treating a wide range of diseases including cancers, immune diseases, and neurological disorders. However, the current limitations of non-viral vectors for efficient and safe delivery of mRNA therapies, such as low encapsulation efficiency, potential toxicity, and limited stability, necessitate the exploration of novel strategies to overcome these challenges and fully realize the potential of mRNA-based therapeutics. Coacervate-based delivery systems have recently emerged as promising strategies for enhancing mRNA delivery. Coacervates, which are formed by the aggregation of two or more macromolecules, have shown great potential in delivering a wide range of therapeutics due to their ability to form a separated macromolecular-rich fluid phase in an aqueous environment. This phase separation enables the entrapment and protection of therapeutic agents from degradation as well as efficient cellular uptake and controlled release. Additionally, the natural affinity of coacervates for mRNA molecules presents an excellent opportunity for enhancing mRNA delivery to targeted cells and tissues, making coacervate-based delivery systems an attractive option for mRNA-based therapies. This review highlights the limitations of current strategies for mRNA delivery and the advantages of coacervate-based delivery systems to enable mRNA therapeutics. Coacervates protect mRNA from enzymatic degradation and enhance cellular uptake, leading to sustained and controlled gene expression. Despite their promising properties, the specific use of coacervates as mRNA delivery vehicles remains underexplored. This review aims to provide a comprehensive overview of coacervate-mediated delivery of mRNA, exploring the properties and applications of different coacervating agents as well as the challenges and optimization strategies involved in mRNA encapsulation, release, stability, and translation via coacervate-mediated delivery. Through a comprehensive analysis of recent advancements and recommended future directions, our review sheds light on the promising role of coacervate-mediated delivery for RNA therapeutics, highlighting its potential to enable groundbreaking applications in drug delivery and gene therapy. FAU - Forenzo, Chloe AU - Forenzo C AUID- ORCID: 0009-0006-9255-0537 FAU - Larsen, Jessica AU - Larsen J AUID- ORCID: 0000-0003-2756-9523 LA - eng PT - Journal Article PT - Review DEP - 20230810 PL - United States TA - Mol Pharm JT - Molecular pharmaceutics JID - 101197791 RN - 0 (RNA, Messenger) RN - 0 (COVID-19 Vaccines) RN - 0 (Macromolecular Substances) RN - 0 (Excipients) SB - IM MH - Humans MH - RNA, Messenger/genetics MH - *COVID-19 Vaccines MH - *COVID-19/therapy MH - Drug Delivery Systems MH - Macromolecular Substances MH - Excipients OTO - NOTNLM OT - Coacervation OT - Controlled Release OT - Nanotechnology OT - Phase Separation OT - Targeted Delivery OT - mRNA-Based Therapeutics EDAT- 2023/08/10 18:41 MHDA- 2023/09/05 06:42 CRDT- 2023/08/10 13:03 PHST- 2023/09/05 06:42 [medline] PHST- 2023/08/10 18:41 [pubmed] PHST- 2023/08/10 13:03 [entrez] AID - 10.1021/acs.molpharmaceut.3c00439 [doi] PST - ppublish SO - Mol Pharm. 2023 Sep 4;20(9):4387-4403. doi: 10.1021/acs.molpharmaceut.3c00439. Epub 2023 Aug 10. PMID- 37552991 OWN - NLM STAT- MEDLINE DCOM- 20230818 LR - 20260921 IS - 2666-3791 (Electronic) IS - 2666-3791 (Linking) VI - 4 IP - 8 DP - 2023 Aug 15 TI - mRNA vaccination boosts S-specific T cell memory and promotes expansion of CD45RA(int) T(EMRA)-like CD8(+) T cells in COVID-19 recovered individuals. PG - 101149 LID - S2666-3791(23)00302-6 [pii] LID - 10.1016/j.xcrm.2023.101149 [doi] LID - 101149 AB - SARS-CoV-2 infection and mRNA vaccination both elicit spike (S)-specific T cell responses. To analyze how T cell memory from prior infection influences T cell responses to vaccination, we evaluated functional T cell responses in naive and previously infected vaccine recipients. Pre-vaccine S-specific responses are predictive of subsequent CD8(+) T cell vaccine-response magnitudes. Comparing baseline with post-vaccination TCRbeta repertoires, we observed large clonotypic expansions correlated with the frequency of spike-specific T cells. Epitope mapping the largest CD8(+) T cell responses confirms that an HLA-A *03:01 epitope was highly immunodominant. Peptide-MHC tetramer staining together with mass cytometry and single-cell sequencing permit detailed phenotyping and clonotypic tracking of these S-specific CD8(+) T cells. Our results demonstrate that infection-induced S-specific CD8(+) T cell memory plays a significant role in shaping the magnitude and clonal composition of the circulating T cell repertoire after vaccination, with mRNA vaccination promoting CD8(+) memory T cells to a T(EMRA)-like phenotype. CI - Copyright (c) 2023 The Author(s). Published by Elsevier Inc. All rights reserved. FAU - Mayer-Blackwell, Koshlan AU - Mayer-Blackwell K AD - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA. FAU - Ryu, Heeju AU - Ryu H AD - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA. FAU - Codd, Amy S AU - Codd AS AD - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA. FAU - Parks, K Rachael AU - Parks KR AD - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA. FAU - MacMillan, Hugh R AU - MacMillan HR AD - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA. FAU - Cohen, Kristen W AU - Cohen KW AD - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA. FAU - Stewart, Terri L AU - Stewart TL AD - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA. FAU - Seese, Aaron AU - Seese A AD - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA. FAU - Lemos, Maria P AU - Lemos MP AD - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA. FAU - De Rosa, Stephen C AU - De Rosa SC AD - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA. FAU - Czartoski, Julie L AU - Czartoski JL AD - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA. FAU - Moodie, Zoe AU - Moodie Z AD - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA. FAU - Nguyen, Long T AU - Nguyen LT AD - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA. FAU - McGuire, Donald J AU - McGuire DJ AD - Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA 30329, USA; Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA 30322, USA. FAU - Ahmed, Rafi AU - Ahmed R AD - Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA 30329, USA; Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA 30322, USA. FAU - Fiore-Gartland, Andrew AU - Fiore-Gartland A AD - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA. FAU - McElrath, M Juliana AU - McElrath MJ AD - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA. Electronic address: jmcelrat@fredhutch.org. FAU - Newell, Evan W AU - Newell EW AD - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA. Electronic address: enewell@fredhutch.org. LA - eng GR - U19 AI128914/AI/NIAID NIH HHS/United States GR - UM1 AI068618/AI/NIAID NIH HHS/United States GR - UM1 AI068635/AI/NIAID NIH HHS/United States GR - UM1 AI069481/AI/NIAID NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20230807 PL - United States TA - Cell Rep Med JT - Cell reports. Medicine JID - 101766894 RN - 0 (Epitopes) RN - EC 3.1.3.48 (Leukocyte Common Antigens) SB - IM MH - Humans MH - *CD8-Positive T-Lymphocytes MH - *COVID-19/prevention & control MH - Memory T Cells MH - SARS-CoV-2 MH - Vaccination MH - Epitopes MH - Leukocyte Common Antigens PMC - PMC10439252 OTO - NOTNLM OT - CD4 T cells OT - CD8 T cells OT - CyTOF OT - SARS-CoV-2 OT - vaccination COIS- Declaration of interests E.W.N. is a cofounder, advisor, and shareholder of ImmunoScape and is an advisor for Neogene Therapeutics and NanoString Technologies. EDAT- 2023/08/09 01:05 MHDA- 2023/08/18 06:43 PMCR- 2023/08/07 CRDT- 2023/08/08 18:41 PHST- 2023/01/30 00:00 [received] PHST- 2023/06/01 00:00 [revised] PHST- 2023/07/17 00:00 [accepted] PHST- 2023/08/18 06:43 [medline] PHST- 2023/08/09 01:05 [pubmed] PHST- 2023/08/08 18:41 [entrez] PHST- 2023/08/07 00:00 [pmc-release] AID - S2666-3791(23)00302-6 [pii] AID - 101149 [pii] AID - 10.1016/j.xcrm.2023.101149 [doi] PST - ppublish SO - Cell Rep Med. 2023 Aug 15;4(8):101149. doi: 10.1016/j.xcrm.2023.101149. Epub 2023 Aug 7. PMID- 37543032 OWN - NLM STAT- MEDLINE DCOM- 20230915 LR - 20230918 IS - 1097-4180 (Electronic) IS - 1074-7613 (Linking) VI - 56 IP - 9 DP - 2023 Sep 12 TI - SARS-CoV-2 Omicron BA.1 breakthrough infection drives late remodeling of the memory B cell repertoire in vaccinated individuals. PG - 2137-2151.e7 LID - S1074-7613(23)00320-5 [pii] LID - 10.1016/j.immuni.2023.07.007 [doi] AB - How infection by a viral variant showing antigenic drift impacts a preformed mature human memory B cell (MBC) repertoire remains an open question. Here, we studied the MBC response up to 6 months after SARS-CoV-2 Omicron BA.1 breakthrough infection in individuals previously vaccinated with three doses of the COVID-19 mRNA vaccine. Longitudinal analysis, using single-cell multi-omics and functional analysis of monoclonal antibodies from RBD-specific MBCs, revealed that a BA.1 breakthrough infection mostly recruited pre-existing cross-reactive MBCs with limited de novo response against BA.1-restricted epitopes. Reorganization of clonal hierarchy and new rounds of germinal center reactions, however, combined to maintain diversity and induce progressive maturation of the MBC repertoire against common Hu-1 and BA.1, but not BA.5-restricted, SARS-CoV-2 Spike RBD epitopes. Such remodeling was further associated with a marked improvement in overall neutralizing breadth and potency. These findings have fundamental implications for the design of future vaccination booster strategies. CI - Copyright (c) 2023 Elsevier Inc. All rights reserved. FAU - Sokal, Aurelien AU - Sokal A AD - Institut Necker Enfants Malades, INSERM U1151/CNRS UMR 8253, Action thematique incitative sur programme-Avenir Team, Auto-Immune and Immune B cells, Universite Paris Cite, Universite Paris Est-Creteil, Creteil, France; Service de Medecine interne, Hopital Beaujon, Assistance Publique-Hopitaux de Paris (AP-HP), Universite de Paris Cite, Clichy, France; Service de Medecine Interne, Centre Hospitalier Universitaire Henri-Mondor, Assistance Publique-Hopitaux de Paris (AP-HP), Universite Paris-Est Creteil (UPEC), Creteil, France. FAU - Barba-Spaeth, Giovanna AU - Barba-Spaeth G AD - Institut Pasteur, Universite de Paris Cite, CNRS UMR 3569, Unite de Virologie Structurale, Paris, France. FAU - Hunault, Lise AU - Hunault L AD - Institut Pasteur, Universite de Paris Cite, INSERM UMR1222, Unit of Antibodies in Therapy and Pathology, Paris, France; Sorbonne University, ED394, Paris, France; Sorbonne Universite, INSERM, CNRS, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), 75013 Paris, France. FAU - Fernandez, Ignacio AU - Fernandez I AD - Institut Pasteur, Universite de Paris Cite, CNRS UMR 3569, Unite de Virologie Structurale, Paris, France. FAU - Broketa, Matteo AU - Broketa M AD - Institut Pasteur, Universite de Paris Cite, INSERM UMR1222, Unit of Antibodies in Therapy and Pathology, Paris, France; Sorbonne University, ED394, Paris, France. FAU - Meola, Annalisa AU - Meola A AD - Institut Pasteur, Universite de Paris Cite, CNRS UMR 3569, Unite de Virologie Structurale, Paris, France. FAU - Fourati, Slim AU - Fourati S AD - Departement de Virologie, Bacteriologie, Hygiene et Mycologie-Parasitologie, Centre Hospitalier Universitaire Henri Mondor, Assistance Publique-Hopitaux de Paris (AP-HP), Creteil, France; INSERM U955, equipe 18. Institut Mondor de Recherche Biomedicale (IMRB), Universite Paris-Est Creteil (UPEC), Creteil, France. FAU - Azzaoui, Imane AU - Azzaoui I AD - Service de Medecine Interne, Centre Hospitalier Universitaire Henri-Mondor, Assistance Publique-Hopitaux de Paris (AP-HP), Universite Paris-Est Creteil (UPEC), Creteil, France; INSERM U955, equipe 2. Institut Mondor de Recherche Biomedicale (IMRB), Universite Paris-Est Creteil (UPEC), Creteil, France. FAU - Vandenberghe, Alexis AU - Vandenberghe A AD - Institut Necker Enfants Malades, INSERM U1151/CNRS UMR 8253, Action thematique incitative sur programme-Avenir Team, Auto-Immune and Immune B cells, Universite Paris Cite, Universite Paris Est-Creteil, Creteil, France; Service de Medecine Interne, Centre Hospitalier Universitaire Henri-Mondor, Assistance Publique-Hopitaux de Paris (AP-HP), Universite Paris-Est Creteil (UPEC), Creteil, France; INSERM U955, equipe 2. Institut Mondor de Recherche Biomedicale (IMRB), Universite Paris-Est Creteil (UPEC), Creteil, France. FAU - Lagouge-Roussey, Pauline AU - Lagouge-Roussey P AD - Institut Necker Enfants Malades, INSERM U1151/CNRS UMR 8253, Action thematique incitative sur programme-Avenir Team, Auto-Immune and Immune B cells, Universite Paris Cite, Universite Paris Est-Creteil, Creteil, France; Service de Medecine Interne, Centre Hospitalier Universitaire Henri-Mondor, Assistance Publique-Hopitaux de Paris (AP-HP), Universite Paris-Est Creteil (UPEC), Creteil, France; INSERM U955, equipe 2. Institut Mondor de Recherche Biomedicale (IMRB), Universite Paris-Est Creteil (UPEC), Creteil, France. FAU - Broutin, Manon AU - Broutin M AD - Institut Necker Enfants Malades, INSERM U1151/CNRS UMR 8253, Action thematique incitative sur programme-Avenir Team, Auto-Immune and Immune B cells, Universite Paris Cite, Universite Paris Est-Creteil, Creteil, France; INSERM U955, equipe 2. Institut Mondor de Recherche Biomedicale (IMRB), Universite Paris-Est Creteil (UPEC), Creteil, France. FAU - Roeser, Anais AU - Roeser A AD - Institut Necker Enfants Malades, INSERM U1151/CNRS UMR 8253, Action thematique incitative sur programme-Avenir Team, Auto-Immune and Immune B cells, Universite Paris Cite, Universite Paris Est-Creteil, Creteil, France; Service de Medecine Interne, Centre Hospitalier Universitaire Henri-Mondor, Assistance Publique-Hopitaux de Paris (AP-HP), Universite Paris-Est Creteil (UPEC), Creteil, France. FAU - Bouvier-Alias, Magali AU - Bouvier-Alias M AD - Departement de Virologie, Bacteriologie, Hygiene et Mycologie-Parasitologie, Centre Hospitalier Universitaire Henri Mondor, Assistance Publique-Hopitaux de Paris (AP-HP), Creteil, France; INSERM U955, equipe 18. Institut Mondor de Recherche Biomedicale (IMRB), Universite Paris-Est Creteil (UPEC), Creteil, France. FAU - Crickx, Etienne AU - Crickx E AD - Institut Necker Enfants Malades, INSERM U1151/CNRS UMR 8253, Action thematique incitative sur programme-Avenir Team, Auto-Immune and Immune B cells, Universite Paris Cite, Universite Paris Est-Creteil, Creteil, France; Service de Medecine Interne, Centre Hospitalier Universitaire Henri-Mondor, Assistance Publique-Hopitaux de Paris (AP-HP), Universite Paris-Est Creteil (UPEC), Creteil, France; INSERM U955, equipe 2. Institut Mondor de Recherche Biomedicale (IMRB), Universite Paris-Est Creteil (UPEC), Creteil, France. FAU - Languille, Laetitia AU - Languille L AD - Service de Medecine Interne, Centre Hospitalier Universitaire Henri-Mondor, Assistance Publique-Hopitaux de Paris (AP-HP), Universite Paris-Est Creteil (UPEC), Creteil, France. FAU - Fournier, Morgane AU - Fournier M AD - Institut Necker Enfants Malades, INSERM U1151/CNRS UMR 8253, Action thematique incitative sur programme-Avenir Team, Auto-Immune and Immune B cells, Universite Paris Cite, Universite Paris Est-Creteil, Creteil, France; Service de Medecine Interne, Centre Hospitalier Universitaire Henri-Mondor, Assistance Publique-Hopitaux de Paris (AP-HP), Universite Paris-Est Creteil (UPEC), Creteil, France. FAU - Michel, Marc AU - Michel M AD - Service de Medecine Interne, Centre Hospitalier Universitaire Henri-Mondor, Assistance Publique-Hopitaux de Paris (AP-HP), Universite Paris-Est Creteil (UPEC), Creteil, France. FAU - Godeau, Bertrand AU - Godeau B AD - Service de Medecine Interne, Centre Hospitalier Universitaire Henri-Mondor, Assistance Publique-Hopitaux de Paris (AP-HP), Universite Paris-Est Creteil (UPEC), Creteil, France. FAU - Gallien, Sebastien AU - Gallien S AD - Service de Maladies Infectieuses, Centre Hospitalier Universitaire Henri Mondor, Assistance Publique-Hopitaux de Paris (AP-HP), Universite Paris-Est Creteil (UPEC), Creteil, France. FAU - Melica, Giovanna AU - Melica G AD - Service de Maladies Infectieuses, Centre Hospitalier Universitaire Henri Mondor, Assistance Publique-Hopitaux de Paris (AP-HP), Universite Paris-Est Creteil (UPEC), Creteil, France. FAU - Nguyen, Yann AU - Nguyen Y AD - Service de Medecine Interne, Centre Hospitalier Universitaire Cochin, Assistance Publique-Hopitaux de Paris (AP-HP), Paris, France. FAU - Canoui-Poitrine, Florence AU - Canoui-Poitrine F AD - Departement de Sante Publique, Unite de Recherche Clinique (URC), CEpiA (Clinical Epidemiology and Ageing), EA 7376- Institut Mondor de Recherche Biomedicale (IMRB), Centre Hospitalier Universitaire Henri-Mondor, Assistance Publique-Hopitaux de Paris (AP-HP), Universite Paris-Est Creteil (UPEC), Creteil, France. FAU - Pirenne, France AU - Pirenne F AD - INSERM U955, equipe 18. Institut Mondor de Recherche Biomedicale (IMRB), Universite Paris-Est Creteil (UPEC), Creteil, France; Etablissement Francais du Sang (EFS) Ile de France, Creteil, France. FAU - Megret, Jerome AU - Megret J AD - Plateforme de Cytometrie en Flux, Structure Federative de Recherche Necker, INSERM US24-CNRS UMS3633, Paris, France. FAU - Pawlotsky, Jean-Michel AU - Pawlotsky JM AD - Departement de Virologie, Bacteriologie, Hygiene et Mycologie-Parasitologie, Centre Hospitalier Universitaire Henri Mondor, Assistance Publique-Hopitaux de Paris (AP-HP), Creteil, France; INSERM U955, equipe 18. Institut Mondor de Recherche Biomedicale (IMRB), Universite Paris-Est Creteil (UPEC), Creteil, France. FAU - Fillatreau, Simon AU - Fillatreau S AD - Institut Necker Enfants Malades (INEM), INSERM U1151/CNRS UMR 8253, Universite de Paris, Paris, France. FAU - Reynaud, Claude-Agnes AU - Reynaud CA AD - Institut Necker Enfants Malades, INSERM U1151/CNRS UMR 8253, Action thematique incitative sur programme-Avenir Team, Auto-Immune and Immune B cells, Universite Paris Cite, Universite Paris Est-Creteil, Creteil, France. FAU - Weill, Jean-Claude AU - Weill JC AD - Institut Necker Enfants Malades, INSERM U1151/CNRS UMR 8253, Action thematique incitative sur programme-Avenir Team, Auto-Immune and Immune B cells, Universite Paris Cite, Universite Paris Est-Creteil, Creteil, France. FAU - Rey, Felix A AU - Rey FA AD - Institut Pasteur, Universite de Paris Cite, CNRS UMR 3569, Unite de Virologie Structurale, Paris, France. FAU - Bruhns, Pierre AU - Bruhns P AD - Institut Pasteur, Universite de Paris Cite, INSERM UMR1222, Unit of Antibodies in Therapy and Pathology, Paris, France. FAU - Mahevas, Matthieu AU - Mahevas M AD - Institut Necker Enfants Malades, INSERM U1151/CNRS UMR 8253, Action thematique incitative sur programme-Avenir Team, Auto-Immune and Immune B cells, Universite Paris Cite, Universite Paris Est-Creteil, Creteil, France; Service de Medecine Interne, Centre Hospitalier Universitaire Henri-Mondor, Assistance Publique-Hopitaux de Paris (AP-HP), Universite Paris-Est Creteil (UPEC), Creteil, France; INSERM U955, equipe 2. Institut Mondor de Recherche Biomedicale (IMRB), Universite Paris-Est Creteil (UPEC), Creteil, France. Electronic address: matthieu.mahevas@aphp.fr. FAU - Chappert, Pascal AU - Chappert P AD - Institut Necker Enfants Malades, INSERM U1151/CNRS UMR 8253, Action thematique incitative sur programme-Avenir Team, Auto-Immune and Immune B cells, Universite Paris Cite, Universite Paris Est-Creteil, Creteil, France; INSERM U955, equipe 2. Institut Mondor de Recherche Biomedicale (IMRB), Universite Paris-Est Creteil (UPEC), Creteil, France. Electronic address: pascal.chappert@inserm.fr. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230804 PL - United States TA - Immunity JT - Immunity JID - 9432918 RN - 0 (COVID-19 Vaccines) RN - 0 (Epitopes) RN - 0 (Antibodies, Viral) RN - 0 (Antibodies, Neutralizing) RN - COVID-19 breakthrough infections SB - IM MH - Humans MH - *COVID-19 Vaccines MH - *COVID-19 MH - SARS-CoV-2 MH - Memory B Cells MH - Breakthrough Infections MH - Epitopes MH - Antibodies, Viral MH - Antibodies, Neutralizing OTO - NOTNLM OT - Omicron BA.1 OT - SARS-CoV-2 OT - breakthrough infection OT - germinal center OT - mRNA vaccine OT - memory B cells COIS- Declaration of interests Outside of the submitted work, M. Mahevas received research funds from GSK and personal fees from LFB and Amgen. J.-C.W. received consulting fees from Institut Merieux. P.B. received consulting fees from Regeneron Pharmaceuticals. EDAT- 2023/08/06 05:42 MHDA- 2023/09/15 06:42 CRDT- 2023/08/05 18:41 PHST- 2023/01/27 00:00 [received] PHST- 2023/05/12 00:00 [revised] PHST- 2023/07/06 00:00 [accepted] PHST- 2023/09/15 06:42 [medline] PHST- 2023/08/06 05:42 [pubmed] PHST- 2023/08/05 18:41 [entrez] AID - S1074-7613(23)00320-5 [pii] AID - 10.1016/j.immuni.2023.07.007 [doi] PST - ppublish SO - Immunity. 2023 Sep 12;56(9):2137-2151.e7. doi: 10.1016/j.immuni.2023.07.007. Epub 2023 Aug 4. PMID- 37515731 OWN - NLM STAT- MEDLINE DCOM- 20230921 LR - 20230930 IS - 1432-1459 (Electronic) IS - 0340-5354 (Print) IS - 0340-5354 (Linking) VI - 270 IP - 10 DP - 2023 Oct TI - Neurological symptoms after COVID-19 vaccination: a report on the clinical presentation of the first 50 patients. PG - 4673-4677 LID - 10.1007/s00415-023-11895-9 [doi] AB - OBJECTIVES: Neurological symptoms associated with Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) vaccination were discovered in the context of billions of administered vaccine doses. The clinical manifestations often resemble post Coronavirus Disease 2019 (post-COVID-19) syndrome (PCS) features and may be considered as post-COVID-19 vaccine syndrome (PVS). Data regarding frequency, severity and pathophysiological mechanisms are scarce. METHODS: We assessed routine clinical examinations in 50 patients reporting new-onset neurological symptoms after SARS-CoV-2 vaccination, including neurological examination, laboratory and electrophysiology tests, as well as self-report questionnaires measuring fatigue, depressive symptoms, anxiety, risk of somatic symptom disorder, and health-related quality of life. Patients were included when symptoms occurred after confirmed COVID-19 vaccination and without prior SARS-CoV-2 infection, and if no alternative diagnosis was found to explain the symptoms. RESULTS: The most frequently reported symptoms were paraesthesia (56%), fatigue (46%) and cognitive impairment (36%). Neurological, routine laboratory, and electrophysiological examinations did not yield distinct pathological findings. Neuropsychological testing of a subgroup revealed deficits in attention, executive function and memory. DISCUSSION: The spectrum of clinical manifestations post-vaccination poses a substantial overlap with PCS symptoms. As no pathological findings were obtained in routine diagnostics, uncertainty remains about the underlying pathophysiological mechanisms and requires further investigation beyond routine work-up. CI - (c) 2023. The Author(s). FAU - Gerhard, Ameli AU - Gerhard A AD - Department of Neurology and Experimental Neurology, Charite-Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat Zu Berlin, Berlin, Germany. FAU - Raeder, Vanessa AU - Raeder V AD - Department of Neurology and Experimental Neurology, Charite-Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat Zu Berlin, Berlin, Germany. FAU - Pernice, Helena Franziska AU - Pernice HF AD - Department of Neurology and Experimental Neurology, Charite-Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat Zu Berlin, Berlin, Germany. FAU - Boesl, Fabian AU - Boesl F AD - Department of Neurology and Experimental Neurology, Charite-Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat Zu Berlin, Berlin, Germany. FAU - Schroeder, Maria AU - Schroeder M AD - Department of Neurology and Experimental Neurology, Charite-Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat Zu Berlin, Berlin, Germany. FAU - Richter, Jonathan AU - Richter J AD - Department of Neurology and Experimental Neurology, Charite-Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat Zu Berlin, Berlin, Germany. FAU - Endres, Matthias AU - Endres M AD - Department of Neurology and Experimental Neurology, Charite-Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat Zu Berlin, Berlin, Germany. AD - Center for Stroke Research Berlin, Berlin, Germany. AD - German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany. AD - Excellence Cluster NeuroCure, Berlin, Germany. AD - German Center for Cardiovascular Research (DZHK), Berlin, Germany. FAU - Pruss, Harald AU - Pruss H AD - Department of Neurology and Experimental Neurology, Charite-Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat Zu Berlin, Berlin, Germany. AD - German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany. FAU - Hahn, Katrin AU - Hahn K AD - Department of Neurology and Experimental Neurology, Charite-Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat Zu Berlin, Berlin, Germany. AD - Berlin Institute of Health (BIH), Berlin, Germany. FAU - Audebert, Heinrich J AU - Audebert HJ AD - Department of Neurology and Experimental Neurology, Charite-Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat Zu Berlin, Berlin, Germany. AD - Center for Stroke Research Berlin, Berlin, Germany. FAU - Franke, Christiana AU - Franke C AUID- ORCID: 0000-0002-5609-2472 AD - Department of Neurology and Experimental Neurology, Charite-Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat Zu Berlin, Berlin, Germany. christiana.franke@charite.de. LA - eng GR - FR 4479/1-1/Deutsche Forschungsgemeinschaft/ GR - PR 1274/8-1/Deutsche Forschungsgemeinschaft/ PT - Journal Article DEP - 20230729 PL - Germany TA - J Neurol JT - Journal of neurology JID - 0423161 RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - *COVID-19/prevention & control MH - COVID-19 Vaccines/adverse effects MH - Quality of Life MH - SARS-CoV-2 MH - Vaccination/adverse effects MH - Fatigue/etiology MH - Neurologic Examination PMC - PMC10511371 OTO - NOTNLM OT - Cognitive impairment OT - Fatigue OT - Paresthesia OT - Post-COVID-19 syndrome (PCS) OT - Post-COVID-19 vaccine syndrome (PVS) OT - SARS-CoV-2 vaccination COIS- All other authors have no competing interests to declare that are relevant to the content of this article. EDAT- 2023/07/29 21:45 MHDA- 2023/09/21 06:42 PMCR- 2023/07/29 CRDT- 2023/07/29 11:13 PHST- 2023/06/13 00:00 [received] PHST- 2023/07/20 00:00 [accepted] PHST- 2023/07/18 00:00 [revised] PHST- 2023/09/21 06:42 [medline] PHST- 2023/07/29 21:45 [pubmed] PHST- 2023/07/29 11:13 [entrez] PHST- 2023/07/29 00:00 [pmc-release] AID - 10.1007/s00415-023-11895-9 [pii] AID - 11895 [pii] AID - 10.1007/s00415-023-11895-9 [doi] PST - ppublish SO - J Neurol. 2023 Oct;270(10):4673-4677. doi: 10.1007/s00415-023-11895-9. Epub 2023 Jul 29. PMID- 37483174 OWN - NLM STAT- MEDLINE DCOM- 20230908 LR - 20230911 IS - 1468-1331 (Electronic) IS - 1351-5101 (Linking) VI - 30 IP - 10 DP - 2023 Oct TI - Effect of the COVID-19 pandemic on disease activity in multiple sclerosis patients treated with hematopoietic stem cell transplantation. PG - 3362-3366 LID - 10.1111/ene.15989 [doi] AB - BACKGROUND AND PURPOSE: It is still debated whether the COVID-19 pandemic affected disease activity in people with autoimmune diseases, including multiple sclerosis (MS). The aim of this study, therefore, was to explore the impact of COVID-19 in people with MS (pwMS) not receiving continuative disease-modifying therapy (DMT) after previous treatment with autologous hematopoietic stem cell transplantation (AHSCT). MATERIALS AND METHODS: We included pwMS treated with AHSCT who were in disease remission without receiving DMTs during the pandemic and who were followed up at our centre during the study period. Data on SARS-CoV-2 infection and vaccination were recorded, with details of adverse events and clinical-radiological disease activity. RESULTS: A total of 36 pwMS (31 females; 86%) were included, of whom 23 (64%) had relapsing-remitting (RR-MS) and 13 had secondary progressive MS (SP-MS). Thirty-three pwMS (92%) received anti-SARS-CoV-2 mRNA vaccines. Thirteen patients (36%) developed mild to moderate COVID-19 a median (range) of 58 (4-224) months after AHSCT; seven (54%) of these patients were not yet vaccinated. Transient neurological symptoms after vaccination or infection were reported in 9% and 36% of the patients, respectively. The rate of new inflammatory events (relapses or asymptomatic magnetic resonance imaging [MRI] activity) after AHSCT increased from 0.006 (one asymptomatic new lesion/159 patient-years) before the pandemic to 0.083 (five relapses plus two cases of asymptomatic MRI activity/84 patient-years) since the pandemic start (p = 0.004). CONCLUSIONS: People with MS with a history of highly active disease, who are untreated or receiving moderate-efficacy DMTs might be more vulnerable to disease reactivation, possibly elicited by exogenous triggers. Careful monitoring and further investigation are warranted to ascertain whether special precautions are needed in these cases. CI - (c) 2023 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology. FAU - Mariottini, Alice AU - Mariottini A AD - Department of Neurosciences, Drug and Child Health, University of Florence, Florence, Italy. AD - Department of Neurology 2 and Tuscan Region Multiple Sclerosis Referral Centre, Careggi University Hospital, Florence, Italy. FAU - Lotti, Antonio AU - Lotti A AD - Department of Neurosciences, Drug and Child Health, University of Florence, Florence, Italy. FAU - Innocenti, Chiara AU - Innocenti C AD - Cell Therapy and Transfusion Medicine Unit, Careggi University Hospital, Florence, Italy. FAU - Repice, Anna Maria AU - Repice AM AD - Department of Neurology 2 and Tuscan Region Multiple Sclerosis Referral Centre, Careggi University Hospital, Florence, Italy. FAU - Nozzoli, Chiara AU - Nozzoli C AD - Cell Therapy and Transfusion Medicine Unit, Careggi University Hospital, Florence, Italy. FAU - Boncompagni, Riccardo AU - Boncompagni R AD - Cell Therapy and Transfusion Medicine Unit, Careggi University Hospital, Florence, Italy. FAU - Fainardi, Enrico AU - Fainardi E AD - Neuroradiology Unit, Careggi University Hospital, Florence, Italy. AD - Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy. FAU - Saccardi, Riccardo AU - Saccardi R AD - Cell Therapy and Transfusion Medicine Unit, Careggi University Hospital, Florence, Italy. FAU - Massacesi, Luca AU - Massacesi L AD - Department of Neurosciences, Drug and Child Health, University of Florence, Florence, Italy. AD - Department of Neurology 2 and Tuscan Region Multiple Sclerosis Referral Centre, Careggi University Hospital, Florence, Italy. LA - eng PT - Journal Article DEP - 20230802 PL - England TA - Eur J Neurol JT - European journal of neurology JID - 9506311 SB - IM MH - Female MH - Humans MH - *Multiple Sclerosis/complications/therapy MH - Pandemics MH - *Multiple Sclerosis, Relapsing-Remitting/therapy MH - Treatment Outcome MH - *COVID-19 MH - SARS-CoV-2 MH - *Hematopoietic Stem Cell Transplantation/adverse effects OTO - NOTNLM OT - COVID-19 OT - SARS-CoV-2 OT - hematopoietic stem cell transplantation OT - multiple sclerosis OT - vaccination EDAT- 2023/07/24 06:43 MHDA- 2023/09/08 06:43 CRDT- 2023/07/24 04:25 PHST- 2023/07/09 00:00 [revised] PHST- 2023/04/20 00:00 [received] PHST- 2023/07/17 00:00 [accepted] PHST- 2023/09/08 06:43 [medline] PHST- 2023/07/24 06:43 [pubmed] PHST- 2023/07/24 04:25 [entrez] AID - 10.1111/ene.15989 [doi] PST - ppublish SO - Eur J Neurol. 2023 Oct;30(10):3362-3366. doi: 10.1111/ene.15989. Epub 2023 Aug 2. PMID- 37457966 OWN - NLM STAT- MEDLINE DCOM- 20230718 LR - 20230718 IS - 2235-2988 (Electronic) IS - 2235-2988 (Linking) VI - 13 DP - 2023 TI - Humoral immune responses to inactivated COVID-19 vaccine up to 1 year in children with chronic hepatitis B infection. PG - 1201101 LID - 10.3389/fcimb.2023.1201101 [doi] LID - 1201101 AB - BACKGROUND: Inactivated SARS-CoV-2 vaccination has recently been approved for children aged 3-17 years in China. However, data on long-term humoral responses to inactivated vaccines in children with chronic hepatitis B (CHB) are still limited. METHODS: In this prospective observational study, CHB children after primary inactivated SARS-CoV-2 vaccines were recruited consecutively and followed up for 1 year. CHB adults from another cohort study (NCT05007665) were used as a control. The receptor-binding domain IgG antibody (anti-RBD-IgG), neutralizing antibody (NAb), neutralization against Omicron (BA2.12.1, BA.4 and BA.5), and memory B -cell (MBC) responses were evaluated. RESULTS: Overall, 115 CHB children and 351 CHB adults were included in this analysis. The antibody titers decreased over the first ~180 days and then plateaued up to 1 year in CHB children. However, lower and faster declines in antibody responses were observed in CHB adults. Interestingly, the seroprevalence of antibodies was still high after over 8 months in CHB children (anti-RBD-IgG [90%] and NAbs [83%]). However, neutralization against Omicron subvariants was significantly reduced in CHB children (-3.68-fold to -8.60-fold). Notably, neutralization against the BA.5 subvariant was obviously diminished in CHB children compared with adults. Moreover, CHB children had similar RBD-specific MBCs but higher RBD-specific atypical MBCs compared with adults. CONCLUSION: Inactivated vaccination could elicit more robust and durable antibody responses to the wild-type SARS-CoV-2 strain in CHB children than in CHB adults but showed inferior responses to Omicron subvariants (especially to the BA.5 strain). Hence, new Omicron-related or all-in-one vaccines are needed immediately for CHB children. CI - Copyright (c) 2023 Zhou, Chen, He, Peng, Chang, Tan, Li, Cai, Hu, Chen, Peng, Xu and Ren. FAU - Zhou, Yingzhi AU - Zhou Y AD - Department of Infectious Diseases, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Child Infection and Immunity, Chongqing, China. FAU - Chen, Zhiwei AU - Chen Z AD - Department of Infectious Diseases, Key Laboratory of Molecular Biology for Infectious Diseases, Ministry of Education, Institute for Viral Hepatitis, the Second Affiliated Hospital, Chongqing Medical University, Chongqing, China. FAU - He, Yi AU - He Y AD - Department of Infectious Diseases, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Child Infection and Immunity, Chongqing, China. FAU - Peng, Xiaorong AU - Peng X AD - Department of Infectious Diseases, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Child Infection and Immunity, Chongqing, China. FAU - Chang, Yunan AU - Chang Y AD - Department of Infectious Diseases, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Child Infection and Immunity, Chongqing, China. FAU - Tan, Aoxue AU - Tan A AD - Department of Infectious Diseases, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Child Infection and Immunity, Chongqing, China. FAU - Li, Hu AU - Li H AD - Department of Infectious Diseases, Key Laboratory of Molecular Biology for Infectious Diseases, Ministry of Education, Institute for Viral Hepatitis, the Second Affiliated Hospital, Chongqing Medical University, Chongqing, China. FAU - Cai, Dachuan AU - Cai D AD - Department of Infectious Diseases, Key Laboratory of Molecular Biology for Infectious Diseases, Ministry of Education, Institute for Viral Hepatitis, the Second Affiliated Hospital, Chongqing Medical University, Chongqing, China. FAU - Hu, Peng AU - Hu P AD - Department of Infectious Diseases, Key Laboratory of Molecular Biology for Infectious Diseases, Ministry of Education, Institute for Viral Hepatitis, the Second Affiliated Hospital, Chongqing Medical University, Chongqing, China. FAU - Chen, Min AU - Chen M AD - Department of Infectious Diseases, Key Laboratory of Molecular Biology for Infectious Diseases, Ministry of Education, Institute for Viral Hepatitis, the Second Affiliated Hospital, Chongqing Medical University, Chongqing, China. FAU - Peng, Mingli AU - Peng M AD - Department of Infectious Diseases, Key Laboratory of Molecular Biology for Infectious Diseases, Ministry of Education, Institute for Viral Hepatitis, the Second Affiliated Hospital, Chongqing Medical University, Chongqing, China. FAU - Xu, Hongmei AU - Xu H AD - Department of Infectious Diseases, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Child Infection and Immunity, Chongqing, China. FAU - Ren, Hong AU - Ren H AD - Department of Infectious Diseases, Key Laboratory of Molecular Biology for Infectious Diseases, Ministry of Education, Institute for Viral Hepatitis, the Second Affiliated Hospital, Chongqing Medical University, Chongqing, China. LA - eng SI - ClinicalTrials.gov/NCT05007665 PT - Journal Article PT - Observational Study PT - Research Support, Non-U.S. Gov't DEP - 20230629 PL - Switzerland TA - Front Cell Infect Microbiol JT - Frontiers in cellular and infection microbiology JID - 101585359 RN - 0 (COVID-19 Vaccines) RN - 0 (Antibodies, Neutralizing) RN - 0 (Immunoglobulin G) RN - 0 (Antibodies, Viral) SB - IM MH - Adult MH - Humans MH - Child MH - Immunity, Humoral MH - COVID-19 Vaccines MH - Cohort Studies MH - *Hepatitis B, Chronic MH - Seroepidemiologic Studies MH - *COVID-19/prevention & control MH - SARS-CoV-2 MH - Antibodies, Neutralizing MH - *Hepatitis B MH - Immunoglobulin G MH - Antibodies, Viral PMC - PMC10339386 OTO - NOTNLM OT - COVID-19 OT - adolescent OT - antibody response OT - chronic hepatitis B OT - inactivated vaccine OT - memory B cells OT - omicron COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2023/07/17 06:42 MHDA- 2023/07/18 13:10 PMCR- 2023/06/29 CRDT- 2023/07/17 04:48 PHST- 2023/04/06 00:00 [received] PHST- 2023/06/13 00:00 [accepted] PHST- 2023/07/18 13:10 [medline] PHST- 2023/07/17 06:42 [pubmed] PHST- 2023/07/17 04:48 [entrez] PHST- 2023/06/29 00:00 [pmc-release] AID - 10.3389/fcimb.2023.1201101 [doi] PST - epublish SO - Front Cell Infect Microbiol. 2023 Jun 29;13:1201101. doi: 10.3389/fcimb.2023.1201101. eCollection 2023. PMID- 37457721 OWN - NLM STAT- MEDLINE DCOM- 20230718 LR - 20230718 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 14 DP - 2023 TI - Breakthrough infection evokes the nasopharyngeal innate immune responses established by SARS-CoV-2-inactivated vaccine. PG - 1181121 LID - 10.3389/fimmu.2023.1181121 [doi] LID - 1181121 AB - Nasopharyngeal immune responses are vital for defense against SARS-CoV-2 infection. Although vaccination via muscle immunization has shown a high efficacy in reducing severity and death in COVID-19 infection, breakthrough infection frequently happens because of mutant variants and incompletely established mucosal immunity, especially in the upper respiratory tract. Here, we performed a single-cell RNA and T-cell receptor repertoire sequencing and delineated a high-resolution transcriptome landscape of nasopharyngeal mucosal immune and epithelial cells in vaccinated persons with breakthrough infection and non-vaccinated persons with natural infection as control. The epithelial cells showed anti-virus gene expression diversity and potentially recruited innate immune cells into the nasopharyngeal mucous of vaccinated patients. Upon infection, they released significant pro-inflammatory cytokines and chemokines by macrophages and monocytes and expressed antigen-presenting relevant genes by dendritic cells. Such immune responses of nasopharyngeal innate immune cells would facilitate the strengthened expression of cytotoxic genes in virus-specific T-cell or B-cell differentiation into antibody-secreting cells at the early stage of breakthrough infection through cell interaction between innate and adaptive immune cells. Notably, these alterations of nasopharyngeal immune cells in breakthrough infection depended on the activated Nuclear factor-kappaB (NF-kappaB) and NOD-, LRR- and pyrin domain-containing protein 3 (NLRP3) signaling rather than type I interferon responses due to the general reduction in interferon-stimulated gene expression. Our findings suggest that vaccination potentially strengthens innate immune barriers and virus-specific memory immune cell responses, which could be quickly activated to defend against variant breakthrough infection and maintain nasopharyngeal epithelial cell integrity. Thus, this study highlights the necessity of a boost via nasal mucous after intramuscular immunization. CI - Copyright (c) 2023 He, Cao, Lu, Qi, Wang, Liao, Xu, Yang, Ma, Li, Tang and Zhang. FAU - He, Xiaomeng AU - He X AD - Institute of Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong, China. FAU - Cao, Yingyin AU - Cao Y AD - Institute of Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong, China. FAU - Lu, Yanmei AU - Lu Y AD - Institute of Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong, China. FAU - Qi, Furong AU - Qi F AD - Institute of Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong, China. FAU - Wang, Haiyan AU - Wang H AD - Institute of Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong, China. FAU - Liao, Xuejiao AU - Liao X AD - Institute of Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong, China. FAU - Xu, Gang AU - Xu G AD - Institute of Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong, China. FAU - Yang, Biao AU - Yang B AD - Institute of Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong, China. FAU - Ma, Junhua AU - Ma J AD - Institute of Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong, China. FAU - Li, Dapeng AU - Li D AD - Institute of Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong, China. FAU - Tang, Xian AU - Tang X AD - Institute of Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong, China. FAU - Zhang, Zheng AU - Zhang Z AD - Institute of Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong, China. AD - Shenzhen Research Center for Communicable Disease Diagnosis and Treatment of Chinese Academy of Medical Science, Shenzhen, Guangdong, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230629 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 RN - 0 (COVID-19 Vaccines) RN - 0 (Vaccines, Inactivated) SB - IM MH - Humans MH - *COVID-19 Vaccines MH - SARS-CoV-2 MH - *COVID-19/prevention & control MH - Breakthrough Infections MH - Immunity, Innate MH - Vaccines, Inactivated PMC - PMC10349640 OTO - NOTNLM OT - SARS-CoV-2 OT - breakthrough infection OT - innate immune memory OT - mucosal immunity OT - single-cell RNA sequencing COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2023/07/17 06:42 MHDA- 2023/07/18 13:08 PMCR- 2023/06/29 CRDT- 2023/07/17 04:43 PHST- 2023/03/07 00:00 [received] PHST- 2023/05/30 00:00 [accepted] PHST- 2023/07/18 13:08 [medline] PHST- 2023/07/17 06:42 [pubmed] PHST- 2023/07/17 04:43 [entrez] PHST- 2023/06/29 00:00 [pmc-release] AID - 10.3389/fimmu.2023.1181121 [doi] PST - epublish SO - Front Immunol. 2023 Jun 29;14:1181121. doi: 10.3389/fimmu.2023.1181121. eCollection 2023. PMID- 37457694 OWN - NLM STAT- MEDLINE DCOM- 20230718 LR - 20230718 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 14 DP - 2023 TI - mRNA-based SARS-CoV-2 Comirnaty vaccine elicits weak and short specific memory B cell response in individuals with no previous infection. PG - 1127379 LID - 10.3389/fimmu.2023.1127379 [doi] LID - 1127379 AB - OBJECTIVES: The dynamics of the memory B cell (MBC) repertoire after SARS-CoV-2 vaccination is crucial for assessing long-term immunity. We compare spike-specific MBC responses between SARS-CoV-2 unexposed and recovered individuals, and their impact on breakthrough infections during follow-up. METHODS: Spike-specific MBC and T cells were quantified at inclusion and after two doses of mRNA vaccine in a longitudinal cohort of 85 naive and 64 recovered participants (47 with positive serology and 17 with negative serology after infection). RESULTS: At inclusion, there was minimal spike-specific MBC in naive SARS-CoV-2 individuals. After the second vaccine dose, MBCs were significantly boosted in naive individuals, but reached a significantly lower level than that observed even in unvaccinated SARS-CoV-2 convalescents (p<0.001). Furthermore, while the secondary memory B cell (MBC) population consisted of 100%, 33%, and 76% IgG(+), IgM(+), and IgA(+) expressing cells, respectively, in the unexposed group, the MBC response showed a significant decrease across all isotypes. Similarly, although secondary specific IgG(+), IgM(+), and IgA(+)-MBC isotypes were found in 100%, 39%, and 76% of the unexposed participants, respectively, the magnitude of the MBC levels was significantly lower for all the isotypes compared to convalescents. Interestingly, convalescents without an initial serological response had a lower MBC response, like what found in unexposed subjects. There was an inverse correlation between specific MBCs (r=-0.307; p=0.027), especially for isotype IgA(+) (r=-0.279, p=0.045), and the time since the second vaccination dose. Furthermore, during a median follow-up of 434 days (IQR, 339-495), 49 out of 149 individuals (33%) became infected, 29 in naive and 20 in convalescent individuals, showing a significant correlation between spike-specific MBC magnitude after vaccination and the time for SARS-CoV-2 infection, especially for IgA(+)/IgG(+) MBC isotypes. CONCLUSIONS: MBCs were primed by mRNA-based vaccination in most cases, but SARS-CoV-2 naive individuals had a blunted specific MBC response, and this was associated with a shorter time to breakthrough SARS-CoV-2 infection. CI - Copyright (c) 2023 Casado, Vizcarra, Martin-Hondarza, Gomez-Maldonado, Muedra-Sanchez, del Pino, Mirabella, Martin-Colmenarejo, Haemmerle, Fernandez-Escribano and Vallejo. FAU - Casado, Jose L AU - Casado JL AD - Department of Infectious Diseases, CIBERINFEC (Biomedical Research Center Network in Infectious Diseases), Madrid, Spain. AD - IRYCIS, Instituto Ramon y Cajal de Investigaciones Sanitarias, University Hospital Ramon y Cajal, Madrid, Spain. FAU - Vizcarra, Pilar AU - Vizcarra P AD - Department of Infectious Diseases, CIBERINFEC (Biomedical Research Center Network in Infectious Diseases), Madrid, Spain. AD - IRYCIS, Instituto Ramon y Cajal de Investigaciones Sanitarias, University Hospital Ramon y Cajal, Madrid, Spain. FAU - Martin-Hondarza, Adrian AU - Martin-Hondarza A AD - Laboratory of Immunovirology, University Hospital Ramon y Cajal, Madrid, Spain. FAU - Gomez-Maldonado, Sandra AU - Gomez-Maldonado S AD - Department of Infectious Diseases, CIBERINFEC (Biomedical Research Center Network in Infectious Diseases), Madrid, Spain. FAU - Muedra-Sanchez, Magdalena AU - Muedra-Sanchez M AD - Department of Occupational Safety and Health, University Hospital Ramon y Cajal, Madrid, Spain. FAU - Del Pino, Judith AU - Del Pino J AD - Department of Infectious Diseases, CIBERINFEC (Biomedical Research Center Network in Infectious Diseases), Madrid, Spain. FAU - Mirabella, Itria G AU - Mirabella IG AD - Department of Occupational Safety and Health, University Hospital Ramon y Cajal, Madrid, Spain. FAU - Martin-Colmenarejo, Sara AU - Martin-Colmenarejo S AD - Department of Infectious Diseases, CIBERINFEC (Biomedical Research Center Network in Infectious Diseases), Madrid, Spain. FAU - Haemmerle, Johannes AU - Haemmerle J AD - Department of Occupational Safety and Health, University Hospital Ramon y Cajal, Madrid, Spain. FAU - Fernandez-Escribano, Marina AU - Fernandez-Escribano M AD - Department of Occupational Safety and Health, University Hospital Ramon y Cajal, Madrid, Spain. FAU - Vallejo, Alejandro AU - Vallejo A AD - Department of Infectious Diseases, CIBERINFEC (Biomedical Research Center Network in Infectious Diseases), Madrid, Spain. AD - IRYCIS, Instituto Ramon y Cajal de Investigaciones Sanitarias, University Hospital Ramon y Cajal, Madrid, Spain. AD - Laboratory of Immunovirology, University Hospital Ramon y Cajal, Madrid, Spain. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230629 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 RN - 0 (COVID-19 Vaccines) RN - 0 (BNT162 Vaccine) RN - 0 (RNA, Messenger) RN - 0 (Immunoglobulin A) RN - 0 (Immunoglobulin G) RN - 0 (Immunoglobulin M) SB - IM MH - Humans MH - *COVID-19 Vaccines MH - *COVID-19/prevention & control MH - BNT162 Vaccine MH - SARS-CoV-2 MH - Memory B Cells MH - RNA, Messenger/genetics MH - Immunoglobulin A MH - Immunoglobulin G MH - Immunoglobulin M PMC - PMC10338867 OTO - NOTNLM OT - B cell response OT - COVID-19 OT - SARS-CoV-2 OT - convalescents OT - longterm immunity COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2023/07/17 06:42 MHDA- 2023/07/18 13:09 PMCR- 2023/06/29 CRDT- 2023/07/17 04:43 PHST- 2022/12/19 00:00 [received] PHST- 2023/06/14 00:00 [accepted] PHST- 2023/07/18 13:09 [medline] PHST- 2023/07/17 06:42 [pubmed] PHST- 2023/07/17 04:43 [entrez] PHST- 2023/06/29 00:00 [pmc-release] AID - 10.3389/fimmu.2023.1127379 [doi] PST - epublish SO - Front Immunol. 2023 Jun 29;14:1127379. doi: 10.3389/fimmu.2023.1127379. eCollection 2023. PMID- 37440409 OWN - NLM STAT- MEDLINE DCOM- 20230731 LR - 20250530 IS - 2211-1247 (Electronic) VI - 42 IP - 7 DP - 2023 Jul 25 TI - Tracking B cell responses to the SARS-CoV-2 mRNA-1273 vaccine. PG - 112780 LID - S2211-1247(23)00791-X [pii] LID - 10.1016/j.celrep.2023.112780 [doi] AB - Protective immunity following vaccination is sustained by long-lived antibody-secreting cells and resting memory B cells (MBCs). Responses to two-dose SARS-CoV-2 mRNA-1273 vaccination are evaluated longitudinally by multimodal single-cell analysis in three infection-naive individuals. Integrated surface protein, transcriptomics, and B cell receptor (BCR) repertoire analysis of sorted plasmablasts and spike(+) (S-2P(+)) and S-2P(-) B cells reveal clonal expansion and accumulating mutations among S-2P(+) cells. These cells are enriched in a cluster of immunoglobulin G-expressing MBCs and evolve along a bifurcated trajectory rooted in CXCR3(+) MBCs. One branch leads to CD11c(+) atypical MBCs while the other develops from CD71(+) activated precursors to resting MBCs, the dominant population at month 6. Among 12 evolving S-2P(+) clones, several are populated with plasmablasts at early timepoints as well as CD71(+) activated and resting MBCs at later timepoints, and display intra- and/or inter-cohort BCR convergence. These relationships suggest a coordinated and predictable evolution of SARS-CoV-2 vaccine-generated MBCs. CI - Published by Elsevier Inc. FAU - Lopes de Assis, Felipe AU - Lopes de Assis F AD - Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. FAU - Hoehn, Kenneth B AU - Hoehn KB AD - Department of Pathology, Yale School of Medicine, New Haven, CT 06520, USA. FAU - Zhang, Xiaozhen AU - Zhang X AD - Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. FAU - Kardava, Lela AU - Kardava L AD - Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. FAU - Smith, Connor D AU - Smith CD AD - Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. FAU - El Merhebi, Omar AU - El Merhebi O AD - Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. FAU - Buckner, Clarisa M AU - Buckner CM AD - Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. FAU - Trihemasava, Krittin AU - Trihemasava K AD - Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. FAU - Wang, Wei AU - Wang W AD - Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. FAU - Seamon, Catherine A AU - Seamon CA AD - Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. FAU - Chen, Vicky AU - Chen V AD - Integrated Data Sciences Section, Research Technologies Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. FAU - Schaughency, Paul AU - Schaughency P AD - Integrated Data Sciences Section, Research Technologies Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. FAU - Cheung, Foo AU - Cheung F AD - NIH Center for Human Immunology, NIAID, NIH, Bethesda, MD 20892, USA. FAU - Martins, Andrew J AU - Martins AJ AD - Multiscale Systems Biology Section, Laboratory of Immune System Biology, NIAID, NIH, Bethesda, MD 20892, USA. FAU - Chiang, Chi-I AU - Chiang CI AD - Institute for Bioscience and Biotechnology Research, Rockville, MD 20850, USA. FAU - Li, Yuxing AU - Li Y AD - Institute for Bioscience and Biotechnology Research, Rockville, MD 20850, USA; Department of Microbiology and Immunology and Center for Biomolecular Therapeutics, University of Maryland School of Medicine, Baltimore, MD 21201, USA. FAU - Tsang, John S AU - Tsang JS AD - NIH Center for Human Immunology, NIAID, NIH, Bethesda, MD 20892, USA; Multiscale Systems Biology Section, Laboratory of Immune System Biology, NIAID, NIH, Bethesda, MD 20892, USA. FAU - Chun, Tae-Wook AU - Chun TW AD - Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. FAU - Kleinstein, Steven H AU - Kleinstein SH AD - Department of Pathology, Yale School of Medicine, New Haven, CT 06520, USA; Program in Computational Biology and Bioinformatics, Yale University, New Haven, CT 06511, USA; Department of Immunobiology, Yale School of Medicine, New Haven, CT 06520, USA. FAU - Moir, Susan AU - Moir S AD - Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. Electronic address: smoir@niaid.nih.gov. LA - eng GR - R01 AI136756/AI/NIAID NIH HHS/United States GR - ZIA AI001325/ImNIH/Intramural NIH HHS/United States GR - K99 AI159302/AI/NIAID NIH HHS/United States GR - R01 AI104739/AI/NIAID NIH HHS/United States GR - R01 AI102766/AI/NIAID NIH HHS/United States GR - P30 AI036214/AI/NIAID NIH HHS/United States GR - R01 AI126587/AI/NIAID NIH HHS/United States GR - R41 AI147929/AI/NIAID NIH HHS/United States GR - R01 AI175439/AI/NIAID NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20230712 PL - United States TA - Cell Rep JT - Cell reports JID - 101573691 RN - EPK39PL4R4 (2019-nCoV Vaccine mRNA-1273) RN - 0 (COVID-19 Vaccines) RN - 0 (Antibodies, Viral) SB - IM MH - Humans MH - *2019-nCoV Vaccine mRNA-1273 MH - SARS-CoV-2 MH - COVID-19 Vaccines MH - *COVID-19/prevention & control MH - B-Lymphocytes MH - Antibodies, Viral MH - Vaccination PMC - PMC10529190 MID - NIHMS1920508 OTO - NOTNLM OT - B cells OT - BCR repertoire OT - CP: Immunology OT - SARS-CoV-2 OT - immunological memory OT - mRNA vaccine OT - single-cell profiling COIS- Declaration of interests S.H.K. receives consulting fees from Peraton. K.B.H. receives consulting fees from Prellis Biologics. EDAT- 2023/07/13 19:15 MHDA- 2023/07/31 06:43 PMCR- 2023/09/27 CRDT- 2023/07/13 12:35 PHST- 2023/02/21 00:00 [received] PHST- 2023/03/15 00:00 [revised] PHST- 2023/06/23 00:00 [accepted] PHST- 2023/07/31 06:43 [medline] PHST- 2023/07/13 19:15 [pubmed] PHST- 2023/07/13 12:35 [entrez] PHST- 2023/09/27 00:00 [pmc-release] AID - S2211-1247(23)00791-X [pii] AID - 10.1016/j.celrep.2023.112780 [doi] PST - ppublish SO - Cell Rep. 2023 Jul 25;42(7):112780. doi: 10.1016/j.celrep.2023.112780. Epub 2023 Jul 12. PMID- 37398654 OWN - NLM STAT- MEDLINE DCOM- 20230705 LR - 20240921 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 14 DP - 2023 TI - Immunity following SARS-CoV-2 vaccination in autoimmune neurological disorders treated with rituximab or ocrelizumab. PG - 1149629 LID - 10.3389/fimmu.2023.1149629 [doi] LID - 1149629 AB - BACKGROUND: Rituximab (RTX) and ocrelizumab (OCR), B cell-depleting therapy targeting CD20 molecules, affect the humoral immune response after vaccination. How these therapies influence T-cell-mediated immune response against SARS-CoV-2 after immunization remains unclear. We aimed to evaluate the humoral and cellular immune response to the COVID-19 vaccine in a cohort of patients with multiple sclerosis (MS), neuromyelitis optica spectrum disorders (NMOSD), and myasthenia gravis (MG). METHODS: Patients with MS (83), NMOSD (19), or MG (7) undergoing RTX (n=47) or OCR (n=62) treatment were vaccinated twice with the mRNA BNT162b2 vaccine. Antibodies were quantified using the SARS-CoV-2 IgG chemiluminescence immunoassay, targeting the spike protein. SARS-CoV-2-specific T cell responses were quantified by interferon gamma release assays (IGRA). The responses were evaluated at two different time points (4-8 weeks and 16-20 weeks following the 2nd dose of the vaccine). Immunocompetent vaccinated individuals (n=41) were included as controls. RESULTS: Almost all immunocompetent controls developed antibodies against the SARS-CoV-2 trimeric spike protein, but only 34.09% of the patients, without a COVID-19 history and undergoing anti-CD20 treatment (via RTX or OCR), seroconverted. This antibody response was higher in patients with intervals of longer than 3 weeks between vaccinations. The duration of therapy was significantly shorter in seroconverted patients (median 24 months), than in the non-seroconverted group. There was no correlation between circulating B cells and the levels of antibodies. Even patients with a low proportion of circulating CD19(+) B cells (<1%, 71 patients) had detectable SARS-CoV-2 specific antibody responses. SARS-CoV-2 specific T cell response measured by released interferon gamma was detected in 94.39% of the patients, independently of a humoral immune response. CONCLUSION: The majority of MS, MG, and NMOSD patients developed a SARS-CoV-2-specific T cell response. The data suggest that vaccination can induce SARS-CoV-2-specific antibodies in a portion of anti-CD20 treated patients. The seroconversion rate was higher in OCR-treated patients compared to those on RTX. The response represented by levels of antibodies was better in individuals, with intervals of longer than 3 weeks between vaccinations. CI - Copyright (c) 2023 Nytrova, Stastna, Tesar, Menkyova, Posova, Koprivova, Mikulova, Hrdy, Smela, Horakova, Rysankova, Doleckova and Tyblova. FAU - Nytrova, Petra AU - Nytrova P AD - Department of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czechia. FAU - Stastna, Dominika AU - Stastna D AD - Department of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czechia. FAU - Tesar, Adam AU - Tesar A AD - Department of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czechia. AD - Institute of Biophysics and Informatics of the First Faculty of Medicine, Charles University in Prague, Prague, Czechia. FAU - Menkyova, Ingrid AU - Menkyova I AD - Department of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czechia. AD - 2nd Department of Neurology, Faculty of Medicine, Comenius University, Bratislava, Slovakia. FAU - Posova, Helena AU - Posova H AD - Laboratory of Clinical Immunology and Allergology, Institute of Clinical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czechia. FAU - Koprivova, Helena AU - Koprivova H AD - Laboratory of Clinical Immunology and Allergology, Institute of Clinical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czechia. FAU - Mikulova, Veronika AU - Mikulova V AD - Laboratory of Clinical Immunology and Allergology, Institute of Clinical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czechia. FAU - Hrdy, Jiri AU - Hrdy J AD - Institute of Immunology and Microbiology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czechia. FAU - Smela, Gabriela AU - Smela G AD - Laboratory of Clinical Immunology and Allergology, Institute of Clinical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czechia. FAU - Horakova, Dana AU - Horakova D AD - Department of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czechia. FAU - Rysankova, Irena AU - Rysankova I AD - Department of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czechia. FAU - Doleckova, Kristyna AU - Doleckova K AD - Department of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czechia. FAU - Tyblova, Michaela AU - Tyblova M AD - Department of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czechia. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230616 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 RN - A10SJL62JY (ocrelizumab) RN - 0 (COVID-19 Vaccines) RN - 4F4X42SYQ6 (Rituximab) RN - 0 (Spike Glycoprotein, Coronavirus) RN - 0 (BNT162 Vaccine) RN - 0 (Antibodies, Monoclonal, Humanized) RN - 0 (Antibodies, Viral) RN - 0 (spike protein, SARS-CoV-2) SB - IM MH - Humans MH - COVID-19 Vaccines MH - Rituximab/therapeutic use MH - SARS-CoV-2 MH - Spike Glycoprotein, Coronavirus MH - BNT162 Vaccine MH - *COVID-19 MH - *Autoimmune Diseases of the Nervous System MH - Antibodies, Monoclonal, Humanized/therapeutic use MH - Vaccination MH - *Multiple Sclerosis/drug therapy MH - *Myasthenia Gravis MH - Antibodies, Viral PMC - PMC10312310 OTO - NOTNLM OT - IFN gamma release assay OT - SARS-CoV-2 OT - SARS-CoV-2 mRNA vaccine OT - humoral immune response OT - multiple sclerosis OT - myasthenia gravis OT - neuromyelitis optica spectrum disorder COIS- PN has received speaker honoraria and consultant fees from Biogen Idec, Novartis, Merck, Roche, and financial support for research activities from Roche and Merck. DS has received financial support for conference travel and/or speaker honoraria from Novartis, Biogen, Merck, Sanofi, and Janssen-Cilag. DH received speaker honoraria and consultant fees from Biogen Idec, Novartis, Merck Serono, Teva, and Bayer Schering and financial support for research activities from Biogen Idec. MT has received speaker honoraria and consultant fees from Biogen Idec, Sanofi, Teva, Merck, Medion Pharma, UCB, and Astra Zeneca. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2023/07/03 13:06 MHDA- 2023/07/05 06:42 PMCR- 2023/06/16 CRDT- 2023/07/03 11:49 PHST- 2023/01/22 00:00 [received] PHST- 2023/05/22 00:00 [accepted] PHST- 2023/07/05 06:42 [medline] PHST- 2023/07/03 13:06 [pubmed] PHST- 2023/07/03 11:49 [entrez] PHST- 2023/06/16 00:00 [pmc-release] AID - 10.3389/fimmu.2023.1149629 [doi] PST - epublish SO - Front Immunol. 2023 Jun 16;14:1149629. doi: 10.3389/fimmu.2023.1149629. eCollection 2023. PMID- 37390017 OWN - NLM STAT- MEDLINE DCOM- 20230703 LR - 20240611 IS - 1087-0415 (Electronic) IS - 1081-0730 (Linking) VI - 28 IP - sup1 DP - 2023 Apr 7 TI - Knowledge Gaps, Cognition and Media Learning: Designing Tailored Messages to Address COVID-19 Communication Inequalities. PG - 97-106 LID - 10.1080/10810730.2023.2208049 [doi] AB - Various health and crisis studies have demonstrated support for the existence of knowledge gaps-a hypothesis suggesting that information will reach those in the lower socioeconomic status last, worsening health disparities. At the point at which COVID-19 vaccines were becoming widely accessible, the present study surveyed 651 Black Americans to understand vaccine hesitancy, intentions, and media learning variations after exposure to different types of social media posts about the COVID-19 vaccine. Although exposure to any of the message conditions in our study resulted in a decrease in vaccine hesitancy, we found mixed support for the knowledge gap hypothesis. Results show that lack of knowledge because of socioeconomic status is not a key factor driving vaccine hesitancy among Black Americans. Instead, public communication (government) campaigns may consider focusing on strategies to target Black American communities by age to improve media learning, and consider increasing social control and communal message functions to increase cognitive processing of pro-vaccine messages, and over the longer term, influence COVID-19 vaccine hesitancy and uptake. FAU - McFARLANE, Soroya Julian AU - McFARLANE SJ AUID- ORCID: 0000-0002-2826-0926 AD - Department of Communication Studies, University of Georgia, Athens, Georgia, USA. FAU - Yook, Bora AU - Yook B AD - College of Arts & Sciences, Fairfield University, Fairfield, Connecticut, USA. FAU - Wicke, Rebekah AU - Wicke R AUID- ORCID: 0000-0003-4047-4748 AD - College of Agriculture and Life Sciences, Cornell University, Ithaca, New York, USA. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - J Health Commun JT - Journal of health communication JID - 9604100 RN - 0 (COVID-19 Vaccines) MH - Humans MH - Black or African American MH - Cognition MH - *COVID-19/prevention & control MH - *COVID-19 Vaccines/therapeutic use MH - Social Media MH - Vaccination Hesitancy MH - *Health Communication EDAT- 2023/06/30 19:14 MHDA- 2023/07/03 06:42 CRDT- 2023/06/30 12:53 PHST- 2023/07/03 06:42 [medline] PHST- 2023/06/30 19:14 [pubmed] PHST- 2023/06/30 12:53 [entrez] AID - 10.1080/10810730.2023.2208049 [doi] PST - ppublish SO - J Health Commun. 2023 Apr 7;28(sup1):97-106. doi: 10.1080/10810730.2023.2208049. PMID- 37384407 OWN - NLM STAT- MEDLINE DCOM- 20230809 LR - 20260127 IS - 2379-3708 (Electronic) IS - 2379-3708 (Linking) VI - 8 IP - 15 DP - 2023 Aug 8 TI - Longitudinal analysis of memory Tfh cells and antibody response following CoronaVac vaccination. LID - 10.1172/jci.insight.168437 [doi] LID - e168437 AB - The inactivated vaccine CoronaVac is one of the most widely used COVID-19 vaccines globally. However, the longitudinal evolution of the immune response induced by CoronaVac remains elusive compared with other vaccine platforms. Here, we recruited 88 healthy individuals who received 3 doses of CoronaVac vaccine. We longitudinally evaluated their polyclonal and antigen-specific CD4+ T cells and neutralizing antibody response after receiving each dose of vaccine for over 300 days. Both the second and third doses of vaccine induced robust spike-specific neutralizing antibodies, with a third vaccine further increasing the overall magnitude of antibody response and neutralization against Omicron sublineages B.1.1.529, BA.2, BA.4/BA.5, and BA.2.75.2. Spike-specific CD4+ T cells and circulating T follicular helper (cTfh) cells were markedly increased by the second and third dose of CoronaVac vaccine, accompanied by altered composition of functional cTfh cell subsets with distinct effector and memory potential. Additionally, cTfh cells were positively correlated with neutralizing antibody titers. Our results suggest that CoronaVac vaccine-induced spike-specific T cells are capable of supporting humoral immunity for long-term immune protection. FAU - Zhou, Pengcheng AU - Zhou P AD - Department of Laboratory Medicine, Affiliated Hospital of Jiangnan University, Wuxi, China. AD - The University of Queensland Diamantina Institute, Brisbane, Queensland, Australia. FAU - Cao, Cheng AU - Cao C AD - Department of Laboratory Medicine, Affiliated Hospital of Jiangnan University, Wuxi, China. AD - Wuxi School of Medicine, Jiangnan University, Wuxi, China. FAU - Ji, Tuo AU - Ji T AD - Department of Laboratory Medicine, Affiliated Hospital of Jiangnan University, Wuxi, China. AD - Department of Central Laboratory, The Second People's Hospital of Lianyungang City (Cancer Hospital of Lianyungang), Lianyungang, China. FAU - Zheng, Ting AU - Zheng T AD - Hospital for Special Surgery, Weill Cornell Medical College, New York, New York, USA. FAU - Dai, Yaping AU - Dai Y AD - Department of Laboratory Medicine, The Fifth People's Hospital of Wuxi, Wuxi, China. FAU - Liu, Min AU - Liu M AD - School of Biotechnology, Jiangnan University, Wuxi, China. FAU - Jiang, Junfeng AU - Jiang J AD - Department of Laboratory Medicine, Affiliated Hospital of Jiangnan University, Wuxi, China. AD - Wuxi School of Medicine, Jiangnan University, Wuxi, China. FAU - Sun, Daoqi AU - Sun D AD - Department of Laboratory Medicine, Affiliated Hospital of Jiangnan University, Wuxi, China. FAU - Bai, Zhonghu AU - Bai Z AD - School of Biotechnology, Jiangnan University, Wuxi, China. FAU - Lu, Xiaojie AU - Lu X AD - Department of Laboratory Medicine, Affiliated Hospital of Jiangnan University, Wuxi, China. FAU - Gong, Fang AU - Gong F AD - Department of Laboratory Medicine, Affiliated Hospital of Jiangnan University, Wuxi, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230808 PL - United States TA - JCI Insight JT - JCI insight JID - 101676073 RN - 0 (COVID-19 Vaccines) RN - 0 (Antibodies, Neutralizing) RN - 0 (sinovac COVID-19 vaccine) RN - 0 (Vaccines, Inactivated) SB - IM MH - Humans MH - *COVID-19 Vaccines MH - Antibody Formation MH - T Follicular Helper Cells MH - *COVID-19/prevention & control MH - Vaccination MH - Antibodies, Neutralizing MH - Vaccines, Inactivated PMC - PMC10445683 OTO - NOTNLM OT - Adaptive immunity OT - COVID-19 OT - Infectious disease OT - T cells EDAT- 2023/06/29 19:12 MHDA- 2023/08/09 06:43 PMCR- 2023/08/08 CRDT- 2023/06/29 12:08 PHST- 2023/01/03 00:00 [received] PHST- 2023/06/28 00:00 [accepted] PHST- 2023/08/09 06:43 [medline] PHST- 2023/06/29 19:12 [pubmed] PHST- 2023/06/29 12:08 [entrez] PHST- 2023/08/08 00:00 [pmc-release] AID - 168437 [pii] AID - 10.1172/jci.insight.168437 [doi] PST - epublish SO - JCI Insight. 2023 Aug 8;8(15):e168437. doi: 10.1172/jci.insight.168437. PMID- 37376662 OWN - NLM STAT- MEDLINE DCOM- 20230707 LR - 20260127 IS - 1999-4915 (Electronic) IS - 1999-4915 (Linking) VI - 15 IP - 6 DP - 2023 Jun 13 TI - VSV-DeltaG-Spike Candidate Vaccine Induces Protective Immunity and Protects K18-hACE2 Mice against SARS-CoV-2 Variants. LID - 10.3390/v15061364 [doi] LID - 1364 AB - Since the emergence of the original SARS-CoV-2, several variants were described, raising questions as to the ability of recently developed vaccine platforms to induce immunity and provide protection against these variants. Here, we utilized the K18-hACE2 mouse model to show that VSV-DeltaG-spike vaccination provides protection against several SARS-CoV-2 variants: alpha, beta, gamma, and delta. We show an overall robust immune response, regardless of variant identity, leading to reduction in viral load in target organs, prevention of morbidity and mortality, as well as prevention of severe brain immune response, which follows infection with various variants. Additionally, we provide a comprehensive comparison of the brain transcriptomic profile in response to infection with different variants of SARS-CoV-2 and show how vaccination prevents these disease manifestations. Taken together, these results highlight the robust VSV-DeltaG-spike protective response against diverse SARS-CoV-2 variants, as well as its promising potential against newly arising variants. FAU - Yahalom-Ronen, Yfat AU - Yahalom-Ronen Y AD - Department of Infectious Diseases, Israel Institute for Biological Research, Ness Ziona 74100, Israel. FAU - Tamir, Hadas AU - Tamir H AD - Department of Infectious Diseases, Israel Institute for Biological Research, Ness Ziona 74100, Israel. FAU - Melamed, Sharon AU - Melamed S AD - Department of Infectious Diseases, Israel Institute for Biological Research, Ness Ziona 74100, Israel. FAU - Politi, Boaz AU - Politi B AD - Department of Infectious Diseases, Israel Institute for Biological Research, Ness Ziona 74100, Israel. FAU - Achdout, Hagit AU - Achdout H AUID- ORCID: 0000-0003-0664-8628 AD - Department of Infectious Diseases, Israel Institute for Biological Research, Ness Ziona 74100, Israel. FAU - Erez, Noam AU - Erez N AUID- ORCID: 0000-0001-5241-8028 AD - Department of Infectious Diseases, Israel Institute for Biological Research, Ness Ziona 74100, Israel. FAU - Israeli, Ofir AU - Israeli O AUID- ORCID: 0000-0002-4590-6151 AD - Department of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, Ness Ziona 74100, Israel. FAU - Cohen-Gihon, Inbar AU - Cohen-Gihon I AD - Department of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, Ness Ziona 74100, Israel. FAU - Chery Mimran, Lilach AU - Chery Mimran L AD - Department of Infectious Diseases, Israel Institute for Biological Research, Ness Ziona 74100, Israel. FAU - Barlev-Gross, Moria AU - Barlev-Gross M AD - Department of Infectious Diseases, Israel Institute for Biological Research, Ness Ziona 74100, Israel. FAU - Mandelboim, Michal AU - Mandelboim M AD - Central Virology Laboratory, Ministry of Health, Sheba Medical Center, Tel Hashomer, Ramat Gan 76100, Israel. FAU - Orr, Irit AU - Orr I AD - Bioinformatics Unit, Life Science Core Facilities, Weizmann Institute of Science, Rehovot 52621, Israel. FAU - Feldmesser, Ester AU - Feldmesser E AUID- ORCID: 0000-0002-7017-4861 AD - Bioinformatics Unit, Life Science Core Facilities, Weizmann Institute of Science, Rehovot 52621, Israel. FAU - Weiss, Shay AU - Weiss S AD - Department of Infectious Diseases, Israel Institute for Biological Research, Ness Ziona 74100, Israel. FAU - Beth-Din, Adi AU - Beth-Din A AUID- ORCID: 0000-0002-9602-2532 AD - Department of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, Ness Ziona 74100, Israel. FAU - Paran, Nir AU - Paran N AUID- ORCID: 0000-0001-5143-9660 AD - Department of Infectious Diseases, Israel Institute for Biological Research, Ness Ziona 74100, Israel. FAU - Israely, Tomer AU - Israely T AUID- ORCID: 0000-0003-0246-4477 AD - Department of Infectious Diseases, Israel Institute for Biological Research, Ness Ziona 74100, Israel. LA - eng PT - Journal Article DEP - 20230613 PL - Switzerland TA - Viruses JT - Viruses JID - 101509722 RN - 0 (Spike Glycoprotein, Coronavirus) RN - 0 (COVID-19 Vaccines) RN - 0 (K-18 conjugate) RN - 0 (gamma-Globulins) RN - Q41OR9510P (Melphalan) RN - 0 (spike protein, SARS-CoV-2) RN - SARS-CoV-2 variants SB - IM MH - Animals MH - Humans MH - Mice MH - *COVID-19/prevention & control MH - SARS-CoV-2/genetics MH - Spike Glycoprotein, Coronavirus MH - *COVID-19 Vaccines MH - gamma-Globulins MH - Melphalan PMC - PMC10303402 OTO - NOTNLM OT - K18-hACE2 OT - SARS-CoV-2 OT - VSV-DeltaG-Spike OT - brain OT - vaccine OT - variants COIS- The authors declare no conflict of interest. EDAT- 2023/06/28 06:42 MHDA- 2023/06/29 06:42 PMCR- 2023/06/13 CRDT- 2023/06/28 01:40 PHST- 2023/05/18 00:00 [received] PHST- 2023/06/07 00:00 [revised] PHST- 2023/06/08 00:00 [accepted] PHST- 2023/06/29 06:42 [medline] PHST- 2023/06/28 06:42 [pubmed] PHST- 2023/06/28 01:40 [entrez] PHST- 2023/06/13 00:00 [pmc-release] AID - v15061364 [pii] AID - viruses-15-01364 [pii] AID - 10.3390/v15061364 [doi] PST - epublish SO - Viruses. 2023 Jun 13;15(6):1364. doi: 10.3390/v15061364. PMID- 37376503 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20241007 IS - 2076-393X (Print) IS - 2076-393X (Electronic) IS - 2076-393X (Linking) VI - 11 IP - 6 DP - 2023 Jun 19 TI - Neurological Disorders following COVID-19 Vaccination. LID - 10.3390/vaccines11061114 [doi] LID - 1114 AB - Nowadays, people all over the world have been receiving different types of coronavirus disease 2019 (COVID-19) vaccines. While their effectiveness has been well recognized, various post-vaccination disorders are not fully understood. In this review, we discuss neurological disorders related to vascular, immune, infectious, and functional factors following COVID-19 vaccination, and attempt to provide neuroscientists, psychiatrists, and vaccination staff with a reference for the diagnosis and treatment of these diseases. These disorders may present as a recurrence of previous neurological disorders or new-onset diseases. Their incidence rate, host and vaccine characteristics, clinical manifestations, treatment, and prognosis differ significantly. The pathogenesis of many of them remains unclear, and further studies are needed to provide more evidence. The incidence rate of severe neurological disorders is relatively low, most of which are reversible or treatable. Therefore, the benefits of vaccination outweigh the risk of COVID-19 infection, especially among fragile populations. FAU - Yang, Ying AU - Yang Y AUID- ORCID: 0000-0003-2294-7249 AD - Department of Infectious Diseases, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou 310052, China. FAU - Huang, Lisu AU - Huang L AUID- ORCID: 0000-0001-8193-7353 AD - Department of Infectious Diseases, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou 310052, China. LA - eng PT - Journal Article PT - Review DEP - 20230619 PL - Switzerland TA - Vaccines (Basel) JT - Vaccines JID - 101629355 PMC - PMC10302665 OTO - NOTNLM OT - COVID-19 vaccine OT - functional factors OT - immune factors OT - infectious factors OT - neurological disorder OT - vascular factors COIS- The authors declare no conflict of interest. EDAT- 2023/06/28 06:42 MHDA- 2023/06/28 06:43 PMCR- 2023/06/19 CRDT- 2023/06/28 01:39 PHST- 2023/04/30 00:00 [received] PHST- 2023/06/08 00:00 [revised] PHST- 2023/06/14 00:00 [accepted] PHST- 2023/06/28 06:43 [medline] PHST- 2023/06/28 06:42 [pubmed] PHST- 2023/06/28 01:39 [entrez] PHST- 2023/06/19 00:00 [pmc-release] AID - vaccines11061114 [pii] AID - vaccines-11-01114 [pii] AID - 10.3390/vaccines11061114 [doi] PST - epublish SO - Vaccines (Basel). 2023 Jun 19;11(6):1114. doi: 10.3390/vaccines11061114. PMID- 37333561 OWN - NLM STAT- MEDLINE DCOM- 20230620 LR - 20230620 IS - 2296-2565 (Electronic) IS - 2296-2565 (Linking) VI - 11 DP - 2023 TI - COVID-19 vaccination coverage and its cognitive determinants among older adults in Shanghai, China, during the COVID-19 epidemic. PG - 1163616 LID - 10.3389/fpubh.2023.1163616 [doi] LID - 1163616 AB - OBJECTIVES: This study aimed to examine the coverage of coronavirus disease 2019 (COVID-19) vaccination and its cognitive determinants among older adults. METHODS: A cross-sectional study was conducted using a questionnaire to conduct a survey among 725 Chinese older adults aged 60 years and above in June 2022, 2 months after the mass COVID-19 outbreak in Shanghai, China. The questionnaire covered demographic characteristics, COVID-19 vaccination status, internal risk perception, knowledge, and attitude toward the efficacy and safety of COVID-19 vaccines. RESULTS: The vaccination rate was 78.3% among the surveyed individuals. Self-reported reasons for unwillingness to get vaccinated (multiple selections) were "concerns about acute exacerbation of chronic diseases after vaccination (57.3%)" and "concerns regarding vaccine side effects (41.4%)." Compared to the unvaccinated group, the vaccinated group tended to have a higher score in internal risk perception (t = 2.64, P < 0.05), better knowledge of COVID-19 vaccines (t = 5.84, P < 0.05), and a more positive attitude toward the efficacy and safety of COVID-19 vaccines (t = 7.92, P < 0.05). The path analysis showed that the cognitive effect on vaccination behavior is relatively large, followed by the internal risk perception, and then the attitude toward COVID-19 vaccines. The more knowledgeable the participants were about COVID-19 vaccines, the more likely they were to receive the COVID-19 vaccines. In the multivariate logistic regression, the increased coverage of COVID-19 vaccination was associated with reduced age (OR = 0.53 95% CI 0.43-0.66, P < 0.001), being a resident in other places than Shanghai (OR = 0.40, 95% CI 0.17-0.92, P < 0.05), a shorter time of lockdown (OR = 0.33, 95% CI 0.13-0.83, P < 0.05), a history of other vaccines (OR = 2.58, 95% CI 1.45-4.60, P < 0.01), a fewer number of chronic diseases (OR = 0.49, 95% CI 0.38-0.62, P < 0.001), better knowledge about COVID-19 vaccines (OR = 1.60, 95% CI 1.17-2.19, P < 0.01), and a positive attitude toward COVID-19 vaccines (OR = 9.22, 95% CI 4.69-18.09, P < 0.001). CONCLUSION: Acquiring accurate knowledge and developing a positive attitude toward COVID-19 vaccines are important factors associated with COVID-19 vaccination. Disseminating informed information on COVID-19 vaccines and ensuring efficacious communication regarding their efficacy and safety would enhance awareness about COVID-19 vaccination among older adults and consequently boost their vaccination coverage. CI - Copyright (c) 2023 Wei, Zeng, Huang, Ye, Chen, Yang and Cai. FAU - Wei, Lu AU - Wei L AD - Department of Geriatrics, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. FAU - Zeng, Wu AU - Zeng W AD - Department of Global Health, School of Health, Georgetown University, Washington, DC, United States. FAU - Huang, Yangyang AU - Huang Y AD - Department of Geriatrics, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. FAU - Ye, Guoxin AU - Ye G AD - Department of Geriatrics, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. FAU - Chen, Ying AU - Chen Y AD - Department of Geriatrics, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. FAU - Yang, Ling AU - Yang L AD - Department of Geriatrics, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. AD - Department of Geriatrics, Shanghai Fourth People's Hospital Affiliated to Tongji University, Shanghai, China. FAU - Cai, Yuyang AU - Cai Y AD - School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230602 PL - Switzerland TA - Front Public Health JT - Frontiers in public health JID - 101616579 RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - Aged MH - *COVID-19/epidemiology/prevention & control MH - COVID-19 Vaccines MH - Vaccination Coverage MH - Cross-Sectional Studies MH - China/epidemiology MH - Communicable Disease Control MH - Cognition PMC - PMC10272832 OTO - NOTNLM OT - COVID-19 OT - attitude OT - cognition OT - older adults OT - vaccine OT - vaccine hesitancy COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2023/06/19 06:42 MHDA- 2023/06/20 06:42 PMCR- 2023/06/02 CRDT- 2023/06/19 02:51 PHST- 2023/02/11 00:00 [received] PHST- 2023/05/09 00:00 [accepted] PHST- 2023/06/20 06:42 [medline] PHST- 2023/06/19 06:42 [pubmed] PHST- 2023/06/19 02:51 [entrez] PHST- 2023/06/02 00:00 [pmc-release] AID - 10.3389/fpubh.2023.1163616 [doi] PST - epublish SO - Front Public Health. 2023 Jun 2;11:1163616. doi: 10.3389/fpubh.2023.1163616. eCollection 2023. PMID- 37322095 OWN - NLM STAT- MEDLINE DCOM- 20230914 LR - 20230922 IS - 1573-2592 (Electronic) IS - 0271-9142 (Print) IS - 0271-9142 (Linking) VI - 43 IP - 7 DP - 2023 Oct TI - COVID-19 Adenoviral Vector Vaccination Elicits a Robust Memory B Cell Response with the Capacity to Recognize Omicron BA.2 and BA.5 Variants. PG - 1506-1518 LID - 10.1007/s10875-023-01527-2 [doi] AB - Following the COVID-19 pandemic, novel vaccines have successfully reduced severe disease and death. Despite eliciting lower antibody responses, adenoviral vector vaccines are nearly as effective as mRNA vaccines. Therefore, protection against severe disease may be mediated by immune memory cells. We here evaluated plasma antibody and memory B cells (Bmem) targeting the SARS-CoV-2 Spike receptor-binding domain (RBD) elicited by the adenoviral vector vaccine ChAdOx1 (AstraZeneca), their capacity to bind Omicron subvariants, and compared this to the response to mRNA BNT162b2 (Pfizer-BioNTech) vaccination. Whole blood was sampled from 31 healthy adults pre-vaccination and 4 weeks after dose one and dose two of ChAdOx1. Neutralizing antibodies (NAb) against SARS-CoV-2 were quantified at each time point. Recombinant RBDs of the Wuhan-Hu-1 (WH1), Delta, BA.2, and BA.5 variants were produced for ELISA-based quantification of plasma IgG and incorporated separately into fluorescent tetramers for flow cytometric identification of RBD-specific Bmem. NAb and RBD-specific IgG levels were over eight times lower following ChAdOx1 vaccination than BNT162b2. In ChAdOx1-vaccinated individuals, median plasma IgG recognition of BA.2 and BA.5 as a proportion of WH1-specific IgG was 26% and 17%, respectively. All donors generated resting RBD-specific Bmem, which were boosted after the second dose of ChAdOx1 and were similar in number to those produced by BNT162b2. The second dose of ChAdOx1 boosted Bmem that recognized VoC, and 37% and 39% of WH1-specific Bmem recognized BA.2 and BA.5, respectively. These data uncover mechanisms by which ChAdOx1 elicits immune memory to confer effective protection against severe COVID-19. CI - (c) 2023. The Author(s). FAU - Fryer, Holly A AU - Fryer HA AUID- ORCID: 0000-0003-0779-490X AD - Allergy and Clinical Immunology Laboratory, Department of Immunology, Central Clinical School, Monash University, Melbourne, VIC, Australia. FAU - Hartley, Gemma E AU - Hartley GE AUID- ORCID: 0000-0002-3174-231X AD - Allergy and Clinical Immunology Laboratory, Department of Immunology, Central Clinical School, Monash University, Melbourne, VIC, Australia. FAU - Edwards, Emily S J AU - Edwards ESJ AUID- ORCID: 0000-0002-0240-4370 AD - Allergy and Clinical Immunology Laboratory, Department of Immunology, Central Clinical School, Monash University, Melbourne, VIC, Australia. FAU - Varese, Nirupama AU - Varese N AUID- ORCID: 0000-0001-9074-3710 AD - Allergy and Clinical Immunology Laboratory, Department of Immunology, Central Clinical School, Monash University, Melbourne, VIC, Australia. AD - Immune Therapies Group, Burnet Institute, Melbourne, VIC, Australia. FAU - Boo, Irene AU - Boo I AUID- ORCID: 0000-0003-0923-0972 AD - Viral Entry and Vaccines Group, Burnet Institute, Melbourne, VIC, Australia. FAU - Bornheimer, Scott J AU - Bornheimer SJ AD - BD Biosciences, San Jose, CA, USA. FAU - Hogarth, P Mark AU - Hogarth PM AUID- ORCID: 0000-0002-0360-7890 AD - Allergy and Clinical Immunology Laboratory, Department of Immunology, Central Clinical School, Monash University, Melbourne, VIC, Australia. AD - Immune Therapies Group, Burnet Institute, Melbourne, VIC, Australia. AD - Department of Pathology, The University of Melbourne, Parkville, VIC, Australia. FAU - Drummer, Heidi E AU - Drummer HE AUID- ORCID: 0000-0002-0042-6277 AD - Viral Entry and Vaccines Group, Burnet Institute, Melbourne, VIC, Australia. AD - Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC, Australia. AD - Department of Microbiology, Monash University, Clayton, VIC, Australia. FAU - O'Hehir, Robyn E AU - O'Hehir RE AUID- ORCID: 0000-0002-3489-7595 AD - Allergy and Clinical Immunology Laboratory, Department of Immunology, Central Clinical School, Monash University, Melbourne, VIC, Australia. AD - Allergy, Asthma and Clinical Immunology Service, Alfred Hospital, Melbourne, VIC, Australia. FAU - van Zelm, Menno C AU - van Zelm MC AUID- ORCID: 0000-0003-4161-1919 AD - Allergy and Clinical Immunology Laboratory, Department of Immunology, Central Clinical School, Monash University, Melbourne, VIC, Australia. menno.vanzelm@monash.edu. AD - Allergy, Asthma and Clinical Immunology Service, Alfred Hospital, Melbourne, VIC, Australia. menno.vanzelm@monash.edu. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230616 PL - Netherlands TA - J Clin Immunol JT - Journal of clinical immunology JID - 8102137 RN - 0 (BNT162 Vaccine) RN - 0 (Antibodies, Neutralizing) RN - 0 (Immunoglobulin G) RN - 0 (Antibodies, Viral) SB - IM MH - Adult MH - Humans MH - *BNT162 Vaccine MH - Memory B Cells MH - Pandemics MH - *COVID-19/prevention & control MH - SARS-CoV-2 MH - Vaccination MH - Adenoviridae MH - Antibodies, Neutralizing MH - Immunoglobulin G MH - Antibodies, Viral PMC - PMC10499924 OTO - NOTNLM OT - COVID-19 vaccine OT - adenoviral vector vaccine OT - memory B cells OT - neutralizing antibodies OT - variant of concern COIS- MCvZ, REO'H, and PMH are inventors on a patent application related to this work. SJB is an employee of and owns stock in BD Biosciences. All the other authors declare no conflict of interest. EDAT- 2023/06/16 01:08 MHDA- 2023/09/14 06:42 PMCR- 2023/06/16 CRDT- 2023/06/15 23:22 PHST- 2023/03/30 00:00 [received] PHST- 2023/05/27 00:00 [accepted] PHST- 2023/09/14 06:42 [medline] PHST- 2023/06/16 01:08 [pubmed] PHST- 2023/06/15 23:22 [entrez] PHST- 2023/06/16 00:00 [pmc-release] AID - 10.1007/s10875-023-01527-2 [pii] AID - 1527 [pii] AID - 10.1007/s10875-023-01527-2 [doi] PST - ppublish SO - J Clin Immunol. 2023 Oct;43(7):1506-1518. doi: 10.1007/s10875-023-01527-2. Epub 2023 Jun 16. PMID- 37315198 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230729 IS - 2561-326X (Electronic) IS - 2561-326X (Linking) VI - 7 DP - 2023 Jul 26 TI - Assessing How Risk Communication Surveillance Prompts COVID-19 Vaccine Acceptance Among Internet Users by Applying the Situational Theory of Problem Solving: Cross-Sectional Study. PG - e43628 LID - 10.2196/43628 [doi] LID - e43628 AB - BACKGROUND: The World Health Organization has recently raised concerns regarding the low number of people fully vaccinated against COVID-19. The low ratio of fully vaccinated people and the emergence of renewed infectious variants correspond to worsening public health. Global health managers have highlighted COVID-19 vaccine-related infodemics as a significant risk perception factor hindering mass vaccination campaigns. OBJECTIVE: Given the ambiguous digital communication environment that has fostered infodemics, resource-limited nations struggle to boost public willingness to encourage people to fully vaccinate. Authorities have launched some risk communication-laden digital interventions in response to infodemics. However, the value of the risk communication strategies used to tackle infodemics needs to be evaluated. The current research using the tenets of the Situational Theory of Problem Solving is novel, as it explores the impending effects of risk communication strategies. The relationship between infodemic-induced risk perception of COVID-19 vaccine safety and risk communication actions to intensify willingness to be fully vaccinated was examined. METHODS: This study used a cross-sectional research design vis-a-vis a nationally representative web-based survey. We collected data from 1946 internet users across Pakistan. Participants voluntarily participated in this research after completing the consent form and reading ethical permissions. Responses were received over 3 months, from May 2022 to July 2022. RESULTS: The results delineated that infodemics positively affected risk perception. This realization pushed the public to engage in risky communicative actions through reliance on and searches for accurate information. Therefore, the prospect of managing infodemics through risk information exposure (eg, digital interventions) using the situational context could predict robust willingness to be fully vaccinated against COVID-19. CONCLUSIONS: These pioneering results offer strategic considerations for health authorities to effectively manage the descending spiral of optimal protection against COVID-19. This research concludes that the likelihood of managing infodemics using situational context through exposure to relevant information could improve one's knowledge of forfending and selection, which can lead to robust protection against COVID-19. Hence, more situation-specific information about the underlying problem (ie, the selection of an appropriate vaccine) can be made accessible through several official digital sources to achieve a more active public health response. CI - (c)Qiang Jin, Syed Hassan Raza, Muhammad Yousaf, Umer Zaman, Emenyeonu C Ogadimma, Amjad Ali Shah, Rachel Core, Aqdas Malik. Originally published in JMIR Formative Research (https://formative.jmir.org), 26.07.2023. FAU - Jin, Qiang AU - Jin Q AUID- ORCID: 0000-0001-9308-3375 AD - Intercultural Communication Research Center, Hebei University, Baoding, China. FAU - Raza, Syed Hassan AU - Raza SH AUID- ORCID: 0000-0002-1318-7818 AD - Institute of Media and Communication Studies, Bahauddin Zakariya University, Multan, Pakistan. FAU - Yousaf, Muhammad AU - Yousaf M AUID- ORCID: 0000-0003-3203-2966 AD - Centre for Media and Communication Studies, University of Gujrat, Gujrat, Pakistan. FAU - Zaman, Umer AU - Zaman U AUID- ORCID: 0000-0002-3729-3543 AD - Endicott College of International Studies, Woosong University, Daejeon, Republic of Korea. FAU - Ogadimma, Emenyeonu C AU - Ogadimma EC AUID- ORCID: 0000-0002-8918-7419 AD - College of Communication, University of Sharjah, Sharjah, United Arab Emirates. FAU - Shah, Amjad Ali AU - Shah AA AUID- ORCID: 0000-0001-6449-1476 AD - Institute of Media and Communication Studies, Bahauddin Zakariya University, Multan, Pakistan. FAU - Core, Rachel AU - Core R AUID- ORCID: 0000-0002-0550-887X AD - Sociology & Anthropology Department, Stetson University, DeLand, FL, United States. FAU - Malik, Aqdas AU - Malik A AUID- ORCID: 0000-0002-3517-8760 AD - Department of Information Systems, Sultan Qaboos University, Muscat, Oman. LA - eng PT - Journal Article DEP - 20230726 PL - Canada TA - JMIR Form Res JT - JMIR formative research JID - 101726394 PMC - PMC10373922 OTO - NOTNLM OT - COVID-19 OT - Situational Theory of Problem Solving OT - digital interventions OT - health communication OT - risk communication OT - vaccine safety COIS- Conflicts of Interest: None declared. EDAT- 2023/06/14 19:10 MHDA- 2023/06/14 19:11 PMCR- 2023/07/26 CRDT- 2023/06/14 14:54 PHST- 2022/10/18 00:00 [received] PHST- 2023/05/29 00:00 [accepted] PHST- 2023/02/17 00:00 [revised] PHST- 2023/06/14 19:11 [medline] PHST- 2023/06/14 19:10 [pubmed] PHST- 2023/06/14 14:54 [entrez] PHST- 2023/07/26 00:00 [pmc-release] AID - v7i1e43628 [pii] AID - 10.2196/43628 [doi] PST - epublish SO - JMIR Form Res. 2023 Jul 26;7:e43628. doi: 10.2196/43628. PMID- 37261310 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230604 IS - 2055-1029 (Print) IS - 2055-1029 (Electronic) IS - 2055-1029 (Linking) VI - 10 IP - 1 DP - 2023 Jan-Jun TI - Do cognition and emotion matter? A study of COVID-19 vaccination decision-making in college students. PG - 20551029231179163 LID - 10.1177/20551029231179163 [doi] LID - 20551029231179163 AB - The unparalleled speed of COVID-19 vaccine development has necessitated an expansion of existing knowledge on vaccination decision-making. The current study explored (1) how cognitions and emotions shaped college students' COVID-19 vaccination decisions, and (2) where vaccination-inclined and vaccination-hesitant students converged and diverged in their decision-making process. Seventy-seven students participated in 26 focus groups to discuss their complex thoughts and feelings regarding COVID-19 vaccination, offering a more nuanced understanding of COVID-19 vaccination decision-making that has not been fully captured by quantitative studies. Thematic analysis found that vaccination-inclined participants and their hesitant counterparts reported differential patterns of positive and negative emotions, systematic appraisals, and heuristics in decision-making. Future research should investigate the roles of hope and relief, non-health-related benefits of vaccination, social trust, and interpersonal influence in vaccination decision-making. CI - (c) The Author(s) 2023. FAU - Chen, Nien-Tsu Nancy AU - Chen NN AUID- ORCID: 0000-0001-8814-2115 AD - Department of Communication, , Camarillo, CA, USACalifornia State University Channel Islands. RINGGOLD: 14703 FAU - Kee, Kimmy AU - Kee K AD - Department of Psychology, , Camarillo, CA, USACalifornia State University Channel Islands. RINGGOLD: 14703 FAU - Villalobos, Bianca T AU - Villalobos BT AD - Department of Psychological Science, , Edinburg, TX, USAUniversity of Texas Rio Grande Valley. FAU - Ortiz, Miriam AU - Ortiz M AD - Department of Psychological Science, , Edinburg, TX, USAUniversity of Texas Rio Grande Valley. FAU - Lee, HyeSun AU - Lee H AD - Department of Psychology, , Camarillo, CA, USACalifornia State University Channel Islands. RINGGOLD: 14703 LA - eng PT - Journal Article DEP - 20230530 PL - England TA - Health Psychol Open JT - Health psychology open JID - 101642883 PMC - PMC10227488 OTO - NOTNLM OT - affect OT - beliefs OT - cognitive processing OT - emotions OT - health behaviour OT - health promotion OT - public health psychology OT - qualitative methods OT - theory of planned behaviour COIS- The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2023/06/01 13:09 MHDA- 2023/06/01 13:10 PMCR- 2023/05/30 CRDT- 2023/06/01 10:39 PHST- 2023/06/01 13:10 [medline] PHST- 2023/06/01 13:09 [pubmed] PHST- 2023/06/01 10:39 [entrez] PHST- 2023/05/30 00:00 [pmc-release] AID - 10.1177_20551029231179163 [pii] AID - 10.1177/20551029231179163 [doi] PST - epublish SO - Health Psychol Open. 2023 May 30;10(1):20551029231179163. doi: 10.1177/20551029231179163. eCollection 2023 Jan-Jun. PMID- 37231308 OWN - NLM STAT- MEDLINE DCOM- 20230619 LR - 20230619 IS - 1432-1041 (Electronic) IS - 0031-6970 (Print) IS - 0031-6970 (Linking) VI - 79 IP - 7 DP - 2023 Jul TI - Seronegative acute encephalitis following COVID-19 vaccines: a case series of an overlooked diagnosis with literature review. PG - 975-987 LID - 10.1007/s00228-023-03510-7 [doi] AB - PURPOSE: Autoimmune encephalitis is a neurological emergency of new-onset altered mental status, caused by an exaggerated immune-mediated response that targets the central nervous system. Autoimmune encephalitis has become an emerging differential diagnosis, when a classical infection cannot explain neurological symptoms. Displaying overlapping clinical presentations, ranging from the insidious onset of cognitive deficiency to more severe forms of encephalopathy with refractory seizures, autoimmune encephalitis can be challenging for clinicians. When evidence of malignancy is absent and pathogenic autoantibodies are undetected, with typical clinical and imaging features of autoimmune encephalitis, seronegative autoimmune encephalitis may be considered. Recently, vaccination-related autoimmune encephalitis and acute encephalitis after COVID-19 vaccination have attracted attention. METHODS AND RESULTS: We report a case series consisting of three patients with autoimmune encephalitis occurring shortly after COVID-19 vaccination and a current review of all previous reported autoimmune encephalitis related to COVID-19 vaccines. CONCLUSION: We emphasise on the prompt diagnosis of autoimmune encephalitis induced by Covid-19 vaccines and its timely treatment to improve the clinical outcome of this severe neurological condition. Post-licencing vaccine safety surveillance for potential adverse events is essential for vaccine safety and public confidence. CI - (c) 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Mansour, Khadija AU - Mansour K AD - Department of Pharmacology, Fattouma Bourguiba University Hospital of Monastir, Monastir, Tunisia. khadija.mansour2@gmail.com. FAU - Chadli, Zohra AU - Chadli Z AD - Department of Pharmacology, Fattouma Bourguiba University Hospital of Monastir, Monastir, Tunisia. FAU - Ghachem, Ichrak AU - Ghachem I AD - Department of Neurology, Taher Sfar University Hospital, Mahdia, Tunisia. FAU - Fredj, Nadia Ben AU - Fredj NB AD - Department of Pharmacology, Fattouma Bourguiba University Hospital of Monastir, Monastir, Tunisia. FAU - Romdhane, Haifa Ben AU - Romdhane HB AD - Department of Pharmacology, Fattouma Bourguiba University Hospital of Monastir, Monastir, Tunisia. FAU - Fadhel, Najah Ben AU - Fadhel NB AD - Department of Pharmacology, Fattouma Bourguiba University Hospital of Monastir, Monastir, Tunisia. FAU - Boughatas, Naceurs AU - Boughatas N AD - Department of Pharmacology, Fattouma Bourguiba University Hospital of Monastir, Monastir, Tunisia. FAU - Aouam, Karim AU - Aouam K AD - Department of Pharmacology, Fattouma Bourguiba University Hospital of Monastir, Monastir, Tunisia. FAU - Chaabane, Amel AU - Chaabane A AD - Department of Pharmacology, Fattouma Bourguiba University Hospital of Monastir, Monastir, Tunisia. FAU - Younes, Samia AU - Younes S AD - Department of Neurology, Taher Sfar University Hospital, Mahdia, Tunisia. LA - eng PT - Journal Article PT - Review DEP - 20230526 PL - Germany TA - Eur J Clin Pharmacol JT - European journal of clinical pharmacology JID - 1256165 RN - 0 (COVID-19 Vaccines) RN - Hashimoto's encephalitis SB - IM MH - *COVID-19/prevention & control MH - COVID-19 Vaccines/adverse effects MH - *Autoimmune Diseases of the Nervous System MH - Hashimoto Disease MH - Humans MH - COVID-19 Testing MH - *Encephalitis/diagnosis/etiology PMC - PMC10212735 OTO - NOTNLM OT - Adverse drug reaction OT - Autoimmune encephalitis OT - COVID-19 vaccines OT - Neuroinflammation OT - Neurological complications COIS- The authors declare no competing interests. EDAT- 2023/05/26 01:05 MHDA- 2023/06/19 13:08 PMCR- 2023/05/26 CRDT- 2023/05/25 23:34 PHST- 2023/02/19 00:00 [received] PHST- 2023/05/16 00:00 [accepted] PHST- 2023/06/19 13:08 [medline] PHST- 2023/05/26 01:05 [pubmed] PHST- 2023/05/25 23:34 [entrez] PHST- 2023/05/26 00:00 [pmc-release] AID - 10.1007/s00228-023-03510-7 [pii] AID - 3510 [pii] AID - 10.1007/s00228-023-03510-7 [doi] PST - ppublish SO - Eur J Clin Pharmacol. 2023 Jul;79(7):975-987. doi: 10.1007/s00228-023-03510-7. Epub 2023 May 26. PMID- 37230943 OWN - NLM STAT- MEDLINE DCOM- 20230615 LR - 20230627 IS - 2049-632X (Electronic) IS - 2049-632X (Linking) VI - 81 DP - 2023 Jan 17 TI - Assessment of long-term adverse events regarding different COVID-19 vaccine regimens within an 18-month follow-up study. LID - ftad010 [pii] LID - 10.1093/femspd/ftad010 [doi] AB - Early reports on coronavirus disease 2019 (COVID-19) vaccines presented the short-term adverse events (AEs). This follow-up study investigated a standard regimen based on protein subunit vaccines, PastoCovac and PastoCovac Plus, and the combinational vaccine regimens including AstraZeneca/PastoCovac Plus and Sinopharm/PastoCovac Plus. The participants were followed up to 6 months post the booster shot. All the AEs were collected through in-depth interviews using a valid researcher-made questionnaire and were evaluated regarding the association with the vaccines. Of the 509 individuals, 6.2% of the combinational vaccine participants had late AEs, of whom 3.3% suffered from cutaneous manifestations, followed by 1.1% arthralgia complaints, 1.1% with neurologic disorders, 0.3% ocular problems and 0.3% metabolic complications, with no significant difference between the vaccine regimens. For the standard regimen, 2% of the individuals experienced late AEs as (1%), neurological disorders (0.3%), metabolic problems (0.3%) and involvement of joints (0.3%). Notably, 75% of the AEs were persistent up to the end of the study. A low number of late AEs were captured in 18 months as 12 improbable, 5 unclassifiable, 4 possible and 3 probable associated AEs with the vaccine regimens. The benefits of COVID-19 vaccination far exceed the potential risks and late AEs seem to be uncommon. CI - (c) The Author(s) 2023. Published by Oxford University Press on behalf of FEMS. FAU - Sadat Larijani, Mona AU - Sadat Larijani M AD - Clinical Research Department, Pasteur Institute of Iran, Tehran 1316943551, Iran. FAU - Sorouri, Rahim AU - Sorouri R AD - IPI Directorate, Pasteur Institute of Iran, Tehran 1316943551, Iran. FAU - Eybpoosh, Sana AU - Eybpoosh S AD - Quality Control Department, Production and research Complex, Pasteur Institute of Iran, Tehran-Karaj 3159915111, Iran. FAU - Doroud, Delaram AU - Doroud D AD - Department of Epidemiology and Biostatics, Research Centre for Emerging and Reemerging Infectious Diseases, Pasteur Institute of Iran, Tehran 1316943551, Iran. FAU - Moradi, Ladan AU - Moradi L AD - Clinical Research Department, Pasteur Institute of Iran, Tehran 1316943551, Iran. FAU - Ahmadinezhad, Mozhgan AU - Ahmadinezhad M AD - Quality Control Department, Production and research Complex, Pasteur Institute of Iran, Tehran-Karaj 3159915111, Iran. FAU - Bavand, Anahita AU - Bavand A AD - Clinical Research Department, Pasteur Institute of Iran, Tehran 1316943551, Iran. FAU - Ashrafian, Fatemeh AU - Ashrafian F AD - Clinical Research Department, Pasteur Institute of Iran, Tehran 1316943551, Iran. FAU - Tajmehrabi Namini, Parinaz AU - Tajmehrabi Namini P AD - Clinical Research Department, Pasteur Institute of Iran, Tehran 1316943551, Iran. FAU - Zali, Mahsan AU - Zali M AD - Clinical Research Department, Pasteur Institute of Iran, Tehran 1316943551, Iran. FAU - Ramezani, Amitis AU - Ramezani A AUID- ORCID: 0000-0003-3502-8524 AD - Clinical Research Department, Pasteur Institute of Iran, Tehran 1316943551, Iran. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Pathog Dis JT - Pathogens and disease JID - 101595366 RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - *COVID-19 Vaccines/adverse effects MH - Follow-Up Studies MH - *COVID-19/prevention & control MH - Vaccination/adverse effects OTO - NOTNLM OT - COVID-19 OT - late adverse events OT - long-term AEs OT - safety OT - vaccine EDAT- 2023/05/26 01:05 MHDA- 2023/06/15 06:42 CRDT- 2023/05/25 22:52 PHST- 2023/04/19 00:00 [received] PHST- 2023/05/10 00:00 [revised] PHST- 2023/05/23 00:00 [accepted] PHST- 2023/06/15 06:42 [medline] PHST- 2023/05/26 01:05 [pubmed] PHST- 2023/05/25 22:52 [entrez] AID - 7179983 [pii] AID - 10.1093/femspd/ftad010 [doi] PST - ppublish SO - Pathog Dis. 2023 Jan 17;81:ftad010. doi: 10.1093/femspd/ftad010. PMID- 37215146 OWN - NLM STAT- MEDLINE DCOM- 20230524 LR - 20230524 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 14 DP - 2023 TI - Detection of specific RBD(+) IgG(+) memory B cells by flow cytometry in healthcare workers and patients with inborn errors of immunity after BNT162b2 m RNA COVID-19 vaccination. PG - 1136308 LID - 10.3389/fimmu.2023.1136308 [doi] LID - 1136308 AB - INTRODUCTION: Inborn errors of immunity (IEI) are a heterogeneous group of diseases caused by intrinsic defects of the immune system. Estimating the immune competence of immunocompromised patients for an infection risk assessment or after SARS-CoV-2 vaccination constituted a challenge. METHODS: The aim of this study was to determine the humoral responses of patients with IEI through a comprehensive analysis of specific receptor-binding domain-positive (RBD+) IgG+ memory B cells (MBCs) by flow cytometry, together with routine S-specific IgG antibodies and QuantiFERON SARS-CoV-2 (T-cell response), before the vaccine and 3 weeks after a second dose. RESULTS AND DISCUSSION: We first analyzed the percentage of specific RBD+ IgG+ MBCs in healthy healthcare workers. Within the control group, there was an increase in the percentage of specific IgG+ RBD+ MBCs 21 days after the second dose, which was consistent with S-specific IgG antibodies.Thirty-one patients with IEI were included for the pre- and post-vaccination study; IgG+ RBD+ MBCs were not evaluated in 6 patients due to an absence of B cells in peripheral blood. We detected various patterns among the patients with IEI with circulating B cells (25, 81%): an adequate humoral response was observed in 12/25, consider by the detection of positive S-specific IgG antibodies and the presence of specific IgG+ RBD+ MBCs, presenting a positive T-cell response; in 4/25, very low S-specific IgG antibody counts correlated with undetectable events in the IgG+ RBD+ MBC compartment but with positive cellular response. Despite the presence of S-specific IgG antibodies, we were unable to detect a relevant percentage of IgG+ RBD+ MBCs in 5/25; however, all presented positive T-cell response. Lastly, we observed a profound failure of B and T-cell response in 3 (10%) patients with IEI, with no assessment of S-specific IgG antibodies, IgG+ RBD+ MBCs, and negative cellular response. The identification of specific IgG+ RBD+ MBCs by flow cytometry provides information on different humoral immune response outcomes in patients with IEI and aids the assessment of immune competence status after SARS-CoV-2 mRNA vaccine (BNT162b2), together with S-specific IgG antibodies and T-cell responses. CI - Copyright (c) 2023 del Pino Molina, Bravo Gallego, Nozal, Soto-Serrano, Martinez-Feito, Reche-Yebra, Gonzalez-Torbay, Cuesta-Martin de la Camara, Gianelli, Camara, Gonzalez-Garcia, Gonzalez-Munoz, Rodriguez-Pena and Lopez Granados. FAU - Del Pino Molina, Lucia AU - Del Pino Molina L AD - Center for Biomedical Network Research on Rare Diseases (CIBERER U767), ISCIII, Madrid, Spain. AD - Lymphocyte Pathophysiology in Immunodeficiencies Group, La Paz Institute for Health Research (IdiPAZ), Madrid, Spain. FAU - Bravo Gallego, Luz Yadira AU - Bravo Gallego LY AD - Center for Biomedical Network Research on Rare Diseases (CIBERER U767), ISCIII, Madrid, Spain. AD - Lymphocyte Pathophysiology in Immunodeficiencies Group, La Paz Institute for Health Research (IdiPAZ), Madrid, Spain. FAU - Nozal, Pilar AU - Nozal P AD - Clinical Immunology Department, La Paz University Hospital, Madrid, Spain. AD - Center for Biomedical Network Research on Rare Diseases (CIBERER U754), ISCIII, Madrid, Spain. AD - Complement Research Group, La Paz Institute for Health Research (IdiPAZ), Madrid, Spain. FAU - Soto-Serrano, Yolanda AU - Soto-Serrano Y AD - Lymphocyte Pathophysiology in Immunodeficiencies Group, La Paz Institute for Health Research (IdiPAZ), Madrid, Spain. FAU - Martinez-Feito, Ana AU - Martinez-Feito A AD - Clinical Immunology Department, La Paz University Hospital, Madrid, Spain. AD - Immuno-Rheumatology Research Group, La Paz Institute for Health Research (IdiPAZ), Madrid, Spain. FAU - Reche-Yebra, Keren AU - Reche-Yebra K AD - Lymphocyte Pathophysiology in Immunodeficiencies Group, La Paz Institute for Health Research (IdiPAZ), Madrid, Spain. FAU - Gonzalez-Torbay, Andrea AU - Gonzalez-Torbay A AD - Clinical Immunology Department, La Paz University Hospital, Madrid, Spain. FAU - Cuesta-Martin de la Camara, Ricardo AU - Cuesta-Martin de la Camara R AD - Clinical Immunology Department, La Paz University Hospital, Madrid, Spain. FAU - Gianelli, Carla AU - Gianelli C AD - Lymphocyte Pathophysiology in Immunodeficiencies Group, La Paz Institute for Health Research (IdiPAZ), Madrid, Spain. AD - Clinical Immunology Department, La Paz University Hospital, Madrid, Spain. FAU - Camara, Carmen AU - Camara C AD - Lymphocyte Pathophysiology in Immunodeficiencies Group, La Paz Institute for Health Research (IdiPAZ), Madrid, Spain. AD - Clinical Immunology Department, La Paz University Hospital, Madrid, Spain. FAU - Gonzalez-Garcia, J AU - Gonzalez-Garcia J AD - HIV Unit, Internal Medicine Department, La Paz University Hospital, AIDS and Infectious Diseases Group, Center for Biomedical Network Research on Infectious Diseases (CIBERINFEC CB21/13/00039), La Paz Institute for Health Research (IdiPAZ), Madrid, Spain. FAU - Gonzalez-Munoz, Miguel AU - Gonzalez-Munoz M AD - Clinical Immunology Department, La Paz University Hospital, Madrid, Spain. FAU - Rodriguez-Pena, Rebeca AU - Rodriguez-Pena R AD - Center for Biomedical Network Research on Rare Diseases (CIBERER U767), ISCIII, Madrid, Spain. AD - Lymphocyte Pathophysiology in Immunodeficiencies Group, La Paz Institute for Health Research (IdiPAZ), Madrid, Spain. AD - Clinical Immunology Department, La Paz University Hospital, Madrid, Spain. FAU - Lopez Granados, Eduardo AU - Lopez Granados E AD - Center for Biomedical Network Research on Rare Diseases (CIBERER U767), ISCIII, Madrid, Spain. AD - Lymphocyte Pathophysiology in Immunodeficiencies Group, La Paz Institute for Health Research (IdiPAZ), Madrid, Spain. AD - Clinical Immunology Department, La Paz University Hospital, Madrid, Spain. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230504 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 RN - 0 (COVID-19 Vaccines) RN - 0 (BNT162 Vaccine) RN - 0 (Immunoglobulin G) SB - IM MH - Humans MH - *Memory B Cells MH - COVID-19 Vaccines MH - BNT162 Vaccine MH - Flow Cytometry MH - *COVID-19/prevention & control MH - SARS-CoV-2 MH - Vaccination MH - Health Personnel MH - Immunoglobulin G PMC - PMC10192857 OTO - NOTNLM OT - B cells OT - SARS - CoV - 2 OT - humoral and cellular response OT - inborn errors of immunity (IEI) OT - memory B cells (MBCs) OT - vaccine COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2023/05/22 19:11 MHDA- 2023/05/24 06:42 PMCR- 2023/05/04 CRDT- 2023/05/22 12:21 PHST- 2023/01/02 00:00 [received] PHST- 2023/04/13 00:00 [accepted] PHST- 2023/05/24 06:42 [medline] PHST- 2023/05/22 19:11 [pubmed] PHST- 2023/05/22 12:21 [entrez] PHST- 2023/05/04 00:00 [pmc-release] AID - 10.3389/fimmu.2023.1136308 [doi] PST - epublish SO - Front Immunol. 2023 May 4;14:1136308. doi: 10.3389/fimmu.2023.1136308. eCollection 2023. PMID- 37214142 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230523 IS - 2287-3651 (Print) IS - 2287-366X (Electronic) IS - 2287-3651 (Linking) VI - 12 IP - 2 DP - 2023 Apr TI - Exploring the underlying factors of COVID-19 vaccination hesitancy in Ahvaz, Iran: a comprehensive cross-sectional study. PG - 127-133 LID - 10.7774/cevr.2023.12.2.127 [doi] AB - PURPOSE: Around 70% of the Iranian population had received two doses of coronavirus disease 2019 (COVID-19) vaccines by the end of 2021. In this study, we evaluated the reasons for vaccination refusal among people in Ahvaz, Iran. MATERIALS AND METHODS: In this cross-sectional study, 800 participants (400 vaccinated and 400 unvaccinated) were recruited. A demographic questionnaire was completed through interviews. The unvaccinated participants were asked about the reasons for their refusal. The Shapiro-Wilk test, independent t-test, chi-square test, and logistic regression were used for analyzing data. RESULTS: Older people were 1.018 times more likely to refrain from vaccination (95% confidence interval [CI], 1.001-1.039; p=043). People who were manual workers as well as those who were unemployed/housewives were 0.288 and 0.423 times less likely to receive vaccination, respectively. Those with high school education and married women were 0.319 and 0.280 times less likely to receive vaccination, respectively (95% CI, 198-0.515; p<0.001; 95% CI, 0.186-0.422; p<0.001). Participants who had hypertension or suffered from neurological disorders were more likely to receive the vaccination. Finally, people affected with severe COVID-19 infection were 3.157 times more likely to get vaccinated (95% CI, 1.672-5.961; p<0.001). CONCLUSION: The results of this study showed that lower level of education and older age were contributed to reluctance for vaccination, while having chronic diseases or being already infected with severe COVID-19 infection were associated with more acceptance of vaccination. CI - (c) Korean Vaccine Society. FAU - Afshari, Poorandokht AU - Afshari P AUID- ORCID: 0000-0002-3383-9908 AD - Midwifery Department, Reproductive Health Promotion Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. FAU - Alavi, Seyed Mohammad AU - Alavi SM AUID- ORCID: 0000-0002-3733-4173 AD - Infectious and Tropical Diseases Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. FAU - Abedi, Parvin AU - Abedi P AUID- ORCID: 0000-0002-6980-0693 AD - Midwifery Department, Menopause Andropause Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. FAU - Beheshtinasab, Maryam AU - Beheshtinasab M AUID- ORCID: 0000-0002-4885-8212 AD - Midwifery Department, Reproductive Health Promotion Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. FAU - Dashtpayma, Shohreh AU - Dashtpayma S AD - Midwifery Department, Reproductive Health Promotion Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. FAU - Amiri, Homayon AU - Amiri H AD - Infectious and Tropical Diseases Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. LA - eng PT - Journal Article DEP - 20230430 PL - Korea (South) TA - Clin Exp Vaccine Res JT - Clinical and experimental vaccine research JID - 101592344 PMC - PMC10193107 OTO - NOTNLM OT - COVID-19 vaccination OT - Chronic disease OT - Infection OT - Iran OT - Vaccination refusal COIS- No potential conflict of interest relevant to this article was reported. EDAT- 2023/05/22 19:11 MHDA- 2023/05/22 19:12 PMCR- 2023/04/01 CRDT- 2023/05/22 12:07 PHST- 2022/12/03 00:00 [received] PHST- 2023/01/25 00:00 [revised] PHST- 2023/02/03 00:00 [accepted] PHST- 2023/05/22 19:12 [medline] PHST- 2023/05/22 19:11 [pubmed] PHST- 2023/05/22 12:07 [entrez] PHST- 2023/04/01 00:00 [pmc-release] AID - 10.7774/cevr.2023.12.2.127 [doi] PST - ppublish SO - Clin Exp Vaccine Res. 2023 Apr;12(2):127-133. doi: 10.7774/cevr.2023.12.2.127. Epub 2023 Apr 30. PMID- 37212205 OWN - NLM STAT- MEDLINE DCOM- 20231023 LR - 20231024 IS - 1440-1711 (Electronic) IS - 0818-9641 (Linking) VI - 101 IP - 7 DP - 2023 Aug TI - SARS-CoV-2 clearance after breakthrough infection correlates with fit and happy T cells. PG - 587-589 LID - 10.1111/imcb.12654 [doi] AB - Koutsakos et al. have recently published an article showing that SARS-CoV-2 breakthrough infection results in robust naive and memory T cell activation, and the activity of CD8 T cells strongly correlates with viral clearance. CI - (c) 2023 the Australian and New Zealand Society for Immunology, Inc. FAU - Veldhoen, Marc AU - Veldhoen M AD - Instituto de Medicina Molecular, Joao Lobo Antunes, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal. FAU - Bertoletti, Antonio AU - Bertoletti A AD - Emerging Infectious Diseases Program, Duke-NUS Medical School, Singapore, Singapore. AD - Singapore Immunology Network, A*STAR, Singapore, Singapore. LA - eng PT - Journal Article DEP - 20230522 PL - United States TA - Immunol Cell Biol JT - Immunology and cell biology JID - 8706300 RN - 0 (Antibodies, Viral) SB - IM EIN - Immunol Cell Biol. 2023 Aug;101(7):672. doi: 10.1111/imcb.12667. PMID: 37401266 MH - Humans MH - *SARS-CoV-2 MH - Breakthrough Infections MH - *COVID-19 MH - CD8-Positive T-Lymphocytes MH - Lymphocyte Activation MH - Antibodies, Viral OTO - NOTNLM OT - SARS-CoV-2 clearance OT - robust naive and memory T cells OT - viral clearance EDAT- 2023/05/22 06:42 MHDA- 2023/10/23 12:43 CRDT- 2023/05/22 05:43 PHST- 2023/10/23 12:43 [medline] PHST- 2023/05/22 06:42 [pubmed] PHST- 2023/05/22 05:43 [entrez] AID - 10.1111/imcb.12654 [doi] PST - ppublish SO - Immunol Cell Biol. 2023 Aug;101(7):587-589. doi: 10.1111/imcb.12654. Epub 2023 May 22. PMID- 37185852 OWN - NLM STAT- MEDLINE DCOM- 20230517 LR - 20230622 IS - 1096-9071 (Electronic) IS - 0146-6615 (Linking) VI - 95 IP - 4 DP - 2023 Apr TI - Dynamic immunogenicity after primary and booster inactivated SARS-CoV-2 vaccination in people living with HIV: A longitudinal observational study. PG - e28730 LID - 10.1002/jmv.28730 [doi] AB - People living with HIV (PLWH) have poor outcomes from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); vaccination reduces the associated mortality. The humoral immune response dynamics after booster inactivated vaccinations in PLWH remain unclear. In this longitudinal observational study, 100 PLWH after primary inactivated SARS-CoV-2 vaccination were consecutively recruited and followed up. After booster vaccination (BV), neutralizing antibodies (NAbs) were detected at 1 month from all the PLWH, and the titer increased sixfold compared to that associated with the primary vaccination (PV), similar to that in healthy controls after BV. The NAbs titer declined over time after BV, but remained higher at 6 months than after PV. The NAbs response was elevated after BV with CD4 count <200 cells/muL, it was the poorest among the different CD4 cell count subgroups. Similar results were observed for anti-RBD-IgG responses. Moreover, RBD-specific MBCs were significantly elevated after BV in PLWH. No serious AEs were observed after BV in PLWH. In conclusion, booster inactivated SARS-CoV-2 vaccination is well tolerated and can elicit robust and durable humoral responses in PLWH. PLWH may benefit from a third dose of the inactivated vaccine. CI - (c) 2023 Wiley Periodicals LLC. FAU - Lu, Ting AU - Lu T AD - Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China. AD - The People's Hospital of Tongliang District, Chongqing, China. FAU - Chen, Zhiwei AU - Chen Z AD - Department of Infectious Diseases, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China. FAU - Cao, Yu AU - Cao Y AD - The People's Hospital of Tongliang District, Chongqing, China. FAU - Ao, Ling AU - Ao L AD - Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China. FAU - Li, Zisheng AU - Li Z AD - The People's Hospital of Tongliang District, Chongqing, China. FAU - Gu, Xiaoyi AU - Gu X AD - The People's Hospital of Tongliang District, Chongqing, China. FAU - Ren, Xingqian AU - Ren X AD - The People's Hospital of Tongliang District, Chongqing, China. FAU - Wang, Yixuan AU - Wang Y AD - Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China. FAU - Zhang, Gaoli AU - Zhang G AD - Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China. FAU - Xiang, Dejuan AU - Xiang D AD - Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China. FAU - Chen, Min AU - Chen M AD - Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China. FAU - Cai, Dachuan AU - Cai D AD - Department of Infectious Diseases, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China. FAU - Hu, Peng AU - Hu P AUID- ORCID: 0000-0001-8481-0841 AD - Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China. AD - Department of Infectious Diseases, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China. FAU - Zhang, Dazhi AU - Zhang D AD - Department of Infectious Diseases, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China. FAU - Peng, Mingli AU - Peng M AD - Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China. FAU - Shi, Xiaofeng AU - Shi X AUID- ORCID: 0000-0002-0357-6967 AD - Department of Infectious Diseases, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China. FAU - Ren, Hong AU - Ren H AUID- ORCID: 0000-0002-4557-0918 AD - Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China. AD - Department of Infectious Diseases, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China. LA - eng PT - Journal Article PT - Observational Study PT - Research Support, Non-U.S. Gov't PL - United States TA - J Med Virol JT - Journal of medical virology JID - 7705876 RN - 0 (COVID-19 Vaccines) RN - 0 (Antibodies, Neutralizing) RN - 0 (Antibodies, Viral) SB - IM MH - Humans MH - *COVID-19/prevention & control MH - COVID-19 Vaccines MH - SARS-CoV-2 MH - Antibodies, Neutralizing MH - Vaccination MH - *HIV Infections MH - Antibodies, Viral OTO - NOTNLM OT - HIV OT - SARS-CoV-2 OT - immunogenicity OT - inactivated vaccines OT - memory B cells EDAT- 2023/05/15 19:12 MHDA- 2023/05/17 06:42 CRDT- 2023/05/15 13:51 PHST- 2023/03/17 00:00 [revised] PHST- 2023/01/06 00:00 [received] PHST- 2023/04/04 00:00 [accepted] PHST- 2023/05/17 06:42 [medline] PHST- 2023/05/15 19:12 [pubmed] PHST- 2023/05/15 13:51 [entrez] AID - 10.1002/jmv.28730 [doi] PST - ppublish SO - J Med Virol. 2023 Apr;95(4):e28730. doi: 10.1002/jmv.28730. PMID- 37179389 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20241114 IS - 2059-0105 (Electronic) IS - 2059-0105 (Linking) VI - 8 IP - 1 DP - 2023 May 13 TI - Intranasal COVID-19 vaccine induces respiratory memory T cells and protects K18-hACE mice against SARS-CoV-2 infection. PG - 68 LID - 10.1038/s41541-023-00665-3 [doi] LID - 68 AB - Current COVID-19 vaccines prevent severe disease, but do not induce mucosal immunity or prevent infection with SARS-CoV-2, especially with recent variants. Furthermore, serum antibody responses wane soon after immunization. We assessed the immunogenicity and protective efficacy of an experimental COVID-19 vaccine based on the SARS-CoV-2 Spike trimer formulated with a novel adjuvant LP-GMP, comprising TLR2 and STING agonists. We demonstrated that immunization of mice twice by the intranasal (i.n.) route or by heterologous intramuscular (i.m.) prime and i.n. boost with the Spike-LP-GMP vaccine generated potent Spike-specific IgG, IgA and tissue-resident memory (T(RM)) T cells in the lungs and nasal mucosa that persisted for at least 3 months. Furthermore, Spike-LP-GMP vaccine delivered by i.n./i.n., i.m./i.n., or i.m./i.m. routes protected human ACE-2 transgenic mice against respiratory infection and COVID-19-like disease following lethal challenge with ancestral or Delta strains of SARS-CoV-2. Our findings underscore the potential for nasal vaccines in preventing infection with SARS-CoV-2 and other respiratory pathogen. CI - (c) 2023. The Author(s). FAU - Diallo, Bere K AU - Diallo BK AUID- ORCID: 0000-0002-2655-6811 AD - Immune Regulation Research Group, School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland. FAU - Ni Chasaide, Caitlin AU - Ni Chasaide C AUID- ORCID: 0000-0001-7016-2468 AD - Immune Regulation Research Group, School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland. FAU - Wong, Ting Y AU - Wong TY AD - Department of Microbiology, Immunology, and Cell Biology and Vaccine Development Center, West Virginia University, Health Sciences Center, Morgantown, West Virginia, USA. FAU - Schmitt, Pauline AU - Schmitt P AD - Immune Regulation Research Group, School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland. FAU - Lee, Katherine S AU - Lee KS AUID- ORCID: 0000-0002-2067-1405 AD - Department of Microbiology, Immunology, and Cell Biology and Vaccine Development Center, West Virginia University, Health Sciences Center, Morgantown, West Virginia, USA. FAU - Weaver, Kelly AU - Weaver K AUID- ORCID: 0000-0002-6954-2479 AD - Department of Microbiology, Immunology, and Cell Biology and Vaccine Development Center, West Virginia University, Health Sciences Center, Morgantown, West Virginia, USA. FAU - Miller, Olivia AU - Miller O AD - Department of Microbiology, Immunology, and Cell Biology and Vaccine Development Center, West Virginia University, Health Sciences Center, Morgantown, West Virginia, USA. FAU - Cooper, Melissa AU - Cooper M AD - Department of Microbiology, Immunology, and Cell Biology and Vaccine Development Center, West Virginia University, Health Sciences Center, Morgantown, West Virginia, USA. FAU - Jazayeri, Seyed D AU - Jazayeri SD AD - Immune Regulation Research Group, School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland. FAU - Damron, F Heath AU - Damron FH AUID- ORCID: 0000-0002-3140-402X AD - Department of Microbiology, Immunology, and Cell Biology and Vaccine Development Center, West Virginia University, Health Sciences Center, Morgantown, West Virginia, USA. FAU - Mills, Kingston H G AU - Mills KHG AUID- ORCID: 0000-0003-3646-8222 AD - Immune Regulation Research Group, School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland. kingston.mills@tcd.ie. LA - eng GR - R01 AI137155/AI/NIAID NIH HHS/United States GR - R01 AI153250/AI/NIAID NIH HHS/United States GR - 20/SPP/3685/Science Foundation Ireland (SFI)/ PT - Journal Article DEP - 20230513 PL - England TA - NPJ Vaccines JT - NPJ vaccines JID - 101699863 PMC - PMC10182552 COIS- Kingston Mills is an inventor on a patent application around a novel vaccine adjuvant and has collaborative research funding from and acts as consultant to Pharmaceutical and Biotech companies. Bere K. Diallo, Caitlin Ni Chasaide, Pauline Schmitt are inventors on a patent application around a novel vaccine adjuvant. The other authors have no competing interests. EDAT- 2023/05/14 01:07 MHDA- 2023/05/14 01:08 PMCR- 2023/05/13 CRDT- 2023/05/13 23:19 PHST- 2022/10/13 00:00 [received] PHST- 2023/04/26 00:00 [accepted] PHST- 2023/05/14 01:08 [medline] PHST- 2023/05/14 01:07 [pubmed] PHST- 2023/05/13 23:19 [entrez] PHST- 2023/05/13 00:00 [pmc-release] AID - 10.1038/s41541-023-00665-3 [pii] AID - 665 [pii] AID - 10.1038/s41541-023-00665-3 [doi] PST - epublish SO - NPJ Vaccines. 2023 May 13;8(1):68. doi: 10.1038/s41541-023-00665-3. PMID- 37148294 OWN - NLM STAT- MEDLINE DCOM- 20230808 LR - 20260410 IS - 1460-2377 (Electronic) IS - 0953-8178 (Print) IS - 0953-8178 (Linking) VI - 35 IP - 8 DP - 2023 Aug 7 TI - An update on studies characterizing adaptive immune responses in SARS-CoV-2 infection and COVID-19 vaccination. PG - 353-359 LID - 10.1093/intimm/dxad014 [doi] AB - In this brief opinion piece, we highlight our studies characterizing adaptive SARS-CoV-2 immune responses in infection and vaccination, and the ability of SARS-CoV-2-specific T cells to recognize emerging variants of concern, and the role of pre-existing cross-reactive T cells. In the context of the debate on correlates of protection, the pandemic's progression in the past 3 years underlined the need to consider how different adaptive immune responses might differentially contribute to protection from SARS-CoV-2 infection versus COVID-19 disease. Lastly, we discuss how cross-reactive T cell responses may be useful in generating a broad adaptive immunity, recognizing different variants and viral families. Considering vaccines with broadly conserved antigens could improve preparedness for future infectious disease outbreaks. CI - (c) The Author(s) 2023. Published by Oxford University Press on behalf of The Japanese Society for Immunology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. FAU - da Silva Antunes, Ricardo AU - da Silva Antunes R AUID- ORCID: 0000-0001-9785-5272 AD - Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI); La Jolla, CA 92037, USA. FAU - Grifoni, Alba AU - Grifoni A AD - Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI); La Jolla, CA 92037, USA. FAU - Frazier, April AU - Frazier A AD - Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI); La Jolla, CA 92037, USA. FAU - Weiskopf, Daniela AU - Weiskopf D AD - Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI); La Jolla, CA 92037, USA. FAU - Sette, Alessandro AU - Sette A AD - Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI); La Jolla, CA 92037, USA. AD - Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego (UCSD), La Jolla, CA, USA. LA - eng GR - 75N93019C00065/AI/NIAID NIH HHS/United States GR - 75N93021C00016/AI/NIAID NIH HHS/United States GR - U19 AI142742/AI/NIAID NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PL - England TA - Int Immunol JT - International immunology JID - 8916182 RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - *COVID-19/prevention & control MH - COVID-19 Vaccines MH - SARS-CoV-2 MH - Vaccination MH - Adaptive Immunity PMC - PMC10406159 OTO - NOTNLM OT - T cell OT - antibody responses OT - correlates of protection OT - pre-existing memory OT - variants EDAT- 2023/05/06 19:42 MHDA- 2023/08/08 06:42 PMCR- 2024/05/06 CRDT- 2023/05/06 14:47 PHST- 2023/03/10 00:00 [received] PHST- 2023/05/03 00:00 [accepted] PHST- 2023/08/08 06:42 [medline] PHST- 2023/05/06 19:42 [pubmed] PHST- 2023/05/06 14:47 [entrez] PHST- 2024/05/06 00:00 [pmc-release] AID - 7156413 [pii] AID - dxad014 [pii] AID - 10.1093/intimm/dxad014 [doi] PST - ppublish SO - Int Immunol. 2023 Aug 7;35(8):353-359. doi: 10.1093/intimm/dxad014. PMID- 37139906 OWN - NLM STAT- MEDLINE DCOM- 20230619 LR - 20231119 IS - 2328-9503 (Electronic) IS - 2328-9503 (Linking) VI - 10 IP - 6 DP - 2023 Jun TI - Evaluation of serum and cerebrospinal fluid biomarkers after vaccination against SARS-CoV-2. PG - 1025-1034 LID - 10.1002/acn3.51785 [doi] AB - OBJECTIVE: Vaccines are a major achievement of science, and new vaccines against SARS-CoV-2 are protecting the entire population from a life-threatening infection. Although several neurological complications or worsening of pre-existing neurological conditions after vaccination have been observed, whether a biological plausibility exist between new vaccines against-SARS-CoV-2 and neurological consequences is unclear. The aim of this study is to evaluate whether vaccines against SARS-CoV-2 induce systemic or cerebrospinal fluid alterations in patients with neurological disorders. METHODS: Patients who underwent lumbar puncture (LP) between February 2021 and October 2022 were enrolled. Serum C-reactive protein (CRP), neutrophil to lymphocyte ratio (NLR), cerebrospinal fluid total protein content (CSF-TPc), glucose CSF/serum ratio, number of CSF cells per cubic millimeter, and CSF neurofilament light chain (CSF-NfL) were compared between unvaccinated and vaccinated patients. RESULTS: A total of 110 patients were included and fitted into three groups according firstly to vaccination status (vaccinated and unvaccinated) and then to time from last dose of vaccine to LP (within or after 3 months). TPc, CSF/S(Glu) ratio, number of cells per cubic millimeter, CSF-NfL, CRP, and NLR were not different between groups (all p > 0.05), and also, they did not differ neither according to age nor diagnosis. No relevant differences between groups were also noticed when the at-risk time window was set to 6 weeks. INTERPRETATION: No signs of neuroinflammation, axonal loss and systemic inflammation were found in patients with neurological disorders after anti-SARS-CoV-2 vaccination compared with unvaccinated ones. CI - (c) 2023 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association. FAU - Iacono, Salvatore AU - Iacono S AUID- ORCID: 0000-0003-0035-5859 AD - Neurology Unit, Department of Biomedicine, Neuroscience and Advanced Diagnostics (BiND), University of Palermo, Palermo, Italy. FAU - Piccoli, Tommaso AU - Piccoli T AD - Neurology Unit, Department of Biomedicine, Neuroscience and Advanced Diagnostics (BiND), University of Palermo, Palermo, Italy. FAU - Aridon, Paolo AU - Aridon P AD - Neurology Unit, Department of Biomedicine, Neuroscience and Advanced Diagnostics (BiND), University of Palermo, Palermo, Italy. FAU - Schiro, Giuseppe AU - Schiro G AD - Neurology Unit, Department of Biomedicine, Neuroscience and Advanced Diagnostics (BiND), University of Palermo, Palermo, Italy. FAU - Blandino, Valeria AU - Blandino V AD - Neurology Unit, Department of Biomedicine, Neuroscience and Advanced Diagnostics (BiND), University of Palermo, Palermo, Italy. FAU - Tarantino, Domenico AU - Tarantino D AD - Neurology Unit, Department of Biomedicine, Neuroscience and Advanced Diagnostics (BiND), University of Palermo, Palermo, Italy. FAU - Agnello, Luisa AU - Agnello L AD - Department of Biomedicine, Neurosciences and Advanced Diagnostics, Institute of Clinical Biochemistry, Clinical Molecular Medicine and Clinical Laboratory Medicine, University Hospital "P. Giaccone", Palermo, Italy. FAU - Ciaccio, Marcello AU - Ciaccio M AD - Department of Biomedicine, Neurosciences and Advanced Diagnostics, Institute of Clinical Biochemistry, Clinical Molecular Medicine and Clinical Laboratory Medicine, University Hospital "P. Giaccone", Palermo, Italy. FAU - Ragonese, Paolo AU - Ragonese P AUID- ORCID: 0000-0003-2516-1567 AD - Neurology Unit, Department of Biomedicine, Neuroscience and Advanced Diagnostics (BiND), University of Palermo, Palermo, Italy. FAU - Salemi, Giuseppe AU - Salemi G AD - Neurology Unit, Department of Biomedicine, Neuroscience and Advanced Diagnostics (BiND), University of Palermo, Palermo, Italy. LA - eng PT - Journal Article DEP - 20230504 PL - United States TA - Ann Clin Transl Neurol JT - Annals of clinical and translational neurology JID - 101623278 RN - 0 (COVID-19 Vaccines) RN - 0 (Biomarkers) SB - IM MH - Humans MH - *SARS-CoV-2 MH - COVID-19 Vaccines/adverse effects MH - *COVID-19/prevention & control MH - Vaccination/adverse effects MH - Biomarkers PMC - PMC10270270 COIS- The authors declare that they have no conflict of interest. EDAT- 2023/05/04 12:41 MHDA- 2023/06/19 13:08 PMCR- 2023/05/04 CRDT- 2023/05/04 06:13 PHST- 2023/04/11 00:00 [revised] PHST- 2023/01/03 00:00 [received] PHST- 2023/04/15 00:00 [accepted] PHST- 2023/06/19 13:08 [medline] PHST- 2023/05/04 12:41 [pubmed] PHST- 2023/05/04 06:13 [entrez] PHST- 2023/05/04 00:00 [pmc-release] AID - ACN351785 [pii] AID - 10.1002/acn3.51785 [doi] PST - ppublish SO - Ann Clin Transl Neurol. 2023 Jun;10(6):1025-1034. doi: 10.1002/acn3.51785. Epub 2023 May 4. PMID- 37114058 OWN - NLM STAT- MEDLINE DCOM- 20230501 LR - 20240917 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 14 DP - 2023 TI - Non-spike and spike-specific memory T cell responses after the third dose of inactivated COVID-19 vaccine. PG - 1139620 LID - 10.3389/fimmu.2023.1139620 [doi] LID - 1139620 AB - BACKGROUND: During the COVID-19 epidemic, vaccination has become the most safe and effective way to prevent severe illness and death. Inactivated vaccines are the most widely used type of COVID-19 vaccines in the world. In contrast to spike-based mRNA/protein COVID-19 vaccines, inactivated vaccines generate antibodies and T cell responses against both spike and non-spike antigens. However, the knowledge of inactivated vaccines in inducing non-spike-specific T cell response is very limited. METHODS: In this study, eighteen healthcare volunteers received a homogenous booster (third) dose of the CoronaVac vaccine at least 6 months after the second dose. CD4(+) and CD8(+) T cell responses against a peptide pool from wild-type (WT) non-spike proteins and spike peptide pools from WT, Delta, and Omicron SARS-CoV-2 were examined before and 1-2 weeks after the booster dose. RESULTS: The booster dose elevated cytokine response in CD4(+) and CD8(+) T cells as well as expression of cytotoxic marker CD107a in CD8(+) T cells in response to non-spike and spike antigens. The frequencies of cytokine-secreting non-spike-specific CD4(+) and CD8(+) T cells correlated well with those of spike-specific from WT, Delta, and Omicron. Activation-induced markers (AIM) assay also revealed that booster vaccination elicited non-spike-specific CD4(+) and CD8(+) T cell responses. In addition, booster vaccination produced similar spike-specific AIM(+)CD4(+) and AIM(+)CD8(+) T cell responses to WT, Delta, and Omicron, indicting strong cross-reactivity of functional cellular response between WT and variants. Furthermore, booster vaccination induced effector memory phenotypes of spike-specific and non-spike-specific CD4(+) and CD8(+) T cells. CONCLUSIONS: These data suggest that the booster dose of inactive vaccines broadens both non-spike-specific and spike-specific T cell responses against SARS-CoV-2. CI - Copyright (c) 2023 Huang, Ying, Wang, Xia, Zhang, Mao, Zhang, Zang, Le, Shu and Xu. FAU - Huang, Ruoqiong AU - Huang R AD - Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, Zhejiang, China. FAU - Ying, Liyang AU - Ying L AD - Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, Zhejiang, China. FAU - Wang, Jiangmei AU - Wang J AD - Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, Zhejiang, China. FAU - Xia, Jie AU - Xia J AD - Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, Zhejiang, China. FAU - Zhang, Yanjun AU - Zhang Y AD - Department of Microbiology, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, Zhejiang, China. FAU - Mao, Haiyan AU - Mao H AD - Department of Microbiology, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, Zhejiang, China. FAU - Zhang, Ruoyang AU - Zhang R AD - Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, Zhejiang, China. FAU - Zang, Ruoxi AU - Zang R AD - Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, Zhejiang, China. FAU - Le, Zhenkai AU - Le Z AD - Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, Zhejiang, China. FAU - Shu, Qiang AU - Shu Q AD - Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, Zhejiang, China. FAU - Xu, Jianguo AU - Xu J AD - Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, Zhejiang, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230411 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 RN - 0 (sinovac COVID-19 vaccine) RN - 0 (COVID-19 Vaccines) RN - 0 (Cytokines) RN - 0 (Vaccines, Inactivated) SB - IM MH - Humans MH - *COVID-19 Vaccines MH - CD8-Positive T-Lymphocytes MH - Memory T Cells MH - *COVID-19/prevention & control MH - SARS-CoV-2 MH - Cytokines MH - Vaccines, Inactivated PMC - PMC10126277 OTO - NOTNLM OT - COVID-19 OT - CoronaVac OT - T cell responses OT - inactivated vaccines OT - non-spike OT - spike COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2023/04/28 06:42 MHDA- 2023/05/01 06:42 PMCR- 2023/04/11 CRDT- 2023/04/28 02:37 PHST- 2023/01/07 00:00 [received] PHST- 2023/03/24 00:00 [accepted] PHST- 2023/05/01 06:42 [medline] PHST- 2023/04/28 06:42 [pubmed] PHST- 2023/04/28 02:37 [entrez] PHST- 2023/04/11 00:00 [pmc-release] AID - 10.3389/fimmu.2023.1139620 [doi] PST - epublish SO - Front Immunol. 2023 Apr 11;14:1139620. doi: 10.3389/fimmu.2023.1139620. eCollection 2023. PMID- 37099427 OWN - NLM STAT- MEDLINE DCOM- 20231004 LR - 20231010 IS - 2211-1247 (Electronic) VI - 42 IP - 4 DP - 2023 Apr 25 TI - Vaccination provides superior in vivo recall capacity of SARS-CoV-2-specific memory CD8 T cells. PG - 112395 LID - S2211-1247(23)00406-0 [pii] LID - 10.1016/j.celrep.2023.112395 [doi] AB - Memory CD8 T cells play an important role in the protection against breakthrough infections with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Whether the route of antigen exposure impacts these cells at a functional level is incompletely characterized. Here, we compare the memory CD8 T cell response against a common SARS-CoV-2 epitope after vaccination, infection, or both. CD8 T cells demonstrate comparable functional capacity when restimulated directly ex vivo, independent of the antigenic history. However, analysis of T cell receptor usage shows that vaccination results in a narrower scope than infection alone or in combination with vaccination. Importantly, in an in vivo recall model, memory CD8 T cells from infected individuals show equal proliferation but secrete less tumor necrosis factor (TNF) compared with those from vaccinated people. This difference is negated when infected individuals have also been vaccinated. Our findings shed more light on the differences in susceptibility to re-infection after different routes of SARS-CoV-2 antigen exposure. CI - Copyright (c) 2023 The Author(s). Published by Elsevier Inc. All rights reserved. FAU - Kavazovic, Inga AU - Kavazovic I AD - Department of Histology and Embryology, Faculty of Medicine, University of Rijeka, 51000 Rijeka, Croatia. FAU - Dimitropoulos, Christoforos AU - Dimitropoulos C AD - Innate Immunity, German Rheumatism Research Centre-a Leibniz Institute, 10117 Berlin, Germany. FAU - Gasparini, Dora AU - Gasparini D AD - Department of Histology and Embryology, Faculty of Medicine, University of Rijeka, 51000 Rijeka, Croatia. FAU - Roncevic Filipovic, Mari AU - Roncevic Filipovic M AD - Department of Infectiology, Clinical Hospital Center Rijeka, 51000 Rijeka, Croatia. FAU - Barkovic, Igor AU - Barkovic I AD - Department of Internal Medicine, Faculty of Medicine, University of Rijeka, 51000 Rijeka, Croatia. FAU - Koster, Jan AU - Koster J AD - Amsterdam UMC Location University of Amsterdam, Center for Experimental and Molecular Medicine, 1105AZ Amsterdam, the Netherlands. FAU - Lemmermann, Niels A AU - Lemmermann NA AD - Institute for Virology and Research Center for Immunotherapy (FZI) at the University Medical Center of the Johannes Gutenberg University, 55131 Mainz, Germany. FAU - Babic, Marina AU - Babic M AD - Department of Histology and Embryology, Faculty of Medicine, University of Rijeka, 51000 Rijeka, Croatia; Innate Immunity, German Rheumatism Research Centre-a Leibniz Institute, 10117 Berlin, Germany. FAU - Cekinovic Grbesa, Durdica AU - Cekinovic Grbesa D AD - Department of Infectiology, Clinical Hospital Center Rijeka, 51000 Rijeka, Croatia. FAU - Wensveen, Felix M AU - Wensveen FM AD - Department of Histology and Embryology, Faculty of Medicine, University of Rijeka, 51000 Rijeka, Croatia. Electronic address: felix.wensveen@medri.uniri.hr. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230404 PL - United States TA - Cell Rep JT - Cell reports JID - 101573691 RN - 0 (Tumor Necrosis Factor-alpha) SB - IM MH - Humans MH - *COVID-19 MH - SARS-CoV-2 MH - Vaccination MH - CD8-Positive T-Lymphocytes MH - Tumor Necrosis Factor-alpha PMC - PMC10070771 OTO - NOTNLM OT - CD8 T cells OT - COVID-19 OT - CP: Immunology OT - SARS-CoV-2 OT - antigen-specific T cells OT - clonal diversity OT - infection OT - influenza OT - memory cells OT - transcriptome OT - vaccination COIS- Declaration of interests The authors declare no competing interests. EDAT- 2023/04/26 18:42 MHDA- 2023/10/04 06:44 PMCR- 2023/04/04 CRDT- 2023/04/26 12:36 PHST- 2022/08/22 00:00 [received] PHST- 2022/12/07 00:00 [revised] PHST- 2023/03/30 00:00 [accepted] PHST- 2023/10/04 06:44 [medline] PHST- 2023/04/26 18:42 [pubmed] PHST- 2023/04/26 12:36 [entrez] PHST- 2023/04/04 00:00 [pmc-release] AID - S2211-1247(23)00406-0 [pii] AID - 112395 [pii] AID - 10.1016/j.celrep.2023.112395 [doi] PST - ppublish SO - Cell Rep. 2023 Apr 25;42(4):112395. doi: 10.1016/j.celrep.2023.112395. Epub 2023 Apr 4. PMID- 37091031 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230425 IS - 2249-4863 (Print) IS - 2278-7135 (Electronic) IS - 2249-4863 (Linking) VI - 12 IP - 2 DP - 2023 Feb TI - Impact of COVID-19 vaccines on the health status of young female adults from India: A cross-sectional study. PG - 338-351 LID - 10.4103/jfmpc.jfmpc_1574_22 [doi] AB - PURPOSE: Reports suggest that females experience more adverse events post-coronavirus disease 2019 (COVID-19) vaccination compared to males. However, no gender-specific data on the impact of vaccines on the Indian population are available. The present study was intended to understand the impact of COVID-19 vaccines on the health status of young Indian female adults and to identify the factors associated with experiencing adverse events post-vaccination. METHODS: A web-based survey was conducted among 433 young female adults who have taken at least one dose of the COVID-19 vaccine. The prevalence and duration of systemic and generalized symptoms were analyzed using descriptive statistics. The factors associated with symptoms post-vaccination were analyzed using binary logistic regression. Adjusted odds ratios and 95% confidence intervals were computed. A P value of /=18) patients with PASC. PASC was defined as experiencing constitutional (palpitations, malaise/fatigue, headache) or systemic (sleep disorder, shortness of breath, mood/anxiety disorders, cough and cognitive impairment) symptoms beyond the 28-day postinfection period. STATISTICAL ANALYSIS: We fit multivariable logistic regression models and report estimated likelihood of PASC associated with vaccination or mAb treatment as adjusted ORs with 95% CIs. RESULTS: Primary analyses included 53 239 subjects (54.9% female), of whom 5929, 11.1% (95% CI 10.9% to 11.4%), experienced PASC. Both vaccinated breakthrough cases (vs unvaccinated) and mAb-treated patients (vs untreated) had lower likelihoods for developing PASC, aOR (95% CI): 0.58 (0.52-0.66), and 0.77 (0.69-0.86), respectively. Vaccination was associated with decreased odds of developing all constitutional and systemic symptoms except for taste and smell changes. For all symptoms, vaccination was associated with lower likelihood of experiencing PASC compared with mAb treatment. Replication analysis found identical frequency of PASC (11.2%, 95% CI 11.1 to 11.3) and similar protective effects against PASC for the COVID-19 vaccine: 0.25 (0.21-0.30) and mAb treatment: 0.62 (0.59-0.66). CONCLUSION: Although both COVID-19 vaccines and mAbs decreased the likelihood of PASC, vaccination remains the most effective tool for the prevention of long-term consequences of COVID-19. CI - (c) Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Tannous, Jonika AU - Tannous J AUID- ORCID: 0000-0003-4022-9267 AD - Department of Neurosurgery, Houston Methodist Research Institute, Houston, Texas, USA. FAU - Pan, Alan P AU - Pan AP AUID- ORCID: 0000-0002-8782-8024 AD - Houston Methodist Research Institute, Houston, Texas, USA. FAU - Potter, Thomas AU - Potter T AD - Houston Methodist Research Institute, Houston, Texas, USA. FAU - Bako, Abdulaziz T AU - Bako AT AD - Houston Methodist Research Institute, Houston, Texas, USA. FAU - Dlouhy, Katharine AU - Dlouhy K AD - Houston Methodist Research Institute, Houston, Texas, USA. FAU - Drews, Ashley AU - Drews A AD - Houston Methodist Academic Institute, Houston, Texas, USA. AD - Department of Population Health Sciences, Weill Cornell Medicine, New York, New York, USA. FAU - Sostman, Henry Dirk AU - Sostman HD AD - Houston Methodist Academic Institute, Houston Methodist, Houston, Texas, USA. FAU - Vahidy, Farhaan S AU - Vahidy FS AUID- ORCID: 0000-0002-3464-2111 AD - Houston Methodist Research Institute, Houston, Texas, USA fvahidy@houstonmethodist.org. AD - Houston Methodist Academic Institute, Houston, Texas, USA. LA - eng PT - Journal Article DEP - 20230405 PL - England TA - BMJ Open JT - BMJ open JID - 101552874 RN - 0 (Antibodies, Monoclonal) RN - 0 (Antibodies, Viral) RN - 0 (COVID-19 Vaccines) SB - IM MH - Adult MH - Female MH - Humans MH - Male MH - Antibodies, Monoclonal/therapeutic use MH - Antibodies, Viral MH - *COVID-19/prevention & control/therapy MH - *COVID-19 Vaccines MH - Disease Progression MH - Registries MH - Retrospective Studies MH - SARS-CoV-2 MH - *Post-Acute COVID-19 Syndrome/drug therapy/prevention & control PMC - PMC10083521 OTO - NOTNLM OT - COVID-19 OT - Epidemiology OT - Public health COIS- Competing interests: None declared. EDAT- 2023/04/06 06:00 MHDA- 2023/04/07 10:18 PMCR- 2023/04/05 CRDT- 2023/04/05 20:53 PHST- 2023/04/07 10:18 [medline] PHST- 2023/04/05 20:53 [entrez] PHST- 2023/04/06 06:00 [pubmed] PHST- 2023/04/05 00:00 [pmc-release] AID - bmjopen-2022-067611 [pii] AID - 10.1136/bmjopen-2022-067611 [doi] PST - epublish SO - BMJ Open. 2023 Apr 5;13(4):e067611. doi: 10.1136/bmjopen-2022-067611. PMID- 37018462 OWN - NLM STAT- MEDLINE DCOM- 20260311 LR - 20260316 IS - 1876-4479 (Electronic) IS - 1873-9946 (Linking) VI - 17 IP - 9 DP - 2023 Oct 20 TI - Reduced Serological Response to COVID-19 Booster Vaccine is Associated with Reduced B Cell Memory in Patients With Inflammatory Bowel Disease; VARIATION [VAriability in Response in IBD AgainsT SARS-COV-2 ImmunisatiON]. PG - 1445-1456 LID - 10.1093/ecco-jcc/jjad065 [doi] AB - BACKGROUND AND AIMS: Patients with inflammatory bowel disease [IBD] have an attenuated response to initial COVID-19 vaccination. We sought to characterize the impact of IBD and its treatment on responses after the third vaccine against SARS-CoV-2. METHODS: This was a prospective multicentre observational study of patients with IBD [n = 202] and healthy controls [HC, n = 92]. Serological response to vaccination was assessed by quantification of anti-spike protein [SP] immunoglobulin [Ig]G levels [anti-SPIgG] and in vitro neutralization of binding to angiotensin-converting enzyme 2 [ACE2]. Peripheral blood B-cell phenotype populations were assessed by flow cytometry. SARS-CoV-2 antigen-specific B-cell responses were assessed in ex vivo culture. RESULTS: Median anti-SP IgG post-third vaccination in our IBD cohort was significantly lower than HCs [7862 vs 19 622 AU/mL, p < 0.001] as was ACE2 binding inhibition [p < 0.001]. IBD patients previously infected with COVID-19 [30%] had similar quantitative antibody response as HCs previously infected with COVID-19 [p = 0.12]. Lowest anti-SP IgG titres and neutralization were seen in IBD patients on anti-tumour necrosis factor [anti-TNF] agents, without prior COVID-19 infection, but all IBD patients show an attenuated vaccine response compared to HCs. Patients with IBD have reduced memory B-cell populations and attenuated B-cell responses to SARS-CoV-2 antigens if not previously infected with COVID-19 [p = 0.01]. Higher anti-TNF drug levels and zinc levels <65 ng/ml were associated with significantly lower serological responses. CONCLUSIONS: Patients with IBD have an attenuated response to three doses of SARS-CoV-2 vaccine. Physicians should consider patients with higher anti-TNF drug levels and/or zinc deficiency as potentially at higher risk of attenuated response to vaccination. CI - (c) The Author(s) 2023. Published by Oxford University Press on behalf of European Crohn's and Colitis Organisation. All rights reserved. For permissions, please email: journals.permissions@oup.com. FAU - Doherty, Jayne AU - Doherty J AUID- ORCID: 0000-0002-1599-1447 AD - Centre for Colorectal Disease, St Vincent's University Hospital, Dublin, Ireland. AD - School of Medicine, University College Dublin, Dublin, Ireland. AD - INITIative IBD Research Network (www.initiativeibd.ie). FAU - O'Morain, Neil AU - O'Morain N AD - Centre for Colorectal Disease, St Vincent's University Hospital, Dublin, Ireland. AD - School of Medicine, University College Dublin, Dublin, Ireland. FAU - Stack, Roisin AU - Stack R AD - Centre for Colorectal Disease, St Vincent's University Hospital, Dublin, Ireland. AD - School of Medicine, University College Dublin, Dublin, Ireland. FAU - Tosetto, Miriam AU - Tosetto M AD - School of Medicine, University College Dublin, Dublin, Ireland. FAU - Inzitiari, Rosanna AU - Inzitiari R AD - School of Medicine, University College Dublin, Dublin, Ireland. FAU - O'Reilly, Sophie AU - O'Reilly S AD - Centre for Experimental Pathogen Host Research, School of Medicine, University College Dublin, Ireland. FAU - Gu, Lili AU - Gu L AD - Centre for Experimental Pathogen Host Research, School of Medicine, University College Dublin, Ireland. FAU - Sheridan, Juliette AU - Sheridan J AD - Centre for Colorectal Disease, St Vincent's University Hospital, Dublin, Ireland. AD - School of Medicine, University College Dublin, Dublin, Ireland. FAU - Cullen, Garret AU - Cullen G AD - Centre for Colorectal Disease, St Vincent's University Hospital, Dublin, Ireland. AD - School of Medicine, University College Dublin, Dublin, Ireland. AD - INITIative IBD Research Network (www.initiativeibd.ie). FAU - Mc Dermott, Edel AU - Mc Dermott E AD - Centre for Colorectal Disease, St Vincent's University Hospital, Dublin, Ireland. FAU - Buckley, Maire AU - Buckley M AD - Centre for Colorectal Disease, St Vincent's University Hospital, Dublin, Ireland. AD - St Michaels Hospital, Dun Laoghaire, Co Dublin, Ireland. FAU - Horgan, Gareth AU - Horgan G AD - Centre for Colorectal Disease, St Vincent's University Hospital, Dublin, Ireland. AD - St Columcille's Hospital, Loughlinstown, Co Dublin, Ireland. FAU - Mulcahy, Hugh AU - Mulcahy H AD - Centre for Colorectal Disease, St Vincent's University Hospital, Dublin, Ireland. AD - School of Medicine, University College Dublin, Dublin, Ireland. FAU - Walshe, Margaret AU - Walshe M AD - Centre for Colorectal Disease, St Vincent's University Hospital, Dublin, Ireland. AD - School of Medicine, University College Dublin, Dublin, Ireland. AD - INITIative IBD Research Network (www.initiativeibd.ie). FAU - Ryan, Elizabeth J AU - Ryan EJ AD - Department of Biological Sciences, Health Research Institute, University of Limerick, Limerick, Ireland. FAU - Gautier, Virginie AU - Gautier V AD - Centre for Experimental Pathogen Host Research, School of Medicine, University College Dublin, Ireland. FAU - Prostko, John AU - Prostko J AD - Abbott Laboratories, Abbott Diagnostics, Lake Forest, IL 60045, USA. FAU - Frias, Edwin AU - Frias E AD - Abbott Laboratories, Abbott Diagnostics, Lake Forest, IL 60045, USA. FAU - Daghfal, David AU - Daghfal D AD - Abbott Laboratories, Abbott Diagnostics, Lake Forest, IL 60045, USA. FAU - Doran, Peter AU - Doran P AD - School of Medicine, University College Dublin, Dublin, Ireland. FAU - O'Morain, Colm AU - O'Morain C AD - Beacon Hospital, Sandyford, Co. Dublin and Trinity College Dublin, Ireland. AD - INITIative IBD Research Network (www.initiativeibd.ie). FAU - Doherty, Glen A AU - Doherty GA AD - Centre for Colorectal Disease, St Vincent's University Hospital, Dublin, Ireland. AD - School of Medicine, University College Dublin, Dublin, Ireland. AD - INITIative IBD Research Network (www.initiativeibd.ie). LA - eng GR - University College Dublin/ PT - Journal Article PT - Multicenter Study PT - Observational Study PL - England TA - J Crohns Colitis JT - Journal of Crohn's & colitis JID - 101318676 RN - 0 (COVID-19 Vaccines) RN - 0 (Antibodies, Viral) RN - 0 (Immunoglobulin G) RN - 0 (Spike Glycoprotein, Coronavirus) RN - 0 (spike protein, SARS-CoV-2) SB - IM MH - Humans MH - *Inflammatory Bowel Diseases/immunology/drug therapy/blood MH - Female MH - Male MH - *COVID-19/prevention & control/immunology MH - Adult MH - Middle Aged MH - *SARS-CoV-2/immunology MH - *COVID-19 Vaccines/immunology/administration & dosage MH - Prospective Studies MH - *Immunization, Secondary MH - Antibodies, Viral/blood/immunology MH - *Memory B Cells/immunology MH - Immunoglobulin G/blood/immunology MH - Spike Glycoprotein, Coronavirus/immunology MH - Immunologic Memory MH - *B-Lymphocytes/immunology OTO - NOTNLM OT - COVID-19 vaccination OT - Inflammatory bowel disease OT - immune response OT - memory B-cell response EDAT- 2023/04/06 06:00 MHDA- 2026/03/11 18:59 CRDT- 2023/04/05 14:42 PHST- 2026/03/11 18:59 [medline] PHST- 2023/04/06 06:00 [pubmed] PHST- 2023/04/05 14:42 [entrez] AID - 7109171 [pii] AID - 10.1093/ecco-jcc/jjad065 [doi] PST - ppublish SO - J Crohns Colitis. 2023 Oct 20;17(9):1445-1456. doi: 10.1093/ecco-jcc/jjad065. PMID- 36992336 OWN - NLM STAT- MEDLINE DCOM- 20230331 LR - 20230414 IS - 1999-4915 (Electronic) IS - 1999-4915 (Linking) VI - 15 IP - 3 DP - 2023 Feb 24 TI - Impact of Previous Common Human Coronavirus Exposure on SARS-CoV-2-Specific T-Cell and Memory B-Cell Response after mRNA-Based Vaccination. LID - 10.3390/v15030627 [doi] LID - 627 AB - OBJECTIVE: T-cell responses against SARS-CoV-2 are observed in unexposed individuals, attributed to previous common human coronavirus (HCoV) infections. We evaluated the evolution of this T-cell cross-reactive response and the specific memory B-cells (MBCs) after the SARS-CoV-2 mRNA-based vaccination and its impact on incident SARS-CoV-2 infections. METHODS: This was a longitudinal study of 149 healthcare workers (HCWs) that included 85 unexposed individuals that were subdivided according to previous T-cell cross-reactivity, who were compared to 64 convalescent HCWs. Changes in specific T-cell response and memory B-cell (MBC) levels were compared at baseline and after two doses of the SARS-CoV-2 mRNA-based vaccine. RESULTS: A cross-reactive T-cell response was found in 59% of unexposed individuals before vaccination. Antibodies against HKU1 positively correlated with OC43 and 229E antibodies. Spike-specific MBCs was scarce in unexposed HCWs regardless of the presence of baseline T-cell cross-reactivity. After vaccination, 92% and 96% of unexposed HCWs with cross-reactive T-cells had CD4+ and CD8+ T-cell responses to the spike protein, respectively. Similar results to that were found in convalescents (83% and 92%, respectively). Contrarily, higher than that which was observed in unexposed individuals without T-cell cross-reactivity showed lower CD4+ and CD8+ T-cell responses (73% in both cases, p = 0.03). Nevertheless, previous cross-reactive T-cell response was not associated with higher levels of MBCs after vaccination in unexposed HCWs. During a follow-up of 434 days (IQR, 339-495) after vaccination, 49 HCWs (33%) became infected, with a significant positive correlation between spike-specific MBC levels and isotypes IgG+ and IgA+ after vaccination and a longer time to get infected. Interestingly, T-cell cross-reactivity did not reduce the time to vaccine breakthrough infections. CONCLUSION: While pre-existing T-cell cross-reactivity enhances the T-cell response after vaccination, it does not increase SARS-CoV-2-specific MBC levels in the absence of previous infection. Overall, the level of specific MBCs determines the time to breakthrough infections, regardless of the presence of T-cell cross-reactivity. FAU - Casado, Jose L AU - Casado JL AUID- ORCID: 0000-0002-7639-8591 AD - Department of Infectious Diseases, CIBERINFEC (Biomedical Research Center Network in Infectious Diseases, Centro de Investigacion en Red en Enfermedades Infecciosas), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain. AD - IRYCIS, Instituto Ramon y Cajal de Investigaciones Sanitarias, 28034 Madrid, Spain. FAU - Vizcarra, Pilar AU - Vizcarra P AUID- ORCID: 0000-0001-8553-6995 AD - Department of Infectious Diseases, CIBERINFEC (Biomedical Research Center Network in Infectious Diseases, Centro de Investigacion en Red en Enfermedades Infecciosas), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain. AD - IRYCIS, Instituto Ramon y Cajal de Investigaciones Sanitarias, 28034 Madrid, Spain. FAU - Martin-Hondarza, Adrian AU - Martin-Hondarza A AD - IRYCIS, Instituto Ramon y Cajal de Investigaciones Sanitarias, 28034 Madrid, Spain. AD - Laboratory of Immunovirology, IRYCIS, 28034 Madrid, Spain. FAU - Blasco, Magdalena AU - Blasco M AD - Department of Occupational Safety and Health, Hospital Universitario Ramon y Cajal, 28034 Madrid, Spain. FAU - Grandal-Platero, Marta AU - Grandal-Platero M AD - Department of Occupational Safety and Health, Hospital Universitario Ramon y Cajal, 28034 Madrid, Spain. FAU - Haemmerle, Johannes AU - Haemmerle J AD - Department of Occupational Safety and Health, Hospital Universitario Ramon y Cajal, 28034 Madrid, Spain. FAU - Fernandez-Escribano, Marina AU - Fernandez-Escribano M AD - Department of Occupational Safety and Health, Hospital Universitario Ramon y Cajal, 28034 Madrid, Spain. FAU - Vallejo, Alejandro AU - Vallejo A AUID- ORCID: 0000-0001-5360-878X AD - Department of Infectious Diseases, CIBERINFEC (Biomedical Research Center Network in Infectious Diseases, Centro de Investigacion en Red en Enfermedades Infecciosas), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain. AD - IRYCIS, Instituto Ramon y Cajal de Investigaciones Sanitarias, 28034 Madrid, Spain. AD - Laboratory of Immunovirology, IRYCIS, 28034 Madrid, Spain. LA - eng PT - Journal Article DEP - 20230224 PL - Switzerland TA - Viruses JT - Viruses JID - 101509722 RN - 0 (Antibodies) RN - 0 (RNA, Messenger) RN - 0 (Antibodies, Viral) RN - 0 (Spike Glycoprotein, Coronavirus) RN - 0 (spike protein, SARS-CoV-2) SB - IM MH - Humans MH - *SARS-CoV-2/genetics MH - Longitudinal Studies MH - *COVID-19/prevention & control MH - Antibodies MH - Breakthrough Infections MH - RNA, Messenger MH - Vaccination MH - Antibodies, Viral MH - Spike Glycoprotein, Coronavirus/genetics PMC - PMC10059801 OTO - NOTNLM OT - SARS-CoV-2 OT - coronavirus OT - cross-reactive OT - mRNA vaccine OT - memory B-cells COIS- The authors declare no conflict of interest. EDAT- 2023/03/31 06:00 MHDA- 2023/03/31 06:42 PMCR- 2023/02/24 CRDT- 2023/03/30 01:06 PHST- 2023/01/18 00:00 [received] PHST- 2023/02/14 00:00 [revised] PHST- 2023/02/24 00:00 [accepted] PHST- 2023/03/31 06:42 [medline] PHST- 2023/03/30 01:06 [entrez] PHST- 2023/03/31 06:00 [pubmed] PHST- 2023/02/24 00:00 [pmc-release] AID - v15030627 [pii] AID - viruses-15-00627 [pii] AID - 10.3390/v15030627 [doi] PST - epublish SO - Viruses. 2023 Feb 24;15(3):627. doi: 10.3390/v15030627. PMID- 36990297 OWN - NLM STAT- MEDLINE DCOM- 20230612 LR - 20260127 IS - 1090-2139 (Electronic) IS - 0889-1591 (Print) IS - 0889-1591 (Linking) VI - 111 DP - 2023 Jul TI - COVID-19 vaccination for the prevention and treatment of long COVID: A systematic review and meta-analysis. PG - 211-229 LID - S0889-1591(23)00079-X [pii] LID - 10.1016/j.bbi.2023.03.022 [doi] AB - Empirical evidence addressing the association between SARS-CoV-2 vaccination and long COVID would guide public health priorities and inform personal health decisions. Herein, the co-primary objectives are to determine the differential risk of long COVID in vaccinated versus unvaccinated patients, and the trajectory of long COVID following vaccination. Of 2775 articles identified via systematic search, 17 were included, and 6 were meta-analyzed. Meta-analytic results determined that at least one vaccine dose was associated with a protective effect against long COVID (OR 0.539, 95% CI 0.295-0.987, p = 0.045, N = 257 817). Qualitative analysis revealed that trajectories of pre-existing long COVID following vaccination were mixed, with most patients reporting no changes. The evidence herein supports SARS-CoV-2 vaccination for the prevention of long COVID, and recommends long COVID patients adhere to standard SARS-CoV-2 vaccination schedules. CI - Copyright (c) 2023 Elsevier Inc. All rights reserved. FAU - Ceban, Felicia AU - Ceban F AD - Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada; Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada; Brain and Cognition Discovery Foundation, Toronto, Ontario, Canada. FAU - Kulzhabayeva, Dana AU - Kulzhabayeva D AD - Department of Psychology, University of Toronto, Toronto, Ontario, Canada. FAU - Rodrigues, Nelson B AU - Rodrigues NB AD - Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada. FAU - Di Vincenzo, Joshua D AU - Di Vincenzo JD AD - Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada. FAU - Gill, Hartej AU - Gill H AD - Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada; Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada. FAU - Subramaniapillai, Mehala AU - Subramaniapillai M AD - Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada; Brain and Cognition Discovery Foundation, Toronto, Ontario, Canada. FAU - Lui, Leanna M W AU - Lui LMW AD - Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada; Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada. FAU - Cao, Bing AU - Cao B AD - Key Laboratory of Cognition and Personality, Faculty of Psychology, Ministry of Education, Southwest University, Chongqing 400715, China. FAU - Mansur, Rodrigo B AU - Mansur RB AD - Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada; Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada. FAU - Ho, Roger C AU - Ho RC AD - Department of Psychological Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228, Singapore; Institute for Health Innovation and Technology (iHealthtech), National University of Singapore, Singapore 119077, Singapore. FAU - Burke, Matthew J AU - Burke MJ AD - Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada; Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Canada; Department of Neurology, Division of Cognitive Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. FAU - Rhee, Taeho Greg AU - Rhee TG AD - Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA; Department of Public Health Sciences, University of Connecticut School of Medicine, Farmington, CT, USA. FAU - Rosenblat, Joshua D AU - Rosenblat JD AD - Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada; Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada. FAU - McIntyre, Roger S AU - McIntyre RS AD - Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada; Brain and Cognition Discovery Foundation, Toronto, Ontario, Canada; Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada; Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada; Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada. Electronic address: roger.mcintyre@bcdf.org. LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20230327 PL - Netherlands TA - Brain Behav Immun JT - Brain, behavior, and immunity JID - 8800478 RN - 0 (COVID-19 Vaccines) RN - 0 (CI 987) RN - 0 (Phenols) RN - 0 (Thiazoles) SB - IM EIN - Brain Behav Immun. 2024 Jan;115:758. doi: 10.1016/j.bbi.2023.09.020. PMID: 37806865 MH - Humans MH - *COVID-19 Vaccines MH - Post-Acute COVID-19 Syndrome MH - *COVID-19/prevention & control MH - SARS-CoV-2 MH - Vaccination MH - Phenols MH - Thiazoles PMC - PMC10067136 OTO - NOTNLM OT - Bipolar disorder OT - COVID-19 OT - Cognition OT - Depression OT - Inflammation OT - Long COVID OT - Mood disorders OT - Population health OT - Post-COVID-19 condition OT - Post-COVID-19 syndrome OT - Post-acute sequelae of COVID-19 PASC OT - Prevention OT - SARS-CoV-2 OT - Treatment OT - Vaccination COIS- Declaration of Competing Interest Dr. Roger S. McIntyre has received research grant support from CIHR/GACD/National Natural Science Foundation of China (NSFC) and the Milken Institute; speaker/consultation fees from Lundbeck, Janssen, Alkermes,Neumora Therapeutics, Boehringer Ingelheim,Sage,Biogen, Mitsubishi Tanabe, Purdue, Pfizer, Otsuka, Takeda, Neurocrine, Sunovion, Bausch Health, Axsome, Novo Nordisk, Kris, Sanofi, Eisai, IntraCellular, NewBridge Pharmaceuticals, Viatris, Abbvie, Atai Life Sciences. Dr. Roger S. McIntyre is a CEO of Braxia Scientific Corp. Dr. Roger Ho received funding from NUS Department of Psychological Medicine (R-177-000-100-001/R-177-000-003-001) and NUS iHeathtech Other Operating Expenses (R-722-000-004-731). Leanna M. W. Lui has received personal fees from Braxia Scientific Corp and honoraria from Medscape. Dr. Joshua D. Rosenblat is the medical director of Braxia Health (formally known as the Canadian Rapid Treatment Center of Excellence and is a fully owned subsidiary of Braxia Scientific Corp) which provides ketamine and esketamine treatment for depression; he has received research grant support from the American Psychiatric Association, the American Society of Psychopharmacology, the Canadian Cancer Society, the Canadian Psychiatric Association, the Joseph M. West Family Memorial Fund, the Timeposters Fellowship, the University Health Network Centre for Mental Health, and the University of Toronto and speaking, consultation, or research fees from Allergan, COMPASS, Janssen, Lundbeck, and Sunovion. Leanna Lui has received personal fees from Braxia Scientific Corp and honoraria Medscape. EDAT- 2023/03/30 06:00 MHDA- 2023/06/12 06:42 PMCR- 2023/03/27 CRDT- 2023/03/29 19:33 PHST- 2022/09/13 00:00 [received] PHST- 2023/03/10 00:00 [revised] PHST- 2023/03/23 00:00 [accepted] PHST- 2023/06/12 06:42 [medline] PHST- 2023/03/30 06:00 [pubmed] PHST- 2023/03/29 19:33 [entrez] PHST- 2023/03/27 00:00 [pmc-release] AID - S0889-1591(23)00079-X [pii] AID - 10.1016/j.bbi.2023.03.022 [doi] PST - ppublish SO - Brain Behav Immun. 2023 Jul;111:211-229. doi: 10.1016/j.bbi.2023.03.022. Epub 2023 Mar 27. PMID- 36963124 OWN - NLM STAT- MEDLINE DCOM- 20230411 LR - 20250626 IS - 1532-2653 (Electronic) IS - 0967-5868 (Print) IS - 0967-5868 (Linking) VI - 111 DP - 2023 May TI - Acute disseminated encephalomyelitis (ADEM) following COVID-19 vaccination: A systematic review. PG - 57-70 LID - S0967-5868(23)00066-8 [pii] LID - 10.1016/j.jocn.2023.03.008 [doi] AB - BACKGROUND: Although global vaccination against COVID-19 infection has its excellence, potential side effects are yet of concern. Several lines of evidence have proposed ADEM occurrence after SARS-CoV-2 infection. Moreover, a large number of case reports and case series have also suggested the casual association between ADEM and COVID-19 vaccination. To better understand the development of ADEM following COVID-19 vaccination and its potential association, we aimed to systematically review ADEM cases reported after COVID-19 vaccination. METHODS: We conducted a comprehensive systematic search using three databases including PubMed, Scopus, and Web of Science. Studies that reported ADEM after COVID-19 vaccination were eligible to include in our study. Observational studies, case reports, and case series which reported cases of ADEM with sufficient detail to confirm clinical diagnosis following COVID-19 vaccination were eligible to enter our study. RESULTS: Twenty studies were included in our systematic review after the abstract and full-text screening with a total of 54 cases. Among included patients, 45 (85.1 %) developed ADEM after the first dose of the COVID-19 vaccine, and seven (12.9 %) cases experienced ADEM after the second dose. The median time interval between vaccination and neurological symptoms was 14 days which ranged from 12 h to 63 days. Twelve (22.2 %) patients experienced symptoms of muscle weakness, ten (18.5 %) presented unconsciousness, nine (16.6 %) patients had urinary complaints, nine (16.6 %) had visual impairments, and five (9.2 %) experienced a seizure. After treatments, four (13.8 %) patients died. Forty-six patients had clinical improvement (85.1 %), also improvement in brain MRI was observed among 44 (81.4 %) patients. CONCLUSION: In conclusion, it is not clear that ADEM could be a potential complication of COVID-19 vaccination based on the current evidence and further studies are needed. However, this rare condition should not trigger stopping the mass vaccination programs since the only way to eradicate the current pandemic of COVID-19 is to extend the number of immunized people. CI - Copyright (c) 2023 Elsevier Ltd. All rights reserved. FAU - Nabizadeh, Fardin AU - Nabizadeh F AD - Neuroscience Research Group (NRG), Universal Scientific Education and Research Network (USERN), Tehran, Iran; School of Medicine, Iran University of Medical Sciences, Tehran, Iran. Electronic address: Fardinnabizade1378@gmail.com. FAU - Noori, Maryam AU - Noori M AD - Student Research Committee, School of Medicine, Iran University of Medical Sciences, Tehran, Iran; Urology Research Center, Tehran University of Medical Science, Tehran, Iran. FAU - Rahmani, Shayan AU - Rahmani S AD - School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. FAU - Hosseini, Helia AU - Hosseini H AD - Faculty of Medicine, Tehran University of Medical Sciences, Iran. LA - eng PT - Journal Article PT - Systematic Review DEP - 20230322 PL - Scotland TA - J Clin Neurosci JT - Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia JID - 9433352 RN - 0 (COVID-19 Vaccines) SB - IM CIN - J Clin Neurosci. 2023 Sep;115:164. doi: 10.1016/j.jocn.2023.04.010. PMID: 37088619 MH - Humans MH - *COVID-19/prevention & control/complications MH - *COVID-19 Vaccines/adverse effects MH - *Encephalomyelitis, Acute Disseminated/etiology/diagnosis MH - Observational Studies as Topic MH - SARS-CoV-2 MH - Vaccination/adverse effects PMC - PMC10030273 OTO - NOTNLM OT - ADEM OT - Acute disseminated encephalomyelitis OT - COVID-19 vaccination OT - Neurological OT - SARS-CoV-2 COIS- Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2023/03/25 06:00 MHDA- 2023/04/11 06:41 PMCR- 2023/03/22 CRDT- 2023/03/24 19:00 PHST- 2022/11/09 00:00 [received] PHST- 2023/03/13 00:00 [revised] PHST- 2023/03/16 00:00 [accepted] PHST- 2023/04/11 06:41 [medline] PHST- 2023/03/25 06:00 [pubmed] PHST- 2023/03/24 19:00 [entrez] PHST- 2023/03/22 00:00 [pmc-release] AID - S0967-5868(23)00066-8 [pii] AID - 10.1016/j.jocn.2023.03.008 [doi] PST - ppublish SO - J Clin Neurosci. 2023 May;111:57-70. doi: 10.1016/j.jocn.2023.03.008. Epub 2023 Mar 22. PMID- 36958334 OWN - NLM STAT- MEDLINE DCOM- 20230414 LR - 20240916 IS - 1097-4180 (Electronic) IS - 1074-7613 (Print) IS - 1074-7613 (Linking) VI - 56 IP - 4 DP - 2023 Apr 11 TI - SARS-CoV-2 breakthrough infection induces rapid memory and de novo T cell responses. PG - 879-892.e4 LID - S1074-7613(23)00091-2 [pii] LID - 10.1016/j.immuni.2023.02.017 [doi] AB - Although the protective role of neutralizing antibodies against COVID-19 is well established, questions remain about the relative importance of cellular immunity. Using 6 pMHC multimers in a cohort with early and frequent sampling, we define the phenotype and kinetics of recalled and primary T cell responses following Delta or Omicron breakthrough infection in previously vaccinated individuals. Recall of spike-specific CD4(+) T cells was rapid, with cellular proliferation and extensive activation evident as early as 1 day post symptom onset. Similarly, spike-specific CD8(+) T cells were rapidly activated but showed variable degrees of expansion. The frequency of activated SARS-CoV-2-specific CD8(+) T cells at baseline and peak inversely correlated with peak SARS-CoV-2 RNA levels in nasal swabs and accelerated viral clearance. Our study demonstrates that a rapid and extensive recall of memory T cell populations occurs early after breakthrough infection and suggests that CD8(+) T cells contribute to the control of viral replication in breakthrough SARS-CoV-2 infections. CI - Copyright (c) 2023 Elsevier Inc. All rights reserved. FAU - Koutsakos, Marios AU - Koutsakos M AD - Department of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia. Electronic address: marios.koutsakos@unimelb.edu.au. FAU - Reynaldi, Arnold AU - Reynaldi A AD - Kirby Institute, University of New South Wales, Kensington, NSW, Australia. FAU - Lee, Wen Shi AU - Lee WS AD - Department of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia. FAU - Nguyen, Julie AU - Nguyen J AD - Department of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia. FAU - Amarasena, Thakshila AU - Amarasena T AD - Department of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia. FAU - Taiaroa, George AU - Taiaroa G AD - Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital at The Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia; Department of Infectious Diseases, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia. FAU - Kinsella, Paul AU - Kinsella P AD - Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital at The Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia. FAU - Liew, Kwee Chin AU - Liew KC AD - Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital at The Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia. FAU - Tran, Thomas AU - Tran T AD - Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital at The Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia. FAU - Kent, Helen E AU - Kent HE AD - Department of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia. FAU - Tan, Hyon-Xhi AU - Tan HX AD - Department of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia. FAU - Rowntree, Louise C AU - Rowntree LC AD - Department of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia. FAU - Nguyen, Thi H O AU - Nguyen THO AD - Department of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia. FAU - Thomas, Paul G AU - Thomas PG AD - Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN, USA. FAU - Kedzierska, Katherine AU - Kedzierska K AD - Department of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia; Global Station for Zoonosis Control, Global Institution for Collaborative Research and Education (GI-CoRE), Hokkaido University, Sapporo, Japan. FAU - Petersen, Jan AU - Petersen J AD - Infection and Immunity Program and The Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, VIC, Australia. FAU - Rossjohn, Jamie AU - Rossjohn J AD - Infection and Immunity Program and The Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, VIC, Australia; Institute of Infection and Immunity, Cardiff University School of Medicine, Heath Park, Cardiff, UK. FAU - Williamson, Deborah A AU - Williamson DA AD - Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital at The Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia; Department of Infectious Diseases, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia. FAU - Khoury, David AU - Khoury D AD - Kirby Institute, University of New South Wales, Kensington, NSW, Australia. FAU - Davenport, Miles P AU - Davenport MP AD - Kirby Institute, University of New South Wales, Kensington, NSW, Australia. FAU - Kent, Stephen J AU - Kent SJ AD - Department of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia; Melbourne Sexual Health Centre and Department of Infectious Diseases, Alfred Hospital and Central Clinical School, Monash University, Melbourne, VIC, Australia. FAU - Wheatley, Adam K AU - Wheatley AK AD - Department of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia. FAU - Juno, Jennifer A AU - Juno JA AD - Department of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia. Electronic address: jennifer.juno@unimelb.edu.au. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230228 PL - United States TA - Immunity JT - Immunity JID - 9432918 RN - 0 (RNA, Viral) RN - 0 (Antibodies, Neutralizing) RN - 0 (Antibodies, Viral) RN - COVID-19 breakthrough infections SB - IM CIN - Nat Immunol. 2023 Apr;24(4):560. doi: 10.1038/s41590-023-01489-y. PMID: 36959298 MH - Humans MH - *COVID-19 MH - SARS-CoV-2 MH - CD8-Positive T-Lymphocytes MH - Breakthrough Infections MH - RNA, Viral MH - Antibodies, Neutralizing MH - Antibodies, Viral MH - Vaccination PMC - PMC9970913 OTO - NOTNLM OT - CD4 T cell immunity OT - CD8 T cell immunity OT - COVID-19 vaccines OT - Delta OT - Omicron OT - SARS-CoV-2 OT - T cell OT - breakthrough infection OT - multimer OT - vaccination COIS- Declaration of interests M.K. has acted as a consultant for Sanofi group of companies. EDAT- 2023/03/24 06:00 MHDA- 2023/04/14 06:42 PMCR- 2023/02/28 CRDT- 2023/03/23 19:42 PHST- 2022/12/15 00:00 [received] PHST- 2023/01/26 00:00 [revised] PHST- 2023/02/24 00:00 [accepted] PHST- 2023/04/14 06:42 [medline] PHST- 2023/03/24 06:00 [pubmed] PHST- 2023/03/23 19:42 [entrez] PHST- 2023/02/28 00:00 [pmc-release] AID - S1074-7613(23)00091-2 [pii] AID - 10.1016/j.immuni.2023.02.017 [doi] PST - ppublish SO - Immunity. 2023 Apr 11;56(4):879-892.e4. doi: 10.1016/j.immuni.2023.02.017. Epub 2023 Feb 28. PMID- 36944716 OWN - NLM STAT- MEDLINE DCOM- 20230323 LR - 20260127 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 13 IP - 1 DP - 2023 Mar 21 TI - Human memory T cell dynamics after aluminum-adjuvanted inactivated whole-virion SARS-CoV-2 vaccination. PG - 4610 LID - 10.1038/s41598-023-31347-8 [doi] LID - 4610 AB - This study evaluates the functional capacity of CD4(+) and CD8(+) terminally-differentiated effector (T(EMRA)), central memory (T(CM)), and effector memory (T(EM)) cells obtained from the volunteers vaccinated with an aluminum-adjuvanted inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac). The volunteers were followed for T cell immune responses following the termination of a randomized phase III clinical trial. Seven days and four months after the second dose of the vaccine, the memory T cell subsets were collected and stimulated by autologous monocyte-derived dendritic cells (mDCs) loaded with SARS-CoV-2 spike glycoprotein S1. Compared to the placebo group, memory T cells from the vaccinated individuals significantly proliferated in response to S1-loaded mDCs. CD4(+) and CD8(+) memory T cell proliferation was detected in 86% and 78% of the vaccinated individuals, respectively. More than 73% (after a short-term) and 62% (after an intermediate-term) of the vaccinated individuals harbored T(CM) and/or T(EM) cells that responded to S1-loaded mDCs by secreting IFN-gamma. The expression of CD25, CD38, 4-1BB, PD-1, and CD107a indicated a modulation in the memory T cell subsets. Especially on day 120, PD-1 was upregulated on CD4(+) T(EMRA) and T(CM), and on CD8(+) T(EM) and T(CM) cells; accordingly, proliferation and IFN-gamma secretion capacities tended to decline after 4 months. In conclusion, the combination of inactivated whole-virion particles with aluminum adjuvants possesses capacities to induce functional T cell responses. CI - (c) 2023. The Author(s). FAU - Tavukcuoglu, Ece AU - Tavukcuoglu E AD - Department of Basic Oncology, Hacettepe University Cancer Institute, 06100, Sihhiye, Ankara, Turkey. FAU - Yanik, Hamdullah AU - Yanik H AD - Department of Basic Oncology, Hacettepe University Cancer Institute, 06100, Sihhiye, Ankara, Turkey. FAU - Parveen, Mubaida AU - Parveen M AD - Department of Basic Oncology, Hacettepe University Cancer Institute, 06100, Sihhiye, Ankara, Turkey. FAU - Uluturk, Sila AU - Uluturk S AD - Department of Basic Oncology, Hacettepe University Cancer Institute, 06100, Sihhiye, Ankara, Turkey. FAU - Durusu-Tanriover, Mine AU - Durusu-Tanriover M AD - Department of Internal Medicine, Faculty of Medicine, Hacettepe University, Ankara, Turkey. FAU - Inkaya, Ahmet Cagkan AU - Inkaya AC AD - Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Hacettepe University, Ankara, Turkey. FAU - Akova, Murat AU - Akova M AD - Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Hacettepe University, Ankara, Turkey. FAU - Unal, Serhat AU - Unal S AD - Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Hacettepe University, Ankara, Turkey. FAU - Esendagli, Gunes AU - Esendagli G AD - Department of Basic Oncology, Hacettepe University Cancer Institute, 06100, Sihhiye, Ankara, Turkey. gunese@hacettepe.edu.tr. LA - eng PT - Clinical Trial, Phase III PT - Journal Article PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't DEP - 20230321 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 RN - 0 (COVID-19 Vaccines) RN - CPD4NFA903 (Aluminum) RN - 0 (Programmed Cell Death 1 Receptor) RN - 0 (Adjuvants, Immunologic) RN - 0 (sinovac COVID-19 vaccine) RN - 0 (Vaccines, Inactivated) SB - IM MH - Humans MH - *COVID-19 Vaccines MH - Aluminum MH - SARS-CoV-2 MH - CD8-Positive T-Lymphocytes MH - Memory T Cells MH - Programmed Cell Death 1 Receptor MH - *COVID-19/prevention & control MH - Adjuvants, Immunologic MH - Vaccination MH - Virion MH - Vaccines, Inactivated PMC - PMC10028771 COIS- The publication and article processing charges were covered by the funding received from Sinovac Life Sciences Co., Ltd. The funder was not involved in the study design, collection, analysis, interpretation of the data, the writing of this article or the decision to submit it for publication. The authors declare no other competing interests. EDAT- 2023/03/23 06:00 MHDA- 2023/03/24 06:00 PMCR- 2023/03/21 CRDT- 2023/03/22 00:20 PHST- 2022/11/22 00:00 [received] PHST- 2023/03/10 00:00 [accepted] PHST- 2023/03/22 00:20 [entrez] PHST- 2023/03/23 06:00 [pubmed] PHST- 2023/03/24 06:00 [medline] PHST- 2023/03/21 00:00 [pmc-release] AID - 10.1038/s41598-023-31347-8 [pii] AID - 31347 [pii] AID - 10.1038/s41598-023-31347-8 [doi] PST - epublish SO - Sci Rep. 2023 Mar 21;13(1):4610. doi: 10.1038/s41598-023-31347-8. PMID- 36932291 OWN - NLM STAT- MEDLINE DCOM- 20230619 LR - 20231121 IS - 1573-2592 (Electronic) IS - 0271-9142 (Print) IS - 0271-9142 (Linking) VI - 43 IP - 5 DP - 2023 Jul TI - Impaired B Cell Recall Memory and Reduced Antibody Avidity but Robust T Cell Response in CVID Patients After COVID-19 Vaccination. PG - 869-881 LID - 10.1007/s10875-023-01468-w [doi] AB - PURPOSE: Humoral and cellular immune responses were described after COVID-19 vaccination in patients with common variable immunodeficiency disorder (CVID). This study aimed to investigate SARS-CoV-2-specific antibody quality and memory function of B cell immunity as well as T cell responses after COVID-19 vaccination in seroresponding and non-responding CVID patients. METHODS: We evaluated antibody avidity and applied a memory B cell ELSPOT assay for functional B cell recall memory response to SARS-CoV-2 after COVID-19 vaccination in CVID seroresponders. We comparatively analyzed SARS-CoV-2 spike reactive polyfunctional T cell response and reactive peripheral follicular T helper cells (pT(FH)) by flow cytometry in seroresponding and non-seroresponding CVID patients. All CVID patients had previously failed to mount a humoral response to pneumococcal conjugate vaccine. RESULTS: SARS-CoV-2 spike antibody avidity of seroresponding CVID patients was significantly lower than in healthy controls. Only 30% of seroresponding CVID patients showed a minimal memory B cell recall response in ELISPOT assay. One hundred percent of CVID seroresponders and 83% of non-seroresponders had a detectable polyfunctional T cell response. Induction of antigen-specific CD4(+)CD154(+)CD137(+)CXCR5(+) pT(FH) cells by the COVID-19 vaccine was higher in CVID seroresponder than in non-seroresponder. Levels of pT(FH) did not correlate with antibody response or avidity. CONCLUSION: Reduced avidity and significantly impaired recall memory formation after COVID-19 vaccination in seroresponding CVID patients stress the importance of a more differentiated analysis of humoral immune response in CVID patients. Our observations challenge the clinical implications that follow the binary categorization into seroresponder and non-seroresponder. CI - (c) 2023. The Author(s). FAU - Steiner, Sophie AU - Steiner S AUID- ORCID: 0000-0002-2217-7566 AD - Institute of Medical Immunology, Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt Universitat Zu Berlin, Campus Virchow, Augustenburger Platz 1/Sudstrasse 2, 13353, Berlin, Germany. AD - Berlin Institute of Health, Berlin, Germany. FAU - Schwarz, Tatjana AU - Schwarz T AUID- ORCID: 0000-0002-6054-4750 AD - Berlin Institute of Health, Berlin, Germany. AD - Institute of Virology, Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat Zu Berlin, German Centre for Infection Research (DZIF), Associated Partner, Chariteplatz 1, 13353, Berlin, Germany. FAU - Corman, Victor M AU - Corman VM AUID- ORCID: 0000-0002-3605-0136 AD - Berlin Institute of Health, Berlin, Germany. AD - Institute of Virology, Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat Zu Berlin, German Centre for Infection Research (DZIF), Associated Partner, Chariteplatz 1, 13353, Berlin, Germany. AD - Labor Berlin-Charite Vivantes GmbH, Berlin, Germany. FAU - Jeworowski, Lara M AU - Jeworowski LM AUID- ORCID: 0000-0002-4159-4189 AD - Berlin Institute of Health, Berlin, Germany. AD - Institute of Virology, Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat Zu Berlin, German Centre for Infection Research (DZIF), Associated Partner, Chariteplatz 1, 13353, Berlin, Germany. FAU - Bauer, Sandra AU - Bauer S AUID- ORCID: 0000-0002-3497-4730 AD - Institute of Medical Immunology, Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt Universitat Zu Berlin, Campus Virchow, Augustenburger Platz 1/Sudstrasse 2, 13353, Berlin, Germany. AD - Berlin Institute of Health, Berlin, Germany. FAU - Drosten, Christian AU - Drosten C AUID- ORCID: 0000-0001-7923-0519 AD - Berlin Institute of Health, Berlin, Germany. AD - Institute of Virology, Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat Zu Berlin, German Centre for Infection Research (DZIF), Associated Partner, Chariteplatz 1, 13353, Berlin, Germany. FAU - Scheibenbogen, Carmen AU - Scheibenbogen C AUID- ORCID: 0000-0002-8554-9638 AD - Institute of Medical Immunology, Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt Universitat Zu Berlin, Campus Virchow, Augustenburger Platz 1/Sudstrasse 2, 13353, Berlin, Germany. AD - Berlin Institute of Health, Berlin, Germany. AD - Berlin Institute of Health at Charite - Universitatsmedizin Berlin, BIH Center for Regenerative Therapies (BCRT), Chariteplatz 1, Berlin, Germany. FAU - Hanitsch, Leif G AU - Hanitsch LG AUID- ORCID: 0000-0002-8181-0093 AD - Institute of Medical Immunology, Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt Universitat Zu Berlin, Campus Virchow, Augustenburger Platz 1/Sudstrasse 2, 13353, Berlin, Germany. leif-gunnar.hanitsch@charite.de. AD - Berlin Institute of Health, Berlin, Germany. leif-gunnar.hanitsch@charite.de. AD - Berlin Institute of Health at Charite - Universitatsmedizin Berlin, BIH Center for Regenerative Therapies (BCRT), Chariteplatz 1, Berlin, Germany. leif-gunnar.hanitsch@charite.de. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230317 PL - Netherlands TA - J Clin Immunol JT - Journal of clinical immunology JID - 8102137 RN - 0 (COVID-19 Vaccines) RN - 0 (Antibodies, Viral) SB - IM MH - Humans MH - Memory B Cells MH - COVID-19 Vaccines MH - Antibody Affinity MH - *Common Variable Immunodeficiency/therapy MH - *COVID-19 MH - SARS-CoV-2 MH - Vaccination MH - Antibodies, Viral PMC - PMC10023009 OTO - NOTNLM OT - COVID-19 OT - CVID OT - T cell response OT - antibody response OT - memory OT - vaccination COIS- VMC is named together with Charite-Universitatsmedizin Berlin and Euroimmun GmbH on a patent application (Methods and reagents for diagnosis of SARS-CoV-2 infection. Pub number 20210190797) filed recently regarding the diagnostic of SARS-CoV-2 by antibody testing. The other authors have no relevant financial or non-financial interests to disclose. EDAT- 2023/03/19 06:00 MHDA- 2023/06/19 13:08 PMCR- 2023/03/17 CRDT- 2023/03/18 00:28 PHST- 2022/12/23 00:00 [received] PHST- 2023/03/05 00:00 [accepted] PHST- 2023/06/19 13:08 [medline] PHST- 2023/03/19 06:00 [pubmed] PHST- 2023/03/18 00:28 [entrez] PHST- 2023/03/17 00:00 [pmc-release] AID - 10.1007/s10875-023-01468-w [pii] AID - 1468 [pii] AID - 10.1007/s10875-023-01468-w [doi] PST - ppublish SO - J Clin Immunol. 2023 Jul;43(5):869-881. doi: 10.1007/s10875-023-01468-w. Epub 2023 Mar 17. PMID- 36921035 OWN - NLM STAT- MEDLINE DCOM- 20230320 LR - 20230417 IS - 1946-6242 (Electronic) IS - 1946-6234 (Linking) VI - 15 IP - 687 DP - 2023 Mar 15 TI - Prior SARS-CoV-2 infection enhances and reshapes spike protein-specific memory induced by vaccination. PG - eade0550 LID - 10.1126/scitranslmed.ade0550 [doi] AB - The diversity of vaccination modalities and infection history are both variables that have an impact on the immune memory of individuals vaccinated against SARS-CoV-2. To gain more accurate knowledge of how these parameters imprint on immune memory, we conducted a long-term follow-up of SARS-CoV-2 spike protein-specific immune memory in unvaccinated and vaccinated COVID-19 convalescent individuals as well as in infection-naive vaccinated individuals. Here, we report that individuals from the convalescent vaccinated (hybrid immunity) group have the highest concentrations of spike protein-specific antibodies at 6 months after vaccination. As compared with infection-naive vaccinated individuals, they also display increased frequencies of an atypical mucosa-targeted memory B cell subset. These individuals also exhibited enhanced T(H)1 polarization of their SARS-CoV-2 spike protein-specific follicular T helper cell pool. Together, our data suggest that prior SARS-CoV-2 infection increases the titers of SARS-CoV-2 spike protein-specific antibody responses elicited by subsequent vaccination and induces modifications in the composition of the spike protein-specific memory B cell pool that are compatible with enhanced functional protection at mucosal sites. FAU - Barateau, Veronique AU - Barateau V AUID- ORCID: 0000-0001-7265-4335 AD - CIRI-Centre International de Recherche en Infectiologie, Univ Lyon, Universite Claude Bernard Lyon 1 Inserm, U1111, CNRS, UMR5308, ENS Lyon, Universite Jean Monnet de Saint-Etienne, Lyon 69007, France. FAU - Peyrot, Loic AU - Peyrot L AUID- ORCID: 0000-0001-8437-8470 AD - CIRI-Centre International de Recherche en Infectiologie, Univ Lyon, Universite Claude Bernard Lyon 1 Inserm, U1111, CNRS, UMR5308, ENS Lyon, Universite Jean Monnet de Saint-Etienne, Lyon 69007, France. FAU - Saade, Carla AU - Saade C AUID- ORCID: 0000-0001-5964-0588 AD - CIRI-Centre International de Recherche en Infectiologie, Univ Lyon, Universite Claude Bernard Lyon 1 Inserm, U1111, CNRS, UMR5308, ENS Lyon, Universite Jean Monnet de Saint-Etienne, Lyon 69007, France. FAU - Pozzetto, Bruno AU - Pozzetto B AUID- ORCID: 0000-0002-2603-8467 AD - CIRI-Centre International de Recherche en Infectiologie, Univ Lyon, Universite Claude Bernard Lyon 1 Inserm, U1111, CNRS, UMR5308, ENS Lyon, Universite Jean Monnet de Saint-Etienne, Lyon 69007, France. AD - Immunology laboratory, CIC1408, CHU Saint Etienne, Saint Etienne 42055, France. FAU - Brengel-Pesce, Karen AU - Brengel-Pesce K AUID- ORCID: 0000-0001-8795-0647 AD - Laboratoire Commun de Recherche Hospices Civils de Lyon-bioMerieux, Hospices Civils de Lyon, Hopital Lyon Sud, Pierre-Benite 69495, France. FAU - Elsensohn, Mad-Helenie AU - Elsensohn MH AD - Hospices Civils de Lyon, Pole Sante Publique, Service de Biostatistique et Bioinformatique, Lyon 69003, France. AD - CNRS, UMR 5558, Laboratoire de Biometrie et Biologie Evolutive, Equipe Biostatistique-Sante, Villeurbanne 69100, France. FAU - Allatif, Omran AU - Allatif O AUID- ORCID: 0000-0002-2539-972X AD - CIRI-Centre International de Recherche en Infectiologie, Univ Lyon, Universite Claude Bernard Lyon 1 Inserm, U1111, CNRS, UMR5308, ENS Lyon, Universite Jean Monnet de Saint-Etienne, Lyon 69007, France. FAU - Guibert, Nicolas AU - Guibert N AUID- ORCID: 0000-0002-1192-8301 AD - Occupational Health and Medicine Department, Hospices Civils de Lyon, Universite Claude Bernard Lyon1, Ifsttar, UMRESTTE, UMR T_9405, Lyon University, Avenue Rockefeller, Lyon 69008, France. FAU - Compagnon, Christelle AU - Compagnon C AD - Laboratoire Commun de Recherche Hospices Civils de Lyon-bioMerieux, Hospices Civils de Lyon, Hopital Lyon Sud, Pierre-Benite 69495, France. FAU - Mariano, Natacha AU - Mariano N AUID- ORCID: 0000-0001-8184-6830 AD - BIOASTER, 40 Avenue Tony Garnier, Lyon 69007, France. FAU - Chaix, Julie AU - Chaix J AD - BIOASTER, 40 Avenue Tony Garnier, Lyon 69007, France. FAU - Djebali, Sophia AU - Djebali S AUID- ORCID: 0000-0002-0567-5387 AD - CIRI-Centre International de Recherche en Infectiologie, Univ Lyon, Universite Claude Bernard Lyon 1 Inserm, U1111, CNRS, UMR5308, ENS Lyon, Universite Jean Monnet de Saint-Etienne, Lyon 69007, France. FAU - Fassier, Jean-Baptiste AU - Fassier JB AUID- ORCID: 0000-0003-3885-4987 AD - Occupational Health and Medicine Department, Hospices Civils de Lyon, Universite Claude Bernard Lyon1, Ifsttar, UMRESTTE, UMR T_9405, Lyon University, Avenue Rockefeller, Lyon 69008, France. FAU - Lina, Bruno AU - Lina B AD - CIRI-Centre International de Recherche en Infectiologie, Univ Lyon, Universite Claude Bernard Lyon 1 Inserm, U1111, CNRS, UMR5308, ENS Lyon, Universite Jean Monnet de Saint-Etienne, Lyon 69007, France. AD - Virology laboratory, Institute of Infectious Agents, National Reference Centre for Respiratory Viruses, Hospices Civils de Lyon, Lyon 69317, France. FAU - Lefsihane, Katia AU - Lefsihane K AD - CIRI-Centre International de Recherche en Infectiologie, Univ Lyon, Universite Claude Bernard Lyon 1 Inserm, U1111, CNRS, UMR5308, ENS Lyon, Universite Jean Monnet de Saint-Etienne, Lyon 69007, France. FAU - Espi, Maxime AU - Espi M AUID- ORCID: 0000-0003-1000-4737 AD - CIRI-Centre International de Recherche en Infectiologie, Univ Lyon, Universite Claude Bernard Lyon 1 Inserm, U1111, CNRS, UMR5308, ENS Lyon, Universite Jean Monnet de Saint-Etienne, Lyon 69007, France. FAU - Thaunat, Olivier AU - Thaunat O AUID- ORCID: 0000-0002-3648-8963 AD - CIRI-Centre International de Recherche en Infectiologie, Univ Lyon, Universite Claude Bernard Lyon 1 Inserm, U1111, CNRS, UMR5308, ENS Lyon, Universite Jean Monnet de Saint-Etienne, Lyon 69007, France. FAU - Marvel, Jacqueline AU - Marvel J AUID- ORCID: 0000-0001-6241-459X AD - CIRI-Centre International de Recherche en Infectiologie, Univ Lyon, Universite Claude Bernard Lyon 1 Inserm, U1111, CNRS, UMR5308, ENS Lyon, Universite Jean Monnet de Saint-Etienne, Lyon 69007, France. FAU - Rosa-Calatrava, Manuel AU - Rosa-Calatrava M AUID- ORCID: 0000-0002-7559-9527 AD - CIRI-Centre International de Recherche en Infectiologie, Univ Lyon, Universite Claude Bernard Lyon 1 Inserm, U1111, CNRS, UMR5308, ENS Lyon, Universite Jean Monnet de Saint-Etienne, Lyon 69007, France. FAU - Pizzorno, Andres AU - Pizzorno A AUID- ORCID: 0000-0002-0918-6804 AD - CIRI-Centre International de Recherche en Infectiologie, Univ Lyon, Universite Claude Bernard Lyon 1 Inserm, U1111, CNRS, UMR5308, ENS Lyon, Universite Jean Monnet de Saint-Etienne, Lyon 69007, France. FAU - Maucort-Boulch, Delphine AU - Maucort-Boulch D AUID- ORCID: 0000-0003-0042-7787 AD - Hospices Civils de Lyon, Pole Sante Publique, Service de Biostatistique et Bioinformatique, Lyon 69003, France. AD - CNRS, UMR 5558, Laboratoire de Biometrie et Biologie Evolutive, Equipe Biostatistique-Sante, Villeurbanne 69100, France. FAU - Henaff, Laetitia AU - Henaff L AD - CIRI-Centre International de Recherche en Infectiologie, Univ Lyon, Universite Claude Bernard Lyon 1 Inserm, U1111, CNRS, UMR5308, ENS Lyon, Universite Jean Monnet de Saint-Etienne, Lyon 69007, France. AD - Service D'Hygiene, Epidemiologie, Infectiovigilance et Prevention, Hopital Edouard Herriot, Hospices Civils de Lyon, Lyon 69008, France. FAU - Saadatian-Elahi, Mitra AU - Saadatian-Elahi M AUID- ORCID: 0000-0003-1265-8806 AD - CIRI-Centre International de Recherche en Infectiologie, Univ Lyon, Universite Claude Bernard Lyon 1 Inserm, U1111, CNRS, UMR5308, ENS Lyon, Universite Jean Monnet de Saint-Etienne, Lyon 69007, France. AD - Service D'Hygiene, Epidemiologie, Infectiovigilance et Prevention, Hopital Edouard Herriot, Hospices Civils de Lyon, Lyon 69008, France. FAU - Vanhems, Philippe AU - Vanhems P AD - CIRI-Centre International de Recherche en Infectiologie, Univ Lyon, Universite Claude Bernard Lyon 1 Inserm, U1111, CNRS, UMR5308, ENS Lyon, Universite Jean Monnet de Saint-Etienne, Lyon 69007, France. AD - Service D'Hygiene, Epidemiologie, Infectiovigilance et Prevention, Hopital Edouard Herriot, Hospices Civils de Lyon, Lyon 69008, France. FAU - Paul, Stephane AU - Paul S AUID- ORCID: 0000-0002-8830-4273 AD - CIRI-Centre International de Recherche en Infectiologie, Univ Lyon, Universite Claude Bernard Lyon 1 Inserm, U1111, CNRS, UMR5308, ENS Lyon, Universite Jean Monnet de Saint-Etienne, Lyon 69007, France. AD - Immunology laboratory, CIC1408, CHU Saint Etienne, Saint Etienne 42055, France. FAU - Walzer, Thierry AU - Walzer T AUID- ORCID: 0000-0002-0857-8179 AD - CIRI-Centre International de Recherche en Infectiologie, Univ Lyon, Universite Claude Bernard Lyon 1 Inserm, U1111, CNRS, UMR5308, ENS Lyon, Universite Jean Monnet de Saint-Etienne, Lyon 69007, France. FAU - Trouillet-Assant, Sophie AU - Trouillet-Assant S AUID- ORCID: 0000-0001-6439-4705 AD - CIRI-Centre International de Recherche en Infectiologie, Univ Lyon, Universite Claude Bernard Lyon 1 Inserm, U1111, CNRS, UMR5308, ENS Lyon, Universite Jean Monnet de Saint-Etienne, Lyon 69007, France. AD - Laboratoire Commun de Recherche Hospices Civils de Lyon-bioMerieux, Hospices Civils de Lyon, Hopital Lyon Sud, Pierre-Benite 69495, France. FAU - Defrance, Thierry AU - Defrance T AUID- ORCID: 0000-0002-6943-358X AD - CIRI-Centre International de Recherche en Infectiologie, Univ Lyon, Universite Claude Bernard Lyon 1 Inserm, U1111, CNRS, UMR5308, ENS Lyon, Universite Jean Monnet de Saint-Etienne, Lyon 69007, France. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230315 PL - United States TA - Sci Transl Med JT - Science translational medicine JID - 101505086 RN - 0 (spike protein, SARS-CoV-2) RN - 0 (Spike Glycoprotein, Coronavirus) RN - 0 (Antibodies) RN - 0 (Antibodies, Viral) RN - 0 (Antibodies, Neutralizing) SB - IM MH - Humans MH - *COVID-19/prevention & control MH - SARS-CoV-2 MH - Spike Glycoprotein, Coronavirus MH - Antibodies MH - Vaccination MH - Antibodies, Viral MH - Antibodies, Neutralizing EDAT- 2023/03/16 06:00 MHDA- 2023/03/21 06:00 CRDT- 2023/03/15 14:04 PHST- 2023/03/15 14:04 [entrez] PHST- 2023/03/16 06:00 [pubmed] PHST- 2023/03/21 06:00 [medline] AID - 10.1126/scitranslmed.ade0550 [doi] PST - ppublish SO - Sci Transl Med. 2023 Mar 15;15(687):eade0550. doi: 10.1126/scitranslmed.ade0550. Epub 2023 Mar 15. PMID- 36914088 OWN - NLM STAT- MEDLINE DCOM- 20231019 LR - 20231019 IS - 1872-7905 (Electronic) IS - 0022-1759 (Print) IS - 0022-1759 (Linking) VI - 515 DP - 2023 Apr TI - A FluoroSpot B assay for the detection of IgA and IgG SARS-CoV-2 spike-specific memory B cells: Optimization and qualification for use in COVID-19 vaccine trials. PG - 113457 LID - S0022-1759(23)00039-X [pii] LID - 10.1016/j.jim.2023.113457 [doi] AB - BACKGROUND: The generation of antigen-specific memory B cells is crucial to the long-term effectiveness of vaccines. When the protective antibodies circulating in the blood wane, memory B cells (MBC) can be rapidly reactivated and differentiated into antibody-secreting cells during a new infection. Such MBC responses are considered to be key in providing long-term protection after infection or vaccination. Here, we describe the optimization and qualification of a FluoroSpot assay to measure MBCs directed against the SARS-CoV-2 spike protein in the peripheral blood, for use in COVID-19 vaccine trials. METHODS: We developed a FluoroSpot assay enabling simultaneous enumeration of B cells secreting IgA or IgG spike-specific antibodies after polyclonal stimulation of peripheral blood mononuclear cells (PBMCs) with interleukin-2 and the toll-like receptor agonist R848 for 5 days. The antigen coating was optimized using a capture antibody directed against the spike subunit-2 glycoprotein of SARS-CoV-2 to immobilize recombinant trimeric spike protein onto the membrane. RESULTS: Compared to a direct spike protein coating, the addition of a capture antibody increased the number and the quality of detected spots for both spike-specific IgA and IgG secreting cells in PBMCs from COVID-19 convalescents. The qualification showed good sensitivity of the dual-color IgA-IgG FluoroSpot assay, with lower limits of quantitation of 18 background-subtracted (BS) antibody-secreting cells (ASCs)/well for spike-specific IgA and IgG responses. Linearity was demonstrated at values ranging from 18 to 73 and from 18 to 607 BS ASCs/well for spike-specific IgA and IgG, respectively, as was precision, with intermediate precision (percentage geometric coefficients of variation) of 12% and 26% for the proportion of spike-specific IgA and IgG MBCs (ratio specific/total IgA or Ig). The assay was specific, since no spike-specific MBCs were detected in PBMCs from pre-pandemic samples; the results were below the limit of detection of 17 BS ASCs/well. CONCLUSIONS: These results show that the dual-color IgA-IgG FluoroSpot provides a sensitive, specific, linear, and precise tool to detect spike-specific MBC responses. This MBC FluoroSpot assay is a method of choice for monitoring spike-specific IgA and IgG MBC responses induced by COVID-19 candidate vaccines in clinical trials. CI - Copyright (c) 2023. Published by Elsevier B.V. FAU - Bisceglia, Helene AU - Bisceglia H AD - Research Global Immunology Department, Sanofi, Marcy l'Etoile, France. FAU - Barrier, Julie AU - Barrier J AD - Research Global Immunology Department, Sanofi, Marcy l'Etoile, France. FAU - Ruiz, Joseline AU - Ruiz J AD - Translational and Early Development Biostatistics, Sanofi, Marcy l'Etoile, France. FAU - Pagnon, Anke AU - Pagnon A AD - Research Global Immunology Department, Sanofi, Marcy l'Etoile, France. Electronic address: anke.pagnon@sanofi.com. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230311 PL - Netherlands TA - J Immunol Methods JT - Journal of immunological methods JID - 1305440 RN - 0 (Antibodies, Viral) RN - 0 (COVID-19 Vaccines) RN - 0 (Immunoglobulin A) RN - 0 (Immunoglobulin G) RN - 0 (Spike Glycoprotein, Coronavirus) RN - 0 (spike protein, SARS-CoV-2) SB - IM MH - Humans MH - Antibodies, Viral MH - *COVID-19/prevention & control MH - *COVID-19 Vaccines MH - Immunoglobulin A MH - Immunoglobulin G MH - Leukocytes, Mononuclear MH - Memory B Cells MH - SARS-CoV-2 MH - Spike Glycoprotein, Coronavirus PMC - PMC10008040 OTO - NOTNLM OT - Assay optimization OT - COVID-19 OT - FluoroSpot OT - Memory B cells OT - Qualification OT - SARS-CoV-2 spike COIS- Declaration of Competing Interest All authors are employees of Sanofi and may hold stock. EDAT- 2023/03/14 06:00 MHDA- 2023/04/03 06:41 PMCR- 2023/03/11 CRDT- 2023/03/13 20:25 PHST- 2022/10/27 00:00 [received] PHST- 2023/02/23 00:00 [revised] PHST- 2023/03/08 00:00 [accepted] PHST- 2023/04/03 06:41 [medline] PHST- 2023/03/14 06:00 [pubmed] PHST- 2023/03/13 20:25 [entrez] PHST- 2023/03/11 00:00 [pmc-release] AID - S0022-1759(23)00039-X [pii] AID - 113457 [pii] AID - 10.1016/j.jim.2023.113457 [doi] PST - ppublish SO - J Immunol Methods. 2023 Apr;515:113457. doi: 10.1016/j.jim.2023.113457. Epub 2023 Mar 11. PMID- 36889911 OWN - NLM STAT- MEDLINE DCOM- 20230816 LR - 20230818 IS - 1468-330X (Electronic) IS - 0022-3050 (Linking) VI - 94 IP - 9 DP - 2023 Sep TI - Functional neurological disorders after COVID-19 and SARS-CoV-2 vaccines: a national multicentre observational study. PG - 776-777 LID - 10.1136/jnnp-2022-330885 [doi] FAU - Alonso-Canovas, Araceli AU - Alonso-Canovas A AUID- ORCID: 0000-0003-1702-2655 AD - Medicine Department, Universidad de Alcala, Madrid, Spain aracelialonsocanovas@gmail.com. AD - Movement Disorders Unit, Neurology Department. IRYCIS, Hospital Universitario Ramon y Cajal, Madrid, Spain. FAU - Kurtis, Monica M AU - Kurtis MM AD - Functional Movement Disorders Unit, Neurology Department, Hospital Ruber Internacional, Madrid, Spain. FAU - Gomez-Mayordomo, Victor AU - Gomez-Mayordomo V AUID- ORCID: 0000-0001-9343-8439 AD - Department of Neurology, Institute of Neurosciences, Vithas Hospital Group, Madrid, Spain. FAU - Macias-Garcia, Daniel AU - Macias-Garcia D AD - CIBERNED, Madrid, Spain. AD - Movement Disorders Unit, Neurology and Neurophysiology Department, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocio/CSIC/Universidad de Sevilla, Seville, Spain. FAU - Gutierrez Viedma, Alvaro AU - Gutierrez Viedma A AUID- ORCID: 0000-0003-0676-0433 AD - Functional Disorders Unit, Neurology Department, Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain. FAU - Mondragon Rezola, Elisabet AU - Mondragon Rezola E AD - Department of Neurology, Hospital Universitario Donostia, Instituto de Investigacion Sanitaria Biodonostia, San Sebastian, Spain. FAU - Pagonabarraga, Javier AU - Pagonabarraga J AD - Neurology Department, Hospital Sant Pau, Universitat Autonoma de Barcelona (UAB), Movement Disorders Unit, Barcelona, Spain. AD - Sant Pau Institute of Biomedical Research (IIB-Sant Pau), Barcelona, Spain. FAU - Aranzabal Orgaz, Lidia AU - Aranzabal Orgaz L AD - Internal Medicine Department, Hospital Universitario Ramon y Cajal, Madrid, Spain. FAU - Masjuan, Jaime AU - Masjuan J AD - Medicine Department, Universidad de Alcala, Madrid, Spain. AD - Movement Disorders Unit, Neurology Department. IRYCIS, Hospital Universitario Ramon y Cajal, Madrid, Spain. FAU - Martinez-Castrillo, Juan Carlos AU - Martinez-Castrillo JC AUID- ORCID: 0000-0001-7744-6850 AD - Medicine Department, Universidad de Alcala, Madrid, Spain. AD - Movement Disorders Unit, Neurology Department. IRYCIS, Hospital Universitario Ramon y Cajal, Madrid, Spain. FAU - Parees, Isabel AU - Parees I AD - Movement Disorders Unit, Neurology Department. IRYCIS, Hospital Universitario Ramon y Cajal, Madrid, Spain. AD - Functional Movement Disorders Unit, Neurology Department, Hospital Ruber Internacional, Madrid, Spain. LA - eng PT - Letter PT - Multicenter Study PT - Observational Study DEP - 20230308 PL - England TA - J Neurol Neurosurg Psychiatry JT - Journal of neurology, neurosurgery, and psychiatry JID - 2985191R RN - 0 (COVID-19 Vaccines) SB - IM CIN - J Neurol Neurosurg Psychiatry. 2023 Sep;94(9):777-778. doi: 10.1136/jnnp-2023-331447. PMID: 37028922 MH - Humans MH - *Conversion Disorder MH - *COVID-19/prevention & control MH - *COVID-19 Vaccines/adverse effects MH - SARS-CoV-2 OTO - NOTNLM OT - CONVERSION DISORDER OT - COVID-19 OT - FUNCTIONAL NEUROLOGICAL DISORDER COIS- Competing interests: None declared. EDAT- 2023/03/09 06:00 MHDA- 2023/08/16 06:43 CRDT- 2023/03/08 21:12 PHST- 2022/12/07 00:00 [received] PHST- 2023/02/23 00:00 [accepted] PHST- 2023/08/16 06:43 [medline] PHST- 2023/03/09 06:00 [pubmed] PHST- 2023/03/08 21:12 [entrez] AID - jnnp-2022-330885 [pii] AID - 10.1136/jnnp-2022-330885 [doi] PST - ppublish SO - J Neurol Neurosurg Psychiatry. 2023 Sep;94(9):776-777. doi: 10.1136/jnnp-2022-330885. Epub 2023 Mar 8. PMID- 36860850 OWN - NLM STAT- MEDLINE DCOM- 20230303 LR - 20230307 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 14 DP - 2023 TI - Persistent memory despite rapid contraction of circulating T Cell responses to SARS-CoV-2 mRNA vaccination. PG - 1100594 LID - 10.3389/fimmu.2023.1100594 [doi] LID - 1100594 AB - INTRODUCTION: While antibodies raised by SARS-CoV-2 mRNA vaccines have had compromised efficacy to prevent breakthrough infections due to both limited durability and spike sequence variation, the vaccines have remained highly protective against severe illness. This protection is mediated through cellular immunity, particularly CD8+ T cells, and lasts at least a few months. Although several studies have documented rapidly waning levels of vaccine-elicited antibodies, the kinetics of T cell responses have not been well defined. METHODS: Interferon (IFN)-gamma enzyme-linked immunosorbent spot (ELISpot) assay and intracellular cytokine staining (ICS) were utilized to assess cellular immune responses (in isolated CD8+ T cells or whole peripheral blood mononuclear cells, PBMCs) to pooled peptides spanning spike. ELISA was performed to quantitate serum antibodies against the spike receptor binding domain (RBD). RESULTS: In two persons receiving primary vaccination, tightly serially evaluated frequencies of anti-spike CD8+ T cells using ELISpot assays revealed strikingly short-lived responses, peaking after about 10 days and becoming undetectable by about 20 days after each dose. This pattern was also observed in cross-sectional analyses of persons after the first and second doses during primary vaccination with mRNA vaccines. In contrast, cross-sectional analysis of COVID-19-recovered persons using the same assay showed persisting responses in most persons through 45 days after symptom onset. Cross-sectional analysis using IFN-gamma ICS of PBMCs from persons 13 to 235 days after mRNA vaccination also demonstrated undetectable CD8+ T cells against spike soon after vaccination, and extended the observation to include CD4+ T cells. However, ICS analyses of the same PBMCs after culturing with the mRNA-1273 vaccine in vitro showed CD4+ and CD8+ T cell responses that were readily detectable in most persons out to 235 days after vaccination. DISCUSSION: Overall, we find that detection of spike-targeted responses from mRNA vaccines using typical IFN-gamma assays is remarkably transient, which may be a function of the mRNA vaccine platform and an intrinsic property of the spike protein as an immune target. However, robust memory, as demonstrated by capacity for rapid expansion of T cells responding to spike, is maintained at least several months after vaccination. This is consistent with the clinical observation of vaccine protection from severe illness lasting months. The level of such memory responsiveness required for clinical protection remains to be defined. CI - Copyright (c) 2023 Taus, Hofmann, Ibarrondo, Gong, Hausner, Fulcher, Krogstad, Kitchen, Ferbas, Tobin, Rimoin, Aldrovandi and Yang. FAU - Taus, Ellie AU - Taus E AD - Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States. FAU - Hofmann, Christian AU - Hofmann C AD - Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, United States. FAU - Ibarrondo, F Javier AU - Ibarrondo FJ AD - Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, United States. FAU - Gong, Laura S AU - Gong LS AD - Department of Microbiology, Immunology, and Molecular Genetics, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, United States. FAU - Hausner, Mary Ann AU - Hausner MA AD - Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, United States. FAU - Fulcher, Jennifer A AU - Fulcher JA AD - Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, United States. FAU - Krogstad, Paul AU - Krogstad P AD - Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States. AD - Department of Pediatrics, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, United States. FAU - Kitchen, Scott G AU - Kitchen SG AD - Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, United States. FAU - Ferbas, Kathie G AU - Ferbas KG AD - Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, United States. FAU - Tobin, Nicole H AU - Tobin NH AD - Department of Pediatrics, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, United States. FAU - Rimoin, Anne W AU - Rimoin AW AD - Fielding School of Public Health, University of California Los Angeles, Los Angeles, CA, United States. FAU - Aldrovandi, Grace M AU - Aldrovandi GM AD - Department of Pediatrics, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, United States. FAU - Yang, Otto O AU - Yang OO AD - Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, United States. AD - Department of Microbiology, Immunology, and Molecular Genetics, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, United States. LA - eng PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20230213 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 RN - EPK39PL4R4 (2019-nCoV Vaccine mRNA-1273) RN - 0 (Cytokines) RN - 0 (Antibodies, Viral) SB - IM MH - Humans MH - *SARS-CoV-2 MH - 2019-nCoV Vaccine mRNA-1273 MH - Cross-Sectional Studies MH - Leukocytes, Mononuclear MH - *COVID-19/prevention & control MH - Vaccination MH - Cytokines MH - Antibodies, Viral MH - Enzyme-Linked Immunospot Assay PMC - PMC9968837 OTO - NOTNLM OT - SARS-CoV-2 OT - SARS-CoV-2 mRNA vaccines OT - T cell memory OT - T cells OT - cellular immunity OT - elispot OT - intracellular cytokine staining COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be constructed as a potential conflict of interest. EDAT- 2023/03/03 06:00 MHDA- 2023/03/04 06:00 PMCR- 2023/02/13 CRDT- 2023/03/02 02:14 PHST- 2022/11/17 00:00 [received] PHST- 2023/01/24 00:00 [accepted] PHST- 2023/03/02 02:14 [entrez] PHST- 2023/03/03 06:00 [pubmed] PHST- 2023/03/04 06:00 [medline] PHST- 2023/02/13 00:00 [pmc-release] AID - 10.3389/fimmu.2023.1100594 [doi] PST - epublish SO - Front Immunol. 2023 Feb 13;14:1100594. doi: 10.3389/fimmu.2023.1100594. eCollection 2023. PMID- 36851668 OWN - NLM STAT- MEDLINE DCOM- 20230307 LR - 20230410 IS - 1999-4915 (Electronic) IS - 1999-4915 (Linking) VI - 15 IP - 2 DP - 2023 Feb 6 TI - Humoral SARS-CoV-2 Immune Response in COVID-19 Recovered Vaccinated and Unvaccinated Individuals Related to Post-COVID-Syndrome. LID - 10.3390/v15020454 [doi] LID - 454 AB - BACKGROUND: The duration of anti-SARS-CoV-2-antibody detectability up to 12 months was examined in individuals after either single convalescence or convalescence and vaccination. Moreover, variables that might influence an anti-RBD/S1 antibody decline and the existence of a post-COVID-syndrome (PCS) were addressed. METHODS: Forty-nine SARS-CoV-2-qRT-PCR-confirmed participants completed a 12-month examination of anti-SARS-CoV-2-antibody levels and PCS-associated long-term sequelae. Overall, 324 samples were collected. Cell-free DNA (cfDNA) was isolated and quantified from EDTA-plasma. As cfDNA is released into the bloodstream from dying cells, it might provide information on organ damage in the late recovery of COIVD-19. Therefore, we evaluated cfDNA concentrations as a biomarker for a PCS. In the context of antibody dynamics, a random forest-based logistic regression with antibody decline as the target was performed and internally validated. RESULTS: The mean percentage dynamic related to the maximum measured value was 96 (+/-38)% for anti-RBD/S1 antibodies and 30 (+/-26)% for anti-N antibodies. Anti-RBD/S1 antibodies decreased in 37%, whereas anti-SARS-CoV-2-anti-N antibodies decreased in 86% of the subjects. Clinical anti-RBD/S1 antibody decline prediction models, including vascular and other diseases, were cross-validated (highest AUC 0.74). Long-term follow-up revealed no significant reduction in PCS prevalence but an increase in cognitive impairment, with no indication for cfDNA as a marker for a PCS. CONCLUSION: Long-term anti-RBD/S1-antibody positivity was confirmed, and clinical parameters associated with declining titers were presented. A fulminant decrease in anti-SARS-CoV-2-anti-N antibodies was observed (mean change to maximum value 30 (+/-26)%). Anti-RBD/S1 antibody titers of SARS-CoV-2 recovered subjects boosted with a vaccine exceeded the maximum values measured after single infection by 235 +/- 382-fold, with no influence on preexisting PCS. PCS long-term prevalence was 38.6%, with an increase in cognitive impairment compromising the quality of life. Quantified cfDNA measured in the early post-COVID-19 phase might not be an effective marker for PCS identification. FAU - Gerhards, Catharina AU - Gerhards C AUID- ORCID: 0000-0001-7197-9242 AD - Institute for Clinical Chemistry, Medical Faculty Mannheim of the University of Heidelberg, Theodor Kutzer Ufer 1-3, 68167 Mannheim, Germany. FAU - Kittel, Maximilian AU - Kittel M AUID- ORCID: 0000-0002-2580-5038 AD - Institute for Clinical Chemistry, Medical Faculty Mannheim of the University of Heidelberg, Theodor Kutzer Ufer 1-3, 68167 Mannheim, Germany. FAU - Ast, Volker AU - Ast V AD - Institute for Clinical Chemistry, Medical Faculty Mannheim of the University of Heidelberg, Theodor Kutzer Ufer 1-3, 68167 Mannheim, Germany. FAU - Bugert, Peter AU - Bugert P AD - Institute of Transfusion Medicine and Immunology, Heidelberg University, 68167 Mannheim, Germany. AD - Medical Faculty Mannheim, European Center for Angioscience (ECAS), Heidelberg University, 68167 Mannheim, Germany. FAU - Froelich, Matthias F AU - Froelich MF AUID- ORCID: 0000-0001-8501-2147 AD - Department of Radiology and Nuclear Medicine, University Medical Center Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim, Germany. FAU - Hetjens, Michael AU - Hetjens M AD - Department of Biomedical Informatics, Center for Preventive Medicine and Digital Health, Medical Faculty Mannheim, Heidelberg University, 68167 Mannheim, Germany. FAU - Haselmann, Verena AU - Haselmann V AUID- ORCID: 0000-0002-8380-6581 AD - Institute for Clinical Chemistry, Medical Faculty Mannheim of the University of Heidelberg, Theodor Kutzer Ufer 1-3, 68167 Mannheim, Germany. FAU - Neumaier, Michael AU - Neumaier M AD - Institute for Clinical Chemistry, Medical Faculty Mannheim of the University of Heidelberg, Theodor Kutzer Ufer 1-3, 68167 Mannheim, Germany. FAU - Thiaucourt, Margot AU - Thiaucourt M AD - Institute for Clinical Chemistry, Medical Faculty Mannheim of the University of Heidelberg, Theodor Kutzer Ufer 1-3, 68167 Mannheim, Germany. LA - eng PT - Journal Article DEP - 20230206 PL - Switzerland TA - Viruses JT - Viruses JID - 101509722 RN - 0 (Antibodies, Viral) RN - 0 (Cell-Free Nucleic Acids) RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - Antibodies, Viral MH - *Cell-Free Nucleic Acids MH - Convalescence MH - *COVID-19/complications MH - Immunity, Humoral MH - Quality of Life MH - SARS-CoV-2 MH - COVID-19 Vaccines MH - Post-Acute COVID-19 Syndrome/etiology PMC - PMC9966735 OTO - NOTNLM OT - anti-SARS-CoV-2 antibodies OT - antibody dynamics OT - antibody kinetics OT - longitudinal assessment OT - post-COVID syndrome OT - post-vaccination boosting OT - serological immune response COIS- The authors have declared no conflict of interest. EDAT- 2023/03/01 06:00 MHDA- 2023/03/03 06:00 PMCR- 2023/02/06 CRDT- 2023/02/28 01:40 PHST- 2022/12/20 00:00 [received] PHST- 2023/02/01 00:00 [revised] PHST- 2023/02/03 00:00 [accepted] PHST- 2023/02/28 01:40 [entrez] PHST- 2023/03/01 06:00 [pubmed] PHST- 2023/03/03 06:00 [medline] PHST- 2023/02/06 00:00 [pmc-release] AID - v15020454 [pii] AID - viruses-15-00454 [pii] AID - 10.3390/v15020454 [doi] PST - epublish SO - Viruses. 2023 Feb 6;15(2):454. doi: 10.3390/v15020454. PMID- 36851087 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230301 IS - 2076-393X (Print) IS - 2076-393X (Electronic) IS - 2076-393X (Linking) VI - 11 IP - 2 DP - 2023 Jan 17 TI - Can COVID-19 Vaccines Induce Premature Non-Communicable Diseases: Where Are We Heading to? LID - 10.3390/vaccines11020208 [doi] LID - 208 AB - According to the WHO, as of January 2023, more than 850 million cases and over 6.6 million deaths from COVID-19 have been reported worldwide. Currently, the death rate has been reduced due to the decreased pathogenicity of new SARS-CoV-2 variants, but the major factor in the reduced death rates is the administration of more than 12.8 billion vaccine doses globally. While the COVID-19 vaccines are saving lives, serious side effects have been reported after vaccinations for several premature non-communicable diseases (NCDs). However, the reported adverse events are low in number. The scientific community must investigate the entire spectrum of COVID-19-vaccine-induced complications so that necessary safety measures can be taken, and current vaccines can be re-engineered to avoid or minimize their side effects. We describe in depth severe adverse events for premature metabolic, mental, and neurological disorders; cardiovascular, renal, and autoimmune diseases, and reproductive health issues detected after COVID-19 vaccinations and whether these are causal or incidental. In any case, it has become clear that the benefits of vaccinations outweigh the risks by a large margin. However, pre-existing conditions in vaccinated individuals need to be taken into account in the prevention and treatment of adverse events. FAU - Hromic-Jahjefendic, Altijana AU - Hromic-Jahjefendic A AD - Department of Genetics and Bioengineering, Faculty of Engineering and Natural Sciences, International University of Sarajevo, Hrasnicka Cesta 15, 71000 Sarajevo, Bosnia and Herzegovina. FAU - Barh, Debmalya AU - Barh D AUID- ORCID: 0000-0002-2557-7768 AD - Department of Genetics, Ecology and Evolution, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte 31270-901, Brazil. AD - Institute of Integrative Omics and Applied Biotechnology (IIOAB), Nonakuri, Purba Medinipur 721172, India. FAU - Uversky, Vladimir AU - Uversky V AUID- ORCID: 0000-0002-4037-5857 AD - Department of Molecular Medicine and USF Health Byrd Alzheimer's Institute, Morsani College of Medicine, University of South Florida, Tampa, FL 33612, USA. FAU - Aljabali, Alaa A AU - Aljabali AA AUID- ORCID: 0000-0002-9519-6338 AD - Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Yarmouk University, P.O. Box 566, Irbid 21163, Jordan. FAU - Tambuwala, Murtaza M AU - Tambuwala MM AUID- ORCID: 0000-0001-8499-9891 AD - Lincoln Medical School, Brayford Pool Campus, University of Lincoln, Lincoln LN6 7TS, UK. FAU - Alzahrani, Khalid J AU - Alzahrani KJ AUID- ORCID: 0000-0002-6688-0106 AD - Department of Clinical Laboratories Sciences, College of Applied Medical Sciences, Taif University, P.O. Box 11099, Taif 21944, Saudi Arabia. FAU - Alzahrani, Fuad M AU - Alzahrani FM AUID- ORCID: 0000-0001-6930-5214 AD - Department of Clinical Laboratories Sciences, College of Applied Medical Sciences, Taif University, P.O. Box 11099, Taif 21944, Saudi Arabia. FAU - Alshammeri, Saleh AU - Alshammeri S AUID- ORCID: 0000-0002-0179-0767 AD - Department of Optometry, College of Applied Medical Sciences, Qassim University, Buraydah 51452, Saudi Arabia. FAU - Lundstrom, Kenneth AU - Lundstrom K AD - PanTherapeutics, Route de Lavaux 49, CH1095 Lutry, Switzerland. LA - eng PT - Journal Article PT - Review DEP - 20230117 PL - Switzerland TA - Vaccines (Basel) JT - Vaccines JID - 101629355 PMC - PMC9960675 OTO - NOTNLM OT - COVID-19 vaccines OT - SARS-CoV-2 OT - premature NCDs OT - vaccine hesitancy COIS- The authors declare no conflict of interest. EDAT- 2023/03/01 06:00 MHDA- 2023/03/01 06:01 PMCR- 2023/01/17 CRDT- 2023/02/28 01:29 PHST- 2022/11/23 00:00 [received] PHST- 2023/01/05 00:00 [revised] PHST- 2023/01/13 00:00 [accepted] PHST- 2023/02/28 01:29 [entrez] PHST- 2023/03/01 06:00 [pubmed] PHST- 2023/03/01 06:01 [medline] PHST- 2023/01/17 00:00 [pmc-release] AID - vaccines11020208 [pii] AID - vaccines-11-00208 [pii] AID - 10.3390/vaccines11020208 [doi] PST - epublish SO - Vaccines (Basel). 2023 Jan 17;11(2):208. doi: 10.3390/vaccines11020208. PMID- 36841774 OWN - NLM STAT- MEDLINE DCOM- 20230228 LR - 20240928 IS - 2047-783X (Electronic) IS - 0949-2321 (Print) IS - 0949-2321 (Linking) VI - 28 IP - 1 DP - 2023 Feb 25 TI - A review of neurological side effects of COVID-19 vaccination. PG - 102 LID - 10.1186/s40001-023-00992-0 [doi] LID - 102 AB - Following the COVID-19 virus epidemic, extensive, coordinated international research has led to the rapid development of effective vaccines. Although vaccines are now considered the best way to achieve collective safety and control mortality, due to the critical situation, these vaccines have been issued the emergency use licenses and some of their potential subsequence side effects have been overlooked. At the same time, there are many reports of side effects after getting a COVID-19 vaccine. According to these reports, vaccination can have an adverse event, especially on nervous system. The most important and common complications are cerebrovascular disorders including cerebral venous sinus thrombosis, transient ischemic attack, intracerebral hemorrhage, ischemic stroke, and demyelinating disorders including transverse myelitis, first manifestation of MS, and neuromyelitis optica. These effects are often acute and transient, but they can be severe and even fatal in a few cases. Herein, we have provided a comprehensive review of documents reporting neurological side effects of COVID-19 vaccines in international databases from 2020 to 2022 and discussed neurological disorders possibly caused by vaccination. CI - (c) 2023. The Author(s). FAU - Hosseini, Roya AU - Hosseini R AD - Department of Biology, Faculty of Sciences, Shahid Bahonar University of Kerman, P.O.Box 76135-133, Kerman, Islamic Republic of Iran. FAU - Askari, Nayere AU - Askari N AD - Department of Biology, Faculty of Sciences, Shahid Bahonar University of Kerman, P.O.Box 76135-133, Kerman, Islamic Republic of Iran. askari.nr@uk.ac.ir. AD - Immunoregulation Research Center, Shahed University, Tehran, Islamic Republic of Iran. askari.nr@uk.ac.ir. LA - eng PT - Journal Article PT - Review DEP - 20230225 PL - England TA - Eur J Med Res JT - European journal of medical research JID - 9517857 RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - COVID-19 Vaccines MH - *COVID-19 MH - Vaccination MH - *Ischemic Stroke MH - SARS-CoV-2 PMC - PMC9959958 OTO - NOTNLM OT - COVID-19 OT - Myelitis OT - Neurological side effects OT - SARS Covid-2 OT - Thrombosis OT - Vaccine COIS- Not applicable. EDAT- 2023/02/26 06:00 MHDA- 2023/03/03 06:00 PMCR- 2023/02/25 CRDT- 2023/02/25 23:35 PHST- 2022/06/18 00:00 [received] PHST- 2023/01/04 00:00 [accepted] PHST- 2023/02/25 23:35 [entrez] PHST- 2023/02/26 06:00 [pubmed] PHST- 2023/03/03 06:00 [medline] PHST- 2023/02/25 00:00 [pmc-release] AID - 10.1186/s40001-023-00992-0 [pii] AID - 992 [pii] AID - 10.1186/s40001-023-00992-0 [doi] PST - epublish SO - Eur J Med Res. 2023 Feb 25;28(1):102. doi: 10.1186/s40001-023-00992-0. PMID- 36840605 OWN - NLM STAT- MEDLINE DCOM- 20230501 LR - 20230503 IS - 1477-0970 (Electronic) IS - 1352-4585 (Print) IS - 1352-4585 (Linking) VI - 29 IP - 4-5 DP - 2023 Apr TI - Acute central nervous system inflammation following COVID-19 vaccination: An observational cohort study. PG - 595-605 LID - 10.1177/13524585231154780 [doi] AB - BACKGROUND: Reports suggest a potential association between coronavirus disease 2019 (COVID-19) vaccines and acute central nervous system (CNS) inflammation. OBJECTIVE: The main objective of this study is to describe features of acute CNS inflammation following COVID-19 vaccination. METHODS: A retrospective observational cohort study was performed at the BARLO MS Centre in Toronto, Canada. Clinicians reported acute CNS inflammatory events within 60 days after a COVID-19 vaccine from March 2021 to August 2022. Clinical characteristics were evaluated. RESULTS: Thirty-eight patients (median age 39 (range: 20-82) years; 60.5% female) presented within 0-55 (median 15) days of a receiving a COVID-19 vaccine and were diagnosed with relapsing remitting multiple sclerosis (MS) (n = 16), post-vaccine transverse myelitis (n = 7), clinically isolated syndrome (n = 5), MS relapse (n = 4), tumefactive demyelination (n = 2), myelin oligodendrocyte glycoprotein antibody disease (n = 1), neuromyelitis optica spectrum disorder (n = 1), chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (n = 1) and primary autoimmune cerebellar ataxia (n = 1). Twenty-two received acute treatment and 21 started disease-modifying therapy. Sixteen received subsequent COVID-19 vaccination, of which 87.5% had no new or worsening neurological symptoms. CONCLUSION: To our knowledge, this is the largest study describing acute CNS inflammation after COVID-19 vaccination. We could not determine whether the number of inflammatory events was higher than expected. FAU - Lee, Sydney AU - Lee S AUID- ORCID: 0000-0002-8591-2062 AD - Department of Medicine, University of Toronto, St. Michael's Hospital, Toronto, ON, Canada. FAU - Muccilli, Alexandra AU - Muccilli A AD - Division of Neurology, Department of Medicine, BARLO MS Centre, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada. FAU - Schneider, Raphael AU - Schneider R AD - Division of Neurology, Department of Medicine, BARLO MS Centre, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada Li Ka Shing Knowledge Institute, Toronto, ON, Canada. FAU - Selchen, Daniel AU - Selchen D AD - Division of Neurology, Department of Medicine, BARLO MS Centre, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada. FAU - Krysko, Kristen M AU - Krysko KM AUID- ORCID: 0000-0003-0090-597X AD - Division of Neurology, Department of Medicine, BARLO MS Centre, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada Li Ka Shing Knowledge Institute, Toronto, ON, Canada. LA - eng PT - Journal Article PT - Observational Study DEP - 20230225 PL - England TA - Mult Scler JT - Multiple sclerosis (Houndmills, Basingstoke, England) JID - 9509185 RN - 0 (COVID-19 Vaccines) RN - 0 (Myelin-Oligodendrocyte Glycoprotein) SB - IM MH - Female MH - Humans MH - Male MH - COVID-19 Vaccines/adverse effects MH - Retrospective Studies MH - *COVID-19/prevention & control MH - Neoplasm Recurrence, Local MH - Central Nervous System MH - *Neuromyelitis Optica MH - Cohort Studies MH - Inflammation/etiology MH - Vaccination/adverse effects MH - Myelin-Oligodendrocyte Glycoprotein PMC - PMC9969223 OTO - NOTNLM OT - COVID-19 OT - central nervous system OT - demyelinating diseases OT - multiple sclerosis OT - neuroinflammatory diseases OT - vaccination COIS- The author(s) declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article. EDAT- 2023/02/26 06:00 MHDA- 2023/05/01 06:42 PMCR- 2023/02/25 CRDT- 2023/02/25 06:52 PHST- 2023/05/01 06:42 [medline] PHST- 2023/02/26 06:00 [pubmed] PHST- 2023/02/25 06:52 [entrez] PHST- 2023/02/25 00:00 [pmc-release] AID - 10.1177_13524585231154780 [pii] AID - 10.1177/13524585231154780 [doi] PST - ppublish SO - Mult Scler. 2023 Apr;29(4-5):595-605. doi: 10.1177/13524585231154780. Epub 2023 Feb 25. PMID- 36818474 OWN - NLM STAT- MEDLINE DCOM- 20230227 LR - 20230306 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 13 DP - 2022 TI - Nanocell COVID-19 vaccine triggers a novel immune response pathway producing high-affinity antibodies which neutralize all variants of concern. PG - 1038562 LID - 10.3389/fimmu.2022.1038562 [doi] LID - 1038562 AB - Most current anti-viral vaccines elicit a humoral and cellular immune response via the pathway of phagocytic cell mediated viral antigen presentation to B and T cell surface receptors. However, this pathway results in reduced ability to neutralize S-protein Receptor Binding Domains (RBDs) from several Variants of Concern (VOC) and the rapid waning of memory B cell response requiring vaccine reformulation to cover dominant VOC S-proteins and multiple boosters. Here we show for the first time in mice and humans, that a bacterially derived, non-living, nanocell (EDV; EnGeneIC Dream Vector) packaged with plasmid expressed SARS-CoV-2 S-protein and alpha-galactosyl ceramide adjuvant (EDV-COVID-alphaGC), stimulates an alternate pathway due to dendritic cells (DC) displaying both S-polypeptides and alphaGC thereby recruiting and activating iNKT cells with release of IFNgamma. This triggers DC activation/maturation, activation of follicular helper T cells (T(FH)), cognate help to B cells with secretion of a cytokine milieu promoting B cell maturation, somatic hypermutation in germinal centers to result in high affinity antibodies. Surrogate virus neutralization tests show 90-100% neutralization of ancestral and early VOC in mice and human trial volunteers. EDV-COVID-alphaGC as a third dose booster neutralized Omicron BA. 4/5. Serum and PBMC analyses reveal long lasting S-specific memory B and T cells. In contrast, control EDVs lacking alphaGC, did not engage the iNKT/DC pathway resulting in antibody responses unable to neutralize all VOCs and had a reduced B cell memory. The vaccine is lyophilized, stored and transported at room temperature with a shelf-life of over a year. CI - Copyright (c) 2023 Gao, Amaro-Mugridge, Madrid-Weiss, Petkovic, Vanegas, Visvanathan, Williams, MacDiarmid and Brahmbhatt. FAU - Gao, Steven Y AU - Gao SY AD - EngeneIC Pty Ltd., Sydney, NSW, Australia. FAU - Amaro-Mugridge, Nancy B AU - Amaro-Mugridge NB AD - EngeneIC Pty Ltd., Sydney, NSW, Australia. FAU - Madrid-Weiss, Jocelyn AU - Madrid-Weiss J AD - EngeneIC Pty Ltd., Sydney, NSW, Australia. FAU - Petkovic, Nikolina AU - Petkovic N AD - EngeneIC Pty Ltd., Sydney, NSW, Australia. FAU - Vanegas, Natasha AU - Vanegas N AD - EngeneIC Pty Ltd., Sydney, NSW, Australia. FAU - Visvanathan, Kumar AU - Visvanathan K AD - Kumar Visvanathan, Department of Medicine, University of Melbourne, Fitzroy, VIC, Australia. FAU - Williams, Bryan R G AU - Williams BRG AD - Department of Molecular and Translational Science, Hudson Institute of Medical Research, Monash University Faculty of Medicine, Nursing and Health Sciences, Clayton, VIC, Australia. FAU - MacDiarmid, Jennifer A AU - MacDiarmid JA AD - EngeneIC Pty Ltd., Sydney, NSW, Australia. FAU - Brahmbhatt, Himanshu AU - Brahmbhatt H AD - EngeneIC Pty Ltd., Sydney, NSW, Australia. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230127 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - Animals MH - Mice MH - *COVID-19 Vaccines MH - Leukocytes, Mononuclear MH - *COVID-19 MH - SARS-CoV-2 MH - Antigen Presentation PMC - PMC9929940 OTO - NOTNLM OT - COVID-19 OT - iNKT activation OT - memory B cell OT - memory T cell OT - nanocell vaccine OT - variants of concern COIS- HB, JM, NA-M, JM-W and BW are shareholders in EnGeneIC Ltd. HB, JM, and BW are on the Board of EnGeneIC Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2023/02/24 06:00 MHDA- 2023/03/03 06:00 PMCR- 2023/01/27 CRDT- 2023/02/23 09:51 PHST- 2022/09/07 00:00 [received] PHST- 2022/12/19 00:00 [accepted] PHST- 2023/02/23 09:51 [entrez] PHST- 2023/02/24 06:00 [pubmed] PHST- 2023/03/03 06:00 [medline] PHST- 2023/01/27 00:00 [pmc-release] AID - 10.3389/fimmu.2022.1038562 [doi] PST - epublish SO - Front Immunol. 2023 Jan 27;13:1038562. doi: 10.3389/fimmu.2022.1038562. eCollection 2022. PMID- 36812215 OWN - NLM STAT- MEDLINE DCOM- 20230224 LR - 20230407 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 18 IP - 2 DP - 2023 TI - Post COVID-19 condition after Wildtype, Delta, and Omicron SARS-CoV-2 infection and prior vaccination: Pooled analysis of two population-based cohorts. PG - e0281429 LID - 10.1371/journal.pone.0281429 [doi] LID - e0281429 AB - BACKGROUND: Post COVID-19 condition (PCC) is an important complication of SARS-CoV-2 infection, affecting millions worldwide. This study aimed to evaluate the prevalence and severity of post COVID-19 condition (PCC) with novel SARS-CoV-2 variants and after prior vaccination. METHODS: We used pooled data from 1350 SARS-CoV-2-infected individuals from two representative population-based cohorts in Switzerland, diagnosed between Aug 5, 2020, and Feb 25, 2022. We descriptively analysed the prevalence and severity of PCC, defined as the presence and frequency of PCC-related symptoms six months after infection, among vaccinated and non-vaccinated individuals infected with Wildtype, Delta, and Omicron SARS-CoV-2. We used multivariable logistic regression models to assess the association and estimate the risk reduction of PCC after infection with newer variants and prior vaccination. We further assessed associations with the severity of PCC using multinomial logistic regression. To identify groups of individuals with similar symptom patterns and evaluate differences in the presentation of PCC across variants, we performed exploratory hierarchical cluster analyses. RESULTS: We found strong evidence that vaccinated individuals infected with Omicron had reduced odds of developing PCC compared to non-vaccinated Wildtype-infected individuals (odds ratio 0.42, 95% confidence interval 0.24-0.68). The odds among non-vaccinated individuals were similar after infection with Delta or Omicron compared to Wildtype SARS-CoV-2. We found no differences in PCC prevalence with respect to the number of received vaccine doses or timing of last vaccination. The prevalence of PCC-related symptoms among vaccinated, Omicron-infected individuals was lower across severity levels. In cluster analyses, we identified four clusters of diverse systemic, neurocognitive, cardiorespiratory, and musculoskeletal symptoms, with similar patterns across variants. CONCLUSION: The risk of PCC appears to be lowered with infection by the Omicron variant and after prior vaccination. This evidence is crucial to guide future public health measures and vaccination strategies. CI - Copyright: (c) 2023 Ballouz et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. FAU - Ballouz, Tala AU - Ballouz T AUID- ORCID: 0000-0003-2334-8600 AD - Epidemiology, Biostatistics and Prevention Institute (EBPI), University of Zurich (UZH), Zurich, Switzerland. FAU - Menges, Dominik AU - Menges D AUID- ORCID: 0000-0001-5970-1846 AD - Epidemiology, Biostatistics and Prevention Institute (EBPI), University of Zurich (UZH), Zurich, Switzerland. FAU - Kaufmann, Marco AU - Kaufmann M AD - Epidemiology, Biostatistics and Prevention Institute (EBPI), University of Zurich (UZH), Zurich, Switzerland. FAU - Amati, Rebecca AU - Amati R AUID- ORCID: 0000-0001-5698-9071 AD - Faculty of Biomedical Sciences, Institute of Public Health (IPH), Universita della Svizzera Italiana (USI), Lugano, Switzerland. FAU - Frei, Anja AU - Frei A AD - Epidemiology, Biostatistics and Prevention Institute (EBPI), University of Zurich (UZH), Zurich, Switzerland. FAU - von Wyl, Viktor AU - von Wyl V AD - Epidemiology, Biostatistics and Prevention Institute (EBPI), University of Zurich (UZH), Zurich, Switzerland. FAU - Fehr, Jan S AU - Fehr JS AD - Epidemiology, Biostatistics and Prevention Institute (EBPI), University of Zurich (UZH), Zurich, Switzerland. FAU - Albanese, Emiliano AU - Albanese E AD - Faculty of Biomedical Sciences, Institute of Public Health (IPH), Universita della Svizzera Italiana (USI), Lugano, Switzerland. FAU - Puhan, Milo A AU - Puhan MA AUID- ORCID: 0000-0003-4721-1879 AD - Epidemiology, Biostatistics and Prevention Institute (EBPI), University of Zurich (UZH), Zurich, Switzerland. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230222 PL - United States TA - PLoS One JT - PloS one JID - 101285081 RN - SARS-CoV-2 variants SB - IM MH - Humans MH - *COVID-19 MH - SARS-CoV-2 MH - Vaccination MH - Cluster Analysis PMC - PMC9946205 COIS- The authors have declared that no competing interests exist. EDAT- 2023/02/23 06:00 MHDA- 2023/02/25 06:00 PMCR- 2023/02/22 CRDT- 2023/02/22 16:21 PHST- 2022/10/27 00:00 [received] PHST- 2023/01/23 00:00 [accepted] PHST- 2023/02/22 16:21 [entrez] PHST- 2023/02/23 06:00 [pubmed] PHST- 2023/02/25 06:00 [medline] PHST- 2023/02/22 00:00 [pmc-release] AID - PONE-D-22-29701 [pii] AID - 10.1371/journal.pone.0281429 [doi] PST - epublish SO - PLoS One. 2023 Feb 22;18(2):e0281429. doi: 10.1371/journal.pone.0281429. eCollection 2023. PMID- 36804404 OWN - NLM STAT- MEDLINE DCOM- 20230418 LR - 20230623 IS - 1600-0641 (Electronic) IS - 0168-8278 (Print) IS - 0168-8278 (Linking) VI - 78 IP - 5 DP - 2023 May TI - Boosting compromised SARS-CoV-2-specific immunity with mRNA vaccination in liver transplant recipients. PG - 1017-1027 LID - S0168-8278(23)00095-8 [pii] LID - 10.1016/j.jhep.2023.02.007 [doi] AB - BACKGROUND & AIMS: Liver transplant recipients (LTRs) demonstrate a reduced response to COVID-19 mRNA vaccination; however, a detailed understanding of the interplay between humoral and cellular immunity, especially after a third (and fourth) vaccine dose, is lacking. METHODS: We longitudinally compared the humoral, as well as CD4+ and CD8+ T-cell, responses between LTRs (n = 24) and healthy controls (n = 19) after three (LTRs: n = 9 to 16; healthy controls: n = 9 to 14 per experiment) to four (LTRs: n = 4; healthy controls: n = 4) vaccine doses, including in-depth phenotypical and functional characterization. RESULTS: Compared to healthy controls, development of high antibody titers required a third vaccine dose in most LTRs, while spike-specific CD8+ T cells with robust recall capacity plateaued after the second vaccine dose, albeit with a reduced frequency and epitope repertoire compared to healthy controls. This overall attenuated vaccine response was linked to a reduced frequency of spike-reactive follicular T helper cells in LTRs. CONCLUSION: Three doses of a COVID-19 mRNA vaccine induce an overall robust humoral and cellular memory response in most LTRs. Decisions regarding additional booster doses may thus be based on individual vaccine responses as well as evolution of novel variants of concern. IMPACT AND IMPLICATIONS: Due to immunosuppressive medication, liver transplant recipients (LTR) display reduced antibody titers upon COVID-19 mRNA vaccination, but the impact on long-term immune memory is not clear. Herein, we demonstrate that after three vaccine doses, the majority of LTRs not only exhibit substantial antibody titers, but also a robust memory T-cell response. Additional booster vaccine doses may be of special benefit for a small subset of LTRs with inferior vaccine response and may provide superior protection against evolving novel viral variants. These findings will help physicians to guide LTRs regarding the benefit of booster vaccinations. CI - Copyright (c) 2023 The Author(s). Published by Elsevier B.V. All rights reserved. FAU - Luxenburger, Hendrik AU - Luxenburger H AD - Department of Medicine II (Gastroenterology, Hepatology, Endocrinology and Infectious Diseases), Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany; IMM-PACT, Faculty of Medicine, University of Freiburg, Freiburg, Germany. FAU - Reeg, David B AU - Reeg DB AD - Department of Medicine II (Gastroenterology, Hepatology, Endocrinology and Infectious Diseases), Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany. FAU - Lang-Meli, Julia AU - Lang-Meli J AD - Department of Medicine II (Gastroenterology, Hepatology, Endocrinology and Infectious Diseases), Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany; IMM-PACT, Faculty of Medicine, University of Freiburg, Freiburg, Germany. FAU - Reinscheid, Matthias AU - Reinscheid M AD - Department of Medicine II (Gastroenterology, Hepatology, Endocrinology and Infectious Diseases), Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany; Faculty of Biology, University of Freiburg, Freiburg, Germany. FAU - Eisner, Miriam AU - Eisner M AD - Institute for Immunodeficiency, Center for Chronic Immunodeficiency (CCI), University Medical Center, Faculty of Medicine, University of Freiburg, 79106, Freiburg, Germany; Center for Pediatrics and Adolescent Medicine, University Medical Center, 79106, Freiburg, Germany. FAU - Bettinger, Dominik AU - Bettinger D AD - Department of Medicine II (Gastroenterology, Hepatology, Endocrinology and Infectious Diseases), Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany. FAU - Oberhardt, Valerie AU - Oberhardt V AD - Department of Medicine II (Gastroenterology, Hepatology, Endocrinology and Infectious Diseases), Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany. FAU - Salimi Alizei, Elahe AU - Salimi Alizei E AD - Department of Medicine II (Gastroenterology, Hepatology, Endocrinology and Infectious Diseases), Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany. FAU - Wild, Katharina AU - Wild K AD - Department of Medicine II (Gastroenterology, Hepatology, Endocrinology and Infectious Diseases), Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany. FAU - Graeser, Anne AU - Graeser A AD - Department of Medicine II (Gastroenterology, Hepatology, Endocrinology and Infectious Diseases), Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany. FAU - Karl, Vivien AU - Karl V AD - Department of Medicine II (Gastroenterology, Hepatology, Endocrinology and Infectious Diseases), Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany; Faculty of Biology, University of Freiburg, Freiburg, Germany. FAU - Sagar AU - Sagar AD - Department of Medicine II (Gastroenterology, Hepatology, Endocrinology and Infectious Diseases), Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany. FAU - Emmerich, Florian AU - Emmerich F AD - Institute for Transfusion Medicine and Gene Therapy, Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany. FAU - Klein, Florian AU - Klein F AD - Institute of Virology, Faculty of Medicine, University Hospital Cologne, University of Cologne, Cologne, Germany; Center for Molecular Medicine Cologne, University of Cologne, Cologne, Germany; German Center for Infection Research, Partner Site Bonn-Cologne, Cologne, Germany. FAU - Panning, Marcus AU - Panning M AD - Institute of Virology, Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany. FAU - Huzly, Daniela AU - Huzly D AD - Institute of Virology, Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany. FAU - Bengsch, Bertram AU - Bengsch B AD - Department of Medicine II (Gastroenterology, Hepatology, Endocrinology and Infectious Diseases), Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany; Signalling Research Centres BIOSS and CIBSS, University of Freiburg, Freiburg, Germany. FAU - Boettler, Tobias AU - Boettler T AD - Department of Medicine II (Gastroenterology, Hepatology, Endocrinology and Infectious Diseases), Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany. FAU - Elling, Roland AU - Elling R AD - Institute for Immunodeficiency, Center for Chronic Immunodeficiency (CCI), University Medical Center, Faculty of Medicine, University of Freiburg, 79106, Freiburg, Germany; Center for Pediatrics and Adolescent Medicine, University Medical Center, 79106, Freiburg, Germany. FAU - Thimme, Robert AU - Thimme R AD - Department of Medicine II (Gastroenterology, Hepatology, Endocrinology and Infectious Diseases), Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany. Electronic address: robert.thimme@uniklinik-freiburg.de. FAU - Hofmann, Maike AU - Hofmann M AD - Department of Medicine II (Gastroenterology, Hepatology, Endocrinology and Infectious Diseases), Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany. Electronic address: maike.hofmann@uniklinik-freiburg.de. FAU - Neumann-Haefelin, Christoph AU - Neumann-Haefelin C AD - Department of Medicine II (Gastroenterology, Hepatology, Endocrinology and Infectious Diseases), Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany. Electronic address: christoph.neumann-haefelin@uniklinik-freiburg.de. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230218 PL - Netherlands TA - J Hepatol JT - Journal of hepatology JID - 8503886 RN - 0 (COVID-19 Vaccines) RN - 0 (RNA, Messenger) RN - 0 (Antibodies, Viral) SB - IM MH - Humans MH - COVID-19 Vaccines MH - SARS-CoV-2 MH - *Liver Transplantation MH - *COVID-19/prevention & control MH - Vaccination MH - Immunity, Cellular MH - RNA, Messenger/genetics MH - Antibodies, Viral MH - Transplant Recipients PMC - PMC10019593 OTO - NOTNLM OT - COVID-19 OT - immunological memory OT - immunosuppression OT - liver transplantation OT - vaccine response EDAT- 2023/02/23 06:00 MHDA- 2023/04/18 10:16 PMCR- 2023/02/18 CRDT- 2023/02/22 08:42 PHST- 2022/10/25 00:00 [received] PHST- 2023/01/10 00:00 [revised] PHST- 2023/02/04 00:00 [accepted] PHST- 2023/04/18 10:16 [medline] PHST- 2023/02/23 06:00 [pubmed] PHST- 2023/02/22 08:42 [entrez] PHST- 2023/02/18 00:00 [pmc-release] AID - S0168-8278(23)00095-8 [pii] AID - 10.1016/j.jhep.2023.02.007 [doi] PST - ppublish SO - J Hepatol. 2023 May;78(5):1017-1027. doi: 10.1016/j.jhep.2023.02.007. Epub 2023 Feb 18. PMID- 36799523 OWN - NLM STAT- MEDLINE DCOM- 20230321 LR - 20230321 IS - 0028-3843 (Print) IS - 0028-3843 (Linking) VI - 57 IP - 1 DP - 2023 TI - Incidence and characteristics of post-COVID-19 parkinsonism and dyskinesia related to COVID-19 vaccines. PG - 53-62 LID - 10.5603/PJNNS.a2023.0011 [doi] AB - BACKGROUND: Coronavirus disease 2019 (COVID-19) is an infectious disease mainly affecting the respiratory system; however, a significant prevalence of neurological symptoms has been noted. OBJECTIVES: To investigate the incidence and characteristics of post-COVID-19 parkinsonism and to study dyskinesia related to COVID-19 vaccines. MATERIAL AND METHODS: The MEDLINE, PubMed, Scopus, and Web of Science databases were searched for all manuscripts relevant to post-COVID-19 parkinsonism and dyskinesia related to COVID-19 vaccines. Subsequently, we extracted and analysed data from the manuscripts in a structured manner. RESULTS: We found 24 patients with post-COVID-19 parkinsonism, with a mean onset age of 58 years after a mean of 30 days from the COVID-19 onset. Akinetic-rigid (n = 11) and mixed (n = 6) subtypes were the most common. Asymmetry was present in 13/15 patients. Brain MRI was unremarkable in 11/19, whereas dopaminergic system imaging was abnormal in 8/8 patients. Responsiveness to dopaminergic treatment was observed in 12/15 patients. Four patients improved after immunomodulatory therapy. Comorbidities were present in 9/24, encephalopathy symptoms in 11/24, and loss of smell in 9/13 patients. Most patients (n = 14) suffered serious COVID-19- related complications and three were treated with haloperidol. Parkinsonism improved (n = 5) or resolved (n = 4) during the follow-up. Five patients, with a mean age of 52, developed dyskinesia at a mean of 25 hours after receiving the COVID-19 mRNA vaccines. One patient had a history of neuropsychiatric symptoms and developed functional dyskinesia of the tongue. Four patients had a previous history of Parkinson's Disease (PD) with a mean duration of 10 years and developed dyskinesia and dystonia, which resolved (n = 2) or improved (n = 2) during the follow-up. CONCLUSIONS: Post-COVID-19 parkinsonism is a very rare complication, and it is likely that this is an umbrella syndrome that includes many different etiologies. Dyskinesia due to COVID-19 vaccines is exceedingly rare and probably has the same pathophysiological basis as in other conditions with exacerbation of PD symptoms. FAU - Dulski, Jaroslaw AU - Dulski J AUID- ORCID: 0000-0002-5517-9875 AD - Department of Neurology, Mayo Clinic, Jacksonville, Florida, USA. Dulski.Jaroslaw@mayo.edu. AD - Division of Neurological and Psychiatric Nursing, Faculty of Health Sciences, Medical University of Gdansk, Poland. Dulski.Jaroslaw@mayo.edu. AD - Neurology Department, St. Adalbert Hospital, Copernicus, Gdansk, Poland. Dulski.Jaroslaw@mayo.edu. FAU - Slawek, Jaroslaw AU - Slawek J AUID- ORCID: 0000-0001-6816-0877 AD - Division of Neurological and Psychiatric Nursing, Faculty of Health Sciences, Medical University of Gdansk, Poland. AD - Neurology Department, St. Adalbert Hospital, Copernicus, Gdansk, Poland. LA - eng PT - Journal Article DEP - 20230217 PL - Poland TA - Neurol Neurochir Pol JT - Neurologia i neurochirurgia polska JID - 0101265 RN - 0 (COVID-19 Vaccines) RN - VTD58H1Z2X (Dopamine) SB - IM MH - Humans MH - Middle Aged MH - *COVID-19/complications MH - *COVID-19 Vaccines/adverse effects MH - Dopamine MH - *Dyskinesia, Drug-Induced/diagnosis/etiology MH - Incidence MH - *Parkinsonian Disorders/etiology OTO - NOTNLM OT - Parkinson's Disease OT - SARS-CoV-2 OT - dopaminergic OT - dystonia OT - levodopa OT - vaccination EDAT- 2023/02/18 06:00 MHDA- 2023/03/03 06:00 CRDT- 2023/02/17 08:23 PHST- 2023/01/16 00:00 [received] PHST- 2023/01/30 00:00 [accepted] PHST- 2023/01/27 00:00 [revised] PHST- 2023/02/18 06:00 [pubmed] PHST- 2023/03/03 06:00 [medline] PHST- 2023/02/17 08:23 [entrez] AID - VM/OJS/J/93722 [pii] AID - 10.5603/PJNNS.a2023.0011 [doi] PST - ppublish SO - Neurol Neurochir Pol. 2023;57(1):53-62. doi: 10.5603/PJNNS.a2023.0011. Epub 2023 Feb 17. PMID- 36785539 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231216 IS - 2667-3215 (Electronic) IS - 2667-3215 (Linking) VI - 3 DP - 2023 Jun TI - Understanding the concept of trust and other factors related to COVID-19 vaccine intentions among Black/African American older adults prior to vaccine development. PG - 100230 LID - 10.1016/j.ssmqr.2023.100230 [doi] AB - BACKGROUND: Black/African Americans are receiving COVID-19 vaccines at much lower rates than whites. However, research is still evolving that explains why these vaccination rates are lower. The aim of this study was to examine the effects of the pandemic among older Black/African Americans, with an emphasis on trust and vaccine intention prior to vaccine development. METHODS: Data were collected between July and September 2020 from 8 virtual focus groups in Detroit, MI and San Francisco Bay Area, CA with 33 older African Americans and 11 caregivers of older African Americans with cognitive impairment, supplemented by one virtual meeting with the project's Community Advisory Board. Inductive/deductive content analysis was used to identify themes. RESULTS: Five major themes influenced the intention to be vaccinated: uncertainty, systemic abandonment, decrease in trust, resistance to vaccines, and opportunities for vaccination. The last theme, opportunities for vaccination, emerged as a result of interaction with our CAB while collecting project data after the vaccines were available which provided additional insights about potential opportunities that would promote the uptake of COVID-19 vaccination among older Black/African Americans. The results also include application of the themes to a multi-layer framework for understanding precarity and the development of an Integrated Logic Model for a Public Health Crisis. CONCLUSIONS: These findings suggest that trust and culturally relevant information need to be addressed immediately to accelerate vaccine uptake among older Black/African Americans. New initiatives are needed to foster trust and address systemic abandonment from all institutions. In addition, culturally relevant public health campaigns about vaccine uptake are needed. Thus, systemic issues need immediate attention to reduce health disparities associated with COVID-19. CI - (c) 2023 The Authors. FAU - Harris, Orlando O AU - Harris OO AD - Department of Community Health Systems, School of Nursing, University of California, San Francisco, San Francisco, CA, USA. FAU - Perry, Tam E AU - Perry TE AD - School of Social Work, Wayne State University, Detroit, MI, USA. FAU - Johnson, Julene K AU - Johnson JK AD - Institute for Health & Aging, School of Nursing, University of California, San Francisco, San Francisco, CA, USA. FAU - Lichtenberg, Peter AU - Lichtenberg P AD - Institute of Gerontology and Merrill Palmer Skillman Institute, Wayne State University, Detroit, MI, USA. FAU - Washington, Tangy AU - Washington T AD - Community Advisory Board, USA. FAU - Kitt, Bonita AU - Kitt B AD - Community Advisory Board, USA. FAU - Shaw, Michael AU - Shaw M AD - Community Advisory Board, USA. AD - Alameda County Public Health Department, Urban Male Health Initiative, USA. FAU - Keiser, Sahru AU - Keiser S AD - Institute for Health & Aging, School of Nursing, University of California, San Francisco, San Francisco, CA, USA. FAU - Tran, Thi AU - Tran T AD - Institute for Health & Aging, School of Nursing, University of California, San Francisco, San Francisco, CA, USA. FAU - Vest, Leah AU - Vest L AD - Institute for Health & Aging, School of Nursing, University of California, San Francisco, San Francisco, CA, USA. FAU - Maloof, Marsha AU - Maloof M AD - Maloof & Associates, San Francisco, CA, USA. FAU - Portacolone, Elena AU - Portacolone E AD - Institute for Health & Aging, School of Nursing, University of California, San Francisco, San Francisco, CA, USA. AD - Philip Lee Institute of Health Policy, University of California, San Francisco, San Francisco, CA, USA. LA - eng GR - K23 MH130250/MH/NIMH NIH HHS/United States GR - L30 MH134327/MH/NIMH NIH HHS/United States PT - Journal Article DEP - 20230204 PL - England TA - SSM Qual Res Health JT - SSM. Qualitative research in health JID - 9918300877606676 PMC - PMC9898052 COIS- The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2023/02/15 06:00 MHDA- 2023/02/15 06:01 PMCR- 2023/02/04 CRDT- 2023/02/14 01:53 PHST- 2022/02/25 00:00 [received] PHST- 2023/02/02 00:00 [revised] PHST- 2023/02/03 00:00 [accepted] PHST- 2023/02/14 01:53 [entrez] PHST- 2023/02/15 06:00 [pubmed] PHST- 2023/02/15 06:01 [medline] PHST- 2023/02/04 00:00 [pmc-release] AID - S2667-3215(23)00014-8 [pii] AID - 100230 [pii] AID - 10.1016/j.ssmqr.2023.100230 [doi] PST - ppublish SO - SSM Qual Res Health. 2023 Jun;3:100230. doi: 10.1016/j.ssmqr.2023.100230. Epub 2023 Feb 4. PMID- 36773014 OWN - NLM STAT- MEDLINE DCOM- 20230406 LR - 20230406 IS - 1468-1331 (Electronic) IS - 1351-5101 (Linking) VI - 30 IP - 5 DP - 2023 May TI - Decompressive surgery in cerebral venous sinus thrombosis due to vaccine-induced immune thrombotic thrombocytopenia. PG - 1335-1345 LID - 10.1111/ene.15735 [doi] AB - BACKGROUND AND PURPOSE: Cerebral venous sinus thrombosis due to vaccine-induced immune thrombotic thrombocytopenia (CVST-VITT) is an adverse drug reaction occurring after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. CVST-VITT patients often present with large intracerebral haemorrhages and a high proportion undergoes decompressive surgery. Clinical characteristics, therapeutic management and outcomes of CVST-VITT patients who underwent decompressive surgery are described and predictors of in-hospital mortality in these patients are explored. METHODS: Data from an ongoing international registry of patients who developed CVST within 28 days of SARS-CoV-2 vaccination, reported between 29 March 2021 and 10 May 2022, were used. Definite, probable and possible VITT cases, as defined by Pavord et al. (N Engl J Med 2021; 385: 1680-1689), were included. RESULTS: Decompressive surgery was performed in 34/128 (27%) patients with CVST-VITT. In-hospital mortality was 22/34 (65%) in the surgical and 27/94 (29%) in the non-surgical group (p < 0.001). In all surgical cases, the cause of death was brain herniation. The highest mortality rates were found amongst patients with preoperative coma (17/18, 94% vs. 4/14, 29% in the non-comatose; p < 0.001) and bilaterally absent pupillary reflexes (7/7, 100% vs. 6/9, 67% with unilaterally reactive pupil, and 4/11, 36% with bilaterally reactive pupils; p = 0.023). Postoperative imaging revealed worsening of index haemorrhagic lesion in 19 (70%) patients and new haemorrhagic lesions in 16 (59%) patients. At a median follow-up of 6 months, 8/10 of surgical CVST-VITT who survived admission were functionally independent. CONCLUSIONS: Almost two-thirds of surgical CVST-VITT patients died during hospital admission. Preoperative coma and bilateral absence of pupillary responses were associated with higher mortality rates. Survivors often achieved functional independence. CI - (c) 2023 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology. FAU - Krzywicka, Katarzyna AU - Krzywicka K AUID- ORCID: 0000-0002-9478-0401 AD - Department of Neurology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands. FAU - Aguiar de Sousa, Diana AU - Aguiar de Sousa D AUID- ORCID: 0000-0002-6702-7924 AD - Stroke Centre, Lisbon Central University Hospital Center, Lisbon, Portugal. AD - CEEM and Institute of Anatomy, Faculty of Medicine, University of Lisbon, Lisbon, Portugal. FAU - Cordonnier, Charlotte AU - Cordonnier C AD - INSERM, CHU Lille, U1172 - LilNCog - Lille Neuroscience & Cognition, University of Lille, Lille, France. FAU - Bode, Felix J AU - Bode FJ AD - Department of Neurology, Universitatsklinikum Bonn, Bonn, Germany. FAU - Field, Thalia S AU - Field TS AD - Vancouver Stroke Program, Division of Neurology, University of British Columbia, Vancouver, British Columbia, Canada. FAU - Michalski, Dominik AU - Michalski D AD - Department of Neurology, Leipzig University Hospital, Leipzig, Germany. FAU - Pelz, Johann AU - Pelz J AUID- ORCID: 0000-0003-4391-2280 AD - Department of Neurology, Leipzig University Hospital, Leipzig, Germany. FAU - Skjelland, Mona AU - Skjelland M AD - Department of Neurology, Oslo University Hospital, Oslo, Norway. FAU - Wiedmann, Markus AU - Wiedmann M AD - Department of Surgery, Oslo University Hospital, Oslo, Norway. FAU - Zimmermann, Julian AU - Zimmermann J AD - Department of Neurology, Universitatsklinikum Bonn, Bonn, Germany. FAU - Wittstock, Matthias AU - Wittstock M AD - Department of Neurology, University Hospital Rostock, Rostock, Germany. FAU - Zanotti, Bruno AU - Zanotti B AD - Department of Neuroscience, Neurology with Neurosurgical Activity, C. Poma Hospital, ASST di Mantova, Mantua, Italy. FAU - Ciccone, Alfonso AU - Ciccone A AUID- ORCID: 0000-0002-4590-3575 AD - Department of Neuroscience, Neurology with Neurosurgical Activity, C. Poma Hospital, ASST di Mantova, Mantua, Italy. FAU - Bandettini di Poggio, Monica AU - Bandettini di Poggio M AUID- ORCID: 0000-0001-8871-1103 AD - Department of Neuroscience, Policlinic San Martino Hospital, Genoa, Italy. FAU - Borhani-Haghighi, Afshin AU - Borhani-Haghighi A AD - Clinical Neurology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. FAU - Chatterton, Sophie AU - Chatterton S AD - Department of Neurology, Royal North Shore Hospital, Sydney, New South Wales, Australia. FAU - Aujayeb, Avinash AU - Aujayeb A AD - Respiratory Department, Northumbria Healthcare NHS Foundation Trust, Cramlington, UK. FAU - Devroye, Annemie AU - Devroye A AD - Department of Neurology, University Hospitals Leuven, Leuven, Belgium. FAU - Dizonno, Vanessa AU - Dizonno V AD - Vancouver Stroke Program, Division of Neurology, University of British Columbia, Vancouver, British Columbia, Canada. FAU - Geeraerts, Thomas AU - Geeraerts T AD - Department of Anesthesiology and Critical Care, University Toulouse 3-Paul-Sabatier, University Hospital of Toulouse, Hopital Pierre-Paul Riquet, CHU Toulouse-Purpan, Toulouse, France. FAU - Giammello, Fabrizio AU - Giammello F AUID- ORCID: 0000-0002-2828-1305 AD - Translational Molecular Medicine and Surgery, XXXVI Cycle, Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina, Italy. AD - Stroke Unit, Department of Clinical and Experimental Medicine, Polyclinic Hospital G. Martino, Messina, Italy. FAU - Gunther, Albrecht AU - Gunther A AUID- ORCID: 0000-0002-2394-3947 AD - Department of Neurology, Jena University Hospital, Jena, Germany. FAU - Ichaporia, Nasli R AU - Ichaporia NR AD - Department of Neurology, Jahangir Hospital, Pune, India. FAU - Kleinig, Timothy AU - Kleinig T AD - Department of Neurology, Royal Adelaide Hospital, Adelaide, South Australia, Australia. FAU - Kristoffersen, Espen S AU - Kristoffersen ES AUID- ORCID: 0000-0002-8999-5424 AD - Department of Neurology, Akershus University Hospital, Oslo, Norway. AD - Department of General Practice, University of Oslo, Oslo, Norway. FAU - Lemmens, Robin AU - Lemmens R AD - Department of Neurology, University Hospitals Leuven, Leuven, Belgium. FAU - De Maistre, Emmanuel AU - De Maistre E AD - Laboratoire d'Hematologie-Hemostase, Centre Hospitalier Universitaire Dijon, Dijon, France. FAU - Mirzaasgari, Zahra AU - Mirzaasgari Z AD - Department of Neurology, Firoozgar Hospital, School of Medicine, Iran University of Medical Science, Tehran, Iran. FAU - Payen, Jean-Francois AU - Payen JF AD - Department of Anaesthesia and Intensive Care, Grenoble Alpes University Hospital, and Grenoble Alpes University, Grenoble Institut des Neurosciences, INSERM U1216, Grenoble, France. FAU - Putaala, Jukka AU - Putaala J AD - Department of Neurology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland. FAU - Petruzzellis, Marco AU - Petruzzellis M AD - Department of Neurology, AOU Consorziale Policlinico di Bari, Bari, Italy. FAU - Raposo, Nicolas AU - Raposo N AUID- ORCID: 0000-0002-9152-4445 AD - Department of Neurology, Hopital Pierre-Paul Riquet, Centre Hospitalier Universitaire de Toulouse, Toulouse, France. AD - Inserm, Toulouse NeuroImaging Center, Universite de Toulouse, Toulouse, France. FAU - Sadeghi-Hokmabadi, Elyar AU - Sadeghi-Hokmabadi E AD - Department of Neurology, Imam-Reza Hospital, Tabriz University of Medical Sciences, Tabriz, Iran. FAU - Schoenenberger, Silvia AU - Schoenenberger S AUID- ORCID: 0000-0002-3348-6719 AD - Department of Neurology, Heidelberg University Hospital, Heidelberg, Germany. FAU - Umaiorubahan, Meenakshisundaram AU - Umaiorubahan M AD - Department of Neurology, Sri Ramachandra Medical College, Chennai, India. FAU - Sylaja, Padmavathy N AU - Sylaja PN AD - Comprehensive Stroke Care Program, Department of Neurology, Sree Chitra Tirunal Institute for Medical Sciences and Technology, Trivandrum, India. FAU - van de Munckhof, Anita AU - van de Munckhof A AD - Department of Neurology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands. FAU - Sanchez van Kammen, Mayte AU - Sanchez van Kammen M AD - Department of Neurology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands. FAU - Lindgren, Erik AU - Lindgren E AUID- ORCID: 0000-0002-7628-5044 AD - Department of Neurology, Sahlgrenska University Hospital and Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. AD - Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, Gothenburg, Sweden. FAU - Jood, Katarina AU - Jood K AD - Department of Neurology, Sahlgrenska University Hospital and Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. AD - Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, Gothenburg, Sweden. FAU - Scutelnic, Adrian AU - Scutelnic A AUID- ORCID: 0000-0001-9053-584X AD - Department of Neurology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. FAU - Heldner, Mirjam R AU - Heldner MR AUID- ORCID: 0000-0002-3594-2159 AD - Department of Neurology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. FAU - Poli, Sven AU - Poli S AD - Department of Neurology & Stroke, Eberhard-Karls University, Tuebingen, Germany. AD - Hertie Institute for Clinical Brain Research, Eberhard-Karls University, Tuebingen, Germany. FAU - Kruip, Marieke J H A AU - Kruip MJHA AD - Department of Hematology, Erasmus MC, Erasmus University Medical Center, Rotterdam, Netherlands. FAU - Arauz, Antonio AU - Arauz A AD - National Institute of Neurology and Surgery Manuel Velasco Suarez, Mexico City, Mexico. FAU - Conforto, Adriana B AU - Conforto AB AD - Hospital das Clinicas/Sao Paulo University and Hospital Israelita Albert Einstein, Sao Paulo, Brazil. FAU - Aaron, Sanjith AU - Aaron S AD - Neurology Unit, Department of Neurological Sciences, Christian Medical College and Hospital, Vellore, Tamil Nadu, India. FAU - Middeldorp, Saskia AU - Middeldorp S AD - Department of Internal Medicine and Radboud Institute of Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - Tatlisumak, Turgut AU - Tatlisumak T AD - Department of Neurology, Sahlgrenska University Hospital and Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. AD - Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, Gothenburg, Sweden. FAU - Arnold, Marcel AU - Arnold M AD - Department of Neurology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. FAU - Coutinho, Jonathan M AU - Coutinho JM AD - Department of Neurology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands. FAU - Ferro, Jose M AU - Ferro JM AD - Instituto de Medicina Molecular Joao Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal. CN - Cerebral Venous Sinus Thrombosis with Thrombocytopenia Syndrome Study Group LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230305 PL - England TA - Eur J Neurol JT - European journal of neurology JID - 9506311 RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - Coma MH - *COVID-19/prevention & control MH - *COVID-19 Vaccines/adverse effects MH - *Sinus Thrombosis, Intracranial/chemically induced/surgery MH - *Thrombocytopenia/chemically induced/surgery MH - *Purpura, Thrombocytopenic, Idiopathic/chemically induced/surgery OTO - NOTNLM OT - COVID-19 vaccinations OT - brain death OT - cerebral venous thrombosis OT - coma OT - surgery EDAT- 2023/02/12 06:00 MHDA- 2023/04/06 10:16 CRDT- 2023/02/11 09:03 PHST- 2023/01/22 00:00 [revised] PHST- 2022/11/22 00:00 [received] PHST- 2023/02/02 00:00 [accepted] PHST- 2023/04/06 10:16 [medline] PHST- 2023/02/12 06:00 [pubmed] PHST- 2023/02/11 09:03 [entrez] AID - 10.1111/ene.15735 [doi] PST - ppublish SO - Eur J Neurol. 2023 May;30(5):1335-1345. doi: 10.1111/ene.15735. Epub 2023 Mar 5. PMID- 36767087 OWN - NLM STAT- MEDLINE DCOM- 20230214 LR - 20240912 IS - 1660-4601 (Electronic) IS - 1661-7827 (Print) IS - 1660-4601 (Linking) VI - 20 IP - 3 DP - 2023 Jan 17 TI - Not Getting Vaccinated? It Is a Matter of Problem-Solving Abilities and Socio-Cognitive Polarization. LID - 10.3390/ijerph20031721 [doi] LID - 1721 AB - The anti-COVID-19 vaccination campaign in the United States provided a significant contribution to the control of the virus spread. Despite the recommendations by public health institutions, vaccine skepticism and hesitancy contributed to low vaccine uptake, thus possibly disrupting the management of preventable diseases associated with the COVID-19 infection. The process that led individuals to accept COVID-19 vaccines required the ability to gather, synthesize, and weigh-up information within a novel, dynamically changing, complex, and ambiguous context. To deal with such complexity, we hypothesized that both the ability of reflection and flexible adaptation played a fundamental role. Based on previous research on cognitive predictors of vaccine refusal, we decided to investigate the combined role of two constructs, namely, problem-solving skills and socio-cognitive polarization (SCP), on vaccine acceptance and uptake. Two-hundred-seventy-seven US participants completed an online survey aimed to measure problem-solving ability, through a rebus puzzles task, and SCP, through a composite measure of absolutist thinking, political conservatism, and xenophobia. Mediation analyses indicated that SCP mediated the association between problem-solving ability and vaccine acceptance, so lower problem-solving abilities associated with higher polarization predicted vaccine rejection. Thus, our findings suggested that low problem-solving skills may represent a risk factor for COVID-19 vaccine refusal, with cognitive and social rigidity playing a crucial role in undermining the anti-COVID-19 vaccine uptake. FAU - Cancer, Alice AU - Cancer A AUID- ORCID: 0000-0003-3545-8540 AD - Department of Psychology, Universita Cattolica del Sacro Cuore, 20123 Milan, Italy. FAU - Salvi, Carola AU - Salvi C AD - Department of Psychiatry and Behavioral Sciences, University of Texas at Austin, Austin, TX 78712, USA. AD - Department of Psychology and Social Sciences, John Cabot University, 00165 Rome, Italy. FAU - Antonietti, Alessandro AU - Antonietti A AUID- ORCID: 0000-0002-7212-8076 AD - Department of Psychology, Universita Cattolica del Sacro Cuore, 20123 Milan, Italy. FAU - Iannello, Paola AU - Iannello P AD - Department of Psychology, Universita Cattolica del Sacro Cuore, 20123 Milan, Italy. LA - eng PT - Journal Article DEP - 20230117 PL - Switzerland TA - Int J Environ Res Public Health JT - International journal of environmental research and public health JID - 101238455 RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - *COVID-19 Vaccines MH - *COVID-19/epidemiology/prevention & control MH - Acclimatization MH - Biological Transport MH - Cognition MH - Vaccination PMC - PMC9914091 OTO - NOTNLM OT - anti-COVID-19 vaccine OT - cognitive flexibility OT - political beliefs OT - problem solving OT - socio-cognitive polarization COIS- The authors declare no conflict of interest. EDAT- 2023/02/12 06:00 MHDA- 2023/02/15 06:00 PMCR- 2023/01/17 CRDT- 2023/02/11 01:11 PHST- 2022/12/31 00:00 [received] PHST- 2023/01/13 00:00 [revised] PHST- 2023/01/15 00:00 [accepted] PHST- 2023/02/11 01:11 [entrez] PHST- 2023/02/12 06:00 [pubmed] PHST- 2023/02/15 06:00 [medline] PHST- 2023/01/17 00:00 [pmc-release] AID - ijerph20031721 [pii] AID - ijerph-20-01721 [pii] AID - 10.3390/ijerph20031721 [doi] PST - epublish SO - Int J Environ Res Public Health. 2023 Jan 17;20(3):1721. doi: 10.3390/ijerph20031721. PMID- 36754764 OWN - NLM STAT- MEDLINE DCOM- 20230310 LR - 20230421 IS - 1873-2518 (Electronic) IS - 0264-410X (Print) IS - 0264-410X (Linking) VI - 41 IP - 10 DP - 2023 Mar 3 TI - A heterologous AZD1222 priming and BNT162b2 boosting regimen more efficiently elicits neutralizing antibodies, but not memory T cells, than the homologous BNT162b2 regimen. PG - 1694-1702 LID - S0264-410X(23)00094-4 [pii] LID - 10.1016/j.vaccine.2023.01.063 [doi] AB - BACKGROUND: Comparative analyses of SARS-CoV-2-specific immune responses elicited by diverse prime-boost regimens are required to establish efficient regimens for the control of COVID-19. METHOD: In this prospective observational cohort study, spike-specific immunoglobulin G (IgG) and neutralizing antibodies (nAbs) alongside spike-specific T-cell responses in age-matched groups of homologous BNT162b2/BNT162b2 or AZD1222/AZD1222 vaccination, heterologous AZD1222/BNT162b2 vaccination, and prior wild-type SARS-CoV-2 infection/vaccination were evaluated. RESULTS: Peak immune responses were achieved after the second vaccine dose in the naive vaccinated groups and after the first dose in the prior infection/vaccination group. Peak titers of anti-spike IgG and nAb were significantly higher in the AZD1222/BNT162b2 vaccination and prior infection/vaccination groups than in the BNT162b2/BNT162b2 or AZD1222/AZD1222 groups. However, the frequency of interferon-gamma-producing CD4(+) T cells was highest in the BNT162b2/BNT162b2 vaccination group. Similar results were observed in the analysis of polyfunctional T cells. When nAb and CD4(+)T-cell responses against the Delta variant were analyzed, the prior infection/vaccination group exhibited higher responses than the groups of other homologous or heterologous vaccination regimens. CONCLUSION: nAbs are efficiently elicited by heterologous AZD1222/BNT162b2 vaccination, as well as prior infection/vaccination, whereas spike-specific CD4(+)T-cell responses are efficiently elicited by homologous BNT162b2 vaccination. Variant-recognizing immunity is more efficiently generated by prior infection/vaccination than the other homologous or heterologous vaccination regimens. CI - Copyright (c) 2023 Elsevier Ltd. All rights reserved. FAU - Baek, Yae Jee AU - Baek YJ AD - Division of Infectious Diseases, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul 03722, Republic of Korea; Division of Infectious Diseases, Department of Internal Medicine, Soonchunhyang University Seoul Hospital, Soonchunhyang University College of Medicine, Seoul 04401, Republic of Korea. FAU - Kim, Woo-Joong AU - Kim WJ AD - Laboratory of Immunology and Infectious Diseases, Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon 34141, Republic of Korea. FAU - Ko, Jae-Hoon AU - Ko JH AD - Division of Infectious Diseases, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Republic of Korea. FAU - Lee, Youn-Jung AU - Lee YJ AD - Division of Infectious Diseases, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul 03722, Republic of Korea. FAU - Ahn, Jin Young AU - Ahn JY AD - Division of Infectious Diseases, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul 03722, Republic of Korea. FAU - Kim, Jung Ho AU - Kim JH AD - Division of Infectious Diseases, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul 03722, Republic of Korea. FAU - Jang, Ho Cheol AU - Jang HC AD - Laboratory of Immunology and Infectious Diseases, Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon 34141, Republic of Korea. FAU - Jeong, Hye Won AU - Jeong HW AD - Department of Internal Medicine, Chungbuk National University College of Medicine, Cheongju 28644, Republic of Korea. FAU - Kim, Yong Chan AU - Kim YC AD - Division of Infectious Disease, Department of Internal Medicine, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin 16995, Republic of Korea. FAU - Park, Yoon Soo AU - Park YS AD - Division of Infectious Disease, Department of Internal Medicine, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin 16995, Republic of Korea. FAU - Kim, Sung-Han AU - Kim SH AD - Department of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Republic of Korea. FAU - Peck, Kyong Ran AU - Peck KR AD - Division of Infectious Diseases, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Republic of Korea. FAU - Shin, Eui-Cheol AU - Shin EC AD - Laboratory of Immunology and Infectious Diseases, Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon 34141, Republic of Korea; The Center for Viral Immunology, Korea Virus Research Institute, Institute for Basic Science (IBS), Daejeon 34126, Republic of Korea. Electronic address: ecshin@kaist.ac.kr. FAU - Choi, Jun Yong AU - Choi JY AD - Division of Infectious Diseases, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul 03722, Republic of Korea. Electronic address: seran@yuhs.ac. LA - eng PT - Journal Article PT - Observational Study PT - Research Support, Non-U.S. Gov't DEP - 20230206 PL - Netherlands TA - Vaccine JT - Vaccine JID - 8406899 RN - 0 (Antibodies, Neutralizing) RN - 0 (Antibodies, Viral) RN - 0 (BNT162 Vaccine) RN - B5S3K2V0G8 (ChAdOx1 nCoV-19) RN - 0 (Immunoglobulin G) RN - SARS-CoV-2 variants SB - IM MH - Humans MH - *Antibodies, Neutralizing MH - Antibodies, Viral MH - BNT162 Vaccine MH - ChAdOx1 nCoV-19 MH - *COVID-19 MH - Immunoglobulin G MH - Prospective Studies MH - SARS-CoV-2 MH - Vaccination MH - T-Lymphocytes/immunology MH - Immunologic Memory PMC - PMC9901539 OTO - NOTNLM OT - Heterologous vaccination OT - Hybrid immunity OT - Neutralizing antibody OT - SARS-CoV-2 OT - T cell OT - Vaccine COIS- Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2023/02/09 06:00 MHDA- 2023/03/04 06:00 PMCR- 2023/02/06 CRDT- 2023/02/08 22:03 PHST- 2022/08/25 00:00 [received] PHST- 2022/10/28 00:00 [revised] PHST- 2023/01/25 00:00 [accepted] PHST- 2023/02/09 06:00 [pubmed] PHST- 2023/03/04 06:00 [medline] PHST- 2023/02/08 22:03 [entrez] PHST- 2023/02/06 00:00 [pmc-release] AID - S0264-410X(23)00094-4 [pii] AID - 10.1016/j.vaccine.2023.01.063 [doi] PST - ppublish SO - Vaccine. 2023 Mar 3;41(10):1694-1702. doi: 10.1016/j.vaccine.2023.01.063. Epub 2023 Feb 6. PMID- 36750902 OWN - NLM STAT- MEDLINE DCOM- 20230210 LR - 20230214 IS - 1743-422X (Electronic) IS - 1743-422X (Linking) VI - 20 IP - 1 DP - 2023 Feb 7 TI - Impaired antibody responses were observed in patients with type 2 diabetes mellitus after receiving the inactivated COVID-19 vaccines. PG - 22 LID - 10.1186/s12985-023-01983-7 [doi] LID - 22 AB - BACKGROUND: Patients with type 2 diabetes mellitus (T2DM) have been reported to be more susceptible to 2019 novel coronavirus (2019-nCoV) and more likely to develop severe pneumonia. However, the safety and immunological responses of T2DM patients after receiving the inactivated vaccines are not quite definite. Therefore, we aimed to explore the safety, antibody responses, and B-cell immunity of T2DM patients who were vaccinated with inactivated coronavirus disease 2019 (COVID-19) vaccines. METHODS: Eighty-nine patients with T2DM and 100 healthy controls (HCs) were enrolled, all of whom had received two doses of full-course inactivated vaccines. At 21-105 days after full-course vaccines: first, the safety of the vaccines was assessed by questionnaires; second, the titers of anti-receptor binding domain IgG (anti-RBD-IgG) and neutralizing antibodies (NAbs) were measured; third, we detected the frequency of RBD-specific memory B cells (RBD-specific MBCs) to explore the cellular immunity of T2DM patients. RESULTS: The overall incidence of adverse events was similar between T2DM patients and HCs, and no serious adverse events were recorded in either group. Compared with HCs, significantly lower titers of anti-RBD-IgG (p = 0.004) and NAbs (p = 0.013) were observed in T2DM patients. Moreover, the frequency of RBD-specific MBCs was lower in T2DM patients than in HCs (p = 0.027). Among the 89 T2DM patients, individuals with lower body mass index (BMI) had higher antibody titers (anti-RBD-IgG: p = 0.009; NAbs: p = 0.084). Furthermore, we found that sex, BMI, and days after vaccination were correlated with antibody titers. CONCLUSIONS: Inactivated COVID-19 vaccines were safe in patients with T2DM, but the antibody responses and memory B-cell responses were significantly decreased compared to HCs. TRIAL REGISTRATION NUMBER AND DATE: NCT05043246. September 14, 2021. (Clinical Trials.gov). CI - (c) 2023. The Author(s). FAU - Xiang, Feng AU - Xiang F AD - Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases, the Second Affiliated Hospital, Chongqing Medical University, Chongqing, China. FAU - Long, Boyu AU - Long B AD - Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases, the Second Affiliated Hospital, Chongqing Medical University, Chongqing, China. FAU - He, Jiaoxia AU - He J AD - Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases, the Second Affiliated Hospital, Chongqing Medical University, Chongqing, China. FAU - Cheng, Feifei AU - Cheng F AD - Department of Endocrine, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China. FAU - Zhang, Sijing AU - Zhang S AD - Department of Endocrine, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China. FAU - Liu, Qing AU - Liu Q AD - Department of Endocrine, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China. FAU - Chen, Zhiwei AU - Chen Z AD - Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases, the Second Affiliated Hospital, Chongqing Medical University, Chongqing, China. FAU - Li, Hu AU - Li H AD - Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases, the Second Affiliated Hospital, Chongqing Medical University, Chongqing, China. FAU - Chen, Min AU - Chen M AD - Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases, the Second Affiliated Hospital, Chongqing Medical University, Chongqing, China. FAU - Peng, Mingli AU - Peng M AD - Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases, the Second Affiliated Hospital, Chongqing Medical University, Chongqing, China. FAU - Yin, Wenwei AU - Yin W AD - Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases, the Second Affiliated Hospital, Chongqing Medical University, Chongqing, China. FAU - Liu, Dongfang AU - Liu D AD - Department of Endocrine, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China. ldf023023@qq.com. FAU - Ren, Hong AU - Ren H AD - Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases, the Second Affiliated Hospital, Chongqing Medical University, Chongqing, China. renhong0531@cqmu.edu.cn. LA - eng SI - ClinicalTrials.gov/NCT05043246 PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230207 PL - England TA - Virol J JT - Virology journal JID - 101231645 RN - 0 (Antibodies, Neutralizing) RN - 0 (Antibodies, Viral) RN - 0 (COVID-19 Vaccines) RN - 0 (Immunoglobulin G) RN - 0 (Vaccines, Inactivated) SB - IM MH - Humans MH - Antibodies, Neutralizing MH - Antibodies, Viral MH - Antibody Formation MH - *COVID-19/prevention & control MH - *COVID-19 Vaccines/adverse effects MH - *Diabetes Mellitus, Type 2 MH - Immunoglobulin G MH - SARS-CoV-2 MH - Vaccines, Inactivated MH - Case-Control Studies PMC - PMC9902824 OTO - NOTNLM OT - Antibody responses OT - COVID-19 vaccines OT - Memory B cells OT - Safety OT - Type 2 diabetes mellitus COIS- The authors declare no conflict of interest. EDAT- 2023/02/09 06:00 MHDA- 2023/02/10 06:00 PMCR- 2023/02/07 CRDT- 2023/02/08 00:15 PHST- 2022/12/17 00:00 [received] PHST- 2023/02/02 00:00 [accepted] PHST- 2023/02/08 00:15 [entrez] PHST- 2023/02/09 06:00 [pubmed] PHST- 2023/02/10 06:00 [medline] PHST- 2023/02/07 00:00 [pmc-release] AID - 10.1186/s12985-023-01983-7 [pii] AID - 1983 [pii] AID - 10.1186/s12985-023-01983-7 [doi] PST - epublish SO - Virol J. 2023 Feb 7;20(1):22. doi: 10.1186/s12985-023-01983-7. PMID- 36703960 OWN - NLM STAT- MEDLINE DCOM- 20230131 LR - 20230202 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 13 DP - 2022 TI - Three doses of BNT162b2 COVID-19 mRNA vaccine establish long-lasting CD8(+) T cell immunity in CLL and MDS patients. PG - 1035344 LID - 10.3389/fimmu.2022.1035344 [doi] LID - 1035344 AB - Patients with hematological malignancies are prioritized for COVID-19 vaccine due to their high risk for severe SARS-CoV-2 infection-related disease and mortality. To understand T cell immunity, its long-term persistence, and its correlation with antibody response, we evaluated the BNT162b2 COVID-19 mRNA vaccine-specific immune response in chronic lymphocytic leukemia (CLL) and myeloid dysplastic syndrome (MDS) patients. Longitudinal analysis of CD8(+) T cells using DNA-barcoded peptide-MHC multimers covering the full SARS-CoV-2 Spike-protein (415 peptides) showed vaccine-specific T cell activation and persistence of memory T cells up to six months post-vaccination. Surprisingly, a higher frequency of vaccine-induced antigen-specific CD8(+) T cells was observed in the patient group compared to a healthy donor group. Furthermore, and importantly, immunization with the second booster dose significantly increased the frequency of antigen-specific CD8(+) T cells as well as the total number of T cell specificities. Altogether 59 BNT162b2 mRNA vaccine-derived immunogenic responses were identified, of which 23 established long-term CD8(+) T cell memory response with a strong immunodominance for NYNYLYRLF (HLA-A24:02) and YLQPRTFLL (HLA-A02:01) epitopes. In summary, we mapped the vaccine-induced antigen-specific CD8(+) T cells and showed a booster-specific activation and enrichment of memory T cells that could be important for long-term disease protection in this patient group. CI - Copyright (c) 2023 Hernandez, Hersby, Munk, Tamhane, Trubach, Tagliamonte, Buonaguro, Gang, Hadrup and Saini. FAU - Hernandez, Susana Patricia Amaya AU - Hernandez SPA AD - Department of Health Technology, Section of Experimental and Translational Immunology, Technical University of Denmark, Kongens Lyngby, Denmark. FAU - Hersby, Ditte Stampe AU - Hersby DS AD - Department of Hematology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark. FAU - Munk, Kamilla Kjaergaard AU - Munk KK AD - Department of Health Technology, Section of Experimental and Translational Immunology, Technical University of Denmark, Kongens Lyngby, Denmark. FAU - Tamhane, Tripti AU - Tamhane T AD - Department of Health Technology, Section of Experimental and Translational Immunology, Technical University of Denmark, Kongens Lyngby, Denmark. FAU - Trubach, Darya AU - Trubach D AD - Department of Health Technology, Section of Experimental and Translational Immunology, Technical University of Denmark, Kongens Lyngby, Denmark. FAU - Tagliamonte, Maria AU - Tagliamonte M AD - Innovative Immunological Models Unit, National Cancer Institute Pascale Foundation - IRCCS, Napoli, Italy. FAU - Buonaguro, Luigi AU - Buonaguro L AD - Innovative Immunological Models Unit, National Cancer Institute Pascale Foundation - IRCCS, Napoli, Italy. FAU - Gang, Anne Ortved AU - Gang AO AD - Department of Hematology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark. FAU - Hadrup, Sine Reker AU - Hadrup SR AD - Department of Health Technology, Section of Experimental and Translational Immunology, Technical University of Denmark, Kongens Lyngby, Denmark. FAU - Saini, Sunil Kumar AU - Saini SK AD - Department of Health Technology, Section of Experimental and Translational Immunology, Technical University of Denmark, Kongens Lyngby, Denmark. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230110 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 RN - 0 (BNT162 Vaccine) SB - IM MH - Humans MH - *BNT162 Vaccine/immunology MH - CD8-Positive T-Lymphocytes MH - *COVID-19/prevention & control MH - *Leukemia, Lymphocytic, Chronic, B-Cell MH - *Myelodysplastic Syndromes MH - SARS-CoV-2 PMC - PMC9873231 OTO - NOTNLM OT - CD8+ T cell OT - Hematological cancer OT - SARS - CoV - 2 OT - T cell memory OT - T-cell immunity OT - mRNA vaccine against SARS-CoV-2 COIS- SH is the cofounder of PokeAcell and is the co-inventor of the patents WO2015185067 and WO2015188839 for the barcoded MHC technology which is licensed to Immudex and co-inventor of the licensed patent for Combination encoding of MHC multimers EP2088/009356, licensee: Sanquin, NL. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2023/01/28 06:00 MHDA- 2023/01/31 06:00 PMCR- 2023/01/10 CRDT- 2023/01/27 02:18 PHST- 2022/09/02 00:00 [received] PHST- 2022/12/20 00:00 [accepted] PHST- 2023/01/27 02:18 [entrez] PHST- 2023/01/28 06:00 [pubmed] PHST- 2023/01/31 06:00 [medline] PHST- 2023/01/10 00:00 [pmc-release] AID - 10.3389/fimmu.2022.1035344 [doi] PST - epublish SO - Front Immunol. 2023 Jan 10;13:1035344. doi: 10.3389/fimmu.2022.1035344. eCollection 2022. PMID- 36681970 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230202 IS - 2694-1902 (Electronic) IS - 2694-1902 (Linking) VI - 4 IP - 24 DP - 2022 Dec 12 TI - Transverse myelitis after Johnson & Johnson COVID-19 vaccine: illustrative case. LID - CASE22244 [pii] LID - 10.3171/CASE22244 [doi] AB - BACKGROUND: Transverse myelitis is a rare neurological occurrence with varied presentation. Imaging is necessary to properly diagnose this condition; however, identifying the cause of this condition may often be difficult. OBSERVATIONS: An otherwise healthy patient presented to the clinic with peculiar neurological symptoms without an obvious underlying cause. Imaging evidenced no significant structural defects but did lead to discovery of cord enhancement compatible with a diagnosis of transverse myelitis. Corticosteroid treatment was initiated rapidly to address this pathology, and the patient recovered without deficits. To identify the underlying cause, patient medical history was reviewed thoroughly and compared with existing literature. Previous tuberculosis infection could be a less likely cause of the neurological symptoms. However, recent vaccination with the Johnson & Johnson coronavirus disease 2019 (COVID-19) vaccine could be a more likely cause of the transverse myelitis, which has been rarely reported. LESSONS: Transverse myelitis after COVID-19 infection has been an escalating phenomenon. However, transverse myelitis after COVID-19 vaccination is a rare occurrence that is also on the rise. Given the increased rates of vaccination, transverse myelitis should not be overlooked as a potential pathology, due to the severity of neurological impairment if this condition is not treated rapidly. FAU - Mathew, Ezek AU - Mathew E AD - 1University of North Texas Health Science Center, Fort Worth, Texas; and. FAU - Williamson, Julie AU - Williamson J AD - 2Department of Neurosurgery, The Medical City of Frisco, Frisco, Texas. FAU - Mamo, Lois AU - Mamo L AD - 2Department of Neurosurgery, The Medical City of Frisco, Frisco, Texas. FAU - Dickerman, Rob AU - Dickerman R AD - 2Department of Neurosurgery, The Medical City of Frisco, Frisco, Texas. LA - eng PT - Journal Article DEP - 20221212 PL - United States TA - J Neurosurg Case Lessons JT - Journal of neurosurgery. Case lessons JID - 9918227275606676 PMC - PMC9745584 OTO - NOTNLM OT - Johnson & Johnson COVID-19 vaccine OT - rapid corticosteroid initiation OT - transverse myelitis COIS- Disclosures The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper. EDAT- 2023/01/23 06:00 MHDA- 2023/01/23 06:01 PMCR- 2022/12/12 CRDT- 2023/01/22 14:04 PHST- 2022/05/31 00:00 [received] PHST- 2022/08/12 00:00 [accepted] PHST- 2023/01/22 14:04 [entrez] PHST- 2023/01/23 06:00 [pubmed] PHST- 2023/01/23 06:01 [medline] PHST- 2022/12/12 00:00 [pmc-release] AID - CASE22244 [pii] AID - 10.3171/CASE22244 [doi] PST - epublish SO - J Neurosurg Case Lessons. 2022 Dec 12;4(24):CASE22244. doi: 10.3171/CASE22244. Print 2022 Dec 12. PMID- 36679929 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230201 IS - 2076-393X (Print) IS - 2076-393X (Electronic) IS - 2076-393X (Linking) VI - 11 IP - 1 DP - 2022 Dec 30 TI - Development and Validation of the Outcome Expectancy Scale for COVID-19 Vaccination in the Adult General Population. LID - 10.3390/vaccines11010085 [doi] LID - 85 AB - Promotion of COVID-19 vaccination requires understanding its determinants, an important one of which is outcome expectancy. However, reliable and valid measurement tools are absent. This study thus developed and validated an Outcome Expectancy Scale for COVID-19 Vaccination (OES-COVID-19). An inductive approach was used for scale development; content validity of the items was then assessed by an independent evaluation expert panel. Iteratively, 17 scale items were created and validated in a population-based telephone survey conducted among 500 adults of the general population in Hong Kong, China, from August to September 2021. Using half of the sample (n = 249), exploratory factor analyses identified four factors of the OES-COVID-19, including (a) positive contribution to society, (b) functional benefits, (c) protective effect, and (d) negative impacts. Confirmatory factor analysis of these factors conducted on the second subsample (n = 251) was satisfactory. The OES-COVID-19 showed good psychometric properties in terms of internal consistency, absence of floor/ceiling effects, and concurrent validity. The newly created and validated OES-COVID-19 is deemed suitable for application. It may advance future studies related to COVID-19 vaccination behavior and intention, and potentially allows for comparisons across studies. Further validation with modifications across countries, populations, and phase of the pandemic are warranted. FAU - Yu, Yanqiu AU - Yu Y AD - Department of Preventive Medicine and Health Education, School of Public Health, Fudan University, Shanghai 200032, China. AD - Key Laboratory of Public Health Safety, Fudan University, Shanghai 200032, China. FAU - Fong, Vivian W I AU - Fong VWI AD - Centre for Health Behaviours Research, Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong SAR, China. FAU - Lau, Mason M C AU - Lau MMC AD - Centre for Health Behaviours Research, Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong SAR, China. FAU - Lau, Joseph T F AU - Lau JTF AUID- ORCID: 0000-0003-2344-7107 AD - Zhejiang Provincial Clinical Research Center for Mental Disorders, The Affiliated Wenzhou Kangning Hospital, Wenzhou Medical University, Wenzhou 325000, China. AD - School of Mental Health, Wenzhou Medical University, Wenzhou 325000, China. AD - School of Public Health, Zhejiang University, Hangzhou 310058, China. LA - eng GR - NA/Internal funding of the Center for Health Behaviours Research, the Chinese University of Hong Kong/ PT - Journal Article DEP - 20221230 PL - Switzerland TA - Vaccines (Basel) JT - Vaccines JID - 101629355 PMC - PMC9866430 OTO - NOTNLM OT - COVID-19 vaccination OT - China OT - cognition OT - outcome expectancy OT - scale development OT - validation COIS- The authors declare no conflict of interest. EDAT- 2023/01/22 06:00 MHDA- 2023/01/22 06:01 PMCR- 2022/12/30 CRDT- 2023/01/21 01:57 PHST- 2022/12/01 00:00 [received] PHST- 2022/12/25 00:00 [revised] PHST- 2022/12/28 00:00 [accepted] PHST- 2023/01/21 01:57 [entrez] PHST- 2023/01/22 06:00 [pubmed] PHST- 2023/01/22 06:01 [medline] PHST- 2022/12/30 00:00 [pmc-release] AID - vaccines11010085 [pii] AID - vaccines-11-00085 [pii] AID - 10.3390/vaccines11010085 [doi] PST - epublish SO - Vaccines (Basel). 2022 Dec 30;11(1):85. doi: 10.3390/vaccines11010085. PMID- 36618402 OWN - NLM STAT- MEDLINE DCOM- 20230110 LR - 20231006 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 13 DP - 2022 TI - SARS-CoV-2 booster vaccination rescues attenuated IgG1 memory B cell response in primary antibody deficiency patients. PG - 1033770 LID - 10.3389/fimmu.2022.1033770 [doi] LID - 1033770 AB - BACKGROUND: Although SARS-CoV-2 vaccines have proven effective in eliciting a protective immune response in healthy individuals, their ability to induce a durable immune response in immunocompromised individuals remains poorly understood. Primary antibody deficiency (PAD) syndromes are among the most common primary immunodeficiency disorders in adults and are characterized by hypogammaglobulinemia and impaired ability to mount robust antibody responses following infection or vaccination. METHODS: Here, we present an analysis of both the B and T cell response in a prospective cohort of 30 individuals with PAD up to 150 days following initial COVID-19 vaccination and 150 days post mRNA booster vaccination. RESULTS: After the primary vaccination series, many of the individuals with PAD syndromes mounted SARS-CoV-2 specific memory B and CD4(+) T cell responses that overall were comparable to healthy individuals. Nonetheless, individuals with PAD syndromes had reduced IgG1(+) and CD11c(+) memory B cell responses following the primary vaccination series, with the defect in IgG1 class-switching rescued following mRNA booster doses. Boosting also elicited an increase in the SARS-CoV-2-specific B and T cell response and the development of Omicron-specific memory B cells in COVID-19-naive PAD patients. Individuals that lacked detectable B cell responses following primary vaccination did not benefit from booster vaccination. CONCLUSION: Together, these data indicate that SARS-CoV-2 vaccines elicit memory B and T cells in most PAD patients and highlights the importance of booster vaccination in immunodeficient individuals. CI - Copyright (c) 2022 Lin, Doss, Davis-Adams, Adams, Hanson, VanBlargan, Liang, Chen, Monroy, Wedner, Kulczycki, Mantia, O'Shaughnessy, Raju, Zhao, Rizzi, Rigell, Dy, Kau, Ren, Turner, O'Halloran, Presti, Fremont, Kendall, Ellebedy, Mudd, Diamond, Zimmerman and Laidlaw. FAU - Lin, Frank J AU - Lin FJ AD - Department of Medicine, Washington University School of Medicine, St. Louis, MO, United States. FAU - Doss, Alexa Michelle Altman AU - Doss AMA AD - Department of Pediatrics, Washington University School of Medicine, St. Louis, MO, United States. FAU - Davis-Adams, Hannah G AU - Davis-Adams HG AD - Department of Medicine, Washington University School of Medicine, St. Louis, MO, United States. FAU - Adams, Lucas J AU - Adams LJ AD - Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, United States. FAU - Hanson, Christopher H AU - Hanson CH AD - Department of Medicine, Washington University School of Medicine, St. Louis, MO, United States. FAU - VanBlargan, Laura A AU - VanBlargan LA AD - Department of Medicine, Washington University School of Medicine, St. Louis, MO, United States. FAU - Liang, Chieh-Yu AU - Liang CY AD - Department of Medicine, Washington University School of Medicine, St. Louis, MO, United States. AD - Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, United States. FAU - Chen, Rita E AU - Chen RE AD - Department of Medicine, Washington University School of Medicine, St. Louis, MO, United States. AD - Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, United States. FAU - Monroy, Jennifer Marie AU - Monroy JM AD - Department of Medicine, Washington University School of Medicine, St. Louis, MO, United States. FAU - Wedner, H James AU - Wedner HJ AD - Department of Medicine, Washington University School of Medicine, St. Louis, MO, United States. FAU - Kulczycki, Anthony AU - Kulczycki A AD - Department of Medicine, Washington University School of Medicine, St. Louis, MO, United States. FAU - Mantia, Tarisa L AU - Mantia TL AD - Department of Medicine, Washington University School of Medicine, St. Louis, MO, United States. FAU - O'Shaughnessy, Caitlin C AU - O'Shaughnessy CC AD - Department of Medicine, Washington University School of Medicine, St. Louis, MO, United States. FAU - Raju, Saravanan AU - Raju S AD - Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, United States. FAU - Zhao, Fang R AU - Zhao FR AD - Department of Medicine, Washington University School of Medicine, St. Louis, MO, United States. FAU - Rizzi, Elise AU - Rizzi E AD - Department of Medicine, Washington University School of Medicine, St. Louis, MO, United States. FAU - Rigell, Christopher J AU - Rigell CJ AD - Department of Medicine, Washington University School of Medicine, St. Louis, MO, United States. FAU - Dy, Tiffany Biason AU - Dy TB AD - Department of Medicine, Washington University School of Medicine, St. Louis, MO, United States. FAU - Kau, Andrew L AU - Kau AL AD - Department of Medicine, Washington University School of Medicine, St. Louis, MO, United States. AD - Center for Women's Infectious Disease Research, Washington University School of Medicine, St. Louis, MO, United States. FAU - Ren, Zhen AU - Ren Z AD - Department of Medicine, Washington University School of Medicine, St. Louis, MO, United States. FAU - Turner, Jackson S AU - Turner JS AD - Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, United States. FAU - O'Halloran, Jane A AU - O'Halloran JA AD - Department of Medicine, Washington University School of Medicine, St. Louis, MO, United States. FAU - Presti, Rachel M AU - Presti RM AD - Department of Medicine, Washington University School of Medicine, St. Louis, MO, United States. AD - Center for Vaccines and Immunity to Microbial Pathogens, Washington University School of Medicine, Saint Louis, MO, United States. FAU - Fremont, Daved H AU - Fremont DH AD - Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, United States. FAU - Kendall, Peggy L AU - Kendall PL AD - Department of Medicine, Washington University School of Medicine, St. Louis, MO, United States. FAU - Ellebedy, Ali H AU - Ellebedy AH AD - Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, United States. AD - Center for Vaccines and Immunity to Microbial Pathogens, Washington University School of Medicine, Saint Louis, MO, United States. AD - The Andrew M. and Jane M. Bursky Center for Human Immunology & Immunotherapy Programs, Washington University School of Medicine, Saint Louis, MO, United States. FAU - Mudd, Philip A AU - Mudd PA AD - Center for Vaccines and Immunity to Microbial Pathogens, Washington University School of Medicine, Saint Louis, MO, United States. AD - Department of Emergency Medicine, Washington University School of Medicine, St. Louis, MO, United States. FAU - Diamond, Michael S AU - Diamond MS AD - Department of Medicine, Washington University School of Medicine, St. Louis, MO, United States. AD - Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, United States. AD - Center for Vaccines and Immunity to Microbial Pathogens, Washington University School of Medicine, Saint Louis, MO, United States. AD - The Andrew M. and Jane M. Bursky Center for Human Immunology & Immunotherapy Programs, Washington University School of Medicine, Saint Louis, MO, United States. AD - Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO, United States. FAU - Zimmerman, Ofer AU - Zimmerman O AD - Department of Medicine, Washington University School of Medicine, St. Louis, MO, United States. FAU - Laidlaw, Brian J AU - Laidlaw BJ AD - Department of Medicine, Washington University School of Medicine, St. Louis, MO, United States. LA - eng GR - DP2 AI169978/AI/NIAID NIH HHS/United States GR - U01 AI150747/AI/NIAID NIH HHS/United States GR - HHSN272201400008C/AI/NIAID NIH HHS/United States GR - T32 GM007200/GM/NIGMS NIH HHS/United States GR - R01 AI157155/AI/NIAID NIH HHS/United States GR - U01 AI141990/AI/NIAID NIH HHS/United States GR - UL1 TR002345/TR/NCATS NIH HHS/United States GR - K22 AI153015/AI/NIAID NIH HHS/United States GR - U01 AI151810/AI/NIAID NIH HHS/United States GR - HHSN272201400006C/AI/NIAID NIH HHS/United States GR - 75N93019C00051/AI/NIAID NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, U.S. Gov't, Non-P.H.S. DEP - 20221222 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 RN - 0 (Immunoglobulin G) RN - 0 (COVID-19 Vaccines) RN - 0 (RNA, Messenger) SB - IM MH - Adult MH - Humans MH - Immunoglobulin G MH - Memory B Cells MH - COVID-19 Vaccines MH - SARS-CoV-2 MH - Prospective Studies MH - *COVID-19/prevention & control MH - RNA, Messenger MH - Vaccination MH - *Primary Immunodeficiency Diseases PMC - PMC9817149 OTO - NOTNLM OT - B cells OT - SARS-CoV-2 OT - common variable immunodeficiency OT - hypogammaglobulinemia OT - immune memory OT - primary antibody deficiency OT - specific antibody deficiency OT - vaccination COIS- MD is a consultant for Inbios, Vir Biotechnology, Senda Biosciences, Moderna, and Immunome. The Diamond laboratory has received unrelated funding support in sponsored research agreements from Moderna, Vir Biotechnology, Immunome, and Emergent BioSolutions. OZ and family own Moderna stock. The Ellebedy laboratory received unrelated funding support from Emergent BioSolutions and AbbVie. AE is a consultant for Mubadala Investment Company and the founder of ImmuneBio Consulting. JT is a consultant for Gerson Lehrman Group. JT and AE are recipients of a licensing agreement with Abbvie that is unrelated to this manuscript. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2023/01/10 06:00 MHDA- 2023/01/11 06:00 PMCR- 2022/12/22 CRDT- 2023/01/09 03:31 PHST- 2022/08/31 00:00 [received] PHST- 2022/12/05 00:00 [accepted] PHST- 2023/01/09 03:31 [entrez] PHST- 2023/01/10 06:00 [pubmed] PHST- 2023/01/11 06:00 [medline] PHST- 2022/12/22 00:00 [pmc-release] AID - 10.3389/fimmu.2022.1033770 [doi] PST - epublish SO - Front Immunol. 2022 Dec 22;13:1033770. doi: 10.3389/fimmu.2022.1033770. eCollection 2022. PMID- 36603767 OWN - NLM STAT- MEDLINE DCOM- 20230503 LR - 20230515 IS - 1995-820X (Electronic) IS - 1674-0769 (Print) IS - 1995-820X (Linking) VI - 38 IP - 2 DP - 2023 Apr TI - Omicron variants breakthrough infection elicited higher specific memory immunity than third dose booster in healthy vaccinees. PG - 233-243 LID - S1995-820X(22)00214-0 [pii] LID - 10.1016/j.virs.2022.12.008 [doi] AB - Homologous booster, heterologous booster, and Omicron variants breakthrough infection (OBI) could improve the humoral immunity against Omicron variants. Questions concerning about memory B cells (MBCs) and T cells immunity against Omicron variants, features of long-term immunity, after booster and OBI, needs to be explored. Here, comparative analysis demonstrate antibody and T cell immunity against ancestral strain, Delta and Omicron variants in Omicron breakthrough infected patients (OBIPs) are comparable to that in Ad5-nCoV boosted healthy volunteers (HVs), higher than that in inactivated vaccine (InV) boosted HVs. However, memory B cells (MBCs) immunity against Omicron variants was highest in OBIPs, followed by Ad5-nCoV boosted and InV boosted HVs. OBIPs and Ad5-nCoV boosted HVs have higher classical MBCs and activated MBCs, and lower naive MBCs and atypical MBCs relative to both vaccine boosted HVs. Collectively, these data indicate Omicron breakthrough infection elicit higher MBCs and T cells against SARS-CoV-2 especially Omicron variants relative to homologous InV booster and heterologous Ad5-nCoV booster. CI - Copyright (c) 2023 The Authors. Publishing services by Elsevier B.V. All rights reserved. FAU - Yu, Pei AU - Yu P AD - Clinical Laboratory Medicine Department, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510260, China. FAU - Liu, Zijian AU - Liu Z AD - State Key Laboratories of Respiratory Diseases, Guangdong-Hong Kong-Macao Joint Laboratory of Infectious Respiratory Disease, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, 510535, China. FAU - Zhu, Zhuoqi AU - Zhu Z AD - Clinical Laboratory Medicine Department, Dongguan Ninth People's Hospital, Dongguan, 523016, China. FAU - Yang, Jiaqing AU - Yang J AD - State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120, China. FAU - Deng, Min AU - Deng M AD - Clinical Laboratory Medicine Department, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510260, China. FAU - Chen, Mingxiao AU - Chen M AD - Clinical Laboratory Medicine Department, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510260, China. FAU - Lai, Changchun AU - Lai C AD - Clinical Laboratory Medicine Department, Maoming People's Hospital, Maoming, 525000, China. FAU - Kong, Weiya AU - Kong W AD - Clinical Laboratory Medicine Department, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510260, China. FAU - Xiong, Shilong AU - Xiong S AD - Clinical Laboratory Medicine Department, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510260, China. FAU - Wan, Li AU - Wan L AD - Clinical Laboratory Medicine Department, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510260, China. FAU - Mai, Weikang AU - Mai W AD - Clinical Laboratory Medicine Department, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510260, China. FAU - Chen, Lu AU - Chen L AD - Clinical Laboratory Medicine Department, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510260, China. FAU - Lei, Yu AU - Lei Y AD - Clinical Laboratory Medicine Department, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510260, China. FAU - Khan, Shahzad Akbar AU - Khan SA AD - Laboratory of Pathology, Department of Pathobiology, University of Poonch Rawalakot Azad Kashmir Pakistan 12350, Pakistan. FAU - Ruan, Jianfeng AU - Ruan J AD - Hospital Infection-Control Department, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510260, China. FAU - Kang, An AU - Kang A AD - Medical Examination Department, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510260, China. FAU - Guo, Xuguang AU - Guo X AD - Department of Clinical Laboratory Medicine, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510140, China. FAU - Zhou, Qiang AU - Zhou Q AD - Clinical Laboratory Medicine Department, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510260, China. FAU - Li, Wenrui AU - Li W AD - Clinical Laboratory Medicine Department, Dongguan Ninth People's Hospital, Dongguan, 523016, China. FAU - Chen, Zheng AU - Chen Z AD - Kidney Transplant Department, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510260, China. Electronic address: docchenzheng@163.com. FAU - Liang, Yuemei AU - Liang Y AD - Clinical Laboratory Medicine Department, Dongguan Ninth People's Hospital, Dongguan, 523016, China. Electronic address: 784604898@qq.com. FAU - Li, Pingchao AU - Li P AD - State Key Laboratories of Respiratory Diseases, Guangdong-Hong Kong-Macao Joint Laboratory of Infectious Respiratory Disease, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, 510535, China. Electronic address: li_pingchao@gibh.ac.cn. FAU - Zhang, Lei AU - Zhang L AD - Kidney Transplant Department, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510260, China; Department of Organ Transplantation, The Third Affiliated Hospital of Sun Yat-sen University, 510630, China. Electronic address: 517728181@qq.com. FAU - Ji, Tianxing AU - Ji T AD - Clinical Laboratory Medicine Department, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510260, China; Guangzhou Key Laboratory for Clinical Rapid Diagnosis and Early Warning of Infectious Diseases, KingMed School of Laboratory Medicine, Guangzhou Medical University, Guangzhou, 511436, China. Electronic address: jitianxing7021@163.com. LA - eng PT - Journal Article DEP - 20230102 PL - Netherlands TA - Virol Sin JT - Virologica Sinica JID - 101514185 RN - 0 (Antibodies) RN - 0 (Antibodies, Viral) RN - 0 (Antibodies, Neutralizing) RN - SARS-CoV-2 variants SB - IM MH - Humans MH - *Breakthrough Infections MH - *COVID-19 MH - SARS-CoV-2 MH - Antibodies MH - Antibodies, Viral MH - Antibodies, Neutralizing PMC - PMC10176432 OTO - NOTNLM OT - Ad5-nCoV booster OT - Binding antibody OT - Inactivated vaccine booster OT - Memory immunity OT - Omicron variants breakthrough infection COIS- Conflict of interest All authors declare that there is no competing interests. EDAT- 2023/01/06 06:00 MHDA- 2023/05/03 06:42 PMCR- 2023/01/02 CRDT- 2023/01/05 19:13 PHST- 2022/09/16 00:00 [received] PHST- 2022/12/30 00:00 [accepted] PHST- 2023/05/03 06:42 [medline] PHST- 2023/01/06 06:00 [pubmed] PHST- 2023/01/05 19:13 [entrez] PHST- 2023/01/02 00:00 [pmc-release] AID - S1995-820X(22)00214-0 [pii] AID - 10.1016/j.virs.2022.12.008 [doi] PST - ppublish SO - Virol Sin. 2023 Apr;38(2):233-243. doi: 10.1016/j.virs.2022.12.008. Epub 2023 Jan 2. PMID- 36570119 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240910 IS - 1568-4946 (Print) IS - 1872-9681 (Electronic) IS - 1568-4946 (Linking) VI - 133 DP - 2023 Jan TI - Post-pandemic healthcare for COVID-19 vaccine: Tissue-aware diagnosis of cervical lymphadenopathy via multi-modal ultrasound semantic segmentation. PG - 109947 LID - 10.1016/j.asoc.2022.109947 [doi] AB - With the widespread deployment of COVID-19 vaccines all around the world, billions of people have benefited from the vaccination and thereby avoiding infection. However, huge amount of clinical cases revealed diverse side effects of COVID-19 vaccines, among which cervical lymphadenopathy is one of the most frequent local reactions. Therefore, rapid detection of cervical lymph node (LN) is essential in terms of vaccine recipients' healthcare and avoidance of misdiagnosis in the post-pandemic era. This paper focuses on a novel deep learning-based framework for the rapid diagnosis of cervical lymphadenopathy towards COVID-19 vaccine recipients. Existing deep learning-based computer-aided diagnosis (CAD) methods for cervical LN enlargement mostly only depend on single modal images, e.g., grayscale ultrasound (US), color Doppler ultrasound, and CT, while failing to effectively integrate information from the multi-source medical images. Meanwhile, both the surrounding tissue objects of the cervical LNs and different regions inside the cervical LNs may imply valuable diagnostic knowledge which is pending for mining. In this paper, we propose an Tissue-Aware Cervical Lymph Node Diagnosis method (TACLND) via multi-modal ultrasound semantic segmentation. The method effectively integrates grayscale and color Doppler US images and realizes a pixel-level localization of different tissue objects, i.e., lymph, muscle, and blood vessels. With inter-tissue and intra-tissue attention mechanisms applied, our proposed method can enhance the implicit tissue-level diagnostic knowledge in both spatial and channel dimension, and realize diagnosis of cervical LN with normal, benign or malignant state. Extensive experiments conducted on our collected cervical LN US dataset demonstrate the effectiveness of our methods on both tissue detection and cervical lymphadenopathy diagnosis. Therefore, our proposed framework can guarantee efficient diagnosis for the vaccine recipients' cervical LN, and assist doctors to discriminate between COVID-related reactive lymphadenopathy and metastatic lymphadenopathy. CI - (c) 2022 Elsevier B.V. All rights reserved. FAU - Gao, Yue AU - Gao Y AD - School of Computer Science (National Pilot Software Engineering School), Beijing University of Posts and Telecommunications, Beijing, 100876, China. AD - Key Laboratory of Trustworthy Distributed Computing and Service (BUPT), Ministry of Education, Beijing, 100876, China. FAU - Fu, Xiangling AU - Fu X AD - School of Computer Science (National Pilot Software Engineering School), Beijing University of Posts and Telecommunications, Beijing, 100876, China. AD - Key Laboratory of Trustworthy Distributed Computing and Service (BUPT), Ministry of Education, Beijing, 100876, China. FAU - Chen, Yuepeng AU - Chen Y AD - School of Computer Science (National Pilot Software Engineering School), Beijing University of Posts and Telecommunications, Beijing, 100876, China. AD - Key Laboratory of Trustworthy Distributed Computing and Service (BUPT), Ministry of Education, Beijing, 100876, China. FAU - Guo, Chenyi AU - Guo C AD - Department of Electronic Engineering, Tsinghua University, Beijing, 100084, China. FAU - Wu, Ji AU - Wu J AD - Department of Electronic Engineering, Tsinghua University, Beijing, 100084, China. LA - eng PT - Journal Article DEP - 20221219 PL - United States TA - Appl Soft Comput JT - Applied soft computing JID - 101536968 PMC - PMC9762098 OTO - NOTNLM OT - Attention mechanism OT - COVID-19 OT - Cervical lymphadenopathy OT - Computer-aided diagnosis OT - Healthcare administration OT - Human-in-the-loop OT - Image classification OT - Multi-modal OT - Semantic segmentation COIS- The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2022/12/27 06:00 MHDA- 2022/12/27 06:01 PMCR- 2022/12/19 CRDT- 2022/12/26 04:29 PHST- 2022/04/29 00:00 [received] PHST- 2022/11/30 00:00 [revised] PHST- 2022/12/15 00:00 [accepted] PHST- 2022/12/26 04:29 [entrez] PHST- 2022/12/27 06:00 [pubmed] PHST- 2022/12/27 06:01 [medline] PHST- 2022/12/19 00:00 [pmc-release] AID - S1568-4946(22)00996-6 [pii] AID - 109947 [pii] AID - 10.1016/j.asoc.2022.109947 [doi] PST - ppublish SO - Appl Soft Comput. 2023 Jan;133:109947. doi: 10.1016/j.asoc.2022.109947. Epub 2022 Dec 19. PMID- 36562048 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20221224 IS - 1664-1078 (Print) IS - 1664-1078 (Electronic) IS - 1664-1078 (Linking) VI - 13 DP - 2022 TI - COVID-19 vaccination motivation and underlying believing processes: A comparison study between individuals with affective disorder and healthy controls. PG - 935278 LID - 10.3389/fpsyg.2022.935278 [doi] LID - 935278 AB - BACKGROUND: Believing processes represent fundamental brain functions between cognition and emotion. Shortly before the introduction of a compulsory vaccination against COVID-19 in Austria, motives and underlying believing processes regarding the vaccination were collected in individuals with affective disorder (AD) and healthy controls (HC). METHODS: 79 individuals with AD and 173 HC were surveyed online to assess believing processes with the parameters of the credition model (narratives, certainty, emotion, mightiness) about (1) the coronavirus itself and (2) why someone is vaccinated or not. In addition, we calculated congruence scores between content of narrative and type of emotion and divided the narrative content into positive, negative, and indifferent. RESULTS: There were no differences in vaccination status between AD and HC. Higher levels of certainty were observed in HC compared to AD in both vaccinated and unvaccinated individuals. The effects were higher when asked about the motivation to vaccinate or not than about the coronavirus itself. In HC, more positive emotions and more congruence between emotions and narratives were reported during believing in their vaccination motives. No group differences were found in mightiness for both items. Independently from diagnosis, unvaccinated people had high levels of certainty and more negative emotions and narratives while believing in their motives for not getting vaccinated. CONCLUSION: When believing about the COVID-19 vaccination, individuals with AD were more uncertain and experienced fewer positive emotions than HC, although both groups did not differ in vaccination status. These effects were not that strong when believing about the coronavirus in general. CI - Copyright (c) 2022 Dalkner, Fleischmann, Fellendorf, Wagner-Skacel, Schonthaler, Bengesser, Haussl, Tietz, Tmava-Berisha, Lenger and Reininghaus. FAU - Dalkner, Nina AU - Dalkner N AD - Clinical Department of Psychiatry and Psychotherapeutic Medicine, Medical University Graz, Graz, Austria. FAU - Fleischmann, Eva AU - Fleischmann E AD - Clinical Department of Psychiatry and Psychotherapeutic Medicine, Medical University Graz, Graz, Austria. FAU - Fellendorf, Frederike T AU - Fellendorf FT AD - Clinical Department of Psychiatry and Psychotherapeutic Medicine, Medical University Graz, Graz, Austria. FAU - Wagner-Skacel, Jolana AU - Wagner-Skacel J AD - Clinical Department of Medical Psychology, Psychosomatic, and Psychotherapy, Medical University Graz, Graz, Austria. FAU - Schonthaler, Elena M D AU - Schonthaler EMD AD - Clinical Department of Psychiatry and Psychotherapeutic Medicine, Medical University Graz, Graz, Austria. FAU - Bengesser, Susanne AU - Bengesser S AD - Clinical Department of Psychiatry and Psychotherapeutic Medicine, Medical University Graz, Graz, Austria. FAU - Haussl, Alfred AU - Haussl A AD - Clinical Department of Psychiatry and Psychotherapeutic Medicine, Medical University Graz, Graz, Austria. FAU - Tietz, Sophie AU - Tietz S AD - Clinical Department of Psychiatry and Psychotherapeutic Medicine, Medical University Graz, Graz, Austria. FAU - Tmava-Berisha, Adelina AU - Tmava-Berisha A AD - Clinical Department of Psychiatry and Psychotherapeutic Medicine, Medical University Graz, Graz, Austria. FAU - Lenger, Melanie AU - Lenger M AD - Clinical Department of Psychiatry and Psychotherapeutic Medicine, Medical University Graz, Graz, Austria. FAU - Reininghaus, Eva Z AU - Reininghaus EZ AD - Clinical Department of Psychiatry and Psychotherapeutic Medicine, Medical University Graz, Graz, Austria. LA - eng PT - Journal Article DEP - 20221206 PL - Switzerland TA - Front Psychol JT - Frontiers in psychology JID - 101550902 PMC - PMC9765308 OTO - NOTNLM OT - COVID-19 vaccination OT - affective disorder OT - cognition OT - credition OT - emotion COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/12/24 06:00 MHDA- 2022/12/24 06:01 PMCR- 2022/12/06 CRDT- 2022/12/23 02:42 PHST- 2022/05/03 00:00 [received] PHST- 2022/08/01 00:00 [accepted] PHST- 2022/12/23 02:42 [entrez] PHST- 2022/12/24 06:00 [pubmed] PHST- 2022/12/24 06:01 [medline] PHST- 2022/12/06 00:00 [pmc-release] AID - 10.3389/fpsyg.2022.935278 [doi] PST - epublish SO - Front Psychol. 2022 Dec 6;13:935278. doi: 10.3389/fpsyg.2022.935278. eCollection 2022. PMID- 36560442 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231106 IS - 2076-393X (Print) IS - 2076-393X (Electronic) IS - 2076-393X (Linking) VI - 10 IP - 12 DP - 2022 Nov 28 TI - COVID-19 Vaccination in Young People with Functional Neurological Disorder: A Case-Control Study. LID - 10.3390/vaccines10122031 [doi] LID - 2031 AB - BACKGROUND: The emergence of acute-onset functional neurological symptoms, the focus of this study, is one of three stress responses related to immunisation. This case-control study documents the experience of 61 young people with past or current functional neurological disorder (FND) in relation to the COVID-19 vaccination program in Australia. METHODS: Information about the young person's/parent's choice and response pertaining to COVID-19 vaccination was collected as part of routine clinical care or FND research program follow-up. RESULTS: 61 young people treated for FND (47 females, mean age = 16.22 years) and 46 healthy controls (34 females, mean age = 16.37 years) were included in the study. Vaccination rates were high: 58/61 (95.1%) in the FND group and 45/46 (97.8%) in the control group. In the FND group, 2 young people (2/61, 3.3%) presented with new-onset FND following COVID-19 vaccination; two young people with resolved FND reported an FND relapse (2/36, 5.56%); and two young people with unresolved FND (2/20, 10.0%) reported an FND exacerbation. In the control group no FND symptoms were reported. CONCLUSIONS: Acute-onset FND symptoms following COVID-19 vaccination are uncommon in the general population. In young people prone to FND, COVID-19 vaccination can sometimes trigger new-onset FND, FND relapse, or FND exacerbation. FAU - Lim, Natalie AU - Lim N AD - Department of Psychological Medicine, The Children's Hospital at Westmead, Westmead, NSW 2145, Australia. FAU - Wood, Nicholas AU - Wood N AD - National Centre for Immunisation Research and Surveillance, Kids Research, Sydney Children's Hospitals Network, Westmead, NSW 2145, Australia. AD - The Children's Hospital at Westmead Clinical School, Faculty of Medicine and Health, University of Sydney, Westmead, NSW 2145, Australia. FAU - Prasad, Archana AU - Prasad A AD - Department of General Medicine, The Children's Hospital at Westmead Clinical School, Westmead, NSW 2145, Australia. FAU - Waters, Karen AU - Waters K AD - Sleep Medicine, The Children's Hospital at Westmead, Westmead Clinical School, Westmead, NSW 2145, Australia. AD - Specialty of Child and Adolescent Health, Faculty of Medicine and Health, University of Sydney, Westmead, NSW 2145, Australia. FAU - Singh-Grewal, Davinder AU - Singh-Grewal D AD - Specialty of Child and Adolescent Health, Faculty of Medicine and Health, University of Sydney, Westmead, NSW 2145, Australia. AD - Department of Rheumatology, Sydney Children's Hospital Network, Westmead, NSW 2145, Australia. AD - School of Women's and Children's Health, University of New South Wales, Randwick, NSW 2031, Australia. FAU - Dale, Russell C AU - Dale RC AD - Kids Neuroscience Centre, Faculty of Medicine and Health, University of Sydney, Westmead, NSW 2145, Australia. AD - The Brain and Mind Centre, University of Sydney, Camperdown, NSW 2050, Australia. FAU - Elkadi, Joseph AU - Elkadi J AD - Department of Psychological Medicine, The Children's Hospital at Westmead, Westmead, NSW 2145, Australia. FAU - Scher, Stephen AU - Scher S AD - McLean Hospital, Belmont, MA 02478, USA. AD - Department of Psychiatry, Harvard Medical School, Boston, MA 02215, USA. AD - Speciality of Psychiatry, Faculty of Medicine and Health, University of Sydney, Westmead, NSW 2145, Australia. FAU - Kozlowska, Kasia AU - Kozlowska K AUID- ORCID: 0000-0002-9578-0753 AD - Department of Psychological Medicine, The Children's Hospital at Westmead, Westmead, NSW 2145, Australia. AD - The Children's Hospital at Westmead Clinical School, Faculty of Medicine and Health, University of Sydney, Westmead, NSW 2145, Australia. AD - Specialty of Child and Adolescent Health, Faculty of Medicine and Health, University of Sydney, Westmead, NSW 2145, Australia. AD - Brain Dynamics Centre at Westmead Institute of Medical Research, Faculty of Medicine and Health, University of Sydney, Westmead, NSW 2145, Australia. LA - eng PT - Journal Article DEP - 20221128 PL - Switzerland TA - Vaccines (Basel) JT - Vaccines JID - 101629355 PMC - PMC9782633 OTO - NOTNLM OT - COVID-19 vaccines OT - SARS-CoV-2 vaccines OT - adolescents OT - children OT - dissociative neurological symptom reactions (DNSRs) OT - functional (dissociative) seizures OT - functional neurological (conversion) disorder (FND) OT - immunisation stress-related responses (ISRRs) OT - young people COIS- The authors declare no conflict of interest. EDAT- 2022/12/24 06:00 MHDA- 2022/12/24 06:01 PMCR- 2022/11/28 CRDT- 2022/12/23 02:04 PHST- 2022/10/10 00:00 [received] PHST- 2022/11/19 00:00 [revised] PHST- 2022/11/22 00:00 [accepted] PHST- 2022/12/23 02:04 [entrez] PHST- 2022/12/24 06:00 [pubmed] PHST- 2022/12/24 06:01 [medline] PHST- 2022/11/28 00:00 [pmc-release] AID - vaccines10122031 [pii] AID - vaccines-10-02031 [pii] AID - 10.3390/vaccines10122031 [doi] PST - epublish SO - Vaccines (Basel). 2022 Nov 28;10(12):2031. doi: 10.3390/vaccines10122031. PMID- 36556422 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20221227 IS - 2075-1729 (Print) IS - 2075-1729 (Electronic) IS - 2075-1729 (Linking) VI - 12 IP - 12 DP - 2022 Dec 8 TI - Effect of Vaccination against SARS-CoV-2 on Long COVID-19: A Narrative Review. LID - 10.3390/life12122057 [doi] LID - 2057 AB - Vaccines against SARS-CoV-2 have saved millions of lives and played an important role in containing the COVID-19 pandemic. Vaccination against SARS-CoV-2 is also associated with reduced disease severity and, perhaps, with COVID-19 symptom burden. In this narrative review, we present, in a clinically relevant question-and-answer manner, the evidence regarding the association between vaccination against SARS-CoV-2 and long COVID-19. We discuss how the mechanism of action of vaccines could interplay with the pathophysiology of post-COVID-19 condition. Furthermore, we describe how specific factors, such as the number of vaccine doses and the type of SARS-CoV-2 variants, may affect post-COVID-19 condition. We also discuss the role of timing for vaccination in relation to the onset of long COVID-19 symptoms, as it seems to affect the frequency and severity of the condition. Additionally, we describe the potential modifying effect of age, as well as the association of type and level of immune response with long COVID-19. We also describe how system-specific long COVID-19 sequelae, namely neurocognitive-psychologic symptoms and cardiovascular pathology, could be altered by vaccination. Last, we address the question of whether seasonal influenza vaccination has a meaningful impact on the frequency of long COVID-19. FAU - Tofarides, Andreas G AU - Tofarides AG AD - Department of Internal Medicine, Nicosia General Hospital, Nicosia 2029, Cyprus. AD - Department of Internal Medicine, Faculty of Medicine, School of Health Sciences, University of Ioannina, 451 10 Ioannina, Greece. FAU - Christaki, Eirini AU - Christaki E AD - Department of Internal Medicine, Faculty of Medicine, School of Health Sciences, University of Ioannina, 451 10 Ioannina, Greece. FAU - Milionis, Haralampos AU - Milionis H AUID- ORCID: 0000-0003-3958-2266 AD - Department of Internal Medicine, Faculty of Medicine, School of Health Sciences, University of Ioannina, 451 10 Ioannina, Greece. FAU - Nikolopoulos, Georgios K AU - Nikolopoulos GK AUID- ORCID: 0000-0002-3307-0246 AD - Medical School, University of Cyprus, Nicosia 2029, Cyprus. LA - eng PT - Journal Article PT - Review DEP - 20221208 PL - Switzerland TA - Life (Basel) JT - Life (Basel, Switzerland) JID - 101580444 PMC - PMC9785763 OTO - NOTNLM OT - SARS-CoV-2 OT - SARS-CoV-2 vaccination OT - SARS-CoV-2 vaccines OT - immunity OT - long COVID-19 OT - post-COVID-19 condition OT - post-COVID-19 sequelae OT - variant COIS- The authors declare no conflict of interest. EDAT- 2022/12/24 06:00 MHDA- 2022/12/24 06:01 PMCR- 2022/12/08 CRDT- 2022/12/23 01:40 PHST- 2022/11/10 00:00 [received] PHST- 2022/12/01 00:00 [revised] PHST- 2022/12/02 00:00 [accepted] PHST- 2022/12/23 01:40 [entrez] PHST- 2022/12/24 06:00 [pubmed] PHST- 2022/12/24 06:01 [medline] PHST- 2022/12/08 00:00 [pmc-release] AID - life12122057 [pii] AID - life-12-02057 [pii] AID - 10.3390/life12122057 [doi] PST - epublish SO - Life (Basel). 2022 Dec 8;12(12):2057. doi: 10.3390/life12122057. PMID- 36552017 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231106 IS - 2227-9059 (Print) IS - 2227-9059 (Electronic) IS - 2227-9059 (Linking) VI - 10 IP - 12 DP - 2022 Dec 15 TI - Fourth Dose of mRNA COVID-19 Vaccine Transiently Reactivates Spike-Specific Immunological Memory in People Living with HIV (PLWH). LID - 10.3390/biomedicines10123261 [doi] LID - 3261 AB - Background: People Living With HIV (PLWH), with advanced disease, lower CD4+ T cell counts or an unsuppressed HIV viral load can have a suboptimal vaccine response. For this reason, in the current COVID-19 pandemic, they represent a prioritized population for the SARS-CoV-2 fourth (or second booster) vaccine dose. This work aims to investigate the effects of a second booster on the reactivation of the spike-specific humoral and cell-mediated immune responses in PLWH. Methods: A total of eight PLWH, who received a fourth dose of the original mRNA vaccines were enrolled. They were evaluated before and then 7 days, 1 month and 2 months after the injection. The humoral response was assessed via a chemiluminescent immunoassay. Immunophenotyping and the functional evaluation of the SARS-CoV-2-specific cellular immune responses were performed via flow cytometry. Results: Anti-spike IgG levels were above the cut-off value for all subjects at all timepoints. The spike-specific CD4+ T cell response was reactivated one week after the fourth vaccine dose, and on average declined at two months post-vaccination. A similar trend was observed for the spike-specific B cells. A low percentage of spike-specific CD4+ T cells was activated by the B.1.1.529 BA.1 Omicron-spike mutated peptides, and the majority of these cells were reactive to the conserved portions of the spike protein. Similarly, the majority of the spike-specific memory B cells were able to bind both Wuhan and Omicron-spike entire protein. Conclusions: Spike-specific adaptive immune responses are transiently reactivated in PLWH following the fourth mRNA vaccine dose. The breadth of the immune responses to the mutated spike protein provides insight on the possible cross-reactivity for the SARS-CoV-2 variants of concern (VOCs). FAU - Lamacchia, Giulia AU - Lamacchia G AUID- ORCID: 0000-0001-5011-9972 AD - Department of Experimental and Clinical Medicine, University of Florence, 50121 Florence, Italy. FAU - Salvati, Lorenzo AU - Salvati L AUID- ORCID: 0000-0001-5831-0392 AD - Department of Experimental and Clinical Medicine, University of Florence, 50121 Florence, Italy. FAU - Kiros, Seble Tekle AU - Kiros ST AD - Infectious and Tropical Diseases Unit, Careggi University Hospital, 50134 Florence, Italy. FAU - Mazzoni, Alessio AU - Mazzoni A AD - Department of Experimental and Clinical Medicine, University of Florence, 50121 Florence, Italy. AD - Flow Cytometry Diagnostic Center and Immunotherapy, Careggi University Hospital, 50134 Florence, Italy. FAU - Vanni, Anna AU - Vanni A AD - Department of Experimental and Clinical Medicine, University of Florence, 50121 Florence, Italy. FAU - Capone, Manuela AU - Capone M AD - Department of Experimental and Clinical Medicine, University of Florence, 50121 Florence, Italy. AD - Flow Cytometry Diagnostic Center and Immunotherapy, Careggi University Hospital, 50134 Florence, Italy. FAU - Carnasciali, Alberto AU - Carnasciali A AUID- ORCID: 0000-0003-1142-6755 AD - Department of Experimental and Clinical Medicine, University of Florence, 50121 Florence, Italy. FAU - Farahvachi, Parham AU - Farahvachi P AD - Department of Experimental and Clinical Medicine, University of Florence, 50121 Florence, Italy. FAU - Lagi, Filippo AU - Lagi F AD - Infectious and Tropical Diseases Unit, Careggi University Hospital, 50134 Florence, Italy. FAU - Di Lauria, Nicoletta AU - Di Lauria N AD - Infectious and Tropical Diseases Unit, Careggi University Hospital, 50134 Florence, Italy. FAU - Rocca, Arianna AU - Rocca A AD - Microbiology and Virology Unit, Careggi University Hospital, 50134 Florence, Italy. FAU - Colao, Maria Grazia AU - Colao MG AD - Microbiology and Virology Unit, Careggi University Hospital, 50134 Florence, Italy. FAU - Liotta, Francesco AU - Liotta F AUID- ORCID: 0000-0003-1746-9967 AD - Department of Experimental and Clinical Medicine, University of Florence, 50121 Florence, Italy. AD - Flow Cytometry Diagnostic Center and Immunotherapy, Careggi University Hospital, 50134 Florence, Italy. AD - Immunology and Cell Therapy Unit, Careggi University Hospital, 50134 Florence, Italy. FAU - Cosmi, Lorenzo AU - Cosmi L AUID- ORCID: 0000-0002-8150-8177 AD - Department of Experimental and Clinical Medicine, University of Florence, 50121 Florence, Italy. AD - Immunoallergology Unit, Careggi University Hospital, 50134 Florence, Italy. FAU - Rossolini, Gian Maria AU - Rossolini GM AD - Department of Experimental and Clinical Medicine, University of Florence, 50121 Florence, Italy. AD - Microbiology and Virology Unit, Careggi University Hospital, 50134 Florence, Italy. FAU - Bartoloni, Alessandro AU - Bartoloni A AUID- ORCID: 0000-0001-9758-1523 AD - Department of Experimental and Clinical Medicine, University of Florence, 50121 Florence, Italy. AD - Infectious and Tropical Diseases Unit, Careggi University Hospital, 50134 Florence, Italy. FAU - Maggi, Laura AU - Maggi L AUID- ORCID: 0000-0003-2862-9591 AD - Department of Experimental and Clinical Medicine, University of Florence, 50121 Florence, Italy. FAU - Annunziato, Francesco AU - Annunziato F AD - Department of Experimental and Clinical Medicine, University of Florence, 50121 Florence, Italy. AD - Flow Cytometry Diagnostic Center and Immunotherapy, Careggi University Hospital, 50134 Florence, Italy. LA - eng GR - RICTD2122/University of Florence/ GR - TagSARS CoV 2/Tuscany Region/ GR - Project Excellence Departments 2018-2022/Ministry of Education, Universities and Research/ PT - Journal Article DEP - 20221215 PL - Switzerland TA - Biomedicines JT - Biomedicines JID - 101691304 PMC - PMC9775459 OTO - NOTNLM OT - B cell response OT - HIV OT - Omicron OT - SARS-CoV-2 OT - T cell response OT - fourth dose OT - humoral response OT - mRNA vaccine OT - people living with HIV COIS- The authors declare no conflict of interest. EDAT- 2022/12/24 06:00 MHDA- 2022/12/24 06:01 PMCR- 2022/12/15 CRDT- 2022/12/23 01:13 PHST- 2022/10/04 00:00 [received] PHST- 2022/12/06 00:00 [revised] PHST- 2022/12/13 00:00 [accepted] PHST- 2022/12/23 01:13 [entrez] PHST- 2022/12/24 06:00 [pubmed] PHST- 2022/12/24 06:01 [medline] PHST- 2022/12/15 00:00 [pmc-release] AID - biomedicines10123261 [pii] AID - biomedicines-10-03261 [pii] AID - 10.3390/biomedicines10123261 [doi] PST - epublish SO - Biomedicines. 2022 Dec 15;10(12):3261. doi: 10.3390/biomedicines10123261. PMID- 36550578 OWN - NLM STAT- MEDLINE DCOM- 20221226 LR - 20260127 IS - 1743-422X (Electronic) IS - 1743-422X (Linking) VI - 19 IP - 1 DP - 2022 Dec 22 TI - Adaptive immune responses and cytokine immune profiles in humans following prime and boost vaccination with the SARS-CoV-2 CoronaVac vaccine. PG - 223 LID - 10.1186/s12985-022-01957-1 [doi] LID - 223 AB - BACKGROUND: Adaptive immune response has been thought to play a key role in SARS-CoV-2 infection. The role of B cells, CD4(+)T, and CD8(+)T cells are different in vaccine-induced immune response, thus it is imperative to explore the functions and kinetics of adaptive immune response. We collected blood samples from unvaccinated and vaccinated individuals. To assess the mechanisms contributing to protective immunity of CoronaVac vaccines, we mapped the kinetics and durability of humoral and cellular immune responses after primary and boost vaccination with CoronaVac vaccine in different timepoints. MATERIALS AND METHODS: We separate PBMC and plasma from blood samples. The differentiation and function of RBD-spcific CD4(+)T and CD8(+)T cells were analyzed by flow cytometry and ELISA. Antibodies response was analyzed by ELISA. ELISPOT analysis was perfomed to detected the RBD-spcific memory B cells. CBA analysis was performed to detected the cytokine immune profiles. Graphpad prism 8 and Origin 2021 were used for statistical analysis. RESULTS: Vaccine-induced CD4(+)T cell responses to RBD were more prominent than CD8(+)T cell responses, and characterized by a predominant Th1 and weak Th17 helper response. CoronaVac vaccine triggered predominant IgG1 antibody response and effectively recalled specific antibodies to RBD protein after booster vaccination. Robust antigen-specific memory B cells were detected (p < 0.0001) following booster vaccination and maintained at 6 months (p < 0.0001) following primary vaccination. Vaccine-induced CD4(+)T cells correlated with CD8(+)T cells (r = 0.7147, 0.3258, p < 0.0001, p = 0.04), memory B cell responses (r = 0.7083, p < 0.0001), and IgG and IgA (r = 0.6168, 0.5519, p = 0.0006, 0.003) after vaccination. In addition, vaccine induced a broader and complex cytokine pattern in plasma at early stage. CONCLUSION: Taken together, these results highlight the potential role of B cell and T cell responses in vaccine-induced long-term immunity. CI - (c) 2022. The Author(s). FAU - Wang, Chan AU - Wang C AD - School of Basic Medicine, Ningxia Medical University, Yinchuan, 750004, Ningxia Hui Autonomous Region, People's Republic of China. AD - Key Laboratory of Hydatid Disease of Ningxia Medical University, Yinchuan, 750004, Ningxia Hui Autonomous Region, People's Republic of China. FAU - Yang, Songhao AU - Yang S AD - School of Basic Medicine, Ningxia Medical University, Yinchuan, 750004, Ningxia Hui Autonomous Region, People's Republic of China. AD - Key Laboratory of Hydatid Disease of Ningxia Medical University, Yinchuan, 750004, Ningxia Hui Autonomous Region, People's Republic of China. FAU - Duan, Liangwei AU - Duan L AD - Henan Key Laboratory of Immunology and Targeted Drugs, School of Laboratory Medicine, Xinxiang Medical University, Xinxiang, China. FAU - Du, Xiancai AU - Du X AD - School of Basic Medicine, Ningxia Medical University, Yinchuan, 750004, Ningxia Hui Autonomous Region, People's Republic of China. AD - Key Laboratory of Hydatid Disease of Ningxia Medical University, Yinchuan, 750004, Ningxia Hui Autonomous Region, People's Republic of China. FAU - Tao, Jia AU - Tao J AD - School of Basic Medicine, Ningxia Medical University, Yinchuan, 750004, Ningxia Hui Autonomous Region, People's Republic of China. AD - Key Laboratory of Hydatid Disease of Ningxia Medical University, Yinchuan, 750004, Ningxia Hui Autonomous Region, People's Republic of China. FAU - Wang, Yana AU - Wang Y AD - School of Basic Medicine, Ningxia Medical University, Yinchuan, 750004, Ningxia Hui Autonomous Region, People's Republic of China. FAU - Yang, Jihui AU - Yang J AD - Key Laboratory of Hydatid Disease of Ningxia Medical University, Yinchuan, 750004, Ningxia Hui Autonomous Region, People's Republic of China. AD - Center of Scientific Technology of Ningxia Medical University, Yinchuan, 750004, Ningxia Hui Autonomous Region, People's Republic of China. FAU - Lv, Yongxue AU - Lv Y AD - School of Basic Medicine, Ningxia Medical University, Yinchuan, 750004, Ningxia Hui Autonomous Region, People's Republic of China. AD - Key Laboratory of Hydatid Disease of Ningxia Medical University, Yinchuan, 750004, Ningxia Hui Autonomous Region, People's Republic of China. FAU - Li, Junliang AU - Li J AD - School of Basic Medicine, Ningxia Medical University, Yinchuan, 750004, Ningxia Hui Autonomous Region, People's Republic of China. AD - Key Laboratory of Hydatid Disease of Ningxia Medical University, Yinchuan, 750004, Ningxia Hui Autonomous Region, People's Republic of China. FAU - Zhang, Cuiying AU - Zhang C AD - School of Basic Medicine, Ningxia Medical University, Yinchuan, 750004, Ningxia Hui Autonomous Region, People's Republic of China. AD - Key Laboratory of Hydatid Disease of Ningxia Medical University, Yinchuan, 750004, Ningxia Hui Autonomous Region, People's Republic of China. FAU - Wen, Jia AU - Wen J AD - School of Basic Medicine, Ningxia Medical University, Yinchuan, 750004, Ningxia Hui Autonomous Region, People's Republic of China. AD - Key Laboratory of Hydatid Disease of Ningxia Medical University, Yinchuan, 750004, Ningxia Hui Autonomous Region, People's Republic of China. FAU - Zhu, Yazhou AU - Zhu Y AD - School of Basic Medicine, Ningxia Medical University, Yinchuan, 750004, Ningxia Hui Autonomous Region, People's Republic of China. AD - Key Laboratory of Hydatid Disease of Ningxia Medical University, Yinchuan, 750004, Ningxia Hui Autonomous Region, People's Republic of China. FAU - Chang, Liangliang AU - Chang L AD - School of Basic Medicine, Ningxia Medical University, Yinchuan, 750004, Ningxia Hui Autonomous Region, People's Republic of China. AD - Key Laboratory of Hydatid Disease of Ningxia Medical University, Yinchuan, 750004, Ningxia Hui Autonomous Region, People's Republic of China. FAU - Wang, Hui AU - Wang H AD - Henan Key Laboratory of Immunology and Targeted Drugs, School of Laboratory Medicine, Xinxiang Medical University, Xinxiang, China. FAU - Wang, Qi AU - Wang Q AD - School of Basic Medicine, Ningxia Medical University, Yinchuan, 750004, Ningxia Hui Autonomous Region, People's Republic of China. wqmam@126.com. FAU - Zhao, Wei AU - Zhao W AD - School of Basic Medicine, Ningxia Medical University, Yinchuan, 750004, Ningxia Hui Autonomous Region, People's Republic of China. Weizhao@nxmu.edu.cn. AD - Key Laboratory of Hydatid Disease of Ningxia Medical University, Yinchuan, 750004, Ningxia Hui Autonomous Region, People's Republic of China. Weizhao@nxmu.edu.cn. AD - Center of Scientific Technology of Ningxia Medical University, Yinchuan, 750004, Ningxia Hui Autonomous Region, People's Republic of China. Weizhao@nxmu.edu.cn. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20221222 PL - England TA - Virol J JT - Virology journal JID - 101231645 RN - 0 (Cytokines) RN - 0 (Antibodies, Viral) RN - 0 (sinovac COVID-19 vaccine) RN - 0 (Vaccines, Inactivated) RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - *SARS-CoV-2 MH - Leukocytes, Mononuclear MH - *COVID-19/prevention & control MH - Vaccination MH - Cytokines MH - Enzyme-Linked Immunospot Assay MH - Immunity MH - Antibodies, Viral MH - Vaccines, Inactivated MH - COVID-19 Vaccines PMC - PMC9774075 OTO - NOTNLM OT - CD4+T cells OT - CD8+T cells OT - Inactivated vaccine OT - Memory B cells OT - SARS-CoV-2 COIS- The authors declare that they have no competing interests. EDAT- 2022/12/23 06:00 MHDA- 2022/12/27 06:00 PMCR- 2022/12/22 CRDT- 2022/12/22 23:58 PHST- 2022/10/26 00:00 [received] PHST- 2022/12/19 00:00 [accepted] PHST- 2022/12/22 23:58 [entrez] PHST- 2022/12/23 06:00 [pubmed] PHST- 2022/12/27 06:00 [medline] PHST- 2022/12/22 00:00 [pmc-release] AID - 10.1186/s12985-022-01957-1 [pii] AID - 1957 [pii] AID - 10.1186/s12985-022-01957-1 [doi] PST - epublish SO - Virol J. 2022 Dec 22;19(1):223. doi: 10.1186/s12985-022-01957-1. PMID- 36538327 OWN - NLM STAT- MEDLINE DCOM- 20221222 LR - 20260127 IS - 2574-3805 (Electronic) IS - 2574-3805 (Linking) VI - 5 IP - 12 DP - 2022 Dec 1 TI - Cross-Clade Memory Immunity in Adults Following SARS-CoV-1 Infection in 2003. PG - e2247723 LID - 10.1001/jamanetworkopen.2022.47723 [doi] LID - e2247723 AB - IMPORTANCE: Knowledge of the longevity and breath of immune response to coronavirus infection is crucial for the development of next-generation vaccines to control the COVID-19 pandemic. OBJECTIVES: To determine the profile of SARS-CoV-2 antibodies among persons infected with the closely related virus, SARS-CoV-1, in 2003 (SARS03 survivors) and to characterize their antibody response soon after the first and second doses of COVID-19 vaccines. DESIGN, SETTING, AND PARTICIPANTS: This prospective cohort study examined SARS-CoV-2 antibodies among SARS03 survivors compared with sex- and age-matched infection-naive controls. Participants received the COVID-19 vaccines between March 1 and September 30, 2021. INTERVENTIONS: One of the 2 COVID-19 vaccines (inactivated [CoronaVac] or messenger RNA [BNT162b2]) available in Hong Kong. Two doses were given according to the recommended schedule. The vaccine type administered was known to both participants and observers. MAIN OUTCOMES AND MEASURES: SARS-CoV-2 antibodies were measured prevaccination, 7 days after the first dose, and 14 days after the second dose. RESULTS: Eighteen SARS03 adult survivors (15 women and 3 men; median age, 46.5 [IQR, 40.0-54.3] years) underwent prevaccination serologic examination. The vast majority retained a detectable level of antibodies that cross-reacted with SARS-CoV-2 (16 of 18 [88.9%] with nucleocapsid protein antibodies and 17 of 18 [94.4%] with receptor-binding domain of spike protein antibodies); a substantial proportion (11 of 18 [61.1%]) had detectable cross-neutralizing antibodies. Twelve SARS03 adult survivors (10 women and 2 men) underwent postvaccination serologic examination. At 7 days after the first dose of vaccine, SARS03 survivors mounted significantly higher levels of neutralizing antibodies compared with controls (median inhibition: 89.5% [IQR, 77.1%-93.7%] vs 13.9% [IQR, 11.8%-16.1%] for BNT162b2; 64.9% [IQR, 60.8%-69.5%] vs 13.4% [IQR, 9.5%-16.8%] for CoronaVac; P < .001 for both). At 14 days after the second dose, SARS03 survivors generated a broader antibody response with significantly higher levels of neutralizing antibodies against variants of concern compared with controls (eg, median inhibition against Omicron variant, 52.1% [IQR, 35.8%-66.0%] vs 14.7% [IQR, 2.5%-20.7%]; P < .001). CONCLUSIONS AND RELEVANCE: The findings of this prospective cohort study suggest that infection with SARS-CoV-1 was associated with detectable levels of antibodies that cross-react and cross-neutralize SARS-CoV-2, which belongs to a distinct clade under the same subgenus Sarbecovirus. These findings support the development of broadly protective vaccines to cover sarbecoviruses that caused 2 devastating zoonotic outbreaks in humans over the last 2 decades. FAU - Ng, Rita W Y AU - Ng RWY AD - Department of Microbiology, Faculty of Medicine, Chinese University of Hong Kong, Hong Kong. FAU - Boon, Siaw S AU - Boon SS AD - Department of Microbiology, Faculty of Medicine, Chinese University of Hong Kong, Hong Kong. FAU - Chen, Zigui AU - Chen Z AD - Department of Microbiology, Faculty of Medicine, Chinese University of Hong Kong, Hong Kong. FAU - Ho, Wendy C S AU - Ho WCS AD - Department of Microbiology, Faculty of Medicine, Chinese University of Hong Kong, Hong Kong. FAU - Fung, Kitty S C AU - Fung KSC AD - Department of Pathology, United Christian Hospital, Hong Kong. FAU - Wong, Barry K C AU - Wong BKC AD - Department of Pathology, United Christian Hospital, Hong Kong. FAU - Yeung, Apple C M AU - Yeung ACM AD - Department of Microbiology, Faculty of Medicine, Chinese University of Hong Kong, Hong Kong. FAU - Wong, Martin C S AU - Wong MCS AD - JC School of Public Health and Primary Care, Chinese University of Hong Kong, Hong Kong. FAU - Chan, Paul K S AU - Chan PKS AD - Department of Microbiology, Faculty of Medicine, Chinese University of Hong Kong, Hong Kong. AD - Stanley Ho Centre for Emerging Infectious Diseases, Faulty of Medicine, Chinese University of Hong Kong, Hong Kong. LA - eng PT - Journal Article DEP - 20221201 PL - United States TA - JAMA Netw Open JT - JAMA network open JID - 101729235 RN - 0 (COVID-19 Vaccines) RN - 0 (BNT162 Vaccine) RN - 0 (Antibodies, Neutralizing) RN - 0 (Antibodies, Viral) RN - 0 (sinovac COVID-19 vaccine) RN - 0 (Vaccines, Inactivated) RN - SARS-CoV-2 variants SB - IM MH - Male MH - Humans MH - Adult MH - Female MH - Middle Aged MH - *COVID-19 Vaccines MH - BNT162 Vaccine MH - *COVID-19 MH - Pandemics MH - Prospective Studies MH - SARS-CoV-2 MH - Antibodies, Neutralizing MH - Antibodies, Viral MH - Vaccines, Inactivated PMC - PMC9856533 COIS- Conflict of Interest Disclosures: None reported. EDAT- 2022/12/21 06:00 MHDA- 2022/12/23 06:00 PMCR- 2022/12/20 CRDT- 2022/12/20 11:33 PHST- 2022/12/20 11:33 [entrez] PHST- 2022/12/21 06:00 [pubmed] PHST- 2022/12/23 06:00 [medline] PHST- 2022/12/20 00:00 [pmc-release] AID - 2799725 [pii] AID - zoi221351 [pii] AID - 10.1001/jamanetworkopen.2022.47723 [doi] PST - epublish SO - JAMA Netw Open. 2022 Dec 1;5(12):e2247723. doi: 10.1001/jamanetworkopen.2022.47723. PMID- 36512034 OWN - NLM STAT- MEDLINE DCOM- 20221215 LR - 20230613 IS - 1540-9538 (Electronic) IS - 0022-1007 (Print) IS - 0022-1007 (Linking) VI - 220 IP - 2 DP - 2023 Feb 6 TI - Antibody feedback contributes to facilitating the development of Omicron-reactive memory B cells in SARS-CoV-2 mRNA vaccinees. LID - 10.1084/jem.20221786 [doi] LID - e20221786 AB - In contrast to a second dose of the SARS-CoV-2 mRNA vaccine, a third dose elicits potent neutralizing activity against the Omicron variant. To address the underlying mechanism for this differential antibody response, we examined spike receptor-binding domain (RBD)-specific memory B cells in vaccinated individuals. Frequency of Omicron-reactive memory B cells increased approximately 9 mo after the second vaccine dose. These memory B cells show an altered distribution of epitopes from pre-second memory B cells, presumably due to an antibody feedback mechanism. This hypothesis was tested using mouse models, showing that an addition or a depletion of RBD-induced serum antibodies results in a concomitant increase or decrease, respectively, of Omicron-reactive germinal center (GC) and memory B cells. Our data suggest that pre-generated antibodies modulate the selection of GC and subsequent memory B cells after the second vaccine dose, accumulating more Omicron-reactive memory B cells over time, which contributes to the generation of Omicron-neutralizing antibodies elicited by the third vaccine dose. CI - (c) 2022 Inoue et al. FAU - Inoue, Takeshi AU - Inoue T AUID- ORCID: 0000-0002-9972-6105 AD - Laboratory of Lymphocyte Differentiation, WPI Immunology Frontier Research Center, Osaka University, Osaka, Japan. FAU - Shinnakasu, Ryo AU - Shinnakasu R AUID- ORCID: 0000-0002-5369-3424 AD - Laboratory of Lymphocyte Differentiation, WPI Immunology Frontier Research Center, Osaka University, Osaka, Japan. AD - Division of Medical Research Support, Advanced Research Support Center, Ehime University, Ehime, Japan. AD - Translational Research Center, Ehime University Hospital, Ehime, Japan. FAU - Kawai, Chie AU - Kawai C AUID- ORCID: 0000-0001-5883-2377 AD - Laboratory of Lymphocyte Differentiation, WPI Immunology Frontier Research Center, Osaka University, Osaka, Japan. FAU - Yamamoto, Hiromi AU - Yamamoto H AUID- ORCID: 0000-0002-3495-9936 AD - Laboratory of Lymphocyte Differentiation, WPI Immunology Frontier Research Center, Osaka University, Osaka, Japan. FAU - Sakakibara, Shuhei AU - Sakakibara S AUID- ORCID: 0000-0003-3157-5870 AD - Laboratory of Immune Regulation, WPI Immunology Frontier Research Center, Osaka University, Osaka, Japan. FAU - Ono, Chikako AU - Ono C AUID- ORCID: 0000-0002-3965-6715 AD - Laboratory of Virus Control, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan. AD - Laboratory of Virus Control, Center for Infectious Disease Education and Research, Osaka University, Osaka, Japan. FAU - Itoh, Yumi AU - Itoh Y AUID- ORCID: 0000-0001-5501-3413 AD - Institute for Advanced Co-Creation Studies, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan. FAU - Terooatea, Tommy AU - Terooatea T AUID- ORCID: 0000-0002-7814-3736 AD - KOTAI Biotechnologies, Inc., Osaka, Japan. FAU - Yamashita, Kazuo AU - Yamashita K AUID- ORCID: 0000-0002-0085-2057 AD - KOTAI Biotechnologies, Inc., Osaka, Japan. FAU - Okamoto, Toru AU - Okamoto T AUID- ORCID: 0000-0003-4000-3102 AD - Institute for Advanced Co-Creation Studies, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan. FAU - Hashii, Noritaka AU - Hashii N AUID- ORCID: 0000-0003-1363-2050 AD - Division of Biological Chemistry and Biologicals, National Institute of Health Sciences, Kanagawa, Japan. FAU - Ishii-Watabe, Akiko AU - Ishii-Watabe A AUID- ORCID: 0000-0003-2167-2263 AD - Division of Biological Chemistry and Biologicals, National Institute of Health Sciences, Kanagawa, Japan. FAU - Butler, Noah S AU - Butler NS AUID- ORCID: 0000-0002-1429-0796 AD - Department of Microbiology and Immunology, The University of Iowa, Iowa City, IA, USA. FAU - Matsuura, Yoshiharu AU - Matsuura Y AUID- ORCID: 0000-0001-9091-8285 AD - Laboratory of Virus Control, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan. AD - Laboratory of Virus Control, Center for Infectious Disease Education and Research, Osaka University, Osaka, Japan. FAU - Matsumoto, Hisatake AU - Matsumoto H AUID- ORCID: 0000-0001-5771-570X AD - Department of Traumatology and Acute Critical Medicine, Osaka University Graduate School of Medicine, Osaka, Japan. FAU - Otsuka, Shinya AU - Otsuka S AUID- ORCID: 0000-0002-2489-9992 AD - Department of Surgery, National Hospital Organization Hakodate National Hospital, Hokkaido, Japan. FAU - Hiraoka, Kei AU - Hiraoka K AUID- ORCID: 0000-0002-5378-0421 AD - Department of Surgery, National Hospital Organization Hakodate National Hospital, Hokkaido, Japan. FAU - Teshima, Takanori AU - Teshima T AUID- ORCID: 0000-0002-0941-271X AD - Division of Laboratory and Transfusion Medicine, Hokkaido University Hospital, Sapporo, Japan. AD - Department of Hematology, Faculty of Medicine, Hokkaido University, Sapporo, Japan. FAU - Murakami, Masaaki AU - Murakami M AUID- ORCID: 0000-0001-7159-7279 AD - Molecular Psychoimmunology, Institute for Genetic Medicine, Graduate School of Medicine, Hokkaido University, Sapporo, Japan. AD - Team of Quantum immunology, Institute for Quantum Life Science, National Institute for Quantum and Radiological Science and Technology, Chiba, Japan. AD - Division of Molecular Neuroimmunology, Department of Homeostatic Regulation, National Institute for Physiological Sciences, National Institutes of Natural Sciences, Aichi, Japan. FAU - Kurosaki, Tomohiro AU - Kurosaki T AUID- ORCID: 0000-0002-6352-304X AD - Laboratory of Lymphocyte Differentiation, WPI Immunology Frontier Research Center, Osaka University, Osaka, Japan. AD - Center for Infectious Disease Education and Research, Osaka University, Osaka, Japan. AD - Laboratory for Lymphocyte Differentiation, RIKEN Center for Integrative Medical Sciences, Kanagawa, Japan. LA - eng GR - R01 AI125446/AI/NIAID NIH HHS/United States GR - R01 AI127481/AI/NIAID NIH HHS/United States GR - R01 AI167058/AI/NIAID NIH HHS/United States PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20221213 PL - United States TA - J Exp Med JT - The Journal of experimental medicine JID - 2985109R RN - 0 (COVID-19 Vaccines) RN - 0 (RNA, Messenger) RN - 0 (Antibodies, Neutralizing) RN - 0 (Antibodies, Viral) RN - SARS-CoV-2 variants SB - IM MH - Animals MH - Mice MH - Humans MH - *COVID-19 Vaccines MH - Feedback MH - Memory B Cells MH - SARS-CoV-2 MH - *COVID-19/prevention & control MH - RNA, Messenger MH - Antibodies, Neutralizing MH - Antibodies, Viral PMC - PMC9750191 COIS- Disclosures: K. Yamashita is a founder and board member of KOTAI Biotechnologies, Inc. No other disclosures were reported. EDAT- 2022/12/14 06:00 MHDA- 2022/12/16 06:00 PMCR- 2022/12/13 CRDT- 2022/12/13 11:13 PHST- 2022/10/19 00:00 [received] PHST- 2022/11/16 00:00 [revised] PHST- 2022/11/23 00:00 [accepted] PHST- 2022/12/13 11:13 [entrez] PHST- 2022/12/14 06:00 [pubmed] PHST- 2022/12/16 06:00 [medline] PHST- 2022/12/13 00:00 [pmc-release] AID - 213745 [pii] AID - jem.20221786 [pii] AID - 10.1084/jem.20221786 [doi] PST - ppublish SO - J Exp Med. 2023 Feb 6;220(2):e20221786. doi: 10.1084/jem.20221786. Epub 2022 Dec 13. PMID- 36508885 OWN - NLM STAT- MEDLINE DCOM- 20230202 LR - 20230213 IS - 1878-3279 (Electronic) IS - 0171-2985 (Print) IS - 0171-2985 (Linking) VI - 228 IP - 1 DP - 2023 Jan TI - CD4 and IL-2 mediated NK cell responses after COVID-19 infection and mRNA vaccination in adults. PG - 152304 LID - S0171-2985(22)00130-9 [pii] LID - 10.1016/j.imbio.2022.152304 [doi] AB - A detailed understanding of protective immunity against SARS-CoV-2 is incredibly important in fighting the pandemic. Central to protective immunity is the ability of the immune system to recall previous exposures. Although antibody and T cell immunity have gained considerable attention, the contribution of the NK cell compartment to immune recall and protection from SARS-CoV-2 has not been explored. In this study, we investigate the NK cell responses to stimulation with SARS-CoV-2 in previously exposed and non-exposed individuals. We show that NK cells demonstrate an enhanced CD4+ T cell dependent response when re-exposed to SARS-CoV-2 antigen. The enhanced response is dependent on T cells and correlates with the number of SARS-CoV-2 specific CD4 T cells. We find that IL-2 is a critical mediator of NK cell function. These findings suggest that NK cells contribute to the protective responses against SARS-CoV-2 through a cooperation with antigen-specific CD4 T cells and have significant implications on our understanding of protective immunity in SARS-CoV-2. CI - Copyright (c) 2022. Published by Elsevier GmbH. FAU - Alhajjat, Amir M AU - Alhajjat AM AD - Stanley Manne Children's Research Institute, Department of Surgery, Ann & Robert Lurie Children's Hospital of Chicago, Northwestern University, Chicago, IL, USA. Electronic address: aalhajjat@luriechildrens.org. FAU - Redden, Catherine R AU - Redden CR AD - Stanley Manne Children's Research Institute, Department of Surgery, Ann & Robert Lurie Children's Hospital of Chicago, Northwestern University, Chicago, IL, USA. FAU - Langereis, Morgan AU - Langereis M AD - Stanley Manne Children's Research Institute, Department of Surgery, Ann & Robert Lurie Children's Hospital of Chicago, Northwestern University, Chicago, IL, USA. FAU - Papastefan, Steven T AU - Papastefan ST AD - Stanley Manne Children's Research Institute, Department of Surgery, Ann & Robert Lurie Children's Hospital of Chicago, Northwestern University, Chicago, IL, USA. FAU - Ito, Joy A S AU - Ito JAS AD - Stanley Manne Children's Research Institute, Department of Surgery, Ann & Robert Lurie Children's Hospital of Chicago, Northwestern University, Chicago, IL, USA. FAU - Ott, Katherine C AU - Ott KC AD - Stanley Manne Children's Research Institute, Department of Surgery, Ann & Robert Lurie Children's Hospital of Chicago, Northwestern University, Chicago, IL, USA. FAU - Turner, Lucas E AU - Turner LE AD - Stanley Manne Children's Research Institute, Department of Surgery, Ann & Robert Lurie Children's Hospital of Chicago, Northwestern University, Chicago, IL, USA. FAU - Kang, HeeKap K AU - Kang HK AD - Stanley Manne Children's Research Institute, Department of Surgery, Ann & Robert Lurie Children's Hospital of Chicago, Northwestern University, Chicago, IL, USA. FAU - Shaaban, Aimen F AU - Shaaban AF AD - Stanley Manne Children's Research Institute, Department of Surgery, Ann & Robert Lurie Children's Hospital of Chicago, Northwestern University, Chicago, IL, USA. LA - eng PT - Journal Article DEP - 20221123 PL - Netherlands TA - Immunobiology JT - Immunobiology JID - 8002742 RN - 0 (Antibodies, Viral) RN - 0 (Interleukin-2) RN - 0 (mRNA Vaccines) SB - IM MH - Adult MH - Humans MH - Antibodies, Viral/immunology MH - *COVID-19/immunology/prevention & control MH - *Interleukin-2 MH - *Killer Cells, Natural/immunology MH - SARS-CoV-2 MH - Vaccination MH - CD4-Positive T-Lymphocytes MH - *mRNA Vaccines/immunology PMC - PMC9683520 OTO - NOTNLM OT - Adaptive immunity OT - BNT162b2 OT - CD4 OT - COVID-19 OT - IL-2 OT - Memory OT - NK cells COIS- Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2022/12/13 06:00 MHDA- 2023/01/11 06:00 PMCR- 2022/11/23 CRDT- 2022/12/12 18:19 PHST- 2022/08/16 00:00 [received] PHST- 2022/11/08 00:00 [revised] PHST- 2022/11/18 00:00 [accepted] PHST- 2022/12/13 06:00 [pubmed] PHST- 2023/01/11 06:00 [medline] PHST- 2022/12/12 18:19 [entrez] PHST- 2022/11/23 00:00 [pmc-release] AID - S0171-2985(22)00130-9 [pii] AID - 152304 [pii] AID - 10.1016/j.imbio.2022.152304 [doi] PST - ppublish SO - Immunobiology. 2023 Jan;228(1):152304. doi: 10.1016/j.imbio.2022.152304. Epub 2022 Nov 23. PMID- 36505416 OWN - NLM STAT- MEDLINE DCOM- 20221216 LR - 20240908 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 13 DP - 2022 TI - Profiling the B cell immune response elicited by vaccination against the respiratory virus SARS-CoV-2. PG - 1058748 LID - 10.3389/fimmu.2022.1058748 [doi] LID - 1058748 AB - B cells play a fundamental role in host defenses against viral infections. Profiling the B cell response elicited by SARS-CoV-2 vaccination, including the generation and persistence of antigen-specific memory B cells, is essential for improving the knowledge of vaccine immune responsiveness, beyond the antibody response. mRNA-based vaccines have shown to induce a robust class-switched memory B cell response that persists overtime and is boosted by further vaccine administration, suggesting that memory B cells are critical in driving a recall response upon re-exposure to SARS-CoV-2 antigens. Here, we focus on the role of the B cell response in the context of SARS-CoV-2 vaccination, offering an overview of the different technologies that can be used to identify spike-specific B cells, characterize their phenotype using machine learning approaches, measure their capacity to reactivate following antigen encounter, and tracking the maturation of the B cell receptor antigenic affinity. CI - Copyright (c) 2022 Pettini, Medaglini and Ciabattini. FAU - Pettini, Elena AU - Pettini E AD - Laboratory of Molecular Microbiology and Biotechnology, Department of Medical Biotechnologies, University of Siena, Siena, Italy. FAU - Medaglini, Donata AU - Medaglini D AD - Laboratory of Molecular Microbiology and Biotechnology, Department of Medical Biotechnologies, University of Siena, Siena, Italy. FAU - Ciabattini, Annalisa AU - Ciabattini A AD - Laboratory of Molecular Microbiology and Biotechnology, Department of Medical Biotechnologies, University of Siena, Siena, Italy. LA - eng PT - Journal Article PT - Review DEP - 20221124 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - *SARS-CoV-2 MH - COVID-19 Vaccines MH - *COVID-19/prevention & control MH - Vaccination MH - Immunity PMC - PMC9729280 OTO - NOTNLM OT - B cell ELISpot OT - BCR repertoire OT - COVID-19 vaccines OT - SARS-CoV-2 OT - computational flow cytometry OT - memory B cells OT - respiratory virus COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/12/13 06:00 MHDA- 2022/12/15 06:00 PMCR- 2022/11/24 CRDT- 2022/12/12 11:00 PHST- 2022/09/30 00:00 [received] PHST- 2022/11/04 00:00 [accepted] PHST- 2022/12/12 11:00 [entrez] PHST- 2022/12/13 06:00 [pubmed] PHST- 2022/12/15 06:00 [medline] PHST- 2022/11/24 00:00 [pmc-release] AID - 10.3389/fimmu.2022.1058748 [doi] PST - epublish SO - Front Immunol. 2022 Nov 24;13:1058748. doi: 10.3389/fimmu.2022.1058748. eCollection 2022. PMID- 36480298 OWN - NLM STAT- MEDLINE DCOM- 20230307 LR - 20231212 IS - 1365-2249 (Electronic) IS - 0009-9104 (Print) IS - 0009-9104 (Linking) VI - 210 IP - 3 DP - 2022 Dec 31 TI - The role of antigen availability during B cell induction and its effect on sustained memory and antibody production after infection and vaccination-lessons learned from the SARS-CoV-2 pandemic. PG - 273-282 LID - 10.1093/cei/uxac113 [doi] AB - The importance of antibodies, particularly neutralizing antibodies, has been known for decades. When examining the immune responses against a pathogen after a vaccination or infection it is easier to measure the levels of antigen-specific antibodies than the T-cell response, but it does not give the whole picture. The levels of neutralizing antibodies are harder to determine but give a better indication of the quality of the antibody response. The induction of long-lived antibody-secreting plasma cells is crucial for a persistent humoral immune response, which has been shown for example after vaccination with the vaccinia vaccine, where antibody levels have been shown to persist for decades. With the SARS-CoV-2 pandemic ravaging the world for the past years and the monumental effort in designing and releasing novel vaccines against the virus, much effort has been put into analysing the quantity, quality, and persistence of antibody responses. CI - (c) The Author(s) 2022. Published by Oxford University Press on behalf of the British Society for Immunology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. FAU - Bjarnarson, Stefania P AU - Bjarnarson SP AD - Department of Immunology, Landspitali-The National University Hospital of Iceland, Reykjavik, Iceland. AD - Faculty of Medicine, Biomedical Center, University of Iceland, Reykjavik, Iceland. FAU - Brynjolfsson, Siggeir F AU - Brynjolfsson SF AUID- ORCID: 0000-0003-0451-5581 AD - Department of Immunology, Landspitali-The National University Hospital of Iceland, Reykjavik, Iceland. AD - Faculty of Medicine, Biomedical Center, University of Iceland, Reykjavik, Iceland. LA - eng PT - Journal Article PL - England TA - Clin Exp Immunol JT - Clinical and experimental immunology JID - 0057202 RN - 0 (Antibodies, Viral) RN - 0 (Antigens) RN - 0 (Antibodies, Neutralizing) SB - IM MH - Humans MH - *Antibody Formation MH - SARS-CoV-2 MH - Pandemics MH - Antibodies, Viral MH - *COVID-19 MH - Vaccination MH - Antigens MH - Antibodies, Neutralizing PMC - PMC9985164 OTO - NOTNLM OT - B cells OT - antibodies OT - antigens OT - memory OT - vaccine EDAT- 2022/12/09 06:00 MHDA- 2023/03/08 06:00 PMCR- 2023/12/08 CRDT- 2022/12/08 14:58 PHST- 2022/07/01 00:00 [received] PHST- 2022/10/05 00:00 [revised] PHST- 2022/12/06 00:00 [accepted] PHST- 2022/12/09 06:00 [pubmed] PHST- 2023/03/08 06:00 [medline] PHST- 2022/12/08 14:58 [entrez] PHST- 2023/12/08 00:00 [pmc-release] AID - 6884048 [pii] AID - uxac113 [pii] AID - 10.1093/cei/uxac113 [doi] PST - ppublish SO - Clin Exp Immunol. 2022 Dec 31;210(3):273-282. doi: 10.1093/cei/uxac113. PMID- 36473496 OWN - NLM STAT- MEDLINE DCOM- 20230201 LR - 20260127 IS - 1476-4687 (Electronic) IS - 0028-0836 (Print) IS - 0028-0836 (Linking) VI - 613 IP - 7945 DP - 2023 Jan TI - Antibody feedback regulates immune memory after SARS-CoV-2 mRNA vaccination. PG - 735-742 LID - 10.1038/s41586-022-05609-w [doi] AB - Feedback inhibition of humoral immunity by antibodies was first documented in 1909(1). Subsequent studies showed that, depending on the context, antibodies can enhance or inhibit immune responses(2,3). However, little is known about how pre-existing antibodies influence the development of memory B cells. Here we examined the memory B cell response in individuals who received two high-affinity anti-SARS-CoV-2 monoclonal antibodies and subsequently two doses of an mRNA vaccine(4-8). We found that the recipients of the monoclonal antibodies produced antigen-binding and neutralizing titres that were only fractionally lower compared than in control individuals. However, the memory B cells of the individuals who received the monoclonal antibodies differed from those of control individuals in that they predominantly expressed low-affinity IgM antibodies that carried small numbers of somatic mutations and showed altered receptor binding domain (RBD) target specificity, consistent with epitope masking. Moreover, only 1 out of 77 anti-RBD memory antibodies tested neutralized the virus. The mechanism underlying these findings was examined in experiments in mice that showed that germinal centres formed in the presence of the same antibodies were dominated by low-affinity B cells. Our results indicate that pre-existing high-affinity antibodies bias germinal centre and memory B cell selection through two distinct mechanisms: (1) by lowering the activation threshold for B cells, thereby permitting abundant lower-affinity clones to participate in the immune response; and (2) through direct masking of their cognate epitopes. This may in part explain the shifting target profile of memory antibodies elicited by booster vaccinations(9). CI - (c) 2022. The Author(s). FAU - Schaefer-Babajew, Dennis AU - Schaefer-Babajew D AUID- ORCID: 0000-0002-5380-2950 AD - Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA. FAU - Wang, Zijun AU - Wang Z AUID- ORCID: 0000-0002-2095-2151 AD - Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA. FAU - Muecksch, Frauke AU - Muecksch F AUID- ORCID: 0000-0002-0132-5101 AD - Laboratory of Retrovirology, The Rockefeller University, New York, NY, USA. FAU - Cho, Alice AU - Cho A AUID- ORCID: 0000-0001-6354-6148 AD - Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA. FAU - Loewe, Maximilian AU - Loewe M AUID- ORCID: 0000-0003-2935-3750 AD - Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA. FAU - Cipolla, Melissa AU - Cipolla M AD - Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA. FAU - Raspe, Raphael AU - Raspe R AUID- ORCID: 0000-0003-3409-4968 AD - Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA. FAU - Johnson, Brianna AU - Johnson B AUID- ORCID: 0000-0003-3214-284X AD - Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA. FAU - Canis, Marie AU - Canis M AD - Laboratory of Retrovirology, The Rockefeller University, New York, NY, USA. FAU - DaSilva, Justin AU - DaSilva J AD - Laboratory of Retrovirology, The Rockefeller University, New York, NY, USA. FAU - Ramos, Victor AU - Ramos V AD - Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA. FAU - Turroja, Martina AU - Turroja M AUID- ORCID: 0000-0001-9640-0559 AD - Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA. FAU - Millard, Katrina G AU - Millard KG AUID- ORCID: 0000-0003-2247-3178 AD - Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA. FAU - Schmidt, Fabian AU - Schmidt F AD - Laboratory of Retrovirology, The Rockefeller University, New York, NY, USA. FAU - Witte, Leander AU - Witte L AUID- ORCID: 0000-0002-4704-8461 AD - Laboratory of Retrovirology, The Rockefeller University, New York, NY, USA. FAU - Dizon, Juan AU - Dizon J AD - Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA. FAU - Shimeliovich, Irina AU - Shimeliovich I AD - Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA. FAU - Yao, Kai-Hui AU - Yao KH AD - Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA. FAU - Oliveira, Thiago Y AU - Oliveira TY AUID- ORCID: 0000-0002-2654-0879 AD - Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA. FAU - Gazumyan, Anna AU - Gazumyan A AD - Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA. AD - Howard Hughes Medical Institute, New York, NY, USA. FAU - Gaebler, Christian AU - Gaebler C AUID- ORCID: 0000-0001-7295-8128 AD - Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA. FAU - Bieniasz, Paul D AU - Bieniasz PD AUID- ORCID: 0000-0002-2368-3719 AD - Laboratory of Retrovirology, The Rockefeller University, New York, NY, USA. pbieniasz@rockefeller.edu. AD - Howard Hughes Medical Institute, New York, NY, USA. pbieniasz@rockefeller.edu. FAU - Hatziioannou, Theodora AU - Hatziioannou T AUID- ORCID: 0000-0002-7889-0766 AD - Laboratory of Retrovirology, The Rockefeller University, New York, NY, USA. thatziio@rockefeller.edu. FAU - Caskey, Marina AU - Caskey M AUID- ORCID: 0000-0003-1727-8693 AD - Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA. mcaskey@rockefeller.edu. FAU - Nussenzweig, Michel C AU - Nussenzweig MC AUID- ORCID: 0000-0003-0592-8564 AD - Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA. nussen@rockefeller.edu. AD - Howard Hughes Medical Institute, New York, NY, USA. nussen@rockefeller.edu. LA - eng GR - UM1 AI126620/AI/NIAID NIH HHS/United States GR - T32 AI070084/AI/NIAID NIH HHS/United States GR - R01 AI078788/AI/NIAID NIH HHS/United States GR - UL1 TR001866/TR/NCATS NIH HHS/United States GR - U19 AI111825/AI/NIAID NIH HHS/United States GR - R01 AI037526/AI/NIAID NIH HHS/United States GR - UM1 AI144462/AI/NIAID NIH HHS/United States GR - R37 AI037526/AI/NIAID NIH HHS/United States GR - R37 AI064003/AI/NIAID NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20221206 PL - England TA - Nature JT - Nature JID - 0410462 RN - 0 (Antibodies, Monoclonal) RN - 0 (Antibodies, Neutralizing) RN - 0 (Antibodies, Viral) RN - 0 (mRNA Vaccines) RN - 0 (COVID-19 Vaccines) RN - 0 (Epitopes, B-Lymphocyte) RN - 0 (Immunoglobulin M) RN - 0 (spike protein, SARS-CoV-2) RN - 0 (Spike Glycoprotein, Coronavirus) SB - IM UOF - medRxiv. 2022 Aug 10:2022.08.05.22278483. doi: 10.1101/2022.08.05.22278483. PMID: 35982682 MH - Animals MH - Mice MH - Antibodies, Monoclonal/immunology/therapeutic use MH - Antibodies, Neutralizing/immunology MH - *Antibodies, Viral/immunology MH - *COVID-19/immunology/prevention & control/therapy/virology MH - *Immunologic Memory MH - SARS-CoV-2/immunology MH - *Vaccination MH - *mRNA Vaccines/immunology MH - *COVID-19 Vaccines/immunology MH - *B-Lymphocytes/immunology/metabolism MH - Epitopes, B-Lymphocyte/chemistry/immunology MH - *Feedback, Physiological MH - Immunoglobulin M/immunology MH - Germinal Center/cytology/immunology MH - Immunization, Secondary MH - Somatic Hypermutation, Immunoglobulin MH - Spike Glycoprotein, Coronavirus PMC - PMC9876794 COIS- The Rockefeller University has filed a provisional patent application in connection with this work, on which M.C.N. is listed as an inventor (US patent 63/021,387). The patent has been licensed by Rockefeller University to Bristol Meyers Squib. P.D.B. has received remuneration from Pfizer for consulting services related to SARS-CoV-2 vaccines. EDAT- 2022/12/07 06:00 MHDA- 2023/01/28 06:00 PMCR- 2022/12/06 CRDT- 2022/12/06 19:12 PHST- 2022/06/04 00:00 [received] PHST- 2022/11/30 00:00 [accepted] PHST- 2022/12/07 06:00 [pubmed] PHST- 2023/01/28 06:00 [medline] PHST- 2022/12/06 19:12 [entrez] PHST- 2022/12/06 00:00 [pmc-release] AID - 10.1038/s41586-022-05609-w [pii] AID - 5609 [pii] AID - 10.1038/s41586-022-05609-w [doi] PST - ppublish SO - Nature. 2023 Jan;613(7945):735-742. doi: 10.1038/s41586-022-05609-w. Epub 2022 Dec 6. PMID- 36455555 OWN - NLM STAT- MEDLINE DCOM- 20221223 LR - 20250530 IS - 2666-3791 (Electronic) IS - 2666-3791 (Linking) VI - 3 IP - 12 DP - 2022 Dec 20 TI - Tfh cells and the germinal center are required for memory B cell formation & humoral immunity after ChAdOx1 nCoV-19 vaccination. PG - 100845 LID - S2666-3791(22)00409-8 [pii] LID - 10.1016/j.xcrm.2022.100845 [doi] LID - 100845 AB - Emergence from the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has been facilitated by the rollout of effective vaccines. Successful vaccines generate high-affinity plasma blasts and long-lived protective memory B cells. Here, we show a requirement for T follicular helper (Tfh) cells and the germinal center reaction for optimal serum antibody and memory B cell formation after ChAdOx1 nCoV-19 vaccination. We found that Tfh cells play an important role in expanding antigen-specific B cells while identifying Tfh-cell-dependent and -independent memory B cell subsets. Upon secondary vaccination, germinal center B cells generated during primary immunizations can be recalled as germinal center B cells again. Likewise, primary immunization GC-Tfh cells can be recalled as either Tfh or Th1 cells, highlighting the pluripotent nature of Tfh cell memory. This study demonstrates that ChAdOx1 nCoV-19-induced germinal centers are a critical source of humoral immunity. CI - Copyright (c) 2022 The Author(s). Published by Elsevier Inc. All rights reserved. FAU - Foster, William S AU - Foster WS AD - Lymphocyte Signalling and Development, Babraham Institute, Babraham Research Campus, Cambridge CB22 3AT, UK. FAU - Lee, Jia Le AU - Lee JL AD - Lymphocyte Signalling and Development, Babraham Institute, Babraham Research Campus, Cambridge CB22 3AT, UK. FAU - Thakur, Nazia AU - Thakur N AD - The Pirbright Institute, Ash Road, Pirbright GU24 0NF, UK; Oxford Vaccine Group, Department of Paediatrics, Medical Sciences Division, University of Oxford and Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), Oxford OX3 7BN, UK. FAU - Newman, Joseph AU - Newman J AD - The Pirbright Institute, Ash Road, Pirbright GU24 0NF, UK. FAU - Spencer, Alexandra J AU - Spencer AJ AD - The Jenner Institute, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford OX3 7DQ, UK. FAU - Davies, Sophie AU - Davies S AD - Oxford Vaccine Group, Department of Paediatrics, Medical Sciences Division, University of Oxford and Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), Oxford OX3 7BN, UK. FAU - Woods, Danielle AU - Woods D AD - The Jenner Institute, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford OX3 7DQ, UK. FAU - Godfrey, Leila AU - Godfrey L AD - The Jenner Institute, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford OX3 7DQ, UK. FAU - Hay, Iain M AU - Hay IM AD - Signalling Programme, Babraham Institute, Babraham Research Campus, Cambridge CB22 3AT, UK; Cambridge Institute for Medical Research, Hills Road, Cambridge CB2 0XY, UK. FAU - Innocentin, Silvia AU - Innocentin S AD - Lymphocyte Signalling and Development, Babraham Institute, Babraham Research Campus, Cambridge CB22 3AT, UK. FAU - Yam-Puc, Juan Carlos AU - Yam-Puc JC AD - MRC Toxicology Unit, Gleeson Building, Tennis Court Road, Cambridge CB2 1QR, UK. FAU - Horner, Emily C AU - Horner EC AD - MRC Toxicology Unit, Gleeson Building, Tennis Court Road, Cambridge CB2 1QR, UK. FAU - Sharpe, Hayley J AU - Sharpe HJ AD - Signalling Programme, Babraham Institute, Babraham Research Campus, Cambridge CB22 3AT, UK. FAU - Thaventhiran, James E AU - Thaventhiran JE AD - MRC Toxicology Unit, Gleeson Building, Tennis Court Road, Cambridge CB2 1QR, UK. FAU - Bailey, Dalan AU - Bailey D AD - The Pirbright Institute, Ash Road, Pirbright GU24 0NF, UK. FAU - Lambe, Teresa AU - Lambe T AD - Oxford Vaccine Group, Department of Paediatrics, Medical Sciences Division, University of Oxford and Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), Oxford OX3 7BN, UK. Electronic address: teresa.lambe@paediatrics.ox.ac.uk. FAU - Linterman, Michelle A AU - Linterman MA AD - Lymphocyte Signalling and Development, Babraham Institute, Babraham Research Campus, Cambridge CB22 3AT, UK. Electronic address: michelle.linterman@babraham.ac.uk. LA - eng GR - MRF-057-0002-RG-THAV-C0798/MRF_/MRF_/United Kingdom GR - MR/W005611/1/MRC_/Medical Research Council/United Kingdom GR - BBS/E/I/COV07001/BB_/Biotechnology and Biological Sciences Research Council/United Kingdom GR - BBS/E/I/00007031/BB_/Biotechnology and Biological Sciences Research Council/United Kingdom GR - MC_UU_0025/12/MRC_/Medical Research Council/United Kingdom GR - WT_/Wellcome Trust/United Kingdom GR - BB/T008784/1/BB_/Biotechnology and Biological Sciences Research Council/United Kingdom PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20221115 PL - United States TA - Cell Rep Med JT - Cell reports. Medicine JID - 101766894 RN - B5S3K2V0G8 (ChAdOx1 nCoV-19) SB - IM MH - Humans MH - *Immunity, Humoral MH - ChAdOx1 nCoV-19 MH - Memory B Cells MH - T Follicular Helper Cells MH - T-Lymphocytes, Helper-Inducer MH - *COVID-19/prevention & control MH - SARS-CoV-2 MH - Germinal Center MH - Vaccination MH - Immunization, Secondary PMC - PMC9663747 OTO - NOTNLM OT - CD40L OT - ChAdOx1 nCoV-19 OT - SARS-CoV-2 OT - Tfh cells OT - germinal center OT - vaccine COIS- Declaration of interests T.L. is named on a patent application covering ChAdOx1 nCoV-19. The funders played no role in the conceptualization, design, data collection, analysis, decision to publish, or preparation of the manuscript. EDAT- 2022/12/02 06:00 MHDA- 2022/12/24 06:00 PMCR- 2022/11/15 CRDT- 2022/12/01 18:42 PHST- 2022/07/04 00:00 [received] PHST- 2022/10/19 00:00 [revised] PHST- 2022/11/10 00:00 [accepted] PHST- 2022/12/02 06:00 [pubmed] PHST- 2022/12/24 06:00 [medline] PHST- 2022/12/01 18:42 [entrez] PHST- 2022/11/15 00:00 [pmc-release] AID - S2666-3791(22)00409-8 [pii] AID - 100845 [pii] AID - 10.1016/j.xcrm.2022.100845 [doi] PST - ppublish SO - Cell Rep Med. 2022 Dec 20;3(12):100845. doi: 10.1016/j.xcrm.2022.100845. Epub 2022 Nov 15. PMID- 36451484 OWN - NLM STAT- MEDLINE DCOM- 20221202 LR - 20230103 IS - 1536-5964 (Electronic) IS - 0025-7974 (Print) IS - 0025-7974 (Linking) VI - 101 IP - 47 DP - 2022 Nov 25 TI - Brain perfusion single photon emission computed tomography abnormality in MRI-negative stroke-like patients post COVID-19 vaccination. PG - e31965 LID - 10.1097/MD.0000000000031965 [doi] LID - e31965 AB - Stroke-like symptoms after COVID-19 vaccination was thought to be functional if there was no anatomical image abnormality. We aimed to analyze brain perfusion changes in these patients. A case-control study of brain perfusion single photon emission computed tomography (SPECT) of 12 vaccinated patients with left-sided stroke-like symptoms were compared with 12 age- and gender-matched normal interictal brain SPECTs using voxel-based analysis. Significant hyperperfusion was seen on the right side in postcentral, inferior parietal, mid temporal, parahippocampal, and caudate regions, and on the left side in the thalamus, hippocampus, and mid temporal areas. In addition, there were hypoperfused bilateral superior frontal gyri and right mid/posterior cingulate cortex (Family-wise-error corrected p-values < .05). Both hypoperfusion and hyperperfusion in the brain are demonstrated. We hypothesize that these findings might be the result of the functional neurological disorder. However, based on other previous studies, circulating spike protein in the patients' plasma early after vaccination might also be the cause. CI - Copyright (c) 2022 the Author(s). Published by Wolters Kluwer Health, Inc. FAU - Tepmongkol, Supatporn AU - Tepmongkol S AUID- ORCID: 0000-0002-6092-0488 AD - Division of Nuclear Medicine, Department of Radiology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. AD - Chulalongkorn University Biomedical Imaging Group (CUBIG), Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. AD - Chula Neuroscience Center, King Chulalongkorn Memorial Hospital, Bangkok, Thailand. AD - Cognitive Impairment and Dementia Research Unit, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. FAU - Suwanwela, Nijasri C AU - Suwanwela NC AD - Chula Neuroscience Center, King Chulalongkorn Memorial Hospital, Bangkok, Thailand. AD - Division of Neurology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. AD - Chulalongkorn Comprehensive Stroke Center, King Chulalongkorn Memorial Hospital, Bangkok, Thailand. FAU - Hirankarn, Nattiya AU - Hirankarn N AD - Center of Excellence in Immunology and Immune-mediated Diseases, Department of Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. FAU - Tangwongchai, Sookjaroen AU - Tangwongchai S AUID- ORCID: 0000-0003-1407-3211 AD - Chula Neuroscience Center, King Chulalongkorn Memorial Hospital, Bangkok, Thailand. AD - Cognitive Impairment and Dementia Research Unit, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. AD - Department of Psychiatry, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. FAU - Vorasayan, Pongpat AU - Vorasayan P AD - Chula Neuroscience Center, King Chulalongkorn Memorial Hospital, Bangkok, Thailand. AD - Division of Neurology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. AD - Chulalongkorn Comprehensive Stroke Center, King Chulalongkorn Memorial Hospital, Bangkok, Thailand. FAU - Sukprakun, Chanan AU - Sukprakun C AD - Division of Nuclear Medicine, Department of Radiology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. FAU - Siritaranon, Natakorn AU - Siritaranon N AD - Division of Nuclear Medicine, Department of Radiology, King Chulalongkorn Memorial Hospital, Bangkok, Thailand. FAU - Kijpaisalratana, Naruchorn AU - Kijpaisalratana N AD - Chula Neuroscience Center, King Chulalongkorn Memorial Hospital, Bangkok, Thailand. AD - Chulalongkorn Comprehensive Stroke Center, King Chulalongkorn Memorial Hospital, Bangkok, Thailand. AD - Division of Academic Affairs, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. FAU - Akarathanawat, Wasan AU - Akarathanawat W AD - Division of Neurology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. AD - Chulalongkorn Comprehensive Stroke Center, King Chulalongkorn Memorial Hospital, Bangkok, Thailand. FAU - Chutinet, Aurauma AU - Chutinet A AD - Chula Neuroscience Center, King Chulalongkorn Memorial Hospital, Bangkok, Thailand. AD - Division of Neurology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. AD - Chulalongkorn Comprehensive Stroke Center, King Chulalongkorn Memorial Hospital, Bangkok, Thailand. FAU - Tantivatana, Jarturon AU - Tantivatana J AD - Chula Neuroscience Center, King Chulalongkorn Memorial Hospital, Bangkok, Thailand. AD - Division of Diagnostic Radiology, Department of Radiology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. LA - eng PT - Journal Article PL - United States TA - Medicine (Baltimore) JT - Medicine JID - 2985248R RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - COVID-19 Vaccines/adverse effects MH - Case-Control Studies MH - *COVID-19/prevention & control MH - Perfusion MH - *Stroke/diagnostic imaging MH - Brain/diagnostic imaging MH - Vaccination MH - Tomography, Emission-Computed, Single-Photon MH - Magnetic Resonance Imaging PMC - PMC9704968 COIS- The authors have no funding and conflicts of interest to disclose. EDAT- 2022/12/02 06:00 MHDA- 2022/12/03 06:00 PMCR- 2022/11/25 CRDT- 2022/12/01 01:05 PHST- 2022/12/01 01:05 [entrez] PHST- 2022/12/02 06:00 [pubmed] PHST- 2022/12/03 06:00 [medline] PHST- 2022/11/25 00:00 [pmc-release] AID - 00005792-202211250-00108 [pii] AID - 10.1097/MD.0000000000031965 [doi] PST - ppublish SO - Medicine (Baltimore). 2022 Nov 25;101(47):e31965. doi: 10.1097/MD.0000000000031965. PMID- 36445631 OWN - NLM STAT- MEDLINE DCOM- 20230117 LR - 20231117 IS - 1534-6293 (Electronic) IS - 1528-4042 (Print) IS - 1528-4042 (Linking) VI - 23 IP - 1 DP - 2023 Jan TI - Neurological Complications Following COVID-19 Vaccination. PG - 1-14 LID - 10.1007/s11910-022-01247-x [doi] AB - PURPOSE OF REVIEW: A variety of neurological complications have been reported following the widespread use of the COVID-19 vaccines which may lead to vaccine hesitancy and serve as a major barrier to the public health aim of achieving protective herd immunity by vaccination. In this article, we review the available evidence regarding these neurological adverse events reported, to provide clarity regarding the same so that unfounded fears maybe put to rest. RECENT FINDINGS: There is a greater than expected occurrence of severe neurological adverse events such as cortical sinus venous thrombosis, Bell's palsy, transverse myelitis, and Guillain-Barre syndromes along with other common effects such as headaches following different kinds of COVID-19 vaccination. Precipitation of new onset demyelinating brain lesions with or without detection of specific antibodies and worsening of pre-existing neurological disorders (like epilepsy, multiple sclerosis) are also a matter of great concern though no conclusive evidence implicating the vaccines is available as of now. The COVID-19 pandemic is far from being over. Till such time that a truly effective anti-viral drug is discovered, or an appropriate therapeutic strategy is developed, COVID-appropriate behavior and highly effective mass vaccination remain the only weapons in our armamentarium to fight this deadly disease. As often occurs with most therapeutic means for the treatment and prevention of any disease, vaccination against COVID-19 has its hazards. These range from the most trivial ones like fever, local pain and myalgias to several potentially serious cardiac and neurological complications. The latter group includes conditions like cerebral venous thrombosis (curiously often with thrombocytopenia), transverse myelitis and acute inflammatory demyelinating polyneuropathy amongst others. Fortunately, the number of reported patients with any of these serious complications is far too low for the total number of people vaccinated. Hence, the current evidence suggests that the benefits of vaccination far outweigh the risk of these events in majority of the patients. As of now, available evidence also does not recommend withholding vaccination in patients with pre-existing neurological disorders like epilepsy and MS, though adenoviral vaccines should be avoided in those with history of thrombotic events. CI - (c) 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Chatterjee, Aparajita AU - Chatterjee A AD - Department of Neurology, Fortis Hospital, Kolkata, India. FAU - Chakravarty, Ambar AU - Chakravarty A AD - Department of Neurology, Vivekananda Institute of Medical Sciences, Kolkata, India. saschakra@yahoo.com. LA - eng PT - Journal Article PT - Review DEP - 20221129 PL - United States TA - Curr Neurol Neurosci Rep JT - Current neurology and neuroscience reports JID - 100931790 RN - 0 (COVID-19 Vaccines) SB - IM CIN - Neurol India. 2023 Jul-Aug;71(4):790-791. doi: 10.4103/0028-3886.383838. PMID: 37635524 MH - Humans MH - *COVID-19/complications/epidemiology/prevention & control MH - *COVID-19 Vaccines/adverse effects MH - *Guillain-Barre Syndrome/epidemiology/etiology MH - *Myelitis, Transverse MH - Pandemics MH - Vaccination/adverse effects MH - *Venous Thrombosis PMC - PMC9707152 OTO - NOTNLM OT - COVID-19 vaccination OT - Cortical sinus venous thrombosis OT - Guillain-Barre syndrome OT - Multiple sclerosis (MS) OT - Neurological complications OT - Transverse myelitis (TM) COIS- Aparajita Chatterjee and Ambar Chakravarty each declare no potential conflicts of interest. EDAT- 2022/11/30 06:00 MHDA- 2023/01/14 06:00 PMCR- 2022/11/29 CRDT- 2022/11/29 11:24 PHST- 2022/11/16 00:00 [accepted] PHST- 2022/11/30 06:00 [pubmed] PHST- 2023/01/14 06:00 [medline] PHST- 2022/11/29 11:24 [entrez] PHST- 2022/11/29 00:00 [pmc-release] AID - 10.1007/s11910-022-01247-x [pii] AID - 1247 [pii] AID - 10.1007/s11910-022-01247-x [doi] PST - ppublish SO - Curr Neurol Neurosci Rep. 2023 Jan;23(1):1-14. doi: 10.1007/s11910-022-01247-x. Epub 2022 Nov 29. PMID- 36440826 OWN - NLM STAT- MEDLINE DCOM- 20230512 LR - 20231106 IS - 1477-0970 (Electronic) IS - 1352-4585 (Print) IS - 1352-4585 (Linking) VI - 29 IP - 6 DP - 2023 May TI - T cell responses to COVID-19 infection and vaccination in patients with multiple sclerosis receiving disease-modifying therapy. PG - 648-656 LID - 10.1177/13524585221134216 [doi] AB - BACKGROUND: Multiple sclerosis (MS) is a neurological disorder marked by accumulating immune-mediated damage to the central nervous system. The dysregulated immune system in MS combined with immune effects of disease-modifying therapies (DMTs) used in MS treatment could alter responses to infections, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes coronavirus disease 2019 (COVID-19). Most of the literature on immune response to SARS-CoV-2 infection and COVID-19 vaccination, in both the general population and patients with MS on DMTs, has focused on humoral immunity. However, immune response to COVID-19 involves multiple lines of defense, including T cells. OBJECTIVE AND METHODS: We review innate and adaptive immunity to COVID-19 and expand on the role of T cells in mediating protective immunity against SARS-CoV-2 infection and in responses to COVID-19 vaccination in MS. RESULTS: Innate, humoral, and T cell immune responses combat COVID-19 and generate protective immunity. Assays detecting cytokine expression by T cells show an association between SARS-CoV-2-specific T cell responses and milder/asymptomatic COVID-19 and protective immune memory. CONCLUSION: Studies of COVID-19 immunity in people with MS on DMTs should ideally include comprehensive assessment of innate, humoral, and T cell responses. FAU - Reder, Anthony T AU - Reder AT AD - Department of Neurology, University of Chicago Medicine, Chicago, IL, USA. FAU - Stuve, Olaf AU - Stuve O AUID- ORCID: 0000-0002-0469-6872 AD - Peter O'Donnell Jr. Brain Institute, UT Southwestern Medical Center, Dallas, TX, USA; VA North Texas Health Care System, Dallas VA Medical Center, Dallas, TX, USA. FAU - Tankou, Stephanie K AU - Tankou SK AD - Mount Sinai Health System, New York, NY, USA. FAU - Leist, Thomas P AU - Leist TP AD - Department of Neurology, Thomas Jefferson University, Philadelphia, PA, USA. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20221128 PL - England TA - Mult Scler JT - Multiple sclerosis (Houndmills, Basingstoke, England) JID - 9509185 RN - 0 (COVID-19 Vaccines) RN - 0 (Antibodies, Viral) SB - IM MH - Humans MH - *COVID-19/prevention & control MH - SARS-CoV-2 MH - T-Lymphocytes MH - *Multiple Sclerosis/drug therapy MH - COVID-19 Vaccines MH - Vaccination MH - Antibodies, Viral PMC - PMC9708532 OTO - NOTNLM OT - COVID-19 OT - SARS-CoV-2 OT - T cell OT - disease-modifying therapy OT - multiple sclerosis COIS- The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: A.T.R. is a consultant for or has received unrestricted research support from Bayer, Biogen, Bristol Myers Squibb, Genentech/Roche, NKMax America, Mallinckrodt, Merck Serono, Novartis, and TG Therapeutics. O.S. serves on the editorial board of Therapeutic Advances in Neurological Disorders and has served on data monitoring committees for Genentech/Roche, Pfizer, Novartis, and TG Therapeutics without monetary compensation. He has advised Celgene, EMD Serono, Genentech, Genzyme, and TG Therapeutics, and currently receives grant support from EMD Serono and Exalys. S.K.T. has no disclosures. T.P.L. serves as site investigator for Biogen, Bristol Myers Squibb, EMD Serono, Genentech/Roche, Janssen, Novartis, and Sanofi. He has advised Biogen, Genentech/Roche, Horizon, Janssen, and Novartis. EDAT- 2022/11/29 06:00 MHDA- 2023/05/12 07:06 PMCR- 2022/11/28 CRDT- 2022/11/28 07:52 PHST- 2023/05/12 07:06 [medline] PHST- 2022/11/29 06:00 [pubmed] PHST- 2022/11/28 07:52 [entrez] PHST- 2022/11/28 00:00 [pmc-release] AID - 10.1177_13524585221134216 [pii] AID - 10.1177/13524585221134216 [doi] PST - ppublish SO - Mult Scler. 2023 May;29(6):648-656. doi: 10.1177/13524585221134216. Epub 2022 Nov 28. PMID- 36430845 OWN - NLM STAT- MEDLINE DCOM- 20221129 LR - 20250530 IS - 1422-0067 (Electronic) IS - 1422-0067 (Linking) VI - 23 IP - 22 DP - 2022 Nov 19 TI - Durable CD8 T Cell Memory against SARS-CoV-2 by Prime/Boost and Multi-Dose Vaccination: Considerations on Inter-Dose Time Intervals. LID - 10.3390/ijms232214367 [doi] LID - 14367 AB - Facing the COVID-19 pandemic, anti-SARS-CoV-2 vaccines were developed at unprecedented pace, productively exploiting contemporary fundamental research and prior art. Large-scale use of anti-SARS-CoV-2 vaccines has greatly limited severe morbidity and mortality. Protection has been correlated with high serum titres of neutralizing antibodies capable of blocking the interaction between the viral surface protein spike and the host SARS-CoV-2 receptor, ACE-2. Yet, vaccine-induced protection subsides over time, and breakthrough infections are commonly observed, mostly reflecting the decay of neutralizing antibodies and the emergence of variant viruses with mutant spike proteins. Memory CD8 T cells are a potent weapon against viruses, as they are against tumour cells. Anti-SARS-CoV-2 memory CD8 T cells are induced by either natural infection or vaccination and can be potentially exploited against spike-mutated viruses. We offer here an overview of current research about the induction of anti-SARS-CoV-2 memory CD8 T cells by vaccination, in the context of prior knowledge on vaccines and on fundamental mechanisms of immunological memory. We focus particularly on how vaccination by two doses (prime/boost) or more (boosters) promotes differentiation of memory CD8 T cells, and on how the time-length of inter-dose intervals may influence the magnitude and persistence of CD8 T cell memory. FAU - Natalini, Ambra AU - Natalini A AUID- ORCID: 0000-0002-7618-493X AD - Institute of Molecular Biology and Pathology, National Research Council of Italy (CNR), 00161 Rome, Italy. AD - Immunosurveillance Laboratory, The Francis Crick Institute, London NW1 1AT, UK. FAU - Simonetti, Sonia AU - Simonetti S AD - Institute of Molecular Biology and Pathology, National Research Council of Italy (CNR), 00161 Rome, Italy. AD - Medical Oncology Department, Campus Bio-Medico University, 00128 Rome, Italy. FAU - Sher, Carmel AU - Sher C AD - Institute of Molecular Biology and Pathology, National Research Council of Italy (CNR), 00161 Rome, Italy. AD - Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel. FAU - D'Oro, Ugo AU - D'Oro U AD - GSK, 53100 Siena, Italy. FAU - Hayday, Adrian C AU - Hayday AC AD - Immunosurveillance Laboratory, The Francis Crick Institute, London NW1 1AT, UK. AD - Peter Gorer Department of Immunobiology, King's College London, London WC2R 2LS, UK. AD - National Institute for Health and Research (NIHR) Biomedical Research Center (BRC), Guy's and St Thomas' NHS Foundation Trust, King's College London, London WC2R 2LS, UK. FAU - Di Rosa, Francesca AU - Di Rosa F AUID- ORCID: 0000-0003-0252-9138 AD - Institute of Molecular Biology and Pathology, National Research Council of Italy (CNR), 00161 Rome, Italy. LA - eng GR - FC001003/WT_/Wellcome Trust/United Kingdom PT - Journal Article PT - Review DEP - 20221119 PL - Switzerland TA - Int J Mol Sci JT - International journal of molecular sciences JID - 101092791 RN - 0 (Antibodies, Neutralizing) SB - IM MH - Humans MH - *SARS-CoV-2 MH - Pandemics MH - *COVID-19/prevention & control MH - CD8-Positive T-Lymphocytes MH - Vaccination MH - Antibodies, Neutralizing PMC - PMC9698736 OTO - NOTNLM OT - CD8 T cells OT - COVID-19 OT - immunological memory OT - vaccination COIS- U.D. is an employee of the GSK group of companies and hold shares in the GSK group of companies. A.C.H. is a board member and equity holder in ImmunoQure, AG., and Gamma Delta Therapeutics, and is an equity holder in Adaptate Biotherapeutics. EDAT- 2022/11/27 06:00 MHDA- 2022/11/30 06:00 PMCR- 2022/11/19 CRDT- 2022/11/26 01:19 PHST- 2022/10/03 00:00 [received] PHST- 2022/11/08 00:00 [revised] PHST- 2022/11/14 00:00 [accepted] PHST- 2022/11/26 01:19 [entrez] PHST- 2022/11/27 06:00 [pubmed] PHST- 2022/11/30 06:00 [medline] PHST- 2022/11/19 00:00 [pmc-release] AID - ijms232214367 [pii] AID - ijms-23-14367 [pii] AID - 10.3390/ijms232214367 [doi] PST - epublish SO - Int J Mol Sci. 2022 Nov 19;23(22):14367. doi: 10.3390/ijms232214367. PMID- 36426984 OWN - NLM STAT- MEDLINE DCOM- 20221129 LR - 20260519 IS - 1550-6606 (Electronic) IS - 0022-1767 (Linking) VI - 209 IP - 11 DP - 2022 Dec 1 TI - Memory B Cells and Memory T Cells Induced by SARS-CoV-2 Booster Vaccination or Infection Show Different Dynamics and Responsiveness to the Omicron Variant. PG - 2104-2113 LID - 10.4049/jimmunol.2200525 [doi] AB - Although the immunological memory produced by BNT162b2 vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been well studied and established, further information using different racial cohorts is necessary to understand the overall immunological response to vaccination. We evaluated memory B and T cell responses to the severe acute respiratory syndrome coronavirus 2 spike protein before and after the third booster using a Japanese cohort. Although the Ab titer against the spike receptor-binding domain (RBD) decreased significantly 8 mo after the second vaccination, the number of memory B cells continued to increase, whereas the number of memory T cells decreased slowly. Memory B and T cells from unvaccinated infected patients showed similar kinetics. After the third vaccination, the Ab titer increased to the level of the second vaccination, and memory B cells increased at significantly higher levels before the booster, whereas memory T cells recovered close to the second vaccination levels. In memory T cells, the frequency of CXCR5+CXCR3+CCR6- circulating follicular Th1 was positively correlated with RBD-specific Ab-secreting B cells. For the response to variant RBDs, although 60-80% of memory B cells could bind to the omicron RBD, their avidity was low, whereas memory T cells show an equal response to the omicron spike. Thus, the persistent presence of memory B and T cells will quickly upregulate Ab production and T cell responses after omicron strain infection, which prevents severe illness and death due to coronavirus disease 2019. CI - Copyright (c) 2022 by The American Association of Immunologists, Inc. FAU - Mise-Omata, Setsuko AU - Mise-Omata S AD - Department of Microbiology and Immunology, Keio University School of Medicine, Tokyo, Japan. FAU - Ikeda, Mari AU - Ikeda M AD - Department of Microbiology and Immunology, Keio University School of Medicine, Tokyo, Japan. FAU - Takeshita, Masaru AU - Takeshita M AD - Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan. FAU - Uwamino, Yoshifumi AU - Uwamino Y AD - Department of Laboratory Medicine, Keio University School of Medicine, Tokyo, Japan. AD - Department of Infectious Diseases, Keio University School of Medicine, Tokyo, Japan. FAU - Wakui, Masatoshi AU - Wakui M AD - Department of Laboratory Medicine, Keio University School of Medicine, Tokyo, Japan. FAU - Arai, Tomoko AU - Arai T AD - Clinical Laboratory, Keio University Hospital, Tokyo, Japan. FAU - Yoshifuji, Ayumi AU - Yoshifuji A AUID- ORCID: 0000-0001-8246-8675 AD - Division of Nephrology, Department of Internal Medicine, Tokyo Saiseikai Central Hospital, Tokyo, Japan. FAU - Murano, Kensaku AU - Murano K AUID- ORCID: 0000-0001-7269-8119 AD - Department of Molecular Biology, Keio University School of Medicine, Tokyo, Japan. FAU - Siomi, Haruhiko AU - Siomi H AD - Department of Molecular Biology, Keio University School of Medicine, Tokyo, Japan. FAU - Nakagawara, Kensuke AU - Nakagawara K AUID- ORCID: 0000-0001-5249-6923 AD - Department of Microbiology and Immunology, Keio University School of Medicine, Tokyo, Japan. AD - Division of Pulmonary Medicine, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan. FAU - Ohyagi, Masaki AU - Ohyagi M AUID- ORCID: 0000-0002-6009-450X AD - Department of Microbiology and Immunology, Keio University School of Medicine, Tokyo, Japan. FAU - Ando, Makoto AU - Ando M AUID- ORCID: 0000-0003-1836-8885 AD - Department of Microbiology and Immunology, Keio University School of Medicine, Tokyo, Japan. FAU - Hasegawa, Naoki AU - Hasegawa N AD - Department of Infectious Diseases, Keio University School of Medicine, Tokyo, Japan. FAU - Saya, Hideyuki AU - Saya H AD - Division of Gene Regulation, Institute for Advanced Medical Research, Keio University School of Medicine, Tokyo, Japan. FAU - Murata, Mitsuru AU - Murata M AUID- ORCID: 0000-0002-2728-6198 AD - Department of Laboratory Medicine, Keio University School of Medicine, Tokyo, Japan. FAU - Fukunaga, Koichi AU - Fukunaga K AD - Division of Pulmonary Medicine, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan. FAU - Namkoong, Ho AU - Namkoong H AUID- ORCID: 0000-0001-6181-4284 AD - Department of Infectious Diseases, Keio University School of Medicine, Tokyo, Japan. FAU - Lu, Xiuyuan AU - Lu X AUID- ORCID: 0000-0002-0784-2871 AD - Laboratory of Molecular Immunology, Immunology Frontier Research Center, Osaka University, Osaka, Japan; and. FAU - Yamasaki, Sho AU - Yamasaki S AD - Laboratory of Molecular Immunology, Immunology Frontier Research Center, Osaka University, Osaka, Japan; and. AD - Department of Molecular Immunology, Research Institute Microbial Disease, Osaka University, Osaka, Japan. FAU - Yoshimura, Akihiko AU - Yoshimura A AUID- ORCID: 0000-0001-5676-8949 AD - Department of Microbiology and Immunology, Keio University School of Medicine, Tokyo, Japan. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - England TA - J Immunol JT - Journal of immunology (Baltimore, Md. : 1950) JID - 2985117R RN - 0 (BNT162 Vaccine) RN - 0 (spike protein, SARS-CoV-2) RN - 0 (Spike Glycoprotein, Coronavirus) RN - SARS-CoV-2 variants SB - IM MH - Humans MH - *Memory B Cells MH - SARS-CoV-2 MH - Memory T Cells MH - BNT162 Vaccine MH - *COVID-19 MH - Vaccination MH - Spike Glycoprotein, Coronavirus EDAT- 2022/11/26 06:00 MHDA- 2022/11/30 06:00 CRDT- 2022/11/25 09:33 PHST- 2022/07/20 00:00 [received] PHST- 2022/09/21 00:00 [accepted] PHST- 2022/11/25 09:33 [entrez] PHST- 2022/11/26 06:00 [pubmed] PHST- 2022/11/30 06:00 [medline] AID - 237343 [pii] AID - 10.4049/jimmunol.2200525 [doi] PST - ppublish SO - J Immunol. 2022 Dec 1;209(11):2104-2113. doi: 10.4049/jimmunol.2200525. PMID- 36423150 OWN - NLM STAT- MEDLINE DCOM- 20221128 LR - 20230130 IS - 1999-4915 (Electronic) IS - 1999-4915 (Linking) VI - 14 IP - 11 DP - 2022 Nov 17 TI - Host Protective Immunity against Severe Acute Respiratory Coronavirus 2 (SARS-CoV-2) and the COVID-19 Vaccine-Induced Immunity against SARS-CoV-2 and Its Variants. LID - 10.3390/v14112541 [doi] LID - 2541 AB - The world is now apparently at the last/recovery stage of the COVID-19 pandemic, starting from 29 December 2019, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). With the progression of time, several mutations have taken place in the original SARS-CoV-2 Wuhan strain, which have generated variants of concern (VOC). Therefore, combatting COVID-19 has required the development of COVID-19 vaccines using several platforms. The immunity induced by those vaccines is vital to study in order to assure total protection against SARS-CoV-2 and its emerging variants. Indeed, understanding and identifying COVID-19 protection mechanisms or the host immune responses are of significance in terms of designing both new and repurposed drugs as well as the development of novel vaccines with few to no side effects. Detecting the immune mechanisms for host protection against SARS-CoV-2 and its variants is crucial for the development of novel COVID-19 vaccines as well as to monitor the effectiveness of the currently used vaccines worldwide. Immune memory in terms of the production of neutralizing antibodies (NAbs) during reinfection is also very crucial to formulate the vaccine administration schedule/vaccine doses. The response of antigen-specific antibodies and NAbs as well as T cell responses, along with the protective cytokine production and the innate immunity generated upon COVID-19 vaccination, are discussed in the current review in comparison to the features of naturally induced protective immunity. FAU - Noor, Rashed AU - Noor R AUID- ORCID: 0000-0003-4837-221X AD - Department of Life Sciences (DLS), School of Environment and Life Sciences (SELS), Independent University, Bangladesh (IUB), Dhaka 1229, Bangladesh. LA - eng PT - Journal Article PT - Review DEP - 20221117 PL - Switzerland TA - Viruses JT - Viruses JID - 101509722 RN - 0 (COVID-19 Vaccines) RN - 0 (Viral Vaccines) SB - IM MH - Humans MH - COVID-19 Vaccines MH - SARS-CoV-2/genetics MH - *COVID-19/prevention & control MH - Pandemics/prevention & control MH - *Viral Vaccines PMC - PMC9697230 OTO - NOTNLM OT - COVID-19 pandemic OT - COVID-19 vaccine-induced immunity OT - immune memory OT - neutralizing antibodies (NAbs) OT - severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) OT - variants of concern (VOC) COIS- The author declares no conflict of interest. EDAT- 2022/11/25 06:00 MHDA- 2022/11/29 06:00 PMCR- 2022/11/17 CRDT- 2022/11/24 12:04 PHST- 2022/10/11 00:00 [received] PHST- 2022/11/14 00:00 [revised] PHST- 2022/11/15 00:00 [accepted] PHST- 2022/11/24 12:04 [entrez] PHST- 2022/11/25 06:00 [pubmed] PHST- 2022/11/29 06:00 [medline] PHST- 2022/11/17 00:00 [pmc-release] AID - v14112541 [pii] AID - viruses-14-02541 [pii] AID - 10.3390/v14112541 [doi] PST - epublish SO - Viruses. 2022 Nov 17;14(11):2541. doi: 10.3390/v14112541. PMID- 36421662 OWN - NLM STAT- MEDLINE DCOM- 20221220 LR - 20221222 IS - 1470-8752 (Electronic) IS - 0300-5127 (Print) IS - 0300-5127 (Linking) VI - 50 IP - 6 DP - 2022 Dec 16 TI - Humoral immunity and B-cell memory in response to SARS-CoV-2 infection and vaccination. PG - 1643-1658 LID - 10.1042/BST20220415 [doi] AB - Natural infection with SARS-CoV-2 induces a robust circulating memory B cell (Bmem) population, which remains stable in number at least 8 months post-infection despite the contraction of antibody levels after 1 month. Multiple vaccines have been developed to combat the virus. These include two new formulations, mRNA and adenoviral vector vaccines, which have varying efficacy rates, potentially related to their distinct capacities to induce humoral immune responses. The mRNA vaccines BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) elicit significantly higher serum IgG and neutralizing antibody levels than the adenoviral vector ChAdOx1 (AstraZeneca) and Ad26.COV2.S (Janssen) vaccines. However, all vaccines induce Spike- and RBD-specific Bmem, which are vital in providing long-lasting protection in the form of rapid recall responses to subsequent infections. Past and current SARS-CoV-2 variants of concern (VoC) have shown the capacity to escape antibody neutralization to varying degrees. A booster dose with an mRNA vaccine following primary vaccination restores antibody levels and improves the capacity of these antibodies and Bmem to bind viral variants, including the current VoC Omicron. Future experimental research will be essential to evaluate the durability of protection against VoC provided by each vaccine and to identify immune markers of protection to enable prognostication of people who are at risk of severe complications from COVID-19. CI - (c) 2022 The Author(s). FAU - Fryer, Holly A AU - Fryer HA AD - Allergy and Clinical Immunology Laboratory, Department of Immunology and Pathology, Central Clinical School, Monash University, Melbourne, VIC, Australia. FAU - Hartley, Gemma E AU - Hartley GE AD - Allergy and Clinical Immunology Laboratory, Department of Immunology and Pathology, Central Clinical School, Monash University, Melbourne, VIC, Australia. FAU - Edwards, Emily S J AU - Edwards ESJ AD - Allergy and Clinical Immunology Laboratory, Department of Immunology and Pathology, Central Clinical School, Monash University, Melbourne, VIC, Australia. FAU - O'Hehir, Robyn E AU - O'Hehir RE AD - Allergy and Clinical Immunology Laboratory, Department of Immunology and Pathology, Central Clinical School, Monash University, Melbourne, VIC, Australia. AD - Allergy, Asthma and Clinical Immunology Service, Alfred Hospital, Melbourne, VIC, Australia. FAU - van Zelm, Menno C AU - van Zelm MC AUID- ORCID: 0000-0003-4161-1919 AD - Allergy and Clinical Immunology Laboratory, Department of Immunology and Pathology, Central Clinical School, Monash University, Melbourne, VIC, Australia. AD - Allergy, Asthma and Clinical Immunology Service, Alfred Hospital, Melbourne, VIC, Australia. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - England TA - Biochem Soc Trans JT - Biochemical Society transactions JID - 7506897 RN - JT2NS6183B (Ad26COVS1) RN - 0 (BNT162 Vaccine) RN - 0 (Antibodies, Neutralizing) RN - SARS-CoV-2 variants SB - IM MH - Humans MH - *Immunity, Humoral MH - *COVID-19/prevention & control MH - SARS-CoV-2 MH - Ad26COVS1 MH - BNT162 Vaccine MH - Memory B Cells MH - Vaccination MH - Antibodies, Neutralizing PMC - PMC9788580 OTO - NOTNLM OT - COVID-19 OT - IgG OT - Omicron OT - SARS-CoV-2 OT - memory B cell OT - neutralizing antibody COIS- M.C.v.Z. and R.O.H. are inventors on a patent application related to generation of fluorescently labeled antigen tetramers used for flow cytometric analysis of antigen-specific B cells. The other authors declare that there are no competing interests associated with the manuscript. EDAT- 2022/11/25 06:00 MHDA- 2022/12/21 06:00 PMCR- 2022/11/24 CRDT- 2022/11/24 09:56 PHST- 2022/07/14 00:00 [received] PHST- 2022/11/08 00:00 [revised] PHST- 2022/11/09 00:00 [accepted] PHST- 2022/11/25 06:00 [pubmed] PHST- 2022/12/21 06:00 [medline] PHST- 2022/11/24 09:56 [entrez] PHST- 2022/11/24 00:00 [pmc-release] AID - 232160 [pii] AID - BST-50-1643 [pii] AID - 10.1042/BST20220415 [doi] PST - ppublish SO - Biochem Soc Trans. 2022 Dec 16;50(6):1643-1658. doi: 10.1042/BST20220415. PMID- 36420879 OWN - NLM STAT- MEDLINE DCOM- 20230516 LR - 20230516 IS - 2589-9783 (Electronic) IS - 2589-9775 (Linking) VI - 15 IP - 2 DP - 2023 TI - Controversies Around COVID-19 Vaccines and Antidepressants: Scope and Perspective in Malaysia. PG - 159-169 LID - 10.2174/2589977515666221123093522 [doi] AB - BACKGROUND: Individuals with severe mental illness are prone to severe COVID-19 infection with increased morbidity and mortality. Psychiatric patients are often concerned about the potential interactions between the newly approved COVID-19 vaccines in Malaysia and psychotropic drugs like antidepressants. To date, such data are unavailable. OBJECTIVES: This review aims to clear the polemics of COVID-19 vaccine-antidepressants interaction in these 3 aspects: (1) cytokines and cytochrome P450 pathway, (2) blood-brain barrier (BBB) involvement and (3) and its interaction with polyethylene glycol (PEG), the potential allergenic culprit following COVID-19 vaccination. METHODS: A scoping approach was employed to search for peer-reviewed journal articles across four healthcare and scientific databases (PubMed, MEDLINE, PsycINFO and Cumulative Index to Nursing and Allied Health Literature (CINAHL)). RESULTS: Antidepressants metabolism often involves the CYP450 enzymes. Vaccine-antidepressants interactions are probable, likely to be triggered by interactions of CYP450 enzymes and inflammatory cytokines, resulting in diminished drug metabolism and chemical detoxification. Aside, PEG, the excipient in mRNA-based COVID-19 vaccines and antidepressants, has been reported as an anaphylaxis causative allergen. However, whether it leads to synergistic, potentiation or antagonistic effects when used in combination remains to be elucidated. CONCLUSION: Psychotropic medications, including antidepressants, showed potentially relevant safety risks for COVID-19 patients. These vulnerable patient group must be prioritized for early access to safe and efficacious COVID-19 vaccines, as vaccination remains the most important public health intervention to tackle the ongoing COVID-19 pandemic. CI - Copyright(c) Bentham Science Publishers; For any queries, please email at epub@benthamscience.net. FAU - Chong Guan, Ng AU - Chong Guan N AD - Department of Psychological Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, 50603 Malaysia. FAU - Weng Hou, Siew AU - Weng Hou S AD - Department of Psychological Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, 50603 Malaysia. FAU - Abousheishaa, Aya Ahmed AU - Abousheishaa AA AD - Department of Psychological Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, 50603 Malaysia. FAU - Sue Yin, Low AU - Sue Yin L AD - Department of Psychology, Faculty of Behavioural Sciences, HELP University, Kuala Lumpur, 50490 Malaysia. FAU - Bin Sulaiman, Abdul Rasyid AU - Bin Sulaiman AR AD - School of Medicine, International Medical University, Kuala Lumpur, 57000 Malaysia. FAU - Chee Khin, Kok AU - Chee Khin K AD - Department of Psychological Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, 50603 Malaysia. LA - eng PT - Journal Article PT - Review PL - United Arab Emirates TA - Curr Drug Res Rev JT - Current drug research reviews JID - 101735701 RN - 0 (COVID-19 Vaccines) RN - 0 (Antidepressive Agents) RN - 0 (Cytokines) SB - IM MH - Humans MH - *COVID-19 Vaccines/adverse effects MH - *COVID-19/prevention & control MH - Malaysia MH - Pandemics MH - Antidepressive Agents/therapeutic use MH - Cytokines OTO - NOTNLM OT - COVID-19 vaccines OT - antidepressants OT - blood brain barrier OT - cytochrome P450 OT - cytokines OT - polyethylene glycol EDAT- 2022/11/25 06:00 MHDA- 2023/05/16 06:42 CRDT- 2022/11/24 07:03 PHST- 2022/04/13 00:00 [received] PHST- 2022/08/22 00:00 [revised] PHST- 2022/09/22 00:00 [accepted] PHST- 2023/05/16 06:42 [medline] PHST- 2022/11/25 06:00 [pubmed] PHST- 2022/11/24 07:03 [entrez] AID - CDRR-EPUB-127762 [pii] AID - 10.2174/2589977515666221123093522 [doi] PST - ppublish SO - Curr Drug Res Rev. 2023;15(2):159-169. doi: 10.2174/2589977515666221123093522. PMID- 36413270 OWN - NLM STAT- MEDLINE DCOM- 20230428 LR - 20230428 IS - 2240-2993 (Electronic) IS - 0300-9009 (Print) IS - 0300-9009 (Linking) VI - 123 IP - 2 DP - 2023 Apr TI - Diagnostic challenges of functional neurological disorders after covid-19 disease or vaccination: case series and review of the literature. PG - 553-564 LID - 10.1007/s13760-022-02140-7 [doi] AB - BACKGROUND: Functional neurological disorders have rarely been described in patients recovering from Covid-19 or after vaccination but they are probably under diagnosed. MATERIAL AND METHODS: Six patients referred for rehabilitation of persistent symptoms and/or sequelae of Coronavirus disease 2019 (COVID-19) were diagnosed with functional neurological disorders. A literature review was conducted to identify reported cases of functional neurological disorders after Covid-19 infection or vaccination. RESULTS: In the current case series, patients diagnosed with functional neurological disorders presented high variability of clinical symptoms including hemiplegia, lower limb unilateral or bilateral paralysis, myoclonus, dystonia, tremor and sensory impairment. Four patients were young females with mild Covid-19 infection without hospital admission. Their neurological symptoms developed over the course of 4 weeks after the beginning of Covid-19 symptoms or vaccine administration with normal ancillary exams. One patient presented overlapping functional neurological symptoms and mild impairment of the left common peroneal nerve after prolonged ICU stay. In addition, all patients in our case series reported other non-motor symptoms such as fatigue, cognitive impairment and diffuse pain or dysesthesia, which are compatible with post Covid-19 condition. CONCLUSIONS: It is important that clinicians recognize functional neurological symptoms and consider it as a differential diagnosis in patients with neurological complications of Covid-19 infection and vaccination. CI - (c) 2022. The Author(s) under exclusive licence to Belgian Neurological Society. FAU - Albu, Sergiu AU - Albu S AUID- ORCID: 0000-0001-8310-4208 AD - Fundacio Institut Guttmann, Institut Universitari de Neurorehabilitacio Adscrit a la Universitat Autonoma de Barcelona, Badalona, Barcelona, Spain. salbu@guttmann.com. AD - Universitat Autonoma de Barcelona, Bellaterra (Cerdanyola del Valles), Barcelona, Spain. salbu@guttmann.com. AD - Fundacio Institut d'Investigacio en Ciencies de la Salut Germans Trias i Pujol, Badalona, Barcelona, Spain. salbu@guttmann.com. FAU - Valles, Margarita AU - Valles M AD - Fundacio Institut Guttmann, Institut Universitari de Neurorehabilitacio Adscrit a la Universitat Autonoma de Barcelona, Badalona, Barcelona, Spain. AD - Universitat Autonoma de Barcelona, Bellaterra (Cerdanyola del Valles), Barcelona, Spain. AD - Fundacio Institut d'Investigacio en Ciencies de la Salut Germans Trias i Pujol, Badalona, Barcelona, Spain. FAU - Kumru, Hatice AU - Kumru H AD - Fundacio Institut Guttmann, Institut Universitari de Neurorehabilitacio Adscrit a la Universitat Autonoma de Barcelona, Badalona, Barcelona, Spain. AD - Universitat Autonoma de Barcelona, Bellaterra (Cerdanyola del Valles), Barcelona, Spain. AD - Fundacio Institut d'Investigacio en Ciencies de la Salut Germans Trias i Pujol, Badalona, Barcelona, Spain. LA - eng PT - Journal Article PT - Review DEP - 20221121 PL - Italy TA - Acta Neurol Belg JT - Acta neurologica Belgica JID - 0247035 SB - IM MH - Female MH - Humans MH - *COVID-19/complications/prevention & control MH - Hemiplegia MH - *Dystonic Disorders MH - *Conversion Disorder MH - COVID-19 Testing PMC - PMC9685139 OTO - NOTNLM OT - Covid-19 OT - Functional neurological disorders OT - Post Covid-19 condition OT - Vaccine COIS- The authors have no competing interests to declare that are relevant to the content of this article. EDAT- 2022/11/23 06:00 MHDA- 2023/04/28 06:41 PMCR- 2022/11/24 CRDT- 2022/11/22 11:13 PHST- 2022/09/10 00:00 [received] PHST- 2022/10/31 00:00 [accepted] PHST- 2023/04/28 06:41 [medline] PHST- 2022/11/23 06:00 [pubmed] PHST- 2022/11/22 11:13 [entrez] PHST- 2022/11/24 00:00 [pmc-release] AID - 10.1007/s13760-022-02140-7 [pii] AID - 2140 [pii] AID - 10.1007/s13760-022-02140-7 [doi] PST - ppublish SO - Acta Neurol Belg. 2023 Apr;123(2):553-564. doi: 10.1007/s13760-022-02140-7. Epub 2022 Nov 21. PMID- 36396813 OWN - NLM STAT- MEDLINE DCOM- 20230301 LR - 20230310 IS - 1432-1459 (Electronic) IS - 0340-5354 (Print) IS - 0340-5354 (Linking) VI - 270 IP - 3 DP - 2023 Mar TI - Persistent hiccups as main COVID-19 manifestation with transient cytotoxic lesion of the corpus callosum splenium during the Omicron wave in the post-vaccination era. PG - 1211-1214 LID - 10.1007/s00415-022-11487-z [doi] FAU - Sassi, Celeste AU - Sassi C AUID- ORCID: 0000-0002-2837-1765 AD - Department of Experimental Neurology, Center for Stroke Research Berlin (CSB), Charite-Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin, Humboldt-Universitat Zu Berlin, Berlin Institute of Health, Chariteplatz 1, 10117, Berlin, Germany. celeste.sassi@charite.de. AD - Department of Neurology, Martin Gropius Hospital, Eberswalde, Germany. celeste.sassi@charite.de. FAU - Mehmed, Emel AU - Mehmed E AD - Department of Neurology, Martin Gropius Hospital, Eberswalde, Germany. FAU - Alkhatib, Amir AU - Alkhatib A AD - Department of Neurology, Martin Gropius Hospital, Eberswalde, Germany. FAU - Forero-Padilla, Mario Alberto AU - Forero-Padilla MA AD - Department of Neurology, Martin Gropius Hospital, Eberswalde, Germany. FAU - Goranov, Dragan S AU - Goranov DS AD - Department of Neurology, Martin Gropius Hospital, Eberswalde, Germany. FAU - Habermann, Sylvia AU - Habermann S AD - Department of Neurology, Martin Gropius Hospital, Eberswalde, Germany. FAU - Rekow, Sven AU - Rekow S AD - Department of Neurology, Martin Gropius Hospital, Eberswalde, Germany. FAU - Gruger, Albert AU - Gruger A AD - Department of Neurology, Martin Gropius Hospital, Eberswalde, Germany. FAU - Schmitt, Hans-Michael AU - Schmitt HM AD - Department of Neurology, Martin Gropius Hospital, Eberswalde, Germany. LA - eng PT - Letter PT - Research Support, Non-U.S. Gov't DEP - 20221118 PL - Germany TA - J Neurol JT - Journal of neurology JID - 0423161 RN - 0 (Antineoplastic Agents) SB - IM MH - Humans MH - Corpus Callosum/diagnostic imaging/pathology MH - *Hiccup/etiology/pathology MH - *COVID-19 MH - Magnetic Resonance Imaging MH - *Antineoplastic Agents PMC - PMC9672561 COIS- The authors declare that they have no conflict of interest. EDAT- 2022/11/18 06:00 MHDA- 2023/03/03 06:00 PMCR- 2022/11/18 CRDT- 2022/11/17 23:46 PHST- 2022/10/05 00:00 [received] PHST- 2022/11/10 00:00 [accepted] PHST- 2022/11/09 00:00 [revised] PHST- 2022/11/18 06:00 [pubmed] PHST- 2023/03/03 06:00 [medline] PHST- 2022/11/17 23:46 [entrez] PHST- 2022/11/18 00:00 [pmc-release] AID - 10.1007/s00415-022-11487-z [pii] AID - 11487 [pii] AID - 10.1007/s00415-022-11487-z [doi] PST - ppublish SO - J Neurol. 2023 Mar;270(3):1211-1214. doi: 10.1007/s00415-022-11487-z. Epub 2022 Nov 18. PMID- 36369800 OWN - NLM STAT- MEDLINE DCOM- 20230303 LR - 20230317 IS - 1464-0686 (Electronic) IS - 0965-8211 (Linking) VI - 31 IP - 2 DP - 2023 Feb TI - Remembering and forgetting information about the COVID-19 vaccine on Twitter. PG - 247-258 LID - 10.1080/09658211.2022.2144892 [doi] AB - Social media exposes people to selective information of what they have previously known. We conducted two laboratory studies to examine in a simulated online context the phenomenon of retrieval-induced forgetting, where information reposted on social media is likely to be later remembered and relevant but not reposted information may be forgotten. Specifically, we examined how exposure to selective information about the COVID-19 vaccine via tweets affected subsequent memory and whether people's attitudes towards vaccination played a role in their memory for the information. Young adults (N = 119; Study 1) and community members (N = 92; Study 2) were presented with information about the COVID-19 vaccine that included both pro- and anti-vaccine arguments, organised in four categories (i.e., science, children, religion, morality). They then read tweets that repeated half of the arguments from two of the categories. In a subsequent memory test, participants remembered best the statements repeated in the tweets and remembered worst the statements from the same category but not repeated in the tweets, thus exhibiting retrieval-induced forgetting. This pattern of results was similar across pro- and anti-vaccine arguments, regardless of the participants' level of support for vaccination. We discussed the findings in light of remembering and forgetting in the context of the pandemic and social media. FAU - Bilgin, Ezgi AU - Bilgin E AUID- ORCID: 0000-0001-9477-7379 AD - Culture & Cognition Lab, College of Human Ecology, Cornell University, Ithaca, NY, USA. FAU - Wang, Qi AU - Wang Q AUID- ORCID: 0000-0002-2404-2585 AD - Culture & Cognition Lab, College of Human Ecology, Cornell University, Ithaca, NY, USA. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20221111 PL - England TA - Memory JT - Memory (Hove, England) JID - 9306862 RN - 0 (COVID-19 Vaccines) SB - IM MH - Young Adult MH - Child MH - Humans MH - COVID-19 Vaccines MH - *COVID-19 MH - *Social Media MH - Mental Recall OTO - NOTNLM OT - COVID-19 vaccine OT - Retrieval-induced forgetting OT - Twitter OT - attitudes OT - selective retrieval OT - social media EDAT- 2022/11/13 06:00 MHDA- 2023/03/04 06:00 CRDT- 2022/11/12 02:13 PHST- 2022/11/13 06:00 [pubmed] PHST- 2023/03/04 06:00 [medline] PHST- 2022/11/12 02:13 [entrez] AID - 10.1080/09658211.2022.2144892 [doi] PST - ppublish SO - Memory. 2023 Feb;31(2):247-258. doi: 10.1080/09658211.2022.2144892. Epub 2022 Nov 11. PMID- 36366936 OWN - NLM STAT- MEDLINE DCOM- 20230210 LR - 20230323 IS - 1468-1331 (Electronic) IS - 1351-5101 (Print) IS - 1351-5101 (Linking) VI - 30 IP - 3 DP - 2023 Mar TI - Functional disorders as a common motor manifestation of COVID-19 infection or vaccination. PG - 678-691 LID - 10.1111/ene.15630 [doi] AB - BACKGROUND AND PURPOSE: There have been over 500 million confirmed cases of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), also known as coronavirus disease 2019 (COVID-19), across the globe. To date, a broad spectrum of neurological manifestations following acute infections as well as COVID-19 vaccines have been reported. The aim of this study was to describe the spectrum of neurological manifestations seen in the 'COVID-19 clinic' established in a tertiary Movement Disorders clinic. METHODS: In this consecutive case-series study over the period March 2020-January 2022, clinical information regarding demographic data, clinical history and examination findings, investigation results and video recordings of outpatients with motor manifestations associated with COVID-19 infection or vaccination were reviewed. RESULTS: Twenty-one adult patients were reviewed in this ad hoc clinic at Toronto Western Hospital. The majority of the patients were female (76%) and the mean (range) age was 50.7 +/- 17.2 (21-80) years. Nine patients (43%) presented with motor manifestations following COVID-19 infection. Twelve patients (57%) developed neurological symptoms following at least one dose of the mRNA or viral vector-based COVID-19 vaccine. The most common manifestation observed was a functional movement disorder (43%). The vaccine group demonstrated a higher number of functional disorders compared to the infection group (58% vs. 22%; p = 0.08). CONCLUSION: Functional motor manifestations can be associated with COVID-19 and are likely to be under-reported. In view of the co-existence of functional symptoms, movement disorders and mental health conditions observed in this study, we would advocate the use of dedicated COVID-19 Neurology clinics with full access to an experienced multidisciplinary team. CI - (c) 2022 European Academy of Neurology. FAU - Fung, Wilson K W AU - Fung WKW AUID- ORCID: 0000-0001-7169-4175 AD - Edmond J. Safra Program in Parkinson's Disease and Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN, Toronto, Ontario, Canada. FAU - Sa'di, Qais AU - Sa'di Q AUID- ORCID: 0000-0002-3499-4483 AD - Edmond J. Safra Program in Parkinson's Disease and Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN, Toronto, Ontario, Canada. FAU - Katzberg, Hans AU - Katzberg H AD - Division of Neurology, University of Toronto, Toronto, Ontario, Canada. AD - Krembil Research Institute, Toronto, Ontario, Canada. FAU - Chen, Robert AU - Chen R AD - Edmond J. Safra Program in Parkinson's Disease and Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN, Toronto, Ontario, Canada. AD - Division of Neurology, University of Toronto, Toronto, Ontario, Canada. AD - Krembil Research Institute, Toronto, Ontario, Canada. FAU - Lang, Anthony E AU - Lang AE AD - Edmond J. Safra Program in Parkinson's Disease and Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN, Toronto, Ontario, Canada. AD - Division of Neurology, University of Toronto, Toronto, Ontario, Canada. AD - Krembil Research Institute, Toronto, Ontario, Canada. FAU - Cheung, Angela M AU - Cheung AM AD - Department of Medicine, UHN, Toronto, Ontario, Canada. AD - Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada. FAU - Fasano, Alfonso AU - Fasano A AD - Edmond J. Safra Program in Parkinson's Disease and Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN, Toronto, Ontario, Canada. AD - Division of Neurology, University of Toronto, Toronto, Ontario, Canada. AD - Krembil Research Institute, Toronto, Ontario, Canada. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20221208 PL - England TA - Eur J Neurol JT - European journal of neurology JID - 9506311 RN - 0 (COVID-19 Vaccines) SB - IM CIN - Eur J Neurol. 2023 Feb;30(2):560-561. doi: 10.1111/ene.15639. PMID: 36404130 MH - Adult MH - Aged MH - Female MH - Humans MH - Male MH - Middle Aged MH - *COVID-19/complications/prevention & control MH - *COVID-19 Vaccines/adverse effects MH - *Movement Disorders MH - SARS-CoV-2 MH - Vaccination/adverse effects PMC - PMC9878181 OTO - NOTNLM OT - COVID-19 OT - SARS-CoV-2 OT - functional OT - movement disorders OT - vaccine COIS- None relevant to this work. EDAT- 2022/11/12 06:00 MHDA- 2023/02/11 06:00 PMCR- 2022/12/08 CRDT- 2022/11/11 03:32 PHST- 2022/10/16 00:00 [revised] PHST- 2022/07/17 00:00 [received] PHST- 2022/11/03 00:00 [accepted] PHST- 2022/11/12 06:00 [pubmed] PHST- 2023/02/11 06:00 [medline] PHST- 2022/11/11 03:32 [entrez] PHST- 2022/12/08 00:00 [pmc-release] AID - ENE15630 [pii] AID - 10.1111/ene.15630 [doi] PST - ppublish SO - Eur J Neurol. 2023 Mar;30(3):678-691. doi: 10.1111/ene.15630. Epub 2022 Dec 8. PMID- 36354024 OWN - NLM STAT- MEDLINE DCOM- 20230105 LR - 20241207 IS - 2222-1751 (Electronic) IS - 2222-1751 (Linking) VI - 12 IP - 1 DP - 2023 Dec TI - Structural insights into broadly neutralizing antibodies elicited by hybrid immunity against SARS-CoV-2. PG - 2146538 LID - 10.1080/22221751.2022.2146538 [doi] LID - 2146538 AB - ABSTRACTIncreasing spread by SARS-CoV-2 Omicron variants challenges existing vaccines and broadly reactive neutralizing antibodies (bNAbs) against COVID-19. Here we determine the diversity, potency, breadth and structural insights of bNAbs derived from memory B cells of BNT162b2-vaccinee after homogeneous Omicron BA.1 breakthrough infection. The infection activates diverse memory B cell clonotypes for generating potent class I/II and III bNAbs with new epitopes mapped to the receptor-binding domain (RBD). The top eight bNAbs neutralize wildtype and BA.1 potently but display divergent IgH/IgL sequences and neuralization profiles against other variants of concern (VOCs). Two of them (P2D9 and P3E6) belonging to class III NAbs display comparable potency against BA.4/BA.5, although structural analysis reveals distinct modes of action. P3E6 neutralizes all variants tested through a unique bivalent interaction with two RBDs. Our findings provide new insights into hybrid immunity on BNT162b2-induced diverse memory B cells in response to Omicron breakthrough infection for generating diverse bNAbs with distinct structural basis. FAU - Luo, Mengxiao AU - Luo M AD - AIDS Institute, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, People's Republic of China. AD - Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, People's Republic of China. FAU - Zhou, Biao AU - Zhou B AD - AIDS Institute, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, People's Republic of China. AD - Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, People's Republic of China. FAU - Reddem, Eswar R AU - Reddem ER AD - Zuckerman Mind Brain Behaviour Institute, New York, NY, USA. FAU - Tang, Bingjie AU - Tang B AD - Division of Life Science, Center of Systems Biology and Human Health, The Hong Kong University of Science and Technology, Clear Water Bay, Kowloon, Hong Kong Special Administrative Region, People's Republic of China. FAU - Chen, Bohao AU - Chen B AD - AIDS Institute, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, People's Republic of China. AD - Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, People's Republic of China. FAU - Zhou, Runhong AU - Zhou R AD - AIDS Institute, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, People's Republic of China. AD - Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, People's Republic of China. FAU - Liu, Hang AU - Liu H AD - Division of Life Science, Center of Systems Biology and Human Health, The Hong Kong University of Science and Technology, Clear Water Bay, Kowloon, Hong Kong Special Administrative Region, People's Republic of China. FAU - Liu, Lihong AU - Liu L AD - Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA. FAU - Katsamba, Phinikoula S AU - Katsamba PS AD - Zuckerman Mind Brain Behaviour Institute, New York, NY, USA. FAU - Au, Ka-Kit AU - Au KK AD - AIDS Institute, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, People's Republic of China. AD - Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, People's Republic of China. FAU - Man, Hiu-On AU - Man HO AD - AIDS Institute, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, People's Republic of China. AD - Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, People's Republic of China. FAU - To, Kelvin Kai-Wang AU - To KK AUID- ORCID: 0000-0002-1921-5824 AD - Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, People's Republic of China. AD - State Key Laboratory of Emerging Infectious Diseases, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, People's Republic of China. AD - Centre for Virology, Vaccinology and Therapeutics, Health@InnoHK, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, People's Republic of China. AD - Department of Clinical Microbiology and Infection Control, The University of Hong Kong-Shenzhen Hospital, Shenzhen, People's Republic of China. AD - Department of Microbiology, Queen Mary Hospital, Pokfulam, Hong Kong Special Administrative Region, People's Republic of China. FAU - Yuen, Kwok-Yung AU - Yuen KY AUID- ORCID: 0000-0002-2083-1552 AD - Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, People's Republic of China. AD - State Key Laboratory of Emerging Infectious Diseases, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, People's Republic of China. AD - Centre for Virology, Vaccinology and Therapeutics, Health@InnoHK, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, People's Republic of China. AD - Department of Clinical Microbiology and Infection Control, The University of Hong Kong-Shenzhen Hospital, Shenzhen, People's Republic of China. AD - Department of Microbiology, Queen Mary Hospital, Pokfulam, Hong Kong Special Administrative Region, People's Republic of China. FAU - Shapiro, Lawrence AU - Shapiro L AD - Zuckerman Mind Brain Behaviour Institute, New York, NY, USA. AD - Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA. FAU - Dang, Shangyu AU - Dang S AD - Division of Life Science, Center of Systems Biology and Human Health, The Hong Kong University of Science and Technology, Clear Water Bay, Kowloon, Hong Kong Special Administrative Region, People's Republic of China. AD - Southern Marine Science and Engineering Guangdong Laboratory (Guangzhou), Guangzhou, People's Republic of China. AD - HKUST-Shenzhen Research Institute, Nanshan, People's Republic of China. FAU - Ho, David D AU - Ho DD AD - Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA. FAU - Chen, Zhiwei AU - Chen Z AUID- ORCID: 0000-0002-4511-2888 AD - AIDS Institute, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, People's Republic of China. AD - Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, People's Republic of China. AD - State Key Laboratory of Emerging Infectious Diseases, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, People's Republic of China. AD - Centre for Virology, Vaccinology and Therapeutics, Health@InnoHK, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, People's Republic of China. AD - Department of Clinical Microbiology and Infection Control, The University of Hong Kong-Shenzhen Hospital, Shenzhen, People's Republic of China. LA - eng GR - WT_/Wellcome Trust/United Kingdom PT - Journal Article PL - United States TA - Emerg Microbes Infect JT - Emerging microbes & infections JID - 101594885 RN - 0 (Broadly Neutralizing Antibodies) RN - 0 (BNT162 Vaccine) RN - 0 (Antibodies, Viral) RN - 0 (Antibodies, Neutralizing) RN - 0 (Spike Glycoprotein, Coronavirus) RN - 0 (spike protein, SARS-CoV-2) RN - SARS-CoV-2 variants SB - IM MH - Humans MH - *SARS-CoV-2 MH - *COVID-19 MH - Broadly Neutralizing Antibodies MH - BNT162 Vaccine MH - Breakthrough Infections MH - Adaptive Immunity MH - Antibodies, Viral MH - Antibodies, Neutralizing MH - Spike Glycoprotein, Coronavirus/genetics PMC - PMC9817130 OTO - NOTNLM OT - Omicron BA.1 breakthrough infection OT - SARS-CoV-2 OT - broadly neutralizing antibody OT - hybrid immunity OT - memory B cell OT - structural basis of antibody COIS- No potential conflict of interest was reported by the author(s). EDAT- 2022/11/11 06:00 MHDA- 2023/01/06 06:00 PMCR- 2023/01/03 CRDT- 2022/11/10 05:22 PHST- 2022/11/11 06:00 [pubmed] PHST- 2023/01/06 06:00 [medline] PHST- 2022/11/10 05:22 [entrez] PHST- 2023/01/03 00:00 [pmc-release] AID - 2146538 [pii] AID - 10.1080/22221751.2022.2146538 [doi] PST - ppublish SO - Emerg Microbes Infect. 2023 Dec;12(1):2146538. doi: 10.1080/22221751.2022.2146538. PMID- 36353634 OWN - NLM STAT- MEDLINE DCOM- 20221111 LR - 20240907 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 13 DP - 2022 TI - In-silico evaluation of adenoviral COVID-19 vaccination protocols: Assessment of immunological memory up to 6 months after the third dose. PG - 998262 LID - 10.3389/fimmu.2022.998262 [doi] LID - 998262 AB - BACKGROUND: The immune response to adenoviral COVID-19 vaccines is affected by the interval between doses. The optimal interval is unknown. AIM: We aim to explore in-silico the effect of the interval between vaccine administrations on immunogenicity and to analyze the contribution of pre-existing levels of antibodies, plasma cells, and memory B and T lymphocytes. METHODS: We used a stochastic agent-based immune simulation platform to simulate two-dose and three-dose vaccination protocols with an adenoviral vaccine. We identified the model's parameters fitting anti-Spike antibody levels from individuals immunized with the COVID-19 vaccine AstraZeneca (ChAdOx1-S, Vaxzevria). We used several statistical methods, such as principal component analysis and binary classification, to analyze the correlation between pre-existing levels of antibodies, plasma cells, and memory B and T cells to the magnitude of the antibody response following a booster dose. RESULTS AND CONCLUSIONS: We find that the magnitude of the antibody response to a booster depends on the number of pre-existing memory B cells, which, in turn, is highly correlated to the number of T helper cells and plasma cells, and the antibody titers. Pre-existing memory T cytotoxic cells and antibodies directly influence antigen availability hence limiting the magnitude of the immune response. The optimal immunogenicity of the third dose is achieved over a large time window, spanning from 6 to 16 months after the second dose. Interestingly, after any vaccine dose, individuals can be classified into two groups, sustainers and decayers, that differ in the kinetics of decline of their antibody titers due to differences in long-lived plasma cells. This suggests that the decayers may benefit from a tailored boosting schedule with a shorter interval to avoid the temporary loss of serological immunity. CI - Copyright (c) 2022 Stolfi, Castiglione, Mastrostefano, Di Biase, Di Biase, Palmieri and Prisco. FAU - Stolfi, Paola AU - Stolfi P AD - Institute for Applied Computing, National Research Council of Italy, Rome, Italy. FAU - Castiglione, Filippo AU - Castiglione F AD - Institute for Applied Computing, National Research Council of Italy, Rome, Italy. FAU - Mastrostefano, Enrico AU - Mastrostefano E AD - Institute for Applied Computing, National Research Council of Italy, Rome, Italy. FAU - Di Biase, Immacolata AU - Di Biase I AD - MeriGen Res, Naples, Italy. FAU - Di Biase, Sebastiano AU - Di Biase S AD - MeriGen Res, Naples, Italy. FAU - Palmieri, Gianna AU - Palmieri G AD - Institute of Biosciences and BioResources, National Research Council, Naples, Italy. FAU - Prisco, Antonella AU - Prisco A AD - Institute of Genetics and Biophysics, National Research Council, Naples, Italy. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20221024 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - *COVID-19 Vaccines MH - Immunologic Memory MH - Immunization, Secondary MH - *COVID-19/prevention & control MH - Vaccination MH - Adenoviridae/genetics PMC - PMC9639861 OTO - NOTNLM OT - adenoviral COVID-19 vaccine OT - agent-based modeling (ABM) OT - anti-vector immunity OT - booster OT - immunological memory OT - in silico OT - simulation COIS- Authors IDB and SDB were employed by company MeriGen Res. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/11/11 06:00 MHDA- 2022/11/15 06:00 PMCR- 2022/10/24 CRDT- 2022/11/10 02:24 PHST- 2022/07/19 00:00 [received] PHST- 2022/09/22 00:00 [accepted] PHST- 2022/11/10 02:24 [entrez] PHST- 2022/11/11 06:00 [pubmed] PHST- 2022/11/15 06:00 [medline] PHST- 2022/10/24 00:00 [pmc-release] AID - 10.3389/fimmu.2022.998262 [doi] PST - epublish SO - Front Immunol. 2022 Oct 24;13:998262. doi: 10.3389/fimmu.2022.998262. eCollection 2022. PMID- 36353624 OWN - NLM STAT- MEDLINE DCOM- 20221115 LR - 20221222 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 13 DP - 2022 TI - Short-term safety and immunogenicity of inactivated and peptide-based SARS-CoV-2 vaccines in patients with endocrine-related cancer. PG - 1028246 LID - 10.3389/fimmu.2022.1028246 [doi] LID - 1028246 AB - BACKGROUND: The aim of this study was to explore the short-term safety and immunogenicity of inactivated and peptide-based SARS-CoV-2 vaccines in patients with endocrine-related cancer (ER). METHODS: Eighty-eight patients with ER cancer and 82 healthy controls who had completed a full course of inactivated or peptide-based SARS-CoV-2 vaccines were recruited. Adverse events (AEs) were recorded. Responses to receptor-binding domain IgG antibody (anti-RBD-IgG), neutralizing antibodies (NAbs) and RBD+ memory B cells (MBCs) were evaluated. RESULTS: Approximately 26.14% (23/88) of patients with ER cancer reported AEs within 7 days, which was comparable to that reported by healthy controls (24.39%, 20/82). Both the overall seroprevalence of anti-RBD-IgG and NAbs was obviously lower in the cancer group (70.45% vs. 86.59%, P < 0.05; 69.32% vs. 82.93%, P < 0.05, respectively). Anti-RBD-IgG and NAbs titers exhibited similar results, and dropped gradually over time. Patients with ongoing treatment had an attenuated immune response, especially in patients receiving active chemotherapy. The frequency of overall RBD+ MBCs was similar between the two groups, but the percentage of active MBCs was remarkably reduced in patients with ER cancer. Unlike antibody titers, MBCs responses were relatively constant over time. CONCLUSION: Inactivated and peptide-based COVID-19 vaccines were well tolerated, but with lower immunogenicity for ER cancer patients. More intensive antibody monitoring and timely booster immunization is recommended for patients with ER cancer presenting disordered subpopulations of RBD+ MBCs. CI - Copyright (c) 2022 Song, Liu, Pan, Liu, Tan, Deng, Deng, Lin, Chen, Peng, Ren and Ming. FAU - Song, Rui AU - Song R AD - Department of Infectious Diseases, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China. FAU - Liu, Li AU - Liu L AD - Department of Breast and Thyroid Surgery, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China. FAU - Pan, Qingbo AU - Pan Q AD - Department of Infectious Diseases, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China. FAU - Liu, Jin AU - Liu J AD - Department of Breast and Thyroid Surgery, The First People's Hospital of Yibin, Sichuan, China. FAU - Tan, Jiahe AU - Tan J AD - Department of Neurosurgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. FAU - Deng, Juan AU - Deng J AD - Department of Breast and Thyroid Surgery, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China. FAU - Deng, Qin AU - Deng Q AD - Department of Breast and Thyroid Surgery, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China. FAU - Lin, Zijin AU - Lin Z AD - Department of Breast and Thyroid Surgery, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China. FAU - Chen, Min AU - Chen M AD - Department of Infectious Diseases, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China. FAU - Peng, Mingli AU - Peng M AD - Department of Infectious Diseases, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China. FAU - Ren, Hong AU - Ren H AD - Department of Infectious Diseases, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China. FAU - Ming, Jia AU - Ming J AD - Department of Breast and Thyroid Surgery, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20221024 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 RN - 0 (Antibodies, Neutralizing) RN - 0 (Antibodies, Viral) RN - 0 (COVID-19 Vaccines) RN - 0 (Immunoglobulin G) RN - 0 (Peptides) RN - 0 (Viral Vaccines) SB - IM MH - Humans MH - Antibodies, Neutralizing MH - Antibodies, Viral MH - *COVID-19/prevention & control MH - *COVID-19 Vaccines/adverse effects MH - Immunoglobulin G MH - *Neoplasms/chemically induced MH - Peptides MH - SARS-CoV-2 MH - Seroepidemiologic Studies MH - Viral Vaccines PMC - PMC9637626 OTO - NOTNLM OT - COVID-19 OT - SARS-COV-2 OT - cancer OT - memory B cells OT - vaccine COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/11/11 06:00 MHDA- 2022/11/15 06:00 PMCR- 2022/10/24 CRDT- 2022/11/10 02:24 PHST- 2022/08/25 00:00 [received] PHST- 2022/10/06 00:00 [accepted] PHST- 2022/11/10 02:24 [entrez] PHST- 2022/11/11 06:00 [pubmed] PHST- 2022/11/15 06:00 [medline] PHST- 2022/10/24 00:00 [pmc-release] AID - 10.3389/fimmu.2022.1028246 [doi] PST - epublish SO - Front Immunol. 2022 Oct 24;13:1028246. doi: 10.3389/fimmu.2022.1028246. eCollection 2022. PMID- 36341425 OWN - NLM STAT- MEDLINE DCOM- 20221110 LR - 20260928 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 13 DP - 2022 TI - Humoral and cellular immune responses to CoronaVac up to one year after vaccination. PG - 1032411 LID - 10.3389/fimmu.2022.1032411 [doi] LID - 1032411 AB - Coronavac is a widely used SARS-CoV-2 inactivated vaccine, but its long-term immune response assessment is still lacking. We evaluated SARS-CoV-2-specific immune responses, including T cell activation markers, antigen-specific cytokine production and antibody response following vaccination in 53 adult and elderly individuals participating in a phase 3 clinical trial. Activated follicular helper T (Tfh), non-Tfh and memory CD4(+) T cells were detected in almost all subjects early after the first vaccine dose. Activated memory CD4(+) T cells were predominantly of central and effector memory T cell phenotypes and were sustained for at least 6 months. We also detected a balanced Th1-, Th2- and Th17/Th22-type cytokine production that was associated with response over time, together with particular cytokine profile linked to poor responses in older vaccinees. SARS-CoV-2-specific IgG levels peaked 14 days after the second dose and were mostly stable over one year. CoronaVac was able to induce a potent and durable antiviral antigen-specific cellular response and the cytokine profiles related to the response over time and impacted by the senescence were defined. CI - Copyright (c) 2022 Costa, Correia, Marmorato, Dias, Thomazella, Cabral da Silva, de Oliveira, Gusmao, Ferrari, Freitas, Patino, Grifoni, Weiskopf, Sette, Scharf, Kallas and Silveira. FAU - Costa, Priscilla Ramos AU - Costa PR AD - Medical Investigation Laboratory 60 (LIM-60), School of Medicine, University of Sao Paulo, Sao Paulo, Brazil. FAU - Correia, Carolina Argondizo AU - Correia CA AD - Medical Investigation Laboratory 60 (LIM-60), School of Medicine, University of Sao Paulo, Sao Paulo, Brazil. FAU - Marmorato, Mariana Prado AU - Marmorato MP AD - Medical Investigation Laboratory 60 (LIM-60), School of Medicine, University of Sao Paulo, Sao Paulo, Brazil. FAU - Dias, Juliana Zanatta de Carvalho AU - Dias JZC AD - Medical Investigation Laboratory 60 (LIM-60), School of Medicine, University of Sao Paulo, Sao Paulo, Brazil. FAU - Thomazella, Mateus Vailant AU - Thomazella MV AD - Medical Investigation Laboratory 60 (LIM-60), School of Medicine, University of Sao Paulo, Sao Paulo, Brazil. FAU - Cabral da Silva, Amanda AU - Cabral da Silva A AD - Medical Investigation Laboratory 60 (LIM-60), School of Medicine, University of Sao Paulo, Sao Paulo, Brazil. FAU - de Oliveira, Ana Carolina Soares AU - de Oliveira ACS AD - Medical Investigation Laboratory 60 (LIM-60), School of Medicine, University of Sao Paulo, Sao Paulo, Brazil. FAU - Gusmao, Arianne Fagotti AU - Gusmao AF AD - Medical Investigation Laboratory 60 (LIM-60), School of Medicine, University of Sao Paulo, Sao Paulo, Brazil. FAU - Ferrari, Lilian AU - Ferrari L AD - Medical Investigation Laboratory 60 (LIM-60), School of Medicine, University of Sao Paulo, Sao Paulo, Brazil. FAU - Freitas, Angela Carvalho AU - Freitas AC AD - Department of Infectious and Parasitic Diseases, Clinicas Hospital, School of Medicine, University of Sao Paulo, Sao Paulo, Brazil. FAU - Patino, Elizabeth Gonzalez AU - Patino EG AD - Center for Clinical Trials and Pharmacovigilance Butantan Institute, Sao Paulo, Brazil. FAU - Grifoni, Alba AU - Grifoni A AD - Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, San Diego, CA, United States. FAU - Weiskopf, Daniela AU - Weiskopf D AD - Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, San Diego, CA, United States. FAU - Sette, Alessandro AU - Sette A AD - Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, San Diego, CA, United States. AD - Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California San Diego, San Diego, CA, United States. FAU - Scharf, Rami AU - Scharf R AD - PATH, Washington, DC, United States. FAU - Kallas, Esper Georges AU - Kallas EG AD - Medical Investigation Laboratory 60 (LIM-60), School of Medicine, University of Sao Paulo, Sao Paulo, Brazil. AD - Department of Infectious and Parasitic Diseases, Clinicas Hospital, School of Medicine, University of Sao Paulo, Sao Paulo, Brazil. FAU - Silveira, Cassia Gisele Terrassani AU - Silveira CGT AD - Medical Investigation Laboratory 60 (LIM-60), School of Medicine, University of Sao Paulo, Sao Paulo, Brazil. LA - eng GR - 75N93019C00065/AI/NIAID NIH HHS/United States GR - INV-021239/Bill & Melinda Gates Foundation/United States PT - Clinical Trial, Phase III PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20221021 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 RN - 0 (Antibodies, Viral) RN - 0 (COVID-19 Vaccines) RN - 0 (Cytokines) RN - 0 (Immunoglobulin G) SB - IM UOF - medRxiv. 2022 Jul 07:2022.03.16.22272513. doi: 10.1101/2022.03.16.22272513. PMID: 35821982 MH - Humans MH - Antibodies, Viral MH - *COVID-19 MH - *COVID-19 Vaccines MH - Cytokines MH - Immunity, Cellular MH - Immunoglobulin G MH - SARS-CoV-2 MH - Vaccination PMC - PMC9634255 OTO - NOTNLM OT - CoronaVac OT - cellular response OT - humoral response OT - immune memory OT - vaccination COIS- Employees of Fundacao Butantan and Instituto Butantan participated in the clinical trial design and data collection. Author AS is a consultant for Gritstone Bio, Flow Pharma, ImmunoScape, Moderna, AstraZeneca, Avalia, Fortress, Repertoire, Gilead, Gerson Lehrman Group, RiverVest, MedaCorp, and Guggenheim. The La Jolla Institute (LJI) has filed for patent protection for various aspects of T cell epitope and vaccine design work. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/11/08 06:00 MHDA- 2022/11/09 06:00 PMCR- 2022/10/21 CRDT- 2022/11/07 05:18 PHST- 2022/08/30 00:00 [received] PHST- 2022/10/03 00:00 [accepted] PHST- 2022/11/07 05:18 [entrez] PHST- 2022/11/08 06:00 [pubmed] PHST- 2022/11/09 06:00 [medline] PHST- 2022/10/21 00:00 [pmc-release] AID - 10.3389/fimmu.2022.1032411 [doi] PST - epublish SO - Front Immunol. 2022 Oct 21;13:1032411. doi: 10.3389/fimmu.2022.1032411. eCollection 2022. PMID- 36304475 OWN - NLM STAT- MEDLINE DCOM- 20221031 LR - 20221031 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 13 DP - 2022 TI - Comparing the B and T cell-mediated immune responses in patients with type 2 diabetes receiving mRNA or inactivated COVID-19 vaccines. PG - 1018393 LID - 10.3389/fimmu.2022.1018393 [doi] LID - 1018393 AB - Acquiring protective immunity through vaccination is essential, especially for patients with type 2 diabetes who are vulnerable for adverse clinical outcomes during coronavirus disease 2019 (COVID-19) infection. Type 2 diabetes (T2D) is associated with immune dysfunction. Here, we evaluated the impact of T2D on the immunological responses induced by mRNA (BNT162b2) and inactivated (CoronaVac) vaccines, the two most commonly used COVID-19 vaccines. The study consisted of two parts. In Part 1, the sera titres of IgG antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) alpha receptor binding domain (RBD), their neutralizing capacity, and antigen-specific CD4(+)T and CD8(+)T cell responses at 3-6 months after vaccination were compared between BNT162b2 (n=60) and CoronaVac (n=50) vaccinees with or without T2D. Part 2 was a time-course study investigating the initial B and T cell responses induced by BNT162b2 among vaccinees (n=16) with or without T2D. Our data showed that T2D impaired both cellular and humoral immune responses induced by CoronaVac. For BNT162b2, T2D patients displayed a reduction in CD4(+)T-helper 1 (Th1) differentiation following their first dose. However, this initial defect was rectified by the second dose of BNT162b2, resulting in comparable levels of memory CD4(+) and CD8(+)T cells, anti-RBD IgG, and neutralizing antibodies with healthy individuals at 3-6 months after vaccination. Hence, T2D influences the effectiveness of COVID-19 vaccines depending on their platform. Our findings provide a potential mechanism for the susceptibility of developing adverse outcomes observed in COVID-19 patients with T2D and received either CoronaVac or just one dose of BNT162b2. CI - Copyright (c) 2022 Lee, Gray, Teo, Tam, Fong, Lui, Pang, Chan, Hung, Tan and Ling. FAU - Lee, Chi-Ho AU - Lee CH AD - Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, Hong Kong SAR, China. FAU - Gray, Victor AU - Gray V AD - School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, Hong Kong SAR, China. FAU - Teo, Jia Ming Nickolas AU - Teo JMN AD - School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, Hong Kong SAR, China. FAU - Tam, Anthony Raymond AU - Tam AR AD - Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, Hong Kong SAR, China. FAU - Fong, Carol Ho-Yi AU - Fong CH AD - Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, Hong Kong SAR, China. FAU - Lui, David Tak-Wai AU - Lui DT AD - Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, Hong Kong SAR, China. FAU - Pang, Polly AU - Pang P AD - Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, Hong Kong SAR, China. FAU - Chan, Kwok Hung AU - Chan KH AD - Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, Hong Kong SAR, China. FAU - Hung, Ivan Fan-Ngai AU - Hung IF AD - Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, Hong Kong SAR, China. FAU - Tan, Kathryn Choon-Beng AU - Tan KC AD - Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, Hong Kong SAR, China. FAU - Ling, Guang Sheng AU - Ling GS AD - School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, Hong Kong SAR, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20221011 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 RN - 0 (COVID-19 Vaccines) RN - 0 (RNA, Messenger) RN - 0 (Viral Vaccines) RN - 0 (BNT162 Vaccine) RN - 0 (RNA, Viral) RN - 0 (Immunoglobulin G) SB - IM MH - Humans MH - COVID-19 Vaccines MH - RNA, Messenger MH - *Viral Vaccines MH - *Diabetes Mellitus, Type 2 MH - *COVID-19/prevention & control MH - BNT162 Vaccine MH - RNA, Viral MH - SARS-CoV-2 MH - Immunity, Cellular MH - Immunoglobulin G PMC - PMC9592994 OTO - NOTNLM OT - BNT162b2 OT - COVID-19 vaccine OT - CoronaVac OT - immunological memory response OT - type 2 diabetes COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/10/29 06:00 MHDA- 2022/11/01 06:00 PMCR- 2022/10/11 CRDT- 2022/10/28 02:51 PHST- 2022/08/13 00:00 [received] PHST- 2022/09/26 00:00 [accepted] PHST- 2022/10/28 02:51 [entrez] PHST- 2022/10/29 06:00 [pubmed] PHST- 2022/11/01 06:00 [medline] PHST- 2022/10/11 00:00 [pmc-release] AID - 10.3389/fimmu.2022.1018393 [doi] PST - epublish SO - Front Immunol. 2022 Oct 11;13:1018393. doi: 10.3389/fimmu.2022.1018393. eCollection 2022. PMID- 36303493 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20221031 IS - 2694-1902 (Electronic) IS - 2694-1902 (Linking) VI - 3 IP - 16 DP - 2022 Apr 18 TI - Trigeminal neuropathy after tozinameran vaccination against COVID-19 in postmicrovascular decompression for trigeminal neuralgia: illustrative case. LID - CASE22101 [pii] LID - 10.3171/CASE22101 [doi] AB - BACKGROUND: Vaccines against coronavirus disease 2019 have a high level of efficacy and safety across all populations. However, numerous case series have been published on neurological disorders, including Bell's palsy, Guillain-Barre syndrome, transverse myelitis, and multiple sclerosis. The authors presented a case of trigeminal neuropathy after coronavirus vaccination in a patient who had undergone microvascular decompression (MVD) for trigeminal neuralgia (TN). OBSERVATIONS: A 77-year-old woman presented with acute trigeminal neuropathy after receiving a Pfizer-BioNtech vaccination (tozinameran) against severe acute respiratory syndrome coronavirus 2. The patient had undergone MVD for TN and the facial pain completely disappeared. One month later, she received the first injection of the tozinameran vaccine. Twelve hours after vaccination, she presented with numbness and pain induced by touching any place on the entire right face. No eruption was observed on her face. The serum herpes zoster virus antibodies were confirmed within the normal range. Magnetic resonance imaging revealed no abnormalities. The authors suspected a right trigeminal neuropathy after vaccination. Administration of carbamazepine and pregabalin improved TN but facial numbness persisted, especially in the mandibular division. LESSONS: The coronavirus is a possible etiology of secondary trigeminal neuropathy in the case of MVD for TN. FAU - Onoda, Keisuke AU - Onoda K FAU - Sashida, Ryohei AU - Sashida R FAU - Fujiwara, Ren AU - Fujiwara R FAU - Wakamiya, Tomihiro AU - Wakamiya T FAU - Michiwaki, Yuhei AU - Michiwaki Y FAU - Tanaka, Tatsuya AU - Tanaka T FAU - Shimoji, Kazuaki AU - Shimoji K FAU - Suehiro, Eiichi AU - Suehiro E FAU - Yamane, Fumitaka AU - Yamane F FAU - Kawashima, Masatou AU - Kawashima M FAU - Matsuno, Akira AU - Matsuno A LA - eng PT - Journal Article DEP - 20220418 PL - United States TA - J Neurosurg Case Lessons JT - Journal of neurosurgery. Case lessons JID - 9918227275606676 PMC - PMC9379720 OTO - NOTNLM OT - COVID-19 OT - case report OT - microvascular decompression OT - trigeminal neuropathy OT - vaccination COIS- Disclosures The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper. EDAT- 2022/10/29 06:00 MHDA- 2022/10/29 06:01 PMCR- 2022/04/18 CRDT- 2022/10/28 02:23 PHST- 2022/03/02 00:00 [received] PHST- 2022/03/08 00:00 [accepted] PHST- 2022/10/28 02:23 [entrez] PHST- 2022/10/29 06:00 [pubmed] PHST- 2022/10/29 06:01 [medline] PHST- 2022/04/18 00:00 [pmc-release] AID - CASE22101 [pii] AID - 10.3171/CASE22101 [doi] PST - epublish SO - J Neurosurg Case Lessons. 2022 Apr 18;3(16):CASE22101. doi: 10.3171/CASE22101. Print 2022 Apr 18. PMID- 36288776 OWN - NLM STAT- MEDLINE DCOM- 20250127 LR - 20250513 IS - 2173-5808 (Electronic) IS - 2173-5808 (Linking) VI - 40 IP - 1 DP - 2025 Jan-Feb TI - Neurological manifestations associated with COVID-19 vaccine. PG - 66-76 LID - S2173-5808(22)00141-9 [pii] LID - 10.1016/j.nrleng.2022.09.007 [doi] AB - INTRODUCTION: Coronavirus disease 2019 (COVID-19) has spread rapidly, giving rise to a pandemic, causing significant morbidity and mortality. In this context, many vaccines have emerged to try to deal with this disease. OBJECTIVE: To review the reported cases of neurological manifestations after the application of COVID-19 vaccines, describing clinical, analytical and neuroimaging findings and health outcomes. METHODS: We carried out a review through bibliographic searches in PubMed. RESULTS: We found 86 articles, including 13 809 patients with a wide spectrum of neurological manifestations temporally associated with COVID-19 vaccination. Most occurred in women (63.89%), with a median age of 50 years. The most frequently reported adverse events were Bell's palsy 4936/13 809 (35.7%), headache (4067/13 809), cerebrovascular events 2412/13 809 (17.47%), Guillain-Barre syndrome 868/13 809 (6.28%), central nervous system demyelination 258/13 809 (1.86%) and functional neurological disorder 398/13 809 (2.88%). Most of the published cases occurred in temporal association with the Pfizer vaccine (BNT162b2), followed by the AstraZeneca vaccine (ChAdOX1-S). CONCLUSIONS: It is not possible to establish a causal relationship between these adverse events and COVID-19 vaccines with the currently existing data, nor to calculate the frequency of appearance of these disorders. However, it is necessary for health professionals to be familiar with these events, facilitating their early diagnosis and treatment. Large controlled epidemiological studies are necessary to establish a possible causal relationship between vaccination against COVID-19 and neurological adverse events. CI - Copyright (c) 2022. Published by Elsevier Espana, S.L.U. FAU - Alonso Castillo, R AU - Alonso Castillo R AD - Servicio de Neurologia, Hospital Universitario Ramon y Cajal, Universidad de Alcala, Madrid, Spain. FAU - Martinez Castrillo, J C AU - Martinez Castrillo JC AD - Servicio de Neurologia, Hospital Universitario Ramon y Cajal, Universidad de Alcala, Madrid, Spain. Electronic address: jcmcastrillo@gmail.com. LA - eng PT - Journal Article PT - Review DEP - 20221023 PL - Spain TA - Neurologia (Engl Ed) JT - Neurologia JID - 101778590 RN - 0 (COVID-19 Vaccines) RN - B5S3K2V0G8 (ChAdOx1 nCoV-19) RN - 0 (BNT162 Vaccine) SB - IM MH - Humans MH - *COVID-19 Vaccines/adverse effects MH - *Nervous System Diseases/chemically induced/etiology MH - *COVID-19/prevention & control MH - Female MH - Middle Aged MH - Male MH - Headache/etiology MH - ChAdOx1 nCoV-19/adverse effects MH - BNT162 Vaccine/adverse effects MH - Guillain-Barre Syndrome/etiology MH - SARS-CoV-2 MH - Adult MH - Bell Palsy/etiology PMC - PMC9595420 OTO - NOTNLM OT - Adverse event OT - COVID-19 vaccines OT - Evento adverso OT - Manifestaciones neurologicas OT - Neurological manifestations OT - Neurological pathology OT - Patologia neurologica OT - SARS-COV-2 vaccines OT - Safety OT - Seguridad OT - Vacunas COVID-19 OT - Vacunas SARS-COV-2 EDAT- 2022/10/27 06:00 MHDA- 2025/01/28 00:21 PMCR- 2022/10/23 CRDT- 2022/10/26 19:23 PHST- 2022/07/22 00:00 [received] PHST- 2022/09/28 00:00 [accepted] PHST- 2025/01/28 00:21 [medline] PHST- 2022/10/27 06:00 [pubmed] PHST- 2022/10/26 19:23 [entrez] PHST- 2022/10/23 00:00 [pmc-release] AID - S2173-5808(22)00141-9 [pii] AID - 10.1016/j.nrleng.2022.09.007 [doi] PST - ppublish SO - Neurologia (Engl Ed). 2025 Jan-Feb;40(1):66-76. doi: 10.1016/j.nrleng.2022.09.007. Epub 2022 Oct 23. PMID- 36284639 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240906 IS - 2475-0379 (Electronic) IS - 2475-0379 (Linking) VI - 6 IP - 7 DP - 2022 Oct TI - Hereditary thrombotic thrombocytopenic purpura and COVID-19: Impacts of vaccination and infection in this rare disease. PG - e12814 LID - 10.1002/rth2.12814 [doi] LID - e12814 AB - INTRODUCTION: Severe COVID-19 is associated with an important increase of von Willebrand factor and mild lowering of ADAMTS13 activity that may, in the presence of a strong inflammatory reaction, increase the risk of acute thrombotic thrombocytopenic purpura (TTP). Although acute episodes of immune-mediated TTP associated with COVID-19 or SARS-CoV-2 vaccination have been reported, data about clinical evolution of hereditary TTP (hTTP) during the pandemic are scarce. METHOD: We conducted a survey among adult patients of the International Hereditary TTP Registry about SARS-CoV-2 vaccination, COVID-19, and occurrence of acute hTTP episodes. RESULTS: Of 122 adult hTTP patients invited to participate, 86 (70.5%) responded. Sixty-five had been vaccinated (75.6%), of which 14 had received in addition a booster, resulting in 139 individual vaccine shots. Although vaccinations in patients on plasma prophylaxis were done within 1 week of the last plasma infusion, all 23 patients treated with plasma on demand were vaccinated without prior plasma infusions. One patient on uninterrupted weekly plasma infusions presented within 3 days from his second vaccination with neurological symptoms and computed tomography scan 9 days later showed subacute ischemic/hemorrhagic frontal lobe infarction. A second male patient developed acute myocarditis after his second dose of mRNA-1273 vaccine. Twelve (14%) patients had COVID-19, associated with an acute hTTP episode in three of them: one patient had a transient ischemic attack, one a stroke, and a pregnant woman was hospitalized to intensify plasma treatment. DISCUSSION: The risk of an acute episode triggered by COVID-19 seems higher than following vaccination in hTTP patients, who can be safely vaccinated against SARS-CoV-2. CI - (c) 2022 The Authors. Research and Practice in Thrombosis and Haemostasis published by Wiley Periodicals LLC on behalf of International Society on Thrombosis and Haemostasis (ISTH). FAU - Tarasco, Erika AU - Tarasco E AUID- ORCID: 0000-0002-4387-8476 AD - Department of Hematology and Central Hematology Laboratory Inselspital, Bern University Hospital Bern Switzerland. AD - Department for BioMedical Research (DBMR) University of Bern Bern Switzerland. FAU - von Krogh, Anne Sophie AU - von Krogh AS AD - Department of Hematology St. Olavs Hospital, Trondheim University Hospital Trondheim Norway. AD - Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences Norwegian University of Science and Technology Trondheim Norway. FAU - Hrdlickova, Radomira AU - Hrdlickova R AD - Blood Center University Hospital Ostrava Ostrava Czech Republic. FAU - Braschler, Thomas R AU - Braschler TR AD - Center for Clinical Hematology Luzerne Kantonsspital Lucerne Switzerland. FAU - Iwaniec, Teresa AU - Iwaniec T AD - Department of Hematology Jagiellonian University Medical College Krakow Poland. FAU - Knobl, Paul N AU - Knobl PN AUID- ORCID: 0000-0002-7909-7225 AD - Division of Hematology and Hemostasis, Department of Medicine I Medical University of Vienna Vienna Austria. FAU - Hamada, Eriko AU - Hamada E AUID- ORCID: 0000-0003-0913-2475 AD - Department of Blood Transfusion Medicine Nara Medical University Kashihara Japan. FAU - Pikovsky, Oleg AU - Pikovsky O AD - Transfusion Medicine Institute, Faculty of Health Sciences, Ben-Gurion University of the Negev Soroka University Medical Center Beer-Sheva Israel. FAU - Farese, Stefan AU - Farese S AD - Department of Nephrology Burgerspital Solothurn Switzerland. FAU - Gutwein, Odit AU - Gutwein O AD - Department of Hematology Shamir Medical Center Zerifin Israel. FAU - Kessler, Petr AU - Kessler P AD - Department of Hematology and Transfusion Medicine Hospital Pelhrimov Pelhrimov Czech Republic. FAU - Schultz, Nina H AU - Schultz NH AD - Department of Hematology Oslo University Hospital Oslo Norway. FAU - von Auer, Charis AU - von Auer C AD - Department of Hematology, Oncology, and Pneumology, Center for Thrombosis and Hemostasis University Medical Center Mainz Mainz Germany. FAU - Windyga, Jerzy AU - Windyga J AD - Department of Haemostasis Disorders and Internal Medicine Institute of Hematology and Transfusion Medicine Warsaw Poland. FAU - Friedman, Kenneth AU - Friedman K AD - Division of Hematology and Oncology, Versiti Blood Center of Wisconsin Medical College of Wisconsin Milwaukee Wisconsin USA. FAU - Hrachovinova, Ingrid AU - Hrachovinova I AUID- ORCID: 0000-0003-0300-2063 AD - Institute of Hematology and Blood Transfusion Prague Czech Republic. FAU - George, James N AU - George JN AD - Department of Biostatistics & Epidemiology College of Public Health, University of Oklahoma Health Sciences Center Oklahoma City Oklahoma USA. FAU - Matsumoto, Masanori AU - Matsumoto M AUID- ORCID: 0000-0002-7243-3126 AD - Department of Blood Transfusion Medicine Nara Medical University Kashihara Japan. FAU - Schneppenheim, Reinhard AU - Schneppenheim R AD - Department of Pediatric Hematology and Oncology University Medical Center Hamburg-Eppendorf Hamburg Germany. FAU - Lammle, Bernhard AU - Lammle B AUID- ORCID: 0000-0003-4538-5154 AD - Department of Hematology and Central Hematology Laboratory Inselspital, Bern University Hospital Bern Switzerland. AD - Center for Thrombosis and Hemostasis University Medical Center Mainz Mainz Germany. FAU - Kremer Hovinga, Johanna Anna AU - Kremer Hovinga JA AUID- ORCID: 0000-0002-1300-7135 AD - Department of Hematology and Central Hematology Laboratory Inselspital, Bern University Hospital Bern Switzerland. AD - Department for BioMedical Research (DBMR) University of Bern Bern Switzerland. LA - eng PT - Journal Article DEP - 20221021 PL - United States TA - Res Pract Thromb Haemost JT - Research and practice in thrombosis and haemostasis JID - 101703775 PMC - PMC9585384 OTO - NOTNLM OT - COVID-19 OT - SARS-CoV-2 OT - congenital thrombotic thrombocytopenic purpura (cTTP) OT - hereditary thrombotic thrombocytopenic purpura (hTTP) OT - vaccines EDAT- 2022/10/27 06:00 MHDA- 2022/10/27 06:01 PMCR- 2022/10/21 CRDT- 2022/10/26 02:06 PHST- 2022/04/08 00:00 [received] PHST- 2022/06/17 00:00 [revised] PHST- 2022/07/25 00:00 [accepted] PHST- 2022/10/26 02:06 [entrez] PHST- 2022/10/27 06:00 [pubmed] PHST- 2022/10/27 06:01 [medline] PHST- 2022/10/21 00:00 [pmc-release] AID - S2475-0379(22)02450-5 [pii] AID - RTH212814 [pii] AID - 10.1002/rth2.12814 [doi] PST - epublish SO - Res Pract Thromb Haemost. 2022 Oct 21;6(7):e12814. doi: 10.1002/rth2.12814. eCollection 2022 Oct. PMID- 36282593 OWN - NLM STAT- MEDLINE DCOM- 20221214 LR - 20230918 IS - 2379-3708 (Electronic) IS - 2379-3708 (Linking) VI - 7 IP - 22 DP - 2022 Nov 22 TI - Consecutive BNT162b2 mRNA vaccination induces short-term epigenetic memory in innate immune cells. LID - 10.1172/jci.insight.163347 [doi] LID - e163347 AB - Consecutive mRNA vaccinations against SARS-CoV-2 reinforced both innate and adaptive immune responses. However, it remains unclear whether the enhanced innate immune responses are mediated by epigenetic regulation and, if so, whether these effects persist. Using mass cytometry, RNA-Seq, and ATAC-Seq, we show that BNT162b2 mRNA vaccination upregulated antiviral and IFN-stimulated gene expression in monocytes with greater effects after the second vaccination than those after the first vaccination. Transcription factor-binding motif analysis also revealed enriched IFN regulatory factors and PU.1 motifs in accessible chromatin regions. Importantly, although consecutive BNT162b2 mRNA vaccinations boosted innate immune responses and caused epigenetic changes in isolated monocytes, we show that these effects occurred only transiently and disappeared 4 weeks after the second vaccination. Furthermore, single-cell RNA-Seq analysis revealed that a similar gene signature was impaired in the monocytes of unvaccinated patients with COVID-19 with acute respiratory distress syndrome. These results reinforce the importance of the innate immune response in the determination of COVID-19 severity but indicate that, unlike adaptive immunity, innate immunity is not unexpectedly sustained even after consecutive vaccination. This study, which focuses on innate immune memory, may provide novel insights into the vaccine development against infectious diseases. FAU - Yamaguchi, Yuta AU - Yamaguchi Y AD - Immunopathology, WPI Immunology Frontier Research Center, Osaka University, Suita, Japan. AD - Department of Respiratory Medicine and Clinical Immunology and. FAU - Kato, Yasuhiro AU - Kato Y AD - Immunopathology, WPI Immunology Frontier Research Center, Osaka University, Suita, Japan. AD - Department of Respiratory Medicine and Clinical Immunology and. FAU - Edahiro, Ryuya AU - Edahiro R AD - Department of Respiratory Medicine and Clinical Immunology and. AD - Department of Statistical Genetics, Osaka University Graduate School of Medicine, Suita, Japan. FAU - Sondergaard, Jonas N AU - Sondergaard JN AD - Human Immunology Team, Center for Infectious Diseases Education and Research. FAU - Murakami, Teruaki AU - Murakami T AD - Immunopathology, WPI Immunology Frontier Research Center, Osaka University, Suita, Japan. AD - Department of Respiratory Medicine and Clinical Immunology and. FAU - Amiya, Saori AU - Amiya S AD - Immunopathology, WPI Immunology Frontier Research Center, Osaka University, Suita, Japan. AD - Department of Respiratory Medicine and Clinical Immunology and. FAU - Nameki, Shinichiro AU - Nameki S AD - Immunopathology, WPI Immunology Frontier Research Center, Osaka University, Suita, Japan. AD - Department of Respiratory Medicine and Clinical Immunology and. FAU - Yoshimine, Yuko AU - Yoshimine Y AD - Immunopathology, WPI Immunology Frontier Research Center, Osaka University, Suita, Japan. AD - Department of Respiratory Medicine and Clinical Immunology and. FAU - Morita, Takayoshi AU - Morita T AD - Immunopathology, WPI Immunology Frontier Research Center, Osaka University, Suita, Japan. AD - Department of Respiratory Medicine and Clinical Immunology and. FAU - Takeshima, Yusuke AU - Takeshima Y AD - Laboratory of Experimental Immunology, WPI Immunology Frontier Research Center. FAU - Sakakibara, Shuhei AU - Sakakibara S AD - Laboratory of Immune Regulation, WPI Immunology Frontier Research Center. FAU - Naito, Yoko AU - Naito Y AD - Genome Information Research Center, Research Institute for Microbial Diseases. FAU - Motooka, Daisuke AU - Motooka D AD - Genome Information Research Center, Research Institute for Microbial Diseases. AD - Single Cell Genomics, Human Immunology, WPI Immunology Frontier Research Center. AD - Integrated Frontier Research for Medical Science Division, Institute for Open and Transdisciplinary Research Initiatives. FAU - Liu, Yu-Chen AU - Liu YC AD - Single Cell Genomics, Human Immunology, WPI Immunology Frontier Research Center. FAU - Shirai, Yuya AU - Shirai Y AD - Department of Respiratory Medicine and Clinical Immunology and. AD - Department of Statistical Genetics, Osaka University Graduate School of Medicine, Suita, Japan. FAU - Okita, Yasutaka AU - Okita Y AD - Immunopathology, WPI Immunology Frontier Research Center, Osaka University, Suita, Japan. AD - Department of Respiratory Medicine and Clinical Immunology and. FAU - Fujimoto, Jun AU - Fujimoto J AD - Immunopathology, WPI Immunology Frontier Research Center, Osaka University, Suita, Japan. AD - Department of Respiratory Medicine and Clinical Immunology and. FAU - Hirata, Haruhiko AU - Hirata H AD - Department of Respiratory Medicine and Clinical Immunology and. FAU - Takeda, Yoshito AU - Takeda Y AD - Department of Respiratory Medicine and Clinical Immunology and. FAU - Wing, James B AU - Wing JB AD - Human Immunology Team, Center for Infectious Diseases Education and Research. AD - Single Cell Immunology, Human Immunology, WPI Immunology Frontier Research Center. FAU - Okuzaki, Daisuke AU - Okuzaki D AD - Genome Information Research Center, Research Institute for Microbial Diseases. AD - Single Cell Genomics, Human Immunology, WPI Immunology Frontier Research Center. AD - Integrated Frontier Research for Medical Science Division, Institute for Open and Transdisciplinary Research Initiatives. AD - Center for Infectious Diseases Education and Research, and. FAU - Okada, Yukinori AU - Okada Y AD - Department of Statistical Genetics, Osaka University Graduate School of Medicine, Suita, Japan. AD - Integrated Frontier Research for Medical Science Division, Institute for Open and Transdisciplinary Research Initiatives. AD - Center for Infectious Diseases Education and Research, and. AD - Statistical Immunology, WPI Immunology Frontier Research Center, Osaka University, Osaka, Japan. AD - Laboratory for Systems Genetics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan. FAU - Kumanogoh, Atsushi AU - Kumanogoh A AD - Immunopathology, WPI Immunology Frontier Research Center, Osaka University, Suita, Japan. AD - Department of Respiratory Medicine and Clinical Immunology and. AD - Integrated Frontier Research for Medical Science Division, Institute for Open and Transdisciplinary Research Initiatives. AD - Center for Infectious Diseases Education and Research, and. AD - Japan Agency for Medical Research and Development - Core Research for Evolutional Science and Technology, Osaka University, Osaka, Japan. AD - Center for Advanced Modalities and DDS, Osaka University, Osaka, Suita, Japan. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20221122 PL - United States TA - JCI Insight JT - JCI insight JID - 101676073 RN - 0 (RNA, Messenger) RN - 0 (BNT162 Vaccine) SB - IM MH - Humans MH - RNA, Messenger MH - *BNT162 Vaccine MH - Epigenesis, Genetic MH - Epigenetic Memory MH - SARS-CoV-2 MH - *COVID-19/prevention & control MH - Immunity, Innate PMC - PMC9746816 OTO - NOTNLM OT - COVID-19 OT - Cellular immune response OT - Epigenetics OT - Innate immunity OT - Vaccines COIS- Conflict of interest: The authors have declared that no conflict of interest exists. EDAT- 2022/10/26 06:00 MHDA- 2022/12/15 06:00 PMCR- 2022/11/22 CRDT- 2022/10/25 12:03 PHST- 2022/07/06 00:00 [received] PHST- 2022/10/07 00:00 [accepted] PHST- 2022/10/26 06:00 [pubmed] PHST- 2022/12/15 06:00 [medline] PHST- 2022/10/25 12:03 [entrez] PHST- 2022/11/22 00:00 [pmc-release] AID - 163347 [pii] AID - 10.1172/jci.insight.163347 [doi] PST - epublish SO - JCI Insight. 2022 Nov 22;7(22):e163347. doi: 10.1172/jci.insight.163347. PMID- 36257313 OWN - NLM STAT- MEDLINE DCOM- 20221116 LR - 20260127 IS - 1097-4172 (Electronic) IS - 0092-8674 (Print) IS - 0092-8674 (Linking) VI - 185 IP - 23 DP - 2022 Nov 10 TI - Interval between prior SARS-CoV-2 infection and booster vaccination impacts magnitude and quality of antibody and B cell responses. PG - 4333-4346.e14 LID - S0092-8674(22)01251-X [pii] LID - 10.1016/j.cell.2022.09.032 [doi] AB - SARS-CoV-2 mRNA booster vaccines provide protection from severe disease, eliciting strong immunity that is further boosted by previous infection. However, it is unclear whether these immune responses are affected by the interval between infection and vaccination. Over a 2-month period, we evaluated antibody and B cell responses to a third-dose mRNA vaccine in 66 individuals with different infection histories. Uninfected and post-boost but not previously infected individuals mounted robust ancestral and variant spike-binding and neutralizing antibodies and memory B cells. Spike-specific B cell responses from recent infection (<180 days) were elevated at pre-boost but comparatively less so at 60 days post-boost compared with uninfected individuals, and these differences were linked to baseline frequencies of CD27(lo) B cells. Day 60 to baseline ratio of BCR signaling measured by phosphorylation of Syk was inversely correlated to days between infection and vaccination. Thus, B cell responses to booster vaccines are impeded by recent infection. CI - Published by Elsevier Inc. FAU - Buckner, Clarisa M AU - Buckner CM AD - Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. FAU - Kardava, Lela AU - Kardava L AD - Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. FAU - El Merhebi, Omar AU - El Merhebi O AD - Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. FAU - Narpala, Sandeep R AU - Narpala SR AD - Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. FAU - Serebryannyy, Leonid AU - Serebryannyy L AD - Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. FAU - Lin, Bob C AU - Lin BC AD - Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. FAU - Wang, Wei AU - Wang W AD - Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. FAU - Zhang, Xiaozhen AU - Zhang X AD - Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. FAU - Lopes de Assis, Felipe AU - Lopes de Assis F AD - Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. FAU - Kelly, Sophie E M AU - Kelly SEM AD - Bioengineering and Physical Sciences Shared Resource, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, MD 20892, USA. FAU - Teng, I-Ting AU - Teng IT AD - Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. FAU - McCormack, Genevieve E AU - McCormack GE AD - Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. FAU - Praiss, Lauren H AU - Praiss LH AD - Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. FAU - Seamon, Catherine A AU - Seamon CA AD - Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA. FAU - Rai, M Ali AU - Rai MA AD - Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. FAU - Kalish, Heather AU - Kalish H AD - Bioengineering and Physical Sciences Shared Resource, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, MD 20892, USA. FAU - Kwong, Peter D AU - Kwong PD AD - Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. FAU - Proschan, Michael A AU - Proschan MA AD - Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. FAU - McDermott, Adrian B AU - McDermott AB AD - Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. FAU - Fauci, Anthony S AU - Fauci AS AD - Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. FAU - Chun, Tae-Wook AU - Chun TW AD - Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. FAU - Moir, Susan AU - Moir S AD - Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. Electronic address: smoir@niaid.nih.gov. LA - eng GR - ZIA AI001325/ImNIH/Intramural NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Intramural DEP - 20220927 PL - United States TA - Cell JT - Cell JID - 0413066 RN - 0 (Antibodies, Neutralizing) RN - 0 (Antibodies, Viral) RN - 0 (COVID-19 Vaccines) RN - 0 (Viral Vaccines) RN - 0 (mRNA Vaccines) SB - IM UOF - medRxiv. 2022 Aug 31:2022.08.30.22279344. doi: 10.1101/2022.08.30.22279344. PMID: 36093348 MH - Humans MH - Antibodies, Neutralizing MH - Antibodies, Viral MH - *COVID-19/prevention & control MH - COVID-19 Vaccines MH - SARS-CoV-2 MH - Vaccination MH - *Viral Vaccines MH - *B-Lymphocytes/immunology MH - mRNA Vaccines PMC - PMC9513331 MID - NIHMS1839216 OTO - NOTNLM OT - SARS-CoV-2 OT - antibodies OT - booster vaccination OT - hybrid immunity OT - infection OT - mRNA vaccines OT - memory B cells OT - variants COIS- Declaration of interests The authors declare no competing interests. EDAT- 2022/10/19 06:00 MHDA- 2022/11/16 06:00 PMCR- 2022/09/27 CRDT- 2022/10/18 18:52 PHST- 2022/08/18 00:00 [received] PHST- 2022/09/15 00:00 [revised] PHST- 2022/09/23 00:00 [accepted] PHST- 2022/10/19 06:00 [pubmed] PHST- 2022/11/16 06:00 [medline] PHST- 2022/10/18 18:52 [entrez] PHST- 2022/09/27 00:00 [pmc-release] AID - S0092-8674(22)01251-X [pii] AID - 10.1016/j.cell.2022.09.032 [doi] PST - ppublish SO - Cell. 2022 Nov 10;185(23):4333-4346.e14. doi: 10.1016/j.cell.2022.09.032. Epub 2022 Sep 27. PMID- 36248803 OWN - NLM STAT- MEDLINE DCOM- 20221018 LR - 20260127 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 13 DP - 2022 TI - The third dose of mRNA SARS-CoV-2 vaccines enhances the spike-specific antibody and memory B cell response in myelofibrosis patients. PG - 1017863 LID - 10.3389/fimmu.2022.1017863 [doi] LID - 1017863 AB - Vaccination against SARS-CoV-2 using mRNA-based vaccines has been highly recommended for fragile subjects, including myelofibrosis patients (MF). Available data on the immune responsiveness of MF patients to mRNA SARS-CoV-2 vaccination, and the impact of the therapy with the JAK inhibitor ruxolitinib, are still fragmented. Here, we profile the spike-specific IgG and memory B-cell response in MF patients, treated or not with ruxolitinib, after the second and the third dose of SARS-CoV-2 BNT162b2 (BioNTech) and mRNA-1273 (Moderna) vaccines. Plasma and peripheral blood mononuclear cells samples were collected before vaccination, post the second and the third doses and tested for spike-specific antibodies, ACE2/RBD antibody inhibition binding activity and spike-specific B cells. The third vaccine dose significantly increased the spike-specific IgG titers in both ruxolitinib-treated and untreated patients, and strongly enhanced the percentage of subjects with antibodies capable of in vitro blocking ACE2/RBD interaction, from 50% up to 80%. While a very low frequency of spike-specific B cells was measured in blood 7 days after the second vaccination dose, a strong and significant increase was elicited by the third dose administration, generating a B cell response similar to the one detected in healthy controls. Despite the overall positive impact of the third dose in MF patients, two patients that were under active concomitant immunosuppressive treatment at the time of vaccination, and a patient that received lymphodepleting therapies in the past, remained low responders. The third mRNA vaccine dose strongly increases the SARS-CoV-2 specific humoral and B cell responses in MF patients, promoting a reactivation of the immune response similar to the one observed in healthy controls. CI - Copyright (c) 2022 Fiorino, Ciabattini, Sicuranza, Pastore, Santoni, Simoncelli, Polvere, Galimberti, Barate, Sammartano, Montagnani, Bocchia and Medaglini. FAU - Fiorino, Fabio AU - Fiorino F AD - Laboratory of Molecular Microbiology and Biotechnology, Department of Medical Biotechnologies, University of Siena, Siena, Italy. FAU - Ciabattini, Annalisa AU - Ciabattini A AD - Laboratory of Molecular Microbiology and Biotechnology, Department of Medical Biotechnologies, University of Siena, Siena, Italy. FAU - Sicuranza, Anna AU - Sicuranza A AD - Hematology Unit, Department of Medical Science, Surgery and Neuroscience, Azienda Ospedaliero Universitaria Senese, University of Siena, Siena, Italy. FAU - Pastore, Gabiria AU - Pastore G AD - Laboratory of Molecular Microbiology and Biotechnology, Department of Medical Biotechnologies, University of Siena, Siena, Italy. FAU - Santoni, Adele AU - Santoni A AD - Hematology Unit, Department of Medical Science, Surgery and Neuroscience, Azienda Ospedaliero Universitaria Senese, University of Siena, Siena, Italy. FAU - Simoncelli, Martina AU - Simoncelli M AD - Hematology Unit, Department of Medical Science, Surgery and Neuroscience, Azienda Ospedaliero Universitaria Senese, University of Siena, Siena, Italy. FAU - Polvere, Jacopo AU - Polvere J AD - Laboratory of Molecular Microbiology and Biotechnology, Department of Medical Biotechnologies, University of Siena, Siena, Italy. FAU - Galimberti, Sara AU - Galimberti S AD - Section of Hematology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy. FAU - Barate, Claudia AU - Barate C AD - Section of Hematology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy. FAU - Sammartano, Vincenzo AU - Sammartano V AD - Hematology Unit, Department of Medical Science, Surgery and Neuroscience, Azienda Ospedaliero Universitaria Senese, University of Siena, Siena, Italy. FAU - Montagnani, Francesca AU - Montagnani F AD - Department of Medical Biotechnologies, University of Siena, Siena, Italy. AD - Department of Medical Sciences, Infectious and Tropical Diseases Unit, Azienda Ospedaliero Universitaria Senese, University Hospital of Siena, Siena, Italy. FAU - Bocchia, Monica AU - Bocchia M AD - Hematology Unit, Department of Medical Science, Surgery and Neuroscience, Azienda Ospedaliero Universitaria Senese, University of Siena, Siena, Italy. FAU - Medaglini, Donata AU - Medaglini D AD - Laboratory of Molecular Microbiology and Biotechnology, Department of Medical Biotechnologies, University of Siena, Siena, Italy. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220929 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 RN - EC 3.4.17.23 (Angiotensin-Converting Enzyme 2) RN - 0 (Antibodies, Viral) RN - 0 (BNT162 Vaccine) RN - 0 (COVID-19 Vaccines) RN - 0 (Immunoglobulin G) RN - 0 (Janus Kinase Inhibitors) RN - 0 (Nitriles) RN - 0 (Pyrazoles) RN - 0 (Pyrimidines) RN - 0 (RNA, Messenger) RN - 0 (Spike Glycoprotein, Coronavirus) RN - 0 (Vaccines, Synthetic) RN - 0 (Viral Vaccines) RN - 0 (mRNA Vaccines) RN - 0 (spike protein, SARS-CoV-2) RN - 82S8X8XX8H (ruxolitinib) SB - IM MH - Angiotensin-Converting Enzyme 2 MH - Antibodies, Viral MH - BNT162 Vaccine MH - *COVID-19/prevention & control MH - COVID-19 Vaccines MH - Humans MH - Immunoglobulin G MH - *Janus Kinase Inhibitors MH - Leukocytes, Mononuclear MH - Memory B Cells MH - Nitriles MH - *Primary Myelofibrosis MH - Pyrazoles MH - Pyrimidines MH - RNA, Messenger MH - SARS-CoV-2 MH - Spike Glycoprotein, Coronavirus/*immunology MH - Vaccines, Synthetic MH - *Viral Vaccines MH - mRNA Vaccines PMC - PMC9556722 OTO - NOTNLM OT - B-cell response OT - COVID-19 OT - antibody response OT - mRNA SARS-CoV-2 vaccination OT - myelofibrosis OT - ruxolitinib OT - third booster dose COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/10/18 06:00 MHDA- 2022/10/19 06:00 PMCR- 2022/09/29 CRDT- 2022/10/17 05:13 PHST- 2022/08/12 00:00 [received] PHST- 2022/09/06 00:00 [accepted] PHST- 2022/10/17 05:13 [entrez] PHST- 2022/10/18 06:00 [pubmed] PHST- 2022/10/19 06:00 [medline] PHST- 2022/09/29 00:00 [pmc-release] AID - 10.3389/fimmu.2022.1017863 [doi] PST - epublish SO - Front Immunol. 2022 Sep 29;13:1017863. doi: 10.3389/fimmu.2022.1017863. eCollection 2022. PMID- 36232710 OWN - NLM STAT- MEDLINE DCOM- 20221017 LR - 20230308 IS - 1422-0067 (Electronic) IS - 1422-0067 (Linking) VI - 23 IP - 19 DP - 2022 Sep 27 TI - Comparison of Homologous and Heterologous Booster SARS-CoV-2 Vaccination in Autoimmune Rheumatic and Musculoskeletal Patients. LID - 10.3390/ijms231911411 [doi] LID - 11411 AB - Vaccination against SARS-CoV-2 to prevent COVID-19 is highly recommended for immunocompromised patients with autoimmune rheumatic and musculoskeletal diseases (aiRMDs). Little is known about the effect of booster vaccination or infection followed by previously completed two-dose vaccination in aiRMDs. We determined neutralizing anti-SARS-CoV-2 antibody levels and applied flow cytometric immunophenotyping to quantify the SARS-CoV-2 reactive B- and T-cell mediated immunity in aiRMDs receiving homologous or heterologous boosters or acquired infection following vaccination. Patients receiving a heterologous booster had a higher proportion of IgM+ SARS-CoV-2 S+ CD19+CD27+ peripheral memory B-cells in comparison to those who acquired infection. Biologic therapy decreased the number of S+CD19+; S+CD19+CD27+IgG+; and S+CD19+CD27+IgM+ B-cells. The response rate to a booster event in cellular immunity was the highest in the S-, M-, and N-reactive CD4+CD40L+ T-cell subset. Patients with a disease duration of more than 10 years had higher proportions of CD8+TNF-alpha+ and CD8+IFN-gamma+ T-cells in comparison to patients who were diagnosed less than 10 years ago. We detected neutralizing antibodies, S+ reactive peripheral memory B-cells, and five S-, M-, and N-reactive T-cells subsets in our patient cohort showing the importance of booster events. Biologic therapy and <10 years disease duration may confound anti-SARS-CoV-2 specific immunity in aiRMDs. FAU - Honfi, Daniel AU - Honfi D AD - Department of Rheumatology and Immunology, Faculty of Medicine, Albert Szent-Gyorgyi Health Centre, University of Szeged, H6725 Szeged, Hungary. FAU - Gemes, Nikolett AU - Gemes N AD - Biological Research Centre, H6726 Szeged, Hungary. AD - PhD School in Biology, University of Szeged, H6726 Szeged, Hungary. FAU - Szabo, Eniko AU - Szabo E AD - Biological Research Centre, H6726 Szeged, Hungary. FAU - Neuperger, Patricia AU - Neuperger P AD - Biological Research Centre, H6726 Szeged, Hungary. AD - PhD School in Biology, University of Szeged, H6726 Szeged, Hungary. FAU - Balog, Jozsef A AU - Balog JA AUID- ORCID: 0000-0001-8208-9157 AD - Biological Research Centre, H6726 Szeged, Hungary. AD - PhD School in Biology, University of Szeged, H6726 Szeged, Hungary. FAU - Nagy, Lajos I AU - Nagy LI AD - Avidin Ltd., H6726 Szeged, Hungary. FAU - Toldi, Gergely AU - Toldi G AUID- ORCID: 0000-0003-0178-1243 AD - Liggins Institute, University of Auckland, Auckland 1023, New Zealand. FAU - Puskas, Laszlo G AU - Puskas LG AD - Biological Research Centre, H6726 Szeged, Hungary. AD - Avidin Ltd., H6726 Szeged, Hungary. FAU - Szebeni, Gabor J AU - Szebeni GJ AUID- ORCID: 0000-0002-6998-5632 AD - Biological Research Centre, H6726 Szeged, Hungary. AD - Department of Physiology, Anatomy and Neuroscience, Faculty of Science and Informatics, University of Szeged, H6726 Szeged, Hungary. AD - CS-Smartlab Devices, H7761 Kozarmisleny, Hungary. FAU - Balog, Attila AU - Balog A AD - Department of Rheumatology and Immunology, Faculty of Medicine, Albert Szent-Gyorgyi Health Centre, University of Szeged, H6725 Szeged, Hungary. LA - eng GR - 2020-1.1.6-JOVO-2021-0000/National Research, Development, and Innovation Office/ GR - C1764415/Ministry of Innovation and Technology, financed by the National Research, Development, and Innovation Fund/ GR - BO/00582/22/8/Janos Bolyai Research Scholarship of the Hungarian Academy of Sciences/ PT - Journal Article DEP - 20220927 PL - Switzerland TA - Int J Mol Sci JT - International journal of molecular sciences JID - 101092791 RN - 0 (Antibodies, Neutralizing) RN - 0 (Antibodies, Viral) RN - 0 (COVID-19 Vaccines) RN - 0 (Immunoglobulin G) RN - 0 (Immunoglobulin M) RN - 0 (Tumor Necrosis Factor-alpha) RN - 147205-72-9 (CD40 Ligand) SB - IM MH - Antibodies, Neutralizing MH - Antibodies, Viral MH - CD40 Ligand MH - *COVID-19/prevention & control MH - COVID-19 Vaccines MH - Humans MH - Immunoglobulin G MH - Immunoglobulin M MH - *SARS-CoV-2 MH - Tumor Necrosis Factor-alpha MH - Vaccination PMC - PMC9569441 OTO - NOTNLM OT - SARS-CoV-2 booster vaccination OT - SARS-CoV-2 specific T-cell immunity OT - SARS-CoV-2 specific peripheral B-cell memory OT - anti-Spike (RBD) antibodies OT - rheumatic and musculoskeletal diseases COIS- LIN is an employee at Avidin Ltd. LGP is the CEO of Avidin Ltd. GJS is an employee at CS-Smartlab-Devices Ltd. The authors declare no conflict of interest. EDAT- 2022/10/15 06:00 MHDA- 2022/10/18 06:00 PMCR- 2022/09/27 CRDT- 2022/10/14 02:09 PHST- 2022/08/14 00:00 [received] PHST- 2022/09/17 00:00 [revised] PHST- 2022/09/22 00:00 [accepted] PHST- 2022/10/14 02:09 [entrez] PHST- 2022/10/15 06:00 [pubmed] PHST- 2022/10/18 06:00 [medline] PHST- 2022/09/27 00:00 [pmc-release] AID - ijms231911411 [pii] AID - ijms-23-11411 [pii] AID - 10.3390/ijms231911411 [doi] PST - epublish SO - Int J Mol Sci. 2022 Sep 27;23(19):11411. doi: 10.3390/ijms231911411. PMID- 36231717 OWN - NLM STAT- MEDLINE DCOM- 20221017 LR - 20250623 IS - 1660-4601 (Electronic) IS - 1661-7827 (Print) IS - 1660-4601 (Linking) VI - 19 IP - 19 DP - 2022 Sep 29 TI - Effect of COVID-19 Vaccines on Reducing the Risk of Long COVID in the Real World: A Systematic Review and Meta-Analysis. LID - 10.3390/ijerph191912422 [doi] LID - 12422 AB - The coronavirus disease 2019 (COVID-19) is still in a global pandemic state. Some studies have reported that COVID-19 vaccines had a protective effect against long COVID. However, the conclusions of the studies on the effect of COVID-19 vaccines on long COVID were not consistent. This study aimed to systematically review relevant studies in the real world, and performed a meta-analysis to explore the relationship between vaccination and long COVID. We systematically searched PubMed, Embase, Web of science, and ScienceDirect from inception to 19 September 2022. The PICO (P: patients; I: intervention; C: comparison; O: outcome) was as follows: patients diagnosed with COVID-19 (P); vaccination with COVID-19 vaccines (I); the patients were divided into vaccinated and unvaccinated groups (C); the outcomes were the occurrence of long COVID, as well as the various symptoms of long COVID (O). A fixed-effect model and random-effects model were chosen based on the heterogeneity between studies in order to pool the effect value. The results showed that the vaccinated group had a 29% lower risk of developing long COVID compared with the unvaccinated group (RR = 0.71, 95% CI: 0.58-0.87, p < 0.01). Compared with patients who were not vaccinated, vaccination showed its protective effect in patients vaccinated with two doses (RR = 0.83, 95% CI: 0.74-0.94, p < 0.01), but not one dose (RR = 0.83, 95% CI: 0.65-1.07, p = 0.14). In addition, vaccination was effective against long COVD in patients either vaccinated before SARS-CoV-2 infection/COVID-19 (RR = 0.82, 95% CI: 0.74-0.91, p < 0.01) or vaccinated after SARS-CoV-2 infection/COVID-19 (RR = 0.83, 95% CI: 0.74-0.92, p < 0.01). For long COVID symptoms, vaccination reduced the risk of cognitive dysfunction/symptoms, kidney diseases/problems, myalgia, and sleeping disorders/problems sleeping. Our study shows that COVID-19 vaccines had an effect on reducing the risk of long COVID in patients vaccinated before or after SARS-CoV-2 infection/COVID-19. We suggest that the vaccination rate should be improved as soon as possible, especially for a complete vaccination course. There should be more studies to explore the basic mechanisms of the protective effect of COVID-19 vaccines on long COVID in the future. FAU - Gao, Peng AU - Gao P AD - Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Xueyuan Road No. 38, Haidian District, Beijing 100191, China. FAU - Liu, Jue AU - Liu J AUID- ORCID: 0000-0002-1938-9365 AD - Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Xueyuan Road No. 38, Haidian District, Beijing 100191, China. AD - Institute for Global Health and Development, Peking University, Yiheyuan Road No. 5, Haidian District, Beijing 100871, China. FAU - Liu, Min AU - Liu M AUID- ORCID: 0000-0002-5059-3743 AD - Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Xueyuan Road No. 38, Haidian District, Beijing 100191, China. LA - eng PT - Journal Article PT - Meta-Analysis PT - Research Support, Non-U.S. Gov't PT - Systematic Review DEP - 20220929 PL - Switzerland TA - Int J Environ Res Public Health JT - International journal of environmental research and public health JID - 101238455 RN - 0 (COVID-19 Vaccines) SB - IM MH - *COVID-19/complications/epidemiology/prevention & control MH - *COVID-19 Vaccines/therapeutic use MH - Humans MH - SARS-CoV-2 MH - Vaccination MH - Post-Acute COVID-19 Syndrome PMC - PMC9566528 OTO - NOTNLM OT - COVID-19 vaccine OT - long COVID OT - meta-analysis OT - post COVID-19 condition OT - systematic review COIS- The authors declare no conflict of interest. EDAT- 2022/10/15 06:00 MHDA- 2022/10/18 06:00 PMCR- 2022/09/29 CRDT- 2022/10/14 02:00 PHST- 2022/09/06 00:00 [received] PHST- 2022/09/26 00:00 [revised] PHST- 2022/09/27 00:00 [accepted] PHST- 2022/10/14 02:00 [entrez] PHST- 2022/10/15 06:00 [pubmed] PHST- 2022/10/18 06:00 [medline] PHST- 2022/09/29 00:00 [pmc-release] AID - ijerph191912422 [pii] AID - ijerph-19-12422 [pii] AID - 10.3390/ijerph191912422 [doi] PST - epublish SO - Int J Environ Res Public Health. 2022 Sep 29;19(19):12422. doi: 10.3390/ijerph191912422. PMID- 36229519 OWN - NLM STAT- MEDLINE DCOM- 20221017 LR - 20230103 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 12 IP - 1 DP - 2022 Oct 13 TI - Immediate protein expression from exogenous mRNAs in embryonic brain. PG - 17145 LID - 10.1038/s41598-022-21668-5 [doi] LID - 17145 AB - mRNA vaccines for SARS-CoV-2 have been widely used and saving millions of people in the world. How efficiently proteins are produced from exogenous mRNAs in the embryonic brain, however, is less known. Here we show that protein expression occurs highly efficiently in neural stem cells, in a very narrow time window after mRNA electroporation in the embryonic mouse brain, where plasmids have been successfully transfected. Protein expression is detected 1 h and 12 h after the electroporation of mRNAs and plasmids, respectively. The delivery of exogenous mRNAs may be useful for not only vaccines but also functional analysis in the brain. CI - (c) 2022. The Author(s). FAU - Naruse, Masae AU - Naruse M AD - Department of Developmental Biology, Graduate School of Medicine, Chiba University, Chiba, 260-8670, Japan. FAU - Saito, Tetsuichiro AU - Saito T AD - Department of Developmental Biology, Graduate School of Medicine, Chiba University, Chiba, 260-8670, Japan. tesaito@faculty.chiba-u.jp. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20221013 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 RN - 0 (COVID-19 Vaccines) RN - 0 (RNA, Messenger) SB - IM MH - Animals MH - Brain/metabolism MH - *COVID-19/genetics MH - *COVID-19 Vaccines MH - Electroporation MH - Humans MH - Mice MH - Plasmids MH - RNA, Messenger/genetics/metabolism MH - SARS-CoV-2 PMC - PMC9558027 COIS- The authors declare no competing interests. EDAT- 2022/10/14 06:00 MHDA- 2022/10/18 06:00 PMCR- 2022/10/13 CRDT- 2022/10/13 23:22 PHST- 2022/05/12 00:00 [received] PHST- 2022/09/29 00:00 [accepted] PHST- 2022/10/13 23:22 [entrez] PHST- 2022/10/14 06:00 [pubmed] PHST- 2022/10/18 06:00 [medline] PHST- 2022/10/13 00:00 [pmc-release] AID - 10.1038/s41598-022-21668-5 [pii] AID - 21668 [pii] AID - 10.1038/s41598-022-21668-5 [doi] PST - epublish SO - Sci Rep. 2022 Oct 13;12(1):17145. doi: 10.1038/s41598-022-21668-5. PMID- 36213920 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20221011 IS - 1664-0640 (Print) IS - 1664-0640 (Electronic) IS - 1664-0640 (Linking) VI - 13 DP - 2022 TI - Believing processes around COVID-19 vaccination: An exploratory study investigating workers in the health sector. PG - 993323 LID - 10.3389/fpsyt.2022.993323 [doi] LID - 993323 AB - BACKGROUND: The processes underlying believing have been labeled "creditions", which are important brain functions between emotion and cognition. Creditions are influenced by both internal and external factors, one of which is the coronavirus disease 2019 (COVID-19) pandemic and the vaccination against the disease. METHODS: To investigate believing processes shortly before the implementation of a mandatory vaccination in Austria, both vaccinated and unvaccinated workers in the health sector (WHS) were surveyed in December 2021/January 2022. In total, 1,062 vaccinated and 97 unvaccinated WHS (920 females) completed the online survey. Beliefs were assessed using the parameters of the credition model (narrative, certainty, emotion, and mightiness) with regard to (1) the COVID-19 pandemic in general, and (2) the vaccination. Type of emotion and narrative were divided into positive, negative, and indifferent. Moreover, the congruence between emotion and narrative was calculated. RESULTS: The vaccination rate of the sample was 91.6%, with a significantly higher percentage of men being in the group of vaccinated (21.1%) as compared to unvaccinated individuals (12.4%). Pertaining beliefs about the COVID-19 vaccination, unvaccinated WHS reported more negative and less positive emotions as well as content of narrative than vaccinated WHS. In addition, they showed higher levels of certainty as well as mightiness while believing and felt less sufficiently informed about governmental and workplace-related COVID-19 measures. The groups did not differ in the type of emotion or content of narrative in their beliefs about the pandemic in general. CONCLUSION: In conclusion, unvaccinated WHS had more negative and less positive emotions and thoughts than vaccinated WHS in their beliefs about the COVID-19 vaccination and their motivations for not having received it. They were more certain about their beliefs and felt stronger negative emotions in their beliefs compared to vaccinated individuals. Providing unvaccinated WHS with adequate information might be helpful in reducing their mental burden. CI - Copyright (c) 2022 Fleischmann, Fellendorf, Schonthaler, Lenger, Hiendl, Bonkat, Wagner-Skacel, Bengesser, Angel, Seitz, Reininghaus and Dalkner. FAU - Fleischmann, Eva AU - Fleischmann E AD - Department of Psychiatry and Psychotherapeutic Medicine, Medical University of Graz, Graz, Austria. FAU - Fellendorf, Frederike AU - Fellendorf F AD - Department of Psychiatry and Psychotherapeutic Medicine, Medical University of Graz, Graz, Austria. FAU - Schonthaler, Elena M AU - Schonthaler EM AD - Department of Psychiatry and Psychotherapeutic Medicine, Medical University of Graz, Graz, Austria. FAU - Lenger, Melanie AU - Lenger M AD - Department of Psychiatry and Psychotherapeutic Medicine, Medical University of Graz, Graz, Austria. FAU - Hiendl, Lena AU - Hiendl L AD - Department of Psychiatry and Psychotherapeutic Medicine, Medical University of Graz, Graz, Austria. FAU - Bonkat, Nina AU - Bonkat N AD - Department of Psychiatry and Psychotherapeutic Medicine, Medical University of Graz, Graz, Austria. FAU - Wagner-Skacel, Jolana AU - Wagner-Skacel J AD - Department of Medical Psychology and Psychotherapy, Medical University of Graz, Graz, Austria. FAU - Bengesser, Susanne AU - Bengesser S AD - Department of Psychiatry and Psychotherapeutic Medicine, Medical University of Graz, Graz, Austria. FAU - Angel, Hans-Ferdinand AU - Angel HF AD - Department of Catechetics and Religious Education, Karl-Franzens-University of Graz, Graz, Austria. FAU - Seitz, Rudiger J AU - Seitz RJ AD - Department of Neurology, Medical Faculty, Centre of Neurology and Neuropsychiatry, LVR-Klinikum Dusseldorf, Heinrich-Heine-University of Dusseldorf, Dusseldorf, Germany. FAU - Reininghaus, Eva Z AU - Reininghaus EZ AD - Department of Psychiatry and Psychotherapeutic Medicine, Medical University of Graz, Graz, Austria. FAU - Dalkner, Nina AU - Dalkner N AD - Department of Psychiatry and Psychotherapeutic Medicine, Medical University of Graz, Graz, Austria. LA - eng PT - Journal Article DEP - 20220921 PL - Switzerland TA - Front Psychiatry JT - Frontiers in psychiatry JID - 101545006 PMC - PMC9532762 OTO - NOTNLM OT - COVID-19 vaccination OT - beliefs OT - cognition OT - credition OT - emotion OT - workers in the health sector COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/10/11 06:00 MHDA- 2022/10/11 06:01 PMCR- 2022/09/21 CRDT- 2022/10/10 04:39 PHST- 2022/07/13 00:00 [received] PHST- 2022/08/30 00:00 [accepted] PHST- 2022/10/10 04:39 [entrez] PHST- 2022/10/11 06:00 [pubmed] PHST- 2022/10/11 06:01 [medline] PHST- 2022/09/21 00:00 [pmc-release] AID - 10.3389/fpsyt.2022.993323 [doi] PST - epublish SO - Front Psychiatry. 2022 Sep 21;13:993323. doi: 10.3389/fpsyt.2022.993323. eCollection 2022. PMID- 36211689 OWN - NLM STAT- MEDLINE DCOM- 20221011 LR - 20250530 IS - 2296-2565 (Electronic) IS - 2296-2565 (Linking) VI - 10 DP - 2022 TI - COVID-19 vaccination roll-outs in eleven small countries within the WHO European region; Lessons learned. PG - 959227 LID - 10.3389/fpubh.2022.959227 [doi] LID - 959227 AB - The development and administration of COVID-19 vaccines has been an essential element in controlling the COVID-19 pandemic. However, countries worldwide have faced challenges in planning and implementing vaccination strategies. The aim of the current paper is to describe the situation faced by small countries in the WHO European Region in implementing their national vaccination strategies during the first stages of the planned roll-out (up to May 2021). This paper uses information from the WHO Small Countries Initiative (SCI), which includes a network of 11 countries with populations of /=60 years, males, with diabetes, chronic kidney diseases, chronic liver disease, malignancy and tuberculosis, presenting with dyspnoea and neurological symptoms. WHO ordinal scale 4 or above at admission carried the highest odds of dying [5.6 (95% CI: 4.6-7.0)]. Patients receiving one [OR: 0.5 (95% CI: 0.4-0.7)] or two doses of anti-SARS CoV-2 vaccine [OR: 0.4 (95% CI: 0.3-0.7)] were protected from in-hospital mortality. CONCLUSIONS: WHO ordinal scale at admission is the most important independent predictor for in-hospital death in COVID-19 patients. Anti-SARS-CoV2 vaccination provides significant protection against mortality. CI - (c) The Author(s) 2022. Published by Oxford University Press on behalf of the Association of Physicians. All rights reserved. For permissions, please email: journals.permissions@oup.com. FAU - Mukherjee, A AU - Mukherjee A AD - From the Indian Council of Medical Research, New Delhi, India. FAU - Kumar, G AU - Kumar G AD - From the Indian Council of Medical Research, New Delhi, India. FAU - Turuk, A AU - Turuk A AD - From the Indian Council of Medical Research, New Delhi, India. FAU - Bhalla, A AU - Bhalla A AD - Postgraduate Institute of Medical Education & Research, Chandigarh, India. FAU - Bingi, T C AU - Bingi TC AD - Gandhi Medical College, Telangana, India. FAU - Bhardwaj, P AU - Bhardwaj P AD - All Indian Institute of Medical Sciences, Jodhpur, Rajasthan, India. FAU - Baruah, T D AU - Baruah TD AD - All Indian Institute of Medical Sciences, Raipur, Chhattisgarh, India. FAU - Mukherjee, S AU - Mukherjee S AD - College of Medicine, Sagore Dutta Hospital, Kolkata, West Bengal, India. FAU - Talukdar, A AU - Talukdar A AD - Medical College, Kolkata, West Bengal, India. FAU - Ray, Y AU - Ray Y AD - Infectious Disease and Beliaghata General Hospital, Kolkata, West Bengal, India. FAU - John, M AU - John M AD - Christian Medical College, Ludhiana, Punjab, India. FAU - Khambholja, J R AU - Khambholja JR AD - Smt. NHL, Municipal Medical College, Ahmedabad, Gujarat, India. FAU - Patel, A H AU - Patel AH AD - CIMS Hospital, Ahmedabad, Gujarat, India. FAU - Bhuniya, S AU - Bhuniya S AD - All India Institute of Medical Sciences, Bhubaneswar, Odisha, India. FAU - Joshi, R AU - Joshi R AD - All India Institute of Medical Sciences, Bhopal, Madhya Pradesh, India. FAU - Menon, G R AU - Menon GR AD - National Institute of Medical Statistics, Indian Council of Medical Research, Delhi, India. FAU - Sahu, D AU - Sahu D AD - National Institute of Medical Statistics, Indian Council of Medical Research, Delhi, India. FAU - Rao, V V AU - Rao VV AD - National Institute of Medical Statistics, Indian Council of Medical Research, Delhi, India. FAU - Bhargava, B AU - Bhargava B AD - From the Indian Council of Medical Research, New Delhi, India. FAU - Panda, S AU - Panda S AD - From the Indian Council of Medical Research, New Delhi, India. CN - NCRC Study Team LA - eng GR - Indian Council of Medical Research/ PT - Journal Article PL - England TA - QJM JT - QJM : monthly journal of the Association of Physicians JID - 9438285 SB - IM MH - Adult MH - Humans MH - Male MH - Middle Aged MH - *COVID-19/prevention & control MH - SARS-CoV-2 MH - Hospital Mortality MH - Time and Motion Studies MH - Vaccination MH - Chronic Disease PMC - PMC9494346 FIR - Mishra, P IR - Mishra P FIR - Panchal, Y IR - Panchal Y FIR - Sharma, L K IR - Sharma LK FIR - Agarwal, A IR - Agarwal A FIR - Puri, G D IR - Puri GD FIR - Suri, V IR - Suri V FIR - Singla, K IR - Singla K FIR - Mesipogu, R IR - Mesipogu R FIR - Aedula, V S IR - Aedula VS FIR - Mohiuddin, M A IR - Mohiuddin MA FIR - Kumar, D IR - Kumar D FIR - Saurabh, S IR - Saurabh S FIR - Misra, S IR - Misra S FIR - Kannauje, P K IR - Kannauje PK FIR - Kumar, A IR - Kumar A FIR - Shukla, A IR - Shukla A FIR - Pal, A IR - Pal A FIR - Chakraborty, S IR - Chakraborty S FIR - Dutta, M IR - Dutta M FIR - Mondal, T IR - Mondal T FIR - Chakravorty, S IR - Chakravorty S FIR - Bhattacharjee, B IR - Bhattacharjee B FIR - Paul, S R IR - Paul SR FIR - Majumder, D IR - Majumder D FIR - Chatterjee, S IR - Chatterjee S FIR - Abraham, A IR - Abraham A FIR - Varghese, D IR - Varghese D FIR - Thomas, M IR - Thomas M FIR - Shah, N IR - Shah N FIR - Patel, M IR - Patel M FIR - Madan, S IR - Madan S FIR - Desai, A IR - Desai A FIR - Kala Yadhav, M L IR - Kala Yadhav ML FIR - Madhumathi, R IR - Madhumathi R FIR - Chetna, G S IR - Chetna GS FIR - Ojha, U K IR - Ojha UK FIR - Jha, R R IR - Jha RR FIR - Kumar, A IR - Kumar A FIR - Pathak, A IR - Pathak A FIR - Sharma, A IR - Sharma A FIR - Purohit, M IR - Purohit M FIR - Sarangi, L IR - Sarangi L FIR - Rath, M IR - Rath M FIR - Shah, A D IR - Shah AD FIR - Kumar, L IR - Kumar L FIR - Patel, P IR - Patel P FIR - Dulhani, N IR - Dulhani N FIR - Dube, S IR - Dube S FIR - Shrivastava, J IR - Shrivastava J FIR - Mittal, A IR - Mittal A FIR - Patnaik, L IR - Patnaik L FIR - Sahoo, J P IR - Sahoo JP FIR - Sharma, S IR - Sharma S FIR - Katyal, V K IR - Katyal VK FIR - Katyal, A IR - Katyal A FIR - Yadav, N IR - Yadav N FIR - Upadhyay, R IR - Upadhyay R FIR - Srivastava, S IR - Srivastava S FIR - Srivastava, A IR - Srivastava A FIR - Suthar, N N IR - Suthar NN FIR - Shah, N M IR - Shah NM FIR - Rajvansh, K IR - Rajvansh K FIR - Purohit, H IR - Purohit H FIR - Mohapatra, P R IR - Mohapatra PR FIR - Panigrahi, M K IR - Panigrahi MK FIR - Saigal, S IR - Saigal S FIR - Khurana, A IR - Khurana A FIR - Panchal, M IR - Panchal M FIR - Anderpa, M IR - Anderpa M FIR - Patel, D IR - Patel D FIR - Salgar, V IR - Salgar V FIR - Algur, S IR - Algur S FIR - Choudhury, R IR - Choudhury R FIR - Rao, M IR - Rao M FIR - Nithya, D IR - Nithya D FIR - Gupta, B K IR - Gupta BK FIR - Kumar, B IR - Kumar B FIR - Gupta, J IR - Gupta J FIR - Bhandari, S IR - Bhandari S FIR - Agrawal, A IR - Agrawal A FIR - Shameem, M IR - Shameem M FIR - Fatima, N IR - Fatima N FIR - Pala, S IR - Pala S FIR - Nongpiur, V IR - Nongpiur V FIR - Chatterji, S IR - Chatterji S FIR - Mukherjee, S IR - Mukherjee S FIR - Shivnitwar, S K IR - Shivnitwar SK FIR - Tripathy, S IR - Tripathy S FIR - Lokhande, P IR - Lokhande P FIR - Dandu, H IR - Dandu H FIR - Gupta, A IR - Gupta A FIR - Kumar, V IR - Kumar V FIR - Sharma, N IR - Sharma N FIR - Vohra, R IR - Vohra R FIR - Paliwal, A IR - Paliwal A FIR - Pavan Kumar, M IR - Pavan Kumar M FIR - Bikshapathi Rao, A IR - Bikshapathi Rao A FIR - Kikon, N IR - Kikon N FIR - Kikon, R IR - Kikon R FIR - Manohar, K IR - Manohar K FIR - Sathyanarayana Raju, Y IR - Sathyanarayana Raju Y FIR - Madharia, A IR - Madharia A FIR - Chakravarty, J IR - Chakravarty J FIR - Chaubey, M IR - Chaubey M FIR - Bandaru, R K IR - Bandaru RK FIR - Ali Mirza, M IR - Ali Mirza M FIR - Kataria, S IR - Kataria S FIR - Sharma, P IR - Sharma P FIR - Ghosh, S IR - Ghosh S FIR - Hazra, A IR - Hazra A EDAT- 2022/09/03 06:00 MHDA- 2023/02/17 06:00 PMCR- 2022/09/02 CRDT- 2022/09/02 10:04 PHST- 2022/07/04 00:00 [received] PHST- 2022/08/16 00:00 [revised] PHST- 2022/09/03 06:00 [pubmed] PHST- 2023/02/17 06:00 [medline] PHST- 2022/09/02 10:04 [entrez] PHST- 2022/09/02 00:00 [pmc-release] AID - 6687141 [pii] AID - hcac202 [pii] AID - 10.1093/qjmed/hcac202 [doi] PST - ppublish SO - QJM. 2023 Feb 14;116(1):47-56. doi: 10.1093/qjmed/hcac202. PMID- 36048132 OWN - NLM STAT- MEDLINE DCOM- 20221130 LR - 20230127 IS - 1398-9995 (Electronic) IS - 0105-4538 (Print) IS - 0105-4538 (Linking) VI - 77 IP - 12 DP - 2022 Dec TI - New insights into human immune memory from SARS-CoV-2 infection and vaccination. PG - 3553-3566 LID - 10.1111/all.15502 [doi] AB - Since early 2020, the world has been embroiled in an ongoing viral pandemic with SARS-CoV-2 and emerging variants resulting in mass morbidity and an estimated 6 million deaths globally. The scientific community pivoted rapidly, providing unique and innovative means to identify infected individuals, technologies to evaluate immune responses to infection and vaccination, and new therapeutic strategies to treat infected individuals. Never before has immunology been so critically at the forefront of combatting a global pandemic. It has now become evident that not just antibody responses, but formation and durability of immune memory cells following vaccination are associated with protection against severe disease from SARS-CoV-2 infection. Furthermore, the emergence of variants of concern (VoC) highlight the need for immunological markers to quantify the protective capacity of Wuhan-based vaccines. Thus, harnessing and modulating the immune response is key to successful vaccination and treatment of disease. We here review the latest knowledge about immune memory generation and durability following natural infection and vaccination, and provide insights into the attributes of immune memory that may protect from emerging variants. CI - (c) 2022 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd. FAU - Hartley, Gemma E AU - Hartley GE AUID- ORCID: 0000-0002-3174-231X AD - Allergy and Clinical Immunology Laboratory, Department of Immunology and Pathology, Central Clinical School, Monash University, Melbourne, Victoria, Australia. FAU - Edwards, Emily S J AU - Edwards ESJ AUID- ORCID: 0000-0002-0240-4370 AD - Allergy and Clinical Immunology Laboratory, Department of Immunology and Pathology, Central Clinical School, Monash University, Melbourne, Victoria, Australia. FAU - O'Hehir, Robyn E AU - O'Hehir RE AUID- ORCID: 0000-0002-3489-7595 AD - Allergy and Clinical Immunology Laboratory, Department of Immunology and Pathology, Central Clinical School, Monash University, Melbourne, Victoria, Australia. AD - Allergy, Asthma and Clinical Immunology Service, Alfred Hospital, Melbourne, Victoria, Australia. FAU - van Zelm, Menno C AU - van Zelm MC AUID- ORCID: 0000-0003-4161-1919 AD - Allergy and Clinical Immunology Laboratory, Department of Immunology and Pathology, Central Clinical School, Monash University, Melbourne, Victoria, Australia. AD - Allergy, Asthma and Clinical Immunology Service, Alfred Hospital, Melbourne, Victoria, Australia. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20220920 PL - Denmark TA - Allergy JT - Allergy JID - 7804028 SB - IM MH - Humans MH - *COVID-19/prevention & control MH - SARS-CoV-2 MH - Immunologic Memory MH - Vaccination MH - Pandemics PMC - PMC9538469 OTO - NOTNLM OT - COVID-19 OT - SARS-CoV-2 OT - antibodies OT - immune memory OT - memory B cells OT - memory T cells COIS- MCvZ and REO'H are inventors on a patent application related to this work. The other authors declare no conflict of interest. EDAT- 2022/09/02 06:00 MHDA- 2022/12/01 06:00 PMCR- 2022/09/20 CRDT- 2022/09/01 10:52 PHST- 2022/08/13 00:00 [revised] PHST- 2022/06/20 00:00 [received] PHST- 2022/08/29 00:00 [accepted] PHST- 2022/09/02 06:00 [pubmed] PHST- 2022/12/01 06:00 [medline] PHST- 2022/09/01 10:52 [entrez] PHST- 2022/09/20 00:00 [pmc-release] AID - ALL15502 [pii] AID - 10.1111/all.15502 [doi] PST - ppublish SO - Allergy. 2022 Dec;77(12):3553-3566. doi: 10.1111/all.15502. Epub 2022 Sep 20. PMID- 36032111 OWN - NLM STAT- MEDLINE DCOM- 20220830 LR - 20250728 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 13 DP - 2022 TI - Persistent but atypical germinal center reaction among 3(rd) SARS-CoV-2 vaccination after rituximab exposure. PG - 943476 LID - 10.3389/fimmu.2022.943476 [doi] LID - 943476 AB - BACKGROUND: Durable vaccine-mediated immunity relies on the generation of long-lived plasma cells and memory B cells (MBCs), differentiating upon germinal center (GC) reactions. SARS-CoV-2 mRNA vaccination induces a strong GC response in healthy volunteers (HC), but limited data is available about response longevity upon rituximab treatment. METHODS: We evaluated humoral and cellular responses upon 3rd vaccination in seven patients with rheumatoid arthritis (RA) who initially mounted anti-spike SARS-CoV-2 IgG antibodies after primary 2x vaccination and got re-exposed to rituximab (RTX) 1-2 months after the second vaccination. Ten patients with RA on other therapies and ten HC represented the control groups. As control for known long-lived induced immunity, we analyzed humoral and cellular tetanus toxoid (TT) immune responses in steady-state. RESULTS: After 3(rd) vaccination, 5/7 seroconverted RTX patients revealed lower anti-SARS-CoV-2 IgG levels but similar neutralizing capacity compared with HC. Antibody levels after 3rd vaccination correlated with values after 2nd vaccination. Despite significant reduction of circulating total and antigen-specific B cells in RTX re-exposed patients, we observed the induction of IgG+ MBCs upon 3(rd) vaccination. Notably, only RTX treated patients revealed a high amount of IgA+ MBCs before and IgA+ plasmablasts after 3(rd) vaccination. IgA+ B cells were not part of the steady state TT+ B cell pool. TNF-secretion and generation of effector memory CD4 spike-specific T cells were significantly boosted upon 3(rd) vaccination. SUMMARY: On the basis of pre-existing affinity matured MBCs within primary immunisation, RTX re-exposed patients revealed a persistent but atypical GC immune response accompanied by boosted spike-specific memory CD4 T cells upon SARS-CoV-2 recall vaccination. CI - Copyright (c) 2022 Stefanski, Rincon-Arevalo, Schrezenmeier, Karberg, Szelinski, Ritter, Chen, Meisel, Jahrsdorfer, Ludwig, Schrezenmeier, Lino and Dorner. FAU - Stefanski, Ana-Luisa AU - Stefanski AL AD - Department of Rheumatology and Clinical Immunology, Charite Universitatsmedizin Berlin, Berlin, Germany. AD - Deutsches Rheumaforschungszentrum (DRFZ), Berlin, Germany. FAU - Rincon-Arevalo, Hector AU - Rincon-Arevalo H AD - Department of Rheumatology and Clinical Immunology, Charite Universitatsmedizin Berlin, Berlin, Germany. AD - Deutsches Rheumaforschungszentrum (DRFZ), Berlin, Germany. AD - Department of Nephrology and Medical Intensive Care, Charite Universitatsmedizin Berlin, Berlin, Germany. AD - Grupo de Inmunologia Celular e Inmunogenetica, Facultad de Medicina, Instituto de Investigaciones Medicas, Universidad de Antioquia (UdeA), Medellin, Colombia. FAU - Schrezenmeier, Eva AU - Schrezenmeier E AD - Deutsches Rheumaforschungszentrum (DRFZ), Berlin, Germany. AD - Department of Nephrology and Medical Intensive Care, Charite Universitatsmedizin Berlin, Berlin, Germany. AD - Berlin Institute of Health Charite Universitatsmedizin Berlin, Berlin Institute of Health (BIH) Academy, Berlin, Germany. FAU - Karberg, Kirsten AU - Karberg K AD - Rheumatology Outpatient Office RheumaPraxis Steglitz, Berlin, Germany. FAU - Szelinski, Franziska AU - Szelinski F AD - Department of Rheumatology and Clinical Immunology, Charite Universitatsmedizin Berlin, Berlin, Germany. AD - Deutsches Rheumaforschungszentrum (DRFZ), Berlin, Germany. FAU - Ritter, Jacob AU - Ritter J AD - Department of Rheumatology and Clinical Immunology, Charite Universitatsmedizin Berlin, Berlin, Germany. AD - Berlin Institute of Health Charite Universitatsmedizin Berlin, Berlin Institute of Health (BIH) Academy, Berlin, Germany. FAU - Chen, Yidan AU - Chen Y AD - Department of Rheumatology and Clinical Immunology, Charite Universitatsmedizin Berlin, Berlin, Germany. AD - Deutsches Rheumaforschungszentrum (DRFZ), Berlin, Germany. FAU - Meisel, Christian AU - Meisel C AD - Department of Medical Immunology, Charite University Medicine and Labor Berlin-Charite Vivantes, Berlin, Germany. FAU - Jahrsdorfer, Bernd AU - Jahrsdorfer B AD - Institute of Transfusion Medicine, Ulm University, Ulm, Germany. AD - Institute for Clinical Transfusion Medicine and Immunogenetics, German Red Cross Blood Transfusion Service Baden-Wurttemberg - Hessen and University Hospital Ulm, Ulm, Germany. FAU - Ludwig, Carolin AU - Ludwig C AD - Institute of Transfusion Medicine, Ulm University, Ulm, Germany. AD - Institute for Clinical Transfusion Medicine and Immunogenetics, German Red Cross Blood Transfusion Service Baden-Wurttemberg - Hessen and University Hospital Ulm, Ulm, Germany. FAU - Schrezenmeier, Hubert AU - Schrezenmeier H AD - Institute of Transfusion Medicine, Ulm University, Ulm, Germany. AD - Institute for Clinical Transfusion Medicine and Immunogenetics, German Red Cross Blood Transfusion Service Baden-Wurttemberg - Hessen and University Hospital Ulm, Ulm, Germany. FAU - Lino, Andreia C AU - Lino AC AD - Deutsches Rheumaforschungszentrum (DRFZ), Berlin, Germany. FAU - Dorner, Thomas AU - Dorner T AD - Department of Rheumatology and Clinical Immunology, Charite Universitatsmedizin Berlin, Berlin, Germany. AD - Deutsches Rheumaforschungszentrum (DRFZ), Berlin, Germany. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220810 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 RN - 0 (Antibodies, Viral) RN - 0 (COVID-19 Vaccines) RN - 0 (Immunoglobulin A) RN - 0 (Immunoglobulin G) RN - 4F4X42SYQ6 (Rituximab) SB - IM MH - Antibodies, Viral MH - *Arthritis, Rheumatoid MH - *COVID-19 MH - COVID-19 Vaccines MH - Germinal Center MH - Humans MH - Immunoglobulin A MH - Immunoglobulin G MH - Rituximab MH - SARS-CoV-2 MH - Vaccination PMC - PMC9399943 OTO - NOTNLM OT - SARS-CoV-2 OT - germinal center (GC) OT - memory B cell (MBC) OT - rituximab (RTX) OT - vaccination COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/08/30 06:00 MHDA- 2022/08/31 06:00 PMCR- 2022/08/10 CRDT- 2022/08/29 04:36 PHST- 2022/05/13 00:00 [received] PHST- 2022/07/08 00:00 [accepted] PHST- 2022/08/29 04:36 [entrez] PHST- 2022/08/30 06:00 [pubmed] PHST- 2022/08/31 06:00 [medline] PHST- 2022/08/10 00:00 [pmc-release] AID - 10.3389/fimmu.2022.943476 [doi] PST - epublish SO - Front Immunol. 2022 Aug 10;13:943476. doi: 10.3389/fimmu.2022.943476. eCollection 2022. PMID- 35992463 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230916 IS - 1664-1078 (Print) IS - 1664-1078 (Electronic) IS - 1664-1078 (Linking) VI - 13 DP - 2022 TI - The Role of Positive and Negative Information Processing in COVID-19 Vaccine Uptake in Women of Generation X, Y, and Z: The Power of Good is Stronger Than Bad in Youngsters? PG - 925675 LID - 10.3389/fpsyg.2022.925675 [doi] LID - 925675 AB - BACKGROUND: Positive and negative focus in information processing associated with age has a diverse role in COVID-19 vaccine uptake. The aim of the study was the exploration of the generational diversity among psychological predictors of COVID-19 vaccine uptake. METHODS: A cross-sectional research was conducted. The sample included 978 Hungarian women. Based on former literature findings, the COVID-19 vaccine uptake predictors were chosen from the health beliefs model, COVID-19 vaccine hesitancy, and psychological flexibility. Multivariate logistic regression analysis was conducted to investigate the predictors of COVID-19 vaccine uptake in women of Gen X, Gen Y, and Gen Z. RESULTS: In Gen X women, the influence of significant predictors are more prone to the positivity in COVID-19 vaccine uptake behavior, perceived benefits being the most relevant, increasing the likelihood of vaccine uptake more than four times. In Gen Y women, perceived barriers, lack of confidence/skepticism and avoidance significantly reduce the probability of vaccine uptake, showing an accentuated negative focus in information processing related to COVID-19 vaccination. The vaccine uptake in Gen Z is predicted only by the perceived benefits, and the likelihood of COVID-19 vaccine uptake is heightened in chance more than 19 times. CONCLUSION: Women belonging to Gen X or Gen Y, the perceived benefits hold the key to vaccine uptake, while in women of Gen Z, low risks, lack of threats, and accessibility could motivate the decision of vaccine uptake. The findings are useful in generation-adapted vaccination campaigns and can also serve as inspiration for evolutionary psychology studies on health behavior and the broad area of study in cognitive biases in health information processing. CI - Copyright (c) 2022 Marschalko, Szabo, Kotta and Kalcza-Janosi. FAU - Marschalko, Eszter Eniko AU - Marschalko EE AD - Applied Psychology Department, Faculty of Psychology and Educational Sciences, Babes-Bolyai University, Cluj-Napoca, Romania. FAU - Szabo, Kinga AU - Szabo K AD - Applied Psychology Department, Faculty of Psychology and Educational Sciences, Babes-Bolyai University, Cluj-Napoca, Romania. FAU - Kotta, Ibolya AU - Kotta I AD - Applied Psychology Department, Faculty of Psychology and Educational Sciences, Babes-Bolyai University, Cluj-Napoca, Romania. FAU - Kalcza-Janosi, Kinga AU - Kalcza-Janosi K AD - Applied Psychology Department, Faculty of Psychology and Educational Sciences, Babes-Bolyai University, Cluj-Napoca, Romania. LA - eng SI - figshare/10.6084/m9.figshare.19603585 PT - Journal Article DEP - 20220805 PL - Switzerland TA - Front Psychol JT - Frontiers in psychology JID - 101550902 PMC - PMC9389232 OTO - NOTNLM OT - cognition OT - generational identity OT - health OT - health belief model OT - psychological flexibility OT - vaccine hesitancy OT - vaccine uptake OT - women COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/08/23 06:00 MHDA- 2022/08/23 06:01 PMCR- 2022/08/05 CRDT- 2022/08/22 04:27 PHST- 2022/04/21 00:00 [received] PHST- 2022/06/23 00:00 [accepted] PHST- 2022/08/22 04:27 [entrez] PHST- 2022/08/23 06:00 [pubmed] PHST- 2022/08/23 06:01 [medline] PHST- 2022/08/05 00:00 [pmc-release] AID - 10.3389/fpsyg.2022.925675 [doi] PST - epublish SO - Front Psychol. 2022 Aug 5;13:925675. doi: 10.3389/fpsyg.2022.925675. eCollection 2022. PMID- 35970543 OWN - NLM STAT- MEDLINE DCOM- 20220817 LR - 20251031 IS - 1488-2329 (Electronic) IS - 0820-3946 (Print) IS - 0820-3946 (Linking) VI - 194 IP - 31 DP - 2022 Aug 15 TI - Functional neurologic disorder associated with SARS-CoV-2 vaccination. PG - E1086-E1088 LID - 10.1503/cmaj.220039 [doi] FAU - Zhu, Annie AU - Zhu A AD - Division of Neurology, Department of Medicine (Zhu, Burke) and Neuropsychiatry Program, Department of Psychiatry (Burke), Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ont.; Division of Cognitive Neurology, Department of Neurology (Burke), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Mass. FAU - Burke, Matthew J AU - Burke MJ AD - Division of Neurology, Department of Medicine (Zhu, Burke) and Neuropsychiatry Program, Department of Psychiatry (Burke), Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ont.; Division of Cognitive Neurology, Department of Neurology (Burke), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Mass. matthew.burke@sunnybrook.ca. LA - eng PT - Journal Article PL - Canada TA - CMAJ JT - CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne JID - 9711805 RN - 0 (COVID-19 Vaccines) SB - IM MH - *COVID-19/prevention & control MH - *COVID-19 Vaccines/adverse effects MH - Humans MH - *Nervous System Diseases/etiology MH - SARS-CoV-2 MH - Vaccination/adverse effects PMC - PMC9377566 COIS- Competing interests: None declared. EDAT- 2022/08/16 06:00 MHDA- 2022/08/18 06:00 PMCR- 2022/08/15 CRDT- 2022/08/15 20:43 PHST- 2022/08/15 20:43 [entrez] PHST- 2022/08/16 06:00 [pubmed] PHST- 2022/08/18 06:00 [medline] PHST- 2022/08/15 00:00 [pmc-release] AID - 194/31/E1086 [pii] AID - 194e1086 [pii] AID - 10.1503/cmaj.220039 [doi] PST - ppublish SO - CMAJ. 2022 Aug 15;194(31):E1086-E1088. doi: 10.1503/cmaj.220039. PMID- 35958601 OWN - NLM STAT- MEDLINE DCOM- 20220815 LR - 20260127 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 13 DP - 2022 TI - BNT162b2 booster after heterologous prime-boost vaccination induces potent neutralizing antibodies and T cell reactivity against SARS-CoV-2 Omicron BA.1 in young adults. PG - 882918 LID - 10.3389/fimmu.2022.882918 [doi] LID - 882918 AB - In light of the decreasing immune protection against symptomatic SARS-CoV-2 infection after initial vaccinations and the now dominant immune-evasive Omicron variants, 'booster' vaccinations are regularly performed to restore immune responses. Many individuals have received a primary heterologous prime-boost vaccination with long intervals between vaccinations, but the resulting long-term immunity and the effects of a subsequent 'booster', particularly against Omicron BA.1, have not been defined. We followed a cohort of 23 young adults, who received a primary heterologous ChAdOx1 nCoV-19 BNT162b2 prime-boost vaccination, over a 7-month period and analysed how they responded to a BNT162b2 'booster'. We show that already after the primary heterologous vaccination, neutralization titers against Omicron BA.1 are recognizable but that humoral and cellular immunity wanes over the course of half a year. Residual responsive memory T cells recognized spike epitopes of the early SARS-CoV-2 B.1 strain as well as the Delta and BA.1 variants of concern (VOCs). However, the remaining antibody titers hardly neutralized these VOCs. The 'booster' vaccination was well tolerated and elicited both high antibody titers and increased memory T cell responses against SARS-CoV-2 including BA.1. Strikingly, in this young heterologously vaccinated cohort the neutralizing activity after the 'booster' was almost as potent against BA.1 as against the early B.1 strain. Our results suggest that a 'booster' after heterologous vaccination results in effective immune maturation and potent protection against the Omicron BA.1 variant in young adults. CI - Copyright (c) 2022 Seidel, Zanoni, Gross, Krnavek, Erdemci-Evin, von Maltitz, Albers, Conzelmann, Liu, Weil, Mayer, Hoffmann, Pohlmann, Beil, Kroschel, Kirchhoff, Munch and Muller. FAU - Seidel, Alina AU - Seidel A AD - Institute of Molecular Virology, Ulm University Medical Center, Ulm, Germany. FAU - Zanoni, Michelle AU - Zanoni M AD - Institute of Molecular Virology, Ulm University Medical Center, Ulm, Germany. FAU - Gross, Rudiger AU - Gross R AD - Institute of Molecular Virology, Ulm University Medical Center, Ulm, Germany. FAU - Krnavek, Daniela AU - Krnavek D AD - Institute of Molecular Virology, Ulm University Medical Center, Ulm, Germany. FAU - Erdemci-Evin, Sumeyye AU - Erdemci-Evin S AD - Institute of Molecular Virology, Ulm University Medical Center, Ulm, Germany. FAU - von Maltitz, Pascal AU - von Maltitz P AD - Institute of Molecular Virology, Ulm University Medical Center, Ulm, Germany. FAU - Albers, Dan P J AU - Albers DPJ AD - Institute of Molecular Virology, Ulm University Medical Center, Ulm, Germany. FAU - Conzelmann, Carina AU - Conzelmann C AD - Institute of Molecular Virology, Ulm University Medical Center, Ulm, Germany. FAU - Liu, Sichen AU - Liu S AD - Institute of Molecular Virology, Ulm University Medical Center, Ulm, Germany. FAU - Weil, Tatjana AU - Weil T AD - Institute of Molecular Virology, Ulm University Medical Center, Ulm, Germany. FAU - Mayer, Benjamin AU - Mayer B AD - Institute for Epidemiology and Medical Biometry, Ulm University, Ulm, Germany. FAU - Hoffmann, Markus AU - Hoffmann M AD - Infection Biology Unit, German Primate Center - Leibniz Institute for Primate Research, Gottingen, Germany. AD - Faculty of Biology and Psychology, Georg-August-University Gottingen, Gottingen, Germany. FAU - Pohlmann, Stefan AU - Pohlmann S AD - Infection Biology Unit, German Primate Center - Leibniz Institute for Primate Research, Gottingen, Germany. AD - Faculty of Biology and Psychology, Georg-August-University Gottingen, Gottingen, Germany. FAU - Beil, Alexandra AU - Beil A AD - Central Department for Clinical Chemistry, University Hospital Ulm, Ulm, Germany. FAU - Kroschel, Joris AU - Kroschel J AD - Central Department for Clinical Chemistry, University Hospital Ulm, Ulm, Germany. FAU - Kirchhoff, Frank AU - Kirchhoff F AD - Institute of Molecular Virology, Ulm University Medical Center, Ulm, Germany. FAU - Munch, Jan AU - Munch J AD - Institute of Molecular Virology, Ulm University Medical Center, Ulm, Germany. AD - Core Facility Functional Peptidomics, Ulm University Medical Center, Ulm, Germany. FAU - Muller, Janis A AU - Muller JA AD - Institute of Virology, Philipps University of Marburg, Marburg, Germany. AD - Institute of Molecular Virology, Ulm University Medical Center, Ulm, Germany. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220725 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 RN - 0 (Antibodies, Neutralizing) RN - 0 (Antibodies, Viral) RN - 0 (BNT162 Vaccine) RN - B5S3K2V0G8 (ChAdOx1 nCoV-19) RN - SARS-CoV-2 variants SB - IM MH - *Antibodies, Neutralizing MH - Antibodies, Viral MH - BNT162 Vaccine MH - *COVID-19/prevention & control MH - ChAdOx1 nCoV-19 MH - Humans MH - SARS-CoV-2 MH - Vaccination MH - Young Adult PMC - PMC9357986 OTO - NOTNLM OT - B.1.1.529.1 OT - BA.1 OT - COVID-19 OT - ChadOx1 nCoV-19 OT - delta OT - humoral immunity OT - memory T cells OT - vaccination interval COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/08/13 06:00 MHDA- 2022/08/16 06:00 PMCR- 2022/07/25 CRDT- 2022/08/12 03:00 PHST- 2022/02/24 00:00 [received] PHST- 2022/06/28 00:00 [accepted] PHST- 2022/08/12 03:00 [entrez] PHST- 2022/08/13 06:00 [pubmed] PHST- 2022/08/16 06:00 [medline] PHST- 2022/07/25 00:00 [pmc-release] AID - 10.3389/fimmu.2022.882918 [doi] PST - epublish SO - Front Immunol. 2022 Jul 25;13:882918. doi: 10.3389/fimmu.2022.882918. eCollection 2022. PMID- 35954625 OWN - NLM STAT- MEDLINE DCOM- 20220815 LR - 20250728 IS - 1660-4601 (Electronic) IS - 1661-7827 (Print) IS - 1660-4601 (Linking) VI - 19 IP - 15 DP - 2022 Jul 28 TI - Acceptance and Adherence to COVID-19 Vaccination-The Role of Cognitive and Emotional Representations. LID - 10.3390/ijerph19159268 [doi] LID - 9268 AB - Vaccine hesitation is a topic of utmost importance, with the COVID-19 pandemic serving as a clear reminder of its timeliness. Besides evaluating COVID-19 vaccine acceptance in a sample of Portuguese people, this study aims at understanding cognitive and emotional representations related to vaccination, and their influence on vaccination hesitation. A cross-sectional online survey was conducted between 27 December 2020 and 27 January 2021. It assessed cognitive and emotional COVID-19 representations; vaccination status; cognitive and emotional representations of vaccination and perceived necessity and concerns about vaccines. Of 31 x 58 participants, 91% accepted taking a COVID-19 vaccine. Among several other significant findings, women (71.3%) more often considered that the pandemic affected their lives (p < 0.001) and were more often concerned with being infected (p < 0.001). Likewise, there were significantly more female participants concerned about taking a COVID-19 vaccine and its possible effects, when compared to the number of male participants (p < 0.001). The number of participants with a higher education level that were more worried about becoming infected was greater (p = 0.001), when compared with those less educated. Regarding age groups, people aged 18 to 24 had fewer concerned participants (9.6%), while the number of individuals aged 55 to 64 had the most (p < 0.001). Somewhat surprisingly, perceiving oneself as extremely informed about COVID-19 was not associated with greater vaccine acceptance (OR = 1.534 [1.160-2.029]; (p = 0.003)). Moreover, people aged 25 to 64 years old and with lower education level were more likely not to accept vaccination (OR = 2.799 [1.085-7.221]; (p = 0.033)). Finally, being more concerned about taking a vaccine lowers its acceptance (OR = 4.001 [2.518-6.356]; (p < 0.001)). Cognitive and emotional representations have a great impact and are reliable predictors of vaccine acceptance. Thus, it is of extreme importance that public health messages be adapted to the different characteristics of the population. FAU - Pinho, Simao AU - Pinho S AUID- ORCID: 0000-0003-1433-3052 AD - Department of Biomedicine, Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal. AD - Sao Joao University Hospital Center, 4200-319 Porto, Portugal. FAU - Cruz, Mariana AU - Cruz M AD - Department of Biomedicine, Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal. FAU - Dias, Claudia Camila AU - Dias CC AUID- ORCID: 0000-0001-9356-3272 AD - CINTESIS@RISE, MEDCIDS, Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal. AD - Knowledge Management Unit and Department of Community Medicine, Information and Health Decision Sciences, Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal. FAU - Castro-Lopes, Jose M AU - Castro-Lopes JM AD - Department of Biomedicine, Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal. FAU - Sampaio, Rute AU - Sampaio R AUID- ORCID: 0000-0002-9009-6653 AD - Department of Biomedicine, Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal. AD - CINTESIS@RISE, MEDCIDS, Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal. LA - eng PT - Journal Article DEP - 20220728 PL - Switzerland TA - Int J Environ Res Public Health JT - International journal of environmental research and public health JID - 101238455 RN - 0 (COVID-19 Vaccines) SB - IM MH - Adult MH - *COVID-19/epidemiology/prevention & control MH - *COVID-19 Vaccines/therapeutic use MH - Cognition MH - Cross-Sectional Studies MH - Female MH - Humans MH - Male MH - Middle Aged MH - Pandemics MH - Patient Acceptance of Health Care MH - Vaccination PMC - PMC9368462 OTO - NOTNLM OT - COVID-19 OT - adherence OT - cognition OT - emotion OT - representations OT - vaccination COIS- The authors have no relevant financial or non-financial interests to disclose. EDAT- 2022/08/13 06:00 MHDA- 2022/08/16 06:00 PMCR- 2022/07/28 CRDT- 2022/08/12 01:06 PHST- 2022/06/20 00:00 [received] PHST- 2022/07/24 00:00 [revised] PHST- 2022/07/25 00:00 [accepted] PHST- 2022/08/12 01:06 [entrez] PHST- 2022/08/13 06:00 [pubmed] PHST- 2022/08/16 06:00 [medline] PHST- 2022/07/28 00:00 [pmc-release] AID - ijerph19159268 [pii] AID - ijerph-19-09268 [pii] AID - 10.3390/ijerph19159268 [doi] PST - epublish SO - Int J Environ Res Public Health. 2022 Jul 28;19(15):9268. doi: 10.3390/ijerph19159268. PMID- 35944882 OWN - NLM STAT- MEDLINE DCOM- 20220913 LR - 20221222 IS - 1521-7035 (Electronic) IS - 1521-6616 (Print) IS - 1521-6616 (Linking) VI - 242 DP - 2022 Sep TI - Decrease in CD8(+)CD45(+)CCR7(+)CD62L(+) T cells in individuals vaccinated with Sinovac-CoronaVac following COVID-19 infection. PG - 109092 LID - S1521-6616(22)00173-5 [pii] LID - 10.1016/j.clim.2022.109092 [doi] AB - Vaccines induce antibodies, but T cell responses are also important for protection against Coronavirus disease 2019. Here, we analyzed the frequency of memory T cells in infected and/or vaccinated individuals and observed a decrease in central memory T cells in individuals who were vaccinated following COVID-19 infection. CI - Copyright (c) 2022 Elsevier Inc. All rights reserved. FAU - Fonseca, Damaris C S C AU - Fonseca DCSC AD - Graduate Program in Microbial Biology, CEUMA University - UniCEUMA, Sao Luis, Brazil. FAU - Rocha, Mirtes C B AU - Rocha MCB AD - Central Public Health Laboratory of Maranhao - LACEN-MA, Sao Luis, Brazil; Graduate Program in Health Sciences, Federal University of Maranhao - UFMA, Sao Luis, Brazil. FAU - Pereira, Lucca A AU - Pereira LA AD - Graduate Program in Microbial Biology, CEUMA University - UniCEUMA, Sao Luis, Brazil. FAU - Botega, Leticia P AU - Botega LP AD - Graduate Program in Microbial Biology, CEUMA University - UniCEUMA, Sao Luis, Brazil. FAU - Cutrim, Susanne C P F AU - Cutrim SCPF AD - Graduate Program in Microbial Biology, CEUMA University - UniCEUMA, Sao Luis, Brazil. FAU - Silva, Fabiano V AU - Silva FV AD - Central Public Health Laboratory of Maranhao - LACEN-MA, Sao Luis, Brazil; IOC/FIOCRUZ-RJ - Graduate Program in Tropical Medicine, Brazil. FAU - Batista, Flavio D AU - Batista FD AD - Graduate Program in Health and Services Management, CEUMA University - UniCEUMA, Sao Luis, Brazil. FAU - Rego, Adriana S AU - Rego AS AD - Graduate Program in Health and Services Management, CEUMA University - UniCEUMA, Sao Luis, Brazil. FAU - Falcai, Angela AU - Falcai A AD - Graduate Program in Health and Services Management, CEUMA University - UniCEUMA, Sao Luis, Brazil. FAU - Lima-Neto, Lidio G AU - Lima-Neto LG AD - Graduate Program in Microbial Biology, CEUMA University - UniCEUMA, Sao Luis, Brazil; Central Public Health Laboratory of Maranhao - LACEN-MA, Sao Luis, Brazil. FAU - Santos, Ana Paula S A AU - Santos APSA AD - Graduate Program in Health Sciences, Federal University of Maranhao - UFMA, Sao Luis, Brazil. FAU - Carvalho, Rafael C AU - Carvalho RC AD - Graduate Program in Health and Services Management, CEUMA University - UniCEUMA, Sao Luis, Brazil. FAU - Sousa, Eduardo M AU - Sousa EM AD - Graduate Program in Microbial Biology, CEUMA University - UniCEUMA, Sao Luis, Brazil; Graduate Program in Health and Services Management, CEUMA University - UniCEUMA, Sao Luis, Brazil. Electronic address: eduardo.martins@ceuma.br. LA - eng PT - Letter PT - Research Support, Non-U.S. Gov't DEP - 20220806 PL - United States TA - Clin Immunol JT - Clinical immunology (Orlando, Fla.) JID - 100883537 RN - 0 (Antibodies, Viral) RN - 0 (COVID-19 Vaccines) SB - IM MH - Antibodies, Viral MH - *CD8-Positive T-Lymphocytes/cytology MH - *COVID-19/prevention & control MH - *COVID-19 Vaccines/immunology MH - Humans MH - Memory T Cells/cytology MH - Vaccination PMC - PMC9356635 OTO - NOTNLM OT - COVID-19 OT - Immune memory OT - T cells OT - Vaccination COIS- Declaration of Competing Interest The authors declare no conflicts of interest. EDAT- 2022/08/10 06:00 MHDA- 2022/09/14 06:00 PMCR- 2022/08/06 CRDT- 2022/08/09 19:37 PHST- 2022/06/01 00:00 [received] PHST- 2022/07/23 00:00 [revised] PHST- 2022/07/25 00:00 [accepted] PHST- 2022/08/10 06:00 [pubmed] PHST- 2022/09/14 06:00 [medline] PHST- 2022/08/09 19:37 [entrez] PHST- 2022/08/06 00:00 [pmc-release] AID - S1521-6616(22)00173-5 [pii] AID - 109092 [pii] AID - 10.1016/j.clim.2022.109092 [doi] PST - ppublish SO - Clin Immunol. 2022 Sep;242:109092. doi: 10.1016/j.clim.2022.109092. Epub 2022 Aug 6. PMID- 35940286 OWN - NLM STAT- MEDLINE DCOM- 20230206 LR - 20240911 IS - 1541-3527 (Electronic) IS - 0091-2174 (Print) IS - 0091-2174 (Linking) VI - 58 IP - 2 DP - 2023 Mar TI - COVID-19 vaccine compliance in adolescents with attention-deficit/hyperactivity disorder. PG - 145-159 LID - 10.1177/00912174221116734 [doi] AB - OBJECTIVE: To compare the rate of the administration of the Pfizer-BioNTech COVID-19 vaccinations between adolescents diagnosed with attention-deficit/hyperactivity disorder (ADHD) and non-ADHD subjects. METHOD: A retrospective chart review was performed on all adolescents aged 12-17 years registered at a central district in Israel from January 1(st) 2021 to October 31(st) 2021. RESULTS: Of the 46,544 subjects included in the study, 8241 (17.7%) were diagnosed with ADHD. Of them, 3% were PCR-COVID-19 positive. Among the patients with ADHD, the older adolescents were more likely to be vaccinated: 48.8% of those aged 12-15 years were vaccinated versus 59.6% of patients aged 16-17 years. The ultra-orthodox Jewish and Arab adolescents in the ADHD group were far less likely to be vaccinated (22.9% and 34.6%, respectively), compared to the adolescents with ADHD in the general population (60.5%). Girls were also somewhat more likely to be vaccinated. CONCLUSIONS: Adolescents diagnosed with ADHD had a higher COVID-19 vaccination rate compared to their non-ADHD counterparts. The vaccine uptake was lower amongst Arab and ultra-orthodox Jewish populations. FAU - Shkalim Zemer, Vered AU - Shkalim Zemer V AUID- ORCID: 0000-0003-1733-5395 AD - Dan-Petach-Tikva District, Clalit Health Services, Petach Tikva, Israel. AD - 58408Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel. FAU - Hoshen, Moshe AU - Hoshen M AD - Dan-Petach-Tikva District, Clalit Health Services, Petach Tikva, Israel. FAU - Gerstein, Maya AU - Gerstein M AD - 58408Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel. AD - Pediatric Ambulatory Community Clinic, Petach Tikva, Israel. FAU - Richenberg, Yael AU - Richenberg Y AD - Dan-Petach-Tikva District, Clalit Health Services, Petach Tikva, Israel. FAU - Jacobson, Eyal AU - Jacobson E AD - Dan-Petach-Tikva District, Clalit Health Services, Petach Tikva, Israel. FAU - Grossu, Roy AU - Grossu R AD - Dan-Petach-Tikva District, Clalit Health Services, Petach Tikva, Israel. FAU - Cohen, Moriya AU - Cohen M AD - 42732Ariel University, Ariel, Israel. FAU - Cohen, Herman Avner AU - Cohen HA AD - 58408Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel. AD - Pediatric Ambulatory Community Clinic, Petach Tikva, Israel. LA - eng PT - Journal Article DEP - 20220808 PL - United States TA - Int J Psychiatry Med JT - International journal of psychiatry in medicine JID - 0365646 RN - 0 (COVID-19 Vaccines) SB - IM MH - Female MH - Humans MH - Adolescent MH - *Attention Deficit Disorder with Hyperactivity/epidemiology MH - COVID-19 Vaccines MH - Retrospective Studies MH - *COVID-19/prevention & control MH - Patient Compliance PMC - PMC9364072 OTO - NOTNLM OT - ADHD OT - COVID-19 OT - adolescents OT - vaccination COIS- The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: This study was approved by the community institutional review board which adheres to the Declaration of Helsinki and its amendments, and was exempt from individual informed consent. EDAT- 2022/08/09 06:00 MHDA- 2023/02/07 06:00 PMCR- 2023/03/01 CRDT- 2022/08/08 19:33 PHST- 2022/08/09 06:00 [pubmed] PHST- 2023/02/07 06:00 [medline] PHST- 2022/08/08 19:33 [entrez] PHST- 2023/03/01 00:00 [pmc-release] AID - 10.1177_00912174221116734 [pii] AID - 10.1177/00912174221116734 [doi] PST - ppublish SO - Int J Psychiatry Med. 2023 Mar;58(2):145-159. doi: 10.1177/00912174221116734. Epub 2022 Aug 8. PMID- 35909330 OWN - NLM STAT- MEDLINE DCOM- 20240205 LR - 20240205 IS - 2576-2095 (Electronic) IS - 2096-5451 (Print) IS - 2576-2095 (Linking) VI - 5 IP - 5 DP - 2022 Oct TI - The effects of inactivated SARS-CoV-2 vaccination and subsequent infection of pregnant mice on the behaviors of offspring. PG - 430-435 LID - 10.1002/ame2.12261 [doi] AB - The mass inoculation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines to induce herd immunity is one of the most effective measures we can deploy in the fight against coronavirus disease 2019 (COVID-19). Pregnant women are prone to a higher risk of COVID-19, and maternal infection is a risk factor for a range of neurological disorders leading to abnormal behavior in adulthood. However, there are limited clinical data to support whether vaccination or infection post-immunization in pregnant women can affect the behavioral cognition of fetuses in adulthood. In this study, human angiotensin-converting enzyme 2 pregnant mice (F0 generation) were immunized with CoronaVac and then infected with SARS-CoV-2. Subsequently, we analyzed the behavioral cognition of their adult offspring (F1 generation) using the open-field test and Morris water maze test. The adult F1 generation did not exhibit any impairments in spontaneous locomotor activity or spatial reference memory. CI - (c) 2022 The Authors. Animal Models and Experimental Medicine published by John Wiley & Sons Australia, Ltd on behalf of The Chinese Association for Laboratory Animal Sciences. FAU - Lin, Kaili AU - Lin K AUID- ORCID: 0000-0002-6021-1948 AD - Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Comparative Medicine Center, Peking Union Medical College, Beijing, China. FAU - Liu, Meixuan AU - Liu M AD - Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Comparative Medicine Center, Peking Union Medical College, Beijing, China. FAU - Sun, Lu AU - Sun L AD - Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Comparative Medicine Center, Peking Union Medical College, Beijing, China. FAU - Qiao, Hongwei AU - Qiao H AD - Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Comparative Medicine Center, Peking Union Medical College, Beijing, China. FAU - Wang, Shunyi AU - Wang S AD - Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Comparative Medicine Center, Peking Union Medical College, Beijing, China. FAU - Pan, Sidan AU - Pan S AD - Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Comparative Medicine Center, Peking Union Medical College, Beijing, China. FAU - Fu, Hanjun AU - Fu H AD - Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Comparative Medicine Center, Peking Union Medical College, Beijing, China. FAU - Wang, Jingzhu AU - Wang J AD - Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Comparative Medicine Center, Peking Union Medical College, Beijing, China. FAU - Wei, Qiang AU - Wei Q AD - Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Comparative Medicine Center, Peking Union Medical College, Beijing, China. FAU - Gao, Hong AU - Gao H AD - Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Comparative Medicine Center, Peking Union Medical College, Beijing, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220731 PL - United States TA - Animal Model Exp Med JT - Animal models and experimental medicine JID - 101726292 RN - 0 (COVID-19 Vaccines) SB - IM MH - Animals MH - Female MH - Mice MH - Pregnancy MH - *COVID-19/prevention & control MH - COVID-19 Vaccines MH - Immunity, Herd MH - *SARS-CoV-2 MH - Vaccination PMC - PMC9353298 OTO - NOTNLM OT - offspring OT - spatial reference memory OT - spontaneous locomotor activity COIS- The authors declare that they have no conflicts of interest. EDAT- 2022/08/02 06:00 MHDA- 2022/11/01 06:00 PMCR- 2022/07/31 CRDT- 2022/08/01 02:43 PHST- 2022/03/09 00:00 [received] PHST- 2022/06/30 00:00 [accepted] PHST- 2022/08/02 06:00 [pubmed] PHST- 2022/11/01 06:00 [medline] PHST- 2022/08/01 02:43 [entrez] PHST- 2022/07/31 00:00 [pmc-release] AID - AME212261 [pii] AID - 10.1002/ame2.12261 [doi] PST - ppublish SO - Animal Model Exp Med. 2022 Oct;5(5):430-435. doi: 10.1002/ame2.12261. Epub 2022 Jul 31. PMID- 35905950 OWN - NLM STAT- MEDLINE DCOM- 20221027 LR - 20230124 IS - 1878-3511 (Electronic) IS - 1201-9712 (Print) IS - 1201-9712 (Linking) VI - 122 DP - 2022 Sep TI - Safety and immunogenicity of inactivated SARS-CoV-2 vaccines in people with gastrointestinal cancer. PG - 874-884 LID - S1201-9712(22)00446-5 [pii] LID - 10.1016/j.ijid.2022.07.050 [doi] AB - OBJECTIVES: This study aimed to evaluate the safety and immunogenicity of inactivated COVID-19 vaccines in patients with gastrointestinal cancer (GI) cancer. The role of memory B cells (MBCs) in the humoral response to COVID-19 vaccination was also investigated. METHODS: In this prospective observational study, GI cancer patients and healthy individuals who had received 2 doses of inactivated COVID-19 vaccines were included. The data regarding adverse effects, serum anti-receptor binding domain (RBD)-IgG, neutralizing antibodies (NAbs), and frequencies of MBCs were collected prospectively. RESULTS: The inactivated COVID-19 vaccines were safe and well tolerated. Serum anti-RBG-IgG and NAbs were lower for cancer patients. Old age, high ASA score, and receiving active chemotherapy were risk factors for lower antibody titers. The frequencies of activated and resting MBCs decreased in (17.45% vs 38.11%, P = 0.002; 16.98% vs 34.13%, P = 0.023), while the frequencies of intermediate and atypical MBCs increased in cancer patients (40.06% vs 19.87%, P = 0.010; 25.47% vs 16.61%, P = 0.025). The serum antibody titer decreased gradually during follow-up but increased when a booster vaccine was given. CONCLUSION: The inactivated COVID-19 vaccines were well tolerated in patients with GI cancer but with lower immunogenicity. The subpopulations of MBCs were disordered in cancer patients, and a booster vaccine may be prioritized for them. CI - Copyright (c) 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved. FAU - Li, Tong AU - Li T AD - Department of Gastrointestinal Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China. FAU - Song, Rui AU - Song R AD - Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China. FAU - Wang, Jingjie AU - Wang J AD - Department of Gastrointestinal Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China. FAU - Zhang, Jianbo AU - Zhang J AD - Department of Gastrointestinal Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China. FAU - Cai, Hongxing AU - Cai H AD - Department of Gastrointestinal Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China. FAU - He, Hongmei AU - He H AD - Department of Gastrointestinal Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China. FAU - Hu, Wei AU - Hu W AD - Department of General Surgery, The Renmin Hospital of Wushan country, Chongqing, China. FAU - Yu, Dajun AU - Yu D AD - Department of General Surgery, The Renmin Hospital of Wushan country, Chongqing, China. FAU - Wang, Chuanhu AU - Wang C AD - Department of General Surgery, The Renmin Hospital of Wushan country, Chongqing, China. FAU - Pan, Qingbo AU - Pan Q AD - Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China. FAU - Peng, Mingli AU - Peng M AD - Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China. FAU - Ren, Hong AU - Ren H AD - Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China. Electronic address: renhong0531@cqmu.edu.cn. FAU - Zhu, Peng AU - Zhu P AD - Department of Gastrointestinal Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China. Electronic address: zupeng@cqmu.edu.cn. LA - eng PT - Journal Article PT - Observational Study DEP - 20220726 PL - Canada TA - Int J Infect Dis JT - International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases JID - 9610933 RN - 0 (Antibodies, Neutralizing) RN - 0 (Antibodies, Viral) RN - 0 (COVID-19 Vaccines) RN - 0 (Immunoglobulin G) RN - 0 (Vaccines, Inactivated) SB - IM MH - Humans MH - Antibodies, Neutralizing MH - Antibodies, Viral MH - *COVID-19/prevention & control MH - *COVID-19 Vaccines/immunology MH - *Gastrointestinal Neoplasms/chemically induced MH - Immunoglobulin G MH - SARS-CoV-2 MH - Vaccines, Inactivated/immunology MH - Immunogenicity, Vaccine PMC - PMC9316719 OTO - NOTNLM OT - COVID-19 OT - Inactivated vaccine OT - Memory B cells COIS- Declaration of Competing Interest The authors have no conflicts of interest to declare. EDAT- 2022/07/30 06:00 MHDA- 2022/09/09 06:00 PMCR- 2022/07/26 CRDT- 2022/07/29 19:23 PHST- 2022/07/05 00:00 [received] PHST- 2022/07/18 00:00 [revised] PHST- 2022/07/21 00:00 [accepted] PHST- 2022/07/30 06:00 [pubmed] PHST- 2022/09/09 06:00 [medline] PHST- 2022/07/29 19:23 [entrez] PHST- 2022/07/26 00:00 [pmc-release] AID - S1201-9712(22)00446-5 [pii] AID - 10.1016/j.ijid.2022.07.050 [doi] PST - ppublish SO - Int J Infect Dis. 2022 Sep;122:874-884. doi: 10.1016/j.ijid.2022.07.050. Epub 2022 Jul 26. PMID- 35891278 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220731 IS - 2076-393X (Print) IS - 2076-393X (Electronic) IS - 2076-393X (Linking) VI - 10 IP - 7 DP - 2022 Jul 13 TI - A Rare Adverse Effect of the COVID-19 Vaccine on Autoimmune Encephalitis. LID - 10.3390/vaccines10071114 [doi] LID - 1114 AB - Since countries commenced COVID-19 vaccination around the world, many vaccine-related adverse effects have been reported. Among them, short-term memory loss with autoimmune encephalitis (AE) was reported as a rare adverse effect. Since case numbers are limited, this brief report may draw the attention of the medical community to this uncommon adverse effect and serve as a reference for future vaccine improvement. However, given the high risk of adverse outcomes when infected with SARS-CoV-2 and the clearly favorable safety/tolerability profile of existing vaccines, vaccination is still recommended. FAU - Huang, Ying-Fong AU - Huang YF AD - Department of Nuclear Medicine, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan. AD - Department of Medical Imaging and Radiological Sciences, Kaohsiung Medical University, Kaohsiung 807, Taiwan. FAU - Ho, Tzu-Chuan AU - Ho TC AD - Department of Medical Imaging and Radiological Sciences, Kaohsiung Medical University, Kaohsiung 807, Taiwan. FAU - Chang, Chin-Chuan AU - Chang CC AD - Department of Nuclear Medicine, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan. AD - School of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan. AD - Neuroscience Research Center, Kaohsiung Medical University, Kaohsiung 807, Taiwan. AD - Department of Electrical Engineering, I-Shou University, Kaohsiung 840, Taiwan. FAU - Shen, Daniel Hueng-Yuan AU - Shen DH AD - Department of Nuclear Medicine, Kaohsiung Veterans General Hospital, Kaohsiung 813, Taiwan. FAU - Chan, Hung-Pin AU - Chan HP AUID- ORCID: 0000-0001-9741-5824 AD - Department of Nuclear Medicine, Kaohsiung Veterans General Hospital, Kaohsiung 813, Taiwan. FAU - Chuang, Kuo-Pin AU - Chuang KP AUID- ORCID: 0000-0002-3973-8390 AD - Graduate Institute of Animal Vaccine Technology, College of Veterinary Medicine, National Pingtung University of Science and Technology, Pingtung 912, Taiwan. FAU - Tyan, Yu-Chang AU - Tyan YC AUID- ORCID: 0000-0002-1917-5893 AD - Department of Nuclear Medicine, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan. AD - Department of Medical Imaging and Radiological Sciences, Kaohsiung Medical University, Kaohsiung 807, Taiwan. AD - School of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan. AD - Graduate Institute of Animal Vaccine Technology, College of Veterinary Medicine, National Pingtung University of Science and Technology, Pingtung 912, Taiwan. AD - Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan. AD - Department of Medical Research, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan. AD - Center for Cancer Research, Kaohsiung Medical University, Kaohsiung 807, Taiwan. AD - Research Center for Environmental Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan. FAU - Yang, Ming-Hui AU - Yang MH AUID- ORCID: 0000-0001-5856-0498 AD - Department of Medical Education and Research, Kaohsiung Veterans General Hospital, Kaohsiung 813, Taiwan. AD - Center of General Education, Shu-Zen Junior College of Medicine and Management, Kaohsiung 821, Taiwan. LA - eng GR - MOST 109-2221-E-037-001-MY3/Ministry of Science and Technology/ GR - KMUH110-0T02/Kaohsiung Medical University/ GR - NPUST-KMU-111-P002/NPUST-KMU JOINT RESEARCH PROJECT/ PT - Journal Article DEP - 20220713 PL - Switzerland TA - Vaccines (Basel) JT - Vaccines JID - 101629355 PMC - PMC9319671 OTO - NOTNLM OT - COVID-19 vaccine OT - adverse effect OT - autoimmune encephalitis OT - lymphocytic pleocytosis OT - short-term memory loss COIS- The authors declare no conflict of interest. EDAT- 2022/07/28 06:00 MHDA- 2022/07/28 06:01 PMCR- 2022/07/13 CRDT- 2022/07/27 01:43 PHST- 2022/05/12 00:00 [received] PHST- 2022/06/28 00:00 [revised] PHST- 2022/07/06 00:00 [accepted] PHST- 2022/07/27 01:43 [entrez] PHST- 2022/07/28 06:00 [pubmed] PHST- 2022/07/28 06:01 [medline] PHST- 2022/07/13 00:00 [pmc-release] AID - vaccines10071114 [pii] AID - vaccines-10-01114 [pii] AID - 10.3390/vaccines10071114 [doi] PST - epublish SO - Vaccines (Basel). 2022 Jul 13;10(7):1114. doi: 10.3390/vaccines10071114. PMID- 35876629 OWN - NLM STAT- MEDLINE DCOM- 20221011 LR - 20221017 IS - 1440-1819 (Electronic) IS - 1323-1316 (Print) IS - 1323-1316 (Linking) VI - 76 IP - 10 DP - 2022 Oct TI - Functional neurological disorders after COVID-19 vaccination: Case series and literature review. PG - 529-531 LID - 10.1111/pcn.13453 [doi] FAU - Takahashi, Osamu AU - Takahashi O AD - Clinical Physiology Unit, Sakura Medical Center, Toho University, Sakura, Japan. FAU - Sakakibara, Ryuji AU - Sakakibara R AUID- ORCID: 0000-0002-5803-169X AD - Neurology, Sakura Medical Center, Toho University, Sakura, Japan. FAU - Sawai, Setsu AU - Sawai S AD - Neurology, Sakura Medical Center, Toho University, Sakura, Japan. FAU - Ogata, Tsuyoshi AU - Ogata T AD - Neurology, Sakura Medical Center, Toho University, Sakura, Japan. LA - eng PT - Letter PT - Review DEP - 20220812 PL - Australia TA - Psychiatry Clin Neurosci JT - Psychiatry and clinical neurosciences JID - 9513551 RN - 0 (COVID-19 Vaccines) SB - IM MH - *COVID-19/prevention & control MH - *COVID-19 Vaccines/adverse effects MH - *Conversion Disorder MH - Humans MH - Vaccination/adverse effects PMC - PMC9350106 EDAT- 2022/07/26 06:00 MHDA- 2022/10/12 06:00 PMCR- 2022/07/25 CRDT- 2022/07/25 09:42 PHST- 2022/06/30 00:00 [revised] PHST- 2022/06/06 00:00 [received] PHST- 2022/07/11 00:00 [accepted] PHST- 2022/07/26 06:00 [pubmed] PHST- 2022/10/12 06:00 [medline] PHST- 2022/07/25 09:42 [entrez] PHST- 2022/07/25 00:00 [pmc-release] AID - PCN13453 [pii] AID - 10.1111/pcn.13453 [doi] PST - ppublish SO - Psychiatry Clin Neurosci. 2022 Oct;76(10):529-531. doi: 10.1111/pcn.13453. Epub 2022 Aug 12. PMID- 35862718 OWN - NLM STAT- MEDLINE DCOM- 20220812 LR - 20251031 IS - 1098-5514 (Electronic) IS - 0022-538X (Print) IS - 0022-538X (Linking) VI - 96 IP - 15 DP - 2022 Aug 10 TI - Persistent Maintenance of Intermediate Memory B Cells Following SARS-CoV-2 Infection and Vaccination Recall Response. PG - e0076022 LID - 10.1128/jvi.00760-22 [doi] LID - e00760-22 AB - Robust population-wide immunity will help to curb the SARS-CoV-2 pandemics. To maintain the immunity at protective levels, the quality and persistence of the immune response elicited by infection or vaccination must be determined. We analyzed the dynamics of B cell response during 12 months following SARS-CoV-2 infection on an individual level. In contrast to antibodies, memory B cells specific for the spike (S) protein persisted at high levels throughout the period. These cells efficiently secreted neutralizing antibodies and correlated with IFN-gamma-secreting CD4(+) T cells. Interestingly, the CD27(-)CD21(+) intermediate memory B cell phenotype was associated with high B cell receptor avidity and the production of neutralizing antibodies. Vaccination of previously infected individuals triggered a recall response enhancing neutralizing antibody and memory B cell levels. Collectively, our findings provide a detailed insight into the longevity of SARS-CoV-2-infection-induced B cell immunity and highlight the importance of vaccination among previously infected. IMPORTANCE To efficiently maintain immunity against SARS-CoV-2 infection, we must first determine the durability of the immune response following infection or vaccination. Here, we demonstrated that, unlike antibodies, virus-specific memory B cells persist at high levels for at least 12 months postinfection and successfully respond to a secondary antigen challenge. Furthermore, we demonstrated that vaccination of previously infected individuals significantly boosters B cell immunity. FAU - Pusnik, Jernej AU - Pusnik J AD - Institute of Virology, University Hospital Bonn, Bonn, Germany. AD - German Center for Infection Research (DZIF), partner site Bonn-Cologne, Braunschweig, Germany. FAU - Konig, Julia AU - Konig J AD - Institute of Virology, University Hospital Bonn, Bonn, Germany. AD - German Center for Infection Research (DZIF), partner site Bonn-Cologne, Braunschweig, Germany. FAU - Mai, Karola AU - Mai K AD - Institute of Virology, University Hospital Bonn, Bonn, Germany. AD - German Center for Infection Research (DZIF), partner site Bonn-Cologne, Braunschweig, Germany. FAU - Richter, Enrico AU - Richter E AD - Institute of Virology, University Hospital Bonn, Bonn, Germany. AD - German Center for Infection Research (DZIF), partner site Bonn-Cologne, Braunschweig, Germany. FAU - Zorn, Jasmin AU - Zorn J AD - Institute of Virology, University Hospital Bonn, Bonn, Germany. AD - German Center for Infection Research (DZIF), partner site Bonn-Cologne, Braunschweig, Germany. FAU - Proksch, Hannah AU - Proksch H AD - Institute of Virology, University Hospital Bonn, Bonn, Germany. AD - German Center for Infection Research (DZIF), partner site Bonn-Cologne, Braunschweig, Germany. FAU - Schulte, Bianca AU - Schulte B AD - Institute of Virology, University Hospital Bonn, Bonn, Germany. AD - German Center for Infection Research (DZIF), partner site Bonn-Cologne, Braunschweig, Germany. FAU - Alter, Galit AU - Alter G AD - Ragon Institute of MGH, MIT, and Harvard, Massachusetts General Hospital, Boston, Massachusetts, USA. FAU - Streeck, Hendrik AU - Streeck H AUID- ORCID: 0000-0002-0335-6390 AD - Institute of Virology, University Hospital Bonn, Bonn, Germany. AD - German Center for Infection Research (DZIF), partner site Bonn-Cologne, Braunschweig, Germany. LA - eng PT - Journal Article DEP - 20220712 PL - United States TA - J Virol JT - Journal of virology JID - 0113724 RN - 0 (Antibodies, Neutralizing) RN - 0 (Antibodies, Viral) RN - 0 (COVID-19 Vaccines) RN - 0 (IFNG protein, human) RN - 0 (Spike Glycoprotein, Coronavirus) RN - 0 (spike protein, SARS-CoV-2) RN - 82115-62-6 (Interferon-gamma) SB - IM MH - Antibodies, Neutralizing MH - Antibodies, Viral MH - CD4-Positive T-Lymphocytes/immunology MH - *COVID-19/immunology MH - *COVID-19 Vaccines/chemistry/immunology MH - Humans MH - *Immunologic Memory MH - Interferon-gamma/immunology MH - *Memory B Cells/cytology/immunology MH - *SARS-CoV-2/immunology MH - Spike Glycoprotein, Coronavirus/immunology MH - Time Factors MH - *Vaccination PMC - PMC9364791 OTO - NOTNLM OT - CD4+ T cell OT - COVID-19 OT - SARS-CoV-2 OT - antibody OT - immunity OT - immunization OT - kinetics OT - longevity OT - longitudinal OT - memory B cells OT - neutralization OT - recovered OT - spike OT - vaccination COIS- The authors declare no conflict of interest. EDAT- 2022/07/22 06:00 MHDA- 2022/08/13 06:00 PMCR- 2022/07/12 CRDT- 2022/07/21 15:04 PHST- 2022/07/22 06:00 [pubmed] PHST- 2022/08/13 06:00 [medline] PHST- 2022/07/21 15:04 [entrez] PHST- 2022/07/12 00:00 [pmc-release] AID - 00760-22 [pii] AID - jvi.00760-22 [pii] AID - 10.1128/jvi.00760-22 [doi] PST - ppublish SO - J Virol. 2022 Aug 10;96(15):e0076022. doi: 10.1128/jvi.00760-22. Epub 2022 Jul 12. PMID- 35858586 OWN - NLM STAT- MEDLINE DCOM- 20220722 LR - 20260518 IS - 2666-3791 (Electronic) IS - 2666-3791 (Linking) VI - 3 IP - 7 DP - 2022 Jul 19 TI - Persistence of MERS-CoV-spike-specific B cells and antibodies after late third immunization with the MVA-MERS-S vaccine. PG - 100685 LID - S2666-3791(22)00221-X [pii] LID - 10.1016/j.xcrm.2022.100685 [doi] LID - 100685 AB - The Middle East respiratory syndrome (MERS) is a respiratory disease caused by MERS coronavirus (MERS-CoV). In follow up to a phase 1 trial, we perform a longitudinal analysis of immune responses following immunization with the modified vaccinia virus Ankara (MVA)-based vaccine MVA-MERS-S encoding the MERS-CoV-spike protein. Three homologous immunizations were administered on days 0 and 28 with a late booster vaccination at 12 +/- 4 months. Antibody isotypes, subclasses, and neutralization capacity as well as T and B cell responses were monitored over a period of 3 years using standard and bead-based enzyme-linked immunosorbent assay (ELISA), 50% plaque-reduction neutralization test (PRNT50), enzyme-linked immunospot (ELISpot), and flow cytometry. The late booster immunization significantly increases the frequency and persistence of spike-specific B cells, binding immunoglobulin G1 (IgG1) and neutralizing antibodies but not T cell responses. Our data highlight the potential of a late boost to enhance long-term antibody and B cell immunity against MERS-CoV. Our findings on the MVA-MERS-S vaccine may be of relevance for coronavirus 2019 (COVID-19) vaccination strategies. CI - Copyright (c) 2022 The Author(s). Published by Elsevier Inc. All rights reserved. FAU - Weskamm, Leonie M AU - Weskamm LM AD - Institute for Infection Research and Vaccine Development (IIRVD), University Medical Centre Hamburg-Eppendorf, Hamburg, Germany; Department for Clinical Immunology of Infectious Diseases, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany; German Centre for Infection Research, Hamburg-Lubeck-Borstel-Riems, Germany. Electronic address: m.weskamm@uke.de. FAU - Fathi, Anahita AU - Fathi A AD - Institute for Infection Research and Vaccine Development (IIRVD), University Medical Centre Hamburg-Eppendorf, Hamburg, Germany; Department for Clinical Immunology of Infectious Diseases, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany; German Centre for Infection Research, Hamburg-Lubeck-Borstel-Riems, Germany; First Department of Medicine, Division of Infectious Diseases, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany. FAU - Raadsen, Matthijs P AU - Raadsen MP AD - Department of Virology, Erasmus Medical Centre, Rotterdam, the Netherlands. FAU - Mykytyn, Anna Z AU - Mykytyn AZ AD - Department of Virology, Erasmus Medical Centre, Rotterdam, the Netherlands. FAU - Koch, Till AU - Koch T AD - Institute for Infection Research and Vaccine Development (IIRVD), University Medical Centre Hamburg-Eppendorf, Hamburg, Germany; Department for Clinical Immunology of Infectious Diseases, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany; German Centre for Infection Research, Hamburg-Lubeck-Borstel-Riems, Germany; First Department of Medicine, Division of Infectious Diseases, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany. FAU - Spohn, Michael AU - Spohn M AD - Research Institute Children's Cancer Centre Hamburg, Hamburg, Germany; Department of Pediatric Hematology and Oncology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany; Bioinformatics Core Unit, Hamburg University Medical Centre, Hamburg, Germany. FAU - Friedrich, Monika AU - Friedrich M AD - Institute for Infection Research and Vaccine Development (IIRVD), University Medical Centre Hamburg-Eppendorf, Hamburg, Germany; Department for Clinical Immunology of Infectious Diseases, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany; German Centre for Infection Research, Hamburg-Lubeck-Borstel-Riems, Germany. CN - MVA-MERS-S Study Group FAU - Haagmans, Bart L AU - Haagmans BL AD - Department of Virology, Erasmus Medical Centre, Rotterdam, the Netherlands. FAU - Becker, Stephan AU - Becker S AD - German Centre for Infection Research, Giessen-Marburg-Langen, Germany; Institute for Virology, Philipps University Marburg, Marburg, Germany. FAU - Sutter, Gerd AU - Sutter G AD - German Centre for Infection Research, Munchen, Germany; Division of Virology, Institute for Infectious Diseases and Zoonoses, Department of Veterinary Sciences, LMU Munich, Munich, Germany. FAU - Dahlke, Christine AU - Dahlke C AD - Institute for Infection Research and Vaccine Development (IIRVD), University Medical Centre Hamburg-Eppendorf, Hamburg, Germany; Department for Clinical Immunology of Infectious Diseases, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany; German Centre for Infection Research, Hamburg-Lubeck-Borstel-Riems, Germany. Electronic address: c.dahlke@uke.de. FAU - Addo, Marylyn M AU - Addo MM AD - Institute for Infection Research and Vaccine Development (IIRVD), University Medical Centre Hamburg-Eppendorf, Hamburg, Germany; Department for Clinical Immunology of Infectious Diseases, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany; German Centre for Infection Research, Hamburg-Lubeck-Borstel-Riems, Germany; First Department of Medicine, Division of Infectious Diseases, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany. LA - eng SI - ClinicalTrials.gov/NCT03615911 PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Cell Rep Med JT - Cell reports. Medicine JID - 101766894 RN - 0 (Antibodies, Viral) RN - 0 (Viral Vaccines) SB - IM MH - Antibodies, Viral MH - *COVID-19/prevention & control MH - Clinical Trials, Phase I as Topic MH - Follow-Up Studies MH - Humans MH - *Middle East Respiratory Syndrome Coronavirus MH - Vaccination MH - Vaccinia virus MH - *Viral Vaccines PMC - PMC9295383 OTO - NOTNLM OT - IgG ELISpot OT - IgG subclasses OT - MERS-CoV OT - MVA-MERS-S OT - immune persistence OT - late booster vaccination OT - long-term immunity OT - memory B cells OT - neutralizing antibodies OT - viral vector vaccine COIS- Declaration of interests The authors declare no competing interests. FIR - Bartels, Etienne IR - Bartels E FIR - Gundlach, Swantje IR - Gundlach S FIR - Hesterkamp, Thomas IR - Hesterkamp T FIR - Krahling, Verena IR - Krahling V FIR - Lassen, Susan IR - Lassen S FIR - Ly, My Linh IR - Ly ML FIR - Potsch, Joseph H IR - Potsch JH FIR - Schmiedel, Stefan IR - Schmiedel S FIR - Volz, Asisa IR - Volz A FIR - Zinser, Madeleine E IR - Zinser ME EDAT- 2022/07/21 06:00 MHDA- 2022/07/23 06:00 PMCR- 2022/07/19 CRDT- 2022/07/20 18:23 PHST- 2020/10/08 00:00 [received] PHST- 2022/02/25 00:00 [revised] PHST- 2022/06/16 00:00 [accepted] PHST- 2022/07/20 18:23 [entrez] PHST- 2022/07/21 06:00 [pubmed] PHST- 2022/07/23 06:00 [medline] PHST- 2022/07/19 00:00 [pmc-release] AID - S2666-3791(22)00221-X [pii] AID - 100685 [pii] AID - 10.1016/j.xcrm.2022.100685 [doi] PST - ppublish SO - Cell Rep Med. 2022 Jul 19;3(7):100685. doi: 10.1016/j.xcrm.2022.100685. PMID- 35857310 OWN - NLM STAT- MEDLINE DCOM- 20220805 LR - 20250728 IS - 1557-8976 (Electronic) IS - 0882-8245 (Linking) VI - 35 IP - 6 DP - 2022 Jul TI - SARS-CoV-2-Specific Memory B Cell Responses Are Maintained After Recovery from Natural Infection and Postvaccination. PG - 425-436 LID - 10.1089/vim.2022.0013 [doi] AB - Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory coronavirus 2 (SARS-CoV-2), has resulted in major worldwide disruption and loss of life over the last 2 years. Many research studies have shown waning serological SARS-CoV-2-specific IgG antibody titers over time, yet, it is unclear whether these changes are reflected in the potential functional reactivation of SARS-CoV-2 antigen-specific memory B cells (MBC) populations. This is especially true in the contexts of differing COVID-19 disease severity and after vaccination regimens. This study aimed to investigate these by polyclonal in vitro reactivation of MBC populations followed by analysis using SAR-CoV-2 antigen-specific B cell ELISpots and IgG antibody ELISAs. Natural disease-associated differences were investigated in 52 donors who have recovered from COVID-19 with varying disease severity, from asymptomatic to severe COVID-19 disease, accompanied by a longitudinal evaluation in a subset of donors. Overall, these data showed limited disease severity-associated differences between donor groups but did show that COVID-19 serologically positive donors had strong antigen-specific MBC-associated responses. MBC responses were better maintained 6 months after recovery from infection when compared to serological antigen-specific IgG antibody titers. A similar investigation after vaccination using 14 donors showed robust serological antigen-specific antibody responses against spike protein that waned over time. MBC-associated responses against spike protein were also observed but showed less waning over time, indicating maintenance of a protective response 6 months after vaccination. Further research is required to evaluate these putatively functional SARS-CoV-2-specific responses in the context of long-term protection mediated by vaccination against this pathogen. FAU - Moore, Tom AU - Moore T AUID- ORCID: 0000-0002-4143-9453 AD - MRC & Asthma UK Centre in Allergic Mechanisms of Asthma, Peter Gorer Department of Immunobiology, School of Immunology & Microbial Sciences, King's College London, United Kingdom. FAU - Hossain, Rojony AU - Hossain R AD - MRC & Asthma UK Centre in Allergic Mechanisms of Asthma, Peter Gorer Department of Immunobiology, School of Immunology & Microbial Sciences, King's College London, United Kingdom. FAU - Doores, Katie J AU - Doores KJ AD - Department of Infectious Diseases, School of Immunology & Microbial Sciences, King's College London, United Kingdom. FAU - Shankar-Hari, Manu AU - Shankar-Hari M AUID- ORCID: 0000-0002-5338-2538 AD - MRC & Asthma UK Centre in Allergic Mechanisms of Asthma, Peter Gorer Department of Immunobiology, School of Immunology & Microbial Sciences, King's College London, United Kingdom. AD - The Queen's Medical Research Institute, Centre for Inflammation Research, University of Edinburgh, Edinburgh, United Kingdom. AD - Royal Infirmary of Edinburgh, NHS Lothian, Edinburgh, United Kingdom. FAU - Fear, David J AU - Fear DJ AUID- ORCID: 0000-0003-0239-8385 AD - MRC & Asthma UK Centre in Allergic Mechanisms of Asthma, Peter Gorer Department of Immunobiology, School of Immunology & Microbial Sciences, King's College London, United Kingdom. LA - eng GR - CS-2016-16-011/DH_/Department of Health/United Kingdom PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220720 PL - United States TA - Viral Immunol JT - Viral immunology JID - 8801552 RN - 0 (Antibodies, Viral) RN - 0 (Immunoglobulin G) RN - 0 (Spike Glycoprotein, Coronavirus) RN - 0 (spike protein, SARS-CoV-2) SB - IM MH - Antibodies, Viral MH - *COVID-19/prevention & control MH - Humans MH - Immunoglobulin G MH - Memory B Cells MH - SARS-CoV-2 MH - *Spike Glycoprotein, Coronavirus MH - Vaccination OTO - NOTNLM OT - SARS-CoV-2 OT - adaptive immunity OT - humoral immunity OT - memory B cell OT - natural infection OT - vaccination EDAT- 2022/07/21 06:00 MHDA- 2022/08/06 06:00 CRDT- 2022/07/20 11:33 PHST- 2022/07/21 06:00 [pubmed] PHST- 2022/08/06 06:00 [medline] PHST- 2022/07/20 11:33 [entrez] AID - 10.1089/vim.2022.0013 [doi] PST - ppublish SO - Viral Immunol. 2022 Jul;35(6):425-436. doi: 10.1089/vim.2022.0013. Epub 2022 Jul 20. PMID- 35839774 OWN - NLM STAT- MEDLINE DCOM- 20220802 LR - 20260127 IS - 2211-1247 (Electronic) VI - 40 IP - 4 DP - 2022 Jul 26 TI - The generation of stem cell-like memory cells early after BNT162b2 vaccination is associated with durability of memory CD8(+) T cell responses. PG - 111138 LID - S2211-1247(22)00947-0 [pii] LID - 10.1016/j.celrep.2022.111138 [doi] AB - COVID-19 vaccines elicit humoral and cellular immune responses. Durable maintenance of vaccine-induced immunity is required for long-term protection of the host. Here, we examine activation and differentiation of vaccine-induced CD8(+) T cells using MHC class I (MHC-I) multimers and correlations between early differentiation and the durability of CD8(+) T cell responses among healthcare workers immunized with two doses of BNT162b2. The frequency of MHC-I multimer(+) cells is robustly increased by BNT162b2 but decreases 6 months post-second vaccination to 2.4%-65.6% (23.0% on average) of the peak. MHC-I multimer(+) cells dominantly exhibit phenotypes of activated effector cells 1-2 weeks post-second vaccination and gradually acquire phenotypes of long-term memory cells, including stem cell-like memory T (T(SCM)) cells. Importantly, the frequency of T(SCM) cells 1-2 weeks post-second vaccination significantly correlates with the 6-month durability of CD8(+) T cells, indicating that early generation of T(SCM) cells determines the longevity of vaccine-induced memory CD8(+) T cell responses. CI - Copyright (c) 2022 The Author(s). Published by Elsevier Inc. All rights reserved. FAU - Jung, Sungmin AU - Jung S AD - Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon 34141, Republic of Korea. FAU - Jung, Jae Hyung AU - Jung JH AD - Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon 34141, Republic of Korea. FAU - Noh, Ji Yun AU - Noh JY AD - Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon 34141, Republic of Korea; Division of Infectious Diseases, Department of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine, Seoul 08308, Republic of Korea. FAU - Kim, Woo-Joong AU - Kim WJ AD - Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon 34141, Republic of Korea. FAU - Yoon, Soo-Young AU - Yoon SY AD - Department of Laboratory Medicine, Korea University Guro Hospital, Korea University College of Medicine, Seoul 08308, Republic of Korea. FAU - Jung, Jongtak AU - Jung J AD - Division of Infectious Diseases, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam 13620, Republic of Korea. FAU - Kim, Eu Suk AU - Kim ES AD - Division of Infectious Diseases, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam 13620, Republic of Korea. FAU - Kim, Hong Bin AU - Kim HB AD - Division of Infectious Diseases, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam 13620, Republic of Korea. FAU - Cheong, Hee Jin AU - Cheong HJ AD - Division of Infectious Diseases, Department of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine, Seoul 08308, Republic of Korea. FAU - Kim, Woo Joo AU - Kim WJ AD - Division of Infectious Diseases, Department of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine, Seoul 08308, Republic of Korea. FAU - Park, Su-Hyung AU - Park SH AD - Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon 34141, Republic of Korea. FAU - Song, Kyoung-Ho AU - Song KH AD - Division of Infectious Diseases, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam 13620, Republic of Korea. Electronic address: khsongmd@snu.ac.kr. FAU - Song, Joon Young AU - Song JY AD - Division of Infectious Diseases, Department of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine, Seoul 08308, Republic of Korea. Electronic address: infection@korea.ac.kr. FAU - Shin, Eui-Cheol AU - Shin EC AD - Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon 34141, Republic of Korea; The Center for Viral Immunology, Korea Virus Research Institute, Institute for Basic Science (IBS), Daejeon 34126, Republic of Korea. Electronic address: ecshin@kaist.ac.kr. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220708 PL - United States TA - Cell Rep JT - Cell reports JID - 101573691 RN - 0 (Antibodies, Viral) RN - 0 (BNT162 Vaccine) RN - 0 (COVID-19 Vaccines) SB - IM MH - Antibodies, Viral MH - BNT162 Vaccine MH - *CD8-Positive T-Lymphocytes MH - *COVID-19/prevention & control MH - COVID-19 Vaccines MH - Humans MH - Stem Cells MH - Vaccination PMC - PMC9263810 OTO - NOTNLM OT - CD8(+) T cell OT - COVID-19 OT - CP: Immunology OT - MHC class I multimer OT - SARS-CoV-2 OT - memory cell OT - vaccine COIS- Declaration of interests The authors declare no competing interests. EDAT- 2022/07/16 06:00 MHDA- 2022/08/03 06:00 PMCR- 2022/07/08 CRDT- 2022/07/15 18:43 PHST- 2022/01/19 00:00 [received] PHST- 2022/06/08 00:00 [revised] PHST- 2022/07/06 00:00 [accepted] PHST- 2022/07/16 06:00 [pubmed] PHST- 2022/08/03 06:00 [medline] PHST- 2022/07/15 18:43 [entrez] PHST- 2022/07/08 00:00 [pmc-release] AID - S2211-1247(22)00947-0 [pii] AID - 111138 [pii] AID - 10.1016/j.celrep.2022.111138 [doi] PST - ppublish SO - Cell Rep. 2022 Jul 26;40(4):111138. doi: 10.1016/j.celrep.2022.111138. Epub 2022 Jul 8. PMID- 35805076 OWN - NLM STAT- MEDLINE DCOM- 20220712 LR - 20231105 IS - 2073-4409 (Electronic) IS - 2073-4409 (Linking) VI - 11 IP - 13 DP - 2022 Jun 21 TI - Functional Profiling of In Vitro Reactivated Memory B Cells Following Natural SARS-CoV-2 Infection and Gam-COVID-Vac Vaccination. LID - 10.3390/cells11131991 [doi] LID - 1991 AB - Both SARS-CoV-2 infection and vaccination have previously been demonstrated to elicit robust, yet somewhat limited immunity against the evolving variants of SARS-CoV-2. Nevertheless, reports performing side-by-side comparison of immune responses following infection vs. vaccination have been relatively scarce. The aim of this study was to compare B-cell response to adenovirus-vectored vaccination in SARS-CoV-2-naive individuals with that observed in the COVID-19 convalescent patients six months after the first encounter with the viral antigens. We set out to use a single analytical platform and performed comprehensive analysis of serum levels of receptor binding domain (RBD)-specific and virus-neutralizing antibodies, frequencies of RBD-binding circulating memory B cells (MBCs), MBC-derived antibody-secreting cells, as well as RBD-specific and virus-neutralizing activity of MBC-derived antibodies after Gam-COVID-Vac (Sputnik V) vaccination and/or natural SARS-CoV-2 infection. Overall, natural immunity was superior to Gam-COVID-Vac vaccination. The levels of neutralizing MBC-derived antibodies in the convalescent patients turned out to be significantly higher than those found following vaccination. Our results suggest that after six months, SARS-CoV-2-specific MBC immunity is more robust in COVID-19 convalescent patients than in Gam-COVID-Vac recipients. Collectively, our data unambiguously indicate that natural immunity outperforms Gam-COVID-Vac-induced immunity six months following recovery/vaccination, which should inform healthcare and vaccination decisions. FAU - Astakhova, Ekaterina A AU - Astakhova EA AD - Laboratory of Immunochemistry, National Research Center Institute of Immunology, Federal Medical Biological Agency of Russia, 115522 Moscow, Russia. AD - Department of Immunology, Faculty of Biology, Lomonosov Moscow State University, 119234 Moscow, Russia. FAU - Byazrova, Maria G AU - Byazrova MG AD - Laboratory of Immunochemistry, National Research Center Institute of Immunology, Federal Medical Biological Agency of Russia, 115522 Moscow, Russia. AD - Department of Immunology, Faculty of Biology, Lomonosov Moscow State University, 119234 Moscow, Russia. AD - Department of Immunology, Institute of Medicine, Peoples' Friendship University of Russia (RUDN University), 117198 Moscow, Russia. FAU - Yusubalieva, Gaukhar M AU - Yusubalieva GM AD - Laboratory of Cell Technology, Federal Research and Clinical Center for Specialized Types of Medical Care and Medical Technologies of the FMBA of Russia, 115682 Moscow, Russia. FAU - Kulemzin, Sergey V AU - Kulemzin SV AD - Laboratory of Immunogenetics, Institute of Molecular and Cellular Biology, Siberian Branch of the Russian Academy of Sciences, 630090 Novosibirsk, Russia. FAU - Kruglova, Natalia A AU - Kruglova NA AUID- ORCID: 0000-0002-3984-4927 AD - Laboratory of Gene Therapy of Socially Significant Diseases, Center for Precision Genome Editing and Genetic Technologies for Biomedicine, Institute of Gene Biology of the Russian Academy of Sciences, 119334 Moscow, Russia. FAU - Prilipov, Alexey G AU - Prilipov AG AD - Laboratory of Immunochemistry, National Research Center Institute of Immunology, Federal Medical Biological Agency of Russia, 115522 Moscow, Russia. AD - Laboratory of Molecular Genetics, N.F. Gamaleya National Research Center for Epidemiology and Microbiology, Ministry of Health of the Russian Federation, 123098 Moscow, Russia. FAU - Baklaushev, Vladimir P AU - Baklaushev VP AD - Laboratory of Cell Technology, Federal Research and Clinical Center for Specialized Types of Medical Care and Medical Technologies of the FMBA of Russia, 115682 Moscow, Russia. FAU - Gorchakov, Andrey A AU - Gorchakov AA AUID- ORCID: 0000-0003-2830-4236 AD - Laboratory of Immunogenetics, Institute of Molecular and Cellular Biology, Siberian Branch of the Russian Academy of Sciences, 630090 Novosibirsk, Russia. FAU - Taranin, Alexander V AU - Taranin AV AUID- ORCID: 0000-0002-9184-4238 AD - Laboratory of Immunogenetics, Institute of Molecular and Cellular Biology, Siberian Branch of the Russian Academy of Sciences, 630090 Novosibirsk, Russia. FAU - Filatov, Alexander V AU - Filatov AV AUID- ORCID: 0000-0002-6460-9427 AD - Laboratory of Immunochemistry, National Research Center Institute of Immunology, Federal Medical Biological Agency of Russia, 115522 Moscow, Russia. AD - Department of Immunology, Faculty of Biology, Lomonosov Moscow State University, 119234 Moscow, Russia. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220621 PL - Switzerland TA - Cells JT - Cells JID - 101600052 RN - 0 (Antibodies, Neutralizing) RN - 0 (Antibodies, Viral) RN - 0 (Spike Glycoprotein, Coronavirus) RN - 0 (spike protein, SARS-CoV-2) SB - IM MH - Antibodies, Neutralizing MH - Antibodies, Viral MH - *COVID-19/prevention & control MH - Humans MH - Memory B Cells MH - SARS-CoV-2 MH - Spike Glycoprotein, Coronavirus MH - Vaccination PMC - PMC9265778 OTO - NOTNLM OT - COVID-19 OT - Gam-COVID-Vac vaccine OT - SARS-CoV-2 OT - Sputnik V vaccine OT - humoral immunity OT - memory B cells OT - neutralizing antibodies COIS- The authors declare no conflict of interest. EDAT- 2022/07/10 06:00 MHDA- 2022/07/14 06:00 PMCR- 2022/06/21 CRDT- 2022/07/09 01:05 PHST- 2022/04/14 00:00 [received] PHST- 2022/06/17 00:00 [revised] PHST- 2022/06/20 00:00 [accepted] PHST- 2022/07/09 01:05 [entrez] PHST- 2022/07/10 06:00 [pubmed] PHST- 2022/07/14 06:00 [medline] PHST- 2022/06/21 00:00 [pmc-release] AID - cells11131991 [pii] AID - cells-11-01991 [pii] AID - 10.3390/cells11131991 [doi] PST - epublish SO - Cells. 2022 Jun 21;11(13):1991. doi: 10.3390/cells11131991. PMID- 35764089 OWN - NLM STAT- MEDLINE DCOM- 20220712 LR - 20260127 IS - 1097-4172 (Electronic) IS - 0092-8674 (Print) IS - 0092-8674 (Linking) VI - 185 IP - 14 DP - 2022 Jul 7 TI - Humoral and cellular immune memory to four COVID-19 vaccines. PG - 2434-2451.e17 LID - S0092-8674(22)00653-5 [pii] LID - 10.1016/j.cell.2022.05.022 [doi] AB - Multiple COVID-19 vaccines, representing diverse vaccine platforms, successfully protect against symptomatic COVID-19 cases and deaths. Head-to-head comparisons of T cell, B cell, and antibody responses to diverse vaccines in humans are likely to be informative for understanding protective immunity against COVID-19, with particular interest in immune memory. Here, SARS-CoV-2-spike-specific immune responses to Moderna mRNA-1273, Pfizer/BioNTech BNT162b2, Janssen Ad26.COV2.S, and Novavax NVX-CoV2373 were examined longitudinally for 6 months 100% of individuals made memory CD4(+) T cells, with cTfh and CD4-CTL highly represented after mRNA or NVX-CoV2373 vaccination. mRNA vaccines and Ad26.COV2.S induced comparable CD8(+) T cell frequencies, though only detectable in 60-67% of subjects at 6 months. A differentiating feature of Ad26.COV2.S immunization was a high frequency of CXCR3(+) memory B cells. mRNA vaccinees had substantial declines in antibodies, while memory T and B cells were comparatively stable. These results may also be relevant for insights against other pathogens. CI - Copyright (c) 2022 Elsevier Inc. All rights reserved. FAU - Zhang, Zeli AU - Zhang Z AD - Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA. FAU - Mateus, Jose AU - Mateus J AD - Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA. FAU - Coelho, Camila H AU - Coelho CH AD - Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA. FAU - Dan, Jennifer M AU - Dan JM AD - Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA; Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego (UCSD), La Jolla, CA 92037, USA. FAU - Moderbacher, Carolyn Rydyznski AU - Moderbacher CR AD - Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA. FAU - Galvez, Rosa Isela AU - Galvez RI AD - Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA. FAU - Cortes, Fernanda H AU - Cortes FH AD - Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA; Laboratory of AIDS and Molecular Immunology, Institute Oswaldo Cruz, Fiocruz, Rio de Janeiro, RJ 21040-360, Brazil. FAU - Grifoni, Alba AU - Grifoni A AD - Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA. FAU - Tarke, Alison AU - Tarke A AD - Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA. FAU - Chang, James AU - Chang J AD - Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA. FAU - Escarrega, E Alexandar AU - Escarrega EA AD - Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA. FAU - Kim, Christina AU - Kim C AD - Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA. FAU - Goodwin, Benjamin AU - Goodwin B AD - Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA. FAU - Bloom, Nathaniel I AU - Bloom NI AD - Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA. FAU - Frazier, April AU - Frazier A AD - Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA. FAU - Weiskopf, Daniela AU - Weiskopf D AD - Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA. Electronic address: daniela@lji.org. FAU - Sette, Alessandro AU - Sette A AD - Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA; Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego (UCSD), La Jolla, CA 92037, USA. Electronic address: alex@lji.org. FAU - Crotty, Shane AU - Crotty S AD - Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA; Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego (UCSD), La Jolla, CA 92037, USA. Electronic address: shane@lji.org. LA - eng GR - R25 AI147376/AI/NIAID NIH HHS/United States GR - U01 CA260541/CA/NCI NIH HHS/United States GR - R01 AI135193/AI/NIAID NIH HHS/United States GR - K08 AI135078/AI/NIAID NIH HHS/United States GR - U19 AI142742/AI/NIAID NIH HHS/United States GR - P40 OD012217/OD/NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20220527 PL - United States TA - Cell JT - Cell JID - 0413066 RN - JT2NS6183B (Ad26COVS1) RN - 0 (Antibodies, Viral) RN - 0 (BNT162 Vaccine) RN - 0 (COVID-19 Vaccines) RN - 2SCD8Q63PF (NVX-CoV2373 adjuvated lipid nanoparticle) SB - IM UOF - bioRxiv. 2022 Mar 21:2022.03.18.484953. doi: 10.1101/2022.03.18.484953. PMID: 35350195 MH - Ad26COVS1 MH - Antibodies, Viral MH - BNT162 Vaccine MH - *COVID-19/prevention & control MH - *COVID-19 Vaccines MH - Humans MH - Immunity, Humoral MH - Immunologic Memory MH - SARS-CoV-2 PMC - PMC9135677 OTO - NOTNLM OT - COVID-19 vaccine OT - SARS-COV2 OT - cellular immunity OT - humoral immunity OT - immune memory COIS- Declaration of interests A.S. is a consultant for Gritstone Bio, Flow Pharma, ImmunoScape, Avalia, Moderna, Fortress, Repertoire, Gerson Lehrman Group, RiverVest, MedaCorp, and Guggenheim. S.C. has consulted for GSK, JP Morgan, Citi, Morgan Stanley, Avalia NZ, Nutcracker Therapeutics, University of California, California State Universities, United Airlines, Adagio, and Roche. LJI has filed for patent protection for various aspects of T cell epitope and vaccine design work. All other authors declare no conflict of interest. EDAT- 2022/06/29 06:00 MHDA- 2022/07/14 06:00 PMCR- 2022/05/27 CRDT- 2022/06/28 18:42 PHST- 2022/03/18 00:00 [received] PHST- 2022/04/21 00:00 [revised] PHST- 2022/05/23 00:00 [accepted] PHST- 2022/06/29 06:00 [pubmed] PHST- 2022/07/14 06:00 [medline] PHST- 2022/06/28 18:42 [entrez] PHST- 2022/05/27 00:00 [pmc-release] AID - S0092-8674(22)00653-5 [pii] AID - 10.1016/j.cell.2022.05.022 [doi] PST - ppublish SO - Cell. 2022 Jul 7;185(14):2434-2451.e17. doi: 10.1016/j.cell.2022.05.022. Epub 2022 May 27. PMID- 35751563 OWN - NLM STAT- MEDLINE DCOM- 20220929 LR - 20250530 IS - 1365-2567 (Electronic) IS - 0019-2805 (Print) IS - 0019-2805 (Linking) VI - 167 IP - 2 DP - 2022 Oct TI - Comparison of the immunogenicity of five COVID-19 vaccines in Sri Lanka. PG - 263-274 LID - 10.1111/imm.13535 [doi] AB - To determine the antibody responses elicited by different vaccines against SARS-CoV-2, we compared antibody responses in individuals 3 months post-vaccination in those who had received different vaccines in Sri Lanka. Abs to the receptor binding domain (RBD) of the ancestral (wild type) virus (WT) as well as to variants of concern (VoCs), and ACE2 blocking Abs, were assessed in individuals vaccinated with Moderna (n = 225), Sputnik V (n = 128) or Sputnik light (n = 184) and the results were compared with previously reported data on Sinopharm and AZD1222 vaccinees. A total of 99.5% of Moderna, >94% of AZD1222 or Sputnik V and >70% of Sputnik light, >60% of Sinopharm vaccine recipients, had a positive response to ACE2 blocking antibodies. The ACE2 blocking antibody levels were highest to lowest was Moderna > Sputnik V/AZD1222 (had equal levels) > Sputnik light > Sinopharm. All Moderna recipients had antibodies to the RBD of WT, alpha and beta, while positivity rates for delta variant was 80%. The positivity rates for Sputnik V vaccinees for the WT and VoCs were higher than for AZD1222 vaccinees while those who received Sinopharm had the lowest positivity rates (<16.7%). The total antibodies to the RBD were highest for the Sputnik V and AZD1222 vaccinees. The Moderna vaccine elicited the highest ACE2 blocking antibody levels followed by Sputnik V/AZD1222, while those who received Sinopharm had the lowest levels. These findings highlight the need for further studies to understand the effects on clinical outcomes. CI - (c) 2022 The Authors. Immunology published by John Wiley & Sons Ltd. FAU - Jeewandara, Chandima AU - Jeewandara C AD - Allergy Immunology and Cell Biology Unit, Department of Immunology and Molecular Medicine, University of Sri Jayewardenepura, Nugegoda, Sri Lanka. FAU - Aberathna, Inoka Sepali AU - Aberathna IS AD - Allergy Immunology and Cell Biology Unit, Department of Immunology and Molecular Medicine, University of Sri Jayewardenepura, Nugegoda, Sri Lanka. FAU - Danasekara, Saubhagya AU - Danasekara S AD - Allergy Immunology and Cell Biology Unit, Department of Immunology and Molecular Medicine, University of Sri Jayewardenepura, Nugegoda, Sri Lanka. FAU - Gomes, Laksiri AU - Gomes L AD - Allergy Immunology and Cell Biology Unit, Department of Immunology and Molecular Medicine, University of Sri Jayewardenepura, Nugegoda, Sri Lanka. FAU - Fernando, Suranga AU - Fernando S AD - Ministry of Health, Colombo, Sri Lanka. FAU - Guruge, Dinuka AU - Guruge D AD - Colombo Municipal Council, Colombo, Sri Lanka. FAU - Ranasinghe, Thushali AU - Ranasinghe T AD - Allergy Immunology and Cell Biology Unit, Department of Immunology and Molecular Medicine, University of Sri Jayewardenepura, Nugegoda, Sri Lanka. FAU - Gunasekera, Banuri AU - Gunasekera B AD - Allergy Immunology and Cell Biology Unit, Department of Immunology and Molecular Medicine, University of Sri Jayewardenepura, Nugegoda, Sri Lanka. FAU - Kamaladasa, Achala AU - Kamaladasa A AD - Allergy Immunology and Cell Biology Unit, Department of Immunology and Molecular Medicine, University of Sri Jayewardenepura, Nugegoda, Sri Lanka. FAU - Kuruppu, Heshan AU - Kuruppu H AD - Allergy Immunology and Cell Biology Unit, Department of Immunology and Molecular Medicine, University of Sri Jayewardenepura, Nugegoda, Sri Lanka. FAU - Somathilake, Gayasha AU - Somathilake G AD - Allergy Immunology and Cell Biology Unit, Department of Immunology and Molecular Medicine, University of Sri Jayewardenepura, Nugegoda, Sri Lanka. FAU - Jayamali, Jeewantha AU - Jayamali J AD - Allergy Immunology and Cell Biology Unit, Department of Immunology and Molecular Medicine, University of Sri Jayewardenepura, Nugegoda, Sri Lanka. FAU - Jayathilaka, Deshni AU - Jayathilaka D AUID- ORCID: 0000-0002-3334-2811 AD - Allergy Immunology and Cell Biology Unit, Department of Immunology and Molecular Medicine, University of Sri Jayewardenepura, Nugegoda, Sri Lanka. FAU - Wijayatilake, Helanka Dinesh Kumara AU - Wijayatilake HDK AD - Ministry of Health, Colombo, Sri Lanka. FAU - Pushpakumara, Pradeep Darshana AU - Pushpakumara PD AD - Allergy Immunology and Cell Biology Unit, Department of Immunology and Molecular Medicine, University of Sri Jayewardenepura, Nugegoda, Sri Lanka. FAU - Harvie, Michael AU - Harvie M AD - Allergy Immunology and Cell Biology Unit, Department of Immunology and Molecular Medicine, University of Sri Jayewardenepura, Nugegoda, Sri Lanka. FAU - Nimasha, Thashmi AU - Nimasha T AD - Allergy Immunology and Cell Biology Unit, Department of Immunology and Molecular Medicine, University of Sri Jayewardenepura, Nugegoda, Sri Lanka. FAU - de Silva, Shiromi Devika Grace AU - de Silva SDG AD - Colombo Municipal Council, Colombo, Sri Lanka. FAU - Wijayamuni, Ruwan AU - Wijayamuni R AD - Ministry of Health, Colombo, Sri Lanka. FAU - Schimanski, Lisa AU - Schimanski L AD - MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK. AD - Centre for Translational Immunology, Chinese Academy of Medical Sciences Oxford Institute, University of Oxford, Oxford, UK. FAU - Rijal, Pramila AU - Rijal P AD - MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK. AD - Centre for Translational Immunology, Chinese Academy of Medical Sciences Oxford Institute, University of Oxford, Oxford, UK. FAU - Tan, Jack AU - Tan J AD - MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK. AD - Centre for Translational Immunology, Chinese Academy of Medical Sciences Oxford Institute, University of Oxford, Oxford, UK. FAU - Townsend, Alain AU - Townsend A AD - MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK. AD - Centre for Translational Immunology, Chinese Academy of Medical Sciences Oxford Institute, University of Oxford, Oxford, UK. FAU - Ogg, Graham S AU - Ogg GS AD - MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK. AD - Centre for Translational Immunology, Chinese Academy of Medical Sciences Oxford Institute, University of Oxford, Oxford, UK. FAU - Malavige, Gathsaurie Neelika AU - Malavige GN AUID- ORCID: 0000-0001-9201-0449 AD - Allergy Immunology and Cell Biology Unit, Department of Immunology and Molecular Medicine, University of Sri Jayewardenepura, Nugegoda, Sri Lanka. AD - Centre for Translational Immunology, Chinese Academy of Medical Sciences Oxford Institute, University of Oxford, Oxford, UK. LA - eng GR - MC_UU_00008/5/MRC_/Medical Research Council/United Kingdom GR - U01 AI151788/AI/NIAID NIH HHS/United States PT - Comparative Study PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20220709 PL - England TA - Immunology JT - Immunology JID - 0374672 RN - 0 (Antibodies, Blocking) RN - 0 (Antibodies, Viral) RN - 0 (COVID-19 Vaccines) RN - 0 (Vaccines) RN - B5S3K2V0G8 (ChAdOx1 nCoV-19) RN - EC 3.4.17.23 (Angiotensin-Converting Enzyme 2) RN - SARS-CoV-2 variants SB - IM MH - Angiotensin-Converting Enzyme 2 MH - Antibodies, Blocking MH - Antibodies, Viral MH - *COVID-19/prevention & control MH - COVID-19 Vaccines MH - ChAdOx1 nCoV-19 MH - Humans MH - SARS-CoV-2 MH - Sri Lanka MH - *Vaccines PMC - PMC9349502 OTO - NOTNLM OT - COVID-19 OT - antibodies OT - memory OT - vaccination COIS- None of the authors have any conflicts of interest. EDAT- 2022/06/26 06:00 MHDA- 2022/09/30 06:00 PMCR- 2022/07/09 CRDT- 2022/06/25 07:42 PHST- 2022/01/10 00:00 [received] PHST- 2022/05/09 00:00 [accepted] PHST- 2022/06/26 06:00 [pubmed] PHST- 2022/09/30 06:00 [medline] PHST- 2022/06/25 07:42 [entrez] PHST- 2022/07/09 00:00 [pmc-release] AID - IMM13535 [pii] AID - 10.1111/imm.13535 [doi] PST - ppublish SO - Immunology. 2022 Oct;167(2):263-274. doi: 10.1111/imm.13535. Epub 2022 Jul 9. PMID- 35741048 OWN - NLM STAT- MEDLINE DCOM- 20220627 LR - 20260127 IS - 2073-4409 (Electronic) IS - 2073-4409 (Linking) VI - 11 IP - 12 DP - 2022 Jun 14 TI - T-Cell Defects Associated to Lack of Spike-Specific Antibodies after BNT162b2 Full Immunization Followed by a Booster Dose in Patients with Common Variable Immune Deficiencies. LID - 10.3390/cells11121918 [doi] LID - 1918 AB - Following the third booster dose of the mRNA vaccine, Common Variable Immune Deficiencies (CVID) patients may not produce specific antibodies against the virus spike protein. The T-cell abnormalities associated with the absence of antibodies are still a matter of investigation. Spike-specific IgG and IgA, peripheral T cell subsets, CD40L and cytokine expression, and Spike-specific specific T-cells responses were evaluated in 47 CVID and 26 healthy donors after three doses of BNT162b2 vaccine. Testing was performed two weeks after the third vaccine dose. Thirty-six percent of the patients did not produce anti-SARS-CoV-2 IgG or IgA antibodies. Non responder patients had lower peripheral blood lymphocyte counts, circulating naive and central memory T-cells, low CD40L expression on the CD4+CD45+RO+ and CD8+CD45+RO+ T-cells, high frequencies of TNFalpha and IFNgamma expressing CD8+ T-cells, and defective release of IFNgamma and TNFalpha following stimulation with Spike peptides. Non responders had a more complex disease phenotype, with higher frequencies of structural lung damage and autoimmunity, especially autoimmune cytopenia. Thirty-five percent of them developed a SARS-CoV-2 infection after immunization in comparison to twenty percent of CVID who responded to immunization with antibodies production. CVID-associated T cell abnormalities contributed to the absence of SARS-CoV-2 specific antibodies after full immunization. FAU - Pulvirenti, Federica AU - Pulvirenti F AD - Reference Centre for Primary Immune Deficiencies, Azienda Ospedaliera Universitaria Policlinico Umberto I, 00185 Rome, Italy. FAU - Di Cecca, Stefano AU - Di Cecca S AUID- ORCID: 0000-0003-2595-9261 AD - Department Onco-Haematology, and Cell and Gene Therapy, Bambino Gesu Children Hospital, IRCCS, 00116 Rome, Italy. FAU - Sinibaldi, Matilde AU - Sinibaldi M AUID- ORCID: 0000-0001-5277-8998 AD - Department Onco-Haematology, and Cell and Gene Therapy, Bambino Gesu Children Hospital, IRCCS, 00116 Rome, Italy. FAU - Piano Mortari, Eva AU - Piano Mortari E AUID- ORCID: 0000-0002-0054-4732 AD - B Cell Unit, Immunology Research Area, Bambino Gesu Children's Hospital, IRCCS, Viale di San Paolo, 00146 Rome, Italy. AD - Department of Molecular Medicine, Sapienza University of Rome, 00185 Rome, Italy. FAU - Terreri, Sara AU - Terreri S AUID- ORCID: 0000-0002-5791-6306 AD - B Cell Unit, Immunology Research Area, Bambino Gesu Children's Hospital, IRCCS, Viale di San Paolo, 00146 Rome, Italy. FAU - Albano, Christian AU - Albano C AD - B Cell Unit, Immunology Research Area, Bambino Gesu Children's Hospital, IRCCS, Viale di San Paolo, 00146 Rome, Italy. FAU - Guercio, Marika AU - Guercio M AUID- ORCID: 0000-0002-1356-5874 AD - Department Onco-Haematology, and Cell and Gene Therapy, Bambino Gesu Children Hospital, IRCCS, 00116 Rome, Italy. FAU - Sculco, Eleonora AU - Sculco E AD - Department of Molecular Medicine, Sapienza University of Rome, 00185 Rome, Italy. FAU - Milito, Cinzia AU - Milito C AUID- ORCID: 0000-0003-2581-9250 AD - Department of Molecular Medicine, Sapienza University of Rome, 00185 Rome, Italy. FAU - Ferrari, Simona AU - Ferrari S AD - Medical Genetics Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy. FAU - Locatelli, Franco AU - Locatelli F AD - Department Onco-Haematology, and Cell and Gene Therapy, Bambino Gesu Children Hospital, IRCCS, 00116 Rome, Italy. FAU - Quintarelli, Concetta AU - Quintarelli C AD - Department Onco-Haematology, and Cell and Gene Therapy, Bambino Gesu Children Hospital, IRCCS, 00116 Rome, Italy. FAU - Carsetti, Rita AU - Carsetti R AD - B Cell Unit, Immunology Research Area, Bambino Gesu Children's Hospital, IRCCS, Viale di San Paolo, 00146 Rome, Italy. FAU - Quinti, Isabella AU - Quinti I AUID- ORCID: 0000-0002-3328-7584 AD - Department of Molecular Medicine, Sapienza University of Rome, 00185 Rome, Italy. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220614 PL - Switzerland TA - Cells JT - Cells JID - 101600052 RN - 0 (Antibodies, Viral) RN - 0 (BNT162 Vaccine) RN - 147205-72-9 (CD40 Ligand) RN - 0 (Immunoglobulin A) RN - 0 (Immunoglobulin G) RN - 0 (Tumor Necrosis Factor-alpha) RN - 0 (Vaccines, Synthetic) RN - 0 (mRNA Vaccines) SB - IM MH - Antibodies, Viral MH - *BNT162 Vaccine MH - CD40 Ligand MH - *COVID-19/prevention & control MH - Humans MH - Immunization MH - Immunoglobulin A MH - Immunoglobulin G MH - SARS-CoV-2 MH - Tumor Necrosis Factor-alpha MH - Vaccines, Synthetic MH - mRNA Vaccines PMC - PMC9221747 OTO - NOTNLM OT - BNT162b2 OT - COVID-19 OT - Common Variable Immune Deficiencies OT - SARS-CoV-2 OT - T-cells OT - antibody response OT - booster dose OT - memory B cells OT - spike protein OT - vaccine COIS- Authors declare that they have no competing interest. EDAT- 2022/06/25 06:00 MHDA- 2022/06/28 06:00 PMCR- 2022/06/14 CRDT- 2022/06/24 01:09 PHST- 2022/05/10 00:00 [received] PHST- 2022/06/03 00:00 [revised] PHST- 2022/06/09 00:00 [accepted] PHST- 2022/06/24 01:09 [entrez] PHST- 2022/06/25 06:00 [pubmed] PHST- 2022/06/28 06:00 [medline] PHST- 2022/06/14 00:00 [pmc-release] AID - cells11121918 [pii] AID - cells-11-01918 [pii] AID - 10.3390/cells11121918 [doi] PST - epublish SO - Cells. 2022 Jun 14;11(12):1918. doi: 10.3390/cells11121918. PMID- 35735743 OWN - NLM STAT- MEDLINE DCOM- 20220902 LR - 20250728 IS - 2150-7511 (Electronic) VI - 13 IP - 4 DP - 2022 Aug 30 TI - Antibody and Memory B-Cell Immunity in a Heterogeneously SARS-CoV-2-Infected and -Vaccinated Population. PG - e0084022 LID - 10.1128/mbio.00840-22 [doi] LID - e00840-22 AB - Global population immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is accumulating through heterogeneous combinations of infection and vaccination. Vaccine distribution in low- and middle-income countries has been variable and reliant on diverse vaccine platforms. We studied B-cell immunity in Mexico, a middle-income country where five different vaccines have been deployed to populations with high SARS-CoV-2 incidences. Levels of antibodies that bound a stabilized prefusion spike trimer, neutralizing antibody titers, and memory B-cell expansion correlated with each other across vaccine platforms. Nevertheless, the vaccines elicited variable levels of B-cell immunity, and the majority of recipients had undetectable neutralizing activity against the recently emergent omicron variant. SARS-CoV-2 infection, experienced before or after vaccination, potentiated B-cell immune responses and enabled the generation of neutralizing activity against omicron and SARS-CoV for all vaccines in nearly all individuals. These findings suggest that broad population immunity to SARS-CoV-2 will eventually be achieved but by heterogeneous paths. IMPORTANCE The majority of studies on SARS-CoV-2 vaccine-elicited immunity and immune evasion have focused on single vaccines corresponding to those distributed in high-income countries. However, in low- and middle-income countries, vaccine deployment has been far less uniform. It is therefore important to determine the levels of immunity elicited by vaccines that have been deployed globally. Such data should help inform policy. Thus, this paper is very much a "real-world" study that focuses on a middle-income country, Mexico, in which five different vaccines based on mRNA, adenovirus, and inactivated-virus platforms have been extensively deployed, while (as documented in our study) SARS-CoV-2 variants with increasing degrees of immune evasiveness have propagated in the Mexican population, culminating in the recent emergence of B.1.1.529 (omicron). FAU - Bednarski, Eva AU - Bednarski E AD - Laboratory of Retrovirology, The Rockefeller Universitygrid.134907.8, New York, New York, USA. FAU - Del Rio Estrada, Perla M AU - Del Rio Estrada PM AD - Centro de Investigacion en Enfermedades Infecciosas, Instituto Nacional de Enfermedades Respiratoriasgrid.419179.3 Ismael Cosio Villegas, Mexico City, Mexico. FAU - DaSilva, Justin AU - DaSilva J AUID- ORCID: 0000-0001-6393-0000 AD - Laboratory of Retrovirology, The Rockefeller Universitygrid.134907.8, New York, New York, USA. FAU - Boukadida, Celia AU - Boukadida C AD - Centro de Investigacion en Enfermedades Infecciosas, Instituto Nacional de Enfermedades Respiratoriasgrid.419179.3 Ismael Cosio Villegas, Mexico City, Mexico. FAU - Zhang, Fengwen AU - Zhang F AD - Laboratory of Retrovirology, The Rockefeller Universitygrid.134907.8, New York, New York, USA. FAU - Luna-Villalobos, Yara A AU - Luna-Villalobos YA AD - Centro de Investigacion en Enfermedades Infecciosas, Instituto Nacional de Enfermedades Respiratoriasgrid.419179.3 Ismael Cosio Villegas, Mexico City, Mexico. FAU - Rodriguez-Rangel, Ximena AU - Rodriguez-Rangel X AUID- ORCID: 0000-0002-5076-4979 AD - Centro de Investigacion en Enfermedades Infecciosas, Instituto Nacional de Enfermedades Respiratoriasgrid.419179.3 Ismael Cosio Villegas, Mexico City, Mexico. FAU - Piten-Isidro, Elvira AU - Piten-Isidro E AD - Centro de Investigacion en Enfermedades Infecciosas, Instituto Nacional de Enfermedades Respiratoriasgrid.419179.3 Ismael Cosio Villegas, Mexico City, Mexico. FAU - Luna-Garcia, Edgar AU - Luna-Garcia E AD - Centro de Investigacion en Enfermedades Infecciosas, Instituto Nacional de Enfermedades Respiratoriasgrid.419179.3 Ismael Cosio Villegas, Mexico City, Mexico. FAU - Diaz Rivera, Dafne AU - Diaz Rivera D AD - Centro de Investigacion en Enfermedades Infecciosas, Instituto Nacional de Enfermedades Respiratoriasgrid.419179.3 Ismael Cosio Villegas, Mexico City, Mexico. FAU - Lopez-Sanchez, Dulce M AU - Lopez-Sanchez DM AD - Centro de Investigacion en Enfermedades Infecciosas, Instituto Nacional de Enfermedades Respiratoriasgrid.419179.3 Ismael Cosio Villegas, Mexico City, Mexico. FAU - Tapia-Trejo, Daniela AU - Tapia-Trejo D AD - Centro de Investigacion en Enfermedades Infecciosas, Instituto Nacional de Enfermedades Respiratoriasgrid.419179.3 Ismael Cosio Villegas, Mexico City, Mexico. FAU - Soto-Nava, Maribel AU - Soto-Nava M AD - Centro de Investigacion en Enfermedades Infecciosas, Instituto Nacional de Enfermedades Respiratoriasgrid.419179.3 Ismael Cosio Villegas, Mexico City, Mexico. FAU - Astorga-Castaneda, Myriam AU - Astorga-Castaneda M AD - Jurisdiccion Sanitaria Coyoacan, Servicios de Salud Publica de la Ciudad de Mexico, Mexico City, Mexico. FAU - Martinez-Moreno, Jose O AU - Martinez-Moreno JO AD - Jurisdiccion Sanitaria Coyoacan, Servicios de Salud Publica de la Ciudad de Mexico, Mexico City, Mexico. FAU - Urbina-Granados, Guadalupe S AU - Urbina-Granados GS AD - Jurisdiccion Sanitaria Cuajimalpa, Servicios de Salud Publica de la Ciudad de Mexico, Mexico City, Mexico. FAU - Jimenez-Jacinto, Jose A AU - Jimenez-Jacinto JA AD - Jurisdiccion Sanitaria Magdalena Contreras, Servicios de Salud Publica de la Ciudad de Mexico, Mexico City, Mexico. FAU - Serna Alvarado, Francisco J AU - Serna Alvarado FJ AD - Jurisdiccion Sanitaria Iztapalapa, Servicios de Salud Publica de la Ciudad de Mexico, Mexico City, Mexico. FAU - Enriquez-Lopez, Yerania E AU - Enriquez-Lopez YE AD - Jurisdiccion Sanitaria Tlalpan, Servicios de Salud Publica de la Ciudad de Mexico, Mexico City, Mexico. FAU - Lopez-Arellano, Oliva AU - Lopez-Arellano O AD - Secretaria de Salud, Mexico City, Mexico. FAU - Reyes-Teran, Gustavo AU - Reyes-Teran G AD - Institutos Nacionales de Salud y Hospitales de Alta Especialidad, Secretaria de Salud de Mexico, Mexico City, Mexico. FAU - Bieniasz, Paul D AU - Bieniasz PD AUID- ORCID: 0000-0002-2368-3719 AD - Laboratory of Retrovirology, The Rockefeller Universitygrid.134907.8, New York, New York, USA. AD - Howard Hughes Medical Institute, Chevy Chase, Maryland, USA. FAU - Avila-Rios, Santiago AU - Avila-Rios S AD - Centro de Investigacion en Enfermedades Infecciosas, Instituto Nacional de Enfermedades Respiratoriasgrid.419179.3 Ismael Cosio Villegas, Mexico City, Mexico. FAU - Hatziioannou, Theodora AU - Hatziioannou T AUID- ORCID: 0000-0002-7889-0766 AD - Laboratory of Retrovirology, The Rockefeller Universitygrid.134907.8, New York, New York, USA. LA - eng GR - R01 AI078788/AI/NIAID NIH HHS/United States GR - P01 AI165075/AI/NIAID NIH HHS/United States GR - R37 AI064003/AI/NIAID NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20220623 PL - United States TA - mBio JT - mBio JID - 101519231 RN - 0 (Antibodies, Neutralizing) RN - 0 (Antibodies, Viral) RN - 0 (COVID-19 Vaccines) RN - 0 (Spike Glycoprotein, Coronavirus) RN - 0 (Viral Vaccines) RN - 0 (spike protein, SARS-CoV-2) RN - SARS-CoV-2 variants SB - IM UOF - medRxiv. 2022 Feb 08:2022.02.07.22270626. doi: 10.1101/2022.02.07.22270626. PMID: 35169812 MH - Antibodies, Neutralizing MH - Antibodies, Viral MH - *COVID-19/prevention & control MH - COVID-19 Vaccines MH - Humans MH - SARS-CoV-2/genetics MH - Spike Glycoprotein, Coronavirus/genetics MH - *Viral Vaccines PMC - PMC9426429 OTO - NOTNLM OT - SARS-CoV-2 OT - infection OT - memory B cells OT - neutralizing antibodies OT - vaccination COIS- The authors declare a conflict of interest. PDB has received compensation from Pfizer for consultation in the areaof SARS-CoV-2 vaccines. TH has received funding from Bristol Myers Squibb for evaluating monoclonal antibodies against SARS-CoV-2. EDAT- 2022/06/24 06:00 MHDA- 2022/09/03 06:00 PMCR- 2022/06/23 CRDT- 2022/06/23 08:33 PHST- 2022/06/24 06:00 [pubmed] PHST- 2022/09/03 06:00 [medline] PHST- 2022/06/23 08:33 [entrez] PHST- 2022/06/23 00:00 [pmc-release] AID - 00840-22 [pii] AID - mbio.00840-22 [pii] AID - 10.1128/mbio.00840-22 [doi] PST - ppublish SO - mBio. 2022 Aug 30;13(4):e0084022. doi: 10.1128/mbio.00840-22. Epub 2022 Jun 23. PMID- 35733376 OWN - NLM STAT- MEDLINE DCOM- 20220913 LR - 20260728 IS - 1600-065X (Electronic) IS - 0105-2896 (Print) IS - 0105-2896 (Linking) VI - 310 IP - 1 DP - 2022 Sep TI - Immunological memory to SARS-CoV-2 infection and COVID-19 vaccines. PG - 27-46 LID - 10.1111/imr.13089 [doi] AB - Immunological memory is the basis of protective immunity provided by vaccines and previous infections. Immunological memory can develop from multiple branches of the adaptive immune system, including CD4 T cells, CD8 T cells, B cells, and long-lasting antibody responses. Extraordinary progress has been made in understanding memory to SARS-CoV-2 infection and COVID-19 vaccines, addressing development; quantitative and qualitative features of different cellular and anatomical compartments; and durability of each cellular component and antibodies. Given the sophistication of the measurements; the size of the human studies; the use of longitudinal samples and cross-sectional studies; and head-to-head comparisons between infection and vaccines or between multiple vaccines, the understanding of immune memory for 1 year to SARS-CoV-2 infection and vaccines already supersedes that of any other acute infectious disease. This knowledge may help inform public policies regarding COVID-19 and COVID-19 vaccines, as well as the scientific development of future vaccines against SARS-CoV-2 and other diseases. CI - (c) 2022 The Authors. Immunological Reviews published by John Wiley & Sons Ltd. FAU - Sette, Alessandro AU - Sette A AD - Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, California, USA. AD - Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California, San Diego (UCSD), La Jolla, California, USA. FAU - Crotty, Shane AU - Crotty S AUID- ORCID: 0000-0002-6484-6262 AD - Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, California, USA. AD - Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California, San Diego (UCSD), La Jolla, California, USA. LA - eng GR - U19 AI142742/AI/NIAID NIH HHS/United States GR - UM1 AI144462/AI/NIAID NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Review DEP - 20220622 PL - England TA - Immunol Rev JT - Immunological reviews JID - 7702118 RN - 0 (Antibodies, Viral) RN - 0 (COVID-19 Vaccines) SB - IM MH - Antibodies, Viral MH - *COVID-19/prevention & control MH - *COVID-19 Vaccines MH - Cross-Sectional Studies MH - Humans MH - Immunologic Memory MH - SARS-CoV-2 PMC - PMC9349657 MID - NIHMS1809885 OTO - NOTNLM OT - adenoviral vectors OT - coronavirus OT - hybrid immunity OT - mRNA vaccines OT - memory B cells OT - memory T cells OT - natural immunity OT - protein vaccine COIS- SC has consulted for GSK, JP Morgan, Citi, Morgan Stanley, Avalia NZ, Nutcracker Therapeutics, University of California, California State Universities, United Airlines, and Roche. A.S. is a consultant for Gritstone Bio, Flow Pharma, ImmunoScape, Moderna, AstraZeneca, Avalia, Fortress, Repertoire, Gilead, Gerson Lehrman Group, RiverVest, MedaCorp, and Guggenheim. EDAT- 2022/06/24 06:00 MHDA- 2022/09/14 06:00 PMCR- 2022/06/22 CRDT- 2022/06/23 02:02 PHST- 2021/10/16 00:00 [received] PHST- 2022/05/04 00:00 [accepted] PHST- 2022/06/24 06:00 [pubmed] PHST- 2022/09/14 06:00 [medline] PHST- 2022/06/23 02:02 [entrez] PHST- 2022/06/22 00:00 [pmc-release] AID - IMR13089 [pii] AID - 10.1111/imr.13089 [doi] PST - ppublish SO - Immunol Rev. 2022 Sep;310(1):27-46. doi: 10.1111/imr.13089. Epub 2022 Jun 22. PMID- 35731277 OWN - NLM STAT- MEDLINE DCOM- 20220914 LR - 20250728 IS - 1432-1459 (Electronic) IS - 0340-5354 (Print) IS - 0340-5354 (Linking) VI - 269 IP - 10 DP - 2022 Oct TI - NMOSD typical brain lesions after COVID-19 mRNA vaccination. PG - 5213-5215 LID - 10.1007/s00415-022-11229-1 [doi] FAU - Levi-Strauss, Julie AU - Levi-Strauss J AUID- ORCID: 0000-0002-5827-5678 AD - Department of Neurology, GHU Paris Psychiatrie et Neurosciences, Universite Paris Cite, Sainte-Anne Hospital, 1 rue Cabanis, 75014, Paris, France. julie.levi.strauss@gmail.com. AD - INSERM U1266, Institute of Psychiatry and Neuroscience of Paris, FHU NeuroVasc, Paris, France. julie.levi.strauss@gmail.com. FAU - Provost, Corentin AU - Provost C AD - INSERM U1266, Institute of Psychiatry and Neuroscience of Paris, FHU NeuroVasc, Paris, France. AD - Department of Neuroradiology, GHU Paris Psychiatrie et Neurosciences, Sainte-Anne Hospital, Universite Paris Cite, Paris, France. FAU - Wane, Noemie AU - Wane N AD - Department of Neurology, GHU Paris Psychiatrie et Neurosciences, Universite Paris Cite, Sainte-Anne Hospital, 1 rue Cabanis, 75014, Paris, France. AD - INSERM U1266, Institute of Psychiatry and Neuroscience of Paris, FHU NeuroVasc, Paris, France. FAU - Jacquemont, Thomas AU - Jacquemont T AD - Department of Neurology, GHU Paris Psychiatrie et Neurosciences, Universite Paris Cite, Sainte-Anne Hospital, 1 rue Cabanis, 75014, Paris, France. AD - INSERM U1266, Institute of Psychiatry and Neuroscience of Paris, FHU NeuroVasc, Paris, France. FAU - Mele, Nicolas AU - Mele N AD - Department of Neurology, GHU Paris Psychiatrie et Neurosciences, Universite Paris Cite, Sainte-Anne Hospital, 1 rue Cabanis, 75014, Paris, France. AD - INSERM U1266, Institute of Psychiatry and Neuroscience of Paris, FHU NeuroVasc, Paris, France. LA - eng PT - Letter DEP - 20220622 PL - Germany TA - J Neurol JT - Journal of neurology JID - 0423161 RN - 0 (Aquaporin 4) RN - 0 (Autoantibodies) RN - 0 (RNA, Messenger) SB - IM MH - Aquaporin 4 MH - Autoantibodies MH - Brain/diagnostic imaging/pathology MH - *COVID-19/prevention & control MH - Humans MH - *Nervous System Diseases/pathology MH - *Neuromyelitis Optica/pathology MH - RNA, Messenger MH - Vaccination PMC - PMC9214460 COIS- The authors declare no potential conflicts of interest with respect to the research, authorship and/or publication of this article. EDAT- 2022/06/23 06:00 MHDA- 2022/09/15 06:00 PMCR- 2022/06/22 CRDT- 2022/06/22 11:25 PHST- 2022/04/21 00:00 [received] PHST- 2022/06/13 00:00 [accepted] PHST- 2022/06/13 00:00 [revised] PHST- 2022/06/23 06:00 [pubmed] PHST- 2022/09/15 06:00 [medline] PHST- 2022/06/22 11:25 [entrez] PHST- 2022/06/22 00:00 [pmc-release] AID - 10.1007/s00415-022-11229-1 [pii] AID - 11229 [pii] AID - 10.1007/s00415-022-11229-1 [doi] PST - ppublish SO - J Neurol. 2022 Oct;269(10):5213-5215. doi: 10.1007/s00415-022-11229-1. Epub 2022 Jun 22. PMID- 35716665 OWN - NLM STAT- MEDLINE DCOM- 20220712 LR - 20260127 IS - 2666-6340 (Electronic) IS - 2666-6359 (Print) IS - 2666-6340 (Linking) VI - 3 IP - 7 DP - 2022 Jul 8 TI - B cell-derived cfDNA after primary BNT162b2 mRNA vaccination anticipates memory B cells and SARS-CoV-2 neutralizing antibodies. PG - 468-480.e5 LID - S2666-6340(22)00221-5 [pii] LID - 10.1016/j.medj.2022.05.005 [doi] AB - BACKGROUND: Much remains unknown regarding the response of the immune system to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccination. METHODS: We employed circulating cell-free DNA (cfDNA) to assess the turnover of specific immune cell types following administration of the Pfizer/BioNTech vaccine. FINDINGS: The levels of B cell cfDNA after the primary dose correlated with development of neutralizing antibodies and memory B cells after the booster, revealing a link between early B cell turnover-potentially reflecting affinity maturation-and later development of effective humoral response. We also observed co-elevation of B cell, T cell, and monocyte cfDNA after the booster, underscoring the involvement of innate immune cell turnover in the development of humoral and cellular adaptive immunity. Actual cell counts remained largely stable following vaccination, other than a previously demonstrated temporary reduction in neutrophil and lymphocyte counts. CONCLUSIONS: Immune cfDNA dynamics reveal the crucial role of the primary SARS-CoV-2 vaccine in shaping responses of the immune system following the booster vaccine. FUNDING: This work was supported by a generous gift from Shlomo Kramer. Supported by grants from Human Islet Research Network (HIRN UC4DK116274 and UC4DK104216 to R.S. and Y.D.), Ernest and Bonnie Beutler Research Program of Excellence in Genomic Medicine, The Alex U Soyka Pancreatic Cancer Fund, The Israel Science Foundation, the Waldholtz/Pakula family, the Robert M. and Marilyn Sternberg Family Charitable Foundation, the Helmsley Charitable Trust, Grail, and the DON Foundation (to Y.D.). Y.D. holds the Walter and Greta Stiel Chair and Research Grant in Heart Studies. I.F.-F. received a fellowship from the Glassman Hebrew University Diabetes Center. CI - Copyright (c) 2022 Elsevier Inc. All rights reserved. FAU - Fox-Fisher, Ilana AU - Fox-Fisher I AD - Department of Developmental Biology and Cancer Research, The Institute for Medical Research Israel-Canada, The Hebrew University-Hadassah Medical School, Jerusalem, Israel. FAU - Piyanzin, Sheina AU - Piyanzin S AD - Department of Developmental Biology and Cancer Research, The Institute for Medical Research Israel-Canada, The Hebrew University-Hadassah Medical School, Jerusalem, Israel. FAU - Briller, Mayan AU - Briller M AD - Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel. FAU - Oiknine-Djian, Esther AU - Oiknine-Djian E AD - Clinical Virology Unit, Department of Clinical Microbiology and Infectious Diseases, Hadassah-Hebrew University Medical Center, Jerusalem, Israel. FAU - Alfi, Or AU - Alfi O AD - Clinical Virology Unit, Department of Clinical Microbiology and Infectious Diseases, Hadassah-Hebrew University Medical Center, Jerusalem, Israel. FAU - Ben-Ami, Roni AU - Ben-Ami R AD - Department of Developmental Biology and Cancer Research, The Institute for Medical Research Israel-Canada, The Hebrew University-Hadassah Medical School, Jerusalem, Israel. FAU - Peretz, Ayelet AU - Peretz A AD - Department of Developmental Biology and Cancer Research, The Institute for Medical Research Israel-Canada, The Hebrew University-Hadassah Medical School, Jerusalem, Israel. FAU - Neiman, Daniel AU - Neiman D AD - Department of Developmental Biology and Cancer Research, The Institute for Medical Research Israel-Canada, The Hebrew University-Hadassah Medical School, Jerusalem, Israel. FAU - Ochana, Bracha-Lea AU - Ochana BL AD - Department of Developmental Biology and Cancer Research, The Institute for Medical Research Israel-Canada, The Hebrew University-Hadassah Medical School, Jerusalem, Israel. FAU - Fridlich, Ori AU - Fridlich O AD - Department of Developmental Biology and Cancer Research, The Institute for Medical Research Israel-Canada, The Hebrew University-Hadassah Medical School, Jerusalem, Israel. FAU - Drawshy, Zeina AU - Drawshy Z AD - Department of Developmental Biology and Cancer Research, The Institute for Medical Research Israel-Canada, The Hebrew University-Hadassah Medical School, Jerusalem, Israel. FAU - Klochendler, Agnes AU - Klochendler A AD - Department of Developmental Biology and Cancer Research, The Institute for Medical Research Israel-Canada, The Hebrew University-Hadassah Medical School, Jerusalem, Israel. FAU - Magenheim, Judith AU - Magenheim J AD - Department of Developmental Biology and Cancer Research, The Institute for Medical Research Israel-Canada, The Hebrew University-Hadassah Medical School, Jerusalem, Israel. FAU - Share, Danielle AU - Share D AD - Department of Developmental Biology and Cancer Research, The Institute for Medical Research Israel-Canada, The Hebrew University-Hadassah Medical School, Jerusalem, Israel. FAU - Avrahami, Ran AU - Avrahami R AD - Department of Developmental Biology and Cancer Research, The Institute for Medical Research Israel-Canada, The Hebrew University-Hadassah Medical School, Jerusalem, Israel. FAU - Ribak, Yaarit AU - Ribak Y AD - Allergy and Clinical Immunology Unit, Department of Medicine, Jerusalem, Israel. FAU - Talmon, Aviv AU - Talmon A AD - Allergy and Clinical Immunology Unit, Department of Medicine, Jerusalem, Israel. FAU - Rubin, Limor AU - Rubin L AD - Allergy and Clinical Immunology Unit, Department of Medicine, Jerusalem, Israel. FAU - Milman, Neta AU - Milman N AD - Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel. FAU - Segev, Meital AU - Segev M AD - Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel. FAU - Feldman, Erik AU - Feldman E AD - Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel. FAU - Tal, Yuval AU - Tal Y AD - Allergy and Clinical Immunology Unit, Department of Medicine, Jerusalem, Israel. FAU - Shen-Orr, Shai S AU - Shen-Orr SS AD - Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel. FAU - Glaser, Benjamin AU - Glaser B AD - Endocrinology and Metabolism Service, Hadassah Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel. FAU - Shemer, Ruth AU - Shemer R AD - Department of Developmental Biology and Cancer Research, The Institute for Medical Research Israel-Canada, The Hebrew University-Hadassah Medical School, Jerusalem, Israel. FAU - Wolf, Dana AU - Wolf D AD - Clinical Virology Unit, Department of Clinical Microbiology and Infectious Diseases, Hadassah-Hebrew University Medical Center, Jerusalem, Israel. FAU - Dor, Yuval AU - Dor Y AD - Department of Developmental Biology and Cancer Research, The Institute for Medical Research Israel-Canada, The Hebrew University-Hadassah Medical School, Jerusalem, Israel. Electronic address: yuvald@ekmd.huji.ac.il. LA - eng GR - UC4 DK104216/DK/NIDDK NIH HHS/United States GR - UC4 DK116274/DK/NIDDK NIH HHS/United States PT - Journal Article DEP - 20220519 PL - United States TA - Med JT - Med (New York, N.Y.) JID - 101769215 RN - 0 (Antibodies, Neutralizing) RN - 0 (Antibodies, Viral) RN - 0 (BNT162 Vaccine) RN - 0 (Cell-Free Nucleic Acids) SB - IM MH - Adult MH - Aged MH - Antibodies, Neutralizing/genetics/immunology MH - Antibodies, Viral/genetics/immunology MH - *BNT162 Vaccine/administration & dosage MH - *COVID-19/immunology/prevention & control MH - *Cell-Free Nucleic Acids/genetics/immunology MH - Female MH - Humans MH - Immunization, Secondary MH - Male MH - Memory B Cells/immunology/metabolism MH - Middle Aged MH - *SARS-CoV-2/immunology MH - Young Adult PMC - PMC9117261 OTO - NOTNLM OT - BNT162b2 OT - DNA methylation OT - SARS-CoV-2 OT - Translation to patients OT - cfDNA OT - liquid biopsy OT - mRNA vaccine OT - memory B-cell OT - neutralizing antibody OT - tissue dynamics COIS- Declaration of interests I.F.-F., B.G., R.S., and Y.D. have filed patents related to DNA methylation markers. EDAT- 2022/06/19 06:00 MHDA- 2022/07/14 06:00 PMCR- 2022/05/19 CRDT- 2022/06/18 18:42 PHST- 2021/10/14 00:00 [received] PHST- 2022/02/17 00:00 [revised] PHST- 2022/05/12 00:00 [accepted] PHST- 2022/06/19 06:00 [pubmed] PHST- 2022/07/14 06:00 [medline] PHST- 2022/06/18 18:42 [entrez] PHST- 2022/05/19 00:00 [pmc-release] AID - S2666-6340(22)00221-5 [pii] AID - 10.1016/j.medj.2022.05.005 [doi] PST - ppublish SO - Med. 2022 Jul 8;3(7):468-480.e5. doi: 10.1016/j.medj.2022.05.005. Epub 2022 May 19. PMID- 35714550 OWN - NLM STAT- MEDLINE DCOM- 20220726 LR - 20251031 IS - 1879-1379 (Electronic) IS - 0022-3956 (Print) IS - 0022-3956 (Linking) VI - 152 DP - 2022 Aug TI - Adolescents with ADHD are at increased risk for COVID-19 vaccine hesitancy. PG - 25-30 LID - S0022-3956(22)00302-8 [pii] LID - 10.1016/j.jpsychires.2022.06.005 [doi] AB - Identifying factors that influence adolescent intentions for COVID-19 vaccination is essential for developing strategic interventions to increase uptake, particularly in subgroups of at-risk adolescents. Attention-deficit/hyperactivity disorder (ADHD) in adolescence is characterized by difficulties regulating attention and behavior, social impairment, and impulsive risk-taking behaviors, which may impact vaccine hesitancy and vaccine uptake. This study examined hesitancy toward COVID-19 vaccines among adolescents with and without ADHD, and explored how ADHD status interacted with malleable social mechanisms and other social determinants of health in predicting vaccine hesitancy. Participants were 196 U.S. adolescents (44.4% male), 45.6% diagnosed with ADHD. Adolescents reported their confidence and willingness toward COVID-19 vaccines from March to May 2021. Adolescents with ADHD reported greater hesitancy and less confidence in COVID-19 vaccine safety compared to adolescents without ADHD (p < .01). Only 61.8% of adolescents with ADHD reported vaccine acceptance, compared to 81.3% of adolescents without ADHD. For all adolescents, those who identified as Black or Latinx and with lower family income had greater hesitancy and reduced confidence, whereas greater COVID-19 concerns, media use, and perceived negative impact on relationships was associated with greater vaccination willingness. Social contextual processes significantly interacted with ADHD status such that for adolescents without ADHD, concerns about COVID-19 were associated with increased confidence in vaccine safety. Being noncompliant with social distancing guidelines was associated with greater vaccine hesitancy, only for adolescents with ADHD. A concerted effort is needed to increase trust, confidence, and social relevance among adolescents, especially those with ADHD and from lower socio-economic backgrounds. CI - Copyright (c) 2022 Elsevier Ltd. All rights reserved. FAU - Dvorsky, Melissa R AU - Dvorsky MR AD - Division of Psychology and Behavioral Health, Children's National Hospital, Washington, DC, USA; Department of Psychiatry & Behavioral Sciences, Department of Pediatrics, The George Washington University School of Medicine and Health Sciences, Washington, DC, USA. Electronic address: mdvorsky@childrensnational.org. FAU - Breaux, Rosanna AU - Breaux R AD - Department of Psychology, Virginia Polytechnic Institute and State University, Blacksburg, VA, USA. FAU - Langberg, Joshua M AU - Langberg JM AD - Department of Psychology, Virginia Commonwealth University, Richmond, VA, USA. FAU - Becker, Stephen P AU - Becker SP AD - Division of Behavioral Medicine and Clinical Psychology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA. LA - eng GR - K23 MH122839/MH/NIMH NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20220609 PL - England TA - J Psychiatr Res JT - Journal of psychiatric research JID - 0376331 RN - 0 (COVID-19 Vaccines) SB - IM MH - Adolescent MH - Black or African American MH - *Attention Deficit Disorder with Hyperactivity/epidemiology MH - *COVID-19/prevention & control MH - *COVID-19 Vaccines/administration & dosage MH - Female MH - Hispanic or Latino MH - Humans MH - Male MH - Social Class MH - United States MH - *Vaccination Hesitancy PMC - PMC9179933 OTO - NOTNLM OT - Adolescence OT - Attention-deficit/hyperactivity disorder OT - Coronavirus OT - Social determinants OT - Vaccination OT - Vaccine hesitancy COIS- The authors declare no conflict of interest. EDAT- 2022/06/18 06:00 MHDA- 2022/07/27 06:00 PMCR- 2022/06/09 CRDT- 2022/06/17 18:23 PHST- 2021/10/17 00:00 [received] PHST- 2022/04/25 00:00 [revised] PHST- 2022/06/06 00:00 [accepted] PHST- 2022/06/18 06:00 [pubmed] PHST- 2022/07/27 06:00 [medline] PHST- 2022/06/17 18:23 [entrez] PHST- 2022/06/09 00:00 [pmc-release] AID - S0022-3956(22)00302-8 [pii] AID - 10.1016/j.jpsychires.2022.06.005 [doi] PST - ppublish SO - J Psychiatr Res. 2022 Aug;152:25-30. doi: 10.1016/j.jpsychires.2022.06.005. Epub 2022 Jun 9. PMID- 35707317 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20260518 IS - 2632-2498 (Electronic) IS - 2632-2498 (Linking) VI - 4 IP - 1 DP - 2022 Jan-Dec TI - Brain tumor patients and COVID-19 vaccines: results of an international survey. PG - vdac063 LID - 10.1093/noajnl/vdac063 [doi] LID - vdac063 AB - BACKGROUND: As the COVID-19 pandemic continues to unfold, the advent of multiple approved vaccines has led to a milestone in the fight against the virus. While vaccination rates and side effects are well established in the general population, these are largely unknown in patients with brain tumors. The purpose of this study was to determine if brain tumor patients and their caregivers have received a COVID-19 vaccine, and explore their thoughts and opinions on these vaccines. METHODS: An anonymous 31-question online survey available in 8 languages was conducted from June 30, 2021 to August 31, 2021. The survey was open to adult brain tumor patients over the age of 18 and included both categorical and open-ended questions. Descriptive statistics and modified thematic analyses were performed for all questions as appropriate. RESULTS: A total of 965 unique surveys were completed from 42 countries. The vast majority of both brain tumor patients and their caregivers have been vaccinated against COVID-19 (84.5% and 89.9%, respectively). No patient reported serious adverse events from any vaccine. Less than 10% of patients decided against receiving a vaccination against COVID-19, with the most common reason being concerns over the safety of the vaccine. Patients wanted more specific information on how COVID-19 vaccines might impact their future brain tumor treatment. CONCLUSIONS: In conclusion, the majority of brain tumor patients and their caregivers have received COVID-19 vaccines with no major side effects. Patients want more information on how COVID-19 vaccines might directly impact their brain tumor and future management. CI - (c) The Author(s) 2022. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology. FAU - Voisin, Mathew R AU - Voisin MR AUID- ORCID: 0000-0002-1191-9579 AD - Division of Neurosurgery, Department of Surgery, University of Toronto, Toronto, Ontario, Canada. FAU - Oliver, Kathy AU - Oliver K AD - International Brain Tumour Alliance (IBTA), Tadworth, UK. FAU - Farrimond, Stuart AU - Farrimond S AD - International Brain Tumour Alliance (IBTA), Tadworth, UK. FAU - Chee, Tess AU - Chee T AD - Department of Health Sciences, McMaster University, Hamilton, Ontario, Canada. FAU - O'Halloran, Philip AU - O'Halloran P AD - Department of Physiology and Medical Physics, Royal College of Surgeons in Ireland (RCSI), Dublin, Ireland. FAU - Glas, Martin AU - Glas M AD - Division of Clinical Neurooncology, Department of Neurology and German Cancer Consortium (DKTK) Partner Site, University Hospital Essen, University Duisburg-Essen, Essen, Germany. CN - International Brain Tumour Alliance (IBTA) Senior Advisors FAU - Zadeh, Gelareh AU - Zadeh G AUID- ORCID: 0000-0002-6637-4502 AD - Division of Neurosurgery, Department of Surgery, University of Toronto, Toronto, Ontario, Canada. LA - eng PT - Journal Article DEP - 20220503 PL - England TA - Neurooncol Adv JT - Neuro-oncology advances JID - 101755003 PMC - PMC9129166 OTO - NOTNLM OT - COVID-19 OT - brain tumor OT - patients OT - survey OT - vaccine FIR - Arzbaecher, Jean IR - Arzbaecher J FIR - Kruchko, Carol IR - Kruchko C FIR - Maher, Mary Ellen IR - Maher ME FIR - Tse, Chris IR - Tse C FIR - Cashman, Rosemary IR - Cashman R FIR - Daniels, Maureen IR - Daniels M FIR - Mungoshi, Christine IR - Mungoshi C FIR - Lamb, Sharon IR - Lamb S FIR - Granero, Anita IR - Granero A FIR - Lovely, Mary IR - Lovely M FIR - Baker, Jenifer IR - Baker J FIR - Payne, Sally IR - Payne S EDAT- 2022/06/17 06:00 MHDA- 2022/06/17 06:01 PMCR- 2022/05/03 CRDT- 2022/06/16 02:36 PHST- 2022/06/16 02:36 [entrez] PHST- 2022/06/17 06:00 [pubmed] PHST- 2022/06/17 06:01 [medline] PHST- 2022/05/03 00:00 [pmc-release] AID - vdac063 [pii] AID - 10.1093/noajnl/vdac063 [doi] PST - epublish SO - Neurooncol Adv. 2022 May 3;4(1):vdac063. doi: 10.1093/noajnl/vdac063. eCollection 2022 Jan-Dec. PMID- 35696935 OWN - NLM STAT- MEDLINE DCOM- 20220708 LR - 20221221 IS - 1525-5069 (Electronic) IS - 1525-5050 (Print) IS - 1525-5050 (Linking) VI - 133 DP - 2022 Aug TI - COVID-19 vaccine-related frequently asked questions (FAQs) by people with epilepsy and carers in Iran; educational video is included. PG - 108763 LID - S1525-5050(22)00212-8 [pii] LID - 10.1016/j.yebeh.2022.108763 [doi] AB - OBJECTIVE: The aim of the current study was to inquire the questions and concerns of people with epilepsy (PWE) about COVID-19 vaccines in order to provide a more realistic list of their frequently asked questions (FAQs). METHODS: We surveyed all the consecutive PWE or their care-givers who were referred to our neurology clinics (Shiraz University of Medical Sciences) during January-February 2022. We collected their questions and concerns in relation to COVID vaccines based on a predesigned brief questionnaire. Informed consent to participate in the study was obtained from the participants. RESULTS: In total, 452 people participated in the study; 291 people (64.4%) did not have any questions or concerns with regard to the COVID-19 vaccination. Having any questions or concerns about COVID-19 vaccination was significantly associated with not being vaccinated. Questions and concerns about the adverse effects of COVID-19 vaccines [seizure worsening, general adverse effects, long-term effects (e.g., infertility, cognitive dysfunction)] were by far the most common questions by people with epilepsy and their carers. CONCLUSION: Our findings may be used by policy-makers to prepare appropriate educational materials to provide the best targeted and tailored information to people with epilepsy and their carers to convince them of the necessity and safety of COVID-19 vaccination. Such an educational material must include enough information on the associated adverse effects of COVID-19 vaccines and should also discuss some other important issues such as indications of these vaccines in special populations and drug-vaccine interactions. CI - Copyright (c) 2022 Elsevier Inc. All rights reserved. FAU - Asadi-Pooya, Ali A AU - Asadi-Pooya AA AD - Epilepsy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran; Jefferson Comprehensive Epilepsy Center, Department of Neurology, Thomas Jefferson University, Philadelphia, USA. Electronic address: aliasadipooya@yahoo.com. FAU - Karimi, Afrooz AU - Karimi A AD - Epilepsy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. FAU - Razavizadegan, Seyed Mohammad Ali AU - Razavizadegan SMA AD - Epilepsy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. FAU - Ashjazadeh, Nahid AU - Ashjazadeh N AD - Department of Neurology, Shiraz University of Medical Sciences, Shiraz, Iran. FAU - Nemati, Hamid AU - Nemati H AD - Epilepsy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220519 PL - United States TA - Epilepsy Behav JT - Epilepsy & behavior : E&B JID - 100892858 RN - 0 (COVID-19 Vaccines) RN - 0 (Vaccines) SB - IM MH - *COVID-19/prevention & control MH - COVID-19 Vaccines/adverse effects MH - Caregivers MH - *Epilepsy/psychology MH - Humans MH - Iran/epidemiology MH - SARS-CoV-2 MH - *Vaccines PMC - PMC9117255 OTO - NOTNLM OT - COVID-19 OT - Coronavirus OT - Epilepsy OT - Seizure OT - Vaccine EDAT- 2022/06/14 06:00 MHDA- 2022/07/09 06:00 PMCR- 2022/05/19 CRDT- 2022/06/13 18:24 PHST- 2022/03/09 00:00 [received] PHST- 2022/04/21 00:00 [revised] PHST- 2022/05/17 00:00 [accepted] PHST- 2022/06/14 06:00 [pubmed] PHST- 2022/07/09 06:00 [medline] PHST- 2022/06/13 18:24 [entrez] PHST- 2022/05/19 00:00 [pmc-release] AID - S1525-5050(22)00212-8 [pii] AID - 108763 [pii] AID - 10.1016/j.yebeh.2022.108763 [doi] PST - ppublish SO - Epilepsy Behav. 2022 Aug;133:108763. doi: 10.1016/j.yebeh.2022.108763. Epub 2022 May 19. PMID- 35687921 OWN - NLM STAT- MEDLINE DCOM- 20220712 LR - 20230328 IS - 1532-2653 (Electronic) IS - 0967-5868 (Print) IS - 0967-5868 (Linking) VI - 102 DP - 2022 Aug TI - Meaningful use of imaging resources to rule out cerebral venous sinus thrombosis after ChAdOx1 COVID-19 vaccination: Evaluation of the AHA diagnostic algorithm with a clinical cohort and a systematic data review. PG - 5-12 LID - S0967-5868(22)00245-4 [pii] LID - 10.1016/j.jocn.2022.05.031 [doi] AB - Vaccine-induced immune thrombotic thrombocytopenia (VITT) with cerebral venous thrombosis (CVST) is an improbable (0.0005%), however potentially lethal complication after ChAdOx1 vaccination. On the other hand, headache is among the most frequent side effects of ChAdOx1 (29.3%). In September 2021, the American Heart Association (AHA) suggested a diagnostic workflow to facilitate risk-adapted use of imaging resources for patients with neurological symptoms after ChAdOx1. We aimed to evaluate the AHA workflow in a retrospective patient cohort presenting at four primary care hospitals in Germany for neurological complaints after ChAdOx1. Scientific literature was screened for case reports of VITT with CVST after ChAdOx1, published until September 1st, 2021. One-hundred-thirteen consecutive patients (77 female, mean age 38.7 +/- 11.9 years) were evaluated at our institutes, including one case of VITT with CVST. Further 228 case reports of VITT with CVST are published in recent literature, which share thrombocytopenia (225/227 reported) and elevated d-dimer levels (100/101 reported). The AHA workflow would have recognized all VITT cases with CVST (100% sensitivity), the number needed to diagnose (NND) was 1:113. Initial evaluation of thrombocytopenia or elevated d-dimer levels would have lowered the NND to 1:68, without cost of sensitivity. Hence, we suggest that in case of normal thrombocyte and d-dimer levels, the access to further diagnostics should be limited by the established clinical considerations regardless of vaccination history. CI - Copyright (c) 2022 Elsevier Ltd. All rights reserved. FAU - Fervers, Philipp AU - Fervers P AD - Department of Diagnostic and Interventional Radiology, Faculty of Medicine and University Hospital Cologne, University Cologne, Cologne, Germany. Electronic address: Philipp.Fervers@uk-koeln.de. FAU - Kottlors, Jonathan AU - Kottlors J AD - Department of Diagnostic and Interventional Radiology, Faculty of Medicine and University Hospital Cologne, University Cologne, Cologne, Germany. Electronic address: Jonathan.Kottlors@uk-koeln.de. FAU - Persigehl, Thorsten AU - Persigehl T AD - Department of Diagnostic and Interventional Radiology, Faculty of Medicine and University Hospital Cologne, University Cologne, Cologne, Germany. Electronic address: Thorsten.Persigehl@uk-koeln.de. FAU - Lennartz, Simon AU - Lennartz S AD - Department of Diagnostic and Interventional Radiology, Faculty of Medicine and University Hospital Cologne, University Cologne, Cologne, Germany. Electronic address: Simon.Lennartz@uk-koeln.de. FAU - Maus, Volker AU - Maus V AD - Department of Diagnostic and Interventional Radiology, University Hospital Knappschaftskrankenhaus Bochum-Langendreer, University Bochum, Bochum, Germany. Electronic address: Volker.Maus@kk-bochum.de. FAU - Fischer, Sebastian AU - Fischer S AD - Department of Diagnostic and Interventional Radiology, University Hospital Knappschaftskrankenhaus Bochum-Langendreer, University Bochum, Bochum, Germany. Electronic address: Sebastian.Fischer@kk-bochum.de. FAU - Styczen, Hanna AU - Styczen H AD - Institute for Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany. Electronic address: Hanna.Styczen@uk-essen.de. FAU - Deuschl, Cornelius AU - Deuschl C AD - Institute for Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany. Electronic address: Cornelius.Deuschl@uk-essen.de. FAU - Schlamann, Marc AU - Schlamann M AD - Department of Diagnostic and Interventional Radiology, Faculty of Medicine and University Hospital Cologne, University Cologne, Cologne, Germany. Electronic address: Marc.Schlamann@uk-koeln.de. FAU - Mpotsaris, Anastasios AU - Mpotsaris A AD - University Clinic for Neuroradiology, Otto-von-Guericke-University Magdeburg, Magdeburg, Germany. Electronic address: Anastasios.Mpotsaris@med.ovgu.de. FAU - Zubel, Seraphine AU - Zubel S AD - University Clinic for Neuroradiology, Otto-von-Guericke-University Magdeburg, Magdeburg, Germany. Electronic address: Seraphine.Zubel@med.ovgu.de. FAU - Schroeter, Michael AU - Schroeter M AD - Department of Neurology, Faculty of Medicine and University Hospital Cologne, University Cologne, Cologne, Germany. Electronic address: Michael.Schroeter@uk-koeln.de. FAU - Maintz, David AU - Maintz D AD - Department of Diagnostic and Interventional Radiology, Faculty of Medicine and University Hospital Cologne, University Cologne, Cologne, Germany. Electronic address: David.Maintz@uk-koeln.de. FAU - Fink, Gereon Rudolf AU - Fink GR AD - Department of Neurology, Faculty of Medicine and University Hospital Cologne, University Cologne, Cologne, Germany; Cognitive Neuroscience, Institute of Neuroscience and Medicine (INM-3), Research Center Julich, Julich, Germany. Electronic address: G.R.Fink@fz-juelich.de. FAU - Abdullayev, Nuran AU - Abdullayev N AD - Department of Diagnostic and Interventional Radiology, Faculty of Medicine and University Hospital Cologne, University Cologne, Cologne, Germany. Electronic address: Nuran.Abdullayev@uk-koeln.de. LA - eng PT - Journal Article PT - Systematic Review DEP - 20220606 PL - Scotland TA - J Clin Neurosci JT - Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia JID - 9433352 RN - 0 (COVID-19 Vaccines) SB - IM MH - Adult MH - Algorithms MH - COVID-19/prevention & control MH - *COVID-19 Vaccines/adverse effects MH - Female MH - Humans MH - Male MH - Meaningful Use MH - Middle Aged MH - Retrospective Studies MH - *Sinus Thrombosis, Intracranial/diagnostic imaging/etiology PMC - PMC9167954 OTO - NOTNLM OT - American Heart Association OT - Headache OT - Intracranial thrombosis OT - Meaningful use OT - Vaccines COIS- The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: DM is on the speaker's bureau of Philips Healthcare. AM is a consultant for Stryker, Perflow, Phenox and Balt. SF is a consultant for Microvention. MS received personal honoraria from Alexion, Biogen, Gilead, Roche, and Sanofi. All other authors have nothing to disclose. EDAT- 2022/06/11 06:00 MHDA- 2022/07/14 06:00 PMCR- 2022/06/06 CRDT- 2022/06/10 18:13 PHST- 2022/03/23 00:00 [received] PHST- 2022/05/30 00:00 [revised] PHST- 2022/05/31 00:00 [accepted] PHST- 2022/06/11 06:00 [pubmed] PHST- 2022/07/14 06:00 [medline] PHST- 2022/06/10 18:13 [entrez] PHST- 2022/06/06 00:00 [pmc-release] AID - S0967-5868(22)00245-4 [pii] AID - 10.1016/j.jocn.2022.05.031 [doi] PST - ppublish SO - J Clin Neurosci. 2022 Aug;102:5-12. doi: 10.1016/j.jocn.2022.05.031. Epub 2022 Jun 6. PMID- 35672709 OWN - NLM STAT- MEDLINE DCOM- 20220609 LR - 20220716 IS - 1471-2377 (Electronic) IS - 1471-2377 (Linking) VI - 22 IP - 1 DP - 2022 Jun 7 TI - Inactivated COVID-19 vaccine induced acute stroke-like focal neurologic symptoms: a case series. PG - 210 LID - 10.1186/s12883-022-02739-6 [doi] LID - 210 AB - BACKGROUND: A subgroup of individuals experienced stroke-like symptoms after receiving an inactivated COVID-19 vaccine. We present clinical characteristics, neuroimaging, and outcome of these patients. METHODS: Medical personals who had neurological symptoms after receiving inactivated COVID-19 vaccine were enrolled. Clinical, laboratory investigation and neuroimaging were collected. Subjects were prospectively followed-up on clinical and neuroimaging to detect brain parenchymal or cerebrovascular abnormality. RESULTS: Nineteen out of 385 subjects (4.9%) developed neurological symptoms after vaccination. There was a female predominance (89.5%) with mean age of 34 +/- 7.5 years. Majority of patients (52.6%) had symptoms within 60 min after vaccination. The most common neurological symptoms were numbness (94.7%) followed by headache (52.6%) and weakness (47.4%). The most common neurological signs were sensory deficit (79%) followed by motor weakness (52.6%) and tongue deviation (26.3%). Recurrent headache was observed in most patients (89.5%) during followed up. Serial brain imaging was done in all patients with median follow-up interval of 18 days. There was no evidence of acute brain infarction in any of the patients, 84.2% had no vascular abnormality, 15.8% had transient focal narrowing of cerebral vessels. Outcome was favorable, modified ranking scale 0-1 for all patients at 4 weeks after vaccination. CONCLUSIONS: Transient focal neurological symptoms and deficits can be found after COVID-19 vaccination. However, benefit to stop COVID-19 pandemic by vaccination is outweighed by these seemingly reversible side effects. The pathophysiology underlined these phenomena should be further investigated. CI - (c) 2022. The Author(s). FAU - Roongpiboonsopit, Duangnapa AU - Roongpiboonsopit D AD - Division of Neurology, Department of Medicine, Faculty of Medicine, Naresuan University, 99 Moo 9, Tha Pho, Mueang, Phitsanulok, 65000, Thailand. Duangnapar@nu.ac.th. FAU - Nithisathienchai, Chichaya AU - Nithisathienchai C AD - Division of Neurology, Department of Medicine, Faculty of Medicine, Naresuan University, 99 Moo 9, Tha Pho, Mueang, Phitsanulok, 65000, Thailand. FAU - Akarathanawat, Wasan AU - Akarathanawat W AD - Division of Neurology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. AD - Chulalongkorn Comprehensive Stroke Center, King Chulalongkorn Memorial Hospital, Bangkok, Thailand. FAU - Lertutsahakul, Krittanon AU - Lertutsahakul K AD - Department of Radiology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. FAU - Tantivattana, Jarturon AU - Tantivattana J AD - Department of Radiology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. FAU - Viswanathan, Anand AU - Viswanathan A AD - Department of Neurology, Harvard Medical School, Massachusetts General Hospital, Boston, MA, USA. FAU - Suwanwela, Nijasri Charnnarong AU - Suwanwela NC AD - Division of Neurology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. AD - Chulalongkorn Comprehensive Stroke Center, King Chulalongkorn Memorial Hospital, Bangkok, Thailand. AD - Chula Neuroscience Center, King Chulalongkorn Memorial Hospital, Bangkok, Thailand. LA - eng PT - Journal Article DEP - 20220607 PL - England TA - BMC Neurol JT - BMC neurology JID - 100968555 RN - 0 (COVID-19 Vaccines) SB - IM MH - Adult MH - *COVID-19/prevention & control MH - COVID-19 Vaccines/adverse effects MH - Female MH - Headache/etiology MH - Humans MH - Male MH - Pandemics MH - SARS-CoV-2 MH - *Stroke/etiology PMC - PMC9170873 OTO - NOTNLM OT - Case series OT - Inactivated COVID-19 vaccine OT - Neurological complication OT - Stroke-like symptoms COIS- The authors declare that they have no competing interests. EDAT- 2022/06/08 06:00 MHDA- 2022/06/10 06:00 PMCR- 2022/06/07 CRDT- 2022/06/07 23:40 PHST- 2021/11/15 00:00 [received] PHST- 2022/05/24 00:00 [accepted] PHST- 2022/06/07 23:40 [entrez] PHST- 2022/06/08 06:00 [pubmed] PHST- 2022/06/10 06:00 [medline] PHST- 2022/06/07 00:00 [pmc-release] AID - 10.1186/s12883-022-02739-6 [pii] AID - 2739 [pii] AID - 10.1186/s12883-022-02739-6 [doi] PST - epublish SO - BMC Neurol. 2022 Jun 7;22(1):210. doi: 10.1186/s12883-022-02739-6. PMID- 35653438 OWN - NLM STAT- MEDLINE DCOM- 20220920 LR - 20260127 IS - 2470-9468 (Electronic) IS - 2470-9468 (Linking) VI - 7 IP - 75 DP - 2022 Sep 16 TI - Omicron BA.1 breakthrough infection drives cross-variant neutralization and memory B cell formation against conserved epitopes. PG - eabq2427 LID - 10.1126/sciimmunol.abq2427 [doi] LID - eabq2427 AB - Omicron is the evolutionarily most distinct severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant of concern (VOC) to date. We report that Omicron BA.1 breakthrough infection in BNT162b2-vaccinated individuals resulted in strong neutralizing activity against Omicron BA.1, BA.2, and previous SARS-CoV-2 VOCs but not against the Omicron sublineages BA.4 and BA.5. BA.1 breakthrough infection induced a robust recall response, primarily expanding memory B (B(MEM)) cells against epitopes shared broadly among variants, rather than inducing BA.1-specific B cells. The vaccination-imprinted B(MEM) cell pool had sufficient plasticity to be remodeled by heterologous SARS-CoV-2 spike glycoprotein exposure. Whereas selective amplification of B(MEM) cells recognizing shared epitopes allows for effective neutralization of most variants that evade previously established immunity, susceptibility to escape by variants that acquire alterations at hitherto conserved sites may be heightened. FAU - Quandt, Jasmin AU - Quandt J AUID- ORCID: 0000-0001-9589-9941 AD - BioNTech, An der Goldgrube 12, 55131 Mainz, Germany. FAU - Muik, Alexander AU - Muik A AUID- ORCID: 0000-0003-4561-2273 AD - BioNTech, An der Goldgrube 12, 55131 Mainz, Germany. FAU - Salisch, Nadine AU - Salisch N AD - BioNTech, An der Goldgrube 12, 55131 Mainz, Germany. FAU - Lui, Bonny Gaby AU - Lui BG AUID- ORCID: 0000-0002-8260-5075 AD - BioNTech, An der Goldgrube 12, 55131 Mainz, Germany. FAU - Lutz, Sebastian AU - Lutz S AUID- ORCID: 0000-0002-8415-6437 AD - BioNTech, An der Goldgrube 12, 55131 Mainz, Germany. FAU - Kruger, Kimberly AU - Kruger K AD - BioNTech, An der Goldgrube 12, 55131 Mainz, Germany. FAU - Wallisch, Ann-Kathrin AU - Wallisch AK AUID- ORCID: 0000-0001-5450-3218 AD - BioNTech, An der Goldgrube 12, 55131 Mainz, Germany. FAU - Adams-Quack, Petra AU - Adams-Quack P AUID- ORCID: 0000-0003-0056-0844 AD - BioNTech, An der Goldgrube 12, 55131 Mainz, Germany. FAU - Bacher, Maren AU - Bacher M AD - BioNTech, An der Goldgrube 12, 55131 Mainz, Germany. FAU - Finlayson, Andrew AU - Finlayson A AUID- ORCID: 0000-0003-0793-7878 AD - BioNTech, An der Goldgrube 12, 55131 Mainz, Germany. FAU - Ozhelvaci, Orkun AU - Ozhelvaci O AUID- ORCID: 0000-0002-9841-3369 AD - BioNTech, An der Goldgrube 12, 55131 Mainz, Germany. FAU - Vogler, Isabel AU - Vogler I AUID- ORCID: 0000-0001-9757-9618 AD - BioNTech, An der Goldgrube 12, 55131 Mainz, Germany. FAU - Grikscheit, Katharina AU - Grikscheit K AUID- ORCID: 0000-0003-1102-078X AD - Institute for Medical Virology, University Hospital, Goethe University Frankfurt, 60596 Frankfurt am Main, Germany. FAU - Hoehl, Sebastian AU - Hoehl S AUID- ORCID: 0000-0002-5100-9385 AD - Institute for Medical Virology, University Hospital, Goethe University Frankfurt, 60596 Frankfurt am Main, Germany. FAU - Goetsch, Udo AU - Goetsch U AD - Health Protection Authority, City of Frankfurt, 60313 Frankfurt am Main, Germany. FAU - Ciesek, Sandra AU - Ciesek S AD - Institute for Medical Virology, University Hospital, Goethe University Frankfurt, 60596 Frankfurt am Main, Germany. AD - DZIF-German Centre for Infection Research, External Partner Site, 60596 Frankfurt am Main, Germany. FAU - Tureci, Ozlem AU - Tureci O AUID- ORCID: 0000-0002-0623-1497 AD - BioNTech, An der Goldgrube 12, 55131 Mainz, Germany. AD - HI-TRON-Helmholtz Institute for Translational Oncology Mainz by DKFZ, Obere Zahlbacherstr. 63, 55131 Mainz, Germany. FAU - Sahin, Ugur AU - Sahin U AUID- ORCID: 0000-0003-0363-1564 AD - BioNTech, An der Goldgrube 12, 55131 Mainz, Germany. AD - TRON gGmbH-Translational Oncology at the University Medical Center of the Johannes Gutenberg University, Freiligrathstrasse 12, 55131 Mainz, Germany. LA - eng SI - ClinicalTrials.gov/NCT04380701 SI - ClinicalTrials.gov/NCT04949490 SI - ClinicalTrials.gov/NCT04380701 SI - EudraCT/2020-001038-36 SI - EudraCT/2021-002387-50 PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220916 PL - United States TA - Sci Immunol JT - Science immunology JID - 101688624 RN - 0 (BNT162 Vaccine) RN - 0 (Epitopes) RN - 0 (Membrane Glycoproteins) RN - 0 (Viral Envelope Proteins) SB - IM CIN - Sci Immunol. 2022 Aug 26;7(74):eabq5901. doi: 10.1126/sciimmunol.abq5901. PMID: 35653497 MH - BNT162 Vaccine MH - *COVID-19 MH - Epitopes MH - Humans MH - Membrane Glycoproteins MH - Memory B Cells MH - Neutralization Tests MH - SARS-CoV-2 MH - *Viral Envelope Proteins PMC - PMC9162083 EDAT- 2022/06/03 06:00 MHDA- 2022/09/21 06:00 PMCR- 2022/06/02 CRDT- 2022/06/02 14:03 PHST- 2022/06/03 06:00 [pubmed] PHST- 2022/09/21 06:00 [medline] PHST- 2022/06/02 14:03 [entrez] PHST- 2022/06/02 00:00 [pmc-release] AID - abq2427 [pii] AID - 10.1126/sciimmunol.abq2427 [doi] PST - ppublish SO - Sci Immunol. 2022 Sep 16;7(75):eabq2427. doi: 10.1126/sciimmunol.abq2427. Epub 2022 Sep 16. PMID- 35640838 OWN - NLM STAT- MEDLINE DCOM- 20220718 LR - 20221227 IS - 1872-9649 (Electronic) IS - 1568-1637 (Print) IS - 1568-1637 (Linking) VI - 79 DP - 2022 Aug TI - Is COVID-19 really a geriatric syndrome? PG - 101657 LID - S1568-1637(22)00099-X [pii] LID - 10.1016/j.arr.2022.101657 [doi] AB - Geriatric syndromes are a group of medical conditions, such as cognitive impairment, delirium, frailty, dizziness, syncope, and incontinence, associated with age increase. Many studies have reported a higher mortality rate for older COVID-19 patients, which could be explained by the complications of COVID-19, including the components of geriatric syndromes. We read with great interest the paper "Prevalence of unwillingness and uncertainty to vaccinate against COVID-19 in older people: A systematic review and meta-analysis" by Nicola Veronese et al. Their valuable work determines how uncertainty and unwillingness towards receiving the COVID-19 vaccine are more prevalent among older adults and how this hesitancy could affect vaccine uptake, and ultimately, the mortality rate. Regarding this paper, we wish to address some points. CI - Copyright (c) 2022 Elsevier B.V. All rights reserved. FAU - Akbarzadeh, Mohammad Amin AU - Akbarzadeh MA AD - Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran; Research Center for Evidence-Based Medicine, Tabriz University of Medical Sciences, Tabriz, Iran; Iranian Evidence-Based Medicine (EBM) Centre, Joanna Briggs Institute Affiliated Group, Tabriz, Iran. FAU - Hosseini, Mohammad-Salar AU - Hosseini MS AD - Research Center for Evidence-Based Medicine, Tabriz University of Medical Sciences, Tabriz, Iran; Iranian Evidence-Based Medicine (EBM) Centre, Joanna Briggs Institute Affiliated Group, Tabriz, Iran; Aging Research Institute, Tabriz University of Medical Sciences, Tabriz, Iran. Electronic address: hosseini.msalar@gmail.com. LA - eng PT - Journal Article DEP - 20220529 PL - England TA - Ageing Res Rev JT - Ageing research reviews JID - 101128963 RN - 0 (COVID-19 Vaccines) SB - IM MH - Aged MH - *COVID-19 MH - COVID-19 Vaccines MH - *Geriatric Assessment MH - Humans MH - Prevalence MH - Syndrome PMC - PMC9148424 OTO - NOTNLM OT - COVID-19 OT - Geriatric syndrome OT - Immunosenescence OT - Older adults OT - Vaccination EDAT- 2022/06/01 06:00 MHDA- 2022/07/19 06:00 PMCR- 2022/05/29 CRDT- 2022/05/31 19:26 PHST- 2022/03/31 00:00 [received] PHST- 2022/04/23 00:00 [revised] PHST- 2022/05/27 00:00 [accepted] PHST- 2022/06/01 06:00 [pubmed] PHST- 2022/07/19 06:00 [medline] PHST- 2022/05/31 19:26 [entrez] PHST- 2022/05/29 00:00 [pmc-release] AID - S1568-1637(22)00099-X [pii] AID - 101657 [pii] AID - 10.1016/j.arr.2022.101657 [doi] PST - ppublish SO - Ageing Res Rev. 2022 Aug;79:101657. doi: 10.1016/j.arr.2022.101657. Epub 2022 May 29. PMID- 35632452 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220716 IS - 2076-393X (Print) IS - 2076-393X (Electronic) IS - 2076-393X (Linking) VI - 10 IP - 5 DP - 2022 Apr 29 TI - The Effect of Waning on Antibody Levels and Memory B Cell Recall following SARS-CoV-2 Infection or Vaccination. LID - 10.3390/vaccines10050696 [doi] LID - 696 AB - In order to longitudinally track SARS-CoV-2 antibody levels after vaccination or infection, we assessed anti-RBD antibody levels in over 1000 people and found no significant decrease in antibody levels during the first 14 months after infection in unvaccinated participants, however, a significant waning of antibody levels was observed following vaccination. Participants who were pre-immune to SARS-CoV-2 prior to vaccination seroconverted to higher antibody levels, which were maintained at higher levels than in previously infected, unvaccinated participants. Older participants exhibited lower level of antibodies after vaccination, but a higher level after infection than younger people. The rate of antibody waning was not affected by pre-immunity or age. Participants who received a third dose of an mRNA vaccine not only increased their antibody levels ~14-fold, but also had ~3 times more antibodies compared to when they received their primary vaccine series. PBMC-derived memory B cells from 13 participants who lost all circulating antibodies were differentiated into antibody secreting cells (ASCs). There was a significant recall of memory B cell ASCs in the absence of serum antibodies in 5-8 of the 10 vaccinated participants, but not in any of the 3 infected participants, suggesting a strong connection between antibody levels and the effectiveness of memory B cell recall. FAU - Forgacs, David AU - Forgacs D AUID- ORCID: 0000-0002-3553-3320 AD - Center for Vaccines and Immunology, University of Georgia, Athens, GA 30605, USA. FAU - Silva-Moraes, Vanessa AU - Silva-Moraes V AUID- ORCID: 0000-0003-2991-7210 AD - Center for Vaccines and Immunology, University of Georgia, Athens, GA 30605, USA. FAU - Sautto, Giuseppe A AU - Sautto GA AUID- ORCID: 0000-0002-0273-2235 AD - Center for Vaccines and Immunology, University of Georgia, Athens, GA 30605, USA. FAU - Hanley, Hannah B AU - Hanley HB AD - Center for Vaccines and Immunology, University of Georgia, Athens, GA 30605, USA. FAU - Gattiker, Jasper L AU - Gattiker JL AD - Center for Vaccines and Immunology, University of Georgia, Athens, GA 30605, USA. FAU - Jefferson, Alexandria M AU - Jefferson AM AD - Center for Vaccines and Immunology, University of Georgia, Athens, GA 30605, USA. FAU - Kolhe, Ravindra AU - Kolhe R AUID- ORCID: 0000-0002-8283-2403 AD - Department of Pathology, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA. FAU - Ross, Ted M AU - Ross TM AUID- ORCID: 0000-0003-1947-7469 AD - Center for Vaccines and Immunology, University of Georgia, Athens, GA 30605, USA. AD - Department of Infectious Diseases, University of Georgia, Athens, GA 30605, USA. LA - eng GR - 75N93019C00052/AI/NIAID NIH HHS/United States GR - UL1 TR002378/TR/NCATS NIH HHS/United States GR - GRA-001/Georgia Research Alliance/ GR - UGA-001/University of Georgia/ PT - Journal Article DEP - 20220429 PL - Switzerland TA - Vaccines (Basel) JT - Vaccines JID - 101629355 UOF - bioRxiv. 2022 Mar 17:2022.03.16.484099. doi: 10.1101/2022.03.16.484099. PMID: 35313572 PMC - PMC9143792 OTO - NOTNLM OT - COVID-19 OT - SARS-CoV-2 OT - antibody decay OT - antibody secreting cells OT - infection OT - memory B cell recall OT - pre-immunity OT - vaccination OT - waning COIS- The authors declare no conflict of interest. EDAT- 2022/05/29 06:00 MHDA- 2022/05/29 06:01 PMCR- 2022/04/29 CRDT- 2022/05/28 01:43 PHST- 2022/04/01 00:00 [received] PHST- 2022/04/25 00:00 [revised] PHST- 2022/04/27 00:00 [accepted] PHST- 2022/05/28 01:43 [entrez] PHST- 2022/05/29 06:00 [pubmed] PHST- 2022/05/29 06:01 [medline] PHST- 2022/04/29 00:00 [pmc-release] AID - vaccines10050696 [pii] AID - vaccines-10-00696 [pii] AID - 10.3390/vaccines10050696 [doi] PST - epublish SO - Vaccines (Basel). 2022 Apr 29;10(5):696. doi: 10.3390/vaccines10050696. PMID- 35632417 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230308 IS - 2076-393X (Print) IS - 2076-393X (Electronic) IS - 2076-393X (Linking) VI - 10 IP - 5 DP - 2022 Apr 22 TI - Analyses of Public Attention and Sentiments towards Different COVID-19 Vaccines Using Data Mining Techniques. LID - 10.3390/vaccines10050661 [doi] LID - 661 AB - COVID-19 is a widely spread disease, and in order to overcome its spread, vaccination is necessary. Different vaccines are available in the market and people have different sentiments about different vaccines. This study aims to identify variations and explore temporal trends in the sentiments of tweets related to different COVID-19 vaccines (Covaxin, Moderna, Pfizer, and Sinopharm). We used the Valence Aware Dictionary and Sentiment Reasoner (VADER) tool to analyze the public sentiments related to each vaccine separately and identify whether the sentiments are positive (compound >/= 0.05), negative (compound /=6 weeks after vaccination with any of the approved SARS-CoV-2 vaccines. Demographics, clinical data, and information regarding previous SARS-CoV-2 infection and vaccination were collected. Disease relapses were considered "post-infectious" or "post-vaccination" when occurring within 6 weeks from infection/vaccination. RESULTS: We included 66 patients; 7/66 (11%) had a previous history of SARS-CoV-2 infection and 1/7 (14%) had post-infection relapses. BNT162b2-Pfizer-BioNTec was administered in 55 cases (83.3%) and mRNA-1273-Moderna in 11 (16.7%). The median number of doses administered per patient was 2 (1-3) and >50% of patients did not experience side effects. Five patients (8%) had post-vaccination relapses (seizure 3/5); 4/5 improved after immunotherapy, while one did not receive immunotherapy and worsened. Patients with post-vaccination relapses had higher disability scores at vaccination (p = 0.025), a trend favoring Leucine-rich glioma-inactivated protein 1 LGI1 glutamic acid decarboxylase 65 (GAD65) antibodies (p = 0.054) and shorter time from last relapse (p = 0.057). DISCUSSION: Our data support the safety of SARS-CoV-2 vaccines in patients with neurological disorders associated with antibodies to neuronal and synaptic antigens. CI - Copyright (c) 2022 Elsevier B.V. All rights reserved. FAU - Dinoto, Alessandro AU - Dinoto A AD - Neurology Unit, Department of Neuroscience, Biomedicine and Movement Sciences, University of Verona, Verona, Italy. FAU - Gastaldi, Matteo AU - Gastaldi M AD - Neuroimmunology Laboratory, IRCCS Mondino Foundation, Pavia, Italy. FAU - Iorio, Raffaele AU - Iorio R AD - UOC Neurologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy; Universita Cattolica del Sacro Cuore, Rome, Italy. FAU - Marini, Sofia AU - Marini S AD - Universita Cattolica del Sacro Cuore, Rome, Italy. FAU - Damato, Valentina AU - Damato V AD - Department of Neurosciences, Drug and Child Health, University of Florence, Florence, Italy. FAU - Farina, Antonio AU - Farina A AD - Department of Neurosciences, Drug and Child Health, University of Florence, Florence, Italy. FAU - Zoccarato, Marco AU - Zoccarato M AD - UOC Neurologia O.S.A. - Azienda Ospedale Universita Di Padova, Padua, Italy. FAU - Sechi, Elia AU - Sechi E AD - Azienda Ospedaliera Universitaria Sassari, Unit of Neurology, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy. FAU - Pinna, Francesca AU - Pinna F AD - Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy. FAU - Maniscalco, Giorgia Teresa AU - Maniscalco GT AD - Neurological Clinic and Stroke Unit, Multiple Sclerosis Center, "A. Cardarelli" Hospital, Naples, Italy. FAU - Barnabei, Ruggero AU - Barnabei R AD - Neurology Unit, University of Pavia, Italy. FAU - Zuliani, Luigi AU - Zuliani L AD - Neurology Unit, AULSS8 Berica, Vicenza, Italy. FAU - Ferrari, Sergio AU - Ferrari S AD - Neurology Unit, Department of Neuroscience, Biomedicine and Movement Sciences, University of Verona, Verona, Italy. FAU - Mariotto, Sara AU - Mariotto S AD - Neurology Unit, Department of Neuroscience, Biomedicine and Movement Sciences, University of Verona, Verona, Italy. Electronic address: sara.mariotto@gmail.com. LA - eng PT - Letter PT - Multicenter Study DEP - 20220425 PL - Netherlands TA - Mult Scler Relat Disord JT - Multiple sclerosis and related disorders JID - 101580247 RN - 0 (Antibodies, Viral) RN - 0 (Autoantibodies) RN - 0 (BNT162 Vaccine) RN - 0 (COVID-19 Vaccines) RN - 0 (Viral Vaccines) SB - IM MH - Antibodies, Viral MH - Autoantibodies MH - BNT162 Vaccine MH - *COVID-19/prevention & control MH - COVID-19 Vaccines/adverse effects MH - Humans MH - Neoplasm Recurrence, Local MH - SARS-CoV-2 MH - Vaccination MH - *Viral Vaccines PMC - PMC9035564 OTO - NOTNLM OT - Autoimmune encephalitis OT - CNS autoantibodies OT - SARS-CoV-2 OT - Safety OT - Vaccination COIS- The authors report no competing interests in relation to this study. EDAT- 2022/05/05 06:00 MHDA- 2022/06/29 06:00 PMCR- 2022/04/25 CRDT- 2022/05/04 18:14 PHST- 2022/03/29 00:00 [received] PHST- 2022/04/11 00:00 [revised] PHST- 2022/04/21 00:00 [accepted] PHST- 2022/05/05 06:00 [pubmed] PHST- 2022/06/29 06:00 [medline] PHST- 2022/05/04 18:14 [entrez] PHST- 2022/04/25 00:00 [pmc-release] AID - S2211-0348(22)00339-X [pii] AID - 103827 [pii] AID - 10.1016/j.msard.2022.103827 [doi] PST - ppublish SO - Mult Scler Relat Disord. 2022 Jul;63:103827. doi: 10.1016/j.msard.2022.103827. Epub 2022 Apr 25. PMID- 35503375 OWN - NLM STAT- MEDLINE DCOM- 20220720 LR - 20260518 IS - 1432-1459 (Electronic) IS - 0340-5354 (Print) IS - 0340-5354 (Linking) VI - 269 IP - 8 DP - 2022 Aug TI - Difference in safety and humoral response to mRNA SARS-CoV-2 vaccines in patients with autoimmune neurological disorders: the ANCOVAX study. PG - 4000-4012 LID - 10.1007/s00415-022-11142-7 [doi] AB - BACKGROUND: Assessing the safety of SARS-CoV-2 mRNA vaccines and the effect of immunotherapies on the seroconversion rate in patients with autoimmune neurological conditions (ANC) is relevant to clinical practice. Our aim was to assess the antibody response to and safety of SARS-CoV-2 mRNA vaccines in ANC. METHODS: This longitudinal study included ANC patients vaccinated with two doses of BNT162b2 or mRNA-1273 between March and August 2021. Side effects were assessed 2-10 days after each dose. Neurological status and anti-spike receptor binding domain antibody levels were evaluated before vaccination and 4 weeks after the second dose. Healthcare-workers served as controls for antibody levels. RESULTS: We included 300 ANC patients (median age 52, IQR 40-65), and 347 healthcare-workers (median age 45, IQR 34-54). mRNA-1273 vaccine was associated with an increased risk of both local (OR 2.52 95% CI 1.45-4.39, p = 0.001) and systemic reactions (OR 2.51% CI 1.49-4.23, p = 0.001). The incidence of relapse was not different before and after vaccine (Incidence rate ratio 0.72, 95% CI 0.29-1.83). Anti-SARS-CoV-2 IgG were detected in 268 (89.9%) patients and in all controls (p < 0.0001). BNT162b2 vaccine (OR 8.84 95% CI 2.32-33.65, p = 0.001), anti-CD20 mAb (OR 0.004 95% CI 0.0007-0.026, p < 0.0001) and fingolimod (OR 0.036 95% CI 0.002-0.628, p = 0.023) were associated with an increased risk of not developing anti-SARS-CoV-2 IgG. CONCLUSION: SARS-CoV-2 mRNA vaccines were safe in a large group of ANC patients. Anti-CD20 and fingolimod treatment, as well as vaccination with the BNT162b2 vaccine, led to a reduced humoral response. These findings could inform vaccine policies in ANC patients undergoing immunotherapy. CI - (c) 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany. FAU - Giannoccaro, Maria Pia AU - Giannoccaro MP AUID- ORCID: 0000-0003-2208-376X AD - Dipartimento di Scienze Biomediche e Neuromotorie, Universita di Bologna, Bologna, Italy. mpgiannoccaro@gmail.com. AD - IRCCS Istituto delle Scienze Neurologiche di Bologna, Via Altura 3, 40139, Bologna, Italy. mpgiannoccaro@gmail.com. FAU - Vacchiano, Veria AU - Vacchiano V AD - Dipartimento di Scienze Biomediche e Neuromotorie, Universita di Bologna, Bologna, Italy. AD - IRCCS Istituto delle Scienze Neurologiche di Bologna, Via Altura 3, 40139, Bologna, Italy. FAU - Leone, Marta AU - Leone M AD - Microbiology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. AD - Section of Microbiology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy. FAU - Camilli, Federico AU - Camilli F AD - Dipartimento di Scienze Biomediche e Neuromotorie, Universita di Bologna, Bologna, Italy. FAU - Zenesini, Corrado AU - Zenesini C AD - IRCCS Istituto delle Scienze Neurologiche di Bologna, Via Altura 3, 40139, Bologna, Italy. FAU - Panzera, Ivan AU - Panzera I AD - Dipartimento di Scienze Biomediche e Neuromotorie, Universita di Bologna, Bologna, Italy. FAU - Balboni, Alice AU - Balboni A AD - Microbiology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. AD - Section of Microbiology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy. FAU - Tappata, Maria AU - Tappata M AD - IRCCS Istituto delle Scienze Neurologiche di Bologna, Via Altura 3, 40139, Bologna, Italy. FAU - Borghi, Annamaria AU - Borghi A AD - IRCCS Istituto delle Scienze Neurologiche di Bologna, Neurology and Metropolitan Stroke Center, "C.A. Pizzardi" Maggiore Hospital, Bologna, Italy. FAU - Salvi, Fabrizio AU - Salvi F AD - IRCCS Istituto delle Scienze Neurologiche di Bologna, Via Altura 3, 40139, Bologna, Italy. FAU - Lugaresi, Alessandra AU - Lugaresi A AD - Dipartimento di Scienze Biomediche e Neuromotorie, Universita di Bologna, Bologna, Italy. AD - IRCCS Istituto delle Scienze Neurologiche di Bologna, Via Altura 3, 40139, Bologna, Italy. FAU - Rinaldi, Rita AU - Rinaldi R AD - IRCCS Istituto delle Scienze Neurologiche di Bologna, UOC Interaziendale Metropolitana (NeuroMet), - Neurologia AOU S.Orsola-Malpighi, Bologna, Italy. FAU - Di Felice, Giulia AU - Di Felice G AD - Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy. AD - Occupational Health Unit, Istituto di Ricovero e Cura a Carattere Scientifico St. Orsola Polyclinic, University of Bologna, Bologna, Italy. FAU - Lodi, Vittorio AU - Lodi V AD - Occupational Health Unit, Istituto di Ricovero e Cura a Carattere Scientifico St. Orsola Polyclinic, University of Bologna, Bologna, Italy. FAU - Lazzarotto, Tiziana AU - Lazzarotto T AD - Microbiology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. AD - Section of Microbiology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy. FAU - Liguori, Rocco AU - Liguori R AD - Dipartimento di Scienze Biomediche e Neuromotorie, Universita di Bologna, Bologna, Italy. AD - IRCCS Istituto delle Scienze Neurologiche di Bologna, Via Altura 3, 40139, Bologna, Italy. CN - ANCOVAX study group LA - eng PT - Journal Article DEP - 20220503 PL - Germany TA - J Neurol JT - Journal of neurology JID - 0423161 RN - EPK39PL4R4 (2019-nCoV Vaccine mRNA-1273) RN - 0 (Antibodies, Viral) RN - 0 (BNT162 Vaccine) RN - 0 (COVID-19 Vaccines) RN - G926EC510T (Fingolimod Hydrochloride) RN - 0 (Immunoglobulin G) SB - IM MH - 2019-nCoV Vaccine mRNA-1273 MH - Adult MH - Aged MH - Antibodies, Viral MH - *Autoimmune Diseases of the Nervous System MH - BNT162 Vaccine MH - *COVID-19/prevention & control MH - *COVID-19 Vaccines/adverse effects/immunology MH - Fingolimod Hydrochloride MH - Humans MH - *Immunity, Humoral MH - Immunoglobulin G MH - Longitudinal Studies MH - Middle Aged MH - SARS-CoV-2 PMC - PMC9063626 OTO - NOTNLM OT - Autoimmune neurological disorders OT - Humoral response OT - Immune therapy OT - Multiple sclerosis OT - Sars-Cov2-mRNA vaccine COIS- MPG, VV, ML, FC, CZ, IP, AB, MT, AB, FS, RR, GDF, VL, TZ, declare no competing interest; AL, has served as a Biogen, Bristol Myers Squibb, Merck Serono, Novartis, Roche, Sanofi/ Genzyme and Teva Advisory Board Member. She received congress and travel/accommodation expense compensations or speaker honoraria from Biogen, Merck, Mylan, Novartis, Roche, Sanofi/Genzyme, Teva and Fondazione Italiana Sclerosi Multipla (FISM). Her institutions received research grants from Novartis and Sanofi Genzyme. RL has received: Lecture fees from LT3 s.r.l., NICO s.r.l., SUMMEET s.r.l. and GALEN SYMPOSION s.r.o.; fees for consultancy (Advisory Board) from LT3 s.r.l. and PREX s.r.l.; fees for scientific meeting organization from I&C s.r.l.; Chair meeting fees from PLANNING CONGRESSI s.r.l. FIR - Donadio, Vincenzo IR - Donadio V FIR - Avoni, Patrizia IR - Avoni P FIR - D'Angelo, Roberto IR - D'Angelo R FIR - Ricciardiello, Fortuna IR - Ricciardiello F FIR - Masullo, Marco IR - Masullo M FIR - De Marco, Giovanna IR - De Marco G FIR - Salvi, Filippo IR - Salvi F FIR - Zini, Andrea IR - Zini A FIR - Galletti, Margherita IR - Galletti M FIR - Biundo, Giampaolo IR - Biundo G FIR - Pastorelli, Francesca IR - Pastorelli F FIR - Michelucci, Roberto IR - Michelucci R EDAT- 2022/05/04 06:00 MHDA- 2022/07/22 06:00 PMCR- 2022/05/03 CRDT- 2022/05/03 12:42 PHST- 2022/01/13 00:00 [received] PHST- 2022/04/12 00:00 [accepted] PHST- 2022/04/11 00:00 [revised] PHST- 2022/05/04 06:00 [pubmed] PHST- 2022/07/22 06:00 [medline] PHST- 2022/05/03 12:42 [entrez] PHST- 2022/05/03 00:00 [pmc-release] AID - 10.1007/s00415-022-11142-7 [pii] AID - 11142 [pii] AID - 10.1007/s00415-022-11142-7 [doi] PST - ppublish SO - J Neurol. 2022 Aug;269(8):4000-4012. doi: 10.1007/s00415-022-11142-7. Epub 2022 May 3. PMID- 35496775 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20260301 IS - 2666-3546 (Electronic) IS - 2666-3546 (Linking) VI - 22 DP - 2022 Jul TI - Cognitive deficits and memory impairments after COVID-19 (Covishield) vaccination. PG - 100463 LID - 10.1016/j.bbih.2022.100463 [doi] AB - Vaccination is an essential public health strategy to control the 2019 Coronavirus (COVID-19) pandemic. While the benefits of the COVID-19 vaccines far outweigh the risks, side effects continue to be reported in the literature. We report a 65-year-old man who developed cognitive deficits and memory impairments following his first dose of Oxford AstraZeneca vaccine (Covishield). The onset of acute cognitive deficits and memory impairments could be another complication to COVID-19 vaccination that physicians and neurologists need to be warned to. Monitoring the safety of COVID-19 vaccines and describing side effects associated with them is essential to improve safety profiles and enhance public trust. CI - (c) 2022 The Authors. FAU - Chaurasia, Bipin AU - Chaurasia B AD - Department of Neurosurgery, Bhawani Hospital and Research Centre, Birgunj, Nepal. FAU - Chavda, Vishal AU - Chavda V AD - Department of Pathology, Stanford School of Medicine, Stanford University Medical Center, USA. FAU - Lu, Bingwei AU - Lu B AD - Department of Pathology, Stanford School of Medicine, Stanford University Medical Center, USA. FAU - Garg, Kanwaljeet AU - Garg K AD - Department of Neurosurgery, All India Institute of Medical Sciences, New Delhi, India. FAU - Montemurro, Nicola AU - Montemurro N AD - Department of Neurosurgery, Azienda Ospedaliera Universitaria Pisana (AOUP), University of Pisa, Pisa, Italy. LA - eng PT - Journal Article DEP - 20220423 PL - United States TA - Brain Behav Immun Health JT - Brain, behavior, & immunity - health JID - 101759062 PMC - PMC9034829 OTO - NOTNLM OT - COVID-19 OT - Cognitive deficits OT - Coronavirus OT - SARS-CoV OT - Vaccination COIS- The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2022/05/03 06:00 MHDA- 2022/05/03 06:01 PMCR- 2022/04/23 CRDT- 2022/05/02 06:54 PHST- 2022/03/05 00:00 [received] PHST- 2022/04/12 00:00 [revised] PHST- 2022/04/20 00:00 [accepted] PHST- 2022/05/02 06:54 [entrez] PHST- 2022/05/03 06:00 [pubmed] PHST- 2022/05/03 06:01 [medline] PHST- 2022/04/23 00:00 [pmc-release] AID - S2666-3546(22)00053-9 [pii] AID - 100463 [pii] AID - 10.1016/j.bbih.2022.100463 [doi] PST - ppublish SO - Brain Behav Immun Health. 2022 Jul;22:100463. doi: 10.1016/j.bbih.2022.100463. Epub 2022 Apr 23. PMID- 35483354 OWN - NLM STAT- MEDLINE DCOM- 20220617 LR - 20221221 IS - 1097-4180 (Electronic) IS - 1074-7613 (Print) IS - 1074-7613 (Linking) VI - 55 IP - 6 DP - 2022 Jun 14 TI - Analysis of mRNA vaccination-elicited RBD-specific memory B cells reveals strong but incomplete immune escape of the SARS-CoV-2 Omicron variant. PG - 1096-1104.e4 LID - S1074-7613(22)00173-X [pii] LID - 10.1016/j.immuni.2022.04.002 [doi] AB - The SARS-CoV-2 Omicron variant can escape neutralization by vaccine-elicited and convalescent antibodies. Memory B cells (MBCs) represent another layer of protection against SARS-CoV-2, as they persist after infection and vaccination and improve their affinity. Whether MBCs elicited by mRNA vaccines can recognize the Omicron variant remains unclear. We assessed the affinity and neutralization potency against the Omicron variant of several hundred naturally expressed MBC-derived monoclonal IgG antibodies from vaccinated COVID-19-recovered and -naive individuals. Compared with other variants of concern, Omicron evaded recognition by a larger proportion of MBC-derived antibodies, with only 30% retaining high affinity against the Omicron RBD, and the reduction in neutralization potency was even more pronounced. Nonetheless, neutralizing MBC clones could be found in all the analyzed individuals. Therefore, despite the strong immune escape potential of the Omicron variant, these results suggest that the MBC repertoire generated by mRNA vaccines still provides some protection against the Omicron variant in vaccinated individuals. CI - Copyright (c) 2022. Published by Elsevier Inc. FAU - Sokal, Aurelien AU - Sokal A AD - Institut Necker Enfants Malades (INEM), INSERM U1151/CNRS UMR 8253, Universite Paris Cite, Paris, France. FAU - Broketa, Matteo AU - Broketa M AD - Institut Pasteur, Universite Paris Cite, INSERM UMR1222, Unit of Antibodies in Therapy and Pathology, Paris, France. FAU - Barba-Spaeth, Giovanna AU - Barba-Spaeth G AD - Institut Pasteur, Universite Paris Cite, CNRS UMR 3569, Unite de Virologie Structurale, Paris, France. FAU - Meola, Annalisa AU - Meola A AD - Institut Pasteur, Universite Paris Cite, CNRS UMR 3569, Unite de Virologie Structurale, Paris, France. FAU - Fernandez, Ignacio AU - Fernandez I AD - Institut Pasteur, Universite Paris Cite, CNRS UMR 3569, Unite de Virologie Structurale, Paris, France. FAU - Fourati, Slim AU - Fourati S AD - Departement de Virologie, Bacteriologie, Hygiene et Mycologie-Parasitologie, Centre Hospitalier Universitaire Henri-Mondor, Assistance Publique-Hopitaux de Paris (AP-HP), Creteil, France; INSERM U955, equipe 18, Institut Mondor de Recherche Biomedicale (IMRB), Universite Paris-Est Creteil (UPEC), Creteil, France. FAU - Azzaoui, Imane AU - Azzaoui I AD - Service de Medecine Interne, Centre Hospitalier Universitaire Henri-Mondor, Publique-Hopitaux de Paris (AP-HP), Universite Paris-Est Creteil, Creteil, France; INSERM U955, equipe 2, Institut Mondor de Recherche Biomedicale (IMRB), Universite Paris-Est Creteil, Creteil, France. FAU - de La Selle, Andrea AU - de La Selle A AD - Institut Necker Enfants Malades (INEM), INSERM U1151/CNRS UMR 8253, Universite Paris Cite, Paris, France; Service de Medecine Interne, Centre Hospitalier Universitaire Henri-Mondor, Publique-Hopitaux de Paris (AP-HP), Universite Paris-Est Creteil, Creteil, France. FAU - Vandenberghe, Alexis AU - Vandenberghe A AD - Service de Medecine Interne, Centre Hospitalier Universitaire Henri-Mondor, Publique-Hopitaux de Paris (AP-HP), Universite Paris-Est Creteil, Creteil, France; INSERM U955, equipe 2, Institut Mondor de Recherche Biomedicale (IMRB), Universite Paris-Est Creteil, Creteil, France. FAU - Roeser, Anais AU - Roeser A AD - Institut Necker Enfants Malades (INEM), INSERM U1151/CNRS UMR 8253, Universite Paris Cite, Paris, France; Service de Medecine Interne, Centre Hospitalier Universitaire Henri-Mondor, Publique-Hopitaux de Paris (AP-HP), Universite Paris-Est Creteil, Creteil, France. FAU - Bouvier-Alias, Magali AU - Bouvier-Alias M AD - Departement de Virologie, Bacteriologie, Hygiene et Mycologie-Parasitologie, Centre Hospitalier Universitaire Henri-Mondor, Assistance Publique-Hopitaux de Paris (AP-HP), Creteil, France; INSERM U955, equipe 18, Institut Mondor de Recherche Biomedicale (IMRB), Universite Paris-Est Creteil (UPEC), Creteil, France. FAU - Crickx, Etienne AU - Crickx E AD - Institut Necker Enfants Malades (INEM), INSERM U1151/CNRS UMR 8253, Universite Paris Cite, Paris, France; Service de Medecine Interne, Centre Hospitalier Universitaire Henri-Mondor, Publique-Hopitaux de Paris (AP-HP), Universite Paris-Est Creteil, Creteil, France. FAU - Languille, Laetitia AU - Languille L AD - Service de Medecine Interne, Centre Hospitalier Universitaire Henri-Mondor, Publique-Hopitaux de Paris (AP-HP), Universite Paris-Est Creteil, Creteil, France. FAU - Michel, Marc AU - Michel M AD - Service de Medecine Interne, Centre Hospitalier Universitaire Henri-Mondor, Publique-Hopitaux de Paris (AP-HP), Universite Paris-Est Creteil, Creteil, France. FAU - Godeau, Bertrand AU - Godeau B AD - Service de Medecine Interne, Centre Hospitalier Universitaire Henri-Mondor, Publique-Hopitaux de Paris (AP-HP), Universite Paris-Est Creteil, Creteil, France. FAU - Gallien, Sebastien AU - Gallien S AD - Service de Maladies Infectieuses, Centre Hospitalier Universitaire Henri-Mondor, Assistance Publique-Hopitaux de Paris (AP-HP), Universite Paris-Est Creteil (UPEC), Creteil, France. FAU - Melica, Giovanna AU - Melica G AD - Service de Maladies Infectieuses, Centre Hospitalier Universitaire Henri-Mondor, Assistance Publique-Hopitaux de Paris (AP-HP), Universite Paris-Est Creteil (UPEC), Creteil, France. FAU - Nguyen, Yann AU - Nguyen Y AD - Service de Medecine interne, Hopital Beaujon, Assistance Publique-Hopitaux de Paris, Universite de Paris, Clichy, France. FAU - Zarrouk, Virginie AU - Zarrouk V AD - Service de Medecine interne, Hopital Beaujon, Assistance Publique-Hopitaux de Paris, Universite de Paris, Clichy, France. FAU - Canoui-Poitrine, Florence AU - Canoui-Poitrine F AD - Departement de Sante Publique, Unite de Recherche Clinique (URC), CEpiA (Clinical Epidemiology and Ageing), EA 7376, Institut Mondor de Recherche Biomedicale (IMRB), Centre Hospitalier Universitaire Henri-Mondor, Assistance Publique-Hopitaux de Paris (AP-HP), Universite Paris-Est Creteil (UPEC), Creteil, France. FAU - Noizat-Pirenne, France AU - Noizat-Pirenne F AD - INSERM U955, equipe 2, Institut Mondor de Recherche Biomedicale (IMRB), Universite Paris-Est Creteil, Creteil, France; Etablissement Francais du Sang (EFS) Ile de France, Creteil, France. FAU - Megret, Jerome AU - Megret J AD - Plateforme de Cytometrie en Flux, Structure Federative de Recherche Necker, INSERM US24-CNRS UMS3633, Paris, France. FAU - Pawlotsky, Jean-Michel AU - Pawlotsky JM AD - Departement de Virologie, Bacteriologie, Hygiene et Mycologie-Parasitologie, Centre Hospitalier Universitaire Henri-Mondor, Assistance Publique-Hopitaux de Paris (AP-HP), Creteil, France; INSERM U955, equipe 18, Institut Mondor de Recherche Biomedicale (IMRB), Universite Paris-Est Creteil (UPEC), Creteil, France. FAU - Fillatreau, Simon AU - Fillatreau S AD - Institut Necker Enfants Malades (INEM), INSERM U1151/CNRS UMR 8253, Universite Paris Cite, Paris, France. FAU - Simon-Loriere, Etienne AU - Simon-Loriere E AD - Institut Pasteur, Evolutionary genomics of RNA viruses, Universite Paris Cite, Paris, France. FAU - Weill, Jean-Claude AU - Weill JC AD - Institut Necker Enfants Malades (INEM), INSERM U1151/CNRS UMR 8253, Universite Paris Cite, Paris, France. FAU - Reynaud, Claude-Agnes AU - Reynaud CA AD - Institut Necker Enfants Malades (INEM), INSERM U1151/CNRS UMR 8253, Universite Paris Cite, Paris, France. FAU - Rey, Felix A AU - Rey FA AD - Institut Pasteur, Universite Paris Cite, CNRS UMR 3569, Unite de Virologie Structurale, Paris, France. FAU - Bruhns, Pierre AU - Bruhns P AD - Institut Pasteur, Universite Paris Cite, INSERM UMR1222, Unit of Antibodies in Therapy and Pathology, Paris, France. FAU - Chappert, Pascal AU - Chappert P AD - Institut Necker Enfants Malades (INEM), INSERM U1151/CNRS UMR 8253, Universite Paris Cite, Paris, France; INSERM U955, equipe 2, Institut Mondor de Recherche Biomedicale (IMRB), Universite Paris-Est Creteil, Creteil, France. Electronic address: pascal.chappert@inserm.fr. FAU - Mahevas, Matthieu AU - Mahevas M AD - Institut Necker Enfants Malades (INEM), INSERM U1151/CNRS UMR 8253, Universite Paris Cite, Paris, France; Service de Medecine Interne, Centre Hospitalier Universitaire Henri-Mondor, Publique-Hopitaux de Paris (AP-HP), Universite Paris-Est Creteil, Creteil, France; INSERM U955, equipe 2, Institut Mondor de Recherche Biomedicale (IMRB), Universite Paris-Est Creteil, Creteil, France. Electronic address: matthieu.mahevas@aphp.fr. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220407 PL - United States TA - Immunity JT - Immunity JID - 9432918 RN - 0 (Antibodies, Neutralizing) RN - 0 (Antibodies, Viral) RN - 0 (RNA, Messenger) RN - 0 (Spike Glycoprotein, Coronavirus) RN - 0 (spike protein, SARS-CoV-2) RN - SARS-CoV-2 variants SB - IM CIN - Signal Transduct Target Ther. 2022 Oct 2;7(1):343. doi: 10.1038/s41392-022-01192-8. PMID: 36184648 MH - Antibodies, Neutralizing MH - Antibodies, Viral MH - *COVID-19/prevention & control MH - Humans MH - Memory B Cells MH - RNA, Messenger/genetics MH - *SARS-CoV-2 MH - Spike Glycoprotein, Coronavirus/genetics MH - Vaccination PMC - PMC8986479 OTO - NOTNLM OT - B cells OT - COVID-19 OT - MBC OT - Omicron OT - SARS-CoV-2 OT - VOC OT - affinity OT - germinal center OT - mRNA vaccine OT - memory B cells OT - variants COIS- Declaration of interests Outside of the submitted work, M. Mahevas received research funds from GSK and personal fees from LFB and Amgen. J.-C.W. received consulting fees from Institut Merieux. P.B. received consulting fees from Regeneron Pharmaceuticals. J.-M.P. received personal fees from Abbvie, Gilead, Merck, and Siemens Healthcare. F.A.R. is a member of the board of MELETIOS Therapeutics and of the Scientific Advisory Board of eureKARE. EDAT- 2022/04/29 06:00 MHDA- 2022/06/18 06:00 PMCR- 2022/04/07 CRDT- 2022/04/28 18:42 PHST- 2021/12/21 00:00 [received] PHST- 2022/02/16 00:00 [revised] PHST- 2022/04/04 00:00 [accepted] PHST- 2022/04/29 06:00 [pubmed] PHST- 2022/06/18 06:00 [medline] PHST- 2022/04/28 18:42 [entrez] PHST- 2022/04/07 00:00 [pmc-release] AID - S1074-7613(22)00173-X [pii] AID - 10.1016/j.immuni.2022.04.002 [doi] PST - ppublish SO - Immunity. 2022 Jun 14;55(6):1096-1104.e4. doi: 10.1016/j.immuni.2022.04.002. Epub 2022 Apr 7. PMID- 35480625 OWN - NLM STAT- MEDLINE DCOM- 20220429 LR - 20221022 IS - 2666-3791 (Electronic) IS - 2666-3791 (Linking) VI - 3 IP - 4 DP - 2022 Apr 19 TI - Pre-existing SARS-CoV-2 immunity influences potency, breadth, and durability of the humoral response to SARS-CoV-2 vaccination. PG - 100603 LID - S2666-3791(22)00120-3 [pii] LID - 10.1016/j.xcrm.2022.100603 [doi] LID - 100603 AB - The ongoing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic highlights the importance of determining the breadth and durability of humoral immunity to SARS-CoV-2 mRNA vaccination. Herein, we characterize the humoral response in 27 naive and 40 recovered vaccinees. SARS-CoV-2-specific antibody and memory B cell (MBC) responses are durable up to 6 months, although antibody half-lives are shorter for naive recipients. The magnitude of the humoral responses to vaccination strongly correlates with responses to initial SARS-CoV-2 infection. Neutralization titers are lower against SARS-CoV-2 variants in both recovered and naive vaccinees, with titers more reduced in naive recipients. While the receptor-binding domain (RBD) is the main neutralizing target of circulating antibodies, Moderna-vaccinated naives show a lesser reliance on RBDs, with >25% neutralization remaining after depletion of RBD-binding antibodies. Overall, we observe that vaccination induces higher peak titers and improves durability in recovered compared with naive vaccinees. These findings have broad implications for current vaccine strategies deployed against the SARS-CoV-2 pandemic. CI - (c) 2022 The Author(s). FAU - Mantus, Grace AU - Mantus G AD - Department of Pediatrics, Centers for Childhood Infections and Vaccines, Children's Healthcare of Atlanta and Emory University, Atlanta, GA 30329, USA; Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA 30329, USA; Division of Infectious Diseases, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA. FAU - Nyhoff, Lindsay E AU - Nyhoff LE AD - Department of Pediatrics, Centers for Childhood Infections and Vaccines, Children's Healthcare of Atlanta and Emory University, Atlanta, GA 30329, USA; Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA 30329, USA; Division of Infectious Diseases, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA. FAU - Edara, Venkata-Viswanadh AU - Edara VV AD - Department of Pediatrics, Centers for Childhood Infections and Vaccines, Children's Healthcare of Atlanta and Emory University, Atlanta, GA 30329, USA; Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA 30329, USA; Division of Infectious Diseases, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA; Yerkes National Primate Research Center, Atlanta, GA 30329, USA. FAU - Zarnitsyna, Veronika I AU - Zarnitsyna VI AD - Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA 30322, USA. FAU - Ciric, Caroline R AU - Ciric CR AD - Department of Pediatrics, Centers for Childhood Infections and Vaccines, Children's Healthcare of Atlanta and Emory University, Atlanta, GA 30329, USA; Division of Infectious Diseases, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA. FAU - Flowers, Maria W AU - Flowers MW AD - Department of Pediatrics, Centers for Childhood Infections and Vaccines, Children's Healthcare of Atlanta and Emory University, Atlanta, GA 30329, USA; Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA 30329, USA; Division of Infectious Diseases, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA. FAU - Norwood, Carson AU - Norwood C AD - Department of Pediatrics, Centers for Childhood Infections and Vaccines, Children's Healthcare of Atlanta and Emory University, Atlanta, GA 30329, USA; Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA 30329, USA; Division of Infectious Diseases, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA. FAU - Ellis, Madison AU - Ellis M AD - Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA 30329, USA; Division of Infectious Diseases, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA; Yerkes National Primate Research Center, Atlanta, GA 30329, USA. FAU - Hussaini, Laila AU - Hussaini L AD - Department of Pediatrics, Centers for Childhood Infections and Vaccines, Children's Healthcare of Atlanta and Emory University, Atlanta, GA 30329, USA; Division of Infectious Diseases, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA. FAU - Manning, Kelly E AU - Manning KE AD - Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA 30329, USA; Division of Infectious Diseases, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA; Yerkes National Primate Research Center, Atlanta, GA 30329, USA. FAU - Stephens, Kathy AU - Stephens K AD - Department of Pediatrics, Centers for Childhood Infections and Vaccines, Children's Healthcare of Atlanta and Emory University, Atlanta, GA 30329, USA; Division of Infectious Diseases, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA. FAU - Anderson, Evan J AU - Anderson EJ AD - Department of Pediatrics, Centers for Childhood Infections and Vaccines, Children's Healthcare of Atlanta and Emory University, Atlanta, GA 30329, USA; Division of Infectious Diseases, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA; Department of Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA. FAU - Ahmed, Rafi AU - Ahmed R AD - Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA 30329, USA; Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA 30322, USA. FAU - Suthar, Mehul S AU - Suthar MS AD - Department of Pediatrics, Centers for Childhood Infections and Vaccines, Children's Healthcare of Atlanta and Emory University, Atlanta, GA 30329, USA; Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA 30329, USA; Division of Infectious Diseases, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA; Yerkes National Primate Research Center, Atlanta, GA 30329, USA; Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA 30322, USA. FAU - Wrammert, Jens AU - Wrammert J AD - Department of Pediatrics, Centers for Childhood Infections and Vaccines, Children's Healthcare of Atlanta and Emory University, Atlanta, GA 30329, USA; Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA 30329, USA; Division of Infectious Diseases, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA. Electronic address: jwramme@emory.edu. LA - eng GR - P51 OD011132/OD/NIH HHS/United States GR - 75N93021C00017/AI/NIAID NIH HHS/United States GR - U19 AI057266/AI/NIAID NIH HHS/United States GR - T32 AI074492/AI/NIAID NIH HHS/United States GR - U54 CA260563/CA/NCI NIH HHS/United States GR - HHSN272201400004C/AI/NIAID NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20220329 PL - United States TA - Cell Rep Med JT - Cell reports. Medicine JID - 101766894 RN - 0 (Antibodies, Viral) RN - 0 (COVID-19 Vaccines) RN - 0 (Viral Vaccines) RN - SARS-CoV-2 variants SB - IM MH - Antibodies, Viral MH - *COVID-19/prevention & control MH - COVID-19 Vaccines MH - Humans MH - SARS-CoV-2/genetics MH - Vaccination MH - *Viral Vaccines PMC - PMC8960152 OTO - NOTNLM OT - RBD OT - SARS-CoV-2 OT - antibody durability OT - humoral response OT - mRNA vaccination OT - memory B cells COIS- E.J.A. has consulted for Pfizer, Sanofi Pasteur, Janssen, and Medscape, and his institution receives funds to conduct clinical research unrelated to this manuscript from MedImmune, Regeneron, PaxVax, Pfizer, GSK, Merck, Sanofi-Pasteur, Janssen, and Micron. He also serves on a safety monitoring board for Kentucky BioProcessing, Inc., and Sanofi Pasteur. His institution has also received funding from NIH to conduct clinical trials of Moderna and Janssen COVID-19 vaccines. M.S.S. serves on the advisory board for Moderna. EDAT- 2022/04/29 06:00 MHDA- 2022/04/30 06:00 PMCR- 2022/03/29 CRDT- 2022/04/28 06:31 PHST- 2021/12/12 00:00 [received] PHST- 2022/02/07 00:00 [revised] PHST- 2022/03/21 00:00 [accepted] PHST- 2022/04/28 06:31 [entrez] PHST- 2022/04/29 06:00 [pubmed] PHST- 2022/04/30 06:00 [medline] PHST- 2022/03/29 00:00 [pmc-release] AID - S2666-3791(22)00120-3 [pii] AID - 100603 [pii] AID - 10.1016/j.xcrm.2022.100603 [doi] PST - epublish SO - Cell Rep Med. 2022 Mar 29;3(4):100603. doi: 10.1016/j.xcrm.2022.100603. eCollection 2022 Apr 19. PMID- 35466898 OWN - NLM STAT- MEDLINE DCOM- 20230517 LR - 20230517 IS - 0317-1671 (Print) IS - 0317-1671 (Linking) VI - 50 IP - 3 DP - 2023 May TI - Vaccine-Induced Functional Neurological Disorders in the Covid-19 Era. PG - 346-350 LID - 10.1017/cjn.2022.48 [doi] AB - The large amount of information available to the public regarding vaccines against Covid-19 coupled with pandemic stress and increased somatic attention could potentially precipitate development of functional neurological disorders (FNDs) following vaccination. A growing number of reports indicate that functional symptoms may follow Covid-19 vaccination, similar to those observed with other vaccines previously. We review previously reported cases of FND following vaccination against Covid-19 and present three additional cases. While two patients presented to the Emergency Department with functional movement disorders, one patient presented with protracted limb weakness and sensory dysfunction. The superficial resemblance to Guillain-Barre syndrome, a known but uncommon complication of vaccination prompted an extensive workup. Clinicians need to convey the diagnosis of FND in clear and unequivocal terms to facilitate institution of appropriate therapy and rehabilitation, but importantly also to dispel any doubts in the minds of the public regarding the safety of the available vaccines. Given the presence of significant vaccine hesitancy in many countries, this is critical to the success of the global immunisation effort. FAU - de Souza, Aaron AU - de Souza A AUID- ORCID: 0000-0001-6941-5683 AD - Department of Medicine, Launceston General Hospital, Launceston, TAS, Australia. AD - Faculty of Medicine, Launceston Clinical School, University of Tasmania, Launceston, TAS, Australia. FAU - Jacques, Rainha AU - Jacques R AD - Department of Emergency Medicine, Launceston General Hospital, Launceston, TAS, Australia. FAU - Mohan, Sangeeth AU - Mohan S AD - Department of Emergency Medicine, Launceston General Hospital, Launceston, TAS, Australia. LA - eng PT - Journal Article PT - Review DEP - 20220425 PL - England TA - Can J Neurol Sci JT - The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques JID - 0415227 RN - 0 (COVID-19 Vaccines) RN - 0 (Vaccines) SB - IM MH - Humans MH - *Conversion Disorder MH - *COVID-19/prevention & control MH - *COVID-19 Vaccines/adverse effects MH - Emergency Service, Hospital MH - *Guillain-Barre Syndrome/etiology MH - Vaccination MH - *Vaccines OTO - NOTNLM OT - AstraZeneca vaccine OT - Covid-19 OT - Functional neurological disorder OT - Guillain-Barre syndrome EDAT- 2022/04/26 06:00 MHDA- 2023/05/17 06:42 CRDT- 2022/04/25 08:57 PHST- 2023/05/17 06:42 [medline] PHST- 2022/04/26 06:00 [pubmed] PHST- 2022/04/25 08:57 [entrez] AID - S0317167122000488 [pii] AID - 10.1017/cjn.2022.48 [doi] PST - ppublish SO - Can J Neurol Sci. 2023 May;50(3):346-350. doi: 10.1017/cjn.2022.48. Epub 2022 Apr 25. PMID- 35455293 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230308 IS - 2076-393X (Print) IS - 2076-393X (Electronic) IS - 2076-393X (Linking) VI - 10 IP - 4 DP - 2022 Apr 1 TI - Cognition and Behavior of COVID-19 Vaccination Based on the Health Belief Model: A Cross-Sectional Study. LID - 10.3390/vaccines10040544 [doi] LID - 544 AB - Background: Vaccination is the most effective method for the prevention of COVID-19. However, willingness to be vaccinated is not consistent. This study aimed to explore vaccine cognition, risk perception, and health behavior of COVID-19 in China. Methods: A cross-sectional survey was performed in Guangdong province, China, including demographic characteristics, health status and preventive behaviors, cognition of COVID-19 vaccination, and the health belief model (HBM). Results: A total of 1640 participants were recruited. The main access to information about COVID-19 and vaccination as through official news and broadcasts (67.3%), social network software (58.7%), and professional popularization (46.2%). The precautions taken were wearing a mask (67.0%) and avoiding gathering together (71.3%). COVID-19 vaccination acceptability was different among different age groups and educational levels (p < 0.001). The major reasons for accepting vaccination included that it was an effective way to prevent COVID-19 (61.8%) and that it was required by working units/schools (51.1%). The fitting effect indexes of the (HBM) Model 2 showed better fitting than those of Model 1. In Model 2, perceived benefits (OR = 3.13, 95% CI: 1.79-5.47), cues to action (OR = 2.23, 95% CI: 1.60-3.11), and different occupations (OR = 1.13, 95% CI: 1.04-1.23) were positively correlated with vaccine acceptance; while perceived susceptibility (OR = 0.47, 95% CI: 0.30-0.74) and perceived barriers (OR = 0.44, 95% CI: 0.29-0.69) were negative factors associated with vaccine acceptance. Conclusion: Different sociodemographic characteristics lead to differences in acceptance of vaccination, and the publicity and credibility of government play an indispensable role in epidemic control. The establishment of the HBM further predicted that perceived susceptibility to COVID-19, benefits of vaccination, barriers of cognition, and cue to action were the influencing factors of intention and health behaviors. FAU - Cai, Zemin AU - Cai Z AD - Department of Preventive Medicine, Shantou University Medical College, Shantou 515041, China. FAU - Hu, Wei AU - Hu W AD - Department of Epidemiology, School of Public Health, Sun Yat-sen University, Guangzhou 510080, China. FAU - Zheng, Shukai AU - Zheng S AD - Department of Preventive Medicine, Shantou University Medical College, Shantou 515041, China. FAU - Wen, Xilin AU - Wen X AD - Department of Preventive Medicine, Shantou University Medical College, Shantou 515041, China. FAU - Wu, Kusheng AU - Wu K AUID- ORCID: 0000-0001-5163-2524 AD - Department of Preventive Medicine, Shantou University Medical College, Shantou 515041, China. LA - eng GR - SFK2020-53-42/Kusheng Wu/ GR - 2021ZDZX2023/Kusheng Wu/ PT - Journal Article DEP - 20220401 PL - Switzerland TA - Vaccines (Basel) JT - Vaccines JID - 101629355 PMC - PMC9030847 OTO - NOTNLM OT - COVID-19 vaccination OT - behavior OT - cognition OT - health belief model COIS- The authors declare no conflict of interest. EDAT- 2022/04/24 06:00 MHDA- 2022/04/24 06:01 PMCR- 2022/04/01 CRDT- 2022/04/23 01:06 PHST- 2022/02/25 00:00 [received] PHST- 2022/03/15 00:00 [revised] PHST- 2022/03/30 00:00 [accepted] PHST- 2022/04/23 01:06 [entrez] PHST- 2022/04/24 06:00 [pubmed] PHST- 2022/04/24 06:01 [medline] PHST- 2022/04/01 00:00 [pmc-release] AID - vaccines10040544 [pii] AID - vaccines-10-00544 [pii] AID - 10.3390/vaccines10040544 [doi] PST - epublish SO - Vaccines (Basel). 2022 Apr 1;10(4):544. doi: 10.3390/vaccines10040544. PMID- 35452000 OWN - NLM STAT- MEDLINE DCOM- 20220908 LR - 20250728 IS - 1536-0229 (Electronic) IS - 0363-9762 (Linking) VI - 47 IP - 10 DP - 2022 Oct 1 TI - Alterations in 18 F-FDG PET/MRI and 15 O-Water PET Brain Findings in Patients With Neurological Symptoms After COVID-19 Vaccination: A Pilot Study: Reply. PG - e671-e672 LID - 10.1097/RLU.0000000000004223 [doi] FAU - Siripongsatian, Dheeratama AU - Siripongsatian D AD - National Cyclotron and PET Centre, Chulabhorn Hospital, Bangkok, Thailand Dheeratama.sir@cra.ac.th. FAU - Chotipanich, Chanisa AU - Chotipanich C LA - eng PT - Letter DEP - 20220422 PL - United States TA - Clin Nucl Med JT - Clinical nuclear medicine JID - 7611109 RN - 0 (COVID-19 Vaccines) RN - 0 (Radiopharmaceuticals) RN - 059QF0KO0R (Water) RN - 0Z5B2CJX4D (Fluorodeoxyglucose F18) SB - IM MH - Brain/diagnostic imaging MH - *COVID-19 MH - COVID-19 Vaccines MH - *Fluorodeoxyglucose F18 MH - Humans MH - Magnetic Resonance Imaging MH - Pilot Projects MH - Positron Emission Tomography Computed Tomography MH - Positron-Emission Tomography MH - Radiopharmaceuticals MH - Vaccination MH - Water COIS- Conflicts of interest and sources of funding: none declared. EDAT- 2022/04/23 06:00 MHDA- 2022/09/09 06:00 CRDT- 2022/04/22 12:13 PHST- 2022/04/23 06:00 [pubmed] PHST- 2022/09/09 06:00 [medline] PHST- 2022/04/22 12:13 [entrez] AID - 00003072-202210000-00046 [pii] AID - 10.1097/RLU.0000000000004223 [doi] PST - ppublish SO - Clin Nucl Med. 2022 Oct 1;47(10):e671-e672. doi: 10.1097/RLU.0000000000004223. Epub 2022 Apr 22. PMID- 35447027 OWN - NLM STAT- MEDLINE DCOM- 20220708 LR - 20240831 IS - 1476-4687 (Electronic) IS - 0028-0836 (Print) IS - 0028-0836 (Linking) VI - 607 IP - 7917 DP - 2022 Jul TI - Increased memory B cell potency and breadth after a SARS-CoV-2 mRNA boost. PG - 128-134 LID - 10.1038/s41586-022-04778-y [doi] AB - The Omicron variant of SARS-CoV-2 infected many vaccinated and convalescent individuals(1-3). Despite the reduced protection from infection, individuals who received three doses of an mRNA vaccine were highly protected from more serious consequences of infection(4). Here we examine the memory B cell repertoire in a longitudinal cohort of individuals receiving three mRNA vaccine doses(5,6). We find that the third dose is accompanied by an increase in, and evolution of, receptor-binding domain (RBD)-specific memory B cells. The increase is due to expansion of memory B cell clones that were present after the second dose as well as the emergence of new clones. The antibodies encoded by these cells showed significantly increased potency and breadth when compared with antibodies obtained after the second dose. Notably, the increase in potency was especially evident among newly developing clones of memory cells, which differed from persisting clones in targeting more conserved regions of the RBD. Overall, more than 50% of the analysed neutralizing antibodies in the memory compartment after the third mRNA vaccine dose neutralized the Omicron variant. Thus, individuals receiving three doses of an mRNA vaccine have a diverse memory B cell repertoire that can respond rapidly and produce antibodies capable of clearing even diversified variants such as Omicron. These data help to explain why a third dose of a vaccine that was not specifically designed to protect against variants is effective against variant-induced serious disease. CI - (c) 2022. The Author(s). FAU - Muecksch, Frauke AU - Muecksch F AUID- ORCID: 0000-0002-0132-5101 AD - Laboratory of Retrovirology, The Rockefeller University, New York, NY, USA. FAU - Wang, Zijun AU - Wang Z AD - Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA. FAU - Cho, Alice AU - Cho A AUID- ORCID: 0000-0001-6354-6148 AD - Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA. FAU - Gaebler, Christian AU - Gaebler C AUID- ORCID: 0000-0001-7295-8128 AD - Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA. FAU - Ben Tanfous, Tarek AU - Ben Tanfous T AD - Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA. FAU - DaSilva, Justin AU - DaSilva J AD - Laboratory of Retrovirology, The Rockefeller University, New York, NY, USA. FAU - Bednarski, Eva AU - Bednarski E AUID- ORCID: 0000-0003-4438-5590 AD - Laboratory of Retrovirology, The Rockefeller University, New York, NY, USA. FAU - Ramos, Victor AU - Ramos V AUID- ORCID: 0000-0001-7353-3420 AD - Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA. FAU - Zong, Shuai AU - Zong S AUID- ORCID: 0000-0002-7067-6757 AD - Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA. FAU - Johnson, Brianna AU - Johnson B AUID- ORCID: 0000-0003-3214-284X AD - Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA. FAU - Raspe, Raphael AU - Raspe R AD - Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA. FAU - Schaefer-Babajew, Dennis AU - Schaefer-Babajew D AUID- ORCID: 0000-0002-5380-2950 AD - Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA. FAU - Shimeliovich, Irina AU - Shimeliovich I AD - Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA. FAU - Daga, Mridushi AU - Daga M AD - Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA. FAU - Yao, Kai-Hui AU - Yao KH AD - Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA. FAU - Schmidt, Fabian AU - Schmidt F AD - Laboratory of Retrovirology, The Rockefeller University, New York, NY, USA. FAU - Millard, Katrina G AU - Millard KG AUID- ORCID: 0000-0003-2247-3178 AD - Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA. FAU - Turroja, Martina AU - Turroja M AUID- ORCID: 0000-0001-9640-0559 AD - Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA. FAU - Jankovic, Mila AU - Jankovic M AD - Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA. FAU - Oliveira, Thiago Y AU - Oliveira TY AD - Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA. FAU - Gazumyan, Anna AU - Gazumyan A AD - Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA. FAU - Caskey, Marina AU - Caskey M AUID- ORCID: 0000-0003-1727-8693 AD - Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA. FAU - Hatziioannou, Theodora AU - Hatziioannou T AUID- ORCID: 0000-0002-7889-0766 AD - Laboratory of Retrovirology, The Rockefeller University, New York, NY, USA. thatziio@rockefeller.edu. FAU - Bieniasz, Paul D AU - Bieniasz PD AUID- ORCID: 0000-0002-2368-3719 AD - Laboratory of Retrovirology, The Rockefeller University, New York, NY, USA. pbieniasz@rockefeller.edu. AD - Howard Hughes Medical Institute, The Rockefeller University, New York, NY, USA. pbieniasz@rockefeller.edu. FAU - Nussenzweig, Michel C AU - Nussenzweig MC AUID- ORCID: 0000-0003-0592-8564 AD - Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA. nussen@rockefeller.edu. AD - Howard Hughes Medical Institute, The Rockefeller University, New York, NY, USA. nussen@rockefeller.edu. LA - eng GR - R01 AI078788/AI/NIAID NIH HHS/United States GR - P01 AI138938/AI/NIAID NIH HHS/United States GR - R37-AI64003/U.S. Department of Health & Human Services | National Institutes of Health (NIH)/ GR - R01AI78788/U.S. Department of Health & Human Services | National Institutes of Health (NIH)/ GR - R37 AI064003/AI/NIAID NIH HHS/United States GR - U19 AI111825/AI/NIAID NIH HHS/United States GR - HHMI/Howard Hughes Medical Institute/United States GR - UL1 TR001866/TR/NCATS NIH HHS/United States GR - 2U19AI111825/U.S. Department of Health & Human Services | National Institutes of Health (NIH)/ GR - P01-AI138398-S1/U.S. Department of Health & Human Services | National Institutes of Health (NIH)/ GR - P01 AI165075/AI/NIAID NIH HHS/United States PT - Journal Article DEP - 20220421 PL - England TA - Nature JT - Nature JID - 0410462 RN - 0 (Antibodies, Neutralizing) RN - 0 (Antibodies, Viral) RN - 0 (COVID-19 Vaccines) RN - 0 (RNA, Messenger) RN - 0 (mRNA Vaccines) RN - SARS-CoV-2 variants SB - IM MH - Antibodies, Neutralizing/immunology MH - Antibodies, Viral/immunology MH - *COVID-19/immunology/prevention & control/virology MH - *COVID-19 Vaccines/administration & dosage/immunology MH - Humans MH - *Immunization, Secondary MH - *Memory B Cells/immunology MH - RNA, Messenger/genetics MH - *SARS-CoV-2/genetics/immunology MH - *mRNA Vaccines/administration & dosage/immunology PMC - PMC9259484 MID - NIHMS1809130 COIS- The Rockefeller University has filed a provisional patent application in connection with this work, on which M.C.N. is an inventor (US patent 63/021,387). The patent has been licensed by Rockefeller University to Bristol Meyers Squib. P.D.B. has received remuneration from Pfizer for consulting services related to SARS-CoV-2 vaccines. EDAT- 2022/04/22 06:00 MHDA- 2022/07/09 06:00 PMCR- 2022/04/21 CRDT- 2022/04/21 20:01 PHST- 2022/02/13 00:00 [received] PHST- 2022/04/20 00:00 [accepted] PHST- 2022/04/22 06:00 [pubmed] PHST- 2022/07/09 06:00 [medline] PHST- 2022/04/21 20:01 [entrez] PHST- 2022/04/21 00:00 [pmc-release] AID - 10.1038/s41586-022-04778-y [pii] AID - 4778 [pii] AID - 10.1038/s41586-022-04778-y [doi] PST - ppublish SO - Nature. 2022 Jul;607(7917):128-134. doi: 10.1038/s41586-022-04778-y. Epub 2022 Apr 21. PMID- 35431254 OWN - NLM STAT- MEDLINE DCOM- 20220621 LR - 20220722 IS - 1875-8908 (Electronic) IS - 1387-2877 (Linking) VI - 87 IP - 4 DP - 2022 TI - Prevalence and Safety of COVID-19 Vaccination in Community-Dwelling People with Dementia: Findings from a Tertiary Memory Clinic in Italy. PG - 1467-1474 LID - 10.3233/JAD-220077 [doi] AB - This study aimed to explore the prevalence and safety of SARS-CoV-2 vaccination in individuals with dementia. Patients with mild cognitive impairment or dementia were recruited at a tertiary memory clinic, from March 15 to September 15, 2021. Information on COVID-19 vaccination and adverse events experienced after vaccine administration were collected from caregivers. Two-hundred-seventy subjects were finally recruited. Among them, 253 (93.7%) had received the vaccine and only 69 (27.3%) experienced adverse events. Cognitive and behavioral changes following immunization were only rarely reported. COVID-19 vaccination is safe and well-tolerated in patients with cognitive impairment who should be prioritized in the vaccination campaign. FAU - Valletta, Martina AU - Valletta M AD - Department of Human Neuroscience, "Sapienza" University, Rome, Italy. FAU - Canevelli, Marco AU - Canevelli M AD - Department of Human Neuroscience, "Sapienza" University, Rome, Italy. AD - National Center for Disease Prevention and Health Promotion, National Institute of Health, Rome, Italy. FAU - D'Antonio, Fabrizia AU - D'Antonio F AD - Department of Human Neuroscience, "Sapienza" University, Rome, Italy. FAU - Trebbastoni, Alessandro AU - Trebbastoni A AD - Department of Human Neuroscience, "Sapienza" University, Rome, Italy. FAU - Talarico, Giuseppina AU - Talarico G AD - Department of Human Neuroscience, "Sapienza" University, Rome, Italy. FAU - Campanelli, Alessandra AU - Campanelli A AD - Department of Human Neuroscience, "Sapienza" University, Rome, Italy. FAU - Sepe Monti, Micaela AU - Sepe Monti M AD - Department of Human Neuroscience, "Sapienza" University, Rome, Italy. FAU - Di Vita, Antonella AU - Di Vita A AD - Department of Human Neuroscience, "Sapienza" University, Rome, Italy. FAU - Salati, Emanuela AU - Salati E AD - Department of Human Neuroscience, "Sapienza" University, Rome, Italy. FAU - Imbriano, Letizia AU - Imbriano L AD - Department of Human Neuroscience, "Sapienza" University, Rome, Italy. FAU - Margiotta, Roberta AU - Margiotta R AD - Department of Human Neuroscience, "Sapienza" University, Rome, Italy. FAU - Barbetti, Sonia AU - Barbetti S AD - Department of Human Neuroscience, "Sapienza" University, Rome, Italy. FAU - Diana, Sofia AU - Diana S AD - Department of Human Neuroscience, "Sapienza" University, Rome, Italy. FAU - Buscarnera, Simona AU - Buscarnera S AD - Department of Human Neuroscience, "Sapienza" University, Rome, Italy. FAU - Toccaceli Blasi, Marco AU - Toccaceli Blasi M AD - Department of Human Neuroscience, "Sapienza" University, Rome, Italy. FAU - Salzillo, Martina AU - Salzillo M AD - Department of Human Neuroscience, "Sapienza" University, Rome, Italy. FAU - Pugliese, Giuseppe AU - Pugliese G AD - Department of Human Neuroscience, "Sapienza" University, Rome, Italy. FAU - Vanacore, Nicola AU - Vanacore N AD - National Center for Disease Prevention and Health Promotion, National Institute of Health, Rome, Italy. FAU - Bruno, Giuseppe AU - Bruno G AD - Department of Human Neuroscience, "Sapienza" University, Rome, Italy. LA - eng PT - Letter PL - United States TA - J Alzheimers Dis JT - Journal of Alzheimer's disease : JAD JID - 9814863 RN - 0 (COVID-19 Vaccines) RN - 0 (Vaccines) SB - IM MH - *COVID-19/prevention & control MH - COVID-19 Vaccines/adverse effects MH - *Dementia/epidemiology/psychology MH - Humans MH - Independent Living MH - Prevalence MH - SARS-CoV-2 MH - Vaccination/adverse effects MH - *Vaccines OTO - NOTNLM OT - COVID-19 OT - Cognitive impairment OT - SARS-CoV-2 OT - dementia OT - vaccination OT - vaccines EDAT- 2022/04/19 06:00 MHDA- 2022/06/22 06:00 CRDT- 2022/04/18 05:54 PHST- 2022/04/19 06:00 [pubmed] PHST- 2022/06/22 06:00 [medline] PHST- 2022/04/18 05:54 [entrez] AID - JAD220077 [pii] AID - 10.3233/JAD-220077 [doi] PST - ppublish SO - J Alzheimers Dis. 2022;87(4):1467-1474. doi: 10.3233/JAD-220077. PMID- 35430818 OWN - NLM STAT- MEDLINE DCOM- 20220419 LR - 20220621 IS - 1551-0018 (Electronic) IS - 1547-1063 (Linking) VI - 19 IP - 5 DP - 2022 Feb 28 TI - Solution of a dynamical memory effect COVID-19 infection system with leaky vaccination efficacy by non-singular kernel fractional derivatives. PG - 4341-4367 LID - 10.3934/mbe.2022201 [doi] AB - In this paper, the recent trends of COVID-19 infection spread have been studied to explore the advantages of leaky vaccination dynamics in SEVR (Susceptible Effected Vaccinated Recovered) compartmental model with the help of Caputo-Fabrizio (CF) and Atangana-Baleanu derivative in the Caputo sense (ABC) non-singular kernel fractional derivative operators with memory effect within the model to show possible long-term approaches of the infection along with limited defensive vaccine efficacy that can be designed numerically over the closed interval ranging from 0 to 1. One of the main goals is to provide a stepping information about the usefulness of the aforementioned non-singular kernel fractional approaches for a lenient case as well as a critical case in COVID-19 infection spread. Another is to investigate the effect of death rate on state variables. The estimation of death rate for state variables with suitable vaccine efficacy has a significant role in the stability of state variables in terms of basic reproduction number that is derived using next generation matrix method, and order of the fractional derivative. For non-integral orders the pandemic modeling sense viz, CF and ABC, has been compared thoroughly. Graphical presentations together with numerical results have proposed that the methodology is powerful and accurate which can provide new speculations for COVID-19 dynamical systems. FAU - Dhar, Biplab AU - Dhar B AD - Department of Mathematics-SoPS, DIT University, Uttarakhand 248009, India. FAU - Gupta, Praveen Kumar AU - Gupta PK AD - Department of Mathematics, NIT Silchar, Assam 788010, India. FAU - Sajid, Mohammad AU - Sajid M AD - Department of Mechanical Engineering, College of Engineering, Qassim University, Buraydah 51452, Saudi Arabia. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Math Biosci Eng JT - Mathematical biosciences and engineering : MBE JID - 101197794 SB - IM MH - Basic Reproduction Number MH - *COVID-19/prevention & control MH - Epidemiological Models MH - Humans MH - Pandemics/prevention & control MH - Vaccination OTO - NOTNLM OT - Banach fixed-point theorem OT - basic reproduction number OT - non-singular kernel fractional derivative OT - stability analysis OT - vaccine efficacy EDAT- 2022/04/19 06:00 MHDA- 2022/04/20 06:00 CRDT- 2022/04/18 05:32 PHST- 2022/04/18 05:32 [entrez] PHST- 2022/04/19 06:00 [pubmed] PHST- 2022/04/20 06:00 [medline] AID - 10.3934/mbe.2022201 [doi] PST - ppublish SO - Math Biosci Eng. 2022 Feb 28;19(5):4341-4367. doi: 10.3934/mbe.2022201. PMID- 35417628 OWN - NLM STAT- MEDLINE DCOM- 20230217 LR - 20250930 IS - 1552-5279 (Electronic) IS - 1552-5260 (Print) IS - 1552-5260 (Linking) VI - 19 IP - 2 DP - 2023 Feb TI - COVID-19 breakthrough infections and hospitalizations among vaccinated patients with dementia in the United States between December 2020 and August 2021. PG - 421-432 LID - 10.1002/alz.12669 [doi] AB - INTRODUCTION: There is lack of data on COVID-19 breakthrough infections in vaccinated patients with dementia in the United States. METHODS: This is a retrospective cohort study of 262,847 vaccinated older adults (age 73.8 +/- 6.81 years old) between December 2020 and August 2021. RESULTS: Among the fully vaccinated patients with dementia, the overall risk of COVID-19 breakthrough infections ranged from 8.6% to 12.4%. Patients with dementia were at increased risk for breakthrough infections compared with patients without dementia, with the highest odds for patients with Lewy body dementia (LBD) (adjusted odds ratio or AOR: 3.06, 95% confidence interval or CI [1.45 to 6.66]), followed by vascular dementia (VD) (AOR: 1.99, 95% CI [1.42 to 2.80]), Alzheimer's disease (AD) (1.53, 95% CI [1.22 to 1.92]), and mild cognitive impairment (MCI) (AOR: 1.78, 95% CI [1.51 to 2.11]). The incidence rate of breakthrough infections among fully vaccinated patients with dementia increased since December 2020 and accelerated after May 2021. The overall risk for hospitalization after breakthrough infections in patients with dementia was 39.5% for AD, 46.2% for VD, and 30.4% for MCI. DISCUSSION: These results highlight the need to continuously monitor breakthrough severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections and outcomes in vaccinated patients with dementia. CI - (c) 2022 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association. FAU - Wang, Lindsey AU - Wang L AD - Center for Artificial Intelligence in Drug Discovery, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA. FAU - Davis, Pamela B AU - Davis PB AD - Center for Community Health Integration, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA. FAU - Kaelber, David C AU - Kaelber DC AD - The Center for Clinical Informatics Research and Education, The MetroHealth System, Cleveland, Ohio, USA. FAU - Xu, Rong AU - Xu R AD - Center for Artificial Intelligence in Drug Discovery, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA. LA - eng GR - R01 AG057557/AG/NIA NIH HHS/United States GR - R01 AG076649/AG/NIA NIH HHS/United States GR - UL1 TR002548/TR/NCATS NIH HHS/United States GR - R01 AA029831/AA/NIAAA NIH HHS/United States GR - R56 AG062272/AG/NIA NIH HHS/United States GR - R01 AG061388/AG/NIA NIH HHS/United States GR - RF1 AG076649/AG/NIA NIH HHS/United States GR - R01 EY029297/EY/NEI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20220413 PL - United States TA - Alzheimers Dement JT - Alzheimer's & dementia : the journal of the Alzheimer's Association JID - 101231978 RN - COVID-19 breakthrough infections SB - IM MH - Humans MH - United States/epidemiology MH - Aged MH - Aged, 80 and over MH - *COVID-19/epidemiology MH - Breakthrough Infections MH - Retrospective Studies MH - SARS-CoV-2 MH - Hospitalization MH - *Alzheimer Disease/epidemiology MH - *Dementia, Vascular PMC - PMC9073984 MID - NIHMS1790795 OTO - NOTNLM OT - Alzheimer's Disease OT - COVID-19 OT - Lewy body dementia OT - breakthrough infections OT - dementia OT - frontotemporal dementia OT - mild cognitive impairment OT - patient electronic health records OT - vaccine OT - vascular dementia COIS- Pamela B. Davis has served on External Advisory Board of University of Chicago, Board of trustees of Judson foundation, Board of directors of clinical research forum, Board of directors BioEnterprise. Lindsey Want, David C. Kaelber, and Rong Xu have no outside interests to declare. Lindsey Wang, David C. Kaelber, Pamela B. Davis, and Rong Xu have no financial interests to disclose. EDAT- 2022/04/14 06:00 MHDA- 2023/02/18 06:00 PMCR- 2022/04/13 CRDT- 2022/04/13 17:13 PHST- 2022/01/31 00:00 [revised] PHST- 2022/01/10 00:00 [received] PHST- 2022/03/02 00:00 [accepted] PHST- 2022/04/14 06:00 [pubmed] PHST- 2023/02/18 06:00 [medline] PHST- 2022/04/13 17:13 [entrez] PHST- 2022/04/13 00:00 [pmc-release] AID - ALZ12669 [pii] AID - 10.1002/alz.12669 [doi] PST - ppublish SO - Alzheimers Dement. 2023 Feb;19(2):421-432. doi: 10.1002/alz.12669. Epub 2022 Apr 13. PMID- 35413241 OWN - NLM STAT- MEDLINE DCOM- 20220503 LR - 20240923 IS - 1097-4172 (Electronic) IS - 0092-8674 (Print) IS - 0092-8674 (Linking) VI - 185 IP - 9 DP - 2022 Apr 28 TI - Imprinted SARS-CoV-2-specific memory lymphocytes define hybrid immunity. PG - 1588-1601.e14 LID - S0092-8674(22)00328-2 [pii] LID - 10.1016/j.cell.2022.03.018 [doi] AB - Immune memory is tailored by cues that lymphocytes perceive during priming. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic created a situation in which nascent memory could be tracked through additional antigen exposures. Both SARS-CoV-2 infection and vaccination induce multifaceted, functional immune memory, but together, they engender improved protection from disease, termed hybrid immunity. We therefore investigated how vaccine-induced memory is shaped by previous infection. We found that following vaccination, previously infected individuals generated more SARS-CoV-2 RBD-specific memory B cells and variant-neutralizing antibodies and a distinct population of IFN-gamma and IL-10-expressing memory SARS-CoV-2 spike-specific CD4(+) T cells than previously naive individuals. Although additional vaccination could increase humoral memory in previously naive individuals, it did not recapitulate the distinct CD4(+) T cell cytokine profile observed in previously infected subjects. Thus, imprinted features of SARS-CoV-2-specific memory lymphocytes define hybrid immunity. CI - Copyright (c) 2022 Elsevier Inc. All rights reserved. FAU - Rodda, Lauren B AU - Rodda LB AD - Department of Immunology, University of Washington School of Medicine, Seattle, WA 98109, USA. FAU - Morawski, Peter A AU - Morawski PA AD - Center for Fundamental Immunology, Benaroya Research Institute, Seattle, WA 98101, USA. FAU - Pruner, Kurt B AU - Pruner KB AD - Department of Immunology, University of Washington School of Medicine, Seattle, WA 98109, USA. FAU - Fahning, Mitchell L AU - Fahning ML AD - Center for Fundamental Immunology, Benaroya Research Institute, Seattle, WA 98101, USA. FAU - Howard, Christian A AU - Howard CA AD - Department of Immunology, University of Washington School of Medicine, Seattle, WA 98109, USA. FAU - Franko, Nicholas AU - Franko N AD - Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA 98109, USA. FAU - Logue, Jennifer AU - Logue J AD - Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA 98109, USA. FAU - Eggenberger, Julie AU - Eggenberger J AD - Department of Immunology, Center for Innate Immunity and Immune Disease, University of Washington, Seattle, WA 98109, USA. FAU - Stokes, Caleb AU - Stokes C AD - Department of Immunology, Center for Innate Immunity and Immune Disease, University of Washington, Seattle, WA 98109, USA. FAU - Golez, Inah AU - Golez I AD - Department of Immunology, Center for Innate Immunity and Immune Disease, University of Washington, Seattle, WA 98109, USA. FAU - Hale, Malika AU - Hale M AD - Center for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, WA 98101, USA. FAU - Gale, Michael Jr AU - Gale M Jr AD - Department of Immunology, Center for Innate Immunity and Immune Disease, University of Washington, Seattle, WA 98109, USA. FAU - Chu, Helen Y AU - Chu HY AD - Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA 98109, USA. FAU - Campbell, Daniel J AU - Campbell DJ AD - Department of Immunology, University of Washington School of Medicine, Seattle, WA 98109, USA; Center for Fundamental Immunology, Benaroya Research Institute, Seattle, WA 98101, USA. FAU - Pepper, Marion AU - Pepper M AD - Department of Immunology, University of Washington School of Medicine, Seattle, WA 98109, USA. Electronic address: mpepper@uw.edu. LA - eng GR - R01 AI118803/AI/NIAID NIH HHS/United States GR - R21 AI158788/AI/NIAID NIH HHS/United States GR - T32 AI106677/AI/NIAID NIH HHS/United States GR - S10 OD024979/OD/NIH HHS/United States GR - T32 AI007140/AI/NIAID NIH HHS/United States GR - R01 AI127726/AI/NIAID NIH HHS/United States GR - U01 AI142001/AI/NIAID NIH HHS/United States GR - U01 AI151698/AI/NIAID NIH HHS/United States GR - U19 AI125378/AI/NIAID NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20220317 PL - United States TA - Cell JT - Cell JID - 0413066 RN - 0 (Antibodies, Neutralizing) RN - 0 (Antibodies, Viral) RN - 0 (COVID-19 Vaccines) RN - 0 (Spike Glycoprotein, Coronavirus) RN - 0 (spike protein, SARS-CoV-2) SB - IM MH - Antibodies, Neutralizing MH - Antibodies, Viral MH - *COVID-19/immunology MH - COVID-19 Vaccines/*immunology MH - Humans MH - Immunity, Humoral MH - *SARS-CoV-2 MH - Spike Glycoprotein, Coronavirus MH - T-Lymphocytes PMC - PMC8926873 OTO - NOTNLM OT - COVID-19 OT - SARS-CoV-2 OT - adaptive immune response OT - human OT - hybrid Immunity OT - memory B cell OT - memory T cell OT - vaccine COIS- Declaration of interests M.P. is a member of the Scientific Advisory Board of VaxArt and NeoLeukin Inc. EDAT- 2022/04/13 06:00 MHDA- 2022/05/04 06:00 PMCR- 2022/03/17 CRDT- 2022/04/12 20:10 PHST- 2022/01/13 00:00 [received] PHST- 2022/02/23 00:00 [revised] PHST- 2022/03/14 00:00 [accepted] PHST- 2022/04/13 06:00 [pubmed] PHST- 2022/05/04 06:00 [medline] PHST- 2022/04/12 20:10 [entrez] PHST- 2022/03/17 00:00 [pmc-release] AID - S0092-8674(22)00328-2 [pii] AID - 10.1016/j.cell.2022.03.018 [doi] PST - ppublish SO - Cell. 2022 Apr 28;185(9):1588-1601.e14. doi: 10.1016/j.cell.2022.03.018. Epub 2022 Mar 17. PMID- 35397666 OWN - NLM STAT- MEDLINE DCOM- 20220608 LR - 20231105 IS - 1420-908X (Electronic) IS - 1023-3830 (Print) IS - 1023-3830 (Linking) VI - 71 IP - 5-6 DP - 2022 Jun TI - Anti-coronavirus vaccines will not accelerate the transition of humanity to a non-pandemic period, but the pandemic will take fewer victims. PG - 521-536 LID - 10.1007/s00011-022-01567-1 [doi] AB - The vaccination rate worldwide has reached enormous proportions, and it is likely that at least 75% of the world's population will be vaccinated. The controversy is that, while people aged 65 and older suffer a significantly higher mortality rate from COVID-19, plans are being made to vaccinate young people under the age of 20. Equally thorny is the question of vaccinating people who already have antibodies to SARS-CoV-2, as well as B and T memory cells, because they contracted and survived the virus. The possible consequences of large-scale vaccination are difficult to predict, when some people do not have access to the vaccine at all and others have already received 3 doses of the vaccine. SARS-CoV-2 will circulate through the human population forever and continue to mutate, as viruses do. Therefore, in the coming years, the need to develop and use effective vaccines and medicines for the prevention and treatment of COVID-19 will remain urgent in view of the high mortality rate from this disease. To date, three vaccine platforms have been most used: adenoviral vector, inactivated, and mRNA. There is some concern about the side effects that occur after vaccination. Whether modern anti-coronavirus vaccines can raise the safety threshold, only time will answer. It is obvious that the pandemic will end, but the virus will remain in the human population, leaving behind invaluable experience and tens of millions of victims. This article is based on search retrieves in research articles devoted to COVID-19 mainly published in 2020-2021 and examines the possible consequences of the worldwide vaccination against SARS-CoV-2 and suggests that, while anti-coronavirus vaccines will not magically transport humanity to a non-pandemic world, they may greatly reduce the number of victims of the pandemic and help us learn how to live with COVID-19. CI - (c) 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG. FAU - Oberemok, V V AU - Oberemok VV AUID- ORCID: 0000-0001-7472-2389 AD - Department of Molecular Genetics and Biotechnologies, V.I. Vernadsky Crimean Federal University, Simferopol, Crimea. genepcr@mail.ru. AD - Department of DNA Technologies of Engineering Center, V.I. Vernadsky Crimean Federal University, Simferopol, Crimea. genepcr@mail.ru. FAU - Andreeva, O A AU - Andreeva OA AD - Department of Molecular Genetics and Biotechnologies, V.I. Vernadsky Crimean Federal University, Simferopol, Crimea. AD - Department of DNA Technologies of Engineering Center, V.I. Vernadsky Crimean Federal University, Simferopol, Crimea. FAU - Laikova, K V AU - Laikova KV AD - Department of Molecular Genetics and Biotechnologies, V.I. Vernadsky Crimean Federal University, Simferopol, Crimea. AD - Department of DNA Technologies of Engineering Center, V.I. Vernadsky Crimean Federal University, Simferopol, Crimea. FAU - Novikov, I A AU - Novikov IA AD - Department of Molecular Genetics and Biotechnologies, V.I. Vernadsky Crimean Federal University, Simferopol, Crimea. FAU - Puzanova, Y V AU - Puzanova YV AD - Department of Molecular Genetics and Biotechnologies, V.I. Vernadsky Crimean Federal University, Simferopol, Crimea. AD - Department of DNA Technologies of Engineering Center, V.I. Vernadsky Crimean Federal University, Simferopol, Crimea. FAU - Kubyshkin, A V AU - Kubyshkin AV AD - Department of DNA Technologies of Engineering Center, V.I. Vernadsky Crimean Federal University, Simferopol, Crimea. LA - eng GR - No. FZEG-2021-0009/Ministry of Science and Higher Education of the Russian Federation/ PT - Journal Article PT - Review DEP - 20220410 PL - Switzerland TA - Inflamm Res JT - Inflammation research : official journal of the European Histamine Research Society ... [et al.] JID - 9508160 RN - 0 (COVID-19 Vaccines) SB - IM MH - *COVID-19/prevention & control MH - *COVID-19 Vaccines/therapeutic use MH - Humans MH - *Pandemics/prevention & control MH - SARS-CoV-2 MH - Vaccination PMC - PMC8994861 OTO - NOTNLM OT - COVID-19 OT - Immunity OT - Immunological memory OT - Pandemic OT - Reinfection OT - SARS-CoV-2 OT - Vaccine COIS- The authors declare no conflict of interest. EDAT- 2022/04/11 06:00 MHDA- 2022/06/09 06:00 PMCR- 2022/04/10 CRDT- 2022/04/10 20:12 PHST- 2022/01/17 00:00 [received] PHST- 2022/03/21 00:00 [accepted] PHST- 2022/03/17 00:00 [revised] PHST- 2022/04/11 06:00 [pubmed] PHST- 2022/06/09 06:00 [medline] PHST- 2022/04/10 20:12 [entrez] PHST- 2022/04/10 00:00 [pmc-release] AID - 10.1007/s00011-022-01567-1 [pii] AID - 1567 [pii] AID - 10.1007/s00011-022-01567-1 [doi] PST - ppublish SO - Inflamm Res. 2022 Jun;71(5-6):521-536. doi: 10.1007/s00011-022-01567-1. Epub 2022 Apr 10. PMID- 35397014 OWN - NLM STAT- MEDLINE DCOM- 20220523 LR - 20260127 IS - 1590-3478 (Electronic) IS - 1590-1874 (Print) IS - 1590-1874 (Linking) VI - 43 IP - 6 DP - 2022 Jun TI - COV-BT Ire study: safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with brain tumors. PG - 3519-3522 LID - 10.1007/s10072-022-06054-3 [doi] AB - BACKGROUND: The BNT162b2 vaccine conferred 95% protection against COVID-19 in people aged 16 years or older. OBJECTIVE: The aim of this observational study was to evaluate safety and efficacy of vaccine in patients affected by primary brain tumor (PBT). METHODS: We proposed COVID-19 vaccine to all patients affected by PBT followed by Neuroncology Unit of National Cancer Institute Regina Elena. RESULTS: 102 patients received the first dose, 100 the second, and 73 patients received the booster dose. After first dose, we observed one patient with fever and severe fatigue, while after the second one, we recorded adverse events in ten patients. No correlation was observed between adverse events and comorbidities. CONCLUSIONS: The COVID-19 vaccine is safe and well tolerated in PBT patients. CI - (c) 2022. Fondazione Societa Italiana di Neurologia. FAU - Tanzilli, Antonio AU - Tanzilli A AUID- ORCID: 0000-0001-5747-2808 AD - Neuro-Oncology Unit, IRCCS National Cancer Institute Regina Elena, Via Elio Chianesi 53 00144, Rome, Italy. antonio.tanzilli@ifo.it. FAU - Pace, Andrea AU - Pace A AD - Neuro-Oncology Unit, IRCCS National Cancer Institute Regina Elena, Via Elio Chianesi 53 00144, Rome, Italy. FAU - Ciliberto, Gennaro AU - Ciliberto G AD - Scientific Direction, IRCCS National Cancer Institute Regina Elena, Via Elio Chianesi 53 00144, Rome, Italy. FAU - La Malfa, Antonia Marina AU - La Malfa AM AD - Hospital Pharmacy, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53 00144, Rome, Italy. FAU - Buonomo, Valentina AU - Buonomo V AD - Neuro-Oncology Unit, IRCCS National Cancer Institute Regina Elena, Via Elio Chianesi 53 00144, Rome, Italy. FAU - Benincasa, Dario AU - Benincasa D AD - Neuro-Oncology Unit, IRCCS National Cancer Institute Regina Elena, Via Elio Chianesi 53 00144, Rome, Italy. FAU - Biscu, Annamaria AU - Biscu A AD - Neuro-Oncology Unit, IRCCS National Cancer Institute Regina Elena, Via Elio Chianesi 53 00144, Rome, Italy. FAU - Galie, Edvina AU - Galie E AD - Neuro-Oncology Unit, IRCCS National Cancer Institute Regina Elena, Via Elio Chianesi 53 00144, Rome, Italy. FAU - Villani, Veronica AU - Villani V AD - Neuro-Oncology Unit, IRCCS National Cancer Institute Regina Elena, Via Elio Chianesi 53 00144, Rome, Italy. LA - eng PT - Journal Article PT - Observational Study DEP - 20220409 PL - Italy TA - Neurol Sci JT - Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology JID - 100959175 RN - 0 (BNT162 Vaccine) RN - 0 (COVID-19 Vaccines) RN - 0 (RNA, Messenger) SB - IM MH - BNT162 Vaccine MH - *Brain Neoplasms/complications MH - *COVID-19/prevention & control MH - COVID-19 Vaccines/adverse effects MH - Humans MH - RNA, Messenger MH - SARS-CoV-2 PMC - PMC8994182 OTO - NOTNLM OT - Brain tumors OT - COVID-19 OT - Efficacy OT - Safety OT - Vaccine COIS- The authors declare no competing interests. EDAT- 2022/04/10 06:00 MHDA- 2022/05/24 06:00 PMCR- 2022/04/09 CRDT- 2022/04/09 12:03 PHST- 2022/03/21 00:00 [received] PHST- 2022/03/31 00:00 [accepted] PHST- 2022/04/10 06:00 [pubmed] PHST- 2022/05/24 06:00 [medline] PHST- 2022/04/09 12:03 [entrez] PHST- 2022/04/09 00:00 [pmc-release] AID - 10.1007/s10072-022-06054-3 [pii] AID - 6054 [pii] AID - 10.1007/s10072-022-06054-3 [doi] PST - ppublish SO - Neurol Sci. 2022 Jun;43(6):3519-3522. doi: 10.1007/s10072-022-06054-3. Epub 2022 Apr 9. PMID- 35395612 OWN - NLM STAT- MEDLINE DCOM- 20220603 LR - 20230508 IS - 1873-5347 (Electronic) IS - 0277-9536 (Print) IS - 0277-9536 (Linking) VI - 301 DP - 2022 May TI - Cognitive underpinnings of COVID-19 vaccine hesitancy. PG - 114911 LID - S0277-9536(22)00217-9 [pii] LID - 10.1016/j.socscimed.2022.114911 [doi] AB - RATIONALE: Vaccines save lives. Despite the undisputed value of vaccination, vaccine hesitancy continues to be a major global challenge, particularly throughout the COVID-19 global pandemic. Since vaccination decisions are counter-intuitive and cognitively demanding, we propose that vaccine hesitancy is associated with executive function-a group of high-level cognitive skills including attentional control, working memory, inhibition, self-regulation, cognitive flexibility, and strategic planning. OBJECTIVE: We set out to test (i) whether vaccine hesitancy is driven by individual differences in executive function beyond established socio-demographic factors (e.g., education, political orientation, gender, ethnicity, age, religiosity) and depressed mood, and (ii) whether this relationship is exacerbated by situational stress. METHODS: Two studies were conducted with U.S. residents. Using a cross-sectional design, Study 1 examined the associations between executive function, socio-demographic factors, COVID-19 conspiracy beliefs, trust in health authorities, and COVID-19 vaccine hesitancy. Using an experimental design, Study 2 focused solely on unvaccinated individuals and tested the interactive effect of executive function and stress on willingness to receive a COVID-19 vaccine. We used ordinal logistic regressions to analyze the data. RESULTS: Individual differences in executive function predicted participants' COVID-19 conspiracy beliefs, trust in health authorities, and their willingness to vaccinate against COVID-19. Importantly, the unique contribution of executive function to vaccine hesitancy could not be explained by socio-demographic factors or depressed mood. Furthermore, Study 2 revealed that weaker executive function had detrimental effects on COVID-19 vaccine acceptance and trust in health authorities mainly under heightened stress. CONCLUSIONS: Individual differences in executive function and situational stress jointly impact COVID-19 vaccination decisions and need to be considered together when designing health communications aimed at reducing COVID-19 vaccine hesitancy. Interventions that lower stress and promote trust have the potential to increase vaccine acceptance, especially for individuals with weaker executive function. CI - Copyright (c) 2022. Published by Elsevier Ltd. FAU - Acar-Burkay, Sinem AU - Acar-Burkay S AD - University of South-Eastern Norway, Norway. Electronic address: Sinem.Acar-Burkay@usn.no. FAU - Cristian, Daniela-Carmen AU - Cristian DC AD - Bayes Business School, City, University of London, United Kingdom. Electronic address: Daniela.Cristian@city.ac.uk. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220315 PL - England TA - Soc Sci Med JT - Social science & medicine (1982) JID - 8303205 RN - 0 (COVID-19 Vaccines) RN - 0 (Vaccines) SB - IM MH - *COVID-19/prevention & control MH - COVID-19 Vaccines/therapeutic use MH - Cognition MH - Cross-Sectional Studies MH - Humans MH - SARS-CoV-2 MH - Vaccination MH - Vaccination Hesitancy MH - *Vaccines PMC - PMC8920576 OTO - NOTNLM OT - COVID-19 OT - Cognition OT - Executive function OT - Stress OT - Stroop task OT - Trust OT - Vaccination intentions OT - Vaccine acceptance OT - Vaccine hesitancy COIS- The authors declare no competing interest. EDAT- 2022/04/09 06:00 MHDA- 2022/06/07 06:00 PMCR- 2022/03/15 CRDT- 2022/04/08 20:15 PHST- 2021/07/15 00:00 [received] PHST- 2022/01/28 00:00 [revised] PHST- 2022/03/12 00:00 [accepted] PHST- 2022/04/09 06:00 [pubmed] PHST- 2022/06/07 06:00 [medline] PHST- 2022/04/08 20:15 [entrez] PHST- 2022/03/15 00:00 [pmc-release] AID - S0277-9536(22)00217-9 [pii] AID - 114911 [pii] AID - 10.1016/j.socscimed.2022.114911 [doi] PST - ppublish SO - Soc Sci Med. 2022 May;301:114911. doi: 10.1016/j.socscimed.2022.114911. Epub 2022 Mar 15. PMID- 35357785 OWN - NLM STAT- MEDLINE DCOM- 20220404 LR - 20230309 IS - 0019-1442 (Print) IS - 0019-1442 (Linking) VI - 75 IP - 3-04 DP - 2022 Mar 31 TI - Can we influence the negative drug attitude? Interpretation of the rejection of COVID-19 vaccine in the light of results of a pilot study. PG - 111-116 LID - 10.18071/isz.75.0111 [doi] AB - BACKGROUND AND PURPOSE: Vaccination refusal is a serious obstacle to minimizing the spread of COVID-19. Nevertheless, the rejection of vaccine can be considered the result of a negative attitude towards medical treatment, and according to our previously published data, it can be influenced by the underlying affective state. Increased incidence of affective disorders and anxiety could be observed globally during the pandemic, which may have a significant impact on vaccination acceptance. The aim of our pilot study was to determine the association between clinical improvement of affective and neurocognitive symptoms and change of drug attitude and health control beliefs in a sample of psychiatric patients. METHODS: A data set of 85 patients with psychiatric disorder has been analysed with the use of Patient's Health Belief Questionnaire on Psychiatric Treatment (PHBQPT) with 5 subscales (Negative Aspect of Medication - NA; Positive Aspect of Medication - PA; Doctor health locus of control- Doctor HLOC; Internal HLOC; Psychological Reactance - PR); Hospital Anxiety Depression Scale (HADS-Anx; HADS-Dep) and neurocognitive tests, such as the Stroop test and the Trail Making Tests. All the tests were performed before and after a 14 days treatment. Paired t-tests and generalized linear models were performed to assess the associations between the variables. RESULTS: The baseline scores of NA and HADS-Anx correlated significantly (p=0.001) and after two weeks of treatment NA decreased (p=0.001), while Doctor HLOC and Internal HLOC increased (p=0.001 and p=0.006). The patients performance of the neurocognitive tests improved (all p<0.05). The reduction of HADS-Anx (p=0.002) and HADS-Dep (p=0.006) scores showed significant associations with the decrease of NA. Increase of the PA score was associated with reduction of HADS-Dep (p=0.028). Improvement of neurocognitive functions had no effect on PHBQPT scores. CONCLUSION: Important conclusions can be drawn regarding the rejection of the COVID-19 vaccine based on the associations found between the intensity of affective and anxiety symptoms and the attitude towards treatment. Our findings suggest that affective symptoms have a negative influence on the attitude towards treatment and that the improvement of these symptoms can facilitate the acceptance of the therapy, regardless of diagnosis. The modest effect of the improvement of neurocognitive functioning on the attitude towards drugs and the significant role of affective-emotional factors suggest that the accep-tance of vaccination probably cannot be facilitated solely with the aid of educational programs. Considering the increasing incidence of affective disorders during the COVID-19 pandemic, the screening of affective and anxiety symptoms and treatment of these disorders could be an important step towards the acceptance of the vaccine. Although psychiatry is not considered as a frontline care unit of the COVID cases, more attention is needed to pay on the availability of mental health services because refuse of vaccine can develop due to affective disorders too. FAU - Pogany, Laszlo AU - Pogany L AD - National Institute of Mental Health, Neurology and Neurosurgery, Budapest. AD - Janos Szentagothai Doctoral School of Neurosciences, Semmelweis University, Budapest. FAU - Horvath, Andras A AU - Horvath AA AD - National Institute of Mental Health, Neurology and Neurosurgery, Budapest. FAU - Lazary, Judit AU - Lazary J AD - National Institute of Mental Health, Neurology and Neurosurgery, Budapest. AD - Janos Szentagothai Doctoral School of Neurosciences, Semmelweis University, Budapest. LA - eng PT - Journal Article TT - Befolyasolhato-e a negativ gyogyszerszedesi attitud? A Covid-19-vakcinat elutasito magatartas interpretacioja egy elokeszito vizsgalat eredmenyeinek tukreben. PL - Hungary TA - Ideggyogy Sz JT - Ideggyogyaszati szemle JID - 17510500R RN - 0 (COVID-19 Vaccines) SB - IM MH - Anxiety Disorders/diagnosis/epidemiology/psychology MH - *COVID-19/prevention & control MH - *COVID-19 Vaccines/therapeutic use MH - Humans MH - Pandemics MH - Pilot Projects OTO - NOTNLM OT - anti-vax behavior OT - drug attitude OT - health beliefs OT - psychological reactance OT - rejection of vaccination EDAT- 2022/04/01 06:00 MHDA- 2022/04/05 06:00 CRDT- 2022/03/31 12:07 PHST- 2022/03/31 12:07 [entrez] PHST- 2022/04/01 06:00 [pubmed] PHST- 2022/04/05 06:00 [medline] AID - 10.18071/isz.75.0111 [doi] PST - ppublish SO - Ideggyogy Sz. 2022 Mar 31;75(3-04):111-116. doi: 10.18071/isz.75.0111. PMID- 35342247 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220329 IS - 0972-2327 (Print) IS - 1998-3549 (Electronic) IS - 0972-2327 (Linking) VI - 25 IP - 1 DP - 2022 Jan-Feb TI - COVID-19 Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT) and Cerebral Venous Sinus Thrombosis (CVST)- Lessons for India. PG - 15-20 LID - 10.4103/aian.aian_669_21 [doi] AB - The COVID-19 pandemic evolved rapidly, overwhelming health care systems around the world. The cost to life and socioeconomic burden prompted a search for new treatments and vaccines. Several collaborations developed and could deliver state-of-the-art vaccines with acceptable efficacy and safety in record time. Recently, vaccination with Oxford-AstraZeneca and Johnson and Johnson vaccines was halted due to the reported adverse effects of vaccine-induced immune thrombotic thrombocytopenia (VITT) and cerebral venous sinus thrombosis (CVST). Although a detailed risk-benefit analysis led to their reinstitution, physicians across the world are still trying to understand the pathophysiology and mechanisms of these neurological adverse effects in order to better identify, diagnose, and treat them. One of the mechanisms that have been implicated is related to the adenovirus-based vector of these vaccines. COVISHIELD, which is the most widely administered vaccine in India, also shares the same vector. As India enters the next phase of vaccine distribution for younger adults, there are chances that such adverse effects may emerge. In this review, we analyze the temporary suspension of the administration of the vaccines due to VITT/CVST, summarize the existing guidelines about diagnosis and treatment of these neurological disorders as well as the need for increasing pharmacovigilance and awareness among physicians. Screening for potential risk factors, avoiding aggravating factors like dehydration, and providing choices in vaccinating the high-risk populations could help in avoiding these rare but potentially fatal adverse outcome. CI - Copyright: (c) 2006 - 2021 Annals of Indian Academy of Neurology. FAU - Khan, Erum AU - Khan E AD - Department of Medicine, BJ Medical College and Civil Hospital, Ahmedabad, Gujarat, India. FAU - Bavishi, Shriya AU - Bavishi S AD - Department of Medicine, BJ Medical College and Civil Hospital, Ahmedabad, Gujarat, India. FAU - Sharma, Arvind K AU - Sharma AK AD - Department of Medicine, BJ Medical College and Civil Hospital, Ahmedabad, Gujarat, India. AD - Department of Neurology, Zydus Hospital, Ahmedabad, Gujarat, India. FAU - Sharma, Vijay K AU - Sharma VK AD - Yong Loo Lin School of Medicine, National University of Singapore and Division of Neurology, National University Hospital, Singapore. FAU - Goyal, Vinay AU - Goyal V AD - Department of Neurology, Medanta The Medicity, Gurugram, Haryana, India. LA - eng PT - Journal Article DEP - 20211022 PL - India TA - Ann Indian Acad Neurol JT - Annals of Indian Academy of Neurology JID - 101273955 PMC - PMC8954332 OTO - NOTNLM OT - COVID-19 OT - CVST OT - VITT OT - vaccine COIS- There are no conflicts of interest. EDAT- 2022/03/29 06:00 MHDA- 2022/03/29 06:01 PMCR- 2022/01/01 CRDT- 2022/03/28 05:30 PHST- 2021/07/22 00:00 [received] PHST- 2021/08/14 00:00 [revised] PHST- 2021/08/25 00:00 [accepted] PHST- 2022/03/28 05:30 [entrez] PHST- 2022/03/29 06:00 [pubmed] PHST- 2022/03/29 06:01 [medline] PHST- 2022/01/01 00:00 [pmc-release] AID - AIAN-25-15 [pii] AID - 10.4103/aian.aian_669_21 [doi] PST - ppublish SO - Ann Indian Acad Neurol. 2022 Jan-Feb;25(1):15-20. doi: 10.4103/aian.aian_669_21. Epub 2021 Oct 22. PMID- 35335073 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220329 IS - 2076-393X (Print) IS - 2076-393X (Electronic) IS - 2076-393X (Linking) VI - 10 IP - 3 DP - 2022 Mar 14 TI - Investigation of a Cluster of Immunization Stress-Related Reactions after Coronavirus Disease 2019 (COVID-19) Vaccination, Thailand, 2021. LID - 10.3390/vaccines10030441 [doi] LID - 441 AB - On 28 April 2021, the investigation team of the Department of Disease Control, Ministry of Public Health, was notified of a cluster of people developing neurological symptoms following COVID-19 vaccination in a province in eastern Thailand. We conducted an investigation from 29 April to 20 May 2021 to confirm the outbreak, describe the epidemiological characteristics and identify possible risk factors. A matched case-control study was conducted. Matching factors were gender and vaccination site. A confirmed case was a person receiving COVID-19 vaccination in the province and developed at least one neurological symptom between 21 April and 20 May 2021. The rapid assessment of the vaccination cold chain system was carried out. We found a total of 36 cases out of 3920 vaccinees (attack rate = 0.92%), all cases were recovered and classified as an immunization stress-related reaction (ISRR) by the National AEFI Expert Committee. An analytic study found that menstruation was significantly associated with ISRR (AOR = 6.84 [95%CI = 1.09-42.91]). The environmental survey suggested that the cold chain system was properly managed. Further studies on other precipitating causes of ISRR should be performed. In terms of recommendation, health providers should pay greater attention to women menstruating during and after COVID-19 immunization. FAU - Mahasing, Chayanit AU - Mahasing C AUID- ORCID: 0000-0002-6023-2124 AD - Division of Epidemiology, Department of Disease Control, Ministry of Public Health, Nonthaburi 11000, Thailand. FAU - Yasopa, Oiythip AU - Yasopa O AD - Division of Epidemiology, Department of Disease Control, Ministry of Public Health, Nonthaburi 11000, Thailand. FAU - Sansilapin, Chalo AU - Sansilapin C AD - Division of Epidemiology, Department of Disease Control, Ministry of Public Health, Nonthaburi 11000, Thailand. FAU - Rattanathumsakul, Thanit AU - Rattanathumsakul T AUID- ORCID: 0000-0002-2629-7370 AD - Division of Epidemiology, Department of Disease Control, Ministry of Public Health, Nonthaburi 11000, Thailand. FAU - Thammawijaya, Panithee AU - Thammawijaya P AD - Division of Epidemiology, Department of Disease Control, Ministry of Public Health, Nonthaburi 11000, Thailand. FAU - Suphanchaimat, Rapeepong AU - Suphanchaimat R AD - Division of Epidemiology, Department of Disease Control, Ministry of Public Health, Nonthaburi 11000, Thailand. AD - International Health Policy Program, Ministry of Public Health, Nonthaburi 11000, Thailand. FAU - Doung-Ngern, Pawinee AU - Doung-Ngern P AUID- ORCID: 0000-0002-1154-4527 AD - Division of Epidemiology, Department of Disease Control, Ministry of Public Health, Nonthaburi 11000, Thailand. LA - eng GR - 7200AA19CA00002/United States Agency for International Development/ PT - Journal Article DEP - 20220314 PL - Switzerland TA - Vaccines (Basel) JT - Vaccines JID - 101629355 PMC - PMC8954559 OTO - NOTNLM OT - COVID-19 vaccination OT - CoronaVac OT - adverse event following immunization OT - immunization stress-related reaction COIS- The authors declare that there is no conflict of interest. EDAT- 2022/03/27 06:00 MHDA- 2022/03/27 06:01 PMCR- 2022/03/14 CRDT- 2022/03/26 01:02 PHST- 2022/01/11 00:00 [received] PHST- 2022/02/16 00:00 [revised] PHST- 2022/02/22 00:00 [accepted] PHST- 2022/03/26 01:02 [entrez] PHST- 2022/03/27 06:00 [pubmed] PHST- 2022/03/27 06:01 [medline] PHST- 2022/03/14 00:00 [pmc-release] AID - vaccines10030441 [pii] AID - vaccines-10-00441 [pii] AID - 10.3390/vaccines10030441 [doi] PST - epublish SO - Vaccines (Basel). 2022 Mar 14;10(3):441. doi: 10.3390/vaccines10030441. PMID- 35334195 OWN - NLM STAT- MEDLINE DCOM- 20220929 LR - 20221011 IS - 2191-0200 (Electronic) IS - 0334-1763 (Linking) VI - 33 IP - 7 DP - 2022 Oct 26 TI - Neurological and neuropsychological adverse effects of SARS-CoV-2 vaccines - where do we stand? PG - 721-743 LID - 10.1515/revneuro-2022-0006 [doi] AB - The devastating characteristic of COVID-19 pandemic calls for immediate and effective solutions to tackle it. Vaccines seem to be the only promising and effective way to fight against the novel coronavirus - even against new mutated variants. Because of the rapid development and distribution of numerous COVID-19 vaccines in different platforms, meticulous evaluation of vaccines' safety is more critical than ever - especially given the fact that most of the candidates have not completed the clinical phase. Therefore, to optimize the vaccines' safety and efficacy, it is highly important to carefully report and scientifically discuss the serious adverse effects following vaccination. In this respect, we discuss different neurological and neuropsychological adverse effects of COVID-19 vaccines including demyelinating diseases, Bell's palsy (BP), cerebrovascular complications, seizures, functional neurological disorders (FNDs), and some other rare adverse events, and hypothetical mechanisms which can lead to the reported side effects. Given the fact that the incidence of such events are rare and most of them are treatable, the current review aims to shed light on how much the relationship between COVID-19 vaccines and these complications can be reliable and provide an insight for future studies with much more meticulous methodologies to discuss the possible correlational or causal relationship between these complications and COVID-19 vaccines and elucidate whether or not the neurological side effects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines can count as a considerable threat to public health. CI - (c) 2022 Walter de Gruyter GmbH, Berlin/Boston. FAU - Aliasin, Mohammad Mahdi AU - Aliasin MM AUID- ORCID: 0000-0002-9097-7207 AD - School of Medicine, Tehran University of Medical Sciences, 14176 13151 Tehran, Iran. AD - Students' Scientific Research Center, Tehran University of Medical Sciences, 14177 55331 Tehran, Iran. AD - Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), 14197 33151 Tehran, Iran. FAU - Yazdanpanah, Niloufar AU - Yazdanpanah N AUID- ORCID: 0000-0003-4333-2163 AD - School of Medicine, Tehran University of Medical Sciences, 14176 13151 Tehran, Iran. AD - Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, 14197 33151 Tehran, Iran. AD - Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), 14197 33151 Tehran, Iran. FAU - Rezaei, Nima AU - Rezaei N AUID- ORCID: 0000-0002-3836-1827 AD - Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, 14197 33151 Tehran, Iran. AD - Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), 14197 33151 Tehran, Iran. AD - Department of Immunology, School of Medicine, Tehran University of Medical Sciences, 14176 13151 Tehran, Iran. LA - eng PT - Journal Article PT - Review DEP - 20220325 PL - Germany TA - Rev Neurosci JT - Reviews in the neurosciences JID - 8711016 RN - 0 (COVID-19 Vaccines) RN - 0 (Viral Vaccines) SB - IM MH - *COVID-19/prevention & control MH - *COVID-19 Vaccines/adverse effects MH - Humans MH - Pandemics/prevention & control MH - SARS-CoV-2 MH - Viral Vaccines/adverse effects OTO - NOTNLM OT - COVID-19 vaccines OT - SARS-CoV-2 OT - cerebrovascular complications OT - demyelinating diseases OT - neurological complications EDAT- 2022/03/26 06:00 MHDA- 2022/09/30 06:00 CRDT- 2022/03/25 17:27 PHST- 2022/01/17 00:00 [received] PHST- 2022/02/14 00:00 [accepted] PHST- 2022/03/26 06:00 [pubmed] PHST- 2022/09/30 06:00 [medline] PHST- 2022/03/25 17:27 [entrez] AID - revneuro-2022-0006 [pii] AID - 10.1515/revneuro-2022-0006 [doi] PST - epublish SO - Rev Neurosci. 2022 Mar 25;33(7):721-743. doi: 10.1515/revneuro-2022-0006. Print 2022 Oct 26. PMID- 35309303 OWN - NLM STAT- MEDLINE DCOM- 20220408 LR - 20260127 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 13 DP - 2022 TI - Persistence of Immune Response in Health Care Workers After Two Doses BNT162b2 in a Longitudinal Observational Study. PG - 839922 LID - 10.3389/fimmu.2022.839922 [doi] LID - 839922 AB - BACKGROUND: The mRNA-based vaccine BNT162b2 of BioNTech/Pfizer has shown high efficacy against SARS-CoV-2 infection and a severe course of the COVID-19 disease. However, little is known about the long-term durability of the induced immune response resulting from the vaccination. METHODS: In a longitudinal observational study in employees at a German hospital we compared the humoral and cellular immune response in 184 participants after two doses of the BioNTech/Pfizer vaccine (BNT162b2) with a mid-term follow-up after 9 months. Anti-SARS-CoV-2 binding antibodies were determined using both a quantitative and a semi-quantitative assay. For a qualitative assessment of the humoral immune response, we additionally measured neutralizing antibodies. Cellular immune response was evaluated by measuring Interferon-gamma release after stimulating blood-cells with SARS-CoV-2 specific peptides using a commercial assay. RESULTS: In the first analysis, a 100% humoral response rate was described after two doses of BNT162b2 vaccine with a mean antibody ratio of 8.01 +/- 1.00. 9 months after the second dose of BNT162b2, serological testing showed a significant decreased mean antibody ratio of 3.84 +/- 1.69 (p < 0.001). Neutralizing antibodies were still detectable in 96% of all participants, showing an average binding inhibition value of 68.20% +/- 18.87%. Older age (p < 0.001) and obesity (p = 0.01) had a negative effect on the antibody persistence. SARS-CoV-2 specific cellular immune response was proven in 75% of individuals (mean Interferon-gamma release: 579.68 mlU/ml +/- 705.56 mlU/ml). CONCLUSION: Our data shows a declining immune response 9 months after the second dose of BNT162b2, supporting the potentially beneficial effect of booster vaccinations, the negative effect of obesity and age stresses the need of booster doses especially in these groups. CI - Copyright (c) 2022 Herzberg, Fischer, Lindenkamp, Becher, Becker, Honarpisheh, Guraya, Strate and Knabbe. FAU - Herzberg, Jonas AU - Herzberg J AD - Department of Surgery, Krankenhaus Reinbek St. Adolf-Stift, Reinbek, Germany. FAU - Fischer, Bastian AU - Fischer B AD - Institut fur Laboratoriums- und Transfusionsmedizin, Herz- und Diabeteszentrum Nordrhein-Westfalen, Universitatsklinik der Ruhr-Universitat Bochum, Bad Oeynhausen, Germany. FAU - Lindenkamp, Christopher AU - Lindenkamp C AD - Institut fur Laboratoriums- und Transfusionsmedizin, Herz- und Diabeteszentrum Nordrhein-Westfalen, Universitatsklinik der Ruhr-Universitat Bochum, Bad Oeynhausen, Germany. FAU - Becher, Heiko AU - Becher H AD - Institute of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Becker, Ann-Kristin AU - Becker AK AD - Asklepios Klinik Harburg, Abteilung fur Psychiatrie und Psychotherapie, Hamburg, Germany. FAU - Honarpisheh, Human AU - Honarpisheh H AD - Department of Surgery, Krankenhaus Reinbek St. Adolf-Stift, Reinbek, Germany. FAU - Guraya, Salman Yousuf AU - Guraya SY AD - Clinical Sciences Department, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates. FAU - Strate, Tim AU - Strate T AD - Department of Surgery, Krankenhaus Reinbek St. Adolf-Stift, Reinbek, Germany. FAU - Knabbe, Cornelius AU - Knabbe C AD - Institut fur Laboratoriums- und Transfusionsmedizin, Herz- und Diabeteszentrum Nordrhein-Westfalen, Universitatsklinik der Ruhr-Universitat Bochum, Bad Oeynhausen, Germany. LA - eng PT - Journal Article PT - Observational Study DEP - 20220304 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 RN - 0 (Antibodies, Neutralizing) RN - 0 (Antibodies, Viral) RN - 0 (BNT162 Vaccine) RN - 0 (COVID-19 Vaccines) RN - 82115-62-6 (Interferon-gamma) SB - IM MH - Antibodies, Neutralizing MH - Antibodies, Viral MH - *BNT162 Vaccine MH - *COVID-19 MH - COVID-19 Vaccines MH - Health Personnel MH - Humans MH - Immunity, Humoral MH - Interferon-gamma MH - Obesity MH - SARS-CoV-2 PMC - PMC8931311 OTO - NOTNLM OT - BNT162b2 OT - SARS-CoV-2 OT - health care worker OT - humoral and cellular immunity OT - immunological memory OT - vaccination COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/03/22 06:00 MHDA- 2022/04/09 06:00 PMCR- 2022/03/04 CRDT- 2022/03/21 08:50 PHST- 2021/12/20 00:00 [received] PHST- 2022/02/07 00:00 [accepted] PHST- 2022/03/21 08:50 [entrez] PHST- 2022/03/22 06:00 [pubmed] PHST- 2022/04/09 06:00 [medline] PHST- 2022/03/04 00:00 [pmc-release] AID - 10.3389/fimmu.2022.839922 [doi] PST - epublish SO - Front Immunol. 2022 Mar 4;13:839922. doi: 10.3389/fimmu.2022.839922. eCollection 2022. PMID- 35304352 OWN - NLM STAT- MEDLINE DCOM- 20220324 LR - 20260127 IS - 2059-7908 (Print) IS - 2059-7908 (Electronic) IS - 2059-7908 (Linking) VI - 7 IP - 3 DP - 2022 Mar TI - Attention for sex in COVID-19 trials: a review of regulatory dossiers. LID - 10.1136/bmjgh-2021-008173 [doi] LID - e008173 AB - An under-representation of women and a lack of sex-specific analyses in COVID-19 trials has been suggested. However, the higher number of men than women who are severely affected by COVID-19 and the restricted information in scientific publications may have biased these suggestions. Therefore, we evaluated sex proportionality and sex-specific efficacy and safety data in trials of COVID-19 treatments and vaccines using both publicly available regulatory documents and confidential documents used by regulators in their review of medicinal products. Included were two treatments (ie, remdesivir and dexamethasone) and four vaccines (ie, BNT162b2 mRNA (BioNTech/Pfizer), mRNA-1273 (Moderna), ChAdOx1-S (AstraZeneca) and Ad26.COV2-S (Janssen)) that received marketing authorisation by the European Commission at the time of the study conduct. An under-representation of women was shown in three of the nine data sets for one treatment (ie, remdesivir), but the proportion of women included was representative in each of the data sets for the other five products. This indicates that there is no structural under-representation of women in the COVID-19 trials. Currently, sex-specific efficacy data are available for five of the six assessed products and sex-specific safety data are available for half of the products only. It is important that this information will also be made available for the other products. There are only small differences in efficacy and safety between men and women which are likely to be of limited clinical relevance. Sex-specific efficacy information can generally be found in the publicly available regulatory documents other than the Summary of Product Characteristics, for which more awareness might be required. CI - (c) Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. FAU - de Vries, Sieta T AU - de Vries ST AUID- ORCID: 0000-0001-6090-2434 AD - Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. AD - Dutch Medicines Evaluation Board, Utrecht, The Netherlands. FAU - Starokozhko, Viktoriia AU - Starokozhko V AUID- ORCID: 0000-0002-7451-6793 AD - Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. AD - Dutch Medicines Evaluation Board, Utrecht, The Netherlands. FAU - Schellens, Ingrid M M AU - Schellens IMM AD - Dutch Medicines Evaluation Board, Utrecht, The Netherlands. FAU - Wijnans, Leonoor AU - Wijnans L AD - Dutch Medicines Evaluation Board, Utrecht, The Netherlands. FAU - Enzmann, Harald AU - Enzmann H AD - Committee for Medicinal Products for Human Use, European Medicines Agency (EMA), Amsterdam, The Netherlands. AD - Bundesinstitut fur Arzneimittel und Medizinprodukte, Bonn, Germany. FAU - Cavaleri, Marco AU - Cavaleri M AD - European Medicines Agency (EMA), Amsterdam, The Netherlands. FAU - Mol, Peter G M AU - Mol PGM AUID- ORCID: 0000-0002-4262-3180 AD - Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands p.mol@cbg-meb.nl. AD - Dutch Medicines Evaluation Board, Utrecht, The Netherlands. AD - Scientific Advice Working Party, European Medicines Agency (EMA), Amsterdam, The Netherlands. LA - eng PT - Journal Article PT - Review PL - England TA - BMJ Glob Health JT - BMJ global health JID - 101685275 RN - 0 (BNT162 Vaccine) SB - IM MH - Attention MH - *BNT162 Vaccine MH - *COVID-19 MH - Female MH - Humans MH - Male PMC - PMC8935005 OTO - NOTNLM OT - COVID-19 OT - public health OT - review OT - treatment OT - vaccines COIS- Competing interests: All authors are affiliated to a regulatory authority and therefore had access to the confidential marketing authorisation application dossiers. In addition, several of the authors (IMMS, LW, MC and HE) are directly involved in the regulatory assessment of COVID-19 treatments and vaccines. EDAT- 2022/03/20 06:00 MHDA- 2022/03/25 06:00 PMCR- 2022/03/18 CRDT- 2022/03/19 05:30 PHST- 2021/12/02 00:00 [received] PHST- 2022/02/08 00:00 [accepted] PHST- 2022/03/19 05:30 [entrez] PHST- 2022/03/20 06:00 [pubmed] PHST- 2022/03/25 06:00 [medline] PHST- 2022/03/18 00:00 [pmc-release] AID - bmjgh-2021-008173 [pii] AID - 10.1136/bmjgh-2021-008173 [doi] PST - ppublish SO - BMJ Glob Health. 2022 Mar;7(3):e008173. doi: 10.1136/bmjgh-2021-008173. PMID- 35280987 OWN - NLM STAT- MEDLINE DCOM- 20220321 LR - 20240824 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 13 DP - 2022 TI - Memory B Cells Induced by Sputnik V Vaccination Produce SARS-CoV-2 Neutralizing Antibodies Upon Ex Vivo Restimulation. PG - 840707 LID - 10.3389/fimmu.2022.840707 [doi] LID - 840707 AB - The development of effective vaccines against SARS-CoV-2 remains a global health priority. Despite extensive use, the effects of Sputnik V on B cell immunity need to be explored in detail. We performed comprehensive profiling of humoral and B cell responses in a cohort of vaccinated subjects (n = 22), and demonstrate that Sputnik vaccination results in robust B cell immunity. We show that B memory cell (MBC) and antibody responses to Sputnik V were heavily dependent on whether the vaccinee had a history of SARS-CoV-2 infection or not. 85 days after the first dose of the vaccine, ex vivo stimulated MBCs from the vast majority of Sputnik V vaccinees produced antibodies that robustly neutralized the Wuhan Spike-pseudotyped lentivirus. MBC-derived antibodies from all previously infected and some of the naive vaccine recipients could also cross-neutralize Beta (B.1.351) variant of SARS-CoV-2. Virus-neutralizing activity of MBC-derived antibodies correlated well with that of the serum antibodies, suggesting the interplay between the MBC and long-lived plasma cell responses. Thus, our in-depth analysis of MBC responses in Sputnik V vaccinees complements traditional serological approaches and may provide important outlook into future B cell responses upon re-encounter with the emerging variants of SARS-CoV-2. CI - Copyright (c) 2022 Byazrova, Kulemzin, Astakhova, Belovezhets, Efimov, Chikaev, Kolotygin, Gorchakov, Taranin and Filatov. FAU - Byazrova, Maria G AU - Byazrova MG AD - Laboratory of Immunochemistry, National Research Center Institute of Immunology, Federal Medical Biological Agency of Russia, Moscow, Russia. AD - Department of Immunology, Faculty of Biology, Lomonosov Moscow State University, Moscow, Russia. FAU - Kulemzin, Sergey V AU - Kulemzin SV AD - Laboratory of Immunogenetics, Institute of Molecular and Cellular Biology, Siberian Branch of the Russian Academy of Sciences, Novosibirsk, Russia. FAU - Astakhova, Ekaterina A AU - Astakhova EA AD - Laboratory of Immunochemistry, National Research Center Institute of Immunology, Federal Medical Biological Agency of Russia, Moscow, Russia. AD - Department of Immunology, Faculty of Biology, Lomonosov Moscow State University, Moscow, Russia. FAU - Belovezhets, Tatyana N AU - Belovezhets TN AD - Laboratory of Immunogenetics, Institute of Molecular and Cellular Biology, Siberian Branch of the Russian Academy of Sciences, Novosibirsk, Russia. FAU - Efimov, Grigory A AU - Efimov GA AD - Laboratory of Transplantation Immunology, National Research Center for Hematology, Moscow, Russia. FAU - Chikaev, Anton N AU - Chikaev AN AD - Laboratory of Immunogenetics, Institute of Molecular and Cellular Biology, Siberian Branch of the Russian Academy of Sciences, Novosibirsk, Russia. FAU - Kolotygin, Ilya O AU - Kolotygin IO AD - Laboratory of Immunogenetics, Institute of Molecular and Cellular Biology, Siberian Branch of the Russian Academy of Sciences, Novosibirsk, Russia. FAU - Gorchakov, Andrey A AU - Gorchakov AA AD - Laboratory of Immunogenetics, Institute of Molecular and Cellular Biology, Siberian Branch of the Russian Academy of Sciences, Novosibirsk, Russia. FAU - Taranin, Alexander V AU - Taranin AV AD - Laboratory of Immunogenetics, Institute of Molecular and Cellular Biology, Siberian Branch of the Russian Academy of Sciences, Novosibirsk, Russia. FAU - Filatov, Alexander V AU - Filatov AV AD - Laboratory of Immunochemistry, National Research Center Institute of Immunology, Federal Medical Biological Agency of Russia, Moscow, Russia. AD - Department of Immunology, Faculty of Biology, Lomonosov Moscow State University, Moscow, Russia. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220224 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 RN - 0 (Antibodies, Neutralizing) RN - 0 (Antibodies, Viral) RN - 0 (COVID-19 Vaccines) RN - 0 (Gam-COVID-Vac vaccine) RN - 0 (Vaccines, Synthetic) SB - IM MH - Aged MH - Antibodies, Neutralizing/blood MH - Antibodies, Viral/blood MH - COVID-19/*immunology MH - COVID-19 Vaccines/*immunology MH - Cells, Cultured MH - Cohort Studies MH - Female MH - Humans MH - Immunization MH - Male MH - Memory B Cells/*immunology MH - Middle Aged MH - SARS-CoV-2/*physiology MH - Vaccination MH - Vaccines, Synthetic/*immunology PMC - PMC8907154 OTO - NOTNLM OT - COVID-19 OT - SARS-CoV-2 OT - Sputnik V vaccine OT - memory B cells OT - vaccination COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/03/15 06:00 MHDA- 2022/03/22 06:00 PMCR- 2022/02/24 CRDT- 2022/03/14 05:17 PHST- 2021/12/21 00:00 [received] PHST- 2022/02/07 00:00 [accepted] PHST- 2022/03/14 05:17 [entrez] PHST- 2022/03/15 06:00 [pubmed] PHST- 2022/03/22 06:00 [medline] PHST- 2022/02/24 00:00 [pmc-release] AID - 10.3389/fimmu.2022.840707 [doi] PST - epublish SO - Front Immunol. 2022 Feb 24;13:840707. doi: 10.3389/fimmu.2022.840707. eCollection 2022. PMID- 35278975 OWN - NLM STAT- MEDLINE DCOM- 20220331 LR - 20240909 IS - 1873-5347 (Electronic) IS - 0277-9536 (Print) IS - 0277-9536 (Linking) VI - 298 DP - 2022 Apr TI - Inside the 'black box' of COVID-19 vaccination beliefs: Revealing the relative importance of public confidence and news consumption habits. PG - 114874 LID - S0277-9536(22)00180-0 [pii] LID - 10.1016/j.socscimed.2022.114874 [doi] AB - RATIONALE: President Biden's goal for 70% of U.S. adults to have received at least one vaccine by July 4, 2021 was not achieved. OBJECTIVE: The aim of this research was to assess the 'black box' of positive COVID-19 vaccination beliefs to determine the relative importance of each factor and thus inform well-targeted and tailored health promotion efforts. METHODS: A cross-sectional survey was conducted in a sample of U.S. adults (N = 1656), assessing the influence of demographic characteristics, cognitive effects, public confidence, and news source variety and evaluation on positive COVID-19 vaccination beliefs. RESULTS: Overall, the strongest predictor of positive beliefs was high confidence in public health officials and political institutions to handle the COVID-19 pandemic effectively, yet negative sentiments toward COVID-19 research and science and COVID-19 vaccine ambivalence reduced the likelihood that beliefs were positive. Cognitive effects and public confidence were identified as key predictors of positive COVID-19 vaccination beliefs over and above party identification. Importantly, high levels of confidence in science and government were mostly driven by positive evaluations of liberal news sources. High levels of COVID-19 science backlash were mostly driven by positive evaluations of conservative news sources. CONCLUSIONS: To motivate COVID-19 vaccination among hesitant or resistant groups in the population, health promotion efforts should seek to reinforce positive COVID-19 vaccination beliefs by increasing public confidence and by reducing COVID-19 science backlash, largely by choosing specific news media and social media platforms (e.g., Breitbart, Fox News, and Facebook) as channels for health promotion and health information dissemination. CI - Copyright (c) 2022 Elsevier Ltd. All rights reserved. FAU - Lueck, Jennifer A AU - Lueck JA AD - Department of Communication, Texas A&M University, 456 Ross St., College Station, TX, USA. Electronic address: jlueck@tamu.edu. FAU - Callaghan, Timothy AU - Callaghan T AD - Department of Health Policy and Management, School of Public Health, Texas A&M University. 212 Adriance Lab Rd. 1266 TAMU, College Station, TX, USA. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220301 PL - England TA - Soc Sci Med JT - Social science & medicine (1982) JID - 8303205 RN - 0 (COVID-19 Vaccines) SB - IM MH - Adult MH - *COVID-19/prevention & control MH - *COVID-19 Vaccines/therapeutic use MH - Cross-Sectional Studies MH - Habits MH - Humans MH - Pandemics/prevention & control MH - Vaccination/psychology PMC - PMC8885110 OTO - NOTNLM OT - Attitude OT - COVID-19 OT - Cognition OT - Health promotion OT - News media OT - Public confidence OT - Vaccine COIS- None. EDAT- 2022/03/13 06:00 MHDA- 2022/04/01 06:00 PMCR- 2022/03/01 CRDT- 2022/03/12 20:16 PHST- 2021/06/28 00:00 [received] PHST- 2022/01/11 00:00 [revised] PHST- 2022/02/26 00:00 [accepted] PHST- 2022/03/13 06:00 [pubmed] PHST- 2022/04/01 06:00 [medline] PHST- 2022/03/12 20:16 [entrez] PHST- 2022/03/01 00:00 [pmc-release] AID - S0277-9536(22)00180-0 [pii] AID - 114874 [pii] AID - 10.1016/j.socscimed.2022.114874 [doi] PST - ppublish SO - Soc Sci Med. 2022 Apr;298:114874. doi: 10.1016/j.socscimed.2022.114874. Epub 2022 Mar 1. PMID- 35251795 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240824 IS - 2168-8184 (Print) IS - 2168-8184 (Electronic) IS - 2168-8184 (Linking) VI - 14 IP - 1 DP - 2022 Jan TI - Comorbidities and Vaccination Status of COVID-19 All-Cause Mortality at a Tertiary Care Center of Western India. PG - e21721 LID - 10.7759/cureus.21721 [doi] LID - e21721 AB - INTRODUCTION: COVID-19 vaccines have been found to be efficacious for preventing severe disease, yet breakthrough infections and deaths have occurred in a small proportion of vaccinated individuals. This study aimed to describe the vaccination status and comorbidities of COVID-19 all-cause deaths. METHODS: This descriptive observational study was conducted at a tertiary care center in western India. A total of 310, RT-PCR positive COVID-19 deaths, aged 45 years and above irrespective of the cause of death (all-cause mortality), were included in the study. Death after breakthrough infection was defined as death in patient with disease onset after 14 days of the second dose of vaccine. RESULTS: Diabetes was the most common comorbidity found in 17.1% of the deaths, followed by hypertension. Cardiovascular disease and renal disease were other common comorbidities seen in 8.7% and 4.83% deaths respectively. Other less common comorbidities include neurological disorders, HIV, autoimmune disorders. Out of these 310 deaths, 21.4% of patients developed disease within 14 days of the first dose. Death after true breakthrough infection (after 14 days of both doses) was seen in only two patients (0.6%). One of these two patients was aged 60 years and had diabetes, while the other was aged 72 years and had a history of smoking. CONCLUSION: Diabetes and hypertension were the most common comorbidities, indicating a higher risk of mortality among comorbid patients. Only a small proportion of deaths (0.6%) occurred after breakthrough infection beyond 14 days of two doses. COVID-19 vaccines have shown promising efficacy against severe disease, thus high vaccination coverage needs to be achieved to prevent morbidity and mortality. CI - Copyright (c) 2022, Verma et al. FAU - Verma, Manoj AU - Verma M AD - Community Medicine, Dr. Sampurnanand (S. N. Medical College), Jodhpur, IND. FAU - Sharma, Savitri AU - Sharma S AD - Community Medicine, Dr. Sampurnanand (S. N. Medical College), Jodhpur, IND. FAU - Kumar, Arun AU - Kumar A AD - Community Medicine, Dr. Sampurnanand (S. N. Medical College), Jodhpur, IND. FAU - Hakim, Afzal AU - Hakim A AD - Community Medicine, Dr. Sampurnanand (S. N. Medical College), Jodhpur, IND. FAU - Bhansali, Suman AU - Bhansali S AD - Community Medicine, Dr. Sampurnanand (S. N. Medical College), Jodhpur, IND. FAU - Meena, Rita AU - Meena R AD - Community Medicine, Dr. Sampurnanand (S. N. Medical College), Jodhpur, IND. LA - eng PT - Journal Article DEP - 20220130 PL - United States TA - Cureus JT - Cureus JID - 101596737 PMC - PMC8886330 OTO - NOTNLM OT - breakthrough infection OT - corona OT - covaxin OT - covid OT - covishield COIS- The authors have declared that no competing interests exist. EDAT- 2022/03/08 06:00 MHDA- 2022/03/08 06:01 PMCR- 2022/01/30 CRDT- 2022/03/07 06:06 PHST- 2022/01/29 00:00 [accepted] PHST- 2022/03/07 06:06 [entrez] PHST- 2022/03/08 06:00 [pubmed] PHST- 2022/03/08 06:01 [medline] PHST- 2022/01/30 00:00 [pmc-release] AID - 10.7759/cureus.21721 [doi] PST - epublish SO - Cureus. 2022 Jan 30;14(1):e21721. doi: 10.7759/cureus.21721. eCollection 2022 Jan. PMID- 35239452 OWN - NLM STAT- MEDLINE DCOM- 20220415 LR - 20220516 IS - 2164-554X (Electronic) IS - 2164-5515 (Print) IS - 2164-5515 (Linking) VI - 18 IP - 1 DP - 2022 Dec 31 TI - Detection of anti-NMDA receptor antibodies following BBIBP-CorV COVID-19 vaccination in a rituximab-treated person with multiple sclerosis presenting with manifestations of an acute relapse. PG - 2033540 LID - 10.1080/21645515.2022.2033540 [doi] LID - 2033540 AB - Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is a relatively unknown autoimmune entity. Scant reports of post-infection/vaccination anti-NMDAR encephalitis exist. We, hereby, reviewed the relevant cases and added to the literature a possible case of anti-NMDAR encephalitis following COVID-19 vaccination with BBIBP-CorV (Sinopharm). A 50-year-old Persian woman with previously known rituximab-treated MS presented complaining of worsening neurological symptoms all gradually starting and worsening after receiving the second dose of BBVIP-CorV 2 weeks before. Notable findings in her physical examination included ataxic gait and Babinski sign. Considering an acute MS relapse, corticosteroid pulse therapy was initiated, and she was referred for MRI, which revealed multiple new plaques. Her serum sample interestingly tested positive for anti-NMDAR antibodies. CSF analysis was unfortunately not performed. She responded well to the corticosteroid pulse therapy and showed substantial resolution of the symptoms. Considering its relatively low cost of workup and the benefits of correct early diagnosis, clinicians are advised to consider autoimmune encephalitis encountering patients with progressive neurological symptoms after the administration of vaccines, including the ones for COVID-19 which are currently being used extensively. FAU - Etemadifar, Masoud AU - Etemadifar M AD - Department of Neurosurgery, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran. AD - Alzahra Research Institute, Alzahra University Hospital, Isfahan University of Medical Sciences, Isfahan, Iran. FAU - Nouri, Hosein AU - Nouri H AUID- ORCID: 0000-0003-1808-0443 AD - Alzahra Research Institute, Alzahra University Hospital, Isfahan University of Medical Sciences, Isfahan, Iran. AD - Network of Immunity in Infection, Malignancy, and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Isfahan, Iran. FAU - Salari, Mehri AU - Salari M AUID- ORCID: 0000-0001-7102-821X AD - Functional Neurosurgery Research Center, Shohada Tajrish Comprehensive Neurosurgical Center of Excellence, Shahid Beheshti University of Medical Sciences, Tehran, Iran Iran. FAU - Sedaghat, Nahad AU - Sedaghat N AUID- ORCID: 0000-0002-2796-6791 AD - Alzahra Research Institute, Alzahra University Hospital, Isfahan University of Medical Sciences, Isfahan, Iran. AD - Network of Immunity in Infection, Malignancy, and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Isfahan, Iran. LA - eng PT - Journal Article DEP - 20220303 PL - United States TA - Hum Vaccin Immunother JT - Human vaccines & immunotherapeutics JID - 101572652 RN - 0 (Adrenal Cortex Hormones) RN - 0 (COVID-19 Vaccines) RN - 0 (Receptors, N-Methyl-D-Aspartate) RN - 4F4X42SYQ6 (Rituximab) SB - IM MH - Adrenal Cortex Hormones MH - *Anti-N-Methyl-D-Aspartate Receptor Encephalitis/diagnosis/drug therapy MH - *COVID-19 MH - COVID-19 Vaccines MH - Female MH - Humans MH - Middle Aged MH - *Multiple Sclerosis MH - Neoplasm Recurrence, Local MH - Receptors, N-Methyl-D-Aspartate MH - Rituximab/therapeutic use MH - Vaccination PMC - PMC9009911 OTO - NOTNLM OT - Anti-N-Methyl-d-Aspartate receptor antibodies OT - Autoimmune encephalitis OT - COVID-19 vaccination OT - case report OT - multiple sclerosis COIS- The authors have no conflicts of interest to declare. EDAT- 2022/03/04 06:00 MHDA- 2022/04/16 06:00 PMCR- 2022/03/03 CRDT- 2022/03/03 17:13 PHST- 2022/03/04 06:00 [pubmed] PHST- 2022/04/16 06:00 [medline] PHST- 2022/03/03 17:13 [entrez] PHST- 2022/03/03 00:00 [pmc-release] AID - 2033540 [pii] AID - 10.1080/21645515.2022.2033540 [doi] PST - ppublish SO - Hum Vaccin Immunother. 2022 Dec 31;18(1):2033540. doi: 10.1080/21645515.2022.2033540. Epub 2022 Mar 3. PMID- 35237272 OWN - NLM STAT- MEDLINE DCOM- 20220314 LR - 20260127 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 13 DP - 2022 TI - Antigen-Specific CD4(+) T-Cell Activation in Primary Antibody Deficiency After BNT162b2 mRNA COVID-19 Vaccination. PG - 827048 LID - 10.3389/fimmu.2022.827048 [doi] LID - 827048 AB - Previous studies on immune responses following COVID-19 vaccination in patients with common variable immunodeficiency (CVID) were inconclusive with respect to the ability of the patients to produce vaccine-specific IgG antibodies, while patients with milder forms of primary antibody deficiency such as immunoglobulin isotype deficiency or selective antibody deficiency have not been studied at all. In this study we examined antigen-specific activation of CXCR5-positive and CXCR5-negative CD4(+) memory cells and also isotype-specific and functional antibody responses in patients with CVID as compared to other milder forms of primary antibody deficiency and healthy controls six weeks after the second dose of BNT162b2 vaccine against SARS-CoV-2. Expression of the activation markers CD25 and CD134 was examined by multi-color flow cytometry on CD4(+) T cell subsets stimulated with SARS-CoV-2 spike peptides, while in parallel IgG and IgA antibodies and surrogate virus neutralization antibodies against SARS-CoV-2 spike protein were measured by ELISA. The results show that in CVID and patients with other milder forms of antibody deficiency normal IgG responses (titers of spike protein-specific IgG three times the detection limit or more) were associated with intact vaccine-specific activation of CXCR5-negative CD4(+) memory T cells, despite defective activation of circulating T follicular helper cells. In contrast, CVID IgG nonresponders showed defective vaccine-specific and superantigen-induced activation of both CD4(+)T cell subsets. In conclusion, impaired TCR-mediated activation of CXCR5-negative CD4(+) memory T cells following stimulation with vaccine antigen or superantigen identifies patients with primary antibody deficiency and impaired IgG responses after BNT162b2 vaccination. CI - Copyright (c) 2022 Sauerwein, Geier, Stemberger, Akyaman, Illes, Fischer, Eibl, Walter and Wolf. FAU - Sauerwein, Kai M T AU - Sauerwein KMT AD - Immunology Outpatient Clinic, Vienna, Austria. AD - Department for Biomedical Research, Center of Experimental Medicine, Danube University Krems, Krems an der Donau, Austria. AD - Biomedizinische Forschung & Bio-Produkte AG, Vienna, Austria. FAU - Geier, Christoph B AU - Geier CB AD - Immunology Outpatient Clinic, Vienna, Austria. FAU - Stemberger, Roman F AU - Stemberger RF AD - Immunology Outpatient Clinic, Vienna, Austria. FAU - Akyaman, Huseyin AU - Akyaman H AD - Immunology Outpatient Clinic, Vienna, Austria. FAU - Illes, Peter AU - Illes P AD - USF Health Department of Pediatrics, Division of Allergy/Immunology, Children s Research Institute, St. Petersburg, FL, United States. FAU - Fischer, Michael B AU - Fischer MB AD - Department for Biomedical Research, Center of Experimental Medicine, Danube University Krems, Krems an der Donau, Austria. AD - Clinic for Blood Group Serology and Transfusion Medicine, Medical University of Vienna, Vienna, Austria. FAU - Eibl, Martha M AU - Eibl MM AD - Immunology Outpatient Clinic, Vienna, Austria. AD - Biomedizinische Forschung & Bio-Produkte AG, Vienna, Austria. FAU - Walter, Jolan E AU - Walter JE AD - Division of Allergy and Immunology, Department of Pediatrics, Morsani College of Medicine, University of South Florida, Tampa, FL, United States. AD - Division of Allergy/Immunology, Department of Pediatrics, Johns Hopkins All Children's Hospital, St. Petersburg, FL, United States. FAU - Wolf, Hermann M AU - Wolf HM AD - Immunology Outpatient Clinic, Vienna, Austria. AD - Medical School, Sigmund Freud Private University, Vienna, Austria. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220214 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 RN - 0 (Antibodies, Neutralizing) RN - 0 (Antibodies, Viral) RN - 0 (BNT162 Vaccine) RN - 0 (Enterotoxins) RN - 0 (Immunoglobulin G) RN - 0 (Receptors, Antigen, T-Cell) RN - 0 (Receptors, CXCR5) RN - 0 (CXCR5 protein, human) RN - 39424-53-8 (enterotoxin B, staphylococcal) SB - IM MH - Adult MH - Antibodies, Neutralizing/immunology MH - Antibodies, Viral/immunology MH - BNT162 Vaccine/*immunology MH - CD4-Positive T-Lymphocytes/*immunology MH - COVID-19/*immunology/prevention & control MH - Common Variable Immunodeficiency/immunology MH - Enterotoxins/immunology MH - Female MH - Humans MH - Immunoglobulin G/immunology MH - Lymphocyte Activation MH - Male MH - Memory T Cells/immunology MH - Middle Aged MH - Primary Immunodeficiency Diseases/*immunology MH - Receptors, Antigen, T-Cell/immunology MH - Receptors, CXCR5/immunology MH - SARS-CoV-2/*immunology MH - T Follicular Helper Cells/immunology MH - Vaccination PMC - PMC8882590 OTO - NOTNLM OT - CXCR5-negative CD4+ memory T cells OT - activation induced marker assay OT - circulating follicular T helper cells OT - common variable immunodeficiency OT - primary immunoglobulin isotype deficiency OT - surrogate virus neutralization assay COIS- Authors KS and ME were employed by the company Biomedizinische Forschung & Bio-Produkte AG that had no role in the design of this study or during its execution, analyses, interpretation of the data and decision to submit the present manuscript. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/03/04 06:00 MHDA- 2022/03/15 06:00 PMCR- 2022/02/14 CRDT- 2022/03/03 05:35 PHST- 2021/12/01 00:00 [received] PHST- 2022/01/11 00:00 [accepted] PHST- 2022/03/03 05:35 [entrez] PHST- 2022/03/04 06:00 [pubmed] PHST- 2022/03/15 06:00 [medline] PHST- 2022/02/14 00:00 [pmc-release] AID - 10.3389/fimmu.2022.827048 [doi] PST - epublish SO - Front Immunol. 2022 Feb 14;13:827048. doi: 10.3389/fimmu.2022.827048. eCollection 2022. PMID- 35235181 OWN - NLM STAT- MEDLINE DCOM- 20220616 LR - 20220724 IS - 1481-8043 (Electronic) IS - 1481-8035 (Print) IS - 1481-8035 (Linking) VI - 24 IP - 4 DP - 2022 Jun TI - COVID-19 vaccine-related functional neurological disorders in the emergency department. PG - 455-456 LID - 10.1007/s43678-022-00272-6 [doi] FAU - Sanjeev, Om P AU - Sanjeev OP AUID- ORCID: 0000-0002-3041-3514 AD - Department of Emergency Medicine, Sanjay Gandhi Post Graduate Institute of Medical Sciences, House No. 429; Sanskriti EnclaveEldeco Udyan 2; Raebareli Road, Lucknow, 226025, India. opsanjeev@gmail.com. FAU - Verma, Alka AU - Verma A AD - Department of Emergency Medicine, Sanjay Gandhi Post Graduate Institute of Medical Sciences, House No. 429; Sanskriti EnclaveEldeco Udyan 2; Raebareli Road, Lucknow, 226025, India. FAU - Mani, V E AU - Mani VE AD - Department of Neurology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India. FAU - Singh, R K AU - Singh RK AD - Department of Emergency Medicine, Sanjay Gandhi Post Graduate Institute of Medical Sciences, House No. 429; Sanskriti EnclaveEldeco Udyan 2; Raebareli Road, Lucknow, 226025, India. LA - eng PT - Letter DEP - 20220302 PL - England TA - CJEM JT - CJEM JID - 100893237 RN - 0 (COVID-19 Vaccines) SB - IM MH - *COVID-19/prevention & control MH - COVID-19 Vaccines/adverse effects MH - *Conversion Disorder MH - Emergency Service, Hospital MH - Humans PMC - PMC8889866 COIS- We declare there is no conflict of interest with any of the authors. We declare we will abide to the rules of Journal after acceptance for copyright transfer. EDAT- 2022/03/03 06:00 MHDA- 2022/06/18 06:00 PMCR- 2022/03/02 CRDT- 2022/03/02 12:21 PHST- 2021/12/05 00:00 [received] PHST- 2022/01/14 00:00 [accepted] PHST- 2022/03/03 06:00 [pubmed] PHST- 2022/06/18 06:00 [medline] PHST- 2022/03/02 12:21 [entrez] PHST- 2022/03/02 00:00 [pmc-release] AID - 10.1007/s43678-022-00272-6 [pii] AID - 272 [pii] AID - 10.1007/s43678-022-00272-6 [doi] PST - ppublish SO - CJEM. 2022 Jun;24(4):455-456. doi: 10.1007/s43678-022-00272-6. Epub 2022 Mar 2. PMID- 35227552 OWN - NLM STAT- MEDLINE DCOM- 20220401 LR - 20260127 IS - 1873-2364 (Electronic) IS - 0960-8966 (Print) IS - 0960-8966 (Linking) VI - 32 IP - 3 DP - 2022 Mar TI - Early safety and tolerability profile of the BNT162b2 COVID-19 vaccine in myasthenia gravis. PG - 230-235 LID - S0960-8966(22)00030-X [pii] LID - 10.1016/j.nmd.2022.01.013 [doi] AB - Although the COVID-19 vaccines are currently recommended for people with myasthenia gravis (MG), there is no data regarding the safety of the vaccines in this population. In order to investigate the real-life safety data of the BNT162b2 COVID-19 vaccine in people with MG, an anonymous survey was distributed to 142 MG patients. Fifty-six MG patients completed the questionnaire. The median age was 53 years (range 23-83 years); 35 (62.5%) were males, and 25 (44.6%) had associated comorbidities. Thirty-seven participants (66.1%) were treated with immunotherapies. Fifty-five participants (98.2% of the responders) received the BNT162b2 COVID-19 vaccine. Of these, 32 (58.2%) were < 55 years old, and 23 (41.8%) were > 55 years old. Adverse events were more common in patients younger than 55 years old (46.9% Vs. 17.4%; p = 0.0428). Eight participants (14.5%) reported worsening neurological symptoms following the vaccination. Three of those who reported worsening of neurological symptoms (37.5%) required additional treatment. Most events occurred within the first few days after vaccination and resolved within a few weeks. This survey indicates an overall favorable safety and tolerability profile of the BNT162b2 vaccine in people with MG. Additional prospective, large-scale studies are warranted to confirm these findings. CI - Copyright (c) 2022 Elsevier B.V. All rights reserved. FAU - Lotan, Itay AU - Lotan I AD - Department of Neurology, Rabin Medical Center, Petah Tikva, Israel; Neuroimmunology Unit, Rabin Medical Center, Petah Tikva, Israel; Sackler Faculty of Medicine, Tel-Aviv University, Israel. Electronic address: lotan.itay1@gmail.com. FAU - Hellmann, Mark A AU - Hellmann MA AD - Department of Neurology, Rabin Medical Center, Petah Tikva, Israel; Neuroimmunology Unit, Rabin Medical Center, Petah Tikva, Israel; Sackler Faculty of Medicine, Tel-Aviv University, Israel. FAU - Friedman, Yitzhak AU - Friedman Y AD - Department of Neurology, Rabin Medical Center, Petah Tikva, Israel; Neuroimmunology Unit, Rabin Medical Center, Petah Tikva, Israel; Sackler Faculty of Medicine, Tel-Aviv University, Israel. FAU - Stiebel-Kalish, Hadas AU - Stiebel-Kalish H AD - Sackler Faculty of Medicine, Tel-Aviv University, Israel; Department of Ophthalmology and Neuro-Ophthalmology Unit, Rabin Medical Center, Petah Tikva, Israel. FAU - Steiner, Israel AU - Steiner I AD - Department of Neurology, Rabin Medical Center, Petah Tikva, Israel; Sackler Faculty of Medicine, Tel-Aviv University, Israel. FAU - Wilf-Yarkoni, Adi AU - Wilf-Yarkoni A AD - Department of Neurology, Rabin Medical Center, Petah Tikva, Israel; Neuroimmunology Unit, Rabin Medical Center, Petah Tikva, Israel; Sackler Faculty of Medicine, Tel-Aviv University, Israel. LA - eng PT - Journal Article DEP - 20220205 PL - England TA - Neuromuscul Disord JT - Neuromuscular disorders : NMD JID - 9111470 RN - 0 (BNT162 Vaccine) RN - 0 (COVID-19 Vaccines) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - BNT162 Vaccine MH - *COVID-19/prevention & control MH - COVID-19 Vaccines/adverse effects MH - Female MH - Humans MH - Male MH - Middle Aged MH - *Myasthenia Gravis MH - Prospective Studies MH - SARS-CoV-2 MH - Young Adult PMC - PMC8817458 OTO - NOTNLM OT - COVID-19 OT - Myasthenia gravis OT - Safety OT - Tolerability: Adverse events OT - Vaccine COIS- Declaration of Competing Interest none. EDAT- 2022/03/02 06:00 MHDA- 2022/04/02 06:00 PMCR- 2022/02/05 CRDT- 2022/03/01 05:46 PHST- 2021/08/02 00:00 [received] PHST- 2022/01/25 00:00 [revised] PHST- 2022/01/27 00:00 [accepted] PHST- 2022/03/02 06:00 [pubmed] PHST- 2022/04/02 06:00 [medline] PHST- 2022/03/01 05:46 [entrez] PHST- 2022/02/05 00:00 [pmc-release] AID - S0960-8966(22)00030-X [pii] AID - 10.1016/j.nmd.2022.01.013 [doi] PST - ppublish SO - Neuromuscul Disord. 2022 Mar;32(3):230-235. doi: 10.1016/j.nmd.2022.01.013. Epub 2022 Feb 5. PMID- 35201963 OWN - NLM STAT- MEDLINE DCOM- 20220414 LR - 20240826 IS - 2164-554X (Electronic) IS - 2164-5515 (Print) IS - 2164-5515 (Linking) VI - 18 IP - 1 DP - 2022 Dec 31 TI - Self-Reported safety of the BBIBP-CorV (Sinopharm) COVID-19 vaccine among Iranian people with multiple sclerosis. PG - 2041945 LID - 10.1080/21645515.2022.2041945 [doi] LID - 2041945 AB - To affirm the short-term safety of the BBIBP-CorV (Sinopharm) COVID-19 vaccine among people with multiple sclerosis (pwMS), 517 vaccinated and 174 unvaccinated pwMS were interviewed. 16.2% of the vaccinated pwMS reported at least one neurological symptom in their respective vaccine-related at-risk periods (ARP) - a period from the first dose until two weeks after the second dose of the vaccine. In a multivariable logistic regression model, the presence of comorbidities (P = 0.01), use of natalizumab (P = 0.03), and experiencing post-vaccination myalgia (P < 0.01) predicted the development of post-vaccination neurological symptoms. One MS relapse, one COVID-19 contraction, and one ulcerative colitis flare after the first dose, and four MS relapses after the second dose of the vaccine were the only reported serious adverse events during the ARPs. To show if the vaccine provoked MS relapses, we compared the relapse rate of vaccinated pwMS in the vaccine-related ARP with the annualized relapse rate of unvaccinated pwMS in the prior year-a measure of baseline MS relapsing activity in the respective time-using a multivariable Poisson regression model accounting for possible confounders, which failed to show any statistically significant increase (P = 0.78). Hence, subject to replication-as the vaccinated and unvaccinated pwMS differed in baseline characteristics-the BBIBP-CorV vaccine does not seem to affect short-term MS activity. Furthermore, as 83.33% of the unvaccinated pwMS reported fear of possible adverse events to be the reason of their vaccination hesitancy, provision of evidence-based consultations to pwMS is encouraged. Limitations of our study briefly included lack of data for self-controlled analysis of relapse rates, possible presence of recall bias, and lack of on-site validations regarding the clinical outcomes due to the remote nature. FAU - Etemadifar, Masoud AU - Etemadifar M AD - Department of Neurosurgery, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran. AD - Alzahra Research Institute, Alzahra University Hospital, Isfahan University of Medical Sciences, Isfahan, Iran. FAU - Abhari, Amir Parsa AU - Abhari AP AD - Alzahra Research Institute, Alzahra University Hospital, Isfahan University of Medical Sciences, Isfahan, Iran. AD - Network of Immunity in Infection, Malignancy, and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Iran. FAU - Nouri, Hosein AU - Nouri H AUID- ORCID: 0000-0003-1808-0443 AD - Alzahra Research Institute, Alzahra University Hospital, Isfahan University of Medical Sciences, Isfahan, Iran. AD - Network of Immunity in Infection, Malignancy, and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Iran. FAU - Sigari, Amirhossein Akhavan AU - Sigari AA AD - Alzahra Research Institute, Alzahra University Hospital, Isfahan University of Medical Sciences, Isfahan, Iran. FAU - Piran Daliyeh, Seyed Mohammad AU - Piran Daliyeh SM AD - Alzahra Research Institute, Alzahra University Hospital, Isfahan University of Medical Sciences, Isfahan, Iran. FAU - Maracy, Mohammad Reza AU - Maracy MR AD - Department of Epidemiology and Biostatistics, School of Health, Isfahan University of Medical Sciences, Isfahan, Iran. FAU - Salari, Mehri AU - Salari M AUID- ORCID: 0000-0001-7102-821X AD - Functional Neurosurgery Research Center, Shohada Tajrish Comprehensive Neurosurgical Center of Excellence, Shahid Beheshti University of Medical Sciences, Tehran, Iran. FAU - Maleki, Shiva AU - Maleki S AD - Alzahra Research Institute, Alzahra University Hospital, Isfahan University of Medical Sciences, Isfahan, Iran. FAU - Sedaghat, Nahad AU - Sedaghat N AUID- ORCID: 0000-0002-2796-6791 AD - Alzahra Research Institute, Alzahra University Hospital, Isfahan University of Medical Sciences, Isfahan, Iran. AD - Network of Immunity in Infection, Malignancy, and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Iran. LA - eng PT - Journal Article DEP - 20220224 PL - United States TA - Hum Vaccin Immunother JT - Human vaccines & immunotherapeutics JID - 101572652 RN - 0 (COVID-19 Vaccines) SB - IM MH - *COVID-19/prevention & control MH - COVID-19 Vaccines/adverse effects MH - Humans MH - Iran MH - *Multiple Sclerosis MH - Recurrence MH - SARS-CoV-2 MH - Self Report PMC - PMC9009900 OTO - NOTNLM OT - BBIBP-CorV OT - Multiple sclerosis OT - SARS-CoV-2, COVID-19 vaccines OT - adverse events OT - vaccine safety COIS- No potential conflict of interest was reported by the author(s). EDAT- 2022/02/25 06:00 MHDA- 2022/04/15 06:00 PMCR- 2022/02/24 CRDT- 2022/02/24 17:20 PHST- 2022/02/25 06:00 [pubmed] PHST- 2022/04/15 06:00 [medline] PHST- 2022/02/24 17:20 [entrez] PHST- 2022/02/24 00:00 [pmc-release] AID - 2041945 [pii] AID - 10.1080/21645515.2022.2041945 [doi] PST - ppublish SO - Hum Vaccin Immunother. 2022 Dec 31;18(1):2041945. doi: 10.1080/21645515.2022.2041945. Epub 2022 Feb 24. PMID- 35198288 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240824 IS - 2168-8184 (Print) IS - 2168-8184 (Electronic) IS - 2168-8184 (Linking) VI - 14 IP - 1 DP - 2022 Jan TI - Analysis of Neurological Adverse Events Reported in VigiBase From COVID-19 Vaccines. PG - e21376 LID - 10.7759/cureus.21376 [doi] LID - e21376 AB - BACKGROUND: Fifteen COVID-19 vaccines have been granted emergency approval before the completion of conventional phases of clinical trials. The present study aimed to analyze the neurological adverse events (AEs) post-COVID-19 vaccination and focuses on determining the association of AEs with the vaccine. METHODOLOGY: The neurological AEs reported for COVID-19 vaccines in the WHO pharmacovigilance database (VigiBase) were extracted from the System Organ Classes - neurological disorders and investigations. Descriptive statistics are reported as percentage and frequency and the disproportionality analysis was also conducted. RESULTS: For the neurological system, 19,529 AEs were reported. Of these, 15,638 events were reported from BNT162b2 vaccine, 2,751 from AZD1222 vaccine, 1,075 from mRNA-1273 vaccine, eight from Vero vaccine, two from Covaxin, and for 55 AEs, vaccine name was not mentioned. The reason for more AEs reported with BNT162b2 can be maximum vaccination with BNT162b2 vaccine in the study period. According to the disproportionality analysis based on IC(025) value, ageusia, anosmia, burning sensation, dizziness, facial paralysis, headache, hypoaesthesia, lethargy, migraine, neuralgia, paresis, parosmia, poor sleep quality, seizure, transient ischemic attack, and tremor are some of the AEs that can be associated with the administration of the vaccine. CONCLUSION: The vaccines should be monitored for these AEs till the causality of these AEs with COVID-19 vaccines is established through further long-term follow-up studies. These neurological AEs reported in VigiBase should not be taken as conclusive and mass vaccination should be carried out to control the pandemic until a definite link of these adverse effects is established. CI - Copyright (c) 2022, Dutta et al. FAU - Dutta, Siddhartha AU - Dutta S AD - Department of Pharmacology, All India Institute of Medical Sciences, Rajkot, Rajkot, IND. FAU - Kaur, Rimplejeet AU - Kaur R AD - Department of Pharmacology, All India Institute of Medical Sciences, Jodhpur, Jodhpur, IND. FAU - Charan, Jaykaran AU - Charan J AD - Department of Pharmacology, All India Institute of Medical Sciences, Jodhpur, Jodhpur, IND. FAU - Bhardwaj, Pankaj AU - Bhardwaj P AD - Department of Community Medicine & Family Medicine and School of Public Health, All India Institute of Medical Sciences, Jodhpur, Jodhpur, IND. FAU - Ambwani, Sneha R AU - Ambwani SR AD - Department of Pharmacology, All India Institute of Medical Sciences, Jodhpur, Jodhpur, IND. FAU - Babu, Shoban AU - Babu S AD - Department of Pharmacology, All India Institute of Medical Sciences, Jodhpur, Jodhpur, IND. FAU - Goyal, Jagdish P AU - Goyal JP AD - Department of Pediatrics, All India Institute of Medical Sciences, Jodhpur, Jodhpur, IND. FAU - Haque, Mainul AU - Haque M AD - Department of Pharmacology and Therapeutics, National Defence University of Malaysia, Kuala Lumpur, MYS. LA - eng PT - Journal Article DEP - 20220118 PL - United States TA - Cureus JT - Cureus JID - 101596737 PMC - PMC8852793 OTO - NOTNLM OT - adverse events OT - adverse events following immunization OT - azd1222 OT - bnt162b2 OT - covid-19 vaccines OT - mrna-1273 OT - neurological disorders OT - sars-cov-2 (severe acute respiratory syndrome coronavirus -2) COIS- The authors have declared that no competing interests exist. EDAT- 2022/02/25 06:00 MHDA- 2022/02/25 06:01 PMCR- 2022/01/18 CRDT- 2022/02/24 05:42 PHST- 2022/01/18 00:00 [accepted] PHST- 2022/02/24 05:42 [entrez] PHST- 2022/02/25 06:00 [pubmed] PHST- 2022/02/25 06:01 [medline] PHST- 2022/01/18 00:00 [pmc-release] AID - 10.7759/cureus.21376 [doi] PST - epublish SO - Cureus. 2022 Jan 18;14(1):e21376. doi: 10.7759/cureus.21376. eCollection 2022 Jan. PMID- 35184205 OWN - NLM STAT- MEDLINE DCOM- 20220414 LR - 20221207 IS - 1432-1920 (Electronic) IS - 0028-3940 (Print) IS - 0028-3940 (Linking) VI - 64 IP - 5 DP - 2022 May TI - Cerebral venous sinus thrombosis after adenovirus-vectored COVID-19 vaccination: review of the neurological-neuroradiological procedure. PG - 865-874 LID - 10.1007/s00234-022-02914-z [doi] AB - Cerebral venous and sinus thrombosis (CVST) after adenovirus-vectored COVID-19 ChAdOx1 nCov-19 (Oxford-AstraZeneca) and Ad26.COV2.S (Janssen/Johnson & Johnson) is a rare complication, occurring mainly in individuals under 60 years of age and more frequently in women. It manifests 4-24 days after vaccination. In most cases, antibodies against platelet factor-4/polyanion complexes play a pathogenic role, leading to thrombosis with thrombocytopenia syndrome (TTS) and sometimes a severe clinical or even fatal course. The leading symptom is headache, which usually increases in intensity over a few days. Seizures, visual disturbances, focal neurological symptoms, and signs of increased intracranial pressure are also possible. These symptoms may be combined with clinical signs of disseminated intravascular coagulation such as petechiae or gastrointestinal bleeding. If TTS-CVST is suspected, checking D-dimers, platelet count, and screening for heparin-induced thrombocytopenia (HIT-2) are diagnostically and therapeutically guiding. The imaging method of choice for diagnosis or exclusion of CVST is magnetic resonance imaging (MRI) combined with contrast-enhanced venous MR angiography (MRA). On T2*-weighted or susceptibility weighted MR sequences, the thrombus causes susceptibility artefacts (blooming), that allow for the detection even of isolated cortical vein thromboses. The diagnosis of TTS-CVST can usually be made reliably in synopsis with the clinical and laboratory findings. A close collaboration between neurologists and neuroradiologists is mandatory. TTS-CVST requires specific regimens of anticoagulation and immunomodulation therapy if thrombocytopenia and/or pathogenic antibodies to PF4/polyanion complexes are present. In this review article, the diagnostic and therapeutic steps in cases of suspected TTS associated CSVT are presented. CI - (c) 2022. The Author(s). FAU - Wittstock, Matthias AU - Wittstock M AUID- ORCID: 0000-0001-9904-6436 AD - Department of Neurology, Rostock University Medical Centre, Gehlsheimer Str. 20 18147 Rostock, Germany. matthias.wittstock@med.uni-rostock.de. FAU - Walter, Uwe AU - Walter U AD - Department of Neurology, Rostock University Medical Centre, Gehlsheimer Str. 20 18147 Rostock, Germany. FAU - Volmer, Erik AU - Volmer E AD - Institute for Diagnostic and Interventional Radiology, Paediatric Radiology and Neuroradiology, Rostock University Medical Centre, Rostock, Germany. FAU - Storch, Alexander AU - Storch A AD - Department of Neurology, Rostock University Medical Centre, Gehlsheimer Str. 20 18147 Rostock, Germany. FAU - Weber, Marc-Andre AU - Weber MA AD - Institute for Diagnostic and Interventional Radiology, Paediatric Radiology and Neuroradiology, Rostock University Medical Centre, Rostock, Germany. FAU - Grossmann, Annette AU - Grossmann A AD - Institute for Diagnostic and Interventional Radiology, Paediatric Radiology and Neuroradiology, Rostock University Medical Centre, Rostock, Germany. LA - eng PT - Journal Article PT - Review DEP - 20220219 PL - Germany TA - Neuroradiology JT - Neuroradiology JID - 1302751 RN - JT2NS6183B (Ad26COVS1) RN - 0 (COVID-19 Vaccines) RN - B5S3K2V0G8 (ChAdOx1 nCoV-19) SB - IM MH - Ad26COVS1 MH - Adenoviridae MH - *COVID-19 MH - COVID-19 Vaccines/adverse effects MH - ChAdOx1 nCoV-19 MH - Female MH - Humans MH - *Intracranial Thrombosis/complications MH - *Sinus Thrombosis, Intracranial/diagnostic imaging/etiology MH - Syndrome MH - *Thrombocytopenia/chemically induced/diagnostic imaging MH - *Thrombosis/chemically induced/complications MH - Vaccination/adverse effects PMC - PMC8929723 OTO - NOTNLM OT - Adenovirus-vectored COVID-19 vaccination OT - Cerebral venous sinus thrombosis OT - Vaccine-induced immune thrombotic thrombocytopenia COIS- We declare that we have no conflict of interest. EDAT- 2022/02/21 06:00 MHDA- 2022/04/15 06:00 PMCR- 2022/02/19 CRDT- 2022/02/20 20:39 PHST- 2021/11/29 00:00 [received] PHST- 2022/02/03 00:00 [accepted] PHST- 2022/02/21 06:00 [pubmed] PHST- 2022/04/15 06:00 [medline] PHST- 2022/02/20 20:39 [entrez] PHST- 2022/02/19 00:00 [pmc-release] AID - 10.1007/s00234-022-02914-z [pii] AID - 2914 [pii] AID - 10.1007/s00234-022-02914-z [doi] PST - ppublish SO - Neuroradiology. 2022 May;64(5):865-874. doi: 10.1007/s00234-022-02914-z. Epub 2022 Feb 19. PMID- 35180249 OWN - NLM STAT- MEDLINE DCOM- 20220301 LR - 20220301 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 17 IP - 2 DP - 2022 TI - Media attention and Vaccine Hesitancy: Examining the mediating effects of Fear of COVID-19 and the moderating role of Trust in leadership. PG - e0263610 LID - 10.1371/journal.pone.0263610 [doi] LID - e0263610 AB - Vaccination has emerged as the most cost-effective public health strategy for maintaining population health, with various social and economic benefits. These vaccines, however, cannot be effective without widespread acceptance. The present study examines the effect of media attention on COVID-19 vaccine hesitancy by incorporating fear of COVID-19 as a mediator, whereas trust in leadership served as a moderator. An analytical cross-sectional study is performed among rural folks in the Wassa Amenfi Central of Ghana. Using a questionnaire survey, we were able to collect 3079 valid responses. The Smart PLS was used to estimate the relationship among the variables. The results revealed that media attention had a significant influence on vaccine hesitancy. Furthermore, the results showed that fear of COVID-19 played a significant mediating role in the relationship between media and vaccine hesitancy. However, trust in leadership had an insignificant moderating relationship on the fear of COVID-19 and vaccine hesitancy. The study suggests that the health management team can reduce vaccine hesitancy if they focus on lessening the negative impact of media and other antecedents like fear on trust in leadership. FAU - Zhou, Lulin AU - Zhou L AD - School of Management, Jiangsu University, Zhenjiang, PR China. FAU - Ampon-Wireko, Sabina AU - Ampon-Wireko S AUID- ORCID: 0000-0001-6456-3660 AD - School of Management, Jiangsu University, Zhenjiang, PR China. FAU - Xu, Xinglong AU - Xu X AD - School of Management, Jiangsu University, Zhenjiang, PR China. FAU - Quansah, Prince Edwudzie AU - Quansah PE AD - School of Management, Jiangsu University, Zhenjiang, PR China. FAU - Larnyo, Ebenezer AU - Larnyo E AD - School of Management, Jiangsu University, Zhenjiang, PR China. LA - eng PT - Journal Article PT - Observational Study PT - Research Support, Non-U.S. Gov't DEP - 20220218 PL - United States TA - PLoS One JT - PloS one JID - 101285081 RN - 0 (COVID-19 Vaccines) SB - IM MH - Adolescent MH - Adult MH - Aged MH - Anti-Vaccination Movement/psychology/statistics & numerical data MH - COVID-19/epidemiology/*prevention & control MH - COVID-19 Vaccines/*administration & dosage MH - Communications Media/*statistics & numerical data MH - Cross-Sectional Studies MH - Fear MH - Female MH - Ghana/epidemiology MH - Humans MH - Leadership MH - Male MH - Mass Vaccination/*psychology/statistics & numerical data MH - Middle Aged MH - Rural Population/statistics & numerical data MH - Surveys and Questionnaires/statistics & numerical data MH - Trust MH - *Vaccination Hesitancy MH - Young Adult PMC - PMC8856543 COIS- The authors have declared that no competing interests exist. EDAT- 2022/02/19 06:00 MHDA- 2022/03/03 06:00 PMCR- 2022/02/18 CRDT- 2022/02/18 17:09 PHST- 2021/06/26 00:00 [received] PHST- 2022/01/21 00:00 [accepted] PHST- 2022/02/18 17:09 [entrez] PHST- 2022/02/19 06:00 [pubmed] PHST- 2022/03/03 06:00 [medline] PHST- 2022/02/18 00:00 [pmc-release] AID - PONE-D-21-20697 [pii] AID - 10.1371/journal.pone.0263610 [doi] PST - epublish SO - PLoS One. 2022 Feb 18;17(2):e0263610. doi: 10.1371/journal.pone.0263610. eCollection 2022. PMID- 35173705 OWN - NLM STAT- MEDLINE DCOM- 20220224 LR - 20220224 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 12 DP - 2021 TI - Evaluation of the Immune Response Induced by CoronaVac 28-Day Schedule Vaccination in a Healthy Population Group. PG - 766278 LID - 10.3389/fimmu.2021.766278 [doi] LID - 766278 AB - CoronaVac vaccine from Sinovac Life Science is currently being used in several countries. In Chile, the effectiveness of preventing hospitalization is higher than 80% with a vaccination schedule. However, to date, there are no data about immune response induction or specific memory. For this reason, we recruited 15 volunteers without previous suspected/diagnosed COVID-19 and with negative PCR over time to evaluate the immune response to CoronaVac 28 and 90 days after the second immunization (dpi). The CoronaVac administration induces total and neutralizing anti-spike antibodies in all vaccinated volunteers at 28 and 90 dpi. Furthermore, using ELISpot analysis to assay cellular immune responses against SARS-CoV-2 spike protein, we found an increase in IFN-gamma- and Granzyme B-producing cells in vaccinated volunteers at 28 and 90 dpi. Together, our results indicate that CoronaVac induces a robust humoral immune response and cellular immune memory of at least 90 dpi. CI - Copyright (c) 2022 Escobar, Reyes-Lopez, Acevedo, Alonso-Palomares, Valiente-Echeverria, Soto-Rifo, Portillo, Gatica, Flores, Nova-Lamperti, Barrera-Avalos, Bono, Vargas, Simon, Leiva-Salcedo, Vial, Hormazabal, Cortes, Valdes, Sandino, Imarai and Acuna-Castillo. FAU - Escobar, Alejandro AU - Escobar A AD - Laboratorio Biologia Celular y Molecular, Instituto de Investigacion en Ciencias Odontologicas, Facultad de Odontologia, Universidad de Chile, Santiago, Chile. FAU - Reyes-Lopez, Felipe E AU - Reyes-Lopez FE AD - Centro de Biotecnologia Acuicola, Facultad de Quimica y Biologia, Universidad de Santiago de Chile, Santiago, Chile. AD - Department of Cell Biology, Physiology and Immunology, Universitat Autonoma de Barcelona, Bellaterra, Spain. AD - Facultad de Medicina Veterinaria y Agronomia, Universidad de Las Americas, Providencia, Chile. FAU - Acevedo, Monica L AU - Acevedo ML AD - Laboratory of Molecular and Cellular Virology, Virology Program, Institute of Biomedical Sciences, Faculty of Medicine, Universidad de Chile, Santiago, Chile. FAU - Alonso-Palomares, Luis AU - Alonso-Palomares L AD - Laboratory of Molecular and Cellular Virology, Virology Program, Institute of Biomedical Sciences, Faculty of Medicine, Universidad de Chile, Santiago, Chile. FAU - Valiente-Echeverria, Fernando AU - Valiente-Echeverria F AD - Laboratory of Molecular and Cellular Virology, Virology Program, Institute of Biomedical Sciences, Faculty of Medicine, Universidad de Chile, Santiago, Chile. FAU - Soto-Rifo, Ricardo AU - Soto-Rifo R AD - Laboratory of Molecular and Cellular Virology, Virology Program, Institute of Biomedical Sciences, Faculty of Medicine, Universidad de Chile, Santiago, Chile. FAU - Portillo, Hugo AU - Portillo H AD - Laboratorio Biologia Celular y Molecular, Instituto de Investigacion en Ciencias Odontologicas, Facultad de Odontologia, Universidad de Chile, Santiago, Chile. FAU - Gatica, Jimena AU - Gatica J AD - Laboratorio Biologia Celular y Molecular, Instituto de Investigacion en Ciencias Odontologicas, Facultad de Odontologia, Universidad de Chile, Santiago, Chile. FAU - Flores, Ivan AU - Flores I AD - Laboratorio Biologia Celular y Molecular, Instituto de Investigacion en Ciencias Odontologicas, Facultad de Odontologia, Universidad de Chile, Santiago, Chile. FAU - Nova-Lamperti, Estefania AU - Nova-Lamperti E AD - Molecular and Translational Immunology Laboratory, Department of Clinical Biochemistry and Immunology, Faculty of Pharmacy, University of Concepcion, Concepcion, Chile. FAU - Barrera-Avalos, Carlos AU - Barrera-Avalos C AD - Centro de Biotecnologia Acuicola, Facultad de Quimica y Biologia, Universidad de Santiago de Chile, Santiago, Chile. FAU - Bono, Maria Rosa AU - Bono MR AD - Departamento de Biologia, Facultad de Ciencias, Universidad de Chile, Santiago, Chile. FAU - Vargas, Leonardo AU - Vargas L AD - Departamento de Biologia, Facultad de Ciencias, Universidad de Chile, Santiago, Chile. FAU - Simon, Valeska AU - Simon V AD - Departamento de Biologia, Facultad de Ciencias, Universidad de Chile, Santiago, Chile. FAU - Leiva-Salcedo, Elias AU - Leiva-Salcedo E AD - Centro de Biotecnologia Acuicola, Facultad de Quimica y Biologia, Universidad de Santiago de Chile, Santiago, Chile. FAU - Vial, Cecilia AU - Vial C AD - Programa Hantavirus y Zoonosis, Instituto de Ciencias e Innovacion en Medicina, Facultad de Medicina, Clinica Alemana Universidad del Desarrollo, Santiago, Chile. FAU - Hormazabal, Juan AU - Hormazabal J AD - Programa Hantavirus y Zoonosis, Instituto de Ciencias e Innovacion en Medicina, Facultad de Medicina, Clinica Alemana Universidad del Desarrollo, Santiago, Chile. FAU - Cortes, Lina Jimena AU - Cortes LJ AD - Programa Hantavirus y Zoonosis, Instituto de Ciencias e Innovacion en Medicina, Facultad de Medicina, Clinica Alemana Universidad del Desarrollo, Santiago, Chile. FAU - Valdes, Daniel AU - Valdes D AD - Centro de Biotecnologia Acuicola, Facultad de Quimica y Biologia, Universidad de Santiago de Chile, Santiago, Chile. FAU - Sandino, Ana M AU - Sandino AM AD - Centro de Biotecnologia Acuicola, Facultad de Quimica y Biologia, Universidad de Santiago de Chile, Santiago, Chile. FAU - Imarai, Monica AU - Imarai M AD - Centro de Biotecnologia Acuicola, Facultad de Quimica y Biologia, Universidad de Santiago de Chile, Santiago, Chile. FAU - Acuna-Castillo, Claudio AU - Acuna-Castillo C AD - Centro de Biotecnologia Acuicola, Facultad de Quimica y Biologia, Universidad de Santiago de Chile, Santiago, Chile. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220131 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 RN - 0 (Antibodies, Neutralizing) RN - 0 (Antibodies, Viral) RN - 0 (Biomarkers) RN - 0 (COVID-19 Vaccines) RN - 0 (IFNG protein, human) RN - 0 (Spike Glycoprotein, Coronavirus) RN - 0 (spike protein, SARS-CoV-2) RN - 82115-62-6 (Interferon-gamma) RN - EC 3.4.21.- (GZMB protein, human) RN - EC 3.4.21.- (Granzymes) SB - IM MH - Adult MH - Antibodies, Neutralizing/*blood MH - Antibodies, Viral/*blood MH - B-Lymphocytes/*drug effects/immunology/metabolism MH - Biomarkers/blood MH - COVID-19/immunology/*prevention & control/virology MH - COVID-19 Vaccines/*administration & dosage/immunology MH - Chile MH - Female MH - Granzymes/metabolism MH - Healthy Volunteers MH - Humans MH - Immunity, Cellular/drug effects MH - Immunity, Humoral/drug effects MH - *Immunization Schedule MH - *Immunogenicity, Vaccine MH - Immunologic Memory/drug effects MH - Interferon-gamma/metabolism MH - Male MH - Middle Aged MH - SARS-CoV-2/*immunology MH - Spike Glycoprotein, Coronavirus/immunology MH - Time Factors MH - Treatment Outcome PMC - PMC8841433 OTO - NOTNLM OT - COVID-19 OT - CoronaVac OT - SARS-CoV-2 OT - herd immunity OT - immunological memory OT - neutralizing antibodies OT - vaccine COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/02/18 06:00 MHDA- 2022/02/25 06:00 PMCR- 2022/01/31 CRDT- 2022/02/17 05:34 PHST- 2021/08/28 00:00 [received] PHST- 2021/12/14 00:00 [accepted] PHST- 2022/02/17 05:34 [entrez] PHST- 2022/02/18 06:00 [pubmed] PHST- 2022/02/25 06:00 [medline] PHST- 2022/01/31 00:00 [pmc-release] AID - 10.3389/fimmu.2021.766278 [doi] PST - epublish SO - Front Immunol. 2022 Jan 31;12:766278. doi: 10.3389/fimmu.2021.766278. eCollection 2021. PMID- 35137144 OWN - NLM STAT- MEDLINE DCOM- 20220815 LR - 20250728 IS - 1537-6613 (Electronic) IS - 0022-1899 (Print) IS - 0022-1899 (Linking) VI - 226 IP - 1 DP - 2022 Aug 12 TI - Distinct Homologous and Variant-Specific Memory B-Cell and Antibody Response Over Time After Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccination. PG - 23-31 LID - 10.1093/infdis/jiac042 [doi] AB - The durability of protective humoral immunity after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination and infection is largely dependent on the generation and persistence of antigen-specific isotype-switched memory B cells (MBCs) and long-lived plasma cells that reside in the bone marrow and secrete high-affinity neutralizing antibodies. The reactivity of vaccine-induced MBCs to emerging clinically significant SARS-CoV-2 variants of concern (VoCs) is largely unknown. In a longitudinal cohort study (up to 6 months following coronavirus disease 2019 messenger RNA vaccination), we measured MBCs in concert with other functional antibody measures. We found statistically significant differences between the frequencies of MBCs responding to homologous and VoC (Beta, Gamma, and Delta) receptor-binding domains after vaccination that persisted over time. In concert with a waning antibody response, the reduced MBC response to VoCs could translate to a weaker subsequent recall immune response and increased susceptibility to the emerging SARS-CoV-2 variant strains after vaccination. CI - (c) The Author(s) 2022. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com. FAU - Haralambieva, Iana H AU - Haralambieva IH AD - Mayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, Minnesota, USA. FAU - Monroe, Jonathon M AU - Monroe JM AD - Mayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, Minnesota, USA. FAU - Ovsyannikova, Inna G AU - Ovsyannikova IG AD - Mayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, Minnesota, USA. FAU - Grill, Diane E AU - Grill DE AD - Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA. FAU - Poland, Gregory A AU - Poland GA AD - Mayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, Minnesota, USA. FAU - Kennedy, Richard B AU - Kennedy RB AD - Mayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, Minnesota, USA. LA - eng GR - R01 AI048793/AI/NIAID NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't PL - United States TA - J Infect Dis JT - The Journal of infectious diseases JID - 0413675 RN - 0 (Antibodies, Neutralizing) RN - 0 (Antibodies, Viral) RN - 0 (RNA, Messenger) RN - 0 (Spike Glycoprotein, Coronavirus) RN - 0 (spike protein, SARS-CoV-2) RN - SARS-CoV-2 variants SB - IM MH - Antibodies, Neutralizing MH - Antibodies, Viral MH - Antibody Formation MH - *COVID-19/prevention & control MH - Humans MH - Longitudinal Studies MH - RNA, Messenger MH - *SARS-CoV-2/genetics MH - Spike Glycoprotein, Coronavirus/genetics MH - Vaccination PMC - PMC8903425 OTO - NOTNLM OT - B cells OT - COVID-19 OT - SARS-CoV-2 OT - antibodies OT - humoral immune responses OT - immunological memory OT - neutralizing OT - vaccine COIS- Potential conflicts of interest. This research has been reviewed by the Mayo Clinic Conflict of Interest Review Board and was conducted in compliance with Mayo Clinic conflict of interest policies. G. A. P. is the chair of a Safety Evaluation Committee for novel investigational vaccine trials being conducted by Merck Research Laboratories. G. A. P. offers consultative advice on vaccine development to Merck & Co, Avianax, Adjuvance, Valneva, Medicago, Sanofi Pasteur, GlaxoSmithKline, and Emergent Biosolutions. G. A. P. and I. G. O. hold 3 patents related to measles and vaccinia peptide research. G. A. P. and R. B. K. hold a patent on vaccinia peptide research. R. B. K. has received funding from Merck Research Laboratories to study waning immunity to measles and mumps after immunization with the MMR-II vaccine. G. A. P., R. B. K., and I. G. O. have received grant funding from ICW Ventures for preclinical studies on a peptide-based COVID-19 vaccine. All other authors report no potential conflicts of interest. EDAT- 2022/02/10 06:00 MHDA- 2022/08/16 06:00 PMCR- 2023/03/03 CRDT- 2022/02/09 06:00 PHST- 2021/11/18 00:00 [received] PHST- 2022/02/07 00:00 [accepted] PHST- 2022/02/10 06:00 [pubmed] PHST- 2022/08/16 06:00 [medline] PHST- 2022/02/09 06:00 [entrez] PHST- 2023/03/03 00:00 [pmc-release] AID - 6524526 [pii] AID - jiac042 [pii] AID - 10.1093/infdis/jiac042 [doi] PST - ppublish SO - J Infect Dis. 2022 Aug 12;226(1):23-31. doi: 10.1093/infdis/jiac042. PMID- 35134333 OWN - NLM STAT- MEDLINE DCOM- 20220315 LR - 20260127 IS - 1934-6069 (Electronic) IS - 1931-3128 (Print) IS - 1931-3128 (Linking) VI - 30 IP - 3 DP - 2022 Mar 9 TI - Persistent B cell memory after SARS-CoV-2 vaccination is functional during breakthrough infections. PG - 400-408.e4 LID - S1931-3128(22)00039-7 [pii] LID - 10.1016/j.chom.2022.01.003 [doi] AB - Breakthrough SARS-CoV-2 infections in fully vaccinated individuals are considered a consequence of waning immunity. Serum antibodies represent the most measurable outcome of vaccine-induced B cell memory. When antibodies decline, memory B cells are expected to persist and perform their function, preventing clinical disease. We investigated whether BNT162b2 mRNA vaccine induces durable and functional B cell memory in vivo against SARS-CoV-2 3, 6, and 9 months after the second dose in a cohort of health care workers (HCWs). While we observed physiological decline of SARS-CoV-2-specific antibodies, memory B cells persist and increase until 9 months after immunization. HCWs with breakthrough infections had no signs of waning immunity. In 3-4 days, memory B cells responded to SARS-CoV-2 infection by producing high levels of specific antibodies in the serum and anti-Spike IgA in the saliva. Antibodies to the viral nucleoprotein were produced with the slow kinetics typical of the response to a novel antigen. CI - Copyright (c) 2022 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Terreri, Sara AU - Terreri S AD - Diagnostic Immunology Research Unit, Multimodal Medicine Research Area, Bambino Gesu Children's Hospital, IRCCS; Viale di San Paolo, 15, 00146 Rome, Italy. FAU - Piano Mortari, Eva AU - Piano Mortari E AD - Diagnostic Immunology Research Unit, Multimodal Medicine Research Area, Bambino Gesu Children's Hospital, IRCCS; Viale di San Paolo, 15, 00146 Rome, Italy. FAU - Vinci, Maria Rosaria AU - Vinci MR AD - Occupational Medicine/Health Technology Assessment and Safety Research Unit, Clinical-Technological Innovations Research Area, Bambino Gesu Children's Hospital, IRCCS, Viale di San Paolo, 15, 00146 Rome, Italy. FAU - Russo, Cristina AU - Russo C AD - Microbiology and Diagnostic Immunology Unit, Bambino Gesu Children's Hospital, IRCCS; Piazza Sant'Onofrio, 4, 00165 Rome, Italy. FAU - Alteri, Claudia AU - Alteri C AD - Microbiology and Diagnostic Immunology Unit, Bambino Gesu Children's Hospital, IRCCS; Piazza Sant'Onofrio, 4, 00165 Rome, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Via festa del Perdono, 7, 20122 Milan, Italy. FAU - Albano, Christian AU - Albano C AD - Diagnostic Immunology Research Unit, Multimodal Medicine Research Area, Bambino Gesu Children's Hospital, IRCCS; Viale di San Paolo, 15, 00146 Rome, Italy. FAU - Colavita, Francesca AU - Colavita F AD - Laboratory of virology, National Institute for Infectious Diseases "L. Spallanzani" IRCCS, Via Portuense, 292, 00149 Rome, Italy. FAU - Gramigna, Giulia AU - Gramigna G AD - Laboratory of virology, National Institute for Infectious Diseases "L. Spallanzani" IRCCS, Via Portuense, 292, 00149 Rome, Italy. FAU - Agrati, Chiara AU - Agrati C AD - Laboratory of Cellular Immunology, National Institute for Infectious Diseases "L. Spallanzani" IRCCS, Via Portuense, 292, 00149 Rome, Italy. FAU - Linardos, Giulia AU - Linardos G AD - Microbiology and Diagnostic Immunology Unit, Bambino Gesu Children's Hospital, IRCCS; Piazza Sant'Onofrio, 4, 00165 Rome, Italy. FAU - Coltella, Luana AU - Coltella L AD - Microbiology and Diagnostic Immunology Unit, Bambino Gesu Children's Hospital, IRCCS; Piazza Sant'Onofrio, 4, 00165 Rome, Italy. FAU - Colagrossi, Luna AU - Colagrossi L AD - Microbiology and Diagnostic Immunology Unit, Bambino Gesu Children's Hospital, IRCCS; Piazza Sant'Onofrio, 4, 00165 Rome, Italy. FAU - Deriu, Gloria AU - Deriu G AD - Occupational Medicine/Health Technology Assessment and Safety Research Unit, Clinical-Technological Innovations Research Area, Bambino Gesu Children's Hospital, IRCCS, Viale di San Paolo, 15, 00146 Rome, Italy. FAU - Ciofi Degli Atti, Marta AU - Ciofi Degli Atti M AD - Clinical Pathways and Epidemiology Function Area, Bambino Gesu Children's Hospital, IRCCS; Piazza Sant'Onofrio, 4, 00165 Rome, Italy. FAU - Rizzo, Caterina AU - Rizzo C AD - Clinical Pathways and Epidemiology Function Area, Bambino Gesu Children's Hospital, IRCCS; Piazza Sant'Onofrio, 4, 00165 Rome, Italy. FAU - Scarsella, Marco AU - Scarsella M AD - Flow Cytometry Core Facility, Research Centre, Bambino Gesu Children's Hospital, Viale di San Paolo, 15, 00146 Rome, Italy. FAU - Brugaletta, Rita AU - Brugaletta R AD - Occupational Medicine/Health Technology Assessment and Safety Research Unit, Clinical-Technological Innovations Research Area, Bambino Gesu Children's Hospital, IRCCS, Viale di San Paolo, 15, 00146 Rome, Italy. FAU - Camisa, Vincenzo AU - Camisa V AD - Occupational Medicine/Health Technology Assessment and Safety Research Unit, Clinical-Technological Innovations Research Area, Bambino Gesu Children's Hospital, IRCCS, Viale di San Paolo, 15, 00146 Rome, Italy. FAU - Santoro, Annapaola AU - Santoro A AD - Occupational Medicine/Health Technology Assessment and Safety Research Unit, Clinical-Technological Innovations Research Area, Bambino Gesu Children's Hospital, IRCCS, Viale di San Paolo, 15, 00146 Rome, Italy. FAU - Roscilli, Giuseppe AU - Roscilli G AD - Takis s.r.l., Via di Castel Romano, 100, 00128 Rome, Italy. FAU - Pavoni, Emiliano AU - Pavoni E AD - Takis s.r.l., Via di Castel Romano, 100, 00128 Rome, Italy. FAU - Muzi, Alessia AU - Muzi A AD - Takis s.r.l., Via di Castel Romano, 100, 00128 Rome, Italy. FAU - Magnavita, Nicola AU - Magnavita N AD - Post-Graduate School of Occupational Health, Section of Occupational Medicine and Labor Law, University Cattolica del Sacro Cuore; Largo Francesco Vito, 1, 00168 Rome, Italy. FAU - Scutari, Rossana AU - Scutari R AD - Microbiology and Diagnostic Immunology Unit, Bambino Gesu Children's Hospital, IRCCS; Piazza Sant'Onofrio, 4, 00165 Rome, Italy. FAU - Villani, Alberto AU - Villani A AD - Department of Emergency Medicine and General Pediatrics, Bambino Gesu Children's Hospital, IRCCS; Piazza Sant'Onofrio, 4, 00165 Rome, Italy. FAU - Raponi, Massimiliano AU - Raponi M AD - Medical Direction, Bambino Gesu Children's Hospital, IRCCS; Piazza Sant'Onofrio, 4, 00165 Rome, Italy. FAU - Locatelli, Franco AU - Locatelli F AD - Department of Pediatric Hematology and Oncology, Bambino Gesu Children's Hospital, IRCCS; Piazza Sant'Onofrio, 4, 00165 Rome, Italy; Sapienza, University of Rome; Viale dell'Universita, 37, 00185 Rome, Italy. FAU - Perno, Carlo Federico AU - Perno CF AD - Microbiology and Diagnostic Immunology Unit, Bambino Gesu Children's Hospital, IRCCS; Piazza Sant'Onofrio, 4, 00165 Rome, Italy. FAU - Zaffina, Salvatore AU - Zaffina S AD - Occupational Medicine/Health Technology Assessment and Safety Research Unit, Clinical-Technological Innovations Research Area, Bambino Gesu Children's Hospital, IRCCS, Viale di San Paolo, 15, 00146 Rome, Italy. FAU - Carsetti, Rita AU - Carsetti R AD - Diagnostic Immunology Research Unit, Multimodal Medicine Research Area, Bambino Gesu Children's Hospital, IRCCS; Viale di San Paolo, 15, 00146 Rome, Italy; Microbiology and Diagnostic Immunology Unit, Bambino Gesu Children's Hospital, IRCCS; Piazza Sant'Onofrio, 4, 00165 Rome, Italy. Electronic address: rita.carsetti@opbg.net. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220125 PL - United States TA - Cell Host Microbe JT - Cell host & microbe JID - 101302316 RN - 0 (Antibodies, Viral) RN - 0 (BNT162 Vaccine) RN - 0 (COVID-19 Vaccines) RN - 0 (Vaccines, Synthetic) RN - 0 (mRNA Vaccines) SB - IM MH - Antibodies, Viral MH - BNT162 Vaccine MH - *COVID-19/prevention & control MH - COVID-19 Vaccines MH - Humans MH - *SARS-CoV-2 MH - Vaccination MH - Vaccines, Synthetic MH - mRNA Vaccines PMC - PMC8820949 OTO - NOTNLM OT - COVID-19 OT - SARS-CoV-2 OT - breakthrough infections OT - mRNA vaccine OT - memory B cells OT - mucosal immunity OT - salivary IgA OT - waning immunity COIS- Declaration of interests All authors declare no competing interests. EDAT- 2022/02/09 06:00 MHDA- 2022/03/16 06:00 PMCR- 2022/01/25 CRDT- 2022/02/08 20:15 PHST- 2021/11/17 00:00 [received] PHST- 2021/12/24 00:00 [revised] PHST- 2022/01/10 00:00 [accepted] PHST- 2022/02/09 06:00 [pubmed] PHST- 2022/03/16 06:00 [medline] PHST- 2022/02/08 20:15 [entrez] PHST- 2022/01/25 00:00 [pmc-release] AID - S1931-3128(22)00039-7 [pii] AID - 10.1016/j.chom.2022.01.003 [doi] PST - ppublish SO - Cell Host Microbe. 2022 Mar 9;30(3):400-408.e4. doi: 10.1016/j.chom.2022.01.003. Epub 2022 Jan 25. PMID- 35112364 OWN - NLM STAT- MEDLINE DCOM- 20220330 LR - 20260127 IS - 1096-9071 (Electronic) IS - 0146-6615 (Print) IS - 0146-6615 (Linking) VI - 94 IP - 5 DP - 2022 May TI - Comparison of immune responses induced by two or three doses of an alum-adjuvanted inactivated SARS-CoV-2 vaccine in mice. PG - 2250-2258 LID - 10.1002/jmv.27637 [doi] AB - Waning antibodies and rapidly emerging variants are challenges for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine development. Adjusting existing immunization schedules and further boosting strategies are under consideration. Here, the immune responses induced by an alum-adjuvanted inactivated SARS-CoV-2 vaccine in mice were compared among immunization schedules with two or three doses. For the two-dose schedule, a 0-28-day schedule induced 5-fold stronger spike-specific IgG responses than a 0-14-day schedule, with only a slight elevation of spike-specific cellular immunity 14 days after the last immunization. A third homologous boost 2 or 5 months after the second dose for the 0-28-day schedule slightly strengthened humoral responses (1.3-fold for the 0-1-3-month schedule, and 1.8-fold for the 0-1-6-month schedule) 14 days after the last immunization. Additionally, a third homologous boost (especially with the 0-1-3-month schedule) induced significantly stronger cell-mediated immunity than both two-dose immunization schedules for all indexes tested, with a response similar to that induced by a one-dose heterologous boost with BNT162b2 in clinical trials, according to cellular immunity analysis (1.5-fold). These T cell responses were Th2 oriented, with good CD4+ and CD8+ memory. These results may offer clues for applying a homologous boosting strategy for alum-adjuvanted inactivated SARS-CoV-2 vaccines. CI - (c) 2022 Wiley Periodicals LLC. FAU - Luan, Ning AU - Luan N AD - Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, Yunnan, China. FAU - Wang, Yunfei AU - Wang Y AD - Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, Yunnan, China. FAU - Cao, Han AU - Cao H AD - Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, Yunnan, China. FAU - Lin, Kangyang AU - Lin K AD - Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, Yunnan, China. FAU - Liu, Cunbao AU - Liu C AUID- ORCID: 0000-0002-2101-2612 AD - Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, Yunnan, China. LA - eng GR - Funds for High-level Scientific and Technological Talents Selection Special Project of Yunnan Province/ GR - Basic Research Projects of Yunnan Province/ GR - Funds for the Training of High-Level Health Technical Personnel in Yunnan Province/ GR - National Key R&D Program of China/ GR - China Health and Longevity Innovation/ GR - Special Biomedicine Projects of Yunnan Province/ GR - Major Science and Technology Special Projects of Yunnan Province/ GR - CAMS Innovation Fund for Medical Sciences (CIFMS)/ PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220208 PL - United States TA - J Med Virol JT - Journal of medical virology JID - 7705876 RN - 0 (Alum Compounds) RN - 0 (Antibodies, Neutralizing) RN - 0 (Antibodies, Viral) RN - 0 (BNT162 Vaccine) RN - 0 (COVID-19 Vaccines) RN - 0 (Immunoglobulin G) RN - 0 (Spike Glycoprotein, Coronavirus) RN - 0 (spike protein, SARS-CoV-2) RN - 34S289N54E (aluminum sulfate) SB - IM MH - Alum Compounds MH - Animals MH - Antibodies, Neutralizing MH - Antibodies, Viral MH - BNT162 Vaccine MH - *COVID-19/prevention & control MH - *COVID-19 Vaccines MH - Humans MH - Immunity, Cellular MH - Immunoglobulin G MH - Mice MH - SARS-CoV-2 MH - Spike Glycoprotein, Coronavirus PMC - PMC9015325 OTO - NOTNLM OT - alum-adjuvanted inactivated SARS-CoV-2 vaccine OT - boost OT - cellular immunity OT - humoral response OT - immunization schedule OT - memory COIS- The authors declare that there are no conflicts of interest. EDAT- 2022/02/04 06:00 MHDA- 2022/03/31 06:00 PMCR- 2022/02/08 CRDT- 2022/02/03 05:38 PHST- 2022/01/27 00:00 [revised] PHST- 2022/01/18 00:00 [received] PHST- 2022/01/29 00:00 [accepted] PHST- 2022/02/04 06:00 [pubmed] PHST- 2022/03/31 06:00 [medline] PHST- 2022/02/03 05:38 [entrez] PHST- 2022/02/08 00:00 [pmc-release] AID - JMV27637 [pii] AID - 10.1002/jmv.27637 [doi] PST - ppublish SO - J Med Virol. 2022 May;94(5):2250-2258. doi: 10.1002/jmv.27637. Epub 2022 Feb 8. PMID- 35096408 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220201 IS - 2055-2076 (Print) IS - 2055-2076 (Electronic) IS - 2055-2076 (Linking) VI - 8 DP - 2022 Jan-Dec TI - Online Public Attention of COVID-19 Vaccination in Mainland China. PG - 20552076211070454 LID - 10.1177/20552076211070454 [doi] LID - 20552076211070454 AB - With the approval of the vaccine in mainland China, concerns over its safety and efficacy emerged. Since the Chinese vaccine has been promoted by the Chinese government for months and got emergency approval from the World Health Organization. The Chinese vaccination program is yet to be identified from the perspective of local populations. The COVID-19 vaccine-related keywords for the period from January 2019 to April 2021 were examined and queried from the Baidu search index. The searching popularity, searching trend, demographic distributions and users' demand were analyzed. The first vaccine enquiry emerged on 25th January 2020, and 17 vaccination keywords were retrieved and with a total BSI value of 13,708,853. The average monthly searching trend growth is 21.05% (p < 0.05) and was led by people aged 20-29 (39.22%) years old. Over 54.93% of the demand term search were pandemic relevant, and the summed vaccine demand ratio was 44.79%. With the rising search population in COVID-19 vaccination, education programs and materials should be designed for teens and people above the 40 s. Also, vaccine-related birth safety should be alerted and further investigated. CI - (c) The Author(s) 2022. FAU - Jiang, Lisha AU - Jiang L AUID- ORCID: 0000-0002-5602-3792 AD - Day Surgery Center, Sichuan University West China Hospital, Chengdu, P.R China. RINGGOLD: 34753 FAU - Ma, Qingxin AU - Ma Q AD - Healthcare Department, Sichuan University West China Hospital, Chengdu, P.R China. RINGGOLD: 34753 FAU - Wei, Shanzun AU - Wei S AD - Department of Urology, Sichuan University West China Hospital, Chengdu, P.R China. RINGGOLD: 34753 AD - Department of Urology, The Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, P.R China. RINGGOLD: 144991 FAU - Che, Guowei AU - Che G AD - Department of Thoracic Surgery, Sichuan University West China hospital, Chengdu, P.R China. RINGGOLD: 34753 LA - eng PT - Journal Article DEP - 20220120 PL - United States TA - Digit Health JT - Digital health JID - 101690863 PMC - PMC8796085 OTO - NOTNLM OT - Baidu search index OT - COVID-19 OT - infodemiology OT - vaccine COIS- Declaration of conflicting interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2022/02/01 06:00 MHDA- 2022/02/01 06:01 PMCR- 2022/01/20 CRDT- 2022/01/31 05:58 PHST- 2021/08/17 00:00 [received] PHST- 2021/12/14 00:00 [accepted] PHST- 2022/01/31 05:58 [entrez] PHST- 2022/02/01 06:00 [pubmed] PHST- 2022/02/01 06:01 [medline] PHST- 2022/01/20 00:00 [pmc-release] AID - 10.1177_20552076211070454 [pii] AID - 10.1177/20552076211070454 [doi] PST - epublish SO - Digit Health. 2022 Jan 20;8:20552076211070454. doi: 10.1177/20552076211070454. eCollection 2022 Jan-Dec. PMID- 35095267 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240829 IS - 1172-0360 (Print) IS - 1179-1977 (Electronic) IS - 1172-0360 (Linking) VI - 38 IP - 2 DP - 2022 TI - Adverse drug reactions from two COVID-19 vaccines reported in Saudi Arabia. PG - 84-92 LID - 10.1007/s40267-022-00893-y [doi] AB - BACKGROUND: Several reports have been published about the impact of coronavirus disease 2019 (COVID-19) vaccines on human health, and each vaccine has a different safety and efficacy profile. The aim of this study was to reveal the nature and classification of reported adverse drug reactions (ADRs) of the two COVID-19 vaccines (tozinameran and ChAdOx1) among citizens and residents living in Saudi Arabia, and show possible differences between the two vaccines and the differences between each batch on the health of populations. METHODS: A cross-sectional study was conducted in Saudi Arabia between December 2020 and March 2021. Saudi citizens and residents aged >/= 16 years who had at least one dose of any batch of either of the two approved COVID-19 vaccines (tozinameran and ChAdOx1) and who reported at least one ADR from the vaccines were included. The study excluded people who reported ADRs after receiving tozinameran or ChAdOx1 vaccines but no information was provided about the vaccine's batch number. RESULTS: During the study period, 12,868 vaccinated people, including a high-risk group (i.e., those with chronic illness or pregnant women), reported COVID-19 vaccine ADRs that had been documented in the General Directorate of Medical Consultations, Saudi Ministry of Health. The study reported several ADRs associated with COVID-19 vaccines, with the most common (> 25%) being fever/chills, general pain/weakness, headache, and injection site reactions. Among healthy and high-risk people, the median onset of all reported ADRs for tozinameran and ChAdOx1 vaccine batches were 1.96 and 1.64 days, respectively (p < 0.01). Furthermore, significant differences (p < 0.05) were recorded between the two studied vaccines in regard to fever/chills, gastrointestinal symptoms, headache, general pain/weakness, and neurological symptoms, with higher incidence rates of these ADRs observed with the ChAdOx1 vaccine than the tozinameran vaccine. However, the tozinameran vaccine was found to cause significantly (p < 0.05) more palpitation, blood pressure variations, upper respiratory tract symptoms, lymph node swelling, and other unspecified ADRs than the ChAdOx1 vaccine. Among patients vaccinated with seven different batches of the tozinameran vaccine, people vaccinated with the T4 and T5 batches reported the most ADRs. CONCLUSION: There were significant differences regarding most of the reported ADRs and their onset among tozinameran and ChAdOx1 vaccines on both healthy people and high-risk individuals living in Saudi Arabia. Moreover, the study found that the frequencies of most listed ADRs were statistically different when seven batches of tozinameran vaccine were compared. CI - (c) The Author(s), under exclusive licence to Springer Nature Switzerland AG 2022. FAU - Alfaleh, Amjad AU - Alfaleh A AUID- ORCID: 0000-0003-4375-8834 AD - Department of Research, General Directorate of Medical Consultations, Ministry of Health, Riyadh, Saudi Arabia. GRID: grid.415696.9. ISNI: 0000 0004 0573 9824 AD - Research and Development Department, General Directorate of School Health, Ministry of Health, Riyadh, Saudi Arabia. GRID: grid.415696.9. ISNI: 0000 0004 0573 9824 FAU - Alkattan, Abdullah AU - Alkattan A AUID- ORCID: 0000-0001-5294-8088 AD - Department of Research, General Directorate of Medical Consultations, Ministry of Health, Riyadh, Saudi Arabia. GRID: grid.415696.9. ISNI: 0000 0004 0573 9824 AD - Research and Development Department, General Directorate of School Health, Ministry of Health, Riyadh, Saudi Arabia. GRID: grid.415696.9. ISNI: 0000 0004 0573 9824 FAU - Radwan, Nashwa AU - Radwan N AD - Department of Public Health and Community Medicine, Faculty of Medicine, Tanta University, Tanta, Egypt. GRID: grid.412258.8. ISNI: 0000 0000 9477 7793 AD - Department of Research, Assisting Deputyship for Primary Health Care, Ministry of Health, Riyadh, Saudi Arabia. GRID: grid.415696.9. ISNI: 0000 0004 0573 9824 FAU - Elzohri, Mona AU - Elzohri M AD - Department of Research, General Directorate of Medical Consultations, Ministry of Health, Riyadh, Saudi Arabia. GRID: grid.415696.9. ISNI: 0000 0004 0573 9824 AD - Department of Internal Medicine, Rheumatology and Clinical Immunology Unit, Faculty of Medicine, Assiut University, Asyut, Egypt. GRID: grid.252487.e. ISNI: 0000 0000 8632 679X FAU - Alzaher, Abrar AU - Alzaher A AD - Research and Development Department, General Directorate of School Health, Ministry of Health, Riyadh, Saudi Arabia. GRID: grid.415696.9. ISNI: 0000 0004 0573 9824 FAU - Ibrahim, Mona AU - Ibrahim M AD - Research and Development Department, General Directorate of School Health, Ministry of Health, Riyadh, Saudi Arabia. GRID: grid.415696.9. ISNI: 0000 0004 0573 9824 AD - Department of Community, Environmental and Occupational Medicine, Faculty of Medicine, Zagazig University, Zagazig, Egypt. GRID: grid.31451.32. ISNI: 0000 0001 2158 2757 FAU - Alsalameen, Eman AU - Alsalameen E AD - Department of Pharmacy, King Khalid University Hospital, Medical City King Saud University, Riyadh, Saudi Arabia. GRID: grid.56302.32. ISNI: 0000 0004 1773 5396 FAU - Alsultan, Amani AU - Alsultan A AD - Department of Sales, Sanofi Aventis Arabia, Jeddah, Saudi Arabia. FAU - Alhabib, Dina AU - Alhabib D AD - Research and Development Department, General Directorate of School Health, Ministry of Health, Riyadh, Saudi Arabia. GRID: grid.415696.9. ISNI: 0000 0004 0573 9824 FAU - Alshelwah, Alanood AU - Alshelwah A AD - Research and Development Department, General Directorate of School Health, Ministry of Health, Riyadh, Saudi Arabia. GRID: grid.415696.9. ISNI: 0000 0004 0573 9824 FAU - Mahmoud, Nagla AU - Mahmoud N AD - Department of Research, Assisting Deputyship for Primary Health Care, Ministry of Health, Riyadh, Saudi Arabia. GRID: grid.415696.9. ISNI: 0000 0004 0573 9824 FAU - Sagor, Khlood AU - Sagor K AD - Research and Development Department, General Directorate of School Health, Ministry of Health, Riyadh, Saudi Arabia. GRID: grid.415696.9. ISNI: 0000 0004 0573 9824 FAU - Alabdulkareem, Khaled AU - Alabdulkareem K AD - Department of Research, Assisting Deputyship for Primary Health Care, Ministry of Health, Riyadh, Saudi Arabia. GRID: grid.415696.9. ISNI: 0000 0004 0573 9824 AD - Department of Family Medicine, College of Medicine, Al-Imam Mohammad Bin Saud Islamic University, Riyadh, Saudi Arabia. LA - eng PT - Journal Article DEP - 20220122 PL - New Zealand TA - Drugs Ther Perspect JT - Drugs & therapy perspectives : for rational drug selection and use JID - 9308798 PMC - PMC8783585 COIS- Competing interestsAmjad Alfaleh, Abdullah Alkattan, Nashwa Radwan, Mona Elzohri, Abrar Alzaher, Mona Ibrahim, Eman Alsalameen, Amani Alsultan, Dina Alhabib, Alanood Alshelwah, Nagla Mahmoud, Khlood Sagor, and Khaled Alabdulkareem have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript, including employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. EDAT- 2022/02/01 06:00 MHDA- 2022/02/01 06:01 PMCR- 2022/01/22 CRDT- 2022/01/31 05:54 PHST- 2022/01/04 00:00 [accepted] PHST- 2022/02/01 06:00 [pubmed] PHST- 2022/02/01 06:01 [medline] PHST- 2022/01/31 05:54 [entrez] PHST- 2022/01/22 00:00 [pmc-release] AID - 893 [pii] AID - 10.1007/s40267-022-00893-y [doi] PST - ppublish SO - Drugs Ther Perspect. 2022;38(2):84-92. doi: 10.1007/s40267-022-00893-y. Epub 2022 Jan 22. PMID- 35090164 OWN - NLM STAT- MEDLINE DCOM- 20220415 LR - 20261002 IS - 1476-4687 (Electronic) IS - 0028-0836 (Print) IS - 0028-0836 (Linking) VI - 603 IP - 7903 DP - 2022 Mar TI - Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-2 variants. PG - 919-925 LID - 10.1038/s41586-022-04466-x [doi] AB - Omicron (B.1.1.529), the most heavily mutated SARS-CoV-2 variant so far, is highly resistant to neutralizing antibodies, raising concerns about the effectiveness of antibody therapies and vaccines(1,2). Here we examined whether sera from individuals who received two or three doses of inactivated SARS-CoV-2 vaccine could neutralize authentic Omicron. The seroconversion rates of neutralizing antibodies were 3.3% (2 out of 60) and 95% (57 out of 60) for individuals who had received 2 and 3 doses of vaccine, respectively. For recipients of three vaccine doses, the geometric mean neutralization antibody titre for Omicron was 16.5-fold lower than for the ancestral virus (254). We isolated 323 human monoclonal antibodies derived from memory B cells in triple vaccinees, half of which recognized the receptor-binding domain, and showed that a subset (24 out of 163) potently neutralized all SARS-CoV-2 variants of concern, including Omicron. Therapeutic treatments with representative broadly neutralizing monoclonal antibodies were highly protective against infection of mice with SARS-CoV-2 Beta (B.1.351) and Omicron. Atomic structures of the Omicron spike protein in complex with three classes of antibodies that were active against all five variants of concern defined the binding and neutralizing determinants and revealed a key antibody escape site, G446S, that confers greater resistance to a class of antibodies that bind on the right shoulder of the receptor-binding domain by altering local conformation at the binding interface. Our results rationalize the use of three-dose immunization regimens and suggest that the fundamental epitopes revealed by these broadly ultrapotent antibodies are rational targets for a universal sarbecovirus vaccine. CI - (c) 2022. The Author(s). FAU - Wang, Kang AU - Wang K AD - CAS Key Laboratory of Infection and Immunity, National Laboratory of Macromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China. FAU - Jia, Zijing AU - Jia Z AD - CAS Key Laboratory of Infection and Immunity, National Laboratory of Macromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China. AD - University of Chinese Academy of Sciences, Beijing, China. FAU - Bao, Linilin AU - Bao L AD - Key Laboratory of Human Disease Comparative Medicine, Chinese Ministry of Health, Beijing Key Laboratory for Animal Models of Emerging and Remerging Infectious Diseases, Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Comparative Medicine Center, Peking Union Medical College, Beijing, China. FAU - Wang, Lei AU - Wang L AD - CAS Key Laboratory of Infection and Immunity, National Laboratory of Macromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China. AD - University of Chinese Academy of Sciences, Beijing, China. FAU - Cao, Lei AU - Cao L AD - CAS Key Laboratory of Infection and Immunity, National Laboratory of Macromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China. FAU - Chi, Hang AU - Chi H AD - State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology AMMS, Beijing, China. FAU - Hu, Yaling AU - Hu Y AD - Sinovac Biotech, Beijing, China. FAU - Li, Qianqian AU - Li Q AD - Division of HIV/AIDS and Sex-Transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, China. FAU - Zhou, Yunjiao AU - Zhou Y AD - Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), Shanghai Institute of Infectious Disease and Biosecurity, Shanghai Frontiers Science Center of Pathogenic Microbes and Infection, School of Basic Medical Sciences, Shanghai Medical College, Fudan University, Shanghai, China. FAU - Jiang, Yinan AU - Jiang Y AD - Acrobiosystems, Beijing, China. FAU - Zhu, Qianhui AU - Zhu Q AD - CAS Key Laboratory of Infection and Immunity, National Laboratory of Macromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China. AD - University of Chinese Academy of Sciences, Beijing, China. FAU - Deng, Yongqiang AU - Deng Y AUID- ORCID: 0000-0002-2306-1039 AD - State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology AMMS, Beijing, China. FAU - Liu, Pan AU - Liu P AD - CAS Key Laboratory of Infection and Immunity, National Laboratory of Macromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China. AD - University of Chinese Academy of Sciences, Beijing, China. FAU - Wang, Nan AU - Wang N AD - CAS Key Laboratory of Infection and Immunity, National Laboratory of Macromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China. FAU - Wang, Lin AU - Wang L AUID- ORCID: 0000-0002-2571-4320 AD - Sinovac Biotech, Beijing, China. FAU - Liu, Min AU - Liu M AD - Sinovac Biotech, Beijing, China. FAU - Li, Yurong AU - Li Y AD - Sinovac Biotech, Beijing, China. FAU - Zhu, Boling AU - Zhu B AD - CAS Key Laboratory of Infection and Immunity, National Laboratory of Macromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China. FAU - Fan, Kaiyue AU - Fan K AD - CAS Key Laboratory of Infection and Immunity, National Laboratory of Macromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China. AD - University of Chinese Academy of Sciences, Beijing, China. FAU - Fu, Wangjun AU - Fu W AD - CAS Key Laboratory of Infection and Immunity, National Laboratory of Macromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China. AD - University of Chinese Academy of Sciences, Beijing, China. FAU - Yang, Peng AU - Yang P AD - CAS Key Laboratory of Infection and Immunity, National Laboratory of Macromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China. AD - University of Chinese Academy of Sciences, Beijing, China. FAU - Pei, Xinran AU - Pei X AD - CAS Key Laboratory of Infection and Immunity, National Laboratory of Macromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China. FAU - Cui, Zhen AU - Cui Z AD - CAS Key Laboratory of Infection and Immunity, National Laboratory of Macromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China. AD - University of Chinese Academy of Sciences, Beijing, China. FAU - Qin, Lili AU - Qin L AUID- ORCID: 0000-0002-0700-0180 AD - Acrobiosystems, Beijing, China. FAU - Ge, Pingju AU - Ge P AD - Acrobiosystems, Beijing, China. FAU - Wu, Jiajing AU - Wu J AD - Division of HIV/AIDS and Sex-Transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, China. FAU - Liu, Shuo AU - Liu S AD - Division of HIV/AIDS and Sex-Transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, China. FAU - Chen, Yiding AU - Chen Y AD - Acrobiosystems, Beijing, China. FAU - Huang, Weijin AU - Huang W AUID- ORCID: 0000-0002-4246-8889 AD - Division of HIV/AIDS and Sex-Transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, China. FAU - Wang, Qiao AU - Wang Q AD - Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), Shanghai Institute of Infectious Disease and Biosecurity, Shanghai Frontiers Science Center of Pathogenic Microbes and Infection, School of Basic Medical Sciences, Shanghai Medical College, Fudan University, Shanghai, China. wangqiao@fudan.edu.cn. FAU - Qin, Cheng-Feng AU - Qin CF AUID- ORCID: 0000-0002-0632-2807 AD - State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology AMMS, Beijing, China. qincf@bmi.ac.cn. FAU - Wang, Youchun AU - Wang Y AUID- ORCID: 0000-0001-9769-5141 AD - Division of HIV/AIDS and Sex-Transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, China. wangyc@nifdc.org.cn. FAU - Qin, Chuan AU - Qin C AUID- ORCID: 0000-0002-6261-1232 AD - Key Laboratory of Human Disease Comparative Medicine, Chinese Ministry of Health, Beijing Key Laboratory for Animal Models of Emerging and Remerging Infectious Diseases, Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Comparative Medicine Center, Peking Union Medical College, Beijing, China. qinchuan@pumc.edu.cn. FAU - Wang, Xiangxi AU - Wang X AUID- ORCID: 0000-0003-0635-278X AD - CAS Key Laboratory of Infection and Immunity, National Laboratory of Macromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China. xiangxi@ibp.ac.cn. AD - University of Chinese Academy of Sciences, Beijing, China. xiangxi@ibp.ac.cn. LA - eng PT - Journal Article DEP - 20220128 PL - England TA - Nature JT - Nature JID - 0410462 RN - 0 (Antibodies, Monoclonal) RN - 0 (Antibodies, Neutralizing) RN - 0 (Antibodies, Viral) RN - 0 (COVID-19 Vaccines) RN - 0 (Spike Glycoprotein, Coronavirus) RN - 0 (spike protein, SARS-CoV-2) RN - SARS-CoV-2 variants SB - IM CIN - Signal Transduct Target Ther. 2022 Apr 5;7(1):115. doi: 10.1038/s41392-022-00973-5. PMID: 35383164 MH - Animals MH - Antibodies, Monoclonal/immunology/isolation & purification/therapeutic use MH - Antibodies, Neutralizing/immunology/isolation & purification/therapeutic use MH - Antibodies, Viral/immunology/isolation & purification/therapeutic use MH - *COVID-19/immunology/prevention & control/virology MH - *COVID-19 Vaccines/administration & dosage/immunology MH - Disease Models, Animal MH - Humans MH - *Memory B Cells/immunology MH - Mice MH - Neutralization Tests MH - *SARS-CoV-2/classification/genetics/immunology MH - Spike Glycoprotein, Coronavirus/immunology PMC - PMC8967717 COIS- Y.H., Lin Wang and M.L. are employees of Sinovac Biotech Ltd. Y.J., P.G. and Y.C. are employees of Acrobiosystems Inc. The other authors declare no competing interests. EDAT- 2022/01/29 06:00 MHDA- 2022/04/16 06:00 PMCR- 2022/01/28 CRDT- 2022/01/28 20:04 PHST- 2021/12/22 00:00 [received] PHST- 2022/01/20 00:00 [accepted] PHST- 2022/01/29 06:00 [pubmed] PHST- 2022/04/16 06:00 [medline] PHST- 2022/01/28 20:04 [entrez] PHST- 2022/01/28 00:00 [pmc-release] AID - 10.1038/s41586-022-04466-x [pii] AID - 4466 [pii] AID - 10.1038/s41586-022-04466-x [doi] PST - ppublish SO - Nature. 2022 Mar;603(7903):919-925. doi: 10.1038/s41586-022-04466-x. Epub 2022 Jan 28. PMID- 35062869 OWN - NLM STAT- MEDLINE DCOM- 20220125 LR - 20220531 IS - 1129-2377 (Electronic) IS - 1129-2369 (Print) IS - 1129-2369 (Linking) VI - 23 IP - 1 DP - 2022 Jan 21 TI - Prolonged migraine aura resembling ischemic stroke following CoronaVac vaccination: an extended case series. PG - 13 LID - 10.1186/s10194-022-01385-0 [doi] LID - 13 AB - BACKGROUND: After the initiation of the COVID-19 vaccination program in Thailand, thousands of patients have experienced unusual focal neurological symptoms. We report 8 patients with focal neurological symptoms after receiving inactivated virus vaccine, CoronaVac. CASE SERIES: Patients were aged 24-48 years and 75% were female. Acute onset of focal neurological symptoms occurred within the first 24 h after vaccination in 75% and between 1-7d in 25%. All presented with lateralized sensory deficits, motor deficits, or both, of 2-14 day duration. Migraine headache occurred in half of the patients. Magnetic resonance imaging of the brain during and after the attacks did not demonstrate any abnormalities suggesting ischemic stroke. All patients showed moderately large regions of hypoperfusion and concurrent smaller regions of hyperperfusion on SPECT imaging while symptomatic. None developed permanent deficits or structural brain injury. DISCUSSIONS: Here, we present a case series of transient focal neurological syndrome following Coronavac vaccination. The characteristic sensory symptoms, history of migraine, female predominant, and abnormal functional brain imaging without structural changes suggest migraine aura as pathophysiology. We propose that pain related to vaccine injection, component of vaccine, such as aluminum, or inflammation related to vaccination might trigger migraine aura in susceptible patients. CI - (c) 2022. The Author(s). FAU - Suwanwela, Nijasri C AU - Suwanwela NC AD - Division of Neurology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Rama IV Road, Bangkok, 10330, Thailand. nijasri.C@chula.ac.th. AD - Chula Neuroscience Center, King Chulalongkorn Memorial Hospital, Bangkok, Thailand. nijasri.C@chula.ac.th. AD - Chulalongkorn Stroke Center, King Chulalongkorn Memorial Hospital, Bangkok, Thailand. nijasri.C@chula.ac.th. FAU - Kijpaisalratana, Naruchorn AU - Kijpaisalratana N AD - Division of Neurology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Rama IV Road, Bangkok, 10330, Thailand. AD - Chula Neuroscience Center, King Chulalongkorn Memorial Hospital, Bangkok, Thailand. AD - Division of Academic Affairs, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. FAU - Tepmongkol, Supatporn AU - Tepmongkol S AD - Chula Neuroscience Center, King Chulalongkorn Memorial Hospital, Bangkok, Thailand. AD - Division of Nuclear Medicine, Department of Radiology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. AD - Chulalongkorn University Biomedical Imaging Group (CUBIG), Department of Radiology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. FAU - Rattanawong, Wanakorn AU - Rattanawong W AUID- ORCID: 0000-0001-7277-9699 AD - Division of Neurology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Rama IV Road, Bangkok, 10330, Thailand. wanakorn.ra@kmitl.ac.th. AD - Department of Medicine, Faculty of Medicine, King Mongkut's Institute of Technology Ladkrabang, Bangkok, Thailand. wanakorn.ra@kmitl.ac.th. FAU - Vorasayan, Pongpat AU - Vorasayan P AD - Division of Neurology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Rama IV Road, Bangkok, 10330, Thailand. AD - Chulalongkorn Stroke Center, King Chulalongkorn Memorial Hospital, Bangkok, Thailand. FAU - Charnnarong, Chutibhorn AU - Charnnarong C AD - Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. FAU - Tantivattana, Jarturon AU - Tantivattana J AD - Department of Radiology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. FAU - Roongruang, Sirigunya AU - Roongruang S AD - Division of Neurology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Rama IV Road, Bangkok, 10330, Thailand. AD - Golden Jubilee Medical Center, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand. FAU - Ongphichetmetha, Tatchaporn AU - Ongphichetmetha T AD - Division of Neurology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Rama IV Road, Bangkok, 10330, Thailand. FAU - Panjasriprakarn, Poonnakarn AU - Panjasriprakarn P AD - Division of Neurology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Rama IV Road, Bangkok, 10330, Thailand. FAU - Chutinet, Aurauma AU - Chutinet A AD - Division of Neurology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Rama IV Road, Bangkok, 10330, Thailand. AD - Chulalongkorn Stroke Center, King Chulalongkorn Memorial Hospital, Bangkok, Thailand. FAU - Akarathanawat, Wasan AU - Akarathanawat W AD - Division of Neurology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Rama IV Road, Bangkok, 10330, Thailand. AD - Chulalongkorn Stroke Center, King Chulalongkorn Memorial Hospital, Bangkok, Thailand. FAU - Saver, Jeffrey L AU - Saver JL AD - Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. LA - eng PT - Journal Article DEP - 20220121 PL - England TA - J Headache Pain JT - The journal of headache and pain JID - 100940562 RN - 0 (COVID-19 Vaccines) SB - IM MH - Adult MH - *Brain Ischemia/diagnostic imaging/etiology MH - *COVID-19 MH - COVID-19 Vaccines MH - *Epilepsy MH - Female MH - Humans MH - *Ischemic Stroke MH - Male MH - Middle Aged MH - *Migraine Disorders MH - *Migraine with Aura MH - SARS-CoV-2 MH - *Stroke/diagnostic imaging/etiology MH - Vaccination/adverse effects MH - Young Adult PMC - PMC8777408 OTO - NOTNLM OT - COVID-19 OT - CoronaVac vaccine OT - Cortical spreading depression OT - Neurological deficit OT - Sinovac COIS- All authors declare no conflict of interest in this study. EDAT- 2022/01/23 06:00 MHDA- 2022/01/27 06:00 PMCR- 2022/01/21 CRDT- 2022/01/22 05:31 PHST- 2021/12/09 00:00 [received] PHST- 2021/12/29 00:00 [accepted] PHST- 2022/01/22 05:31 [entrez] PHST- 2022/01/23 06:00 [pubmed] PHST- 2022/01/27 06:00 [medline] PHST- 2022/01/21 00:00 [pmc-release] AID - 10.1186/s10194-022-01385-0 [pii] AID - 1385 [pii] AID - 10.1186/s10194-022-01385-0 [doi] PST - epublish SO - J Headache Pain. 2022 Jan 21;23(1):13. doi: 10.1186/s10194-022-01385-0. PMID- 35059799 OWN - NLM STAT- MEDLINE DCOM- 20220301 LR - 20260127 IS - 1437-160X (Electronic) IS - 0172-8172 (Print) IS - 0172-8172 (Linking) VI - 42 IP - 3 DP - 2022 Mar TI - Interferon-gamma release assays outcomes in healthy subjects following BNT162b2 mRNA COVID-19 vaccination. PG - 449-456 LID - 10.1007/s00296-022-05091-7 [doi] AB - The pathogenesis of COVID-19 involves both humoral and cellular immunological responses, with cell-mediated immunity being discussed as the primary and most effective immune response to viral infection. It is supposed that COVID-19 vaccines also elicited effective cell immune response, and specifically IFNgamma secreted by SARS-CoV-2-specific T-helper 1 and Tcytotoxic cells. Using an interferon-gamma release assay (IGRA) test, we aimed to monitor cellular post-vaccination immunity in healthy subjects vaccinated with BNT162b2 mRNA COVID-19 vaccine (Comirnaty). We tested 37 healthcare workers (mean age 54.3 years, range 28-72, 22 females, 15 males) following COVID-19 mRNA COVID-19 vaccine and 15 healthy unvaccinated native persons as control subjects using QuantiFERON SARS-CoV-2 RUO test, performed approximately 1 month after vaccination. We also measured virus-neutralizing antibodies. Thirty-one out of 37 tested subjects had significantly raised levels of SARS-CoV-2 specific IFNgamma against SARS-CoV-2 Ag1 and Ag2 1 month following COVID-19 vaccination. In addition, we found a significant difference between the IFNgamma levels in fully vaccinated subjects and the control group (p < 0.01).We also found a substantial correlation (r = 0.9; p < 0.01) between virus-neutralizing antibodies titers and IFNgamma concentrations released by T cells. We believe that IGRA tests are an excellent tool to assess the development of a post-vaccination immune response when immunized against SARS-CoV-2. However, IGRA-based tests should be performed within a few weeks following vaccination. Therefore, we can speculate that the application of these tests to assess long-term immune response is debatable. CI - (c) 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Kurteva, Ekaterina AU - Kurteva E AUID- ORCID: 0000-0003-1968-5962 AD - Laboratory of Clinical Immunology, Unversity Hospital "St. Ivan Rilski", Akad. Ivan Geshov Blvd 15, 1431, Sofia, Bulgaria. AD - Department of Clinical Immunology, Medical University of Sofia, Sofia, Bulgaria. FAU - Vasilev, Georgi AU - Vasilev G AUID- ORCID: 0000-0002-6314-6889 AD - Laboratory of Clinical Immunology, Unversity Hospital "St. Ivan Rilski", Akad. Ivan Geshov Blvd 15, 1431, Sofia, Bulgaria. AD - Department of Clinical Immunology, Medical University of Sofia, Sofia, Bulgaria. FAU - Tumangelova-Yuzeir, Kalina AU - Tumangelova-Yuzeir K AUID- ORCID: 0000-0001-6143-7538 AD - Laboratory of Clinical Immunology, Unversity Hospital "St. Ivan Rilski", Akad. Ivan Geshov Blvd 15, 1431, Sofia, Bulgaria. AD - Department of Clinical Immunology, Medical University of Sofia, Sofia, Bulgaria. FAU - Ivanova, Irena AU - Ivanova I AUID- ORCID: 0000-0003-2369-0182 AD - Clinical Laboratory, "St. Ivan Rilski", Akad. Ivan Geshov Blvd 15, 1431, Sofia, Bulgaria. FAU - Ivanova-Todorova, Ekaterina AU - Ivanova-Todorova E AUID- ORCID: 0000-0002-1833-838X AD - Laboratory of Clinical Immunology, Unversity Hospital "St. Ivan Rilski", Akad. Ivan Geshov Blvd 15, 1431, Sofia, Bulgaria. AD - Department of Clinical Immunology, Medical University of Sofia, Sofia, Bulgaria. FAU - Velikova, Tsvetelina AU - Velikova T AUID- ORCID: 0000-0002-0593-1272 AD - Department of Clinical Immunology, University Hospital Lozenetz, Kozyak str., 1407, Sofia, Bulgaria. tsvelikova@medfac.mu-sofia.bg. AD - Sofia University St. Kliment Ohridski, Sofia, Bulgaria. tsvelikova@medfac.mu-sofia.bg. FAU - Kyurkchiev, Dobroslav AU - Kyurkchiev D AUID- ORCID: 0000-0002-8257-7764 AD - Laboratory of Clinical Immunology, Unversity Hospital "St. Ivan Rilski", Akad. Ivan Geshov Blvd 15, 1431, Sofia, Bulgaria. AD - Department of Clinical Immunology, Medical University of Sofia, Sofia, Bulgaria. LA - eng PT - Journal Article DEP - 20220120 PL - Germany TA - Rheumatol Int JT - Rheumatology international JID - 8206885 RN - 0 (BNT162 Vaccine) SB - IM MH - Adult MH - Aged MH - *BNT162 Vaccine MH - COVID-19/immunology/*prevention & control MH - Female MH - Humans MH - Immunity, Humoral/*immunology MH - Immunogenicity, Vaccine/*immunology MH - Interferon-gamma Release Tests MH - Male MH - Middle Aged MH - T-Lymphocytes/*immunology PMC - PMC8775149 OTO - NOTNLM OT - BNT162b2 vaccine OT - COVID-19 OT - Cellular immune response OT - Immune memory OT - Interferon-gamma OT - Interferon-gamma release assay OT - SARS-CoV-2 OT - T cytotoxic cells OT - T helper cells OT - mRNA COVID-19 vaccine EDAT- 2022/01/22 06:00 MHDA- 2022/03/03 06:00 PMCR- 2022/01/20 CRDT- 2022/01/21 06:31 PHST- 2021/11/13 00:00 [received] PHST- 2021/12/31 00:00 [accepted] PHST- 2022/01/22 06:00 [pubmed] PHST- 2022/03/03 06:00 [medline] PHST- 2022/01/21 06:31 [entrez] PHST- 2022/01/20 00:00 [pmc-release] AID - 10.1007/s00296-022-05091-7 [pii] AID - 5091 [pii] AID - 10.1007/s00296-022-05091-7 [doi] PST - ppublish SO - Rheumatol Int. 2022 Mar;42(3):449-456. doi: 10.1007/s00296-022-05091-7. Epub 2022 Jan 20. PMID- 35050428 OWN - NLM STAT- MEDLINE DCOM- 20220315 LR - 20220722 IS - 1590-3478 (Electronic) IS - 1590-1874 (Print) IS - 1590-1874 (Linking) VI - 43 IP - 4 DP - 2022 Apr TI - SARS-CoV-2 vaccine-related neurological complications. PG - 2295-2297 LID - 10.1007/s10072-022-05898-z [doi] AB - OBJECTIVE: To describe three cases with neurological symptoms after SARS-CoV-2 vaccination. METHODS: A case series followed by a review of the literature, describing hypotheses on how neurological symptoms might develop after vaccination. RESULTS: The different temporal relationship between the onset or worsening of different neurological symptoms suggests different pathophysiological mechanisms. Progression of post-infectious myoclonus, caused by a previous SARS-CoV-2-infection, shortly after vaccination suggests a renewed auto-immune mediated crossreaction of antibodies to both viral epitopes and central nervous system components. Thunderclap headache after vaccination suggests a similar pathophysiological mechanism to the headache and other flu-like symptoms described after vaccination against other viruses. This might be ascribed to the activation of immunoinflammatory mediators or accompanying fever. Although headache accompanied by encephalopathy and focal neurological deficit might occur as part of a cytokine release syndrome, this is clinically less likely. CONCLUSIONS: A variety of symptoms, including thunderclap headache, focal deficits and movement disorders, can occur after SARS-CoV-2 vaccination, and an activation or reactivation of the immune system is suggested as most likely cause. However, one should be careful about claiming a direct correlation. It remains important to exclude other causes, such as structural lesions, infections or subarachnoid hemorrhage, and future research is required to understand possible pathophysiological mechanisms and associations with the SARS-CoV-2 vaccine. CI - (c) 2022. Fondazione Societa Italiana di Neurologia. FAU - Oonk, Nicol G M AU - Oonk NGM AD - Department of Neurology, Medisch Spectrum Twente, Enschede, the Netherlands. n.oonk@mst.nl. FAU - Ettema, Anne Rozemarijn AU - Ettema AR AD - Department of Neurology, Medisch Spectrum Twente, Enschede, the Netherlands. FAU - van Berghem, Heleen AU - van Berghem H AD - Department of Neurology, Medisch Spectrum Twente, Enschede, the Netherlands. FAU - de Klerk, Jabke J AU - de Klerk JJ AD - TriviumMeulenbeltZorg, Borne, the Netherlands. FAU - van der Vegt, Joyce P M AU - van der Vegt JPM AD - Department of Neurology, Medisch Spectrum Twente, Enschede, the Netherlands. FAU - van der Meulen, Matthijs AU - van der Meulen M AD - Department of Neurology, Medisch Spectrum Twente, Enschede, the Netherlands. LA - eng PT - Journal Article PT - Review DEP - 20220120 PL - Italy TA - Neurol Sci JT - Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology JID - 100959175 RN - 0 (COVID-19 Vaccines) RN - 0 (Viral Vaccines) SB - IM MH - *COVID-19/complications/prevention & control MH - COVID-19 Vaccines/adverse effects MH - Humans MH - SARS-CoV-2 MH - Vaccination/adverse effects MH - *Viral Vaccines PMC - PMC8771172 OTO - NOTNLM OT - COVID-19 OT - Myoclonus OT - SARS-CoV-2 OT - Thunderclap headache OT - Vaccine COIS- The authors declare no competing interests. EDAT- 2022/01/21 06:00 MHDA- 2022/03/16 06:00 PMCR- 2022/01/20 CRDT- 2022/01/20 12:36 PHST- 2021/05/24 00:00 [received] PHST- 2022/01/13 00:00 [accepted] PHST- 2022/01/21 06:00 [pubmed] PHST- 2022/03/16 06:00 [medline] PHST- 2022/01/20 12:36 [entrez] PHST- 2022/01/20 00:00 [pmc-release] AID - 10.1007/s10072-022-05898-z [pii] AID - 5898 [pii] AID - 10.1007/s10072-022-05898-z [doi] PST - ppublish SO - Neurol Sci. 2022 Apr;43(4):2295-2297. doi: 10.1007/s10072-022-05898-z. Epub 2022 Jan 20. PMID- 35043040 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240405 IS - 1110-7782 (Print) IS - 2090-9098 (Electronic) IS - 1110-7782 (Linking) VI - 34 IP - 1 DP - 2022 TI - Two years of SARS-CoV-2 infection (2019-2021): structural biology, vaccination, and current global situation. PG - 5 LID - 10.1186/s43162-021-00092-7 [doi] LID - 5 AB - The deadly SARS-CoV-2 virus has infected more than 259,502,031 confirmed cases with 5,183,003 deaths in 223 countries during the last 22 months (Dec 2019-Nov 2021), whereas approximately 7,702,859,718, vaccine doses have been administered (WHO: https://covid19.who.int/) as of the 24th of Nov 2021. Recent announcements of test trial completion of several new vaccines resulted in the launching of immunization for the common person around the globe highlighting a ray of hope to cope with this infection. Meanwhile, genetic variations in SARS-CoV-2 and third layer of infection spread in numerous countries emerged as a stronger prototype than the parental. New and parental SARS-CoV-2 strains appeared as a risk factor for other pre-existing diseases like cancer, diabetes, neurological disorders, kidney, liver, heart, and eye injury. This situation requires more attention and re-structuring of the currently developed vaccines and/or drugs against SARS-CoV-2 infection. Although a decline in COVID-19 infection has been reported globally, an increase in COVID-19 cases in the subcontinent and east Mediterranean area could be alarming. In this review, we have summarized the current information about the SARS-CoV-2 biology, its interaction and possible infection pathways within the host, epidemiology, risk factors, economic collapse, and possible vaccine and drug development. CI - (c) The Author(s) 2022. FAU - Ahmad, Waqar AU - Ahmad W AUID- ORCID: 0000-0003-0474-6558 AD - Department of Biochemistry, College of Medicine and Health Sciences, UAE University, Al Ain, United Arab Emirates. GRID: grid.43519.3a. ISNI: 0000 0001 2193 6666 AD - The University of Queensland, Brisbane, Australia. GRID: grid.1003.2. ISNI: 0000 0000 9320 7537 FAU - Shabbiri, Khadija AU - Shabbiri K AD - The University of Queensland, Brisbane, Australia. GRID: grid.1003.2. ISNI: 0000 0000 9320 7537 LA - eng PT - Journal Article PT - Review DEP - 20220114 PL - England TA - Egypt J Intern Med JT - The Egyptian journal of internal medicine JID - 101641145 PMC - PMC8759062 OTO - NOTNLM OT - COVID-19 OT - Drugs OT - Epidemiology OT - Risk factors OT - SARS-CoV-2 OT - Structural biology OT - Vaccination COIS- Competing interestsThe authors have no conflicts of interest. EDAT- 2022/01/20 06:00 MHDA- 2022/01/20 06:01 PMCR- 2022/01/14 CRDT- 2022/01/19 06:57 PHST- 2021/10/23 00:00 [received] PHST- 2021/12/03 00:00 [accepted] PHST- 2022/01/19 06:57 [entrez] PHST- 2022/01/20 06:00 [pubmed] PHST- 2022/01/20 06:01 [medline] PHST- 2022/01/14 00:00 [pmc-release] AID - 92 [pii] AID - 10.1186/s43162-021-00092-7 [doi] PST - ppublish SO - Egypt J Intern Med. 2022;34(1):5. doi: 10.1186/s43162-021-00092-7. Epub 2022 Jan 14. PMID- 35025789 OWN - NLM STAT- MEDLINE DCOM- 20220203 LR - 20230925 IS - 1536-0229 (Electronic) IS - 0363-9762 (Print) IS - 0363-9762 (Linking) VI - 47 IP - 3 DP - 2022 Mar 1 TI - Alterations in 18F-FDG PET/MRI and 15O-Water PET Brain Findings in Patients With Neurological Symptoms After COVID-19 Vaccination: A Pilot Study. PG - e230-e239 LID - 10.1097/RLU.0000000000004041 [doi] AB - PURPOSE: This study aimed to investigate functional abnormalities in the brain of patients with neurological adverse effects following COVID-19 (coronavirus disease 2019) vaccination using 18F-FDG PET/MRI and 15O-water PET. METHODS: Eight patients (1 man and 7 women, aged 26-47 years [median age, 36.5 years]) who experienced neurological symptoms after the first COVID-19 vaccination underwent CT, MRI, 18F-FDG PET/MRI, and 15O-water PET of the brain. After 7 days, each patient underwent a follow-up 18F-FDG PET/MRI and 15O-water PET of the brain. Imaging data were analyzed using visual and semiquantitative analyses, which included a cluster subtraction workflow (P = 0.05). RESULTS: There was no evidence of vascular abnormalities, acute infarction, or hemorrhage on the CT or MRI scans. On the 15O-water PET images, 1 patient had mildly significant decreases in perfusion in the bilateral thalamus and bilateral cerebellum, and another patient showed a diffuse increase in perfusion in the cerebral white matter. The visual and semiquantitative analyses showed hypometabolism in the bilateral parietal lobes in all 8 patients on both the first and follow-up 18F-FDG PET/MRI scans. Metabolic changes in the bilateral cuneus were also observed during the first visit; all patients exhibited neurological symptoms. Moreover, 6 patients showed hypometabolism, and 2 patients showed hypermetabolism. CONCLUSION: All regions of metabolic abnormality were part of the fear network model that has been implicated in anxiety. Our study findings support the concepts of and provide evidence for the immunization stress-related response and the biopsychosocial model. CI - Copyright (c) 2022 Wolters Kluwer Health, Inc. All rights reserved. FAU - Siripongsatian, Dheeratama AU - Siripongsatian D AD - From the National Cyclotron and PET Centre. FAU - Kunawudhi, Anchisa AU - Kunawudhi A AD - From the National Cyclotron and PET Centre. FAU - Promteangtrong, Chetsadaporn AU - Promteangtrong C AD - From the National Cyclotron and PET Centre. FAU - Kiatkittikul, Peerapon AU - Kiatkittikul P AD - From the National Cyclotron and PET Centre. FAU - Jantarato, Attapon AU - Jantarato A AD - From the National Cyclotron and PET Centre. FAU - Choolam, Arthita AU - Choolam A AD - Department of Medicine, Chulabhorn Hospital. FAU - Ponglikitmongkol, Krongkamol AU - Ponglikitmongkol K AD - Department of Medicine, Chulabhorn Hospital. FAU - Siripongboonsitti, Taweegrit AU - Siripongboonsitti T AD - Department of Medicine, Chulabhorn Hospital. FAU - Kaeowirun, Tharathorn AU - Kaeowirun T AD - Department of Radiology, Bhumibol Adulyadej Hospital, Royal Thai Air Force, Bangkok, Thailand. FAU - Chotipanich, Chanisa AU - Chotipanich C AD - From the National Cyclotron and PET Centre. LA - eng PT - Journal Article PL - United States TA - Clin Nucl Med JT - Clinical nuclear medicine JID - 7611109 RN - 0 (COVID-19 Vaccines) RN - 0 (Oxygen Radioisotopes) RN - 0 (Oxygen-15) RN - 059QF0KO0R (Water) RN - 0Z5B2CJX4D (Fluorodeoxyglucose F18) SB - IM CIN - Clin Nucl Med. 2022 Oct 1;47(10):e671. doi: 10.1097/RLU.0000000000004227. PMID: 35439207 MH - Adult MH - Brain/diagnostic imaging MH - *COVID-19 MH - COVID-19 Vaccines MH - Female MH - *Fluorodeoxyglucose F18 MH - Humans MH - Magnetic Resonance Imaging MH - Male MH - Oxygen Radioisotopes MH - Pilot Projects MH - Positron-Emission Tomography MH - SARS-CoV-2 MH - Vaccination MH - Water PMC - PMC8820745 COIS- Conflicts of interest and sources of funding: none declared. EDAT- 2022/01/14 06:00 MHDA- 2022/02/04 06:00 PMCR- 2022/01/13 CRDT- 2022/01/13 17:24 PHST- 2022/01/14 06:00 [pubmed] PHST- 2022/02/04 06:00 [medline] PHST- 2022/01/13 17:24 [entrez] PHST- 2022/01/13 00:00 [pmc-release] AID - 00003072-202203000-00031 [pii] AID - CNM_210564 [pii] AID - 10.1097/RLU.0000000000004041 [doi] PST - ppublish SO - Clin Nucl Med. 2022 Mar 1;47(3):e230-e239. doi: 10.1097/RLU.0000000000004041. PMID- 35018613 OWN - NLM STAT- MEDLINE DCOM- 20220223 LR - 20260127 IS - 1573-7373 (Electronic) IS - 0167-594X (Print) IS - 0167-594X (Linking) VI - 156 IP - 3 DP - 2022 Feb TI - Immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in patients with primary brain tumors: a prospective cohort study. PG - 483-489 LID - 10.1007/s11060-021-03911-7 [doi] AB - PURPOSE: Immunogenicity of Covid-19 vaccines may be negatively impacted by anti-cancer treatment. The management of primary brain tumors (PBTs) routinely includes temozolomide and steroids, which are immune-suppressive. We aimed to determine the rate of seropositivity in PBT patients following receipt of two doses of the BNT162b2 vaccine. METHODS: We prospectively evaluated IgG levels against SARS-CoV-2 spike protein in 17 PBT patients following two doses of the BNT162b2 vaccine. IgG levels were collected at two time points: T1-after a median of 44 days from the second vaccine dose and T2-after a median of 130 days from the second dose. Titers were compared against a group of healthy controls (HC) comprised of patients' family members. RESULTS: At T1, 88.2% (15/17) of PBT patients achieved seroconversion, compared with 100% (12/12) of HCs. Median IgG titer was significantly lower in the PBT group (1908 AU/mL vs 8,198 AU/mL; p = 0.002). At T2, 80% (12/15) of PBT patients seroconverted, compared to 100% (10/10) of HCs. Median IgG titer remained significantly lower in the PBT group (410 AU/mLvs 1687 AU/mL; p = 0.002). During the peri-vaccination period, 15 patients received systemic treatment and 8 patients were treated with corticosteroids. All 3 patients who failed to seroconvert at T2 were treated with corticosteroids. In a univariate analysis, steroid use was negatively associated with antibody titer. CONCLUSION: Most PBT patients successfully seroconvert following two doses of the BNT162b2 vaccine, albeit with lower antibody titer compared to HCs. Steroid use during the vaccination period is associated with lower titer. CI - (c) 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Massarweh, Amir AU - Massarweh A AD - Department of Oncology, Davidoff Cancer Center, Rabin Medical Center, Beilinson Hospital, Petach Tikva, Israel. FAU - Tschernichovsky, Roi AU - Tschernichovsky R AUID- ORCID: 0000-0002-3539-1940 AD - Department of Oncology, Davidoff Cancer Center, Rabin Medical Center, Beilinson Hospital, Petach Tikva, Israel. roits@clalit.org.il. FAU - Stemmer, Amos AU - Stemmer A AD - Department of Oncology, Sheba Medical Center, Tel Hashomer, Israel. FAU - Benouaich-Amiel, Alexandra AU - Benouaich-Amiel A AD - Neuro-Oncology Unit, Davidoff Cancer Center, Rabin Medical Center, Beilinson Hospital, Petach Tikva, Israel. FAU - Siegal, Tali AU - Siegal T AD - Neuro-Oncology Unit, Davidoff Cancer Center, Rabin Medical Center, Beilinson Hospital, Petach Tikva, Israel. AD - Faculty of Medicine, Hebrew University, Jerusalem, Israel. FAU - Eliakim-Raz, Noa AU - Eliakim-Raz N AD - Department of Medicine E, Rabin Medical Center, Beilinson Hospital, Petach Tikva, Israel. AD - Infectious Disease Unit, Rabin Medical Center, Beilinson Hospital, Petach Tikva, Israel. FAU - Stemmer, Salomon M AU - Stemmer SM AD - Department of Oncology, Davidoff Cancer Center, Rabin Medical Center, Beilinson Hospital, Petach Tikva, Israel. AD - Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. FAU - Yust-Katz, Shlomit AU - Yust-Katz S AD - Neuro-Oncology Unit, Davidoff Cancer Center, Rabin Medical Center, Beilinson Hospital, Petach Tikva, Israel. AD - Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. LA - eng PT - Journal Article DEP - 20220112 PL - United States TA - J Neurooncol JT - Journal of neuro-oncology JID - 8309335 RN - 0 (Antibodies, Viral) RN - 0 (BNT162 Vaccine) RN - 0 (Immunoglobulin G) RN - 0 (Spike Glycoprotein, Coronavirus) RN - 0 (spike protein, SARS-CoV-2) SB - IM MH - Antibodies, Viral/blood MH - *BNT162 Vaccine/immunology MH - *Brain Neoplasms/drug therapy/immunology MH - COVID-19/prevention & control MH - Case-Control Studies MH - Humans MH - *Immunogenicity, Vaccine/immunology MH - Immunoglobulin G/blood MH - Prospective Studies MH - Spike Glycoprotein, Coronavirus/immunology PMC - PMC8752179 OTO - NOTNLM OT - BNT162b2 OT - Covid-19 OT - Glioma OT - Vaccine OT - mRNA COIS- The authors declare that they have no financial or non-financial interests that are directly or indirectly related to the work submitted for publication. EDAT- 2022/01/13 06:00 MHDA- 2022/02/24 06:00 PMCR- 2022/01/11 CRDT- 2022/01/12 06:43 PHST- 2021/10/19 00:00 [received] PHST- 2021/11/22 00:00 [accepted] PHST- 2022/01/13 06:00 [pubmed] PHST- 2022/02/24 06:00 [medline] PHST- 2022/01/12 06:43 [entrez] PHST- 2022/01/11 00:00 [pmc-release] AID - 10.1007/s11060-021-03911-7 [pii] AID - 3911 [pii] AID - 10.1007/s11060-021-03911-7 [doi] PST - ppublish SO - J Neurooncol. 2022 Feb;156(3):483-489. doi: 10.1007/s11060-021-03911-7. Epub 2022 Jan 12. PMID- 34994081 OWN - NLM STAT- MEDLINE DCOM- 20220309 LR - 20240824 IS - 1757-4684 (Electronic) IS - 1757-4676 (Print) IS - 1757-4676 (Linking) VI - 14 IP - 3 DP - 2022 Mar 7 TI - Decreased memory B cell frequencies in COVID-19 delta variant vaccine breakthrough infection. PG - e15227 LID - 10.15252/emmm.202115227 [doi] LID - e15227 AB - The SARS-CoV-2 Delta (B.1.617.2) variant is capable of infecting vaccinated persons. An open question remains as to whether deficiencies in specific vaccine-elicited immune responses result in susceptibility to vaccine breakthrough infection. We investigated 55 vaccine breakthrough infection cases (mostly Delta) in Singapore, comparing them against 86 vaccinated close contacts who did not contract infection. Vaccine breakthrough cases showed lower memory B cell frequencies against SARS-CoV-2 receptor-binding domain (RBD). Compared to plasma antibodies, antibodies secreted by memory B cells retained a higher fraction of neutralizing properties against the Delta variant. Inflammatory cytokines including IL-1beta and TNF were lower in vaccine breakthrough infections than primary infection of similar disease severity, underscoring the usefulness of vaccination in preventing inflammation. This report highlights the importance of memory B cells against vaccine breakthrough and suggests that lower memory B cell levels may be a correlate of risk for Delta vaccine breakthrough infection. CI - (c) 2022 The Authors. Published under the terms of the CC BY 4.0 license. FAU - Tay, Matthew Zirui AU - Tay MZ AUID- ORCID: 0000-0002-1763-913X AD - A*STAR Infectious Diseases Labs, Agency for Science, Technology and Research (A*STAR), Singapore City, Singapore. FAU - Rouers, Angeline AU - Rouers A AD - A*STAR Infectious Diseases Labs, Agency for Science, Technology and Research (A*STAR), Singapore City, Singapore. FAU - Fong, Siew-Wai AU - Fong SW AUID- ORCID: 0000-0002-5326-489X AD - A*STAR Infectious Diseases Labs, Agency for Science, Technology and Research (A*STAR), Singapore City, Singapore. FAU - Goh, Yun Shan AU - Goh YS AD - A*STAR Infectious Diseases Labs, Agency for Science, Technology and Research (A*STAR), Singapore City, Singapore. FAU - Chan, Yi-Hao AU - Chan YH AD - A*STAR Infectious Diseases Labs, Agency for Science, Technology and Research (A*STAR), Singapore City, Singapore. FAU - Chang, Zi Wei AU - Chang ZW AD - A*STAR Infectious Diseases Labs, Agency for Science, Technology and Research (A*STAR), Singapore City, Singapore. FAU - Xu, Weili AU - Xu W AD - Singapore Immunology Network, A*STAR, Singapore City, Singapore. FAU - Tan, Chee Wah AU - Tan CW AD - Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore City, Singapore. FAU - Chia, Wan Ni AU - Chia WN AD - Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore City, Singapore. FAU - Torres-Ruesta, Anthony AU - Torres-Ruesta A AUID- ORCID: 0000-0003-0447-3131 AD - A*STAR Infectious Diseases Labs, Agency for Science, Technology and Research (A*STAR), Singapore City, Singapore. FAU - Amrun, Siti Naqiah AU - Amrun SN AD - A*STAR Infectious Diseases Labs, Agency for Science, Technology and Research (A*STAR), Singapore City, Singapore. FAU - Huang, Yuling AU - Huang Y AD - A*STAR Infectious Diseases Labs, Agency for Science, Technology and Research (A*STAR), Singapore City, Singapore. FAU - Hor, Pei Xiang AU - Hor PX AD - A*STAR Infectious Diseases Labs, Agency for Science, Technology and Research (A*STAR), Singapore City, Singapore. FAU - Loh, Chiew Yee AU - Loh CY AD - A*STAR Infectious Diseases Labs, Agency for Science, Technology and Research (A*STAR), Singapore City, Singapore. FAU - Yeo, Nicholas Kim-Wah AU - Yeo NK AUID- ORCID: 0000-0002-8294-1474 AD - A*STAR Infectious Diseases Labs, Agency for Science, Technology and Research (A*STAR), Singapore City, Singapore. FAU - Wang, Bei AU - Wang B AUID- ORCID: 0000-0002-3112-7341 AD - Singapore Immunology Network, A*STAR, Singapore City, Singapore. FAU - Ngoh, Eve Zi Xian AU - Ngoh EZX AD - Singapore Immunology Network, A*STAR, Singapore City, Singapore. FAU - Salleh, Siti Nazihah Mohd AU - Salleh SNM AUID- ORCID: 0000-0002-6110-7472 AD - Singapore Immunology Network, A*STAR, Singapore City, Singapore. FAU - Chavatte, Jean-Marc AU - Chavatte JM AD - National Centre for Infectious Diseases, Singapore City, Singapore. AD - National Public Health Laboratory, National Centre for Infectious Diseases, Singapore City, Singapore. FAU - Lim, Alicia Jieling AU - Lim AJ AD - National Centre for Infectious Diseases, Singapore City, Singapore. AD - National Public Health Laboratory, National Centre for Infectious Diseases, Singapore City, Singapore. FAU - Maurer-Stroh, Sebastian AU - Maurer-Stroh S AUID- ORCID: 0000-0003-0813-9640 AD - Bioinformatics Institute, A*STAR, Singapore City, Singapore. FAU - Wang, Lin-Fa AU - Wang LF AD - Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore City, Singapore. AD - SingHealth Duke-NUS Global Health Institute, Singapore City, Singapore. FAU - Lin, Raymond Valentine Tzer Pin AU - Lin RVTP AD - National Centre for Infectious Diseases, Singapore City, Singapore. AD - National Public Health Laboratory, National Centre for Infectious Diseases, Singapore City, Singapore. AD - Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore City, Singapore. FAU - Wang, Cheng-I AU - Wang CI AUID- ORCID: 0000-0001-9170-2996 AD - Singapore Immunology Network, A*STAR, Singapore City, Singapore. FAU - Tan, Seow-Yen AU - Tan SY AD - Department of Infectious Diseases, Changi General Hospital, Singapore City, Singapore. FAU - Young, Barnaby Edward AU - Young BE AD - National Centre for Infectious Diseases, Singapore City, Singapore. AD - Department of Infectious Diseases, Tan Tock Seng Hospital, Singapore City, Singapore. AD - Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore City, Singapore. FAU - Leo, Yee-Sin AU - Leo YS AD - National Centre for Infectious Diseases, Singapore City, Singapore. AD - Department of Infectious Diseases, Tan Tock Seng Hospital, Singapore City, Singapore. AD - Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore City, Singapore. AD - Yong Loo Lin School of Medicine, National University of Singapore and National University Health System, Singapore City, Singapore. FAU - Lye, David C AU - Lye DC AD - National Centre for Infectious Diseases, Singapore City, Singapore. AD - Department of Infectious Diseases, Tan Tock Seng Hospital, Singapore City, Singapore. AD - Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore City, Singapore. AD - Yong Loo Lin School of Medicine, National University of Singapore and National University Health System, Singapore City, Singapore. FAU - Renia, Laurent AU - Renia L AD - A*STAR Infectious Diseases Labs, Agency for Science, Technology and Research (A*STAR), Singapore City, Singapore. AD - Singapore Immunology Network, A*STAR, Singapore City, Singapore. AD - Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore City, Singapore. FAU - Ng, Lisa Fp AU - Ng LF AUID- ORCID: 0000-0003-4071-5222 AD - A*STAR Infectious Diseases Labs, Agency for Science, Technology and Research (A*STAR), Singapore City, Singapore. AD - Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Singapore City, Singapore. AD - National Institute of Health Research, Health Protection Research Unit in Emerging and Zoonotic Infections, University of Liverpool, Liverpool, UK. AD - Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, UK. LA - eng GR - A*STAR|Biomedical Research Council (BMRC)/ GR - ACCL/19-GAP064-R20H-H/Agency for Science, Technology and Research (A*STAR)/ GR - COVID19RF-0008/MOH|National Medical Research Council (NMRC)/ GR - COVID19RF-060/MOH|National Medical Research Council (NMRC)/ GR - COVID19RF-001/MOH|National Medical Research Council (NMRC)/ GR - NRF2017_SISFP09/National Research Foundation Singapore (NRF)/ PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220121 PL - Germany TA - EMBO Mol Med JT - EMBO molecular medicine JID - 101487380 RN - 0 (COVID-19 Vaccines) RN - SARS-CoV-2 variants SB - IM MH - *COVID-19/prevention & control MH - COVID-19 Vaccines MH - Humans MH - Memory B Cells MH - SARS-CoV-2 PMC - PMC8899913 OTO - NOTNLM OT - COVID-19 OT - correlate of risk OT - delta OT - memory B cells OT - vaccine breakthrough COIS- A patent application for the SFB assay has been filed (Singapore patent #10202009679P: A Method Of Detecting Antibodies And Related Products) by Y.S.G, L.R., and L.F.P.N. The authors declare no other competing interests. EDAT- 2022/01/08 06:00 MHDA- 2022/03/11 06:00 PMCR- 2022/03/07 CRDT- 2022/01/07 06:57 PHST- 2021/12/23 00:00 [revised] PHST- 2021/10/01 00:00 [received] PHST- 2021/12/23 00:00 [accepted] PHST- 2022/01/08 06:00 [pubmed] PHST- 2022/03/11 06:00 [medline] PHST- 2022/01/07 06:57 [entrez] PHST- 2022/03/07 00:00 [pmc-release] AID - EMMM202115227 [pii] AID - 10.15252/emmm.202115227 [doi] PST - ppublish SO - EMBO Mol Med. 2022 Mar 7;14(3):e15227. doi: 10.15252/emmm.202115227. Epub 2022 Jan 21. PMID- 34986327 OWN - NLM STAT- MEDLINE DCOM- 20220124 LR - 20260127 IS - 2211-1247 (Electronic) VI - 38 IP - 2 DP - 2022 Jan 11 TI - Cellular and humoral functional responses after BNT162b2 mRNA vaccination differ longitudinally between naive and subjects recovered from COVID-19. PG - 110235 LID - S2211-1247(21)01744-7 [pii] LID - 10.1016/j.celrep.2021.110235 [doi] AB - We have analyzed BNT162b2 vaccine-induced immune responses in naive subjects and individuals recovered from coronavirus disease 2019 (COVID-19), both soon after (14 days) and later after (almost 8 months) vaccination. Plasma spike (S)-specific immunoglobulins peak after one vaccine shot in individuals recovered from COVID-19, while a second dose is needed in naive subjects, although the latter group shows reduced levels all along the analyzed period. Despite how the neutralization capacity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mirrors this behavior early after vaccination, both groups show comparable neutralizing antibodies and S-specific B cell levels late post-vaccination. When studying cellular responses, naive individuals exhibit higher SARS-CoV-2-specific cytokine production, CD4(+) T cell activation, and proliferation than do individuals recovered from COVID-19, with patent inverse correlations between humoral and cellular variables early post-vaccination. However, almost 8 months post-vaccination, SARS-CoV-2-specific responses are comparable between both groups. Our data indicate that a previous history of COVID-19 differentially determines the functional T and B cell-mediated responses to BNT162b2 vaccination over time. CI - Copyright (c) 2021 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Lozano-Rodriguez, Roberto AU - Lozano-Rodriguez R AD - The Innate Immune Response Group, IdiPAZ, La Paz University Hospital, Madrid, Spain; Tumor Immunology Laboratory, IdiPAZ, La Paz University Hospital, Madrid, Spain. FAU - Valentin-Quiroga, Jaime AU - Valentin-Quiroga J AD - The Innate Immune Response Group, IdiPAZ, La Paz University Hospital, Madrid, Spain; Tumor Immunology Laboratory, IdiPAZ, La Paz University Hospital, Madrid, Spain. FAU - Avendano-Ortiz, Jose AU - Avendano-Ortiz J AD - The Innate Immune Response Group, IdiPAZ, La Paz University Hospital, Madrid, Spain; Tumor Immunology Laboratory, IdiPAZ, La Paz University Hospital, Madrid, Spain. FAU - Martin-Quiros, Alejandro AU - Martin-Quiros A AD - Emergency Department and Emergent Pathology Research Group, IdiPAZ La Paz University Hospital, Madrid, Spain. FAU - Pascual-Iglesias, Alejandro AU - Pascual-Iglesias A AD - The Innate Immune Response Group, IdiPAZ, La Paz University Hospital, Madrid, Spain; Tumor Immunology Laboratory, IdiPAZ, La Paz University Hospital, Madrid, Spain. FAU - Terron-Arcos, Veronica AU - Terron-Arcos V AD - The Innate Immune Response Group, IdiPAZ, La Paz University Hospital, Madrid, Spain; Tumor Immunology Laboratory, IdiPAZ, La Paz University Hospital, Madrid, Spain. FAU - Montalban-Hernandez, Karla AU - Montalban-Hernandez K AD - The Innate Immune Response Group, IdiPAZ, La Paz University Hospital, Madrid, Spain; Tumor Immunology Laboratory, IdiPAZ, La Paz University Hospital, Madrid, Spain. FAU - Casalvilla-Duenas, Jose Carlos AU - Casalvilla-Duenas JC AD - The Innate Immune Response Group, IdiPAZ, La Paz University Hospital, Madrid, Spain; Tumor Immunology Laboratory, IdiPAZ, La Paz University Hospital, Madrid, Spain. FAU - Bergon-Gutierrez, Marta AU - Bergon-Gutierrez M AD - The Innate Immune Response Group, IdiPAZ, La Paz University Hospital, Madrid, Spain; Tumor Immunology Laboratory, IdiPAZ, La Paz University Hospital, Madrid, Spain. FAU - Alcami, Jose AU - Alcami J AD - AIDS Immunopathogenesis Unit, National Microbiology Centre, Instituto de Salud Carlos III, Madrid, Spain. FAU - Garcia-Perez, Javier AU - Garcia-Perez J AD - AIDS Immunopathogenesis Unit, National Microbiology Centre, Instituto de Salud Carlos III, Madrid, Spain. FAU - Cascajero, Almudena AU - Cascajero A AD - AIDS Immunopathogenesis Unit, National Microbiology Centre, Instituto de Salud Carlos III, Madrid, Spain. FAU - Garcia-Garrido, Miguel Angel AU - Garcia-Garrido MA AD - Emergency Department and Emergent Pathology Research Group, IdiPAZ La Paz University Hospital, Madrid, Spain. FAU - Balzo-Castillo, Alvaro Del AU - Balzo-Castillo AD AD - The Innate Immune Response Group, IdiPAZ, La Paz University Hospital, Madrid, Spain; Emergency Department and Emergent Pathology Research Group, IdiPAZ La Paz University Hospital, Madrid, Spain. FAU - Peinado, Maria AU - Peinado M AD - Emergency Department and Emergent Pathology Research Group, IdiPAZ La Paz University Hospital, Madrid, Spain. FAU - Gomez, Laura AU - Gomez L AD - Emergency Department and Emergent Pathology Research Group, IdiPAZ La Paz University Hospital, Madrid, Spain. FAU - Llorente-Fernandez, Irene AU - Llorente-Fernandez I AD - Intensive Care Unit, Infanta Cristina University Hospital, Parla, Madrid, Spain. FAU - Martin-Miguel, Gema AU - Martin-Miguel G AD - Pediatric Intensive Care Unit, 12 de Octubre University Hospital, Madrid, Spain. FAU - Herrero-Benito, Carmen AU - Herrero-Benito C AD - Emergency Department and Emergent Pathology Research Group, IdiPAZ La Paz University Hospital, Madrid, Spain. FAU - Benito, Jose Miguel AU - Benito JM AD - HIV and Viral Hepatitis Research Laboratory, Instituto de Investigacion Sanitaria Fundacion Jimenez Diaz, Universidad Autonoma de Madrid (IIS-FJD, UAM), Madrid, Spain; Hospital Universitario Rey Juan Carlos, Mostoles, Spain. FAU - Rallon, Norma AU - Rallon N AD - HIV and Viral Hepatitis Research Laboratory, Instituto de Investigacion Sanitaria Fundacion Jimenez Diaz, Universidad Autonoma de Madrid (IIS-FJD, UAM), Madrid, Spain; Hospital Universitario Rey Juan Carlos, Mostoles, Spain. FAU - Vela-Olmo, Carmen AU - Vela-Olmo C AD - Eurofins-Ingenasa, Madrid, Spain. FAU - Lopez-Morejon, Lissette AU - Lopez-Morejon L AD - Eurofins-Ingenasa, Madrid, Spain. FAU - Cubillos-Zapata, Carolina AU - Cubillos-Zapata C AD - The Innate Immune Response Group, IdiPAZ, La Paz University Hospital, Madrid, Spain; Tumor Immunology Laboratory, IdiPAZ, La Paz University Hospital, Madrid, Spain; CIBER of Respiratory Diseases (CIBERES), Madrid, Spain. FAU - Aguirre, Luis A AU - Aguirre LA AD - The Innate Immune Response Group, IdiPAZ, La Paz University Hospital, Madrid, Spain; Tumor Immunology Laboratory, IdiPAZ, La Paz University Hospital, Madrid, Spain. FAU - Fresno, Carlos Del AU - Fresno CD AD - The Innate Immune Response Group, IdiPAZ, La Paz University Hospital, Madrid, Spain; Tumor Immunology Laboratory, IdiPAZ, La Paz University Hospital, Madrid, Spain. Electronic address: carlos.delfresno.sanchez@idipaz.es. FAU - Lopez-Collazo, Eduardo AU - Lopez-Collazo E AD - The Innate Immune Response Group, IdiPAZ, La Paz University Hospital, Madrid, Spain; Tumor Immunology Laboratory, IdiPAZ, La Paz University Hospital, Madrid, Spain; CIBER of Respiratory Diseases (CIBERES), Madrid, Spain. Electronic address: elopezc@salud.madrid.org. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20211221 PL - United States TA - Cell Rep JT - Cell reports JID - 101573691 RN - 0 (Antibodies, Neutralizing) RN - 0 (Antibodies, Viral) RN - 0 (BNT162 Vaccine) RN - 0 (COVID-19 Vaccines) RN - 0 (Spike Glycoprotein, Coronavirus) RN - 0 (Vaccines, Synthetic) RN - 0 (mRNA Vaccines) SB - IM MH - Animals MH - Antibodies, Neutralizing/immunology MH - Antibodies, Viral/immunology MH - B-Lymphocytes/immunology/virology MH - BNT162 Vaccine/*immunology MH - COVID-19/*immunology/virology MH - COVID-19 Vaccines/*immunology MH - Chlorocebus aethiops MH - Humans MH - Immunity, Cellular/*immunology MH - Immunity, Humoral/*immunology MH - Leukocytes, Mononuclear/immunology/virology MH - Lymphocyte Activation/immunology MH - SARS-CoV-2/immunology MH - Spike Glycoprotein, Coronavirus/immunology MH - Vaccination/methods MH - Vaccines, Synthetic/*immunology MH - Vero Cells MH - mRNA Vaccines/*immunology PMC - PMC8687760 OTO - NOTNLM OT - BNT162b2 vaccine OT - COVID-19-recovered OT - SARS-CoV-2 OT - antigen-specific T cell OT - cellular responses OT - cytokine production OT - humoral responses OT - memory B cell OT - proliferation OT - spike COIS- Declaration of interests The authors declare no competing interests. EDAT- 2022/01/06 06:00 MHDA- 2022/01/27 06:00 PMCR- 2021/12/21 CRDT- 2022/01/05 20:06 PHST- 2021/06/05 00:00 [received] PHST- 2021/09/15 00:00 [revised] PHST- 2021/12/16 00:00 [accepted] PHST- 2022/01/06 06:00 [pubmed] PHST- 2022/01/27 06:00 [medline] PHST- 2022/01/05 20:06 [entrez] PHST- 2021/12/21 00:00 [pmc-release] AID - S2211-1247(21)01744-7 [pii] AID - 110235 [pii] AID - 10.1016/j.celrep.2021.110235 [doi] PST - ppublish SO - Cell Rep. 2022 Jan 11;38(2):110235. doi: 10.1016/j.celrep.2021.110235. Epub 2021 Dec 21. PMID- 34960249 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231108 IS - 2076-393X (Print) IS - 2076-393X (Electronic) IS - 2076-393X (Linking) VI - 9 IP - 12 DP - 2021 Dec 20 TI - mRNA COVID-19 Vaccines and Long-Lived Plasma Cells: A Complicated Relationship. LID - 10.3390/vaccines9121503 [doi] LID - 1503 AB - mRNA COVID-19 vaccines have hegemonized the world market, and their administration to the population promises to stop the pandemic. However, the waning of the humoral immune response, which does not seem to last so many months after the completion of the vaccination program, has led us to study the molecular immunological mechanisms of waning immunity in the case of mRNA COVID-19 vaccines. We consulted the published scientific literature and from the few articles we found, we were convinced that there is an immunological memory problem after vaccination. Although mRNA vaccines have been demonstrated to induce antigen-specific memory B cells (MBCs) in the human population, there is no evidence that these vaccines induce the production of long-lived plasma cells (LLPCs), in a SARS-CoV-2 virus naive population. This obstacle, in our point of view, is caused by the presence, in almost all subjects, of a cellular T and B cross-reactive memory produced during past exposures to the common cold coronaviruses. Due to this interference, it is difficult for a vaccination with the Spike protein alone, without adjuvants capable of prolonging the late phase of the generation of the immunological memory, to be able to determine the production of protective LLPCs. This would explain the possibility of previously and completely vaccinated subjects to become infected, already 4-6 months after the completion of the vaccination cycle. FAU - Giannotta, Girolamo AU - Giannotta G AUID- ORCID: 0000-0001-9766-3326 AD - Azienda Sanitaria Provinciale Vibo Valentia, 89900 Vibo Valentia, Italy. FAU - Giannotta, Nicola AU - Giannotta N AUID- ORCID: 0000-0003-1701-7696 AD - Medical and Surgery Sciences, Faculty of Medicine, Magna Graecia University, 88100 Catanzaro, Italy. LA - eng PT - Journal Article PT - Review DEP - 20211220 PL - Switzerland TA - Vaccines (Basel) JT - Vaccines JID - 101629355 PMC - PMC8703557 OTO - NOTNLM OT - COVID-19 vaccines OT - SARS-CoV-2 OT - SARS-CoV-2 mRNA vaccines OT - immune memory after COVID-19 disease OT - immune memory after COVID-19 vaccination OT - long-lived plasma cells after mRNA COVID-19 vaccines COIS- The authors declare no conflict of interest. EDAT- 2021/12/29 06:00 MHDA- 2021/12/29 06:01 PMCR- 2021/12/20 CRDT- 2021/12/28 01:06 PHST- 2021/10/26 00:00 [received] PHST- 2021/11/21 00:00 [revised] PHST- 2021/12/14 00:00 [accepted] PHST- 2021/12/28 01:06 [entrez] PHST- 2021/12/29 06:00 [pubmed] PHST- 2021/12/29 06:01 [medline] PHST- 2021/12/20 00:00 [pmc-release] AID - vaccines9121503 [pii] AID - vaccines-09-01503 [pii] AID - 10.3390/vaccines9121503 [doi] PST - epublish SO - Vaccines (Basel). 2021 Dec 20;9(12):1503. doi: 10.3390/vaccines9121503. PMID- 34950151 OWN - NLM STAT- MEDLINE DCOM- 20220106 LR - 20220106 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 12 DP - 2021 TI - A Highly Conserved Peptide Vaccine Candidate Activates Both Humoral and Cellular Immunity Against SARS-CoV-2 Variant Strains. PG - 789905 LID - 10.3389/fimmu.2021.789905 [doi] LID - 789905 AB - Facing the imminent need for vaccine candidates with cross-protection against globally circulating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mutants, we present a conserved antigenic peptide RBD9.1 with both T-cell and B-cell epitopes. RBD9.1 can be recognized by coronavirus disease 2019 (COVID-19) convalescent serum, particularly for those with high neutralizing potency. Immunization with RBD9.1 can successfully induce the production of the receptor-binding domain (RBD)-specific antibodies in Balb/c mice. Importantly, the immunized sera exhibit sustained neutralizing efficacy against multiple dominant SARS-CoV-2 variant strains, including B.1.617.2 that carries a point mutation (S(L452R)) within the sequence of RBD9.1. Specifically, S(Y451) and S(Y454) are identified as the key amino acids for the binding of the induced RBD-specific antibodies to RBD9.1. Furthermore, we have confirmed that the RBD9.1 antigenic peptide can induce a S(448-456) (NYNYLYRLF)-specific CD8(+) T-cell response. Both RBD9.1-specific B cells and the S(448-456)-specific T cells can still be activated more than 3 months post the last immunization. This study provides a potential vaccine candidate that can generate long-term protective efficacy over SARS-CoV-2 variants, with the unique functional mechanism of activating both humoral and cellular immunity. CI - Copyright (c) 2021 Gao, Huang, Li, Hu, Shen, Mu, Luo, Song, Hao, Wang, Han, Qian, Wang, Wu, Li, Li and Jin. FAU - Gao, Fengxia AU - Gao F AD - Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, China. AD - Chongqing Key Laboratory of Basic and Translational Research of Tumor Immunology, Chongqing Medical University, Chongqing, China. FAU - Huang, Jingjing AU - Huang J AD - Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, China. AD - Chongqing Key Laboratory of Basic and Translational Research of Tumor Immunology, Chongqing Medical University, Chongqing, China. FAU - Li, Tingting AU - Li T AD - Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, China. AD - Chongqing Key Laboratory of Basic and Translational Research of Tumor Immunology, Chongqing Medical University, Chongqing, China. FAU - Hu, Chao AU - Hu C AD - Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, China. AD - Chongqing Key Laboratory of Basic and Translational Research of Tumor Immunology, Chongqing Medical University, Chongqing, China. FAU - Shen, Meiying AU - Shen M AD - Department of Endocrine Breast Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. FAU - Mu, Song AU - Mu S AD - Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, China. AD - Chongqing Key Laboratory of Basic and Translational Research of Tumor Immunology, Chongqing Medical University, Chongqing, China. FAU - Luo, Feiyang AU - Luo F AD - Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, China. AD - Chongqing Key Laboratory of Basic and Translational Research of Tumor Immunology, Chongqing Medical University, Chongqing, China. FAU - Song, Shuyi AU - Song S AD - Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, China. AD - Chongqing Key Laboratory of Basic and Translational Research of Tumor Immunology, Chongqing Medical University, Chongqing, China. FAU - Hao, Yanan AU - Hao Y AD - Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, China. AD - Chongqing Key Laboratory of Basic and Translational Research of Tumor Immunology, Chongqing Medical University, Chongqing, China. FAU - Wang, Wang AU - Wang W AD - Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, China. AD - Chongqing Key Laboratory of Basic and Translational Research of Tumor Immunology, Chongqing Medical University, Chongqing, China. FAU - Han, Xiaojian AU - Han X AD - Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, China. AD - Chongqing Key Laboratory of Basic and Translational Research of Tumor Immunology, Chongqing Medical University, Chongqing, China. FAU - Qian, Chen AU - Qian C AD - Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, China. AD - Chongqing Key Laboratory of Basic and Translational Research of Tumor Immunology, Chongqing Medical University, Chongqing, China. FAU - Wang, Yingming AU - Wang Y AD - Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, China. AD - Chongqing Key Laboratory of Basic and Translational Research of Tumor Immunology, Chongqing Medical University, Chongqing, China. FAU - Wu, Ruixin AU - Wu R AD - Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, China. AD - Chongqing Key Laboratory of Basic and Translational Research of Tumor Immunology, Chongqing Medical University, Chongqing, China. FAU - Li, Luo AU - Li L AD - Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, China. AD - Chongqing Key Laboratory of Basic and Translational Research of Tumor Immunology, Chongqing Medical University, Chongqing, China. FAU - Li, Shenglong AU - Li S AD - Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, China. AD - Chongqing Key Laboratory of Basic and Translational Research of Tumor Immunology, Chongqing Medical University, Chongqing, China. FAU - Jin, Aishun AU - Jin A AD - Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, China. AD - Chongqing Key Laboratory of Basic and Translational Research of Tumor Immunology, Chongqing Medical University, Chongqing, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20211207 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 RN - 0 (Antibodies, Neutralizing) RN - 0 (Antibodies, Viral) RN - 0 (COVID-19 Vaccines) RN - 0 (Epitopes, B-Lymphocyte) RN - 0 (Epitopes, T-Lymphocyte) RN - 0 (Vaccines, Subunit) RN - SARS-CoV-2 variants SB - IM MH - Animals MH - Antibodies, Neutralizing/immunology MH - Antibodies, Viral/*immunology MH - COVID-19/*prevention & control MH - COVID-19 Vaccines/*immunology/pharmacology MH - Epitopes, B-Lymphocyte/immunology MH - Epitopes, T-Lymphocyte/immunology MH - Humans MH - Immunity, Cellular/*immunology MH - Immunity, Humoral/*immunology MH - Mice MH - Mice, Inbred BALB C MH - SARS-CoV-2/immunology MH - Vaccines, Subunit/immunology PMC - PMC8688401 OTO - NOTNLM OT - RBD9.1 OT - SARS-CoV-2 variants OT - cellular immune response OT - humoral immune response OT - immunological memory OT - vaccine COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2021/12/25 06:00 MHDA- 2022/01/07 06:00 PMCR- 2021/12/07 CRDT- 2021/12/24 05:47 PHST- 2021/10/05 00:00 [received] PHST- 2021/11/10 00:00 [accepted] PHST- 2021/12/24 05:47 [entrez] PHST- 2021/12/25 06:00 [pubmed] PHST- 2022/01/07 06:00 [medline] PHST- 2021/12/07 00:00 [pmc-release] AID - 10.3389/fimmu.2021.789905 [doi] PST - epublish SO - Front Immunol. 2021 Dec 7;12:789905. doi: 10.3389/fimmu.2021.789905. eCollection 2021. PMID- 34907201 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20211217 LR - 20240404 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 11 IP - 1 DP - 2021 Dec 14 TI - Harnessing Twitter data to survey public attention and attitudes towards COVID-19 vaccines in the UK. PG - 23402 LID - 10.1038/s41598-021-02710-4 [doi] LID - 23402 AB - Attitudes to COVID-19 vaccination vary considerably within and between countries. Although the contribution of socio-demographic factors to these attitudes has been studied, the role of social media and how it interacts with news about vaccine development and efficacy is uncertain. We examined around 2 million tweets from 522,893 persons in the UK from November 2020 to January 2021 to evaluate links between Twitter content about vaccines and major scientific news announcements about vaccines. The proportion of tweets with negative vaccine content varied, with reductions of 20-24% on the same day as major news announcement. However, the proportion of negative tweets reverted back to an average of around 40% within a few days. Engagement rates were higher for negative tweets. Public health messaging could consider the dynamics of Twitter-related traffic and the potential contribution of more targeted social media campaigns to address vaccine hesitancy. CI - (c) 2021. The Author(s). FAU - Fazel, Seena AU - Fazel S AD - Warneford Hospital, Department of Psychiatry, University of Oxford, Oxford, UK. seena.fazel@psych.ox.ac.uk. FAU - Zhang, Le AU - Zhang L AD - Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. FAU - Javid, Babak AU - Javid B AD - Division of Experimental Medicine, University of California San Francisco, San Francisco, USA. FAU - Brikell, Isabell AU - Brikell I AD - Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. AD - National Centre for Register-based Research, Department of Economics and Business Economics, Aarhus BSS, Aarhus University, Aarhus, Denmark. FAU - Chang, Zheng AU - Chang Z AD - Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. zheng.chang@ki.se. LA - eng GR - WT_/Wellcome Trust/United Kingdom GR - 202836/Z/16/Z/WT_/Wellcome Trust/United Kingdom PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20211214 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 SB - IM PMC - PMC8671421 COIS- The authors declare no competing interests. EDAT- 2021/12/16 06:00 MHDA- 2021/12/16 06:01 PMCR- 2021/12/14 CRDT- 2021/12/15 06:45 PHST- 2021/03/26 00:00 [received] PHST- 2021/11/16 00:00 [accepted] PHST- 2021/12/15 06:45 [entrez] PHST- 2021/12/16 06:00 [pubmed] PHST- 2021/12/16 06:01 [medline] PHST- 2021/12/14 00:00 [pmc-release] AID - 10.1038/s41598-021-02710-4 [pii] AID - 2710 [pii] AID - 10.1038/s41598-021-02710-4 [doi] PST - epublish SO - Sci Rep. 2021 Dec 14;11(1):23402. doi: 10.1038/s41598-021-02710-4. PMID- 34894403 OWN - NLM STAT- MEDLINE DCOM- 20220310 LR - 20260127 IS - 1532-5415 (Electronic) IS - 0002-8614 (Linking) VI - 70 IP - 3 DP - 2022 Mar TI - Immunogenicity after 6 months of BNT162b2 vaccination in frail or disabled nursing home residents: The COVID-A Study. PG - 650-658 LID - 10.1111/jgs.17620 [doi] AB - BACKGROUND: There is incomplete information regarding evolution of antibody titers against SARS-CoV-2 after a two-dose strategy vaccination with BNT162b2 in older adults in long-term care facilities (LTCFs) with frailty, disability, or cognitive impairment. We aimed to determine IgG antibody titer loss in older adults in LTCFs. METHODS: This is a multicenter longitudinal cohort study including 127 residents (90 females and 37 males) with a mean age of 82.7 years (range 65-99) with different frailty and disability profiles in two LTCFs in Albacete, Spain. Residents received two doses of BNT162b2 as per label, and antibody levels were determined 1 and 6 months after the second dose. Age, sex, previous history of coronavirus disease 2019 (COVID-19), comorbidity (Charlson Index), performance in activities of daily living (Barthel Index), frailty (FRAIL instrument), and cognitive status were assessed. RESULTS: The mean antibody titers 1 and 6 months after the second vaccine dose were 32,145 AU/ml (SD 41,206) and 6182 AU/ml (SD 13,316), respectively. Across all participants, the median antibody titer loss measured 77.6% (interquartile range [IQR] 23.8%). Notably, the decline of titers in individuals with pre-vaccination COVID-19 infection was significantly lower than in those without a history of SARS-CoV-2 infection (72.2% vs. 85.3%; p < 0.001). The median titer decrease per follow-up day was 0.47% (IQR 0.14%) and only pre-vaccination COVID-19 was associated with lower rate of antibody decline at 6 months (hazard ratio 0.17; 95% confidence interval 0.07-0.41; p < 0.001). Frailty, disability, older age, cognitive impairment, or comorbidity were not associated with the extent of antibody loss. CONCLUSIONS: Older adults in LTCFs experience a rapid loss of antibodies over the first 6 months after the second dose of BNT162b2 vaccine. Only pre-vaccination COVID-19 is associated with a slower rate of antibody decrease. Our data support immunization with a third dose in this vulnerable, high-risk population. CI - (c) 2021 The American Geriatrics Society. FAU - Salmeron Rios, Sergio AU - Salmeron Rios S AUID- ORCID: 0000-0002-4405-687X AD - Residencia de Mayores San Vicente de Paul, Diputacion de Albacete, Albacete, Spain. FAU - Cortes Zamora, Elisa Belen AU - Cortes Zamora EB AD - Department of Geriatrics, Complejo Hospitalario Universitario de Albacete, Albacete, Spain. AD - CIBERFES, Ministerio de Economia y Competitividad, Madrid, Spain. FAU - Avendano Cespedes, Almudena AU - Avendano Cespedes A AD - Department of Geriatrics, Complejo Hospitalario Universitario de Albacete, Albacete, Spain. AD - CIBERFES, Ministerio de Economia y Competitividad, Madrid, Spain. AD - Facultad de Medicina, Universidad de Castilla-La Mancha, Albacete, Spain. FAU - Romero Rizos, Luis AU - Romero Rizos L AD - Department of Geriatrics, Complejo Hospitalario Universitario de Albacete, Albacete, Spain. AD - CIBERFES, Ministerio de Economia y Competitividad, Madrid, Spain. AD - Facultad de Medicina, Universidad de Castilla-La Mancha, Albacete, Spain. FAU - Sanchez-Jurado, Pedro Manuel AU - Sanchez-Jurado PM AD - Department of Geriatrics, Complejo Hospitalario Universitario de Albacete, Albacete, Spain. AD - CIBERFES, Ministerio de Economia y Competitividad, Madrid, Spain. AD - Facultad de Medicina, Universidad de Castilla-La Mancha, Albacete, Spain. FAU - Sanchez-Nievas, Gines AU - Sanchez-Nievas G AD - Department of Rheumatology, Complejo Hospitalario Universitario de Albacete, Albacete, Spain. FAU - Mas Romero, Marta AU - Mas Romero M AD - Department of Geriatrics, Complejo Hospitalario Universitario de Albacete, Albacete, Spain. FAU - Tabernero Sahuquillo, Maria Teresa AU - Tabernero Sahuquillo MT AD - Department of Geriatrics, Complejo Hospitalario Universitario de Albacete, Albacete, Spain. FAU - Blas Senalada, Jose Joaquin AU - Blas Senalada JJ AD - Department of Microbiology, Complejo Hospitalario Universitario de Albacete, Albacete, Spain. FAU - Murillo Romero, Antonio AU - Murillo Romero A AD - Complejo Hospitalario Universitario de Albacete, Albacete, Spain. FAU - Garcia Nogueras, Inmaculada AU - Garcia Nogueras I AD - Residencia de Mayores San Vicente de Paul, Diputacion de Albacete, Albacete, Spain. FAU - Estrella Cazalla, Juan de Dios AU - Estrella Cazalla JD AD - Department of Geriatrics, Complejo Hospitalario Universitario de Albacete, Albacete, Spain. AD - CIBERFES, Ministerio de Economia y Competitividad, Madrid, Spain. AD - Residencia de Mayores Nunez de Balboa, Albacete, Spain. FAU - Andres-Pretel, Fernando AU - Andres-Pretel F AD - Department of Statistics, Foundation of the National Paraplegics Hospital of Toledo, Toledo, Spain. FAU - Lauschke, Volker Martin AU - Lauschke VM AUID- ORCID: 0000-0002-1140-6204 AD - Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden. AD - Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany. FAU - Stebbing, Justin AU - Stebbing J AUID- ORCID: 0000-0002-1117-6947 AD - Department of Surgery and Cancer, Imperial College, Hammersmith Hospital, London, UK. FAU - Abizanda, Pedro AU - Abizanda P AUID- ORCID: 0000-0002-4707-2963 AD - Department of Geriatrics, Complejo Hospitalario Universitario de Albacete, Albacete, Spain. AD - CIBERFES, Ministerio de Economia y Competitividad, Madrid, Spain. AD - Facultad de Medicina, Universidad de Castilla-La Mancha, Albacete, Spain. LA - eng GR - CB16/10/00408/Centro de Investigacion Biomedica en Red Fragilidad y Envejecimiento Saludable/ GR - COV20/00004/Instituto de Salud Carlos III/ PT - Journal Article PT - Multicenter Study PT - Research Support, Non-U.S. Gov't DEP - 20211217 PL - United States TA - J Am Geriatr Soc JT - Journal of the American Geriatrics Society JID - 7503062 RN - 0 (BNT162 Vaccine) SB - IM MH - Aged MH - Aged, 80 and over MH - Antibody Formation MH - BNT162 Vaccine/administration & dosage/*immunology MH - COVID-19/*immunology/*prevention & control MH - *Persons with Disabilities MH - Female MH - *Frail Elderly MH - Humans MH - Longitudinal Studies MH - Male MH - Nursing Homes MH - SARS-CoV-2 MH - Spain OTO - NOTNLM OT - BNT162b2 vaccine OT - COVID-19 OT - antibody titers OT - disability OT - frailty OT - immunogenicity OT - nursing homes OT - older adults EDAT- 2021/12/12 06:00 MHDA- 2022/03/11 06:00 CRDT- 2021/12/11 17:03 PHST- 2021/12/02 00:00 [revised] PHST- 2021/09/23 00:00 [received] PHST- 2021/12/05 00:00 [accepted] PHST- 2021/12/12 06:00 [pubmed] PHST- 2022/03/11 06:00 [medline] PHST- 2021/12/11 17:03 [entrez] AID - 10.1111/jgs.17620 [doi] PST - ppublish SO - J Am Geriatr Soc. 2022 Mar;70(3):650-658. doi: 10.1111/jgs.17620. Epub 2021 Dec 17. PMID- 34882956 OWN - NLM STAT- MEDLINE DCOM- 20220913 LR - 20250728 IS - 1557-0681 (Electronic) IS - 1478-2189 (Print) IS - 1478-2189 (Linking) VI - 20 IP - 3 DP - 2022 Sep TI - The systemic immunosuppressive effects of peripheral corticosteroid injections: A narrative review of the evidence in the context of COVID-19. PG - 431-441 LID - 10.1002/msc.1603 [doi] AB - INTRODUCTION: Injected glucocorticoid's (corticosteroids) are commonly used in musculoskeletal practice. The current global COVID-19 pandemic has increased attention on the potential for locally injected corticosteroids to exert a systemic immunosuppressive effect and the implications this may have in relation to COVID-19 infection and vaccination. AIM: This narrative review summarises the evidence regarding the potential systemic immunosuppressive effects of peripheral corticosteroid injections in relation to the ongoing COVID-19 pandemic. METHOD: A narrative review was selected to allow inclusion of evidence related to a diverse range of topics relevant to this subject in order to provide the most comprehensive and clinically relevant guidance for clinicians. RESULTS/DISCUSSION: Current evidence demonstrates that cytotoxic, phagocytic and antigen presenting cells involved in both the innate and adaptive immune responses are suppressed for 48 h post-injection and messenger cytokines that are integral to immune function are suppressed for over 96 h post-injection. This potentially reduces an individual's ability to prevent viral infection, limit early viral replication, and delays activation of adaptive immune mechanisms (T and B lymphocytes) and subsequent viral clearance and elimination. The hypothalamic-pituitary-adrenal (HPA) axis can be suppressed for 2-4 weeks or longer following peripheral corticosteroid injections. The role of the HPA axis in immune function is not fully understood, however this could potentially indicate longer lasting immunosuppression. CONCLUSIONS: This review found evidence of suppression of immune cell numbers for the first 48 h post-injection, cytokines for over 96 h post-injection and HPA axis suppression lasting for 2-4 weeks or longer. There is currently no evidence that these physiological changes translate into a clinically meaningful increased risk of COVID-19 infection or related morbidity or mortality, but there is also no persuasive evidence that they do not. This review discusses the implications of the current evidence in relation to shared decision making, informed consent, risk management and COVID-19 vaccination to provide clinicians with a pragmatic guide to help navigate the current uncertainty regarding the potential immunosuppressive effects of peripheral corticosteroid injections. CI - (c) 2021 John Wiley & Sons Ltd. FAU - Regan, Paul AU - Regan P AUID- ORCID: 0000-0002-6439-5078 AD - Musculoskeletal Clinical and Assessment and Treatment Service, Salford Royal NHS Foundation Trust, Salford Care Organisation (Part of the Northern Care Alliance), Salford, UK. FAU - Elkhalifa, Shuayb AU - Elkhalifa S AD - Department of Immunology, Salford Royal NHS Foundation Trust, Salford Care Organisation (part of the Northern Care Alliance), Salford, UK. FAU - Barratt, Paul AU - Barratt P AD - Musculoskeletal Clinical and Assessment and Treatment Service, Salford Royal NHS Foundation Trust, Salford Care Organisation (Part of the Northern Care Alliance), Salford, UK. LA - eng PT - Journal Article PT - Review DEP - 20211209 PL - England TA - Musculoskeletal Care JT - Musculoskeletal care JID - 101181344 RN - 0 (Adrenal Cortex Hormones) RN - 0 (COVID-19 Vaccines) RN - 0 (Cytokines) SB - IM MH - Adrenal Cortex Hormones MH - *COVID-19 MH - COVID-19 Vaccines MH - Cytokines/pharmacology MH - Humans MH - *Hypothalamo-Hypophyseal System MH - Pandemics MH - Pituitary-Adrenal System PMC - PMC9015551 OTO - NOTNLM OT - COVID-19 OT - corticosteroids OT - immune OT - immunosuppression OT - injections OT - musculoskeletal OT - vaccination COIS- The authors declare no conflicts of interest. EDAT- 2021/12/10 06:00 MHDA- 2022/09/14 06:00 PMCR- 2021/12/09 CRDT- 2021/12/09 17:47 PHST- 2021/11/08 00:00 [received] PHST- 2021/11/13 00:00 [accepted] PHST- 2021/12/10 06:00 [pubmed] PHST- 2022/09/14 06:00 [medline] PHST- 2021/12/09 17:47 [entrez] PHST- 2021/12/09 00:00 [pmc-release] AID - MSC1603 [pii] AID - 10.1002/msc.1603 [doi] PST - ppublish SO - Musculoskeletal Care. 2022 Sep;20(3):431-441. doi: 10.1002/msc.1603. Epub 2021 Dec 9. PMID- 34850576 OWN - NLM STAT- MEDLINE DCOM- 20220228 LR - 20260127 IS - 1930-739X (Electronic) IS - 1930-7381 (Linking) VI - 30 IP - 3 DP - 2022 Mar TI - Antibody responses to BNT162b2 mRNA vaccine: Infection-naive individuals with abdominal obesity warrant attention. PG - 606-613 LID - 10.1002/oby.23353 [doi] AB - OBJECTIVE: The excess of visceral adipose tissue might hinder and delay immune response. How people with abdominal obesity (AO) will respond to mRNA vaccines against SARS-CoV-2 is yet to be established. SARS-CoV-2-specific antibody responses were evaluated after the first and second dose of the BNT162b2 mRNA vaccine, comparing the response of individuals with AO with the response of those without, and discerning between individuals with or without prior infection. METHODS: Immunoglobulin G (IgG)-neutralizing antibodies against the Trimeric complex (IgG-TrimericS) were measured at four time points: at baseline, at day 21 after vaccine dose 1, and at 1 and 3 months after dose 2. Nucleocapsid antibodies were assessed to detect prior SARS-CoV-2 infection. Waist circumference was measured to determine AO. RESULTS: Between the first and third month after vaccine dose 2, the drop in IgG-TrimericS levels was more remarkable in individuals with AO compared with those without AO (2.44-fold [95% CI: 2.22-2.63] vs. 1.82-fold [95% CI: 1.69-1.92], respectively, p < 0.001). Multivariable linear regression confirmed this result after inclusion of assessed confounders (p < 0.001). CONCLUSIONS: The waning antibody levels in individuals with AO may further support recent recommendations to offer booster vaccines to adults with high-risk medical conditions, including obesity, and particularly to those with a more prevalent AO phenotype. CI - (c) 2021 The Authors. Obesity published by Wiley Periodicals LLC on behalf of The Obesity Society (TOS). FAU - Malavazos, Alexis Elias AU - Malavazos AE AUID- ORCID: 0000-0002-0852-9625 AD - Endocrinology Unit, Clinical Nutrition and Cardiovascular Prevention Service, IRCCS San Donato Polyclinic, San Donato Milanese, Milan, Italy. AD - Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy. FAU - Basilico, Sara AU - Basilico S AUID- ORCID: 0000-0001-6860-6429 AD - Endocrinology Unit, Clinical Nutrition and Cardiovascular Prevention Service, IRCCS San Donato Polyclinic, San Donato Milanese, Milan, Italy. FAU - Iacobellis, Gianluca AU - Iacobellis G AUID- ORCID: 0000-0001-7888-9530 AD - Division of Diabetes, Endocrinology and Metabolism, Department of Medicine, University of Miami, Miller School of Medicine, Florida, USA. FAU - Milani, Valentina AU - Milani V AUID- ORCID: 0000-0002-2989-981X AD - Scientific Directorate, IRCCS San Donato Polyclinic, San Donato Milanese, Milan, Italy. FAU - Cardani, Rosanna AU - Cardani R AD - Biobank BioCor, Service of Laboratory Medicine1-Clinical Pathology, IRCCS San Donato Polyclinic, San Donato Milanese, Milan, Italy. FAU - Boniardi, Federico AU - Boniardi F AUID- ORCID: 0000-0002-3925-8362 AD - Endocrinology Unit, Clinical Nutrition and Cardiovascular Prevention Service, IRCCS San Donato Polyclinic, San Donato Milanese, Milan, Italy. FAU - Dubini, Carola AU - Dubini C AUID- ORCID: 0000-0003-1743-6516 AD - Endocrinology Unit, Clinical Nutrition and Cardiovascular Prevention Service, IRCCS San Donato Polyclinic, San Donato Milanese, Milan, Italy. FAU - Prandoni, Ilaria AU - Prandoni I AD - Endocrinology Unit, Clinical Nutrition and Cardiovascular Prevention Service, IRCCS San Donato Polyclinic, San Donato Milanese, Milan, Italy. FAU - Capitanio, Gloria AU - Capitanio G AD - Endocrinology Unit, Clinical Nutrition and Cardiovascular Prevention Service, IRCCS San Donato Polyclinic, San Donato Milanese, Milan, Italy. FAU - Renna, Laura Valentina AU - Renna LV AUID- ORCID: 0000-0003-1316-7478 AD - Biobank BioCor, Service of Laboratory Medicine1-Clinical Pathology, IRCCS San Donato Polyclinic, San Donato Milanese, Milan, Italy. FAU - Boveri, Sara AU - Boveri S AUID- ORCID: 0000-0003-3144-9364 AD - Scientific Directorate, IRCCS San Donato Polyclinic, San Donato Milanese, Milan, Italy. FAU - Rigolini, Roberta AU - Rigolini R AD - Operative Unit of Laboratory Medicine1-Clinical Pathology, Department of Pathology and Laboratory Medicine, IRCCS San Donato Polyclinic, San Donato Milanese, Milan, Italy. FAU - Carrara, Matteo AU - Carrara M AUID- ORCID: 0000-0002-8559-8296 AD - Residency Program in Clinical Pathology and Clinical Biochemistry, University of Milan, Milan, Italy. FAU - Spuria, Giovanni AU - Spuria G AD - Residency Program in Clinical Pathology and Clinical Biochemistry, University of Milan, Milan, Italy. FAU - Cuppone, Teresa AU - Cuppone T AD - Scientific Directorate, IRCCS San Donato Polyclinic, San Donato Milanese, Milan, Italy. FAU - D'acquisto, Aurelia AU - D'acquisto A AD - Scientific Directorate, IRCCS San Donato Polyclinic, San Donato Milanese, Milan, Italy. FAU - Carpinelli, Luca AU - Carpinelli L AD - Scientific Directorate, IRCCS San Donato Polyclinic, San Donato Milanese, Milan, Italy. FAU - Sacchi, Marta AU - Sacchi M AD - Service of Laboratory Medicine, IRCCS San Donato Polyclinic, San Donato Milanese, Milan, Italy. FAU - Morricone, Lelio AU - Morricone L AD - Endocrinology Unit, Clinical Nutrition and Cardiovascular Prevention Service, IRCCS San Donato Polyclinic, San Donato Milanese, Milan, Italy. FAU - Secchi, Francesco AU - Secchi F AUID- ORCID: 0000-0002-0357-1808 AD - Unit of Radiology, IRCCS San Donato Polyclinic, San Donato Milanese, Milan, Italy. AD - Department of Biomedical Sciences for Health, University of Milan, Milan, Italy. FAU - Costa, Elena AU - Costa E AUID- ORCID: 0000-0001-6311-7618 AD - Service of Laboratory Medicine, IRCCS San Donato Polyclinic, San Donato Milanese, Milan, Italy. FAU - Menicanti, Lorenzo AU - Menicanti L AUID- ORCID: 0000-0001-8530-6284 AD - Scientific Directorate, IRCCS San Donato Polyclinic, San Donato Milanese, Milan, Italy. FAU - Nisoli, Enzo AU - Nisoli E AUID- ORCID: 0000-0002-6670-1630 AD - Department of Medical Biotechnology and Translational Medicine, Centre for Study and Research on Obesity, University of Milan, Milan, Italy. FAU - Carruba, Michele AU - Carruba M AD - Department of Medical Biotechnology and Translational Medicine, Centre for Study and Research on Obesity, University of Milan, Milan, Italy. FAU - Ambrogi, Federico AU - Ambrogi F AUID- ORCID: 0000-0001-9358-011X AD - Scientific Directorate, IRCCS San Donato Polyclinic, San Donato Milanese, Milan, Italy. AD - Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy. FAU - Corsi Romanelli, Massimiliano Marco AU - Corsi Romanelli MM AUID- ORCID: 0000-0001-7928-7697 AD - Operative Unit of Laboratory Medicine1-Clinical Pathology, Department of Pathology and Laboratory Medicine, IRCCS San Donato Polyclinic, San Donato Milanese, Milan, Italy. AD - Department of Biomedical Sciences for Health, University of Milan, Milan, Italy. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220211 PL - United States TA - Obesity (Silver Spring) JT - Obesity (Silver Spring, Md.) JID - 101264860 RN - 0 (BNT162 Vaccine) RN - 0 (COVID-19 Vaccines) RN - 0 (Vaccines, Synthetic) RN - 0 (mRNA Vaccines) SB - IM MH - Antibody Formation MH - Attention MH - *BNT162 Vaccine MH - *COVID-19 MH - COVID-19 Vaccines MH - Humans MH - Obesity MH - Obesity, Abdominal MH - SARS-CoV-2 MH - Vaccines, Synthetic MH - mRNA Vaccines EDAT- 2021/12/02 06:00 MHDA- 2022/03/01 06:00 CRDT- 2021/12/01 07:50 PHST- 2021/11/11 00:00 [revised] PHST- 2021/08/31 00:00 [received] PHST- 2021/11/24 00:00 [accepted] PHST- 2021/12/02 06:00 [pubmed] PHST- 2022/03/01 06:00 [medline] PHST- 2021/12/01 07:50 [entrez] AID - 10.1002/oby.23353 [doi] PST - ppublish SO - Obesity (Silver Spring). 2022 Mar;30(3):606-613. doi: 10.1002/oby.23353. Epub 2022 Feb 11. PMID- 34842783 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20211203 IS - 2035-8385 (Print) IS - 2035-8377 (Electronic) IS - 2035-8385 (Linking) VI - 13 IP - 4 DP - 2021 Nov 19 TI - Spectrum of Neuroimaging Findings in Post-COVID-19 Vaccination: A Case Series and Review of Literature. PG - 622-639 LID - 10.3390/neurolint13040061 [doi] AB - Background and Purpose: The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first detected in Wuhan, China in December 2019. Symptoms range from mild flu-like symptoms to more severe presentations, including pneumonia, acute respiratory distress syndrome (ARDS), and even death. In response to the COVID-19 pandemic, the Emergency Use Authorization (EUA) approved the use of several vaccines. Because vaccines have been fast-tracked for emergency use, the short and long-term safety profile has been an area of concern. The aim of this paper is to extensively review published literature regarding post-COVID-19 vaccination neurological complications and characterize neuroimaging findings from three case presentations for early diagnosis and treatment. Methods: The analysis includes data from PubMed and Google Scholar. Articles included were retrieved from database inception beginning December 2020 with no language restrictions. Terms used include "SARS-CoV-2", "post Covid vaccination", "neurological complications", "Guillain-barre Syndrome", "Transverse-myelitis", "Cerebral Venous Sinus thrombosis", and "Cerebral hemorrhage". Results: The literature review yielded several neurological complications post vaccination, including cerebral sinus venous thrombosis, transverse myelitis, Guillain-Barre Syndrome and optic neuritis, to name a few. Patient case presentation findings were consistent with documented results in published literature. Conclusions: We present a case series with a thorough literature review documenting adverse neurological affects following COVID-19 vaccination. Our case presentations and literature review highlight the importance of neuroimaging when diagnosing post-COVID-19 vaccination adverse effects. MRI imaging study is an important tool to be considered in patients presenting with post-COVID-19 vaccination-related unexplained neurological symptoms for accurate diagnosis. FAU - Sriwastava, Shitiz AU - Sriwastava S AUID- ORCID: 0000-0001-6844-3287 AD - Department of Neurology, Rockefeller Neuroscience Institute, West Virginia University, Morgantown, WV 26506, USA. AD - School of Medicine, West Virginia University, Morgantown, WV 26506, USA. AD - West Virginia Clinical and Translational Science Institute, Morgantown, WV 26506, USA. AD - Department of Neurology, Wayne State University, Detroit, MI 48201, USA. FAU - Shrestha, Ashish K AU - Shrestha AK AUID- ORCID: 0000-0002-4614-7783 AD - Katmandu Medical College, School of Medicine, Kathmandu 44600, Nepal. FAU - Khalid, Syed Hassan AU - Khalid SH AD - Department of Neurology, Rockefeller Neuroscience Institute, West Virginia University, Morgantown, WV 26506, USA. FAU - Colantonio, Mark A AU - Colantonio MA AD - School of Medicine, West Virginia University, Morgantown, WV 26506, USA. FAU - Nwafor, Divine AU - Nwafor D AUID- ORCID: 0000-0001-7347-9524 AD - School of Medicine, West Virginia University, Morgantown, WV 26506, USA. FAU - Srivastava, Samiksha AU - Srivastava S AD - Department of Neurology, Wayne State University, Detroit, MI 48201, USA. LA - eng PT - Journal Article PT - Review DEP - 20211119 PL - Switzerland TA - Neurol Int JT - Neurology international JID - 101551564 PMC - PMC8628885 OTO - NOTNLM OT - COVID-19 vaccination OT - GBS OT - optic neuropathy OT - transverse myelitis COIS- The authors declare no conflict of interest. EDAT- 2021/11/30 06:00 MHDA- 2021/11/30 06:01 PMCR- 2021/11/19 CRDT- 2021/11/29 12:33 PHST- 2021/09/30 00:00 [received] PHST- 2021/11/12 00:00 [revised] PHST- 2021/11/17 00:00 [accepted] PHST- 2021/11/29 12:33 [entrez] PHST- 2021/11/30 06:00 [pubmed] PHST- 2021/11/30 06:01 [medline] PHST- 2021/11/19 00:00 [pmc-release] AID - neurolint13040061 [pii] AID - neurolint-13-00061 [pii] AID - 10.3390/neurolint13040061 [doi] PST - epublish SO - Neurol Int. 2021 Nov 19;13(4):622-639. doi: 10.3390/neurolint13040061. PMID- 34839149 OWN - NLM STAT- MEDLINE DCOM- 20220113 LR - 20230104 IS - 1872-8421 (Electronic) IS - 0165-5728 (Print) IS - 0165-5728 (Linking) VI - 362 DP - 2022 Jan 15 TI - A systematic review of cases of CNS demyelination following COVID-19 vaccination. PG - 577765 LID - S0165-5728(21)00292-7 [pii] LID - 10.1016/j.jneuroim.2021.577765 [doi] AB - BACKGROUND: Since the emergency use approval of different types of COVID-19 vaccines, several safety concerns have been raised regarding its early and delayed impact on the nervous system. OBJECTIVE: This study aims to systematically review the reported cases of CNS demyelination in association with COVID-19 vaccination, which has not been performed, to our knowledge. METHODS: A systematic review was performed by screening published articles and preprints of cases of CNS demyelination in association with COVID-19 vaccines in PubMed, SCOPUS, EMBASE, Google Scholar, Ovid and medRxiv databases, until September 30, 2021. This study followed PRISMA guidelines. Descriptive findings of reported cases were reviewed and stratified by demographic and clinical findings, diagnostic work-up, management, and overall outcome. RESULTS: A total of 32 cases were identified, with female predominance (68.8%) and median age of 44 years. Eleven cases were reported after Pfizer vaccine, 8 following AstraZeneca vaccine, 6 following Moderna, 5 following Sinovac/ Sinopharm vaccines, and one following each of Sputnik and Johnson&Johnson vaccines. The majority of cases (71.8%) occurred after the first dose of the vaccine, with neurological symptoms manifesting after a median of 9 days. The most common reported presentations were transverse myelitis (12/32) and MS-like pictures (first diagnosis or a relapse) in another 12/32 cases, followed by ADEM- like (5/32), and NMOSD- like (3/32) presentations. History of a previous immune-mediated disease was reported in 17/32 (53.1%) cases. The mRNA-based vaccines resulted in the greatest number of demyelinating syndromes (17/32), followed by viral vector vaccines (10/32), and inactivated vaccines (5/32). Most MS-like episodes (9/12) were triggered by mRNA-based vaccines, while TM occurred following both viral vector and mRNA-based vaccines. Management included high dose methylprednisolone, PLEX, IVIg, or a combination of those, with a favorable outcome in the majority of case; marked/complete improvement (25/32) or stabilized/ partial recovery in the remaining cases. CONCLUSION: This systematic review identified few cases of CNS demyelination following all types of approved COVID-19 vaccines so far. Clinical presentation was heterogenous, mainly following the first dose, however, half of the reported cases had a history of immune-mediated disease. Favorable outcome was observed in most cases. We suggest long-term post-marketing surveillance for these cases, to assess for causality, and ensure the safety of COVID-19 vaccines. CI - Copyright (c) 2021 Elsevier B.V. All rights reserved. FAU - Ismail, Ismail Ibrahim AU - Ismail II AD - Department of Neurology, Ibn Sina Hospital, Kuwait. Electronic address: dr.ismail.ibrahim2012@gmail.com. FAU - Salama, Sara AU - Salama S AD - Department of Neurology and Psychiatry, University of Alexandria, Alexandria, Egypt. LA - eng PT - Journal Article PT - Systematic Review DEP - 20211109 PL - Netherlands TA - J Neuroimmunol JT - Journal of neuroimmunology JID - 8109498 RN - 0 (COVID-19 Vaccines) SB - IM MH - COVID-19/*prevention & control MH - COVID-19 Vaccines/*adverse effects MH - Demyelinating Autoimmune Diseases, CNS/*chemically induced/*epidemiology/etiology MH - Humans MH - SARS-CoV-2 PMC - PMC8577051 OTO - NOTNLM OT - COVID-19 OT - Demyelinating disease OT - Multiple sclerosis OT - SARS-CoV-2 OT - Transverse myelitis OT - Vaccine EDAT- 2021/11/29 06:00 MHDA- 2022/01/14 06:00 PMCR- 2021/11/09 CRDT- 2021/11/28 21:03 PHST- 2021/09/10 00:00 [received] PHST- 2021/10/15 00:00 [revised] PHST- 2021/11/04 00:00 [accepted] PHST- 2021/11/29 06:00 [pubmed] PHST- 2022/01/14 06:00 [medline] PHST- 2021/11/28 21:03 [entrez] PHST- 2021/11/09 00:00 [pmc-release] AID - S0165-5728(21)00292-7 [pii] AID - 577765 [pii] AID - 10.1016/j.jneuroim.2021.577765 [doi] PST - ppublish SO - J Neuroimmunol. 2022 Jan 15;362:577765. doi: 10.1016/j.jneuroim.2021.577765. Epub 2021 Nov 9. PMID- 34835258 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20211130 IS - 2076-393X (Print) IS - 2076-393X (Electronic) IS - 2076-393X (Linking) VI - 9 IP - 11 DP - 2021 Nov 15 TI - Public Interest in Distribution and Determinants of Influenza and Pneumonia Vaccination during the COVID-19 Pandemic: An Infodemiology and Cross-Sectional Study from China. LID - 10.3390/vaccines9111329 [doi] LID - 1329 AB - BACKGROUND: Following the COVID-19 pandemic, global interest in influenza vaccines and pneumonia vaccines has increased significantly. We aimed to examine public interest in and actual market circulation of influenza and pneumonia vaccines before and after the initial outbreak of COVID-19 and estimate the coverage and determinants of influenza and pneumonia vaccination uptake following the COVID-19 pandemic. METHODS: We obtained search volume data for vaccines using the Baidu search index and collected the numbers of vaccines issued from the National Institutes for Food and Drug Control. We also conducted a cross-sectional survey among 3346 adult residents to evaluate the coverage and determinants of influenza and pneumonia vaccination uptake in the Yangtze River delta, China, from 29 January to 4 February 2021. RESULTS: Public searches and the number of vaccines issued for the influenza vaccines and pneumonia vaccines obviously increased after the initial outbreak of COVID-19. In the total sample, 12.5% were vaccinated against influenza, and 21.5% had at least one family member vaccinated against pneumonia. A minority of participants perceived that they were highly or very highly susceptible to influenza (15.9%) and COVID-19 (6.7%). A range of socio-economic factors and perceived susceptibility to COVID-19 were associated with influenza and pneumonia vaccination uptake. CONCLUSIONS: Public interest in and issued volumes of influenza and pneumonia vaccines increased nationally following the COVID-19 pandemic. Perceptions of high susceptibility to COVID-19 were associated with the uptake of the influenza and pneumonia vaccines. Targeted interventions were needed to improve vaccination coverage. FAU - Gong, Liubing AU - Gong L AD - Chizhou Center for Disease Prevention and Control, Chizhou 247100, China. FAU - Zhang, Xu AU - Zhang X AUID- ORCID: 0000-0003-1109-6880 AD - School of Public Health, NHC Key Laboratory of Health Technology Assessment, Fudan University, Shanghai 200032, China. FAU - Qu, Zhiqiang AU - Qu Z AUID- ORCID: 0000-0003-0259-8467 AD - School of Public Health, NHC Key Laboratory of Health Technology Assessment, Fudan University, Shanghai 200032, China. FAU - Francis, Mark R AU - Francis MR AD - Health Sciences Unit, Faculty of Social Sciences, Tampere University, 33014 Tampere, Finland. FAU - Han, Kaiyi AU - Han K AD - School of Public Health, NHC Key Laboratory of Health Technology Assessment, Fudan University, Shanghai 200032, China. AD - Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London WC1E 7HT, UK. FAU - Xu, Cuilin AU - Xu C AD - Yuhuatai Center for Disease Prevention and Control, Nanjing 210012, China. FAU - Cai, Enmao AU - Cai E AD - Changning Center for Disease Prevention and Control, Shanghai 200051, China. FAU - Shi, Huilin AU - Shi H AD - School of Public Health, Key Laboratory of Public Health Safety (Ministry of Education), Fudan University, Shanghai 200032, China. FAU - Hou, Zhiyuan AU - Hou Z AUID- ORCID: 0000-0003-3413-0076 AD - School of Public Health, NHC Key Laboratory of Health Technology Assessment, Fudan University, Shanghai 200032, China. LA - eng GR - 71874034/National Natural Science Foundation of China/ GR - GWV-10.1-XK23/the Three-Year Initiative Plan for Strengthening Public Health System Construction in Shanghai (2020-2022)/ PT - Journal Article DEP - 20211115 PL - Switzerland TA - Vaccines (Basel) JT - Vaccines JID - 101629355 PMC - PMC8623096 OTO - NOTNLM OT - COVID-19 OT - determinant OT - influenza vaccine OT - pneumonia vaccine OT - public attention OT - vaccination COIS- The authors declare no conflict of interest. EDAT- 2021/11/28 06:00 MHDA- 2021/11/28 06:01 PMCR- 2021/11/15 CRDT- 2021/11/27 01:27 PHST- 2021/10/23 00:00 [received] PHST- 2021/11/09 00:00 [revised] PHST- 2021/11/11 00:00 [accepted] PHST- 2021/11/27 01:27 [entrez] PHST- 2021/11/28 06:00 [pubmed] PHST- 2021/11/28 06:01 [medline] PHST- 2021/11/15 00:00 [pmc-release] AID - vaccines9111329 [pii] AID - vaccines-09-01329 [pii] AID - 10.3390/vaccines9111329 [doi] PST - epublish SO - Vaccines (Basel). 2021 Nov 15;9(11):1329. doi: 10.3390/vaccines9111329. PMID- 34834950 OWN - NLM STAT- MEDLINE DCOM- 20211210 LR - 20211214 IS - 1999-4915 (Electronic) IS - 1999-4915 (Linking) VI - 13 IP - 11 DP - 2021 Oct 24 TI - Impairment of CD4+ T and Memory B Cell Responses but Normal Memory CD8+T-Cell Activation on Crohn's Disease after COVID-19 Vaccination: A Twin Case. LID - 10.3390/v13112143 [doi] LID - 2143 AB - Vaccines to prevent the impact of SARS-CoV-2 are now available, including for patients with autoimmune diseases. However, there is no information about how inflammatory bowel disease (IBD) treatment could impact the cellular and humoral immune responses. This study evaluated SARS-CoV-2-specific humoral and cellular responses after vaccination with a two-dose schedule in a Crohn's disease patient treated with Infliximab (10 mg/kg); we included comparisons with a monozygotic twin. The results showed that the Crohn's disease's twin (twin 2) had no antibody detection and reduced activation of CD4+ T cell responses, unlike the twin without the autoimmune disease (twin 1). Twin 2 developed antigen-specific central memory CD8+ T-cells and IFNgamma production after the second dose of COVID-19 vaccination, similar to twin 1. These findings elucidated the role of T-cell immunity after COVID-19 immunization on IBD patients despite the lack of antibody production. Finally, our observation supports the consensus recommendation for IBD patients to receive COVID-19 vaccines. FAU - Melgaco, Fabiana Gil AU - Melgaco FG AD - Laboratorio de Cultu and s Biologicas, Instituto Federal de Educacao, Ciencia e Tecnologia do Rio de Janeiro, Duque de Caxias 25050-100, Brazil. FAU - Azamor, Tamiris AU - Azamor T AUID- ORCID: 0000-0002-4047-2091 AD - Instituto de Tecnologia em Imunobiologicos, Bio-Manguinhos, Fundacao Oswaldo Cruz, FIOCRUZ, Rio de Janeiro 21040-900, Brazil. FAU - Villar, Livia Melo AU - Villar LM AUID- ORCID: 0000-0001-7644-8969 AD - Laboratorio de Hepatites Virais, Instituto Oswaldo Cruz, Fundacao Oswaldo Cruz, FIOCRUZ, Rio de Janeiro 21040-360, Brazil. FAU - Ano Bom, Ana Paula Dinis AU - Ano Bom APD AD - Instituto de Tecnologia em Imunobiologicos, Bio-Manguinhos, Fundacao Oswaldo Cruz, FIOCRUZ, Rio de Janeiro 21040-900, Brazil. FAU - Melgaco, Juliana Gil AU - Melgaco JG AUID- ORCID: 0000-0003-0087-6531 AD - Instituto de Tecnologia em Imunobiologicos, Bio-Manguinhos, Fundacao Oswaldo Cruz, FIOCRUZ, Rio de Janeiro 21040-900, Brazil. LA - eng GR - BIO-003-FIO-20/Fundacao Oswaldo Cruz/ GR - SEI-260003/002688/2020/Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro/ GR - VPPCB-05-FIO-20-2-52/Fundacao Oswaldo Cruz/ PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20211024 PL - Switzerland TA - Viruses JT - Viruses JID - 101509722 RN - 0 (Antibodies, Viral) RN - 0 (Spike Glycoprotein, Coronavirus) RN - 0 (spike protein, SARS-CoV-2) RN - 82115-62-6 (Interferon-gamma) RN - B5S3K2V0G8 (ChAdOx1 nCoV-19) RN - B72HH48FLU (Infliximab) SB - IM MH - Adult MH - Antibodies, Viral/blood MH - CD4-Positive T-Lymphocytes/*immunology MH - CD8-Positive T-Lymphocytes/*immunology MH - ChAdOx1 nCoV-19/*immunology MH - Crohn Disease/drug therapy/*immunology MH - Female MH - Humans MH - Immunity, Humoral MH - Infliximab/therapeutic use MH - Interferon-gamma/analysis MH - *Lymphocyte Activation MH - Memory B Cells/*immunology MH - SARS-CoV-2/immunology MH - Spike Glycoprotein, Coronavirus/immunology MH - Twins, Monozygotic PMC - PMC8620698 OTO - NOTNLM OT - COVID-19 OT - Crohn's disease OT - SARS-CoV-2 OT - vaccine COIS- The authors declare no conflict of interest. EDAT- 2021/11/28 06:00 MHDA- 2021/12/15 06:00 PMCR- 2021/10/24 CRDT- 2021/11/27 01:26 PHST- 2021/07/22 00:00 [received] PHST- 2021/10/19 00:00 [revised] PHST- 2021/10/20 00:00 [accepted] PHST- 2021/11/27 01:26 [entrez] PHST- 2021/11/28 06:00 [pubmed] PHST- 2021/12/15 06:00 [medline] PHST- 2021/10/24 00:00 [pmc-release] AID - v13112143 [pii] AID - viruses-13-02143 [pii] AID - 10.3390/v13112143 [doi] PST - epublish SO - Viruses. 2021 Oct 24;13(11):2143. doi: 10.3390/v13112143. PMID- 34831138 OWN - NLM STAT- MEDLINE DCOM- 20211210 LR - 20260127 IS - 2073-4409 (Electronic) IS - 2073-4409 (Linking) VI - 10 IP - 11 DP - 2021 Oct 27 TI - B Cell Response Induced by SARS-CoV-2 Infection Is Boosted by the BNT162b2 Vaccine in Primary Antibody Deficiencies. LID - 10.3390/cells10112915 [doi] LID - 2915 AB - BACKGROUND: Patients with primary antibody deficiencies are at risk in the current COVID-19 pandemic due to their impaired response to infection and vaccination. Specifically, patients with common variable immunodeficiency (CVID) generated poor spike-specific antibody and T cell responses after immunization. METHODS: Thirty-four CVID convalescent patients after SARS-CoV-2 infection, 38 CVID patients immunized with two doses of the BNT162b2 vaccine, and 20 SARS-CoV-2 CVID convalescents later and immunized with BNT162b2 were analyzed for the anti-spike IgG production and the generation of spike-specific memory B cells and T cells. RESULTS: Spike-specific IgG was induced more frequently after infection than after vaccination (82% vs. 34%). The antibody response was boosted in convalescents by vaccination. Although immunized patients generated atypical memory B cells possibly by extra-follicular or incomplete germinal center reactions, convalescents responded to infection by generating spike-specific memory B cells that were improved by the subsequent immunization. Poor spike-specific T cell responses were measured independently from the immunological challenge. CONCLUSIONS: SARS-CoV-2 infection primed a more efficient classical memory B cell response, whereas the BNT162b2 vaccine induced non-canonical B cell responses in CVID. Natural infection responses were boosted by subsequent immunization, suggesting the possibility to further stimulate the immune response by additional vaccine doses in CVID. FAU - Pulvirenti, Federica AU - Pulvirenti F AD - Regional Reference Centre for Primary Immune Deficiencies, Azienda Ospedaliera Universitaria Policlinico Umberto I, 00185 Rome, Italy. FAU - Fernandez Salinas, Ane AU - Fernandez Salinas A AD - Department of Molecular Medicine, Sapienza University of Rome, 00185 Rome, Italy. AD - Diagnostic Immunology Research Unit, Multimodal Medicine Research Area, Bambino Gesu Children's Hospital, IRCCS, Viale di San Paolo, 00146 Rome, Italy. FAU - Milito, Cinzia AU - Milito C AUID- ORCID: 0000-0003-2581-9250 AD - Department of Molecular Medicine, Sapienza University of Rome, 00185 Rome, Italy. FAU - Terreri, Sara AU - Terreri S AUID- ORCID: 0000-0002-5791-6306 AD - Diagnostic Immunology Research Unit, Multimodal Medicine Research Area, Bambino Gesu Children's Hospital, IRCCS, Viale di San Paolo, 00146 Rome, Italy. FAU - Piano Mortari, Eva AU - Piano Mortari E AUID- ORCID: 0000-0002-0054-4732 AD - Diagnostic Immunology Research Unit, Multimodal Medicine Research Area, Bambino Gesu Children's Hospital, IRCCS, Viale di San Paolo, 00146 Rome, Italy. FAU - Quintarelli, Concetta AU - Quintarelli C AD - Department Onco-Haematology, and Cell and Gene Therapy, Bambino Gesu Children Hospital, IRCCS, 00116 Rome, Italy. AD - Department of Clinical Medicine and Surgery, University of Naples Federico II, 80131 Naples, Italy. FAU - Di Cecca, Stefano AU - Di Cecca S AD - Department Onco-Haematology, and Cell and Gene Therapy, Bambino Gesu Children Hospital, IRCCS, 00116 Rome, Italy. FAU - Lagnese, Gianluca AU - Lagnese G AD - Department of Translational Medical Sciences, University of Naples Federico II, 80131 Naples, Italy. FAU - Punziano, Alessandra AU - Punziano A AD - Department of Translational Medical Sciences, University of Naples Federico II, 80131 Naples, Italy. FAU - Guercio, Marika AU - Guercio M AD - Department Onco-Haematology, and Cell and Gene Therapy, Bambino Gesu Children Hospital, IRCCS, 00116 Rome, Italy. FAU - Bonanni, Livia AU - Bonanni L AD - Regional Reference Centre for Primary Immune Deficiencies, Azienda Ospedaliera Universitaria Policlinico Umberto I, 00185 Rome, Italy. FAU - Auria, Stefania AU - Auria S AD - Regional Reference Centre for Primary Immune Deficiencies, Azienda Ospedaliera Universitaria Policlinico Umberto I, 00185 Rome, Italy. FAU - Villani, Francesca AU - Villani F AD - Regional Reference Centre for Primary Immune Deficiencies, Azienda Ospedaliera Universitaria Policlinico Umberto I, 00185 Rome, Italy. FAU - Albano, Christian AU - Albano C AD - Diagnostic Immunology Research Unit, Multimodal Medicine Research Area, Bambino Gesu Children's Hospital, IRCCS, Viale di San Paolo, 00146 Rome, Italy. FAU - Locatelli, Franco AU - Locatelli F AD - Department Onco-Haematology, and Cell and Gene Therapy, Bambino Gesu Children Hospital, IRCCS, 00116 Rome, Italy. AD - Dipartimento Materno-Infantile e Scienze Urologiche, Sapienza University of Rome, 00185 Rome, Italy. FAU - Spadaro, Giuseppe AU - Spadaro G AD - Department of Translational Medical Sciences, University of Naples Federico II, 80131 Naples, Italy. FAU - Carsetti, Rita AU - Carsetti R AD - Diagnostic Immunology Research Unit, Multimodal Medicine Research Area, Bambino Gesu Children's Hospital, IRCCS, Viale di San Paolo, 00146 Rome, Italy. FAU - Quinti, Isabella AU - Quinti I AD - Department of Molecular Medicine, Sapienza University of Rome, 00185 Rome, Italy. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20211027 PL - Switzerland TA - Cells JT - Cells JID - 101600052 RN - 0 (Antibodies, Viral) RN - 0 (BNT162 Vaccine) RN - 0 (Immunoglobulin G) RN - 0 (Spike Glycoprotein, Coronavirus) RN - 0 (spike protein, SARS-CoV-2) SB - IM MH - Adult MH - Antibodies, Viral/immunology MH - BNT162 Vaccine/*immunology MH - COVID-19/complications/*immunology/prevention & control MH - Convalescence MH - Female MH - Humans MH - Immunization MH - Immunoglobulin G/immunology MH - Male MH - Memory B Cells/*immunology MH - Middle Aged MH - Primary Immunodeficiency Diseases/complications/*immunology MH - SARS-CoV-2/*immunology MH - Spike Glycoprotein, Coronavirus/immunology MH - T-Lymphocytes/immunology PMC - PMC8616496 OTO - NOTNLM OT - BNT162b2 OT - COVID-1 OT - SARS-CoV-2 OT - antibody response OT - common variable immunodeficiencies OT - memory B cells OT - spike protein OT - third dose OT - vaccine COIS- Authors declare that they have no competing interest. EDAT- 2021/11/28 06:00 MHDA- 2021/12/15 06:00 PMCR- 2021/10/27 CRDT- 2021/11/27 01:14 PHST- 2021/09/16 00:00 [received] PHST- 2021/10/19 00:00 [revised] PHST- 2021/10/24 00:00 [accepted] PHST- 2021/11/27 01:14 [entrez] PHST- 2021/11/28 06:00 [pubmed] PHST- 2021/12/15 06:00 [medline] PHST- 2021/10/27 00:00 [pmc-release] AID - cells10112915 [pii] AID - cells-10-02915 [pii] AID - 10.3390/cells10112915 [doi] PST - epublish SO - Cells. 2021 Oct 27;10(11):2915. doi: 10.3390/cells10112915. PMID- 34809772 OWN - NLM STAT- MEDLINE DCOM- 20211124 LR - 20221221 IS - 1879-1131 (Electronic) IS - 0738-081X (Print) IS - 0738-081X (Linking) VI - 39 IP - 4 DP - 2021 Jul-Aug TI - Attention all anti-vaccinators: The cutaneous adverse events from the mRNA COVID-19 vaccines are not an excuse to avoid them! PG - 674-687 LID - S0738-081X(21)00108-5 [pii] LID - 10.1016/j.clindermatol.2021.05.027 [doi] AB - Despite the growing availability of coronavirus disease 2019 (COVID-19) vaccines in the general population, a significant proportion of individuals demonstrate vaccine hesitancy. We sought to consolidate and update current evidence on cutaneous adverse events from COVID-19 vaccines to aid in the education and counseling of patients concerned about potential cutaneous side effects. We conducted a literature review of PubMed in May 2021 to identify reports of cutaneous events after vaccination with the Pfizer-BioNTech and Moderna vaccines (postauthorization clinical reports pertaining to the Johnson & Johnson and AstraZeneca vaccines were limited). Event reports in the Vaccine Adverse Event Reporting System were reviewed. Localized cutaneous reactions were common after the mRNA vaccines, consistent with clinical trial findings. Reported urticarial and morbilliform eruptions may reflect immediate hypersensitivity but have rarely been associated with anaphylaxis. There are infrequent reports of herpes zoster, dermatologic filler reactions, and immune thrombocytopenia, mainly occurring in high-risk patient groups. Ultimately, the identified cutaneous reactions are largely self-limited and should not discourage vaccination. Existing reports should reassure patients of the overall compelling safety profiles of the mRNA COVID-19 vaccines and benignity of skin reactions after vaccination. CI - Copyright (c) 2021 Elsevier Inc. All rights reserved. FAU - Gronbeck, Christian AU - Gronbeck C AD - University of Connecticut School of Medicine, Farmington, Connecticut, USA. FAU - Grant-Kels, Jane M AU - Grant-Kels JM AD - Department of Dermatology, University of Connecticut School of Medicine, Farmington, Connecticut, USA. Electronic address: grant@uchc.edu. LA - eng PT - Journal Article PT - Review DEP - 20210521 PL - United States TA - Clin Dermatol JT - Clinics in dermatology JID - 8406412 RN - 0 (COVID-19 Vaccines) RN - 0 (RNA, Messenger) RN - 0 (Vaccines) SB - IM MH - Attention MH - *COVID-19 MH - COVID-19 Vaccines MH - Humans MH - RNA, Messenger MH - SARS-CoV-2 MH - *Vaccines PMC - PMC8139532 COIS- Conflict of interest The authors declare no conflict of interest. EDAT- 2021/11/24 06:00 MHDA- 2021/11/25 06:00 PMCR- 2021/05/21 CRDT- 2021/11/23 05:41 PHST- 2021/11/23 05:41 [entrez] PHST- 2021/11/24 06:00 [pubmed] PHST- 2021/11/25 06:00 [medline] PHST- 2021/05/21 00:00 [pmc-release] AID - S0738-081X(21)00108-5 [pii] AID - 10.1016/j.clindermatol.2021.05.027 [doi] PST - ppublish SO - Clin Dermatol. 2021 Jul-Aug;39(4):674-687. doi: 10.1016/j.clindermatol.2021.05.027. Epub 2021 May 21. PMID- 34803439 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231108 IS - 1303-6092 (Electronic) IS - 1300-0152 (Print) IS - 1300-0152 (Linking) VI - 45 IP - 4 DP - 2021 TI - An update comprehensive review on the status of COVID-19: vaccines, drugs, variants and neurological symptoms. PG - 342-357 LID - 10.3906/biy-2106-23 [doi] AB - Various recently reported mutant variants, candidate and urgently approved current vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), many current situations with severe neurological damage and symptoms as well as respiratory tract disorders have begun to be reported. In particular, drug, vaccine, and neutralizing monoclonal antibodies (mAbs) have been developed and are currently being evaluated in clinical trials. Here, we review lessons learned from the use of novel mutant variants of the COVID-19 virus, immunization, new drug solutions, and antibody therapies for infections. Next, we focus on the B 1.1.7, B 1.351, P.1, and B.1.617 lineages or variants of concern that have been reported worldwide, the new manifestations of neurological manifestations, the current therapeutic drug targets for its treatment, vaccine candidates and their efficacy, implantation of convalescent plasma, and neutralization of mAbs. We review specific clinical questions, including many emerging neurological effects and respiratory tract injuries, as well as new potential biomarkers, new studies in addition to known therapeutics, and chronic diseases of vaccines that have received immediate approval. To answer these questions, further understanding of the burden kinetics of COVID-19 and its correlation with neurological clinical outcomes, endogenous antibody responses to vaccines, pharmacokinetics of neutralizing mAbs, and action against emerging viral mutant variants is needed. CI - Copyright (c) 2021 The Author(s). FAU - Ozkan Oktay, Ebru AU - Ozkan Oktay E AUID- ORCID: 0000-0002-0395-9845 AD - Laboratory Technology Program, Vocational School of Health Services, Uskudar University, Istanbul Turkey. FAU - Tuncay, Salih AU - Tuncay S AUID- ORCID: 0000-0003-3838-5228 AD - Food Technology Program, Vocational School of Health Services, Uskudar University, Istanbul Turkey. FAU - Kaman, Tugba AU - Kaman T AUID- ORCID: 0000-0002-5885-0193 AD - Medical and Aromatic Plants Program, Vocational School of Health Services, Uskudar University, Istanbul Turkey. FAU - Karasakal, Omer Faruk AU - Karasakal OF AUID- ORCID: 0000-0001-7803-3249 AD - Medical Laboratory Techniques Program, Vocational School of Health Services, Uskudar University, Istanbul Turkey. FAU - Ozcan, Oznur Ozge AU - Ozcan OO AUID- ORCID: 0000-0001-8992-0556 AD - Physiotherapy Program, Vocational School of Health Services, Uskudar University, Istanbul Turkey. FAU - Soylamis, Tugce AU - Soylamis T AUID- ORCID: 0000-0002-4663-897X AD - Laboratory Technology Program, Vocational School of Health Services, Uskudar University, Istanbul Turkey. FAU - Karahan, Mesut AU - Karahan M AUID- ORCID: 0000-0002-8971-678X AD - Vocational School of Health Services, Uskudar University, Istanbul Turkey. FAU - Konuk, Muhsin AU - Konuk M AUID- ORCID: 0000-0002-6651-718X AD - Department of Molecular Biology and Genetics, Faculty of Engineering and Natural Sciences, Uskudar University, Istanbul Turkey. LA - eng PT - Journal Article PT - Review DEP - 20210830 PL - Turkey TA - Turk J Biol JT - Turkish journal of biology = Turk biyoloji dergisi JID - 9434434 PMC - PMC8573837 OTO - NOTNLM OT - COVID-19 OT - SARS-CoV-2 OT - drugs OT - neurological symptoms OT - neutralizing antibodies OT - vaccines OT - variants COIS- CONFLICT OF INTEREST: none declared EDAT- 2021/11/23 06:00 MHDA- 2021/11/23 06:01 PMCR- 2021/08/30 CRDT- 2021/11/22 06:36 PHST- 2021/06/08 00:00 [received] PHST- 2021/07/28 00:00 [accepted] PHST- 2021/11/22 06:36 [entrez] PHST- 2021/11/23 06:00 [pubmed] PHST- 2021/11/23 06:01 [medline] PHST- 2021/08/30 00:00 [pmc-release] AID - 10.3906/biy-2106-23 [doi] PST - epublish SO - Turk J Biol. 2021 Aug 30;45(4):342-357. doi: 10.3906/biy-2106-23. eCollection 2021. PMID- 34794147 OWN - NLM STAT- MEDLINE DCOM- 20220307 LR - 20260127 IS - 1423-0097 (Electronic) IS - 1018-2438 (Print) IS - 1018-2438 (Linking) VI - 183 IP - 3 DP - 2022 TI - Immune Response to SARS-CoV-2 Vaccine in 2 Men. PG - 350-359 LID - 10.1159/000520046 [doi] AB - INTRODUCTION: In the trials of corona virus vaccines, detailed analyses of subsets of lymphocytes were not carried out. We present perhaps the most comprehensive immunological analysis of 29 subsets of B and T cells in 2 healthy subjects receiving 2 doses of the Pfizer SARS-CoV-2 (COVID-19) vaccine. METHODS: Analyses were performed prior to vaccination, 3 weeks following the 1st dose, and 4 weeks following the 2nd dose. Total, naive (TN), and different memory and effector subsets (TCM, TEM, and TEMRA) of CD4+ and CD8+ T cells; SARS-CoV-2 spike protein-specific tetramer+, and cytotoxic CD8+ T; subsets of T follicular cells (TFH, TFH1, TFH2, TFH1/TFH17, and TFH17); B-cell subsets (mature B cells, naive B cells, transitional B cells, marginal zone B cells, class-switched memory B cells, germinal center B cells, and CD21low B cells), and plasmablasts; and regulatory lymphocytes (CD4+ Treg, CD8+ Treg, Breg, and TFR cells) were evaluated with specific monoclonal antibodies by flow cytometry. RESULTS: A lack of COVID-19 IgG antibodies after the 1st dose in one of 2 subjects was associated with increased regulatory lymphocytes and decreased plasmablasts. Seroconversion after the 2nd dose in this subject was associated with decreased TFR cells and increased plasmablasts. In both subjects, CD4 TEM and CD8 TCM were markedly increased following the 2nd dose. TFH1 and regulatory lymphocytes were increased (except Breg) following the 1st dose. A striking increase in SARS-CoV-2-specific CD8+ T cells was observed following the 2nd dose. CONCLUSION: Our data support the need for 2nd dose of vaccine to induce strong SARS-CoV-2 CD8 T-cell specific response and generation of memory subsets of CD4+ and CD8+ T cells. Regulatory lymphocytes appear to play a role in the magnitude of response. CI - (c) 2021 S. Karger AG, Basel. FAU - Gupta, Sudhir AU - Gupta S AD - Division of Basic and Clinical Immunology, University of California Irvine, Irvine, California, USA. FAU - Su, Houfen AU - Su H AD - Division of Basic and Clinical Immunology, University of California Irvine, Irvine, California, USA. FAU - Agrawal, Sudhanshu AU - Agrawal S AD - Division of Basic and Clinical Immunology, University of California Irvine, Irvine, California, USA. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20211118 PL - Switzerland TA - Int Arch Allergy Immunol JT - International archives of allergy and immunology JID - 9211652 RN - 0 (Antibodies, Viral) RN - 0 (BNT162 Vaccine) RN - 0 (Immunoglobulin G) SB - IM MH - Aged MH - Antibodies, Viral/*blood MH - B-Lymphocytes/immunology MH - BNT162 Vaccine/*immunology MH - CD4-Positive T-Lymphocytes/immunology MH - CD8-Positive T-Lymphocytes/immunology MH - COVID-19/*prevention & control MH - Humans MH - Immunoglobulin G/blood MH - Male MH - Middle Aged MH - SARS-CoV-2/*immunology MH - T-Lymphocytes, Regulatory/immunology MH - *Vaccination PMC - PMC8678225 OTO - NOTNLM OT - COVID-19 OT - Follicular helper T cells OT - Memory B cells OT - Memory T cells OT - Regulatory lymphocytes OT - SARS-CoV-2-specific CD8 T cells OT - Vaccine COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2021/11/19 06:00 MHDA- 2022/03/08 06:00 PMCR- 2021/11/18 CRDT- 2021/11/18 20:26 PHST- 2021/09/06 00:00 [received] PHST- 2021/09/29 00:00 [accepted] PHST- 2021/11/19 06:00 [pubmed] PHST- 2022/03/08 06:00 [medline] PHST- 2021/11/18 20:26 [entrez] PHST- 2021/11/18 00:00 [pmc-release] AID - 000520046 [pii] AID - iaa-0001 [pii] AID - 10.1159/000520046 [doi] PST - ppublish SO - Int Arch Allergy Immunol. 2022;183(3):350-359. doi: 10.1159/000520046. Epub 2021 Nov 18. PMID- 37386550 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230703 IS - 2731-3786 (Electronic) IS - 2731-3786 (Linking) VI - 1 IP - 1 DP - 2021 Nov 18 TI - Cerebral venous sinus thrombosis (CVST) associated with SARS-CoV-2 vaccines: clues for an immunopathogenesis common to CVST observed in COVID-19. PG - 15 LID - 10.1186/s44158-021-00020-9 [doi] LID - 15 AB - Severe acute respiratory syndrome coronavirus type 2 has been responsible for an unprecedented pandemic, and nowadays, several vaccines proved to be effective and safe, representing the only available strategy to stop the pandemic. While millions of people have safely received vaccine, rare and unusual thrombotic events have been reported and are undergoing investigations to elucidate their nature. Understanding initial trigger, underlying pathophysiology and the reasons for specific site localization of thrombotic events are a matter of debate.We here propose that rare cases of cerebral venous sinus thrombosis, a clinical event that may rapidly evolve to brain death, reported after COVID-19 vaccine, might be consequent to an immune response resulting in inflamed/damaged endothelium, an event similar to that described for cases of cerebral venous sinus thrombosis reported during COVID-19 and not necessarily related to anti-Platelets Factor 4 antibodies, as recently described. Remarkably, in the two patients presenting at our hospital with cerebral venous sinus thrombosis and evolved to brain death, proper tissue perfusion and function maintenance allowed organ donation despite extensive thrombosis in the organ donors, with favorable outcome at 6 months.Increased vigilance, close multidisciplinary collaboration, and further prospective research will help to better elucidate a very rare and still not fully understood pathophysiological event associated with vaccines for severe acute respiratory syndrome coronavirus 2. CI - (c) 2021. The Author(s). FAU - Mazzeo, Anna Teresa AU - Mazzeo AT AUID- ORCID: 0000-0002-8454-7243 AD - Division of Anesthesia and Critical Care. Department of Human Pathology G. Barresi, University of Messina, Messina, Italy. annateresamazzeo@unime.it. FAU - Noto, Alberto AU - Noto A AD - Division of Anesthesia and Critical Care. Department of Human Pathology G. Barresi, University of Messina, Messina, Italy. FAU - Asmundo, Alessio AU - Asmundo A AD - Section of Legal Medicine, Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina, Italy. FAU - Granata, Francesca AU - Granata F AD - Neuroradiology Unit, Department of Biomedical, Dental Science and Morphological and Functional Images, University of Messina, Messina, Italy. FAU - Galletta, Karol AU - Galletta K AD - Neuroradiology Unit, Department of Biomedical, Dental Science and Morphological and Functional Images, University of Messina, Messina, Italy. FAU - Mallamace, Raffaella AU - Mallamace R AD - Division of Anesthesia and Critical Care. Department of Human Pathology G. Barresi, University of Messina, Messina, Italy. FAU - De Gregorio, Cesare AU - De Gregorio C AD - Cardiology Unit, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy. FAU - Puliatti, Francesco AU - Puliatti F AD - Transplant Coordination, A.O.U. Policlinico "G. Martino", Messina, Italy. FAU - Fazio, Maria Carolina AU - Fazio MC AD - U.O.S.D Stroke Unit. D.A.I. Emergenze Tempo Dipendenti. A.O.U. Policlinico "G. Martino", Messina, Italy. FAU - Germano', Antonino AU - Germano' A AD - Division of Neurosurgery, BIOMORF Department, University of Messina, Messina, Italy. FAU - Musolino, Caterina AU - Musolino C AD - Division of Haematology, Department of Human Pathology G.Barresi, University of Messina, Messina, Italy. FAU - Ferlazzo, Guido AU - Ferlazzo G AD - Laboratory of Immunology and Biotherapy, Department of Human Pathology G.Barresi and Cell Factory UniMe Research Center, Division of Clinical Pathology, A.O.U. Policlinico "G. Martino", University of Messina, Messina, Italy. LA - eng PT - Letter DEP - 20211118 PL - England TA - J Anesth Analg Crit Care JT - Journal of anesthesia, analgesia and critical care JID - 9918591885906676 PMC - PMC8600336 OTO - NOTNLM OT - Brain death OT - COVID-19 OT - Cerebral venous sinus thrombosis OT - Organ donation OT - SARS-CoV2 OT - Thrombocytopenia OT - Thrombosis OT - VITT OT - Vaccine COIS- GF has received fees as a lecturer and consultant, as well as research grants from the following organizations: Lallemand Pharma, BG-Clinicals, Biogen, Beckman Coulter, Becton-Dickinson, PharmNDev. AA was appointed as technical consultant for the CEO for Italy of the AZD1222 vaccine manufacturer (Astra Zeneca) in a legal proceeding initiated by the Public Prosecutor's Office at the Court of Syracuse. AN has received fees for educational events on hemodynamic monitoring form Edwards Lifescience. ATM, FG, KG, RM, CDG, FP, MCF, AG, and CM have no disclosures. EDAT- 2021/11/18 00:00 MHDA- 2021/11/18 00:01 PMCR- 2021/11/18 CRDT- 2023/06/29 23:46 PHST- 2021/10/10 00:00 [received] PHST- 2021/11/02 00:00 [accepted] PHST- 2021/11/18 00:01 [medline] PHST- 2021/11/18 00:00 [pubmed] PHST- 2023/06/29 23:46 [entrez] PHST- 2021/11/18 00:00 [pmc-release] AID - 10.1186/s44158-021-00020-9 [pii] AID - 20 [pii] AID - 10.1186/s44158-021-00020-9 [doi] PST - epublish SO - J Anesth Analg Crit Care. 2021 Nov 18;1(1):15. doi: 10.1186/s44158-021-00020-9. PMID- 34740112 OWN - NLM STAT- MEDLINE DCOM- 20211203 LR - 20260127 IS - 2352-3964 (Electronic) IS - 2352-3964 (Linking) VI - 73 DP - 2021 Nov TI - Influence of past infection with SARS-CoV-2 on the response to the BNT162b2 mRNA vaccine in health care workers: Kinetics and durability of the humoral immune response. PG - 103656 LID - S2352-3964(21)00450-3 [pii] LID - 10.1016/j.ebiom.2021.103656 [doi] LID - 103656 AB - BACKGROUND: SARS-CoV-2 vaccines are an invaluable resource against COVID-19. Current vaccine shortage makes it necessary to prioritize distribution to the most appropriate segments of the population. METHODS: This is a prospective cohort study of 63 health care workers (HCWs) from a General Hospital. We compared antibody responses to two doses of BNT162b2 mRNA COVID-19 vaccine between HCWs with previous SARS-CoV-2 infection (experienced HCWs) and HCWs without previous infection (naive HCWs). FINDINGS: Seven days after the first vaccine dose, HCWs with previous infection experienced a 126-fold increase in antibody levels (p<0.001). However, in the HCW naive group, response was much lower and only five showed positive antibody levels (>50 AU). After the second dose, no significant increase in antibody levels was found in experienced HCWs, whereas in naive HCWs, levels increased by 16-fold (p<0.001). Approximately two months post-vaccination, antibody levels were much lower in naive HCWs compared to experienced HCWs (p<0.001). INTERPRETATION: The study shows that at least ten months post-COVID-19 infection, the immune system is still capable of producing a rapid and powerful secondary antibody response following one single vaccine dose. Additionally, we found no further improvement in antibody response to the second dose in COVID-19 experienced HCWs. Nonetheless, two months later, antibody levels were still higher for experienced HCWs. These data suggest that immune memory persists in recovered individuals; therefore, the second dose of the COVID-19 vaccine in this group could be postponed until immunization of the remaining population is complete. CI - Copyright (c) 2021 The Author(s). Published by Elsevier B.V. All rights reserved. FAU - Ontanon, Jesus AU - Ontanon J AD - Immunology Unit, Albacete General Hospital, c/ Hermanos Falco 37, E-02008 Albacete, Spain. FAU - Blas, Joaquin AU - Blas J AD - Microbiology Department, Albacete General Hospital, c/ Hermanos Falco 37, E-02008 Albacete, Spain. FAU - de Cabo, Carlos AU - de Cabo C AD - Research Department, Albacete General Hospital, c/ Hermanos Falco 37, E-02008 Albacete, Spain. Electronic address: carlosd@sescam.jccm.es. FAU - Santos, Celia AU - Santos C AD - Internal Medicine Department, Albacete General Hospital, c/ Hermanos Falco 37, E-02008 Albacete, Spain. FAU - Ruiz-Escribano, Elena AU - Ruiz-Escribano E AD - Intensive Care Medicine Department, Albacete General Hospital c/ Hermanos Falco 37, E-02008 Albacete, Spain. FAU - Garcia, Antonio AU - Garcia A AD - Microbiology Department, Albacete General Hospital, c/ Hermanos Falco 37, E-02008 Albacete, Spain. FAU - Marin, Luis AU - Marin L AD - Immunology Unit, Albacete General Hospital, c/ Hermanos Falco 37, E-02008 Albacete, Spain. FAU - Saez, Lourdes AU - Saez L AD - Internal Medicine Department, Albacete General Hospital, c/ Hermanos Falco 37, E-02008 Albacete, Spain; University of Castilla - La Mancha at Albacete, Faculty of Medicine, c/Almansa, 14, E-02008 Albacete, Spain. FAU - Beato, Jose Luis AU - Beato JL AD - Internal Medicine Department, Albacete General Hospital, c/ Hermanos Falco 37, E-02008 Albacete, Spain. FAU - Rada, Ramon AU - Rada R AD - Clinical Analysis Department, Albacete General Hospital c/ Hermanos Falco 37, E-02008 Albacete, Spain. FAU - Navarro, Laura AU - Navarro L AD - Clinical Analysis Department, Albacete General Hospital c/ Hermanos Falco 37, E-02008 Albacete, Spain. FAU - Sainz de Baranda, Caridad AU - Sainz de Baranda C AD - Microbiology Department, Albacete General Hospital, c/ Hermanos Falco 37, E-02008 Albacete, Spain. FAU - Solera, Javier AU - Solera J AD - Internal Medicine Department, Albacete General Hospital, c/ Hermanos Falco 37, E-02008 Albacete, Spain; University of Castilla - La Mancha at Albacete, Faculty of Medicine, c/Almansa, 14, E-02008 Albacete, Spain. Electronic address: solera53@gmail.com. LA - eng PT - Journal Article DEP - 20211030 PL - Netherlands TA - EBioMedicine JT - EBioMedicine JID - 101647039 RN - 0 (Antibodies, Viral) RN - 0 (BNT162 Vaccine) RN - 0 (Immunoglobulin G) SB - IM MH - Adult MH - Aged MH - Antibodies, Viral/blood MH - BNT162 Vaccine/administration & dosage/*immunology MH - COVID-19/immunology/*pathology/prevention & control/virology MH - Health Personnel MH - Humans MH - *Immunity, Humoral MH - Immunoglobulin G/blood MH - Immunologic Memory MH - Linear Models MH - Male MH - Middle Aged MH - Prospective Studies MH - SARS-CoV-2/isolation & purification MH - Vaccination PMC - PMC8556513 OTO - NOTNLM OT - Immune memory OT - Previous SARS-CoV-2 infection OT - SARS-CoV-2 vaccines OT - Secondary antibody response COIS- Declaration of Competing Interest We declare no competing interests. EDAT- 2021/11/06 06:00 MHDA- 2021/12/15 06:00 PMCR- 2021/10/30 CRDT- 2021/11/05 20:17 PHST- 2021/07/01 00:00 [received] PHST- 2021/10/13 00:00 [revised] PHST- 2021/10/14 00:00 [accepted] PHST- 2021/11/06 06:00 [pubmed] PHST- 2021/12/15 06:00 [medline] PHST- 2021/11/05 20:17 [entrez] PHST- 2021/10/30 00:00 [pmc-release] AID - S2352-3964(21)00450-3 [pii] AID - 103656 [pii] AID - 10.1016/j.ebiom.2021.103656 [doi] PST - ppublish SO - EBioMedicine. 2021 Nov;73:103656. doi: 10.1016/j.ebiom.2021.103656. Epub 2021 Oct 30. PMID- 34739662 OWN - NLM STAT- MEDLINE DCOM- 20220315 LR - 20220716 IS - 1573-742X (Electronic) IS - 0929-5305 (Print) IS - 0929-5305 (Linking) VI - 53 IP - 2 DP - 2022 Feb TI - Brain venography performance following the pause of Ad.26.COV2.S COVID-19 vaccine administration. PG - 359-362 LID - 10.1007/s11239-021-02592-3 [doi] AB - Cases of cerebral venous thrombosis (CVT) associated with vaccine induced thrombotic thrombocytopenia (VITT) were reported following administration of the adenoviral vector COVID-19 vaccines, resulting in a pause in Ad.26.COV2.S vaccine administration in the United States, beginning on April 14, 2021. We aimed to quantify and characterize an anticipated increase in brain venograms performed in response to this pause. Brain venogram cases were retrospectively identified during the three-week period following the vaccine pause and during the same calendar period in 2019. For venograms performed in 2021, we compared COVID vaccinated to unvaccinated patients. There was a 262% increase in venograms performed between 2019 (n = 26) and 2021 (n = 94), compared to only a 19% increase in all radiologic studies. Fifty-seven percent of patients in 2021 had a history of COVID-19 vaccination, with the majority being Ad.26.COV2.S. All patients diagnosed with CVT were unvaccinated. COVID vaccinated patients lacked platelet or D-dimer measurements consistent with VITT. Significantly more vaccinated versus unvaccinated patients had a headache (94% vs 70%, p = 0.0014), but otherwise lacked compelling CVT presentations, such as decreased/altered consciousness (7% vs 23%, p = 0.036), neurologic deficit (28% vs 48%, p = 0.049), and current/recent pregnancy (2% vs 28%, p = 0.0003). We found a dramatic increase in brain venograms performed following publicity of rare COVID-19 vaccine associated CVT cases, with no CVTs identified in vaccinated patients. Clinicians should carefully consider if brain venogram performance is indicated in COVID-19 vaccinated patients lacking thrombocytopenia and D-dimer elevation, especially without other compelling CVT risk factors or symptoms. CI - (c) 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Long, Clayton V AU - Long CV AUID- ORCID: 0000-0002-5183-9004 AD - Department of Emergency Medicine, Medical Education Building, Atrium Health's Carolinas Medical Center, 1000 Blythe Blvd, Charlotte, NC, 28203, USA. FAU - Clemente, Jonathan D AU - Clemente JD AD - Charlotte Radiology, Charlotte, PANC, USA. FAU - Singh, Sam AU - Singh S AD - Atrium Health, Information and Analytics Services, Charlotte, NC, USA. FAU - Strong, Dale AU - Strong D AD - Atrium Health, Information and Analytics Services, Charlotte, NC, USA. FAU - Rhoten, Jeremy B AU - Rhoten JB AD - Atrium Health, Neurosciences Institute, Charlotte, NC, USA. FAU - Prasad, Tanushree AU - Prasad T AD - Clinical Analytics, Atrium Health, Charlotte, USA. FAU - Asimos, Andrew W AU - Asimos AW AD - Department of Emergency Medicine, Medical Education Building, Atrium Health's Carolinas Medical Center, 1000 Blythe Blvd, Charlotte, NC, 28203, USA. andrew.asimos@atriumhealth.org. LA - eng PT - Journal Article DEP - 20211105 PL - Netherlands TA - J Thromb Thrombolysis JT - Journal of thrombosis and thrombolysis JID - 9502018 RN - 0 (COVID-19 Vaccines) SB - IM MH - Brain MH - *COVID-19/prevention & control MH - *COVID-19 Vaccines/adverse effects MH - Humans MH - *Intracranial Thrombosis/etiology MH - Phlebography/adverse effects MH - Retrospective Studies MH - *Thrombocytopenia/etiology MH - *Thrombosis/etiology MH - United States MH - Vaccination/adverse effects PMC - PMC8568674 OTO - NOTNLM OT - Ad.26.COV2.S OT - COVID-19 OT - CVT OT - Thrombosis OT - Vaccine OT - Venogram COIS- None. EDAT- 2021/11/06 06:00 MHDA- 2022/03/16 06:00 PMCR- 2021/11/05 CRDT- 2021/11/05 17:26 PHST- 2021/10/13 00:00 [accepted] PHST- 2021/11/06 06:00 [pubmed] PHST- 2022/03/16 06:00 [medline] PHST- 2021/11/05 17:26 [entrez] PHST- 2021/11/05 00:00 [pmc-release] AID - 10.1007/s11239-021-02592-3 [pii] AID - 2592 [pii] AID - 10.1007/s11239-021-02592-3 [doi] PST - ppublish SO - J Thromb Thrombolysis. 2022 Feb;53(2):359-362. doi: 10.1007/s11239-021-02592-3. Epub 2021 Nov 5. PMID- 34735684 OWN - NLM STAT- MEDLINE DCOM- 20220323 LR - 20220716 IS - 1556-2891 (Electronic) IS - 1547-769X (Print) IS - 1547-769X (Linking) VI - 18 IP - 1 DP - 2022 Mar TI - Acute disseminated encephalomyelitis (ADEM) following recent Oxford/AstraZeneca COVID-19 vaccination. PG - 74-79 LID - 10.1007/s12024-021-00440-7 [doi] AB - This report describes the clinical context and autopsy findings in the first reported fatal case of acute disseminated encephalomyelitis (ADEM), developed after being vaccinated using the Oxford/AstraZeneca COVID-19 vaccine. ADEM is a rare autoimmune disease, causing demyelination in the brain and spinal cord. A wide variety of precipitating factors can trigger ADEM, and it has long been known to be a rare adverse event following some types of vaccinations. Recently, ADEM has also been associated with COVID-19 infection and (very rarely) with COVID-19 vaccination. The reports of the latter however all pertain to living patients. Our case demonstrates that ADEM should be considered in patients developing neurological symptoms post COVID-19 vaccination, although that this adverse reaction is likely to remain extremely rare. Our report further emphasizes the added value of comprehensive post mortem investigation to confirm ante mortem diagnosis and to determine vaccination safety. CI - (c) 2021. Springer Science+Business Media, LLC, part of Springer Nature. FAU - Permezel, Fiona AU - Permezel F AD - Department of Neurology, Austin Health, Heidelberg, VIC, Australia. FAU - Borojevic, Branko AU - Borojevic B AD - Department of General Medicine, Austin Health, Heidelberg, VIC, Australia. FAU - Lau, Stephanie AU - Lau S AUID- ORCID: 0000-0001-8564-7142 AD - Department of Anatomical Pathology, Austin Health, Heidelberg, VIC, Australia. FAU - de Boer, Hans H AU - de Boer HH AUID- ORCID: 0000-0001-8590-0945 AD - Victorian Institute of Forensic Medicine, Southbank, VIC, Australia. Hans.de.Boer@vifm.org. AD - Department of Forensic Medicine, Monash University, Southbank, VIC, Australia. Hans.de.Boer@vifm.org. LA - eng PT - Journal Article DEP - 20211104 PL - United States TA - Forensic Sci Med Pathol JT - Forensic science, medicine, and pathology JID - 101236111 RN - 0 (COVID-19 Vaccines) SB - IM MH - Brain MH - *COVID-19/prevention & control MH - COVID-19 Vaccines/adverse effects MH - *Encephalomyelitis, Acute Disseminated/diagnosis/etiology MH - Humans MH - Vaccination/adverse effects PMC - PMC8567127 OTO - NOTNLM OT - ADEM OT - Acute disseminated encephalomyelitis OT - Adverse event OT - COVID-19 OT - Forensic pathology OT - Vaccination COIS- The authors have no relevant financial or non-financial interests to disclose. EDAT- 2021/11/05 06:00 MHDA- 2022/03/24 06:00 PMCR- 2021/11/04 CRDT- 2021/11/04 17:35 PHST- 2021/10/13 00:00 [accepted] PHST- 2021/11/05 06:00 [pubmed] PHST- 2022/03/24 06:00 [medline] PHST- 2021/11/04 17:35 [entrez] PHST- 2021/11/04 00:00 [pmc-release] AID - 10.1007/s12024-021-00440-7 [pii] AID - 440 [pii] AID - 10.1007/s12024-021-00440-7 [doi] PST - ppublish SO - Forensic Sci Med Pathol. 2022 Mar;18(1):74-79. doi: 10.1007/s12024-021-00440-7. Epub 2021 Nov 4. PMID- 34726470 OWN - NLM STAT- MEDLINE DCOM- 20220104 LR - 20260127 IS - 2470-9468 (Electronic) IS - 2470-9468 (Linking) VI - 6 IP - 66 DP - 2021 Dec 24 TI - BNT162b2 vaccination induces durable SARS-CoV-2-specific T cells with a stem cell memory phenotype. PG - eabl5344 LID - 10.1126/sciimmunol.abl5344 [doi] AB - Vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is effective in preventing hospitalization from severe COVID-19. However, multiple reports of breakthrough infections and of waning antibody titers have raised concerns on the durability of the vaccine, and current vaccination strategies now propose administration of a third dose. Here, we monitored T cell responses to the Spike protein of SARS-CoV-2 in 71 healthy donors vaccinated with two doses of the Pfizer-BioNTech mRNA vaccine (BNT162b2) for up to 6 months after vaccination. We found that vaccination induced the development of a sustained anti-viral CD4(+) and CD8(+) T cell response. These cells appeared before the development of high antibody titers, displayed markers of immunological maturity and stem cell memory, survived the physiological contraction of the immune response, and persisted for at least 6 months. Collectively, these data show that vaccination with BNT162b2 elicits an immunologically competent and long-lived SARS-CoV-2-specific T cell population. FAU - Guerrera, Gisella AU - Guerrera G AUID- ORCID: 0000-0002-3467-6469 AD - Neuroimmunology Unit, Santa Lucia Foundation IRCCS, Rome, Italy. FAU - Picozza, Mario AU - Picozza M AUID- ORCID: 0000-0002-2529-6456 AD - Neuroimmunology Unit, Santa Lucia Foundation IRCCS, Rome, Italy. FAU - D'Orso, Silvia AU - D'Orso S AUID- ORCID: 0000-0002-5294-5255 AD - Neuroimmunology Unit, Santa Lucia Foundation IRCCS, Rome, Italy. FAU - Placido, Roberta AU - Placido R AUID- ORCID: 0000-0001-6083-8292 AD - Neuroimmunology Unit, Santa Lucia Foundation IRCCS, Rome, Italy. FAU - Pirronello, Marta AU - Pirronello M AUID- ORCID: 0000-0002-9907-2279 AD - Neuroimmunology Unit, Santa Lucia Foundation IRCCS, Rome, Italy. FAU - Verdiani, Alice AU - Verdiani A AUID- ORCID: 0000-0001-9367-9574 AD - Neuroimmunology Unit, Santa Lucia Foundation IRCCS, Rome, Italy. FAU - Termine, Andrea AU - Termine A AUID- ORCID: 0000-0003-4374-7430 AD - Data Science Unit, Santa Lucia Foundation IRCCS, Rome, Italy. FAU - Fabrizio, Carlo AU - Fabrizio C AUID- ORCID: 0000-0002-7824-8423 AD - Data Science Unit, Santa Lucia Foundation IRCCS, Rome, Italy. FAU - Giannessi, Flavia AU - Giannessi F AUID- ORCID: 0000-0002-6125-6531 AD - Neuroimmunology Unit, Santa Lucia Foundation IRCCS, Rome, Italy. FAU - Sambucci, Manolo AU - Sambucci M AUID- ORCID: 0000-0003-1124-7327 AD - Neuroimmunology Unit, Santa Lucia Foundation IRCCS, Rome, Italy. FAU - Balice, Maria Pia AU - Balice MP AD - Clinical Microbiology Laboratory, Santa Lucia Foundation IRCCS, Rome, Italy. FAU - Caltagirone, Carlo AU - Caltagirone C AD - Department of Clinical and Behavioral Neurology, Santa Lucia Foundation IRCCS, Rome, Italy. FAU - Salvia, Antonino AU - Salvia A AD - Medical Services, Santa Lucia Foundation IRCCS, Rome, Italy. FAU - Rossini, Angelo AU - Rossini A AUID- ORCID: 0000-0002-0173-7325 AD - Medical Services, Santa Lucia Foundation IRCCS, Rome, Italy. FAU - Battistini, Luca AU - Battistini L AUID- ORCID: 0000-0002-6488-4891 AD - Neuroimmunology Unit, Santa Lucia Foundation IRCCS, Rome, Italy. FAU - Borsellino, Giovanna AU - Borsellino G AUID- ORCID: 0000-0002-4227-6481 AD - Neuroimmunology Unit, Santa Lucia Foundation IRCCS, Rome, Italy. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20211224 PL - United States TA - Sci Immunol JT - Science immunology JID - 101688624 RN - 0 (BNT162 Vaccine) SB - IM MH - BNT162 Vaccine/*administration & dosage MH - CD4-Positive T-Lymphocytes/*immunology MH - CD8-Positive T-Lymphocytes/*immunology MH - COVID-19/*immunology/prevention & control MH - Female MH - Humans MH - Immunity, Cellular/*drug effects MH - Male MH - Memory T Cells/*immunology MH - SARS-CoV-2/*immunology MH - Stem Cells/*immunology EDAT- 2021/11/03 06:00 MHDA- 2022/01/05 06:00 CRDT- 2021/11/02 12:13 PHST- 2021/11/03 06:00 [pubmed] PHST- 2022/01/05 06:00 [medline] PHST- 2021/11/02 12:13 [entrez] AID - 10.1126/sciimmunol.abl5344 [doi] PST - ppublish SO - Sci Immunol. 2021 Dec 24;6(66):eabl5344. doi: 10.1126/sciimmunol.abl5344. Epub 2021 Dec 24. PMID- 34700363 OWN - NLM STAT- MEDLINE DCOM- 20220328 LR - 20220401 IS - 1365-2796 (Electronic) IS - 0954-6820 (Linking) VI - 291 IP - 4 DP - 2022 Apr TI - Shared decision-making interventions: An overview and a meta-analysis of their impact on vaccine uptake. PG - 408-425 LID - 10.1111/joim.13405 [doi] AB - BACKGROUND: The interest in shared decision making (SDM) and the use of patient decision aids have increased significantly. Research indicates that this approach has benefits, and yet, implementation remains a challenge. To illustrate this development, we focus on vaccine hesitancy which has become a serious public health challenge during the COVID-19 pandemic. Various strategies have been used in healthcare, with limited success, to help patients overcome vaccine hesitancy. It is unclear whether SDM interventions can increase vaccination rates. AIMS: Our aim was two-fold: to provide an overview of SDM and the use of patient decision aids and to determine the effect of SDM interventions on vaccine uptake. METHODS: To provide an overview, we drew on our knowledge of the field and summarized the most recent systematic reviews. We examined the impact on vaccine hesitancy by searching for randomized controlled trials (RCTs) of SDM interventions, conducted a meta-analysis and calculated a pooled odds ratio. Additional outcomes were reported in a narrative synthesis. RESULTS: SDM is viewed as the pinnacle of patient-centred care, supported by an ethical imperative and by empirical evidence of benefits. We found 10 RCTs that met our inclusion criteria. SDM interventions significantly increased vaccine uptake compared to control groups (odds ratio = 1.45; 95% confidence interval [1.17-1.80]; p < 0.01). Some RCTs also reported significantly decreased decisional conflict and increased decision confidence. CONCLUSION: Future healthcare delivery systems will need to consider how to support the implementation of SDM. Interventions designed to facilitate this approach can represent a helpful, ethically defensible, strategy to increase vaccination rates. CI - (c) 2021 The Association for the Publication of the Journal of Internal Medicine. FAU - Scalia, P AU - Scalia P AD - The Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine, Dartmouth College, Lebanon, New Hampshire, USA. FAU - Durand, M-A AU - Durand MA AD - The Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine, Dartmouth College, Lebanon, New Hampshire, USA. AD - Unite mixte de recherche, Centre d'Epidemiologie et de Recherche en sante des Populations, Universite de Toulouse, Toulouse, France. AD - Institut national de la sante et de la recherche medicale, Universite Paul Sabatier Toulouse III, Toulouse, France. AD - Unisante, Centre universitaire de medecine generale et sante publique, Lausanne, Switzerland. FAU - Elwyn, G AU - Elwyn G AUID- ORCID: 0000-0002-0917-6286 AD - The Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine, Dartmouth College, Lebanon, New Hampshire, USA. LA - eng PT - Journal Article PT - Meta-Analysis PT - Review DEP - 20211126 PL - England TA - J Intern Med JT - Journal of internal medicine JID - 8904841 RN - 0 (Vaccines) SB - IM MH - *COVID-19/prevention & control MH - Decision Making MH - Decision Making, Shared MH - Humans MH - Patient Participation MH - *Vaccines OTO - NOTNLM OT - shared decision making OT - vaccination EDAT- 2021/10/27 06:00 MHDA- 2022/03/29 06:00 CRDT- 2021/10/26 20:34 PHST- 2021/10/27 06:00 [pubmed] PHST- 2022/03/29 06:00 [medline] PHST- 2021/10/26 20:34 [entrez] AID - 10.1111/joim.13405 [doi] PST - ppublish SO - J Intern Med. 2022 Apr;291(4):408-425. doi: 10.1111/joim.13405. Epub 2021 Nov 26. PMID- 34688190 OWN - NLM STAT- MEDLINE DCOM- 20211116 LR - 20260127 IS - 1878-5883 (Electronic) IS - 0022-510X (Print) IS - 0022-510X (Linking) VI - 430 DP - 2021 Nov 15 TI - Hospital-based observational study of neurological disorders in patients recently vaccinated with COVID-19 mRNA vaccines. PG - 120030 LID - S0022-510X(21)02732-5 [pii] LID - 10.1016/j.jns.2021.120030 [doi] AB - PURPOSE: We describe the spectrum of acute neurological disorders among hospitalized patients who recently had COVID-19 mRNA vaccination. METHOD: We performed a prospective study at 7 acute hospitals in Singapore. Hospitalized patients who were referred for neurological complaints and had COVID-19 mRNA vaccines, BNT162b2 and mRNA-1273, in the last 6 weeks were classified into central nervous system (CNS) syndromes, cerebrovascular disorders, peripheral nervous system (PNS) disorders, autonomic nervous system (ANS) disorders and immunization stress-related responses (ISRR). RESULTS: From 30 December 2020 to 20 April 2021, 1,398,074 persons (median age 59 years, 54.5% males) received COVID-19 mRNA vaccine (86.7% BNT162b2, 13.3% mRNA-1273); 915,344(65.5%) completed 2 doses. Four hundred and fifty-seven(0.03%) patients were referred for neurological complaints [median age 67(20-97) years, 281(61.5%) males; 95.8% received BNT162b2 and 4.2% mRNA-1273], classified into 73(16.0%) CNS syndromes, 286(62.6%) cerebrovascular disorders, 59(12.9%) PNS disorders, 0 ANS disorders and 39(8.5%) ISRRs. Eleven of 27 patients with cranial mononeuropathy had Bell's palsy. Of 33 patients with seizures, only 4 were unprovoked and occurred within 2 weeks of vaccination. All strokes occurred among individuals with pre-existing cardiovascular risk factors. We recorded 2 cases of cerebral venous thrombosis; none were vaccine-induced thrombotic thrombocytopenia. Five had mild flares of immune-mediated diseases. CONCLUSION: Our observational study does not establish causality of the described disorders to vaccines. Though limited by the lack of baseline incidence data of several conditions, we observed no obvious signal of serious neurological morbidity associated with mRNA vaccination. The benefits of COVID-19 vaccination outweigh concerns over neurological adverse events. CI - Copyright (c) 2021 Elsevier B.V. All rights reserved. FAU - Koh, Jasmine Shimin AU - Koh JS AD - Department of Neurology, National Neuroscience Institute (Tan Tock Seng Hospital Campus), Singapore. Electronic address: jasmine.koh.s.m@singhealth.com.sg. FAU - Hoe, Rebecca Hui Min AU - Hoe RHM AD - Department of Neurology, National Neuroscience Institute (Tan Tock Seng Hospital Campus), Singapore. FAU - Yong, Ming Hui AU - Yong MH AD - Department of Neurology, National Neuroscience Institute (Singapore General Hospital Campus), Singapore. FAU - Chiew, Hui Jin AU - Chiew HJ AD - Department of Neurology, National Neuroscience Institute (Tan Tock Seng Hospital Campus), Singapore. FAU - Goh, Yihui AU - Goh Y AD - Division of Neurology, Department of Medicine, National University Health System, Singapore. FAU - Yong, Kok Pin AU - Yong KP AD - Department of Neurology, National Neuroscience Institute (Singapore General Hospital Campus), Singapore; Department of Neurology, Sengkang General Hospital, Singapore. FAU - Tu, Tian Ming AU - Tu TM AD - Department of Neurology, National Neuroscience Institute (Tan Tock Seng Hospital Campus), Singapore; Division of Neurology, Department of General Medicine, Changi General Hospital, Singapore. FAU - Chan, Derrick Wei Shih AU - Chan DWS AD - Department of Paediatrics, Neurology Service, KK Women's and Children's Hospital, Singapore. FAU - Tan, Benjamin Yong-Qiang AU - Tan BY AD - Division of Neurology, Department of Medicine, National University Health System, Singapore. FAU - Yeo, Leonard Leong Litt AU - Yeo LLL AD - Division of Neurology, Department of Medicine, National University Health System, Singapore. FAU - Quek, Amy May Lin AU - Quek AML AD - Division of Neurology, Department of Medicine, National University Health System, Singapore. FAU - Siow, Isabel AU - Siow I AD - Yong Loo Lin School of Medicine, National University, Singapore. FAU - Saini, Monica AU - Saini M AD - Department of Neurology, National Neuroscience Institute (Tan Tock Seng Hospital Campus), Singapore. FAU - Angon, Jasmyn AU - Angon J AD - Department of General Medicine, Khoo Teck Puat Hospital, Singapore. FAU - Rathakrishnan, Sharmini AU - Rathakrishnan S AD - Department of General Medicine, Khoo Teck Puat Hospital, Singapore. FAU - Chen, Geraldine Jiangyan AU - Chen GJ AD - Clinical Trials and Research Unit, National Neuroscience Institute (Tan Tock Seng Hospital Campus), Singapore. FAU - Hui, Andrew Che-Fai AU - Hui AC AD - Division of Neurology, Department of Medicine, Ng Teng Fong General Hospital, Singapore. FAU - Ahmad, Aftab AU - Ahmad A AD - Division of Neurology, Department of Medicine, Ng Teng Fong General Hospital, Singapore. FAU - Shwe, Moe Pearl AU - Shwe MP AD - Division of Neurology, Department of Medicine, Ng Teng Fong General Hospital, Singapore. FAU - Tan, Kevin AU - Tan K AD - Department of Neurology, National Neuroscience Institute (Tan Tock Seng Hospital Campus), Singapore. FAU - Seet, Raymond Chee Seong AU - Seet RCS AD - Division of Neurology, Department of Medicine, National University Health System, Singapore. FAU - Cai, Mingshi AU - Cai M AD - National Immunization Registry, Health Promotion Board, Singapore. FAU - Kuo, Si Min AU - Kuo SM AD - National Immunization Registry, Health Promotion Board, Singapore. FAU - Foo, Ling Li AU - Foo LL AD - National Immunization Registry, Health Promotion Board, Singapore. FAU - Umapathi, Thirugnanam AU - Umapathi T AD - Department of Neurology, National Neuroscience Institute (Tan Tock Seng Hospital Campus), Singapore. LA - eng PT - Journal Article PT - Observational Study DEP - 20211013 PL - Netherlands TA - J Neurol Sci JT - Journal of the neurological sciences JID - 0375403 RN - 0 (BNT162 Vaccine) RN - 0 (COVID-19 Vaccines) RN - 0 (RNA, Messenger) SB - IM MH - Aged MH - Aged, 80 and over MH - BNT162 Vaccine MH - *COVID-19 MH - COVID-19 Vaccines MH - Female MH - Hospitals MH - Humans MH - Male MH - Middle Aged MH - *Nervous System Diseases MH - Prospective Studies MH - RNA, Messenger MH - SARS-CoV-2 PMC - PMC8511874 OTO - NOTNLM OT - Adverse events OT - Clinical study OT - SARS-CoV-2 OT - Safety OT - Vaccination COIS- None. EDAT- 2021/10/24 06:00 MHDA- 2021/11/17 06:00 PMCR- 2021/10/13 CRDT- 2021/10/23 20:30 PHST- 2021/07/22 00:00 [received] PHST- 2021/09/22 00:00 [revised] PHST- 2021/10/10 00:00 [accepted] PHST- 2021/10/24 06:00 [pubmed] PHST- 2021/11/17 06:00 [medline] PHST- 2021/10/23 20:30 [entrez] PHST- 2021/10/13 00:00 [pmc-release] AID - S0022-510X(21)02732-5 [pii] AID - 120030 [pii] AID - 10.1016/j.jns.2021.120030 [doi] PST - ppublish SO - J Neurol Sci. 2021 Nov 15;430:120030. doi: 10.1016/j.jns.2021.120030. Epub 2021 Oct 13. PMID- 34685521 OWN - NLM STAT- MEDLINE DCOM- 20211115 LR - 20260127 IS - 2073-4409 (Electronic) IS - 2073-4409 (Linking) VI - 10 IP - 10 DP - 2021 Sep 26 TI - Highly Specific Memory B Cells Generation after the 2nd Dose of BNT162b2 Vaccine Compensate for the Decline of Serum Antibodies and Absence of Mucosal IgA. LID - 10.3390/cells10102541 [doi] LID - 2541 AB - Specific memory B cells and antibodies are a reliable read-out of vaccine efficacy. We analysed these biomarkers after one and two doses of BNT162b2 vaccine. The second dose significantly increases the level of highly specific memory B cells and antibodies. Two months after the second dose, specific antibody levels decline, but highly specific memory B cells continue to increase, thus predicting a sustained protection from COVID-19. We show that although mucosal IgA is not induced by the vaccination, memory B cells migrate in response to inflammation and secrete IgA at mucosal sites. We show that the first vaccine dose may lead to an insufficient number of highly specific memory B cells and low concentration of serum antibodies, thus leaving vaccinees without the immune robustness needed to ensure viral elimination and herd immunity. We also clarify that the reduction of serum antibodies does not diminish the force and duration of the immune protection induced by vaccination. The vaccine does not induce sterilizing immunity. Infection after vaccination may be caused by the lack of local preventive immunity because of the absence of mucosal IgA. FAU - Piano Mortari, Eva AU - Piano Mortari E AUID- ORCID: 0000-0002-0054-4732 AD - Diagnostic Immunology Research Unit, Multimodal Medicine Research Area, Bambino Gesu Children's Hospital, IRCCS, Viale di San Paolo,15, 00146 Rome, Italy. FAU - Russo, Cristina AU - Russo C AD - Microbiology and Diagnostic Immunology Unit, Bambino Gesu Children's Hospital, IRCCS, Piazza Sant'Onofrio, 4, 00165 Rome, Italy. FAU - Vinci, Maria Rosaria AU - Vinci MR AD - Occupational Medicine/Health Technology Assessment and Safety Research Unit, Clinical-Technological Innovations Research Area, Bambino Gesu Children's Hospital, IRCCS, Viale di San Paolo, 15, 00146 Rome, Italy. AD - Health Directorate, Bambino Gesu Children's Hospital, IRCCS, Piazza Sant'Onofrio, 4, 00165 Rome, Italy. FAU - Terreri, Sara AU - Terreri S AD - Diagnostic Immunology Research Unit, Multimodal Medicine Research Area, Bambino Gesu Children's Hospital, IRCCS, Viale di San Paolo,15, 00146 Rome, Italy. FAU - Fernandez Salinas, Ane AU - Fernandez Salinas A AD - Diagnostic Immunology Research Unit, Multimodal Medicine Research Area, Bambino Gesu Children's Hospital, IRCCS, Viale di San Paolo,15, 00146 Rome, Italy. AD - Department of Molecular Medicine, Sapienza University of Rome, Viale dell'Universita, 37, 00185 Rome, Italy. FAU - Piccioni, Livia AU - Piccioni L AD - Microbiology and Diagnostic Immunology Unit, Bambino Gesu Children's Hospital, IRCCS, Piazza Sant'Onofrio, 4, 00165 Rome, Italy. FAU - Alteri, Claudia AU - Alteri C AD - Diagnostic Immunology Research Unit, Multimodal Medicine Research Area, Bambino Gesu Children's Hospital, IRCCS, Viale di San Paolo,15, 00146 Rome, Italy. AD - Department of Oncology and Hemato-Oncology, University of Milan, Via festa del Perdono, 7, 20122 Milan, Italy. FAU - Colagrossi, Luna AU - Colagrossi L AD - Microbiology and Diagnostic Immunology Unit, Bambino Gesu Children's Hospital, IRCCS, Piazza Sant'Onofrio, 4, 00165 Rome, Italy. FAU - Coltella, Luana AU - Coltella L AUID- ORCID: 0000-0002-4933-4242 AD - Microbiology and Diagnostic Immunology Unit, Bambino Gesu Children's Hospital, IRCCS, Piazza Sant'Onofrio, 4, 00165 Rome, Italy. FAU - Ranno, Stefania AU - Ranno S AD - Microbiology and Diagnostic Immunology Unit, Bambino Gesu Children's Hospital, IRCCS, Piazza Sant'Onofrio, 4, 00165 Rome, Italy. FAU - Linardos, Giulia AU - Linardos G AD - Microbiology and Diagnostic Immunology Unit, Bambino Gesu Children's Hospital, IRCCS, Piazza Sant'Onofrio, 4, 00165 Rome, Italy. FAU - Agosta, Marilena AU - Agosta M AUID- ORCID: 0000-0002-6017-3232 AD - Microbiology and Diagnostic Immunology Unit, Bambino Gesu Children's Hospital, IRCCS, Piazza Sant'Onofrio, 4, 00165 Rome, Italy. FAU - Albano, Christian AU - Albano C AD - Diagnostic Immunology Research Unit, Multimodal Medicine Research Area, Bambino Gesu Children's Hospital, IRCCS, Viale di San Paolo,15, 00146 Rome, Italy. FAU - Agrati, Chiara AU - Agrati C AD - National Institute for Infectious Diseases Lazzaro Spallanzani, IRCCS, Via Portuense, 2, 00146 Rome, Italy. FAU - Castilletti, Concetta AU - Castilletti C AUID- ORCID: 0000-0001-9819-236X AD - National Institute for Infectious Diseases Lazzaro Spallanzani, IRCCS, Via Portuense, 2, 00146 Rome, Italy. FAU - Meschi, Silvia AU - Meschi S AD - National Institute for Infectious Diseases Lazzaro Spallanzani, IRCCS, Via Portuense, 2, 00146 Rome, Italy. FAU - Romania, Paolo AU - Romania P AD - Diagnostic Immunology Research Unit, Multimodal Medicine Research Area, Bambino Gesu Children's Hospital, IRCCS, Viale di San Paolo,15, 00146 Rome, Italy. AD - Department of Molecular Medicine, Sapienza University of Rome, Viale dell'Universita, 37, 00185 Rome, Italy. FAU - Roscilli, Giuseppe AU - Roscilli G AD - Takis s.r.l., Via di Castel Romano, 100, 00128 Rome, Italy. FAU - Pavoni, Emiliano AU - Pavoni E AD - Takis s.r.l., Via di Castel Romano, 100, 00128 Rome, Italy. FAU - Camisa, Vincenzo AU - Camisa V AD - Occupational Medicine/Health Technology Assessment and Safety Research Unit, Clinical-Technological Innovations Research Area, Bambino Gesu Children's Hospital, IRCCS, Viale di San Paolo, 15, 00146 Rome, Italy. AD - Health Directorate, Bambino Gesu Children's Hospital, IRCCS, Piazza Sant'Onofrio, 4, 00165 Rome, Italy. FAU - Santoro, Annapaola AU - Santoro A AD - Occupational Medicine/Health Technology Assessment and Safety Research Unit, Clinical-Technological Innovations Research Area, Bambino Gesu Children's Hospital, IRCCS, Viale di San Paolo, 15, 00146 Rome, Italy. AD - Health Directorate, Bambino Gesu Children's Hospital, IRCCS, Piazza Sant'Onofrio, 4, 00165 Rome, Italy. FAU - Brugaletta, Rita AU - Brugaletta R AD - Occupational Medicine/Health Technology Assessment and Safety Research Unit, Clinical-Technological Innovations Research Area, Bambino Gesu Children's Hospital, IRCCS, Viale di San Paolo, 15, 00146 Rome, Italy. AD - Health Directorate, Bambino Gesu Children's Hospital, IRCCS, Piazza Sant'Onofrio, 4, 00165 Rome, Italy. FAU - Magnavita, Nicola AU - Magnavita N AUID- ORCID: 0000-0002-0988-7344 AD - Section of Occupational Medicine and Labor Law, Post-Graduate School of Occupational Health, University Cattolica del Sacro Cuore, Largo Francesco Vito, 1, 00168 Rome, Italy. AD - Department of Woman, Child & Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Via della Pineta Sacchetti, 217, 00168 Rome, Italy. FAU - Ruggiero, Alessandra AU - Ruggiero A AUID- ORCID: 0000-0002-1041-7489 AD - Academic Department of Pediatrics (DPUO), Research Unit of Clinical Immunology and Vaccinology, Bambino Gesu Children's Hospital, IRCCS, 00165 Rome, Italy. AD - Department of Neuroscience, Biomedicine and Movement Sciences, University of Verona, Via San Francesco, 22, 37129 Verona, Italy. FAU - Cotugno, Nicola AU - Cotugno N AUID- ORCID: 0000-0002-7748-1581 AD - Academic Department of Pediatrics (DPUO), Research Unit of Clinical Immunology and Vaccinology, Bambino Gesu Children's Hospital, IRCCS, 00165 Rome, Italy. FAU - Amodio, Donato AU - Amodio D AD - Academic Department of Pediatrics (DPUO), Research Unit of Clinical Immunology and Vaccinology, Bambino Gesu Children's Hospital, IRCCS, 00165 Rome, Italy. FAU - Ciofi Degli Atti, Marta Luisa AU - Ciofi Degli Atti ML AD - Clinical Pathways and Epidemiology Unit, Bambino Gesu Children's Hospital, IRCCS, Piazza Sant'Onofrio, 4, 00165 Rome, Italy. FAU - Giorgio, Daniela AU - Giorgio D AD - Neonatal Intensive Care Unit and Human Milk Bank, Department of Neonatology, Bambino Gesu Children's Hospital, IRCSS, Piazza Sant'Onofrio, 4, 00165 Rome, Italy. FAU - Russo, Nicoletta AU - Russo N AD - Neonatal Intensive Care Unit and Human Milk Bank, Department of Neonatology, Bambino Gesu Children's Hospital, IRCSS, Piazza Sant'Onofrio, 4, 00165 Rome, Italy. FAU - Salvatori, Guglielmo AU - Salvatori G AD - Neonatal Intensive Care Unit and Human Milk Bank, Department of Neonatology, Bambino Gesu Children's Hospital, IRCSS, Piazza Sant'Onofrio, 4, 00165 Rome, Italy. FAU - Corsetti, Tiziana AU - Corsetti T AD - Hospital Pharmacy Unit, Bambino Gesu Children's Hospital, IRCCS, Piazza Sant'Onofrio, 4, 00165 Rome, Italy. FAU - Locatelli, Franco AU - Locatelli F AUID- ORCID: 0000-0002-7976-3654 AD - Department of Hematology/Oncology, Bambino Gesu Children's Hospital, IRCCS, Piazza Sant'Onofrio, 4, 00165 Rome, Italy. AD - Department of Pediatrics, Sapienza, University of Rome, Viale dell'Universita, 37, 00185 Rome, Italy. FAU - Perno, Carlo Federico AU - Perno CF AD - Diagnostic Immunology Research Unit, Multimodal Medicine Research Area, Bambino Gesu Children's Hospital, IRCCS, Viale di San Paolo,15, 00146 Rome, Italy. AD - Microbiology and Diagnostic Immunology Unit, Bambino Gesu Children's Hospital, IRCCS, Piazza Sant'Onofrio, 4, 00165 Rome, Italy. FAU - Zaffina, Salvatore AU - Zaffina S AUID- ORCID: 0000-0002-8858-5423 AD - Occupational Medicine/Health Technology Assessment and Safety Research Unit, Clinical-Technological Innovations Research Area, Bambino Gesu Children's Hospital, IRCCS, Viale di San Paolo, 15, 00146 Rome, Italy. AD - Health Directorate, Bambino Gesu Children's Hospital, IRCCS, Piazza Sant'Onofrio, 4, 00165 Rome, Italy. FAU - Carsetti, Rita AU - Carsetti R AD - Diagnostic Immunology Research Unit, Multimodal Medicine Research Area, Bambino Gesu Children's Hospital, IRCCS, Viale di San Paolo,15, 00146 Rome, Italy. AD - Microbiology and Diagnostic Immunology Unit, Bambino Gesu Children's Hospital, IRCCS, Piazza Sant'Onofrio, 4, 00165 Rome, Italy. LA - eng GR - RF2013-02358960 grant/Italian Ministry of Health/ GR - COVID-2020-12371817 grant/Italian Ministry of Health/ PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210926 PL - Switzerland TA - Cells JT - Cells JID - 101600052 RN - 0 (Antibodies, Neutralizing) RN - 0 (Antibodies, Viral) RN - 0 (Antigens, Viral) RN - 0 (BNT162 Vaccine) RN - 0 (COVID-19 Vaccines) RN - 0 (Immunoglobulin A) RN - 0 (Immunoglobulin G) RN - 0 (Immunoglobulin M) SB - IM MH - Adult MH - Antibodies, Neutralizing/blood MH - Antibodies, Viral/*immunology MH - Antigens, Viral/immunology MH - B-Lymphocytes/*cytology/immunology MH - BNT162 Vaccine MH - COVID-19/*immunology/*prevention & control MH - COVID-19 Vaccines/*therapeutic use MH - Cryopreservation MH - Female MH - Health Personnel MH - Healthy Volunteers MH - Hospitals, Pediatric MH - Humans MH - Immunoglobulin A/*immunology MH - Immunoglobulin G MH - Immunoglobulin M/immunology MH - *Immunologic Memory MH - Lactation MH - Male MH - Middle Aged MH - Mucous Membrane/immunology MH - Patient Safety MH - SARS-CoV-2 MH - Vaccination PMC - PMC8533837 OTO - NOTNLM OT - BNT162b2 OT - IgA OT - SARS-CoV-2 OT - immunity OT - memory B cells OT - vaccine COIS- Authors declare that they have no competing interests. EDAT- 2021/10/24 06:00 MHDA- 2021/11/16 06:00 PMCR- 2021/09/26 CRDT- 2021/10/23 01:22 PHST- 2021/08/25 00:00 [received] PHST- 2021/09/15 00:00 [revised] PHST- 2021/09/22 00:00 [accepted] PHST- 2021/10/23 01:22 [entrez] PHST- 2021/10/24 06:00 [pubmed] PHST- 2021/11/16 06:00 [medline] PHST- 2021/09/26 00:00 [pmc-release] AID - cells10102541 [pii] AID - cells-10-02541 [pii] AID - 10.3390/cells10102541 [doi] PST - epublish SO - Cells. 2021 Sep 26;10(10):2541. doi: 10.3390/cells10102541. PMID- 34677889 OWN - NLM STAT- MEDLINE DCOM- 20220519 LR - 20220716 IS - 1099-1654 (Electronic) IS - 1052-9276 (Print) IS - 1052-9276 (Linking) VI - 32 IP - 3 DP - 2022 May TI - Coronavirus disease 2019 (Covid-19) vaccination recommendations in special populations and patients with existing comorbidities. PG - e2309 LID - 10.1002/rmv.2309 [doi] LID - e2309 AB - Vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a crucial step in ending the current worldwide pandemic. However, several particularly vulnerable groups in the population were not included in sufficient numbers in coronavirus disease 2019 (Covid-19) vaccine trials. Therefore, as science advances, the advice for vaccinating these special populations against Covid-19 will continue to evolve. This focused review provides the latest recommendations and considerations for these special populations (i.e., patients with rheumatologic and autoimmune disorders, cancer, transplant recipients, chronic liver diseases, end-stage renal disease, neurologic disorders, psychiatric disorders, diabetes mellitus, obesity, cardiovascular diseases, chronic obstructive pulmonary disease, human immunodeficiency virus, current smokers, pregnant and breastfeeding women, the elderly, children, and patients with allergic reactions) using the currently available research evidence. CI - (c) 2021 John Wiley & Sons Ltd. FAU - Mohseni Afshar, Zeinab AU - Mohseni Afshar Z AUID- ORCID: 0000-0002-1085-374X AD - Clinical Research Development Center, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran. FAU - Babazadeh, Arefeh AU - Babazadeh A AUID- ORCID: 0000-0002-1362-7203 AD - Infectious Diseases and Tropical Medicine Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran. FAU - Janbakhsh, Alireza AU - Janbakhsh A AUID- ORCID: 0000-0001-6339-4666 AD - Clinical Research Development Center, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran. FAU - Mansouri, Feizollah AU - Mansouri F AUID- ORCID: 0000-0002-2099-5362 AD - Clinical Research Development Center, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran. FAU - Sio, Terence T AU - Sio TT AUID- ORCID: 0000-0003-4210-5479 AD - Department of Radiation Oncology, Mayo Clinic, Phoenix, Arizona, USA. FAU - Sullman, Mark J M AU - Sullman MJM AUID- ORCID: 0000-0001-7920-6818 AD - Department of Social Sciences, University of Nicosia, Nicosia, Cyprus. AD - Department of Life and Health Sciences, University of Nicosia, Nicosia, Cyprus. FAU - Carson-Chahhoud, Kristin AU - Carson-Chahhoud K AUID- ORCID: 0000-0001-9966-9289 AD - Australian Centre for Precision Health, University of South Australia, Adelaide, Australia. FAU - Hosseinzadeh, Rezvan AU - Hosseinzadeh R AUID- ORCID: 0000-0001-9399-3854 AD - Student Research Committee, Babol University of Medical Sciences, Babol, Iran. FAU - Barary, Mohammad AU - Barary M AUID- ORCID: 0000-0001-8733-9370 AD - Student Research Committee, Babol University of Medical Sciences, Babol, Iran. FAU - Ebrahimpour, Soheil AU - Ebrahimpour S AUID- ORCID: 0000-0003-3204-0448 AD - Infectious Diseases and Tropical Medicine Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran. LA - eng PT - Journal Article PT - Review DEP - 20211022 PL - England TA - Rev Med Virol JT - Reviews in medical virology JID - 9112448 RN - 0 (COVID-19 Vaccines) SB - IM MH - Aged MH - *COVID-19/epidemiology/prevention & control MH - COVID-19 Vaccines MH - Child MH - Female MH - Humans MH - Pandemics MH - Pregnancy MH - SARS-CoV-2 MH - Vaccination PMC - PMC8646697 OTO - NOTNLM OT - Covid-19 OT - SARS-CoV-2 OT - efficacy OT - immunocompromise OT - safety OT - vaccination EDAT- 2021/10/23 06:00 MHDA- 2022/05/20 06:00 PMCR- 2021/10/22 CRDT- 2021/10/22 12:33 PHST- 2021/10/01 00:00 [revised] PHST- 2021/08/09 00:00 [received] PHST- 2021/10/04 00:00 [accepted] PHST- 2021/10/23 06:00 [pubmed] PHST- 2022/05/20 06:00 [medline] PHST- 2021/10/22 12:33 [entrez] PHST- 2021/10/22 00:00 [pmc-release] AID - RMV2309 [pii] AID - 10.1002/rmv.2309 [doi] PST - ppublish SO - Rev Med Virol. 2022 May;32(3):e2309. doi: 10.1002/rmv.2309. Epub 2021 Oct 22. PMID- 34669144 OWN - NLM STAT- MEDLINE DCOM- 20211130 LR - 20220309 IS - 1573-2592 (Electronic) IS - 0271-9142 (Print) IS - 0271-9142 (Linking) VI - 41 IP - 8 DP - 2021 Nov TI - SARS-CoV-2 Vaccine Induced Atypical Immune Responses in Antibody Defects: Everybody Does their Best. PG - 1709-1722 LID - 10.1007/s10875-021-01133-0 [doi] AB - BACKGROUND: Data on immune responses to SARS-CoV-2 in patients with Primary Antibody Deficiencies (PAD) are limited to infected patients and to heterogeneous cohorts after immunization. METHODS: Forty-one patients with Common Variable Immune Deficiencies (CVID), six patients with X-linked Agammaglobulinemia (XLA), and 28 healthy age-matched controls (HD) were analyzed for anti-Spike and anti-receptor binding domain (RBD) antibody production, generation of Spike-specific memory B-cells, and Spike-specific T-cells before vaccination and one week after the second dose of BNT162b2 vaccine. RESULTS: The vaccine induced Spike-specific IgG and IgA antibody responses in all HD and in 20% of SARS-CoV-2 naive CVID patients. Anti-Spike IgG were detectable before vaccination in 4 out 7 CVID previously infected with SARS-CoV-2 and were boosted in six out of seven patients by the subsequent immunization raising higher levels than patients naive to infection. While HD generated Spike-specific memory B-cells, and RBD-specific B-cells, CVID generated Spike-specific atypical B-cells, while RBD-specific B-cells were undetectable in all patients, indicating the incapability to generate this new specificity. Specific T-cell responses were evident in all HD and defective in 30% of CVID. All but one patient with XLA responded by specific T-cell only. CONCLUSION: In PAD patients, early atypical immune responses after BNT162b2 immunization occurred, possibly by extra-follicular or incomplete germinal center reactions. If these responses to vaccination might result in a partial protection from infection or reinfection is now unknown. Our data suggests that SARS-CoV-2 infection more effectively primes the immune response than the immunization alone, possibly suggesting the need for a third vaccine dose for patients not previously infected. CI - (c) 2021. The Author(s). FAU - Salinas, Ane Fernandez AU - Salinas AF AD - Department of Molecular Medicine, Sapienza University of Rome, Viale Dell'Universita, 37, Rome, Italy. AD - Diagnostic Immunology Research Unit, Multimodal Medicine Research Area, Bambino Gesu Children's Hospital, IRCCS, Viale Di San Paolo, 15, Rome, Italy. FAU - Mortari, Eva Piano AU - Mortari EP AD - Diagnostic Immunology Research Unit, Multimodal Medicine Research Area, Bambino Gesu Children's Hospital, IRCCS, Viale Di San Paolo, 15, Rome, Italy. FAU - Terreri, Sara AU - Terreri S AD - Diagnostic Immunology Research Unit, Multimodal Medicine Research Area, Bambino Gesu Children's Hospital, IRCCS, Viale Di San Paolo, 15, Rome, Italy. FAU - Quintarelli, Concetta AU - Quintarelli C AD - Department Onco-Haematology, and Cell and Gene Therapy, Bambino Gesu Children Hospital, IRCCS, Rome, Italy. AD - Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy. FAU - Pulvirenti, Federica AU - Pulvirenti F AD - Regional Reference Centre for Primary Immune Deficiencies, Azienda Ospedaliera Universitaria Policlinico Umberto I, Rome, Italy. FAU - Di Cecca, Stefano AU - Di Cecca S AD - Department Onco-Haematology, and Cell and Gene Therapy, Bambino Gesu Children Hospital, IRCCS, Rome, Italy. FAU - Guercio, Marika AU - Guercio M AD - Department Onco-Haematology, and Cell and Gene Therapy, Bambino Gesu Children Hospital, IRCCS, Rome, Italy. FAU - Milito, Cinzia AU - Milito C AD - Department of Molecular Medicine, Sapienza University of Rome, Viale Dell'Universita, 37, Rome, Italy. FAU - Bonanni, Livia AU - Bonanni L AD - Regional Reference Centre for Primary Immune Deficiencies, Azienda Ospedaliera Universitaria Policlinico Umberto I, Rome, Italy. FAU - Auria, Stefania AU - Auria S AD - Department of Molecular Medicine, Sapienza University of Rome, Viale Dell'Universita, 37, Rome, Italy. FAU - Romaggioli, Laura AU - Romaggioli L AD - Department of Molecular Medicine, Sapienza University of Rome, Viale Dell'Universita, 37, Rome, Italy. FAU - Cusano, Giuseppina AU - Cusano G AD - Department of Molecular Medicine, Sapienza University of Rome, Viale Dell'Universita, 37, Rome, Italy. FAU - Albano, Christian AU - Albano C AD - Diagnostic Immunology Research Unit, Multimodal Medicine Research Area, Bambino Gesu Children's Hospital, IRCCS, Viale Di San Paolo, 15, Rome, Italy. FAU - Zaffina, Salvatore AU - Zaffina S AD - Occupational Medicine/Health Technology Assessment and Safety Research Unit, Clinical-Technological Innovations Research Area, Bambino Gesu Children's Hospital, IRCCS, Viale di San Paolo, 15, Rome, Italy. AD - Health Directorate, Bambino Gesu Children's Hospital, IRCCS, Piazza Sant'Onofrio, 4, Rome, Italy. FAU - Perno, Carlo Federico AU - Perno CF AD - Multimodal Medicine Research Area, Bambino Gesu Children's Hospital, IRCCS, Piazza Sant'Onofrio, 4, Rome, Italy. AD - Microbiology and Diagnostic Immunology Unit, Bambino Gesu Children's Hospital, IRCCS, Piazza Sant'Onofrio, 4, Rome, Italy. FAU - Spadaro, Giuseppe AU - Spadaro G AD - Department of Translational Medical Sciences, University of Naples Federico II, 80131, Naples, Italy. FAU - Locatelli, Franco AU - Locatelli F AD - Department Onco-Haematology, and Cell and Gene Therapy, Bambino Gesu Children Hospital, IRCCS, Rome, Italy. AD - Dipartimento Materno-Infantile E Scienze Urologiche, Sapienza University of Rome, Rome, Italy. FAU - Carsetti, Rita AU - Carsetti R AD - Diagnostic Immunology Research Unit, Multimodal Medicine Research Area, Bambino Gesu Children's Hospital, IRCCS, Viale Di San Paolo, 15, Rome, Italy. AD - Diagnostic Immunology Clinical Unit, Bambino Gesu Children's Hospital, IRCCS, Viale Di San Paolo,15, Rome, Italy. FAU - Quinti, Isabella AU - Quinti I AUID- ORCID: 0000-0002-3328-7584 AD - Department of Molecular Medicine, Sapienza University of Rome, Viale Dell'Universita, 37, Rome, Italy. isabella.quinti@uniroma1.it. LA - eng GR - RF2013-02358960/ministero della salute/ GR - COVID-2020-12371817/ministero della salute/ PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20211020 PL - Netherlands TA - J Clin Immunol JT - Journal of clinical immunology JID - 8102137 RN - 0 (Antibodies, Viral) RN - 0 (COVID-19 Vaccines) RN - 0 (Immunoglobulin G) RN - 0 (Spike Glycoprotein, Coronavirus) RN - 0 (spike protein, SARS-CoV-2) SB - IM MH - Antibodies, Viral/*blood MH - COVID-19/*prevention & control MH - COVID-19 Vaccines/*immunology MH - Humans MH - Immunoglobulin G/blood MH - Immunologic Deficiency Syndromes/*immunology MH - Immunologic Memory MH - Lymphocytes/immunology MH - SARS-CoV-2/*immunology MH - Spike Glycoprotein, Coronavirus/immunology PMC - PMC8527979 OTO - NOTNLM OT - BNT162b2 vaccine OT - COVID-19 OT - Common variable immune deficiencies OT - Memory cells OT - Primary antibody deficiencies OT - Receptor-binding-domain OT - SARS-CoV-2 OT - Spike protein OT - X-linked agammaglobulinemia COIS- Authors declare that they have no conflict interest. EDAT- 2021/10/21 06:00 MHDA- 2021/12/01 06:00 PMCR- 2021/10/20 CRDT- 2021/10/20 12:33 PHST- 2021/06/19 00:00 [received] PHST- 2021/09/03 00:00 [accepted] PHST- 2021/10/21 06:00 [pubmed] PHST- 2021/12/01 06:00 [medline] PHST- 2021/10/20 12:33 [entrez] PHST- 2021/10/20 00:00 [pmc-release] AID - 10.1007/s10875-021-01133-0 [pii] AID - 1133 [pii] AID - 10.1007/s10875-021-01133-0 [doi] PST - ppublish SO - J Clin Immunol. 2021 Nov;41(8):1709-1722. doi: 10.1007/s10875-021-01133-0. Epub 2021 Oct 20. PMID- 34667668 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240403 IS - 2168-8184 (Print) IS - 2168-8184 (Electronic) IS - 2168-8184 (Linking) VI - 13 IP - 9 DP - 2021 Sep TI - High COVID-19 Vaccine Hesitancy Among Healthcare Workers: Should Such a Trend Require Closer Attention by Policymakers? PG - e17990 LID - 10.7759/cureus.17990 [doi] LID - e17990 AB - Background The newly developed coronavirus disease 2019 (COVID-19) vaccines are considered to be a powerful tool to contain the devastating pandemic. Healthcare workers (HCWs) are at the highest risk of exposure to COVID-19 and, therefore, they are the priority group for vaccination. Objectives The study aimed to examine the perceptions, attitudes, and acceptability of the COVID-19 vaccination among HCWs in India. Study design A cross-sectional pilot survey was conducted using an online questionnaire between 13 and 25 January 2021. Results Among 264 respondents, 40.2% of HCWs would receive the vaccine against COVID-19 if available and 32.2% were willing to take the vaccine after observing adverse effects in others. Infected members in the immediate social network (OR:2.15; 95%CI:0.426-10.844), COVID-19 knowledge (OR:5.113; 95%CI:0.974-26.853), the safety of vaccines (OR:7.608; 95%CI:2.618-22.11), and those who did not receive a flu vaccine last year (OR:2.612; 95%CI:1.120-6.091) were found to have a statistically significant association with vaccine acceptance. The main reasons to delay/refuse vaccination included: 'quick vaccine development and compromised quality' (43.7%) and 'lack of trusted information regarding COVID-19' (41.3%). Conclusions The finding showed a high rate of vaccine hesitancy among HCWs. Policymakers should take steps to increase public awareness and secure timely and affordable vaccines for the HCWs and general population with effective vaccine promotion campaigns. CI - Copyright (c) 2021, Ashok et al. FAU - Ashok, Narmada AU - Ashok N AD - Department of Pediatrics, Nalam Medical Centre and Hospital, Vellore, IND. FAU - Krishnamurthy, Kandamaran AU - Krishnamurthy K AD - Department of Pediatrics, The University of the West Indies, Bridgetown, BRB. AD - Pediatric Intensive Care Unit, The Queen Elizabeth Hospital, The University of the West Indies, Bridgetown, BRB. FAU - Singh, Keerti AU - Singh K AD - Faculty of Medical Sciences, The University of the West Indies, Bridgetown, BRB. FAU - Rahman, Sayeeda AU - Rahman S AD - School of Medicine, American University of Integrative Sciences, Bridgetown, BRB. FAU - Majumder, Md Anwarul A AU - Majumder MAA AD - Faculty of Medical Sciences, The University of the West Indies, Bridgetown, BRB. LA - eng PT - Journal Article DEP - 20210915 PL - United States TA - Cureus JT - Cureus JID - 101596737 PMC - PMC8519358 OTO - NOTNLM OT - covid-19 OT - healthcare workers OT - india OT - tamil nadu OT - vaccine acceptance OT - vaccine hesitancy OT - vaccine literacy COIS- The authors have declared that no competing interests exist. EDAT- 2021/10/21 06:00 MHDA- 2021/10/21 06:01 PMCR- 2021/09/15 CRDT- 2021/10/20 06:45 PHST- 2021/09/15 00:00 [accepted] PHST- 2021/10/20 06:45 [entrez] PHST- 2021/10/21 06:00 [pubmed] PHST- 2021/10/21 06:01 [medline] PHST- 2021/09/15 00:00 [pmc-release] AID - 10.7759/cureus.17990 [doi] PST - epublish SO - Cureus. 2021 Sep 15;13(9):e17990. doi: 10.7759/cureus.17990. eCollection 2021 Sep. PMID- 34650563 OWN - NLM STAT- MEDLINE DCOM- 20211025 LR - 20260127 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 12 DP - 2021 TI - Evidence of SARS-CoV-2-Specific Memory B Cells Six Months After Vaccination With the BNT162b2 mRNA Vaccine. PG - 740708 LID - 10.3389/fimmu.2021.740708 [doi] LID - 740708 AB - SARS-CoV-2 mRNA vaccines have demonstrated high efficacy and immunogenicity, but limited information is currently available on memory B cell generation and long-term persistence. Here, we investigated spike-specific memory B cells and humoral responses in 145 subjects, up to 6 months after the BNT162b2 vaccine (Comirnaty) administration. Spike-specific antibodies peaked 7 days after the second dose and significant antibody titers and ACE2/RBD binding inhibiting activity were still observed after 6 months, despite a progressive decline over time. Concomitant to antibody reduction, spike-specific memory B cells, mostly IgG class-switched, increased in the blood of vaccinees and persisted 6 months after vaccination. Following the in vitro restimulation, circulating memory B cells reactivated and produced spike-specific antibodies. A high frequency of spike-specific IgG(+) plasmablasts, identified by computational analysis 7 days after boost, positively correlated with the generation of IgG(+) memory B cells at 6 months. These data demonstrate that mRNA BNT162b2 vaccine elicits strong B cell immunity with spike-specific memory B cells that still persist 6 months after vaccination, playing a crucial role for a rapid response to SARS-CoV-2 virus encounter. CI - Copyright (c) 2021 Ciabattini, Pastore, Fiorino, Polvere, Lucchesi, Pettini, Auddino, Rancan, Durante, Miscia, Rossetti, Fabbiani, Montagnani and Medaglini. FAU - Ciabattini, Annalisa AU - Ciabattini A AD - Laboratory of Molecular Microbiology and Biotechnology, Department of Medical Biotechnologies, University of Siena, Siena, Italy. FAU - Pastore, Gabiria AU - Pastore G AD - Laboratory of Molecular Microbiology and Biotechnology, Department of Medical Biotechnologies, University of Siena, Siena, Italy. FAU - Fiorino, Fabio AU - Fiorino F AD - Laboratory of Molecular Microbiology and Biotechnology, Department of Medical Biotechnologies, University of Siena, Siena, Italy. FAU - Polvere, Jacopo AU - Polvere J AD - Laboratory of Molecular Microbiology and Biotechnology, Department of Medical Biotechnologies, University of Siena, Siena, Italy. FAU - Lucchesi, Simone AU - Lucchesi S AD - Laboratory of Molecular Microbiology and Biotechnology, Department of Medical Biotechnologies, University of Siena, Siena, Italy. FAU - Pettini, Elena AU - Pettini E AD - Laboratory of Molecular Microbiology and Biotechnology, Department of Medical Biotechnologies, University of Siena, Siena, Italy. FAU - Auddino, Stefano AU - Auddino S AD - Laboratory of Molecular Microbiology and Biotechnology, Department of Medical Biotechnologies, University of Siena, Siena, Italy. FAU - Rancan, Ilaria AU - Rancan I AD - Department of Medical Biotechnologies, University of Siena, Siena, Italy. AD - Department of Medical Sciences, Infectious and Tropical Diseases Unit, University Hospital of Siena, Siena, Italy. FAU - Durante, Miriam AU - Durante M AD - Department of Medical Biotechnologies, University of Siena, Siena, Italy. FAU - Miscia, Michele AU - Miscia M AD - Department of Medical Biotechnologies, University of Siena, Siena, Italy. AD - Department of Medical Sciences, Infectious and Tropical Diseases Unit, University Hospital of Siena, Siena, Italy. FAU - Rossetti, Barbara AU - Rossetti B AD - Department of Medical Sciences, Infectious and Tropical Diseases Unit, University Hospital of Siena, Siena, Italy. FAU - Fabbiani, Massimiliano AU - Fabbiani M AD - Department of Medical Sciences, Infectious and Tropical Diseases Unit, University Hospital of Siena, Siena, Italy. FAU - Montagnani, Francesca AU - Montagnani F AD - Department of Medical Biotechnologies, University of Siena, Siena, Italy. AD - Department of Medical Sciences, Infectious and Tropical Diseases Unit, University Hospital of Siena, Siena, Italy. FAU - Medaglini, Donata AU - Medaglini D AD - Laboratory of Molecular Microbiology and Biotechnology, Department of Medical Biotechnologies, University of Siena, Siena, Italy. LA - eng PT - Journal Article DEP - 20210928 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 RN - 0 (Antibodies, Viral) RN - 0 (Antigens, Viral) RN - 0 (BNT162 Vaccine) RN - 0 (COVID-19 Vaccines) RN - 0 (Immunoglobulin G) RN - 0 (Spike Glycoprotein, Coronavirus) RN - 0 (Vaccines, Synthetic) RN - 0 (mRNA Vaccines) RN - 0 (spike protein, SARS-CoV-2) SB - IM MH - Adult MH - Aged MH - Antibodies, Viral/blood MH - Antigens, Viral/immunology MH - B-Lymphocytes/*immunology MH - BNT162 Vaccine MH - COVID-19/*prevention & control MH - COVID-19 Vaccines/*administration & dosage MH - Female MH - Humans MH - Immunoglobulin G/blood MH - Immunologic Memory MH - Male MH - Middle Aged MH - SARS-CoV-2/*immunology MH - Spike Glycoprotein, Coronavirus/immunology MH - Vaccination MH - Vaccines, Synthetic/*administration & dosage MH - Young Adult MH - mRNA Vaccines PMC - PMC8505800 OTO - NOTNLM OT - BNT162b2 vaccine OT - COVID-19 OT - SARS-CoV-2 OT - memory B cells OT - vaccination COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2021/10/16 06:00 MHDA- 2021/10/26 06:00 PMCR- 2021/09/28 CRDT- 2021/10/15 06:35 PHST- 2021/07/13 00:00 [received] PHST- 2021/08/27 00:00 [accepted] PHST- 2021/10/15 06:35 [entrez] PHST- 2021/10/16 06:00 [pubmed] PHST- 2021/10/26 06:00 [medline] PHST- 2021/09/28 00:00 [pmc-release] AID - 10.3389/fimmu.2021.740708 [doi] PST - epublish SO - Front Immunol. 2021 Sep 28;12:740708. doi: 10.3389/fimmu.2021.740708. eCollection 2021. PMID- 34647691 OWN - NLM STAT- MEDLINE DCOM- 20211213 LR - 20231108 IS - 1757-4684 (Electronic) IS - 1757-4676 (Print) IS - 1757-4676 (Linking) VI - 13 IP - 12 DP - 2021 Dec 7 TI - Brain cross-protection against SARS-CoV-2 variants by a lentiviral vaccine in new transgenic mice. PG - e14459 LID - 10.15252/emmm.202114459 [doi] LID - e14459 AB - COVID-19 vaccines already in use or in clinical development may have reduced efficacy against emerging SARS-CoV-2 variants. In addition, although the neurotropism of SARS-CoV-2 is well established, the vaccine strategies currently developed have not taken into account protection of the central nervous system. Here, we generated a transgenic mouse strain expressing the human angiotensin-converting enzyme 2, and displaying unprecedented brain permissiveness to SARS-CoV-2 replication, in addition to high permissiveness levels in the lung. Using this stringent transgenic model, we demonstrated that a non-integrative lentiviral vector, encoding for the spike glycoprotein of the ancestral SARS-CoV-2, used in intramuscular prime and intranasal boost elicits sterilizing protection of lung and brain against both the ancestral virus, and the Gamma (P.1) variant of concern, which carries multiple vaccine escape mutations. Beyond induction of strong neutralizing antibodies, the mechanism underlying this broad protection spectrum involves a robust protective T-cell immunity, unaffected by the recent mutations accumulated in the emerging SARS-CoV-2 variants. CI - (c) 2021 The Authors. Published under the terms of the CC BY 4.0 license. FAU - Ku, Min-Wen AU - Ku MW AD - Virology Department, Institut Pasteur-TheraVectys Joint Lab, Paris, France. FAU - Authie, Pierre AU - Authie P AUID- ORCID: 0000-0002-8293-3239 AD - Virology Department, Institut Pasteur-TheraVectys Joint Lab, Paris, France. FAU - Bourgine, Maryline AU - Bourgine M AD - Virology Department, Institut Pasteur-TheraVectys Joint Lab, Paris, France. FAU - Anna, Francois AU - Anna F AD - Virology Department, Institut Pasteur-TheraVectys Joint Lab, Paris, France. FAU - Noirat, Amandine AU - Noirat A AD - Virology Department, Institut Pasteur-TheraVectys Joint Lab, Paris, France. FAU - Moncoq, Fanny AU - Moncoq F AUID- ORCID: 0000-0002-2525-4715 AD - Virology Department, Institut Pasteur-TheraVectys Joint Lab, Paris, France. FAU - Vesin, Benjamin AU - Vesin B AUID- ORCID: 0000-0001-9458-9861 AD - Virology Department, Institut Pasteur-TheraVectys Joint Lab, Paris, France. FAU - Nevo, Fabien AU - Nevo F AD - Virology Department, Institut Pasteur-TheraVectys Joint Lab, Paris, France. FAU - Lopez, Jodie AU - Lopez J AUID- ORCID: 0000-0003-3103-0731 AD - Virology Department, Institut Pasteur-TheraVectys Joint Lab, Paris, France. FAU - Souque, Philippe AU - Souque P AD - Virology Department, Institut Pasteur-TheraVectys Joint Lab, Paris, France. FAU - Blanc, Catherine AU - Blanc C AD - Virology Department, Institut Pasteur-TheraVectys Joint Lab, Paris, France. FAU - Fert, Ingrid AU - Fert I AD - Virology Department, Institut Pasteur-TheraVectys Joint Lab, Paris, France. FAU - Chardenoux, Sebastien AU - Chardenoux S AD - Plate-Forme Centre d'Ingenierie Genetique Murine CIGM, Institut Pasteur, Paris, France. FAU - Lafosse, Llta AU - Lafosse L AD - Plate-Forme Centre d'Ingenierie Genetique Murine CIGM, Institut Pasteur, Paris, France. FAU - Cussigh, Delphine AU - Cussigh D AD - Plate-Forme Centre d'Ingenierie Genetique Murine CIGM, Institut Pasteur, Paris, France. FAU - Hardy, David AU - Hardy D AUID- ORCID: 0000-0001-5874-4377 AD - Experimental Neuropatholgy Unit, Institut Pasteur, Paris, France. FAU - Nemirov, Kirill AU - Nemirov K AD - Virology Department, Institut Pasteur-TheraVectys Joint Lab, Paris, France. FAU - Guinet, Francoise AU - Guinet F AUID- ORCID: 0000-0001-5032-8117 AD - Lymphocytes and Immunity Unit, Immunology Department, Institut Pasteur, Paris, France. FAU - Langa Vives, Francina AU - Langa Vives F AD - Plate-Forme Centre d'Ingenierie Genetique Murine CIGM, Institut Pasteur, Paris, France. FAU - Majlessi, Laleh AU - Majlessi L AUID- ORCID: 0000-0001-8648-4058 AD - Virology Department, Institut Pasteur-TheraVectys Joint Lab, Paris, France. FAU - Charneau, Pierre AU - Charneau P AUID- ORCID: 0000-0003-1184-5773 AD - Virology Department, Institut Pasteur-TheraVectys Joint Lab, Paris, France. LA - eng GR - URGENCE COVID-19/Institut Pasteur/ GR - HuMoCID/Agence Nationale de la Recherche (ANR)/ GR - 665807/EC | H2020 | H2020 Priority Excellent Science | H2020 Marie Sklodowska-Curie Actions (MSCA)/ PT - Journal Article DEP - 20211025 PL - Germany TA - EMBO Mol Med JT - EMBO molecular medicine JID - 101487380 RN - 0 (Antibodies, Neutralizing) RN - 0 (Antibodies, Viral) RN - 0 (COVID-19 Vaccines) RN - 0 (Spike Glycoprotein, Coronavirus) RN - SARS-CoV-2 variants SB - IM MH - Animals MH - Antibodies, Neutralizing MH - Antibodies, Viral MH - Brain/metabolism MH - *COVID-19 MH - COVID-19 Vaccines MH - Humans MH - Mice MH - Mice, Transgenic MH - *SARS-CoV-2 MH - Spike Glycoprotein, Coronavirus/metabolism PMC - PMC8646827 OTO - NOTNLM OT - SARS-CoV-2 emerging variants of concern OT - central nervous system OT - hACE2 transgenic mice OT - intranasal vaccination OT - olfactory bulb COIS- PC is the founder and CSO of TheraVectys. MWK, FA, PA, AN, FM, BV, FN, JL, IF, and KN are employees of TheraVectys. Other authors declare that they have no conflict of interest. MWK, FA, AN, FLV, LM, and PC are inventors of a pending patent directed to the B6.K18-hACE2(IP-THV) transgenic mice and the potential of i.n. LV::S vaccination at protecting brain against SARS-CoV-2. EDAT- 2021/10/15 06:00 MHDA- 2021/12/15 06:00 PMCR- 2021/12/07 CRDT- 2021/10/14 08:47 PHST- 2021/10/07 00:00 [revised] PHST- 2021/04/22 00:00 [received] PHST- 2021/10/08 00:00 [accepted] PHST- 2021/10/15 06:00 [pubmed] PHST- 2021/12/15 06:00 [medline] PHST- 2021/10/14 08:47 [entrez] PHST- 2021/12/07 00:00 [pmc-release] AID - EMMM202114459 [pii] AID - 10.15252/emmm.202114459 [doi] PST - ppublish SO - EMBO Mol Med. 2021 Dec 7;13(12):e14459. doi: 10.15252/emmm.202114459. Epub 2021 Oct 25. PMID- 34614412 OWN - NLM STAT- MEDLINE DCOM- 20211223 LR - 20260127 IS - 1097-4180 (Electronic) IS - 1074-7613 (Print) IS - 1074-7613 (Linking) VI - 54 IP - 12 DP - 2021 Dec 14 TI - mRNA vaccination of naive and COVID-19-recovered individuals elicits potent memory B cells that recognize SARS-CoV-2 variants. PG - 2893-2907.e5 LID - S1074-7613(21)00396-4 [pii] LID - 10.1016/j.immuni.2021.09.011 [doi] AB - In addition to serum immunoglobulins, memory B cell (MBC) generation against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is another layer of immune protection, but the quality of MBC responses in naive and coronavirus disease 2019 (COVID-19)-recovered individuals after vaccination remains ill defined. We studied longitudinal cohorts of naive and disease-recovered individuals for up to 2 months after SARS-CoV-2 mRNA vaccination. We assessed the quality of the memory response by analysis of antibody repertoires, affinity, and neutralization against variants of concern (VOCs) using unbiased cultures of 2,452 MBCs. Upon boosting, the MBC pool of recovered individuals expanded selectively, matured further, and harbored potent neutralizers against VOCs. Although naive individuals had weaker neutralizing serum responses, half of their RBD-specific MBCs displayed high affinity toward multiple VOCs, including delta (B.1.617.2), and one-third retained neutralizing potency against beta (B.1.351). Our data suggest that an additional challenge in naive vaccinees could recall such affinity-matured MBCs and allow them to respond efficiently to VOCs. CI - Copyright (c) 2021. Published by Elsevier Inc. FAU - Sokal, Aurelien AU - Sokal A AD - Institut Necker Enfants Malades (INEM), INSERM U1151/CNRS UMS 8253, Universite de Paris, Paris, France; Service de Medecine Interne, Centre Hospitalier Universitaire Henri-Mondor, Assistance Publique-Hopitaux de Paris (AP-HP), Universite Paris-Est Creteil (UPEC), Creteil, France. FAU - Barba-Spaeth, Giovanna AU - Barba-Spaeth G AD - Institut Pasteur, Universite de Paris, Unite de Virologie Structurale, CNRS UMR 3569, Paris 75015, France. FAU - Fernandez, Ignacio AU - Fernandez I AD - Institut Pasteur, Universite de Paris, Unite de Virologie Structurale, CNRS UMR 3569, Paris 75015, France. FAU - Broketa, Matteo AU - Broketa M AD - Institut Pasteur, Universite de Paris, INSERM UMR 1222, Unit of Antibodies in Therapy and Pathology, Paris 75015, France; Sorbonne Universite, College doctoral, Paris 75005, France. FAU - Azzaoui, Imane AU - Azzaoui I AD - Service de Medecine Interne, Centre Hospitalier Universitaire Henri-Mondor, Assistance Publique-Hopitaux de Paris (AP-HP), Universite Paris-Est Creteil (UPEC), Creteil, France; INSERM U955, Equipe 2, Institut Mondor de Recherche Biomedicale (IMRB), Universite Paris-Est Creteil (UPEC), Creteil, France. FAU - de La Selle, Andrea AU - de La Selle A AD - Institut Necker Enfants Malades (INEM), INSERM U1151/CNRS UMS 8253, Universite de Paris, Paris, France; Service de Medecine Interne, Centre Hospitalier Universitaire Henri-Mondor, Assistance Publique-Hopitaux de Paris (AP-HP), Universite Paris-Est Creteil (UPEC), Creteil, France. FAU - Vandenberghe, Alexis AU - Vandenberghe A AD - Service de Medecine Interne, Centre Hospitalier Universitaire Henri-Mondor, Assistance Publique-Hopitaux de Paris (AP-HP), Universite Paris-Est Creteil (UPEC), Creteil, France; INSERM U955, Equipe 2, Institut Mondor de Recherche Biomedicale (IMRB), Universite Paris-Est Creteil (UPEC), Creteil, France. FAU - Fourati, Slim AU - Fourati S AD - Departement de Virologie, Bacteriologie, Hygiene et Mycologie-Parasitologie, Centre Hospitalier Universitaire Henri-Mondor, Assistance Publique-Hopitaux de Paris (AP-HP), Creteil, France; INSERM U955, Equipe 18, Institut Mondor de Recherche Biomedicale (IMRB), Universite Paris-Est Creteil (UPEC), Creteil, France. FAU - Roeser, Anais AU - Roeser A AD - Institut Necker Enfants Malades (INEM), INSERM U1151/CNRS UMS 8253, Universite de Paris, Paris, France; Service de Medecine Interne, Centre Hospitalier Universitaire Henri-Mondor, Assistance Publique-Hopitaux de Paris (AP-HP), Universite Paris-Est Creteil (UPEC), Creteil, France. FAU - Meola, Annalisa AU - Meola A AD - Institut Pasteur, Universite de Paris, Unite de Virologie Structurale, CNRS UMR 3569, Paris 75015, France. FAU - Bouvier-Alias, Magali AU - Bouvier-Alias M AD - Departement de Virologie, Bacteriologie, Hygiene et Mycologie-Parasitologie, Centre Hospitalier Universitaire Henri-Mondor, Assistance Publique-Hopitaux de Paris (AP-HP), Creteil, France; INSERM U955, Equipe 18, Institut Mondor de Recherche Biomedicale (IMRB), Universite Paris-Est Creteil (UPEC), Creteil, France. FAU - Crickx, Etienne AU - Crickx E AD - Institut Necker Enfants Malades (INEM), INSERM U1151/CNRS UMS 8253, Universite de Paris, Paris, France; Service de Medecine Interne, Centre Hospitalier Universitaire Henri-Mondor, Assistance Publique-Hopitaux de Paris (AP-HP), Universite Paris-Est Creteil (UPEC), Creteil, France. FAU - Languille, Laetitia AU - Languille L AD - Service de Medecine Interne, Centre Hospitalier Universitaire Henri-Mondor, Assistance Publique-Hopitaux de Paris (AP-HP), Universite Paris-Est Creteil (UPEC), Creteil, France. FAU - Michel, Marc AU - Michel M AD - Service de Medecine Interne, Centre Hospitalier Universitaire Henri-Mondor, Assistance Publique-Hopitaux de Paris (AP-HP), Universite Paris-Est Creteil (UPEC), Creteil, France. FAU - Godeau, Bertrand AU - Godeau B AD - Service de Medecine Interne, Centre Hospitalier Universitaire Henri-Mondor, Assistance Publique-Hopitaux de Paris (AP-HP), Universite Paris-Est Creteil (UPEC), Creteil, France. FAU - Gallien, Sebastien AU - Gallien S AD - Service de Maladies Infectieuses, Centre Hospitalier Universitaire Henri-Mondor, Assistance Publique-Hopitaux de Paris (AP-HP), Universite Paris-Est Creteil (UPEC), Creteil, France. FAU - Melica, Giovanna AU - Melica G AD - Service de Maladies Infectieuses, Centre Hospitalier Universitaire Henri-Mondor, Assistance Publique-Hopitaux de Paris (AP-HP), Universite Paris-Est Creteil (UPEC), Creteil, France. FAU - Nguyen, Yann AU - Nguyen Y AD - Service de Medecine Interne, Hopital Beaujon, Assistance Publique-Hopitaux de Paris, Universite de Paris, Clichy, France. FAU - Zarrouk, Virginie AU - Zarrouk V AD - Service de Medecine Interne, Hopital Beaujon, Assistance Publique-Hopitaux de Paris, Universite de Paris, Clichy, France. FAU - Canoui-Poitrine, Florence AU - Canoui-Poitrine F AD - Departement de Sante Publique, Unite de Recherche Clinique (URC), CEpiA (Clinical Epidemiology and Ageing), EA 7376, Institut Mondor de Recherche Biomedicale (IMRB), Centre Hospitalier Universitaire Henri-Mondor, Assistance Publique-Hopitaux de Paris (AP-HP), Universite Paris-Est Creteil (UPEC), Creteil, France. FAU - Pirenne, France AU - Pirenne F AD - INSERM U955, Equipe 2, Institut Mondor de Recherche Biomedicale (IMRB), Universite Paris-Est Creteil (UPEC), Creteil, France; Etablissement Francais du Sang (EFS) Ile de France, Creteil, France. FAU - Megret, Jerome AU - Megret J AD - Plateforme de Cytometrie en Flux, Structure Federative de Recherche Necker, INSERM US24-CNRS UMS3633, Paris, France. FAU - Pawlotsky, Jean-Michel AU - Pawlotsky JM AD - Departement de Virologie, Bacteriologie, Hygiene et Mycologie-Parasitologie, Centre Hospitalier Universitaire Henri-Mondor, Assistance Publique-Hopitaux de Paris (AP-HP), Creteil, France; INSERM U955, Equipe 18, Institut Mondor de Recherche Biomedicale (IMRB), Universite Paris-Est Creteil (UPEC), Creteil, France. FAU - Fillatreau, Simon AU - Fillatreau S AD - Institut Necker Enfants Malades (INEM), INSERM U1151/CNRS UMS 8253, Universite de Paris, Paris, France. FAU - Bruhns, Pierre AU - Bruhns P AD - Institut Pasteur, Universite de Paris, INSERM UMR 1222, Unit of Antibodies in Therapy and Pathology, Paris 75015, France. FAU - Rey, Felix A AU - Rey FA AD - Institut Pasteur, Universite de Paris, Unite de Virologie Structurale, CNRS UMR 3569, Paris 75015, France. FAU - Weill, Jean-Claude AU - Weill JC AD - Institut Necker Enfants Malades (INEM), INSERM U1151/CNRS UMS 8253, Universite de Paris, Paris, France. Electronic address: jean-claude.weill@inserm.fr. FAU - Reynaud, Claude-Agnes AU - Reynaud CA AD - Institut Necker Enfants Malades (INEM), INSERM U1151/CNRS UMS 8253, Universite de Paris, Paris, France. Electronic address: claude-agnes.reynaud@inserm.fr. FAU - Chappert, Pascal AU - Chappert P AD - Institut Necker Enfants Malades (INEM), INSERM U1151/CNRS UMS 8253, Universite de Paris, Paris, France; Inovarion, Paris, France. Electronic address: pascal.chappert@inserm.fr. FAU - Mahevas, Matthieu AU - Mahevas M AD - Institut Necker Enfants Malades (INEM), INSERM U1151/CNRS UMS 8253, Universite de Paris, Paris, France; Service de Medecine Interne, Centre Hospitalier Universitaire Henri-Mondor, Assistance Publique-Hopitaux de Paris (AP-HP), Universite Paris-Est Creteil (UPEC), Creteil, France; INSERM U955, Equipe 2, Institut Mondor de Recherche Biomedicale (IMRB), Universite Paris-Est Creteil (UPEC), Creteil, France. Electronic address: matthieu.mahevas@aphp.fr. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210921 PL - United States TA - Immunity JT - Immunity JID - 9432918 RN - 0 (Antibodies, Neutralizing) RN - 0 (Antibodies, Viral) RN - 0 (BNT162 Vaccine) RN - 0 (RNA, Messenger) RN - 0 (Spike Glycoprotein, Coronavirus) RN - SARS-CoV-2 variants SB - IM MH - Animals MH - Antibodies, Neutralizing/metabolism MH - Antibodies, Viral/metabolism MH - Antibody Affinity MH - BNT162 Vaccine/*immunology MH - COVID-19/*immunology MH - Cells, Cultured MH - Convalescence MH - Humans MH - Immunization, Secondary MH - Immunologic Memory MH - Mass Vaccination MH - Memory B Cells/*immunology MH - Precursor Cells, B-Lymphoid/*immunology MH - RNA, Messenger/*genetics MH - SARS-CoV-2/genetics/immunology/*physiology MH - Spike Glycoprotein, Coronavirus/immunology PMC - PMC8452492 OTO - NOTNLM OT - B-cell memory OT - BNT162b2 vaccine OT - COVID-19 OT - RBD OT - affinity maturation OT - germinal center OT - neutralizing antibody OT - plasma cells OT - somatic hypermutation COIS- Declaration of interests Outside of the submitted work, M. Mahevas. received research funds from GSK and personal fees from LFB and Amgen. J.-C.W. received consulting fees from Institut Merieux. P.B. received consulting fees from Regeneron Pharmaceuticals. J.-M.P. received personal fees from Abbvie, Gilead, Merck, and Siemens Healthcare. F.R. is a member of the board of MELETIOS Therapeutics and of the Scientific Advisory Board of eureKARE. EDAT- 2021/10/07 06:00 MHDA- 2021/12/24 06:00 PMCR- 2021/09/21 CRDT- 2021/10/06 20:07 PHST- 2021/06/17 00:00 [received] PHST- 2021/08/05 00:00 [revised] PHST- 2021/09/14 00:00 [accepted] PHST- 2021/10/07 06:00 [pubmed] PHST- 2021/12/24 06:00 [medline] PHST- 2021/10/06 20:07 [entrez] PHST- 2021/09/21 00:00 [pmc-release] AID - S1074-7613(21)00396-4 [pii] AID - 10.1016/j.immuni.2021.09.011 [doi] PST - ppublish SO - Immunity. 2021 Dec 14;54(12):2893-2907.e5. doi: 10.1016/j.immuni.2021.09.011. Epub 2021 Sep 21. PMID- 34610291 OWN - NLM STAT- MEDLINE DCOM- 20211101 LR - 20220329 IS - 2211-1247 (Electronic) VI - 37 IP - 2 DP - 2021 Oct 12 TI - High-affinity memory B cells induced by SARS-CoV-2 infection produce more plasmablasts and atypical memory B cells than those primed by mRNA vaccines. PG - 109823 LID - S2211-1247(21)01287-0 [pii] LID - 10.1016/j.celrep.2021.109823 [doi] AB - Although both infections and vaccines induce memory B cell (MBC) populations that participate in secondary immune responses, the MBCs generated in each case can differ. Here, we compare SARS-CoV-2 spike receptor binding domain (S1-RBD)-specific primary MBCs that form in response to infection or a single mRNA vaccination. Both primary MBC populations have similar frequencies in the blood and respond to a second S1-RBD exposure by rapidly producing plasmablasts with an abundant immunoglobulin (Ig)A(+) subset and secondary MBCs that are mostly IgG(+) and cross-react with the B.1.351 variant. However, infection-induced primary MBCs have better antigen-binding capacity and generate more plasmablasts and secondary MBCs of the classical and atypical subsets than do vaccine-induced primary MBCs. Our results suggest that infection-induced primary MBCs have undergone more affinity maturation than vaccine-induced primary MBCs and produce more robust secondary responses. CI - Copyright (c) 2021 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Pape, Kathryn A AU - Pape KA AD - Department of Microbiology and Immunology, University of Minnesota Medical School, Minneapolis, MN 55455, USA; Center for Immunology, University of Minnesota Medical School, Minneapolis, MN 55455, USA. FAU - Dileepan, Thamotharampillai AU - Dileepan T AD - Department of Microbiology and Immunology, University of Minnesota Medical School, Minneapolis, MN 55455, USA; Center for Immunology, University of Minnesota Medical School, Minneapolis, MN 55455, USA. FAU - Kabage, Amanda J AU - Kabage AJ AD - Department of Medicine, Division of Gastroenterology, University of Minnesota Medical School, Minneapolis, MN 55455, USA. FAU - Kozysa, Daria AU - Kozysa D AD - Department of Medicine, Division of Gastroenterology, University of Minnesota Medical School, Minneapolis, MN 55455, USA. FAU - Batres, Rodolfo AU - Batres R AD - Department of Medicine, Division of Infectious Disease, University of Minnesota Medical School, Minneapolis, MN 55455, USA. FAU - Evert, Clayton AU - Evert C AD - Department of Medicine, Division of Gastroenterology, University of Minnesota Medical School, Minneapolis, MN 55455, USA. FAU - Matson, Michael AU - Matson M AD - Department of Medicine, Division of Gastroenterology, University of Minnesota Medical School, Minneapolis, MN 55455, USA. FAU - Lopez, Sharon AU - Lopez S AD - Department of Medicine, Division of Gastroenterology, University of Minnesota Medical School, Minneapolis, MN 55455, USA. FAU - Krueger, Peter D AU - Krueger PD AD - Department of Microbiology and Immunology, University of Minnesota Medical School, Minneapolis, MN 55455, USA; Center for Immunology, University of Minnesota Medical School, Minneapolis, MN 55455, USA. FAU - Graiziger, Carolyn AU - Graiziger C AD - Department of Medicine, Division of Gastroenterology, University of Minnesota Medical School, Minneapolis, MN 55455, USA. FAU - Vaughn, Byron P AU - Vaughn BP AD - Department of Medicine, Division of Gastroenterology, University of Minnesota Medical School, Minneapolis, MN 55455, USA. FAU - Shmidt, Eugenia AU - Shmidt E AD - Department of Medicine, Division of Gastroenterology, University of Minnesota Medical School, Minneapolis, MN 55455, USA. FAU - Rhein, Joshua AU - Rhein J AD - Department of Medicine, Division of Infectious Disease, University of Minnesota Medical School, Minneapolis, MN 55455, USA. FAU - Schacker, Timothy W AU - Schacker TW AD - Department of Medicine, Division of Infectious Disease, University of Minnesota Medical School, Minneapolis, MN 55455, USA. FAU - Khoruts, Alexander AU - Khoruts A AD - Center for Immunology, University of Minnesota Medical School, Minneapolis, MN 55455, USA; Department of Medicine, Division of Gastroenterology, University of Minnesota Medical School, Minneapolis, MN 55455, USA. FAU - Jenkins, Marc K AU - Jenkins MK AD - Department of Microbiology and Immunology, University of Minnesota Medical School, Minneapolis, MN 55455, USA; Center for Immunology, University of Minnesota Medical School, Minneapolis, MN 55455, USA. Electronic address: jenki002@umn.edu. LA - eng PT - Journal Article DEP - 20210925 PL - United States TA - Cell Rep JT - Cell reports JID - 101573691 RN - 0 (Antibodies, Viral) RN - 0 (COVID-19 Vaccines) RN - 0 (RNA, Messenger) RN - 0 (Spike Glycoprotein, Coronavirus) RN - 0 (Vaccines) RN - 0 (spike protein, SARS-CoV-2) SB - IM MH - Adult MH - Animals MH - Antibodies, Viral/immunology MH - B-Lymphocyte Subsets/immunology MH - B-Lymphocytes/immunology MH - COVID-19/immunology/metabolism MH - COVID-19 Vaccines/*immunology MH - Cross Reactions/immunology MH - Female MH - HEK293 Cells MH - Humans MH - Immunization/methods MH - Immunologic Memory MH - Male MH - Mice MH - Mice, Inbred C57BL MH - Middle Aged MH - Plasma Cells/*immunology MH - RNA, Messenger/immunology MH - SARS-CoV-2/*immunology/pathogenicity MH - Spike Glycoprotein, Coronavirus/immunology/metabolism MH - Vaccination/methods MH - Vaccines/immunology PMC - PMC8463313 OTO - NOTNLM OT - SARS-CoV-2 OT - atypical memory B cell OT - mRNA vaccine OT - memory B cell OT - plasmablast COIS- Declaration of interests The authors declare no competing interests. EDAT- 2021/10/06 06:00 MHDA- 2021/11/03 06:00 PMCR- 2021/09/25 CRDT- 2021/10/05 20:09 PHST- 2021/06/18 00:00 [received] PHST- 2021/08/16 00:00 [revised] PHST- 2021/09/20 00:00 [accepted] PHST- 2021/10/06 06:00 [pubmed] PHST- 2021/11/03 06:00 [medline] PHST- 2021/10/05 20:09 [entrez] PHST- 2021/09/25 00:00 [pmc-release] AID - S2211-1247(21)01287-0 [pii] AID - 109823 [pii] AID - 10.1016/j.celrep.2021.109823 [doi] PST - ppublish SO - Cell Rep. 2021 Oct 12;37(2):109823. doi: 10.1016/j.celrep.2021.109823. Epub 2021 Sep 25. PMID- 34562997 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20211002 IS - 2036-7430 (Print) IS - 2036-7449 (Electronic) IS - 2036-7430 (Linking) VI - 13 IP - 3 DP - 2021 Aug 30 TI - Variables Associated with Coronavirus Disease 2019 Vaccine Hesitancy Amongst Patients with Neurological Disorders. PG - 763-810 LID - 10.3390/idr13030072 [doi] AB - INTRODUCTION: Given that the success of vaccines against coronavirus disease 2019 (COVID-19) relies on herd immunity, identifying patients at risk for vaccine hesitancy is imperative-particularly for those at high risk for severe COVID-19 (i.e., minorities and patients with neurological disorders). METHODS: Among patients from a large neuroscience institute in Hawaii, vaccine hesitancy was investigated in relation to over 30 sociodemographic variables and medical comorbidities, via a telephone quality improvement survey conducted between 23 January 2021 and 13 February 2021. RESULTS: Vaccine willingness (n = 363) was 81.3%. Univariate analysis identified that the odds of vaccine acceptance reduced for patients who do not regard COVID-19 as a severe illness, are of younger age, have a lower Charlson Comorbidity Index, use illicit drugs, or carry Medicaid insurance. Multivariable logistic regression identified the best predictors of vaccine hesitancy to be: social media use to obtain COVID-19 information, concerns regarding vaccine safety, self-perception of a preexisting medical condition contraindicated with vaccination, not having received the annual influenza vaccine, having some high school education only, being a current smoker, and not having a prior cerebrovascular accident. Unique amongst males, a conservative political view strongly predicted vaccine hesitancy. Specifically for Asians, a higher body mass index, while for Native Hawaiians and other Pacific Islanders (NHPI), a positive depression screen, both reduced the odds of vaccine acceptance. CONCLUSION: Upon identifying the variables associated with vaccine hesitancy amongst patients with neurological disorders, our clinic is now able to efficiently provide ancillary COVID-19 education to sub-populations at risk for vaccine hesitancy. While our results may be limited to the sub-population of patients with neurological disorders, the findings nonetheless provide valuable insight to understanding vaccine hesitancy. FAU - Ghaffari-Rafi, Arash AU - Ghaffari-Rafi A AD - Department of Neurological Surgery, School of Medicine, University of California Davis, Sacramento, CA 95817, USA. AD - John A. Burns School of Medicine, University of Hawai'i at Manoa, Honolulu, HI 96813, USA. FAU - Teehera, Kimberly Bergenholtz AU - Teehera KB AUID- ORCID: 0000-0003-0049-3098 AD - John A. Burns School of Medicine, University of Hawai'i at Manoa, Honolulu, HI 96813, USA. FAU - Higashihara, Tate Justin AU - Higashihara TJ AD - John A. Burns School of Medicine, University of Hawai'i at Manoa, Honolulu, HI 96813, USA. FAU - Morden, Frances Tiffany Cava AU - Morden FTC AUID- ORCID: 0000-0003-2520-3333 AD - John A. Burns School of Medicine, University of Hawai'i at Manoa, Honolulu, HI 96813, USA. FAU - Goo, Connor AU - Goo C AUID- ORCID: 0000-0002-2989-7224 AD - John A. Burns School of Medicine, University of Hawai'i at Manoa, Honolulu, HI 96813, USA. FAU - Pang, Michelle AU - Pang M AD - John A. Burns School of Medicine, University of Hawai'i at Manoa, Honolulu, HI 96813, USA. FAU - Sutton, Cori Xiu Yue AU - Sutton CXY AUID- ORCID: 0000-0003-2840-806X AD - John A. Burns School of Medicine, University of Hawai'i at Manoa, Honolulu, HI 96813, USA. FAU - Kim, Kyung Moo AU - Kim KM AUID- ORCID: 0000-0001-9362-8910 AD - John A. Burns School of Medicine, University of Hawai'i at Manoa, Honolulu, HI 96813, USA. FAU - Lew, Rachel Jane AU - Lew RJ AD - John A. Burns School of Medicine, University of Hawai'i at Manoa, Honolulu, HI 96813, USA. FAU - Luu, Kayti AU - Luu K AD - John A. Burns School of Medicine, University of Hawai'i at Manoa, Honolulu, HI 96813, USA. FAU - Yamashita, Shaina AU - Yamashita S AD - University of Hawai'i at Manoa, Honolulu, HI 96822, USA. FAU - Mitchell, Catherine AU - Mitchell C AD - Brain Research, Innovation and Translation Lab, Hawaii Pacific Neuroscience, Honolulu, HI 96817, USA. FAU - Carrazana, Enrique AU - Carrazana E AUID- ORCID: 0000-0001-8788-0722 AD - John A. Burns School of Medicine, University of Hawai'i at Manoa, Honolulu, HI 96813, USA. AD - Brain Research, Innovation and Translation Lab, Hawaii Pacific Neuroscience, Honolulu, HI 96817, USA. FAU - Viereck, Jason AU - Viereck J AD - John A. Burns School of Medicine, University of Hawai'i at Manoa, Honolulu, HI 96813, USA. AD - Brain Research, Innovation and Translation Lab, Hawaii Pacific Neuroscience, Honolulu, HI 96817, USA. FAU - Liow, Kore Kai AU - Liow KK AD - John A. Burns School of Medicine, University of Hawai'i at Manoa, Honolulu, HI 96813, USA. AD - Brain Research, Innovation and Translation Lab, Hawaii Pacific Neuroscience, Honolulu, HI 96817, USA. LA - eng PT - Journal Article DEP - 20210830 PL - Switzerland TA - Infect Dis Rep JT - Infectious disease reports JID - 101537203 PMC - PMC8482072 OTO - NOTNLM OT - Hawaii OT - coronavirus disease 2019 OT - demographic OT - neurological disorders OT - quality improvement OT - risk factors OT - socioeconomic OT - vaccine hesitancy COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2021/09/26 06:00 MHDA- 2021/09/26 06:01 PMCR- 2021/08/30 CRDT- 2021/09/25 20:27 PHST- 2021/06/15 00:00 [received] PHST- 2021/08/24 00:00 [revised] PHST- 2021/08/25 00:00 [accepted] PHST- 2021/09/25 20:27 [entrez] PHST- 2021/09/26 06:00 [pubmed] PHST- 2021/09/26 06:01 [medline] PHST- 2021/08/30 00:00 [pmc-release] AID - idr13030072 [pii] AID - idr-13-00072 [pii] AID - 10.3390/idr13030072 [doi] PST - epublish SO - Infect Dis Rep. 2021 Aug 30;13(3):763-810. doi: 10.3390/idr13030072. PMID- 34519540 OWN - NLM STAT- MEDLINE DCOM- 20211029 LR - 20240923 IS - 1095-9203 (Electronic) IS - 0036-8075 (Print) IS - 0036-8075 (Linking) VI - 374 IP - 6566 DP - 2021 Oct 22 TI - Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells. PG - eabj9853 LID - 10.1126/science.abj9853 [doi] LID - eabj9853 AB - Vaccine-specific CD4(+) T cell, CD8(+) T cell, binding antibody, and neutralizing antibody responses to the 25-mug Moderna messenger RNA (mRNA)-1273 vaccine were examined over the course of 7 months after immunization, including in multiple age groups, with a particular interest in assessing whether preexisting cross-reactive T cell memory affects vaccine-generated immunity. Vaccine-generated spike-specific memory CD4(+) T cells 6 months after the second dose of the vaccine were comparable in quantity and quality to COVID-19 cases, including the presence of T follicular helper cells and interferon-gamma-expressing cells. Spike-specific CD8(+) T cells were generated in 88% of subjects, with equivalent memory at 6 months post-boost compared with COVID-19 cases. Lastly, subjects with preexisting cross-reactive CD4(+) T cell memory exhibited stronger CD4(+) T cell and antibody responses to the vaccine, demonstrating the biological relevance of severe acute respiratory syndrome coronavirus 2-cross-reactive CD4(+) T cells. FAU - Mateus, Jose AU - Mateus J AUID- ORCID: 0000-0002-1402-3452 AD - Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA. FAU - Dan, Jennifer M AU - Dan JM AUID- ORCID: 0000-0002-1672-0657 AD - Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA. AD - Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego (UCSD), La Jolla, CA 92037, USA. FAU - Zhang, Zeli AU - Zhang Z AD - Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA. FAU - Rydyznski Moderbacher, Carolyn AU - Rydyznski Moderbacher C AUID- ORCID: 0000-0002-7965-9902 AD - Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA. FAU - Lammers, Marshall AU - Lammers M AUID- ORCID: 0000-0003-2237-847X AD - Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA. FAU - Goodwin, Benjamin AU - Goodwin B AUID- ORCID: 0000-0002-5485-2861 AD - Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA. FAU - Sette, Alessandro AU - Sette A AUID- ORCID: 0000-0001-7013-2250 AD - Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA. AD - Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego (UCSD), La Jolla, CA 92037, USA. FAU - Crotty, Shane AU - Crotty S AUID- ORCID: 0000-0002-6484-6262 AD - Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA. AD - Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego (UCSD), La Jolla, CA 92037, USA. FAU - Weiskopf, Daniela AU - Weiskopf D AUID- ORCID: 0000-0003-2968-7371 AD - Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA. LA - eng GR - R25 AI147376/AI/NIAID NIH HHS/United States GR - UM1 AI148373/AI/NIAID NIH HHS/United States GR - R01 AI135193/AI/NIAID NIH HHS/United States GR - HHSN272201500002C/AI/NIAID NIH HHS/United States GR - K08 AI135078/AI/NIAID NIH HHS/United States GR - U19 AI142742/AI/NIAID NIH HHS/United States GR - P51 OD011132/OD/NIH HHS/United States GR - UM1 AI148576/AI/NIAID NIH HHS/United States GR - U01 AI149644/AI/NIAID NIH HHS/United States GR - UM1 AI148684/AI/NIAID NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20211022 PL - United States TA - Science JT - Science (New York, N.Y.) JID - 0404511 RN - 0 (Antibodies, Viral) RN - 0 (COVID-19 Vaccines) RN - 0 (Spike Glycoprotein, Coronavirus) RN - 0 (spike protein, SARS-CoV-2) RN - EPK39PL4R4 (2019-nCoV Vaccine mRNA-1273) SB - IM MH - 2019-nCoV Vaccine mRNA-1273 MH - Adolescent MH - Adult MH - Aged MH - Aged, 80 and over MH - Antibodies, Viral/blood MH - CD4-Positive T-Lymphocytes/*immunology MH - CD8-Positive T-Lymphocytes/*immunology MH - COVID-19/immunology/*prevention & control MH - COVID-19 Vaccines/administration & dosage/*immunology MH - Clinical Trials, Phase I as Topic MH - Cross Reactions MH - Humans MH - *Immunogenicity, Vaccine MH - *Immunologic Memory MH - Middle Aged MH - Spike Glycoprotein, Coronavirus/*immunology MH - Vaccination MH - Young Adult PMC - PMC8542617 MID - NIHMS1743942 EDAT- 2021/09/15 06:00 MHDA- 2021/10/30 06:00 PMCR- 2021/10/22 CRDT- 2021/09/14 12:25 PHST- 2021/09/15 06:00 [pubmed] PHST- 2021/10/30 06:00 [medline] PHST- 2021/09/14 12:25 [entrez] PHST- 2021/10/22 00:00 [pmc-release] AID - abj9853 [pii] AID - 10.1126/science.abj9853 [doi] PST - ppublish SO - Science. 2021 Oct 22;374(6566):eabj9853. doi: 10.1126/science.abj9853. Epub 2021 Oct 22. PMID- 34507266 OWN - NLM STAT- MEDLINE DCOM- 20211112 LR - 20221221 IS - 1873-4499 (Electronic) IS - 0899-7071 (Print) IS - 0899-7071 (Linking) VI - 80 DP - 2021 Dec TI - Neurological symptoms and neuroimaging alterations related with COVID-19 vaccine: Cause or coincidence? PG - 348-352 LID - S0899-7071(21)00355-7 [pii] LID - 10.1016/j.clinimag.2021.08.021 [doi] AB - Although vaccination against Coronavirus disease-2019 (COVID-19) is still occurring, several adverse effects temporally related to these vaccines are already being reported, even if through isolated case reports. In the present study, we describe the lesions seen on magnetic resonance imaging (MRI) of three patients who developed neurological symptoms after receiving the ChAdOX1 nCoV-19 vaccine (Oxford/AstraZeneca). The first patient presented with an ischemic stroke in the posterior limb of the left internal capsule, two days after vaccination. The second patient presented with a left facial nerve palsy, seven days after vaccination. The third patient presented with myelitis, eight days after receiving the vaccine. All patients presented the symptoms after the first dose of the vaccine and did not have a history of previous COVID-19. The real incidence of these types of complications is not known yet, but it is important to consider the possibility of COVID-19 vaccine complications, in patients with a recent history of vaccination and recent development of neurological symptoms, even though this association is only casual. Longitudinal studies are necessary to further analyze the incidence of the adverse effects of each vaccine against SARS-CoV-2. CI - Copyright (c) 2021 Elsevier Inc. All rights reserved. FAU - Correa, Diogo Goulart AU - Correa DG AD - Department of Radiology, Clinica de Diagnostico por Imagem (CDPI), Avenida das Americas, 4666, 302A, 303, 307, 325, 326, Barra da Tijuca, Rio de Janeiro, RJ Zip Code: 2640-102, Brazil; Department of Radiology, Federal Fluminense University, Rua Marques de Parana, 303, Centro, Niteroi, RJ Zip code: 24070-035, Brazil. Electronic address: diogogoulartcorrea@yahoo.com.br. FAU - Canete, Luis Alcides Quevedo AU - Canete LAQ AD - Department of Radiology, Clinica de Diagnostico por Imagem (CDPI), Avenida das Americas, 4666, 302A, 303, 307, 325, 326, Barra da Tijuca, Rio de Janeiro, RJ Zip Code: 2640-102, Brazil. FAU - Dos Santos, Gutemberg Augusto Cruz AU - Dos Santos GAC AD - Department of Neurology, Estacio de Sa University, Avenida das Americas, 700, bloco 8, loja 218, Barra da Tijuca, Rio de Janeiro, RJ Zip code: 22640-100, Brazil. FAU - de Oliveira, Romulo Varella AU - de Oliveira RV AD - Department of Radiology, Clinica de Diagnostico por Imagem (CDPI), Avenida das Americas, 4666, 302A, 303, 307, 325, 326, Barra da Tijuca, Rio de Janeiro, RJ Zip Code: 2640-102, Brazil. FAU - Brandao, Carlos Otavio AU - Brandao CO AD - Department of Neurology, Neurolife Laboratory, Praia do Flamengo, 66, Bloco B, sala 620, Flamengo, Rio de Janeiro, RJ Zip Code: 22210-903, Brazil. FAU - da Cruz, Luiz Celso Hygino Jr AU - da Cruz LCH Jr AD - Department of Radiology, Clinica de Diagnostico por Imagem (CDPI), Avenida das Americas, 4666, 302A, 303, 307, 325, 326, Barra da Tijuca, Rio de Janeiro, RJ Zip Code: 2640-102, Brazil. LA - eng PT - Journal Article DEP - 20210907 PL - United States TA - Clin Imaging JT - Clinical imaging JID - 8911831 RN - 0 (COVID-19 Vaccines) RN - 0 (Vaccines) RN - B5S3K2V0G8 (ChAdOx1 nCoV-19) SB - IM CIN - Clin Imaging. 2022 Feb;82:13-14. doi: 10.1016/j.clinimag.2021.10.017. PMID: 34768220 MH - *COVID-19 MH - COVID-19 Vaccines MH - ChAdOx1 nCoV-19 MH - Humans MH - Neuroimaging MH - SARS-CoV-2 MH - *Vaccines/adverse effects PMC - PMC8421080 OTO - NOTNLM OT - COVID-19 OT - Facial palsy OT - Myelitis OT - Stroke OT - Vaccines COIS- None. EDAT- 2021/09/11 06:00 MHDA- 2021/11/16 06:00 PMCR- 2021/09/07 CRDT- 2021/09/10 20:30 PHST- 2021/06/01 00:00 [received] PHST- 2021/08/22 00:00 [revised] PHST- 2021/08/23 00:00 [accepted] PHST- 2021/09/11 06:00 [pubmed] PHST- 2021/11/16 06:00 [medline] PHST- 2021/09/10 20:30 [entrez] PHST- 2021/09/07 00:00 [pmc-release] AID - S0899-7071(21)00355-7 [pii] AID - 10.1016/j.clinimag.2021.08.021 [doi] PST - ppublish SO - Clin Imaging. 2021 Dec;80:348-352. doi: 10.1016/j.clinimag.2021.08.021. Epub 2021 Sep 7. PMID- 34487856 OWN - NLM STAT- MEDLINE DCOM- 20211012 LR - 20240923 IS - 1873-2747 (Electronic) IS - 0361-9230 (Print) IS - 0361-9230 (Linking) VI - 176 DP - 2021 Nov TI - Mental Health Issues During and After COVID-19 Vaccine Era. PG - 161-173 LID - S0361-9230(21)00260-4 [pii] LID - 10.1016/j.brainresbull.2021.08.012 [doi] AB - The COVID-19 pandemic has persisted for more than a year, and post-COVID-19 sequelae of neurological complications, including direct and indirect effects on the central nervous system (CNS), have been recognized. There is a plethora of evidence for neurological, cognitive, and emotional deficits in COVID-19 patients. Acute neurological symptoms like neuroinflammation, cognitive impairment, loss of smell, and brain stroke are common direct effects among SARS-CoV-2 infected individuals. Work-associated stress, lockdowns, social distancing, and quarantine in response to contain SARS-CoV-2 have also affected the mental health of large populations, regardless of age. Public health emergencies have affected individuals and communities, resulting in emotional reactions and unhealthy behaviors. Although vaccines have been widely distributed and administered among large populations, vaccine hesitancy still exists and may be due to apprehension about vaccine efficacy, preliminary trials, and associated side effects. This review highlights the impact of COVID-19 on the CNS by outlining direct and indirect effects and factors contributing to the decline in people's mental health throughout the COVID-19 pandemic both during and after vaccine administration. Furthermore, we also discuss reasons for vaccine hesitancy and why some groups of people are deprived of vaccines. Finally, we touched upon the social determinants of mental health and their impact on disadvantaged populations during times of crisis which may help policymakers set up some action plans to mitigate the COVID-19 mental health turmoil during this ongoing pandemic. CI - Copyright (c) 2021 Elsevier Inc. All rights reserved. FAU - Pandey, Kabita AU - Pandey K AD - Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, USA; Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA. FAU - Thurman, Michellie AU - Thurman M AD - Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, USA. FAU - Johnson, Samuel D AU - Johnson SD AD - Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, USA; Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA. FAU - Acharya, Arpan AU - Acharya A AD - Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, USA. FAU - Johnston, Morgan AU - Johnston M AD - Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, USA. FAU - Klug, Elizabeth A AU - Klug EA AD - Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, USA; Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA. FAU - Olwenyi, Omalla A AU - Olwenyi OA AD - Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, USA; Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA. FAU - Rajaiah, Rajesh AU - Rajaiah R AD - Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, USA. FAU - Byrareddy, Siddappa N AU - Byrareddy SN AD - Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, USA; Department of Genetics, Cell Biology, and Anatomy, University of Nebraska Medical Center, Omaha, NE, USA; Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, USA. Electronic address: sid.byrareddy@unmc.edu. LA - eng GR - P30 MH062261/MH/NIMH NIH HHS/United States GR - R01 AI129745/AI/NIAID NIH HHS/United States GR - R01 DA052845/DA/NIDA NIH HHS/United States GR - T32 NS105594/NS/NINDS NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Review DEP - 20210903 PL - United States TA - Brain Res Bull JT - Brain research bulletin JID - 7605818 RN - 0 (COVID-19 Vaccines) RN - 0 (Vaccines) SB - IM MH - COVID-19/*psychology MH - COVID-19 Vaccines/administration & dosage MH - Communicable Disease Control MH - Humans MH - Longitudinal Studies MH - Mental Health/trends MH - Pandemics/prevention & control MH - Public Health MH - SARS-CoV-2/pathogenicity MH - Vaccination/*psychology/trends MH - Vaccination Refusal/*psychology/trends MH - Vaccines PMC - PMC8414813 OTO - NOTNLM OT - COVID-19 OT - SARS-CoV-2 OT - mental health OT - social determinants OT - vaccine EDAT- 2021/09/07 06:00 MHDA- 2021/10/13 06:00 PMCR- 2021/09/03 CRDT- 2021/09/06 20:12 PHST- 2021/05/05 00:00 [received] PHST- 2021/08/01 00:00 [revised] PHST- 2021/08/27 00:00 [accepted] PHST- 2021/09/07 06:00 [pubmed] PHST- 2021/10/13 06:00 [medline] PHST- 2021/09/06 20:12 [entrez] PHST- 2021/09/03 00:00 [pmc-release] AID - S0361-9230(21)00260-4 [pii] AID - 10.1016/j.brainresbull.2021.08.012 [doi] PST - ppublish SO - Brain Res Bull. 2021 Nov;176:161-173. doi: 10.1016/j.brainresbull.2021.08.012. Epub 2021 Sep 3. PMID- 34479746 OWN - NLM STAT- MEDLINE DCOM- 20220210 LR - 20221221 IS - 1873-5134 (Electronic) IS - 0738-3991 (Print) IS - 0738-3991 (Linking) VI - 105 IP - 2 DP - 2022 Feb TI - Vaccine for yourself, your community, or your country? Examining audiences' response to distance framing of COVID-19 vaccine messages. PG - 284-289 LID - S0738-3991(21)00563-2 [pii] LID - 10.1016/j.pec.2021.08.019 [doi] AB - OBJECTIVE: This study explored the effects of COVID-19 vaccine promotion messages highlighting the benefit at individual, community, and country levels. Based on the cultural theory of risks, we investigated how individuals' valuation of individualism vs. communitarianism and hierarchical vs. egalitarian social structure affect their responses to vaccine messages. METHODS: An online experiment (N = 702) with four video message conditions (individual-centered, community-centered, country-centered, and no message) was conducted. Participants were asked about their cultural cognition worldview, then were randomly assigned to view one message. Participants also reported their willingness to receive COVID-19 vaccines and support for vaccine mandate. RESULTS: Respondents were more likely to get vaccinated and support vaccine mandates after viewing an individual-centered message, less with a community-centered message. Individuals who value individualism were more likely to respond positively to individual-centered messages, but those who believe more in communitarianism value were less likely. CONCLUSION: Results showed that individuals are motivated selectively to respond to certain claims that cohere with their worldview and therefore respond differently to vaccine benefit frames. PRACTICE IMPLICATIONS: The results point to the importance of understanding audiences' worldviews. By identifying this process through hierarchical and individualistic values, properly designed health promotion messages can maximize the desired outcomes. CI - Copyright (c) 2021 Elsevier B.V. All rights reserved. FAU - Yuan, Shupei AU - Yuan S AD - Department of Communication Northern Illinois University DeKalb, IL 60008, USA. Electronic address: syuan@niu.edu. FAU - Chu, Haoran AU - Chu H AD - College of Journalism and Communications University of Florida, Gainesville, FL 32611, USA. Electronic address: chu.h@ufl.edu. LA - eng PT - Journal Article PT - Randomized Controlled Trial DEP - 20210825 PL - Ireland TA - Patient Educ Couns JT - Patient education and counseling JID - 8406280 RN - 0 (COVID-19 Vaccines) RN - 0 (Vaccines) MH - *COVID-19 MH - COVID-19 Vaccines MH - Health Promotion MH - Humans MH - SARS-CoV-2 MH - *Vaccines PMC - PMC8384529 OTO - NOTNLM OT - Benefit frames OT - Cultural cognition OT - Health communication OT - Vaccine message COIS- Declaration of Competing Interest The authors have no conflict of interest in the authoring of this manuscript. EDAT- 2021/09/05 06:00 MHDA- 2022/02/11 06:00 PMCR- 2021/08/25 CRDT- 2021/09/04 05:36 PHST- 2021/06/21 00:00 [received] PHST- 2021/08/09 00:00 [revised] PHST- 2021/08/20 00:00 [accepted] PHST- 2021/09/05 06:00 [pubmed] PHST- 2022/02/11 06:00 [medline] PHST- 2021/09/04 05:36 [entrez] PHST- 2021/08/25 00:00 [pmc-release] AID - S0738-3991(21)00563-2 [pii] AID - 10.1016/j.pec.2021.08.019 [doi] PST - ppublish SO - Patient Educ Couns. 2022 Feb;105(2):284-289. doi: 10.1016/j.pec.2021.08.019. Epub 2021 Aug 25. PMID- 34453880 OWN - NLM STAT- MEDLINE DCOM- 20210923 LR - 20260307 IS - 1097-4180 (Electronic) IS - 1074-7613 (Print) IS - 1074-7613 (Linking) VI - 54 IP - 9 DP - 2021 Sep 14 TI - Rapid induction of antigen-specific CD4(+) T cells is associated with coordinated humoral and cellular immunity to SARS-CoV-2 mRNA vaccination. PG - 2133-2142.e3 LID - S1074-7613(21)00308-3 [pii] LID - 10.1016/j.immuni.2021.08.001 [doi] AB - SARS-CoV-2 mRNA vaccines have shown remarkable clinical efficacy, but questions remain about the nature and kinetics of T cell priming. We performed longitudinal antigen-specific T cell analyses on healthy SARS-CoV-2-naive and recovered individuals prior to and following mRNA prime and boost vaccination. Vaccination induced rapid antigen-specific CD4(+) T cell responses in naive subjects after the first dose, whereas CD8(+) T cell responses developed gradually and were variable in magnitude. Vaccine-induced Th1 and Tfh cell responses following the first dose correlated with post-boost CD8(+) T cells and neutralizing antibodies, respectively. Integrated analysis revealed coordinated immune responses with distinct trajectories in SARS-CoV-2-naive and recovered individuals. Last, whereas booster vaccination improved T cell responses in SARS-CoV-2-naive subjects, the second dose had little effect in SARS-CoV-2-recovered individuals. These findings highlight the role of rapidly primed CD4(+) T cells in coordinating responses to the second vaccine dose in SARS-CoV-2-naive individuals. CI - Copyright (c) 2021 Elsevier Inc. All rights reserved. FAU - Painter, Mark M AU - Painter MM AD - Institute for Immunology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA; Immune Health, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA. FAU - Mathew, Divij AU - Mathew D AD - Institute for Immunology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA; Immune Health, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA. FAU - Goel, Rishi R AU - Goel RR AD - Institute for Immunology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA; Immune Health, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA. FAU - Apostolidis, Sokratis A AU - Apostolidis SA AD - Institute for Immunology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA; Immune Health, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA; Division of Rheumatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA. FAU - Pattekar, Ajinkya AU - Pattekar A AD - Immune Health, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA. FAU - Kuthuru, Oliva AU - Kuthuru O AD - Institute for Immunology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA. FAU - Baxter, Amy E AU - Baxter AE AD - Institute for Immunology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA. FAU - Herati, Ramin S AU - Herati RS AD - NYU Langone Vaccine Center, Department of Medicine, New York University School of Medicine, New York, NY 10016, USA. FAU - Oldridge, Derek A AU - Oldridge DA AD - Institute for Immunology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA; Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA. FAU - Gouma, Sigrid AU - Gouma S AD - Department of Microbiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA. FAU - Hicks, Philip AU - Hicks P AD - Department of Microbiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA. FAU - Dysinger, Sarah AU - Dysinger S AD - Department of Microbiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA. FAU - Lundgreen, Kendall A AU - Lundgreen KA AD - Department of Microbiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA. FAU - Kuri-Cervantes, Leticia AU - Kuri-Cervantes L AD - Institute for Immunology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA; Department of Microbiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA. FAU - Adamski, Sharon AU - Adamski S AD - Immune Health, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA. FAU - Hicks, Amanda AU - Hicks A AD - Immune Health, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA. FAU - Korte, Scott AU - Korte S AD - Immune Health, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA. FAU - Giles, Josephine R AU - Giles JR AD - Institute for Immunology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA; Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA; Parker Institute for Cancer Immunotherapy, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA. FAU - Weirick, Madison E AU - Weirick ME AD - Department of Microbiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA. FAU - McAllister, Christopher M AU - McAllister CM AD - Department of Microbiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA. FAU - Dougherty, Jeanette AU - Dougherty J AD - Institute for Immunology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA. FAU - Long, Sherea AU - Long S AD - Institute for Immunology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA. FAU - D'Andrea, Kurt AU - D'Andrea K AD - Institute for Immunology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA. FAU - Hamilton, Jacob T AU - Hamilton JT AD - Immune Health, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA; Department of Microbiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA. FAU - Betts, Michael R AU - Betts MR AD - Institute for Immunology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA; Department of Microbiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA. FAU - Bates, Paul AU - Bates P AD - Department of Microbiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA. FAU - Hensley, Scott E AU - Hensley SE AD - Department of Microbiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA. FAU - Grifoni, Alba AU - Grifoni A AD - Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA. FAU - Weiskopf, Daniela AU - Weiskopf D AD - Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA. FAU - Sette, Alessandro AU - Sette A AD - Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA. FAU - Greenplate, Allison R AU - Greenplate AR AD - Institute for Immunology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA; Immune Health, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA. FAU - Wherry, E John AU - Wherry EJ AD - Institute for Immunology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA; Immune Health, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA; Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA; Parker Institute for Cancer Immunotherapy, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA. Electronic address: wherry@pennmedicine.upenn.edu. LA - eng GR - T32 AR076951/AR/NIAMS NIH HHS/United States GR - R01 AI152236/AI/NIAID NIH HHS/United States GR - T32 AI070077/AI/NIAID NIH HHS/United States GR - T32 CA009140/CA/NCI NIH HHS/United States GR - P30 AI045008/AI/NIAID NIH HHS/United States GR - U19 AI082630/AI/NIAID NIH HHS/United States GR - R38 HL143613/HL/NHLBI NIH HHS/United States GR - P01 AI108545/AI/NIAID NIH HHS/United States GR - R01 AI105343/AI/NIAID NIH HHS/United States GR - T32 AI055400/AI/NIAID NIH HHS/United States GR - R01 AI155577/AI/NIAID NIH HHS/United States GR - U19 AI149680/AI/NIAID NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20210813 PL - United States TA - Immunity JT - Immunity JID - 9432918 RN - EPK39PL4R4 (2019-nCoV Vaccine mRNA-1273) RN - 0 (Antibodies, Neutralizing) RN - 0 (Antibodies, Viral) RN - 0 (Antigens, CD) RN - 0 (Antigens, Differentiation, T-Lymphocyte) RN - 0 (BNT162 Vaccine) RN - 0 (COVID-19 Vaccines) RN - 0 (Lectins, C-Type) RN - 0 (Peptides) RN - 0 (Spike Glycoprotein, Coronavirus) RN - 0 (CD69 Antigens) SB - IM MH - 2019-nCoV Vaccine mRNA-1273 MH - Adult MH - Antibodies, Neutralizing/blood MH - Antibodies, Viral/blood MH - Antigens, CD/metabolism MH - Antigens, Differentiation, T-Lymphocyte/metabolism MH - BNT162 Vaccine MH - CD8-Positive T-Lymphocytes/*immunology MH - COVID-19/*immunology MH - COVID-19 Vaccines/*immunology MH - Female MH - Humans MH - Immunity, Cellular MH - Immunity, Humoral MH - Immunization, Secondary MH - Immunologic Memory MH - Lectins, C-Type/metabolism MH - Lymphocyte Activation MH - Male MH - Middle Aged MH - Peptides/immunology MH - SARS-CoV-2/*physiology MH - Spike Glycoprotein, Coronavirus/immunology MH - Th1 Cells/*immunology MH - Vaccination MH - Young Adult MH - CD69 Antigens PMC - PMC8361141 OTO - NOTNLM OT - AIM OT - SARS-CoV-2 OT - T cells OT - T follicular helper OT - Tfh OT - Th1 OT - activation induced markers OT - immunological memory OT - mRNA vaccine COIS- Declaration of interests S.E.H. has received consultancy fees from Sanofi Pasteur, Lumen, Novavax, and Merk for work unrelated to this study. E.J.W. is a consultant or an adviser for Merck, Elstar, Janssen, Related Sciences, Synthekine, and Surface Oncology. E.J.W. is a founder of Surface Oncology and Arsenal Biosciences. E.J.W. is an inventor on a patent (U.S. Patent No. 10,370,446) submitted by Emory University that covers the use of PD-1 blockade to treat infections and cancer. A.S. is a consultant for Gritstone, Flow Pharma, CellCarta, Arcturus, Oxfordimmunotech, and Avalia. La Jolla Institute for Immunology has filed for patent protection for various aspects of T cell epitope and vaccine design work. EDAT- 2021/08/29 06:00 MHDA- 2021/09/24 06:00 PMCR- 2021/08/13 CRDT- 2021/08/28 20:08 PHST- 2021/04/22 00:00 [received] PHST- 2021/06/23 00:00 [revised] PHST- 2021/08/02 00:00 [accepted] PHST- 2021/08/29 06:00 [pubmed] PHST- 2021/09/24 06:00 [medline] PHST- 2021/08/28 20:08 [entrez] PHST- 2021/08/13 00:00 [pmc-release] AID - S1074-7613(21)00308-3 [pii] AID - 10.1016/j.immuni.2021.08.001 [doi] PST - ppublish SO - Immunity. 2021 Sep 14;54(9):2133-2142.e3. doi: 10.1016/j.immuni.2021.08.001. Epub 2021 Aug 13. PMID- 34453762 OWN - NLM STAT- MEDLINE DCOM- 20211206 LR - 20220731 IS - 1096-8652 (Electronic) IS - 0361-8609 (Print) IS - 0361-8609 (Linking) VI - 96 IP - 12 DP - 2021 Dec 1 TI - Cerebral venous thrombosis and myeloproliferative neoplasms: A three-center study of 74 consecutive cases. PG - 1580-1586 LID - 10.1002/ajh.26336 [doi] AB - The recent association of cerebral venous thrombosis (CVT) with COVID-19 vaccinations prompted the current retrospective review of 74 cases of CVT (median age = 44 years, range 15-85; 61% females) associated with myeloproliferative neoplasms (MPNs), seen at the Mayo Clinic, Catholic University of Rome, and University of Florence, between 1991 and 2021. Disease-specific frequencies were 1.3% (39/2893), 1.2% (21/1811) and 0.2% (3/1888) for essential thrombocythemia, polycythemia vera and primary myelofibrosis, respectively. Cerebral venous thrombosis occurred either prior to (n = 20, 27%), at (n = 32, 44%) or after (n = 22) MPN diagnosis. A total of 72% of patients presented with headaches. Transverse (51%), sagittal (43%) and sigmoid sinuses (35%) were involved with central nervous system hemorrhage noted in 10 (14%) patients. In all, 91% of tested patients harbored JAK2V617F. An underlying thrombophilic condition was identified in 19 (31%) cases and history of thrombosis in 10 (14%). Treatment for CVT included systemic anticoagulation alone (n = 27) or in conjunction with aspirin (n = 24), cytoreductive therapy (n = 14), or both (n = 9). At a median follow-up of 5.1 years (range 0.1-28.6), recurrent CVT was documented in three (4%) patients while recurrent arterial and venous thromboses and major hemorrhage were recorded in 11%, 9% and 14%, respectively. Follow-up neurological assessment revealed headaches (n = 9), vision loss (n = 1) and cognitive impairment (n = 1). The current study lends clarity to MPN-associated CVT and highlights its close association with JAK2V617F, younger age and female gender. Clinical features that distinguish COVID vaccine-related CVT from MPN-associated CVT include, in the latter, lower likelihood of concurrent venous thromboses and intracerebral hemorrhage; as a result, MPN-associated CVT was not fatal. CI - (c) 2021 The Authors. American Journal of Hematology published by Wiley Periodicals LLC. FAU - Gangat, Naseema AU - Gangat N AUID- ORCID: 0000-0002-9104-6172 AD - Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA. FAU - Guglielmelli, Paola AU - Guglielmelli P AD - Department of Experimental and Clinical Medicine, CRIMM, Center Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliera Universitaria Careggi, University of Florence, Florence, Italy. FAU - Betti, Silvia AU - Betti S AD - Section of Hematology, Department of Radiological and Hematological Sciences, Catholic University, Fondazione Policlinico A. Gemelli IRCCS, Rome, Italy. FAU - Farrukh, Faiqa AU - Farrukh F AD - Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA. FAU - Carobbio, Alessandra AU - Carobbio A AD - Foundation of Clinical Research-FROM Ospedale Papa Giovanni XXIII, Bergamo, Italy. FAU - Barbui, Tiziano AU - Barbui T AUID- ORCID: 0000-0003-2747-6327 AD - Foundation of Clinical Research-FROM Ospedale Papa Giovanni XXIII, Bergamo, Italy. FAU - Vannucchi, Alessandro M AU - Vannucchi AM AD - Department of Experimental and Clinical Medicine, CRIMM, Center Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliera Universitaria Careggi, University of Florence, Florence, Italy. FAU - De Stefano, Valerio AU - De Stefano V AUID- ORCID: 0000-0002-5178-5827 AD - Section of Hematology, Department of Radiological and Hematological Sciences, Catholic University, Fondazione Policlinico A. Gemelli IRCCS, Rome, Italy. FAU - Tefferi, Ayalew AU - Tefferi A AUID- ORCID: 0000-0003-4605-3821 AD - Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20210910 PL - United States TA - Am J Hematol JT - American journal of hematology JID - 7610369 RN - 0 (COVID-19 Vaccines) RN - EC 2.7.10.2 (JAK2 protein, human) RN - EC 2.7.10.2 (Janus Kinase 2) SB - IM MH - Adolescent MH - Adult MH - Aged MH - Aged, 80 and over MH - COVID-19/*prevention & control MH - COVID-19 Vaccines/*adverse effects MH - Female MH - Humans MH - Intracranial Thrombosis/*etiology/genetics MH - Janus Kinase 2/genetics MH - Male MH - Middle Aged MH - Myeloproliferative Disorders/*complications/genetics MH - Point Mutation MH - Polycythemia Vera/complications/genetics MH - Primary Myelofibrosis/complications/genetics MH - Retrospective Studies MH - Thrombocythemia, Essential/complications/genetics MH - Venous Thrombosis/*etiology/genetics MH - Young Adult PMC - PMC9293093 EDAT- 2021/08/29 06:00 MHDA- 2021/12/15 06:00 PMCR- 2022/07/18 CRDT- 2021/08/28 12:15 PHST- 2021/08/17 00:00 [received] PHST- 2021/08/24 00:00 [accepted] PHST- 2021/08/29 06:00 [pubmed] PHST- 2021/12/15 06:00 [medline] PHST- 2021/08/28 12:15 [entrez] PHST- 2022/07/18 00:00 [pmc-release] AID - AJH26336 [pii] AID - 10.1002/ajh.26336 [doi] PST - ppublish SO - Am J Hematol. 2021 Dec 1;96(12):1580-1586. doi: 10.1002/ajh.26336. Epub 2021 Sep 10. PMID- 34408875 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240814 IS - 2050-0068 (Print) IS - 2050-0068 (Electronic) IS - 2050-0068 (Linking) VI - 10 IP - 8 DP - 2021 TI - Rapid whole-blood assay to detect SARS-CoV-2-specific memory T-cell immunity following a single dose of AstraZeneca ChAdOx1-S COVID-19 vaccine. PG - e1326 LID - 10.1002/cti2.1326 [doi] LID - e1326 AB - OBJECTIVES: With the ongoing emergence of SARS-CoV-2 variants and potential to evade vaccine-induced neutralisation, understanding the magnitude and breadth of vaccine-induced T-cell immunity will be critical for the ongoing optimisation of vaccine approaches. Strategies that provide a rapid and easily translatable means of assessing virus-specific T-cell responses provide an opportunity to monitor the impact of vaccine rollouts in the community. In this study, we assessed whether our recently developed SARS-CoV-2 whole-blood assay could be used effectively to analyse T-cell responses following vaccination. METHODS: Following a median of 15 days after the first dose of the ChAdOx1-S (AstraZeneca((R))) vaccine, peripheral blood was isolated from 58 participants. Blood was incubated overnight with an overlapping set of spike protein peptides and assessed for cytokine production using a cytometric bead array. RESULTS: The majority of vaccine recipients (51/58) generated a T helper 1 response (IFN-gamma and/or IL-2) following a single dose of ChAdOx1-S. The magnitude of the IFN-gamma and IL-2 response strongly correlated in vaccine recipients. While the production of other cytokines was evident in individuals who did not generate IFN-gamma and IL-2, they showed no correlation in magnitude, nor did we see a correlation between sex or age and the magnitude of the response. CONCLUSIONS: The whole-blood cytokine assay provides a rapid approach to assessing T-cell immunity against SARS-CoV-2 in vaccine recipients. While the majority of participants generated a robust SARS-CoV-2-specific T-cell response following their first dose, some did not, demonstrating the likely importance of the booster dose in improving T-cell immunity. CI - (c) 2021 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of Australian and New Zealand Society for Immunology, Inc. FAU - Lineburg, Katie E AU - Lineburg KE AUID- ORCID: 0000-0002-5712-2610 AD - QIMR Berghofer Centre for Immunotherapy and Vaccine Development and Translational and Human Immunology Laboratory Department of Immunology QIMR Berghofer Medical Research Institute Brisbane QLD Australia. FAU - Neller, Michelle A AU - Neller MA AD - QIMR Berghofer Centre for Immunotherapy and Vaccine Development and Translational and Human Immunology Laboratory Department of Immunology QIMR Berghofer Medical Research Institute Brisbane QLD Australia. FAU - Ambalathingal, George R AU - Ambalathingal GR AD - QIMR Berghofer Centre for Immunotherapy and Vaccine Development and Translational and Human Immunology Laboratory Department of Immunology QIMR Berghofer Medical Research Institute Brisbane QLD Australia. FAU - Le Texier, Laetitia AU - Le Texier L AD - QIMR Berghofer Centre for Immunotherapy and Vaccine Development and Translational and Human Immunology Laboratory Department of Immunology QIMR Berghofer Medical Research Institute Brisbane QLD Australia. FAU - Raju, Jyothy AU - Raju J AD - QIMR Berghofer Centre for Immunotherapy and Vaccine Development and Translational and Human Immunology Laboratory Department of Immunology QIMR Berghofer Medical Research Institute Brisbane QLD Australia. FAU - Swaminathan, Srividhya AU - Swaminathan S AUID- ORCID: 0000-0002-0750-3650 AD - QIMR Berghofer Centre for Immunotherapy and Vaccine Development and Translational and Human Immunology Laboratory Department of Immunology QIMR Berghofer Medical Research Institute Brisbane QLD Australia. AD - Faculty of Medicine The University of Queensland Brisbane QLD Australia. FAU - Lekieffre, Lea AU - Lekieffre L AD - QIMR Berghofer Centre for Immunotherapy and Vaccine Development and Translational and Human Immunology Laboratory Department of Immunology QIMR Berghofer Medical Research Institute Brisbane QLD Australia. FAU - Smith, Caitlyn AU - Smith C AD - QIMR Berghofer Centre for Immunotherapy and Vaccine Development and Translational and Human Immunology Laboratory Department of Immunology QIMR Berghofer Medical Research Institute Brisbane QLD Australia. FAU - Rehan, Sweera AU - Rehan S AD - QIMR Berghofer Centre for Immunotherapy and Vaccine Development and Translational and Human Immunology Laboratory Department of Immunology QIMR Berghofer Medical Research Institute Brisbane QLD Australia. FAU - Crooks, Pauline AU - Crooks P AD - QIMR Berghofer Centre for Immunotherapy and Vaccine Development and Translational and Human Immunology Laboratory Department of Immunology QIMR Berghofer Medical Research Institute Brisbane QLD Australia. FAU - Panikkar, Archana AU - Panikkar A AD - QIMR Berghofer Centre for Immunotherapy and Vaccine Development and Translational and Human Immunology Laboratory Department of Immunology QIMR Berghofer Medical Research Institute Brisbane QLD Australia. FAU - Srihari, Sriganesh AU - Srihari S AD - QIMR Berghofer Centre for Immunotherapy and Vaccine Development and Translational and Human Immunology Laboratory Department of Immunology QIMR Berghofer Medical Research Institute Brisbane QLD Australia. FAU - Khanna, Rajiv AU - Khanna R AD - QIMR Berghofer Centre for Immunotherapy and Vaccine Development and Translational and Human Immunology Laboratory Department of Immunology QIMR Berghofer Medical Research Institute Brisbane QLD Australia. AD - Faculty of Medicine The University of Queensland Brisbane QLD Australia. FAU - Smith, Corey AU - Smith C AUID- ORCID: 0000-0002-7550-9595 AD - QIMR Berghofer Centre for Immunotherapy and Vaccine Development and Translational and Human Immunology Laboratory Department of Immunology QIMR Berghofer Medical Research Institute Brisbane QLD Australia. AD - Faculty of Medicine The University of Queensland Brisbane QLD Australia. LA - eng PT - Journal Article DEP - 20210812 PL - Australia TA - Clin Transl Immunology JT - Clinical & translational immunology JID - 101638268 PMC - PMC8360255 OTO - NOTNLM OT - COVID-19 OT - SARS-CoV-2 OT - T cells OT - vaccine COIS- The authors report no conflict of interest. EDAT- 2021/08/20 06:00 MHDA- 2021/08/20 06:01 PMCR- 2021/08/12 CRDT- 2021/08/19 06:42 PHST- 2021/07/06 00:00 [received] PHST- 2021/07/26 00:00 [revised] PHST- 2021/07/26 00:00 [accepted] PHST- 2021/08/19 06:42 [entrez] PHST- 2021/08/20 06:00 [pubmed] PHST- 2021/08/20 06:01 [medline] PHST- 2021/08/12 00:00 [pmc-release] AID - CTI21326 [pii] AID - 10.1002/cti2.1326 [doi] PST - epublish SO - Clin Transl Immunology. 2021 Aug 12;10(8):e1326. doi: 10.1002/cti2.1326. eCollection 2021. PMID- 34408004 OWN - NLM STAT- MEDLINE DCOM- 20220304 LR - 20220304 IS - 1468-330X (Electronic) IS - 0022-3050 (Linking) VI - 93 IP - 3 DP - 2022 Mar TI - Functional disorders after COVID-19 vaccine fuel vaccination hesitancy. PG - 339-340 LID - 10.1136/jnnp-2021-327000 [doi] FAU - Fasano, Alfonso AU - Fasano A AUID- ORCID: 0000-0001-5346-0180 AD - Department of Medicine, Division of Neurology, University of Toronto, Toronto, Ontario, Canada alfonso.fasano@gmail.com. AD - Edmond J. Safra Program in Parkinson's Disease, Morton and Gloria Shulman Movement Disorders Centre, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada. AD - Krembil Brain Institute, Toronto, Ontario, Canada. FAU - Daniele, Antonio AU - Daniele A AD - Department of Neuroscience, Universita Cattolica del Sacro Cuore, Rome, Italy. AD - Neurology Unit, IRCCS Fondazione Policlinico Universitario A. Gemelli, Rome, Italy. LA - eng PT - Letter PT - Research Support, Non-U.S. Gov't DEP - 20210818 PL - England TA - J Neurol Neurosurg Psychiatry JT - Journal of neurology, neurosurgery, and psychiatry JID - 2985191R RN - 0 (COVID-19 Vaccines) SB - IM MH - COVID-19 Vaccines/*adverse effects MH - Humans MH - Psychogenic Nonepileptic Seizures/diagnosis/*etiology MH - Psychophysiologic Disorders/diagnosis/*etiology MH - Vaccination Hesitancy/*psychology OTO - NOTNLM OT - COVID-19 OT - functional neurological disorder COIS- Competing interests: None declared. EDAT- 2021/08/20 06:00 MHDA- 2022/03/05 06:00 CRDT- 2021/08/19 05:55 PHST- 2021/05/01 00:00 [received] PHST- 2021/08/10 00:00 [accepted] PHST- 2021/08/20 06:00 [pubmed] PHST- 2022/03/05 06:00 [medline] PHST- 2021/08/19 05:55 [entrez] AID - jnnp-2021-327000 [pii] AID - 10.1136/jnnp-2021-327000 [doi] PST - ppublish SO - J Neurol Neurosurg Psychiatry. 2022 Mar;93(3):339-340. doi: 10.1136/jnnp-2021-327000. Epub 2021 Aug 18. PMID- 34405142 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220302 IS - 2632-1297 (Electronic) IS - 2632-1297 (Linking) VI - 3 IP - 3 DP - 2021 TI - Clinical characteristics of headache after vaccination against COVID-19 (coronavirus SARS-CoV-2) with the BNT162b2 mRNA vaccine: a multicentre observational cohort study. PG - fcab169 LID - 10.1093/braincomms/fcab169 [doi] LID - fcab169 AB - The novel coronavirus SARS-CoV-2 causes the infectious disease COVID-19. Newly developed mRNA vaccines can prevent the spread of the virus. Headache is the most common neurological symptom in over 50% of those vaccinated. Detailed information about the clinical characteristics of this form of headache has not yet been described. The aim of the study is to examine in detail the clinical characteristics of headaches occurring after vaccination against COVID-19 with the BNT162b2 mRNA COVID-19 vaccine for the first time. In a multicentre observational cohort study, data on the clinical features and corresponding variables were recorded using a standardized online questionnaire. The questionnaire was circulated to 12 000 residential care homes of the elderly as well as tertiary university hospitals in Germany and the United Arab Emirates. The primary outcomes of this study are the clinical features of headache after vaccination. Comorbidities, treatment with medication and sociodemographic variables are also analysed. A total of 2349 participants reported headaches after vaccination with the BNT162b2 mRNA COVID-19 vaccine. Headaches occur an average of 18.0 +/- 27.0 h after vaccination and last an average duration of 14.2 +/- 21.3 h. Only 9.7% of those affected also report headaches resulting from previous vaccinations. In 66.6% of the participants, headache occurs as a single episode. A bilateral location is indicated by 73.1% of the participants. This is most often found on the forehead (38.0%) and temples (32.1%). A pressing pain character is indicated by 49.2% and 40.7% report a dull pain character. The pain intensity is most often moderate (46.2%), severe (32.1%) or very severe (8.2%). The most common accompanying symptoms are fatigue (38.8%), exhaustion (25.7%) and muscle pain (23.4%). Headaches after COVID-19 vaccination show an extensive complex of symptoms. The constellation of accompanying symptoms together with the temporal and spatial headache characteristics delimit a distinctive headache phenotype. CI - (c) The Author(s) (2021). Published by Oxford University Press on behalf of the Guarantors of Brain. FAU - Gobel, Carl H AU - Gobel CH AUID- ORCID: 0000-0002-4283-6936 AD - Department of Neurology, University Hospital Schleswig-Holstein, Lubeck, Germany. AD - Kiel Migraine and Headache Centre, Kiel, Germany. FAU - Heinze, Axel AU - Heinze A AD - Kiel Migraine and Headache Centre, Kiel, Germany. FAU - Karstedt, Sarah AU - Karstedt S AD - Department of Neurology, University Hospital Schleswig-Holstein, Lubeck, Germany. AD - Kiel Migraine and Headache Centre, Kiel, Germany. FAU - Morscheck, Mascha AU - Morscheck M AD - Kiel Migraine and Headache Centre, Kiel, Germany. FAU - Tashiro, Lilian AU - Tashiro L AD - Kiel Migraine and Headache Centre, Kiel, Germany. FAU - Cirkel, Anna AU - Cirkel A AD - Department of Neurology, University Hospital Schleswig-Holstein, Lubeck, Germany. AD - Kiel Migraine and Headache Centre, Kiel, Germany. FAU - Hamid, Qutayba AU - Hamid Q AD - College of Medicine, University of Sharjah, Sharjah, United Arab Emirates. FAU - Halwani, Rabih AU - Halwani R AD - College of Medicine, University of Sharjah, Sharjah, United Arab Emirates. FAU - Temsah, Mohamad-Hani AU - Temsah MH AD - College of Medicine, King Saud University, Riyadh, Kingdom of Saudi Arabia. FAU - Ziemann, Malte AU - Ziemann M AD - Institute of Transfusion Medicine, University Hospital Schleswig-Holstein, Lubeck, Germany. FAU - Gorg, Siegfried AU - Gorg S AD - Institute of Transfusion Medicine, University Hospital Schleswig-Holstein, Lubeck, Germany. FAU - Munte, Thomas AU - Munte T AD - Department of Neurology, University Hospital Schleswig-Holstein, Lubeck, Germany. FAU - Gobel, Hartmut AU - Gobel H AD - Kiel Migraine and Headache Centre, Kiel, Germany. LA - eng PT - Journal Article DEP - 20210723 PL - England TA - Brain Commun JT - Brain communications JID - 101755125 EIN - Brain Commun. 2021 Sep 03;3(3):fcab195. doi: 10.1093/braincomms/fcab195. PMID: 34514399 PMC - PMC8344581 OTO - NOTNLM OT - COVID-19 OT - International Classification of Headache Disorders OT - headache OT - mRNA vaccine OT - side-effects EDAT- 2021/08/19 06:00 MHDA- 2021/08/19 06:01 PMCR- 2021/07/23 CRDT- 2021/08/18 06:33 PHST- 2021/05/30 00:00 [received] PHST- 2021/05/30 00:00 [revised] PHST- 2021/06/02 00:00 [accepted] PHST- 2021/08/18 06:33 [entrez] PHST- 2021/08/19 06:00 [pubmed] PHST- 2021/08/19 06:01 [medline] PHST- 2021/07/23 00:00 [pmc-release] AID - fcab169 [pii] AID - 10.1093/braincomms/fcab169 [doi] PST - epublish SO - Brain Commun. 2021 Jul 23;3(3):fcab169. doi: 10.1093/braincomms/fcab169. eCollection 2021. PMID- 34383735 OWN - NLM STAT- MEDLINE DCOM- 20210813 LR - 20260127 IS - 1545-861X (Electronic) IS - 0149-2195 (Print) IS - 0149-2195 (Linking) VI - 70 IP - 32 DP - 2021 Aug 13 TI - Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices - United States, July 2021. PG - 1094-1099 LID - 10.15585/mmwr.mm7032e4 [doi] AB - In December 2020, the Food and Drug Administration (FDA) issued Emergency Use Authorizations (EUAs) for Pfizer-BioNTech and Moderna COVID-19 vaccines, and in February 2021, FDA issued an EUA for the Janssen (Johnson & Johnson) COVID-19 vaccine. After each EUA, the Advisory Committee on Immunization Practices (ACIP) issued interim recommendations for vaccine use; currently Pfizer-BioNTech is authorized and recommended for persons aged >/=12 years and Moderna and Janssen for persons aged >/=18 years (1-3). Both Pfizer-BioNTech and Moderna vaccines, administered as 2-dose series, are mRNA-based COVID-19 vaccines, whereas the Janssen COVID-19 vaccine, administered as a single dose, is a recombinant replication-incompetent adenovirus-vector vaccine. As of July 22, 2021, 187 million persons in the United States had received at least 1 dose of COVID-19 vaccine (4); close monitoring of safety surveillance has demonstrated that serious adverse events after COVID-19 vaccination are rare (5,6). Three medical conditions have been reported in temporal association with receipt of COVID-19 vaccines. Two of these (thrombosis with thrombocytopenia syndrome [TTS], a rare syndrome characterized by venous or arterial thrombosis and thrombocytopenia, and Guillain-Barre syndrome [GBS], a rare autoimmune neurologic disorder characterized by ascending weakness and paralysis) have been reported after Janssen COVID-19 vaccination. One (myocarditis, cardiac inflammation) has been reported after Pfizer-BioNTech COVID-19 vaccination or Moderna COVID-19 vaccination, particularly after the second dose; these were reviewed together and will hereafter be referred to as mRNA COVID-19 vaccination. ACIP has met three times to review the data associated with these reports of serious adverse events and has comprehensively assessed the benefits and risks associated with receipt of these vaccines. During the most recent meeting in July 2021, ACIP determined that, overall, the benefits of COVID-19 vaccination in preventing COVID-19 morbidity and mortality outweigh the risks for these rare serious adverse events in adults aged >/=18 years; this balance of benefits and risks varied by age and sex. ACIP continues to recommend COVID-19 vaccination in all persons aged >/=12 years. CDC and FDA continue to closely monitor reports of serious adverse events and will present any additional data to ACIP for consideration. Information regarding risks and how they vary by age and sex and type of vaccine should be disseminated to providers, vaccine recipients, and the public. FAU - Rosenblum, Hannah G AU - Rosenblum HG FAU - Hadler, Stephen C AU - Hadler SC FAU - Moulia, Danielle AU - Moulia D FAU - Shimabukuro, Tom T AU - Shimabukuro TT FAU - Su, John R AU - Su JR FAU - Tepper, Naomi K AU - Tepper NK FAU - Ess, Kevin C AU - Ess KC FAU - Woo, Emily Jane AU - Woo EJ FAU - Mba-Jonas, Adamma AU - Mba-Jonas A FAU - Alimchandani, Meghna AU - Alimchandani M FAU - Nair, Narayan AU - Nair N FAU - Klein, Nicola P AU - Klein NP FAU - Hanson, Kayla E AU - Hanson KE FAU - Markowitz, Lauri E AU - Markowitz LE FAU - Wharton, Melinda AU - Wharton M FAU - McNally, Veronica V AU - McNally VV FAU - Romero, Jose R AU - Romero JR FAU - Talbot, H Keipp AU - Talbot HK FAU - Lee, Grace M AU - Lee GM FAU - Daley, Matthew F AU - Daley MF FAU - Mbaeyi, Sarah A AU - Mbaeyi SA FAU - Oliver, Sara E AU - Oliver SE LA - eng PT - Journal Article DEP - 20210813 PL - United States TA - MMWR Morb Mortal Wkly Rep JT - MMWR. Morbidity and mortality weekly report JID - 7802429 RN - 0 (COVID-19 Vaccines) RN - 0 (Vaccines, Synthetic) RN - 0 (mRNA Vaccines) SB - IM MH - Adult MH - Adverse Drug Reaction Reporting Systems MH - Advisory Committees MH - COVID-19/epidemiology/*prevention & control MH - COVID-19 Vaccines/*administration & dosage/*adverse effects MH - Drug Approval MH - Humans MH - Immunization/*standards MH - *Practice Guidelines as Topic MH - United States/epidemiology MH - Vaccines, Synthetic MH - mRNA Vaccines PMC - PMC8360272 COIS- All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Nicola P. Klein reports institutional research support from Pfizer, Sanofi Pasteur, Merck, GlaxoSmithKline, and Protein Science (now Sanofi Pasteur). No other potential conflicts of interest were disclosed. EDAT- 2021/08/13 06:00 MHDA- 2021/08/14 06:00 PMCR- 2021/08/13 CRDT- 2021/08/12 17:22 PHST- 2021/08/12 17:22 [entrez] PHST- 2021/08/13 06:00 [pubmed] PHST- 2021/08/14 06:00 [medline] PHST- 2021/08/13 00:00 [pmc-release] AID - mm7032e4 [pii] AID - 10.15585/mmwr.mm7032e4 [doi] PST - epublish SO - MMWR Morb Mortal Wkly Rep. 2021 Aug 13;70(32):1094-1099. doi: 10.15585/mmwr.mm7032e4. PMID- 34379509 OWN - NLM STAT- MEDLINE DCOM- 20211008 LR - 20250220 IS - 1098-5514 (Electronic) IS - 0022-538X (Print) IS - 0022-538X (Linking) VI - 95 IP - 20 DP - 2021 Sep 27 TI - A Methyltransferase-Defective Vesicular Stomatitis Virus-Based SARS-CoV-2 Vaccine Candidate Provides Complete Protection against SARS-CoV-2 Infection in Hamsters. PG - e0059221 LID - 10.1128/JVI.00592-21 [doi] LID - e00592-21 AB - The current pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to dramatic economic and health burdens. Although the worldwide SARS-CoV-2 vaccination campaign has begun, exploration of other vaccine candidates is needed due to uncertainties with the current approved vaccines, such as durability of protection, cross-protection against variant strains, and costs of long-term production and storage. In this study, we developed a methyltransferase-defective recombinant vesicular stomatitis virus (mtdVSV)-based SARS-CoV-2 vaccine candidate. We generated mtdVSVs expressing SARS-CoV-2 full-length spike (S) protein, S1, or its receptor-binding domain (RBD). All of these recombinant viruses grew to high titers in mammalian cells despite high attenuation in cell culture. The SARS-CoV-2 S protein and its truncations were highly expressed by the mtdVSV vector. These mtdVSV-based vaccine candidates were completely attenuated in both immunocompetent and immunocompromised mice. Among these constructs, mtdVSV-S induced high levels of SARS-CoV-2-specific neutralizing antibodies (NAbs) and Th1-biased T-cell immune responses in mice. In Syrian golden hamsters, the serum levels of SARS-CoV-2-specific NAbs triggered by mtdVSV-S were higher than the levels of NAbs in convalescent plasma from recovered COVID-19 patients. In addition, hamsters immunized with mtdVSV-S were completely protected against SARS-CoV-2 replication in lung and nasal turbinate tissues, cytokine storm, and lung pathology. Collectively, our data demonstrate that mtdVSV expressing SARS-CoV-2 S protein is a safe and highly efficacious vaccine candidate against SARS-CoV-2 infection. IMPORTANCE Viral mRNA cap methyltransferase (MTase) is essential for mRNA stability, protein translation, and innate immune evasion. Thus, viral mRNA cap MTase activity is an excellent target for development of live attenuated or live vectored vaccine candidates. Here, we developed a panel of MTase-defective recombinant vesicular stomatitis virus (mtdVSV)-based SARS-CoV-2 vaccine candidates expressing full-length S, S1, or several versions of the RBD. These mtdVSV-based vaccine candidates grew to high titers in cell culture and were completely attenuated in both immunocompetent and immunocompromised mice. Among these vaccine candidates, mtdVSV-S induces high levels of SARS-CoV-2-specific neutralizing antibodies (Nabs) and Th1-biased immune responses in mice. Syrian golden hamsters immunized with mtdVSV-S triggered SARS-CoV-2-specific NAbs at higher levels than those in convalescent plasma from recovered COVID-19 patients. Furthermore, hamsters immunized with mtdVSV-S were completely protected against SARS-CoV-2 challenge. Thus, mtdVSV is a safe and highly effective vector to deliver SARS-CoV-2 vaccine. FAU - Lu, Mijia AU - Lu M AD - Department of Veterinary Biosciences, The Ohio State Universitygrid.261331.4, Columbus, Ohio, USA. FAU - Zhang, Yuexiu AU - Zhang Y AD - Department of Veterinary Biosciences, The Ohio State Universitygrid.261331.4, Columbus, Ohio, USA. FAU - Dravid, Piyush AU - Dravid P AD - Center for Vaccines and Immunity, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio, USA. FAU - Li, Anzhong AU - Li A AD - Department of Veterinary Biosciences, The Ohio State Universitygrid.261331.4, Columbus, Ohio, USA. FAU - Zeng, Cong AU - Zeng C AD - Department of Veterinary Biosciences, The Ohio State Universitygrid.261331.4, Columbus, Ohio, USA. FAU - Kc, Mahesh AU - Kc M AD - Center for Vaccines and Immunity, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio, USA. FAU - Trivedi, Sheetal AU - Trivedi S AD - Center for Vaccines and Immunity, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio, USA. FAU - Sharma, Himanshu AU - Sharma H AD - Center for Vaccines and Immunity, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio, USA. FAU - Chaiwatpongsakorn, Supranee AU - Chaiwatpongsakorn S AD - Center for Vaccines and Immunity, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio, USA. FAU - Zani, Ashley AU - Zani A AD - Department of Microbial Infection and Immunity, College of Medicine, The Ohio State Universitygrid.261331.4, Columbus, Ohio, USA. FAU - Kenney, Adam AU - Kenney A AD - Department of Microbial Infection and Immunity, College of Medicine, The Ohio State Universitygrid.261331.4, Columbus, Ohio, USA. FAU - Cai, Chuanxi AU - Cai C AD - Department of Surgery, College of Medicine, The Ohio State Universitygrid.261331.4, Columbus, Ohio, USA. FAU - Ye, Chengjin AU - Ye C AD - Texas Biomedical Research Institutegrid.250889.e, San Antonio, Texas, USA. FAU - Liang, Xueya AU - Liang X AD - Department of Veterinary Biosciences, The Ohio State Universitygrid.261331.4, Columbus, Ohio, USA. FAU - Qiu, Jianming AU - Qiu J AUID- ORCID: 0000-0001-9850-1695 AD - Department of Microbiology, Molecular Genetics and Immunology, University of Kansas Medical Centergrid.412016.0, Kansas City, Kansas, USA. FAU - Martinez-Sobrido, Luis AU - Martinez-Sobrido L AUID- ORCID: 0000-0001-7084-0804 AD - Texas Biomedical Research Institutegrid.250889.e, San Antonio, Texas, USA. FAU - Yount, Jacob S AU - Yount JS AD - Department of Microbial Infection and Immunity, College of Medicine, The Ohio State Universitygrid.261331.4, Columbus, Ohio, USA. FAU - Boyaka, Prosper N AU - Boyaka PN AD - Department of Veterinary Biosciences, The Ohio State Universitygrid.261331.4, Columbus, Ohio, USA. AD - Infectious Disease Institute, The Ohio State Universitygrid.261331.4, Columbus, Ohio, USA. FAU - Liu, Shan-Lu AU - Liu SL AD - Department of Veterinary Biosciences, The Ohio State Universitygrid.261331.4, Columbus, Ohio, USA. AD - Department of Microbial Infection and Immunity, College of Medicine, The Ohio State Universitygrid.261331.4, Columbus, Ohio, USA. AD - Center for Retrovirus Research, The Ohio State Universitygrid.261331.4, Columbus, Ohio, USA. AD - Infectious Disease Institute, The Ohio State Universitygrid.261331.4, Columbus, Ohio, USA. FAU - Peeples, Mark E AU - Peeples ME AUID- ORCID: 0000-0002-4582-317X AD - Center for Vaccines and Immunity, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio, USA. AD - Department of Pediatrics, College of Medicine, The Ohio State Universitygrid.261331.4, Columbus, Ohio, USA. AD - Infectious Disease Institute, The Ohio State Universitygrid.261331.4, Columbus, Ohio, USA. FAU - Kapoor, Amit AU - Kapoor A AD - Center for Vaccines and Immunity, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio, USA. AD - Department of Pediatrics, College of Medicine, The Ohio State Universitygrid.261331.4, Columbus, Ohio, USA. AD - Infectious Disease Institute, The Ohio State Universitygrid.261331.4, Columbus, Ohio, USA. FAU - Li, Jianrong AU - Li J AUID- ORCID: 0000-0002-7130-1084 AD - Department of Veterinary Biosciences, The Ohio State Universitygrid.261331.4, Columbus, Ohio, USA. AD - Infectious Disease Institute, The Ohio State Universitygrid.261331.4, Columbus, Ohio, USA. LA - eng GR - R01 AI090060/AI/NIAID NIH HHS/United States GR - R01 AI151175/AI/NIAID NIH HHS/United States GR - R01 AI123661/AI/NIAID NIH HHS/United States GR - P01 AI112524/AI/NIAID NIH HHS/United States GR - R01 AI145144/AI/NIAID NIH HHS/United States GR - R01 AI070723/AI/NIAID NIH HHS/United States GR - R56 AI090060/AI/NIAID NIH HHS/United States GR - R01 AI150473/AI/NIAID NIH HHS/United States GR - R01 AI137567/AI/NIAID NIH HHS/United States GR - R01 AI161175/AI/NIAID NIH HHS/United States GR - R01 AI112381/AI/NIAID NIH HHS/United States GR - RM1 HG008935/HG/NHGRI NIH HHS/United States GR - U19 AI142733/AI/NIAID NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20210811 PL - United States TA - J Virol JT - Journal of virology JID - 0113724 RN - 0 (Antibodies, Neutralizing) RN - 0 (Antibodies, Viral) RN - 0 (COVID-19 Vaccines) RN - 0 (Spike Glycoprotein, Coronavirus) RN - 0 (Vaccines, Synthetic) RN - 0 (Viral Proteins) RN - 0 (spike protein, SARS-CoV-2) RN - EC 2.1.1.- (Methyltransferases) RN - EC 2.7.7.6 (DNA-Directed RNA Polymerases) RN - EC 2.7.7.6 (L polymerase protein, Vesicular stomatitis-Indiana virus) SB - IM MH - Animals MH - Antibodies, Neutralizing/blood MH - Antibodies, Viral/blood MH - Brain/virology MH - COVID-19/immunology/*prevention & control MH - COVID-19 Vaccines/*immunology MH - Cell Line MH - Cytokine Release Syndrome/prevention & control MH - DNA-Directed RNA Polymerases/genetics/metabolism MH - Humans MH - Immunogenicity, Vaccine MH - Lung/immunology/pathology/virology MH - Mesocricetus MH - Methyltransferases/genetics/metabolism MH - Mice MH - Protein Domains MH - SARS-CoV-2/*immunology MH - Spike Glycoprotein, Coronavirus/chemistry/genetics/immunology MH - Th1 Cells/immunology MH - Vaccines, Synthetic/immunology MH - Vesicular stomatitis Indiana virus/enzymology/*genetics/physiology MH - Viral Proteins/genetics/metabolism MH - Virus Replication PMC - PMC8475528 OTO - NOTNLM OT - SARS-CoV-2 OT - VSV OT - mRNA cap methyltransferase OT - vaccine EDAT- 2021/08/12 06:00 MHDA- 2021/10/09 06:00 PMCR- 2021/09/27 CRDT- 2021/08/11 17:13 PHST- 2021/08/12 06:00 [pubmed] PHST- 2021/10/09 06:00 [medline] PHST- 2021/08/11 17:13 [entrez] PHST- 2021/09/27 00:00 [pmc-release] AID - 00592-21 [pii] AID - 10.1128/JVI.00592-21 [doi] PST - ppublish SO - J Virol. 2021 Sep 27;95(20):e0059221. doi: 10.1128/JVI.00592-21. Epub 2021 Aug 11. PMID- 34375861 OWN - NLM STAT- MEDLINE DCOM- 20211019 LR - 20221221 IS - 2211-0356 (Electronic) IS - 2211-0348 (Print) IS - 2211-0348 (Linking) VI - 55 DP - 2021 Oct TI - Patient-reported safety and tolerability of the COVID-19 vaccines in persons with rare neuroimmunological diseases. PG - 103189 LID - S2211-0348(21)00456-9 [pii] LID - 10.1016/j.msard.2021.103189 [doi] AB - BACKGROUND: The COVID-19 vaccines are currently recommended for people with rare neuroimmunological diseases such as neuromyelitis optica spectrum disorder (NMOSD), MOG-antibody disease (MOGAD), and transverse myelitis. However, the safety profile of the vaccines in this population is uncertain. OBJECTIVE: To report real-world safety data of the COVID-19 vaccines in persons with rare neuroimmunological diseases. METHODS: An anonymous survey was distributed to patients recruited on social media. Participants answered general demographic and disease-related questions, and specific questions about their experiences with the COVID-19 vaccines. RESULTS: 438 participants completed the questionnaire. The median age was 51 (range 18-82 years); 366 were female (83.6%); 102 (23.3%) had associated comorbidities, and 354 (80.1%) were treated with immunotherapies. 242 participants (55.3%) reported a diagnosis of NMOSD; 99 (22.6%) had MOGAD; 79 (18%) had transverse myelitis. 239 participants (66.2%) were younger than 55 years of age. 138 participants (31.5%) reported earlyadverse events. Of these, 93 (67.4%) were < 55 years old, and 45 (32.6%) were > 55 years old (p=0.0086). The most common adverse events were local reactions, including pain, redness, and swelling at the injection site, reported by 155 participants (35.4%). 73 participants (16.7%) reported new or worsening neurological symptoms following the vaccination. Most symptoms occurred within the first week after vaccination and resolved within three days. CONCLUSIONS: This survey indicates an overall favorable safety and tolerability profile of the COVID-19 vaccines among persons with rare neuroimmunological diseases. Longer-term studies are warranted to confirm these data. CI - Copyright (c) 2021 Elsevier B.V. All rights reserved. FAU - Lotan, Itay AU - Lotan I AD - Division of Neuroimmunology & Neuroinfectious Disease, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, USA. Electronic address: ilotan@mgh.harvard.edu. FAU - Romanow, Gabriela AU - Romanow G AD - Division of Neuroimmunology & Neuroinfectious Disease, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, USA. FAU - Levy, Michael AU - Levy M AD - Division of Neuroimmunology & Neuroinfectious Disease, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, USA. LA - eng PT - Journal Article DEP - 20210802 PL - Netherlands TA - Mult Scler Relat Disord JT - Multiple sclerosis and related disorders JID - 101580247 RN - 0 (Aquaporin 4) RN - 0 (COVID-19 Vaccines) SB - IM MH - Adolescent MH - Adult MH - Aged MH - Aged, 80 and over MH - Aquaporin 4 MH - *COVID-19 MH - COVID-19 Vaccines MH - Female MH - Humans MH - Middle Aged MH - *Neuromyelitis Optica MH - Patient Reported Outcome Measures MH - SARS-CoV-2 MH - Young Adult PMC - PMC8327627 OTO - NOTNLM OT - COVID-19 OT - MOGAD OT - NMOSD OT - Safety OT - Tolerability OT - Vaccine COIS- This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. EDAT- 2021/08/11 06:00 MHDA- 2021/10/21 06:00 PMCR- 2021/08/02 CRDT- 2021/08/10 20:19 PHST- 2021/06/23 00:00 [received] PHST- 2021/07/08 00:00 [revised] PHST- 2021/08/01 00:00 [accepted] PHST- 2021/08/11 06:00 [pubmed] PHST- 2021/10/21 06:00 [medline] PHST- 2021/08/10 20:19 [entrez] PHST- 2021/08/02 00:00 [pmc-release] AID - S2211-0348(21)00456-9 [pii] AID - 103189 [pii] AID - 10.1016/j.msard.2021.103189 [doi] PST - ppublish SO - Mult Scler Relat Disord. 2021 Oct;55:103189. doi: 10.1016/j.msard.2021.103189. Epub 2021 Aug 2. PMID- 34326180 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231227 IS - 1526-632X (Electronic) IS - 0028-3878 (Print) IS - 0028-3878 (Linking) VI - 97 IP - 15 DP - 2021 Oct 12 TI - COVID-19 and Vaccination in the Setting of Neurologic Disease: An Emerging Issue in Neurology. PG - 720-728 LID - 10.1212/WNL.0000000000012578 [doi] AB - The COVID-19 pandemic caused by the SARS-CoV-2 virus has left many unanswered questions for patients with neurological disorders and the providers caring for them. Elderly and immunocompromised patients are at increased risk for severe symptoms due to COVID-19, and the virus may increase symptoms of underlying neurological illness, particularly for those with significant bulbar and respiratory weakness or other neurologic disability. Emerging SARS-CoV-2 vaccines offer substantial protection from symptomatic infection, but both patients and providers may have concerns regarding theoretical risks of vaccination, including vaccine safety and efficacy in the context of immunotherapy and the potential for precipitating or exacerbating neurological symptoms. In this statement on behalf of the Quality Committee of the AAN we review the current literature, focusing on COVID-19 infection in adults with neurological disease, in order to elucidate risks and benefits of vaccination in these individuals. Based on existing evidence, neurologists should recommend COVID-19 vaccination to their patients. For those patients being treated with immunotherapies, attention should be paid to timing of vaccination with respect to treatment and the potential for an attenuated immune response. CI - Copyright (c) 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. FAU - Marsh, Elisabeth B AU - Marsh EB AUID- ORCID: 0000-0002-2385-5074 AD - The Johns Hopkins School of Medicine, Baltimore, MD ebmarsh@jhmi.edu. FAU - Kornberg, Michael AU - Kornberg M AUID- ORCID: 0000-0003-2588-7325 AD - The Johns Hopkins School of Medicine, Baltimore, MD. FAU - Kessler, Kevin AU - Kessler K AD - The University of Virginia Medical Center, Charlottesville, VA. FAU - Haq, Ihtsham AU - Haq I AUID- ORCID: 0000-0002-8001-8440 AD - The University of Miami Miller School of Medicine, Miami, FL. FAU - Patel, Anup D AU - Patel AD AUID- ORCID: 0000-0001-9313-1541 AD - Nationwide Children's Hospital, Columbus, OH. FAU - Nath, Avindra AU - Nath A AUID- ORCID: 0000-0003-0927-5855 AD - The National Institutes of Health, Bethesda, MD. FAU - Schierman, Becky AU - Schierman B AD - The American Academy of Neurology, Minneapolis, MN. FAU - Jones, Lyell K Jr AU - Jones LK Jr AUID- ORCID: 0000-0002-5851-8705 AD - The Mayo Clinic, Rochester, MN. CN - Quality Committee of the American Academy of Neurology* LA - eng PT - Journal Article DEP - 20211012 PL - United States TA - Neurology JT - Neurology JID - 0401060 SB - IM PMC - PMC8575134 OTO - NOTNLM OT - COVID-19 vaccine OT - immunosuppression OT - infection OT - neurological disease EDAT- 2021/07/31 06:00 MHDA- 2021/07/31 06:01 PMCR- 2021/10/12 CRDT- 2021/07/30 05:50 PHST- 2021/07/29 00:00 [aheadofprint] PHST- 2021/05/05 00:00 [received] PHST- 2021/07/19 00:00 [accepted] PHST- 2021/07/31 06:01 [medline] PHST- 2021/07/30 05:50 [entrez] PHST- 2021/07/31 06:00 [pubmed] PHST- 2021/10/12 00:00 [pmc-release] AID - WNL.0000000000012578 [pii] AID - NEUROLOGY2021174018 [pii] AID - 10.1212/WNL.0000000000012578 [doi] PST - epublish SO - Neurology. 2021 Oct 12;97(15):720-728. doi: 10.1212/WNL.0000000000012578. PMID- 34324407 OWN - NLM STAT- MEDLINE DCOM- 20220315 LR - 20241207 IS - 2164-554X (Electronic) IS - 2164-5515 (Print) IS - 2164-5515 (Linking) VI - 18 IP - 1 DP - 2022 Dec 31 TI - COVID-19 vaccination in Chinese children: a cross-sectional study on the cognition, psychological anxiety state and the willingness toward vaccination. PG - 1-7 LID - 10.1080/21645515.2021.1949950 [doi] AB - It is important to understand the cognition, willingness, and psychological anxiety state of Chinese guardians toward COVID-19 vaccination for their children to predict the future vaccination rate and to help the design of policies that aim to expand the population with immunity against COVID-19. This study collected data with a professional vaccination registration platform for children named "Xiao Dou Miao" in February 2021. The psychological anxiety state of the guardians was self-evaluated using the psychological anxiety scale. Factors that might influence the willingness of guardians to vaccinate their children were identified using logistic regression analysis. This study included 12,872 questionnaires with 70.9% of guardians showing willingness to vaccinate their children. Guardians who were male, aged 40-49 and from rural area were more willing to vaccinate their children. Fathers, guardians with higher education and income, whose children have a history of adverse vaccine reactions and allergies were less willing to vaccinate their children (p < .001). More than 80% of the guardians expressed a high level of trust for vaccine information released by official and health-related agencies. Guardians who were not vaccinated were more anxious than those who were vaccinated (chi2 = 27.99, p < .001). To protect children from COVID-19, vaccine coverage in children should be expanded rapidly and public awareness on vaccine safety and effectiveness should be improved. FAU - Yang, Jin AU - Yang J AD - School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. FAU - Zhang, Ting AU - Zhang T AD - School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. AD - Institute of Pharmaceutical and Medical Devices Supervision, National Medical Products Administration-Chinese Academy of Medical Sciences, Beijing, China. FAU - Qi, Weiran AU - Qi W AD - School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. FAU - Zhang, Xingxing AU - Zhang X AD - School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. FAU - Jia, Mengmeng AU - Jia M AD - School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. AD - Institute of Pharmaceutical and Medical Devices Supervision, National Medical Products Administration-Chinese Academy of Medical Sciences, Beijing, China. FAU - Leng, Zhiwei AU - Leng Z AD - School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. AD - Institute of Pharmaceutical and Medical Devices Supervision, National Medical Products Administration-Chinese Academy of Medical Sciences, Beijing, China. FAU - Wang, Qing AU - Wang Q AD - School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. FAU - Yang, Yuan AU - Yang Y AD - School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. FAU - Yang, Weizhong AU - Yang W AD - School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. AD - Institute of Pharmaceutical and Medical Devices Supervision, National Medical Products Administration-Chinese Academy of Medical Sciences, Beijing, China. FAU - Ma, Libing AU - Ma L AUID- ORCID: 0000-0002-7234-2312 AD - School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. AD - Institute of Pharmaceutical and Medical Devices Supervision, National Medical Products Administration-Chinese Academy of Medical Sciences, Beijing, China. AD - Department of Respiratory and Critical Care Medicine, Affiliated Hospital of Guilin Medical University, Guilin, China. FAU - Feng, Luzhao AU - Feng L AD - School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. AD - Institute of Pharmaceutical and Medical Devices Supervision, National Medical Products Administration-Chinese Academy of Medical Sciences, Beijing, China. FAU - Wang, Chen AU - Wang C AD - Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210729 PL - United States TA - Hum Vaccin Immunother JT - Human vaccines & immunotherapeutics JID - 101572652 RN - 0 (COVID-19 Vaccines) SB - IM MH - Adult MH - Anxiety MH - *COVID-19/prevention & control MH - *COVID-19 Vaccines MH - Child MH - China/epidemiology MH - Cognition MH - Cross-Sectional Studies MH - Humans MH - Male MH - Middle Aged MH - SARS-CoV-2 MH - Vaccination/psychology PMC - PMC8920157 OTO - NOTNLM OT - COVID-19 vaccine OT - Guardians OT - children OT - cognition OT - psychological anxiety OT - willingness EDAT- 2021/07/30 06:00 MHDA- 2022/03/16 06:00 PMCR- 2021/07/29 CRDT- 2021/07/29 17:19 PHST- 2021/07/30 06:00 [pubmed] PHST- 2022/03/16 06:00 [medline] PHST- 2021/07/29 17:19 [entrez] PHST- 2021/07/29 00:00 [pmc-release] AID - 1949950 [pii] AID - 10.1080/21645515.2021.1949950 [doi] PST - ppublish SO - Hum Vaccin Immunother. 2022 Dec 31;18(1):1-7. doi: 10.1080/21645515.2021.1949950. Epub 2021 Jul 29. PMID- 34324120 OWN - NLM STAT- MEDLINE DCOM- 20210921 LR - 20220218 IS - 1590-3478 (Electronic) IS - 1590-1874 (Print) IS - 1590-1874 (Linking) VI - 42 IP - 10 DP - 2021 Oct TI - Functional neurological disorder after COVID-19 vaccination. PG - 3989-3990 LID - 10.1007/s10072-021-05504-8 [doi] FAU - Ercoli, Tommaso AU - Ercoli T AUID- ORCID: 0000-0002-3260-1754 AD - Department of Medical Sciences and Public Health, Institute of Neurology, University of Cagliari, Cagliari, Italy. ercolitommaso@me.com. FAU - Lutzoni, Laura AU - Lutzoni L AD - Institute of Neurology, Azienda Ospedaliero Universitaria Di Cagliari, 09124, Cagliari, Italy. FAU - Orofino, Gianni AU - Orofino G AD - Institute of Neurology, Azienda Ospedaliero Universitaria Di Cagliari, 09124, Cagliari, Italy. FAU - Muroni, Antonella AU - Muroni A AD - Institute of Neurology, Azienda Ospedaliero Universitaria Di Cagliari, 09124, Cagliari, Italy. FAU - Defazio, Giovanni AU - Defazio G AD - Department of Medical Sciences and Public Health, Institute of Neurology, University of Cagliari, Cagliari, Italy. AD - Institute of Neurology, Azienda Ospedaliero Universitaria Di Cagliari, 09124, Cagliari, Italy. LA - eng PT - Letter DEP - 20210729 PL - Italy TA - Neurol Sci JT - Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology JID - 100959175 RN - 0 (COVID-19 Vaccines) SB - IM MH - *COVID-19 MH - COVID-19 Vaccines MH - Humans MH - *Nervous System Diseases/etiology MH - SARS-CoV-2 MH - Vaccination/adverse effects PMC - PMC8319586 COIS- The authors declare no competing interests. EDAT- 2021/07/30 06:00 MHDA- 2021/09/22 06:00 PMCR- 2021/07/29 CRDT- 2021/07/29 12:31 PHST- 2021/05/06 00:00 [received] PHST- 2021/07/22 00:00 [accepted] PHST- 2021/07/30 06:00 [pubmed] PHST- 2021/09/22 06:00 [medline] PHST- 2021/07/29 12:31 [entrez] PHST- 2021/07/29 00:00 [pmc-release] AID - 10.1007/s10072-021-05504-8 [pii] AID - 5504 [pii] AID - 10.1007/s10072-021-05504-8 [doi] PST - ppublish SO - Neurol Sci. 2021 Oct;42(10):3989-3990. doi: 10.1007/s10072-021-05504-8. Epub 2021 Jul 29. PMID- 34315207 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231121 IS - 2005-940X (Print) IS - 2093-4939 (Electronic) IS - 2005-940X (Linking) VI - 14 IP - 3 DP - 2021 Sep TI - Management of Parkinson's Disease in the COVID-19 Pandemic and Future Perspectives in the Era of Vaccination. PG - 177-183 LID - 10.14802/jmd.21034 [doi] AB - The current coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to a serious global health crisis. Increasing evidence suggests that elderly individuals with underlying chronic diseases, including Parkinson's disease (PD), are particularly vulnerable to this infection. Changes in the routine care of PD patients should be implemented carefully without affecting the quality provided. The utilization of telemedicine for clinical consultation, assessment and rehabilitation has also been widely recommended. Therefore, the aim of this review is to provide recommendations in the management of PD during the pandemic as well as in the early phase of vaccination programs to highlight the potential sequelae and future perspectives of vaccination and further research in PD. Even though a year has passed since COVID- 19 emerged, most of us are still facing great challenges in providing a continuum of care to patients with chronic neurological disorders. However, we should regard this health crisis as an opportunity to change our routine approach in managing PD patients and learn more about the impact of SARS-CoV-2. Hopefully, PD patients can be vaccinated promptly, and more detailed research related to PD in COVID-19 can still be carried out. FAU - Lau, Yue Hui AU - Lau YH AD - Department of Neurology, Hospital Kuala Lumpur, Kuala Lumpur, Malaysia. FAU - Lau, Keng Ming AU - Lau KM AD - Department of Internal Medicine, University Malaya Medical Centre, Kuala Lumpur, Malaysia. FAU - Ibrahim, Norlinah Mohamed AU - Ibrahim NM AD - Division of Neurology, Department of Internal Medicine, National University of Malaysia, Kuala Lumpur, Malaysia. LA - eng PT - Journal Article DEP - 20210729 PL - Korea (South) TA - J Mov Disord JT - Journal of movement disorders JID - 101527867 PMC - PMC8490198 OTO - NOTNLM OT - COVID-19 OT - Future perspective OT - Parkinson's disease OT - SARS-CoV-2 OT - Vaccination COIS- Conflicts of Interest The authors have no financial conflicts of interest. EDAT- 2021/07/29 06:00 MHDA- 2021/07/29 06:01 PMCR- 2021/09/01 CRDT- 2021/07/28 02:04 PHST- 2021/03/14 00:00 [received] PHST- 2021/04/22 00:00 [accepted] PHST- 2021/07/29 06:00 [pubmed] PHST- 2021/07/29 06:01 [medline] PHST- 2021/07/28 02:04 [entrez] PHST- 2021/09/01 00:00 [pmc-release] AID - jmd.21034 [pii] AID - jmd-21034 [pii] AID - 10.14802/jmd.21034 [doi] PST - ppublish SO - J Mov Disord. 2021 Sep;14(3):177-183. doi: 10.14802/jmd.21034. Epub 2021 Jul 29. PMID- 34288285 OWN - NLM STAT- MEDLINE DCOM- 20211026 LR - 20260127 IS - 1468-1331 (Electronic) IS - 1351-5101 (Print) IS - 1351-5101 (Linking) VI - 28 IP - 11 DP - 2021 Nov TI - Safety of the BNT162b2 COVID-19 vaccine in multiple sclerosis (MS): Early experience from a tertiary MS center in Israel. PG - 3742-3748 LID - 10.1111/ene.15028 [doi] AB - BACKGROUND AND PURPOSE: Although the COVID-19 vaccines are currently recommended for people with multiple sclerosis (MS), the fact that they were not specifically tested in people with MS raises uncertainty regarding their safety in this population. The purpose of this study was to report real-life safety data of the BNT162b2 COVID-19 vaccine in a cohort of MS patients. METHODS: An anonymous survey was distributed to 425 MS patients. Participants were asked general demographic and disease-related questions and specific questions regarding the safety profile of the COVID-19 vaccine. RESULTS: Of the 425 MS patients, 262 completed the questionnaire. The median (range) participant age was 42 (22-79) years, 199 participants were women (75.9%), and 66 participants (25.2%) had associated comorbidities. A total of 198 participants (75.6%) were treated with disease-modifying therapies. In all, 239 participants (91.2% of the responders) had received the BNT162b2 COVID-19 vaccine. Of these, 182 (76.1%) were aged <55 years, and 57 (23.9%) were aged >55 years. Adverse events were reported by 136 participants (56.9%; 52.5% of those aged <55 years and 40.3% of those aged >55 years; p = 0.1517) and 36 participants (15.1%) reported new or worsening neurological symptoms following the vaccination, the most frequent being sensory disturbances (21 participants, 58.3%). Most symptoms occurred within the first 24 h after vaccination and resolved within 3 days. A total of 28 participants (77.8%) did not require any medication to treat their symptoms. CONCLUSIONS: This survey indicates an overall favorable safety profile of the BNT162b2 vaccine in people with MS. These data should be confirmed in further prospective, large-scale studies. CI - (c) 2021 European Academy of Neurology. FAU - Lotan, Itay AU - Lotan I AUID- ORCID: 0000-0002-4015-9783 AD - Department of Neurology, Rabin Medical Center, Petah Tikva, Israel. AD - Neuroimmunology Unit, Rabin Medical Center, Petah Tikva, Israel. AD - Sackler Faculty of Medicine, Tel-Aviv University, Israel. FAU - Wilf-Yarkoni, Adi AU - Wilf-Yarkoni A AD - Department of Neurology, Rabin Medical Center, Petah Tikva, Israel. AD - Neuroimmunology Unit, Rabin Medical Center, Petah Tikva, Israel. AD - Sackler Faculty of Medicine, Tel-Aviv University, Israel. FAU - Friedman, Yitzhak AU - Friedman Y AD - Department of Neurology, Rabin Medical Center, Petah Tikva, Israel. AD - Neuroimmunology Unit, Rabin Medical Center, Petah Tikva, Israel. AD - Sackler Faculty of Medicine, Tel-Aviv University, Israel. FAU - Stiebel-Kalish, Hadas AU - Stiebel-Kalish H AD - Sackler Faculty of Medicine, Tel-Aviv University, Israel. AD - Department of Ophthalmology and Neuro-Ophthalmology Unit, Rabin Medical Center, Petah Tikva, Israel. FAU - Steiner, Israel AU - Steiner I AD - Department of Neurology, Rabin Medical Center, Petah Tikva, Israel. AD - Sackler Faculty of Medicine, Tel-Aviv University, Israel. FAU - Hellmann, Mark A AU - Hellmann MA AD - Department of Neurology, Rabin Medical Center, Petah Tikva, Israel. AD - Neuroimmunology Unit, Rabin Medical Center, Petah Tikva, Israel. AD - Sackler Faculty of Medicine, Tel-Aviv University, Israel. LA - eng PT - Journal Article DEP - 20210802 PL - England TA - Eur J Neurol JT - European journal of neurology JID - 9506311 RN - 0 (BNT162 Vaccine) RN - 0 (COVID-19 Vaccines) SB - IM MH - Adult MH - Aged MH - BNT162 Vaccine MH - *COVID-19 MH - COVID-19 Vaccines MH - Female MH - Humans MH - Israel MH - Middle Aged MH - *Multiple Sclerosis MH - SARS-CoV-2 PMC - PMC8444776 OTO - NOTNLM OT - COVID-19 OT - adverse events OT - multiple sclerosis OT - safety OT - vaccine COIS- The authors declare that there is no conflict of interest. The authors do not have any specific agreements with the vaccine manufacturer for data delivery or similar. EDAT- 2021/07/22 06:00 MHDA- 2021/10/27 06:00 PMCR- 2021/08/02 CRDT- 2021/07/21 13:35 PHST- 2021/06/19 00:00 [revised] PHST- 2021/05/11 00:00 [received] PHST- 2021/07/16 00:00 [accepted] PHST- 2021/07/22 06:00 [pubmed] PHST- 2021/10/27 06:00 [medline] PHST- 2021/07/21 13:35 [entrez] PHST- 2021/08/02 00:00 [pmc-release] AID - ENE15028 [pii] AID - 10.1111/ene.15028 [doi] PST - ppublish SO - Eur J Neurol. 2021 Nov;28(11):3742-3748. doi: 10.1111/ene.15028. Epub 2021 Aug 2. PMID- 34133941 OWN - NLM STAT- MEDLINE DCOM- 20210701 LR - 20260416 IS - 1097-4172 (Electronic) IS - 0092-8674 (Print) IS - 0092-8674 (Linking) VI - 184 IP - 13 DP - 2021 Jun 24 TI - Low-dose Ad26.COV2.S protection against SARS-CoV-2 challenge in rhesus macaques. PG - 3467-3473.e11 LID - S0092-8674(21)00693-0 [pii] LID - 10.1016/j.cell.2021.05.040 [doi] AB - We previously reported that a single immunization with an adenovirus serotype 26 (Ad26)-vector-based vaccine expressing an optimized SARS-CoV-2 spike (Ad26.COV2.S) protected rhesus macaques against SARS-CoV-2 challenge. To evaluate reduced doses of Ad26.COV2.S, 30 rhesus macaques were immunized once with 1 x 10(11), 5 x 10(10), 1.125 x 10(10), or 2 x 10(9) viral particles (vp) Ad26.COV2.S or sham and were challenged with SARS-CoV-2. Vaccine doses as low as 2 x 10(9) vp provided robust protection in bronchoalveolar lavage, whereas doses of 1.125 x 10(10) vp were required for protection in nasal swabs. Activated memory B cells and binding or neutralizing antibody titers following vaccination correlated with protective efficacy. At suboptimal vaccine doses, viral breakthrough was observed but did not show enhancement of disease. These data demonstrate that a single immunization with relatively low dose of Ad26.COV2.S effectively protected against SARS-CoV-2 challenge in rhesus macaques, although a higher vaccine dose may be required for protection in the upper respiratory tract. CI - Copyright (c) 2021 Elsevier Inc. All rights reserved. FAU - He, Xuan AU - He X AD - Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA. FAU - Chandrashekar, Abishek AU - Chandrashekar A AD - Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA. FAU - Zahn, Roland AU - Zahn R AD - Janssen Vaccines & Prevention BV, Leiden, the Netherlands. FAU - Wegmann, Frank AU - Wegmann F AD - Janssen Vaccines & Prevention BV, Leiden, the Netherlands. FAU - Yu, Jingyou AU - Yu J AD - Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA. FAU - Mercado, Noe B AU - Mercado NB AD - Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA. FAU - McMahan, Katherine AU - McMahan K AD - Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA. FAU - Martinot, Amanda J AU - Martinot AJ AD - Tufts University Cummings School of Veterinary Medicine, North Grafton, MA 01536, USA. FAU - Piedra-Mora, Cesar AU - Piedra-Mora C AD - Tufts University Cummings School of Veterinary Medicine, North Grafton, MA 01536, USA. FAU - Beecy, Sidney AU - Beecy S AD - Tufts University Cummings School of Veterinary Medicine, North Grafton, MA 01536, USA. FAU - Ducat, Sarah AU - Ducat S AD - Tufts University Cummings School of Veterinary Medicine, North Grafton, MA 01536, USA. FAU - Chamanza, Ronnie AU - Chamanza R AD - Janssen Vaccines & Prevention BV, Leiden, the Netherlands. FAU - Huber, Sietske Rosendahl AU - Huber SR AD - Janssen Vaccines & Prevention BV, Leiden, the Netherlands. FAU - van Heerden, Marjolein AU - van Heerden M AD - Janssen Vaccines & Prevention BV, Leiden, the Netherlands. FAU - van der Fits, Leslie AU - van der Fits L AD - Janssen Vaccines & Prevention BV, Leiden, the Netherlands. FAU - Borducchi, Erica N AU - Borducchi EN AD - Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA. FAU - Lifton, Michelle AU - Lifton M AD - Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA. FAU - Liu, Jinyan AU - Liu J AD - Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA. FAU - Nampanya, Felix AU - Nampanya F AD - Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA. FAU - Patel, Shivani AU - Patel S AD - Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA. FAU - Peter, Lauren AU - Peter L AD - Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA. FAU - Tostanoski, Lisa H AU - Tostanoski LH AD - Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA. FAU - Pessaint, Laurent AU - Pessaint L AD - Bioqual, Rockville, MD 20852, USA. FAU - Van Ry, Alex AU - Van Ry A AD - Bioqual, Rockville, MD 20852, USA. FAU - Finneyfrock, Brad AU - Finneyfrock B AD - Bioqual, Rockville, MD 20852, USA. FAU - Velasco, Jason AU - Velasco J AD - Bioqual, Rockville, MD 20852, USA. FAU - Teow, Elyse AU - Teow E AD - Bioqual, Rockville, MD 20852, USA. FAU - Brown, Renita AU - Brown R AD - Bioqual, Rockville, MD 20852, USA. FAU - Cook, Anthony AU - Cook A AD - Bioqual, Rockville, MD 20852, USA. FAU - Andersen, Hanne AU - Andersen H AD - Bioqual, Rockville, MD 20852, USA. FAU - Lewis, Mark G AU - Lewis MG AD - Bioqual, Rockville, MD 20852, USA. FAU - Schuitemaker, Hanneke AU - Schuitemaker H AD - Janssen Vaccines & Prevention BV, Leiden, the Netherlands. FAU - Barouch, Dan H AU - Barouch DH AD - Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA; Massachusetts Consortium on Pathogen Readiness, Boston, MA 02215, USA. Electronic address: dbarouch@bidmc.harvard.edu. LA - eng GR - UM1 AI126603/AI/NIAID NIH HHS/United States GR - U01 CA260476/CA/NCI NIH HHS/United States GR - UM1 AI124377/AI/NIAID NIH HHS/United States GR - U19 AI128751/AI/NIAID NIH HHS/United States GR - R01 AI129797/AI/NIAID NIH HHS/United States GR - K08 AI135098/AI/NIAID NIH HHS/United States GR - R01 OD024917/OD/NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20210601 PL - United States TA - Cell JT - Cell JID - 0413066 RN - 0 (Antibodies, Neutralizing) RN - 0 (Antibodies, Viral) RN - 0 (COVID-19 Vaccines) RN - 0 (Spike Glycoprotein, Coronavirus) RN - 0 (Viral Vaccines) SB - IM UOF - bioRxiv. 2021 Jan 27:2021.01.27.428380. doi: 10.1101/2021.01.27.428380. PMID: 33532782 MH - Adenoviridae/*immunology MH - Animals MH - Antibodies, Neutralizing/immunology MH - Antibodies, Viral/immunology MH - B-Lymphocytes/immunology MH - COVID-19/*immunology MH - COVID-19 Vaccines/*immunology MH - Female MH - Immunogenicity, Vaccine/immunology MH - Immunologic Memory/immunology MH - Macaca mulatta MH - Male MH - SARS-CoV-2/*immunology MH - Spike Glycoprotein, Coronavirus/immunology MH - Vaccination/methods MH - Viral Vaccines/*immunology PMC - PMC8166510 MID - NIHMS1710150 OTO - NOTNLM OT - Ad26.COV2.S OT - COVID-19 OT - SARS-CoV-2 OT - humoral immunity OT - immunology OT - memory B cells OT - non-human primates OT - protection OT - vaccination COIS- Declaration of interests D.H.B., R.Z., F.W., and H.S are co-inventors on provisional vaccine patents (63/121,482; 63/133,969; 63/135,182). R.Z., F.W., S.R.H., M.v.H., L.v.d.F., and H.S. are employees of Janssen Vaccines & Prevention BV and may hold stock in Johnson & Johnson. EDAT- 2021/06/17 06:00 MHDA- 2021/07/02 06:00 PMCR- 2021/06/01 CRDT- 2021/06/16 20:07 PHST- 2021/02/02 00:00 [received] PHST- 2021/03/18 00:00 [revised] PHST- 2021/05/25 00:00 [accepted] PHST- 2021/06/17 06:00 [pubmed] PHST- 2021/07/02 06:00 [medline] PHST- 2021/06/16 20:07 [entrez] PHST- 2021/06/01 00:00 [pmc-release] AID - S0092-8674(21)00693-0 [pii] AID - 10.1016/j.cell.2021.05.040 [doi] PST - ppublish SO - Cell. 2021 Jun 24;184(13):3467-3473.e11. doi: 10.1016/j.cell.2021.05.040. Epub 2021 Jun 1. PMID- 34093567 OWN - NLM STAT- MEDLINE DCOM- 20210610 LR - 20260127 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 12 DP - 2021 TI - COVID-19 mRNA Vaccines Are Generally Safe in the Short Term: A Vaccine Vigilance Real-World Study Says. PG - 669010 LID - 10.3389/fimmu.2021.669010 [doi] LID - 669010 AB - BACKGROUND: The prophylactic vaccination of COVID-19 mRNA vaccines is the first large-scale application of this kind in the human world. Over 1.8 million doses of the COVID-19 vaccine had been administered in the US until December 2020, and around 0.2% submitted AE reports to the Vaccine Adverse Event Reporting System (VAERS). This study aimed to evaluate the AEs following immunization (AEFIs) and analyze the potential associations based on the information from the VAERS database. METHODS: We searched the VAERS database recorded AEFIs after COVID-19 vaccines in December 2020. After data mapping, we summarized demographic and clinical features of reported cases. Fisher exact test was used to comparing the clinical characteristics among AE groups with an anaphylactic response, concerning neurological disorders and death. RESULTS: VAERS reported 3,908 AEFIs of COVID-19 vaccines in December 2020. Most (79.68%) were reported after the first dose of the vaccine. Among the reported cases, we found that general disorders (48.80%), nervous system disorders (46.39%), and gastrointestinal disorders (25.54%) were the most common AEFIs. The allergy history was more frequent in vaccine recipients with anaphylactic reactions than those without (64.91% vs. 49.62%, OR = 1.88, P <0.017). History of anxiety or depression was more common in subjects reporting severe neurological AEFIs than those reporting other AEFIs (18.37% vs. 7.85%, OR = 2.64, P <0.017). Cases reporting death were significantly older (79.36 +/- 10.41-year-old vs. 42.64 +/- 12.55-year-old, P <0.01, 95% CI 29.30-44.15) and more likely experienced hypertension (50.00% vs. 11.42%, OR = 7.76, P <0.01) and neurological disorders (50.00% vs. 5.36%, OR = 17.65, P <0.01) than other vaccine recipients. The outpatient and emergency room visit rates were 11.92 and 22.42% for AEFIs, and 2.53% of cases needed hospitalization. CONCLUSION: AEFIs of COVID-19 mRNA vaccines were generally non-severe local or systemic reactions. A prior allergy history is the risk factor for anaphylaxis, while a history of anxiety may link with severe neurological AEs. Such vaccine recipients need further evaluation and monitor. CI - Copyright (c) 2021 Chen, Li, Sun, Zhou, Yin, Zhao and Li. FAU - Chen, Gang AU - Chen G AD - Nephrology Department, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China. FAU - Li, Xiaolin AU - Li X AD - Pharmacy Department, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China. AD - State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China. FAU - Sun, Meixing AU - Sun M AD - Nephrology Department, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China. FAU - Zhou, Yangzhong AU - Zhou Y AD - Nephrology Department, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China. FAU - Yin, Meifang AU - Yin M AD - Pharmacy Department, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China. FAU - Zhao, Bin AU - Zhao B AD - Pharmacy Department, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China. FAU - Li, Xuemei AU - Li X AD - Nephrology Department, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210521 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 RN - 0 (COVID-19 Vaccines) RN - 0 (Vaccines, Synthetic) RN - 0 (mRNA Vaccines) SB - IM MH - Adolescent MH - Adult MH - Adverse Drug Reaction Reporting Systems MH - Aged MH - COVID-19/*prevention & control MH - COVID-19 Vaccines/*adverse effects MH - Female MH - Humans MH - Male MH - Middle Aged MH - *SARS-CoV-2 MH - United States MH - Vaccination/adverse effects MH - Vaccines, Synthetic/*adverse effects MH - Young Adult MH - mRNA Vaccines PMC - PMC8177815 OTO - NOTNLM OT - COVID-19 OT - adverse event OT - mRNA OT - safety issue OT - vaccine COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2021/06/08 06:00 MHDA- 2021/06/11 06:00 PMCR- 2021/05/21 CRDT- 2021/06/07 05:50 PHST- 2021/02/17 00:00 [received] PHST- 2021/05/04 00:00 [accepted] PHST- 2021/06/07 05:50 [entrez] PHST- 2021/06/08 06:00 [pubmed] PHST- 2021/06/11 06:00 [medline] PHST- 2021/05/21 00:00 [pmc-release] AID - 10.3389/fimmu.2021.669010 [doi] PST - epublish SO - Front Immunol. 2021 May 21;12:669010. doi: 10.3389/fimmu.2021.669010. eCollection 2021. PMID- 34057580 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231111 IS - 2090-5920 (Electronic) IS - 1687-157X (Print) IS - 1687-157X (Linking) VI - 19 IP - 1 DP - 2021 May 31 TI - PPAR agonists as effective adjuvants for COVID-19 vaccines, by modifying immunogenetics: a review of literature. PG - 82 LID - 10.1186/s43141-021-00179-2 [doi] LID - 82 AB - BACKGROUND: Several coronavirus vaccine have been fast-tracked to halt the pandemic, the usage of immune adjuvants that can boost immunological memory has come up to the surface. This is particularly of importance in view of the rates of failure of seroconversion and re-infection after COVID-19 infection, which could make the vaccine role and response debatable. Peroxisome proliferator-activated receptors (PPARs) have an established immune-modulatory role, but their effects as adjuvants to vaccination have not been explored to date. It is increasingly recognized that PPAR agonists can upregulate the levels of anti-apoptotic factors such as MCL-1. Such effect can improve the results of vaccination by enhancing the longevity of long-lived plasma cells (LLPCs). The interaction between PPAR agonists and the immune system does not halt here, as T cell memory is also stimulated through enhanced T regulatory cells, antagonizing PD-L1 and switching the metabolism of T cells to fatty acid oxidation, which has a remarkable effect on the persistence of T memory cells. What is even of a more significant value is the effect of PPAR gamma on ensuring a profound secretion of antibodies upon re-exposure to the offending antigen through upregulating lipoxin B4, therefore potentially assisting the vaccine response and deterring re-infection. SHORT CONCLUSION: In view of the above, we suggest the use of PPAR as adjuvants to vaccines in general especially the emerging COVID-19 vaccine due to their role in enhancing immunologic memory through DNA-dependent mechanisms. FAU - AbdelMassih, Antoine Fakhry AU - AbdelMassih AF AUID- ORCID: 0000-0001-8876-3229 AD - Pediatric Cardiology Unit, Pediatrics' Department, Cairo University Children Hospital, Faculty of Medicine, Cairo University, Kasr Al Ainy Street, Cairo, 12411, Egypt. antoine.abdelmassih@kasralainy.edu.eg. AD - Pediatric Cardio-Oncology Department, Children Cancer Hospital of Egypt (57357), Cairo, Egypt. antoine.abdelmassih@kasralainy.edu.eg. FAU - Menshawey, Rahma AU - Menshawey R AD - Research Accessibility Team, Student and Internship research program, Faculty of Medicine, Cairo University, Giza, Egypt. FAU - Ismail, Jumana H AU - Ismail JH AD - Pulmonology Department, Faculty of Medicine, Cairo University, Giza, Egypt. FAU - Husseiny, Reem J AU - Husseiny RJ AD - Research Accessibility Team, Student and Internship research program, Faculty of Medicine, Cairo University, Giza, Egypt. FAU - Husseiny, Yousef M AU - Husseiny YM AD - Research Accessibility Team, Student and Internship research program, Faculty of Medicine, New Giza University, 6th of October City, Egypt. FAU - Yacoub, Shenoda AU - Yacoub S AD - Research Accessibility Team, Student and Internship research program, Faculty of Medicine, Cairo University, Giza, Egypt. FAU - Kamel, Aya AU - Kamel A AD - Research Accessibility Team, Student and Internship research program, Faculty of Medicine, Cairo University, Giza, Egypt. FAU - Hozaien, Rafeef AU - Hozaien R AD - Research Accessibility Team, Student and Internship research program, Faculty of Medicine, Cairo University, Giza, Egypt. FAU - Yacoub, Elaria AU - Yacoub E AD - Research Accessibility Team, Student and Internship research program, Faculty of Medicine, Cairo University, Giza, Egypt. FAU - Menshawey, Esraa AU - Menshawey E AD - Research Accessibility Team, Student and Internship research program, Faculty of Medicine, Cairo University, Giza, Egypt. FAU - Abdelmalek, Abanoub AU - Abdelmalek A AD - Research Accessibility Team, Student and Internship research program, Faculty of Medicine, Cairo University, Giza, Egypt. FAU - Abouelazaem, Ahmed AU - Abouelazaem A AD - Research Accessibility Team, Student and Internship research program, Faculty of Medicine, Cairo University, Giza, Egypt. FAU - Elhatw, Ahmed AU - Elhatw A AD - Research Accessibility Team, Student and Internship research program, Faculty of Medicine, Cairo University, Giza, Egypt. FAU - Aboelmaaty, Ahmed AU - Aboelmaaty A AD - Research Accessibility Team, Student and Internship research program, Faculty of Medicine, Cairo University, Giza, Egypt. FAU - Shahib, Alaaelrahman AU - Shahib A AD - Research Accessibility Team, Student and Internship research program, Faculty of Medicine, Cairo University, Giza, Egypt. FAU - Mansour, Amany AU - Mansour A AD - Research Accessibility Team, Student and Internship research program, Faculty of Medicine, Cairo University, Giza, Egypt. FAU - Kamal, Aya AU - Kamal A AD - Research Accessibility Team, Student and Internship research program, Faculty of Medicine, Cairo University, Giza, Egypt. FAU - Mohamed, Basant AU - Mohamed B AD - Research Accessibility Team, Student and Internship research program, Faculty of Medicine, Cairo University, Giza, Egypt. FAU - Atif, Bemen AU - Atif B AD - Research Accessibility Team, Student and Internship research program, Faculty of Medicine, Cairo University, Giza, Egypt. FAU - Ghabreal, Beshoy AU - Ghabreal B AD - Research Accessibility Team, Student and Internship research program, Faculty of Medicine, Cairo University, Giza, Egypt. FAU - Abdelmalak, Catherine AU - Abdelmalak C AD - Research Accessibility Team, Student and Internship research program, Faculty of Medicine, Cairo University, Giza, Egypt. FAU - Ibrahim, David AU - Ibrahim D AD - Research Accessibility Team, Student and Internship research program, Faculty of Medicine, Cairo University, Giza, Egypt. FAU - Elsaify, Ebtesam AU - Elsaify E AD - Research Accessibility Team, Student and Internship research program, Faculty of Medicine, Cairo University, Giza, Egypt. FAU - Magdy, Farah AU - Magdy F AD - Research Accessibility Team, Student and Internship research program, Faculty of Medicine, Cairo University, Giza, Egypt. FAU - Hanna, Farid G AU - Hanna FG AD - Research Accessibility Team, Student and Internship research program, Faculty of Medicine, Cairo University, Giza, Egypt. FAU - Hafez, Hadeer AU - Hafez H AD - Research Accessibility Team, Student and Internship research program, Faculty of Medicine, Cairo University, Giza, Egypt. FAU - Dahir, Hafsa AU - Dahir H AD - Research Accessibility Team, Student and Internship research program, Faculty of Medicine, Cairo University, Giza, Egypt. FAU - Merhom, Kerlos AU - Merhom K AD - Research Accessibility Team, Student and Internship research program, Faculty of Medicine, Cairo University, Giza, Egypt. FAU - Ahmed, Maram AU - Ahmed M AD - Research Accessibility Team, Student and Internship research program, Faculty of Medicine, Cairo University, Giza, Egypt. FAU - Bishara, Mariam AU - Bishara M AD - Research Accessibility Team, Student and Internship research program, Faculty of Medicine, Cairo University, Giza, Egypt. FAU - Tawfik, Mina AU - Tawfik M AD - Research Accessibility Team, Student and Internship research program, Faculty of Medicine, Cairo University, Giza, Egypt. FAU - Youssef, Mina AU - Youssef M AD - University at Buffalo School of Medicine and Biomedical, Buffalo, USA. FAU - El Sharnouby, Mohamed AU - El Sharnouby M AD - Research Accessibility Team, Student and Internship research program, Faculty of Medicine, Cairo University, Giza, Egypt. FAU - Hamouda, Mourad AU - Hamouda M AD - Research Accessibility Team, Student and Internship research program, Faculty of Medicine, Cairo University, Giza, Egypt. FAU - Ammar, Musheera AU - Ammar M AD - Research Accessibility Team, Student and Internship research program, Faculty of Medicine, Cairo University, Giza, Egypt. FAU - Ali, Nada AU - Ali N AD - Research Accessibility Team, Student and Internship research program, Faculty of Medicine, Cairo University, Giza, Egypt. FAU - Daniel, Nada AU - Daniel N AD - Research Accessibility Team, Student and Internship research program, Faculty of Medicine, Ain Shams University, Cairo, Egypt. FAU - El-Husseiny, Nadine AU - El-Husseiny N AD - Faculty of Dentistry, Cairo University, Giza, Egypt. AD - Pixagon graphic design Agency, Cairo, Egypt. FAU - Abdelraouf, Noha AU - Abdelraouf N AD - Research Accessibility Team, Student and Internship research program, Faculty of Medicine, Cairo University, Giza, Egypt. FAU - Abdelhameed, Nuran K AU - Abdelhameed NK AD - Research Accessibility Team, Student and Internship research program, Faculty of Medicine, Cairo University, Giza, Egypt. FAU - Ahmed, Radwa AU - Ahmed R AD - Research Accessibility Team, Student and Internship research program, Faculty of Medicine, Cairo University, Giza, Egypt. FAU - Othman, Radwa AU - Othman R AD - Research Accessibility Team, Student and Internship research program, Faculty of Medicine, Cairo University, Giza, Egypt. FAU - Mohamadein, Rahma AU - Mohamadein R AD - Research Accessibility Team, Student and Internship research program, Faculty of Medicine, Cairo University, Giza, Egypt. FAU - Allam, Rana AU - Allam R AD - Research Accessibility Team, Student and Internship research program, Faculty of Medicine, Cairo University, Giza, Egypt. FAU - Elgendy, Rana AU - Elgendy R AD - Research Accessibility Team, Student and Internship research program, Faculty of Medicine, Cairo University, Giza, Egypt. FAU - Shebl, Rana AU - Shebl R AD - Research Accessibility Team, Student and Internship research program, Faculty of Medicine, Cairo University, Giza, Egypt. FAU - Elsherbiney, Saged AU - Elsherbiney S AD - Research Accessibility Team, Student and Internship research program, Faculty of Medicine, Cairo University, Giza, Egypt. FAU - Fouad, Sarah AU - Fouad S AD - Research Accessibility Team, Student and Internship research program, Faculty of Medicine, Cairo University, Giza, Egypt. FAU - Emel, Sara AU - Emel S AD - Research Accessibility Team, Student and Internship research program, Faculty of Medicine, Cairo University, Giza, Egypt. FAU - Owais, Sara AU - Owais S AD - Research Accessibility Team, Student and Internship research program, Faculty of Medicine, Cairo University, Giza, Egypt. FAU - Hetta, Sarah AU - Hetta S AD - Research Accessibility Team, Student and Internship research program, Faculty of Medicine, Cairo University, Giza, Egypt. FAU - El-Saman, Samah AU - El-Saman S AD - Research Accessibility Team, Student and Internship research program, Faculty of Medicine, Cairo University, Giza, Egypt. FAU - Abdelalim, Shaimaa AU - Abdelalim S AD - Research Accessibility Team, Student and Internship research program, Faculty of Medicine, Ain Shams University, Cairo, Egypt. FAU - Galal, Sherin AU - Galal S AD - Research Accessibility Team, Student and Internship research program, Faculty of Medicine, Cairo University, Giza, Egypt. FAU - Asar, Yara AU - Asar Y AD - Research Accessibility Team, Student and Internship research program, Faculty of Medicine, Cairo University, Giza, Egypt. FAU - Osman, Yara AU - Osman Y AD - Research Accessibility Team, Student and Internship research program, Faculty of Medicine, Ain Shams University, Cairo, Egypt. FAU - Khalaf, Yasmeen AU - Khalaf Y AD - Research Accessibility Team, Student and Internship research program, Faculty of Medicine, Cairo University, Giza, Egypt. FAU - Aziz, Youstina AU - Aziz Y AD - Research Accessibility Team, Student and Internship research program, Faculty of Medicine, 6th October University, 6th of October City, Egypt. FAU - Khafagy, Yousra AU - Khafagy Y AD - Research Accessibility Team, Student and Internship research program, Faculty of Medicine, Cairo University, Giza, Egypt. FAU - Gamal, Nervana AU - Gamal N AD - Research Accessibility Team, Student and Internship research program, Faculty of Medicine, Cairo University, Giza, Egypt. FAU - Castaldi, Biagio AU - Castaldi B AD - Padova University, Padua, Italy. LA - eng PT - Journal Article PT - Review DEP - 20210531 PL - Netherlands TA - J Genet Eng Biotechnol JT - Journal, genetic engineering & biotechnology JID - 101317150 PMC - PMC8165506 OTO - NOTNLM OT - COVID-19 vaccine OT - Immunologic memory OT - PPAR COIS- The authors declare that they have no competing interests. EDAT- 2021/06/01 06:00 MHDA- 2021/06/01 06:01 PMCR- 2021/05/31 CRDT- 2021/05/31 12:54 PHST- 2021/03/12 00:00 [received] PHST- 2021/05/14 00:00 [accepted] PHST- 2021/05/31 12:54 [entrez] PHST- 2021/06/01 06:00 [pubmed] PHST- 2021/06/01 06:01 [medline] PHST- 2021/05/31 00:00 [pmc-release] AID - 10.1186/s43141-021-00179-2 [pii] AID - 179 [pii] AID - 10.1186/s43141-021-00179-2 [doi] PST - epublish SO - J Genet Eng Biotechnol. 2021 May 31;19(1):82. doi: 10.1186/s43141-021-00179-2. PMID- 34057040 OWN - NLM STAT- MEDLINE DCOM- 20210614 LR - 20210625 IS - 2222-1751 (Electronic) IS - 2222-1751 (Linking) VI - 10 IP - 1 DP - 2021 Dec TI - Intensified antibody response elicited by boost suggests immune memory in individuals administered two doses of SARS-CoV-2 inactivated vaccine. PG - 1112-1115 LID - 10.1080/22221751.2021.1937328 [doi] AB - Neutralizing antibodies in the subjects of an inactivated SARS-CoV-2 vaccine clinical trial showed a decreasing trend over months. An investigation studying the third immunization suggested that the waning of neutralizing antibodies in individuals administered two doses of inactivated vaccine does not mean the disappearance of immunity. FAU - Liao, Yun AU - Liao Y AD - Institute of Medical Biology, Chinese Academy of Medicine Sciences and Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming, People's Republic of China. FAU - Zhang, Ying AU - Zhang Y AD - Institute of Medical Biology, Chinese Academy of Medicine Sciences and Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming, People's Republic of China. FAU - Zhao, Heng AU - Zhao H AD - Institute of Medical Biology, Chinese Academy of Medicine Sciences and Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming, People's Republic of China. FAU - Pu, Jing AU - Pu J AD - Institute of Medical Biology, Chinese Academy of Medicine Sciences and Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming, People's Republic of China. FAU - Zhao, Zhimei AU - Zhao Z AD - Institute of Medical Biology, Chinese Academy of Medicine Sciences and Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming, People's Republic of China. FAU - Li, Dandan AU - Li D AD - Institute of Medical Biology, Chinese Academy of Medicine Sciences and Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming, People's Republic of China. FAU - Fan, Shengtao AU - Fan S AD - Institute of Medical Biology, Chinese Academy of Medicine Sciences and Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming, People's Republic of China. FAU - Yu, Li AU - Yu L AD - Institute of Medical Biology, Chinese Academy of Medicine Sciences and Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming, People's Republic of China. FAU - Xu, Xingli AU - Xu X AD - Institute of Medical Biology, Chinese Academy of Medicine Sciences and Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming, People's Republic of China. FAU - Wang, Lichun AU - Wang L AD - Institute of Medical Biology, Chinese Academy of Medicine Sciences and Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming, People's Republic of China. FAU - Jiang, Guorun AU - Jiang G AD - Institute of Medical Biology, Chinese Academy of Medicine Sciences and Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming, People's Republic of China. FAU - Liu, Longding AU - Liu L AD - Institute of Medical Biology, Chinese Academy of Medicine Sciences and Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming, People's Republic of China. FAU - Li, Qihan AU - Li Q AD - Institute of Medical Biology, Chinese Academy of Medicine Sciences and Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming, People's Republic of China. LA - eng PT - Letter PL - United States TA - Emerg Microbes Infect JT - Emerging microbes & infections JID - 101594885 RN - 0 (Antibodies, Neutralizing) RN - 0 (Antibodies, Viral) RN - 0 (COVID-19 Vaccines) RN - 0 (Vaccines, Inactivated) SB - IM MH - Adolescent MH - Adult MH - Antibodies, Neutralizing/immunology MH - Antibodies, Viral/*immunology MH - COVID-19/*prevention & control MH - COVID-19 Vaccines/administration & dosage/*immunology MH - Humans MH - *Immunization, Secondary MH - *Immunologic Memory MH - Middle Aged MH - Vaccination/statistics & numerical data MH - Vaccines, Inactivated/administration & dosage/immunology MH - Young Adult PMC - PMC8204957 OTO - NOTNLM OT - COVID-19 OT - SARS-CoV-2 OT - antibody waning OT - immune memory OT - inactivated vaccine COIS- All authors have completed the Unified Competing Interest form and declare that they have no financial or nonfinancial competing interests. The corresponding authors had full access to all the data generated in the present study and assume full responsibility for the final submission of this manuscript for publication. EDAT- 2021/06/01 06:00 MHDA- 2021/06/16 06:00 PMCR- 2021/06/09 CRDT- 2021/05/31 09:01 PHST- 2021/06/01 06:00 [pubmed] PHST- 2021/06/16 06:00 [medline] PHST- 2021/05/31 09:01 [entrez] PHST- 2021/06/09 00:00 [pmc-release] AID - 1937328 [pii] AID - 10.1080/22221751.2021.1937328 [doi] PST - ppublish SO - Emerg Microbes Infect. 2021 Dec;10(1):1112-1115. doi: 10.1080/22221751.2021.1937328. PMID- 34046033 OWN - NLM STAT- MEDLINE DCOM- 20210607 LR - 20240810 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 12 DP - 2021 TI - Infection and Immune Memory: Variables in Robust Protection by Vaccines Against SARS-CoV-2. PG - 660019 LID - 10.3389/fimmu.2021.660019 [doi] LID - 660019 AB - SARS-CoV-2 is the cause of a recent pandemic that has led to more than 3 million deaths worldwide. Most individuals are asymptomatic or display mild symptoms, which raises an inherent question as to how does the immune response differs from patients manifesting severe disease? During the initial phase of infection, dysregulated effector immune cells such as neutrophils, macrophages, monocytes, megakaryocytes, basophils, eosinophils, erythroid progenitor cells, and Th17 cells can alter the trajectory of an infected patient to severe disease. On the other hand, properly functioning CD4+, CD8+ cells, NK cells, and DCs reduce the disease severity. Detailed understanding of the immune response of convalescent individuals transitioning from the effector phase to the immunogenic memory phase can provide vital clues to understanding essential variables to assess vaccine-induced protection. Although neutralizing antibodies can wane over time, long-lasting B and T memory cells can persist in recovered individuals. The natural immunological memory captures the diverse repertoire of SARS-CoV-2 epitopes after natural infection whereas, currently approved vaccines are based on a single epitope, spike protein. It is essential to understand the nature of the immune response to natural infection to better identify 'correlates of protection' against this disease. This article discusses recent findings regarding immune response against natural infection to SARS-CoV-2 and the nature of immunogenic memory. More precise knowledge of the acute phase of immune response and its transition to immunological memory will contribute to the future design of vaccines and the identification of variables essential to maintain immune protection across diverse populations. CI - Copyright (c) 2021 Ahluwalia, Vaibhav, Ahluwalia, Mondal, Sahajpal, Rojiani and Kolhe. FAU - Ahluwalia, Pankaj AU - Ahluwalia P AD - Department of Pathology, Medical College of Georgia, Augusta University, Augusta, GA, United States. FAU - Vaibhav, Kumar AU - Vaibhav K AD - Department of Neurosurgery, Augusta University, Augusta, GA, United States. FAU - Ahluwalia, Meenakshi AU - Ahluwalia M AD - Department of Neurosurgery, Augusta University, Augusta, GA, United States. FAU - Mondal, Ashis K AU - Mondal AK AD - Department of Pathology, Medical College of Georgia, Augusta University, Augusta, GA, United States. FAU - Sahajpal, Nikhil AU - Sahajpal N AD - Department of Pathology, Medical College of Georgia, Augusta University, Augusta, GA, United States. FAU - Rojiani, Amyn M AU - Rojiani AM AD - Department of Pathology, Medical College of Georgia, Augusta University, Augusta, GA, United States. FAU - Kolhe, Ravindra AU - Kolhe R AD - Department of Pathology, Medical College of Georgia, Augusta University, Augusta, GA, United States. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20210511 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 RN - 0 (Antibodies, Neutralizing) RN - 0 (Antibodies, Viral) RN - 0 (COVID-19 Vaccines) RN - 0 (Epitopes, T-Lymphocyte) SB - IM MH - Animals MH - Antibodies, Neutralizing/metabolism MH - Antibodies, Viral/metabolism MH - CD8-Positive T-Lymphocytes/*immunology MH - COVID-19/*immunology MH - COVID-19 Vaccines/*immunology MH - Disease Resistance MH - Epitopes, T-Lymphocyte/immunology MH - Humans MH - Immunity, Cellular MH - Immunologic Memory MH - SARS-CoV-2/*physiology PMC - PMC8144450 OTO - NOTNLM OT - Immune memory OT - Immune system OT - Immunological memory OT - Pathogen OT - SARS-CoV-2 OT - T cells OT - Vaccine OT - Vaccine design COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2021/05/29 06:00 MHDA- 2021/06/08 06:00 PMCR- 2021/05/11 CRDT- 2021/05/28 07:24 PHST- 2021/01/28 00:00 [received] PHST- 2021/04/27 00:00 [accepted] PHST- 2021/05/28 07:24 [entrez] PHST- 2021/05/29 06:00 [pubmed] PHST- 2021/06/08 06:00 [medline] PHST- 2021/05/11 00:00 [pmc-release] AID - 10.3389/fimmu.2021.660019 [doi] PST - epublish SO - Front Immunol. 2021 May 11;12:660019. doi: 10.3389/fimmu.2021.660019. eCollection 2021. PMID- 34022372 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231107 IS - 1090-2139 (Electronic) IS - 0889-1591 (Print) IS - 0889-1591 (Linking) VI - 96 DP - 2021 Aug TI - Pre-pandemic cognitive function and COVID-19 vaccine hesitancy: cohort study. PG - 100-105 LID - S0889-1591(21)00197-5 [pii] LID - 10.1016/j.bbi.2021.05.016 [doi] AB - BACKGROUND: Whereas several predictors of COVID-19 vaccine hesitancy have been reported, the role of cognitive function is largely unknown. Accordingly, our objective was to evaluate the association between scores from an array of cognitive function tests and self-reported vaccine hesitancy after the announcement of the successful testing of the first COVID-19 vaccine (Oxford University/AstraZeneca). METHODS: We used individual-level data from a pandemic-focused study ('COVID Survey'), a prospective cohort study nested within United Kingdom Understanding Society ('Main Survey'). In the week immediately following the announcement of successful testing of the first efficacious inoculation (November/December 2020), data on vaccine intentionality were collected in 11,740 individuals (6702 women) aged 16-95 years. Pre-pandemic scores on general cognitive function, ascertained from a battery of six tests, were captured in 2011/12 wave of the Main Survey. Study members self-reported their intention to take up a vaccination in the COVID-19 Survey. RESULTS: Of the study sample, 17.2% (N = 1842) indicated they were hesitant about having the vaccine. After adjustment for age, sex, and ethnicity, study members with a lower baseline cognition score were markedly more likely to be vaccine hesitant (odds ratio per standard deviation lower score in cognition; 95% confidence interval: 1.76; 1.62, 1.90). Adjustment for mental and physical health plus household shielding status had no impact on these results, whereas controlling for educational attainment led to partial attenuation but the probability of hesitancy was still elevated (1.52; 1.37, 1.67). There was a linear association for vaccine hesitancy across the full range of cognition scores (p for trend: p < 0.0001). CONCLUSIONS: Erroneous social media reports might have complicated personal decision-making, leading to people with lower cognitive ability being vaccine-hesitant. With individuals with lower cognition also experiencing higher rates of COVID-19 in studies conducted prior to vaccine distribution, these new findings are suggestive of a potential additional disease burden. CI - Copyright (c) 2021 The Author(s). Published by Elsevier Inc. All rights reserved. FAU - Batty, G David AU - Batty GD AD - Department of Epidemiology and Public Health, University College London, UK. Electronic address: david.batty@ucl.ac.uk. FAU - Deary, Ian J AU - Deary IJ AD - Lothian Birth Cohorts, Department of Psychology, University of Edinburgh, UK. FAU - Fawns-Ritchie, Chloe AU - Fawns-Ritchie C AD - Department of Psychology, University of Edinburgh, UK. FAU - Gale, Catharine R AU - Gale CR AD - Lothian Birth Cohorts, Department of Psychology, University of Edinburgh, UK; Medical Research Council Lifecourse Epidemiology Unit, University of Southampton, UK. FAU - Altschul, Drew AU - Altschul D AD - Department of Psychology, University of Edinburgh, UK. LA - eng PT - Journal Article DEP - 20210520 PL - Netherlands TA - Brain Behav Immun JT - Brain, behavior, and immunity JID - 8800478 SB - IM UOF - medRxiv. 2021 Mar 25:2021.03.16.21253634. doi: 10.1101/2021.03.16.21253634. PMID: 33791726 PMC - PMC8133799 OTO - NOTNLM OT - COVID-19 OT - Cognitive ability OT - Cognitive function OT - Cohort OT - IQ OT - Mental ability OT - Vaccine hesitancy COIS- The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2021/05/23 06:00 MHDA- 2021/05/23 06:01 PMCR- 2021/08/01 CRDT- 2021/05/22 20:12 PHST- 2021/05/10 00:00 [received] PHST- 2021/05/17 00:00 [accepted] PHST- 2021/05/23 06:00 [pubmed] PHST- 2021/05/23 06:01 [medline] PHST- 2021/05/22 20:12 [entrez] PHST- 2021/08/01 00:00 [pmc-release] AID - S0889-1591(21)00197-5 [pii] AID - 10.1016/j.bbi.2021.05.016 [doi] PST - ppublish SO - Brain Behav Immun. 2021 Aug;96:100-105. doi: 10.1016/j.bbi.2021.05.016. Epub 2021 May 20. PMID- 34022331 OWN - NLM STAT- MEDLINE DCOM- 20210819 LR - 20210819 IS - 1878-3511 (Electronic) IS - 1201-9712 (Print) IS - 1201-9712 (Linking) VI - 108 DP - 2021 Jul TI - Immunological memory and neutralizing activity to a single dose of COVID-19 vaccine in previously infected individuals. PG - 183-186 LID - S1201-9712(21)00436-7 [pii] LID - 10.1016/j.ijid.2021.05.034 [doi] AB - BACKGROUND: The efficacy of COVID-19 vaccines to generate immunological memory post-vaccination has not previously been studied. OBJECTIVE: To assess immunological memory in previously SARS-CoV-2 infected individuals after a single dose of mRNA vaccine. PATIENTS AND METHODS: Healthcare workers (n = 280) were enrolled after obtaining written informed consent and grouped under previously infected and no prior exposure (reverse transcription-polymerase chain reaction positive and negative, respectively). Blood was drawn at baseline and post-vaccination (single dose of COVISHIELD) for enumerating neutralizing antibodies by chemiluminescence and memory T- and B-cells by flow cytometry. RESULTS: Post vaccination, compared with the no prior exposure group, the previously infected group had higher levels of: antibody response (1124.73 +/- 869.13 vs 94.23 +/- 140.06 AU/ml, p = 0.0001); CD4 memory T-cells: central memory CCR7+CD45RA- (p = 0.0001), effector memory CCR7-/CD45RA- (p = 0.01); total CD8+ T-cells (p = 0.004); CD8+ naive T-cells CCR7+CD45RA+ (p = 0.01); and memory B-cells CD20+CD27+ (p = 0.0001). DISCUSSION: Single-dose vaccination elicited higher neutralizing antibody response and protective immunity in individuals who had recovered from SARS-CoV-2 infection compared with those with no prior exposure. CI - Copyright (c) 2021 The Authors. Published by Elsevier Ltd.. All rights reserved. FAU - Sasikala, Mitnala AU - Sasikala M AD - Institute of Translational Research, Department of Molecular Biology, Asian Healthcare Foundation, AIG Hospitals Complex, Mindspace Road, Gachibowli, Hyderabad, 500032, Telangana, India. Electronic address: drsasikala.mitnala@aighospitals.com. FAU - Shashidhar, Jaggaiahgari AU - Shashidhar J AD - Institute of Translational Research, Department of Molecular Biology, Asian Healthcare Foundation, AIG Hospitals Complex, Mindspace Road, Gachibowli, Hyderabad, 500032, Telangana, India. FAU - Deepika, Gujjarlapudi AU - Deepika G AD - Department of Biochemistry, AIG Hospitals, Mindspace Road, Gachibowli, Hyderabad, 500032, Telangana, India. FAU - Ravikanth, Vishnubhotla AU - Ravikanth V AD - Institute of Translational Research, Department of Molecular Biology, Asian Healthcare Foundation, AIG Hospitals Complex, Mindspace Road, Gachibowli, Hyderabad, 500032, Telangana, India. FAU - Krishna, Vemula Venkata AU - Krishna VV AD - Institute of Translational Research, Department of Molecular Biology, Asian Healthcare Foundation, AIG Hospitals Complex, Mindspace Road, Gachibowli, Hyderabad, 500032, Telangana, India. FAU - Sadhana, Yelamanchili AU - Sadhana Y AD - Department of Microbiology and Virology, AIG Hospitals, Mindspace Road, Gachibowli, Hyderabad, 500032, Telangana, India. FAU - Pragathi, Kottapalli AU - Pragathi K AD - Department of Microbiology and Infection Control, AIG Hospitals, Mindspace Road, Gachibowli, Hyderabad, 500032, Telangana, India. FAU - Reddy, Duvvur Nageshwar AU - Reddy DN AD - Institute of Translational Research, Department of Molecular Biology, Asian Healthcare Foundation, AIG Hospitals Complex, Mindspace Road, Gachibowli, Hyderabad, 500032, Telangana, India. LA - eng PT - Journal Article DEP - 20210519 PL - Canada TA - Int J Infect Dis JT - International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases JID - 9610933 RN - 0 (Antibodies, Viral) RN - 0 (COVID-19 Vaccines) SB - IM MH - Antibodies, Viral MH - CD8-Positive T-Lymphocytes MH - *COVID-19 MH - *COVID-19 Vaccines MH - Humans MH - Immunologic Memory MH - SARS-CoV-2 PMC - PMC8132551 OTO - NOTNLM OT - COVID-19 OT - Memory B-cells OT - Memory T-cells OT - SARS-CoV-2 EDAT- 2021/05/23 06:00 MHDA- 2021/08/20 06:00 PMCR- 2021/05/19 CRDT- 2021/05/22 20:11 PHST- 2021/04/16 00:00 [received] PHST- 2021/05/12 00:00 [revised] PHST- 2021/05/16 00:00 [accepted] PHST- 2021/05/23 06:00 [pubmed] PHST- 2021/08/20 06:00 [medline] PHST- 2021/05/22 20:11 [entrez] PHST- 2021/05/19 00:00 [pmc-release] AID - S1201-9712(21)00436-7 [pii] AID - 10.1016/j.ijid.2021.05.034 [doi] PST - ppublish SO - Int J Infect Dis. 2021 Jul;108:183-186. doi: 10.1016/j.ijid.2021.05.034. Epub 2021 May 19. PMID- 33996731 OWN - NLM STAT- MEDLINE DCOM- 20210519 LR - 20210519 IS - 2296-2565 (Electronic) IS - 2296-2565 (Linking) VI - 9 DP - 2021 TI - SARS-CoV-2 Vaccine Hesitancy in a Sample of US Adults: Role of Perceived Satisfaction With Health, Access to Healthcare, and Attention to COVID-19 News. PG - 665724 LID - 10.3389/fpubh.2021.665724 [doi] LID - 665724 AB - Understanding which communities are most likely to be vaccine hesitant is necessary to increase vaccination rates to control the spread of SARS-CoV-2. This cross-sectional survey of adults (n = 501) from three cities in the United States (Miami, FL, New York City, NY, San Francisco, CA) assessed the role of satisfaction with health and healthcare access and consumption of COVID-19 news, previously un-studied variables related to vaccine hesitancy. Multilevel logistic regression tested the relationship between vaccine hesitancy and study variables. Thirteen percent indicated they would not get vaccinated. Black race (OR 2.6; 95% CI: 1.38-5.3), income (OR = 0.64; 95% CI: 0.50-0.83), inattention to COVID-19 news (OR = 1.6; 95% CI: 1.1-2.5), satisfaction with health (OR 0.72; 95% CI: 0.52-0.99), and healthcare access (OR = 1.7; 95% CI: 1.2-2.7) were associated with vaccine hesitancy. Public health officials should consider these variables when designing public health communication about the vaccine to ensure better uptake. CI - Copyright (c) 2021 Bass, Wilson-Genderson, Garcia, Akinkugbe and Mosavel. FAU - Bass, Sarah Bauerle AU - Bass SB AD - Department of Social and Behavioral Sciences, Temple University College of Public Health, Philadelphia, PA, United States. FAU - Wilson-Genderson, Maureen AU - Wilson-Genderson M AD - Siminoff Research Group, Temple University College of Public Health, Philadelphia, PA, United States. FAU - Garcia, Dina T AU - Garcia DT AD - Department of Health Behavior and Policy, Virginia Commonwealth University, Richmond, VA, United States. FAU - Akinkugbe, Aderonke A AU - Akinkugbe AA AD - Department of Dental Public Health and Policy, Virginia Commonwealth University, Richmond, VA, United States. FAU - Mosavel, Maghboeba AU - Mosavel M AD - Department of Health Behavior and Policy, Virginia Commonwealth University, Richmond, VA, United States. LA - eng PT - Journal Article DEP - 20210429 PL - Switzerland TA - Front Public Health JT - Frontiers in public health JID - 101616579 RN - 0 (COVID-19 Vaccines) RN - 0 (Vaccines) SB - IM MH - Adult MH - *COVID-19 MH - COVID-19 Vaccines MH - Cross-Sectional Studies MH - Delivery of Health Care MH - Humans MH - New York City MH - Personal Satisfaction MH - SARS-CoV-2 MH - San Francisco MH - United States/epidemiology MH - *Vaccines PMC - PMC8116504 OTO - NOTNLM OT - COVID-19 OT - SARS-CoV-2 OT - satisfaction with health OT - satisfaction with healthcare access OT - vaccine hesitancy COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2021/05/18 06:00 MHDA- 2021/05/20 06:00 PMCR- 2021/04/29 CRDT- 2021/05/17 06:16 PHST- 2021/02/08 00:00 [received] PHST- 2021/04/06 00:00 [accepted] PHST- 2021/05/17 06:16 [entrez] PHST- 2021/05/18 06:00 [pubmed] PHST- 2021/05/20 06:00 [medline] PHST- 2021/04/29 00:00 [pmc-release] AID - 10.3389/fpubh.2021.665724 [doi] PST - epublish SO - Front Public Health. 2021 Apr 29;9:665724. doi: 10.3389/fpubh.2021.665724. eCollection 2021. PMID- 33978550 OWN - NLM STAT- MEDLINE DCOM- 20220714 LR - 20240402 IS - 1563-5244 (Electronic) IS - 0883-0185 (Print) IS - 0883-0185 (Linking) VI - 41 IP - 4 DP - 2022 TI - Tapping the immunological imprints to design chimeric SARS-CoV-2 vaccine for elderly population. PG - 448-463 LID - 10.1080/08830185.2021.1925267 [doi] AB - The impact of SARS-CoV-2 and COVID-19 disease susceptibility varies depending on the age and health status of an individual. Currently, there are more than 140 COVID-19 vaccines under development. However, the challenge will be to induce an effective immune response in the elderly population. Analysis of B cell epitopes indicates the minor role of the stalk domain of spike protein in viral neutralization due to low surface accessibility. Nevertheless, the accumulation of mutations in the receptor-binding domain (RBD) might reduce the vaccine efficacy in all age groups. We also propose the concept of chimeric vaccines based on the co-expression of SARS-CoV-2 spike and influenza hemagglutinin (HA) and matrix protein 1 (M1) proteins to generate chimeric virus-like particles (VLP). This review discusses the possible approaches by which influenza-specific memory repertoire developed during the lifetime of the elderly populations can converge to mount an effective immune response against the SARS-CoV-2 spike protein with the possibilities of designing single vaccines for COVID-19 and influenza. HighlightsImmunosenescence aggravates COVID-19 symptoms in elderly individuals.Low immunogenicity of SARS-CoV-2 vaccines in elderly population.Tapping the memory T and B cell repertoire in elderly can enhance vaccine efficiency.Chimeric vaccines can mount effective immune response against COVID-19 in elderly.Chimeric vaccines co-express SARS-CoV-2 spike and influenza HA and M1 proteins. FAU - Biswas, Asim AU - Biswas A AD - Department of Ophthalmology, New York University Grossman School of Medicine, New York, NY, USA. FAU - Mandal, Rahul Shubhra AU - Mandal RS AD - Department of Cancer Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. FAU - Chakraborty, Suparna AU - Chakraborty S AD - Division of Clinical Medicine, National Institute of Cholera and Enteric Diseases, Kolkata, India. FAU - Maiti, George AU - Maiti G AUID- ORCID: 0000-0002-6701-5499 LA - eng PT - Journal Article PT - Review DEP - 20210512 PL - England TA - Int Rev Immunol JT - International reviews of immunology JID - 8712260 RN - 0 (COVID-19 Vaccines) RN - 0 (Spike Glycoprotein, Coronavirus) RN - 0 (Viral Vaccines) RN - 0 (spike protein, SARS-CoV-2) SB - IM MH - Aged MH - *COVID-19/prevention & control MH - COVID-19 Vaccines/genetics MH - Humans MH - *Influenza, Human/prevention & control MH - SARS-CoV-2/genetics MH - Spike Glycoprotein, Coronavirus MH - *Viral Vaccines/chemistry/genetics PMC - PMC8127164 OTO - NOTNLM OT - COVID-19 OT - Immunosenescence OT - Influenza OT - SARS-CoV-2 OT - hemagglutinin OT - memory cells OT - vaccine OT - virus-like particle COIS- The authors declare no financial interest to disclose. EDAT- 2021/05/13 06:00 MHDA- 2022/07/15 06:00 PMCR- 2021/05/17 CRDT- 2021/05/12 12:18 PHST- 2021/05/13 06:00 [pubmed] PHST- 2022/07/15 06:00 [medline] PHST- 2021/05/12 12:18 [entrez] PHST- 2021/05/17 00:00 [pmc-release] AID - 1925267 [pii] AID - 10.1080/08830185.2021.1925267 [doi] PST - ppublish SO - Int Rev Immunol. 2022;41(4):448-463. doi: 10.1080/08830185.2021.1925267. Epub 2021 May 12. PMID- 33939647 OWN - NLM STAT- MEDLINE DCOM- 20210628 LR - 20260127 IS - 1558-8238 (Electronic) IS - 0021-9738 (Print) IS - 0021-9738 (Linking) VI - 131 IP - 12 DP - 2021 Jun 15 TI - First-dose mRNA vaccination is sufficient to reactivate immunological memory to SARS-CoV-2 in subjects who have recovered from COVID-19. LID - 149150 [pii] LID - 10.1172/JCI149150 [doi] LID - e149150 AB - The characterization of the adaptive immune response to COVID-19 vaccination in individuals who recovered from SARS-CoV-2 infection may define current and future clinical practice. To determine the effect of the 2-dose BNT162b2 mRNA COVID-19 vaccination schedule in individuals who recovered from COVID-19 (COVID-19-recovered subjects) compared with naive subjects, we evaluated SARS-CoV-2 Spike-specific T and B cell responses, as well as specific IgA, IgG, IgM, and neutralizing antibodies titers in 22 individuals who received the BNT162b2 mRNA COVID-19 vaccine, 11 of whom had a previous history of SARS-CoV-2 infection. Evaluations were performed before vaccination and then weekly until 7 days after second injection. Data obtained clearly showed that one vaccine dose is sufficient to increase both cellular and humoral immune response in COVID-19-recovered subjects without any additional improvement after the second dose. On the contrary, the second dose proved mandatory in naive subjects to further enhance the immune response. These findings were further confirmed at the serological level in a larger cohort of naive (n = 68) and COVID-19-recovered (n = 29) subjects, tested up to 50 days after vaccination. These results question whether a second vaccine injection in COVID-19-recovered subjects is required, and indicate that millions of vaccine doses may be redirected to naive individuals, thus shortening the time to reach herd immunity. FAU - Mazzoni, Alessio AU - Mazzoni A AD - Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy. FAU - Di Lauria, Nicoletta AU - Di Lauria N AD - Infectious and Tropical Diseases Unit. FAU - Maggi, Laura AU - Maggi L AD - Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy. FAU - Salvati, Lorenzo AU - Salvati L AD - Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy. FAU - Vanni, Anna AU - Vanni A AD - Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy. FAU - Capone, Manuela AU - Capone M AD - Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy. FAU - Lamacchia, Giulia AU - Lamacchia G AD - Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy. FAU - Mantengoli, Elisabetta AU - Mantengoli E AD - Infectious and Tropical Diseases Unit. FAU - Spinicci, Michele AU - Spinicci M AD - Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy. AD - Infectious and Tropical Diseases Unit. FAU - Zammarchi, Lorenzo AU - Zammarchi L AD - Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy. AD - Infectious and Tropical Diseases Unit. FAU - Kiros, Seble Tekle AU - Kiros ST AD - Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy. AD - Infectious and Tropical Diseases Unit. FAU - Rocca, Arianna AU - Rocca A AD - Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy. FAU - Lagi, Filippo AU - Lagi F AD - Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy. FAU - Colao, Maria Grazia AU - Colao MG AD - Microbiology and Virology Unit. FAU - Parronchi, Paola AU - Parronchi P AD - Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy. AD - Immunology and Cell Therapy Unit. FAU - Scaletti, Cristina AU - Scaletti C AD - Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy. FAU - Turco, Lucia AU - Turco L AD - Health Director, and. FAU - Liotta, Francesco AU - Liotta F AD - Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy. AD - Immunology and Cell Therapy Unit. FAU - Rossolini, Gian Maria AU - Rossolini GM AD - Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy. AD - Microbiology and Virology Unit. FAU - Cosmi, Lorenzo AU - Cosmi L AD - Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy. AD - Immunology and Cell Therapy Unit. FAU - Bartoloni, Alessandro AU - Bartoloni A AD - Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy. AD - Infectious and Tropical Diseases Unit. FAU - Annunziato, Francesco AU - Annunziato F AD - Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy. AD - Flow Cytometry Diagnostic Center and Immunotherapy, Careggi University Hospital, Florence, Italy. CN - COVID-19 Research Group LA - eng PT - Evaluation Study PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - J Clin Invest JT - The Journal of clinical investigation JID - 7802877 RN - 0 (Antibodies, Neutralizing) RN - 0 (Antibodies, Viral) RN - 0 (BNT162 Vaccine) RN - 0 (COVID-19 Vaccines) SB - IM CIN - Mounting evidence for immunizing previously infected subjects with a single dose of SARS-CoV-2 vaccine MH - Adult MH - Aged MH - *Antibodies, Neutralizing/blood/immunology MH - *Antibodies, Viral/blood/immunology MH - BNT162 Vaccine MH - *COVID-19/blood/immunology/prevention & control MH - *COVID-19 Vaccines/administration & dosage/immunology MH - Female MH - Humans MH - Immunity, Humoral/*drug effects MH - Immunologic Memory/*drug effects MH - Male MH - Middle Aged MH - *SARS-CoV-2/immunology/metabolism PMC - PMC8203460 OTO - NOTNLM OT - Adaptive immunity OT - COVID-19 OT - Immunoglobulins OT - Immunology OT - T cells COIS- Conflict of interest: The authors have declared that no conflict of interest exists. EDAT- 2021/05/04 06:00 MHDA- 2021/06/29 06:00 PMCR- 2021/09/15 CRDT- 2021/05/03 17:30 PHST- 2021/03/01 00:00 [received] PHST- 2021/04/26 00:00 [accepted] PHST- 2021/05/04 06:00 [pubmed] PHST- 2021/06/29 06:00 [medline] PHST- 2021/05/03 17:30 [entrez] PHST- 2021/09/15 00:00 [pmc-release] AID - 149150 [pii] AID - 10.1172/JCI149150 [doi] PST - ppublish SO - J Clin Invest. 2021 Jun 15;131(12):e149150. doi: 10.1172/JCI149150. PMID- 33903205 OWN - NLM STAT- MEDLINE DCOM- 20220526 LR - 20220602 IS - 2515-4478 (Electronic) IS - 2515-446X (Linking) VI - 27 IP - 3 DP - 2022 Jun TI - Can shared decision making address COVID-19 vaccine hesitancy? PG - 159-161 LID - 10.1136/bmjebm-2021-111695 [doi] FAU - Durand, Marie-Anne AU - Durand MA AUID- ORCID: 0000-0002-8173-1993 AD - Centre d'Epidemiologie et de Recherche en sante des Populations, UMR 1295, Universite Toulouse III Paul Sabatier, Toulouse, France marie-anne.durand@dartmouth.edu. AD - Unisante, Centre universitaire de medecine generale et sante publique, Lausanne, Switzerland. AD - The Dartmouth Institute for Health Policy & Clinical Practice, Dartmouth College, Lebanon, NH, USA. FAU - Scalia, Peter AU - Scalia P AD - Coproduction Laboratory, The Dartmouth Institute for Health Policy & Clinical Practice, Lebanon, New Hampshire, USA. FAU - Elwyn, Glyn AU - Elwyn G AD - Coproduction Laboratory, The Dartmouth Institute for Health Policy & Clinical Practice, Lebanon, New Hampshire, USA. LA - eng PT - Journal Article DEP - 20210426 PL - England TA - BMJ Evid Based Med JT - BMJ evidence-based medicine JID - 101719009 RN - 0 (COVID-19 Vaccines) SB - IM MH - *COVID-19/prevention & control MH - *COVID-19 Vaccines/therapeutic use MH - Decision Making, Shared MH - Humans MH - SARS-CoV-2 MH - Vaccination Hesitancy COIS- Competing interests: GE and M-AD have developed the Option Grid patient decision aids, which are licensed to EBSCO Health. They receive consulting income from EBSCO Health and royalties. No other competing interests to declare. EDAT- 2021/04/28 06:00 MHDA- 2022/05/27 06:00 CRDT- 2021/04/27 06:19 PHST- 2021/04/16 00:00 [accepted] PHST- 2021/04/28 06:00 [pubmed] PHST- 2022/05/27 06:00 [medline] PHST- 2021/04/27 06:19 [entrez] AID - bmjebm-2021-111695 [pii] AID - 10.1136/bmjebm-2021-111695 [doi] PST - ppublish SO - BMJ Evid Based Med. 2022 Jun;27(3):159-161. doi: 10.1136/bmjebm-2021-111695. Epub 2021 Apr 26. PMID- 33858945 OWN - NLM STAT- MEDLINE DCOM- 20210426 LR - 20260127 IS - 2470-9468 (Electronic) IS - 2470-9468 (Linking) VI - 6 IP - 58 DP - 2021 Apr 15 TI - Distinct antibody and memory B cell responses in SARS-CoV-2 naive and recovered individuals following mRNA vaccination. LID - 10.1126/sciimmunol.abi6950 [doi] LID - eabi6950 AB - Novel mRNA vaccines for SARS-CoV-2 have been authorized for emergency use. Despite their efficacy in clinical trials, data on mRNA vaccine-induced immune responses are mostly limited to serological analyses. Here, we interrogated antibody and antigen-specific memory B cells over time in 33 SARS-CoV-2 naive and 11 SARS-CoV-2 recovered subjects. SARS-CoV-2 naive individuals required both vaccine doses for optimal increases in antibodies, particularly for neutralizing titers against the B.1.351 variant. Memory B cells specific for full-length spike protein and the spike receptor binding domain (RBD) were also efficiently primed by mRNA vaccination and detectable in all SARS-CoV-2 naive subjects after the second vaccine dose, though the memory B cell response declined slightly with age. In SARS-CoV-2 recovered individuals, antibody and memory B cell responses were significantly boosted after the first vaccine dose; however, there was no increase in circulating antibodies, neutralizing titers, or antigen-specific memory B cells after the second dose. This robust boosting after the first vaccine dose strongly correlated with levels of pre-existing memory B cells in recovered individuals, identifying a key role for memory B cells in mounting recall responses to SARS-CoV-2 antigens. Together, our data demonstrated robust serological and cellular priming by mRNA vaccines and revealed distinct responses based on prior SARS-CoV-2 exposure, whereby COVID-19 recovered subjects may only require a single vaccine dose to achieve peak antibody and memory B cell responses. These findings also highlight the utility of defining cellular responses in addition to serologies and may inform SARS-CoV-2 vaccine distribution in a resource-limited setting. CI - Copyright (c) 2021, American Association for the Advancement of Science. FAU - Goel, Rishi R AU - Goel RR AUID- ORCID: 0000-0003-1715-5191 AD - Institute for Immunology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. AD - Immune Health, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. FAU - Apostolidis, Sokratis A AU - Apostolidis SA AUID- ORCID: 0000-0002-0224-0097 AD - Institute for Immunology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. AD - Immune Health, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. AD - Division of Rheumatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. FAU - Painter, Mark M AU - Painter MM AUID- ORCID: 0000-0002-0180-2748 AD - Institute for Immunology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. AD - Immune Health, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. FAU - Mathew, Divij AU - Mathew D AUID- ORCID: 0000-0002-8323-7358 AD - Institute for Immunology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. AD - Immune Health, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. FAU - Pattekar, Ajinkya AU - Pattekar A AUID- ORCID: 0000-0002-1416-1230 AD - Immune Health, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. FAU - Kuthuru, Oliva AU - Kuthuru O AUID- ORCID: 0000-0002-9435-9764 AD - Institute for Immunology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. FAU - Gouma, Sigrid AU - Gouma S AUID- ORCID: 0000-0002-7853-8340 AD - Department of Microbiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. FAU - Hicks, Philip AU - Hicks P AUID- ORCID: 0000-0002-1574-5692 AD - Department of Microbiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. FAU - Meng, Wenzhao AU - Meng W AUID- ORCID: 0000-0002-8040-7825 AD - Institute for Immunology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. AD - Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. FAU - Rosenfeld, Aaron M AU - Rosenfeld AM AUID- ORCID: 0000-0002-2266-0355 AD - Institute for Immunology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. AD - Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. FAU - Dysinger, Sarah AU - Dysinger S AUID- ORCID: 0000-0003-0687-0018 AD - Department of Microbiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. FAU - Lundgreen, Kendall A AU - Lundgreen KA AUID- ORCID: 0000-0003-2431-7152 AD - Department of Microbiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. FAU - Kuri-Cervantes, Leticia AU - Kuri-Cervantes L AUID- ORCID: 0000-0002-2432-9500 AD - Institute for Immunology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. AD - Department of Microbiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. FAU - Adamski, Sharon AU - Adamski S AUID- ORCID: 0000-0001-5933-5292 AD - Immune Health, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. FAU - Hicks, Amanda AU - Hicks A AUID- ORCID: 0000-0002-3496-1745 AD - Immune Health, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. FAU - Korte, Scott AU - Korte S AUID- ORCID: 0000-0003-0214-3374 AD - Immune Health, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. FAU - Oldridge, Derek A AU - Oldridge DA AUID- ORCID: 0000-0003-2177-5633 AD - Institute for Immunology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. AD - Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. FAU - Baxter, Amy E AU - Baxter AE AUID- ORCID: 0000-0002-1555-0713 AD - Institute for Immunology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. FAU - Giles, Josephine R AU - Giles JR AUID- ORCID: 0000-0002-3713-338X AD - Institute for Immunology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. AD - Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. AD - Parker Institute for Cancer Immunotherapy, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. FAU - Weirick, Madison E AU - Weirick ME AUID- ORCID: 0000-0003-2112-8102 AD - Department of Microbiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. FAU - McAllister, Christopher M AU - McAllister CM AUID- ORCID: 0000-0002-0011-4089 AD - Department of Microbiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. FAU - Dougherty, Jeanette AU - Dougherty J AUID- ORCID: 0000-0001-9400-6240 AD - Institute for Immunology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. FAU - Long, Sherea AU - Long S AUID- ORCID: 0000-0002-8508-8333 AD - Institute for Immunology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. FAU - D'Andrea, Kurt AU - D'Andrea K AUID- ORCID: 0000-0001-7005-3800 AD - Institute for Immunology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. FAU - Hamilton, Jacob T AU - Hamilton JT AUID- ORCID: 0000-0003-1277-6925 AD - Immune Health, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. AD - Department of Microbiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. FAU - Betts, Michael R AU - Betts MR AUID- ORCID: 0000-0002-7690-1484 AD - Institute for Immunology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. AD - Department of Microbiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. FAU - Luning Prak, Eline T AU - Luning Prak ET AUID- ORCID: 0000-0002-9478-9211 AD - Institute for Immunology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. AD - Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. FAU - Bates, Paul AU - Bates P AUID- ORCID: 0000-0002-3918-5976 AD - Department of Microbiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. FAU - Hensley, Scott E AU - Hensley SE AUID- ORCID: 0000-0002-2928-7506 AD - Department of Microbiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. FAU - Greenplate, Allison R AU - Greenplate AR AUID- ORCID: 0000-0002-2614-3072 AD - Institute for Immunology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. AD - Immune Health, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. FAU - Wherry, E John AU - Wherry EJ AUID- ORCID: 0000-0003-0477-1956 AD - Institute for Immunology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. wherry@pennmedicine.upenn.edu. AD - Immune Health, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. AD - Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. AD - Parker Institute for Cancer Immunotherapy, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. LA - eng GR - R01 AI152236/AI/NIAID NIH HHS/United States GR - AI082630/NH/NIH HHS/United States GR - AI149680/NH/NIH HHS/United States GR - T32 CA009140/CA/NCI NIH HHS/United States GR - AI152236/NH/NIH HHS/United States GR - U19 AI082630/AI/NIAID NIH HHS/United States GR - R38 HL143613/HL/NHLBI NIH HHS/United States GR - P01 AI108545/AI/NIAID NIH HHS/United States GR - R01 AI105343/AI/NIAID NIH HHS/United States GR - T32 AR076951-01/NH/NIH HHS/United States GR - T32 AI055400/AI/NIAID NIH HHS/United States GR - AI105343/NH/NIH HHS/United States GR - AI108545/NH/NIH HHS/United States GR - HL143613/NH/NIH HHS/United States GR - T32 AR076951/AR/NIAMS NIH HHS/United States GR - T32 AI070077/AI/NIAID NIH HHS/United States GR - AI155577/NH/NIH HHS/United States GR - R01 AI155577/AI/NIAID NIH HHS/United States GR - U19 AI149680/AI/NIAID NIH HHS/United States GR - P30 AI0450080/NH/NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't PL - United States TA - Sci Immunol JT - Science immunology JID - 101688624 RN - 0 (Antibodies, Neutralizing) RN - 0 (Antibodies, Viral) RN - 0 (COVID-19 Vaccines) RN - 0 (RNA, Messenger) RN - 0 (Spike Glycoprotein, Coronavirus) RN - 0 (Vaccines, Synthetic) RN - 0 (mRNA Vaccines) SB - IM UOF - medRxiv. 2021 Mar 06:2021.03.03.21252872. doi: 10.1101/2021.03.03.21252872. PMID: 33688691 MH - Adult MH - Antibodies, Neutralizing/immunology MH - Antibodies, Viral/blood/*immunology MH - B-Lymphocytes/*immunology MH - COVID-19/*immunology MH - *COVID-19 Vaccines MH - Female MH - Humans MH - Male MH - Middle Aged MH - RNA, Messenger MH - SARS-CoV-2/*immunology MH - Spike Glycoprotein, Coronavirus/immunology MH - Vaccination MH - *Vaccines, Synthetic MH - Young Adult MH - mRNA Vaccines PMC - PMC8158969 EDAT- 2021/04/17 06:00 MHDA- 2021/04/27 06:00 PMCR- 2021/05/27 CRDT- 2021/04/16 05:54 PHST- 2021/03/26 00:00 [received] PHST- 2021/04/12 00:00 [accepted] PHST- 2021/04/16 05:54 [entrez] PHST- 2021/04/17 06:00 [pubmed] PHST- 2021/04/27 06:00 [medline] PHST- 2021/05/27 00:00 [pmc-release] AID - 6/58/eabi6950 [pii] AID - abi6950 [pii] AID - 10.1126/sciimmunol.abi6950 [doi] PST - ppublish SO - Sci Immunol. 2021 Apr 15;6(58):eabi6950. doi: 10.1126/sciimmunol.abi6950. PMID- 33839780 OWN - NLM STAT- MEDLINE DCOM- 20210610 LR - 20210610 IS - 1526-4637 (Electronic) IS - 1526-2375 (Print) IS - 1526-2375 (Linking) VI - 22 IP - 6 DP - 2021 Jun 4 TI - Do Corticosteroid Injections for the Treatment of Pain Influence the Efficacy of Adenovirus Vector-Based COVID-19 Vaccines? PG - 1441-1464 LID - 10.1093/pm/pnab130 [doi] LID - pnab130 AB - MYTH: Corticosteroid injection for the treatment of pain is known to decrease the efficacy of the adenovirus vector-based vaccines for COVID-19. FACT: There is currently no direct evidence to suggest that a corticosteroid injection before or after the administration of an adenovirus vector-based COVID-19 vaccine decreases the efficacy of the vaccine. However, based on the known timeline of hypothalamic-pituitary-adrenal axis suppression following epidural and intraarticular corticosteroid injections, and the timeline of the reported peak efficacy of the Janssen and AstraZeneca vaccines, physicians should consider timing an elective corticosteroid injection such that it is administered no less than 2 weeks prior to and no less than 2 weeks following a COVID-19 adenovirus vector-based vaccine dose, whenever possible. We emphasize the importance of risk/benefit analysis and shared decision making in determining the timing of corticosteroid injections for pain indications in relation to receipt of a COVID-19 vaccine given that patient-specific factors will vary. CI - (c) The Author(s) 2021. Published by Oxford University Press on behalf of the American Academy of Pain Medicine.All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. FAU - Lee, Haewon AU - Lee H AD - Department of Orthopedic Surgery, University of California, San Diego, San Diego, California, USA. FAU - Punt, Jennifer A AU - Punt JA AD - University of Pennsylvania School of Veterinary Medicine, Philadelphia, Pennsylvania, USA. FAU - Patel, Jaymin AU - Patel J AD - Department of Orthopaedics, Emory University, Atlanta, Georgia. FAU - Stojanovic, Milan P AU - Stojanovic MP AD - Anesthesiology, Critical Care and Pain Medicine Service, VA Boston Healthcare System, Harvard Medical School, Boston, Massachusetts, USA. FAU - Duszynski, Belinda AU - Duszynski B AUID- ORCID: 0000-0002-6433-1816 AD - Spine Intervention Society, Hinsdale, Illinois, USA. FAU - McCormick, Zachary L AU - McCormick ZL AUID- ORCID: 0000-0003-4250-8745 AD - Division of Physical Medicine and Rehabilitation, University of Utah, Salt Lake City, Utah, USA. CN - Spine Intervention Society's Patient Safety Committee LA - eng PT - Journal Article PL - England TA - Pain Med JT - Pain medicine (Malden, Mass.) JID - 100894201 RN - 0 (Adrenal Cortex Hormones) RN - 0 (COVID-19 Vaccines) SB - IM MH - Adenoviridae/genetics MH - Adrenal Cortex Hormones MH - *COVID-19 MH - *COVID-19 Vaccines MH - Humans MH - Hypothalamo-Hypophyseal System MH - Pain/drug therapy MH - Pituitary-Adrenal System MH - SARS-CoV-2 PMC - PMC8083288 EDAT- 2021/04/12 06:00 MHDA- 2021/06/11 06:00 PMCR- 2021/04/29 CRDT- 2021/04/11 20:51 PHST- 2021/03/31 00:00 [received] PHST- 2021/04/03 00:00 [revised] PHST- 2021/04/08 00:00 [accepted] PHST- 2021/04/12 06:00 [pubmed] PHST- 2021/06/11 06:00 [medline] PHST- 2021/04/11 20:51 [entrez] PHST- 2021/04/29 00:00 [pmc-release] AID - 6220338 [pii] AID - pnab130 [pii] AID - 10.1093/pm/pnab130 [doi] PST - ppublish SO - Pain Med. 2021 Jun 4;22(6):1441-1464. doi: 10.1093/pm/pnab130. PMID- 33835153 OWN - NLM STAT- MEDLINE DCOM- 20210715 LR - 20210715 IS - 2168-6157 (Electronic) IS - 2168-6149 (Linking) VI - 78 IP - 7 DP - 2021 Jul 1 TI - Helping the Public Understand Adverse Events Associated With COVID-19 Vaccinations: Lessons Learned From Functional Neurological Disorder. PG - 789-790 LID - 10.1001/jamaneurol.2021.1042 [doi] FAU - Kim, David Dongkyung AU - Kim DD AD - Division of Cognitive Behavioral Neurology, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. AD - Division of Neuropsychiatry, Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. FAU - Kung, Candice S AU - Kung CS AD - Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada. FAU - Perez, David L AU - Perez DL AD - Division of Cognitive Behavioral Neurology, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. AD - Division of Neuropsychiatry, Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. LA - eng PT - Journal Article PL - United States TA - JAMA Neurol JT - JAMA neurology JID - 101589536 RN - 0 (COVID-19 Vaccines) SB - IM MH - COVID-19/prevention & control MH - COVID-19 Vaccines/*adverse effects MH - Centers for Disease Control and Prevention, U.S. MH - *Health Education MH - Humans MH - Nervous System Diseases/*etiology MH - Public Health MH - United States MH - Vaccination/*adverse effects EDAT- 2021/04/10 06:00 MHDA- 2021/07/16 06:00 CRDT- 2021/04/09 12:44 PHST- 2021/04/10 06:00 [pubmed] PHST- 2021/07/16 06:00 [medline] PHST- 2021/04/09 12:44 [entrez] AID - 2778192 [pii] AID - 10.1001/jamaneurol.2021.1042 [doi] PST - ppublish SO - JAMA Neurol. 2021 Jul 1;78(7):789-790. doi: 10.1001/jamaneurol.2021.1042. PMID- 33788271 OWN - NLM STAT- MEDLINE DCOM- 20210614 LR - 20210703 IS - 1521-4141 (Electronic) IS - 0014-2980 (Print) IS - 0014-2980 (Linking) VI - 51 IP - 6 DP - 2021 Jun TI - Antigen-dependent multistep differentiation of T follicular helper cells and its role in SARS-CoV-2 infection and vaccination. PG - 1325-1333 LID - 10.1002/eji.202049148 [doi] AB - T follicular helper (Tfh) cells play an essential role in regulating the GC reaction and, consequently, the generation of high-affinity antibodies and memory B cells. Therefore, Tfh cells are critical for potent humoral immune responses against various pathogens and their dysregulation has been linked to autoimmunity and cancer. Tfh cell differentiation is a multistep process, in which cognate interactions with different APC types, costimulatory and coinhibitory pathways, as well as cytokines are involved. However, it is still not fully understood how a subset of activated CD4(+) T cells begins to express the Tfh cell-defining chemokine receptor CXCR5 during the early stage of the immune response, how some CXCR5(+) pre-Tfh cells enter the B-cell follicles and mature further into GC Tfh cells, and how Tfh cells are maintained in the memory compartment. In this review, we discuss recent advances on how antigen and cognate interactions are important for Tfh cell differentiation and long-term persistence of Tfh cell memory, and how this is relevant to the current understanding of COVID-19 pathogenesis and the development of potent SARS-CoV-2 vaccines. CI - (c) 2021 The Authors. European Journal of Immunology published by Wiley-VCH GmbH. FAU - Baumjohann, Dirk AU - Baumjohann D AD - Medical Clinic III for Oncology, Hematology, Immuno-Oncology and Rheumatology, University Hospital Bonn, University of Bonn, Bonn, Germany. FAU - Fazilleau, Nicolas AU - Fazilleau N AD - Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), University of Toulouse, Inserm, Toulouse, U1291, France. AD - French Germinal Center Club, French Society for Immunology (SFI), Paris, France. LA - eng GR - 5132/1-2 (252623821)/Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)/ GR - #1901175/the Inspire Program from the Region Occitanie/Pyrenees-Mediterranee/ GR - MP0022856/European Regional Development Fund/ GR - ANR-16-CE15-0019-02/Agence Nationale de la Recherche/ GR - ANR-16-CE15-0002-02/Agence Nationale de la Recherche/ GR - EXC2151 (390873048)/Germany's Excellence Strategy/ GR - 01KI20343/Federal Ministry of Education and Research (BMBF)/ GR - INCA-12642/Institut National du Cancer/ GR - BA 5132/1-2/Deutsche Forschungsgemeinschaft/ GR - 252623821/Deutsche Forschungsgemeinschaft/ GR - 390873048/Germany's Excellence Strategy EXC2151/ GR - 1901175/The Inspire Program from the Region Occitanie/Pyrenees-Mediterranee/ GR - MP0022856/the European Regional Development Fund/ GR - COVIMMUNE (01KI20343)/Bundesministerium fur Bildung und Forschung/ PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20210409 PL - Germany TA - Eur J Immunol JT - European journal of immunology JID - 1273201 RN - 0 (Antigens, Viral) RN - 0 (COVID-19 Vaccines) SB - IM MH - Animals MH - Antigens, Viral/*immunology MH - COVID-19/*immunology/pathology/prevention & control MH - COVID-19 Vaccines/*immunology/therapeutic use MH - Cell Differentiation/*immunology MH - Humans MH - *Immunologic Memory MH - SARS-CoV-2/*immunology MH - T-Lymphocytes, Helper-Inducer/*immunology/pathology PMC - PMC8250352 OTO - NOTNLM OT - Antibody formation OT - T cells OT - antigen OT - differentiation OT - memory COIS- The authors declare no commercial or financial conflict of interest. EDAT- 2021/04/01 06:00 MHDA- 2021/06/16 06:00 PMCR- 2021/07/02 CRDT- 2021/03/31 13:33 PHST- 2021/02/05 00:00 [revised] PHST- 2020/12/31 00:00 [received] PHST- 2021/03/16 00:00 [accepted] PHST- 2021/04/01 06:00 [pubmed] PHST- 2021/06/16 06:00 [medline] PHST- 2021/03/31 13:33 [entrez] PHST- 2021/07/02 00:00 [pmc-release] AID - EJI5030 [pii] AID - 10.1002/eji.202049148 [doi] PST - ppublish SO - Eur J Immunol. 2021 Jun;51(6):1325-1333. doi: 10.1002/eji.202049148. Epub 2021 Apr 9. PMID- 33779985 OWN - NLM STAT- MEDLINE DCOM- 20210702 LR - 20210703 IS - 1600-0404 (Electronic) IS - 0001-6314 (Print) IS - 0001-6314 (Linking) VI - 144 IP - 1 DP - 2021 Jul TI - The potential neurological effect of the COVID-19 vaccines: A review. PG - 3-12 LID - 10.1111/ane.13417 [doi] AB - The coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a pandemic with people infected in almost all countries. The most efficient solution to end this pandemic is a safe and efficient vaccine. Classic platforms are used to develop vaccines including live-attenuated vaccine, inactivated vaccine, protein subunit vaccine, and viral vector. Nucleic acid vaccine uses next-generation platforms for their development. Vaccines are now rushing to the market. Eleven candidates are in advance development. These comprise inactivated vaccines, viral vector vaccine, nucleic acid vaccine, and the protein subunit vaccine platform, which are now quite advanced in trials in various geographic and ethnic populations. The reported severe adverse effects raised the worries about their safety. It becomes critical to know whether these vaccines will cause neurologic disorders like previously recognized vaccine-related demyelinating diseases, fever-induced seizure, and other possible deficits. We reviewed the most promising COVID-2 vaccines with a particular interest in mechanism(s) and adverse effect(s). We exemplify potential neurological problems these vaccines could cause by looking at previous studies. The current evidence indicated a minor risk of the acute neurological disorders after the application. The observation of the long-time effect is still needed. CI - (c) 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. FAU - Lu, Lu AU - Lu L AUID- ORCID: 0000-0003-3717-5237 AD - Department of Neurology, West China Hospital of Sichuan University, Chengdu, China. AD - DInstitute of Brain science and Brain-inspired technology of West China Hospital, Sichuan University, Chengdu, China. FAU - Xiong, Weixi AU - Xiong W AUID- ORCID: 0000-0001-6835-8664 AD - Department of Neurology, West China Hospital of Sichuan University, Chengdu, China. AD - DInstitute of Brain science and Brain-inspired technology of West China Hospital, Sichuan University, Chengdu, China. FAU - Mu, Jie AU - Mu J AUID- ORCID: 0000-0002-9773-3838 AD - Department of Neurology, West China Hospital of Sichuan University, Chengdu, China. AD - DInstitute of Brain science and Brain-inspired technology of West China Hospital, Sichuan University, Chengdu, China. FAU - Zhang, Qi AU - Zhang Q AUID- ORCID: 0000-0002-7238-8134 AD - Department of Neurology, West China Hospital of Sichuan University, Chengdu, China. AD - DInstitute of Brain science and Brain-inspired technology of West China Hospital, Sichuan University, Chengdu, China. FAU - Zhang, Hesheng AU - Zhang H AUID- ORCID: 0000-0003-4489-2103 AD - Department of Neurology, West China Hospital of Sichuan University, Chengdu, China. AD - DInstitute of Brain science and Brain-inspired technology of West China Hospital, Sichuan University, Chengdu, China. FAU - Zou, Ling AU - Zou L AUID- ORCID: 0000-0002-3404-0321 AD - Department of Radiology, West China Hospital of Sichuan University, The International Office, West China Hospital of Sichuan University, Chengdu, China. FAU - Li, Weimin AU - Li W AUID- ORCID: 0000-0003-0985-0311 AD - Department of Pulmonary & Critical Care Medicine, West China Hospital of Sichuan University, Chengdu, China. FAU - He, Li AU - He L AUID- ORCID: 0000-0002-2034-1027 AD - Department of Neurology, West China Hospital of Sichuan University, Chengdu, China. AD - DInstitute of Brain science and Brain-inspired technology of West China Hospital, Sichuan University, Chengdu, China. FAU - Sander, Josemir W AU - Sander JW AUID- ORCID: 0000-0001-6041-9661 AD - Department of Neurology, West China Hospital of Sichuan University, Chengdu, China. AD - DInstitute of Brain science and Brain-inspired technology of West China Hospital, Sichuan University, Chengdu, China. AD - NIHR University College London Hospitals Biomedical Research Centre, UCL Queen Square Institute of Neurology, London, United Kingdom. AD - Stichting Epilepsie Instellingen Nederland (SEIN), Heemstede, Netherlands. FAU - Zhou, Dong AU - Zhou D AUID- ORCID: 0000-0001-7101-4125 AD - Department of Neurology, West China Hospital of Sichuan University, Chengdu, China. AD - DInstitute of Brain science and Brain-inspired technology of West China Hospital, Sichuan University, Chengdu, China. LA - eng GR - 81801294/National Natural Science Foundation of China/ GR - 81871017/National Natural Science Foundation of China/ GR - 81420108014/National Natural Science Foundation of China/ GR - ZY2017305/Sichuan University/ GR - ZYGD20011/Sichuan University/ GR - UK Department of Health's Research Centres/ GR - Marvin Weil Epilepsy Research Fund/ GR - UK Epilepsy Society/ GR - Christelijke Vereniging voor de Verpleging van Lijders aan Epilepsie, Netherlands/ PT - Journal Article PT - Review DEP - 20210329 PL - Denmark TA - Acta Neurol Scand JT - Acta neurologica Scandinavica JID - 0370336 RN - 0 (COVID-19 Vaccines) SB - IM CIN - Acta Neurol Scand. 2021 Jul;144(1):109-110. doi: 10.1111/ane.13451. PMID: 34002379 MH - COVID-19/*prevention & control MH - COVID-19 Vaccines/*adverse effects MH - Humans MH - Nervous System Diseases/epidemiology/*etiology PMC - PMC8250748 OTO - NOTNLM OT - SARS-CoV-2 OT - adverse effect OT - demyelinating disease OT - safety COIS- The authors report no conflicts of interest in relation to this work. EDAT- 2021/03/30 06:00 MHDA- 2021/07/03 06:00 PMCR- 2021/07/02 CRDT- 2021/03/29 13:42 PHST- 2021/02/28 00:00 [revised] PHST- 2021/01/07 00:00 [received] PHST- 2021/03/06 00:00 [accepted] PHST- 2021/03/30 06:00 [pubmed] PHST- 2021/07/03 06:00 [medline] PHST- 2021/03/29 13:42 [entrez] PHST- 2021/07/02 00:00 [pmc-release] AID - ANE13417 [pii] AID - 10.1111/ane.13417 [doi] PST - ppublish SO - Acta Neurol Scand. 2021 Jul;144(1):3-12. doi: 10.1111/ane.13417. Epub 2021 Mar 29. PMID- 33768521 OWN - NLM STAT- MEDLINE DCOM- 20210615 LR - 20260127 IS - 1532-5415 (Electronic) IS - 0002-8614 (Print) IS - 0002-8614 (Linking) VI - 69 IP - 6 DP - 2021 Jun TI - Immunogenicity of the BNT162b2 vaccine in frail or disabled nursing home residents: COVID-A study. PG - 1441-1447 LID - 10.1111/jgs.17153 [doi] AB - BACKGROUND/OBJECTIVES: The safety and immunogenicity of the BNT162b2 coronavirus disease 2019 (COVID-19) vaccine in older adults with different frailty and disability profiles have not been well determined. Our objective was to analyze immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in older adults across frailty and disability profiles. DESIGN: Multicenter longitudinal cohort study. SETTING AND PARTICIPANTS: A total of 134 residents aged >/=65 years with different frailty and disability profiles in five long-term care facilities (LTCFs) in Albacete, Spain. INTERVENTION AND MEASUREMENTS: Residents were administered two vaccine doses as per the label, and antibody levels were determined 21.9 days (SD 9.3) after both the first and second dose. Functional variables were assessed using activities of daily living (Barthel Index), and frailty status was determined with the FRAIL instrument. Cognitive status and comorbidity were also evaluated. RESULTS: Mean age was 82.9 years (range 65-99), and 71.6% were female. The mean antibody titers in residents with and without previous COVID-19 infection were 49,878 AU/ml and 15,274 AU/ml, respectively (mean difference 34,604; 95% confidence interval [CI]: 27,699-41,509). No severe adverse reactions were observed, after either vaccine dose. Those with prevaccination COVID-19 had an increased antibody level after the vaccine (B = 31,337; 95% CI: 22,725-39,950; p < 0.001). Frailty, disability, older age, sex, cognitive impairment, or comorbidities were not associated with different antibody titers. CONCLUSIONS: The BNT162b2 mRNA COVID-19 vaccine in older adults is safe and produces immunogenicity, independently of the frailty and disability profiles. Older adults in LTCFs should receive a COVID-19 vaccine. CI - (c) 2021 The American Geriatrics Society. FAU - Salmeron Rios, Sergio AU - Salmeron Rios S AD - Residencia de Mayores San Vicente de Paul, Diputacion de Albacete, Albacete, Spain. FAU - Mas Romero, Marta AU - Mas Romero M AD - Department of Geriatrics, Complejo Hospitalario Universitario de Albacete, Albacete, Spain. FAU - Cortes Zamora, Elisa Belen AU - Cortes Zamora EB AD - Department of Geriatrics, Complejo Hospitalario Universitario de Albacete, Albacete, Spain. FAU - Tabernero Sahuquillo, Maria Teresa AU - Tabernero Sahuquillo MT AD - Department of Geriatrics, Complejo Hospitalario Universitario de Albacete, Albacete, Spain. FAU - Romero Rizos, Luis AU - Romero Rizos L AD - Department of Geriatrics, Complejo Hospitalario Universitario de Albacete, Albacete, Spain. AD - CIBERFES, Ministerio de Economia y Competitividad, Spain. AD - Facultad de Medicina, Universidad de Castilla-La Mancha, Albacete, Spain. FAU - Sanchez-Jurado, Pedro Manuel AU - Sanchez-Jurado PM AD - Department of Geriatrics, Complejo Hospitalario Universitario de Albacete, Albacete, Spain. AD - CIBERFES, Ministerio de Economia y Competitividad, Spain. AD - Facultad de Medicina, Universidad de Castilla-La Mancha, Albacete, Spain. FAU - Sanchez-Nievas, Gines AU - Sanchez-Nievas G AD - Department of Rheumatology, Complejo Hospitalario Universitario de Albacete, Albacete, Spain. FAU - Senalada, Jose Joaquin Blas AU - Senalada JJB AD - Department of Microbiology, Complejo Hospitalario Universitario de Albacete, Albacete, Spain. FAU - Garcia Nogueras, Inmaculada AU - Garcia Nogueras I AD - Residencia de Mayores San Vicente de Paul, Diputacion de Albacete, Albacete, Spain. FAU - Estrella Cazalla, Juan de Dios AU - Estrella Cazalla JD AD - Department of Geriatrics, Complejo Hospitalario Universitario de Albacete, Albacete, Spain. AD - CIBERFES, Ministerio de Economia y Competitividad, Spain. AD - Diputacion de Albacete, Vasco Nunez de Balboa Facility, Albacete, Spain. FAU - Andres-Pretel, Fernando AU - Andres-Pretel F AD - Department of Statistics, Foundation of the National Paraplegics Hospital of Toledo, Toledo, Spain. FAU - Murillo Romero, Antonio AU - Murillo Romero A AD - Long-Term Care Facilities Coordination, Complejo Hospitalario Universitario de Albacete, Albacete, Spain. FAU - Lauschke, Volker Martin AU - Lauschke VM AD - Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden. FAU - Stebbing, Justin AU - Stebbing J AD - Department of Surgery and Cancer, Imperial College, Hammersmith Hospital, ICTEM building, London, United Kingdom. FAU - Abizanda, Pedro AU - Abizanda P AUID- ORCID: 0000-0002-4707-2963 AD - Department of Geriatrics, Complejo Hospitalario Universitario de Albacete, Albacete, Spain. AD - CIBERFES, Ministerio de Economia y Competitividad, Spain. AD - Facultad de Medicina, Universidad de Castilla-La Mancha, Albacete, Spain. LA - eng GR - CB16/10/00408/Centro de Investigacion Biomedica en Red Fragilidad y Envejecimiento Saludable/ GR - COV20/00004/Instituto de Salud Carlos III/ PT - Journal Article PT - Multicenter Study PT - Research Support, Non-U.S. Gov't DEP - 20210402 PL - United States TA - J Am Geriatr Soc JT - Journal of the American Geriatrics Society JID - 7503062 RN - 0 (BNT162 Vaccine) RN - 0 (COVID-19 Vaccines) SB - IM MH - Activities of Daily Living MH - Aged MH - Aged, 80 and over MH - *Antibody Formation MH - BNT162 Vaccine MH - COVID-19/*prevention & control MH - COVID-19 Serological Testing MH - COVID-19 Vaccines/*immunology/*therapeutic use MH - Comorbidity MH - *Persons with Disabilities MH - Female MH - *Frail Elderly MH - Health Status Indicators MH - Humans MH - Longitudinal Studies MH - Male MH - Nursing Homes MH - SARS-CoV-2 MH - Spain PMC - PMC8250586 OTO - NOTNLM OT - BNT162b2 vaccine OT - COVID-19 OT - disability OT - frailty OT - immunogenicity OT - older adults COIS- All authors declare that there are no conflicts of interest, except. V.M.L. declares no conflict of interest according to the ICMJE Uniform Requirements but discloses the following financial relationship: CEO and shareholder of HepaPredict AB; co-founder and chairman of the board PersoMedix AB; consultancy work for Enginzyme AB. JS declares his conflict at https://www.nature.com/onc/editors, and none are relevant here. EDAT- 2021/03/27 06:00 MHDA- 2021/06/16 06:00 PMCR- 2021/07/02 CRDT- 2021/03/26 07:15 PHST- 2021/03/12 00:00 [revised] PHST- 2021/03/10 00:00 [received] PHST- 2021/03/12 00:00 [accepted] PHST- 2021/03/27 06:00 [pubmed] PHST- 2021/06/16 06:00 [medline] PHST- 2021/03/26 07:15 [entrez] PHST- 2021/07/02 00:00 [pmc-release] AID - JGS17153 [pii] AID - 10.1111/jgs.17153 [doi] PST - ppublish SO - J Am Geriatr Soc. 2021 Jun;69(6):1441-1447. doi: 10.1111/jgs.17153. Epub 2021 Apr 2. PMID- 33728097 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240331 IS - 1598-2629 (Print) IS - 2092-6685 (Electronic) IS - 1598-2629 (Linking) VI - 21 IP - 1 DP - 2021 Feb TI - Current Status of COVID-19 Vaccine Development: Focusing on Antigen Design and Clinical Trials on Later Stages. PG - e4 LID - 10.4110/in.2021.21.e4 [doi] LID - e4 AB - The global outbreak of coronavirus disease 2019 (COVID-19) is still threatening human health, economy, and social life worldwide. As a counteraction for this devastating disease, a number of vaccines are being developed with unprecedented speed combined with new technologies. As COVID-19 vaccines are being developed in the absence of a licensed human coronavirus vaccine, there remain further questions regarding the long-term efficacy and safety of the vaccines, as well as immunological mechanisms in depth. This review article discusses the current status of COVID-19 vaccine development, mainly focusing on antigen design, clinical trials in later stages, and immunological considerations for further study. CI - Copyright (c) 2021. The Korean Association of Immunologists. FAU - Lee, Pureum AU - Lee P AUID- ORCID: 0000-0001-9477-8531 AD - Infectious Disease Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon 34141, Korea. AD - Department of Bioscience, University of Science and Technology (UST), Daejeon 34113, Korea. FAU - Kim, Chang-Ung AU - Kim CU AUID- ORCID: 0000-0002-8245-3315 AD - Infectious Disease Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon 34141, Korea. AD - Department of Biochemistry, Chungnam National University, Daejeon 34134, Korea. FAU - Seo, Sang Hawn AU - Seo SH AUID- ORCID: 0000-0002-4518-8858 AD - International Vaccine Institute, Seoul 08826, Korea. FAU - Kim, Doo-Jin AU - Kim DJ AUID- ORCID: 0000-0003-4934-4931 AD - Infectious Disease Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon 34141, Korea. AD - Department of Bioscience, University of Science and Technology (UST), Daejeon 34113, Korea. AD - Department of Biochemistry, Chungnam National University, Daejeon 34134, Korea. LA - eng PT - Journal Article PT - Review DEP - 20210226 PL - Korea (South) TA - Immune Netw JT - Immune network JID - 101137270 PMC - PMC7937514 OTO - NOTNLM OT - Antibody-dependent enhancement OT - COVID-19 OT - Pre-existing immunological memory OT - Prefusion-stabilized OT - VAERD OT - Vaccines COIS- Conflict of Interest: The authors declare no potential conflicts of interest. EDAT- 2021/03/18 06:00 MHDA- 2021/03/18 06:01 PMCR- 2021/02/01 CRDT- 2021/03/17 06:50 PHST- 2021/01/11 00:00 [received] PHST- 2021/02/17 00:00 [revised] PHST- 2021/02/17 00:00 [accepted] PHST- 2021/03/17 06:50 [entrez] PHST- 2021/03/18 06:00 [pubmed] PHST- 2021/03/18 06:01 [medline] PHST- 2021/02/01 00:00 [pmc-release] AID - 10.4110/in.2021.21.e4 [doi] PST - epublish SO - Immune Netw. 2021 Feb 26;21(1):e4. doi: 10.4110/in.2021.21.e4. eCollection 2021 Feb. PMID- 33580169 OWN - NLM STAT- MEDLINE DCOM- 20210308 LR - 20210308 IS - 2042-0226 (Electronic) IS - 1672-7681 (Print) IS - 1672-7681 (Linking) VI - 18 IP - 3 DP - 2021 Mar TI - Ferritin nanoparticle-based SARS-CoV-2 RBD vaccine induces a persistent antibody response and long-term memory in mice. PG - 749-751 LID - 10.1038/s41423-021-00643-6 [doi] FAU - Wang, Wenjun AU - Wang W AD - Key Laboratory of Infection and Immunity, Institute of Biophysics, Chinese Academy of Sciences, Beijing, 100101, China. FAU - Huang, Baoying AU - Huang B AD - National Institute for Viral Disease Control and Prevention, China CDC, Beijing, 102206, China. FAU - Zhu, Yanping AU - Zhu Y AD - Key Laboratory of Infection and Immunity, Institute of Biophysics, Chinese Academy of Sciences, Beijing, 100101, China. FAU - Tan, Wenjie AU - Tan W AD - National Institute for Viral Disease Control and Prevention, China CDC, Beijing, 102206, China. tanwj28@163.com. FAU - Zhu, Mingzhao AU - Zhu M AUID- ORCID: 0000-0003-2001-2669 AD - Key Laboratory of Infection and Immunity, Institute of Biophysics, Chinese Academy of Sciences, Beijing, 100101, China. zhumz@ibp.ac.cn. AD - College of Life Sciences, University of the Chinese Academy of Sciences, Beijing, 100049, China. zhumz@ibp.ac.cn. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210212 PL - China TA - Cell Mol Immunol JT - Cellular & molecular immunology JID - 101242872 RN - 0 (Antibodies, Neutralizing) RN - 0 (Antibodies, Viral) RN - 0 (COVID-19 Vaccines) RN - 9007-73-2 (Ferritins) SB - IM MH - Animals MH - Antibodies, Neutralizing/*immunology MH - Antibodies, Viral/*immunology MH - B-Lymphocytes/immunology MH - COVID-19/*immunology/prevention & control MH - *COVID-19 Vaccines/chemistry/pharmacology MH - *Ferritins/chemistry/pharmacology MH - Humans MH - Immunologic Memory/drug effects MH - Mice MH - *Nanoparticles/chemistry/therapeutic use MH - SARS-CoV-2/*immunology PMC - PMC7880661 COIS- The authors declare no competing interests. EDAT- 2021/02/14 06:00 MHDA- 2021/03/09 06:00 PMCR- 2021/02/12 CRDT- 2021/02/13 05:48 PHST- 2020/12/21 00:00 [received] PHST- 2021/01/19 00:00 [accepted] PHST- 2021/02/14 06:00 [pubmed] PHST- 2021/03/09 06:00 [medline] PHST- 2021/02/13 05:48 [entrez] PHST- 2021/02/12 00:00 [pmc-release] AID - 10.1038/s41423-021-00643-6 [pii] AID - 643 [pii] AID - 10.1038/s41423-021-00643-6 [doi] PST - ppublish SO - Cell Mol Immunol. 2021 Mar;18(3):749-751. doi: 10.1038/s41423-021-00643-6. Epub 2021 Feb 12. PMID- 33573852 OWN - NLM STAT- MEDLINE DCOM- 20211022 LR - 20221221 IS - 1532-8171 (Electronic) IS - 0735-6757 (Print) IS - 0735-6757 (Linking) VI - 48 DP - 2021 Oct TI - COVID-19 vaccination hesitancy among healthcare personnel in the emergency department deserves continued attention. PG - 372-373 LID - S0735-6757(21)00100-5 [pii] LID - 10.1016/j.ajem.2021.01.089 [doi] FAU - Amin, Dhara P AU - Amin DP AD - Department of Emergency Medicine, Cook County Health, Chicago, IL, United States of America. Electronic address: damin@cookcountyhhs.org. FAU - Palter, Joseph S AU - Palter JS AD - Department of Emergency Medicine, Cook County Health, Chicago, IL, United States of America. LA - eng PT - Letter DEP - 20210202 PL - United States TA - Am J Emerg Med JT - The American journal of emergency medicine JID - 8309942 RN - 0 (COVID-19 Vaccines) SB - IM MH - Adult MH - Allied Health Personnel MH - *Attitude of Health Personnel MH - COVID-19/*prevention & control MH - COVID-19 Vaccines/*therapeutic use MH - *Emergency Service, Hospital MH - Female MH - *Health Personnel MH - Humans MH - Male MH - Middle Aged MH - Nurses MH - Patient Acceptance of Health Care MH - Physicians MH - SARS-CoV-2 MH - *Vaccination Refusal PMC - PMC8500988 OTO - NOTNLM OT - COVID-19 OT - Coronavirus OT - Health care personnel OT - Pandemic OT - Vaccination OT - Vaccine acceptance OT - Vaccine hesitancy EDAT- 2021/02/13 06:00 MHDA- 2021/12/28 06:00 PMCR- 2021/02/02 CRDT- 2021/02/12 05:43 PHST- 2021/01/28 00:00 [received] PHST- 2021/01/28 00:00 [accepted] PHST- 2021/02/13 06:00 [pubmed] PHST- 2021/12/28 06:00 [medline] PHST- 2021/02/12 05:43 [entrez] PHST- 2021/02/02 00:00 [pmc-release] AID - S0735-6757(21)00100-5 [pii] AID - 10.1016/j.ajem.2021.01.089 [doi] PST - ppublish SO - Am J Emerg Med. 2021 Oct;48:372-373. doi: 10.1016/j.ajem.2021.01.089. Epub 2021 Feb 2. PMID- 33564969 OWN - NLM STAT- MEDLINE DCOM- 20210325 LR - 20210325 IS - 1573-7403 (Electronic) IS - 1386-341X (Print) IS - 1386-341X (Linking) VI - 24 IP - 2 DP - 2021 Apr TI - Glucocorticoid use in patients with adrenal insufficiency following administration of the COVID-19 vaccine: a pituitary society statement. PG - 143-145 LID - 10.1007/s11102-021-01130-x [doi] AB - PURPOSE: Side effects of the coronavirus disease 2019 (COVID-19) vaccines include pain at the injection site, fatigue, headache, myalgias, arthralgias, chills, and fever, all of which can be early indicators of an increased need for glucocorticoid replacement in patients with adrenal insufficiency. The Pituitary Society surveyed its membership to understand planned approaches to glucocorticoid management in patients with adrenal insufficiency who will receive a COVID-19 vaccine. METHODS: Members were asked to complete up to 3 questions regarding their planned approach for use of glucocorticoid replacement in patients with proven adrenal insufficiency. RESULTS: Surveys were sent to 273 members and 103 responded. Thirty-six percent plan to recommend that patients automatically increase glucocorticoid dosage with administration of the first vaccine injection. Of these, 84% plan to increase glucocorticoid dose on the day of vaccination, and 49% plan to increase glucocorticoid dose prior to vaccination. Of the 64% who do not plan to recommend automatic glucocorticoid dose increase with vaccine administration, 88% plan to increase the dose if the patient develops a fever, and 47% plan to increase the dose if myalgias and arthralgias occur. CONCLUSIONS: Most clinicians plan to maintain the current glucocorticoid dose with vaccine administration. The vast majority plan and to increase glucocorticoid dose in case of fever, and just under half in case of arthralgias and myalgias. These survey results offer suggested management guidance for glucocorticoid management in patients with adrenal insufficiency. FAU - Katznelson, Laurence AU - Katznelson L AUID- ORCID: 0000-0001-8115-5714 AD - Departments of Medicine and Neurosurgery, Stanford University, 875 Blake Wilbur Dr., MC 5821, Stanford, CA, 94305-5821, USA. lkatznelson@stanford.edu. FAU - Gadelha, Monica AU - Gadelha M AD - Neuroendocrinology Research Center/Endocrinology Section, Medical School and Hospital Universitario Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil. LA - eng PT - Journal Article PT - Practice Guideline DEP - 20210210 PL - United States TA - Pituitary JT - Pituitary JID - 9814578 RN - 0 (COVID-19 Vaccines) RN - 0 (Glucocorticoids) RN - 7S5I7G3JQL (Dexamethasone) SB - IM MH - Adrenal Insufficiency/*drug therapy/epidemiology/pathology MH - COVID-19/epidemiology/immunology/*prevention & control MH - COVID-19 Vaccines/adverse effects/*therapeutic use MH - Dexamethasone/adverse effects/therapeutic use MH - Endocrinology/organization & administration/standards MH - Glucocorticoids/*therapeutic use MH - Humans MH - Hypothalamo-Hypophyseal System/drug effects MH - Pandemics MH - Pituitary Diseases/therapy MH - Pituitary-Adrenal System/drug effects MH - Practice Patterns, Physicians'/standards MH - SARS-CoV-2/immunology MH - Societies, Medical MH - Surveys and Questionnaires PMC - PMC7872824 OTO - NOTNLM OT - Adrenal insufficiency OT - COVID-19 OT - Glucocorticoid replacement OT - Vaccines COIS- The authors have no relevant financial or non-financial interests to disclose. EDAT- 2021/02/11 06:00 MHDA- 2021/03/26 06:00 PMCR- 2021/02/09 CRDT- 2021/02/10 05:58 PHST- 2021/01/19 00:00 [accepted] PHST- 2021/02/11 06:00 [pubmed] PHST- 2021/03/26 06:00 [medline] PHST- 2021/02/10 05:58 [entrez] PHST- 2021/02/09 00:00 [pmc-release] AID - 10.1007/s11102-021-01130-x [pii] AID - 1130 [pii] AID - 10.1007/s11102-021-01130-x [doi] PST - ppublish SO - Pituitary. 2021 Apr;24(2):143-145. doi: 10.1007/s11102-021-01130-x. Epub 2021 Feb 10. PMID- 33559128 OWN - NLM STAT- MEDLINE DCOM- 20210318 LR - 20250530 IS - 1600-065X (Electronic) IS - 0105-2896 (Print) IS - 0105-2896 (Linking) VI - 299 IP - 1 DP - 2021 Jan TI - Human antiviral B cell responses: Emerging lessons from hepatitis B and COVID-19. PG - 108-117 LID - 10.1111/imr.12953 [doi] AB - Humoral immunity is a critical component of the coordinated response required to resolve viral infections and mediate protection following pathogen clearance or vaccination. A better understanding of factors shaping the memory B cell response will allow tailored development of efficient preventative vaccines against emerging acute viral infections, therapeutic vaccines, and immunotherapies for chronic viral infections. Here, we use recent data obtained by profiling antigen-specific B cell responses in hepatitis B as a framework to explore lessons that can be learnt from different viral infections about the diverse influences on humoral immunity. Hepatitis B provides a paradigm where successful B cell responses in resolved or vaccinated individuals can be contrasted to the failed response in chronic infection, while also exemplifying the degree to which B cell responses within infected individuals can differ to two antigens from the same virus. Drawing on studies in other human and murine infections, including emerging data from COVID-19, we consider the influence of antigen quantity and structure on the quality of the B cell response, the role of differential CD4 help, the importance of germinal center vs extrafollicular responses and the emerging concept that responses residing in non-lymphoid organs can participate in B cell memory. CI - (c) 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. FAU - Burton, Alice R AU - Burton AR AUID- ORCID: 0000-0003-1049-1176 AD - Division of Infection and Immunity, UCL, London, UK. FAU - Maini, Mala K AU - Maini MK AUID- ORCID: 0000-0001-6384-1462 AD - Division of Infection and Immunity, UCL, London, UK. LA - eng GR - 101849/Z/13/A/WT_/Wellcome Trust/United Kingdom PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20210208 PL - England TA - Immunol Rev JT - Immunological reviews JID - 7702118 RN - 0 (Antibodies, Viral) RN - 0 (Antigens, Viral) RN - 0 (COVID-19 Vaccines) RN - 0 (Immunodominant Epitopes) SB - IM MH - Antibodies, Viral/*metabolism MH - Antibody Formation MH - Antigens, Viral/immunology MH - B-Lymphocytes/*immunology MH - COVID-19/*immunology MH - COVID-19 Vaccines/*immunology MH - Hepatitis B/*immunology MH - Hepatitis B virus/*physiology MH - Humans MH - Immunity, Humoral MH - Immunodominant Epitopes/immunology MH - Immunologic Memory MH - SARS-CoV-2/*physiology MH - T-Lymphocytes, Helper-Inducer/*immunology PMC - PMC8014162 OTO - NOTNLM OT - B cells OT - humoral immunity OT - memory B cell differentiation OT - viral infection COIS- MKM has received collaborative research funding from Gilead Sciences, F. Hoffmann-La Roche and Immunocore and has served as a consultant or on advisory boards for Gilead Sciences, F. Hoffmann-La Roche, Immunocore and GSK. MKM and ARB have filed IP on a method to enhance HBV-specific immune responses. EDAT- 2021/02/10 06:00 MHDA- 2021/03/19 06:00 PMCR- 2021/04/01 CRDT- 2021/02/09 06:38 PHST- 2020/12/04 00:00 [received] PHST- 2021/01/11 00:00 [accepted] PHST- 2021/02/10 06:00 [pubmed] PHST- 2021/03/19 06:00 [medline] PHST- 2021/02/09 06:38 [entrez] PHST- 2021/04/01 00:00 [pmc-release] AID - IMR12953 [pii] AID - 10.1111/imr.12953 [doi] PST - ppublish SO - Immunol Rev. 2021 Jan;299(1):108-117. doi: 10.1111/imr.12953. Epub 2021 Feb 8. PMID- 33504561 OWN - NLM STAT- MEDLINE DCOM- 20210308 LR - 20210417 IS - 1488-2329 (Electronic) IS - 0820-3946 (Print) IS - 0820-3946 (Linking) VI - 193 IP - 9 DP - 2021 Mar 1 TI - Pregnancy, breastfeeding and the SARS-CoV-2 vaccine: an ethics-based framework for shared decision-making. PG - E312-E314 LID - 10.1503/cmaj.202833 [doi] FAU - Zipursky, Jonathan S AU - Zipursky JS AD - Department of Medicine (Zipursky), University of Toronto; Division of Clinical Pharmacology and Toxicology (Zipursky), Sunnybrook Health Sciences Centre; Bioethics Department (Greenberg), Sinai Health, Department of Paediatrics, University of Toronto; Department of Obstetrics and Gynaecology (Maxwell), Sinai Health; Department of Community and Family Medicine (Bogler), St. Michael's Hospital, Toronto, Ont. Jonathan.Zipursky@sunnybrook.ca. FAU - Greenberg, Rebecca A AU - Greenberg RA AD - Department of Medicine (Zipursky), University of Toronto; Division of Clinical Pharmacology and Toxicology (Zipursky), Sunnybrook Health Sciences Centre; Bioethics Department (Greenberg), Sinai Health, Department of Paediatrics, University of Toronto; Department of Obstetrics and Gynaecology (Maxwell), Sinai Health; Department of Community and Family Medicine (Bogler), St. Michael's Hospital, Toronto, Ont. FAU - Maxwell, Cynthia AU - Maxwell C AD - Department of Medicine (Zipursky), University of Toronto; Division of Clinical Pharmacology and Toxicology (Zipursky), Sunnybrook Health Sciences Centre; Bioethics Department (Greenberg), Sinai Health, Department of Paediatrics, University of Toronto; Department of Obstetrics and Gynaecology (Maxwell), Sinai Health; Department of Community and Family Medicine (Bogler), St. Michael's Hospital, Toronto, Ont. FAU - Bogler, Tali AU - Bogler T AD - Department of Medicine (Zipursky), University of Toronto; Division of Clinical Pharmacology and Toxicology (Zipursky), Sunnybrook Health Sciences Centre; Bioethics Department (Greenberg), Sinai Health, Department of Paediatrics, University of Toronto; Department of Obstetrics and Gynaecology (Maxwell), Sinai Health; Department of Community and Family Medicine (Bogler), St. Michael's Hospital, Toronto, Ont. LA - eng PT - Journal Article DEP - 20210127 PL - Canada TA - CMAJ JT - CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne JID - 9711805 RN - 0 (COVID-19 Vaccines) SB - IM MH - *Breast Feeding MH - COVID-19/*prevention & control MH - *COVID-19 Vaccines/adverse effects MH - Canada MH - *Decision Making, Shared MH - *Ethics, Medical MH - Female MH - Humans MH - Practice Guidelines as Topic MH - Pregnancy MH - Pregnancy Complications, Infectious/*prevention & control MH - Risk Assessment MH - SARS-CoV-2 PMC - PMC8034306 COIS- Competing interests: None declared. EDAT- 2021/01/29 06:00 MHDA- 2021/03/09 06:00 PMCR- 2021/03/01 CRDT- 2021/01/28 05:33 PHST- 2021/01/29 06:00 [pubmed] PHST- 2021/03/09 06:00 [medline] PHST- 2021/01/28 05:33 [entrez] PHST- 2021/03/01 00:00 [pmc-release] AID - cmaj.202833 [pii] AID - 193e312 [pii] AID - 10.1503/cmaj.202833 [doi] PST - ppublish SO - CMAJ. 2021 Mar 1;193(9):E312-E314. doi: 10.1503/cmaj.202833. Epub 2021 Jan 27. PMID- 33422626 OWN - NLM STAT- MEDLINE DCOM- 20210426 LR - 20250401 IS - 1097-6787 (Electronic) IS - 0190-9622 (Print) IS - 0190-9622 (Linking) VI - 84 IP - 5 DP - 2021 May TI - National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2-Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments. PG - 1254-1268 LID - S0190-9622(21)00016-5 [pii] LID - 10.1016/j.jaad.2020.12.058 [doi] AB - OBJECTIVE: To update guidance regarding the management of psoriatic disease during the COVID-19 pandemic. STUDY DESIGN: The task force (TF) includes 18 physician voting members with expertise in dermatology, rheumatology, epidemiology, infectious diseases, and critical care. The TF was supplemented by nonvoting members, which included fellows and National Psoriasis Foundation staff. Clinical questions relevant to the psoriatic disease community were informed by inquiries received by the National Psoriasis Foundation. A Delphi process was conducted. RESULTS: The TF updated evidence for the original 22 statements and added 5 new recommendations. The average of the votes was within the category of agreement for all statements, 13 with high consensus and 14 with moderate consensus. LIMITATIONS: The evidence behind many guidance statements is variable in quality and/or quantity. CONCLUSIONS: These statements provide guidance for the treatment of patients with psoriatic disease on topics including how the disease and its treatments affect COVID-19 risk, how medical care can be optimized during the pandemic, what patients should do to lower their risk of getting infected with severe acute respiratory syndrome coronavirus 2 (including novel vaccination), and what they should do if they develop COVID-19. The guidance is a living document that is continuously updated by the TF as data emerge. CI - Copyright (c) 2021 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved. FAU - Gelfand, Joel M AU - Gelfand JM AD - Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania; Department of Biostatistics, Epidemiology and Informatics and Center for Clinical Epidemiology and Biostatistics Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. Electronic address: Joel.Gelfand@pennmedicine.upenn.edu. FAU - Armstrong, April W AU - Armstrong AW AD - Department of Dermatology, Keck School of Medicine, University of Southern California, Los Angeles, California. FAU - Bell, Stacie AU - Bell S AD - National Psoriasis Foundation, Portland, Oregon. FAU - Anesi, George L AU - Anesi GL AD - Department of Biostatistics, Epidemiology and Informatics and Center for Clinical Epidemiology and Biostatistics Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Division of Pulmonary, Allergy, and Critical Care, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania. FAU - Blauvelt, Andrew AU - Blauvelt A AD - Oregon Medical Research Center, Portland, Oregon. FAU - Calabrese, Cassandra AU - Calabrese C AD - Department of Rheumatology and Immunology, Cleveland Clinic, Cleveland, Ohio. FAU - Dommasch, Erica D AU - Dommasch ED AD - Department of Dermatology, Harvard Medical School, Boston, Massachusetts. FAU - Feldman, Steven R AU - Feldman SR AD - Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, North Carolina. FAU - Gladman, Dafna AU - Gladman D AD - Krembil Research Institute, Toronto Western Hospital, Toronto, Ontario, Canada; University of Toronto, Psoriatic Arthritis Program, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada. FAU - Kircik, Leon AU - Kircik L AD - Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York; Indiana University Medical Center, Indianapolis, Indiana. FAU - Lebwohl, Mark AU - Lebwohl M AD - Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York. FAU - Lo Re, Vincent 3rd AU - Lo Re V 3rd AD - Department of Biostatistics, Epidemiology and Informatics and Center for Clinical Epidemiology and Biostatistics Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Division of Infectious Diseases, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania. FAU - Martin, George AU - Martin G AD - Dermatology Associates, Maui, Hawaii. FAU - Merola, Joseph F AU - Merola JF AD - Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. FAU - Scher, Jose U AU - Scher JU AD - Department of Medicine, Division of Rheumatology, New York University Grossman School of Medicine and New York University Langone Orthopedic Hospital, New York, New York. FAU - Schwartzman, Sergio AU - Schwartzman S AD - Department of Rheumatology, Hospital for Special Surgery, New York, New York. FAU - Treat, James R AU - Treat JR AD - Department of Pediatric Dermatology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania. FAU - Van Voorhees, Abby S AU - Van Voorhees AS AD - Department of Dermatology, Eastern Virginia Medical School, Norfolk, Virginia. FAU - Ellebrecht, Christoph T AU - Ellebrecht CT AD - Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania. FAU - Fenner, Justine AU - Fenner J AD - Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York. FAU - Ocon, Anthony AU - Ocon A AD - Division of Allergy, Immunology, and Rheumatology Division, University of Rochester Medical Center, Rochester, New York. FAU - Syed, Maha N AU - Syed MN AD - Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania. FAU - Weinstein, Erica J AU - Weinstein EJ AD - Division of Infectious Diseases, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania. FAU - Gondo, George AU - Gondo G AD - National Psoriasis Foundation, Portland, Oregon. FAU - Heydon, Sue AU - Heydon S AD - National Psoriasis Foundation, Portland, Oregon. FAU - Koons, Samantha AU - Koons S AD - National Psoriasis Foundation, Portland, Oregon. FAU - Ritchlin, Christopher T AU - Ritchlin CT AD - Division of Allergy, Immunology, and Rheumatology Division, University of Rochester Medical Center, Rochester, New York. LA - eng GR - L30 HL154200/HL/NHLBI NIH HHS/United States GR - T32 AI055435/AI/NIAID NIH HHS/United States PT - Journal Article PT - Practice Guideline DEP - 20210107 PL - United States TA - J Am Acad Dermatol JT - Journal of the American Academy of Dermatology JID - 7907132 RN - 0 (Biological Products) RN - 0 (COVID-19 Vaccines) RN - 0 (Immunologic Factors) SB - IM MH - Biological Products/therapeutic use MH - COVID-19/complications/epidemiology/*prevention & control MH - *COVID-19 Vaccines MH - Decision Making, Shared MH - Evidence-Based Medicine MH - Humans MH - Immunologic Factors/therapeutic use MH - Pandemics MH - Psoriasis/complications/*drug therapy MH - Risk Factors MH - United States/epidemiology MH - COVID-19 Drug Treatment PMC - PMC7788316 OTO - NOTNLM OT - COVID-19 OT - SARS-CoV-2 OT - biologics OT - psoriasis OT - psoriatic arthritis OT - vaccines COIS- Conflicts of interest Dr Gelfand has served as a consultant for Bristol Myers Squibb, Boehringer Ingelheim, GlaxoSmithKline, Janssen Biologics, Novartis Corp, Regeneron, UCB (Data Safety and Monitoring Board), Sanofi, and Pfizer, receiving honoraria; has received research grants (to the Trustees of the University of Pennsylvania) from AbbVie, Janssen, Novartis Corp, Sanofi, Celgene, OrthoDermatologics, and Pfizer; has received payment for continuing medical education work related to psoriasis that was supported indirectly by Eli Lilly and Company and Ortho Dermatologics; is a copatent holder of resiquimod for treatment of cutaneous T-cell lymphoma; and is a deputy editor for the Journal of Investigative Dermatology, receiving honoraria from the Society for Investigative Dermatology. Dr Armstrong has served as a research investigator and/or scientific advisor to Leo, AbbVie, UCB, Incyte, Janssen, Lilly, Novartis, Ortho Dermatologics, Sun, Dermavant, Bristol Myers Squibb, Sanofi, Regeneron, Dermira, and Modmed. Dr Bell is an employee of the National Psoriasis Foundation. Dr Anesi is supported by the Agency for Healthcare Research and Quality (K12HS026372) and has received fees from UpToDate for authoring COVID-19 clinical reference material. Dr Blauvelt has served as a scientific advisor and/or clinical study investigator for AbbVie, Almirall, Arena, Athenex, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Eli Lilly and Company, Evommune, Forte, Galderma, Incyte, Janssen, Leo, Novartis, Pfizer, Rapt, Regeneron, Sanofi Genzyme, Sun Pharma, and UCB Pharma. Dr Calabrese is a speaker for Sanofi-Regeneron and consultant for AbbVie. Dr Feldman has received research, speaking, and/or consulting support from Galderma, GlaxoSmithKline/Stiefel, Almirall, Alvotech, Leo Pharma, Bristol Myers Squibb, Boehringer Ingelheim, Mylan, Celgene, Pfizer, Ortho Dermatology, AbbVie, Samsung, Janssen, Lilly, Menlo, Merck, Novartis, Regeneron, Sanofi, Novan, Qurient, National Biological Corporation, Caremark, Advance Medical, Sun Pharma, Suncare Research, Informa, UpToDate, and National Psoriasis Foundation; has consulted for others through Guidepoint Global, Gerson Lehrman, and other consulting organizations; is the founder and majority owner of www.DrScore.com; and is a founder and part owner of Causa Research, a company dedicated to enhancing patients' adherence to treatment. Dr Gladman is a consultant for AbbVie, Amgen, Bristol Myers Squibb, Galapagos, Gilead, Eli Lilly, Janssen, Novartis, Pfizer, and UCB and has received grants from AbbVie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer, and UCB. Dr Kircik has served either as an investigator, consultant, or speaker for AbbVie, Almirall, Amgen, Arcutis, Bausch Health Canada, Bristol Myers Squibb, Boehringer Ingelheim, Cellceutix, Celgene, Coherus, Dermavant, Dermira, Eli Lilly, Leo, MC2, Maruho, Novartis, Ortho Dermatologics, Pfizer, Dr Reddy's Laboratories, Sun Pharma, UCB, Taro, and Xenoport. Dr Lebwohl is an employee of Mount Sinai; receives research funds from AbbVie, Amgen, Arcutis, Boehringer Ingelheim, Dermavant, Eli Lilly, Incyte, Janssen Research and Development, Leo Pharmaceuticals, Ortho Dermatologics, Pfizer, and UCB; and is a consultant for Aditum Bio, Allergan, Almirall, Arcutis, Avotres Therapeutics, BirchBioMed, BMD Skincare, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Castle Biosciences, Corrona, Dermavant Sciences, Evelo, Facilitate International Dermatologic Education, Foundation for Research and Education in Dermatology, Inozyme Pharma, Kyowa Kirin, LEO Pharma, Meiji Seika Pharma, Menlo, Mitsubishi, Neuroderm, Pfizer, Promius/Dr Reddy's Laboratories, Serono, Theravance, and Verrica. Dr Martin is a consultant for Almirall, Athenex, Bristol Meyers Squibb, Celgene, Eli Lilly, LEO, Ortho Dermatologic, Pfizer, and UCB and a scientific advisor for Almirall, Athenex, Bristol Meyers Squibb, Celgene, Eli Lilly, Janssen, LEO, Ortho Dermatologic, Pfizer, and UCB. Dr Merola is a consultant and/or investigator for Bristol Myers Squibb, AbbVie, Dermavant, Eli Lilly, Novartis, Janssen, UCB, Sun Pharma, Pfizer, and EMD Serono. Dr Scher is a consultant for UCB, Janssen, AbbVie, Pfizer, Novartis, Bristol Myers Squibb, and Sanofi and is supported in part by the Riley Family Foundation and the Beatrice Snyder Foundation. Dr Schwartzman is a speaker for AbbVie, Genentech, Janssen, Lilly, Novartis, Pfizer, and UCB; owns stock in Amgen, Boston Scientific, Gilead, Medtronic, and Pfizer; is a consultant for AbbVie, Myriad, Janssen, Gilead, Lilly, Novartis, and UCB; is a scientific advisory board member for Myriad; and is a board member of the National Psoriasis Foundation. Dr Van Voorhees has been an investigator for Celgene, Lilly, and AbbVie and an advisor/consultant for AbbVie, Allergan, AstraZeneca, Celgene, Dermira, Merck, Novartis, Pfizer, UCB, and Valeant. Dr Syed is supported by a grant from Pfizer. Authors Gondo, Heydon, and Koons are employees of the National Psoriasis Foundation. Dr Ritchlin reports personal fees from AbbVie, Amgen, Janssen, Novartis, UCB, and Boehringer Ingelheim, as well as grants from Amgen, UCB, and AbbVie outside the submitted work. Drs Dommasch, Lo Re, Treat, Ellebrecht, Fenner, Ocon, and Weinstein have no conflicts of interest to declare. EDAT- 2021/01/11 06:00 MHDA- 2021/04/27 06:00 PMCR- 2021/01/07 CRDT- 2021/01/10 20:31 PHST- 2020/12/18 00:00 [received] PHST- 2020/12/29 00:00 [accepted] PHST- 2021/01/11 06:00 [pubmed] PHST- 2021/04/27 06:00 [medline] PHST- 2021/01/10 20:31 [entrez] PHST- 2021/01/07 00:00 [pmc-release] AID - S0190-9622(21)00016-5 [pii] AID - 10.1016/j.jaad.2020.12.058 [doi] PST - ppublish SO - J Am Acad Dermatol. 2021 May;84(5):1254-1268. doi: 10.1016/j.jaad.2020.12.058. Epub 2021 Jan 7. PMID- 33256258 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231112 IS - 2079-9721 (Print) IS - 2079-9721 (Electronic) IS - 2079-9721 (Linking) VI - 8 IP - 4 DP - 2020 Nov 26 TI - Can Melatonin Be a Potential "Silver Bullet" in Treating COVID-19 Patients? LID - 10.3390/diseases8040044 [doi] LID - 44 AB - The therapeutic potential of melatonin as a chronobiotic cytoprotective agent to counteract the consequences of COVID-19 infections has been advocated. Because of its wide-ranging effects as an antioxidant, anti-inflammatory, and immunomodulatory compound, melatonin could be unique in impairing the consequences of SARS-CoV-2 infection. Moreover, indirect evidence points out to a possible antiviral action of melatonin by interfering with SARS-CoV-2/angiotensin-converting enzyme 2 association. Melatonin is also an effective chronobiotic agent to reverse the circadian disruption of social isolation and to control delirium in severely affected patients. As a cytoprotector, melatonin serves to combat several comorbidities such as diabetes, metabolic syndrome, and ischemic and non-ischemic cardiovascular diseases, which aggravate COVID-19 disease. In view of evidence on the occurrence of neurological sequels in COVID-19-infected patients, another putative application of melatonin emerges based on its neuroprotective properties. Since melatonin is an effective means to control cognitive decay in minimal cognitive impairment, its therapeutic significance for the neurological sequels of SARS-CoV-2 infection should be considered. Finally, yet importantly, exogenous melatonin can be an adjuvant capable of augmenting the efficacy of anti-SARS-CoV-2 vaccines. We discuss in this review the experimental evidence suggesting that melatonin is a potential "silver bullet" in the COVID 19 pandemic. FAU - Cardinali, Daniel P AU - Cardinali DP AD - Faculty of Medical Sciences, Pontificia Universidad Catolica Argentina, Buenos Aires 1007, Argentina. FAU - Brown, Gregory M AU - Brown GM AD - Centre for Addiction and Mental Health, Department of Psychiatry, University of Toronto, Toronto, ON M5T 1R8, Canada. FAU - Pandi-Perumal, Seithikurippu R AU - Pandi-Perumal SR AUID- ORCID: 0000-0002-8686-7259 AD - Somnogen Canada Inc., College Street, Toronto, ON M6H 1C5, Canada. LA - eng PT - Journal Article PT - Review DEP - 20201126 PL - Switzerland TA - Diseases JT - Diseases (Basel, Switzerland) JID - 101636232 PMC - PMC7709121 OTO - NOTNLM OT - COVID-19 pandemic OT - aging OT - anti-SARS-CoV-2 vaccination OT - chronotherapy OT - cognitive impairment OT - cytoprotection OT - diabetes OT - inflammation OT - melatonin OT - metabolic syndrome OT - neurodegeneration OT - oxidative stress OT - renin-angiotensin system COIS- The authors declare no conflict of interest. EDAT- 2020/12/02 06:00 MHDA- 2020/12/02 06:01 PMCR- 2020/11/26 CRDT- 2020/12/01 01:11 PHST- 2020/11/04 00:00 [received] PHST- 2020/11/24 00:00 [revised] PHST- 2020/11/24 00:00 [accepted] PHST- 2020/12/01 01:11 [entrez] PHST- 2020/12/02 06:00 [pubmed] PHST- 2020/12/02 06:01 [medline] PHST- 2020/11/26 00:00 [pmc-release] AID - diseases8040044 [pii] AID - diseases-08-00044 [pii] AID - 10.3390/diseases8040044 [doi] PST - epublish SO - Diseases. 2020 Nov 26;8(4):44. doi: 10.3390/diseases8040044. PMID- 33117391 OWN - NLM STAT- MEDLINE DCOM- 20201109 LR - 20231104 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 11 DP - 2020 TI - An Effective COVID-19 Vaccine Needs to Engage T Cells. PG - 581807 LID - 10.3389/fimmu.2020.581807 [doi] LID - 581807 FAU - Sauer, Karsten AU - Sauer K AD - Repertoire Immune Medicines, Cambridge, MA, United States. FAU - Harris, Tim AU - Harris T AD - Repertoire Immune Medicines, Cambridge, MA, United States. LA - eng PT - Journal Article DEP - 20200928 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 RN - 0 (Antibodies, Neutralizing) RN - 0 (Antibodies, Viral) RN - 0 (COVID-19 Vaccines) RN - 0 (Epitopes, B-Lymphocyte) RN - 0 (Viral Vaccines) SB - IM MH - Antibodies, Neutralizing/immunology MH - Antibodies, Viral/immunology MH - B-Lymphocytes/immunology MH - Betacoronavirus/*immunology MH - CD4-Positive T-Lymphocytes/*immunology MH - CD8-Positive T-Lymphocytes/*immunology MH - COVID-19 MH - COVID-19 Vaccines MH - Coronavirus Infections/immunology/*prevention & control MH - Epitopes, B-Lymphocyte/genetics/immunology MH - Humans MH - Pandemics/*prevention & control MH - Pneumonia, Viral/immunology/*prevention & control MH - SARS-CoV-2 MH - Viral Vaccines/*immunology PMC - PMC7549399 OTO - NOTNLM OT - COVID-19 OT - SARS-CoV-2 OT - T cell OT - epitope OT - memory OT - neutralizing antibody OT - pandemic OT - vaccine EDAT- 2020/10/30 06:00 MHDA- 2020/11/11 06:00 PMCR- 2020/09/28 CRDT- 2020/10/29 05:52 PHST- 2020/07/09 00:00 [received] PHST- 2020/08/27 00:00 [accepted] PHST- 2020/10/29 05:52 [entrez] PHST- 2020/10/30 06:00 [pubmed] PHST- 2020/11/11 06:00 [medline] PHST- 2020/09/28 00:00 [pmc-release] AID - 10.3389/fimmu.2020.581807 [doi] PST - epublish SO - Front Immunol. 2020 Sep 28;11:581807. doi: 10.3389/fimmu.2020.581807. eCollection 2020. PMID- 33072783 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240329 IS - 2296-858X (Print) IS - 2296-858X (Electronic) IS - 2296-858X (Linking) VI - 7 DP - 2020 TI - Covid-19 Pandemic: Maximizing Future Vaccination Treatments Considering Aging and Frailty. PG - 558835 LID - 10.3389/fmed.2020.558835 [doi] LID - 558835 AB - The COVID-19 pandemic is proving to be a multiplier of inequalities. Especially toward the elderly population. A voiceless scream that comes from geriatrics, nursing homes, hospices from all over Italy. They call it the silent massacre: from North to South, the bulletin of coronavirus positive-or already deceased-elderly people continues to grow exponentially without a chance to counter it. Population aging and chronicity are a question that needs to be addressed. Frailty is the most challenging expression of population aging, with major consequences for public health and clinical practice. It is a geriatric syndrome which consists in a state of higher vulnerability to stressors attributed to a lower homeostatic reserve due to an age-related multisystem physiological change. People over 60, and especially over 80, are particularly vulnerable to severe or fatal infection. Moreover, the age-related dysregulation of the immune system in the elderly (i.e., immunosenescence and inflammaging) results in poorer responses to vaccination. Physical frailty is an effective health indicator and it has previously shown to predict the response to the seasonal flu vaccine. These findings suggest that assessing frailty in the elderly may identify those who are less likely to respond to immunization and be at higher risk for COVID-19 and its complications. Moreover, cognitive frailty and neurocognitive disorders, mental health and reduced awareness of illness negatively impact on adherence to complex medication regimens among elderly patients. A worldwide research and development blueprint have been initiated to accelerate the development of vaccines and therapeutics for the COVID-19 outbreak. Considered the above, I suggest the importance to consider aging in thinking about future Civud-19 vaccination and treatment, focusing on the possible impact of physical and cognitive frailty. CI - Copyright (c) 2020 Palermo. FAU - Palermo, Sara AU - Palermo S AD - Department of Psychology, University of Turin, Turin, Italy. AD - European Innovation Partnership on Active and Healthy Aging, Bruxelles, Belgium. LA - eng PT - Journal Article DEP - 20200918 PL - Switzerland TA - Front Med (Lausanne) JT - Frontiers in medicine JID - 101648047 PMC - PMC7530612 OTO - NOTNLM OT - COVID-19 OT - adherence to treatment OT - ageotype OT - frailty OT - immunology OT - immunosenecence OT - inflammaging OT - vaccination EDAT- 2020/10/20 06:00 MHDA- 2020/10/20 06:01 PMCR- 2020/09/18 CRDT- 2020/10/19 05:59 PHST- 2020/05/18 00:00 [received] PHST- 2020/09/02 00:00 [accepted] PHST- 2020/10/19 05:59 [entrez] PHST- 2020/10/20 06:00 [pubmed] PHST- 2020/10/20 06:01 [medline] PHST- 2020/09/18 00:00 [pmc-release] AID - 10.3389/fmed.2020.558835 [doi] PST - epublish SO - Front Med (Lausanne). 2020 Sep 18;7:558835. doi: 10.3389/fmed.2020.558835. eCollection 2020. PMID- 32973527 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20260829 IS - 1663-9812 (Print) IS - 1663-9812 (Electronic) IS - 1663-9812 (Linking) VI - 11 DP - 2020 TI - Harnessing Memory NK Cell to Protect Against COVID-19. PG - 1309 LID - 10.3389/fphar.2020.01309 [doi] LID - 1309 AB - The worldwide struggle against the coronavirus disease 2019 (COVID-19) as a public health crisis continues to sweep across the globe. Up to now, effective antiviral treatment against COVID-19 is not available. Therefore, throughout virus infections, a thorough clarification of the virus-host immune system interactions will be most probably helpful to encounter these challenges. Emerging evidence suggests that just like SARS and MERS, COVID-19 primarily suppresses the innate immune system, enabling its stable propagation during the early stage of infection. Consequently, proinflammatory cytokines and chemokines have been increasing during infection progression associated with severe lung pathology. It is imperative to consider hyper inflammation in vaccine designing, as vaccine-induced immune responses must have a protective role against infection without leading to immunopathology. Among the front-line responders to viral infections, Natural Killer (NK) cells have immense therapeutic potential, forming a bridge between innate and adaptive responses. A subset of NK cells exhibits putatively increased effector functions against viruses following pathogen-specific and immunization. Memory NK cells have higher cytotoxicity and effector activity, compared with the conventional NK cells. As a pioneering strategy, prompt accumulation and long-term maintenance of these memory NK cells could be an efficacious viral treatment. According to the high prevalence of human cytomegalovirus (HCMV) infection in the world, it remains to be determined whether HCMV adaptive NK cells could play a protective role against this new emerging virus. In addition, the new adaptive-like KIR+NKG2C+ NK cell subset (the adaptive-like lung tissue residue [tr]NK cell) in the context of the respiratory infection at this site could specifically exhibit the expansion upon COVID-19. Another aspect of NK cells we should note, utilizing modified NK cells such as allogeneic off-the-shelf CAR-NK cells as a state-of-the-art strategy for the treatment of COVID-19. In this line, we speculate introducing NKG2C into chimeric antigen receptors in NK cells might be a potential approach in future viral immunotherapy for emerging viruses. In this contribution, we will briefly discuss the current status and future perspective of NK cells, which provide to successfully exploit NK cell-mediated antiviral activity that may offer important new tools in COVID-19 treatment. CI - Copyright (c) 2020 Soleimanian and Yaghobi. FAU - Soleimanian, Saeede AU - Soleimanian S AD - Shiraz Transplant Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. FAU - Yaghobi, Ramin AU - Yaghobi R AD - Shiraz Transplant Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. LA - eng PT - Journal Article PT - Review DEP - 20200820 PL - Switzerland TA - Front Pharmacol JT - Frontiers in pharmacology JID - 101548923 PMC - PMC7468462 OTO - NOTNLM OT - SARS-CoV-2 OT - adaptive NK cell OT - immune system OT - inflammatory cytokine OT - memory NK cell OT - vaccination EDAT- 2020/09/26 06:00 MHDA- 2020/09/26 06:01 PMCR- 2020/08/20 CRDT- 2020/09/25 06:01 PHST- 2020/05/09 00:00 [received] PHST- 2020/08/07 00:00 [accepted] PHST- 2020/09/25 06:01 [entrez] PHST- 2020/09/26 06:00 [pubmed] PHST- 2020/09/26 06:01 [medline] PHST- 2020/08/20 00:00 [pmc-release] AID - 10.3389/fphar.2020.01309 [doi] PST - epublish SO - Front Pharmacol. 2020 Aug 20;11:1309. doi: 10.3389/fphar.2020.01309. eCollection 2020. PMID- 32595955 OWN - NLM STAT- MEDLINE DCOM- 20240109 LR - 20240329 IS - 2046-1402 (Electronic) IS - 2046-1402 (Linking) VI - 9 DP - 2020 TI - Expected immune recognition of COVID-19 virus by memory from earlier infections with common coronaviruses in a large part of the world population. PG - 285 LID - 10.12688/f1000research.23458.2 [doi] LID - 285 AB - SARS-CoV-2 is the coronavirus agent of the COVID-19 pandemic causing high mortalities. In contrast, the widely spread human coronaviruses OC43, HKU1, 229E, and NL63 tend to cause only mild symptoms. The present study shows, by in silico analysis, that these common human viruses are expected to induce immune memory against SARS-CoV-2 by sharing protein fragments (antigen epitopes) for presentation to the immune system by MHC class I. A list of such epitopes is provided. The number of these epitopes and the prevalence of the common coronaviruses suggest that a large part of the world population has some degree of specific immunity against SARS-CoV-2 already, even without having been infected by that virus. For inducing protection, booster vaccinations enhancing existing immunity are less demanding than primary vaccinations against new antigens. Therefore, for the discussion on vaccination strategies against COVID-19, the available immune memory against related viruses should be part of the consideration. CI - Copyright: (c) 2020 Dijkstra JM and Hashimoto K. FAU - Dijkstra, Johannes M AU - Dijkstra JM AUID- ORCID: 0000-0001-7097-3826 AD - Institute for Comprehensive Medical Science, Fujita Health University, Toyoake, Aichi, 470-1192, Japan. FAU - Hashimoto, Keiichiro AU - Hashimoto K AD - Institute for Comprehensive Medical Science, Fujita Health University, Toyoake, Aichi, 470-1192, Japan. LA - eng PT - Journal Article DEP - 20200423 PL - England TA - F1000Res JT - F1000Research JID - 101594320 RN - 0 (Antigens, Viral) RN - 0 (Epitopes) SB - IM MH - Humans MH - *Antigens, Viral/immunology MH - Betacoronavirus MH - Coronavirus/classification MH - *Coronavirus Infections/immunology MH - COVID-19 MH - Epitopes/immunology MH - *Immunologic Memory MH - Pandemics MH - *Pneumonia, Viral/immunology MH - SARS-CoV-2 PMC - PMC7309412 OTO - NOTNLM OT - 229E OT - COVID-19 OT - Coronavirus OT - HKU1 OT - Immunology OT - MHC class I OT - NL63 OT - OC43 OT - SARS-CoV-2 OT - Vaccination COIS- No competing interests were disclosed. EDAT- 2020/07/31 06:00 MHDA- 2020/08/05 06:00 PMCR- 2020/07/17 CRDT- 2020/07/31 06:00 PHST- 2020/07/08 00:00 [accepted] PHST- 2020/07/31 06:00 [entrez] PHST- 2020/07/31 06:00 [pubmed] PHST- 2020/08/05 06:00 [medline] PHST- 2020/07/17 00:00 [pmc-release] AID - 10.12688/f1000research.23458.2 [doi] PST - epublish SO - F1000Res. 2020 Apr 23;9:285. doi: 10.12688/f1000research.23458.2. eCollection 2020. PMID- 32470151 OWN - NLM STAT- MEDLINE DCOM- 20201216 LR - 20210225 IS - 1096-9071 (Electronic) IS - 0146-6615 (Linking) VI - 92 IP - 10 DP - 2020 Oct TI - The perplexing question of trained immunity vs adaptive memory in COVID-19. PG - 1858-1863 LID - 10.1002/jmv.26083 [doi] AB - The wide spectrum of symptoms observed in coronavirus disease 2019 appears to defy explanation. Apart from geographic limitation to people with prior exposure to other coronaviruses and air pollutants, inflammatory comorbidities and older ages are also among the main factors of susceptibility to severe illness. The unusual epidemiological data pointed out in children and African territories have revealed new insights in host-pathogen interplay with more focus on epigenetic regulation of cognitive compartments belonging to innate immunity. Should trained immunity be proven to be involved in timely immune responsiveness against severe acute respiratory syndrome coronavirus 2 and that adaptive memory could be detrimental, both treatment regimens and vaccine design will tremendously change accordingly with more focus on upper respiratory tissue innate immunity to subdue this threat underway. CI - (c) 2020 Wiley Periodicals LLC. FAU - Kerboua, K E AU - Kerboua KE AUID- ORCID: 0000-0003-0618-7614 AD - Laboratory of Immunology, Faculty of Medicine, University of Kasdi Merbah, Ouargla, Algeria. LA - eng GR - Ministry of Higher Education and Scientific Resear/General Directorate of Research and Technology Development/International PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20200714 PL - United States TA - J Med Virol JT - Journal of medical virology JID - 7705876 SB - IM CIN - J Med Virol. 2021 Jan;93(1):122-123. doi: 10.1002/jmv.26214. PMID: 32579301 MH - *Adaptive Immunity MH - COVID-19/*immunology MH - Epigenesis, Genetic MH - Humans MH - *Immunity, Innate MH - Immunologic Memory MH - Inflammation/virology OTO - NOTNLM OT - BCG vaccination OT - SARS-CoV-2 OT - adaptive immune enhancement OT - air pollution OT - alive vaccines OT - mucosal immunity OT - severity variation OT - trained immunity OT - type III hypersensitivity EDAT- 2020/05/30 06:00 MHDA- 2020/12/17 06:00 CRDT- 2020/05/30 06:00 PHST- 2020/05/06 00:00 [received] PHST- 2020/05/26 00:00 [revised] PHST- 2020/05/27 00:00 [accepted] PHST- 2020/05/30 06:00 [pubmed] PHST- 2020/12/17 06:00 [medline] PHST- 2020/05/30 06:00 [entrez] AID - 10.1002/jmv.26083 [doi] PST - ppublish SO - J Med Virol. 2020 Oct;92(10):1858-1863. doi: 10.1002/jmv.26083. Epub 2020 Jul 14. PMID- 33900691 OWN - NLM STAT- MEDLINE DCOM- 20210617 LR - 20210617 IS - 2162-6472 (Electronic) IS - 1040-8401 (Linking) VI - 40 IP - 6 DP - 2020 TI - Viral Proteins under 70 Kilodaltons in Size Prevent the Development of Long-Lasting B-Cell Immune Memory and IgG2a Prevention in COVID-19 Vaccines. PG - 465-473 LID - 10.1615/CritRevImmunol.2020035601 [doi] AB - Coronavirus disease 2019 (COVID-19) consists of a severe involvement of the lower respiratory tract leading to an acute respiratory syndrome. But there exist other infectious respiratory syndromes that have the same initial respiratory symptoms, show similar pattern in the size of the antigenic proteins and release comparable cytokines pathways, but with an unlike response magnitude. Here we propose that COVID-19 disease wrong response in the host immune system can be explained in the perspective of the antigen viral size. In COVID-19 sepsis, the < 70 kDa antigens activate the B-cell receptor (BCR), which modulates the shift in the pattern of T-helper 1 (Th1) to Th2 cytokines, increases the release of interleukin-10 (IL-10) and the up-regulation of the membrane form of tumor necrosis factor alpha (TNF-alpha), promoting the production of immunoglobulin G1 (IgG1)- and IgG3-neutralizing antibodies, but failing in IgG2a production and in developing long-lasting B-cell immune memory. The sustained infected cells lysis overfeeds high levels of viral proteins < 70 kDa, increases B-cell activation and, in the shift from a Th1 to a Th2 immune response, can trigger a cytokine storm. The continuous BCR activation increases IL-10 release that can lead to cytokine storm, apoptosis, and immune paralysis. Here, we propose a new vaccine design using the polymerization of viral antigens that could be ready in short time, would be cheap and easy to develop because it is based on classic technologies available in every country, is safe because it does not employ genetic material, and would able to promote long-lasting B-cell immune memory and IgG2a production. FAU - Martin Oncina, Javier AU - Martin Oncina J AD - Spanish National Health Service. LA - eng PT - Journal Article PL - United States TA - Crit Rev Immunol JT - Critical reviews in immunology JID - 8914819 RN - 0 (Antibodies, Neutralizing) RN - 0 (Antibodies, Viral) RN - 0 (Antigens, Viral) RN - 0 (COVID-19 Vaccines) RN - 0 (Cytokines) RN - 0 (Immunoglobulin G) RN - 0 (Viral Proteins) SB - IM MH - Antibodies, Neutralizing/immunology MH - Antibodies, Viral/immunology MH - Antigens, Viral/chemistry/*immunology MH - B-Lymphocytes/immunology MH - COVID-19/*immunology/prevention & control MH - COVID-19 Vaccines/*immunology MH - Cytokines/metabolism MH - Humans MH - Immunity, Humoral MH - Immunoglobulin G/*immunology MH - *Immunologic Memory MH - Lymphocyte Activation MH - Molecular Weight MH - SARS-CoV-2/*immunology MH - T-Lymphocyte Subsets/immunology/metabolism MH - Viral Proteins/chemistry/*immunology EDAT- 2020/01/01 00:00 MHDA- 2021/06/22 06:00 CRDT- 2021/04/26 12:34 PHST- 2021/04/26 12:34 [entrez] PHST- 2020/01/01 00:00 [pubmed] PHST- 2021/06/22 06:00 [medline] AID - 04a28fd32740cb54,11565908082e3084 [pii] AID - 10.1615/CritRevImmunol.2020035601 [doi] PST - ppublish SO - Crit Rev Immunol. 2020;40(6):465-473. doi: 10.1615/CritRevImmunol.2020035601.